<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<html>
 <body>
  <pmc-articleset>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       BMJ Open
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       BMJ Open
      </journal-id>
      <journal-id journal-id-type="hwp">
       bmjopen
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       bmjopen
      </journal-id>
      <journal-title-group>
       <journal-title>
        BMJ Open
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       2044-6055
      </issn>
      <publisher>
       <publisher-name>
        BMJ Publishing Group
       </publisher-name>
       <publisher-loc>
        BMA House, Tavistock Square, London, WC1H 9JR
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       25903751
      </article-id>
      <article-id pub-id-type="pmc">
       4420971
      </article-id>
      <article-id pub-id-type="publisher-id">
       bmjopen-2014-006577
      </article-id>
      <article-id pub-id-type="doi">
       10.1136/bmjopen-2014-006577
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Infectious Diseases
        </subject>
        <subj-group>
         <subject>
          Research
         </subject>
        </subj-group>
       </subj-group>
       <subj-group subj-group-type="hwp-journal-coll">
        <subject>
         1506
        </subject>
        <subject>
         1706
        </subject>
        <subject>
         1706
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        A cluster randomised trial of cloth masks compared with medical masks in healthcare workers
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          MacIntyre
         </surname>
         <given-names>
          C Raina
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Seale
         </surname>
         <given-names>
          Holly
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Dung
         </surname>
         <given-names>
          Tham Chi
         </given-names>
        </name>
        <xref ref-type="aff" rid="af2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Hien
         </surname>
         <given-names>
          Nguyen Tran
         </given-names>
        </name>
        <xref ref-type="aff" rid="af2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Nga
         </surname>
         <given-names>
          Phan Thi
         </given-names>
        </name>
        <xref ref-type="aff" rid="af2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chughtai
         </surname>
         <given-names>
          Abrar Ahmad
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Rahman
         </surname>
         <given-names>
          Bayzidur
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Dwyer
         </surname>
         <given-names>
          Dominic E
         </given-names>
        </name>
        <xref ref-type="aff" rid="af3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Quanyi
         </given-names>
        </name>
        <xref ref-type="aff" rid="af4">
         4
        </xref>
       </contrib>
      </contrib-group>
      <aff id="af1">
       <label>
        1
       </label>
       <addr-line>
        Faculty of Medicine
       </addr-line>
       ,
       <institution>
        School of Public Health and Community Medicine, University of New South Wales
       </institution>
       ,
       <addr-line>
        Sydney
       </addr-line>
       ,
       <country>
        Australia
       </country>
      </aff>
      <aff id="af2">
       <label>
        2
       </label>
       <institution>
        National Institute of Hygiene and Epidemiology
       </institution>
       ,
       <addr-line>
        Hanoi
       </addr-line>
       ,
       <country>
        Vietnam
       </country>
      </aff>
      <aff id="af3">
       <label>
        3
       </label>
       <institution>
        Institute for Clinical Pathology and Medical Research, Westmead Hospital and University of Sydney
       </institution>
       ,
       <addr-line>
        Sydney, New South Wales
       </addr-line>
       ,
       <country>
        Australia
       </country>
      </aff>
      <aff id="af4">
       <label>
        4
       </label>
       <institution>
        Beijing Centers for Disease Control and Prevention
       </institution>
       ,
       <addr-line>
        Beijing
       </addr-line>
       ,
       <country>
        China
       </country>
      </aff>
      <author-notes>
       <corresp>
        <label>
         Correspondence to
        </label>
        Professor C Raina MacIntyre;
        <email>
         r.macintyre@unsw.edu.au
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="collection">
       <year>
        2015
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        22
       </day>
       <month>
        4
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <volume>
       5
      </volume>
      <issue>
       4
      </issue>
      <elocation-id>
       e006577
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         9
        </day>
        <month>
         9
        </month>
        <year>
         2014
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         25
        </day>
        <month>
         3
        </month>
        <year>
         2015
        </year>
       </date>
       <date date-type="accepted">
        <day>
         26
        </day>
        <month>
         3
        </month>
        <year>
         2015
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
       </copyright-statement>
       <copyright-year>
        2015
       </copyright-year>
       <license license-type="open-access">
        <license-p>
         This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          http://creativecommons.org/licenses/by-nc/4.0/
         </ext-link>
        </license-p>
       </license>
      </permissions>
      <self-uri xlink:href="bmjopen-2014-006577.pdf" xlink:title="pdf">
      </self-uri>
      <abstract>
       <sec>
        <title>
         Objective
        </title>
        <p>
         The aim of this study was to compare the efficacy of cloth masks to medical masks in hospital healthcare workers (HCWs). The null hypothesis is that there is no difference between medical masks and cloth masks.
        </p>
       </sec>
       <sec>
        <title>
         Setting
        </title>
        <p>
         14 secondary-level/tertiary-level hospitals in Hanoi, Vietnam.
        </p>
       </sec>
       <sec>
        <title>
         Participants
        </title>
        <p>
         1607 hospital HCWs aged ≥18 years working full-time in selected high-risk wards.
        </p>
       </sec>
       <sec>
        <title>
         Intervention
        </title>
        <p>
         Hospital wards were randomised to: medical masks, cloth masks or a control group (usual practice, which included mask wearing). Participants used the mask on every shift for 4 consecutive weeks.
        </p>
       </sec>
       <sec>
        <title>
         Main outcome measure
        </title>
        <p>
         Clinical respiratory illness (CRI), influenza-like illness (ILI) and laboratory-confirmed respiratory virus infection.
        </p>
       </sec>
       <sec>
        <title>
         Results
        </title>
        <p>
         The rates of all infection outcomes were highest in the cloth mask arm, with the rate of ILI statistically significantly higher in the cloth mask arm (relative risk (RR)=13.00, 95% CI 1.69 to 100.07) compared with the medical mask arm. Cloth masks also had significantly higher rates of ILI compared with the control arm. An analysis by mask use showed ILI (RR=6.64, 95% CI 1.45 to 28.65) and laboratory-confirmed virus (RR=1.72, 95% CI 1.01 to 2.94) were significantly higher in the cloth masks group compared with the medical masks group. Penetration of cloth masks by particles was almost 97% and medical masks 44%.
        </p>
       </sec>
       <sec>
        <title>
         Conclusions
        </title>
        <p>
         This study is the first RCT of cloth masks, and the results caution against the use of cloth masks. This is an important finding to inform occupational health and safety. Moisture retention, reuse of cloth masks and poor filtration may result in increased risk of infection. Further research is needed to inform the widespread use of cloth masks globally. However, as a precautionary measure, cloth masks should not be recommended for HCWs, particularly in high-risk situations, and guidelines need to be updated.
        </p>
       </sec>
       <sec>
        <title>
         Trial registration number
        </title>
        <p>
         Australian New Zealand Clinical Trials Registry: ACTRN12610000887077.
        </p>
       </sec>
      </abstract>
      <kwd-group>
       <kwd>
        Influenza
       </kwd>
       <kwd>
        Cloth mask
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <boxed-text orientation="portrait" position="float">
     <caption>
      <title>
       Strengths and limitations of this study
      </title>
     </caption>
     <list list-type="bullet">
      <list-item>
       <p>
        The use of cloth masks is widespread around the world, particularly in countries at high-risk for emerging infections, but there have been no efficacy studies to underpin their use.
       </p>
      </list-item>
      <list-item>
       <p>
        This study is large, a prospective randomised clinical trial (RCT) and the first RCT ever conducted of cloth masks.
       </p>
      </list-item>
      <list-item>
       <p>
        The use of cloth masks are not addressed in most guidelines for health care workers—this study provides data to update guidelines.
       </p>
      </list-item>
      <list-item>
       <p>
        The control arm was ‘standard practice’, which comprised mask use in a high proportion of participants. As such (without a no-mask control), the finding of a much higher rate of infection in the cloth mask arm could be interpreted as harm caused by cloth masks, efficacy of medical masks, or most likely a combination of both.
       </p>
      </list-item>
     </list>
    </boxed-text>
    <sec id="s1" sec-type="intro">
     <title>
      Introduction
     </title>
     <p>
      The use of facemasks and respirators for the protection of healthcare workers (HCWs) has received renewed interest following the 2009 influenza pandemic,
      <xref ref-type="bibr" rid="R1">
       1
      </xref>
      and emerging infectious diseases such as avian influenza,
      <xref ref-type="bibr" rid="R2">
       2
      </xref>
      Middle East respiratory syndrome coronavirus (MERS-coronavirus)
      <xref ref-type="bibr" rid="R3">
       3
      </xref>
      <xref ref-type="bibr" rid="R4">
       4
      </xref>
      and Ebola virus.
      <xref ref-type="bibr" rid="R5">
       5
      </xref>
      Historically, various types of cloth/cotton masks (referred to here after as ‘cloth masks’) have been used to protect HCWs.
      <xref ref-type="bibr" rid="R6">
       6
      </xref>
      Disposable medical/surgical masks (referred to here after as ‘medical masks’) were introduced into healthcare in the mid 19th century, followed later by respirators.
      <xref ref-type="bibr" rid="R7">
       7
      </xref>
      Compared with other parts of the world, the use of face masks is more prevalent in Asian countries, such as China and Vietnam.
      <xref ref-type="bibr" rid="R8">
       8–11
      </xref>
     </p>
     <p>
      In high resource settings, disposable medical masks and respirators have long since replaced the use of cloth masks in hospitals. Yet cloth masks remain widely used globally, including in Asian countries, which have historically been affected by emerging infectious diseases, as well as in West Africa, in the context of shortages of personal protective equipment (PPE).
      <xref ref-type="bibr" rid="R12">
       12
      </xref>
      <xref ref-type="bibr" rid="R13">
       13
      </xref>
      It has been shown that medical research disproportionately favours diseases of wealthy countries, and there is a lack of research on the health needs of poorer countries.
      <xref ref-type="bibr" rid="R14">
       14
      </xref>
      Further, there is a lack of high-quality studies around the use of facemasks and respirators in the healthcare setting, with only four randomised clinical trials (RCTs) to date.
      <xref ref-type="bibr" rid="R15">
       15
      </xref>
      Despite widespread use, cloth masks are rarely mentioned in policy documents,
      <xref ref-type="bibr" rid="R16">
       16
      </xref>
      and have never been tested for efficacy in a RCT. Very few studies have been conducted around the clinical effectiveness of cloth masks, and most available studies are observational or in vitro.
      <xref ref-type="bibr" rid="R6">
       6
      </xref>
      Emerging infectious diseases are not constrained within geographical borders, so it is important for global disease control that use of cloth masks be underpinned by evidence. The aim of this study was to determine the efficacy of cloth masks compared with medical masks in HCWs working in high-risk hospital wards, against the prevention of respiratory infections.
     </p>
    </sec>
    <sec id="s2" sec-type="methods">
     <title>
      Methods
     </title>
     <p>
      A cluster-randomised trial of medical and cloth mask use for HCWs was conducted in 14 hospitals in Hanoi, Vietnam. The trial started on the 3 March 2011, with rolling recruitment undertaken between 3 March 2011 and 10 March 2011. Participants were followed during the same calendar time for 4 weeks of facemasks use and then one additional week for appearance of symptoms. An invitation letter was sent to 32 hospitals in Hanoi, of which 16 agreed to participate. One hospital did not meet the eligibility criteria; therefore, 74 wards in 15 hospitals were randomised. Following the randomisation process, one hospital withdrew from the study because of a nosocomial outbreak of rubella.
     </p>
     <p>
      Participants provided written informed consent prior to initiation of the trial.
     </p>
     <sec id="s2a">
      <title>
       Randomisation
      </title>
      <p>
       Seventy-four wards (emergency, infectious/respiratory disease, intensive care and paediatrics) were selected as high-risk settings for occupational exposure to respiratory infections. Cluster randomisation was used because the outcome of interest was respiratory infectious diseases, where prevention of one infection in an individual can prevent a chain of subsequent transmission in closed settings.
       <xref ref-type="bibr" rid="R8">
        8
       </xref>
       <xref ref-type="bibr" rid="R9">
        9
       </xref>
       Epi info V.6 was used to generate a randomisation allocation and 74 wards were randomly allocated to the interventions.
      </p>
      <p>
       From the eligible wards 1868 HCWs were approached to participate. After providing informed consent, 1607 participants were randomised by ward to three arms: (1) medical masks at all times on their work shift; (2) cloth masks at all times on shift or (3) control arm (standard practice, which may or may not include mask use). Standard practice was used as control because the IRB deemed it unethical to ask participants to not wear a mask. We studied continuous mask use (defined as wearing masks all the time during a work shift, except while in the toilet or during tea or lunch breaks) because this reflects current practice in high-risk settings in Asia.
       <xref ref-type="bibr" rid="R8">
        8
       </xref>
      </p>
      <p>
       The laboratory results were blinded and laboratory testing was conducted in a blinded fashion. As facemask use is a visible intervention, clinical end points could not be blinded.
       <xref ref-type="fig" rid="BMJOPEN2014006577F1">
        Figure 1
       </xref>
       outlines the recruitment and randomisation process.
      </p>
      <fig id="BMJOPEN2014006577F1" orientation="portrait" position="float">
       <label>
        Figure 1
       </label>
       <caption>
        <p>
         Consort diagram of recruitment and follow-up (HCWs, healthcare workers).
        </p>
       </caption>
       <graphic xlink:href="bmjopen2014006577f01">
       </graphic>
      </fig>
     </sec>
     <sec id="s2b">
      <title>
       Primary end points
      </title>
      <p>
       There were three primary end points for this study, used in our previous mask RCTs:
       <xref ref-type="bibr" rid="R8">
        8
       </xref>
       <xref ref-type="bibr" rid="R9">
        9
       </xref>
       (1) Clinical respiratory illness (CRI), defined as two or more respiratory symptoms or one respiratory symptom and a systemic symptom;
       <xref ref-type="bibr" rid="R17">
        17
       </xref>
       (2) influenza-like illness (ILI), defined as fever ≥38°C plus one respiratory symptom and (3) laboratory-confirmed viral respiratory infection. Laboratory confirmation was by nucleic acid detection using multiplex reverse transcriptase PCR (RT-PCR) for 17 respiratory viruses: respiratory syncytial virus (RSV) A and B, human metapneumovirus (hMPV), influenza A (H3N2), (H1N1)pdm09, influenza B, parainfluenza viruses 1–4, influenza C, rhinoviruses, severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV), coronaviruses 229E, NL63, OC43 and HKU1, adenoviruses and human bocavirus (hBoV).
       <xref ref-type="bibr" rid="R18">
        18–23
       </xref>
       Additional end points included compliance with mask use, defined as using the mask during the shift for 70% or more of work shift hours.
       <xref ref-type="bibr" rid="R9">
        9
       </xref>
       HCWs were categorised as ‘compliant’ if the average use was equal or more than 70% of the working time. HCW were categorised as ‘non-compliant’ if the average mask use was less than 70% of the working time.
      </p>
     </sec>
     <sec id="s2c">
      <title>
       Eligibility
      </title>
      <p>
       Nurses or doctors aged ≥18 years working full-time were eligible. Exclusion criteria were: (1) Unable or refused to consent; (2) Beards, long moustaches or long facial hair stubble; (3) Current respiratory illness, rhinitis and/or allergy.
      </p>
     </sec>
     <sec id="s2d">
      <title>
       Intervention
      </title>
      <p>
       Participants wore the mask on every shift for four consecutive weeks. Participants in the medical mask arm were supplied with two masks daily for each 8 h shift, while participants in the cloth mask arm were provided with five masks in total for the study duration, which they were asked to wash and rotate over the study period. They were asked to wash cloth masks with soap and water every day after finishing the shifts. Participants were supplied with written instructions on how to clean their cloth masks. Masks used in the study were locally manufactured medical (three layer, made of non-woven material) or cloth masks (two layer, made of cotton) commonly used in Vietnamese hospitals. The control group was asked to continue with their normal practices, which may or may not have included mask wearing. Mask wearing was measured and documented for all participants, including the control arm.
      </p>
     </sec>
     <sec id="s2e">
      <title>
       Data collection and follow-up
      </title>
      <p>
       Data on sociodemographic, clinical and other potential confounding factors were collected at baseline. Participants were followed up daily for 4 weeks (active intervention period), and for an extra week of standard practice, in order to document incident infection after incubation. Participants received a thermometer (traditional glass and mercury) to measure their temperature daily and at symptom onset. Daily diary cards were provided to record number of hours worked and mask use, estimated number of patient contacts (with/without ILI) and number/type of aerosol-generating procedures (AGPs) conducted, such as suctioning of airways, sputum induction, endotracheal intubation and bronchoscopy. Participants in the cloth mask and control group (if they used cloth masks) were also asked to document the process used to clean their mask after use.
      </p>
      <p>
       We also monitored compliance with mask use by a previously validated self-reporting mechanism.
       <xref ref-type="bibr" rid="R8">
        8
       </xref>
       Participants were contacted daily to identify incident cases of respiratory infection. If participants were symptomatic, swabs of both tonsils and the posterior pharyngeal wall were collected on the day of reporting.
      </p>
     </sec>
     <sec id="s2f">
      <title>
       Sample collection and laboratory testing
      </title>
      <p>
       Trained collectors used double rayon-tipped, plastic-shafted swabs to scratch tonsillar areas as well as the posterior pharyngeal wall of symptomatic participants. Testing was conducted using RT-PCR applying published methods.
       <xref ref-type="bibr" rid="R19">
        19–23
       </xref>
       Viral RNA was extracted from each respiratory specimen using the Viral RNA Mini kit (Qiagen, Germany), following the manufacturer's instructions. The RNA extraction step was controlled by amplification of a RNA house-keeping gene (amplify pGEM) using real-time RT-PCR. Only extracted samples with the house keeping gene detected by real-time RT-PCR were submitted for multiplex RT-PCR for viruses.
      </p>
      <p>
       The reverse transcription and PCRs were performed in OneStep (Qiagen, Germany) to amplify viral target genes, and then in five multiplex RT-PCR: RSVA/B, influenza A/H3N2, A(H1N1) and B viruses, hMPV (reaction mix 1); parainfluenza viruses 1–4 (reaction mix 2); rhinoviruses, influenza C virus, SARS-CoV (reaction mix 3); coronaviruses OC43, 229E, NL63 and HKU1 (reaction mix 4); and adenoviruses and hBoV (reaction mix 5), using a method published by others.
       <xref ref-type="bibr" rid="R18">
        18
       </xref>
       All samples with viruses detected by multiplex RT-PCR were confirmed by virus-specific mono nested or heminested PCR. Positive controls were prepared by in vitro transcription to control amplification efficacy and monitor for false negatives, and included in all runs (except for NL63 and HKU1). Each run always included two negatives to monitor amplification quality. Specimen processing, RNA extraction, PCR amplification and PCR product analyses were conducted in different rooms to avoid cross-contamination.
       <xref ref-type="bibr" rid="R19">
        19
       </xref>
       <xref ref-type="bibr" rid="R20">
        20
       </xref>
      </p>
     </sec>
     <sec id="s2g">
      <title>
       Filtration testing
      </title>
      <p>
       The filtration performance of the cloth and medical masks was tested according to the respiratory standard AS/NZS1716.
       <xref ref-type="bibr" rid="R24">
        24
       </xref>
       The equipment used was a TSI 8110 Filter tester. To test the filtration performance, the filter is challenged by a known concentration of sodium chloride particles of a specified size range and at a defined flow rate. The particle concentration is measured before and after adding the filter material and the relative filtration efficiency is calculated. We examined the performance of cloth masks compared with the performance levels—P1, P2 (=N95) and P3, as used for assessment of all particulate filters for respiratory protection. The 3M 9320 N95 and 3M Vflex 9105 N95 were used to compare against the cloth and medical masks.
      </p>
     </sec>
     <sec id="s2h">
      <title>
       Sample size calculation
      </title>
      <p>
       To obtain 80% power at two-sided 5% significance level for detecting a significant difference of attack rate between medical masks and cloth masks, and for a rate of infection of 13% for cloth mask wearers compared with 6% in medical mask wearers, we would need eight clusters per arm and 530 participants in each arm, and intracluster correlation coefficient (ICC) 0.027, obtained from our previous study.
       <xref ref-type="bibr" rid="R8">
        8
       </xref>
       The design effect (deff) for this cluster randomisation trial was 1.65 (deff=1+(m−1)×ICC=1+(25−1)×0.027=1.65). As such, we aimed to recruit a sample size of 1600 participants from up to 15 hospitals.
      </p>
     </sec>
     <sec id="s2i">
      <title>
       Analysis
      </title>
      <p>
       Descriptive statistics were compared among intervention and control arms. Primary end points were analysed by intention to treat. We compared the event rates for the primary outcomes across study arms and calculated p values from cluster-adjusted χ
       <sup>
        2
       </sup>
       tests
       <xref ref-type="bibr" rid="R25">
        25
       </xref>
       and ICC.
       <xref ref-type="bibr" rid="R25">
        25
       </xref>
       <xref ref-type="bibr" rid="R26">
        26
       </xref>
       We also estimated relative risk (RR) after adjusting for clustering using a log-binomial model under generalised estimating equation (GEE) framework.
       <xref ref-type="bibr" rid="R27">
        27
       </xref>
       We checked for variables which were unequally distributed across arms, and conducted an adjusted analysis accordingly. We fitted a multivariable log-binomial model, using GEE to account for clustering by ward, to estimate RR after adjusting for potential confounders. In the initial model, we included all the variables that had p value less than 0.25 in the univariable analysis, along with the main exposure variable (randomisation arm). A backward elimination method was used to remove the variables that did not have any confounding effect.
      </p>
      <p>
       As most participants in the control arm used a mask during the trial period, we carried out a post-hoc analysis comparing all participants who used only a medical mask (from the control arm and the medical mask arm) with all participants who used only a cloth mask (from the control arm and the cloth arm). For this analysis, controls who used both types of mask (n=245) or used N95 respirators (n=3) or did not use any masks (n=2) were excluded. We fitted a multivariable log-binomial model, to estimate RR after adjusting for potential confounders. As we pooled data of participants from all three arms and analysed by mask type, not trial arm, we did not adjust for clustering here. All statistical analyses were conducted using STATA V.12.
       <xref ref-type="bibr" rid="R28">
        28
       </xref>
      </p>
      <p>
       Owing to a very high level of mask use in the control arm, we were unable to determine whether the differences between the medical and cloth mask arms were due to a protective effect of medical masks or a detrimental effect of cloth masks. To assist in interpreting the data, we compared rates of infection in the medical mask arm with rates observed in medical mask arms from two previous RCTs,
       <xref ref-type="bibr" rid="R8">
        8
       </xref>
       <xref ref-type="bibr" rid="R9">
        9
       </xref>
       in which no efficacy of medical masks could be demonstrated when compared with control or N95 respirators, recognising that seasonal and geographic variation in virus activity affects the rates of exposure (and hence rates of infection outcomes) among HCWs. This analysis was possible because the trial designs were similar and the same outcomes were measured in all three trials. The analysis was carried out to determine if the observed results were explained by a detrimental effect of cloth masks or a protective effect of medical masks.
      </p>
     </sec>
    </sec>
    <sec id="s3" sec-type="results">
     <title>
      Results
     </title>
     <p>
      A total of 1607 HCWs were recruited into the study. The participation rate was 86% (1607/1868). The average number of participants per ward was 23 and the mean age was 36 years. On average, HCWs were in contact with 36 patients per day during the trial period (range 0–661 patients per day, median 20 patients per day). The distribution of demographic variables was generally similar between arms (
      <xref ref-type="table" rid="BMJOPEN2014006577TB1">
       table 1
      </xref>
      ).
      <xref ref-type="fig" rid="BMJOPEN2014006577F2">
       Figure 2
      </xref>
      shows the primary outcomes for each of the trial arms. The rates of CRI, ILI and laboratory-confirmed virus infections were lowest in the medical mask arm, followed by the control arm, and highest in the cloth mask arm.
     </p>
     <table-wrap id="BMJOPEN2014006577TB1" orientation="portrait" position="float">
      <label>
       Table 1
      </label>
      <caption>
       <p>
        Demographic and other characteristics by arm of randomisation
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <colgroup span="1">
        <col align="left" span="1"/>
        <col align="left" span="1"/>
        <col align="left" span="1"/>
        <col align="left" span="1"/>
       </colgroup>
       <thead valign="bottom">
        <tr>
         <th align="left" colspan="1" rowspan="1">
          Variable
         </th>
         <th align="left" colspan="1" rowspan="1">
          Medical mask
          <break>
          </break>
          (% and 95% CI)
          <break>
          </break>
          (n=580)
         </th>
         <th align="left" colspan="1" rowspan="1">
          Cloth mask
          <break>
          </break>
          (% and 95% CI)
          <break>
          </break>
          (n=569)
         </th>
         <th align="left" colspan="1" rowspan="1">
          Control
          <break>
          </break>
          (% and 95% CI)
          <break>
          </break>
          (n=458)
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td colspan="1" rowspan="1">
          Gender (male)
         </td>
         <td colspan="1" rowspan="1">
          112/580
          <break>
          </break>
          19.3 (16.2 to 22.8)
         </td>
         <td colspan="1" rowspan="1">
          133/569
          <break>
          </break>
          23.4 (20.0 to 27.1)
         </td>
         <td colspan="1" rowspan="1">
          112/458
          <break>
          </break>
          24.5 (20.6 to 28.7)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Age (mean)
         </td>
         <td colspan="1" rowspan="1">
          36 (35.6 to 37.3)
         </td>
         <td colspan="1" rowspan="1">
          35 (34.6 to 36.3)
         </td>
         <td colspan="1" rowspan="1">
          36 (35.1 to 37.0)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Education (postgraduate)
         </td>
         <td colspan="1" rowspan="1">
          114/580
          <break>
          </break>
          19.7 (16.5 to 23.1)
         </td>
         <td colspan="1" rowspan="1">
          99/569
          <break>
          </break>
          17.4 (14.3 to 20.8)
         </td>
         <td colspan="1" rowspan="1">
          78/458
          <break>
          </break>
          17.0 (13.7 to 20.8)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Smoker (current/ex)
         </td>
         <td colspan="1" rowspan="1">
          78/580
          <break>
          </break>
          13.4 (10.8 to 16.5)
         </td>
         <td colspan="1" rowspan="1">
          79/569
          <break>
          </break>
          13.9 (11.1 to 17.0)
         </td>
         <td colspan="1" rowspan="1">
          66/458
          <break>
          </break>
          14.4 (11.3 to 18.0)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Pre-existing illness*
         </td>
         <td colspan="1" rowspan="1">
          66/580
          <break>
          </break>
          11.4 (9.0 to 14.2)
         </td>
         <td colspan="1" rowspan="1">
          70/569
          <break>
          </break>
          12.3 (9.8 to 15.3)
         </td>
         <td colspan="1" rowspan="1">
          47/458
          <break>
          </break>
          10.3 (7.8 to 13.4)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Influenza vaccination (yes)
         </td>
         <td colspan="1" rowspan="1">
          21/580
          <break>
          </break>
          3.6 (2.4 to 5.4)
         </td>
         <td colspan="1" rowspan="1">
          21/569
          <break>
          </break>
          3.7 (2.4 to 5.6)
         </td>
         <td colspan="1" rowspan="1">
          15/458
          <break>
          </break>
          3.3 (2.0 to 5.3)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Staff (doctors)
         </td>
         <td colspan="1" rowspan="1">
          176/580
          <break>
          </break>
          30.3 (26.6 to 34.3)
         </td>
         <td colspan="1" rowspan="1">
          165/569
          <break>
          </break>
          29.0 (25.3 to 32.9)
         </td>
         <td colspan="1" rowspan="1">
          134/458
          <break>
          </break>
          29.3 (25.1 to 33.7)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Number of hand washings per day (geometric mean)†
         </td>
         <td colspan="1" rowspan="1">
          14 (13.8 to 15.4)
         </td>
         <td colspan="1" rowspan="1">
          11 (10.9 to 11.9)
         </td>
         <td colspan="1" rowspan="1">
          12 (11.5 to 12.7)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Number of patients had contact with (median and range)‡
         </td>
         <td colspan="1" rowspan="1">
          21 (0 to 540)
         </td>
         <td colspan="1" rowspan="1">
          21 (0 to 661)
         </td>
         <td colspan="1" rowspan="1">
          18 (3 to 199)
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         *Includes asthma, immunocompromised and others.
        </p>
       </fn>
       <fn>
        <p>
         †‘Hand wash’ variable was created by taking average of the number of hand washes performed by a healthcare worker (HCW) over the trial period. The variable was log transformed for the multivariate analysis.
        </p>
       </fn>
       <fn>
        <p>
         ‡‘Number of patients had contact with’ variable was created by taking average of the number of patients in contact with a HCW over the trial period. Median and range is presented in the table.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <fig id="BMJOPEN2014006577F2" orientation="portrait" position="float">
      <label>
       Figure 2
      </label>
      <caption>
       <p>
        Outcomes in trial arms (CRI, clinical respiratory illness; ILI, influenza-like illness; Virus, laboratory-confirmed viruses).
       </p>
      </caption>
      <graphic xlink:href="bmjopen2014006577f02">
      </graphic>
     </fig>
     <p>
      <xref ref-type="table" rid="BMJOPEN2014006577TB2">
       Table 2
      </xref>
      shows the intention-to-treat analysis. The rate of CRI was highest in the cloth mask arm, followed by the control arm, and lowest in the medical mask arm. The same trend was seen for ILI and laboratory tests confirmed viral infections. In intention-to-treat analysis, ILI was significantly higher among HCWs in the cloth masks group (RR=13.25 and 95% CI 1.74 to 100.97), compared with the medical masks group. The rate of ILI was also significantly higher in the cloth masks arm (RR=3.49 and 95% CI 1.00 to 12.17), compared with the control arm. Other outcomes were not statistically significant between the three arms.
     </p>
     <table-wrap id="BMJOPEN2014006577TB2" orientation="portrait" position="float">
      <label>
       Table 2
      </label>
      <caption>
       <p>
        Intention-to-treat analysis
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <colgroup span="1">
        <col align="left" span="1"/>
        <col align="char" char="(" span="1"/>
        <col align="char" char="(" span="1"/>
        <col align="char" char="(" span="1"/>
        <col align="char" char="(" span="1"/>
        <col align="char" char="(" span="1"/>
        <col align="char" char="(" span="1"/>
       </colgroup>
       <thead valign="bottom">
        <tr>
         <th colspan="1" rowspan="1">
         </th>
         <th align="left" colspan="1" rowspan="1">
          CRI
          <break>
          </break>
          N (%)
         </th>
         <th align="left" colspan="1" rowspan="1">
          RR
          <break>
          </break>
          (95% CI)
         </th>
         <th align="left" colspan="1" rowspan="1">
          ILI
          <break>
          </break>
          N (%)
         </th>
         <th align="left" colspan="1" rowspan="1">
          RR
          <break>
          </break>
          (95% CI)
         </th>
         <th align="left" colspan="1" rowspan="1">
          Laboratory-
confirmed viruses N (%)
         </th>
         <th align="left" colspan="1" rowspan="1">
          RR
          <break>
          </break>
          (95% CI)
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td colspan="1" rowspan="1">
          Medical mask*
         </td>
         <td colspan="1" rowspan="1">
          28/580 (4.83)
         </td>
         <td align="left" colspan="1" rowspan="1">
          Ref
         </td>
         <td colspan="1" rowspan="1">
          1/580 (0.17)
         </td>
         <td align="left" colspan="1" rowspan="1">
          Ref
         </td>
         <td colspan="1" rowspan="1">
          19/580 (3.28)
         </td>
         <td align="left" colspan="1" rowspan="1">
          Ref
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Cloth masks†
         </td>
         <td colspan="1" rowspan="1">
          43/569 (7.56)
         </td>
         <td colspan="1" rowspan="1">
          1.57 (0.99 to 2.48)
         </td>
         <td colspan="1" rowspan="1">
          13/569 (2.28)
         </td>
         <td colspan="1" rowspan="1">
          <bold>
           13.25 (1.74 to 100.97
          </bold>
          <bold>
           )
          </bold>
         </td>
         <td colspan="1" rowspan="1">
          31/569 (5.45)
         </td>
         <td colspan="1" rowspan="1">
          1.66 (0.95 to 2.91)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Control‡
         </td>
         <td colspan="1" rowspan="1">
          32/458 (6.99)
         </td>
         <td colspan="1" rowspan="1">
          1.45 (0.88 to 2.37)
         </td>
         <td colspan="1" rowspan="1">
          3/458 (0.66)
         </td>
         <td colspan="1" rowspan="1">
          3.80 (0.40 to 36.40)
         </td>
         <td colspan="1" rowspan="1">
          18/458 (3.94)
         </td>
         <td colspan="1" rowspan="1">
          1.20 (0.64 to 2.26)
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         Bold typeface indicates statistically significant.
*p Value from cluster adjusted χ
         <sup>
          2
         </sup>
         tests is 0.510 and intracluster correlation coefficients is 0.065.
        </p>
       </fn>
       <fn>
        <p>
         †p Value from cluster adjusted χ
         <sup>
          2
         </sup>
         tests is 0.028 and intracluster correlation coefficients is 0.029.
        </p>
       </fn>
       <fn>
        <p>
         ‡p Value from cluster adjusted χ
         <sup>
          2
         </sup>
         tests is 0.561 and intracluster correlation coefficients is 0.068.
        </p>
       </fn>
       <fn>
        <p>
         CRI, clinical respiratory illness; ILI, influenza-like illness; RR, relative risk.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <p>
      Among the 68 laboratory-confirmed cases, 58 (85%) were due to rhinoviruses. Other viruses detected were hMPV (7 cases), influenza B (1 case), hMPV/rhinovirus co-infection (1 case) and influenza B/rhinovirus co-infection (1 case) (
      <xref ref-type="table" rid="BMJOPEN2014006577TB3">
       table 3
      </xref>
      ). No influenza A or RSV infections were detected.
     </p>
     <table-wrap id="BMJOPEN2014006577TB3" orientation="portrait" position="float">
      <label>
       Table 3
      </label>
      <caption>
       <p>
        Type of virus isolated
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <colgroup span="1">
        <col align="left" span="1"/>
        <col align="left" span="1"/>
        <col align="left" span="1"/>
        <col align="left" span="1"/>
        <col align="left" span="1"/>
        <col align="left" span="1"/>
        <col align="left" span="1"/>
       </colgroup>
       <thead valign="bottom">
        <tr>
         <th align="left" colspan="1" rowspan="1">
          Study arm
         </th>
         <th align="left" colspan="1" rowspan="1">
          hMPV
         </th>
         <th align="left" colspan="1" rowspan="1">
          Rhino
         </th>
         <th align="left" colspan="1" rowspan="1">
          Influenza B virus
         </th>
         <th align="left" colspan="1" rowspan="1">
          hMPV &amp; rhino
         </th>
         <th align="left" colspan="1" rowspan="1">
          Influenza B virus &amp; rhino
         </th>
         <th align="left" colspan="1" rowspan="1">
          Total
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td colspan="1" rowspan="1">
          Medical masks arm
         </td>
         <td colspan="1" rowspan="1">
          1
         </td>
         <td colspan="1" rowspan="1">
          16
         </td>
         <td colspan="1" rowspan="1">
          1
         </td>
         <td colspan="1" rowspan="1">
          1
         </td>
         <td colspan="1" rowspan="1">
          0
         </td>
         <td colspan="1" rowspan="1">
          19
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Cloth mask arm
         </td>
         <td colspan="1" rowspan="1">
          4
         </td>
         <td colspan="1" rowspan="1">
          26
         </td>
         <td colspan="1" rowspan="1">
          0
         </td>
         <td colspan="1" rowspan="1">
          0
         </td>
         <td colspan="1" rowspan="1">
          1
         </td>
         <td colspan="1" rowspan="1">
          31
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Control arm
         </td>
         <td colspan="1" rowspan="1">
          2
         </td>
         <td colspan="1" rowspan="1">
          16
         </td>
         <td colspan="1" rowspan="1">
          0
         </td>
         <td colspan="1" rowspan="1">
          0
         </td>
         <td colspan="1" rowspan="1">
          0
         </td>
         <td colspan="1" rowspan="1">
          18
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Total
         </td>
         <td colspan="1" rowspan="1">
          7
         </td>
         <td colspan="1" rowspan="1">
          58
         </td>
         <td colspan="1" rowspan="1">
          1
         </td>
         <td colspan="1" rowspan="1">
          1
         </td>
         <td colspan="1" rowspan="1">
          1
         </td>
         <td colspan="1" rowspan="1">
          68
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         hMPV, human metapneumovirus; Rhino, rhinoviruses.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <p>
      Compliance was significantly higher in the cloth mask arm (RR=2.41, 95% CI 2.01 to 2.88) and medical masks arm (RR=2.40, 95% CI 2.00 to 2.87), compared with the control arm.
      <xref ref-type="fig" rid="BMJOPEN2014006577F3">
       Figure 3
      </xref>
      shows the percentage of participants who were compliant in the three arms. A post-hoc analysis adjusted for compliance and other potential confounders showed that the rate of ILI was significantly higher in the cloth mask arm (RR=13.00, 95% CI 1.69 to 100.07), compared with the medical masks arm (
      <xref ref-type="table" rid="BMJOPEN2014006577TB4">
       table 4
      </xref>
      ). There was no significant difference between the medical mask and control arms. Hand washing was significantly protective against laboratory-confirmed viral infection (RR=0.66, 95% CI 0.44 to 0.97).
     </p>
     <table-wrap id="BMJOPEN2014006577TB4" orientation="portrait" position="float">
      <label>
       Table 4
      </label>
      <caption>
       <p>
        Multivariable cluster-adjusted log-binomial model to calculate RR for study outcomes
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <colgroup span="1">
        <col align="left" span="1"/>
        <col align="char" char="(" span="1"/>
        <col align="char" char="(" span="1"/>
        <col align="char" char="(" span="1"/>
       </colgroup>
       <thead valign="bottom">
        <tr>
         <th colspan="1" rowspan="1">
         </th>
         <th align="left" colspan="1" rowspan="1">
          CRI
          <break>
          </break>
          RR (95% CI)
         </th>
         <th align="left" colspan="1" rowspan="1">
          ILI
          <break>
          </break>
          RR (95% CI)
         </th>
         <th align="left" colspan="1" rowspan="1">
          Laboratory-confirmed viruses RR (95% CI)
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td colspan="1" rowspan="1">
          Medical masks arm
         </td>
         <td align="left" colspan="1" rowspan="1">
          Ref
         </td>
         <td align="left" colspan="1" rowspan="1">
          Ref
         </td>
         <td align="left" colspan="1" rowspan="1">
          Ref
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Cloth mask arm
         </td>
         <td colspan="1" rowspan="1">
          1.56 (0.97 to 2.48)
         </td>
         <td colspan="1" rowspan="1">
          <bold>
           13.00 (1.69 to 100.07)
          </bold>
         </td>
         <td colspan="1" rowspan="1">
          1.54 (0.88 to 2.70)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Control arm
         </td>
         <td colspan="1" rowspan="1">
          1.51 (0.90 to 2.52)
         </td>
         <td colspan="1" rowspan="1">
          4.64 (0.47 to 45.97)
         </td>
         <td colspan="1" rowspan="1">
          1.09 (0.57 to 2.09)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Male
         </td>
         <td colspan="1" rowspan="1">
          0.67 (0.41 to 1.12)
         </td>
         <td colspan="1" rowspan="1">
          1.03 (0.34 to 3.13)
         </td>
         <td colspan="1" rowspan="1">
          0.65 (0.34 to 1.22)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Vaccination
         </td>
         <td colspan="1" rowspan="1">
          0.83 (0.27 to 2.52)
         </td>
         <td colspan="1" rowspan="1">
          1.74 (0.24 to 12.56)
         </td>
         <td colspan="1" rowspan="1">
          1.27 (0.41 to 3.92)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Hand washing
         </td>
         <td colspan="1" rowspan="1">
          0.91 (0.66 to 1.26)
         </td>
         <td colspan="1" rowspan="1">
          0.94 (0.40 to 2.20)
         </td>
         <td colspan="1" rowspan="1">
          <bold>
           0.66 (0.44 to 0.97)
          </bold>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Compliance
         </td>
         <td colspan="1" rowspan="1">
          1.14 (0.77 to 1.69)
         </td>
         <td colspan="1" rowspan="1">
          1.86 (0.67 to 5.21)
         </td>
         <td colspan="1" rowspan="1">
          0.86 (0.53 to 1.40)
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         Bold typeface indicates statistically significant.
CRI, clinical respiratory illness; ILI, influenza-like illness; RR, relative risk.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <fig id="BMJOPEN2014006577F3" orientation="portrait" position="float">
      <label>
       Figure 3
      </label>
      <caption>
       <p>
        Compliance with the mask wearing—mask wearing more than 70% of working hours.
       </p>
      </caption>
      <graphic xlink:href="bmjopen2014006577f03">
      </graphic>
     </fig>
     <p>
      In the control arm, 170/458 (37%) used medical masks, 38/458 (8%) used cloth masks, and 245/458 (53%) used a combination of both medical and cloth masks during the study period. The remaining 1% either reported using a N95 respirator (n=3) or did not use any masks (n=2).
     </p>
     <p>
      <xref ref-type="table" rid="BMJOPEN2014006577TB5">
       Table 5
      </xref>
      shows an additional analysis comparing all participants who used only a medical mask (from the control arm and the medical mask arm) with all participants who used only a cloth mask (from the control arm and the cloth arm). In the univariate analysis, all outcomes were significantly higher in the cloth mask group, compared with the medical masks group. After adjusting for other factors, ILI (RR=6.64, 95% CI 1.45 to 28.65) and laboratory-confirmed virus (RR=1.72, 95% CI 1.01 to 2.94) remained significantly higher in the cloth masks group compared with the medical masks group.
     </p>
     <table-wrap id="BMJOPEN2014006577TB5" orientation="portrait" position="float">
      <label>
       Table 5
      </label>
      <caption>
       <p>
        Univariate and adjusted analysis comparing participants who used medical masks and cloth masks*
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <colgroup span="1">
        <col align="left" span="1"/>
        <col align="left" span="1"/>
        <col align="left" span="1"/>
       </colgroup>
       <thead valign="bottom">
        <tr>
         <th colspan="1" rowspan="1">
         </th>
         <th align="left" colspan="1" rowspan="1">
          Univariate
          <break>
          </break>
          RR (95% CI)
         </th>
         <th align="left" colspan="1" rowspan="1">
          Adjusted
          <break>
          </break>
          RR (95% CI)
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td colspan="3" rowspan="1">
          CRI
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Medical mask (35/750, 4.67%)
         </td>
         <td colspan="1" rowspan="1">
          Ref
         </td>
         <td colspan="1" rowspan="1">
          Ref
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Cloth mask (46/607, 7.58%)
         </td>
         <td colspan="1" rowspan="1">
          <bold>
           1.62 (1.06 to 2.49)
          </bold>
         </td>
         <td colspan="1" rowspan="1">
          1.51 (0.97 to 2.32)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Male
         </td>
         <td colspan="1" rowspan="1">
          0.60 (0.32 to 1.12)
         </td>
         <td colspan="1" rowspan="1">
          0.58 (0.31 to 1.08)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Vaccination
         </td>
         <td colspan="1" rowspan="1">
          0.66 (0.17 to 2.62)
         </td>
         <td colspan="1" rowspan="1">
          0.68 (0.17 to 2.67)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Hand washing
         </td>
         <td colspan="1" rowspan="1">
          0.81 (0.58 to 1.15)
         </td>
         <td colspan="1" rowspan="1">
          0.84 (0.59 to 1.20)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Compliance
         </td>
         <td colspan="1" rowspan="1">
          1.01 (1.00 to 1.03)
         </td>
         <td colspan="1" rowspan="1">
          1.01 (1.00 to 1.02)
         </td>
        </tr>
        <tr>
         <td colspan="3" rowspan="1">
          ILI
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Medical mask (2/750, 0.27%)
         </td>
         <td colspan="1" rowspan="1">
          Ref
         </td>
         <td colspan="1" rowspan="1">
          Ref
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Cloth mask (13/607, 2.14%)
         </td>
         <td colspan="1" rowspan="1">
          <bold>
           8.03 (1.82 to 35.45)
          </bold>
         </td>
         <td colspan="1" rowspan="1">
          <bold>
           6.64 (1.45 to 28.65)
          </bold>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Male
         </td>
         <td colspan="1" rowspan="1">
          0.95 (0.27 to 3.35)
         </td>
         <td colspan="1" rowspan="1">
          0.92 (0.26 to 3.22)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Vaccination
         </td>
         <td colspan="1" rowspan="1">
          1.87 (0.25 to 13.92)
         </td>
         <td colspan="1" rowspan="1">
          1.97 (0.27 to 14.45)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Hand washing
         </td>
         <td colspan="1" rowspan="1">
          0.56 (0.24 to 1.27)
         </td>
         <td colspan="1" rowspan="1">
          0.61 (0.23 to 1.57)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Compliance
         </td>
         <td colspan="1" rowspan="1">
          1.04 (1.01 to 1.08)
         </td>
         <td colspan="1" rowspan="1">
          1.04 (1.00 to 1.08)
         </td>
        </tr>
        <tr>
         <td colspan="3" rowspan="1">
          Laboratory-confirmed viruses
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Medical mask (22/750, 2.93%)
         </td>
         <td colspan="1" rowspan="1">
          Ref
         </td>
         <td colspan="1" rowspan="1">
          Ref
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Cloth mask (34/607, 5.60%)
         </td>
         <td colspan="1" rowspan="1">
          <bold>
           1.91 (1.13 to 3.23)
          </bold>
         </td>
         <td colspan="1" rowspan="1">
          <bold>
           1.72 (1.01 to 2.94)
          </bold>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Male
         </td>
         <td colspan="1" rowspan="1">
          0.64 (0.30 to 1.33)
         </td>
         <td colspan="1" rowspan="1">
          0.61 (0.29 to 1.27)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Vaccination
         </td>
         <td colspan="1" rowspan="1">
          0.97 (0.24 to 3.86)
         </td>
         <td colspan="1" rowspan="1">
          1.03 (0.26 to 4.08)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Hand washing
         </td>
         <td colspan="1" rowspan="1">
          0.61 (0.41 to 0.93)
         </td>
         <td colspan="1" rowspan="1">
          0.65 (0.42 to 1.00)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Compliance
         </td>
         <td colspan="1" rowspan="1">
          1.00 (0.99 to 1.02)
         </td>
         <td colspan="1" rowspan="1">
          1.0 (0.99 to 1.02)
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         Bold typeface indicates statistically significant.
*The majority (456/458) of HCWs in the control arm used a mask. Controls who exclusively used a medical mask were categorised and analysed with the medical mask arm participants; and controls who exclusively wore a cloth mask were categorised and analysed with the cloth mask arm.
        </p>
       </fn>
       <fn>
        <p>
         CRI, clinical respiratory illness; HCWs, healthcare workers; ILI, influenza-like illness; RR, relative risk.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <p>
      <xref ref-type="table" rid="BMJOPEN2014006577TB6">
       Table 6
      </xref>
      compares the outcomes in the medical mask arm with two previously published trials.
      <xref ref-type="bibr" rid="R8">
       8
      </xref>
      <xref ref-type="bibr" rid="R9">
       9
      </xref>
      This shows that while the rates of CRI were significantly higher in one of the previously published trials, the rates of laboratory-confirmed viruses were not significantly different between the three trials for medical mask use.
     </p>
     <table-wrap id="BMJOPEN2014006577TB6" orientation="portrait" position="float">
      <label>
       Table 6
      </label>
      <caption>
       <p>
        A comparison of outcome data for the medical mask arm with medical mask outcomes in previously published RCTs
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <colgroup span="1">
        <col align="left" span="1"/>
        <col align="char" char="(" span="1"/>
        <col align="char" char="." span="1"/>
        <col align="char" char="(" span="1"/>
        <col align="char" char="(" span="1"/>
        <col align="char" char="(" span="1"/>
        <col align="char" char="(" span="1"/>
       </colgroup>
       <thead valign="bottom">
        <tr>
         <th colspan="1" rowspan="1">
         </th>
         <th align="left" colspan="1" rowspan="1">
          CRI
          <break>
          </break>
          N (%)
         </th>
         <th align="left" colspan="1" rowspan="1">
          RR
          <break>
          </break>
          (95% CI)
         </th>
         <th align="left" colspan="1" rowspan="1">
          ILI
          <break>
          </break>
          N (%)
         </th>
         <th align="left" colspan="1" rowspan="1">
          RR
          <break>
          </break>
          (95% CI)
         </th>
         <th align="left" colspan="1" rowspan="1">
          Laboratory-
confirmed viruses
          <break>
          </break>
          N (%)
         </th>
         <th align="left" colspan="1" rowspan="1">
          RR
          <break>
          </break>
          (95% CI)
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td colspan="1" rowspan="1">
          Vietnam trial
         </td>
         <td colspan="1" rowspan="1">
          28/580 (4.83)
         </td>
         <td align="left" colspan="1" rowspan="1">
          Ref
         </td>
         <td colspan="1" rowspan="1">
          1/580 (0.17)
         </td>
         <td align="left" colspan="1" rowspan="1">
          Ref
         </td>
         <td colspan="1" rowspan="1">
          19/580 (3.28)
         </td>
         <td align="left" colspan="1" rowspan="1">
          Ref
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Published RCT China 1
          <xref ref-type="bibr" rid="R8">
           8
          </xref>
         </td>
         <td colspan="1" rowspan="1">
          33/492 (6.70)
         </td>
         <td colspan="1" rowspan="1">
          1.40 (0.85 to 2.26)
         </td>
         <td colspan="1" rowspan="1">
          3/492 (0.61)
         </td>
         <td colspan="1" rowspan="1">
          3.53 (0.37 to 33.89)
         </td>
         <td colspan="1" rowspan="1">
          13/492 (2.64)
         </td>
         <td colspan="1" rowspan="1">
          0.80 (0.40 to 1.62)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Published RCT China 2
          <xref ref-type="bibr" rid="R9">
           9
          </xref>
         </td>
         <td colspan="1" rowspan="1">
          98/572 (17.13)
         </td>
         <td colspan="1" rowspan="1">
          <bold>
           3.54 (2.37 to 5.31)
          </bold>
         </td>
         <td colspan="1" rowspan="1">
          4/572 (0.70)
         </td>
         <td colspan="1" rowspan="1">
          4.06 (0.45 to 36.18)
         </td>
         <td colspan="1" rowspan="1">
          19/572 (3.32)
         </td>
         <td colspan="1" rowspan="1">
          1.01 (0.54 to 1.89)
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         Bold typeface indicates statistically significant.
CRI, Clinical respiratory illness; ILI, influenza-like illness; RCT, randomised clinical trial; RR, relative risk.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <p>
      On average, HCWs worked for 25 days during the trial period and washed their cloth masks for 23/25 (92%) days. The most common approach to washing cloth masks was self-washing (456/569, 80%), followed by combined self-washing and hospital laundry (91/569, 16%), and only hospital laundry (22/569, 4%). Adverse events associated with facemask use were reported in 40.4% (227/562) of HCWs in the medical mask arm and 42.6% (242/568) in the cloth mask arm (p value 0.450). General discomfort (35.1%, 397/1130) and breathing problems (18.3%, 207/1130) were the most frequently reported adverse events.
     </p>
     <p>
      Laboratory tests showed the penetration of particles through the cloth masks to be very high (97%) compared with medical masks (44%) (used in trial) and 3M 9320 N95 (&lt;0.01%), 3M Vflex 9105 N95 (0.1%).
     </p>
    </sec>
    <sec id="s4" sec-type="discussion">
     <title>
      Discussion
     </title>
     <p>
      We have provided the first clinical efficacy data of cloth masks, which suggest HCWs should not use cloth masks as protection against respiratory infection. Cloth masks resulted in significantly higher rates of infection than medical masks, and also performed worse than the control arm. The controls were HCWs who observed standard practice, which involved mask use in the majority, albeit with lower compliance than in the intervention arms. The control HCWs also used medical masks more often than cloth masks. When we analysed all mask-wearers including controls, the higher risk of cloth masks was seen for laboratory-confirmed respiratory viral infection.
     </p>
     <p>
      The trend for all outcomes showed the lowest rates of infection in the medical mask group and the highest rates in the cloth mask arm. The study design does not allow us to determine whether medical masks had efficacy or whether cloth masks were detrimental to HCWs by causing an increase in infection risk. Either possibility, or a combination of both effects, could explain our results. It is also unknown whether the rates of infection observed in the cloth mask arm are the same or higher than in HCWs who do not wear a mask, as almost all participants in the control arm used a mask. The physical properties of a cloth mask, reuse, the frequency and effectiveness of cleaning, and increased moisture retention, may potentially increase the infection risk for HCWs. The virus may survive on the surface of the facemasks,
      <xref ref-type="bibr" rid="R29">
       29
      </xref>
      and modelling studies have quantified the contamination levels of masks.
      <xref ref-type="bibr" rid="R30">
       30
      </xref>
      Self-contamination through repeated use and improper doffing is possible. For example, a contaminated cloth mask may transfer pathogen from the mask to the bare hands of the wearer. We also showed that filtration was extremely poor (almost 0%) for the cloth masks. Observations during SARS suggested double-masking and other practices increased the risk of infection because of moisture, liquid diffusion and pathogen retention.
      <xref ref-type="bibr" rid="R31">
       31
      </xref>
      These effects may be associated with cloth masks.
     </p>
     <p>
      We have previously shown that N95 respirators provide superior efficacy to medical masks,
      <xref ref-type="bibr" rid="R8">
       8
      </xref>
      <xref ref-type="bibr" rid="R9">
       9
      </xref>
      but need to be worn continuously in high-risk settings to protect HCWs.
      <xref ref-type="bibr" rid="R9">
       9
      </xref>
      Although efficacy for medical masks was not shown, efficacy of a magnitude that was too small to be detected is possible.
      <xref ref-type="bibr" rid="R8">
       8
      </xref>
      <xref ref-type="bibr" rid="R9">
       9
      </xref>
      The magnitude of difference between cloth masks and medical masks in the current study, if explained by efficacy of medical masks alone, translates to an efficacy of 92% against ILI, which is possible, but not consistent with the lack of efficacy in the two previous RCTs.
      <xref ref-type="bibr" rid="R8">
       8
      </xref>
      <xref ref-type="bibr" rid="R9">
       9
      </xref>
      Further, we found no significant difference in rates of virus isolation in medical mask users between the three trials, suggesting that the results of this study could be interpreted as partly being explained by a detrimental effect of cloth masks. This is further supported by the fact that the rate of virus isolation in the no-mask control group in the first Chinese RCT was 3.1%, which was not significantly different to the rates of virus isolation in the medical mask arms in any of the three trials including this one. Unlike the previous RCTs, circulating influenza and RSV were almost completely absent during this study, with rhinoviruses comprising 85% of isolated pathogens, which means the measured efficacy is against a different range of circulating respiratory pathogens. Influenza and RSV predominantly transmit through droplet and contact routes, while Rhinovirus transmits through multiple routes, including airborne and droplet routes.
      <xref ref-type="bibr" rid="R32">
       32
      </xref>
      <xref ref-type="bibr" rid="R33">
       33
      </xref>
      The data also show that the clinical case definition of ILI is non-specific, and captures a range of pathogens other than influenza. The study suggests medical masks may be protective, but the magnitude of difference raises the possibility that cloth masks cause an increase in infection risk in HCWs. Further, the filtration of the medical mask used in this trial was poor, making extremely high efficacy of medical masks unlikely, particularly given the predominant pathogen was rhinovirus, which spreads by the airborne route. Given the obligations to HCW occupational health and safety, it is important to consider the potential risk of using cloth masks.
     </p>
     <p>
      In many parts of the world, cloth masks and medical masks may be the only options available for HCWs. Cloth masks have been used in West Africa during the Ebola outbreak in 2014, due to shortages of PPE, (personal communication, M Jalloh). The use of cloth masks is recommended by some health organisations, with caveats.
      <xref ref-type="bibr" rid="R34">
       34–36
      </xref>
      In light of our study, and the obligation to ensure occupational health and safety of HCWs, cloth masks should not be recommended for HCWs, particularly during AGPs and in high-risk settings such as emergency, infectious/respiratory disease and intensive care wards. Infection control guidelines need to acknowledge the widespread real-world practice of cloth masks and should comprehensively address their use. In addition, other important infection control measure such as hand hygiene should not be compromised. We confirmed the protective effects of hand hygiene against laboratory-confirmed viral infection in this study, but mask type was an independent predictor of clinical illness, even adjusted for hand hygiene.
     </p>
     <p>
      A limitation of this study is that we did not measure compliance with hand hygiene, and the results reflect self-reported compliance, which may be subject to recall or other types of bias. Another limitation of this study is the lack of a no-mask control group and the high use of masks in the controls, which makes interpretation of the results more difficult. In addition, the quality of paper and cloth masks varies widely around the world, so the results may not be generalisable to all settings. The lack of influenza and RSV (or asymptomatic infections) during the study is also a limitation, although the predominance of rhinovirus is informative about pathogens transmitted by the droplet and airborne routes in this setting. As in previous studies, exposure to infection outside the workplace could not be estimated, but we would assume it to be equally distributed between trial arms. The major strength of the randomised trial study design is in ensuring equal distribution of confounders and effect modifiers (such as exposure outside the workplace) between trial arms.
     </p>
     <p>
      Cloth masks are used in resource-poor settings because of the reduced cost of a reusable option. Various types of cloth masks (made of cotton, gauze and other fibres) have been tested in vitro in the past and show lower filtration capacity compared with disposable masks.
      <xref ref-type="bibr" rid="R7">
       7
      </xref>
      The protection afforded by gauze masks increases with the fineness of the cloth and the number of layers,
      <xref ref-type="bibr" rid="R37">
       37
      </xref>
      indicating potential to develop a more effective cloth mask, for example, with finer weave, more layers and a better fit.
     </p>
     <p>
      Cloth masks are generally retained long term and reused multiple times, with a variety of cleaning methods and widely different intervals of cleaning.
      <xref ref-type="bibr" rid="R34">
       34
      </xref>
      Further studies are required to determine if variations in frequency and type of cleaning affect the efficacy of cloth masks.
     </p>
     <p>
      Pandemics and emerging infections are more likely to arise in low-income or middle-income settings than in wealthy countries. In the interests of global public health, adequate attention should be paid to cloth mask use in such settings. The data from this study provide some reassurance about medical masks, and are the first data to show potential clinical efficacy of medical masks. Medical masks are used to provide protection against droplet spread, splash and spray of blood and body fluids. Medical masks or respirators are recommended by different organisations to prevent transmission of Ebola virus, yet shortages of PPE may result in HCWs being forced to use cloth masks.
      <xref ref-type="bibr" rid="R38">
       38–40
      </xref>
      In the interest of providing safe, low-cost options in low income countries, there is scope for research into more effectively designed cloth masks, but until such research is carried out, cloth masks should not be recommended. We also recommend that infection control guidelines be updated about cloth mask use to protect the occupational health and safety of HCWs.
     </p>
    </sec>
    <back>
     <ack>
      <p>
       The authors would like to thank the staff members from the National Institute of Hygiene and Epidemiology, Hanoi, Vietnam, who were involved with the trial. They thank as well to the staff from the Hanoi hospitals who participated. They also acknowledge the support of 3M for testing of filtration of the facemasks. 3M was industry partner in the ARC linkage project grant; however they were not involved in study design, data collection or analysis. The 3M products were not used in this study.
      </p>
     </ack>
     <fn-group>
      <fn>
       <p>
        <bold>
         Contributors:
        </bold>
        CRM was the lead investigator, and responsible for the conception and design of the trial, obtaining the grant funding, overseeing the whole study, analysing the data and writing of the report. HS contributed to overseeing the study, staff training, form/database development and drafting of the manuscript. TCD was responsible for overseeing the study, database management, recruitment, training and revision of the manuscript. NTH was responsible for the implementation of research and revision of the manuscript. PTN was responsible for the laboratory testing in Vietnam. AAC contributed to the statistical analysis and drafting of the manuscript. BR was responsible for the statistical analysis and revision of the manuscript. DED contributed to the laboratory technical assistance and revision of the manuscript. QW assisted in comparing the rates of infection from two previous RCTs conducted in China and revision of the manuscript.
       </p>
      </fn>
      <fn>
       <p>
        <bold>
         Funding:
        </bold>
        Funding to conduct this study was received from the Australian Research Council (ARC) (grant number LP0990749).
       </p>
      </fn>
      <fn>
       <p>
        <bold>
         Competing interests:
        </bold>
        CRM has held an Australian Research Council Linkage Grant with 3M as the industry partner, for investigator-driven research. 3M has also contributed masks and respirators for investigator-driven clinical trials. CRM has received research grants and laboratory testing as in-kind support from Pfizer, GSK and Bio-CSL for investigator-driven research. HS had a NHMRC Australian-based Public Health Training Fellowship at the time of the study (1012631). She has also received funding from vaccine manufacturers GSK, bio-CSL and Sanofi Pasteur for investigator-driven research and presentations. AAC used filtration testing of masks for his PhD thesis conducted by 3M Australia.
       </p>
      </fn>
      <fn>
       <p>
        <bold>
         Ethics approval:
        </bold>
        National Institute for Hygiene and Epidemiology (NIHE) (approval number 05 IRB) and the Human Research Ethics Committee of the University of New South Wales (UNSW), Australia, (HREC approval number 10306).
       </p>
      </fn>
      <fn>
       <p>
        <bold>
         Provenance and peer review:
        </bold>
        Not commissioned; externally peer reviewed.
       </p>
      </fn>
      <fn>
       <p>
        <bold>
         Data sharing statement:
        </bold>
        No additional data are available.
       </p>
      </fn>
     </fn-group>
     <ref-list>
      <title>
       References
      </title>
      <ref id="R1">
       <label>
        1
       </label>
       <mixed-citation publication-type="other">
        <collab>
         World Health Organization (WHO)
        </collab>
        .
        <comment>
         Global Alert and Response (GAR), Pandemic (H1N1) 2009—update 76 (cited 27 Apr 2012).
         <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/don/2009_11_27a/en/index.html">
          http://www.who.int/csr/don/2009_11_27a/en/index.html
         </ext-link>
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R2">
       <label>
        2
       </label>
       <mixed-citation publication-type="other">
        <collab>
         World Health Organization (WHO)
        </collab>
        .
        <article-title>
         Human infection with avian influenza A(H7N9) virus—update
        </article-title>
        (
        <comment>
         cited 8 May 2013).
         <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/don/2013_05_07/en/index.html">
          http://www.who.int/csr/don/2013_05_07/en/index.html
         </ext-link>
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R3">
       <label>
        3
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bermingham
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Chand
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           CS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2012
        </year>
        ;
        <volume>
         17
        </volume>
        :
        <fpage>
         20290
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         23078800
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R4">
       <label>
        4
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pollack
          </surname>
          <given-names>
           MP
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Pringle
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Madoff
          </surname>
          <given-names>
           LC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Latest outbreak news from ProMED-mail: novel coronavirus—Middle East
        </article-title>
        .
        <source>
         Int J Infect Dis
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         17
        </volume>
        :
        <fpage>
         e143
        </fpage>
        –
        <lpage>
         4
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.ijid.2012.12.001
        </pub-id>
        <pub-id pub-id-type="pmid">
         23270612
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R5">
       <label>
        5
       </label>
       <mixed-citation publication-type="other">
        <collab>
         World Health Organization (WHO)
        </collab>
        .
        <article-title>
         Global Alert and Response (GAR)
        </article-title>
        .
        <comment>
         Ebola virus disease update—west Africa 2014 (cited 28 Aug 2014).
         <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/don/2014_08_28_ebola/en/">
          http://www.who.int/csr/don/2014_08_28_ebola/en/
         </ext-link>
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R6">
       <label>
        6
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chughtai
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Seale
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <name>
          <surname>
           MacIntyre
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of cloth masks in the practice of infection control—evidence and policy gaps
        </article-title>
        .
        <source>
         Int J Infect Control
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         9
        </volume>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         12
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="R7">
       <label>
        7
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Quesnel
          </surname>
          <given-names>
           LB
          </given-names>
         </name>
        </person-group>
        <article-title>
         The efficiency of surgical masks of varying design and composition
        </article-title>
        .
        <source>
         Br J Surg
        </source>
        <year>
         1975
        </year>
        ;
        <volume>
         62
        </volume>
        :
        <fpage>
         936
        </fpage>
        –
        <lpage>
         40
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1002/bjs.1800621203
        </pub-id>
        <pub-id pub-id-type="pmid">
         1203649
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R8">
       <label>
        8
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           MacIntyre
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Cauchemez
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A cluster randomized clinical trial comparing fit-tested and non-fit-tested N95 respirators to medical masks to prevent respiratory virus infection in health care workers
        </article-title>
        .
        <source>
         Influenza Other Respir Viruses
        </source>
        <year>
         2011
        </year>
        ;
        <volume>
         5
        </volume>
        :
        <fpage>
         170
        </fpage>
        –
        <lpage>
         9
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1111/j.1750-2659.2011.00198.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         21477136
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R9">
       <label>
        9
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           MacIntyre
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Seale
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A randomised clinical trial of three options for N95 respirators and medical masks in health workers
        </article-title>
        .
        <source>
         Am J Respir Crit Care Med
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         187
        </volume>
        :
        <fpage>
         960
        </fpage>
        –
        <lpage>
         6
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1164/rccm.201207-1164OC
        </pub-id>
        <pub-id pub-id-type="pmid">
         23413265
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R10">
       <label>
        10
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chughtai
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         ,
         <name>
          <surname>
           MacIntyre
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Examining the policies and guidelines around the use of masks and respirators by healthcare workers in China, Pakistan and Vietnam
        </article-title>
        .
        <source>
         J Infect Prev
        </source>
        <comment>
         2015;16:68–74
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="R11">
       <label>
        11
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chughtai
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Seale
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Chi Dung
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Current practices and barriers to the use of facemasks and respirators among hospital-based health care workers in Vietnam
        </article-title>
        .
        <source>
         Am J Infect Control
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         43
        </volume>
        :
        <fpage>
         72
        </fpage>
        –
        <lpage>
         7
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.ajic.2014.10.009
        </pub-id>
        <pub-id pub-id-type="pmid">
         25564127
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R12">
       <label>
        12
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evaluation of control measures implemented in the severe acute respiratory syndrome outbreak in Beijing
        </article-title>
        .
        <source>
         JAMA
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         290
        </volume>
        :
        <fpage>
         3215
        </fpage>
        –
        <lpage>
         21
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1001/jama.290.24.3215
        </pub-id>
        <pub-id pub-id-type="pmid">
         14693874
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R13">
       <label>
        13
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Seale
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <name>
          <surname>
           MacIntyre
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Mask-wearing and respiratory infection in healthcare workers in Beijing, China
        </article-title>
        .
        <source>
         Braz J Infect Dis
        </source>
        <year>
         2011
        </year>
        ;
        <volume>
         15
        </volume>
        :
        <fpage>
         102
        </fpage>
        –
        <lpage>
         8
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/S1413-8670(11)70153-2
        </pub-id>
        <pub-id pub-id-type="pmid">
         21503394
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R14">
       <label>
        14
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Horton
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Medical journals: evidence of bias against the diseases of poverty
        </article-title>
        .
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         361
        </volume>
        :
        <fpage>
         712
        </fpage>
        –
        <lpage>
         13
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(03)12665-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         12620731
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R15">
       <label>
        15
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           MacIntyre
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Chughtai
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Facemasks for the prevention of infection in healthcare and community settings
        </article-title>
        .
        <source>
         BMJ
        </source>
        <year>
         2015
        </year>
        ;
        <comment>
         350:h694.
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R16">
       <label>
        16
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chughtai
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Seale
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <name>
          <surname>
           MacIntyre
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Availability, consistency and evidence-base of policies and guidelines on the use of mask and respirator to protect hospital health care workers: a global analysis
        </article-title>
        .
        <source>
         BMC Res Notes
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         9
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1186/1756-0500-6-216
        </pub-id>
        <pub-id pub-id-type="pmid">
         23281703
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R17">
       <label>
        17
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           MacIntyre
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Cauchemez
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Dwyer
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Face mask use and control of respiratory virus transmission in households
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         15
        </volume>
        :
        <fpage>
         233
        </fpage>
        –
        <lpage>
         41
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.3201/eid1502.081166
        </pub-id>
        <pub-id pub-id-type="pmid">
         19193267
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R18">
       <label>
        18
       </label>
       <element-citation publication-type="other">
        <collab>
         Buecher C, Mardy S, Wang W,
         <italic>
          et al
         </italic>
         . Use of a multiplex PCR/RT-PCR approach to assess the viral causes of influenza-like illnesses in Cambodia during three consecutive dry seasons.
         <italic>
          J Med Virol
         </italic>
         2010;82:1762-72 [Epub ahead of print 1 Sep 2010].
        </collab>
       </element-citation>
      </ref>
      <ref id="R19">
       <label>
        19
       </label>
       <mixed-citation publication-type="journal">
        <comment>
         Higuchi R, Fockler C, Dollinger G,
         <italic>
          et al
         </italic>
         . Kinetic PCR analysis: real-time monitoring of DNA amplification reactions.
         <italic>
          Biotechnology
         </italic>
         (
         <italic>
          N Y
         </italic>
         ) 1993;11:1026–30 [Epub ahead of print 1 Sep 2010].
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R20">
       <label>
        20
       </label>
       <mixed-citation publication-type="journal">
        <comment>
         Hummel KB, Lowe L, Bellini WJ,
         <italic>
          et al
         </italic>
         . Development of quantitative gene-specific real-time RT-PCR assays for the detection of measles virus in clinical specimens.
         <italic>
          J Virol Methods
         </italic>
         2006;132:166–73 [Epub ahead of print 11 Sep 2005].
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R21">
       <label>
        21
       </label>
       <mixed-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mackay
          </surname>
          <given-names>
           IM
          </given-names>
         </name>
        </person-group>
        <source>
         Real-time PCR in microbiology
        </source>
        .
        <comment>
         Caister Academic Press, 2007
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="R22">
       <label>
        22
       </label>
       <mixed-citation publication-type="journal">
        <comment>
         Wang W, Cavailler P, Ren P,
         <italic>
          et al.
         </italic>
         Molecular monitoring of causative viruses in child acute respiratory infection in endemo-epidemic situations in Shanghai.
         <italic>
          J Clin Virol
         </italic>
         (PASCV) 2010;49:211–8.
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R23">
       <label>
        23
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Thi
          </surname>
          <given-names>
           TN
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Deback
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Malet
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Rapid determination of antiviral drug susceptibility of herpes simplex virus types 1 and 2 by real-time PCR
        </article-title>
        .
        <source>
         Antiviral Res
        </source>
        <year>
         2006
        </year>
        ;
        <volume>
         69
        </volume>
        :
        <fpage>
         152
        </fpage>
        –
        <lpage>
         7
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2005.11.004
        </pub-id>
        <pub-id pub-id-type="pmid">
         16388859
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R24">
       <label>
        24
       </label>
       <mixed-citation publication-type="other">
        <collab>
         Standards Australia Limited/Standards New Zealand
        </collab>
        .
        <comment>
         Respiratory protective devices. Australian/New Zealand Standard. AS/NZS 1716:
        </comment>
        <year>
         2012
        </year>
        .
       </mixed-citation>
      </ref>
      <ref id="R25">
       <label>
        25
       </label>
       <mixed-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Donner
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Klar
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <source>
         Design and analysis of cluster randomization trials in health research
        </source>
        .
        <publisher-loc>
         London
        </publisher-loc>
        :
        <publisher-name>
         Oxford University Press Inc
        </publisher-name>
        ,
        <year>
         2000
        </year>
        .
       </mixed-citation>
      </ref>
      <ref id="R26">
       <label>
        26
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Campbell
          </surname>
          <given-names>
           MK
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Elbourne
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Altman
          </surname>
          <given-names>
           DG
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         CONSORT statement: extension to cluster randomised trials
        </article-title>
        .
        <source>
         BMJ
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         328
        </volume>
        :
        <fpage>
         702
        </fpage>
        –
        <lpage>
         8
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15031246
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R27">
       <label>
        27
       </label>
       <mixed-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vittinghoff
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Glidden
          </surname>
          <given-names>
           DV
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Shiboski
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <source>
         Regression methods in biostatistics
        </source>
        .
        <edition>
         2nd edn
        </edition>
        <comment>
         New York: Springer-Verlag, 2012
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="R28">
       <label>
        28
       </label>
       <mixed-citation publication-type="book">
        <collab>
         StataCorp
        </collab>
        .
        <source>
         Stata 12 base reference manual
        </source>
        .
        <publisher-loc>
         College Station, TX
        </publisher-loc>
        :
        <publisher-name>
         Stata Press
        </publisher-name>
        ,
        <year>
         2011
        </year>
        .
       </mixed-citation>
      </ref>
      <ref id="R29">
       <label>
        29
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Osterholm
          </surname>
          <given-names>
           MT
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Kelley
          </surname>
          <given-names>
           NS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Transmission of Ebola viruses: what we know and what we do not know
        </article-title>
        .
        <source>
         mBio
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <fpage>
         e00137
        </fpage>
        –
        <lpage>
         15
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/mBio.00137-15
        </pub-id>
        <pub-id pub-id-type="pmid">
         25698835
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R30">
       <label>
        30
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fisher
          </surname>
          <given-names>
           EM
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Noti
          </surname>
          <given-names>
           JD
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Lindsley
          </surname>
          <given-names>
           WG
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Validation and application of models to predict facemask influenza contamination in healthcare settings
        </article-title>
        .
        <source>
         Risk Anal
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         34
        </volume>
        :
        <fpage>
         1423
        </fpage>
        –
        <lpage>
         34
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1111/risa.12185
        </pub-id>
        <pub-id pub-id-type="pmid">
         24593662
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R31">
       <label>
        31
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Chung
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         In vivo protective performance of N95 respirator and surgical facemask
        </article-title>
        .
        <source>
         Am J Ind Med
        </source>
        <year>
         2006
        </year>
        ;
        <volume>
         49
        </volume>
        :
        <fpage>
         1056
        </fpage>
        –
        <lpage>
         65
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1002/ajim.20395
        </pub-id>
        <pub-id pub-id-type="pmid">
         17096360
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R32">
       <label>
        32
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dick
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Jennings
          </surname>
          <given-names>
           LC
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Mink
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Aerosol transmission of rhinovirus colds
        </article-title>
        .
        <source>
         J Infect Dis
        </source>
        <year>
         1987
        </year>
        ;
        <volume>
         156
        </volume>
        :
        <fpage>
         442
        </fpage>
        –
        <lpage>
         8
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1093/infdis/156.3.442
        </pub-id>
        <pub-id pub-id-type="pmid">
         3039011
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R33">
       <label>
        33
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bischoff
          </surname>
          <given-names>
           WE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transmission route of rhinovirus type 39 in a monodispersed airborne aerosol
        </article-title>
        .
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <year>
         2010
        </year>
        ;
        <volume>
         31
        </volume>
        :
        <fpage>
         857
        </fpage>
        –
        <lpage>
         9
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1086/655022
        </pub-id>
        <pub-id pub-id-type="pmid">
         20569111
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R34">
       <label>
        34
       </label>
       <mixed-citation publication-type="other">
        <collab>
         Institute of Medicine (IOM)
        </collab>
        .
        <comment>
         Reusability of Facemasks During an Influenza Pandemic: Facing the Flu—Committee on the Development of Reusable Facemasks for Use During an Influenza Pandemic. National Academy of Sciences
        </comment>
        ,
        <year>
         2006
        </year>
        .
       </mixed-citation>
      </ref>
      <ref id="R35">
       <label>
        35
       </label>
       <mixed-citation publication-type="book">
        <collab>
         Center for Disease Control and Prevention and World Health Organization
        </collab>
        .
        <source>
         Infection control for viral haemorrhagic fevers in the African health care setting
        </source>
        .
        <publisher-loc>
         Atlanta
        </publisher-loc>
        :
        <publisher-name>
         Centers for Disease Control and Prevention
        </publisher-name>
        ,
        <year>
         1998
        </year>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         198
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="R36">
       <label>
        36
       </label>
       <mixed-citation publication-type="other">
        <collab>
         World Health Organization (WHO)
        </collab>
        .
        <comment>
         Guidelines for the prevention of tuberculosis in health care facilities in resource limited settings
        </comment>
        ,
        <year>
         1999
        </year>
        .
       </mixed-citation>
      </ref>
      <ref id="R37">
       <label>
        37
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weaver
          </surname>
          <given-names>
           GH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Droplet infection and its prevention by the face mask
        </article-title>
        .
        <source>
         J Infect Dis
        </source>
        <year>
         1919
        </year>
        ;
        <volume>
         24
        </volume>
        :
        <fpage>
         218
        </fpage>
        –
        <lpage>
         30
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1093/infdis/24.3.218
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R38">
       <label>
        38
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           MacIntyre
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Chughtai
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         ,
         <name>
          <surname>
           Seale
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Respiratory protection for healthcare workers treating Ebola virus disease (EVD): are facemasks sufficient to meet occupational health and safety obligations?
        </article-title>
        <source>
         Int J Nurs Stud
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         51
        </volume>
        :
        <fpage>
         1421
        </fpage>
        –
        <lpage>
         6
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.ijnurstu.2014.09.002
        </pub-id>
        <pub-id pub-id-type="pmid">
         25218265
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R39">
       <label>
        39
       </label>
       <mixed-citation publication-type="other">
        <collab>
         Center for Disease Control and Prevention (CDC)
        </collab>
        .
        <comment>
         Guidance on Personal Protective Equipment To Be Used by Healthcare Workers During Management of Patients with Ebola Virus Disease in U.S. Hospitals, Including Procedures for Putting On (Donning) and Removing (Doffing). 2014 (cited 23 Oct 2014).
         <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/vhf/ebola/hcp/procedures-for-ppe.html">
          http://www.cdc.gov/vhf/ebola/hcp/procedures-for-ppe.html
         </ext-link>
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R40">
       <label>
        40
       </label>
       <mixed-citation publication-type="other">
        <collab>
         World Health Organiszation (WHO)
        </collab>
        .
        <comment>
         Infection prevention and control guidance for care of patients in health-care settings, with focus on Ebola. 2014 (cited 23 Oct 2014).
         <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/resources/publications/ebola/filovirus_infection_control/en/">
          http://www.who.int/csr/resources/publications/ebola/filovirus_infection_control/en/
         </ext-link>
        </comment>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Clin Infect Dis
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Clin. Infect. Dis
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       cid
      </journal-id>
      <journal-title-group>
       <journal-title>
        Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1058-4838
      </issn>
      <issn pub-type="epub">
       1537-6591
      </issn>
      <publisher>
       <publisher-name>
        Oxford University Press
       </publisher-name>
       <publisher-loc>
        US
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       29140516
      </article-id>
      <article-id pub-id-type="pmc">
       7108111
      </article-id>
      <article-id pub-id-type="doi">
       10.1093/cid/cix681
      </article-id>
      <article-id pub-id-type="publisher-id">
       cix681
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Review Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Effectiveness of Masks and Respirators Against Respiratory Infections in Healthcare Workers: A Systematic Review and Meta-Analysis
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Offeddu
         </surname>
         <given-names>
          Vittoria
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0001">
         1
        </xref>
        <xref ref-type="corresp" rid="c1">
        </xref>
        <!--<email>vittoria.offeddu@nus.edu.sg</email>-->
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yung
         </surname>
         <given-names>
          Chee Fu
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0002">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Low
         </surname>
         <given-names>
          Mabel Sheau Fong
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0001">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Tam
         </surname>
         <given-names>
          Clarence C
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0001">
         1
        </xref>
        <xref ref-type="aff" rid="AF0003">
         3
        </xref>
       </contrib>
      </contrib-group>
      <aff id="AF0001">
       <label>
        1
       </label>
       <institution>
        Saw Swee Hock School of Public Health, National University of Singapore
       </institution>
      </aff>
      <aff id="AF0002">
       <label>
        2
       </label>
       <institution>
        Infectious Disease Service, Department of Paediatrics, KK Women’s and Children’s Hospital
       </institution>
       ,
       <country>
        Singapore
       </country>
      </aff>
      <aff id="AF0003">
       <label>
        3
       </label>
       <institution>
        London School of Hygiene &amp; Tropical Medicine
       </institution>
       ,
       <addr-line>
        London
       </addr-line>
       ,
       <country>
        United Kingdom
       </country>
      </aff>
      <author-notes>
       <corresp id="c1">
        Correspondence: V. Offeddu, Postdoctoral Fellow, Saw Swee Hock School of Public Health, National University of Singapore Tahir Foundation Bldg, 12 Science Dr 2, No. 10-01, Singapore 117549 (
        <email>
         vittoria.offeddu@nus.edu.sg
        </email>
        ).
       </corresp>
      </author-notes>
      <pub-date pub-type="ppub">
       <day>
        01
       </day>
       <month>
        12
       </month>
       <year>
        2017
       </year>
      </pub-date>
      <pub-date iso-8601-date="2017-08-07" pub-type="epub">
       <day>
        07
       </day>
       <month>
        8
       </month>
       <year>
        2017
       </year>
      </pub-date>
      <volume>
       65
      </volume>
      <issue>
       11
      </issue>
      <fpage>
       1934
      </fpage>
      <lpage>
       1942
      </lpage>
      <history>
       <date date-type="received">
        <day>
         28
        </day>
        <month>
         4
        </month>
        <year>
         2017
        </year>
       </date>
       <date date-type="accepted">
        <day>
         29
        </day>
        <month>
         7
        </month>
        <year>
         2017
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
       </copyright-statement>
       <copyright-year>
        2017
       </copyright-year>
       <license>
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
        </license-p>
       </license>
      </permissions>
      <self-uri xlink:href="cix681.pdf">
      </self-uri>
      <abstract abstract-type="teaser">
       <p>
        In this systematic review and meta-analysis, we found evidence for a protective effect of facemasks and respirators against clinical respiratory infection among healthcare workers, and limited evidence for superiority of respirators. However, the existing evidence is sparse and findings inconsistent.
       </p>
      </abstract>
      <abstract>
       <title>
        Abstract
       </title>
       <p>
        This systematic review and meta-analysis quantified the protective effect of facemasks and respirators against respiratory infections among healthcare workers. Relevant articles were retrieved from Pubmed, EMBASE, and Web of Science. Meta-analyses were conducted to calculate pooled estimates. Meta-analysis of randomized controlled trials (RCTs) indicated a protective effect of masks and respirators against clinical respiratory illness (CRI) (risk ratio [RR] = 0.59; 95% confidence interval [CI]:0.46–0.77) and influenza-like illness (ILI) (RR = 0.34; 95% CI:0.14–0.82). Compared to masks, N95 respirators conferred superior protection against CRI (RR = 0.47; 95% CI: 0.36–0.62) and laboratory-confirmed bacterial (RR = 0.46; 95% CI: 0.34–0.62), but not viral infections or ILI. Meta-analysis of observational studies provided evidence of a protective effect of masks (OR = 0.13; 95% CI: 0.03–0.62) and respirators (OR = 0.12; 95% CI: 0.06–0.26) against severe acute respiratory syndrome (SARS). This systematic review and meta-analysis supports the use of respiratory protection. However, the existing evidence is sparse and findings are inconsistent within and across studies. Multicentre RCTs with standardized protocols conducted outside epidemic periods would help to clarify the circumstances under which the use of masks or respirators is most warranted.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        Facemasks
       </kwd>
       <kwd>
        N95 respirators
       </kwd>
       <kwd>
        respiratory infections
       </kwd>
       <kwd>
        severe acute respiratory syndrome (SARS)
       </kwd>
       <kwd>
        influenza
       </kwd>
      </kwd-group>
      <counts>
       <page-count count="9">
       </page-count>
      </counts>
     </article-meta>
    </front>
    <p>
     The emergence of novel respiratory pathogens, such as severe acute respiratory syndrome (SARS)–Coronavirus (SARS-CoV) [
     <xref ref-type="bibr" rid="CIT0001">
      1
     </xref>
     ] and pandemic H1N1 influenza (pH1N1) [
     <xref ref-type="bibr" rid="CIT0002">
      2
     </xref>
     ] highlighted the vulnerability of healthcare workers (HCWs) to respiratory infections [
     <xref ref-type="bibr" rid="CIT0003">
      3
     </xref>
     ]. Nonpharmaceutical interventions, such as respiratory personal protective equipment (rPPE), are particularly important to decrease the occupational risk of respiratory infection when vaccination or specific anti-infective treatments are unavailable [
     <xref ref-type="bibr" rid="CIT0004">
      4
     </xref>
     ].
    </p>
    <p>
     Medical masks [
     <xref ref-type="bibr" rid="CIT0005">
      5
     </xref>
     ] can help to protect users from large respiratory droplets [
     <xref ref-type="bibr" rid="CIT0006">
      6
     </xref>
     ,
     <xref ref-type="bibr" rid="CIT0007">
      7
     </xref>
     ]. They vary in thickness and permeability and are not certified to protect users from airborne infection [
     <xref ref-type="bibr" rid="CIT0006">
      6
     </xref>
     ]. N95 respirators are specifically designed to protect users from small airborne particles, including aerosols [
     <xref ref-type="bibr" rid="CIT0006">
      6
     </xref>
     ,
     <xref ref-type="bibr" rid="CIT0007">
      7
     </xref>
     ]. Strict regulations dictate the filtration efficiency and breathing resistance of N95 respirators, which also require fit-testing to ensure a tight seal around the user’s face [
     <xref ref-type="bibr" rid="CIT0007">
      7
     </xref>
     ].
    </p>
    <p>
     Current guidelines on rPPE use in healthcare settings are based on limited evidence of their effectiveness [
     <xref ref-type="bibr" rid="CIT0004">
      4
     </xref>
     ]. Studies to investigate the efficacy of rPPE are challenging, because of difficulties ensuring users’ compliance and limited statistical power to evaluate effectiveness against low-incidence outcomes [
     <xref ref-type="bibr" rid="CIT0008">
      8
     </xref>
     ]. Thus, results are often incongruent, leading to inconsistent international guidelines [
     <xref ref-type="bibr" rid="CIT0008">
      8
     </xref>
     ,
     <xref ref-type="bibr" rid="CIT0009">
      9
     </xref>
     ] and conflicting practice recommendations [
     <xref ref-type="bibr" rid="CIT0010">
      10
     </xref>
     ,
     <xref ref-type="bibr" rid="CIT0011">
      11
     </xref>
     ].
    </p>
    <p>
     Previous reviews discussed the performance of rPPE in community and healthcare settings, but did not quantify their protective effect [
     <xref ref-type="bibr" rid="CIT0008">
      8
     </xref>
     ,
     <xref ref-type="bibr" rid="CIT0012">
      12
     </xref>
     ]. One recent meta-analysis compared the effectiveness of N95 respirators and medical masks but did not compare their effectiveness against a “no mask” control [
     <xref ref-type="bibr" rid="CIT0013">
      13
     </xref>
     ]. This information is critical to assess the utility of universal mask use policies relative to targeted rPPE use during high-risk procedures, because universal policies have significant disadvantages in terms of personal discomfort and quality of care.
    </p>
    <p>
     Additionally, the superiority of N95 respirators over medical masks may have limited practical relevance in low-resource settings, where N95 respirators may be unaffordable and resources for respirator fit-testing, regulation, and certification unavailable [
     <xref ref-type="bibr" rid="CIT0009">
      9
     </xref>
     ]. Finally, no reviews have quantified the effectiveness of rPPE against different pathogens, although their effectiveness may differ against viral and bacterial agents or pathogens with potentially different transmission modes [
     <xref ref-type="bibr" rid="CIT0014">
      14
     </xref>
     ,
     <xref ref-type="bibr" rid="CIT0015">
      15
     </xref>
     ].
    </p>
    <p>
     We conducted a systematic review and meta-analysis to quantify the effectiveness of different rPPE in reducing the risk of clinical and laboratory-confirmed respiratory outcomes among HCWs. In addition, we compared the protective effect of masks and respirators against bacterial and viral infections separately and evaluated the frequency of mask use as a potentially contributing factor. The main goal of this review was to develop evidence-based recommendations to reduce the occupational risk of respiratory infection among medical personnel.
    </p>
    <sec id="s1" sec-type="methods">
     <title>
      METHODS
     </title>
     <p>
      We conducted this systematic review and meta-analysis using a prespecified protocol (Appendix C).
     </p>
     <sec id="s2">
      <title>
       Search Strategy
      </title>
      <p>
       We searched Pubmed, Web of Science, and EMBASE databases without language or time restrictions for articles satisfying the following criteria:
      </p>
      <sec id="s3">
       <title>
        Inclusion
       </title>
       <p>
        <italic>
         Study design
        </italic>
        : Published, peer-reviewed randomized control trials (RCTs) and observational studies;
       </p>
       <p>
        <italic>
         Population
        </italic>
        : HCWs;
       </p>
       <p>
        <italic>
         Intervention
        </italic>
        : Any type of rPPE;
       </p>
       <p>
        <italic>
         Outcome
        </italic>
        : Effectiveness of rPPE in reducing the risk of clinical or laboratory-confirmed respiratory outcomes;
       </p>
       <p>
        <italic>
         Settings
        </italic>
        : Healthcare settings worldwide.
       </p>
      </sec>
      <sec id="s4">
       <title>
        Exclusion
       </title>
       <p>
        Editorials, reviews, guidelines, public press articles; theoretical models.
       </p>
       <p>
        A detailed description of the search strategy is provided in Appendix B (Tables S1 and S2). We conducted the literature search on November 3rd, 2015. Two authors independently selected the studies and consulted a third author in case of disagreement.
       </p>
      </sec>
     </sec>
     <sec id="s5">
      <title>
       Data Extraction and Quality Assessment
      </title>
      <p>
       We extracted the following data from all included studies (Appendix B, Tables S3–S12): author, publication year, journal, and location; details of study population and interventions; study design and methods, including randomization procedures (RCTs) and statistical analysis; results, conclusions, and limitations.
      </p>
      <p>
       We used the Cochrane Risk of Bias tool [
       <xref ref-type="bibr" rid="CIT0016">
        16
       </xref>
       ] and Review Manager 5.3 to assess the risk of bias within and across RCTs. Adapted Newcastle-Ottawa scales were used to assess the risk of bias in case-control, cohort [
       <xref ref-type="bibr" rid="CIT0017">
        17
       </xref>
       ], and cross-sectional studies [
       <xref ref-type="bibr" rid="CIT0018">
        18
       </xref>
       ]. Two authors (V. O. and M. S. F. L.) independently assessed study quality and consulted a third author (CCT) in case of disagreement.
      </p>
     </sec>
     <sec id="s6">
      <title>
       Meta-Analysis
      </title>
      <p>
       We performed separate meta-analyses of (i) RCTs and (ii) observational studies conducted during the 2003 SARS pandemic (Appendix B, Table 1). We combined studies in different meta-analyses according to type of rPPE and outcomes assessed (Appendix B, Table 1).
      </p>
      <p>
       We summarized effect sizes and pooled estimates using forest plots and assessed publication bias using funnel plots and the Harbord test for funnel plot asymmetry.
      </p>
      <p>
       We used the odds ratio (OR) as the effect measure for observational studies. This was possible because all identified cohort studies had fixed follow-up times. However, ORs may not approximate risk ratios (RRs) in high-incidence settings such as hospital outbreaks and could give misleading information about the actual protective effect of rPPE [
       <xref ref-type="bibr" rid="CIT0019">
        19
       </xref>
       ]. We therefore calculated a range of plausible RRs for each summary OR using the formula
       <italic>
        RR
       </italic>
       =
       <italic>
        OR/(1-r
       </italic>
       <sub>
        <italic>
         b
        </italic>
       </sub>
       +
       <italic>
        (r
       </italic>
       <sub>
        <italic>
         b
        </italic>
       </sub>
       <italic>
        *OR
       </italic>
       )), where
       <italic>
        r
       </italic>
       <sub>
        <italic>
         b
        </italic>
       </sub>
       is the baseline risk of infection. We assumed baseline risks of SARS infection between 20% and 60%, estimated from the available cohort studies [
       <xref ref-type="bibr" rid="CIT0020">
        20–22
       </xref>
       ]. To allow comparability between studies, we conducted meta-analyses with unadjusted statistics.
      </p>
      <p>
       We assessed between-study heterogeneity using the
       <italic>
        I
       </italic>
       <sup>
        <italic>
         2
        </italic>
       </sup>
       statistic and used a random-effects model for
       <italic>
        I
       </italic>
       <sup>
        <italic>
         2
        </italic>
       </sup>
       &gt; 60% and heterogeneity
       <italic>
        P
       </italic>
       -value &lt; .05. Because of the small number of studies available for each meta-analysis, we did not conduct meta-regression to investigate factors affecting heterogeneity. Statistical analyses were performed with Stata version 12 (Stata Corporation).
      </p>
     </sec>
    </sec>
    <sec id="s7">
     <title>
      RESULTS
     </title>
     <p>
      We retrieved 2333 unique articles from the three databases and 31 potentially relevant publications from reference lists (
      <xref ref-type="fig" rid="F1">
       Figure 1
      </xref>
      ). Of 334 full-text articles assessed for eligibility, 305 did not meet our exclusion criteria. Ultimately, we included 6 RCTs (Table S3) and 23 observational studies (Tables S4–S12). We found no evidence of publication bias (Figure S2).
     </p>
     <fig fig-type="figure" id="F1" orientation="portrait" position="float">
      <label>
       Figure 1.
      </label>
      <caption>
       <p>
        Summary of the literature search and inclusion process.
       </p>
      </caption>
      <graphic xlink:href="cix68101">
      </graphic>
     </fig>
     <sec id="s8">
      <title>
       Randomized Controlled Trials
      </title>
      <p>
       We combined 5 RCTs [
       <xref ref-type="bibr" rid="CIT0023">
        23–27
       </xref>
       ] in different meta-analyses according to type of rPPE and outcomes assessed (Appendix B, Table 1). We excluded one study [
       <xref ref-type="bibr" rid="CIT0028">
        28
       </xref>
       ] with high risk of bias (Figure S1).
      </p>
      <sec id="s9">
       <title>
        Continuous Respiratory Personal Protective Equipment Use vs No Respiratory Personal Protective Equipment
       </title>
       <p>
        Two RCTs compared respiratory infection risk in HCWs wearing rPPE continuously to convenience-selected controls wearing no rPPE [
        <xref ref-type="bibr" rid="CIT0024">
         24
        </xref>
        ] or following routine care [
        <xref ref-type="bibr" rid="CIT0023">
         23
        </xref>
        ]. Wearing a medical mask or N95 respirator throughout the work shift conferred significant protection against self-reported clinical respiratory illness (CRI) (RR = 0.59; 95% CI: 0.46–0.77) (
        <xref ref-type="fig" rid="F2">
         Figure 2A
        </xref>
        ) and influenza-like illness (ILI) (RR = 0.34; 95% CI: 0.14–0.82) (
        <xref ref-type="fig" rid="F2">
         Figure 2B
        </xref>
        ). Meta-analysis suggested a protective, but nonstatistically significant, effect against laboratory-confirmed viral infections (VRI) (RR = 0.70; 95% CI: 0.47–1.03) (
        <xref ref-type="fig" rid="F2">
         Figure 2C
        </xref>
        ).
       </p>
       <fig fig-type="figure" id="F2" orientation="portrait" position="float">
        <label>
         Figure 2.
        </label>
        <caption>
         <p>
          Meta-analysis of RCTs assessing the protective effect of medical masks and N95 respirators against clinical and laboratory-confirmed respiratory outcomes. Meta-analyses comparing the risk of (A) clinical respiratory illness (CRI), (B) influenza-like illness (ILI) or (C) laboratory-confirmed viral respiratory infection (VRI) among HCWs continuously wearing respiratory personal protective equipment (rPPE) during working hours and convenience-selected HCWs wearing no mask (MacIntyre 2011 [
          <xref ref-type="bibr" rid="CIT0042">
           42
          </xref>
          ]) or following routine care, which may or may not include mask wearing (MacIntyre 2015 [
          <xref ref-type="bibr" rid="CIT0041">
           41
          </xref>
          ]). (A) CRI = 2 or more respiratory symptoms, or one respiratory symptom and a systemic symptom; (B) ILI = fever ≥38°C and 1 respiratory symptom; (C) VRI = detection of adenovirus, metapneumovirus, coronavirus 229E ⁄ NL63, parainfluenza 1- 3, influenza A and B, respiratory syncytial virus A and B, rhinovirus A⁄ B or coronavirus OC43⁄HKU1 by multiplex PCR. Abbreviations: CI, confidence interval; HCW, healthcare worker; med, medical mask; n/N, number of cases/number at risk; PCR, polymerase chain reaction; RCT, randomized controlled trial; RR, risk ratio.
         </p>
        </caption>
        <graphic xlink:href="cix68102">
        </graphic>
       </fig>
      </sec>
      <sec id="s10">
       <title>
        N95 Respirators vs Medical Masks
       </title>
       <p>
        Four RCTs compared protection from N95 and medical masks against different clinical or laboratory-confirmed outcomes [
        <xref ref-type="bibr" rid="CIT0024">
         24–27
        </xref>
        ]. Of these, 3 [
        <xref ref-type="bibr" rid="CIT0024">
         24–26
        </xref>
        ] specified rPPE use throughout the work shift. Compared to medical masks, N95 respirators conferred significant protection against self-reported CRI (RR = 0.47; 95% CI: 0.36–0.62) (
        <xref ref-type="fig" rid="F3">
         Figure 3A
        </xref>
        ), but evidence of superiority against ILI was limited (RR = 0.59; 95% CI: 0.27–1.28) (
        <xref ref-type="fig" rid="F3">
         Figure 3B
        </xref>
        ).
       </p>
       <fig fig-type="figure" id="F3" orientation="portrait" position="float">
        <label>
         Figure 3.
        </label>
        <caption>
         <p>
          Meta-analysis of RCTs comparing the protective effect of N95 respirators and medical masks against clinical respiratory outcomes. Protective effect of N95 respirators compared to medical masks against (A) clinical respiratory illness (CRI) or (B) influenza-like illness (ILI). Masks and respirators were worn at all times during the work shift (MacIntyre 2011 [
          <xref ref-type="bibr" rid="CIT0042">
           42
          </xref>
          ] and MacIntyre 2013 [
          <xref ref-type="bibr" rid="CIT0044">
           44
          </xref>
          ]) or only when providing care to patients with febrile respiratory illness (Loeb 2009 [
          <xref ref-type="bibr" rid="CIT0045">
           45
          </xref>
          ]). (A) CRI = 2 or more respiratory symptoms, or 1 respiratory symptom and a systemic symptom; (B) ILI (MacIntyre 2011 [
          <xref ref-type="bibr" rid="CIT0042">
           42
          </xref>
          ] and MacIntyre 2013 [
          <xref ref-type="bibr" rid="CIT0044">
           44
          </xref>
          ]) = fever ≥38°C and 1 respiratory symptom; ILI (Loeb 2009 [
          <xref ref-type="bibr" rid="CIT0045">
           45
          </xref>
          ]) = fever ≥38°C and cough. Abbreviation: CI, confidence interval; n/N, number of cases/number at risk; RCT, randomized controlled trial; RR, risk ratio.
         </p>
        </caption>
        <graphic xlink:href="cix68103">
        </graphic>
       </fig>
       <p>
        Meta-analysis indicated statistically significant superiority of N95 respirators over medical masks against laboratory-confirmed upper respiratory tract bacterial colonization (BRI) (RR = 0.46; 95% CI: 0.34–0.62) (
        <xref ref-type="fig" rid="F4">
         Figure 4A
        </xref>
        ) but not laboratory-confirmed influenza (RR = 0.84; 95% CI: 0.36–1.99) (
        <xref ref-type="fig" rid="F4">
         Figure 4B
        </xref>
        ) or other viral infections (RR = 0.78; 95% CI: 0.54–1.14) (
        <xref ref-type="fig" rid="F4">
         Figure 4C
        </xref>
        ).
       </p>
       <fig fig-type="figure" id="F4" orientation="portrait" position="float">
        <label>
         Figure 4.
        </label>
        <caption>
         <p>
          Meta-analysis of RCTs comparing the protective effect of N95 respirators and medical masks against laboratory-confirmed respiratory outcomes. Protective effect of N95 respirators compared to medical masks against laboratory-confirmed (A) bacterial respiratory infection (BRI), (B) influenza or (C) other viral respiratory infections (VRI). Masks and respirators were worn at all times on shift (MacIntyre 2011 [
          <xref ref-type="bibr" rid="CIT0042">
           42
          </xref>
          ], MacIntyre 2013 [
          <xref ref-type="bibr" rid="CIT0044">
           44
          </xref>
          ] and MacIntyre 2014 [
          <xref ref-type="bibr" rid="CIT0043">
           43
          </xref>
          ]) or only when providing care to patients with febrile respiratory illness (Loeb 2009 [
          <xref ref-type="bibr" rid="CIT0045">
           45
          </xref>
          ]). (A) BRI = detection of
          <italic>
           Streptococcus pneumoniae, Legionella, Bordetella pertussis, Chlamydia, Mycoplasma pneumoniae
          </italic>
          , or
          <italic>
           Haemophilus influenzae
          </italic>
          type B by multiplex PCR. (B) Influenza = laboratory-confirmed influenza A or B in symptomatic subjects. (C) VRI (MacIntyre 2011 [
          <xref ref-type="bibr" rid="CIT0042">
           42
          </xref>
          ], MacIntyre 2013 [
          <xref ref-type="bibr" rid="CIT0044">
           44
          </xref>
          ]) = detection of adenovirus, metapneumovirus, coronavirus 229E ⁄ NL63, parainfluenza 1–3, influenza viruses A and B, respiratory syncytial virus A and B, rhinovirus A/ B or coronavirus OC43 ⁄HKU1 by multiple PCR; VRI (Loeb 2009 [
          <xref ref-type="bibr" rid="CIT0045">
           45
          </xref>
          ]) = detection of respiratory syncytial virus A and B, metapneumovirus, parainfluenza 1–4, rhinovirus, coronavirus OC43, 229E, NL63, and HKU1by multiplex PCR. Abbreviations: CI, confidence interval; n/N = number of cases/number at risk; PCR, polymerase chain reaction; RCT, randomized controlled trial; RR, risk ratio.
         </p>
        </caption>
        <graphic xlink:href="cix68104">
        </graphic>
       </fig>
      </sec>
     </sec>
     <sec id="s11">
      <title>
       Observational Studies
      </title>
      <p>
       Most observational assessed the effectiveness of rPPE during the care of high-risk patients involved in outbreaks. We did not exclude any articles based on quality assessment (Appendix B, Tables S21–S23) but summarized their limitations in the discussion.
      </p>
      <sec id="s12">
       <title>
        Severe Acute Respiratory Syndrome
       </title>
       <p>
        Eight case-control [
        <xref ref-type="bibr" rid="CIT0029">
         29–36
        </xref>
        ] (Table S4) and 4 cohort studies [
        <xref ref-type="bibr" rid="CIT0020">
         20–22
        </xref>
        ,
        <xref ref-type="bibr" rid="CIT0037">
         37
        </xref>
        ] (Table S5) assessed the effectiveness of rPPE in protecting HCWs from SARS infection (Appendix B, Table 2).
       </p>
       <p>
        With one exception [
        <xref ref-type="bibr" rid="CIT0030">
         30
        </xref>
        ], case-control studies consistently reported a protective effect of medical masks against SARS [
        <xref ref-type="bibr" rid="CIT0031">
         31
        </xref>
        ,
        <xref ref-type="bibr" rid="CIT0032">
         32
        </xref>
        ,
        <xref ref-type="bibr" rid="CIT0034">
         34
        </xref>
        ] (Appendix B, Table 2). Compared to “no rPPE” controls, N95 respirators conferred protection against confirmed SARS-CoV infection in 2 of 3 case-control studies [
        <xref ref-type="bibr" rid="CIT0032">
         32
        </xref>
        ,
        <xref ref-type="bibr" rid="CIT0033">
         33
        </xref>
        ]; no protective effect against SARS was reported for disposable [
        <xref ref-type="bibr" rid="CIT0029">
         29
        </xref>
        ,
        <xref ref-type="bibr" rid="CIT0034">
         34
        </xref>
        ], cotton [
        <xref ref-type="bibr" rid="CIT0035">
         35
        </xref>
        ], or paper [
        <xref ref-type="bibr" rid="CIT0032">
         32
        </xref>
        ] masks (Appendix B, Table 2).
       </p>
       <p>
        Evidence from the 4 cohort studies was less conclusive. Two studies reported lower risk of pneumonic SARS (RR = 0.24; 95% CI: 0.08–0.71;
        <italic>
         P
        </italic>
        &lt; .001) [
        <xref ref-type="bibr" rid="CIT0022">
         22
        </xref>
        ] and moderate protection against laboratory-confirmed SARS-CoV infection (RR = 0.23; 95% CI: 0.05–0.93;
        <italic>
         P
        </italic>
        &lt; .058) [
        <xref ref-type="bibr" rid="CIT0020">
         20
        </xref>
        ] among HCWs wearing a N95 respirator (Appendix B, Table 3). Another study reported reduced risk of SARS-CoV infection among HCWs wearing a medical mask (RR = 0.08; 95% CI: 0.01–0.50;
        <italic>
         P
        </italic>
        &lt; .01) [
        <xref ref-type="bibr" rid="CIT0037">
         37
        </xref>
        ]. Two studies found no protective effect of either medical masks or N95 respirators against SARS [
        <xref ref-type="bibr" rid="CIT0020">
         20
        </xref>
        ,
        <xref ref-type="bibr" rid="CIT0021">
         21
        </xref>
        ], although lower attack rates were reported among nurses consistently wearing either type of rPPE (RR = 0.23; 95% CI: 0.07–0.78;
        <italic>
         P
        </italic>
        = .023) (Appendix B, Table 3) [
        <xref ref-type="bibr" rid="CIT0020">
         20
        </xref>
        ].
       </p>
       <p>
        In meta-analyses combining 6 case-control [
        <xref ref-type="bibr" rid="CIT0029">
         29
        </xref>
        ,
        <xref ref-type="bibr" rid="CIT0031">
         31–34
        </xref>
        ,
        <xref ref-type="bibr" rid="CIT0036">
         36
        </xref>
        ] and 3 cohort [
        <xref ref-type="bibr" rid="CIT0020">
         20–22
        </xref>
        ] studies (Appendix B, Table 1), use of rPPE conferred significant protection against SARS among exposed HCWs (OR = 0.22; 95% CI: 0.12–0.40) (
        <xref ref-type="fig" rid="F5">
         Figure 5A
        </xref>
        ). The corresponding RRs under baseline risks of 20% and 60% were 0.26 (95% CI: 0.15–0.45) and 0.41 (95% CI: 0.25–0.63), respectively. More specifically, wearing medical masks (OR = 0.13; 95% CI: 0.03–0.62) (
        <xref ref-type="fig" rid="F5">
         Figure 5B
        </xref>
        ) or N95 respirators (OR = 0.12; 95% CI: 0.06–0.26) (
        <xref ref-type="fig" rid="F5">
         Figure 5C
        </xref>
        ) both reduced the risk of SARS by approximately 80%. The corresponding RRs under baseline risks of 20% and 60% are 0.16 (95% CI: 0.04–0.67) and 0.27 (95% CI: 0.07–0.80) for medical masks and 0.15 (95% CI: 0.07–0.31) and 0.25 (95% CI: 0.14–0.47) for respirators, respectively. There was no significant difference between N95 respirators and medical masks in protecting HCWs from SARS (OR = 0.86; 95% CI: 0.22–3.33), with corresponding RRs of 0.88 (95% CI: 0.26–2.27) and 0.94 (95% CI: 0.41–1.34) under baseline risks of 20% and 60%, respectively (
        <xref ref-type="fig" rid="F5">
         Figure 5D
        </xref>
        ).
       </p>
       <fig fig-type="figure" id="F5" orientation="portrait" position="float">
        <label>
         Figure 5.
        </label>
        <caption>
         <p>
          Meta-analysis of observational studies assessing the protective effect of masks and respirators against SARS infection. (A)–(C) Five case-control (empty squares) and 3 cohort (full squares) studies were combined into different meta-analyses to assess the protective effect of (A) any respiratory personal protective equipment (rPPE), including medical masks, paper masks, disposable masks, and N95 respirators, (B) medical masks or (C) N95 respirators. Controls for studies included in meta-analyses (A)–(C) were HCWs not wearing any rPPE, except for Loeb 2004 [
          <xref ref-type="bibr" rid="CIT0026">
           20
          </xref>
          ] and Lau 2004 [
          <xref ref-type="bibr" rid="CIT0036">
           36
          </xref>
          ], where the control group consisted HCWs reporting “inconsistent use” of masks or respirators; med = medical mask; pap = paper mask; dis = disposable mask; n/N = number of cases/number at risk.
          <sup>
           a
          </sup>
          HCWs wearing N95 during non-invasive positive-pressure ventilation.
          <sup>
           b
          </sup>
          Outcome = incidence of pneumonic SARS (excludes asymptomatic SARS cases). (D) Meta-analyses combining observational studies comparing the protective effect of N95 and medical masks against SARS. NOS scores = Newcastle-Ottawa-Scale scores; for each paper, light gray, mid-gray, and dark gray circles represent the score for the “Selection,” “Comparability” and “Exposure” (case-control studies) or “Outcome” (cohort studies) domains of the Newcastle-Ottawa score, respectively. For each meta-analysis (A–D), panels on the right-hand side display a range of plausible risk ratios corresponding to the summary effect estimate for an estimated baseline risk of SARS ranging from 20% to 60%. Abbreviations: CI, confidence interval; HCW, healthcare worker; med, medical mask; n/N, number of cases/number at risk; RR, risk ratio; SARS, severe acute respiratory syndrome.
         </p>
        </caption>
        <graphic xlink:href="cix68105">
        </graphic>
       </fig>
      </sec>
      <sec id="s13">
       <title>
        Pandemic H1N1 Influenza (pH1N1)
       </title>
       <p>
        Eight observational studies assessed the effectiveness of rPPE in protecting HCWs against pH1N1 infection (Tables S6–S10).
       </p>
       <p>
        Early in the outbreak, the effectiveness of masks and respirators was assessed in HCWs who had been exposed to pH1N1 cases in California [
        <xref ref-type="bibr" rid="CIT0038">
         38
        </xref>
        ]. Seroconversion against pH1N1 was detected in 21% (9/43) of HCWs attending pH1N1-patients without rPPE but none of the HCWs wearing a mask or N95 respirator (Table S14) [
        <xref ref-type="bibr" rid="CIT0038">
         38
        </xref>
        ].
       </p>
       <p>
        In a cohort study from Hong Kong, all HCWs who reported using a medical mask during patient contact remained healthy, whereas 1.5% (4/268) of HCWs not using any rPPE developed laboratory-confirmed pH1N1 infection (Table S14) [
        <xref ref-type="bibr" rid="CIT0039">
         39
        </xref>
        ].
       </p>
       <p>
        Two matched case-control studies in Beijing assessed the protective effect of masks and N95 respirators [
        <xref ref-type="bibr" rid="CIT0040">
         40
        </xref>
        ] or “high protection level masks” [
        <xref ref-type="bibr" rid="CIT0041">
         41
        </xref>
        ], respectively. In one study, the “high protection level mask” reduced the odds of pH1N1 influenza among HCWs (adjusted OR = 0.05; 95% CI: 0.01–0.35) [
        <xref ref-type="bibr" rid="CIT0041">
         41
        </xref>
        ]. In the second study, unadjusted analysis showed no significantly protective effect for N95, medical or cloth masks (Table S13) [
        <xref ref-type="bibr" rid="CIT0040">
         40
        </xref>
        ].
       </p>
       <p>
        In two cross-sectional studies in Thailand [
        <xref ref-type="bibr" rid="CIT0042">
         42
        </xref>
        ] and Japan [
        <xref ref-type="bibr" rid="CIT0043">
         43
        </xref>
        ], use of medical masks or N95 respirators was not associated with pH1N1 seroprevalence. Two additional studies reported no effectiveness of rPPE in protecting HCWs from laboratory-confirmed pH1N1 infection [
        <xref ref-type="bibr" rid="CIT0044">
         44
        </xref>
        ,
        <xref ref-type="bibr" rid="CIT0045">
         45
        </xref>
        ].
       </p>
       <p>
        One cohort study reported an increased risk of pH1N1 seroconversion among HCWs not wearing rPPE continuously [
        <xref ref-type="bibr" rid="CIT0038">
         38
        </xref>
        ]. In 4 other studies, no association was found between compliance with rPPE use and pH1N1 infection [
        <xref ref-type="bibr" rid="CIT0040">
         40–43
        </xref>
        ].
       </p>
      </sec>
     </sec>
    </sec>
    <sec id="s14">
     <title>
      DISCUSSION
     </title>
     <sec id="s15">
      <title>
       Randomized Controlled Trials
      </title>
      <p>
       Compared to non-rPPE wearing HCWs, those wearing medical masks or N95 respirators throughout their work shift were significantly protected against nonspecific respiratory infection. However, assessment of clinical outcomes was self-reported and prone to bias, as the intervention cannot be masked. Evidence of a protective effect of masks or respirators against VRI, a rarer outcome, was not statistically significant, though this may indicate insufficient statistical power in these studies, rather than lack of a protective effect.
      </p>
      <p>
       Compared to medical masks, N95 respirators provided greater protection against CRI and BRI. These 2 outcomes were common in these trials (average risks of 8.7% and 7.3%, respectively), but the studies may have been underpowered to detect a superior protective effect of N95 respirators against influenza and other lower incidence outcomes.
      </p>
      <p>
       Several limitations should be considered. First, the source of infection was not ascertained in any of the trials; some HCWs may have acquired infections in the community rather than the workplace. Second, one RCT required HCWs to wear rPPE only when caring for febrile patients [
       <xref ref-type="bibr" rid="CIT0027">
        27
       </xref>
       ], whereas others specified continuous rPPE use [
       <xref ref-type="bibr" rid="CIT0023">
        23–26
       </xref>
       ]. Third, our meta-analyses included RCTs with different comparison groups, including convenience samples of HCWs not usually wearing masks [
       <xref ref-type="bibr" rid="CIT0024">
        24
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0025">
        25
       </xref>
       ] or following routine infection control policies, which may have included the use of rPPE [
       <xref ref-type="bibr" rid="CIT0023">
        23
       </xref>
       ]. Finally, the number of RCTs was small, and 4 of these were conducted in China by the same investigators, limiting generalizability to other settings.
      </p>
     </sec>
     <sec id="s16">
      <title>
       Observational Studies
      </title>
      <p>
       HCWs wearing N95 respirators were protected against SARS [
       <xref ref-type="bibr" rid="CIT0020">
        20
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0022">
        22
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0032">
        32
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0033">
        33
       </xref>
       ], except when exposed to SARS patients during noninvasive positive-pressure ventilation [
       <xref ref-type="bibr" rid="CIT0021">
        21
       </xref>
       ]. Evidence of protection through medical masks was available from individual articles [
       <xref ref-type="bibr" rid="CIT0031">
        31
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0032">
        32
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0034">
        34
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0037">
        37
       </xref>
       ], although results were inconsistent within [
       <xref ref-type="bibr" rid="CIT0031">
        31
       </xref>
       ] and across studies [
       <xref ref-type="bibr" rid="CIT0020">
        20
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0030">
        30
       </xref>
       ]. Differing levels of exposure could explain such discrepancies, but individual studies provided insufficient information for more detailed analysis.
      </p>
      <p>
       The superiority of N95 respirators over medical masks could reflect the ability of N95 respirators to protect users from infectious aerosols or indicate higher effectiveness against droplet contagion. Nonetheless, our meta-analysis revealed that use of both N95 respirators and medical masks was associated with up to 80% reduction in risk of SARS.
      </p>
      <p>
       For pH1N1, the evidence was inconsistent. Asymptomatic infection, common in pH1N1 patients [
       <xref ref-type="bibr" rid="CIT0043">
        43
       </xref>
       ], could have led to substantial misclassification of infection status in studies without serological confirmation, diluting any protective effect of masks. Compared to SARS cases [
       <xref ref-type="bibr" rid="CIT0046">
        46
       </xref>
       ], pH1N1 patients experienced relatively mild symptoms and lower case fatality rates [
       <xref ref-type="bibr" rid="CIT0047">
        47
       </xref>
       ], which may have resulted in HCWs being less adherent to rPPE use. Moreover, more drastic infection control measures, such as quarantine and patient isolation [
       <xref ref-type="bibr" rid="CIT0048">
        48
       </xref>
       ], may have led to an overestimation of rPPE effectiveness in the SARS studies.
      </p>
     </sec>
     <sec id="s17">
      <title>
       Limitations of Included Studies
      </title>
      <p>
       Specific brands, models, or even the generic type of mask used, was often omitted.
      </p>
      <p>
       In most studies, rPPE adherence was self-reported, and definitions of compliance varied across studies [
       <xref ref-type="bibr" rid="CIT0023">
        23
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0024">
        24
       </xref>
       ]. One RCT included external validation, but auditing was irregular and limited to areas outside patients’ rooms [
       <xref ref-type="bibr" rid="CIT0027">
        27
       </xref>
       ]. Because individuals overestimate compliance [
       <xref ref-type="bibr" rid="CIT0049">
        49
       </xref>
       ], self-reported adherence could result in attenuated effect estimates and potentially biased comparisons of masks and respirators if compliance differs by rPPE type [
       <xref ref-type="bibr" rid="CIT0023">
        23
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0024">
        24
       </xref>
       ]. Continuous adjustments and inappropriate wearing may even reverse the benefits of N95 respirators through the contamination of hands, face, and other PPE [
       <xref ref-type="bibr" rid="CIT0004">
        4
       </xref>
       ].
      </p>
      <p>
       In the included studies, HCWs were usually trained in wearing N95 respirators, but fit-testing was not universal [
       <xref ref-type="bibr" rid="CIT0024">
        24–26
       </xref>
       ]. One trial compared fit-testing with no fit-testing and reported no difference in respiratory infection risk between the 2 groups [
       <xref ref-type="bibr" rid="CIT0024">
        24
       </xref>
       ].
      </p>
      <p>
       In some RCTs, influenza vaccine uptake differed between trial arms [
       <xref ref-type="bibr" rid="CIT0024">
        24
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0026">
        26
       </xref>
       ]. Similarly, not all observational studies accounted for differences in influenza vaccination coverage [
       <xref ref-type="bibr" rid="CIT0038">
        38
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0042">
        42
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0043">
        43
       </xref>
       ] and gown- [
       <xref ref-type="bibr" rid="CIT0031">
        31
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0032">
        32
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0036">
        36
       </xref>
       ] or hand-washing habits [
       <xref ref-type="bibr" rid="CIT0032">
        32
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0033">
        33
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0036">
        36
       </xref>
       ]. Several studies adjusted for confounders [
       <xref ref-type="bibr" rid="CIT0023">
        23
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0025">
        25
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0026">
        26
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0029">
        29
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0031">
        31–33
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0036">
        36
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0037">
        37
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0041">
        41
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0050">
        50
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0051">
        51
       </xref>
       ], but it was not always clear which factors were accounted for [
       <xref ref-type="bibr" rid="CIT0041">
        41
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0050">
        50
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0051">
        51
       </xref>
       ]. Finally, most studies lacked statistical power to estimate protective effects, yielding extremely wide confidence intervals. Failure to detect a significant effect may therefore indicate insufficient statistical power, rather than absence of a protective effect, even when the available studies are pooled into a meta-analysis.
      </p>
     </sec>
     <sec id="s18">
      <title>
       Limitations of the Meta-Analysis of Observational Studies
      </title>
      <p>
       Our meta-analysis of observational studies summarized the protective effect of rPPE on a specific respiratory outcome with an established case definition [
       <xref ref-type="bibr" rid="CIT0052">
        52
       </xref>
       ], among reasonably well-defined populations and over a defined time period. However, it was not possible to account for potential between-study differences in exposure, fluctuating compliance with rPPE use [
       <xref ref-type="bibr" rid="CIT0029">
        29
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0031">
        31
       </xref>
       ], potential decreases in infectiousness over the course of the outbreak, or additional confounders affecting the original studies. Nonetheless, relevant confounders were unlikely to be equally distributed across studies in different settings, so that any protective effect of mask use should have become apparent when results of numerous studies were pooled.
      </p>
     </sec>
     <sec id="s19">
      <title>
       Conclusions
      </title>
      <p>
       In this review and meta-analysis, we analysed the collective evidence from published RCTs and observational studies in order to identify major gaps and methodological shortcomings in the current literature and develop evidence-based recommendations for the use of masks and respirators in healthcare settings. We found evidence to support universal medical mask use in hospital settings as part of infection control measures to reduce the risk of CRI and ILI among HCWs. Overall, N95 respirators may convey greater protection, but universal use throughout a work shift is likely to be less acceptable due to greater discomfort.
      </p>
      <p>
       Our analysis confirms the effectiveness of medical masks and respirators against SARS. Disposable, cotton, or paper masks are not recommended.
      </p>
      <p>
       The confirmed effectiveness of medical masks is crucially important for lower-resource and emergency settings lacking access to N95 respirators. In such cases, single-use medical masks are preferable to cloth masks, for which there is no evidence of protection and which might facilitate transmission of pathogens when used repeatedly without adequate sterilization [
       <xref ref-type="bibr" rid="CIT0008">
        8
       </xref>
       ].
      </p>
      <p>
       We found no clear benefit of either medical masks or N95 respirators against pH1N1. However, current policies mandating standard and droplet precautions when performing routine care for influenza patients are reasonable. RCTs conducted in community settings have demonstrated protective effects of medical masks in combination with hand-hygiene and other infection control interventions [
       <xref ref-type="bibr" rid="CIT0053">
        53
       </xref>
       ].
      </p>
      <p>
       Overall, the evidence to inform policies on mask use in HCWs is poor, with a small number of studies that is prone to reporting biases and lack of statistical power. Multicenter RCTs with standardized protocols conducted outside periods of unusual epidemic events and including the measurement of compliance and fit-testing would overcome many of the methodological difficulties of current studies, including low statistical power, the use of concurrent epidemic control measures, and unusually high compliance during epidemics. Large, well-designed studies would also enable subanalyses to investigate the role of mask use against different types of infections [
       <xref ref-type="bibr" rid="CIT0054">
        54
       </xref>
       ], clarify the circumstances under which rPPE use is most warranted, and yield valuable information about the role of different transmission modes. The inclusion of relevant controls is of paramount importance. Because the source of infection cannot always be ascertained, control groups could include HCWs who do not have any patient contact.
      </p>
      <p>
       In addition, the protective effect of masks is likely to be related to the baseline risk of infection, because outbreaks with higher attack rates offer more opportunities for infection. We recommend that studies indicate the baseline risk of disease, either from a nonintervention group or occupational health records. This is particularly important for case-control studies, for which the interpretation of the OR as a measure of protective effect is problematic in high-incidence scenarios.
      </p>
     </sec>
    </sec>
    <sec id="s20" sec-type="supplementary-material">
     <title>
      Supplementary Data
     </title>
     <p>
      Supplementary materials are available at
      <italic>
       Clinical Infectious Diseases
      </italic>
      online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
     </p>
    </sec>
    <sec sec-type="supplementary-material">
     <title>
      Supplementary Material
     </title>
     <supplementary-material content-type="local-data" id="sup1">
      <label>
       Offeddu_Supplement
      </label>
      <media xlink:href="cix681_suppl_offeddu_supplement.docx">
       <caption>
        <p>
         Click here for additional data file.
        </p>
       </caption>
      </media>
     </supplementary-material>
    </sec>
    <back>
     <notes id="n1">
      <title>
       Note
      </title>
      <p>
       <bold>
        <italic>
         Potential conflicts of interest.
        </italic>
       </bold>
       All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
      </p>
     </notes>
     <ref-list>
      <title>
       References
      </title>
      <ref id="CIT0001">
       <label>
        1.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Peiris
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome (SARS)
        </article-title>
        .
        <source>
         J Clin Virol
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         28
        </volume>
        :
        <fpage>
         245
        </fpage>
        –
        <lpage>
         7
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14522062
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0002">
       <label>
        2.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Peiris
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tu
          </surname>
          <given-names>
           WW
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yen
          </surname>
          <given-names>
           HL
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel H1N1 virus causes the first pandemic of the 21st century
        </article-title>
        .
        <source>
         Eur J Immunol
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         39
        </volume>
        :
        <fpage>
         2946
        </fpage>
        –
        <lpage>
         54
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19790188
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0003">
       <label>
        3.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Trajman
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Menzies
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Occupational respiratory infections
        </article-title>
        .
        <source>
         Curr Opin Pulm Med
        </source>
        <year>
         2010
        </year>
        ;
        <volume>
         16
        </volume>
        :
        <fpage>
         226
        </fpage>
        –
        <lpage>
         34
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         20375784
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0004">
       <label>
        4.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Jefferson
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Del Mar
          </surname>
          <given-names>
           CB
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Dooley
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Physical interventions to interrupt or reduce the spread of respiratory viruses
        </article-title>
        .
        <source>
         Cochrane Database Syst Rev
        </source>
        <year>
         2011
        </year>
        ;
        <fpage>
         CD006207
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         21735402
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0005">
       <label>
        5.
       </label>
       <mixed-citation publication-type="book">
        <collab>
         World Health Organization
        </collab>
        .
        <comment>
         Infection prevention and control of epidemic- and pandemic-prone acute respiratory infections in health care
        </comment>
        <publisher-loc>
         Geneva, Switzerland
        </publisher-loc>
        <year>
         2014
        </year>
        ; Available at:
        <ext-link ext-link-type="uri" xlink:href="http://apps.who.int/iris/bitstream/10665/112656/1/9789241507134_eng.pdf">
         http://apps.who.int/iris/bitstream/10665/112656/1/9789241507134_eng.pdf
        </ext-link>
        . Accessed
        <comment>
         27 April 2017
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0006">
       <label>
        6.
       </label>
       <mixed-citation publication-type="other">
        <collab>
         Occupational Safety and Health Administration
        </collab>
        .
        <comment>
         Respiratory infection control: respirators versus surgical mask. OSHA Fact Sheet
        </comment>
        <year>
         2009
        </year>
        ; Available at:
        <ext-link ext-link-type="uri" xlink:href="https://www.osha.gov/Publications/respirators-vs-surgicalmasks-factsheet.html">
         https://www.osha.gov/Publications/respirators-vs-surgicalmasks-factsheet.html
        </ext-link>
        . Accessed
        <comment>
         27 April 2017
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0007">
       <label>
        7.
       </label>
       <mixed-citation publication-type="book">
        <collab>
         Centres for Disease Control and Prevention
        </collab>
        .
        <comment>
         Respirator Trusted-Source Information
        </comment>
        <publisher-name>
         The National Personal Protective Technology Laboratory
        </publisher-name>
        <year>
         2014
        </year>
        ; Available at:
        <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/niosh/npptl/topics/respirators/disp_part/respsource3healthcare.html-d">
         http://www.cdc.gov/niosh/npptl/topics/respirators/disp_part/respsource3healthcare.html - d
        </ext-link>
        . Accessed
        <comment>
         27 April 2017
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0008">
       <label>
        8.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           MacIntyre
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chughtai
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Facemasks for the prevention of infection in healthcare and community settings
        </article-title>
        .
        <source>
         BMJ
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         350
        </volume>
        :
        <fpage>
         h694
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         25858901
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0009">
       <label>
        9.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chughtai
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Seale
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           MacIntyre
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Availability, consistency and evidence-base of policies and guidelines on the use of mask and respirator to protect hospital health care workers: a global analysis
        </article-title>
        .
        <source>
         BMC Res Notes
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <fpage>
         216
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         23725338
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0010">
       <label>
        10.
       </label>
       <mixed-citation publication-type="other">
        <collab>
         Centers for Disease Control and Prevention
        </collab>
        .
        <comment>
         Interim guidance on infection control measures for 2009 H1N1 influenza in healthcare settings, including protection of healthcare personnel
        </comment>
        <year>
         2010
        </year>
        ; Available at:
        <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/h1n1flu/guidelines_infection_control.htm">
         http://www.cdc.gov/h1n1flu/guidelines_infection_control.htm
        </ext-link>
        . Accessed
        <comment>
         27 April 2017
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0011">
       <label>
        11.
       </label>
       <mixed-citation publication-type="other">
        <collab>
         Centers for Disease Control and Prevention
        </collab>
        .
        <comment>
         Interim Infection Prevention and Control Recommendations for Hospitalized Patients with Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
        </comment>
        <year>
         2015
        </year>
        ; Available at:
        <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/coronavirus/mers/infection-prevention-control.html-infection-prevention">
         http://www.cdc.gov/coronavirus/mers/infection-prevention-control.html - infection-prevention
        </ext-link>
        . Accessed
        <comment>
         27 April 2017
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0012">
       <label>
        12.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Bin-Reza
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lopez Chavarrias
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Nicoll
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chamberland
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
        </person-group>
        <article-title>
         The use of masks and respirators to prevent transmission of influenza: a systematic review of the scientific evidence
        </article-title>
        .
        <source>
         Influenza Other Respir Viruses
        </source>
        <year>
         2012
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <fpage>
         257
        </fpage>
        –
        <lpage>
         67
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22188875
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0013">
       <label>
        13.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Smith
          </surname>
          <given-names>
           JD
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           MacDougall
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Johnstone
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Copes
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Schwartz
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Garber
          </surname>
          <given-names>
           GE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effectiveness of N95 respirators versus surgical masks in protecting health care workers from acute respiratory infection: a systematic review and meta-analysis
        </article-title>
        .
        <source>
         CMAJ
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         188
        </volume>
        :
        <fpage>
         567
        </fpage>
        –
        <lpage>
         74
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26952529
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0014">
       <label>
        14.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Yu
          </surname>
          <given-names>
           ITS
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           YG
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wong
          </surname>
          <given-names>
           TW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evidence of airborne transmission of the severe acute respiratory syndrome virus
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         350
        </volume>
        :
        <fpage>
         1731
        </fpage>
        –
        <lpage>
         9
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15102999
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0015">
       <label>
        15.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Seto
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Airborne transmission and precautions: facts and myths
        </article-title>
        .
        <source>
         J Hosp Infect
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         89
        </volume>
        :
        <fpage>
         225
        </fpage>
        –
        <lpage>
         8
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25578684
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0016">
       <label>
        16.
       </label>
       <mixed-citation publication-type="other">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Higgins
          </surname>
          <given-names>
           JPT
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Green
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <comment>
         Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0)
        </comment>
        <year>
         2011
        </year>
        ; Available at:
        <ext-link ext-link-type="uri" xlink:href="http://handbook.cochrane.org/">
         http://handbook.cochrane.org/
        </ext-link>
        . Accessed
        <comment>
         27 April 2017
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0017">
       <label>
        17.
       </label>
       <mixed-citation publication-type="other">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wells
          </surname>
          <given-names>
           GA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Shea
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           O’Connell
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <comment>
         The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses
        </comment>
        Available at:
        <ext-link ext-link-type="uri" xlink:href="http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp">
         http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
        </ext-link>
        . Accessed
        <comment>
         27 April 2017
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0018">
       <label>
        18.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Herzog
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Álvarez-Pasquin
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Díaz
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Del Barrio
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Estrada
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gil
          </surname>
          <given-names>
           Á
          </given-names>
         </name>
        </person-group>
        <article-title>
         Are healthcare workers’ intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review
        </article-title>
        .
        <source>
         BMC Public Health
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         13
        </volume>
        :
        <fpage>
         154
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         23421987
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0019">
       <label>
        19.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Grant
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Converting an odds ratio to a range of plausible relative risks for better communication of research findings
        </article-title>
        .
        <source>
         BMJ
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         348
        </volume>
        :
        <fpage>
         f7450
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         24464277
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0020">
       <label>
        20.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Loeb
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           McGeer
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Henry
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SARS among critical care nurses, Toronto
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         251
        </fpage>
        –
        <lpage>
         5
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15030692
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0021">
       <label>
        21.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Scales
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Green
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           AK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Illness in intensive care staff after brief exposure to severe acute respiratory syndrome
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         9
        </volume>
        :
        <fpage>
         1205
        </fpage>
        –
        <lpage>
         10
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14609453
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0022">
       <label>
        22.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wilder-Smith
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Teleman
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Heng
          </surname>
          <given-names>
           BH
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Earnest
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ling
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Leo
          </surname>
          <given-names>
           YS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Asymptomatic SARS coronavirus infection among healthcare workers, Singapore
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2005
        </year>
        ;
        <volume>
         11
        </volume>
        :
        <fpage>
         1142
        </fpage>
        –
        <lpage>
         5
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16022801
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0023">
       <label>
        23.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           MacIntyre
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Seale
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Dung
          </surname>
          <given-names>
           TC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A cluster randomised trial of cloth masks compared with medical masks in healthcare workers
        </article-title>
        .
        <source>
         BMJ Open
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         5
        </volume>
        :
        <fpage>
         e006577
        </fpage>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0024">
       <label>
        24.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           MacIntyre
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cauchemez
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A cluster randomized clinical trial comparing fit-tested and non-fit-tested N95 respirators to medical masks to prevent respiratory virus infection in health care workers
        </article-title>
        .
        <source>
         Influenza Other Respir Viruses
        </source>
        <year>
         2011
        </year>
        ;
        <volume>
         5
        </volume>
        :
        <fpage>
         170
        </fpage>
        –
        <lpage>
         9
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         21477136
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0025">
       <label>
        25.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           MacIntyre
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Rahman
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Efficacy of face masks and respirators in preventing upper respiratory tract bacterial colonization and co-infection in hospital healthcare workers - authors’ reply
        </article-title>
        .
        <source>
         Prev Med
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         65
        </volume>
        :
        <fpage>
         154
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         24905863
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0026">
       <label>
        26.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           MacIntyre
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Seale
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A randomized clinical trial of three options for N95 respirators and medical masks in health workers
        </article-title>
        .
        <source>
         Am J Respir Crit Care Med
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         187
        </volume>
        :
        <fpage>
         960
        </fpage>
        –
        <lpage>
         6
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23413265
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0027">
       <label>
        27.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Loeb
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Dafoe
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Mahony
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Surgical mask vs N95 respirator for preventing influenza among health care workers: a randomized trial
        </article-title>
        .
        <source>
         JAMA
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         302
        </volume>
        :
        <fpage>
         1865
        </fpage>
        –
        <lpage>
         71
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19797474
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0028">
       <label>
        28.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Jacobs
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ohde
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Takahashi
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tokuda
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Omata
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Fukui
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of surgical face masks to reduce the incidence of the common cold among health care workers in Japan: a randomized controlled trial
        </article-title>
        .
        <source>
         Am J Infect Control
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         37
        </volume>
        :
        <fpage>
         417
        </fpage>
        –
        <lpage>
         9
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19216002
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0029">
       <label>
        29.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Liu
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tang
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Fang
          </surname>
          <given-names>
           LQ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Risk factors for SARS infection among hospital healthcare workers in Beijing: a case control study
        </article-title>
        .
        <source>
         Trop Med Int Health
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         14
        </volume>
        :
        <fpage>
         52
        </fpage>
        –
        <lpage>
         9
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0030">
       <label>
        30.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ma
          </surname>
          <given-names>
           HJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           HW
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Fang
          </surname>
          <given-names>
           LQ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A case-control study on the risk factors of severe acute respiratory syndromes among health care workers
        </article-title>
        .
        <source>
         Zhonghua Liu Xing Bing Xue Za Zhi
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         25
        </volume>
        :
        <fpage>
         741
        </fpage>
        –
        <lpage>
         4
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15555351
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0031">
       <label>
        31.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Nishiura
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kuratsuji
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Quy
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Rapid awareness and transmission of severe acute respiratory syndrome in Hanoi French Hospital, Vietnam
        </article-title>
        .
        <source>
         Am J Trop Med Hyg
        </source>
        <year>
         2005
        </year>
        ;
        <volume>
         73
        </volume>
        :
        <fpage>
         17
        </fpage>
        –
        <lpage>
         25
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16014825
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0032">
       <label>
        32.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Seto
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tsang
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yung
          </surname>
          <given-names>
           RW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        ;
        <person-group person-group-type="author">
         <collab>
          Advisors of Expert SARS group of Hospital Authority
         </collab>
        </person-group>
        <article-title>
         Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS)
        </article-title>
        .
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         361
        </volume>
        :
        <fpage>
         1519
        </fpage>
        –
        <lpage>
         20
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12737864
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0033">
       <label>
        33.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Teleman
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Boudville
          </surname>
          <given-names>
           IC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Heng
          </surname>
          <given-names>
           BH
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhu
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Leo
          </surname>
          <given-names>
           YS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Factors associated with transmission of severe acute respiratory syndrome among health-care workers in Singapore
        </article-title>
        .
        <source>
         Epidemiol Infect
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         132
        </volume>
        :
        <fpage>
         797
        </fpage>
        –
        <lpage>
         803
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15473141
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0034">
       <label>
        34.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Yin
          </surname>
          <given-names>
           WW
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gao
          </surname>
          <given-names>
           LD
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lin
          </surname>
          <given-names>
           WS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Effectiveness of personal protective measures in prevention of nosocomial transmission of severe acute respiratory syndrome
        </article-title>
        .
        <source>
         Zhonghua Liu Xing Bing Xue Za Zhi
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         25
        </volume>
        :
        <fpage>
         18
        </fpage>
        –
        <lpage>
         22
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15061941
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0035">
       <label>
        35.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chen
          </surname>
          <given-names>
           WQ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ling
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lu
          </surname>
          <given-names>
           CY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Which preventive measures might protect health care workers from SARS?
        </article-title>
        <source>
         BMC Public Health
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         9
        </volume>
        :
        <fpage>
         81
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         19284644
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0036">
       <label>
        36.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Fung
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wong
          </surname>
          <given-names>
           TW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SARS transmission among hospital workers in Hong Kong
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         280
        </fpage>
        –
        <lpage>
         6
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15030698
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0037">
       <label>
        37.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Nishiyama
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wakasugi
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kirikae
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Risk factors for SARS infection within hospitals in Hanoi, Vietnam
        </article-title>
        .
        <source>
         Jpn J Infect Dis
        </source>
        <year>
         2008
        </year>
        ;
        <volume>
         61
        </volume>
        :
        <fpage>
         388
        </fpage>
        –
        <lpage>
         90
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18806349
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0038">
       <label>
        38.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Jaeger
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Patel
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Dharan
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Transmission of 2009 pandemic influenza A (H1N1) virus among healthcare personnel-Southern California, 2009
        </article-title>
        .
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <year>
         2011
        </year>
        ;
        <volume>
         32
        </volume>
        :
        <fpage>
         1149
        </fpage>
        –
        <lpage>
         57
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22080652
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0039">
       <label>
        39.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Cheng
          </surname>
          <given-names>
           VC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tai
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wong
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Prevention of nosocomial transmission of swine-origin pandemic influenza virus A/H1N1 by infection control bundle
        </article-title>
        .
        <source>
         J Hosp Infect
        </source>
        <year>
         2010
        </year>
        ;
        <volume>
         74
        </volume>
        :
        <fpage>
         271
        </fpage>
        –
        <lpage>
         7
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         20061056
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0040">
       <label>
        40.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Seale
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yang
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Factors associated with the transmission of pandemic (H1N1) 2009 among hospital healthcare workers in Beijing, China
        </article-title>
        .
        <source>
         Influenza Other Respir Viruses
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         7
        </volume>
        :
        <fpage>
         466
        </fpage>
        –
        <lpage>
         71
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23078163
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0041">
       <label>
        41.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Deng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           XL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Pandemic influenza A (H1N1) virus infection factors among healthcare workers—a case-control study
        </article-title>
        .
        <source>
         Zhonghua Yu Fang Yi Xue Za Zhi
        </source>
        <year>
         2010
        </year>
        ;
        <volume>
         44
        </volume>
        :
        <fpage>
         1075
        </fpage>
        –
        <lpage>
         8
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         21215106
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0042">
       <label>
        42.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chokephaibulkit
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Assanasen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Apisarnthanarak
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Seroprevalence of 2009 H1N1 virus infection and self-reported infection control practices among healthcare professionals following the first outbreak in Bangkok, Thailand
        </article-title>
        .
        <source>
         Influenza Other Respir Viruses
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         7
        </volume>
        :
        <fpage>
         359
        </fpage>
        –
        <lpage>
         63
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23043536
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0043">
       <label>
        43.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Toyokawa
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sunagawa
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yahata
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Seroprevalence of antibodies to pandemic (H1N1) 2009 influenza virus among health care workers in two general hospitals after first outbreak in Kobe, Japan
        </article-title>
        .
        <source>
         J Infect
        </source>
        <year>
         2011
        </year>
        ;
        <volume>
         63
        </volume>
        :
        <fpage>
         281
        </fpage>
        –
        <lpage>
         7
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         21723615
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0044">
       <label>
        44.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ang
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Poh
          </surname>
          <given-names>
           BF
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Win
          </surname>
          <given-names>
           MK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chow
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Surgical masks for protection of health care personnel against pandemic novel swine-origin influenza A (H1N1)-2009: results from an observational study
        </article-title>
        .
        <source>
         Clin Infect Dis
        </source>
        <year>
         2010
        </year>
        ;
        <volume>
         50
        </volume>
        :
        <fpage>
         1011
        </fpage>
        –
        <lpage>
         4
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         20178418
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0045">
       <label>
        45.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wise
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           De Perio
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Halpin
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Transmission of pandemic (H1N1) 2009 influenza to healthcare personnel in the United States
        </article-title>
        .
        <source>
         Clin Infect Dis
        </source>
        <year>
         2011
        </year>
        ;
        <volume>
         52
        </volume>
        (
        <issue>
         Suppl 1
        </issue>
        ):
        <fpage>
         S198
        </fpage>
        –
        <lpage>
         204
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         21342895
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0046">
       <label>
        46.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Fung
          </surname>
          <given-names>
           WK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yu
          </surname>
          <given-names>
           PL
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS case-fatality rates
        </article-title>
        .
        <source>
         CMAJ
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         169
        </volume>
        :
        <fpage>
         277
        </fpage>
        –
        <lpage>
         8
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0047">
       <label>
        47.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wong
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kelly
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ip
          </surname>
          <given-names>
           DK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wu
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Leung
          </surname>
          <given-names>
           GM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cowling
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Case fatality risk of influenza A (H1N1pdm09): a systematic review
        </article-title>
        .
        <source>
         Epidemiology
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         24
        </volume>
        :
        <fpage>
         830
        </fpage>
        –
        <lpage>
         41
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24045719
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0048">
       <label>
        48.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chan-Yeung
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Xu
          </surname>
          <given-names>
           RH
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS: epidemiology
        </article-title>
        .
        <source>
         Respirology
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         8
        </volume>
        Suppl:
        <fpage>
         S9
        </fpage>
        –
        <lpage>
         14
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15018127
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0049">
       <label>
        49.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           LaFleur
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Oderda
          </surname>
          <given-names>
           GM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Methods to measure patient compliance with medication regimens
        </article-title>
        .
        <source>
         J Pain Palliat Care Pharmacother
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         18
        </volume>
        :
        <fpage>
         81
        </fpage>
        –
        <lpage>
         7
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0050">
       <label>
        50.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ng
          </surname>
          <given-names>
           TC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lee
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hui
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lai
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ip
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Preventing healthcare workers from acquiring influenza
        </article-title>
        .
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         30
        </volume>
        :
        <fpage>
         292
        </fpage>
        –
        <lpage>
         5
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19193127
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0051">
       <label>
        51.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Yang
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Seale
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           MacIntyre
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Mask-wearing and respiratory infection in healthcare workers in Beijing, China
        </article-title>
        .
        <source>
         Braz J Infect Dis
        </source>
        <year>
         2011
        </year>
        ;
        <volume>
         15
        </volume>
        :
        <fpage>
         102
        </fpage>
        –
        <lpage>
         8
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         21503394
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0052">
       <label>
        52.
       </label>
       <mixed-citation publication-type="other">
        <collab>
         World Health Organization
        </collab>
        .
        <comment>
         Case Definitions for Surveillance of Severe Acute Respiratory Syndrome (SARS). Emergencies preparedness, response
        </comment>
        <year>
         2003
        </year>
        , May 1st; Available at:
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/sars/casedefinition/en/">
         http://www.who.int/csr/sars/casedefinition/en/
        </ext-link>
        . Accessed
        <comment>
         27 April 2017
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0053">
       <label>
        53.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wong
          </surname>
          <given-names>
           VW
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cowling
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Aiello
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hand hygiene and risk of influenza virus infections in the community: a systematic review and meta-analysis
        </article-title>
        .
        <source>
         Epidemiol Infect
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         142
        </volume>
        :
        <fpage>
         922
        </fpage>
        –
        <lpage>
         32
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24572643
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0054">
       <label>
        54.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Radonovich
          </surname>
          <given-names>
           LJ
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         ,
         <name name-style="western">
          <surname>
           Bessesen
          </surname>
          <given-names>
           MT
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cummings
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The Respiratory Protection Effectiveness Clinical Trial (ResPECT): a cluster-randomized comparison of respirator and medical mask effectiveness against respiratory infections in healthcare personnel
        </article-title>
        .
        <source>
         BMC Infect Dis
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         16
        </volume>
        :
        <fpage>
         243
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         27255755
        </pub-id>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Autoimmun
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       J. Autoimmun
      </journal-id>
      <journal-title-group>
       <journal-title>
        Journal of Autoimmunity
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0896-8411
      </issn>
      <issn pub-type="epub">
       1095-9157
      </issn>
      <publisher>
       <publisher-name>
        Elsevier Ltd.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32143990
      </article-id>
      <article-id pub-id-type="pmc">
       7126544
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0896-8411(20)30047-0
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.jaut.2020.102434
      </article-id>
      <article-id pub-id-type="publisher-id">
       102434
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au1">
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          Yongshi
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
        <xref ref-type="fn" rid="fn1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au2">
        <name>
         <surname>
          Peng
         </surname>
         <given-names>
          Fujun
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
        <xref ref-type="aff" rid="aff3">
         c
        </xref>
        <xref ref-type="fn" rid="fn1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au3">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Runsheng
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
         d
        </xref>
        <xref ref-type="fn" rid="fn1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au4">
        <name>
         <surname>
          Guan
         </surname>
         <given-names>
          Kai
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au5">
        <name>
         <surname>
          Jiang
         </surname>
         <given-names>
          Taijiao
         </given-names>
        </name>
        <email>
         taijiao@ibms.pumc.edu.cn
        </email>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
        <xref ref-type="aff" rid="aff3">
         c
        </xref>
        <xref ref-type="corresp" rid="cor4">
         ∗∗∗∗
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au6">
        <name>
         <surname>
          Xu
         </surname>
         <given-names>
          Guogang
         </given-names>
        </name>
        <email>
         guogang_xu@qq.com
        </email>
        <xref ref-type="aff" rid="aff5">
         e
        </xref>
        <xref ref-type="corresp" rid="cor3">
         ∗∗∗
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au7">
        <name>
         <surname>
          Sun
         </surname>
         <given-names>
          Jinlyu
         </given-names>
        </name>
        <email>
         sunjinlv@pumch.cn
        </email>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
        <xref ref-type="corresp" rid="cor2">
         ∗∗
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au8">
        <name>
         <surname>
          Chang
         </surname>
         <given-names>
          Christopher
         </given-names>
        </name>
        <email>
         chrchang@ucdavis.edu
        </email>
        <xref ref-type="aff" rid="aff6">
         f
        </xref>
        <xref ref-type="aff" rid="aff7">
         g
        </xref>
        <xref ref-type="corresp" rid="cor1">
         ∗
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        a
       </label>
       Department of Allergy &amp; Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College &amp; Chinese Academy of Medical Sciences, National Clinical Research Center for Immunologic Diseases, Beijing, 100730, China
      </aff>
      <aff id="aff2">
       <label>
        b
       </label>
       Center for Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, 100005, China
      </aff>
      <aff id="aff3">
       <label>
        c
       </label>
       Suzhou Institute of Systems Medicine, Suzhou, Jiangsu 215123, China
      </aff>
      <aff id="aff4">
       <label>
        d
       </label>
       Department of Respiratory Diseases, The Second Medical Center &amp; National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, 100853, China
      </aff>
      <aff id="aff5">
       <label>
        e
       </label>
       Department of Infection Prevention and Disease Control, The Second Medical Center &amp; National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, 100853, China
      </aff>
      <aff id="aff6">
       <label>
        f
       </label>
       Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, Davis, CA, 95616, USA
      </aff>
      <aff id="aff7">
       <label>
        g
       </label>
       Division of Pediatric Immunology and Allergy, Joe DiMaggio Children's Hospital, Hollywood, FL, USA
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         ∗
        </label>
        Corresponding authors. University of California, Davis, 451 Health Sciences Drive, Suite 6510, Davis, CA 95616, USA.
        <email>
         chrchang@ucdavis.edu
        </email>
       </corresp>
       <corresp id="cor2">
        <label>
         ∗∗
        </label>
        Corresponding author. No.1 Shuaifuyuan Wangfujing Dongcheng District, Beijing, 100730, China.
        <email>
         sunjinlv@pumch.cn
        </email>
       </corresp>
       <corresp id="cor3">
        <label>
         ∗∗∗
        </label>
        Corresponding authors. No.28 Fuxing Road, Beijing, 100853, China.
        <email>
         guogang_xu@qq.com
        </email>
       </corresp>
       <corresp id="cor4">
        <label>
         ∗∗∗∗
        </label>
        Corresponding author. No.9, Dongdan 3 rd, Dongcheng District, Beijing, 100005, China.
        <email>
         taijiao@ibms.pumc.edu.cn
        </email>
       </corresp>
       <fn id="fn1">
        <label>
         1
        </label>
        <p id="ntpara0010">
         Yongshi Yang, Fujun Peng, Runsheng Wang contributed equally to this work.
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        3
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
       <day>
        3
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <elocation-id>
       102434
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         19
        </day>
        <month>
         2
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         22
        </day>
        <month>
         2
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         22
        </day>
        <month>
         2
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2020 Elsevier Ltd. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
        Elsevier Ltd
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="abs0010">
       <p>
        The 2019-nCoV is officially called SARS-CoV-2 and the disease is named COVID-19. This viral epidemic in China has led to the deaths of over 1800 people, mostly elderly or those with an underlying chronic disease or immunosuppressed state. This is the third serious Coronavirus outbreak in less than 20 years, following SARS in 2002–2003 and MERS in 2012. While human strains of Coronavirus are associated with about 15% of cases of the common cold, the SARS-CoV-2 may present with varying degrees of severity, from flu-like symptoms to death. It is currently believed that this deadly Coronavirus strain originated from wild animals at the Huanan market in Wuhan, a city in Hubei province. Bats, snakes and pangolins have been cited as potential carriers based on the sequence homology of CoV isolated from these animals and the viral nucleic acids of the virus isolated from SARS-CoV-2 infected patients. Extreme quarantine measures, including sealing off large cities, closing borders and confining people to their homes, were instituted in January 2020 to prevent spread of the virus, but by that time much of the damage had been done, as human-human transmission became evident. While these quarantine measures are necessary and have prevented a historical disaster along the lines of the Spanish flu, earlier recognition and earlier implementation of quarantine measures may have been even more effective. Lessons learned from SARS resulted in faster determination of the nucleic acid sequence and a more robust quarantine strategy. However, it is clear that finding an effective antiviral and developing a vaccine are still significant challenges. The costs of the epidemic are not limited to medical aspects, as the virus has led to significant sociological, psychological and economic effects globally. Unfortunately, emergence of SARS-CoV-2 has led to numerous reports of Asians being subjected to racist behavior and hate crimes across the world.
       </p>
      </abstract>
      <abstract abstract-type="author-highlights" id="abs0015">
       <title>
        Highlights
       </title>
       <p>
        <list id="ulist0010" list-type="simple">
         <list-item id="u0010">
          <p id="p0010">
           •The 2019-nCoV is officially called SARS-CoV-2, and is the cause of the disease named COVID-19.
          </p>
         </list-item>
         <list-item id="u0015">
          <p id="p0015">
           •COVID-19 is the third severe epidemic caused by coronaviruses in the past 20 years.
          </p>
         </list-item>
         <list-item id="u0020">
          <p id="p0020">
           •It is believed that the SARS-CoV-2 virus originated from bats, based on genomic sequencing.
          </p>
         </list-item>
         <list-item id="u0025">
          <p id="p0025">
           •While human strains of Coronavirus are associated with about 15% of cases of the common cold, the SARS-CoV-2 is far more deadly, with a mortality rate around 2.3%.
          </p>
         </list-item>
         <list-item id="u0030">
          <p id="p0030">
           •As of February 19th, 2020, there have been 75,282 confirmed cases and 2012 deaths worldwide.
          </p>
         </list-item>
         <list-item id="u0035">
          <p id="p0035">
           •Lessons learned from SARS in 2003 resulted in faster determination of the nucleic acid sequence and a more robust quarantine strategy.
          </p>
         </list-item>
         <list-item id="u0040">
          <p id="p0040">
           •Extreme quarantine measures, including sealing off large cities, closing borders and confining people to their homes are critical to stemming spread of the virus.
          </p>
         </list-item>
         <list-item id="u0045">
          <p id="p0045">
           •Pyroptosis, a novel form of inflammatory cell death, is a possible mechanism for the increased virulence of the SARS-CoV-2.
          </p>
         </list-item>
        </list>
       </p>
      </abstract>
      <kwd-group id="kwrds0010">
       <title>
        Keywords
       </title>
       <kwd>
        Coronavirus
       </kwd>
       <kwd>
        SARS-CoV-2
       </kwd>
       <kwd>
        SARS-CoV
       </kwd>
       <kwd>
        Epidemiology
       </kwd>
       <kwd>
        Pneumonia
       </kwd>
       <kwd>
        Flu
       </kwd>
       <kwd>
        Bats
       </kwd>
       <kwd>
        Human to human transmission
       </kwd>
       <kwd>
        Epidemic
       </kwd>
       <kwd>
        Pandemic
       </kwd>
       <kwd>
        Pyroptosis
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec1">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="p0050">
      Coronaviruses (CoVs) are named for the crown-like spikes on their surface and belong to the family Coronaviridae within the order Nidovirales. Coronaviruses broadly infect vertebrates including humans, birds, bats, snakes, mice and other wild animals [
      <xref ref-type="bibr" rid="bib1">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="bib2">
       2
      </xref>
      ]. Since the mid-1960s, seven known human coronaviruses (HCoVs) have been identified [
      <xref ref-type="bibr" rid="bib3">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="bib4">
       4
      </xref>
      ]. Four commonly detected HCoVs are 229E, OC43, NL63 and HKU1. In one study, 229E and OC43 accounted for approximately 15–29% of respiratory pathogens with relatively low virulence in humans [
      <xref ref-type="bibr" rid="bib3">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="bib5">
       5
      </xref>
      ]. Another epidemiological study in adults estimates that coronavirus causes about 15% of common colds [
      <xref ref-type="bibr" rid="bib6">
       6
      </xref>
      ]. Other significant causes of upper respiratory infections include influenza virus, rhinovirus, parainfluenza virus, Group A Streptococci, EBV and respiratory syncytial virus (RSV).
     </p>
     <p id="p0055">
      The three other strains of HCoVs, severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have a different pathogenicity and lead to higher mortality rates in human populations. MERS-CoV was isolated from a male patient who died from acute pneumonia and renal failure in Saudi Arabia in 2012 [
      <xref ref-type="bibr" rid="bib7">
       7
      </xref>
      ], and was subsequently responsible for 2494 cases and 858 deaths from 27 different countries (case-fatality rate: 34.4%) [
      <xref ref-type="bibr" rid="bib8">
       8
      </xref>
      ]. Both SARS-CoV and SARS-CoV-2 were first recognized in China. SARS-CoV caused a total of 8422 probable SARS cases, 919 SARS-related deaths (case-fatality rate: 11%) and spread to 32 different countries or regions between November 2002 and August 2003 [
      <xref ref-type="bibr" rid="bib9">
       9
      </xref>
      ]. Since December 2019, the SARS-CoV-2 has infected 73,230 people and caused 1871 deaths (case-fatality rate: 2.6%) and has spread to 25 countries, according to the State Council Information Office in Beijing, China (updated as of Feb. 17, 2020) [
      <xref ref-type="bibr" rid="bib10">
       10
      </xref>
      ]. As of this date, the number of confirmed and suspected cases is still increasing, as is the number of deaths, although there is a significant increase in the number of recovered patients as well.
     </p>
     <p id="p0060">
      Coronaviruses were first identified in the 1960s. It is not known for how long they have existed. Most of the time they are associated with mild disease, but every few years a highly virulent strain appears. The pathogenesis of these deadly epidemics is unclear. An examination of the structure of the viruses and the mechanism of infection may help elucidate and provide information for the development of effective treatment and possibly vaccines. Our purpose of this review is to provide a brief summary of the epidemiology and history of SARS, as well as the lessons learned. The other aim is to review the epidemiology, pathogenesis, clinical characteristics, diagnosis and management of patients infected with SARS-CoV-2 to better understand this deadly coronavirus and suggest prevention, treatment and management strategies.
     </p>
    </sec>
    <sec id="sec2">
     <label>
      2
     </label>
     <title>
      Characteristics of coronaviruses and coronavirus infections
     </title>
     <sec id="sec2.1">
      <label>
       2.1
      </label>
      <title>
       Biology of the coronaviruses
      </title>
      <p id="p0065">
       CoVs are enveloped with a non-segmented, positive-sense, single-strand RNA, with size ranging from 26,000 to 37,000 bases. This is the largest known genome among RNA viruses [
       <xref ref-type="bibr" rid="bib11">
        11
       </xref>
       ]. The genomic structure of CoVs is as follows: 5′-leader-UTR-replicase-S (Spike)–E (Envelope)-M (Membrane)-N (Nucleocapsid)-3′UTRpoly (A) tail. There are accessory genes interspersed within the structural genes at the 3′ end of genome [
       <xref ref-type="bibr" rid="bib12">
        12
       </xref>
       ], some of which have been shown to play an important roles in viral pathogenesis [
       <xref ref-type="bibr" rid="bib13">
        13
       </xref>
       ]. The S protein is responsible for receptor-binding and subsequent viral entry into host cells, the M and E proteins play important roles in viral assembly, and the N protein is necessary for RNA synthesis [
       <xref ref-type="bibr" rid="bib12">
        12
       </xref>
       ,
       <xref ref-type="bibr" rid="bib14">
        14
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec2.2">
      <label>
       2.2
      </label>
      <title>
       Coronavirus transmission
      </title>
      <p id="p0070">
       CoVs can transmit across species barriers. SARS-CoV originated from bats of the Hipposideridae family, using palm civets as intermediary hosts before dissemination to humans [
       <xref ref-type="bibr" rid="bib15">
        15
       </xref>
       ,
       <xref ref-type="bibr" rid="bib16">
        16
       </xref>
       ]. The earliest patients infected with SARS-CoV-2 in Wuhan ultimately caused the epidemic known as COronaVIrus Disease 2019 (COVID-2019). Some of these patients had a history of contact with a wholesale seafood market in the early stages, suggesting animal-to-person spread. Subsequently, a large number of patients reportedly did not have exposure to the markets, suggesting the development of person-to-person spread [
       <xref ref-type="bibr" rid="bib17">
        [17]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib18">
        [18]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib19">
        [19]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib20">
        [20]
       </xref>
       ].
      </p>
      <p id="p0075">
       There are three primary ways to transmit the virus, including close person-to-person contact, aerosol transmission, and transmission by touch [
       <xref ref-type="bibr" rid="bib21">
        [21]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib22">
        [22]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib23">
        [23]
       </xref>
       ]. The virus is thought to be transmitted to other people by respiratory droplets during coughing or sneezing. Droplet spread can occur when an infected person sneezes or coughs, whereupon virus containing droplets are propelled up to 3 feet through the air and are deposited on the mucous membranes of the mouth, nose, or eyes of persons who are nearby. A recent report suggests that transmission through the ocular surface is also possible [
       <xref ref-type="bibr" rid="bib24">
        24
       </xref>
       ]. The other avenues for the spread of the virus are shaking hands with an infected person, touching an infected object/surface, frequent touching of the nose or mouth or coming into contact with a patient's excreta. Another avenue is through “hidden transmission” [
       <xref ref-type="bibr" rid="bib19">
        19
       </xref>
       ], in which asymptomatic infected individuals or carriers unknowingly transmit the virus to unsuspecting contacts.
      </p>
     </sec>
     <sec id="sec2.3">
      <label>
       2.3
      </label>
      <title>
       Variability of clinical presentation
      </title>
      <p id="p0080">
       Before the first outbreak of SARS, a limited number of HCoVs such as HCoV-229E were frequently found to infect humans, and were widely circulating in human populations causing only mild illnesses like the common cold [
       <xref ref-type="bibr" rid="bib3">
        3
       </xref>
       ,
       <xref ref-type="bibr" rid="bib25">
        25
       </xref>
       ]. However, SARS, MERS and SARS-CoV-2 present with a spectrum of disease severity ranging from flu-like symptoms to acute respiratory distress syndrome [
       <xref ref-type="bibr" rid="bib25">
        25
       </xref>
       ,
       <xref ref-type="bibr" rid="bib26">
        26
       </xref>
       ]. Early on, these patients are usually treated with conventional medications which had no clinical benefit, resulting in spread to health care personnel. For those with flu-like symptoms or even more severe disease, it would not be immediately evident that this is an atypical and virulent form of a coronavirus. For comparison, influenza has an estimated mortality rate of 0.07%–0.2%. A high index of suspicion is helpful but not foolproof.
      </p>
     </sec>
     <sec id="sec2.4">
      <label>
       2.4
      </label>
      <title>
       Genetic diversity
      </title>
      <p id="p0085">
       The various CoVs of animal origin undergo evolution and genetic recombination, thereby resulting in mutated CoVs that may be highly pathogenic and potentially be more deadly to humans [
       <xref ref-type="bibr" rid="bib3">
        3
       </xref>
       ,
       <xref ref-type="bibr" rid="bib27">
        27
       </xref>
       ]. For SARS-CoV, the mutation rate in the SARS-CoV genome was estimated to be 0.80–2.38 × 10
       <sup>
        −3
       </sup>
       nucleotide substitutions per site per year, and the nonsynonymous and synonymous substitution rates were estimated to be 1.16–3.30 × 10
       <sup>
        −3
       </sup>
       and 1.67–4.67 × 10
       <sup>
        −3
       </sup>
       per site per year, respectively, which are similar to that of other RNA viruses [
       <xref ref-type="bibr" rid="bib28">
        28
       </xref>
       ]. The various CoVs of animal origin undergo evolution and genetic recombination either within the host species or upon jumping from one species to another. Such changes thus have the potential to lead to variants that have high pathogenic potential when transmitted to humans [
       <xref ref-type="bibr" rid="bib29">
        [29]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib30">
        [30]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib31">
        [31]
       </xref>
       ]. Recently, two mutations of the S protein and N protein SARS-CoV-2 may explain its zoonotic transmission [
       <xref ref-type="bibr" rid="bib32">
        32
       </xref>
       ]. Genomic alignment of 54 SARS-CoV-2 genomes identified two hotspots of hypervariability at positions 8789 (synonymous variant) and 28,151(Ser/Leu change), located in the polyprotein and ORF8 genes respectively [
       <xref ref-type="bibr" rid="bib33">
        33
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec2.5">
      <label>
       2.5
      </label>
      <title>
       Comorbidities
      </title>
      <p id="p0090">
       Most patients who have died from the virus had other chronic medical conditions, were elderly patients or were immunocompromised. One study reported that 6.7% of SARS patients had acute renal impairment and 84.6% had proteinuria [
       <xref ref-type="bibr" rid="bib34">
        34
       </xref>
       ]. Hematological abnormalities such as thrombocytopenia and lymphopenia were frequently observed in SARS [
       <xref ref-type="bibr" rid="bib35">
        35
       </xref>
       ,
       <xref ref-type="bibr" rid="bib36">
        36
       </xref>
       ]. Complications encountered for SARS-CoV-2 include acute respiratory distress syndrome (29%,12/41), anemia (15%, 6/41), acute cardiac injury (12%, 5/41) and secondary infection (10%, 4/41) [
       <xref ref-type="bibr" rid="bib26">
        26
       </xref>
       ]. In a SARS-CoV-2 descriptive study, 11 of 99 patients died of multiple organ failure, and seven were older than 60 years [
       <xref ref-type="bibr" rid="bib37">
        37
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec2.6">
      <label>
       2.6
      </label>
      <title>
       Lack of effective treatment
      </title>
      <p id="p0095">
       To date, there is no anti-viral therapeutics that specifically targets human coronaviruses, so treatment is only supportive.
       <italic>
        In vitro
       </italic>
       , interferons (IFNs) are only partially effective against coronaviruses [
       <xref ref-type="bibr" rid="bib38">
        38
       </xref>
       ].
       <italic>
        In vivo
       </italic>
       , the effectiveness of IFNs combined with ribavirin requires further evaluation [
       <xref ref-type="bibr" rid="bib39">
        39
       </xref>
       ]. A variety of other agents, including antiviral peptides and corticosteroids have been shown to be effective
       <italic>
        in vitro
       </italic>
       and/or in animal models [
       <xref ref-type="bibr" rid="bib40">
        40
       </xref>
       ,
       <xref ref-type="bibr" rid="bib41">
        41
       </xref>
       ]. However, clinical evidence does not support the use of corticosteroid treatment for SARS-CoV-2 lung injury [
       <xref ref-type="bibr" rid="bib42">
        42
       </xref>
       ]. Vaccines that have been developed are either not effective, or in some cases have been reported to be involved in the selection of novel pathogenic CoVs via recombination of circulating strains [
       <xref ref-type="bibr" rid="bib12">
        12
       </xref>
       ,
       <xref ref-type="bibr" rid="bib22">
        22
       </xref>
       ,
       <xref ref-type="bibr" rid="bib40">
        40
       </xref>
       ]. Vaccine development can be a challenge. It is noteworthy that almost 20 years after SARS, there is still no vaccine for coronavirus.
      </p>
     </sec>
    </sec>
    <sec id="sec3">
     <label>
      3
     </label>
     <title>
      A historical review of the epidemiology of SARS and how it was contained
     </title>
     <p id="p0100">
      It has been 17 years since the outbreak of severe acute respiratory syndrome (SARS) caused by the SARS coronavirus (SARS-CoV) [
      <xref ref-type="bibr" rid="bib43">
       43
      </xref>
      ]. This highly contagious atypical pneumonia first appeared in Guangdong Province, China, in November 2002. The initial cases were animal handlers in Guangzhou city having close contact with wild game food. It was suggested that civets could serve as an intermediate amplification host. Three months later, the SARS pandemic was rapidly and globally disseminated due to person-to-person transmission of the virus. On the February 21, 2003, a medical professor from Foshan in Guangdong province who was considered a “super-spreader” went to Hong Kong to visit his relatives. During his stay in Hong Kong, he transmitted the virus to 2 family members, 4 health care workers (HCWs) and 12 other nearby residents. Because of international travel and transmission to HCWs, these patients spread the SARS-CoV to Hong Kong and other countries including Vietnam, Singapore and Canada. Eventually, 8422 people were infected in 32 countries and 919 (11%) died [
      <xref ref-type="bibr" rid="bib9">
       9
      </xref>
      ]. In China, 5328 cases were reported and 349 (6.5%) perished between November 16, 2002 and June 3, 2003 [
      <xref ref-type="bibr" rid="bib9">
       9
      </xref>
      ].
     </p>
     <p id="p0105">
      At the beginning of the outbreaks in Hong Kong, mainland China and other areas, we were unfamiliar with the deadly SARS-CoV. It took about 3 months to complete the sequencing of this coronavirus [
      <xref ref-type="bibr" rid="bib44">
       44
      </xref>
      ]. The global success in the fight against SARS was partly based on epidemiological and biological characteristics of the infectious agent SARS-CoV. An understanding of transmission patterns and the ability to diagnose and confirm affected patients ultimately led to effective containment measures and a slowdown in the spread of the disease. Due to the lack of medications or a vaccine, the options for early intervention were limited to public health measures [
      <xref ref-type="bibr" rid="bib45">
       45
      </xref>
      ].
     </p>
     <p id="p0110">
      The steps that led to the containment of SARS can be illustrated by the events that occurred in Beijing. Beijing experienced the largest outbreak of SARS beginning on the March 5, 2003. The outbreak peaked within 6 weeks on the April 25, 2003 when 173 newly suspected SARS cases were hospitalized daily [
      <xref ref-type="bibr" rid="bib46">
       46
      </xref>
      ]. On the June 20, 2003, the last batch of 18 SARS patients recovered and were discharged from hospital, signaling the end of the pandemic in Beijing. The prompt resolution of the outbreak in Beijing was attributed to the rapid adoption of a series of effective control measures.
      <list id="olist0010" list-type="simple">
       <list-item id="o0010">
        <label>
         1.
        </label>
        <p id="p0115">
         Thousands of local and military health workers were deployed for emergency management of the outbreak. Large quantities of emergency supplies including personal protective equipment (PPE) and medical apparat were sent to front-line medical sectors. These people and materials were key to winning the war against SARS.
        </p>
       </list-item>
       <list-item id="o0015">
        <label>
         2.
        </label>
        <p id="p0120">
         More than 100 fever clinics were set up in all secondary and tertiary hospitals in Beijing. People visiting the fever clinics had a physical examination including body temperature, white blood cell count and chest radiograph. Fever clinics played an important role in screening and triage.
        </p>
       </list-item>
       <list-item id="o0020">
        <label>
         3.
        </label>
        <p id="p0125">
         All actively ill patients with SARS were concentrated in designated hospital wards. On the May 1, 2003, a new 1000-bed SARS hospital (Xiaotangshan Hospital, Beijing) was built and put into operation immediately. The advantages of having such a facility was that it was more conducive to the centralized management of SARS patients, and at the same time, it reduced transmission of the virus to healthy people.
        </p>
       </list-item>
       <list-item id="o0025">
        <label>
         4.
        </label>
        <p id="p0130">
         During the period of the SARS outbreak, more than 60,000 HCWs received medical training in the management of patients with SARS, infection control and the use of PPE.
        </p>
       </list-item>
       <list-item id="o0030">
        <label>
         5.
        </label>
        <p id="p0135">
         Multiple measures were taken to reduce person-to-person transmission, including isolation of patients with SARS, tracing and quarantine of close contacts, transit site surveillance and closing poorly maintained facilities that could enhance spread of the virus.
        </p>
       </list-item>
       <list-item id="o0035">
        <label>
         6.
        </label>
        <p id="p0140">
         Information dissemination was critical. Timely and accurate reporting of the status of the epidemic and scientific guidance on prevention and infection control played important roles in stabilizing people and overcoming the epidemic [
         <xref ref-type="bibr" rid="bib45">
          [45]
         </xref>
         ,
         <xref ref-type="bibr" rid="bib46">
          [46]
         </xref>
         ,
         <xref ref-type="bibr" rid="bib47">
          [47]
         </xref>
         ,
         <xref ref-type="bibr" rid="bib48">
          [48]
         </xref>
         ].
        </p>
       </list-item>
      </list>
     </p>
    </sec>
    <sec id="sec4">
     <label>
      4
     </label>
     <title>
      Lessons learned from the 2003 SARS pandemic
     </title>
     <p id="p0145">
      SARS was the very first coronavirus pandemic with the ability to spread from people to people mainly by droplets, but it would not be the last [
      <xref ref-type="bibr" rid="bib49">
       49
      </xref>
      ]. This section presents lessons learned from the SARS pandemic. Although the SARS-CoV rapidly spread throughout the world and caused great damages to human health, the global success in the fight against SARS ultimately demonstrated that containment was possible [
      <xref ref-type="bibr" rid="bib50">
       50
      </xref>
      ].
     </p>
     <sec id="sec4.1">
      <label>
       4.1
      </label>
      <title>
       Animal source containment
      </title>
      <p id="p0150">
       Early on, there were clues suggesting the link between SARS-CoV and civets, bred for food in China [
       <xref ref-type="bibr" rid="bib51">
        51
       </xref>
       ]. Strengthening the monitoring of these wild animal sources was an important factor in controlling emergence of these virus and their spread in humans. Some scholars advocated that the trading of wild animals in wet markets in Southern China should be banned [
       <xref ref-type="bibr" rid="bib52">
        52
       </xref>
       ]. In fact, the Chinese government had issued bans on rearing, trading, transporting and slaughtering wild animals for dietary purposes over 10 years ago [
       <xref ref-type="bibr" rid="bib53">
        53
       </xref>
       ]. This however, did not stop the practice of illegal trading of wild animals.
      </p>
     </sec>
     <sec id="sec4.2">
      <label>
       4.2
      </label>
      <title>
       Early detection and diagnosis
      </title>
      <p id="p0155">
       The nonspecific symptoms and signs of SARS and the long incubation period accentuated the transmission to HCWs and people in close communities [
       <xref ref-type="bibr" rid="bib54">
        54
       </xref>
       ]. Early identification of suspect cases is the key to inhibiting the spread of the virus. Rapid identification of the viral genome and the development of rapid diagnostic tests will facilitate the isolation of those who are confirmed as infected [
       <xref ref-type="bibr" rid="bib50">
        50
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec4.3">
      <label>
       4.3
      </label>
      <title>
       Rigorous infection control
      </title>
      <p id="p0160">
       <list id="olist0015" list-type="simple">
        <list-item id="o0040">
         <label>
          a)
         </label>
         <p id="p0165">
          Environmental hygiene in medical sectors and personal hygiene of health care workers should be maintained [
          <xref ref-type="bibr" rid="bib55">
           55
          </xref>
          ,
          <xref ref-type="bibr" rid="bib56">
           56
          </xref>
          ].
         </p>
        </list-item>
        <list-item id="o0045">
         <label>
          b)
         </label>
         <p id="p0170">
          Contact tracing, strict isolation of actively ill patients and quarantine of close contacts should be implemented early [
          <xref ref-type="bibr" rid="bib54">
           54
          </xref>
          ].
         </p>
        </list-item>
        <list-item id="o0050">
         <label>
          c)
         </label>
         <p id="p0175">
          Training in the use of personal protective equipment protects the safety of HCWs [
          <xref ref-type="bibr" rid="bib57">
           57
          </xref>
          ].
         </p>
        </list-item>
        <list-item id="o0055">
         <label>
          d)
         </label>
         <p id="p0180">
          Establishing fever clinics, setting up designated hospital wards and SARS hospitals reduced human-to-human transmission [
          <xref ref-type="bibr" rid="bib58">
           58
          </xref>
          ].
         </p>
        </list-item>
        <list-item id="o0060">
         <label>
          e)
         </label>
         <p id="p0185">
          Education of the public on communicable diseases and what measures to take on a personal basis to prevent spread.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="sec4.4">
      <label>
       4.4
      </label>
      <title>
       Timely case report and rapid information dissemination
      </title>
      <p id="p0190">
       A number of studies have shown that clear and timely dissemination of information is essential in handling an outbreak [
       <xref ref-type="bibr" rid="bib54">
        54
       </xref>
       ]. Infection control is based on rapid information dissemination. Since SARS in 2003, China has implemented legislation on the surveillance, reporting and early warning system of infectious diseases, requiring the regular release of information during public health emergencies. There is a clearly defined procedure and schedule for reporting public health emergencies which requires designated medical centers to submit relevant information online. If confirmed, reports on SARS and other infectious diseases can be submitted and received directly within two hours through the Internet [
       <xref ref-type="bibr" rid="bib53">
        53
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec4.5">
      <label>
       4.5
      </label>
      <title>
       Vaccine development
      </title>
      <p id="p0195">
       After SARS, development of a vaccine appeared to be the best approach to prevent future SARS-CoV epidemics. However, there were many obstacles in SARS vaccine development. Firstly, researchers did not have a comprehensive understanding of the pathogenic mechanism of SARS-CoV. Secondly, animal models of SARS-CoV infection could not simulate human disease because of an incongruent pathogenesis. Thirdly, in order to test the efficacy, many people must be tested in areas where the virus is endemic. Once the SARS epidemic ended, human trials were not possible [
       <xref ref-type="bibr" rid="bib59">
        59
       </xref>
       ]. Although several candidate vaccines against SARS-CoV have been produced and tested, at present, unfortunately, there is no FDA approved vaccine against SARS.
      </p>
     </sec>
    </sec>
    <sec id="sec5">
     <label>
      5
     </label>
     <title>
      The current SARS-CoV-2 infection in China
     </title>
     <sec id="sec5.1">
      <label>
       5.1
      </label>
      <title>
       The origin of SARS-CoV-2
      </title>
      <p id="p0200">
       A cluster of cases of viral pneumonia of unknown etiology, now known as SARS-CoV-2 pneumonia, occurred in Wuhan, Hubei Province and were reported to health authorities on the December 29, 2019 [
       <xref ref-type="bibr" rid="bib60">
        60
       </xref>
       ]. This outbreak was associated with a large seafood and animal market [
       <xref ref-type="bibr" rid="bib61">
        61
       </xref>
       ]. Further investigations are ongoing to determine the origin of the infection. To date, many reports have described possible original and intermediate hosts (
       <xref ref-type="fig" rid="fig1">
        Fig. 1
       </xref>
       ). Researchers found that the SARS-CoV-2 showed a higher sequence homology to Bat-CoV-RaTG13 that was previously detected in
       <italic>
        Rhinolophus affinis
       </italic>
       from Yunnan Province than Bat-SL-CoVZC21 and Bat-SL-CoVZC45, which suggested that the Chinese chrysanthemum bat is the origin of SARS-CoV-2. More recently, the pangolin was believed to be the likely intermediate host due to the fact that there appeared to be approximately 99% sequence homology between SARS-Co V-2 and the consensus sequence derived from &gt;1000 metagenomic samples from the pangolin species [
       <xref ref-type="bibr" rid="bib62">
        62
       </xref>
       ].
       <fig id="fig1">
        <label>
         Fig. 1
        </label>
        <caption>
         <p>
          The origin and inter-host timeline of SARS-CoV-2. All the information is derived from published data. Journal name: (a) Emerging Microbes &amp; Infections, (b) bioRvix, (c) J Med Virol, (d) The Lancet, (e) the New England Journal of Medicine, (f) J Virol, (g) Chin Med J (Engl), (h)
          <ext-link ext-link-type="uri" id="intref0115" xlink:href="https://www.scau.edu.cn/2020/0207/c1300a219015/page.htm">
           https://www.scau.edu.cn/2020/0207/c1300a219015/page.htm
          </ext-link>
          . Bat-ZC21: Bat-SL-CoVZC21, GenBank Accession MG772934; Bat-ZC45: Bat-SL-CoVZC45, GenBank Accession MG772933; Bat-RaTG13: yun-nan-Bat-CoV-RaTG13, GISAID accession EPI_ISL_402,131.
         </p>
        </caption>
        <alt-text id="alttext0010">
         Fig. 1
        </alt-text>
        <graphic xlink:href="gr1_lrg">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="sec5.2">
      <label>
       5.2
      </label>
      <title>
       New epidemiological developments
      </title>
      <p id="p0205">
       Currently, person to person transmission from patients with pneumonia or even asymptomatic patients during the incubation period are the main conduits for the spread of the infection [
       <xref ref-type="bibr" rid="bib63">
        63
       </xref>
       ]. Respiratory droplets are the main route of transmission, but the virus can also be transmitted through contact or through the fecal-oral route based on a study which demonstrated the presence of the virus in rectal swabs [
       <xref ref-type="bibr" rid="bib64">
        64
       </xref>
       ]. Fifteen health care workers in a Wuhan hospital were infected while caring for patients with confirmed or suspected infection [
       <xref ref-type="bibr" rid="bib65">
        65
       </xref>
       ,
       <xref ref-type="bibr" rid="bib66">
        66
       </xref>
       ]. As of February 11, 2020, a total of 1716 health care workers have become infected and 5 have died (0.3%) [
       <xref ref-type="bibr" rid="bib67">
        67
       </xref>
       ]. A study of a family cluster reported that five members of a family of six traveled to Wuhan, and four were infected with the SARS-CoV-2. The family member who did not travel became infected with the virus after several days of contact with the four infected members [
       <xref ref-type="bibr" rid="bib19">
        19
       </xref>
       ].
      </p>
      <p id="p0210">
       Li et al. [
       <xref ref-type="bibr" rid="bib65">
        65
       </xref>
       ] showed that human-to-human transmission among close contacts has been occurring since the middle of December 2019. Further dissemination has continued rapidly over the ensuing months. The authors estimated that the reproduction number (R
       <sub>
        0
       </sub>
       ) for SARS-CoV-2 is 2.2, meaning that every infected person can infect a mean of 2.2 people. In another study, the reproduction number of the SARS-CoV-2 was 2.68 with an epidemic doubling time of 6.4 days [
       <xref ref-type="bibr" rid="bib68">
        68
       </xref>
       ]. It is worth noting that a nucleic acid fragment of the SARS-CoV-2 was detected by Guangzhou Centers for Disease Control and Prevention (CDC) on a doorknob touched by a confirmed patient [
       <xref ref-type="bibr" rid="bib69">
        69
       </xref>
       ]. China Daily reported that scientists have discovered that stool samples from patients infected with the SARS-CoV-2 have also tested positive for the virus [
       <xref ref-type="bibr" rid="bib70">
        70
       </xref>
       ], and that the virus was also detected in the loose stool of the first patient in the US infected with the virus [
       <xref ref-type="bibr" rid="bib71">
        71
       </xref>
       ], meaning the virus has the potential to be spread through contaminated fecal material.
      </p>
      <p id="p0215">
       On the January 22, 2020, a member of the national expert panel on pneumonia reported that he was infected by SARS-CoV-2 during an inspection in Wuhan. He had worn an N95 mask but did not wear eye protection. Several days before the onset of pneumonia, he complained of redness of the eyes. Unprotected exposure of the eyes to SARS-CoV-2 in the Wuhan Fever Clinic may have allowed the virus to enter his body [
       <xref ref-type="bibr" rid="bib24">
        24
       </xref>
       ].
      </p>
      <p id="p0220">
       The situation with SARS-CoV-2 is evolving rapidly. According to the National Health Commission (NHC) of China update on February 17, 2020 [
       <xref ref-type="bibr" rid="bib10">
        10
       </xref>
       ], a total of 72,436 cases were confirmed in the Chinese mainland, including 11,741 severe cases and 1868 deaths. A total of 12,552 patients have recovered and have been discharged. An additional total of 6242 suspected cases remain. Most patients (59,989 cases) have been in Hubei province, where the outbreak began, including 10,970 severe cases and 1789 deaths. The Hong Kong and Macao Special Administrative Regions as well as Taiwan reported 92 confirmed cases of the disease, including 2 deaths and 9 patients who have recovered. There are significantly more SARS-CoV-2 cases than SARS cases during the 2003 outbreak. The current spread of the epidemic in China is shown in
       <xref ref-type="fig" rid="fig2">
        Fig. 2
       </xref>
       ,
       <xref ref-type="fig" rid="fig3">
        Fig. 3
       </xref>
       ,
       <xref ref-type="fig" rid="fig4">
        Fig. 4
       </xref>
       .
       <fig id="fig2">
        <label>
         Fig. 2
        </label>
        <caption>
         <p>
          Confirmed cases of SARS-CoV-2, February 17, 2020. (Data from the government website of China's National Health Commission).
         </p>
        </caption>
        <alt-text id="alttext0015">
         Fig. 2
        </alt-text>
        <graphic xlink:href="gr2_lrg">
        </graphic>
       </fig>
       <fig id="fig3">
        <label>
         Fig. 3
        </label>
        <caption>
         <p>
          Numbers of suspected, confirmed and severe cases of SARS-CoV-2 in China and Hubei province, February 17, 2020. (Data from the government website of China's National Health Commission. Since February 12, 2020, Hubei Province has included the number of clinical diagnosis cases into the number of confirmed cases).
         </p>
        </caption>
        <alt-text id="alttext0020">
         Fig. 3
        </alt-text>
        <graphic xlink:href="gr3_lrg">
        </graphic>
       </fig>
       <fig id="fig4">
        <label>
         Fig. 4
        </label>
        <caption>
         <p>
          Numbers of deaths and recovered cases of SARS-CoV-2 in China and Hubei, February 17, 2020. (Data from the government website of China's National Health Commission).
         </p>
        </caption>
        <alt-text id="alttext0025">
         Fig. 4
        </alt-text>
        <graphic xlink:href="gr4_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0225">
       According to World Health Organization (WHO) SARS-CoV-2 Situation Report [
       <xref ref-type="bibr" rid="bib72">
        72
       </xref>
       ], additional cases have been identified in a growing number of other international locations, including 25 countries outside China (
       <xref ref-type="fig" rid="fig5">
        Fig. 5
       </xref>
       ). There are now three deaths that have been reported outside of China (one in the Philippines, one in Japan and one in France). The WHO declared the SARS-CoV-2 epidemic a Public Health Emergency of International Concern (PHEIC) on January 30, 2020, citing that human-to-human infections have been confirmed in multiple countries [
       <xref ref-type="bibr" rid="bib73">
        73
       </xref>
       ].
       <fig id="fig5">
        <label>
         Fig. 5
        </label>
        <caption>
         <p>
          Countries, territories or areas with reported confirmed cases of SARS-CoV-2, February 17, 2020. (Data from the WHO Coronavirus disease 2019 (COVID-19) Situation Report-28).
         </p>
        </caption>
        <alt-text id="alttext0030">
         Fig. 5
        </alt-text>
        <graphic xlink:href="gr5_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0230">
       According to Fang et al. [
       <xref ref-type="bibr" rid="bib74">
        74
       </xref>
       ], fifteen cases of childhood infection had been identified as of January 30, 2020, including 8 boys and 7 girls, ranging in age from 8 months to 12 years. Of the 15 pediatric cases, 13 had a clear history of family clustering in Wuhan. At present, several confirmed pregnant women in Wuhan have given birth during the illness. On February 2, 2020, Wuhan local media reported that a confirmed pregnant woman gave birth to a newborn by cesarean section under strict level three protection, but the newborn's throat swab was positive for the nucleic acid virus test [
       <xref ref-type="bibr" rid="bib75">
        75
       </xref>
       ]. However, Chen et al. tested the SARS-CoV-2 in amniotic fluid, cord blood, neonatal throat swab, and breastmilk samples from six confirmed SARS-CoV-2 pregnant women, and all samples tested negative for the virus, which suggests that there is currently no evidence for intrauterine infection caused by vertical transmission in women who develop COVID-19 pneumonia in late pregnancy [
       <xref ref-type="bibr" rid="bib76">
        76
       </xref>
       ]. No cases of newborns or child deaths have been reported. The NHC has called for close monitoring of outbreaks in children and pregnant women [
       <xref ref-type="bibr" rid="bib77">
        77
       </xref>
       ].
      </p>
      <p id="p0235">
       The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team of the Chinese CDC reported the epidemiology characteristics of 44,672 confirmed cases as of February 11, 2020. Among the confirmed 44,672 cases (74.7% in Hubei Province), 51.4% were male, and 80.9% were mild or moderate cases. The majority of the cases were between 30 and 69 years old (77.8%), while 0-9 year-olds and 10-19 year-olds accounted for 0.9% and 1.2% respectively. Hypertension (12.8%), diabetes (5.3%), cardiovascular disease (4.2%) were the most common underlying diseases. A total of 1023 deaths occurred among confirmed cases for an overall case-fatality rate of 2.3%, and 81% of the deaths were over 60 years old. The mortality rates of those aged 60–69, 70–79 and over 80 years were 3.6%, 8.0%, and 14.8%, respectively. The mortality rate of critical cases was 49% [
       <xref ref-type="bibr" rid="bib67">
        67
       </xref>
       ].
      </p>
      <p id="p0240">
       Based on this evidence, the current SARS-CoV-2 is easily transmissible in humans, even in children and pregnant women. It should also be noted that most patients have a good prognosis. The symptoms in children are relatively mild, and only a minority are in critical condition. The death cases involved mostly the elderly and those with a chronic underlying disease. This fact, however, does not diminish the seriousness of the epidemic.
      </p>
      <p id="p0245">
       During the early stages of the epidemic, several hospitals, including Wuhan Union Hospital, Wuhan Tongji Hospital, and Peking Union Medical College Hospital, had created different diagnosis and treatment programs [
       <xref ref-type="bibr" rid="bib37">
        37
       </xref>
       ,
       <xref ref-type="bibr" rid="bib78">
        [78]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib79">
        [79]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib80">
        [80]
       </xref>
       ]. The WHO and the NHC of China have since then published guidelines for the diagnosis and clinical management of SARS-CoV-2 pneumonia [
       <xref ref-type="bibr" rid="bib81">
        81
       </xref>
       ,
       <xref ref-type="bibr" rid="bib82">
        82
       </xref>
       ].
      </p>
     </sec>
    </sec>
    <sec id="sec6">
     <label>
      6
     </label>
     <title>
      Clinical presentation
     </title>
     <sec id="sec6.1">
      <label>
       6.1
      </label>
      <title>
       Clinical manifestations
      </title>
      <p id="p0250">
       According to the guidelines published by the NHC and based on current epidemiological studies, the incubation period is typically 3–7 days, with a maximum of 14 days [
       <xref ref-type="bibr" rid="bib82">
        82
       </xref>
       ]. Common symptoms of COVID-19 include fever, fatigue, and dry cough. A few patients have symptoms such as nasal congestion, runny nose, sore throat, and diarrhea. Some patients only have a low fever, mild fatigue, and no pneumonia. In severe cases, the infection can cause pneumonia, shortness of breath and breathing difficulties occurring more than one week after infection. Critical patients may progress rapidly to acute respiratory distress syndrome (ARDS), septic shock, metabolic acidosis, coagulation dysfunction, and even death. It is worth noting that during the course of severe and critical patients, there can be moderate to low-grade fever or even no obvious fever.
      </p>
      <p id="p0255">
       Huang et al. provided first-hand data regarding COVID-19 [
       <xref ref-type="bibr" rid="bib26">
        26
       </xref>
       ]. Their study reported the clinical features of the first 41 patients admitted to the designated hospital in Wuhan who were laboratory-confirmed COVID-19 by January 2, 2020. Twenty-seven (66%) of the 41 patients had been exposed to the Huanan seafood market. Common symptoms at the onset of illness were fever (98%), cough (76%), and myalgia or fatigue (44%). Less common symptoms were sputum production, headache, hemoptysis, and diarrhea. Dyspnea developed in 22 (55%) of 40 patients and 26 (63%) of 41 patients had lymphopenia. The median time from onset of symptoms to first hospital admission was 7.0 days, to shortness of breath was 8.0 days, and to ARDS was 9.0 days. Almost a third of patients developed ARDS requiring intensive care, 5 patients had acute cardiac injury, and 4 patients required assisted ventilation. Eventually 28 patients were discharged, 13 patients were admitted to the intensive care unit (ICU) and 6 patients died.
      </p>
      <p id="p0260">
       Chen et al. reported 99 patients with SARS-CoV-2 pneumonia admitted to the Jinyintan Hospital in Wuhan [
       <xref ref-type="bibr" rid="bib37">
        37
       </xref>
       ]. Forty-nine (49%) patients had a history of exposure to the local Huanan seafood market and 50 patients (51%) had chronic underlying diseases. Patients had clinical manifestations of fever (83%), cough (82%), shortness of breath (31%), muscle aches (11%), confusion (9%), headache (8%), sore throat (5%), rhinorrhea (4%), chest pain (2%), and diarrhea (2%). Eighty-nine (90%) patients had more than one symptom. According to their study, many cases presented with organ function damage, including 17 cases with ARDS, 8 cases with acute respiratory injury, 3 cases with acute renal injury, 4 cases with septic shock, and 1 case with ventilator-associated pneumonia. Eventually 31 patients were discharged, 11 patients died, and the remaining 57 patients were still in hospital.
      </p>
      <p id="p0265">
       At Zhongnan Hospital of Wuhan University in Wuhan, Wang et al. [
       <xref ref-type="bibr" rid="bib83">
        83
       </xref>
       ] enrolled 138 hospitalized patients with SARS-CoV-2 pneumonia. Common symptoms included fever (98.6%), fatigue (69.6%), dry cough (59.4%), myalgia (34.8%), and dyspnea (31.2%). The median time from first symptom to dyspnea was 5.0 days, to hospital admission was 7.0 days, and to ARDS was 8.0 days. Major complications during hospitalization included ARDS, arrhythmia, and shock. Of the 138 hospitalized patients, 47 recovered and have been discharged, 36 patients were admitted to the ICU and 6 patients have died.
      </p>
      <p id="p0270">
       Chang et al. [
       <xref ref-type="bibr" rid="bib84">
        84
       </xref>
       ] reported 13 confirmed patients outside of Wuhan, including 2 children (aged 2 years and 15 years). Twelve patients (92%) had fever before hospitalization. Other symptoms included upper airway congestion (62%), cough (46%), myalgia (23%), and headache (23%). All the patients recovered.
      </p>
      <p id="p0275">
       Guan et al. [
       <xref ref-type="bibr" rid="bib85">
        85
       </xref>
       ] reported 1099 confirmed patients from 552 hospitals in the whole of China as of January 29, 2020. The most common symptoms including fever (87.9%) and cough (67.7%), whereas diarrhea (3.7%) and vomiting (5.0%) were rare. They also pointed out that only 43.8% of the patients had fever on presentation but 87.9% developed fever after being hospitalized. Moreover, compared with non-severe cases, any underlying diseases were significantly more common in severe cases. The most common complication was pneumonia (79.1%), ARDS (3.4%) and shock (1.0%). Of the 1099 patients, 55 patients were admitted to the ICU, and 15 patients died.
      </p>
      <p id="p0280">
       There were therefore a total of 41, 99 and 138 (total 278) cases of SARS-CoV pneumonia admitted in the 3 regional hospitals closest to the Huanan Seafood Market that resulted in 6, 11 and 6 deaths (23 deaths) or a case fatality rate of 0.82%.
      </p>
     </sec>
     <sec id="sec6.2">
      <label>
       6.2
      </label>
      <title>
       Laboratory tests
      </title>
      <p id="p0285">
       In the early stages of the disease, the total number of leukocytes in peripheral blood is normal or decreased, the lymphocyte count is decreased, and some patients show increases in liver enzymes, muscle enzymes, and myoglobin. The C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are increased in most patients, and procalcitonin is normal. In severe cases, D-dimer increases, and peripheral blood lymphocytes decrease progressively. Coronavirus nucleic acid can be detected in the throat, sputum, lower respiratory tract secretions, blood and tool.
      </p>
      <p id="p0290">
       In Huang's study [
       <xref ref-type="bibr" rid="bib26">
        26
       </xref>
       ], the blood counts of patients on admission showed leucopenia and lymphopenia. Prothrombin time and D-dimer levels on admission were higher in ICU patients. Compared with non-ICU patients, ICU patients had higher plasma levels of IL-2, IL-7, IL-10, G-SCF, IP-10, MCP-1, MIP-1α, and TNFα. In Chen's study [
       <xref ref-type="bibr" rid="bib37">
        37
       </xref>
       ], all patients were tested for nine respiratory pathogens and nucleic acids of influenza viruses A and B, as well as bacteria and fungi. No other respiratory viruses were detected, but 4 cases of fungal and 1 case of bacterial infection were found. The absolute number of leukocytes was decreased in 9 patients and increased in 24 patients. The absolute neutrophil count was increased in 38 patients and the absolute lymphocyte count was decreased in 35 patients. Forty-three patients had varying degrees of liver dysfunction, seven patients had varying degrees of renal dysfunction, and most patients had abnormal myocardial zymograms. Seventy-three patients were tested for C-reactive protein which was increased in 63 patients. In Guan's study, 82.1%, 36.2%, and 33.7% of the patients had lymphopenia, thrombocytopenia, and leukopenia, respectively. Compared with non-severe cases, severe cases had more prominent laboratory abnormalities [
       <xref ref-type="bibr" rid="bib85">
        85
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec6.3">
      <label>
       6.3
      </label>
      <title>
       Imaging studies
      </title>
      <p id="p0295">
       In Huang's study [
       <xref ref-type="bibr" rid="bib26">
        26
       </xref>
       ], all 41 patients had pneumonia with abnormal findings on chest computed tomography (CT) and 40 (98%) had bilateral involvement. The ICU patients on admission had bilateral multiple lobular and subsegmental areas of consolidation. The non-ICU patients had bilateral ground-glass opacity and subsegmental areas of consolidation. Subsequent chest CT images showed bilateral ground-glass opacity, whereas the consolidation was resolved. In Chen's study [
       <xref ref-type="bibr" rid="bib37">
        37
       </xref>
       ], imaging showed that 74 patients had bilateral pneumonia, 14 patients had multiple mottled and ground-glass opacities, and 1 patient had a pneumothorax. In Wang's study [
       <xref ref-type="bibr" rid="bib83">
        83
       </xref>
       ], imaging showed that 138 patients had bilateral patchy shadows or ground-glass opacity. In Guan's study, 840 of 1099 patients received chest CT on admission which showed that 76.4% had pneumonia, but 23.9% of severe cases had no radiologic abnormality on initial presentation. Ground-glass opacity (50.0%) and bilateral patchy shadow (46.0%) were the most common findings [
       <xref ref-type="bibr" rid="bib85">
        85
       </xref>
       ].
      </p>
     </sec>
    </sec>
    <sec id="sec7">
     <label>
      7
     </label>
     <title>
      Diagnosis
     </title>
     <p id="p0300">
      The earliest cases of SARS-CoV-2 were identified as “pneumonia of unknown etiology”, which was defined as an illness of unknown etiology with 1. Fever with or without a recorded temperature 2. Radiographic evidence of pneumonia 3. Low or normal leukocyte count or low lymphocyte count during the early stage of disease and 4. No improvement or worsening symptoms after 3–5 days of antimicrobial treatment per standard clinical guidelines [
      <xref ref-type="bibr" rid="bib61">
       61
      </xref>
      ]. With increasing research and knowledge of the disease, diagnosis and treatment guidelines have been continuously updated. At present, the NHC has issued the fifth edition of the guidelines. However, because of a shortage of diagnostic reagents for SARS-CoV-2 detection, different guidelines or programs emphasized comprehensive analysis based on epidemiological history, clinical manifestations and imaging examinations in diagnosis.
     </p>
     <sec id="sec7.1">
      <label>
       7.1
      </label>
      <title>
       Diagnostic criteria [
       <xref ref-type="bibr" rid="bib37">
        37
       </xref>
       ,
       <xref ref-type="bibr" rid="bib78">
        [78]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib79">
        [79]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib80">
        [80]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib81">
        [81]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib82">
        [82]
       </xref>
       ]
      </title>
      <p id="p0305">
       The diagnostic criteria of suspected and confirmed cases were summarized in
       <xref ref-type="table" rid="tbl1">
        Table 1
       </xref>
       .
       <table-wrap id="tbl1" position="float">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          The diagnostic criteria for suspected and confirmed cases [
          <xref ref-type="bibr" rid="bib37">
           37
          </xref>
          ,
          <xref ref-type="bibr" rid="bib77">
           [77]
          </xref>
          ,
          <xref ref-type="bibr" rid="bib78">
           [78]
          </xref>
          ,
          <xref ref-type="bibr" rid="bib79">
           [79]
          </xref>
          ,
          <xref ref-type="bibr" rid="bib80">
           [80]
          </xref>
          ,
          <xref ref-type="bibr" rid="bib81">
           [81]
          </xref>
          ].
         </p>
        </caption>
        <alt-text id="alttext0060">
         Table 1
        </alt-text>
        <table frame="hsides" rules="groups">
         <tbody>
          <tr>
           <td align="left">
            Case
           </td>
           <td align="left">
            Diagnostic criteria
           </td>
          </tr>
          <tr>
           <td align="left" rowspan="3">
            Suspected case
           </td>
           <td align="left">
            Anyone with a history of epidemiology and any two of the clinical manifestations or anyone without epidemiological history and three of the clinical manifestations is considered to be a suspected case:
           </td>
          </tr>
          <tr>
           <td align="left">
            <list id="olist0020" list-type="simple">
             <list-item id="o0065">
              <label>
               (1)
              </label>
              <p id="p0540">
               Epidemiological history:
               <list id="olist0025" list-type="simple">
                <list-item id="o0070">
                 <label>
                  1)
                 </label>
                 <p id="p0545">
                  within 14 days before the disease onset, there is a travel history or living history in Wuhan or other areas with local cases
                 </p>
                </list-item>
                <list-item id="o0075">
                 <label>
                  2)
                 </label>
                 <p id="p0550">
                  within 14 days before the disease onset, there is contact with patients who had fever or respiratory symptoms from Wuhan or other areas with local cases
                 </p>
                </list-item>
                <list-item id="o0080">
                 <label>
                  3)
                 </label>
                 <p id="p0555">
                  a clustering of patients or a contact with patients infected with the SARS-CoV-2
                 </p>
                </list-item>
               </list>
              </p>
             </list-item>
            </list>
           </td>
          </tr>
          <tr>
           <td align="left">
            <list id="olist0030" list-type="simple">
             <list-item id="o0085">
              <label>
               (2)
              </label>
              <p id="p0560">
               Clinical manifestations:
               <list id="olist0035" list-type="simple">
                <list-item id="o0090">
                 <label>
                  1)
                 </label>
                 <p id="p0565">
                  fever and/or respiratory symptoms
                 </p>
                </list-item>
                <list-item id="o0095">
                 <label>
                  2)
                 </label>
                 <p id="p0570">
                  with the above-mentioned imaging characteristics of pneumonia
                 </p>
                </list-item>
                <list-item id="o0100">
                 <label>
                  3)
                 </label>
                 <p id="p0575">
                  the total number of leukocytes in the early stage of the disease is normal or decreased, or the lymphocyte count is decreased
                 </p>
                </list-item>
               </list>
              </p>
             </list-item>
            </list>
           </td>
          </tr>
          <tr>
           <td align="left" rowspan="2">
            Confirmed case
           </td>
           <td align="left">
            Any suspected case with one of the following pathogenic features is reclassified as a confirmed case:
           </td>
          </tr>
          <tr>
           <td align="left">
            <list id="olist0040" list-type="simple">
             <list-item id="o0105">
              <label>
               (1)
              </label>
              <p id="p0580">
               Positive results of SARS-CoV-2 nucleic acids by RT-PCR of respiratory or blood specimens
              </p>
             </list-item>
             <list-item id="o0110">
              <label>
               (2)
              </label>
              <p id="p0585">
               DNA highly homologous to SARS-CoV-2 by genetic sequencing of viral genes in respiratory or blood specimens
              </p>
             </list-item>
            </list>
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn>
          <p>
           RT-PCR: real-time reverse-transcriptase polymerase-chain-reaction.
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
      </p>
     </sec>
     <sec id="sec7.2">
      <label>
       7.2
      </label>
      <title>
       Differential diagnosis
      </title>
      <p id="p0310">
       The SARS-CoV-2 needs to be distinguished from other known viral pneumonias including influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human metapneumovirus, SARS coronavirus, MERS coronavirus, as well as
       <italic>
        Mycoplasma pneumoniae
       </italic>
       , chlamydia pneumonia, and bacterial pneumonias. For patients with underlying diseases, attention should be paid to the detection of invasive fungal infections. The differential diagnosis also includes non-infectious diseases such as vasculitis, dermatomyositis, and organizing pneumonia. It should be noted that often patients with viral pneumonia may test positive to multiple viruses, and the potential lethality of a combined SARS-CoV-2/influenza virus infection should not be ignored.
      </p>
     </sec>
    </sec>
    <sec id="sec8">
     <label>
      8
     </label>
     <title>
      The effectiveness of SARS-CoV-2 rapid diagnosis in preventing spread of disease
     </title>
     <p id="p0315">
      Several rapid and sensitive detection tests have been developed for the prevention and control of the SARS-CoV-2 outbreak. At present, seven products including the SARS-CoV-2 nucleic acid detection kit (fluorescent PCR method) and the SARS-CoV-2 nucleic acid sequencing system have been approved on an emergency basis by the National Medical Products Administration. Biological product companies have expanded production of detection kits for the new coronavirus. The use of detection kits can accelerate accurate diagnosis of patients, help to determine quarantine and isolation requirements, assist in determining the treatment of patients and save limited medical resources. However, the rapidity of spread of the disease has led to an insufficient supply of detection kits.
     </p>
     <p id="p0320">
      It is worth noting that there have been confirmed patients whose viral nucleic acid tests are negative multiple times in the early stages, and there have also been confirmed cases whose throat swabs were negative for the viral nucleic acid test but positive in alveolar lavage fluid. Correlation of Chest CT and RT-PCR testing of 1014 cases showed that CT had a 88% had a positive CT scan but only 59% had positive RT-PCR. [
      <xref ref-type="bibr" rid="bib86">
       86
      </xref>
      ]. The poor sensitivity of the current tests makes diagnosis and epidemic control more challenging. Sampling techniques, extraction and detection of viral nucleic acids, and diagnostic reagents may affect the test results. More attention should be paid to the sensitivity and specificity of diagnostic reagents, and diagnostic decisions should rely on comprehensive judgment based on the clinical manifestations, laboratory results and imaging examinations of patients. According to the latest guideline of the NHC [
      <xref ref-type="bibr" rid="bib82">
       82
      </xref>
      ], if the suspected cases in Hubei Province have imaging characteristic of pneumonia, the CT image results can be used as a basis for “clinical diagnosis cases”.
     </p>
    </sec>
    <sec id="sec9">
     <label>
      9
     </label>
     <title>
      The pathogenesis of COVID-19
     </title>
     <p id="p0325">
      Current understanding of the pathogenesis of HCoVs infection is still limited, especially for SARS-CoV-2. Before 2019, there were six CoVs that could infect humans and cause respiratory disease. HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1 are sometimes attributed to the “common cold”, but in rare cases can cause severe infections in infants, young children and elderly people. On the other hand, SARS-CoV and MERS-CoV can infect the lower respiratory tract and cause a severe respiratory syndrome in human [
      <xref ref-type="bibr" rid="bib3">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="bib12">
       12
      </xref>
      ]. The new coronavirus SARS-CoV-2 is similar to SARS-CoV and MERS-CoV and can infect lower respiratory tract and cause severe pneumonia.
     </p>
     <p id="p0330">
      The origin of SARS-CoV-2 was thought to be wild animals in the Huanan Seafood Market in Wuhan. However, not all cases have an apparent connection with the Wuhan Huanan Seafood Wholesale Market. It is evident now that SARS-CoV-2 is capable of person-person transmission. We list the major pathogenic CoVs in
      <xref ref-type="table" rid="tbl2">
       Table 2
      </xref>
      for better understanding of the pathogenesis of HCoV [
      <xref ref-type="bibr" rid="bib87">
       87
      </xref>
      ].
      <table-wrap id="tbl2" position="float">
       <label>
        Table 2
       </label>
       <caption>
        <p>
         Partial list of important pathogenic human coronaviruses [
         <xref ref-type="bibr" rid="bib87">
          87
         </xref>
         ].
        </p>
       </caption>
       <alt-text id="alttext0065">
        Table 2
       </alt-text>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
           Virus
          </th>
          <th>
           Genus
          </th>
          <th>
           Symptoms
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           HCoV-229E
          </td>
          <td align="left">
           <italic>
            alpha
           </italic>
          </td>
          <td align="left">
           mild respiratory tract infections
          </td>
         </tr>
         <tr>
          <td align="left">
           HCoV-NL63
          </td>
          <td align="left">
           <italic>
            alpha
           </italic>
          </td>
          <td align="left">
           mild respiratory tract infections
          </td>
         </tr>
         <tr>
          <td align="left">
           HCoV-OC43
          </td>
          <td align="left">
           <italic>
            beta
           </italic>
          </td>
          <td align="left">
           mild respiratory tract infections
          </td>
         </tr>
         <tr>
          <td align="left">
           HCoV-HKU1
          </td>
          <td align="left">
           <italic>
            beta
           </italic>
          </td>
          <td align="left">
           pneumonia
          </td>
         </tr>
         <tr>
          <td align="left">
           SARS-CoV
          </td>
          <td align="left">
           <italic>
            beta
           </italic>
          </td>
          <td align="left">
           severe acute respiratory syndrome, 11% mortality rate
          </td>
         </tr>
         <tr>
          <td align="left">
           MERS-CoV
          </td>
          <td align="left">
           <italic>
            beta
           </italic>
          </td>
          <td align="left">
           severe acute respiratory syndrome, 34% mortality rate
          </td>
         </tr>
         <tr>
          <td align="left">
           SARS-CoV-2
          </td>
          <td align="left">
           <italic>
            beta
           </italic>
          </td>
          <td align="left">
           severe acute respiratory syndrome, 2.6% mortality rate
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </p>
     <p id="p0335">
      The term “cell pyroptosis” was first proposed in 2001 [
      <xref ref-type="bibr" rid="bib88">
       88
      </xref>
      ]. In recent decades, there has been increasing evidence suggesting that “pyroptosis” is a novel inflammatory form of programmed cell death. In 2019, Chen et al. found that SARS-CoV Viroporin 3a triggered the activation of the NLRP3 inflammasome and the secretion of IL-1β in bone marrow-derived macrophages, suggesting SARS-CoV induced cell pyroptosis [
      <xref ref-type="bibr" rid="bib89">
       89
      </xref>
      ]. Studies have shown that patients infected with SARS-CoV-2 have increased IL-1β in the serum [
      <xref ref-type="bibr" rid="bib26">
       26
      </xref>
      ]. As the rise of IL-1β is a downstream indicator of cell pyroptosis, this may suggest that cell pyroptotic activity is likely to be activated and involved in the pathogenesis of COVID-19 patients. Nevertheless, as both classical and non-classical pyroptosis signaling can induce the release of IL-1β, it is unclear which pathway is involved in COVID-19. Based on existing data, SARS-CoV-2 is likely to cause cell pyroptosis, especially in lymphocytes, through the activation of NLRP3 inflammasome. The pathways involved in the activation of the signaling between NLRP3m IL-1β, IL-18 and GSDMD are illustrated in
      <xref ref-type="fig" rid="fig6">
       Fig. 6
      </xref>
      and are a subject of study in samples from SARS-CoV-2 patients [
      <xref ref-type="bibr" rid="bib90">
       90
      </xref>
      ].
      <fig id="fig6">
       <label>
        Fig. 6
       </label>
       <caption>
        <p>
         A hypothesis of the relationship between SARS-CoV-2 and cell pyroptosis. The COVID-19 may be linked to cell pyroptosis, especially in lymphocytes through the activation of the NLRP3 inflammasome. Morphological changes in lymphocytes and macrophages, nucleic acid and protein levels in classical and non-classical cells, detection of NLRP3 and GSDMD, and the role of inflammatory cytokines IL-1β and IL-18 requires further research.
        </p>
       </caption>
       <alt-text id="alttext0035">
        Fig. 6
       </alt-text>
       <graphic xlink:href="gr6_lrg">
       </graphic>
      </fig>
     </p>
     <sec id="sec9.1">
      <label>
       9.1
      </label>
      <title>
       The genomic structure of SARS-CoV-2
      </title>
      <p id="p0340">
       The rapid sequencing of the nearly 30,000 nucleotide SARS-CoV-2 genome was accomplished in approximately 3 weeks from the time of the first hospitalized patient on the December 12, 2019 by Zhang's group and several others in China [
       <xref ref-type="bibr" rid="bib91">
        91
       </xref>
       ]. The genomic structure is shown in
       <xref ref-type="fig" rid="fig7">
        Fig. 7
       </xref>
       and shows greater than 99.9% consistency [
       <xref ref-type="bibr" rid="bib19">
        19
       </xref>
       ,
       <xref ref-type="bibr" rid="bib91">
        [91]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib92">
        [92]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib93">
        [93]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib94">
        [94]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib95">
        [95]
       </xref>
       ].
       <fig id="fig7">
        <label>
         Fig. 7
        </label>
        <caption>
         <p>
          Schematic diagram of the SARS-CoV-2 genome [
          <xref ref-type="bibr" rid="bib95">
           95
          </xref>
          ]. The genomic structure of SARS-CoV-2 is 5′-UTR-orf1a-orf1ab-S (Spike)–E (Envelope)-M (Membrane)-N (Nucleocapsid)-3′UTRpoly (A) tail. Accessory genes are interspersed within the structural genes at the 3′ end of genome. The pp1a protein encoded by the orf1a gene and the pp1ab protein encoded by the orf1ab gene contains 10 nsps (nsp1-nsp10). The pp1ab protein also includes nsp12-nsp16.
         </p>
        </caption>
        <alt-text id="alttext0040">
         Fig. 7
        </alt-text>
        <graphic xlink:href="gr7_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0345">
       The SARS-CoV-2 genome was found to possess 14 ORFs encoding 27 proteins. The orf1ab and orf1a genes are located at the 5′-terminus of the genome and encode 15 non-structural proteins (nsps) from nsp1 to nsp10, and from nsp12 to nsp16. The 3′-terminus of the genome contains 4 structural proteins (S, E, M and N) and 8 accessory proteins (3a, 3b, p6, 7a, 7b, 8b, 9b and orf14). At the amino acid level, the SARS-CoV-2 is quite similar to that of SARS-CoV, but there are some notable differences. For example, the 8a protein is present in SARS-CoV and absent in SARS-CoV-2; the 3b protein is 154 amino acids in SARS-CoV but shorter in SARS-CoV-2 with only 22 amino acids. Further studies are needed to characterize how these differences affect the functionality and pathogenesis of SARS-CoV-2 [
       <xref ref-type="bibr" rid="bib95">
        95
       </xref>
       ].
      </p>
      <p id="p0350">
       The phylogenetic tree based on whole genomes showed that SARS-CoV-2 is most closely related to bat SARS-like coronavirus bat-SL-CoVZC21 (NCBI accession number MG772934) and bat-SL-CoVZC45 (NCBI accession number MG772933), which share ~89% sequence homology [
       <xref ref-type="bibr" rid="bib91">
        [91]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib92">
        [92]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib93">
        [93]
       </xref>
       ]. Their genomic organization is typical of a lineage B beta coronavirus. Further phylogenetic analysis has posited that SARS-CoV-2 is a product of recombination with previously identified bat coronaviruses, but a recent report has subsequently identified a bat CoVs sequence, RaTG13, with 92–96% sequence identity with the novel virus, demonstrating that RaTG13 is the closest relative of the SARS-CoV-2 and forms a distinct lineage from other SARS-CoVs. This rejects the hypothesis of emergence as a result of a recombination event [
       <xref ref-type="bibr" rid="bib94">
        94
       </xref>
       ,
       <xref ref-type="bibr" rid="bib96">
        96
       </xref>
       ]. Even though there are high similarities between SARS-CoV-2 S and RaTG13 S, there are two distinct differences: one is an “RRAR” furin recognition site formed by an insertion residues in the S1/S2 protease cleavage site in SARS-CoV-2, rather than the single Arginine in SARS-CoV [
       <xref ref-type="bibr" rid="bib97">
        [97]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib98">
        [98]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib99">
        [99]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib100">
        [100]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib101">
        [101]
       </xref>
       ]; the other difference is the presence of 29 variant residues between SARS-CoV-2 S and RaTG13 S, 17 of which mapped to the receptor binding domain (RBD) [
       <xref ref-type="bibr" rid="bib97">
        97
       </xref>
       ].
      </p>
      <p id="p0355">
       The identities of 5′- and 3′-UTR sequences are more than 83.6% consistent between SARS-CoV-2 and other β-CoVs, such as SARS-CoV [
       <xref ref-type="bibr" rid="bib102">
        102
       </xref>
       ]. The replicase polyproteins ppla and pp1ab encoded by the largest genes orf1ab are proteolytic and have been reported to function in the replication of CoVs by regulatory elements located within the non-structural proteins [
       <xref ref-type="bibr" rid="bib102">
        102
       </xref>
       ]. Four structural proteins (S, E, M and N) contribute to virion assembly and infection of CoVs. The spike protein located on the surface of viral particles is made up of homotrimers of S proteins and is the key for the viral attachment to host receptors [
       <xref ref-type="bibr" rid="bib103">
        103
       </xref>
       ,
       <xref ref-type="bibr" rid="bib104">
        104
       </xref>
       ].
      </p>
      <p id="p0360">
       Spike glycoprotein consists of S1 and S2 subunits. The S1 subunit contains a signal peptide, an N-terminal domain (NTD) and RBD, while the S2 subunit includes the conserved fusion peptide (FP), heptad repeat 1 and 2 (HR1 and HR2), transmembrane domain (TM), and cytoplasmic domain (CP) [
       <xref ref-type="bibr" rid="bib102">
        102
       </xref>
       ,
       <xref ref-type="bibr" rid="bib105">
        105
       </xref>
       ]. Furthermore, the S2 subunit of SARS-CoV-2 is highly conserved and shares 99% similarity with those of Bat-SL-CoVZC45, Bat-SL-CoVZC21 and human SARS-CoV [
       <xref ref-type="bibr" rid="bib102">
        102
       </xref>
       ]. The S2 subunit is therefore targeted when screening broad spectrum antiviral peptides, which is an important piece of information that can be used to develop preventive and treatment measures. Most recently, the 3D structure of S protein was elucidated using Cryo-electron microscopy (Cryo-EM), and the RBD structure of the S protein is closer to the central location of SARS-CoV-2 compared to SARS-CoV [
       <xref ref-type="bibr" rid="bib97">
        97
       </xref>
       ].
      </p>
      <p id="p0365">
       The E protein plays a role in virus assembly and release, and is required for pathogenesis [
       <xref ref-type="bibr" rid="bib106">
        106
       </xref>
       ,
       <xref ref-type="bibr" rid="bib107">
        107
       </xref>
       ]. The N protein contains two domains, both of which can bind virus RNA genomes via different mechanisms. It has been reported that the N protein can bind nsp3 protein to help tether the genome to replicase-transcriptase complex (RTC) and package the encapsulated genome into virions [
       <xref ref-type="bibr" rid="bib12">
        12
       </xref>
       ,
       <xref ref-type="bibr" rid="bib108">
        108
       </xref>
       ,
       <xref ref-type="bibr" rid="bib109">
        109
       </xref>
       ]. The N protein is also an antagonist of interferon and viral encoded repressor (VSR) of RNA interference (RNAi), which benefits viral replication [
       <xref ref-type="bibr" rid="bib110">
        110
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec9.2">
      <label>
       9.2
      </label>
      <title>
       Entry into host cell
      </title>
      <p id="p0370">
       Cell entry is an essential component of cross-species transmission, especially for the β-CoVs. All CoVs encode a surface glycoprotein, spike, which binds to the host receptor and mediates viral entry [
       <xref ref-type="bibr" rid="bib111">
        111
       </xref>
       ]. For β-CoVs, the RBD of the spike protein mediates the interaction with host receptor. Upon binding the receptor, the spike protein is cleaved by nearby host proteases and releases the signal peptide to facilitate virus entry into host cells [
       <xref ref-type="bibr" rid="bib112">
        [112]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib113">
        [113]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib114">
        [114]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib115">
        [115]
       </xref>
       ].
      </p>
      <p id="p0375">
       Angiotensin converting enzyme 2 (ACE2) and dipeptidyl peptidase 4 (DPP4) are known host receptors for the β-CoVs SARS-CoV and MERS-CoV, respectively [
       <xref ref-type="bibr" rid="bib116">
        116
       </xref>
       ,
       <xref ref-type="bibr" rid="bib117">
        117
       </xref>
       ]. In similar fashion to SARS-CoV, SARS-CoV-2 also uses ACE2 to gain entry into host cells. Hoffmann et al. found that the cellular protease MPRSS2 blocks entry by cleaving the spike protein and may constitute a treatment option [
       <xref ref-type="bibr" rid="bib118">
        118
       </xref>
       ]. Zhou et al. also confirmed that SARS-CoV-2 is able to use all but mouse ACE2 as an entry receptor for ACE2-expressing cells, but not cells without ACE2, indicating that the cell receptor for SARS-CoV-2 could be ACE2, and not other coronavirus receptors such as aminopeptidase N and dipeptidyl peptidase 4 [
       <xref ref-type="bibr" rid="bib94">
        94
       </xref>
       ]. Huang also showed that the affinity of the SARS-CoV-2 S-RBD binding to ACE2 is less than that of SARS-CoV through Monte Carlo algorithm [
       <xref ref-type="bibr" rid="bib119">
        119
       </xref>
       ]. However, Wrapp et al. found that SARS-CoV-2 S binding to ACE2 has approximately 10- to 20- fold higher affinity than SARS-CoV S, which can provide one explanation why SARS-CoV-2 has more human-to human spread compared to SARS-CoV [
       <xref ref-type="bibr" rid="bib97">
        97
       </xref>
       ].
      </p>
      <p id="p0380">
       The combination of SARS-CoV-2 S and ACE2 of host cells is similar to the combination of SARS-CoV and ACE2, indicating that they have the same mechanism to entry into host cells [
       <xref ref-type="bibr" rid="bib97">
        97
       </xref>
       ]. The S protein of metastable prefusion conformation undergoes a series of structural rearrangements to combine with the viral membrane of host cells [
       <xref ref-type="bibr" rid="bib111">
        111
       </xref>
       ,
       <xref ref-type="bibr" rid="bib120">
        120
       </xref>
       ]. This process consists of the S1 subunit binding to the host cell receptor, triggering of the prefusion trimer's instability, and shedding of the S1 subunit, resulting in a highly stable post-fusion conformation of the S2 subunit [
       <xref ref-type="bibr" rid="bib121">
        121
       </xref>
       ]. During the binding of the subunit S1 to its cognate receptor, it is important to note that the S1 subunit exists in 2 different states, a “down” conformation and an “up” conformation state, which corresponds to a receptor-inaccessible state and an unstable receptor-accessible state, respectively [
       <xref ref-type="bibr" rid="bib122">
        [122]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib123">
        [123]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib124">
        [124]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib125">
        [125]
       </xref>
       ]. Unfortunately, there are significant conformational differences between SARS-CoV and SARS-CoV-2 such that the commercially available monoclonal antibodies against SARS-CoV do not react with SARS-CoV-2 [
       <xref ref-type="bibr" rid="bib97">
        97
       </xref>
       ].
      </p>
      <p id="p0385">
       SARS-CoV-2 may directly bind to ACE2 positive cholangiocytes but not necessarily hepatocytes via specific expression of ACE2 in healthy liver tissues using cell RNA-seq data of two independent cohorts [
       <xref ref-type="bibr" rid="bib126">
        126
       </xref>
       ]. Though the respiratory systems is a primary target of SARS-CoV-2, bioinformatic analysis of single-cell transcriptomes datasets of lung, esophagus, gastric, ileum and colon reveal that the digestive system is also a potential route of entry for COVID-19, as ACE2 was not only highly expressed in lung AT2 cells, esophagus upper and stratified epithelial cells but also in absorptive enterocytes from the ileum and colon [
       <xref ref-type="bibr" rid="bib127">
        127
       </xref>
       ].
      </p>
     </sec>
    </sec>
    <sec id="sec10">
     <label>
      10
     </label>
     <title>
      Recommendations
     </title>
     <sec id="sec10.1">
      <label>
       10.1
      </label>
      <title>
       Preventing the spread of disease
      </title>
      <p id="p0390">
       In response to the outbreak of pneumonia caused by the SARS-CoV-2, China has activated Level I public health emergency response for the entire country. This activates the most comprehensive and rigorous prevention and control measures for health and safety. A team of professionals from the NHC and China CDC was sent to conduct field investigations and implement disease control and prevention measures. The virus was quickly isolated and sequenced. On January 3, 2020, the first complete genome of the SARS-CoV-2 was determined and shared internationally, which led to the rapid development and deployment of diagnostic tests [
       <xref ref-type="bibr" rid="bib60">
        60
       </xref>
       ]. The NHC announced that preventive and control measures of category A infectious diseases would be implemented to effectively fight SARS-CoV-2 and has also introduced public education campaigns. At the same time, all medical expenses of confirmed patients would be covered by central and local financial institutions.
      </p>
     </sec>
     <sec id="sec10.2">
      <label>
       10.2
      </label>
      <title>
       Quarantine
      </title>
      <p id="p0395">
       Quarantine is a traditional but very effective measure to counter a deadly epidemic, but quarantine protocols can be hard to enforce. The local government in Wuhan announced the suspension of public transportation, with closure of airports, railway stations, and highways in the city, to prevent further disease transmission on January 23, 2020. Subsequently, the Chinese government imposed travel bans on several Chinese cities near Wuhan. At the same time, the Chinese government extended the Lunar New Year holidays and postponed the reopening of schools and factories to keep the nationwide migration of the population to a minimum. Travelers from Wuhan and other epidemic areas were advised to report their travel history and to self-quarantine for two weeks to prevent community transmission. In addition, most local governments required that all passengers must wear medical surgical masks or N95 masks when accessing public places, taxis or subways. Temperature screening checkpoints have been set up at subway stations, railway stations, high-speed rail exits and airports to screen passengers in an effort to curb the spread of the novel coronavirus.
      </p>
     </sec>
     <sec id="sec10.3">
      <label>
       10.3
      </label>
      <title>
       Mobilize resources
      </title>
      <p id="p0400">
       With the rapid spread of the epidemic, more designated treatment hospitals and health care workers were needed to meet the growing number of patients. On January 24, 2020, the local government in Wuhan announced the construction of a 1000-bed infirmary, named Huoshenshan hospital, and a 1500-bed infirmary, named Leishenshan hospital within 10 days, to ease the shortage of beds and treat people diagnosed with the SARS-CoV-2. These facilities are specialty hospitals for infectious diseases, rather than simply units to receive and quarantine patients. Wuhan has also been building 11 mobile Fangcang hospitals (a Chinese name which came from Noah's Ark) and creating tens of thousands of beds, to centralize quarantine and provide medical treatment for confirmed patients with mild symptoms, suspected patients and those who need observation. The new facilities further enhance the local public health capacities. Hospitals offer online consultants and medical services to symptomatic patients and suspected patients, which help reduce the frequency that patients go to hospitals and thereby reduce the risk of being infected. Health care workers, including military medical teams, from across the Chinese mainland arrived in Hubei to provide much needed assistance. At present, more than 30,000 health care workers have arrived in Hubei to help fight the novel coronavirus epidemic. In order to prevent health care workers from being infected, the NHC ensured enough supplies of isolation gowns, gloves and masks and issued a technical guideline for the prevention and control of infection caused by the novel coronavirus [
       <xref ref-type="bibr" rid="bib128">
        128
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec10.4">
      <label>
       10.4
      </label>
      <title>
       Disseminate information
      </title>
      <p id="p0405">
       The NHC also formulated a community prevention and control program for SARS-CoV-2 pneumonia to strengthen community-level epidemic prevention measures to control the spread of the outbreak [
       <xref ref-type="bibr" rid="bib129">
        129
       </xref>
       ]. All communities screen patients with fever within the community and monitor and report suspected cases with COVID-19. Various forms of health education have been carried out in the community to disseminate knowledge of epidemic prevention and control, such as using masks and washing hands correctly. The NHC issued guidelines for the protection of people at different levels of risk for COVID-19 [
       <xref ref-type="bibr" rid="bib130">
        130
       </xref>
       ].
      </p>
     </sec>
    </sec>
    <sec id="sec11">
     <label>
      11
     </label>
     <title>
      Treatment and management
     </title>
     <p id="p0410">
      There is no clear, unified and effective treatment plan for COVID-19. Most guidelines emphasize early identification, early isolation, early diagnosis, and early treatment. The treatment and management of SARS-CoV-2 pneumonia mainly include the following aspects (
      <xref ref-type="fig" rid="fig8">
       Fig. 8
      </xref>
      ) [
      <xref ref-type="bibr" rid="bib37">
       37
      </xref>
      ,
      <xref ref-type="bibr" rid="bib78">
       [78]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib79">
       [79]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib80">
       [80]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib81">
       [81]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib82">
       [82]
      </xref>
      ].
      <fig id="fig8">
       <label>
        Fig. 8
       </label>
       <caption>
        <p>
         The treatment and management of COVID-19 pneumonia. ICU: intensive care unit; ECMO: extracorporeal membrane oxygenation.
        </p>
       </caption>
       <alt-text id="alttext0045">
        Fig. 8
       </alt-text>
       <graphic xlink:href="gr8_lrg">
       </graphic>
      </fig>
     </p>
     <p id="p0415">
      Suspected and confirmed cases should be isolated and treated in designated hospitals with effective isolation and protective conditions as soon as possible. Suspected cases should be isolated in a single room. WHO suggests that patients with mild symptoms and without underlying chronic diseases (such as lung or heart disease, renal failure, or immunodeficiency) may be cared for in the home environment in isolation [
      <xref ref-type="bibr" rid="bib131">
       131
      </xref>
      ]. However, severe cases should be hospitalized, and critical cases should be admitted to the ICU as soon as possible.
     </p>
     <p id="p0420">
      Supportive therapy includes bedrest, adequate nutrition, monitoring vital signs and oxygen saturation, prevention of dehydration and maintaining water, electrolyte, and acid-base balance. For severe cases, it may be necessary to proactively prevent complications and secondary infections, treat underlying diseases and provide organ function support according to the patients’ condition such as that reported by Chen et all that involved the administration of intravenous immunoglobulin therapy to 27 of such patients [
      <xref ref-type="bibr" rid="bib37">
       37
      </xref>
      ].
     </p>
     <p id="p0425">
      Supplemental oxygen should be administered to patients with decreased oxygen saturation. In Huang's study [
      <xref ref-type="bibr" rid="bib26">
       26
      </xref>
      ], four (10%) patients needed invasive mechanical ventilation, and two received extracorporeal membrane oxygenation (ECMO). In Chen's study [
      <xref ref-type="bibr" rid="bib37">
       37
      </xref>
      ], 75 of 99 patients received oxygen therapy, 13 patients required non-invasive mechanical ventilation, four patients needed an invasive ventilator to assist ventilation, and three patients were treated with ECMO. In Wang's study [
      <xref ref-type="bibr" rid="bib83">
       83
      </xref>
      ], of the 36 patients in the ICU, four patients received high-flow oxygen therapy, 15 patients received non-invasive ventilation, and 17 patients received invasive ventilation (four patients switched to ECMO). In Guan's study, 418 of 1099 patients received oxygen therapy, 67 patients received mechanical ventilation, and ECMO was adopted in 5 severe cases [
      <xref ref-type="bibr" rid="bib85">
       85
      </xref>
      ].
     </p>
     <p id="p0430">
      Due to lack of valid evidence and possible adverse effects, routine use of corticosteroid should be avoided unless for specific reasons. Baillie JK et al. [
      <xref ref-type="bibr" rid="bib42">
       42
      </xref>
      ] suggested that corticosteroid should not be used for the treatment of SARS-CoV-2-induced lung injury or shock, because of the lack of evidence that patients with COVID-19 will benefit from corticosteroid. In the first 41 patients, only 22% (9/41) patients were given corticosteroid, with six of these in the ICU [
      <xref ref-type="bibr" rid="bib26">
       26
      </xref>
      ]. Chen et al. reported that 19% (19/99) patients received corticosteroid treatment for 3–15 days [
      <xref ref-type="bibr" rid="bib37">
       37
      </xref>
      ]. In Wang's study [
      <xref ref-type="bibr" rid="bib83">
       83
      </xref>
      ], 45% (62/138) patients received corticosteroid treatment. In Guan's study, 18.6% (204/1099) of patients were given systemic corticosteroids [
      <xref ref-type="bibr" rid="bib85">
       85
      </xref>
      ].
     </p>
     <p id="p0435">
      Indiscriminate or inappropriate antimicrobial treatment, especially the combination of broad-spectrum antibiotics, should be avoided. However, in Huang's study [
      <xref ref-type="bibr" rid="bib26">
       26
      </xref>
      ], all his 41 patients received antibiotic therapy. In Chen's study [
      <xref ref-type="bibr" rid="bib37">
       37
      </xref>
      ], 70 patients were given antibiotic treatment, among whom 25 patients were treated with a single antibiotic and 45 patients were given combination therapy. The duration of antibiotic treatment was 3–17 days. In addition, there were 15 patients who received antifungal treatment. In Wang's study [
      <xref ref-type="bibr" rid="bib83">
       83
      </xref>
      ], the 138 hospitalized patients all received antibacterial therapy, including moxifloxacin (64.4%), ceftriaxone (24.6%), azithromycin (18.1%). In Guan's study, 632 patients were given intravenous antibiotics, and 30 patients were given antifungal medications [
      <xref ref-type="bibr" rid="bib85">
       85
      </xref>
      ].
     </p>
     <p id="p0440">
      At present, there is no evidence-based medicine to support the effectiveness of antiviral drugs for COVID-19. The previous experience of treating SARS-CoV, MERS-CoV or influenza infections guides the selection of antiviral agents for COVID-19. The current guideline of the NHC recommends IFN-α, lopinavir/ritonavir, and ribavirin as antiviral therapy. In Huang's study [
      <xref ref-type="bibr" rid="bib26">
       26
      </xref>
      ], 38 of 41 patients were given antiviral therapy. The Jinyintan hospital has launched a randomized, controlled trial of the anti-HIV drug combination of lopinavir and ritonavir. In Chen's study [
      <xref ref-type="bibr" rid="bib37">
       37
      </xref>
      ], 75 patients received antiviral treatment, including oseltamivir, ganciclovir, and lopinavir/ritonavir, and the duration of antiviral treatment was 3–14 days. In Wang's study [
      <xref ref-type="bibr" rid="bib83">
       83
      </xref>
      ], there were 89.9% (124/138) patients who received oseltamivir. And in Guan's study, 35.8% (393/1099) of patients received oseltamivir [
      <xref ref-type="bibr" rid="bib85">
       85
      </xref>
      ]. The anti-viral drug remdesivir (Gilead®) is in clinical trials to treat COVID-19 in Wuhan [
      <xref ref-type="bibr" rid="bib132">
       132
      </xref>
      ]. Chloroquine phosphate has also been shown to be effective in some patients.
     </p>
     <p id="p0445">
      Identifying or developing novel drug treatment options as soon as possible is critical for the response to the SARS-CoV-2 outbreak. Based on the structural information of clinical effective medicines for SARS-CoV-2, Liu et al. predicted 10 commercial medicines which may function as inhibitors of SARS-CoV-2, including colistin, valrubicin, icatibant, bepotastine, epirubicin, etc. Some of these may be more resistant to viral mutation than lopinavir/ritonavir [
      <xref ref-type="bibr" rid="bib133">
       133
      </xref>
      ]. Stebbing et al. suggested that baricitinib may reduce both the viral entry and inflammation [
      <xref ref-type="bibr" rid="bib134">
       134
      </xref>
      ].
     </p>
     <p id="p0450">
      Lu reported that remdesivir may have the greatest potential for the successful treatment of SARS-CoV-2, but the efficacy and safety of remdesivir in COVID-19 needs further evaluation [
      <xref ref-type="bibr" rid="bib135">
       135
      </xref>
      ]. The antiviral efficiency of five FAD-approved drugs and two well-known broad-spectrum antiviral drugs have been studied and it has been found that remdesivir and chloroquine effectively inhibit SARS-CoV-2
      <italic>
       in vitro
      </italic>
      [
      <xref ref-type="bibr" rid="bib136">
       136
      </xref>
      ]. The New England Journal of Medicine reported that the first case of COVID-19 confirmed in the United States was treated with intravenous remdesivir and demonstrated clinical improvement [
      <xref ref-type="bibr" rid="bib71">
       71
      </xref>
      ]. At present, a randomized, double-blind, placebo-controlled phase III clinical trial of remdesivir has been launched and already 761 confirmed cases have been enrolled [
      <xref ref-type="bibr" rid="bib132">
       132
      </xref>
      ]. Lu also pointed out that there is no direct evidence that oseltamivir is effective in the treatment of SARS-CoV-2 [
      <xref ref-type="bibr" rid="bib135">
       135
      </xref>
      ]. However, we found that oral oseltamivir or abidol has been used for suspected or confirmed SARS-CoV-2 cases.
     </p>
     <p id="p0455">
      Favilavir, formerly known as Fapilavir, was the first anti-novel coronavirus drug that has been approved for marketing by the National Medical Products Administration since the outbreak. The drug was developed by Zhejiang Hisun Pharmaceutical Company and is expected to play an important role in preventing and treating the epidemic [
      <xref ref-type="bibr" rid="bib137">
       137
      </xref>
      ].
     </p>
     <p id="p0460">
      The role of intestinal microecological regulators that can be used to maintain intestinal microecological balance and prevent secondary bacterial infections is unclear. Chinese traditional medicine suggests Shufengjiedu and Lianhuaqingwen, which have played a role in the prevention and treatment of new infectious respiratory diseases, may be of benefit [
      <xref ref-type="bibr" rid="bib138">
       138
      </xref>
      ,
      <xref ref-type="bibr" rid="bib139">
       139
      </xref>
      ].
     </p>
     <p id="p0465">
      Anxiety and fear often exist in suspected or confirmed patients. Emergency psychological crisis intervention [
      <xref ref-type="bibr" rid="bib140">
       140
      </xref>
      ], and the implementation of classified intervention for different groups of people, is helpful in order to strengthen psychological counseling and reduce the psychological damage caused by the epidemic. Mass hysteria has also led to incidences of racial discrimination against Asians, particularly in non-Asian countries.
     </p>
    </sec>
    <sec id="sec12">
     <label>
      12
     </label>
     <title>
      Development of vaccines for coronavirus
     </title>
     <p id="p0470">
      Research institutions and pharmaceutical companies worldwide are stepping up research and development for a coronavirus vaccine. Virus strains have been isolated from patients’ samples and provide the basis for research and development of a vaccine for the novel coronavirus. Although vaccines have been developed for SARS-CoV and MERS-CoV, these are not commercially available [
      <xref ref-type="bibr" rid="bib12">
       12
      </xref>
      ,
      <xref ref-type="bibr" rid="bib14">
       14
      </xref>
      ,
      <xref ref-type="bibr" rid="bib141">
       141
      </xref>
      ]. Since the emergence of SARS-CoV and MERS-CoV, basic research on coronaviruses and advances in vaccine preparation technology can significantly shorten the development time of new coronavirus vaccines. However, the difficulties and challenges of developing an effective vaccine have been discussed earlier, and the key to a successful vaccine program is to vaccinate people before an outbreak occurs, not begin to develop the vaccine during the outbreak. Development of animal models that faithfully mimic SARS-CoV-2 infection in humans is critical not only in providing a more refined understanding of the pathogenic mechanisms involved but also to serve as a screening model for potential chemotherapeutic agents and vaccines.
     </p>
    </sec>
    <sec id="sec13">
     <label>
      13
     </label>
     <title>
      Guidelines for the future
     </title>
     <p id="p0475">
      Recommendations for the prevention and management of coronavirus epidemics are summarized in
      <xref ref-type="fig" rid="fig9">
       Fig. 9
      </xref>
      . Since both SARS and SARS-CoV-2 appear to have an exotic animal origin, the purchase, trafficking, and sale of wild animals should be banned, and illegal activities should be prosecuted. Early recognition of the problem, early identification of infected patients and early mobilization of healthcare resources are critical in limiting morbidity and mortality. When an outbreak occurs, it is very important to rapidly identify and characterize the pathogen, in order to be able to develop diagnostic assays. In the early stage of the disease epidemic, summarizing the clinical characteristics and treatment efficacy, formulating the diagnosis procedures, defining suspected cases and locations, determining transmission patterns, isolating contagious patients and formulating the appropriate quarantine strategy are all necessary and need to be implemented promptly.
      <fig id="fig9">
       <label>
        Fig. 9
       </label>
       <caption>
        <p>
         Keys to the control of future hCoV epidemics. Lessons learned from both the SARS and SARS-CoV-2 epidemics.
        </p>
       </caption>
       <alt-text id="alttext0050">
        Fig. 9
       </alt-text>
       <graphic xlink:href="gr9_lrg">
       </graphic>
      </fig>
     </p>
     <p id="p0480">
      The strict control of cross-infection in medical institutions is also key to preventing the further spread of the epidemic. In addition, actively mobilizing the population to participate in epidemic prevention and control is critical, and this can be achieved by accurate information dissemination and ongoing updates. Real-time updating the information of the epidemic situation can help to alleviate panic and reduce societal anxiety. A strong public health surveillance system to guide the response to the outbreak is important in the face of a lack of effective therapeutics or vaccines. Big data and artificial intelligence systems are tools that can be used to fully integrate the information, conduct comprehensive research and analyze public health risks. Last but not least, use of the Internet and the media to conduct health education for the people, publicize the correct knowledge of prevention, and offer online consultation to guide patients to seek medical treatment correctly are additional strategies that can be implemented to achieve viral containment.
     </p>
    </sec>
    <sec id="sec14">
     <label>
      14
     </label>
     <title>
      Discussion
     </title>
     <sec id="sec14.1">
      <label>
       14.1
      </label>
      <title>
       <italic>
        The differences between SARS and
       </italic>
       SARS-CoV-2
      </title>
      <p id="p0485">
       Although SARS-CoV-2 and SARS-CoV have certain similarities in biological, epidemiological and pathological characteristics, there are some important differences. First, the most fundamental difference between the two viruses lies in their gene sequence. Second, during the SARS epidemic, a total of 8422 patients worldwide were infected with SARS-CoV, of whom 919 died, with a mortality rate of 9.5% [
       <xref ref-type="bibr" rid="bib9">
        9
       </xref>
       ]. A total of 5328 patients in China were infected with SARS-CoV, of whom 349 died, with a mortality rate of 6.5% [
       <xref ref-type="bibr" rid="bib9">
        9
       </xref>
       ]. As of February 17, 2020, there were 72,436 confirmed cases of 2019-nCoV in China, of whom 1868 have died, with a mortality rate of 2.6% [
       <xref ref-type="bibr" rid="bib10">
        10
       </xref>
       ]. Compared to SARS, there are more confirmed cases, suspected cases and deaths of SARS-CoV-2, but the mortality rate is lower than that of SARS.
      </p>
      <p id="p0490">
       From 2017 to 2018, influenza ravaged the world, affecting up to 45 million people and killing about 95,000 people, with a reported mortality rate of about 0.2%. Every year millions of people are infected by influenza despite the existence of a yearly vaccine. According to the United States CDC weekly report, the number of childhood deaths in the United States so far from influenza during this flu season alone is 105. Compared with influenza, the number of patients who have died of coronavirus infection is less, but the virulence and mortality rate of coronavirus is significantly higher.
      </p>
      <p id="p0495">
       Clinically, the patients with COVID-19 have no upper respiratory symptoms (such as runny nose, sneezing, sore throat). In 2003, a large number of medical personnel were infected, and iatrogenic transmission occurred in SARS. In contrast, although there are cases of nosocomial infection in SARS-CoV-2, most of them are out-of-hospital infections.
      </p>
     </sec>
     <sec id="sec14.2">
      <label>
       14.2
      </label>
      <title>
       What can we learn from the 2020 nCoV epidemic in China?
      </title>
      <p id="p0500">
       The SARS-CoV-2 epidemic of 2020 in China is an international crisis, affecting human lives, the global economy, societal views and lifestyle. During times of crisis, misinformation, blame and conspiracy theories abound. It is probably prudent to not entirely trust the media, whether local, regional or international, as each most likely has their own agenda. On the other hand, it is the responsibility of doctors and scientists to evaluate the events to ascertain whether or not more effective management of the crisis could have been attained. This comes with its own set of challenges, as hindsight is always 20/20.
      </p>
      <p id="p0505">
       The quarantining of an entire country has been extreme, astounding and unprecedented. This not only involves quarantining measures within China but also internationally, as countries canceled flights into China, quarantined their own nationals as they returned from China and installed thermal scanners to detect ill people. But the quarantine measures inside China are certainly eye-opening. The entire city of Wuhan was shut off, and this was extended to every other city in China. In effect, the entire country was told to stay home, creating an enormous impact on the economy and on people's daily lives. Roads and stores became deserted (
       <xref ref-type="fig" rid="fig10">
        Fig. 10
       </xref>
       ). In Ningbo, each household was only permitted to send one person out for groceries every other day. Schools were closed till the end of March. Everyone wears masks. The objective was to starve the virus, to eliminate hosts. Yet even with these measures, new cases continued to appear. The quarantine measures in China have obviously come under a great deal of scrutiny, with so called “experts” weighing in, some saying that it will not work, that isolating a city deprives it of medical resources. Whatever the criticism, it is humbling to think of what may have happened without these draconian measures. It is also difficult to comprehend if such measures could actually take place in other parts of the world, or if the implementation of these changes could have taken place as quickly. For example, hand shaking is not part of Chinese culture, but it is almost automatic in other parts of the world, and it is normally done without even thinking. This is the first thing that would have to stop to help contain the virus.
       <fig id="fig10">
        <label>
         Fig. 10
        </label>
        <caption>
         <p>
          Life in China in Beijing and Hubei during quarantine measures. Quarantine measures have led to empty streets and shopping centers.
         </p>
        </caption>
        <alt-text id="alttext0055">
         Fig. 10
        </alt-text>
        <graphic xlink:href="gr10_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0510">
       Then there is the matter of the ophthalmologist and others who voiced concerns in the media about a cluster of cases of a flu-like illness near the end of December. At the present time, it is difficult to say whether or not the response could have been faster than it actually was, as this corresponds to the time when work began on viral sequencing. It is possible that medical teams were already working on the sequence at that time. It is also quite possible that officials did not initially sound the alarm publicly because they did not want to cause a panic. Perhaps this was the wrong decision, but these decisions are difficult in times of crisis and it is of course easy to second guess. It is easy to understand that this can be perceived as withholding information and why the public would be frustrated. The lesson here is that dissemination of accurate and validated information and establishing guidelines to prevent the spread of infections is critical.
      </p>
      <p id="p0515">
       There are many “heroes” in these crises, people who have risked their lives and made incredible sacrifices to help society rid itself of this scourge, including those who work on the front lines, epidemiologists, scientists, doctors, first responders, and members of the public. Unfortunately, these events also bring out the worst in people. Numerous accounts of racial discrimination have been perpetrated against Asians across the world, many rising to the level of hate crimes. One must not forget the psychological impact of an infection such as this on people who are not even infected or who will never encounter an infected person.
      </p>
      <p id="p0520">
       The emergence of SARS-CoV, MERS-CoV, and now SARS-CoV-2, suggests that coronavirus will pose a lasting threat to human beings. The epidemic will eventually be contained, and people's memory of the coronavirus may gradually blur. But we must not forget the lessons learned from this crisis, and already begin to take measures to prevent the next new outbreak of Coronavirus or some other virus from appearing in the future. If it does appear, how will we respond to it? What if it does not happen in China? Will other countries have the fortitude to implement even more drastic measures and mobilize resources to prevent the spread of the virus and to care for the sick?
      </p>
      <p id="p0525">
       We can always improve on the handling of global pandemics or epidemics. From the lessons learned during the SARS and now the SARS-CoV-2 epidemics, we can nearly provide a roadmap for the response to future outbreaks. The development of a vaccine for coronavirus is a critical step in prevention, but it may not be effective for future strains, and we must be ready for the next epidemic.
      </p>
     </sec>
    </sec>
    <sec id="sec15">
     <title>
      Funding
     </title>
     <p id="p0530">
      <funding-source id="gs1">
       Beijing Municipal Natural Science Foundation
      </funding-source>
      General Program (7,192,197).
     </p>
    </sec>
    <sec sec-type="COI-statement">
     <title>
      Declaration of competing interest
     </title>
     <p id="p0535">
      The authors declare no conflict of interest.
     </p>
    </sec>
    <back>
     <ref-list id="cebib0010">
      <title>
       References
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <element-citation id="sref1" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Leibowitz
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus pathogenesis
        </article-title>
        <source>
         Adv. Virus Res.
        </source>
        <volume>
         81
        </volume>
        <year>
         2011
        </year>
        <fpage>
         85
        </fpage>
        <lpage>
         164
        </lpage>
        <pub-id pub-id-type="pmid">
         22094080
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <element-citation id="sref2" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Balasuriya
          </surname>
          <given-names>
           U.B.R.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         List of contributors
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           MacLachlan
          </surname>
          <given-names>
           N.J.
          </given-names>
         </name>
         <name>
          <surname>
           Dubovi
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
        </person-group>
        <source>
         Fenner's Veterinary Virology
        </source>
        <edition>
         fifth ed.
        </edition>
        <year>
         2017
        </year>
        <publisher-name>
         Academic Press
        </publisher-name>
        <publisher-loc>
         Boston
        </publisher-loc>
        <fpage>
         xvii
        </fpage>
        <lpage>
         xviii
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation id="sref3" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology, genetic recombination, and pathogenesis of coronaviruses
        </article-title>
        <source>
         Trends Microbiol.
        </source>
        <volume>
         24
        </volume>
        <issue>
         6
        </issue>
        <year>
         2016
        </year>
        <fpage>
         490
        </fpage>
        <lpage>
         502
        </lpage>
        <pub-id pub-id-type="pmid">
         27012512
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <element-citation id="sref4" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         A novel coronavirus from patients with pneumonia in China, 2019
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         N Engl J Med
        </publisher-name>
       </element-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <element-citation id="sref5" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Isaacs
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology of coronavirus respiratory infections
        </article-title>
        <source>
         Arch. Dis. Child.
        </source>
        <volume>
         58
        </volume>
        <issue>
         7
        </issue>
        <year>
         1983
        </year>
        <fpage>
         500
        </fpage>
        <lpage>
         503
        </lpage>
        <pub-id pub-id-type="pmid">
         6307189
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <element-citation id="sref6" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Greenberg
          </surname>
          <given-names>
           S.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Update on human rhinovirus and coronavirus infections
        </article-title>
        <source>
         Semin. Respir. Crit. Care Med.
        </source>
        <volume>
         37
        </volume>
        <issue>
         4
        </issue>
        <year>
         2016
        </year>
        <fpage>
         555
        </fpage>
        <lpage>
         571
        </lpage>
        <pub-id pub-id-type="pmid">
         27486736
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <element-citation id="sref7" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <volume>
         367
        </volume>
        <issue>
         19
        </issue>
        <year>
         2012
        </year>
        <fpage>
         1814
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib8">
       <label>
        8
       </label>
       <element-citation id="sref8" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Organization
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV)
        </article-title>
        <comment>
         [cited Jan 30, 2020; Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0010" xlink:href="http://www.who.int/emergencies/mers-cov/en/">
         http://www.who.int/emergencies/mers-cov/en/
        </ext-link>
        <year>
         2019 Jan 30
        </year>
       </element-citation>
      </ref>
      <ref id="bib9">
       <label>
        9
       </label>
       <element-citation id="sref9" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Organization
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Summary table of SARS cases by country, November 1, 2002-August 7, 2003
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0015" xlink:href="http://www.who.int/csr/sars/country/2003_08_15/en/">
         http://www.who.int/csr/sars/country/2003_08_15/en/
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib10">
       <label>
        10
       </label>
       <element-citation id="sref10" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Commission
          </surname>
          <given-names>
           C.N.H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Update on the Novel Coronavirus Pneumonia Outbreak
        </chapter-title>
        <year>
         2020
        </year>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0020" xlink:href="http://www.nhc.gov.cn/xcs/xxgzbd/gzbd_index.shtml">
         http://www.nhc.gov.cn/xcs/xxgzbd/gzbd_index.shtml
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib11">
       <label>
        11
       </label>
       <element-citation id="sref11" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Navas-Martin
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus
        </article-title>
        <source>
         Microbiol. Mol. Biol. Rev.
        </source>
        <volume>
         69
        </volume>
        <issue>
         4
        </issue>
        <year>
         2005
        </year>
        <fpage>
         635
        </fpage>
        <lpage>
         664
        </lpage>
        <pub-id pub-id-type="pmid">
         16339739
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib12">
       <label>
        12
       </label>
       <element-citation id="sref12" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fehr
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses: an overview of their replication and pathogenesis
        </article-title>
        <source>
         Methods Mol. Biol.
        </source>
        <volume>
         1282
        </volume>
        <year>
         2015
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         23
        </lpage>
        <pub-id pub-id-type="pmid">
         25720466
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <label>
        13
       </label>
       <element-citation id="sref13" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antagonism of the interferon-induced OAS-RNase L pathway by murine coronavirus ns2 protein is required for virus replication and liver pathology
        </article-title>
        <source>
         Cell Host Microbe
        </source>
        <volume>
         11
        </volume>
        <issue>
         6
        </issue>
        <year>
         2012
        </year>
        <fpage>
         607
        </fpage>
        <lpage>
         616
        </lpage>
        <pub-id pub-id-type="pmid">
         22704621
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib14">
       <label>
        14
       </label>
       <element-citation id="sref14" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         From SARS to MERS, thrusting coronaviruses into the spotlight
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         11
        </volume>
        <issue>
         1
        </issue>
        <year>
         2019
        </year>
        <fpage>
         59
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib15">
       <label>
        15
       </label>
       <element-citation id="sref15" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ecoepidemiology and complete genome comparison of different strains of severe acute respiratory syndrome-related Rhinolophus bat coronavirus in China reveal bats as a reservoir for acute, self-limiting infection that allows recombination events
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         84
        </volume>
        <issue>
         6
        </issue>
        <year>
         2010
        </year>
        <fpage>
         2808
        </fpage>
        <lpage>
         2819
        </lpage>
        <pub-id pub-id-type="pmid">
         20071579
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib16">
       <label>
        16
       </label>
       <element-citation id="sref16" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bats are natural reservoirs of SARS-like coronaviruses
        </article-title>
        <source>
         Science
        </source>
        <volume>
         310
        </volume>
        <issue>
         5748
        </issue>
        <year>
         2005
        </year>
        <fpage>
         676
        </fpage>
        <lpage>
         679
        </lpage>
        <pub-id pub-id-type="pmid">
         16195424
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib17">
       <label>
        17
       </label>
       <element-citation id="sref17" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Stratton
          </surname>
          <given-names>
           C.W.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           Y.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Outbreak of pneumonia of unknown etiology in wuhan China: the mystery and the miracle
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <volume>
         92
        </volume>
        <issue>
         4
        </issue>
        <year>
         2020 Apr
        </year>
        <fpage>
         401
        </fpage>
        <lpage>
         402
        </lpage>
        <comment>
         Epub 2020 Feb 12
        </comment>
        <pub-id pub-id-type="pmid">
         31950516
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib18">
       <label>
        18
       </label>
       <element-citation id="sref18" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ji
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zai
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cross-species transmission of the newly identified coronavirus 2019-nCoV
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <volume>
         92
        </volume>
        <issue>
         4
        </issue>
        <year>
         2020 Apr
        </year>
        <fpage>
         433
        </fpage>
        <lpage>
         440
        </lpage>
        <pub-id pub-id-type="pmid">
         31967321
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib19">
       <label>
        19
       </label>
       <element-citation id="sref19" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <year>
         2020 Feb 15
        </year>
        <fpage>
         514
        </fpage>
        <lpage>
         523
        </lpage>
        <comment>
         Epub 2020 Jan 24
        </comment>
        <pub-id pub-id-type="pmid">
         31986261
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib20">
       <label>
        20
       </label>
       <element-citation id="sref20" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nishiura
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Linton
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
         <name>
          <surname>
           Akhmetzhanov
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Initial cluster of novel coronavirus (2019-nCoV) infections in wuhan, China is consistent with substantial human-to-human transmission
        </article-title>
        <source>
         J. Clin. Med.
        </source>
        <volume>
         9
        </volume>
        <issue>
         2
        </issue>
        <year>
         2020
        </year>
        <fpage>
         E488
        </fpage>
        <pub-id pub-id-type="pmid">
         32054045
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib21">
       <label>
        21
       </label>
       <mixed-citation id="sref21" publication-type="other">
        Organization, W.H., Consensus Document on the Epidemiology of Severe Acute Respiratory Syndrome (SARS). 2003, World Health Organization: Geneva.
       </mixed-citation>
      </ref>
      <ref id="bib22">
       <label>
        22
       </label>
       <element-citation id="sref22" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maier
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Bickerton
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Britton
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Coronaviruses: Methods and Protocols
        </chapter-title>
        <year>
         2015
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         282
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib23">
       <label>
        23
       </label>
       <element-citation id="sref23" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Malik
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: current knowledge and future considerations
        </article-title>
        <source>
         EMHJ-Eastern Mediterranean Health J.
        </source>
        <volume>
         22
        </volume>
        <issue>
         7
        </issue>
        <year>
         2016
        </year>
        <fpage>
         533
        </fpage>
        <lpage>
         542
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib24">
       <label>
        24
       </label>
       <element-citation id="sref24" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Jia
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         2019-nCoV transmission through the ocular surface must not be ignored
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <issue>
         10224
        </issue>
        <year>
         2020 Feb 22
        </year>
        <fpage>
         e39
        </fpage>
        <comment>
         Epub 2020 Feb 6
        </comment>
        <pub-id pub-id-type="pmid">
         32035510
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib25">
       <label>
        25
       </label>
       <element-citation id="sref25" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yin
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wunderink
          </surname>
          <given-names>
           R.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS, SARS and other coronaviruses as causes of pneumonia
        </article-title>
        <source>
         Respirology
        </source>
        <volume>
         23
        </volume>
        <issue>
         2
        </issue>
        <year>
         2018
        </year>
        <fpage>
         130
        </fpage>
        <lpage>
         137
        </lpage>
        <pub-id pub-id-type="pmid">
         29052924
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib26">
       <label>
        26
       </label>
       <element-citation id="sref26" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <year>
         2020 Feb 15
        </year>
        <fpage>
         497
        </fpage>
        <lpage>
         506
        </lpage>
        <comment>
         Epub 2020 Jan 24
        </comment>
        <pub-id pub-id-type="pmid">
         31986264
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib27">
       <label>
        27
       </label>
       <element-citation id="sref27" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sabir
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia
        </article-title>
        <source>
         Science
        </source>
        <volume>
         351
        </volume>
        <issue>
         6268
        </issue>
        <year>
         2016
        </year>
        <fpage>
         81
        </fpage>
        <lpage>
         84
        </lpage>
        <pub-id pub-id-type="pmid">
         26678874
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib28">
       <label>
        28
       </label>
       <element-citation id="sref28" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Moderate mutation rate in the SARS coronavirus genome and its implications
        </article-title>
        <source>
         BMC Evol. Biol.
        </source>
        <volume>
         4
        </volume>
        <year>
         2004
        </year>
        <fpage>
         21
        </fpage>
        <pub-id pub-id-type="pmid">
         15222897
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib29">
       <label>
        29
       </label>
       <element-citation id="sref29" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infectious diseases emerging from Chinese wet-markets: zoonotic origins of severe respiratory viral infections
        </article-title>
        <source>
         Curr. Opin. Infect. Dis.
        </source>
        <volume>
         19
        </volume>
        <issue>
         5
        </issue>
        <year>
         2006
        </year>
        <fpage>
         401
        </fpage>
        <lpage>
         407
        </lpage>
        <pub-id pub-id-type="pmid">
         16940861
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib30">
       <label>
        30
       </label>
       <element-citation id="sref30" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus diversity, phylogeny and interspecies jumping
        </article-title>
        <source>
         Exp. Biol. Med.
        </source>
        <volume>
         234
        </volume>
        <issue>
         10
        </issue>
        <year>
         2009
        </year>
        <fpage>
         1117
        </fpage>
        <lpage>
         1127
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib31">
       <label>
        31
       </label>
       <element-citation id="sref31" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative analysis of 22 coronavirus HKU1 genomes reveals a novel genotype and evidence of natural recombination in coronavirus HKU1
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         80
        </volume>
        <issue>
         14
        </issue>
        <year>
         2006
        </year>
        <fpage>
         7136
        </fpage>
        <lpage>
         7145
        </lpage>
        <pub-id pub-id-type="pmid">
         16809319
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib32">
       <label>
        32
       </label>
       <element-citation id="sref32" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Benvenuto
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The 2019-new coronavirus epidemic: evidence for virus evolution
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <volume>
         92
        </volume>
        <issue>
         4
        </issue>
        <year>
         2020 Apr
        </year>
        <fpage>
         455
        </fpage>
        <lpage>
         459
        </lpage>
        <comment>
         Epub 2020 Feb 7
        </comment>
        <pub-id pub-id-type="pmid">
         31994738
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib33">
       <label>
        33
       </label>
       <element-citation id="sref33" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ceraolo
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Giorgi
          </surname>
          <given-names>
           F.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genomic variance of the 2019-nCoV coronavirus
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib34">
       <label>
        34
       </label>
       <element-citation id="sref34" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Acute renal impairment in coronavirus-associated severe acute respiratory syndrome
        </article-title>
        <source>
         Kidney Int.
        </source>
        <volume>
         67
        </volume>
        <issue>
         2
        </issue>
        <year>
         2005
        </year>
        <fpage>
         698
        </fpage>
        <lpage>
         705
        </lpage>
        <pub-id pub-id-type="pmid">
         15673319
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib35">
       <label>
        35
       </label>
       <element-citation id="sref35" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         361
        </volume>
        <issue>
         9371
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1767
        </fpage>
        <lpage>
         1772
        </lpage>
        <pub-id pub-id-type="pmid">
         12781535
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib36">
       <label>
        36
       </label>
       <element-citation id="sref36" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Booth
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area
        </article-title>
        <source>
         J. Am. Med. Assoc.
        </source>
        <volume>
         289
        </volume>
        <issue>
         21
        </issue>
        <year>
         2003
        </year>
        <fpage>
         2801
        </fpage>
        <lpage>
         2809
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib37">
       <label>
        37
       </label>
       <element-citation id="sref37" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: a Descriptive Study
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         Lancet
        </publisher-name>
        <publisher-loc>
         London, England)
        </publisher-loc>
        <comment>
         S0140-6736(20)30211-7
        </comment>
       </element-citation>
      </ref>
      <ref id="bib38">
       <label>
        38
       </label>
       <element-citation id="sref38" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cinatl
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment of SARS with human interferons
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         362
        </volume>
        <issue>
         9380
        </issue>
        <year>
         2003
        </year>
        <fpage>
         293
        </fpage>
        <lpage>
         294
        </lpage>
        <pub-id pub-id-type="pmid">
         12892961
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib39">
       <label>
        39
       </label>
       <element-citation id="sref39" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stockman
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bellamy
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Garner
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS: systematic review of treatment effects
        </article-title>
        <source>
         PLoS Med.
        </source>
        <volume>
         3
        </volume>
        <issue>
         9
        </issue>
        <year>
         2006
        </year>
        <fpage>
         e343
        </fpage>
        <pub-id pub-id-type="pmid">
         16968120
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib40">
       <label>
        40
       </label>
       <element-citation id="sref40" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses - drug discovery and therapeutic options
        </article-title>
        <source>
         Nat. Rev. Drug Discov.
        </source>
        <volume>
         15
        </volume>
        <issue>
         5
        </issue>
        <year>
         2016
        </year>
        <fpage>
         327
        </fpage>
        <lpage>
         347
        </lpage>
        <pub-id pub-id-type="pmid">
         26868298
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib41">
       <label>
        41
       </label>
       <element-citation id="sref41" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients
        </article-title>
        <source>
         J. Clin. Virol.
        </source>
        <volume>
         31
        </volume>
        <issue>
         4
        </issue>
        <year>
         2004
        </year>
        <fpage>
         304
        </fpage>
        <lpage>
         309
        </lpage>
        <pub-id pub-id-type="pmid">
         15494274
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib42">
       <label>
        42
       </label>
       <element-citation id="sref42" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Russell
          </surname>
          <given-names>
           C.D.
          </given-names>
         </name>
         <name>
          <surname>
           Millar
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Baillie
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         The Lancet
        </publisher-name>
       </element-citation>
      </ref>
      <ref id="bib43">
       <label>
        43
       </label>
       <element-citation id="sref43" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus as a possible cause of severe acute respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         361
        </volume>
        <issue>
         9366
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1319
        </fpage>
        <lpage>
         1325
        </lpage>
        <pub-id pub-id-type="pmid">
         12711465
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib44">
       <label>
        44
       </label>
       <element-citation id="sref44" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           NS
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           GQ
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Our strategies for fighting severe acute respiratory syndrome (SARS)
        </article-title>
        <source>
         Am. J. Respir. Crit. Care Med.
        </source>
        <volume>
         168
        </volume>
        <issue>
         1
        </issue>
        <year>
         2003
        </year>
        <fpage>
         7
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         12773318
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib45">
       <label>
        45
       </label>
       <element-citation id="sref45" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           R.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology, transmission dynamics and control of SARS: the 2002-2003 epidemic
        </article-title>
        <source>
         Phil. Trans. Roy. Soc. Lond. B Biol. Sci.
        </source>
        <volume>
         359
        </volume>
        <issue>
         1447
        </issue>
        <year>
         2004
        </year>
        <fpage>
         1091
        </fpage>
        <lpage>
         1105
        </lpage>
        <pub-id pub-id-type="pmid">
         15306395
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib46">
       <label>
        46
       </label>
       <element-citation id="sref46" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of control measures implemented in the severe acute respiratory syndrome outbreak in Beijing
        </article-title>
        <source>
         JAMA, 2003
        </source>
        <volume>
         290
        </volume>
        <issue>
         24
        </issue>
        <year>
         2003
        </year>
        <fpage>
         3215
        </fpage>
        <lpage>
         3221
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib47">
       <label>
        47
       </label>
       <element-citation id="sref47" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Centers for Disease
          </surname>
         </name>
        </person-group>
        <article-title>
         C. and Prevention, Efficiency of quarantine during an epidemic of severe acute respiratory syndrome-Beijing, China
        </article-title>
        <source>
         MMWR. Morbidity Mortality Weekly Rep.
        </source>
        <volume>
         52
        </volume>
        <issue>
         43
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1037
        </fpage>
        <lpage>
         1040
        </lpage>
        <comment>
         2003
        </comment>
       </element-citation>
      </ref>
      <ref id="bib48">
       <label>
        48
       </label>
       <element-citation id="sref48" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Breiman
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Role of China in the quest to define and control severe acute respiratory syndrome
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         9
        </volume>
        <issue>
         9
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1037
        </fpage>
        <lpage>
         1041
        </lpage>
        <pub-id pub-id-type="pmid">
         14519236
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib49">
       <label>
        49
       </label>
       <element-citation id="sref49" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sampathkumar
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS: epidemiology, clinical presentation, management, and infection control measures
        </article-title>
        <source>
         Mayo Clin. Proc.
        </source>
        <volume>
         78
        </volume>
        <issue>
         7
        </issue>
        <year>
         2003
        </year>
        <fpage>
         882
        </fpage>
        <lpage>
         890
        </lpage>
        <pub-id pub-id-type="pmid">
         12839084
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib50">
       <label>
        50
       </label>
       <element-citation id="sref50" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Christian
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <volume>
         38
        </volume>
        <issue>
         10
        </issue>
        <year>
         2004
        </year>
        <fpage>
         1420
        </fpage>
        <lpage>
         1427
        </lpage>
        <pub-id pub-id-type="pmid">
         15156481
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib51">
       <label>
        51
       </label>
       <element-citation id="sref51" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           N
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Learning from the sars outbreak
        </article-title>
        <source>
         Curr. Biol. : CB
        </source>
        <volume>
         14
        </volume>
        <issue>
         3
        </issue>
        <year>
         2004
        </year>
        <fpage>
         R91
        </fpage>
        <lpage>
         R93
        </lpage>
        <pub-id pub-id-type="pmid">
         14986624
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib52">
       <label>
        52
       </label>
       <element-citation id="sref52" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           P.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome and coronavirus
        </article-title>
        <source>
         Infect. Dis. Clin.
        </source>
        <volume>
         24
        </volume>
        <issue>
         3
        </issue>
        <year>
         2010
        </year>
        <fpage>
         619
        </fpage>
        <lpage>
         638
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib53">
       <label>
        53
       </label>
       <element-citation id="sref53" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           NS
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           GQ
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pandemic planning in China: applying lessons from severe acute respiratory syndrome
        </article-title>
        <source>
         Respirology
        </source>
        <year>
         2008
        </year>
        <fpage>
         S33
        </fpage>
        <lpage>
         S35
        </lpage>
        <pub-id pub-id-type="pmid">
         18366527
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib54">
       <label>
        54
       </label>
       <element-citation id="sref54" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           AS
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lessons from the severe acute respiratory syndrome outbreak in Hong Kong
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         9
        </volume>
        <issue>
         9
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1042
        </fpage>
        <lpage>
         1045
        </lpage>
        <pub-id pub-id-type="pmid">
         14519237
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib55">
       <label>
        55
       </label>
       <element-citation id="sref55" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           RP
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           MB
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Listening to SARS: lessons for infection control
        </article-title>
        <source>
         Ann. Intern. Med.
        </source>
        <volume>
         139
        </volume>
        <issue>
         7
        </issue>
        <year>
         2003
        </year>
        <fpage>
         592
        </fpage>
        <lpage>
         593
        </lpage>
        <pub-id pub-id-type="pmid">
         14530231
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib56">
       <label>
        56
       </label>
       <element-citation id="sref56" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical management and infection control of SARS: lessons learned
        </article-title>
        <source>
         Antivir. Res.
        </source>
        <volume>
         100
        </volume>
        <issue>
         2
        </issue>
        <year>
         2013
        </year>
        <fpage>
         407
        </fpage>
        <lpage>
         419
        </lpage>
        <pub-id pub-id-type="pmid">
         23994190
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib57">
       <label>
        57
       </label>
       <element-citation id="sref57" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Parashar
          </surname>
          <given-names>
           U.D.
          </given-names>
         </name>
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome: review and lessons of the 2003 outbreak
        </article-title>
        <source>
         Int. J. Epidemiol.
        </source>
        <volume>
         33
        </volume>
        <issue>
         4
        </issue>
        <year>
         2004
        </year>
        <fpage>
         628
        </fpage>
        <lpage>
         634
        </lpage>
        <pub-id pub-id-type="pmid">
         15155694
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib58">
       <label>
        58
       </label>
       <element-citation id="sref58" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of control measures implemented in the severe acute respiratory syndrome outbreak in Beijing
        </article-title>
        <source>
         JAMA, 2003
        </source>
        <volume>
         290
        </volume>
        <issue>
         24
        </issue>
        <year>
         2003
        </year>
        <fpage>
         3215
        </fpage>
        <lpage>
         3221
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib59">
       <label>
        59
       </label>
       <element-citation id="sref59" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           DR
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Obstacles and advances in SARS vaccine development
        </article-title>
        <source>
         Vaccine
        </source>
        <volume>
         24
        </volume>
        <issue>
         7
        </issue>
        <year>
         2006
        </year>
        <fpage>
         863
        </fpage>
        <lpage>
         871
        </lpage>
        <pub-id pub-id-type="pmid">
         16191455
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib60">
       <label>
        60
       </label>
       <element-citation id="sref60" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wenjie
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel coronavirus genome identified in a cluster of pneumonia cases — wuhan, China 2019−2020
        </article-title>
        <source>
         China CDC Weekly
        </source>
        <volume>
         2
        </volume>
        <issue>
         4
        </issue>
        <year>
         2020
        </year>
        <fpage>
         61
        </fpage>
        <lpage>
         62
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib61">
       <label>
        61
       </label>
       <element-citation id="sref61" publication-type="journal">
        <comment>
         The -nCo, V.O.J.F.E.I.T.
        </comment>
        <person-group person-group-type="author">
         <name>
          <surname>
           Qun
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An outbreak of NCIP (2019-nCoV) infection in China — wuhan, Hubei province, 2019−2020
        </article-title>
        <source>
         China CDC Weekly
        </source>
        <volume>
         2
        </volume>
        <issue>
         5
        </issue>
        <year>
         2020
        </year>
        <fpage>
         79
        </fpage>
        <lpage>
         80
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib62">
       <label>
        62
       </label>
       <element-citation id="sref62" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           University
          </surname>
          <given-names>
           S.C.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pangolin was found to be a potential intermediate-host of new coronavirus
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0025" xlink:href="https://www.scau.edu.cn/2020/0207/c1300a219015/page.htm">
         https://www.scau.edu.cn/2020/0207/c1300a219015/page.htm
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib63">
       <label>
        63
       </label>
       <element-citation id="sref63" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rothe
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transmission of 2019-nCoV infection from an asymptomatic contact in Germany
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2020 Jan 30
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib64">
       <label>
        64
       </label>
       <element-citation id="sref64" publication-type="journal">
        <article-title>
         Clinical updates in women's health care summary: liver disease: reproductive considerations
        </article-title>
        <source>
         Obstet. Gynecol.
        </source>
        <volume>
         129
        </volume>
        <issue>
         1
        </issue>
        <year>
         2017
        </year>
        <fpage>
         236
        </fpage>
        <pub-id pub-id-type="pmid">
         28002308
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib65">
       <label>
        65
       </label>
       <element-citation id="sref65" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Early transmission dynamics in wuhan, China, of novel coronavirus-infected pneumonia
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib66">
       <label>
        66
       </label>
       <element-citation id="sref66" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paules
          </surname>
          <given-names>
           C.I.
          </given-names>
         </name>
         <name>
          <surname>
           Marston
          </surname>
          <given-names>
           H.D.
          </given-names>
         </name>
         <name>
          <surname>
           Fauci
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus infections-more than just the common cold
        </article-title>
        <source>
         J. Am. Med. Assoc.
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib67">
       <label>
        67
       </label>
       <element-citation id="sref67" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Novel Coronavirus Pneumonia Emergency Response Epidemiology
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China
        </article-title>
        <source>
         Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
        </source>
        <volume>
         41
        </volume>
        <issue>
         2
        </issue>
        <year>
         2020
        </year>
        <fpage>
         145
        </fpage>
        <lpage>
         151
        </lpage>
        <pub-id pub-id-type="pmid">
         32064853
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib68">
       <label>
        68
       </label>
       <element-citation id="sref68" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Nowcasting and Forecasting the Potential Domestic and International Spread of the 2019-nCoV Outbreak Originating in Wuhan, China: a Modelling Study
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         Lancet
        </publisher-name>
        <publisher-loc>
         London, England)
        </publisher-loc>
        <comment>
         S0140-6736(20)30260-9
        </comment>
       </element-citation>
      </ref>
      <ref id="bib69">
       <label>
        69
       </label>
       <element-citation id="sref69" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Prevention
          </surname>
         </name>
        </person-group>
        <article-title>
         G.C.f.D.C.a. The virus on the doorknob is not a live virus
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0030" xlink:href="http://www.gd.xinhuanet.com/newscenter/2020-02/04/c_1125528591.htm">
         http://www.gd.xinhuanet.com/newscenter/2020-02/04/c_1125528591.htm
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib70">
       <label>
        70
       </label>
       <element-citation id="sref70" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           ZH
          </surname>
         </name>
        </person-group>
        <article-title>
         Z. Fecal matter of patients tests positive for coronavirus
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0035" xlink:href="https://www.chinadaily.com.cn/a/202002/02/WS5e35b026a310128217274206.html">
         https://www.chinadaily.com.cn/a/202002/02/WS5e35b026a310128217274206.html
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib71">
       <label>
        71
       </label>
       <element-citation id="sref71" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Holshue
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         First case of 2019 novel coronavirus in the United States
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib72">
       <label>
        72
       </label>
       <element-citation id="sref72" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Organization, W.H. Novel Coronavirus
         </collab>
        </person-group>
        <article-title>
         (2019-nCoV) situation reports to data
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0040" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/">
         https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib73">
       <label>
        73
       </label>
       <element-citation id="sref73" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Organization
          </surname>
         </name>
        </person-group>
        <chapter-title>
         W.H. Statement on the Second Meeting of the International Health Regulations (2005) Emergency Committee Regarding the Outbreak of Novel Coronavirus (2019-nCoV). . 2020
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         World Health Organization
        </publisher-name>
        <publisher-loc>
         Geneva
        </publisher-loc>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0045" xlink:href="https://www.who.int/newsroom/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-healthregulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov">
         https://www.who.int/newsroom/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-healthregulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib74">
       <label>
        74
       </label>
       <element-citation id="sref74" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           Z.D.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Diagnosis and prevention of 2019-nCoV virus infection/pneumonia in children
        </article-title>
        <comment>
         (in Chinese) Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0050" xlink:href="https://www.cma.org.cn/art/2020/1/29/art_1822_32177.html">
         https://www.cma.org.cn/art/2020/1/29/art_1822_32177.html
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib75">
       <label>
        75
       </label>
       <element-citation id="sref75" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Technology
          </surname>
         </name>
        </person-group>
        <chapter-title>
         T.H.T.M.C.H.U.o.S.a. Be Alert to the Risk of Mother-To-Child Vertical Transmission and the First New Coronavirus Infection of a Newborn Was Diagnosed in Tongji Hospital
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         ChuTian Metropolis Daily
        </publisher-name>
        <fpage>
         2020
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib76">
       <label>
        76
       </label>
       <element-citation id="sref76" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         The Lancet
        </publisher-name>
       </element-citation>
      </ref>
      <ref id="bib77">
       <label>
        77
       </label>
       <element-citation id="sref77" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Commission
          </surname>
          <given-names>
           C.N.H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Notice on prevention and control of pneumonia in children and pregnant women with new coronavirus infection
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         China National Health Commission
        </publisher-name>
        <publisher-loc>
         Beijing
        </publisher-loc>
        <comment>
         (in Chinese)
        </comment>
        <ext-link ext-link-type="uri" id="intref0055" xlink:href="http://www.nhc.gov.cn/xcs/zhengcwj/202002/de2d62a5711c41ef9b2c4b6f4d1f2136.shtml">
         http://www.nhc.gov.cn/xcs/zhengcwj/202002/de2d62a5711c41ef9b2c4b6f4d1f2136.shtml
        </ext-link>
        <comment>
         2020; Available from:
        </comment>
       </element-citation>
      </ref>
      <ref id="bib78">
       <label>
        78
       </label>
       <mixed-citation id="sref78" publication-type="other">
        Technology, M.e.g.o.T.h.a.t.T.M.C.o.H.U.o.S.a. A rapid guideline for the diagnosis and treatment of pneumonia with new coronavirus infection (Third edition). . Herald of Medicine 2020 1004-0781,CN 42-1293/R]; Available from:
        <ext-link ext-link-type="uri" id="intref0060" xlink:href="http://kns.cnki.net/kcms/detail/42.1293.r.20200130.1803.002.html">
         http://kns.cnki.net/kcms/detail/42.1293.r.20200130.1803.002.html
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib79">
       <label>
        79
       </label>
       <element-citation id="sref79" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Union Hospital
          </surname>
         </name>
        </person-group>
        <article-title>
         T.M.C., Huazhong University of Science and Technology., Wuhan union hospital manage the 2019 new coronavirus infection strategies and instructions
        </article-title>
        <comment>
         (in Chinese)
        </comment>
        <ext-link ext-link-type="uri" id="intref0065" xlink:href="https://mp.weixin.qq.com/s/d7btF9g1wMhNgFnHy5vY1Q">
         https://mp.weixin.qq.com/s/d7btF9g1wMhNgFnHy5vY1Q
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib80">
       <label>
        80
       </label>
       <element-citation id="sref80" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yinghui Jing
          </surname>
          <given-names>
           L.C.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Zhenshui
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Hong
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Diagnosis and Clinical Management of 2019 Novel Coronavirus (2019-nCoV) Infection: an Operational Recommendation of Peking Union Medical College Hospital. (In Chinese)
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         Medical Journal of Chinese People's Liberation Army
        </publisher-name>
        <comment>
         0577-7402,CN 11-1056/R
        </comment>
       </element-citation>
      </ref>
      <ref id="bib81">
       <label>
        81
       </label>
       <element-citation id="sref81" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Organization
          </surname>
         </name>
        </person-group>
        <chapter-title>
         W.H., Clinical Management of Severe Acute Respiratory Infection when Novel Coronavirus (nCoV) Infection Is Suspected
        </chapter-title>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib82">
       <label>
        82
       </label>
       <element-citation id="sref82" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Commission
          </surname>
          <given-names>
           C.N.H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         New Coronavirus Pneumonia Prevention and Control Program
        </chapter-title>
        <edition>
         fifth ed.
        </edition>
        <year>
         2020
        </year>
        <publisher-name>
         China National Health Commission, 2020
        </publisher-name>
        <publisher-loc>
         Beijing
        </publisher-loc>
        <comment>
         (in Chinese)
        </comment>
        <ext-link ext-link-type="uri" id="intref0070" xlink:href="http://www.nhc.gov.cn/xcs/zhengcwj/202002/3b09b894ac9b4204a79db5b8912d4440.shtml">
         http://www.nhc.gov.cn/xcs/zhengcwj/202002/3b09b894ac9b4204a79db5b8912d4440.shtml
        </ext-link>
        <comment>
         Available from:
        </comment>
       </element-citation>
      </ref>
      <ref id="bib83">
       <label>
        83
       </label>
       <element-citation id="sref83" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, China
        </article-title>
        <source>
         J. Am. Med. Assoc.
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib84">
       <label>
        84
       </label>
       <element-citation id="sref84" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside wuhan, China
        </article-title>
        <source>
         J. Am. Med. Assoc.
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib85">
       <label>
        85
       </label>
       <element-citation id="sref85" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           W.-j.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Clinical Characteristics of 2019 Novel Coronavirus Infection in China
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         medRxiv
        </publisher-name>
        <comment>
         2020.02.06.20020974
        </comment>
       </element-citation>
      </ref>
      <ref id="bib86">
       <label>
        86
       </label>
       <element-citation id="sref86" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ai
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Hou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhan
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lv
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of
         <bold>
          1014
         </bold>
         Cases.
        </article-title>
        <source>
         Radiology
        </source>
        <year>
         2020 Feb 26
        </year>
        <object-id pub-id-type="publisher-id">
         200642
        </object-id>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib87">
       <label>
        87
       </label>
       <element-citation id="sref87" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emerging coronaviruses: genome structure, replication, and pathogenesis
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <volume>
         92
        </volume>
        <issue>
         4
        </issue>
        <year>
         2020 Apr
        </year>
        <fpage>
         418
        </fpage>
        <lpage>
         423
        </lpage>
        <comment>
         Epub 2020 Feb 7. Review
        </comment>
        <pub-id pub-id-type="pmid">
         31967327
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib88">
       <label>
        88
       </label>
       <element-citation id="sref88" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cookson
          </surname>
          <given-names>
           B.T.
          </given-names>
         </name>
         <name>
          <surname>
           Brennan
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pro-inflammatory programmed cell death
        </article-title>
        <source>
         Trends Microbiol.
        </source>
        <volume>
         9
        </volume>
        <issue>
         3
        </issue>
        <year>
         2001
        </year>
        <fpage>
         113
        </fpage>
        <lpage>
         114
        </lpage>
        <pub-id pub-id-type="pmid">
         11303500
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib89">
       <label>
        89
       </label>
       <element-citation id="sref89" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           I.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus Viroporin 3a activates the NLRP3 inflammasome
        </article-title>
        <source>
         Front. Microbiol.
        </source>
        <volume>
         10
        </volume>
        <year>
         2019
        </year>
        <fpage>
         50
        </fpage>
        <pub-id pub-id-type="pmid">
         30761102
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib90">
       <label>
        90
       </label>
       <element-citation id="sref90" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Cell Pyroptosis, a Potential Pathogenic Mechanismof 2019 nCoV Infection
        </chapter-title>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib91">
       <label>
        91
       </label>
       <element-citation id="sref91" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gralinski
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           V.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Return of the coronavirus: 2019-nCoV
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         12
        </volume>
        <issue>
         2
        </issue>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib92">
       <label>
        92
       </label>
       <element-citation id="sref92" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <issue>
         10224
        </issue>
        <year>
         2020
        </year>
        <fpage>
         565
        </fpage>
        <lpage>
         574
        </lpage>
        <comment>
         Epub 2020 Jan 30
        </comment>
        <pub-id pub-id-type="pmid">
         32007145
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib93">
       <label>
        93
       </label>
       <element-citation id="sref93" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A new coronavirus associated with human respiratory disease in China
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2020 Feb 3
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib94">
       <label>
        94
       </label>
       <element-citation id="sref94" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A pneumonia outbreak associated with a new coronavirus of probable bat origin
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib95">
       <label>
        95
       </label>
       <element-citation id="sref95" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China
        </article-title>
        <source>
         Cell Host Microbe
        </source>
        <year>
         2020 Feb 7
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib96">
       <label>
        96
       </label>
       <element-citation id="sref96" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paraskevis
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event
        </article-title>
        <source>
         Infect. Genet. Evol.
        </source>
        <volume>
         79
        </volume>
        <year>
         2020
        </year>
        <fpage>
         104212
        </fpage>
        <pub-id pub-id-type="pmid">
         32004758
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib97">
       <label>
        97
       </label>
       <element-citation id="sref97" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wrapp
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         bioRxiv
        </publisher-name>
        <comment>
         2020.02.11.944462
        </comment>
       </element-citation>
      </ref>
      <ref id="bib98">
       <label>
        98
       </label>
       <element-citation id="sref98" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         426
        </volume>
        <issue>
         6965
        </issue>
        <year>
         2003
        </year>
        <fpage>
         450
        </fpage>
        <lpage>
         454
        </lpage>
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib99">
       <label>
        99
       </label>
       <element-citation id="sref99" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bartelink
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           P.J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         82
        </volume>
        <issue>
         17
        </issue>
        <year>
         2008
        </year>
        <fpage>
         8887
        </fpage>
        <lpage>
         8890
        </lpage>
        <pub-id pub-id-type="pmid">
         18562523
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib100">
       <label>
        100
       </label>
       <element-citation id="sref100" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Belouzard
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
         <name>
          <surname>
           Whittaker
          </surname>
          <given-names>
           G.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U. S. A
        </source>
        <volume>
         106
        </volume>
        <issue>
         14
        </issue>
        <year>
         2009
        </year>
        <fpage>
         5871
        </fpage>
        <lpage>
         5876
        </lpage>
        <pub-id pub-id-type="pmid">
         19321428
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib101">
       <label>
        101
       </label>
       <element-citation id="sref101" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Glowacka
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         85
        </volume>
        <issue>
         9
        </issue>
        <year>
         2011
        </year>
        <fpage>
         4122
        </fpage>
        <lpage>
         4134
        </lpage>
        <pub-id pub-id-type="pmid">
         21325420
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib102">
       <label>
        102
       </label>
       <element-citation id="sref102" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan
        </article-title>
        <source>
         Emerg. Microb. Infect.
        </source>
        <volume>
         9
        </volume>
        <issue>
         1
        </issue>
        <year>
         2020
        </year>
        <fpage>
         221
        </fpage>
        <lpage>
         236
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib103">
       <label>
        103
       </label>
       <element-citation id="sref103" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Delmas
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Laude
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Assembly of coronavirus spike protein into trimers and its role in epitope expression
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         64
        </volume>
        <issue>
         11
        </issue>
        <year>
         1990
        </year>
        <fpage>
         5367
        </fpage>
        <lpage>
         5375
        </lpage>
        <pub-id pub-id-type="pmid">
         2170676
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib104">
       <label>
        104
       </label>
       <element-citation id="sref104" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Beniac
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Architecture of the SARS coronavirus prefusion spike
        </article-title>
        <source>
         Nat. Struct. Mol. Biol.
        </source>
        <volume>
         13
        </volume>
        <issue>
         8
        </issue>
        <year>
         2006
        </year>
        <fpage>
         751
        </fpage>
        <lpage>
         752
        </lpage>
        <pub-id pub-id-type="pmid">
         16845391
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib105">
       <label>
        105
       </label>
       <element-citation id="sref105" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
        </article-title>
        <source>
         Cell. Mol. Immunol.
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib106">
       <label>
        106
       </label>
       <element-citation id="sref106" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         81
        </volume>
        <issue>
         4
        </issue>
        <year>
         2007
        </year>
        <fpage>
         1701
        </fpage>
        <lpage>
         1713
        </lpage>
        <pub-id pub-id-type="pmid">
         17108030
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib107">
       <label>
        107
       </label>
       <element-citation id="sref107" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nieto-Torres
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <volume>
         10
        </volume>
        <issue>
         5
        </issue>
        <year>
         2014
        </year>
        <object-id pub-id-type="publisher-id">
         e1004077
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib108">
       <label>
        108
       </label>
       <element-citation id="sref108" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           C.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Modular organization of SARS coronavirus nucleocapsid protein
        </article-title>
        <source>
         J. Biomed. Sci.
        </source>
        <volume>
         13
        </volume>
        <issue>
         1
        </issue>
        <year>
         2006
        </year>
        <fpage>
         59
        </fpage>
        <lpage>
         72
        </lpage>
        <pub-id pub-id-type="pmid">
         16228284
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib109">
       <label>
        109
       </label>
       <element-citation id="sref109" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hurst
          </surname>
          <given-names>
           K.R.
          </given-names>
         </name>
         <name>
          <surname>
           Koetzner
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Masters
          </surname>
          <given-names>
           P.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of in vivo-interacting domains of the murine coronavirus nucleocapsid protein
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         83
        </volume>
        <issue>
         14
        </issue>
        <year>
         2009
        </year>
        <fpage>
         7221
        </fpage>
        <lpage>
         7234
        </lpage>
        <pub-id pub-id-type="pmid">
         19420077
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib110">
       <label>
        110
       </label>
       <element-citation id="sref110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The nucleocapsid protein of coronaviruses acts as a viral suppressor of RNA silencing in mammalian cells
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         89
        </volume>
        <issue>
         17
        </issue>
        <year>
         2015
        </year>
        <fpage>
         9029
        </fpage>
        <lpage>
         9043
        </lpage>
        <pub-id pub-id-type="pmid">
         26085159
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib111">
       <label>
        111
       </label>
       <element-citation id="sref111" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure, function, and evolution of coronavirus spike proteins
        </article-title>
        <source>
         Annu. Rev. Virol.
        </source>
        <volume>
         3
        </volume>
        <issue>
         1
        </issue>
        <year>
         2016
        </year>
        <fpage>
         237
        </fpage>
        <lpage>
         261
        </lpage>
        <pub-id pub-id-type="pmid">
         27578435
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib112">
       <label>
        112
       </label>
       <element-citation id="sref112" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Belouzard
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
         <name>
          <surname>
           Whittaker
          </surname>
          <given-names>
           G.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U. S. A.
        </source>
        <volume>
         106
        </volume>
        <issue>
         14
        </issue>
        <year>
         2009
        </year>
        <fpage>
         5871
        </fpage>
        <lpage>
         5876
        </lpage>
        <pub-id pub-id-type="pmid">
         19321428
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib113">
       <label>
        113
       </label>
       <element-citation id="sref113" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Matsuyama
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         84
        </volume>
        <issue>
         24
        </issue>
        <year>
         2010
        </year>
        <fpage>
         12658
        </fpage>
        <lpage>
         12664
        </lpage>
        <pub-id pub-id-type="pmid">
         20926566
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib114">
       <label>
        114
       </label>
       <element-citation id="sref114" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bertram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         85
        </volume>
        <issue>
         24
        </issue>
        <year>
         2011
        </year>
        <fpage>
         13363
        </fpage>
        <lpage>
         13372
        </lpage>
        <pub-id pub-id-type="pmid">
         21994442
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib115">
       <label>
        115
       </label>
       <element-citation id="sref115" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Simmons
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research
        </article-title>
        <source>
         Antivir. Res.
        </source>
        <volume>
         100
        </volume>
        <issue>
         3
        </issue>
        <year>
         2013
        </year>
        <fpage>
         605
        </fpage>
        <lpage>
         614
        </lpage>
        <pub-id pub-id-type="pmid">
         24121034
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib116">
       <label>
        116
       </label>
       <element-citation id="sref116" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuhn
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus
        </article-title>
        <source>
         Cell. Mol. Life Sci. : CMLS
        </source>
        <volume>
         61
        </volume>
        <issue>
         21
        </issue>
        <year>
         2004
        </year>
        <fpage>
         2738
        </fpage>
        <lpage>
         2743
        </lpage>
        <pub-id pub-id-type="pmid">
         15549175
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib117">
       <label>
        117
       </label>
       <element-citation id="sref117" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         495
        </volume>
        <issue>
         7440
        </issue>
        <year>
         2013
        </year>
        <fpage>
         251
        </fpage>
        <lpage>
         254
        </lpage>
        <pub-id pub-id-type="pmid">
         23486063
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib118">
       <label>
        118
       </label>
       <element-citation id="sref118" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hoffmann
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         The Novel Coronavirus 2019 (2019-nCoV) Uses the SARS-Coronavirus Receptor ACE2 and the Cellular Protease TMPRSS2 for Entry into Target Cells
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         bioRxiv
        </publisher-name>
        <comment>
         2020.01.31.929042
        </comment>
       </element-citation>
      </ref>
      <ref id="bib119">
       <label>
        119
       </label>
       <element-citation id="sref119" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Herrmann
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Fast Assessment of Human Receptor-Binding Capability of 2019 Novel Coronavirus (2019-nCoV)
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         bioRxiv
        </publisher-name>
        <comment>
         2020.02.01.930537
        </comment>
       </element-citation>
      </ref>
      <ref id="bib120">
       <label>
        120
       </label>
       <element-citation id="sref120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         77
        </volume>
        <issue>
         16
        </issue>
        <year>
         2003
        </year>
        <fpage>
         8801
        </fpage>
        <lpage>
         8811
        </lpage>
        <pub-id pub-id-type="pmid">
         12885899
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib121">
       <label>
        121
       </label>
       <element-citation id="sref121" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Walls
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U. S. A
        </source>
        <volume>
         114
        </volume>
        <issue>
         42
        </issue>
        <year>
         2017
        </year>
        <fpage>
         11157
        </fpage>
        <lpage>
         11162
        </lpage>
        <pub-id pub-id-type="pmid">
         29073020
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib122">
       <label>
        122
       </label>
       <element-citation id="sref122" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gui
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding
        </article-title>
        <source>
         Cell Res.
        </source>
        <volume>
         27
        </volume>
        <issue>
         1
        </issue>
        <year>
         2017
        </year>
        <fpage>
         119
        </fpage>
        <lpage>
         129
        </lpage>
        <pub-id pub-id-type="pmid">
         28008928
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib123">
       <label>
        123
       </label>
       <element-citation id="sref123" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pallesen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U. S. A
        </source>
        <volume>
         114
        </volume>
        <issue>
         35
        </issue>
        <year>
         2017
        </year>
        <fpage>
         E7348
        </fpage>
        <lpage>
         E7357
        </lpage>
        <pub-id pub-id-type="pmid">
         28807998
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib124">
       <label>
        124
       </label>
       <element-citation id="sref124" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains
        </article-title>
        <source>
         Nat. Commun.
        </source>
        <volume>
         8
        </volume>
        <year>
         2017
        </year>
        <comment>
         15092-15092
        </comment>
       </element-citation>
      </ref>
      <ref id="bib125">
       <label>
        125
       </label>
       <element-citation id="sref125" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Walls
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Unexpected receptor functional mimicry elucidates activation of coronavirus fusion
        </article-title>
        <source>
         Cell
        </source>
        <volume>
         176
        </volume>
        <issue>
         5
        </issue>
        <year>
         2019
        </year>
        <comment>
         1026-1039.e15
        </comment>
       </element-citation>
      </ref>
      <ref id="bib126">
       <label>
        126
       </label>
       <element-citation id="sref126" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chai
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage after 2019-nCoV Infection
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         bioRxiv
        </publisher-name>
        <comment>
         2020.02.03.931766
        </comment>
       </element-citation>
      </ref>
      <ref id="bib127">
       <label>
        127
       </label>
       <element-citation id="sref127" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         The Digestive System Is a Potential Route of 2019-nCov Infection: a Bioinformatics Analysis Based on Single-Cell Transcriptomes
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         bioRxiv
        </publisher-name>
        <comment>
         2020.01.30.927806
        </comment>
       </element-citation>
      </ref>
      <ref id="bib128">
       <label>
        128
       </label>
       <element-citation id="sref128" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Commission
          </surname>
          <given-names>
           C.N.H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Technical Guideline in Medical Institutions for the Prevention and Control of Infection with the Novel Coronavirus
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         China National Health Commission
        </publisher-name>
        <publisher-loc>
         Beijing
        </publisher-loc>
        <comment>
         (in Chinese)
        </comment>
        <ext-link ext-link-type="uri" id="intref0080" xlink:href="http://www.nhc.gov.cn/xcs/zhengcwj/202001/b91fdab7c304431eb082d67847d27e14.shtml">
         http://www.nhc.gov.cn/xcs/zhengcwj/202001/b91fdab7c304431eb082d67847d27e14.shtml
        </ext-link>
        <comment>
         Available from:
        </comment>
       </element-citation>
      </ref>
      <ref id="bib129">
       <label>
        129
       </label>
       <element-citation id="sref129" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Commission
          </surname>
          <given-names>
           C.N.H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Community Prevention and Control Program for the 2019-nCoV Infected Pneumonia
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         China National Health Commission
        </publisher-name>
        <publisher-loc>
         Beijing
        </publisher-loc>
        <comment>
         (in Chinese)
        </comment>
        <ext-link ext-link-type="uri" id="intref0085" xlink:href="http://www.nhc.gov.cn/xcs/zhengcwj/202001/dd1e502534004a8d88b6a10f329a3369.shtml">
         http://www.nhc.gov.cn/xcs/zhengcwj/202001/dd1e502534004a8d88b6a10f329a3369.shtml
        </ext-link>
        <comment>
         Available from:
        </comment>
       </element-citation>
      </ref>
      <ref id="bib130">
       <label>
        130
       </label>
       <element-citation id="sref130" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Commission
          </surname>
          <given-names>
           C.N.H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         A Guideline for the Protection of People at Different Risk of New Coronavirus Infection
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         China National Health Commission
        </publisher-name>
        <publisher-loc>
         Beijing
        </publisher-loc>
        <comment>
         (in Chinese)
        </comment>
        <ext-link ext-link-type="uri" id="intref0090" xlink:href="http://www.nhc.gov.cn/xcs/zhengcwj/202001/a3a261dabfcf4c3fa365d4eb07ddab34.shtml">
         http://www.nhc.gov.cn/xcs/zhengcwj/202001/a3a261dabfcf4c3fa365d4eb07ddab34.shtml
        </ext-link>
        <comment>
         Available from:
        </comment>
       </element-citation>
      </ref>
      <ref id="bib131">
       <label>
        131
       </label>
       <element-citation id="sref131" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Organization
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Home care for patients with suspected novel coronavirus (nCoV) infection presenting with mild symptoms and management of contacts: interim Guidance
        </article-title>
        <comment>
         (in Chinese)
        </comment>
        <ext-link ext-link-type="uri" id="intref0095" xlink:href="https://www.who.int/publications-detail/home-carefor-patients-with-suspected-novel-coronavirus-(ncov)-infection-presenting-withmild-symptoms-and-management-of-contacts">
         https://www.who.int/publications-detail/home-carefor-patients-with-suspected-novel-coronavirus-(ncov)-infection-presenting-withmild-symptoms-and-management-of-contacts
        </ext-link>
        <year>
         2020
        </year>
        <comment>
         Available from:
        </comment>
       </element-citation>
      </ref>
      <ref id="bib132">
       <label>
        132
       </label>
       <element-citation id="sref132" publication-type="other">
        <comment>
         China., M.o.S.a.T.o.t.P.s.R.o. Clinical trial of antiviral drug remdesivir starts in Wuhan. (in Chinese)
        </comment>
        <ext-link ext-link-type="uri" id="intref0100" xlink:href="http://www.most.gov.cn/kjbgz/202002/t20200206_151440.htm">
         http://www.most.gov.cn/kjbgz/202002/t20200206_151440.htm
        </ext-link>
        <year>
         2020
        </year>
        <comment>
         Available from:
        </comment>
       </element-citation>
      </ref>
      <ref id="bib133">
       <label>
        133
       </label>
       <element-citation id="sref133" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.-J.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Potential Inhibitors for 2019-nCoV Coronavirus M Protease from Clinically Approved Medicines
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         bioRxiv
        </publisher-name>
        <comment>
         2020.01.29.924100
        </comment>
       </element-citation>
      </ref>
      <ref id="bib134">
       <label>
        134
       </label>
       <element-citation id="sref134" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Richardson
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <year>
         2020 Feb 15
        </year>
        <fpage>
         e30
        </fpage>
        <lpage>
         e31
        </lpage>
        <comment>
         Epub 2020 Feb 4
        </comment>
        <pub-id pub-id-type="pmid">
         32032529
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib135">
       <label>
        135
       </label>
       <element-citation id="sref135" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Drug treatment options for the 2019-new coronavirus (2019-nCoV)
        </article-title>
        <source>
         Biosci. Trends
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib136">
       <label>
        136
       </label>
       <element-citation id="sref136" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         Cell research
        </publisher-name>
       </element-citation>
      </ref>
      <ref id="bib137">
       <label>
        137
       </label>
       <element-citation id="sref137" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Daily
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         First antiviral drug approved to fight coronavirus
        </article-title>
        <comment>
         Feb.17,2002]
        </comment>
        <ext-link ext-link-type="uri" id="intref0105" xlink:href="http://global.chinadaily.com.cn/a/202002/17/WS5e49efc2a310128217277fa3.html">
         http://global.chinadaily.com.cn/a/202002/17/WS5e49efc2a310128217277fa3.html
        </ext-link>
        <year>
         2020
        </year>
        <comment>
         Available from:
        </comment>
       </element-citation>
      </ref>
      <ref id="bib138">
       <label>
        138
       </label>
       <element-citation id="sref138" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ji
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Unique synergistic antiviral effects of Shufeng Jiedu Capsule and oseltamivir in influenza A viral-induced acute exacerbation of chronic obstructive pulmonary disease
        </article-title>
        <source>
         Biomed. Pharmacotherapy = Biomed. Pharmacotherapie
        </source>
        <volume>
         121
        </volume>
        <year>
         2020
        </year>
        <comment>
         109652-109652
        </comment>
       </element-citation>
      </ref>
      <ref id="bib139">
       <label>
        139
       </label>
       <element-citation id="sref139" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ding
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function
        </article-title>
        <source>
         BMC Compl. Alternative Med.
        </source>
        <volume>
         17
        </volume>
        <issue>
         1
        </issue>
        <year>
         2017
        </year>
        <comment>
         130-130
        </comment>
       </element-citation>
      </ref>
      <ref id="bib140">
       <label>
        140
       </label>
       <element-citation id="sref140" publication-type="book">
        <person-group person-group-type="author">
         <collab>
          Commission, C.N.H
         </collab>
        </person-group>
        <chapter-title>
         Guiding Principles for the Intervention of Acute Psychological Crisis in Pneumonia Cases with New Coronavirus Infection. (In Chinese)
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         China National Health Commission
        </publisher-name>
        <publisher-loc>
         Beijing
        </publisher-loc>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0110" xlink:href="http://www.nhc.gov.cn/xcs/zhengcwj/202001/6adc08b966594253b2b791be5c3b9467.shtml">
         http://www.nhc.gov.cn/xcs/zhengcwj/202001/6adc08b966594253b2b791be5c3b9467.shtml
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib141">
       <label>
        141
       </label>
       <element-citation id="sref141" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses - drug discovery and therapeutic options
        </article-title>
        <source>
         Nat. Rev. Drug Discov.
        </source>
        <volume>
         15
        </volume>
        <issue>
         5
        </issue>
        <year>
         2016
        </year>
        <fpage>
         327
        </fpage>
        <lpage>
         347
        </lpage>
        <pub-id pub-id-type="pmid">
         26868298
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Pediatr Infect Dis J
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Pediatr. Infect. Dis. J
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       INF
      </journal-id>
      <journal-title-group>
       <journal-title>
        The Pediatric Infectious Disease Journal
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0891-3668
      </issn>
      <issn pub-type="epub">
       1532-0987
      </issn>
      <publisher>
       <publisher-name>
        Williams &amp; Wilkins
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmc">
       7158880
      </article-id>
      <article-id pub-id-type="art-access-id">
       00001
      </article-id>
      <article-id pub-id-type="doi">
       10.1097/INF.0000000000002660
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Special Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Coronavirus Infections in Children Including COVID-19
       </article-title>
       <subtitle>
        An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children
       </subtitle>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Zimmermann
         </surname>
         <given-names>
          Petra
         </given-names>
        </name>
        <degrees>
         MD, PhD
        </degrees>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
        <xref ref-type="aff" rid="aff2">
         †
        </xref>
        <xref ref-type="aff" rid="aff3">
         ‡
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Curtis
         </surname>
         <given-names>
          Nigel
         </given-names>
        </name>
        <degrees>
         FRCPCH, PhD
        </degrees>
        <xref ref-type="aff" rid="aff2">
         †
        </xref>
        <xref ref-type="aff" rid="aff3">
         ‡
        </xref>
        <xref ref-type="aff" rid="aff4">
         §
        </xref>
       </contrib>
       <aff id="aff1">
        From the
        <label>
         *
        </label>
        Department of Paediatrics, Fribourg Hospital HFR and Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland
       </aff>
       <aff id="aff2">
        <label>
         †
        </label>
        Department of Paediatrics, The University of Melbourne
       </aff>
       <aff id="aff3">
        <label>
         ‡
        </label>
        Infectious Diseases Research Group, Murdoch Children’s Research Institute
       </aff>
       <aff id="aff4">
        <label>
         §
        </label>
        Infectious Diseases Unit, The Royal Children’s Hospital Melbourne, Parkville, Victoria, Australia.
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="c1">
        Address for correspondence: Petra Zimmermann, MD, PhD, Faculty of Science and Medicine, University of Fribourg, Route des Arsenaux 41, 1700 Fribourg, Switzerland. E-mail:
        <email xlink:href="petra.zimmermann@unifr.ch">
         petra.zimmermann@unifr.ch
        </email>
        .
       </corresp>
      </author-notes>
      <pub-date pub-type="ppub">
       <month>
        5
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        12
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <volume>
       39
      </volume>
      <issue>
       5
      </issue>
      <fpage>
       355
      </fpage>
      <lpage>
       368
      </lpage>
      <history>
       <date date-type="accepted">
        <day>
         03
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <license license-type="open-access">
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
        </license-p>
       </license>
       <license license-type="NIH OGC">
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
        </license-p>
       </license>
      </permissions>
      <self-uri xlink:href="inf-39-355.pdf" xlink:type="simple">
      </self-uri>
      <abstract>
       <p>
        Coronaviruses (CoVs) are a large family of enveloped, single-stranded, zoonotic RNA viruses. Four CoVs commonly circulate among humans: HCoV2-229E, -HKU1, -NL63 and -OC43. However, CoVs can rapidly mutate and recombine leading to novel CoVs that can spread from animals to humans. The novel CoVs severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012. The 2019 novel coronavirus (SARS-CoV-2) is currently causing a severe outbreak of disease (termed COVID-19) in China and multiple other countries, threatening to cause a global pandemic. In humans, CoVs mostly cause respiratory and gastrointestinal symptoms. Clinical manifestations range from a common cold to more severe disease such as bronchitis, pneumonia, severe acute respiratory distress syndrome, multi-organ failure and even death. SARS-CoV, MERS-CoV and SARS-CoV-2 seem to less commonly affect children and to cause fewer symptoms and less severe disease in this age group compared with adults, and are associated with much lower case-fatality rates. Preliminary evidence suggests children are just as likely as adults to become infected with SARS-CoV-2 but are less likely to be symptomatic or develop severe symptoms. However, the importance of children in transmitting the virus remains uncertain. Children more often have gastrointestinal symptoms compared with adults. Most children with SARS-CoV present with fever, but this is not the case for the other novel CoVs. Many children affected by MERS-CoV are asymptomatic. The majority of children infected by novel CoVs have a documented household contact, often showing symptoms before them. In contrast, adults more often have a nosocomial exposure. In this review, we summarize epidemiologic, clinical and diagnostic findings, as well as treatment and prevention options for common circulating and novel CoVs infections in humans with a focus on infections in children.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        severe acute respiratory syndrome coronavirus
       </kwd>
       <kwd>
        Middle East respiratory syndrome coronavirus
       </kwd>
       <kwd>
        severe acute respiratory syndrome coronavirus 2
       </kwd>
       <kwd>
        epidemiology
       </kwd>
       <kwd>
        symptoms
       </kwd>
       <kwd>
        laboratory
       </kwd>
       <kwd>
        imaging
       </kwd>
       <kwd>
        treatment
       </kwd>
       <kwd>
        vaccines
       </kwd>
       <kwd>
        prevention
       </kwd>
       <kwd>
        treatment
       </kwd>
       <kwd>
        vaccines
       </kwd>
       <kwd>
        prevention
       </kwd>
       <kwd>
        SARS-CoV
       </kwd>
       <kwd>
        MERS-CoV
       </kwd>
       <kwd>
        SARS-CoV-2
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <p>
     Coronaviruses (CoVs) comprise a large family of enveloped, single-stranded, zoonotic RNA viruses belonging to the family
     <italic>
      Coronaviridae
     </italic>
     , order
     <italic>
      Nidovirales
     </italic>
     (Fig.
     <xref ref-type="fig" rid="F1">
      1
     </xref>
     ).
     <sup>
      <xref ref-type="bibr" rid="R1">
       1
      </xref>
     </sup>
     They can infect a variety of animals (including livestock, companion animals and birds), in which they can cause serious respiratory, enteric, cardiovascular and neurologic disease.
     <sup>
      <xref ref-type="bibr" rid="R2">
       2
      </xref>
      ,
      <xref ref-type="bibr" rid="R3">
       3
      </xref>
     </sup>
     In humans, CoVs mostly cause respiratory and gastrointestinal symptoms ranging from the common cold to more severe disease such as bronchitis, pneumonia, severe acute respiratory distress syndrome (ARDS), coagulopathy, multi-organ failure and death.
     <sup>
      <xref ref-type="bibr" rid="R4">
       4
      </xref>
      –
      <xref ref-type="bibr" rid="R8">
       8
      </xref>
     </sup>
     Human coronaviruses (HCoVs) have also been associated with exacerbations of chronic obstructive pulmonary disease,
     <sup>
      <xref ref-type="bibr" rid="R9">
       9
      </xref>
     </sup>
     cystic fibrosis
     <sup>
      <xref ref-type="bibr" rid="R10">
       10
      </xref>
     </sup>
     and asthma.
     <sup>
      <xref ref-type="bibr" rid="R11">
       11
      </xref>
      ,
      <xref ref-type="bibr" rid="R12">
       12
      </xref>
     </sup>
    </p>
    <fig id="F1" position="float">
     <label>
      FIGURE 1.
     </label>
     <caption>
      <p>
       Summary of coronavirus diseases. COVID-19 indicates coronavirus disease 2019.
      </p>
     </caption>
     <graphic xlink:href="inf-39-355-g001">
     </graphic>
    </fig>
    <p>
     CoVs are classified into
     <italic>
      Alphacoronaviruses
     </italic>
     and
     <italic>
      Betacoronaviruses
     </italic>
     (which are mainly found in mammals such as bats, rodents, civets and humans) and
     <italic>
      Gammacoronaviruses
     </italic>
     and
     <italic>
      Deltacoronaviruses
     </italic>
     (which are mainly found in birds).
     <sup>
      <xref ref-type="bibr" rid="R8">
       8
      </xref>
      ,
      <xref ref-type="bibr" rid="R13">
       13
      </xref>
      ,
      <xref ref-type="bibr" rid="R14">
       14
      </xref>
     </sup>
     Four CoVs commonly circulate among humans: HCoV2-229E, -HKU1, -NL63 and -OC43.
     <sup>
      <xref ref-type="bibr" rid="R15">
       15
      </xref>
      ,
      <xref ref-type="bibr" rid="R16">
       16
      </xref>
     </sup>
     These viruses are believed to have originally derived from bats (NL63, 229E),
     <sup>
      <xref ref-type="bibr" rid="R17">
       17
      </xref>
      ,
      <xref ref-type="bibr" rid="R18">
       18
      </xref>
     </sup>
     dromedary camels (229E)
     <sup>
      <xref ref-type="bibr" rid="R19">
       19
      </xref>
     </sup>
     and cattle (OC43).
     <sup>
      <xref ref-type="bibr" rid="R20">
       20
      </xref>
     </sup>
     The origin of HCoV-HKU1 remains unknown. Several CoVs are known to circulate in animals (with bats acting as the main reservoir) but have not been associated with human infection.
     <sup>
      <xref ref-type="bibr" rid="R3">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="R21">
       21
      </xref>
      ,
      <xref ref-type="bibr" rid="R22">
       22
      </xref>
     </sup>
     CoVs are capable of rapid mutation and recombination leading to novel CoVs that can spread from animals to humans. This occurred in China in 2002 when the novel CoV severe acute respiratory syndrome coronavirus (SARS-CoV) emerged, thought to have been transmitted from civet cats or bats to humans.
     <sup>
      <xref ref-type="bibr" rid="R22">
       22
      </xref>
      –
      <xref ref-type="bibr" rid="R25">
       25
      </xref>
     </sup>
     Another novel CoVs emerged in Saudi Arabia in 2012, Middle East respiratory syndrome coronavirus (MERS-CoV), which is transmitted from dromedary camels to humans.
     <sup>
      <xref ref-type="bibr" rid="R26">
       26
      </xref>
      ,
      <xref ref-type="bibr" rid="R27">
       27
      </xref>
     </sup>
     The 2019 novel CoV (SARS-CoV-2), which originated in China and is currently causing outbreaks globally, is a novel
     <italic>
      Betacoronavirus
     </italic>
     belonging to the lineage B or subgenus sarbecovirus, which includes SARS-CoV.
     <sup>
      <xref ref-type="bibr" rid="R28">
       28
      </xref>
     </sup>
     Sequencing shows that the genome is most closely related (87%–89% nucleotide identity) to the bat SARS-related CoV found in Chinese horseshoe bats (bat-SL-CoVZC45).
     <sup>
      <xref ref-type="bibr" rid="R28">
       28
      </xref>
      ,
      <xref ref-type="bibr" rid="R29">
       29
      </xref>
     </sup>
     The outbreak of SARS-CoV-2 started in Wuhan city, Hubei province, China, where The Health Commission of Hubei province first announced a cluster of adults with pneumonia of unexplained etiology on December 31, 2019. A local seafood and animal market was identified as a potential source. However, the main driver of the outbreak is symptomatic and asymptomatic humans infected with SARS-CoV-2 from whom the virus can spread to others through respiratory droplets or direct contact.
     <sup>
      <xref ref-type="bibr" rid="R28">
       28
      </xref>
     </sup>
     From Wuhan city SARS-CoV-2 has spread to other Chinese cities and internationally, threating to cause a global pandemic. The term COVID-19 is used for the clinical disease caused by SARS-CoV-2.
     <sup>
      <xref ref-type="bibr" rid="R30">
       30
      </xref>
     </sup>
    </p>
    <p>
     In this review, we summarize epidemiologic, clinical and diagnostic findings, as well as treatment and prevention options for common circulating and novel CoVs infections in humans with a focus on infections in children.
    </p>
    <sec>
     <title>
      EPIDEMIOLOGY
     </title>
     <sec>
      <title>
       Common Circulating HCoVs
      </title>
      <p>
       Common circulating HCoVs can be isolated from 4% to 6% of children hospitalized for acute respiratory tract infections
       <sup>
        <xref ref-type="bibr" rid="R11">
         11
        </xref>
        ,
        <xref ref-type="bibr" rid="R15">
         15
        </xref>
        ,
        <xref ref-type="bibr" rid="R31">
         31
        </xref>
       </sup>
       and from 8% of children in an ambulatory setting (Table
       <xref ref-type="table" rid="T1">
        1
       </xref>
       ).
       <sup>
        <xref ref-type="bibr" rid="R15">
         15
        </xref>
        ,
        <xref ref-type="bibr" rid="R32">
         32
        </xref>
        ,
        <xref ref-type="bibr" rid="R33">
         33
        </xref>
       </sup>
       Children under the age of 3 years and children with heart disease are the most frequently affected.
       <sup>
        <xref ref-type="bibr" rid="R4">
         4
        </xref>
        ,
        <xref ref-type="bibr" rid="R15">
         15
        </xref>
        ,
        <xref ref-type="bibr" rid="R35">
         35
        </xref>
        ,
        <xref ref-type="bibr" rid="R36">
         36
        </xref>
       </sup>
       Reinfections later in life are common
       <sup>
        <xref ref-type="bibr" rid="R32">
         32
        </xref>
        ,
        <xref ref-type="bibr" rid="R115">
         115
        </xref>
        ,
        <xref ref-type="bibr" rid="R116">
         116
        </xref>
       </sup>
       despite the fact that most individuals seroconvert to HCoVs during childhood.
       <sup>
        <xref ref-type="bibr" rid="R117">
         117
        </xref>
        –
        <xref ref-type="bibr" rid="R120">
         120
        </xref>
       </sup>
       In contrast to other respiratory tract viruses [eg, respiratory syncytial virus (RSV)], there is no decrease in the relative prevalence of HCoVs infections with increasing age.
       <sup>
        <xref ref-type="bibr" rid="R4">
         4
        </xref>
        ,
        <xref ref-type="bibr" rid="R5">
         5
        </xref>
        ,
        <xref ref-type="bibr" rid="R15">
         15
        </xref>
        ,
        <xref ref-type="bibr" rid="R36">
         36
        </xref>
       </sup>
      </p>
      <table-wrap id="T1" position="float">
       <label>
        TABLE 1.
       </label>
       <caption>
        <p>
         Characteristics of Human Coronaviruses
        </p>
       </caption>
       <graphic xlink:href="inf-39-355-g002">
       </graphic>
      </table-wrap>
      <p>
       In 11%–46% of cases, common circulating HCoVs are found as coinfections with other respiratory viruses such as adeno-, boca-, rhino-, RSV, influenza or parainfluenza virus.
       <sup>
        <xref ref-type="bibr" rid="R5">
         5
        </xref>
        ,
        <xref ref-type="bibr" rid="R15">
         15
        </xref>
        ,
        <xref ref-type="bibr" rid="R16">
         16
        </xref>
        ,
        <xref ref-type="bibr" rid="R31">
         31
        </xref>
        –
        <xref ref-type="bibr" rid="R33">
         33
        </xref>
        ,
        <xref ref-type="bibr" rid="R36">
         36
        </xref>
        ,
        <xref ref-type="bibr" rid="R79">
         79
        </xref>
        ,
        <xref ref-type="bibr" rid="R81">
         81
        </xref>
        ,
        <xref ref-type="bibr" rid="R121">
         121
        </xref>
        ,
        <xref ref-type="bibr" rid="R122">
         122
        </xref>
       </sup>
       Symptomatic children whose only detectable respiratory virus is a HCoV are reported to more likely suffer from an underlying chronic disease compared with children coinfected with other respiratory viruses.
       <sup>
        <xref ref-type="bibr" rid="R31">
         31
        </xref>
       </sup>
      </p>
      <p>
       Of the 4 common circulating HCoVs, NL63 and OC43 are the most frequently isolated species.
       <sup>
        <xref ref-type="bibr" rid="R4">
         4
        </xref>
        ,
        <xref ref-type="bibr" rid="R11">
         11
        </xref>
        ,
        <xref ref-type="bibr" rid="R15">
         15
        </xref>
        ,
        <xref ref-type="bibr" rid="R35">
         35
        </xref>
        ,
        <xref ref-type="bibr" rid="R36">
         36
        </xref>
       </sup>
       Cyclical patterns have been observed for 229E and OC43, with outbreaks occurring every 2–4 years.
       <sup>
        <xref ref-type="bibr" rid="R4">
         4
        </xref>
        ,
        <xref ref-type="bibr" rid="R15">
         15
        </xref>
        ,
        <xref ref-type="bibr" rid="R32">
         32
        </xref>
        ,
        <xref ref-type="bibr" rid="R35">
         35
        </xref>
        ,
        <xref ref-type="bibr" rid="R82">
         82
        </xref>
        ,
        <xref ref-type="bibr" rid="R116">
         116
        </xref>
        ,
        <xref ref-type="bibr" rid="R119">
         119
        </xref>
       </sup>
       Seasonal patterns have also been observed: in the Northern Hemisphere, common circulating HCoVs mostly cause infections in humans between December and May, and in the Southern Hemisphere between March and November with peaks in late winter/early spring for 229E and OC43 and in autumn for NL63.
       <sup>
        <xref ref-type="bibr" rid="R4">
         4
        </xref>
        ,
        <xref ref-type="bibr" rid="R5">
         5
        </xref>
        ,
        <xref ref-type="bibr" rid="R11">
         11
        </xref>
        ,
        <xref ref-type="bibr" rid="R15">
         15
        </xref>
        ,
        <xref ref-type="bibr" rid="R32">
         32
        </xref>
        ,
        <xref ref-type="bibr" rid="R123">
         123
        </xref>
       </sup>
       HCoV-HKU1 has been reported to mainly occur in spring and summer in Hong Kong,
       <sup>
        <xref ref-type="bibr" rid="R11">
         11
        </xref>
        ,
        <xref ref-type="bibr" rid="R124">
         124
        </xref>
       </sup>
       but in winter and spring in the United Kingdom and Brazil.
       <sup>
        <xref ref-type="bibr" rid="R4">
         4
        </xref>
        ,
        <xref ref-type="bibr" rid="R15">
         15
        </xref>
       </sup>
      </p>
     </sec>
     <sec>
      <title>
       SARS-CoV and MERS-CoV
      </title>
      <p>
       SARS-CoV is a novel group 2b
       <italic>
        Betacoronavirus
       </italic>
       which initially emerged in Guangdong province, south China in 2002,
       <sup>
        <xref ref-type="bibr" rid="R23">
         23
        </xref>
        –
        <xref ref-type="bibr" rid="R25">
         25
        </xref>
       </sup>
       then spread to Hong Kong and from there rapidly to many other countries.
       <sup>
        <xref ref-type="bibr" rid="R125">
         125
        </xref>
       </sup>
       It caused severe lower respiratory tract infection with a severe morbidity and a high case-fatality rate (approaching 50% in individuals over 60 years of age, overall 10%).
       <sup>
        <xref ref-type="bibr" rid="R63">
         63
        </xref>
        ,
        <xref ref-type="bibr" rid="R106">
         106
        </xref>
        ,
        <xref ref-type="bibr" rid="R107">
         107
        </xref>
        ,
        <xref ref-type="bibr" rid="R126">
         126
        </xref>
       </sup>
       Person-to-person transmission of SARS-CoV is well established.
       <sup>
        <xref ref-type="bibr" rid="R55">
         55
        </xref>
       </sup>
       The virus has spread to 29 countries and has been estimated to have caused more than 8000 infections and 774 deaths worldwide (Table
       <xref ref-type="table" rid="T1">
        1
       </xref>
       ).
       <sup>
        <xref ref-type="bibr" rid="R52">
         52
        </xref>
       </sup>
      </p>
      <p>
       MERS-CoV is a novel group 2c
       <italic>
        Betacoronavirus
       </italic>
       which first appeared in Saudi Arabia in 2012.
       <sup>
        <xref ref-type="bibr" rid="R26">
         26
        </xref>
        ,
        <xref ref-type="bibr" rid="R27">
         27
        </xref>
        ,
        <xref ref-type="bibr" rid="R127">
         127
        </xref>
       </sup>
       It can spread from person-to-person
       <sup>
        <xref ref-type="bibr" rid="R128">
         128
        </xref>
       </sup>
       and can cause severe lower respiratory tract infections with a case-fatality rate of 20% to 40%.
       <sup>
        <xref ref-type="bibr" rid="R67">
         67
        </xref>
        ,
        <xref ref-type="bibr" rid="R106">
         106
        </xref>
        ,
        <xref ref-type="bibr" rid="R108">
         108
        </xref>
        –
        <xref ref-type="bibr" rid="R112">
         112
        </xref>
       </sup>
       Apart from being endemic in the Middle East, there was a nosocomial outbreak of MERS-CoV in South Korea in 2014, involving 16 hospitals and 186 patients, caused by a medical doctor returning from the Middle East.
       <sup>
        <xref ref-type="bibr" rid="R49">
         49
        </xref>
        ,
        <xref ref-type="bibr" rid="R68">
         68
        </xref>
       </sup>
       MERS-CoV spread to 27 countries causing an estimated 2494 infections and 858 deaths (Table
       <xref ref-type="table" rid="T1">
        1
       </xref>
       ).
       <sup>
        <xref ref-type="bibr" rid="R53">
         53
        </xref>
       </sup>
      </p>
      <p>
       The overall reproductive number (R0) for SARS-CoV was estimated to be 0.3–2.9
       <sup>
        <xref ref-type="bibr" rid="R37">
         37
        </xref>
        ,
        <xref ref-type="bibr" rid="R39">
         39
        </xref>
        ,
        <xref ref-type="bibr" rid="R40">
         40
        </xref>
        ,
        <xref ref-type="bibr" rid="R42">
         42
        </xref>
        ,
        <xref ref-type="bibr" rid="R43">
         43
        </xref>
        ,
        <xref ref-type="bibr" rid="R47">
         47
        </xref>
       </sup>
       and for MERS-CoV to be 0.5–3.5 (Table
       <xref ref-type="table" rid="T1">
        1
       </xref>
       ).
       <sup>
        <xref ref-type="bibr" rid="R39">
         39
        </xref>
        ,
        <xref ref-type="bibr" rid="R46">
         46
        </xref>
        ,
        <xref ref-type="bibr" rid="R48">
         48
        </xref>
       </sup>
       R0s largely depend on geographic location, stage of the outbreak and inclusion of only nosocomial versus general transmission. Both viruses have been associated with early super-spreading events with R0s of up to 22 for SARS-CoV
       <sup>
        <xref ref-type="bibr" rid="R39">
         39
        </xref>
        ,
        <xref ref-type="bibr" rid="R40">
         40
        </xref>
        ,
        <xref ref-type="bibr" rid="R43">
         43
        </xref>
       </sup>
       and up to 30 for MERS-CoV.
       <sup>
        <xref ref-type="bibr" rid="R39">
         39
        </xref>
        ,
        <xref ref-type="bibr" rid="R49">
         49
        </xref>
       </sup>
       These large numbers of secondary infections have been mostly associated with nosocomial outbreaks: 30% of all SARS-CoV cases (mostly health care workers) and 44%–100% of all MERS-CoV cases (mostly patients) occurred from nosocomial transmissions.
       <sup>
        <xref ref-type="bibr" rid="R39">
         39
        </xref>
        ,
        <xref ref-type="bibr" rid="R55">
         55
        </xref>
        ,
        <xref ref-type="bibr" rid="R56">
         56
        </xref>
       </sup>
       These super-spreading events were followed by reduced spread in the following generations of viruses with a decrease in the R0s to 0.8 for SARS-CoV
       <sup>
        <xref ref-type="bibr" rid="R39">
         39
        </xref>
       </sup>
       and to 0.7 for MERS-CoV (Table
       <xref ref-type="table" rid="T1">
        1
       </xref>
       ).
       <sup>
        <xref ref-type="bibr" rid="R128">
         128
        </xref>
       </sup>
       Therefore, both SARS-CoV and MERS-CoV have low potential for long-term sustained community transmission. No human SARS-CoV infections have been detected since July 2003. However, SARS-CoV-like viruses can be found in bats, which are known to be able infect human cells without adaptation, making it possible for SARS-CoVs to reemerge
       <sup>
        <xref ref-type="bibr" rid="R84">
         84
        </xref>
       </sup>
       (as has now happened with SARS-CoV-2). The zoonotic transmission of MERS-CoV to humans has continued, attributed to the role of dromedary camels as a reservoir and their close contact with humans (in contrast to human-bat-interactions).
       <sup>
        <xref ref-type="bibr" rid="R21">
         21
        </xref>
       </sup>
      </p>
     </sec>
     <sec>
      <title>
       SARS-CoV-2
      </title>
      <p>
       Early in the SARS-CoV-2 outbreak, it was shown that person-to-person transmission was the main driver.
       <sup>
        <xref ref-type="bibr" rid="R28">
         28
        </xref>
       </sup>
       The R0 for SARS-CoV-2 is currently estimated at 2.7.
       <sup>
        <xref ref-type="bibr" rid="R38">
         38
        </xref>
       </sup>
       The incubation period is estimated at 5–6 days, which is similar to that for SARS-CoV and MERS-CoV.
       <sup>
        <xref ref-type="bibr" rid="R38">
         38
        </xref>
        ,
        <xref ref-type="bibr" rid="R63">
         63
        </xref>
        –
        <xref ref-type="bibr" rid="R65">
         65
        </xref>
        ,
        <xref ref-type="bibr" rid="R67">
         67
        </xref>
        –
        <xref ref-type="bibr" rid="R72">
         72
        </xref>
       </sup>
       The serial interval is estimated to be 8 days, also similar to the other novel CoVs (Table
       <xref ref-type="table" rid="T1">
        1
       </xref>
       ).
       <sup>
        <xref ref-type="bibr" rid="R38">
         38
        </xref>
        ,
        <xref ref-type="bibr" rid="R45">
         45
        </xref>
        ,
        <xref ref-type="bibr" rid="R48">
         48
        </xref>
        ,
        <xref ref-type="bibr" rid="R70">
         70
        </xref>
       </sup>
       By March 2020, the World Health Organization reported that SARS-CoV-2 had spread to over 100 countries and caused over 100,000 infections and over 3500 deaths.
       <sup>
        <xref ref-type="bibr" rid="R54">
         54
        </xref>
       </sup>
       At that time the case-fatality rate was uncertain but estimated at 0.9%–3%,
       <sup>
        <xref ref-type="bibr" rid="R54">
         54
        </xref>
        ,
        <xref ref-type="bibr" rid="R113">
         113
        </xref>
        ,
        <xref ref-type="bibr" rid="R114">
         114
        </xref>
       </sup>
       which is much lower than for SARS-CoV and MERS-CoV (6%–17% and 20%–40%, respectively).
       <sup>
        <xref ref-type="bibr" rid="R63">
         63
        </xref>
        ,
        <xref ref-type="bibr" rid="R67">
         67
        </xref>
        ,
        <xref ref-type="bibr" rid="R106">
         106
        </xref>
        –
        <xref ref-type="bibr" rid="R112">
         112
        </xref>
       </sup>
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      SYMPTOMS
     </title>
     <sec>
      <title>
       Common HCoVs
      </title>
      <p>
       In children, common circulating HCoVs can cause common cold symptoms such as fever,
       <sup>
        <xref ref-type="bibr" rid="R5">
         5
        </xref>
        ,
        <xref ref-type="bibr" rid="R11">
         11
        </xref>
        ,
        <xref ref-type="bibr" rid="R32">
         32
        </xref>
       </sup>
       rhinitis,
       <sup>
        <xref ref-type="bibr" rid="R5">
         5
        </xref>
        ,
        <xref ref-type="bibr" rid="R11">
         11
        </xref>
       </sup>
       otitis,
       <sup>
        <xref ref-type="bibr" rid="R5">
         5
        </xref>
       </sup>
       pharyngitis,
       <sup>
        <xref ref-type="bibr" rid="R5">
         5
        </xref>
        ,
        <xref ref-type="bibr" rid="R11">
         11
        </xref>
       </sup>
       laryngitis
       <sup>
        <xref ref-type="bibr" rid="R5">
         5
        </xref>
       </sup>
       and headache,
       <sup>
        <xref ref-type="bibr" rid="R5">
         5
        </xref>
        ,
        <xref ref-type="bibr" rid="R16">
         16
        </xref>
        ,
        <xref ref-type="bibr" rid="R81">
         81
        </xref>
       </sup>
       but also bronchitis,
       <sup>
        <xref ref-type="bibr" rid="R5">
         5
        </xref>
        ,
        <xref ref-type="bibr" rid="R11">
         11
        </xref>
       </sup>
       bronchiolitis,
       <sup>
        <xref ref-type="bibr" rid="R5">
         5
        </xref>
        ,
        <xref ref-type="bibr" rid="R11">
         11
        </xref>
       </sup>
       wheezing,
       <sup>
        <xref ref-type="bibr" rid="R4">
         4
        </xref>
        ,
        <xref ref-type="bibr" rid="R11">
         11
        </xref>
        ,
        <xref ref-type="bibr" rid="R32">
         32
        </xref>
       </sup>
       pneumonia,
       <sup>
        <xref ref-type="bibr" rid="R5">
         5
        </xref>
        ,
        <xref ref-type="bibr" rid="R81">
         81
        </xref>
        ,
        <xref ref-type="bibr" rid="R82">
         82
        </xref>
       </sup>
       and, in up to 57% of cases, gastrointestinal symptoms (which are more common in children than adults).
       <sup>
        <xref ref-type="bibr" rid="R5">
         5
        </xref>
        –
        <xref ref-type="bibr" rid="R7">
         7
        </xref>
       </sup>
       In a study including children and adults, fatigue, headache, myalgia and sore throat were more common in HCoV-infected patients compared with RSV-infected patients, while fever, cough and dyspnea were more frequent in the later.
       <sup>
        <xref ref-type="bibr" rid="R36">
         36
        </xref>
       </sup>
       Fewer patients infected with HCoVs had fever compared with those infected with RSV or influenza.
       <sup>
        <xref ref-type="bibr" rid="R36">
         36
        </xref>
       </sup>
      </p>
      <p>
       In children, HCoV-NL63 has been associated with conjunctivitis,
       <sup>
        <xref ref-type="bibr" rid="R78">
         78
        </xref>
       </sup>
       croup,
       <sup>
        <xref ref-type="bibr" rid="R11">
         11
        </xref>
        ,
        <xref ref-type="bibr" rid="R79">
         79
        </xref>
        ,
        <xref ref-type="bibr" rid="R80">
         80
        </xref>
       </sup>
       asthma exacerbations,
       <sup>
        <xref ref-type="bibr" rid="R11">
         11
        </xref>
        ,
        <xref ref-type="bibr" rid="R12">
         12
        </xref>
       </sup>
       febrile seizures
       <sup>
        <xref ref-type="bibr" rid="R11">
         11
        </xref>
       </sup>
       and HCoV-HKU1 with febrile seizures.
       <sup>
        <xref ref-type="bibr" rid="R7">
         7
        </xref>
       </sup>
       Rare cases of neurologic diseases have also been described (eg, the detection of HCoV in cerebrospinal fluid in a child presenting with acute disseminated encephalomyelitis
       <sup>
        <xref ref-type="bibr" rid="R83">
         83
        </xref>
       </sup>
       or in cerebrospinal fluid of adults with multiple sclerosis.)
       <sup>
        <xref ref-type="bibr" rid="R129">
         129
        </xref>
        ,
        <xref ref-type="bibr" rid="R130">
         130
        </xref>
       </sup>
       A suspected association between HCoVs and Kawasaki disease could not be confirmed.
       <sup>
        <xref ref-type="bibr" rid="R131">
         131
        </xref>
        ,
        <xref ref-type="bibr" rid="R132">
         132
        </xref>
       </sup>
       Common HCoVs can be isolated from asymptomatic individuals.
       <sup>
        <xref ref-type="bibr" rid="R16">
         16
        </xref>
       </sup>
       During an infection, the viral load is high in the first 2 days and decreases thereafter.
       <sup>
        <xref ref-type="bibr" rid="R29">
         29
        </xref>
       </sup>
       A correlation between viral load and severity of disease has not been observed
       <sup>
        <xref ref-type="bibr" rid="R29">
         29
        </xref>
       </sup>
       This contrasts with SARS-CoV for which a higher initial viral load is independently associated with a worse prognosis, including a higher case-fatality rate.
       <sup>
        <xref ref-type="bibr" rid="R133">
         133
        </xref>
        ,
        <xref ref-type="bibr" rid="R134">
         134
        </xref>
       </sup>
       Virus particles can be isolated from nasopharyngeal secretions up to 14 days after the onset of infection.
       <sup>
        <xref ref-type="bibr" rid="R135">
         135
        </xref>
       </sup>
      </p>
     </sec>
     <sec>
      <title>
       SARS-CoV
      </title>
      <p>
       There are 3 case series that report a total of 41 children who were affected by SARS-CoV.
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
        –
        <xref ref-type="bibr" rid="R59">
         59
        </xref>
       </sup>
       The virus was associated with milder disease in children compared with adults, and no deaths have been reported in children.
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
        –
        <xref ref-type="bibr" rid="R59">
         59
        </xref>
        ,
        <xref ref-type="bibr" rid="R86">
         86
        </xref>
       </sup>
       Symptomatic children with SARS-CoV infection were reported to have fever (91%–100%),
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
        –
        <xref ref-type="bibr" rid="R59">
         59
        </xref>
       </sup>
       myalgia (10%–40%),
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
        ,
        <xref ref-type="bibr" rid="R58">
         58
        </xref>
       </sup>
       rhinitis (33%–60%),
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
        –
        <xref ref-type="bibr" rid="R59">
         59
        </xref>
       </sup>
       sore throat (5%–30%),
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
        –
        <xref ref-type="bibr" rid="R59">
         59
        </xref>
       </sup>
       cough (43%–80%),
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
        –
        <xref ref-type="bibr" rid="R59">
         59
        </xref>
       </sup>
       dyspnea (10%–14%),
       <sup>
        <xref ref-type="bibr" rid="R38">
         38
        </xref>
        ,
        <xref ref-type="bibr" rid="R84">
         84
        </xref>
       </sup>
       headache (14%–40%)
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
        –
        <xref ref-type="bibr" rid="R59">
         59
        </xref>
       </sup>
       and, less commonly, vomiting (20%),
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
        ,
        <xref ref-type="bibr" rid="R59">
         59
        </xref>
       </sup>
       abdominal pain (10%),
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
       </sup>
       diarrhea (10%)
       <sup>
        <xref ref-type="bibr" rid="R58">
         58
        </xref>
        ,
        <xref ref-type="bibr" rid="R59">
         59
        </xref>
       </sup>
       and febrile seizures (10%).
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
       </sup>
       In total, 50%–80% of children had other family members who were infected
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
        –
        <xref ref-type="bibr" rid="R59">
         59
        </xref>
       </sup>
       and 30% had a nosocomial contact with SARS-CoV.
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
       </sup>
       Most children recover quickly from an infection with SARS-CoV.
       <sup>
        <xref ref-type="bibr" rid="R86">
         86
        </xref>
       </sup>
       However, abnormalities on chest computed tomography (CT) can persist for several months (eg, air trapping and ground-glass opacifications).
       <sup>
        <xref ref-type="bibr" rid="R136">
         136
        </xref>
       </sup>
      </p>
      <p>
       There is no evidence that SARS-CoV can be vertically transmitted to the fetus.
       <sup>
        <xref ref-type="bibr" rid="R137">
         137
        </xref>
       </sup>
       However, SARS-CoV infections during pregnancy have been associated with possible miscarriage, intrauterine growth retardation and preterm delivery.
       <sup>
        <xref ref-type="bibr" rid="R137">
         137
        </xref>
        ,
        <xref ref-type="bibr" rid="R138">
         138
        </xref>
       </sup>
      </p>
     </sec>
     <sec>
      <title>
       MERS-CoV
      </title>
      <p>
       Most case series of patients infected with MERS-CoV report a low proportion (0.1%–4%) of children.
       <sup>
        <xref ref-type="bibr" rid="R34">
         34
        </xref>
        ,
        <xref ref-type="bibr" rid="R76">
         76
        </xref>
        ,
        <xref ref-type="bibr" rid="R109">
         109
        </xref>
        ,
        <xref ref-type="bibr" rid="R110">
         110
        </xref>
        ,
        <xref ref-type="bibr" rid="R139">
         139
        </xref>
        ,
        <xref ref-type="bibr" rid="R140">
         140
        </xref>
       </sup>
       In a large case series of 2235 children with acute respiratory tract infection who presented to a tertiary hospital in Saudi Arabia during the MERS-CoV epidemic (2012–2013), none tested positive for MERS-CoV (Table
       <xref ref-type="table" rid="T1">
        1
       </xref>
       ).
       <sup>
        <xref ref-type="bibr" rid="R34">
         34
        </xref>
       </sup>
       There are 2 small case series of children infected with MERS-CoV: one including 31 children with a mean age of 10 years
       <sup>
        <xref ref-type="bibr" rid="R60">
         60
        </xref>
       </sup>
       and the other one only 7 children.
       <sup>
        <xref ref-type="bibr" rid="R76">
         76
        </xref>
       </sup>
       In both studies, 42% of children were asymptomatic.
       <sup>
        <xref ref-type="bibr" rid="R60">
         60
        </xref>
        ,
        <xref ref-type="bibr" rid="R76">
         76
        </xref>
       </sup>
       In the case series of 7 children, 57% suffered from fever, 28% from vomiting and diarrhea and 14% from cough and shortness of breath.
       <sup>
        <xref ref-type="bibr" rid="R76">
         76
        </xref>
       </sup>
       Two children required oxygen supplementation and one mechanical ventilation.
       <sup>
        <xref ref-type="bibr" rid="R76">
         76
        </xref>
       </sup>
       In the other case series, 2 died (6%).
       <sup>
        <xref ref-type="bibr" rid="R60">
         60
        </xref>
       </sup>
       The main sources of MERS-CoV infection in children were household (32%) and other contacts (23%), followed by nosocomial transmission (19%).
       <sup>
        <xref ref-type="bibr" rid="R60">
         60
        </xref>
       </sup>
      </p>
      <p>
       Eight cases of MERS-CoV maternal infections during pregnancy have been reported (occurring between 20 and 28 weeks of pregnancy), three of the affected infants died.
       <sup>
        <xref ref-type="bibr" rid="R141">
         141
        </xref>
        –
        <xref ref-type="bibr" rid="R144">
         144
        </xref>
       </sup>
      </p>
     </sec>
     <sec>
      <title>
       SARS-CoV-2
      </title>
      <p>
       Different case definitions for COVID-19 cases in adults and children from authoritive sources as of March 2020 are detailed in Table
       <xref ref-type="table" rid="T2">
        2
       </xref>
       . Children are less commonly affected by SARS-CoV-2, the Chinese Centers for Disease Control and Prevention reports that of the 72,314 cases reported as of February 11, 2020, only 2% were in individuals of less than 19 years of age.
       <sup>
        <xref ref-type="bibr" rid="R114">
         114
        </xref>
       </sup>
       There are 3 case series of children who have been infected with SARS-CoV-2.
       <sup>
        <xref ref-type="bibr" rid="R61">
         61
        </xref>
        ,
        <xref ref-type="bibr" rid="R72">
         72
        </xref>
        ,
        <xref ref-type="bibr" rid="R77">
         77
        </xref>
       </sup>
       The first included 20 children up to January 31, 2020, in the Province of Zhejiang,
       <sup>
        <xref ref-type="bibr" rid="R72">
         72
        </xref>
       </sup>
       the second 34 children between January 19, 2020, and February 7, 2020, in the Province of Shenzhen,
       <sup>
        <xref ref-type="bibr" rid="R61">
         61
        </xref>
       </sup>
       and the third 9 infants from different provinces in China.
       <sup>
        <xref ref-type="bibr" rid="R77">
         77
        </xref>
       </sup>
       The case series with 34 children provides the most clinical details: none of the children had an underlying disease, 65% had common respiratory symptoms, 26% had mild disease and 9% were asymptomatic.
       <sup>
        <xref ref-type="bibr" rid="R61">
         61
        </xref>
       </sup>
       The most common symptoms were fever (50%) and cough (38%).
       <sup>
        <xref ref-type="bibr" rid="R61">
         61
        </xref>
       </sup>
       In the case series of 20 children, presentation was with low to moderate or no fever, rhinitis, cough, fatigue, headache, diarrhea and, in more severe cases, with dyspnea, cyanosis and poor feeding, but the numbers were not specified.
       <sup>
        <xref ref-type="bibr" rid="R72">
         72
        </xref>
       </sup>
       In the series of 9 infants, only 4 were reported to have fever. One infant was asymptomatic.
       <sup>
        <xref ref-type="bibr" rid="R77">
         77
        </xref>
       </sup>
       Additional asymptomatic children infected with SARS-CoV-2 outside these case series have also been described (eg, a 10-year-old asymptomatic child with radiologic ground-glass lung opacities on chest CT).
       <sup>
        <xref ref-type="bibr" rid="R28">
         28
        </xref>
       </sup>
       Most infected children recover 1–2 weeks after the onset of symptoms and no deaths from SARS-CoV-2 had been reported by February 2020.
       <sup>
        <xref ref-type="bibr" rid="R72">
         72
        </xref>
       </sup>
      </p>
      <table-wrap id="T2" position="float">
       <label>
        TABLE 2.
       </label>
       <caption>
        <p>
         Case Definitions for SARS-CoV-2 Infections in Adults and Children (as of February 2020)
        </p>
       </caption>
       <graphic xlink:href="inf-39-355-g003">
       </graphic>
      </table-wrap>
      <p>
       From these series, it appears that children have milder clinical symptoms than adults
       <sup>
        <xref ref-type="bibr" rid="R61">
         61
        </xref>
        ,
        <xref ref-type="bibr" rid="R72">
         72
        </xref>
       </sup>
       (as has been reported for SARS-CoV and MERS-CoV infections),
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
        –
        <xref ref-type="bibr" rid="R60">
         60
        </xref>
        ,
        <xref ref-type="bibr" rid="R76">
         76
        </xref>
        ,86
       </sup>
       which could mean children might not be tested for SARS-CoV-2 as frequently as adults. It has therefore been suggested that asymptomatic or mildly symptomatic children might transmit the disease.
       <sup>
        <xref ref-type="bibr" rid="R147">
         147
        </xref>
       </sup>
       However, the majority of children infected with SARS-CoV-2 thus far have been part of a family cluster outbreak [100% in the infants series, in which other family member had symptoms before the infants in all cases; 82% in the case series of 34 children;
       <sup>
        <xref ref-type="bibr" rid="R61">
         61
        </xref>
       </sup>
       and the majority in the one with 20 children (exact number not specified)].
       <sup>
        <xref ref-type="bibr" rid="R72">
         72
        </xref>
       </sup>
       This is similar to SARS-CoV, in which 50%–80%
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
        –
        <xref ref-type="bibr" rid="R59">
         59
        </xref>
       </sup>
       of children were reported to have an affected household contact
       <sup>
        <xref ref-type="bibr" rid="R60">
         60
        </xref>
       </sup>
       and to MERS-CoV in which it was 32%.
       <sup>
        <xref ref-type="bibr" rid="R60">
         60
        </xref>
       </sup>
      </p>
      <p>
       A study prepublished in early March 2020 suggests that children are just as likely as adults to become infected with SARS-CoV-2 but are less likely to be symptomatic or develop severe symptoms.
       <sup>
        <xref ref-type="bibr" rid="R246">
         246
        </xref>
       </sup>
       However, the importance of children in transmitting the virus remains uncertain.
      </p>
      <p>
       From a small case series of 9 mothers who were infected with SARS-CoV-2, there is, to date, no evidence that SARS-CoV-2 can be vertically transmitted to the infant.
       <sup>
        <xref ref-type="bibr" rid="R148">
         148
        </xref>
       </sup>
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      LABORATORY FINDINGS
     </title>
     <p>
      Laboratory findings from children are similar with infections caused by different novel CoVs (Table
      <xref ref-type="table" rid="T1">
       1
      </xref>
      ). The white blood cell count is typically normal or reduced with decreased neutrophil
      <sup>
       <xref ref-type="bibr" rid="R85">
        85
       </xref>
      </sup>
      and/or lymphocyte counts.
      <sup>
       <xref ref-type="bibr" rid="R57">
        57
       </xref>
       –
       <xref ref-type="bibr" rid="R59">
        59
       </xref>
       ,
       <xref ref-type="bibr" rid="R72">
        72
       </xref>
       ,86
      </sup>
      Thrombocytopenia may occur.
      <sup>
       <xref ref-type="bibr" rid="R57">
        57
       </xref>
       –
       <xref ref-type="bibr" rid="R59">
        59
       </xref>
       ,
       <xref ref-type="bibr" rid="R76">
        76
       </xref>
       ,86
      </sup>
      C-reactive protein and procalcitonin levels are often normal.
      <sup>
       <xref ref-type="bibr" rid="R72">
        72
       </xref>
      </sup>
      In severe cases, elevated liver enzymes,
      <sup>
       <xref ref-type="bibr" rid="R57">
        57
       </xref>
       –
       <xref ref-type="bibr" rid="R59">
        59
       </xref>
       ,
       <xref ref-type="bibr" rid="R72">
        72
       </xref>
       ,86
      </sup>
      lactate dehydrogenase levels,
      <sup>
       <xref ref-type="bibr" rid="R57">
        57
       </xref>
      </sup>
      as well as a abnormal coagulation and elevated
      <sc>
       d
      </sc>
      -dimers have been reported.
      <sup>
       <xref ref-type="bibr" rid="R57">
        57
       </xref>
       –
       <xref ref-type="bibr" rid="R59">
        59
       </xref>
       ,
       <xref ref-type="bibr" rid="R72">
        72
       </xref>
       ,86
      </sup>
     </p>
     <sec>
      <title>
       SARS-CoV-2
      </title>
      <p>
       The same laboratory findings has above have been observed for children infected with SARS-CoV-2.
       <sup>
        <xref ref-type="bibr" rid="R61">
         61
        </xref>
       </sup>
       In the case series of 34 children, the white blood cell count was normal in 83%, neutropenia and lymphopenia were each found in 1 case (3%). The lactate dehydrogenase level was elevated in 30% of cases.
       <sup>
        <xref ref-type="bibr" rid="R61">
         61
        </xref>
       </sup>
       C-reactive protein and procalcitonin levels were each elevated in 1 case only (3%).
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      RADIOLOGIC FINDINGS
     </title>
     <p>
      Similar to the laboratory findings, radiologic findings from children are also similar across infections with different novel CoVs (Table
      <xref ref-type="table" rid="T1">
       1
      </xref>
      ). On chest radiography, children mostly show bilateral patchy airspace consolidations often at the periphery of the lungs, peribronchial thickening and ground-glass opacities.
      <sup>
       <xref ref-type="bibr" rid="R57">
        57
       </xref>
       –
       <xref ref-type="bibr" rid="R59">
        59
       </xref>
       ,
       <xref ref-type="bibr" rid="R76">
        76
       </xref>
       ,86,87
      </sup>
      Chest CT mostly shows airspace consolidations and ground-glass opacities.
      <sup>
       <xref ref-type="bibr" rid="R89">
        89
       </xref>
      </sup>
     </p>
     <sec>
      <title>
       SARS-CoV-2
      </title>
      <p>
       CT changes observed in children infected with SARS-CoV-2 include bilateral multiple patchy, nodular ground-glass opacities, speckled ground-glass opacities and/or infiltrating shadows in the middle and outer zone of the lung or under the pleura.
       <sup>
        <xref ref-type="bibr" rid="R61">
         61
        </xref>
        ,
        <xref ref-type="bibr" rid="R88">
         88
        </xref>
       </sup>
       These findings are unspecific and milder compared with those in adults.
       <sup>
        <xref ref-type="bibr" rid="R88">
         88
        </xref>
       </sup>
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      DIAGNOSIS
     </title>
     <p>
      The main basis for diagnosis of infections with HCoVs is real-time polymerase chain reaction (RT-PCR) on upper or lower respiratory secretions.
      <sup>
       <xref ref-type="bibr" rid="R5">
        5
       </xref>
       ,
       <xref ref-type="bibr" rid="R15">
        15
       </xref>
       ,
       <xref ref-type="bibr" rid="R90">
        90
       </xref>
       –
       <xref ref-type="bibr" rid="R96">
        96
       </xref>
      </sup>
      For SARS-CoV, MERS-CoV and SARS-CoV-2, higher viral loads have been detected in samples from the lower respiratory tract compared with the upper respiratory tract.
      <sup>
       <xref ref-type="bibr" rid="R28">
        28
       </xref>
       ,
       <xref ref-type="bibr" rid="R149">
        149
       </xref>
      </sup>
      Therefore, in clinically suspected cases with an initially negative result on nasopharyngeal or throat swab, repeat testing of upper respiratory tract samples or (preferably) testing of lower respiratory tract samples should be done. RT-PCRs on stool samples can be positive for HCoVs but is not used for routine diagnosis.
      <sup>
       <xref ref-type="bibr" rid="R91">
        91
       </xref>
       ,
       <xref ref-type="bibr" rid="R98">
        98
       </xref>
       ,
       <xref ref-type="bibr" rid="R99">
        99
       </xref>
      </sup>
      For SARS-CoV and SARS-CoV-2, rare cases with positive PCRs in blood have been reported.
      <sup>
       <xref ref-type="bibr" rid="R28">
        28
       </xref>
       ,
       <xref ref-type="bibr" rid="R150">
        150
       </xref>
      </sup>
      Serology has been used to diagnose infections with SARS-CoV and MERS-CoV, but is not useful in the acute phase of the infection.
      <sup>
       <xref ref-type="bibr" rid="R100">
        100
       </xref>
       –
       <xref ref-type="bibr" rid="R103">
        103
       </xref>
      </sup>
      Cross-reactivities between antibodies against SARS-CoV and common CoVs have been observed.
      <sup>
       <xref ref-type="bibr" rid="R151">
        151
       </xref>
      </sup>
     </p>
     <sec>
      <title>
       SARS-CoV-2
      </title>
      <p>
       Whole genome sequencing allowed the rapid development of molecular diagnostic tests for SARS-CoV-2.
       <sup>
        <xref ref-type="bibr" rid="R28">
         28
        </xref>
       </sup>
       RT-PCR for genes encoding the internal RNA-dependent RNA polymerase and surface spike glycoprotein are commonly used.
       <sup>
        <xref ref-type="bibr" rid="R28">
         28
        </xref>
       </sup>
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      TREATMENT
     </title>
     <p>
      Supportive treatment including sufficient fluid and calorie intake, and additional oxygen supplementation should be used in the treatment of children infected with HCoVs. The aim is to prevent ARDS, organ failure and secondary nosocomial infections. If bacterial infection is suspected broad-spectrum antibiotics such as second or third generation cephalosporins may be used.
     </p>
     <sec>
      <title>
       SARS-CoV
      </title>
      <p>
       In the absence of specific antiviral drugs for CoVs, broad-spectrum antiviral drugs, such as interferon alpha and beta or ribavirin were used for the treatment of SARS-CoV, including in children.
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
        –
        <xref ref-type="bibr" rid="R59">
         59
        </xref>
       </sup>
       Ribavirin was subsequently shown to be ineffective or even harmful because it can cause hemolytic anemia or liver dysfunction.
       <sup>
        <xref ref-type="bibr" rid="R152">
         152
        </xref>
       </sup>
       In adults, interferon-alpha alone or together with ribavirin also did not consistently improve outcomes.
       <sup>
        <xref ref-type="bibr" rid="R152">
         152
        </xref>
        ,
        <xref ref-type="bibr" rid="R153">
         153
        </xref>
       </sup>
       There is some evidence that intravenous corticosteroids led to clinical and radiologic improvement in SARS-CoV-infected individuals.
       <sup>
        <xref ref-type="bibr" rid="R58">
         58
        </xref>
       </sup>
       However, a systematic review showed that the evidence for this is inconclusive and corticosteroids might also be harmful (delayed viral clearance, avascular necrosis, osteoporosis, new onset of diabetes).
       <sup>
        <xref ref-type="bibr" rid="R152">
         152
        </xref>
       </sup>
       There is some evidence from adult studies that lopinavir/ritonavir (Kaletra) started early during infection is associated with improved clinical outcomes (decreased intubation, ARDS and death rates).
       <sup>
        <xref ref-type="bibr" rid="R154">
         154
        </xref>
        ,
        <xref ref-type="bibr" rid="R155">
         155
        </xref>
       </sup>
       However, a systematic review found inconclusive results for the use of lopinavir/ritonavir because of a possible selection bias in many of the studies.
       <sup>
        <xref ref-type="bibr" rid="R152">
         152
        </xref>
       </sup>
       Inconclusive results were also found for intravenous immunoglobulins because studies did not account for comorbidities, stage of illness and effect of other treatments.
       <sup>
        <xref ref-type="bibr" rid="R152">
         152
        </xref>
       </sup>
       There is no evidence for the use of monoclonal antibodies against tumor necrosis factor alpha.
       <sup>
        <xref ref-type="bibr" rid="R156">
         156
        </xref>
       </sup>
      </p>
     </sec>
     <sec>
      <title>
       MERS-CoV
      </title>
      <p>
       There are no studies on treatment outcomes for MERS-CoV in children. In adults, as for SARS-CoV, interferon or ribavirin alone or in combination have not been shown to have a clear benefit.
       <sup>
        <xref ref-type="bibr" rid="R157">
         157
        </xref>
        –
        <xref ref-type="bibr" rid="R159">
         159
        </xref>
       </sup>
       Mycophenolate mofetil, which inhibits guanine (and therefore RNA) synthesis, was identified as a potential anti-MERS-CoV drug in vitro.
       <sup>
        <xref ref-type="bibr" rid="R160">
         160
        </xref>
       </sup>
       However, animal studies showed that the drug leads to worse outcomes with higher viral loads in lung and extrapulmonary tissues.
       <sup>
        <xref ref-type="bibr" rid="R161">
         161
        </xref>
       </sup>
       Consistent with this, renal transplant patients on mycophenolate mofetil have been reported to develop severe and sometimes fatal MERS-CoV infections.
       <sup>
        <xref ref-type="bibr" rid="R162">
         162
        </xref>
       </sup>
      </p>
     </sec>
     <sec>
      <title>
       SARS-CoV-2
      </title>
      <p>
       Until the results of on-going clinical trials become available, there is no definitive evidence on which to base treatment of patients infected with SARS-CoV-2. The only treatment recommendation for children, published by the Zhejiang University School of Medicine, suggests the use of nebulized interferon alpha-2b and oral lopinavir/ritonavir together with corticosteroids for complications (ARDS, encephalitis, hemophagocytic syndrome or septic shock) and intravenous immunoglobulin for severe cases.
       <sup>
        <xref ref-type="bibr" rid="R72">
         72
        </xref>
       </sup>
      </p>
      <p>
       However, as none of these therapies have shown a clear benefit in the treatment of other novel CoVs, it is questionable whether they will be beneficial in the treatment of SARS-CoV-2. Neither the World Health Organization nor the US Centers for Disease Control and Prevention recommends any specific treatment in children or adults.
       <sup>
        <xref ref-type="bibr" rid="R97">
         97
        </xref>
        ,
        <xref ref-type="bibr" rid="R163">
         163
        </xref>
       </sup>
       Despite this, in the previously mentioned case series of the 34 children infected with SARS-CoV-2, 59% were treated with lopinavir/ritonavir.
       <sup>
        <xref ref-type="bibr" rid="R61">
         61
        </xref>
       </sup>
       None of the children received glucocorticoids or immunoglobulins.
       <sup>
        <xref ref-type="bibr" rid="R61">
         61
        </xref>
       </sup>
      </p>
     </sec>
     <sec>
      <title>
       Other Therapeutic Options
      </title>
      <sec>
       <title>
        Monoclonal Antibodies
       </title>
       <p>
        Despite their diversity, CoVs share many proteins among different species, which is helpful for the design of new drugs. One of them is the surface structural spike glycoprotein S, which is responsible for virus-cell interaction.
        <sup>
         <xref ref-type="bibr" rid="R164">
          164
         </xref>
        </sup>
        Monoclonal antibodies (from convalescent human plasma, animal plasma or manufactured) against the spike glycoprotein S have been shown to inhibit fusion of CoVs with human cells and to decrease mortality rate in SARS-CoV-infected patients.
        <sup>
         <xref ref-type="bibr" rid="R165">
          165
         </xref>
         –
         <xref ref-type="bibr" rid="R171">
          171
         </xref>
        </sup>
        A protein, which also inhibits the spike glycoprotein S, although it is not a monoclonal antibody, has been isolated from a red alga called Griffithsia.
        <sup>
         <xref ref-type="bibr" rid="R172">
          172
         </xref>
        </sup>
        However, to date, it has only been tested in animal studies.
        <sup>
         <xref ref-type="bibr" rid="R172">
          172
         </xref>
        </sup>
       </p>
       <p>
        Angiotensin-converting enzyme 2, dipeptidyl peptidase 4, aminopeptidase N, O-acetylated sialic acid are further host receptors for HCoVs and monoclonal antibodies against these proteins might be useful in treatment of infections.
        <sup>
         <xref ref-type="bibr" rid="R173">
          173
         </xref>
         –
         <xref ref-type="bibr" rid="R176">
          176
         </xref>
        </sup>
        However, rapid mutation of CoVs poses a potential problem, which might be diminished by using several monoclonal antibodies targeting different epitopes.
        <sup>
         <xref ref-type="bibr" rid="R166">
          166
         </xref>
        </sup>
       </p>
      </sec>
      <sec>
       <title>
        Protease Inhibitors
       </title>
       <p>
        Endosomal and nonendosomal virus entry into cells can be reduced by inhibiting responsible proteases.
        <sup>
         <xref ref-type="bibr" rid="R177">
          177
         </xref>
         –
         <xref ref-type="bibr" rid="R179">
          179
         </xref>
        </sup>
        Papain-like proteases (PLpro) are involved in viral replication in CoVs and are further potential targets for treatment. Numerous PLpro inhibitors have been identified. However, none of them has been validated in in vivo studies.
        <sup>
         <xref ref-type="bibr" rid="R180">
          180
         </xref>
         ,
         <xref ref-type="bibr" rid="R181">
          181
         </xref>
        </sup>
        Moreover, PLpro enzymes differ between CoVs species, making PLpro inhibitors narrow-spectrum antiviral drugs against CoVs.
        <sup>
         <xref ref-type="bibr" rid="R182">
          182
         </xref>
        </sup>
       </p>
       <p>
        A further protein involved in viral replication is CoV main proteinase, which is inhibited by lopinavir. However, as previously mentioned, lopinavir (plus ritonavir) has been shown to be effective against CoVs in animal and nonrandomized studies of SARS-CoV-infected humans.
        <sup>
         <xref ref-type="bibr" rid="R154">
          154
         </xref>
         ,
         <xref ref-type="bibr" rid="R161">
          161
         </xref>
        </sup>
        However, as previously mentioned, these results are considered inconclusive because of potential selection bias.
        <sup>
         <xref ref-type="bibr" rid="R152">
          152
         </xref>
        </sup>
       </p>
       <sec>
        <title>
         Chloroquine
        </title>
        <p>
         Chloroquine, which is commonly used against malaria and autoimmune diseases, increases the endosomal pH thereby inhibiting virus-cell fusion, and is therefore a potential broad-spectrum antiviral drug.
         <sup>
          <xref ref-type="bibr" rid="R183">
           183
          </xref>
         </sup>
         It also interferes with glycosylation of cellular receptors of SARS-CoV.
         <sup>
          <xref ref-type="bibr" rid="R184">
           184
          </xref>
         </sup>
         In addition, in vitro studies show that chloroquine inhibits entry and postentry stages of SARS-CoV-2 into cells.
         <sup>
          <xref ref-type="bibr" rid="R185">
           185
          </xref>
         </sup>
         Moreover, chloroquine possesses immune-modulating activity, which might enhance its antiviral effect in vivo.
         <sup>
          <xref ref-type="bibr" rid="R185">
           185
          </xref>
         </sup>
        </p>
       </sec>
      </sec>
      <sec>
       <title>
        RNA Synthesis Inhibitors
       </title>
       <p>
        As previously mentioned, ribavirin, a guanosine analog has been shown to be ineffective or even harmful against SARS-CoV
        <sup>
         <xref ref-type="bibr" rid="R152">
          152
         </xref>
        </sup>
        and MERS-CoV.
        <sup>
         <xref ref-type="bibr" rid="R157">
          157
         </xref>
         –
         <xref ref-type="bibr" rid="R159">
          159
         </xref>
        </sup>
        Immucillin-A, a new adenosine analog that has recently been developed, inhibits the viral RNA polymerase of a wide range of RNA viruses, including SARS-CoV and MERS-CoV,
        <sup>
         <xref ref-type="bibr" rid="R186">
          186
         </xref>
        </sup>
        and might be useful in the treatment of other HCoVs. Furthermore, inhibitors of helicase (which are proteins unwinding double-stranded RNA into single strands during replication) might be useful in treatment of CoVs.
        <sup>
         <xref ref-type="bibr" rid="R187">
          187
         </xref>
        </sup>
        RNA synthesis inhibitors, which reduce the formation of double-membrane vesicles, a hallmark of CoV2 replication, have been identified as potential antiviral drugs.
        <sup>
         <xref ref-type="bibr" rid="R188">
          188
         </xref>
         ,
         <xref ref-type="bibr" rid="R189">
          189
         </xref>
        </sup>
        A double-stranded RNA activated caspase oligomerizer (DRACO) that targets long viral double-stranded RNA and induces apoptosis of infected cells, but spares healthy cells, might also be useful in the treatment of CoVs.
        <sup>
         <xref ref-type="bibr" rid="R190">
          190
         </xref>
        </sup>
       </p>
      </sec>
     </sec>
    </sec>
    <sec>
     <title>
      VACCINES
     </title>
     <p>
      Several vaccines against HCoVs are in development with the aim of preventing infection, reducing disease severity and viral shedding. The main antigens for vaccine development are the structural spike glycoprotein S or its receptor-binding domain (RBD).
      <sup>
       <xref ref-type="bibr" rid="R191">
        191
       </xref>
      </sup>
      However, the propensity of CoVs to rapidly mutate and recombine poses a potential problem for vaccine development.
      <sup>
       <xref ref-type="bibr" rid="R192">
        192
       </xref>
       –
       <xref ref-type="bibr" rid="R194">
        194
       </xref>
      </sup>
      Furthermore, the enhanced disease after viral challenges postvaccination has been observed in animal models after several different vaccines.
      <sup>
       <xref ref-type="bibr" rid="R195">
        195
       </xref>
       –
       <xref ref-type="bibr" rid="R197">
        197
       </xref>
      </sup>
     </p>
     <sec>
      <title>
       Live-attenuated Vaccines
      </title>
      <p>
       The advantage of live-attenuated vaccines is that they usually induce a robust and long-lasting immune response, including cellular and humoral immunity to many different antigens. In SARS-CoV animal studies, attenuated mutants with deletion of the structural E gene have been shown to induce neutralizing antibodies, reduce viral loads and protect from clinical symptoms of SARS-CoV infection.
       <sup>
        <xref ref-type="bibr" rid="R198">
         198
        </xref>
        –
        <xref ref-type="bibr" rid="R200">
         200
        </xref>
       </sup>
       In contrast, deletion of open reading frames had little or no effect on viral loads in vitro and in vivo.
       <sup>
        <xref ref-type="bibr" rid="R201">
         201
        </xref>
       </sup>
       Other strategies under development for live-attenuated vaccines against CoVs are genome rearrangement or gene knockouts.
       <sup>
        <xref ref-type="bibr" rid="R202">
         202
        </xref>
        –
        <xref ref-type="bibr" rid="R204">
         204
        </xref>
       </sup>
       These have the advantage that the vaccine virus cannot recombine with wild viruses.
      </p>
     </sec>
     <sec>
      <title>
       Inactivated Vaccines
      </title>
      <p>
       In mouse models, inactivated vaccines successfully induce cellular and humoral immunity (with many different neutralization antibodies) against SARS-CoV
       <sup>
        <xref ref-type="bibr" rid="R191">
         191
        </xref>
        ,
        <xref ref-type="bibr" rid="R205">
         205
        </xref>
        –
        <xref ref-type="bibr" rid="R207">
         207
        </xref>
       </sup>
       and humoral immunity against MERS-CoV.
       <sup>
        <xref ref-type="bibr" rid="R208">
         208
        </xref>
        ,
        <xref ref-type="bibr" rid="R209">
         209
        </xref>
       </sup>
       In a human phase 1 trial, inactivated vaccines against SARS-CoV were well tolerated and elicited neutralizing antibodies.
       <sup>
        <xref ref-type="bibr" rid="R210">
         210
        </xref>
       </sup>
       However, no challenge studies have been done in humans, and in monkey challenge studies, no clear evidence of protection was shown despite the induction of strong cellular and humoral responses.
       <sup>
        <xref ref-type="bibr" rid="R211">
         211
        </xref>
       </sup>
       Moreover, concerns have been raised that inactivated vaccines against SARS-CoV and MERS-CoV may lead to harmful immune and/or inflammatory responses postchallenge.
       <sup>
        <xref ref-type="bibr" rid="R195">
         195
        </xref>
        ,
        <xref ref-type="bibr" rid="R209">
         209
        </xref>
       </sup>
      </p>
     </sec>
     <sec>
      <title>
       Subunit and Recombinant Vaccines
      </title>
      <p>
       Subunit vaccines are purified antigens, usually combined with adjuvants and are the most popular method in the development of vaccines against novel CoVs. For SARS-CoV and MERS-CoV, these are mostly developed from spike glycoprotein S, RBD or nucleocapsid protein.
       <sup>
        <xref ref-type="bibr" rid="R212">
         212
        </xref>
        –
        <xref ref-type="bibr" rid="R216">
         216
        </xref>
       </sup>
       Some studies show that subunit vaccines given intranasally might induce stronger immune responses and mucosal immunity.
       <sup>
        <xref ref-type="bibr" rid="R217">
         217
        </xref>
       </sup>
       Several subunit vaccines have shown to be successful in animal challenging studies.
       <sup>
        <xref ref-type="bibr" rid="R218">
         218
        </xref>
        –
        <xref ref-type="bibr" rid="R220">
         220
        </xref>
       </sup>
      </p>
      <p>
       In a study in monkeys, recombinant RBD protein was used to successfully reduce viral loads in lungs and oropharynx and to prevent MERS-CoV pneumonia.
       <sup>
        <xref ref-type="bibr" rid="R218">
         218
        </xref>
       </sup>
       In mice, similar results were achieved using recombinant RBD protein vaccines from SARS-CoV.
       <sup>
        <xref ref-type="bibr" rid="R221">
         221
        </xref>
       </sup>
      </p>
     </sec>
     <sec>
      <title>
       Viral Vectors Vaccines
      </title>
      <p>
       Adenovirus-based vectors encoding SARS proteins (eg, nucleocapsid protein, spike glycoprotein S and other membrane proteins) have been shown to be immunogenic in mice and rhesus macaques in whom they induced humoral and cellular vaccine responses.
       <sup>
        <xref ref-type="bibr" rid="R222">
         222
        </xref>
        ,
        <xref ref-type="bibr" rid="R223">
         223
        </xref>
       </sup>
       Adenovirus-based vaccines carrying parts MERS-CoV have been shown to reduce morbidity and mortality (undetectable or reduced pulmonary viral loads) in mouse models.
       <sup>
        <xref ref-type="bibr" rid="R196">
         196
        </xref>
        ,
        <xref ref-type="bibr" rid="R224">
         224
        </xref>
       </sup>
       Initially, pulmonary hemorrhages were observed postviral challenge.
       <sup>
        <xref ref-type="bibr" rid="R196">
         196
        </xref>
       </sup>
       However, adding a CD40 ligand to the vaccine enhanced immunogenicity and efficacy, and also prevented inadvertent pulmonary pathology, which makes this vaccine a promising strategy.
       <sup>
        <xref ref-type="bibr" rid="R196">
         196
        </xref>
       </sup>
       Nonetheless, preexisting immunity against adenovirus might reduce efficacy. This might be addressed by giving a viral-based vaccine followed by a recombinant vaccine as a booster.
       <sup>
        <xref ref-type="bibr" rid="R225">
         225
        </xref>
       </sup>
       A adenovirus-based MERS-CoV vaccine has moved into a phase I clinical trial.
       <sup>
        <xref ref-type="bibr" rid="R226">
         226
        </xref>
       </sup>
      </p>
      <p>
       One study, comparing an inactivated SARS-CoV vaccine with an adenovirus-based vaccine against SARS-CoV, found that the first led to higher humoral responses.
       <sup>
        <xref ref-type="bibr" rid="R227">
         227
        </xref>
       </sup>
       Adenovirus-based vaccines administered intranasally led to immunoglobulin A antibody production which has been associated with superior protection from virus replication in lungs.
       <sup>
        <xref ref-type="bibr" rid="R227">
         227
        </xref>
       </sup>
       This indicates that measuring serum neutralizing antibodies might not be a sufficient way of assessing vaccine efficacy for HCoV as mucosal immunity might be more important.
      </p>
      <p>
       For SARS-CoV, a poxvirus has also been used as a vector for an intranasally and intramuscularly administered vaccine. This vaccine-induced neutralizing antibodies and reduced viral loads in the respiratory tract of challenged mice.
       <sup>
        <xref ref-type="bibr" rid="R228">
         228
        </xref>
       </sup>
       However, a similar vaccine used in ferrets led to increased liver damage after SARS-CoV challenge.
       <sup>
        <xref ref-type="bibr" rid="R197">
         197
        </xref>
       </sup>
      </p>
      <p>
       Further vector vaccines for SARS-CoV that have been tested in animals are based on recombinant parainfluenza virus,
       <sup>
        <xref ref-type="bibr" rid="R229">
         229
        </xref>
        ,
        <xref ref-type="bibr" rid="R230">
         230
        </xref>
       </sup>
       live-attenuated recombinant measles virus,
       <sup>
        <xref ref-type="bibr" rid="R231">
         231
        </xref>
       </sup>
       attenuated rabies virus
       <sup>
        <xref ref-type="bibr" rid="R232">
         232
        </xref>
       </sup>
       and attenuated
       <italic>
        Salmonella
       </italic>
       .
       <sup>
        <xref ref-type="bibr" rid="R233">
         233
        </xref>
       </sup>
      </p>
     </sec>
     <sec>
      <title>
       DNA Vaccines
      </title>
      <p>
       Vaccines containing DNA encoding the spike glycoprotein seem to induce a more robust response of neutralizing antibodies against MERS-CoV than vaccines only containing the RBD protein. They have been shown to protect rhesus macaques from MERS-CoV pneumonia.
       <sup>
        <xref ref-type="bibr" rid="R234">
         234
        </xref>
        ,
        <xref ref-type="bibr" rid="R235">
         235
        </xref>
       </sup>
       Three DNA vaccines against MERS-CoV have advanced into clinical trials.
       <sup>
        <xref ref-type="bibr" rid="R236">
         236
        </xref>
        –
        <xref ref-type="bibr" rid="R238">
         238
        </xref>
       </sup>
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      OTHER STRATEGIES FOR CONTROLLING EMERGING CORONAVIRUSES
     </title>
     <p>
      After quickly spreading across the globe, SARS-CoV was contained in 2003 after a highly effective global public health response. This highlights the urgent need for rapid and effectful strategies of infection control. One of the main challenges with novel CoVs is the high potential for nosocomial transmission.
      <sup>
       <xref ref-type="bibr" rid="R239">
        239
       </xref>
      </sup>
      Health care settings seem to increase the risk of viral transmission due to aerosol-generating procedures such as intubation and bronchoscopy. Appropriate hospital hygiene practices are therefore crucial to limit nosocomial outbreaks. The main aims are to effectively triage patients with fever, respiratory symptoms and a contact history
      <sup>
       <xref ref-type="bibr" rid="R240">
        240
       </xref>
      </sup>
      and to apply stringent infection control measures such as isolating patients and quarantine contacts as early as possible. Ideally, each patient is placed in a single negative pressure room. If this is not possible, patients and health care workers should be cohorted.
      <sup>
       <xref ref-type="bibr" rid="R241">
        241
       </xref>
      </sup>
      Protective gear should include water-resistant gowns, disposable gloves, N95 masks and goggles or face shields.
      <sup>
       <xref ref-type="bibr" rid="R240">
        240
       </xref>
      </sup>
      Only suction catheters and mechanical respirators with a closed-circuit system and viral filters should be used.
      <sup>
       <xref ref-type="bibr" rid="R240">
        240
       </xref>
      </sup>
      In contrasts, nebulizers, oxygen masks or nasal continuous positive airway pressure systems should not be used on an open ward.
      <sup>
       <xref ref-type="bibr" rid="R240">
        240
       </xref>
       ,
       <xref ref-type="bibr" rid="R241">
        241
       </xref>
      </sup>
      Needless to say, strict hand hygiene needs to be applied and visitors should be avoided or limited to an absolute minimum. HCoVs have been shown to persist on dry surfaces for up to 9 days.
      <sup>
       <xref ref-type="bibr" rid="R242">
        242
       </xref>
       –
       <xref ref-type="bibr" rid="R244">
        244
       </xref>
      </sup>
      The persistence depends on temperature (shorter duration at 30–40°C) and humidity (longer at higher humidity).
      <sup>
       <xref ref-type="bibr" rid="R245">
        245
       </xref>
      </sup>
      HCoVs, including novel CoVs, can be inactivated by heating to 56°C for 30 minutes or by using lipid solvents such as ethanol (&gt;75%), isopropanol (&gt;70%), formaldehyde (&gt;0.7%), povidone-iodine (&gt;0.23%), sodium hypochlorite (&gt;0.21%), hydrogen peroxide (&gt;0.5%), but not chlorhexidine.
      <sup>
       <xref ref-type="bibr" rid="R72">
        72
       </xref>
       ,
       <xref ref-type="bibr" rid="R244">
        244
       </xref>
      </sup>
     </p>
    </sec>
    <sec>
     <title>
      SUMMARY
     </title>
     <p>
      SARS-CoV, MERS-CoV and SARS-CoV-2 infections seem to affect children less commonly and less severely as compared with adults. This might be because children are less frequently exposed to the main sources of transmission (which until now has been disproportionally nosocomial) or because they are less exposed to animals. However, it could also be that children are less frequently symptomatic or have less severe symptoms and are therefore less often tested, leading to an underestimate of the true numbers infected. In relation to SARS-CoV-2, a study prepublished in early March 2020 suggests that children are just as likely as adults to become infected with this virus but are less likely to be symptomatic or develop severe symptoms.
      <sup>
       <xref ref-type="bibr" rid="R246">
        246
       </xref>
      </sup>
      However, the importance of children in transmitting the virus remains uncertain. The majority of children infected by a novel CoVs reported thus far have a documented household contact, often showing symptoms before them, suggesting the possibility that children are not an important reservoir for novel CoVs. The clinical, laboratory and radiologic features in children are similar for all novel CoVs, except more children infected with SARS-CoV presented with fever compared with SARS-CoV-2 or MERS-CoV. To date, no deaths in children have been reported for SARS-CoV or SARS-CoV-2, except (in the case of the former) for infants of mothers who were infected during pregnancy.
     </p>
    </sec>
    <back>
     <fn-group>
      <fn fn-type="financial-disclosure">
       <p>
        P.Z. is supported by a Fellowship from the European Society for Paediatric Infectious Diseases.
       </p>
      </fn>
      <fn fn-type="COI-statement">
       <p>
        The authors have no conflicts of interest to disclose.
       </p>
      </fn>
      <fn fn-type="equal">
       <p>
        P.Z. drafted the initial article. N.C. critically revised the article and both authors approved the final article as submitted.
       </p>
      </fn>
     </fn-group>
     <ref-list>
      <title>
       REFERENCES
      </title>
      <ref id="R1">
       <label>
        1.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fehr
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses: an overview of their replication and pathogenesis.
        </article-title>
        <source>
         Methods Mol Biol
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         1282
        </volume>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         23
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25720466
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R2">
       <label>
        2.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Amer
          </surname>
          <given-names>
           HM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bovine-like coronaviruses in domestic and wild ruminants.
        </article-title>
        <source>
         Anim Health Res Rev
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         19
        </volume>
        :
        <fpage>
         113
        </fpage>
        –
        <lpage>
         124
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         30683171
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R3">
       <label>
        3.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Saif
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Animal coronaviruses: what can they teach us about the severe acute respiratory syndrome?
        </article-title>
        <source>
         Rev Sci Tech
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         23
        </volume>
        :
        <fpage>
         643
        </fpage>
        –
        <lpage>
         660
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15702725
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R4">
       <label>
        4.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cabeça
          </surname>
          <given-names>
           TK
          </given-names>
         </name>
         <name>
          <surname>
           Granato
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Bellei
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiological and clinical features of human coronavirus infections among different subsets of patients.
        </article-title>
        <source>
         Influenza Other Respir Viruses
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         7
        </volume>
        :
        <fpage>
         1040
        </fpage>
        –
        <lpage>
         1047
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23462106
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R5">
       <label>
        5.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vabret
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Mourez
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Gouarin
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An outbreak of coronavirus OC43 respiratory infection in Normandy, France.
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         36
        </volume>
        :
        <fpage>
         985
        </fpage>
        –
        <lpage>
         989
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12684910
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R6">
       <label>
        6.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Esper
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Ou
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           YT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronaviruses are uncommon in patients with gastrointestinal illness.
        </article-title>
        <source>
         J Clin Virol
        </source>
        .
        <year>
         2010
        </year>
        ;
        <volume>
         48
        </volume>
        :
        <fpage>
         131
        </fpage>
        –
        <lpage>
         133
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         20362494
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R7">
       <label>
        7.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vabret
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Dina
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Gouarin
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Detection of the new human coronavirus HKU1: a report of 6 cases.
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         42
        </volume>
        :
        <fpage>
         634
        </fpage>
        –
        <lpage>
         639
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16447108
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R8">
       <label>
        8.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         79
        </volume>
        :
        <fpage>
         884
        </fpage>
        –
        <lpage>
         895
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15613317
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R9">
       <label>
        9.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gorse
          </surname>
          <given-names>
           GJ
          </given-names>
         </name>
         <name>
          <surname>
           O’Connor
          </surname>
          <given-names>
           TZ
          </given-names>
         </name>
         <name>
          <surname>
           Hall
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human coronavirus and acute respiratory illness in older adults with chronic obstructive pulmonary disease.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2009
        </year>
        ;
        <volume>
         199
        </volume>
        :
        <fpage>
         847
        </fpage>
        –
        <lpage>
         857
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19239338
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R10">
       <label>
        10.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           da Silva Filho
          </surname>
          <given-names>
           LV
          </given-names>
         </name>
         <name>
          <surname>
           Zerbinati
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name>
          <surname>
           Tateno
          </surname>
          <given-names>
           AF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The differential clinical impact of human coronavirus species in children with cystic fibrosis.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2012
        </year>
        ;
        <volume>
         206
        </volume>
        :
        <fpage>
         384
        </fpage>
        –
        <lpage>
         388
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22459737
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R11">
       <label>
        11.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chiu
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           KW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China.
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         40
        </volume>
        :
        <fpage>
         1721
        </fpage>
        –
        <lpage>
         1729
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15909257
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R12">
       <label>
        12.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McIntosh
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Ellis
          </surname>
          <given-names>
           EF
          </given-names>
         </name>
         <name>
          <surname>
           Hoffman
          </surname>
          <given-names>
           LS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The association of viral and bacterial respiratory infections with exacerbations of wheezing in young asthmatic children.
        </article-title>
        <source>
         J Pediatr
        </source>
        .
        <year>
         1973
        </year>
        ;
        <volume>
         82
        </volume>
        :
        <fpage>
         578
        </fpage>
        –
        <lpage>
         590
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         4349062
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R13">
       <label>
        13.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           CS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2012
        </year>
        ;
        <volume>
         86
        </volume>
        :
        <fpage>
         3995
        </fpage>
        –
        <lpage>
         4008
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22278237
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R14">
       <label>
        14.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Discovery of a novel coronavirus, China Rattus coronavirus HKU24, from Norway rats supports the murine origin of Betacoronavirus 1 and has implications for the ancestor of Betacoronavirus lineage A.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         89
        </volume>
        :
        <fpage>
         3076
        </fpage>
        –
        <lpage>
         3092
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25552712
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R15">
       <label>
        15.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gaunt
          </surname>
          <given-names>
           ER
          </given-names>
         </name>
         <name>
          <surname>
           Hardie
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Claas
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method.
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        .
        <year>
         2010
        </year>
        ;
        <volume>
         48
        </volume>
        :
        <fpage>
         2940
        </fpage>
        –
        <lpage>
         2947
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         20554810
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R16">
       <label>
        16.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Davis
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
         <name>
          <surname>
           Foxman
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Monto
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human coronaviruses and other respiratory infections in young adults on a university campus: prevalence, symptoms, and shedding.
        </article-title>
        <source>
         Influenza Other Respir Viruses
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         12
        </volume>
        :
        <fpage>
         582
        </fpage>
        –
        <lpage>
         590
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29660826
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R17">
       <label>
        17.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huynh
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evidence supporting a zoonotic origin of human coronavirus strain NL63.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2012
        </year>
        ;
        <volume>
         86
        </volume>
        :
        <fpage>
         12816
        </fpage>
        –
        <lpage>
         12825
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22993147
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R18">
       <label>
        18.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pfefferle
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Oppong
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Distant relatives of severe acute respiratory syndrome coronavirus and close relatives of human coronavirus 229E in bats, Ghana.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2009
        </year>
        ;
        <volume>
         15
        </volume>
        :
        <fpage>
         1377
        </fpage>
        –
        <lpage>
         1384
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19788804
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R19">
       <label>
        19.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <name>
          <surname>
           Eckerle
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Link of a ubiquitous human coronavirus to dromedary camels.
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         113
        </volume>
        :
        <fpage>
         9864
        </fpage>
        –
        <lpage>
         9869
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27528677
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R20">
       <label>
        20.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vijgen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Keyaerts
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Moës
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         79
        </volume>
        :
        <fpage>
         1595
        </fpage>
        –
        <lpage>
         1604
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15650185
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R21">
       <label>
        21.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SARS and MERS: recent insights into emerging coronaviruses.
        </article-title>
        <source>
         Nat Rev Microbiol
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         14
        </volume>
        :
        <fpage>
         523
        </fpage>
        –
        <lpage>
         534
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27344959
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R22">
       <label>
        22.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
        </person-group>
        <article-title>
         A review of studies on animal reservoirs of the SARS coronavirus.
        </article-title>
        <source>
         Virus Res
        </source>
        .
        <year>
         2008
        </year>
        ;
        <volume>
         133
        </volume>
        :
        <fpage>
         74
        </fpage>
        –
        <lpage>
         87
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17451830
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R23">
       <label>
        23.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Günther
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Preiser
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of a novel coronavirus in patients with severe acute respiratory syndrome.
        </article-title>
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         348
        </volume>
        :
        <fpage>
         1967
        </fpage>
        –
        <lpage>
         1976
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12690091
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R24">
       <label>
        24.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SARS-CoV infection in a restaurant from palm civet.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         11
        </volume>
        :
        <fpage>
         1860
        </fpage>
        –
        <lpage>
         1865
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16485471
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R25">
       <label>
        25.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Luk
          </surname>
          <given-names>
           HKH
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Fung
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Molecular epidemiology, evolution and phylogeny of SARS coronavirus.
        </article-title>
        <source>
         Infect Genet Evol
        </source>
        .
        <year>
         2019
        </year>
        ;
        <volume>
         71
        </volume>
        :
        <fpage>
         21
        </fpage>
        –
        <lpage>
         30
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         30844511
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R26">
       <label>
        26.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Groot
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Baker
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         87
        </volume>
        :
        <fpage>
         7790
        </fpage>
        –
        <lpage>
         7792
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23678167
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R27">
       <label>
        27.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ommeh
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Zohaib
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Genetic evidence of Middle East respiratory syndrome coronavirus (MERS-Cov) and widespread seroprevalence among camels in Kenya.
        </article-title>
        <source>
         Virol Sin
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         33
        </volume>
        :
        <fpage>
         484
        </fpage>
        –
        <lpage>
         492
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         30570714
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R28">
       <label>
        28.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kok
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2020
        </year>
        ;
        <volume>
         395
        </volume>
        :
        <fpage>
         514
        </fpage>
        –
        <lpage>
         523
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         31986261
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R29">
       <label>
        29.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A novel coronavirus from patients with pneumonia in China, 2019.
        </article-title>
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2020
        </year>
        ;
        <volume>
         382
        </volume>
        :
        <fpage>
         727
        </fpage>
        –
        <lpage>
         733
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         31978945
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R30">
       <label>
        30.
       </label>
       <mixed-citation publication-type="other">
        <collab>
         World Health Organization
        </collab>
        .
        <year>
         2020
        </year>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200221-sitrep-32-covid-19.pdf?sfvrsn=4802d089_2">
          https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200221-sitrep-32-covid-19.pdf?sfvrsn=4802d089_2
         </ext-link>
         . Accessed March 2, 2020
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="R31">
       <label>
        31.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuypers
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Martin
          </surname>
          <given-names>
           ET
          </given-names>
         </name>
         <name>
          <surname>
           Heugel
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical disease in children associated with newly described coronavirus subtypes.
        </article-title>
        <source>
         Pediatrics
        </source>
        .
        <year>
         2007
        </year>
        ;
        <volume>
         119
        </volume>
        :
        <fpage>
         e70
        </fpage>
        –
        <lpage>
         e76
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17130280
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R32">
       <label>
        32.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Uddin
          </surname>
          <given-names>
           SMI
          </given-names>
         </name>
         <name>
          <surname>
           Englund
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Kuypers
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Burden and risk factors for coronavirus infections in infants in rural Nepal.
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         67
        </volume>
        :
        <fpage>
         1507
        </fpage>
        –
        <lpage>
         1514
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29668900
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R33">
       <label>
        33.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Taylor
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Lopez
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Weckx
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Respiratory viruses and influenza-like illness: epidemiology and outcomes in children aged 6 months to 10 years in a multi-country population sample.
        </article-title>
        <source>
         J Infect
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         74
        </volume>
        :
        <fpage>
         29
        </fpage>
        –
        <lpage>
         41
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27667752
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R34">
       <label>
        34.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fagbo
          </surname>
          <given-names>
           SF
          </given-names>
         </name>
         <name>
          <surname>
           Garbati
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Hasan
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Acute viral respiratory infections among children in MERS-endemic Riyadh, Saudi Arabia, 2012-2013.
        </article-title>
        <source>
         J Med Virol
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         89
        </volume>
        :
        <fpage>
         195
        </fpage>
        –
        <lpage>
         201
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27430485
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R35">
       <label>
        35.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           SF
          </given-names>
         </name>
         <name>
          <surname>
           Tuo
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           XB
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiology characteristics of human coronaviruses in patients with respiratory infection symptoms and phylogenetic analysis of HCoV-OC43 during 2010-2015 in Guangzhou.
        </article-title>
        <source>
         PLoS One
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         13
        </volume>
        :
        <fpage>
         e0191789
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         29377913
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R36">
       <label>
        36.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Friedman
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Alter
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Hindiyeh
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human
        </article-title>
        <article-title>
         coronavirus infections in Israel: epidemiology, clinical symptoms and summer seasonality of HCoV-HKU1.
        </article-title>
        <source>
         Viruses
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         9
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="R37">
       <label>
        37.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peak
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Childs
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         <name>
          <surname>
           Grad
          </surname>
          <given-names>
           YH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Comparing nonpharmaceutical interventions for containing emerging epidemics.
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         114
        </volume>
        :
        <fpage>
         4023
        </fpage>
        –
        <lpage>
         4028
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28351976
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R38">
       <label>
        38.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           GM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2020
        </year>
        ;
        <volume>
         395
        </volume>
        :
        <fpage>
         689
        </fpage>
        –
        <lpage>
         697
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         32014114
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R39">
       <label>
        39.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chowell
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Abdirizak
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study.
        </article-title>
        <source>
         BMC Med
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         13
        </volume>
        :
        <fpage>
         210
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         26336062
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R40">
       <label>
        40.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lloyd-Smith
          </surname>
          <given-names>
           JO
          </given-names>
         </name>
         <name>
          <surname>
           Schreiber
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
         <name>
          <surname>
           Kopp
          </surname>
          <given-names>
           PE
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Superspreading and the effect of individual variation on disease emergence.
        </article-title>
        <source>
         Nature
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         438
        </volume>
        :
        <fpage>
         355
        </fpage>
        –
        <lpage>
         359
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16292310
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R41">
       <label>
        41.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Majumder
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           Rivers
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Lofgren
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Estimation of MERS-coronavirus reproductive number and case fatality rate for the spring 2014 Saudi Arabia outbreak: insights from publicly available data.
        </article-title>
        <source>
         PLoS Curr
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         20
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="R42">
       <label>
        42.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wallinga
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Teunis
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures.
        </article-title>
        <source>
         Am J Epidemiol
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         160
        </volume>
        :
        <fpage>
         509
        </fpage>
        –
        <lpage>
         516
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15353409
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R43">
       <label>
        43.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chowell
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Castillo-Chavez
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Fenimore
          </surname>
          <given-names>
           PW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Model parameters and outbreak control for SARS.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         1258
        </fpage>
        –
        <lpage>
         1263
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15324546
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R44">
       <label>
        44.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Riley
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Fraser
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Donnelly
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Transmission dynamics of the etiological agent of SARS in Hong Kong: impact of public health interventions.
        </article-title>
        <source>
         Science
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         300
        </volume>
        :
        <fpage>
         1961
        </fpage>
        –
        <lpage>
         1966
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12766206
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R45">
       <label>
        45.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lipsitch
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Cohen
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Cooper
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Transmission dynamics and control of severe acute respiratory syndrome.
        </article-title>
        <source>
         Science
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         300
        </volume>
        :
        <fpage>
         1966
        </fpage>
        –
        <lpage>
         1970
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12766207
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R46">
       <label>
        46.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kucharski
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Althaus
          </surname>
          <given-names>
           CL
          </given-names>
         </name>
        </person-group>
        <article-title>
         The role of superspreading in Middle East respiratory syndrome coronavirus (MERS-CoV) transmission.
        </article-title>
        <source>
         Euro Surveill
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         14
        </fpage>
        –
        <lpage>
         18
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26132768
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R47">
       <label>
        47.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           CF
          </given-names>
         </name>
         <name>
          <surname>
           Liao
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Predictive models of control strategies involved in containing indoor airborne infections.
        </article-title>
        <source>
         Indoor Air
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         16
        </volume>
        :
        <fpage>
         469
        </fpage>
        –
        <lpage>
         481
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17100668
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R48">
       <label>
        48.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cauchemez
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Nouvellet
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Cori
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Unraveling the drivers of MERS-CoV transmission.
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         113
        </volume>
        :
        <fpage>
         9081
        </fpage>
        –
        <lpage>
         9086
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27457935
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R49">
       <label>
        49.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS transmission and risk factors: a systematic review.
        </article-title>
        <source>
         BMC Public Health
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         18
        </volume>
        :
        <fpage>
         574
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         29716568
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R50">
       <label>
        50.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Ran
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak.
        </article-title>
        <source>
         Int J Infect Dis
        </source>
        .
        <year>
         2020
        </year>
        ;
        <volume>
         92
        </volume>
        :
        <fpage>
         214
        </fpage>
        –
        <lpage>
         217
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         32007643
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R51">
       <label>
        51.
       </label>
       <mixed-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cyranoski
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mystery deepens over animal source of coronavirus.
        </article-title>
        <year>
         2020
        </year>
        <comment>
         Accessed March 4, 2020. Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/d41586-020-00548-w">
          https://www.nature.com/articles/d41586-020-00548-w
         </ext-link>
         .
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R52">
       <label>
        52.
       </label>
       <mixed-citation publication-type="webpage">
        <collab>
         World Health Organization.
        </collab>
        .
        <comment>
         Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. 2004. Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/sars/country/table2004_04_21/en/">
          https://www.who.int/csr/sars/country/table2004_04_21/en/
         </ext-link>
         . Accessed March 5, 2020.
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R53">
       <label>
        53.
       </label>
       <mixed-citation publication-type="other">
        <comment>
         Middle East respiratory syndrome coronavirus (MERS-CoV), MERS Monthly Summary, November 2019.
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/mers-cov/en/">
          https://www.who.int/emergencies/mers-cov/en/
         </ext-link>
         . Accessed March 5, 2020.
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R54">
       <label>
        54.
       </label>
       <mixed-citation publication-type="other">
        <comment>
         World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 48. 2020. Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200308-sitrep-48-covid-19.pdf?sfvrsn=16f7ccef_4">
          https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200308-sitrep-48-covid-19.pdf?sfvrsn=16f7ccef_4
         </ext-link>
         . Accessed March 9, 2020.
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R55">
       <label>
        55.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           NS
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         362
        </volume>
        :
        <fpage>
         1353
        </fpage>
        –
        <lpage>
         1358
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14585636
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R56">
       <label>
        56.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hunter
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name>
          <surname>
           Nguyen
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Aden
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Transmission of Middle East respiratory syndrome coronavirus infections in healthcare settings, Abu Dhabi.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         647
        </fpage>
        –
        <lpage>
         656
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26981708
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R57">
       <label>
        57.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hon
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           WT
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical presentations and outcome of severe acute respiratory syndrome in children.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         361
        </volume>
        :
        <fpage>
         1701
        </fpage>
        –
        <lpage>
         1703
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12767737
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R58">
       <label>
        58.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chiu
          </surname>
          <given-names>
           WK
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome in children: experience in a regional hospital in Hong Kong.
        </article-title>
        <source>
         Pediatr Crit Care Med
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         4
        </volume>
        :
        <fpage>
         279
        </fpage>
        –
        <lpage>
         283
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12831407
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R59">
       <label>
        59.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bitnun
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Allen
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         <name>
          <surname>
           Heurter
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <collab>
         Other Members of the Hospital for Sick Children SARS Investigation Team
        </collab>
        .
        <article-title>
         Children hospitalized with severe acute respiratory syndrome-related illness in Toronto.
        </article-title>
        <source>
         Pediatrics
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         112
        </volume>
        :
        <fpage>
         e261
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         14523209
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R60">
       <label>
        60.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Kattan
          </surname>
          <given-names>
           RF
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus disease is rare in children: an update from Saudi Arabia.
        </article-title>
        <source>
         World J Clin Pediatr
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         5
        </volume>
        :
        <fpage>
         391
        </fpage>
        –
        <lpage>
         396
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27872828
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R61">
       <label>
        61.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           XF
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           YJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [Clinical and epidemiological characteristics of 34 children with 2019 novel coronavirus infection in Shenzhen].
        </article-title>
        <source>
         Zhonghua Er Ke Za Zhi
        </source>
        .
        <year>
         2020
        </year>
        ;
        <volume>
         58
        </volume>
        :
        <fpage>
         E008
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         32062875
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R62">
       <label>
        62.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lessler
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Reich
          </surname>
          <given-names>
           NG
          </given-names>
         </name>
         <name>
          <surname>
           Brookmeyer
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Incubation periods of acute respiratory viral infections: a systematic review.
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        .
        <year>
         2009
        </year>
        ;
        <volume>
         9
        </volume>
        :
        <fpage>
         291
        </fpage>
        –
        <lpage>
         300
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19393959
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R63">
       <label>
        63.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           GM
          </given-names>
         </name>
         <name>
          <surname>
           Hedley
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients.
        </article-title>
        <source>
         Ann Intern Med
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         141
        </volume>
        :
        <fpage>
         662
        </fpage>
        –
        <lpage>
         673
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15520422
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R64">
       <label>
        64.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Rayner
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Does SARS-CoV-2 has a longer incubation period than SARS and MERS?
        </article-title>
        <source>
         J Med Virol
        </source>
        .
        <year>
         2020
        </year>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         3
        </lpage>
        .
        <comment>
         [Epub ahead of print]
        </comment>
        <pub-id pub-id-type="pmid">
         31502247
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R65">
       <label>
        65.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           EH
          </given-names>
         </name>
         <name>
          <surname>
           Hsiung
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Cowling
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A comparative epidemiologic analysis of SARS in Hong Kong, Beijing and Taiwan.
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        .
        <year>
         2010
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         50
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         20205928
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R66">
       <label>
        66.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan-Yeung
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           RH
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS: epidemiology.
        </article-title>
        <source>
         Respirology
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         8
        </volume>
        (
        <issue>
         suppl
        </issue>
        ):
        <fpage>
         S9
        </fpage>
        –
        <lpage>
         S14
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15018127
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R67">
       <label>
        67.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Al-Rabeeah
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study.
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         13
        </volume>
        :
        <fpage>
         752
        </fpage>
        –
        <lpage>
         761
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23891402
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R68">
       <label>
        68.
       </label>
       <mixed-citation publication-type="journal">
        <collab>
         Korea Centers for Disease Control and Prevention
        </collab>
        .
        <article-title>
         Middle East respiratory syndrome coronavirus outbreak in the republic of Korea, 2015.
        </article-title>
        <source>
         Osong Public Health Res Perspect
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <fpage>
         269
        </fpage>
        –
        <lpage>
         278
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26473095
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R69">
       <label>
        69.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         386
        </volume>
        :
        <fpage>
         995
        </fpage>
        –
        <lpage>
         1007
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26049252
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R70">
       <label>
        70.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cowling
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015.
        </article-title>
        <source>
         Euro Surveill
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         7
        </fpage>
        –
        <lpage>
         13
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26132767
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R71">
       <label>
        71.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Virlogeux
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Comparison of incubation period distribution of human infections with MERS-CoV in South Korea and Saudi Arabia.
        </article-title>
        <source>
         Sci Rep
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <fpage>
         35839
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         27775012
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R72">
       <label>
        72.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           ZM
          </given-names>
         </name>
         <name>
          <surname>
           Fu
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Shu
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Diagnosis
        </article-title>
        <article-title>
         and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus.
        </article-title>
        <source>
         World J Pediatr
        </source>
        .
        <year>
         2020
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R73">
       <label>
        73.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Martin
          </surname>
          <given-names>
           ET
          </given-names>
         </name>
         <name>
          <surname>
           Fairchok
          </surname>
          <given-names>
           MP
          </given-names>
         </name>
         <name>
          <surname>
           Stednick
          </surname>
          <given-names>
           ZJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiology of multiple respiratory viruses in childcare attendees.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         207
        </volume>
        :
        <fpage>
         982
        </fpage>
        –
        <lpage>
         989
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23288925
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R74">
       <label>
        74.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name>
          <surname>
           Fraser
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Ghani
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiology, transmission dynamics and control of SARS: the 2002-2003 epidemic.
        </article-title>
        <source>
         Philos Trans R Soc Lond B Biol Sci
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         359
        </volume>
        :
        <fpage>
         1091
        </fpage>
        –
        <lpage>
         1105
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15306395
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R75">
       <label>
        75.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           VC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <collab>
         HKU/UCH SARS Study Group
        </collab>
        .
        <article-title>
         Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         361
        </volume>
        :
        <fpage>
         1767
        </fpage>
        –
        <lpage>
         1772
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12781535
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R76">
       <label>
        76.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alfaraj
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Altuwaijri
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus in pediatrics: a report of seven cases from Saudi Arabia.
        </article-title>
        <source>
         Front Med
        </source>
        .
        <year>
         2019
        </year>
        ;
        <volume>
         13
        </volume>
        :
        <fpage>
         126
        </fpage>
        –
        <lpage>
         130
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29623560
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R77">
       <label>
        77.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Novel coronavirus infection in hospitalized infants under 1 year of age in China.
        </article-title>
        <source>
         JAMA
        </source>
        .
        <year>
         2020
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R78">
       <label>
        78.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Pyrc
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Jebbink
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of a new human coronavirus.
        </article-title>
        <source>
         Nat Med
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         368
        </fpage>
        –
        <lpage>
         373
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15034574
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R79">
       <label>
        79.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Sure
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Ihorst
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Croup is associated with the novel coronavirus NL63.
        </article-title>
        <source>
         PLoS Med
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         2
        </volume>
        :
        <fpage>
         e240
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         16104827
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R80">
       <label>
        80.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pyrc
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Berkhout
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         The novel human coronaviruses NL63 and HKU1.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2007
        </year>
        ;
        <volume>
         81
        </volume>
        :
        <fpage>
         3051
        </fpage>
        –
        <lpage>
         3057
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17079323
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R81">
       <label>
        81.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Greenberg
          </surname>
          <given-names>
           SB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Update on human rhinovirus and coronavirus infections.
        </article-title>
        <source>
         Semin Respir Crit Care Med
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         37
        </volume>
        :
        <fpage>
         555
        </fpage>
        –
        <lpage>
         571
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27486736
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R82">
       <label>
        82.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McIntosh
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Kapikian
          </surname>
          <given-names>
           AZ
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           HC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Seroepidemiologic studies of coronavirus infection in adults and children.
        </article-title>
        <source>
         Am J Epidemiol
        </source>
        .
        <year>
         1970
        </year>
        ;
        <volume>
         91
        </volume>
        :
        <fpage>
         585
        </fpage>
        –
        <lpage>
         592
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         4315625
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R83">
       <label>
        83.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yeh
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name>
          <surname>
           Collins
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Cohen
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis.
        </article-title>
        <source>
         Pediatrics
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         113
        </volume>
        (
        <issue>
         1 pt 1
        </issue>
        ):
        <fpage>
         e73
        </fpage>
        –
        <lpage>
         e76
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14702500
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R84">
       <label>
        84.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ge
          </surname>
          <given-names>
           XY
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           XL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor.
        </article-title>
        <source>
         Nature
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         503
        </volume>
        :
        <fpage>
         535
        </fpage>
        –
        <lpage>
         538
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24172901
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R85">
       <label>
        85.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           FW
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Chiu
          </surname>
          <given-names>
           WK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A case-control study of SARS versus community acquired pneumonia.
        </article-title>
        <source>
         Arch Dis Child
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         90
        </volume>
        :
        <fpage>
         747
        </fpage>
        –
        <lpage>
         749
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15970619
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R86">
       <label>
        86.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name>
          <surname>
           Kwan
          </surname>
          <given-names>
           YW
          </given-names>
         </name>
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           PW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome among children.
        </article-title>
        <source>
         Pediatrics
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         113
        </volume>
        :
        <fpage>
         e535
        </fpage>
        –
        <lpage>
         e543
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15173534
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R87">
       <label>
        87.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Babyn
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           WC
          </given-names>
         </name>
         <name>
          <surname>
           Tsou
          </surname>
          <given-names>
           IY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome (SARS): chest radiographic features in children.
        </article-title>
        <source>
         Pediatr Radiol
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         34
        </volume>
        :
        <fpage>
         47
        </fpage>
        –
        <lpage>
         58
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14624321
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R88">
       <label>
        88.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Yun
          </surname>
          <given-names>
           YX
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           XF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [Analysis of CT features of 15 children with 2019 novel coronavirus infection].
        </article-title>
        <source>
         Zhonghua Er Ke Za Zhi
        </source>
        .
        <year>
         2020
        </year>
        ;
        <volume>
         58
        </volume>
        :
        <fpage>
         E007
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         32061200
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R89">
       <label>
        89.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome (SARS) in neonates and children.
        </article-title>
        <source>
         Arch Dis Child Fetal Neonatal Ed
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         90
        </volume>
        :
        <fpage>
         F461
        </fpage>
        –
        <lpage>
         F465
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16244207
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R90">
       <label>
        90.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vabret
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Mouthon
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Mourez
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Direct diagnosis of human respiratory coronaviruses 229E and OC43 by the polymerase chain reaction.
        </article-title>
        <source>
         J Virol Methods
        </source>
        .
        <year>
         2001
        </year>
        ;
        <volume>
         97
        </volume>
        :
        <fpage>
         59
        </fpage>
        –
        <lpage>
         66
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         11483217
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R91">
       <label>
        91.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           PK
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           LK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         363
        </volume>
        :
        <fpage>
         1699
        </fpage>
        –
        <lpage>
         1700
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15158632
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R92">
       <label>
        92.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chim
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         <name>
          <surname>
           Chiu
          </surname>
          <given-names>
           RW
          </given-names>
         </name>
         <name>
          <surname>
           Lo
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genomic sequencing of the severe acute respiratory syndrome-coronavirus.
        </article-title>
        <source>
         Methods Mol Biol
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         336
        </volume>
        :
        <fpage>
         177
        </fpage>
        –
        <lpage>
         194
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16916263
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R93">
       <label>
        93.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chim
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           YK
          </given-names>
         </name>
         <name>
          <surname>
           Hung
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Genomic sequencing of a SARS coronavirus isolate that predated the Metropole Hotel case cluster in Hong Kong.
        </article-title>
        <source>
         Clin Chem
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         50
        </volume>
        :
        <fpage>
         231
        </fpage>
        –
        <lpage>
         233
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14709660
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R94">
       <label>
        94.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Ahn
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           BS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evaluation of a Real-Time Reverse Transcription-PCR (RT-PCR) assay for detection of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in clinical samples from an outbreak in South Korea in 2015.
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         55
        </volume>
        :
        <fpage>
         2554
        </fpage>
        –
        <lpage>
         2555
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28566313
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R95">
       <label>
        95.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           MN
          </given-names>
         </name>
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           YJ
          </given-names>
         </name>
         <name>
          <surname>
           Seong
          </surname>
          <given-names>
           MW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Analytical and clinical validation of six commercial Middle East respiratory syndrome coronavirus RNA detection kits based on real-time reverse-transcription PCR.
        </article-title>
        <source>
         Ann Lab Med
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         36
        </volume>
        :
        <fpage>
         450
        </fpage>
        –
        <lpage>
         456
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27374710
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R96">
       <label>
        96.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al Johani
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Hajeer
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS-CoV diagnosis: an update.
        </article-title>
        <source>
         J Infect Public Health
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         9
        </volume>
        :
        <fpage>
         216
        </fpage>
        –
        <lpage>
         219
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27106390
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R97">
       <label>
        97.
       </label>
       <mixed-citation publication-type="other">
        <collab>
         World Health Organization
        </collab>
        .
        <year>
         2020
        </year>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/handle/10665/330893">
          https://apps.who.int/iris/handle/10665/330893
         </ext-link>
         . Accessed March 5, 2020.
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R98">
       <label>
        98.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jevšnik
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Steyer
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Zrim
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Detection of human coronaviruses in simultaneously collected stool samples and nasopharyngeal swabs from hospitalized children with acute gastroenteritis.
        </article-title>
        <source>
         Virol J
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         46
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         23379823
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R99">
       <label>
        99.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus.
        </article-title>
        <source>
         Sci Adv
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         3
        </volume>
        :
        <fpage>
         eaao4966
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         29152574
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R100">
       <label>
        100.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Serology of severe acute respiratory syndrome: implications for surveillance and outcome.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         189
        </volume>
        :
        <fpage>
         1158
        </fpage>
        –
        <lpage>
         1163
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15031782
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R101">
       <label>
        101.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bermingham
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Heinen
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Iturriza-Gómara
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Laboratory diagnosis of SARS.
        </article-title>
        <source>
         Philos Trans R Soc Lond B Biol Sci
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         359
        </volume>
        :
        <fpage>
         1083
        </fpage>
        –
        <lpage>
         1089
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15306394
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R102">
       <label>
        102.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           LQ
          </given-names>
         </name>
         <name>
          <surname>
           Qian
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           RN
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [Serological analysis of SARS coronavirus in children diagnosed clinically as severe acute respiratory syndrome cases during SARS epidemic in Beijing].
        </article-title>
        <source>
         Zhonghua Er Ke Za Zhi
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         44
        </volume>
        :
        <fpage>
         262
        </fpage>
        –
        <lpage>
         266
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16780645
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R103">
       <label>
        103.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study.
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         15
        </volume>
        :
        <fpage>
         559
        </fpage>
        –
        <lpage>
         564
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25863564
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R104">
       <label>
        104.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oosterhof
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Christensen
          </surname>
          <given-names>
           CB
          </given-names>
         </name>
         <name>
          <surname>
           Sengeløv
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Fatal lower respiratory tract disease with human corona virus NL63 in an adult haematopoietic cell transplant recipient.
        </article-title>
        <source>
         Bone Marrow Transplant
        </source>
        .
        <year>
         2010
        </year>
        ;
        <volume>
         45
        </volume>
        :
        <fpage>
         1115
        </fpage>
        –
        <lpage>
         1116
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19820731
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R105">
       <label>
        105.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cabeça
          </surname>
          <given-names>
           TK
          </given-names>
         </name>
         <name>
          <surname>
           Bellei
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus NL-63 infection in a Brazilian patient suspected of H1N1 2009 influenza infection: description of a fatal case.
        </article-title>
        <source>
         J Clin Virol.
        </source>
        <year>
         2012
        </year>
        ;
        <volume>
         53
        </volume>
        :
        <fpage>
         82
        </fpage>
        –
        <lpage>
         84
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         21978613
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R106">
       <label>
        106.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
         <name>
          <surname>
           Koopmans
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A novel coronavirus emerging in China - key questions for impact assessment.
        </article-title>
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2020
        </year>
        ;
        <volume>
         382
        </volume>
        :
        <fpage>
         692
        </fpage>
        –
        <lpage>
         694
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         31978293
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R107">
       <label>
        107.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jia
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           LQ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Case fatality of SARS in mainland China and associated risk factors.
        </article-title>
        <source>
         Trop Med Int Health
        </source>
        .
        <year>
         2009
        </year>
        ;
        <volume>
         14
        </volume>
        (
        <issue>
         suppl 1
        </issue>
        ):
        <fpage>
         21
        </fpage>
        –
        <lpage>
         27
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19508439
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R108">
       <label>
        108.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nassar
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           Bakhrebah
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Meo
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics.
        </article-title>
        <source>
         Eur Rev Med Pharmacol Sci
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         4956
        </fpage>
        –
        <lpage>
         4961
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         30070331
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R109">
       <label>
        109.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Aleanizy
          </surname>
          <given-names>
           FS
          </given-names>
         </name>
         <name>
          <surname>
           Mohmed
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Alqahtani
          </surname>
          <given-names>
           FY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Outbreak of Middle East respiratory syndrome coronavirus in Saudi Arabia: a retrospective study.
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         17
        </volume>
        :
        <fpage>
         23
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         28056850
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R110">
       <label>
        110.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alhamlan
          </surname>
          <given-names>
           FS
          </given-names>
         </name>
         <name>
          <surname>
           Majumder
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           Brownstein
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Case characteristics among Middle East respiratory syndrome coronavirus outbreak and non-outbreak cases in Saudi Arabia from 2012 to 2015.
        </article-title>
        <source>
         BMJ Open
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         7
        </volume>
        :
        <fpage>
         e011865
        </fpage>
        .
       </mixed-citation>
      </ref>
      <ref id="R111">
       <label>
        111.
       </label>
       <mixed-citation publication-type="other">
        <comment>
         World Health Organization. Disease outbreak news. 24 February 2020. Middle East respiratory syndrome coronavirus (MERS-CoV) – The Kingdom of Saudi Arabia. Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/don/24-february-2020-mers-saudi-arabia/en/">
          https://www.who.int/csr/don/24-february-2020-mers-saudi-arabia/en/
         </ext-link>
         . Accessed March 5, 2020.
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R112">
       <label>
        112.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oh
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           WB
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           SW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome: what we learned from the 2015 outbreak in the Republic of Korea.
        </article-title>
        <source>
         Korean J Intern Med
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         33
        </volume>
        :
        <fpage>
         233
        </fpage>
        –
        <lpage>
         246
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29506344
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R113">
       <label>
        113.
       </label>
       <mixed-citation publication-type="webpage">
        <collab>
         National Health Commission
        </collab>
        <collab>
         of the People’s Republic of China
        </collab>
        .
        <year>
         2020
        </year>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/xcs/yqtb/202002/6c305f6d70f545d59548ba17d79b8229.shtml">
          http://www.nhc.gov.cn/xcs/yqtb/202002/6c305f6d70f545d59548ba17d79b8229.shtml
         </ext-link>
         . Accessed February 15 2020
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="R114">
       <label>
        114.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           McGoogan
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention.
        </article-title>
        <source>
         JAMA
        </source>
        .
        <year>
         2020
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R115">
       <label>
        115.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Isaacs
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Flowers
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Clarke
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiology of coronavirus respiratory infections.
        </article-title>
        <source>
         Arch Dis Child
        </source>
        .
        <year>
         1983
        </year>
        ;
        <volume>
         58
        </volume>
        :
        <fpage>
         500
        </fpage>
        –
        <lpage>
         503
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         6307189
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R116">
       <label>
        116.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Monto
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Tecumseh study of respiratory illness. VI. Frequency of and relationship between outbreaks of coronavirus infection.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         1974
        </year>
        ;
        <volume>
         129
        </volume>
        :
        <fpage>
         271
        </fpage>
        –
        <lpage>
         276
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         4816305
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R117">
       <label>
        117.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dijkman
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Jebbink
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
         <name>
          <surname>
           El Idrissi
          </surname>
          <given-names>
           NB
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human coronavirus NL63 and 229E seroconversion in children.
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        .
        <year>
         2008
        </year>
        ;
        <volume>
         46
        </volume>
        :
        <fpage>
         2368
        </fpage>
        –
        <lpage>
         2373
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18495857
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R118">
       <label>
        118.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hasony
          </surname>
          <given-names>
           HJ
          </given-names>
         </name>
         <name>
          <surname>
           Macnaughton
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevalence of human coronavirus antibody in the population of southern Iraq.
        </article-title>
        <source>
         J Med Virol
        </source>
        .
        <year>
         1982
        </year>
        ;
        <volume>
         9
        </volume>
        :
        <fpage>
         209
        </fpage>
        –
        <lpage>
         216
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         7097257
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R119">
       <label>
        119.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kaye
          </surname>
          <given-names>
           HS
          </given-names>
         </name>
         <name>
          <surname>
           Marsh
          </surname>
          <given-names>
           HB
          </given-names>
         </name>
         <name>
          <surname>
           Dowdle
          </surname>
          <given-names>
           WR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Seroepidemiologic survey of coronavirus (strain OC 43) related infections in a children’s population.
        </article-title>
        <source>
         Am J Epidemiol
        </source>
        .
        <year>
         1971
        </year>
        ;
        <volume>
         94
        </volume>
        :
        <fpage>
         43
        </fpage>
        –
        <lpage>
         49
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         5556222
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R120">
       <label>
        120.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           TF
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           CY
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           WY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiology and clinical presentations of human coronavirus NL63 infections in hong kong children.
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        .
        <year>
         2009
        </year>
        ;
        <volume>
         47
        </volume>
        :
        <fpage>
         3486
        </fpage>
        –
        <lpage>
         3492
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19759228
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R121">
       <label>
        121.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           RF
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           ZP
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Newly identified respiratory viruses associated with acute lower respiratory tract infections in children in Lanzou, China, from 2006 to 2009.
        </article-title>
        <source>
         Clin Microbiol Infect
        </source>
        .
        <year>
         2012
        </year>
        ;
        <volume>
         18
        </volume>
        :
        <fpage>
         74
        </fpage>
        –
        <lpage>
         80
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         21767329
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R122">
       <label>
        122.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           LY
          </given-names>
         </name>
         <name>
          <surname>
           Berkhout
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical manifestations of human coronavirus NL63 infection in children in Taiwan.
        </article-title>
        <source>
         Eur J Pediatr
        </source>
        .
        <year>
         2008
        </year>
        ;
        <volume>
         167
        </volume>
        :
        <fpage>
         75
        </fpage>
        –
        <lpage>
         80
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17297612
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R123">
       <label>
        123.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lina
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Valette
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Foray
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Surveillance of community-acquired viral infections due to respiratory viruses in Rhone-Alpes (France) during winter 1994 to 1995.
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        .
        <year>
         1996
        </year>
        ;
        <volume>
         34
        </volume>
        :
        <fpage>
         3007
        </fpage>
        –
        <lpage>
         3011
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8940439
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R124">
       <label>
        124.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Yip
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Coronavirus HKU1 and other coronavirus infections in Hong Kong.
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         44
        </volume>
        :
        <fpage>
         2063
        </fpage>
        –
        <lpage>
         2071
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16757599
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R125">
       <label>
        125.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Molecular epidemiology of the novel coronavirus that causes severe acute respiratory syndrome.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         363
        </volume>
        :
        <fpage>
         99
        </fpage>
        –
        <lpage>
         104
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14726162
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R126">
       <label>
        126.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           KW
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           PL
          </given-names>
         </name>
         <name>
          <surname>
           Ooi
          </surname>
          <given-names>
           GC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A cluster of cases of severe acute respiratory syndrome in Hong Kong.
        </article-title>
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         348
        </volume>
        :
        <fpage>
         1977
        </fpage>
        –
        <lpage>
         1985
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12671062
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R127">
       <label>
        127.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mackay
          </surname>
          <given-names>
           IM
          </given-names>
         </name>
         <name>
          <surname>
           Arden
          </surname>
          <given-names>
           KE
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS coronavirus: diagnostics, epidemiology and transmission.
        </article-title>
        <source>
         Virol J
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         12
        </volume>
        :
        <fpage>
         222
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         26695637
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R128">
       <label>
        128.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Breban
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Riou
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Fontanet
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         382
        </volume>
        :
        <fpage>
         694
        </fpage>
        –
        <lpage>
         699
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23831141
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R129">
       <label>
        129.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cristallo
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Gambaro
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Biamonti
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human coronavirus polyadenylated RNA sequences in cerebrospinal fluid from multiple sclerosis patients.
        </article-title>
        <source>
         New Microbiol
        </source>
        .
        <year>
         1997
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         105
        </fpage>
        –
        <lpage>
         114
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9208420
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R130">
       <label>
        130.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dessau
          </surname>
          <given-names>
           RB
          </given-names>
         </name>
         <name>
          <surname>
           Lisby
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Frederiksen
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses in spinal fluid of patients with acute monosymptomatic optic neuritis.
        </article-title>
        <source>
         Acta Neurol Scand
        </source>
        .
        <year>
         1999
        </year>
        ;
        <volume>
         100
        </volume>
        :
        <fpage>
         88
        </fpage>
        –
        <lpage>
         91
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         10442448
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R131">
       <label>
        131.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shimizu
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Shike
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Baker
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human coronavirus NL63 is not detected in the respiratory tracts of children with acute Kawasaki disease.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         192
        </volume>
        :
        <fpage>
         1767
        </fpage>
        –
        <lpage>
         1771
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16235175
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R132">
       <label>
        132.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           LY
          </given-names>
         </name>
         <name>
          <surname>
           Chiang
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         <name>
          <surname>
           Kao
          </surname>
          <given-names>
           CL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <collab>
         Kawasaki Disease Research Group
        </collab>
        .
        <article-title>
         Lack of association between infection with a novel human coronavirus (HCoV), HCoV-NH, and Kawasaki disease in Taiwan.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         193
        </volume>
        :
        <fpage>
         283
        </fpage>
        –
        <lpage>
         286
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16362893
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R133">
       <label>
        133.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           LL
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           VC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Initial viral load and the outcomes of SARS.
        </article-title>
        <source>
         CMAJ
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         171
        </volume>
        :
        <fpage>
         1349
        </fpage>
        –
        <lpage>
         1352
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15557587
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R134">
       <label>
        134.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Nasopharyngeal shedding of severe acute respiratory syndrome-associated coronavirus is associated with genetic polymorphisms.
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         42
        </volume>
        :
        <fpage>
         1561
        </fpage>
        –
        <lpage>
         1569
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16652313
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R135">
       <label>
        135.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van Elden
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
         <name>
          <surname>
           van Loon
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           van Alphen
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Frequent detection of human coronaviruses in clinical specimens from patients with respiratory tract infection by use of a novel real-time reverse-transcriptase polymerase chain reaction.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         189
        </volume>
        :
        <fpage>
         652
        </fpage>
        –
        <lpage>
         657
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14767819
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R136">
       <label>
        136.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           So
          </surname>
          <given-names>
           HK
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Radiological and pulmonary function outcomes of children with SARS.
        </article-title>
        <source>
         Pediatr Pulmonol
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         38
        </volume>
        :
        <fpage>
         427
        </fpage>
        –
        <lpage>
         433
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15514972
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R137">
       <label>
        137.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shek
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Fung
          </surname>
          <given-names>
           GP
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Infants born to mothers with severe acute respiratory syndrome.
        </article-title>
        <source>
         Pediatrics
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         112
        </volume>
        :
        <fpage>
         e254
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         14523207
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R138">
       <label>
        138.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           SF
          </given-names>
         </name>
         <name>
          <surname>
           Chow
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           TN
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome.
        </article-title>
        <source>
         Am J Obstet Gynecol
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         191
        </volume>
        :
        <fpage>
         292
        </fpage>
        –
        <lpage>
         297
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15295381
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R139">
       <label>
        139.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Saeed
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Abedi
          </surname>
          <given-names>
           GR
          </given-names>
         </name>
         <name>
          <surname>
           Alzahrani
          </surname>
          <given-names>
           AG
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Surveillance and testing for Middle East respiratory syndrome coronavirus, Saudi Arabia, April 2015-February 2016.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         23
        </volume>
        :
        <fpage>
         682
        </fpage>
        –
        <lpage>
         685
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28322710
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R140">
       <label>
        140.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Makhdoom
          </surname>
          <given-names>
           HQ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Screening for Middle East respiratory syndrome coronavirus infection in hospital patients and their healthcare worker and family contacts: a prospective descriptive study.
        </article-title>
        <source>
         Clin Microbiol Infect
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         469
        </fpage>
        –
        <lpage>
         474
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24460984
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R141">
       <label>
        141.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Payne
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         <name>
          <surname>
           Iblan
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Alqasrawi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <collab>
         Jordan MERS-CoV Investigation Team
        </collab>
        .
        <article-title>
         Stillbirth during infection with Middle East respiratory syndrome coronavirus.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         209
        </volume>
        :
        <fpage>
         1870
        </fpage>
        –
        <lpage>
         1872
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24474813
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R142">
       <label>
        142.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alserehi
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Wali
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Alshukairi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Impact of Middle East respiratory syndrome coronavirus (MERS-CoV) on pregnancy and perinatal outcome.
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         16
        </volume>
        :
        <fpage>
         105
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         26936356
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R143">
       <label>
        143.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Malik
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           El Masry
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name>
          <surname>
           Ravi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus during pregnancy, Abu Dhabi, United Arab Emirates, 2013.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         515
        </fpage>
        –
        <lpage>
         517
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26890613
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R144">
       <label>
        144.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Abedi
          </surname>
          <given-names>
           GR
          </given-names>
         </name>
         <name>
          <surname>
           Al Masri
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus infection during pregnancy: a report of 5 cases from Saudi Arabia.
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         63
        </volume>
        :
        <fpage>
         951
        </fpage>
        –
        <lpage>
         953
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27358348
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R145">
       <label>
        145.
       </label>
       <mixed-citation publication-type="other">
        <comment>
         Centers for Disease Control and Prevention CfDCaP. Evaluating and reporting persons under investigation (PUI). 2020. Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html">
          https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html
         </ext-link>
         . Accessed March 5, 2020.
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R146">
       <label>
        146.
       </label>
       <mixed-citation publication-type="other">
        <collab>
         World Health Organization
        </collab>
        .
        <year>
         2020
        </year>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-ncov)">
          https://www.who.int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-ncov)
         </ext-link>
         and
         <ext-link ext-link-type="uri" xlink:href="https://www.ecdc.europa.eu/en/case-definition-and-european-surveillance-human-infection-novel-coronavirus-2019-ncov">
          https://www.ecdc.europa.eu/en/case-definition-and-european-surveillance-human-infection-novel-coronavirus-2019-ncov
         </ext-link>
         . Accessed March 5, 2020
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="R147">
       <label>
        147.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
         <name>
          <surname>
           Ni
          </surname>
          <given-names>
           ZY
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
         <name>
          <surname>
           Ou
          </surname>
          <given-names>
           CQ
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           JX
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical Characteristics of Coronavirus Disease 2019 in China.
        </article-title>
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2020
        </year>
       </mixed-citation>
      </ref>
      <ref id="R148">
       <label>
        148.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records.
        </article-title>
        <source>
         The Lancet
        </source>
        .
        <year>
         2020
        </year>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         7
        </lpage>
        .
        <comment>
         [Epub ahead of print]
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R149">
       <label>
        149.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Makhdoom
          </surname>
          <given-names>
           HQ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Respiratory tract samples, viral load, and genome fraction yield in patients with Middle East respiratory syndrome.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         210
        </volume>
        :
        <fpage>
         1590
        </fpage>
        –
        <lpage>
         1594
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24837403
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R150">
       <label>
        150.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hung
          </surname>
          <given-names>
           IF
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           VC
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           AK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Viral loads in clinical specimens and SARS manifestations.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         1550
        </fpage>
        –
        <lpage>
         1557
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15498155
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R151">
       <label>
        151.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Che
          </surname>
          <given-names>
           XY
          </given-names>
         </name>
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           LW
          </given-names>
         </name>
         <name>
          <surname>
           Liao
          </surname>
          <given-names>
           ZY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         191
        </volume>
        :
        <fpage>
         2033
        </fpage>
        –
        <lpage>
         2037
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15897988
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R152">
       <label>
        152.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stockman
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
         <name>
          <surname>
           Bellamy
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Garner
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS: systematic review of treatment effects.
        </article-title>
        <source>
         PLoS Med
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         3
        </volume>
        :
        <fpage>
         e343
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         16968120
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R153">
       <label>
        153.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           VC
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           KK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical management and infection control of SARS: lessons learned.
        </article-title>
        <source>
         Antiviral Res
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         100
        </volume>
        :
        <fpage>
         407
        </fpage>
        –
        <lpage>
         419
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23994190
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R154">
       <label>
        154.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           ST
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study.
        </article-title>
        <source>
         Hong Kong Med J
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         9
        </volume>
        :
        <fpage>
         399
        </fpage>
        –
        <lpage>
         406
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14660806
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R155">
       <label>
        155.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           VC
          </given-names>
         </name>
         <name>
          <surname>
           Hung
          </surname>
          <given-names>
           IF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <collab>
         HKU/UCH SARS Study Group
        </collab>
        .
        <article-title>
         Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.
        </article-title>
        <source>
         Thorax
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         59
        </volume>
        :
        <fpage>
         252
        </fpage>
        –
        <lpage>
         256
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14985565
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R156">
       <label>
        156.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inflammatory cytokine profile in children with severe acute respiratory syndrome.
        </article-title>
        <source>
         Pediatrics
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         113
        </volume>
        (
        <issue>
         1 pt 1
        </issue>
        ):
        <fpage>
         e7
        </fpage>
        –
        <lpage>
         e14
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14702488
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R157">
       <label>
        157.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Omrani
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <name>
          <surname>
           Saad
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Baig
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study.
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         14
        </volume>
        :
        <fpage>
         1090
        </fpage>
        –
        <lpage>
         1095
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25278221
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R158">
       <label>
        158.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shalhoub
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Farahat
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Al-Jiffri
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study.
        </article-title>
        <source>
         J Antimicrob Chemother
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         70
        </volume>
        :
        <fpage>
         2129
        </fpage>
        –
        <lpage>
         2132
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25900158
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R159">
       <label>
        159.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Momattin
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Dib
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study.
        </article-title>
        <source>
         Int J Infect Dis
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         42
        </fpage>
        –
        <lpage>
         46
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24406736
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R160">
       <label>
        160.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Kao
          </surname>
          <given-names>
           RY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus.
        </article-title>
        <source>
         J Infect
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         67
        </volume>
        :
        <fpage>
         606
        </fpage>
        –
        <lpage>
         616
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24096239
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R161">
       <label>
        161.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         212
        </volume>
        :
        <fpage>
         1904
        </fpage>
        –
        <lpage>
         1913
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26198719
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R162">
       <label>
        162.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           AlGhamdi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Mushtaq
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Awn
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS CoV infection in two renal transplant recipients: case report.
        </article-title>
        <source>
         Am J Transplant
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         15
        </volume>
        :
        <fpage>
         1101
        </fpage>
        –
        <lpage>
         1104
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25716741
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R163">
       <label>
        163.
       </label>
       <mixed-citation publication-type="other">
        <collab>
         Centers for Disease Control and Prevention CfDCaP
        </collab>
        .
        <year>
         2020
        </year>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html">
          https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html
         </ext-link>
         . Accessed February 21, 2010
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="R164">
       <label>
        164.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           EI
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Coronaviruses - drug discovery and therapeutic options.
        </article-title>
        <source>
         Nat Rev Drug Discov
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         15
        </volume>
        :
        <fpage>
         327
        </fpage>
        –
        <lpage>
         347
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26868298
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R165">
       <label>
        165.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Soo
          </surname>
          <given-names>
           YO
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Use of convalescent plasma therapy in SARS patients in Hong Kong.
        </article-title>
        <source>
         Eur J Clin Microbiol Infect Dis
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         24
        </volume>
        :
        <fpage>
         44
        </fpage>
        –
        <lpage>
         46
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15616839
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R166">
       <label>
        166.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Zuo
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein.
        </article-title>
        <source>
         Sci Transl Med
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <fpage>
         234ra59
        </fpage>
        .
       </mixed-citation>
      </ref>
      <ref id="R167">
       <label>
        167.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ying
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Ju
          </surname>
          <given-names>
           TW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         88
        </volume>
        :
        <fpage>
         7796
        </fpage>
        –
        <lpage>
         7805
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24789777
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R168">
       <label>
        168.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           XC
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         <name>
          <surname>
           Jiao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution.
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         111
        </volume>
        :
        <fpage>
         E2018
        </fpage>
        –
        <lpage>
         E2026
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24778221
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R169">
       <label>
        169.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Channappanavar
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Protective effect of intranasal regimens containing peptidic Middle East respiratory syndrome coronavirus fusion inhibitor against MERS-CoV infection.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         212
        </volume>
        :
        <fpage>
         1894
        </fpage>
        –
        <lpage>
         1903
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26164863
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R170">
       <label>
        170.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Soo
          </surname>
          <given-names>
           YO
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients.
        </article-title>
        <source>
         Clin Microbiol Infect
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         676
        </fpage>
        –
        <lpage>
         678
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15214887
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R171">
       <label>
        171.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine.
        </article-title>
        <source>
         J Gen Virol
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         85
        </volume>
        (
        <issue>
         pt 10
        </issue>
        ):
        <fpage>
         3109
        </fpage>
        –
        <lpage>
         3113
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15448374
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R172">
       <label>
        172.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barton
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Kouokam
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name>
          <surname>
           Lasnik
          </surname>
          <given-names>
           AB
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models.
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         58
        </volume>
        :
        <fpage>
         120
        </fpage>
        –
        <lpage>
         127
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24145548
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R173">
       <label>
        173.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.
        </article-title>
        <source>
         Nature
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         426
        </volume>
        :
        <fpage>
         450
        </fpage>
        –
        <lpage>
         454
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R174">
       <label>
        174.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         <name>
          <surname>
           Mou
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC.
        </article-title>
        <source>
         Nature
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         495
        </volume>
        :
        <fpage>
         251
        </fpage>
        –
        <lpage>
         254
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23486063
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R175">
       <label>
        175.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Milewska
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human coronavirus HKU1 spike protein uses O-acetylated sialic acid as an attachment receptor determinant and employs hemagglutinin-esterase protein as a receptor-destroying enzyme.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         89
        </volume>
        :
        <fpage>
         7202
        </fpage>
        –
        <lpage>
         7213
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25926653
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R176">
       <label>
        176.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vijgen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Keyaerts
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Zlateva
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of six new polymorphisms in the human coronavirus 229E receptor gene (aminopeptidase N/CD13).
        </article-title>
        <source>
         Int J Infect Dis
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         8
        </volume>
        :
        <fpage>
         217
        </fpage>
        –
        <lpage>
         222
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15234325
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R177">
       <label>
        177.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shirato
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Kawase
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Matsuyama
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         87
        </volume>
        :
        <fpage>
         12552
        </fpage>
        –
        <lpage>
         12561
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24027332
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R178">
       <label>
        178.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Vedantham
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Protease inhibitors targeting coronavirus and filovirus entry.
        </article-title>
        <source>
         Antiviral Res
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         116
        </volume>
        :
        <fpage>
         76
        </fpage>
        –
        <lpage>
         84
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25666761
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R179">
       <label>
        179.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kawase
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Shirato
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2012
        </year>
        ;
        <volume>
         86
        </volume>
        :
        <fpage>
         6537
        </fpage>
        –
        <lpage>
         6545
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22496216
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R180">
       <label>
        180.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Báez-Santos
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
         <name>
          <surname>
           St John
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
         <name>
          <surname>
           Mesecar
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
        </person-group>
        <article-title>
         The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
        </article-title>
        <source>
         Antiviral Res
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         115
        </volume>
        :
        <fpage>
         21
        </fpage>
        –
        <lpage>
         38
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25554382
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R181">
       <label>
        181.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ratia
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Pegan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Takayama
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication.
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        .
        <year>
         2008
        </year>
        ;
        <volume>
         105
        </volume>
        :
        <fpage>
         16119
        </fpage>
        –
        <lpage>
         16124
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18852458
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R182">
       <label>
        182.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Lei
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Santarsiero
          </surname>
          <given-names>
           BD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV.
        </article-title>
        <source>
         ACS Chem Biol
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         1456
        </fpage>
        –
        <lpage>
         1465
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25746232
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R183">
       <label>
        183.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savarino
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Di Trani
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Donatelli
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         New insights into the antiviral effects of chloroquine.
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <fpage>
         67
        </fpage>
        –
        <lpage>
         69
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16439323
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R184">
       <label>
        184.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vincent
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Bergeron
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Benjannet
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
        </article-title>
        <source>
         Virol J
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         2
        </volume>
        :
        <fpage>
         69
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         16115318
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R185">
       <label>
        185.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
        </article-title>
        <source>
         Cell Res
        </source>
        .
        <year>
         2020
        </year>
        <fpage>
         269
        </fpage>
        <lpage>
         271
        </lpage>
        .
        <comment>
         [Epub ahead of print]
        </comment>
        <pub-id pub-id-type="pmid">
         32020029
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R186">
       <label>
        186.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Warren
          </surname>
          <given-names>
           TK
          </given-names>
         </name>
         <name>
          <surname>
           Wells
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Panchal
          </surname>
          <given-names>
           RG
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430.
        </article-title>
        <source>
         Nature
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         508
        </volume>
        :
        <fpage>
         402
        </fpage>
        –
        <lpage>
         405
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24590073
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R187">
       <label>
        187.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adedeji
          </surname>
          <given-names>
           AO
          </given-names>
         </name>
         <name>
          <surname>
           Singh
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Kassim
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses.
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         58
        </volume>
        :
        <fpage>
         4894
        </fpage>
        –
        <lpage>
         4898
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24841268
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R188">
       <label>
        188.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lundin
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Dijkman
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Bergström
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the Middle East respiratory syndrome virus.
        </article-title>
        <source>
         PLoS Pathog
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         e1004166
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         24874215
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R189">
       <label>
        189.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rappe
          </surname>
          <given-names>
           JCF
          </given-names>
         </name>
         <name>
          <surname>
           de Wilde
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Di
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Antiviral activity of K22 against members of the order Nidovirales.
        </article-title>
        <source>
         Virus Res
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         246
        </volume>
        :
        <fpage>
         28
        </fpage>
        –
        <lpage>
         34
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29337162
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R190">
       <label>
        190.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rider
          </surname>
          <given-names>
           TH
          </given-names>
         </name>
         <name>
          <surname>
           Zook
          </surname>
          <given-names>
           CE
          </given-names>
         </name>
         <name>
          <surname>
           Boettcher
          </surname>
          <given-names>
           TL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Broad-spectrum antiviral therapeutics.
        </article-title>
        <source>
         PLoS One
        </source>
        .
        <year>
         2011
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <fpage>
         e22572
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         21818340
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R191">
       <label>
        191.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine.
        </article-title>
        <source>
         Vaccine
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         24
        </volume>
        :
        <fpage>
         5498
        </fpage>
        –
        <lpage>
         5508
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16725238
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R192">
       <label>
        192.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiology, genetic recombination, and pathogenesis of coronaviruses.
        </article-title>
        <source>
         Trends Microbiol
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         24
        </volume>
        :
        <fpage>
         490
        </fpage>
        –
        <lpage>
         502
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27012512
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R193">
       <label>
        193.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           DW
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           YJ
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Variations in spike glycoprotein gene of MERS-CoV, South Korea, 2015.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         100
        </fpage>
        –
        <lpage>
         104
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26691200
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R194">
       <label>
        194.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sohrab
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           EI
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genetic diversity of MERS-CoV spike protein gene in Saudi Arabia.
        </article-title>
        <source>
         J Infect Public Health
        </source>
        .
        <year>
         2019
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R195">
       <label>
        195.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Siddiqui
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry.
        </article-title>
        <source>
         Biochem Biophys Res Commun
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         325
        </volume>
        :
        <fpage>
         445
        </fpage>
        –
        <lpage>
         452
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15530413
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R196">
       <label>
        196.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hashem
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Algaissi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Agrawal
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A highly immunogenic, protective, and safe adenovirus-based vaccine expressing Middle East respiratory syndrome coronavirus S1-CD40L fusion protein in a transgenic human dipeptidyl peptidase 4 mouse model.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2019
        </year>
        ;
        <volume>
         220
        </volume>
        :
        <fpage>
         1558
        </fpage>
        –
        <lpage>
         1567
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         30911758
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R197">
       <label>
        197.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Czub
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Weingartl
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Czub
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets.
        </article-title>
        <source>
         Vaccine
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         23
        </volume>
        :
        <fpage>
         2273
        </fpage>
        –
        <lpage>
         2279
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15755610
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R198">
       <label>
        198.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Alvarez
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Almazán
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2007
        </year>
        ;
        <volume>
         81
        </volume>
        :
        <fpage>
         1701
        </fpage>
        –
        <lpage>
         1713
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17108030
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R199">
       <label>
        199.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lamirande
          </surname>
          <given-names>
           EW
          </given-names>
         </name>
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2008
        </year>
        ;
        <volume>
         82
        </volume>
        :
        <fpage>
         7721
        </fpage>
        –
        <lpage>
         7724
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18463152
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R200">
       <label>
        200.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dediego
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Pewe
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Alvarez
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice.
        </article-title>
        <source>
         Virology
        </source>
        .
        <year>
         2008
        </year>
        ;
        <volume>
         376
        </volume>
        :
        <fpage>
         379
        </fpage>
        –
        <lpage>
         389
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18452964
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R201">
       <label>
        201.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         <name>
          <surname>
           Sims
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus group-specific open reading frames encode nonessential functions for replication in cell cultures and mice.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         79
        </volume>
        :
        <fpage>
         14909
        </fpage>
        –
        <lpage>
         14922
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16282490
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R202">
       <label>
        202.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Haan
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Masters
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The group-specific murine coronavirus genes are not essential, but their deletion, by reverse genetics, is attenuating in the natural host.
        </article-title>
        <source>
         Virology
        </source>
        .
        <year>
         2002
        </year>
        ;
        <volume>
         296
        </volume>
        :
        <fpage>
         177
        </fpage>
        –
        <lpage>
         189
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12036329
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R203">
       <label>
        203.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Almazán
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Sola
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate.
        </article-title>
        <source>
         mBio
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         4
        </volume>
        :
        <fpage>
         e00650
        </fpage>
        –
        <lpage>
         e00613
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24023385
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R204">
       <label>
        204.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           VD
          </given-names>
         </name>
         <name>
          <surname>
           Gralinski
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
         <name>
          <surname>
           Mitchell
          </surname>
          <given-names>
           HD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus nonstructural protein 16 is necessary for interferon resistance and viral pathogenesis.
        </article-title>
        <source>
         mSphere
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         2
        </volume>
        :
        <fpage>
         e00346
        </fpage>
        –
        <lpage>
         e00417
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29152578
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R205">
       <label>
        205.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xiong
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           YF
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           MY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Immunogenicity of SARS inactivated vaccine in BALB/c mice.
        </article-title>
        <source>
         Immunol Lett
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         95
        </volume>
        :
        <fpage>
         139
        </fpage>
        –
        <lpage>
         143
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15388253
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R206">
       <label>
        206.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Takasuka
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Fujii
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Takahashi
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice.
        </article-title>
        <source>
         Int Immunol
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         16
        </volume>
        :
        <fpage>
         1423
        </fpage>
        –
        <lpage>
         1430
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15314040
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R207">
       <label>
        207.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Spruth
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Kistner
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Savidis-Dacho
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses.
        </article-title>
        <source>
         Vaccine
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         24
        </volume>
        :
        <fpage>
         652
        </fpage>
        –
        <lpage>
         661
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16214268
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R208">
       <label>
        208.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Lan
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of Middle East respiratory syndrome coronavirus.
        </article-title>
        <source>
         Emerg Microbes Infect
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         7
        </volume>
        :
        <fpage>
         60
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         29618723
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R209">
       <label>
        209.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Agrawal
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Algaissi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus.
        </article-title>
        <source>
         Hum Vaccin Immunother
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         12
        </volume>
        :
        <fpage>
         2351
        </fpage>
        –
        <lpage>
         2356
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27269431
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R210">
       <label>
        210.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine.
        </article-title>
        <source>
         Antivir Ther
        </source>
        .
        <year>
         2007
        </year>
        ;
        <volume>
         12
        </volume>
        :
        <fpage>
         1107
        </fpage>
        –
        <lpage>
         1113
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18018769
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R211">
       <label>
        211.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys.
        </article-title>
        <source>
         Vaccine
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         23
        </volume>
        :
        <fpage>
         3202
        </fpage>
        –
        <lpage>
         3209
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15837221
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R212">
       <label>
        212.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jaume
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Yip
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           Kam
          </surname>
          <given-names>
           YW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement.
        </article-title>
        <source>
         Hong Kong Med J
        </source>
        .
        <year>
         2012
        </year>
        ;
        <volume>
         18
        </volume>
        (
        <issue>
         suppl 2
        </issue>
        ):
        <fpage>
         31
        </fpage>
        –
        <lpage>
         36
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="R213">
       <label>
        213.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The spike protein of SARS-CoV–a target for vaccine and therapeutic development.
        </article-title>
        <source>
         Nat Rev Microbiol
        </source>
        .
        <year>
         2009
        </year>
        ;
        <volume>
         7
        </volume>
        :
        <fpage>
         226
        </fpage>
        –
        <lpage>
         236
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19198616
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R214">
       <label>
        214.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adney
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Efficacy of an adjuvanted Middle East respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas.
        </article-title>
        <source>
         Viruses
        </source>
        .
        <year>
         2019
        </year>
        ;
        <volume>
         11
        </volume>
        :
        <fpage>
         E212
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         30832356
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R215">
       <label>
        215.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Tai
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.
        </article-title>
        <source>
         Hum Vaccin Immunother
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         13
        </volume>
        :
        <fpage>
         1615
        </fpage>
        –
        <lpage>
         1624
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28277821
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R216">
       <label>
        216.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tai
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection.
        </article-title>
        <source>
         Virology
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         499
        </volume>
        :
        <fpage>
         375
        </fpage>
        –
        <lpage>
         382
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27750111
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R217">
       <label>
        217.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: implication for designing novel mucosal MERS vaccines.
        </article-title>
        <source>
         Vaccine.
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         32
        </volume>
        :
        <fpage>
         2100
        </fpage>
        –
        <lpage>
         2108
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24560617
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R218">
       <label>
        218.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lan
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge.
        </article-title>
        <source>
         EBioMedicine
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         2
        </volume>
        :
        <fpage>
         1438
        </fpage>
        –
        <lpage>
         1446
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26629538
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R219">
       <label>
        219.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jiaming
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Yanfeng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
        </article-title>
        <source>
         Vaccine
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         35
        </volume>
        :
        <fpage>
         10
        </fpage>
        –
        <lpage>
         18
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27899228
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R220">
       <label>
        220.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Channappanavar
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.
        </article-title>
        <source>
         Cell Mol Immunol
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         13
        </volume>
        :
        <fpage>
         180
        </fpage>
        –
        <lpage>
         190
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25640653
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R221">
       <label>
        221.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Chag
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate.
        </article-title>
        <source>
         Hum Vaccin Immunother
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         648
        </fpage>
        –
        <lpage>
         658
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24355931
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R222">
       <label>
        222.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zakhartchouk
          </surname>
          <given-names>
           AN
          </given-names>
         </name>
         <name>
          <surname>
           Viswanathan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Mahony
          </surname>
          <given-names>
           JB
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus nucleocapsid protein expressed by an adenovirus vector is phosphorylated and immunogenic in mice.
        </article-title>
        <source>
         J Gen Virol
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         86
        </volume>
        (
        <issue>
         pt 1
        </issue>
        ):
        <fpage>
         211
        </fpage>
        –
        <lpage>
         215
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15604448
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R223">
       <label>
        223.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Tamin
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Soloff
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Effects of a SARS-associated coronavirus vaccine in monkeys.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         362
        </volume>
        :
        <fpage>
         1895
        </fpage>
        –
        <lpage>
         1896
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14667748
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R224">
       <label>
        224.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
         <name>
          <surname>
           Wells
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Lambe
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model.
        </article-title>
        <source>
         NPJ Vaccines
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         2
        </volume>
        :
        <fpage>
         28
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         29263883
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R225">
       <label>
        225.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rocha
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
         <name>
          <surname>
           Caetano
          </surname>
          <given-names>
           BC
          </given-names>
         </name>
         <name>
          <surname>
           Machado
          </surname>
          <given-names>
           AV
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Recombinant viruses as tools to induce protective cellular immunity against infectious diseases.
        </article-title>
        <source>
         Int Microbiol
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         7
        </volume>
        :
        <fpage>
         83
        </fpage>
        –
        <lpage>
         94
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15248156
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R226">
       <label>
        226.
       </label>
       <mixed-citation publication-type="other">
        <collab>
         Hill, A
        </collab>
        .
        <year>
         2018
        </year>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT03399578">
          https://clinicaltrials.gov/ct2/show/study/NCT03399578
         </ext-link>
         . Accessed February 22, 2020
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="R227">
       <label>
        227.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           See
          </surname>
          <given-names>
           RH
          </given-names>
         </name>
         <name>
          <surname>
           Zakhartchouk
          </surname>
          <given-names>
           AN
          </given-names>
         </name>
         <name>
          <surname>
           Petric
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
        </article-title>
        <source>
         J Gen Virol
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         87
        </volume>
        (
        <issue>
         pt 3
        </issue>
        ):
        <fpage>
         641
        </fpage>
        –
        <lpage>
         650
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16476986
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R228">
       <label>
        228.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bisht
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice.
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         101
        </volume>
        :
        <fpage>
         6641
        </fpage>
        –
        <lpage>
         6646
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15096611
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R229">
       <label>
        229.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Buchholz
          </surname>
          <given-names>
           UJ
          </given-names>
         </name>
         <name>
          <surname>
           Bukreyev
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         101
        </volume>
        :
        <fpage>
         9804
        </fpage>
        –
        <lpage>
         9809
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15210961
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R230">
       <label>
        230.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bukreyev
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Lamirande
          </surname>
          <given-names>
           EW
          </given-names>
         </name>
         <name>
          <surname>
           Buchholz
          </surname>
          <given-names>
           UJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         363
        </volume>
        :
        <fpage>
         2122
        </fpage>
        –
        <lpage>
         2127
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15220033
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R231">
       <label>
        231.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liniger
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Zuniga
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Tamin
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses.
        </article-title>
        <source>
         Vaccine
        </source>
        .
        <year>
         2008
        </year>
        ;
        <volume>
         26
        </volume>
        :
        <fpage>
         2164
        </fpage>
        –
        <lpage>
         2174
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18346823
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R232">
       <label>
        232.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Faber
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Lamirande
          </surname>
          <given-names>
           EW
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies.
        </article-title>
        <source>
         J Gen Virol
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         86
        </volume>
        (
        <issue>
         pt 5
        </issue>
        ):
        <fpage>
         1435
        </fpage>
        –
        <lpage>
         1440
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15831955
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R233">
       <label>
        233.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Type IVB pilus operon promoter controlling expression of the severe acute respiratory syndrome-associated coronavirus nucleocapsid gene in Salmonella enterica Serovar Typhi elicits full immune response by intranasal vaccination.
        </article-title>
        <source>
         Clin Vaccine Immunol
        </source>
        .
        <year>
         2007
        </year>
        ;
        <volume>
         14
        </volume>
        :
        <fpage>
         990
        </fpage>
        –
        <lpage>
         997
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17596427
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R234">
       <label>
        234.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Joyce
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evaluation of candidate vaccine approaches for MERS-CoV.
        </article-title>
        <source>
         Nat Commun.
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <fpage>
         7712
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         26218507
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R235">
       <label>
        235.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muthumani
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Reuschel
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates.
        </article-title>
        <source>
         Sci Transl Med
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         7
        </volume>
        :
        <fpage>
         301ra132
        </fpage>
        .
       </mixed-citation>
      </ref>
      <ref id="R236">
       <label>
        236.
       </label>
       <mixed-citation publication-type="other">
        <collab>
         Modjarrad, K
        </collab>
        .
        <year>
         2016
        </year>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02670187?term=GLS-5300">
          https://clinicaltrials.gov/ct2/show/NCT02670187?term=GLS-5300
         </ext-link>
         . Accessed February 22, 2020
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="R237">
       <label>
        237.
       </label>
       <mixed-citation publication-type="other">
        <collab>
         Maslow, J
        </collab>
        .
        <year>
         2018
        </year>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03721718">
          https://clinicaltrials.gov/ct2/show/NCT03721718
         </ext-link>
         . Accessed February 22, 2020
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="R238">
       <label>
        238.
       </label>
       <mixed-citation publication-type="other">
        <collab>
         Addo, M
        </collab>
        .
        <year>
         2018
        </year>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03615911#outcomemeasures">
          https://clinicaltrials.gov/ct2/show/NCT03615911#outcomemeasures
         </ext-link>
         . Accessed February 22, 2020
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="R239">
       <label>
        239.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bin
          </surname>
          <given-names>
           SY
          </given-names>
         </name>
         <name>
          <surname>
           Heo
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Environmental contamination and viral shedding in MERS patients during MERS-CoV outbreak in South Korea.
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         62
        </volume>
        :
        <fpage>
         755
        </fpage>
        –
        <lpage>
         760
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26679623
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R240">
       <label>
        240.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           So
          </surname>
          <given-names>
           KW
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           TF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Infection control for SARS in a tertiary neonatal centre.
        </article-title>
        <source>
         Arch Dis Child Fetal Neonatal Ed
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         88
        </volume>
        :
        <fpage>
         F405
        </fpage>
        –
        <lpage>
         F409
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12937045
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R241">
       <label>
        241.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           TF
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           FW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Infection control for SARS in a tertiary paediatric centre in Hong Kong.
        </article-title>
        <source>
         J Hosp Infect
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         56
        </volume>
        :
        <fpage>
         215
        </fpage>
        –
        <lpage>
         222
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15003670
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R242">
       <label>
        242.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dowell
          </surname>
          <given-names>
           SF
          </given-names>
         </name>
         <name>
          <surname>
           Simmerman
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Erdman
          </surname>
          <given-names>
           DD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus on hospital surfaces.
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         39
        </volume>
        :
        <fpage>
         652
        </fpage>
        –
        <lpage>
         657
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15356778
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R243">
       <label>
        243.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Otter
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Donskey
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Yezli
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination.
        </article-title>
        <source>
         J Hosp Infect
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         92
        </volume>
        :
        <fpage>
         235
        </fpage>
        –
        <lpage>
         250
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26597631
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R244">
       <label>
        244.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kampf
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Todt
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Pfaender
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents.
        </article-title>
        <source>
         J Hosp Infect
        </source>
        .
        <year>
         2020
        </year>
        <fpage>
         246
        </fpage>
        –
        <lpage>
         251
        </lpage>
        .
        <comment>
         [Epub ahead of print]
        </comment>
        <pub-id pub-id-type="pmid">
         32035997
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R245">
       <label>
        245.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ijaz
          </surname>
          <given-names>
           MK
          </given-names>
         </name>
         <name>
          <surname>
           Brunner
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
         <name>
          <surname>
           Sattar
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Survival characteristics of airborne human coronavirus 229E.
        </article-title>
        <source>
         J Gen Virol
        </source>
        .
        <year>
         1985
        </year>
        ;
        <volume>
         66
        </volume>
        (
        <issue>
         pt 12
        </issue>
        ):
        <fpage>
         2743
        </fpage>
        –
        <lpage>
         2748
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         2999318
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R246">
       <label>
        246.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bi
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Mei
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <comment>
         Epidemiology and transmission of COVID-19 in Shenzhen China: analysis of 391 cases and 1,286 of their close contacts. medRxiv 2020. Available at:
        </comment>
        <pub-id pub-id-type="doi">
         10.1101/2020.03.03.20028423
        </pub-id>
        <comment>
         . Accessed March 4, 2020.
        </comment>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Influenza Other Respir Viruses
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Influenza Other Respir Viruses
      </journal-id>
      <journal-id journal-id-type="doi">
       10.1111/(ISSN)1750-2659
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       IRV
      </journal-id>
      <journal-title-group>
       <journal-title>
        Influenza and Other Respiratory Viruses
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1750-2640
      </issn>
      <issn pub-type="epub">
       1750-2659
      </issn>
      <publisher>
       <publisher-name>
        John Wiley and Sons Inc.
       </publisher-name>
       <publisher-loc>
        Hoboken
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       28799710
      </article-id>
      <article-id pub-id-type="pmc">
       5705692
      </article-id>
      <article-id pub-id-type="doi">
       10.1111/irv.12474
      </article-id>
      <article-id pub-id-type="publisher-id">
       IRV12474
      </article-id>
      <article-categories>
       <subj-group subj-group-type="overline">
        <subject>
         Original Article
        </subject>
       </subj-group>
       <subj-group subj-group-type="heading">
        <subject>
         Original Articles
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        The efficacy of medical masks and respirators against respiratory infection in healthcare workers
       </article-title>
       <alt-title alt-title-type="left-running-head">
        MACINTYRE et al.
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="irv12474-cr-0001">
        <name>
         <surname>
          MacIntyre
         </surname>
         <given-names>
          Chandini Raina
         </given-names>
        </name>
        <xref ref-type="aff" rid="irv12474-aff-0001">
         <sup>
          1
         </sup>
        </xref>
        <xref ref-type="aff" rid="irv12474-aff-0002">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes" id="irv12474-cr-0002">
        <name>
         <surname>
          Chughtai
         </surname>
         <given-names>
          Abrar Ahmad
         </given-names>
        </name>
        <contrib-id contrib-id-type="orcid">
         http://orcid.org/0000-0003-4203-7891
        </contrib-id>
        <address>
         <email>
          abrar.chughtai@unsw.edu.au
         </email>
        </address>
        <xref ref-type="aff" rid="irv12474-aff-0001">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" id="irv12474-cr-0003">
        <name>
         <surname>
          Rahman
         </surname>
         <given-names>
          Bayzidur
         </given-names>
        </name>
        <xref ref-type="aff" rid="irv12474-aff-0001">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" id="irv12474-cr-0004">
        <name>
         <surname>
          Peng
         </surname>
         <given-names>
          Yang
         </given-names>
        </name>
        <xref ref-type="aff" rid="irv12474-aff-0003">
         <sup>
          3
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" id="irv12474-cr-0005">
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          Yi
         </given-names>
        </name>
        <xref ref-type="aff" rid="irv12474-aff-0003">
         <sup>
          3
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" id="irv12474-cr-0006">
        <name>
         <surname>
          Seale
         </surname>
         <given-names>
          Holly
         </given-names>
        </name>
        <xref ref-type="aff" rid="irv12474-aff-0001">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" id="irv12474-cr-0007">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Xiaoli
         </given-names>
        </name>
        <xref ref-type="aff" rid="irv12474-aff-0003">
         <sup>
          3
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" id="irv12474-cr-0008">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Quanyi
         </given-names>
        </name>
        <xref ref-type="aff" rid="irv12474-aff-0003">
         <sup>
          3
         </sup>
        </xref>
       </contrib>
      </contrib-group>
      <aff id="irv12474-aff-0001">
       <label>
        <sup>
         1
        </sup>
       </label>
       <named-content content-type="organisation-division">
        School of Public Health and Community Medicine
       </named-content>
       <institution>
        University of New South Wales
       </institution>
       <named-content content-type="city">
        Sydney
       </named-content>
       <named-content content-type="country-part">
        NSW
       </named-content>
       <country country="AU">
        Australia
       </country>
      </aff>
      <aff id="irv12474-aff-0002">
       <label>
        <sup>
         2
        </sup>
       </label>
       <named-content content-type="organisation-division">
        College of Public Service &amp; Community Solutions
       </named-content>
       <named-content content-type="organisation-division">
        and College of Health Solutions
       </named-content>
       <institution>
        Arizona State University
       </institution>
       <named-content content-type="city">
        Phoenix
       </named-content>
       <named-content content-type="country-part">
        AZ
       </named-content>
       <country country="US">
        USA
       </country>
      </aff>
      <aff id="irv12474-aff-0003">
       <label>
        <sup>
         3
        </sup>
       </label>
       <institution>
        The Beijing Centre for Disease Prevention and Control
       </institution>
       <named-content content-type="city">
        Beijing
       </named-content>
       <country country="CN">
        China
       </country>
      </aff>
      <author-notes>
       <corresp id="correspondenceTo">
        <label>
         *
        </label>
        <bold>
         Correspondence
        </bold>
        <break>
        </break>
        Abrar Ahmad Chughtai, School of Public Health and Community Medicine, UNSW Medicine, University of New South Wales, Sydney, NSW, Australia.
        <break>
        </break>
        Email:
        <email>
         abrar.chughtai@unsw.edu.au
        </email>
        <break>
        </break>
       </corresp>
      </author-notes>
      <pub-date pub-type="epub">
       <day>
        30
       </day>
       <month>
        8
       </month>
       <year>
        2017
       </year>
      </pub-date>
      <pub-date pub-type="ppub">
       <month>
        11
       </month>
       <year>
        2017
       </year>
      </pub-date>
      <volume>
       11
      </volume>
      <issue>
       6
      </issue>
      <issue-id pub-id-type="doi">
       10.1111/irv.2017.11.issue-6
      </issue-id>
      <fpage>
       511
      </fpage>
      <lpage>
       517
      </lpage>
      <history>
       <date date-type="accepted">
        <day>
         22
        </day>
        <month>
         7
        </month>
        <year>
         2017
        </year>
       </date>
      </history>
      <permissions>
       <!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2017 John Wiley & Sons Ltd <copyright-statement>-->
       <copyright-statement content-type="article-copyright">
        © 2017 The Authors.
        <italic>
         Influenza and Other Respiratory Viruses
        </italic>
        Published by John Wiley &amp; Sons Ltd.
       </copyright-statement>
       <license license-type="creativeCommonsBy">
        <license-p>
         This is an open access article under the terms of the
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          Creative Commons Attribution
         </ext-link>
         License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
        </license-p>
       </license>
      </permissions>
      <self-uri content-type="pdf" xlink:href="file:IRV-11-511.pdf" xlink:type="simple">
      </self-uri>
      <abstract id="irv12474-abs-0001">
       <sec id="irv12474-sec-0001">
        <title>
         Objective
        </title>
        <p>
         We aimed to examine the efficacy of medical masks and respirators in protecting against respiratory infections using pooled data from two homogenous randomised control clinical trials (
         <styled-content style="fixed-case">
          RCT
         </styled-content>
         s).
        </p>
       </sec>
       <sec id="irv12474-sec-0002">
        <title>
         Methods
        </title>
        <p>
         The data collected on 3591 subjects in two similar
         <styled-content style="fixed-case">
          RCT
         </styled-content>
         s conducted in Beijing, China, which examined the same infection outcomes, were pooled. Four interventions were compared: (i) continuous N95 respirator use, (ii) targeted N95 respirator use, (iii) medical mask use and (iv) control arm. The outcomes were laboratory‐confirmed viral respiratory infection, influenza A or B, laboratory‐confirmed bacterial colonisation and pathogens grouped by mode of transmission.
        </p>
       </sec>
       <sec id="irv12474-sec-0003">
        <title>
         Results
        </title>
        <p>
         Rates of all outcomes were consistently lower in the continuous N95 and/or targeted N95 arms. In adjusted analysis, rates of laboratory‐confirmed bacterial colonisation (
         <styled-content style="fixed-case">
          RR
         </styled-content>
         0.33, 95%
         <styled-content style="fixed-case">
          CI
         </styled-content>
         0.21‐0.51), laboratory‐confirmed viral infections (
         <styled-content style="fixed-case">
          RR
         </styled-content>
         0.46, 95%
         <styled-content style="fixed-case">
          CI
         </styled-content>
         0.23‐0.91) and droplet‐transmitted infections (
         <styled-content style="fixed-case">
          RR
         </styled-content>
         0.26, 95%
         <styled-content style="fixed-case">
          CI
         </styled-content>
         0.16‐0.42) were significantly lower in the continuous N95 arm. Laboratory‐confirmed influenza was also lowest in the continuous N95 arm (
         <styled-content style="fixed-case">
          RR
         </styled-content>
         0.34, 95%
         <styled-content style="fixed-case">
          CI
         </styled-content>
         0.10‐1.11), but the difference was not statistically significant. Rates of laboratory‐confirmed bacterial colonisation (
         <styled-content style="fixed-case">
          RR
         </styled-content>
         0.54, 95%
         <styled-content style="fixed-case">
          CI
         </styled-content>
         0.33‐0.87) and droplet‐transmitted infections (
         <styled-content style="fixed-case">
          RR
         </styled-content>
         0.43, 95%
         <styled-content style="fixed-case">
          CI
         </styled-content>
         0.25‐0.72) were also lower in the targeted N95 arm, but not in medical mask arm.
        </p>
       </sec>
       <sec id="irv12474-sec-0004">
        <title>
         Conclusion
        </title>
        <p>
         The results suggest that the classification of infections into droplet versus airborne transmission is an oversimplification. Most guidelines recommend masks for infections spread by droplets. N95 respirators, as “airborne precautions,” provide superior protection for droplet‐transmitted infections. To ensure the occupational health and safety of healthcare worker, the superiority of respirators in preventing respiratory infections should be reflected in infection control guidelines.
        </p>
       </sec>
      </abstract>
      <kwd-group kwd-group-type="author-generated">
       <kwd id="irv12474-kwd-0001">
        droplet infections
       </kwd>
       <kwd id="irv12474-kwd-0002">
        healthcare workers
       </kwd>
       <kwd id="irv12474-kwd-0003">
        influenza
       </kwd>
       <kwd id="irv12474-kwd-0004">
        masks
       </kwd>
       <kwd id="irv12474-kwd-0005">
        medical masks
       </kwd>
       <kwd id="irv12474-kwd-0006">
        respirators
       </kwd>
      </kwd-group>
      <funding-group>
       <award-group>
        <funding-source>
         Australian National Health &amp; Medical Research Council of Australia
        </funding-source>
        <award-id>
         630787
        </award-id>
       </award-group>
      </funding-group>
      <counts>
       <fig-count count="2">
       </fig-count>
       <table-count count="5">
       </table-count>
       <page-count count="7">
       </page-count>
       <word-count count="5592">
       </word-count>
      </counts>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         source-schema-version-number
        </meta-name>
        <meta-value>
         2.0
        </meta-value>
       </custom-meta>
       <custom-meta>
        <meta-name>
         component-id
        </meta-name>
        <meta-value>
         irv12474
        </meta-value>
       </custom-meta>
       <custom-meta>
        <meta-name>
         cover-date
        </meta-name>
        <meta-value>
         November 2017
        </meta-value>
       </custom-meta>
       <custom-meta>
        <meta-name>
         details-of-publishers-convertor
        </meta-name>
        <meta-value>
         Converter:WILEY_ML3GV2_TO_NLMPMC version:5.2.6.1 mode:remove_FC converted:28.11.2017
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
     <notes>
      <p content-type="self-citation">
       <mixed-citation id="irv12474-cit-1001" publication-type="journal">
        <string-name>
         <surname>
          MacIntyre
         </surname>
         <given-names>
          CR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chughtai
         </surname>
         <given-names>
          AA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rahman
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        , et al.
        <article-title>
         The efficacy of medical masks and respirators against respiratory infection in healthcare workers
        </article-title>
        .
        <source>
         Influenza Other Respi Viruses
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         11
        </volume>
        :
        <fpage>
         511
        </fpage>
        –
        <lpage>
         517
        </lpage>
        .
        <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/irv.12474">
         https://doi.org/10.1111/irv.12474
        </ext-link>
       </mixed-citation>
      </p>
      <fn-group>
       <fn fn-type="funding" id="irv12474-note-1001">
        <p>
         <bold>
          Funding information
         </bold>
        </p>
        <p>
         Trial 1: 3M helped in fit testing, no financial support was provided.
        </p>
        <p>
         Trial 2: Australian National Health &amp; Medical Research Council of Australia (Grant # 630787).
        </p>
        <p>
         Funders were not involved in the design and implementation of the study
        </p>
       </fn>
      </fn-group>
     </notes>
    </front>
    <sec id="irv12474-sec-0005">
     <label>
      1
     </label>
     <title>
      BACKGROUND
     </title>
     <p>
      There is currently a lack of consensus around the efficacy of medical masks and respirators for healthcare workers (HCWs) against influenza, with only five published randomised control trials (RCTs) in HCWs conducted to date.
      <xref ref-type="ref" rid="irv12474-bib-0001">
       1
      </xref>
      ,
      <xref ref-type="ref" rid="irv12474-bib-0002">
       2
      </xref>
      ,
      <xref ref-type="ref" rid="irv12474-bib-0003">
       3
      </xref>
      ,
      <xref ref-type="ref" rid="irv12474-bib-0004">
       4
      </xref>
      ,
      <xref ref-type="ref" rid="irv12474-bib-0005">
       5
      </xref>
      While N95 respirators have been shown to be superior to medical masks in preventing clinical respiratory infection (CRI), influenza illness (ILI) and other outcomes, none of the studies were adequately powered to examine laboratory‐confirmed influenza.
     </p>
     <p>
      In the smallest of the trials, involving only 32 HCWs, there was no difference in the rates of respiratory illnesses between HCWs who used medical masks and the control group.
      <xref ref-type="ref" rid="irv12474-bib-0001">
       1
      </xref>
      A Canadian study of 422 hospital nurses compared targeted use of N95 respirators and medical masks and found that the rate of serologically defined influenza was 25% in both arms.
      <xref ref-type="ref" rid="irv12474-bib-0002">
       2
      </xref>
      However, in the absence of a control arm for comparison, the finding of no difference in outcomes between the intervention arms could represent either equal efficacy or equal inefficacy of the two interventions. The other two published HCW RCTs used a more specific and less sensitive definition of influenza based on nucleic acid testing (NAT) of respiratory specimens in symptomatic subjects. As such, even these substantially larger RCTs were unable to demonstrate any significant difference in influenza infection between N95 respirators and medical masks.
      <xref ref-type="ref" rid="irv12474-bib-0003">
       3
      </xref>
      ,
      <xref ref-type="ref" rid="irv12474-bib-0004">
       4
      </xref>
      Finally, a recent study examined the efficacy of cloth masks compared to medical mask and control groups, and found that cloth masks may increase the risk of infection in HCWs.
      <xref ref-type="ref" rid="irv12474-bib-0005">
       5
      </xref>
     </p>
     <p>
      Guidelines for respiratory protection have been driven by presumed transmission mode alone, and under an assumption that influenza and other pathogens are spread by one mode alone.
      <xref ref-type="ref" rid="irv12474-bib-0006">
       6
      </xref>
      However, the paradigm of unimodal droplet or airborne spread is based on outmoded experiments from the 1940s, which concluded that only large droplets are found at close proximity to the patient, while small droplet nuclei and airborne particles are found at a longer distance.
      <xref ref-type="ref" rid="irv12474-bib-0007">
       7
      </xref>
      ,
      <xref ref-type="ref" rid="irv12474-bib-0008">
       8
      </xref>
      ,
      <xref ref-type="ref" rid="irv12474-bib-0009">
       9
      </xref>
      It has since been shown that both small and large particles can exist at short distances from the patient, and that aerosolised transmission can occur at close proximity.
      <xref ref-type="ref" rid="irv12474-bib-0009">
       9
      </xref>
     </p>
     <p>
      In our two published RCTs conducted in China,
      <xref ref-type="ref" rid="irv12474-bib-0003">
       3
      </xref>
      ,
      <xref ref-type="ref" rid="irv12474-bib-0004">
       4
      </xref>
      we used the same outcomes, case definitions and measurement tools, and used the same testing methods for a range of different pathogens transmitted by different routes. This afforded an opportunity to pool the data from both trials for improved statistical power to examine the outcomes by pathogens and mode of transmission. The aim of this pooled analysis was to examine the efficacy of medical masks and respirators in HCWs against respiratory infection.
     </p>
    </sec>
    <sec id="irv12474-sec-0006">
     <label>
      2
     </label>
     <title>
      METHODS
     </title>
     <p>
      We pooled the results of our two RCTs on mask and respirator use in hospital HCWs in Beijing, China. The first RCT (Trial 1) was conducted from December 2008 to January 2009,
      <xref ref-type="ref" rid="irv12474-bib-0003">
       3
      </xref>
      and included 1441 HCWs randomised to: medical mask arm (n = 492), N95 fit‐tested arm (n = 461) and N95 non‐fit‐tested arm (n = 488). The rate of fit‐test failure was very low (5/461) in this trial, so data from both N95 arms were combined for analysis.
     </p>
     <p>
      An additional 481 healthcare workers from nine hospitals were recruited to a control arm. These hospitals were purposefully selected as they indicated low levels of routine mask/respirator use during a pre‐trial assessment. Participants in the control arms continued their usual mask wearing practices and were followed using the same protocol as applied to the other arms.
      <xref ref-type="ref" rid="irv12474-bib-0003">
       3
      </xref>
     </p>
     <p>
      The second trial (Trial 2) was conducted from 28 December 2009 to 7 February 2010, using the same design.
      <xref ref-type="ref" rid="irv12474-bib-0004">
       4
      </xref>
      In Trial 2, participants were randomised to three arms: medical masks at all times on shift (n = 572), continuous N95 respirators at all times on shift (n = 516) and targeted/intermittent use of N95 respirators only while doing high‐risk procedures or barrier nursing of a patient with known respiratory illness (n = 521). Fit testing was not performed in the second RCT. In both trials, participants were followed for 4 weeks of wearing the medical masks or respirators, and an extra week of non‐wearing of masks for the development of symptoms. Demographic and clinical data were collected, including gender, age, smoking, vaccination status, pre‐existing medical illnesses, hand hygiene and high‐risk procedures. Pharyngeal swabs were collected from symptomatic participants, and samples were tested at the laboratories of the Beijing Centers for Disease Control and Prevention. There was no major difference in the products used in both clinical trials. In the first trial, we used medical masks (3M, catalogue number 1820) and N95 fit/non‐fit‐tested respirator (3M, catalogue number 9132). The following products were used in the second trial: medical masks (3M, catalogue number 1817) and respirator (3M, catalogue number 1860).
     </p>
     <p>
      The interventions compared in the pooled analysis were as follows: (i) continuous use of N95 respirators (pooled data from both trials ‐ 1530 subjects); (ii) targeted N95 respirator use (data from trial 2‐516 subjects); (iii) continuous use of medical masks (pooled data from both trials ‐ 1064 subjects) and (iv) and a control group (data from trial 1‐481 subjects).
     </p>
     <p>
      Only laboratory‐confirmed outcomes were included in the analysis, which were defined and measured identically in both trials, and comprised: (i) laboratory‐confirmed viral respiratory infection (detection of adenoviruses; human metapneumovirus; coronavirus 229E ⁄ NL63; parainfluenza viruses 1, 2 and 3; influenza viruses A and B; respiratory syncytial virus A and B; rhinovirus A⁄B and coronavirus OC43 ⁄HKU1 by multiplex PCR); (ii) laboratory‐confirmed (multiplex PCR) influenza A or B and (iii) laboratory‐confirmed bacterial colonisation (Streptococcus pneumonia, Haemophilus influenza, Bordetella pertussis, Chlamydophila pneumoniae and Mycoplasma pneumonia).
      <xref ref-type="ref" rid="irv12474-bib-0003">
       3
      </xref>
      ,
      <xref ref-type="ref" rid="irv12474-bib-0004">
       4
      </xref>
      The laboratory testing has previously been described.
      <xref ref-type="ref" rid="irv12474-bib-0003">
       3
      </xref>
      ,
      <xref ref-type="ref" rid="irv12474-bib-0004">
       4
      </xref>
     </p>
     <p>
      Laboratory‐confirmed bacteria and viruses identified in participants were categorised according to droplet (n = 285), contact (n = 6) and airborne (n = 3) transmission modes (Table
      <xref ref-type="supplementary-material" rid="irv12474-sup-0001">
       S1
      </xref>
      A). Sixty‐one co‐infection cases with multitransmission were categorised separately. Among the viruses isolated, coronavirus and influenza A/B were included in the droplet category (and thus included in the additional analysis); rhinovirus A/B was included in the airborne category and adenovirus; parainfluenza virus and respiratory syncytial virus (RSV) were included in contact category in the base case analysis. All bacteria were categorised into the droplet transmission category. For consistency, data on the transmission modes were taken from the Pathogen Safety Data Sheets (PSDSs) of the Public Health Agency of Canada
      <xref ref-type="ref" rid="irv12474-bib-0010">
       10
      </xref>
      (Table
      <xref ref-type="supplementary-material" rid="irv12474-sup-0001">
       S1
      </xref>
      A). As the largest number of confirmed infections was in the droplet category, we conducted a subgroup analysis of droplet‐transmitted infections. Given there were a large number of RSV cases (n = 33) in our data set and RSV is variously categorised as either “droplet”
      <xref ref-type="ref" rid="irv12474-bib-0011">
       11
      </xref>
      or “contact” spread
      <xref ref-type="ref" rid="irv12474-bib-0012">
       12
      </xref>
      in different guidelines, we performed a sensitivity analysis by including RSV into the droplet transmission category instead of contact.
     </p>
     <sec id="irv12474-sec-0007">
      <label>
       2.1
      </label>
      <title>
       Ethics
      </title>
      <p>
       Ethics approvals of two clinical trials were obtained from the Institutional Review Board and Human Research Ethics Committee of the Beijing Center for Disease Prevention and Control.
      </p>
     </sec>
     <sec id="irv12474-sec-0008">
      <label>
       2.2
      </label>
      <title>
       Patient involvement
      </title>
      <p>
       We did not involve patients and their families in the design and conduct of the study. We have acknowledged the support of participants, and the results will be published in open access journal.
      </p>
     </sec>
     <sec id="irv12474-sec-0009">
      <label>
       2.3
      </label>
      <title>
       Statistical analysis
      </title>
      <p>
       The data sets from the two trials were pooled incorporating the common variables. We calculated the attack rate (proportion of outcome) of each of the four outcomes by the study arms.
      </p>
      <p>
       We conducted a fixed effect individual patient data (IPD) meta‐analysis by fitting a multivariable log binomial model, using generalised estimating equation (GEE) to account for clustering by hospital/ward. We used a fitted fixed effect model because there are only two trials. Two studies were conducted in the same setting with similar participant characteristics, and they examined the same underlying effect. In the analysis, relative risk (RR) was estimated using the control arm as the referent category after adjusting for potential confounders and their interaction terms with a trial ID number. The overall rates of seasonal infection were higher in the second trial than the first. The consistency assumption (ie between study homogeneity) for the IPD meta‐analysis was tested by fitting an interaction term between trial ID and trial arms where a significant interaction is indicative of inconsistency.
       <xref ref-type="ref" rid="irv12474-bib-0013">
        13
       </xref>
       Any interaction term (between trial ID and covariates other than trial arm) that was not a confounder was subsequently excluded from the model using backward elimination approach. This approach is described in detailed elsewhere.
       <xref ref-type="ref" rid="irv12474-bib-0004">
        4
       </xref>
       We repeated the above‐described methods for each of the outcomes.
      </p>
     </sec>
    </sec>
    <sec id="irv12474-sec-0010">
     <label>
      3
     </label>
     <title>
      RESULTS
     </title>
     <p>
      After combining the data sets from the two trials, 3591 cases were entered into the pooled analysis (1064 cases in the medical mask arm, 516 cases in the targeted N95 arm, 1530 cases in the continuous N95 arm and 481 cases in the control arm). The infection outcomes are presented in Figure
      <xref ref-type="fig" rid="irv12474-fig-0001">
       1
      </xref>
      . The rates of laboratory‐confirmed viral respiratory infection (26/1530, 1.7%), laboratory‐confirmed bacterial colonisation (79/1530, 5.2%) and droplet‐transmitted infections (62/1530, 4.1%) were lowest among the continuous N95 arm. Laboratory‐confirmed influenza A and B was lowest in continuous N95 (6/1530, 0.4%) and targeted N95 arms (2/516, 0.4%).
     </p>
     <fig fig-type="Figure" id="irv12474-fig-0001" orientation="portrait" position="float" xml:lang="en">
      <label>
       Figure 1
      </label>
      <caption>
       <p>
        Rate of infections reported in
        <styled-content style="fixed-case">
         HCW
        </styled-content>
        s in the different arms from Trials 1 and 2
       </p>
      </caption>
      <graphic id="nlm-graphic-1" xlink:href="IRV-11-511-g001">
      </graphic>
     </fig>
     <p>
      In the IPD meta‐analysis, none of the interaction terms between trial arm and trial ID was significant for any of the outcome variables. Thus, the consistency assumption for the IPD meta‐analysis was satisfied. However, a significant interaction was observed between trial ID and hand washing for laboratory‐confirmed bacterial colonisation only; therefore, we estimated the RR for trial ID stratified by hand washing.
     </p>
     <p>
      Figure
      <xref ref-type="fig" rid="irv12474-fig-0002">
       2
      </xref>
      shows the forest plot of outcomes according to various interventions. All outcomes were consistently lower in the continuous N95 and targeted N95 arms. The IPD meta‐analysis shows that the risk of laboratory‐confirmed bacterial colonisation was lower in the continuous N95 arm (RR 0.33, 95% CI 0.21‐0.51 or 67% efficacy) and targeted N95 arm (RR 0.54, 95% CI 0.33‐0.87 or 46% efficacy) (Table
      <xref ref-type="table-wrap" rid="irv12474-tbl-0001">
       1
      </xref>
      ).
     </p>
     <fig fig-type="Figure" id="irv12474-fig-0002" orientation="portrait" position="float" xml:lang="en">
      <label>
       Figure 2
      </label>
      <caption>
       <p>
        Forest plot of outcomes according to various interventions
       </p>
      </caption>
      <graphic id="nlm-graphic-3" xlink:href="IRV-11-511-g002">
      </graphic>
     </fig>
     <table-wrap id="irv12474-tbl-0001" orientation="portrait" position="float" xml:lang="en">
      <label>
       Table 1
      </label>
      <caption>
       <p>
        Multivariable cluster adjusted log binomial model of laboratory‐confirmed bacterial colonisation
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <col span="1" style="border-right:solid 1px #000000"/>
       <col span="1" style="border-right:solid 1px #000000"/>
       <col span="1" style="border-right:solid 1px #000000"/>
       <thead valign="top">
        <tr style="border-bottom:solid 1px #000000">
         <th align="left" colspan="1" rowspan="1" valign="top">
          Variables in the model
         </th>
         <th align="center" colspan="1" rowspan="1" valign="top">
          Relative risk (95% CI)
         </th>
         <th align="center" colspan="1" rowspan="1" valign="top">
          <italic>
           P
          </italic>
          ‐value
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Continuous N95 arm
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          <bold>
           0.33 (0.21‐0.51)
          </bold>
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          <bold>
           &lt;.001
          </bold>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Targeted N95 arm
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          <bold>
           0.54 (0.33‐0.87)
          </bold>
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          <bold>
           .001
          </bold>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Medical mask arm
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          0.74 (0.48
          <bold>
           ‐
          </bold>
          1.13)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          .161
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Control arm
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          Ref
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          Ref
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Sex (Male)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          0.60 (0.42
          <bold>
           ‐
          </bold>
          0.85)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          .005
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Trial
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          2.53 (1.65
          <bold>
           ‐
          </bold>
          3.87)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          &lt;.001
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Influenza vaccine
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          1.13 (0.89
          <bold>
           ‐
          </bold>
          1.43)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          .308
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Trial * Hand wash
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          4.49 (3.12
          <bold>
           ‐
          </bold>
          6.48)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          &lt;.001
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn id="irv12474-note-0101">
        <p>
         Bold value indicates statistically significant results.
        </p>
       </fn>
      </table-wrap-foot>
      <permissions>
       <copyright-holder>
        John Wiley &amp; Sons, Ltd
       </copyright-holder>
      </permissions>
     </table-wrap>
     <p>
      Laboratory‐confirmed viral respiratory infections were significantly lower in the continuous N95 arm (RR 0.46, 95% CI 0.23‐0.91, or 54% efficacy). The rates of laboratory‐confirmed virus were also lower in the targeted N95 arm (RR 0.70, 95% CI 0.30‐1.67) and medical masks arm (RR 0.78, 95% CI 0.39‐1.56); however, the difference was not statistically significant (Table
      <xref ref-type="table-wrap" rid="irv12474-tbl-0002">
       2
      </xref>
      ).
     </p>
     <table-wrap id="irv12474-tbl-0002" orientation="portrait" position="float" xml:lang="en">
      <label>
       Table 2
      </label>
      <caption>
       <p>
        Multivariable cluster adjusted log binomial model of laboratory‐confirmed viral respiratory infection
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <col span="1" style="border-right:solid 1px #000000"/>
       <col span="1" style="border-right:solid 1px #000000"/>
       <col span="1" style="border-right:solid 1px #000000"/>
       <thead valign="top">
        <tr style="border-bottom:solid 1px #000000">
         <th align="left" colspan="1" rowspan="1" valign="top">
          Variables in the model
         </th>
         <th align="center" colspan="1" rowspan="1" valign="top">
          Relative risk (95% CI)
         </th>
         <th align="center" colspan="1" rowspan="1" valign="top">
          <italic>
           P
          </italic>
          ‐value
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Continuous N95 arm
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          <bold>
           0.46 (0.23‐0.91)
          </bold>
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          <bold>
           .026
          </bold>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Targeted N95 arm
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          0.70 (0.30‐1.67)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          .424
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Medical mask arm
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          0.78 (0.39‐1.56)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          .484
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Control arm
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          Ref
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          Ref
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Sex (Male)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          0.69 (0.36‐1.33)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          .272
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Hand washing
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          0.78 (0.51‐1.20)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          .264
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Influenza vaccine
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          0.94 (0.57‐1.55)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          .808
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Trial
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          1.50 (0.89‐2.54)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          .131
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn id="irv12474-note-0102">
        <p>
         Bold value indicates statistically significant results.
        </p>
       </fn>
      </table-wrap-foot>
      <permissions>
       <copyright-holder>
        John Wiley &amp; Sons, Ltd
       </copyright-holder>
      </permissions>
     </table-wrap>
     <p>
      Laboratory‐confirmed influenza was also lowest in continuous N95 arm (RR 0.34, 95% CI 0.10‐1.11) but not significant (Table
      <xref ref-type="table-wrap" rid="irv12474-tbl-0003">
       3
      </xref>
      ). In the subgroup analysis of droplet‐transmitted infections, compared to the control arm, the efficacy of continuous N95 respirators against droplet‐transmitted infections (bacterial and viral) was 74% (RR 0.26, 95% CI 0.16‐0.42) and 57% in the targeted N95 arm (RR 0.43, 95% CI 0.25‐0.72) (Table
      <xref ref-type="table-wrap" rid="irv12474-tbl-0004">
       4
      </xref>
      ).
     </p>
     <table-wrap id="irv12474-tbl-0003" orientation="portrait" position="float" xml:lang="en">
      <label>
       Table 3
      </label>
      <caption>
       <p>
        Multivariable cluster adjusted log binomial model of laboratory‐confirmed influenza A or B
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <col span="1" style="border-right:solid 1px #000000"/>
       <col span="1" style="border-right:solid 1px #000000"/>
       <col span="1" style="border-right:solid 1px #000000"/>
       <thead valign="top">
        <tr style="border-bottom:solid 1px #000000">
         <th align="left" colspan="1" rowspan="1" valign="top">
          Variables in the model
         </th>
         <th align="center" colspan="1" rowspan="1" valign="top">
          Relative risk (95% CI)
         </th>
         <th align="center" colspan="1" rowspan="1" valign="top">
          <italic>
           P
          </italic>
          ‐value
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Continuous N95 arm
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          0.34 (0.10‐1.11)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          .074
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Targeted N95 arm
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          0.46 (0.06‐3.40)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          .445
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Medical mask arm
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          0.55 (0.16‐1.91)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          .350
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Control arm
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          Ref
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          Ref
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Sex (Male)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          0.27 (0.03‐2.01)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          .220
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Hand washing
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          0.70 (0.29‐1.73)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          .446
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Influenza vaccine
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          0.78 (0.26‐2.34)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          .660
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Trial
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          0.64 (0.19‐2.18)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          .477
         </td>
        </tr>
       </tbody>
      </table>
      <permissions>
       <copyright-holder>
        John Wiley &amp; Sons, Ltd
       </copyright-holder>
      </permissions>
     </table-wrap>
     <table-wrap id="irv12474-tbl-0004" orientation="portrait" position="float" xml:lang="en">
      <label>
       Table 4
      </label>
      <caption>
       <p>
        Multivariable cluster adjusted log binomial model of droplet‐transmitted infections
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <col span="1" style="border-right:solid 1px #000000"/>
       <col span="1" style="border-right:solid 1px #000000"/>
       <col span="1" style="border-right:solid 1px #000000"/>
       <thead valign="top">
        <tr style="border-bottom:solid 1px #000000">
         <th align="left" colspan="1" rowspan="1" valign="top">
          Variables in the model
         </th>
         <th align="center" colspan="1" rowspan="1" valign="top">
          Relative risk (95% CI)
         </th>
         <th align="center" colspan="1" rowspan="1" valign="top">
          <italic>
           P
          </italic>
          ‐value
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Continuous N95 arm
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          <bold>
           0.26 (0.16‐0.42)
          </bold>
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          <bold>
           &lt;.001
          </bold>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Targeted N95 arm
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          <bold>
           0.43 (0.25‐0.72)
          </bold>
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          <bold>
           .001
          </bold>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Medical mask arm
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          0.65 (0.41‐1.04)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          .074
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Control arm
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          Ref
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          Ref
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Sex (Male)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          0.63 (0.43‐0.92)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          .016
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Hand washing
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          1.27 (0.99‐1.62)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          .068
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Influenza vaccine
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          1.16 (0.90‐1.50)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          .257
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Trial
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          3.97 (2.83‐5.59)
         </td>
         <td align="char" char="." colspan="1" rowspan="1">
          &lt;.001
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn id="irv12474-note-0104">
        <p>
         Bold value indicates statistically significant results.
        </p>
       </fn>
      </table-wrap-foot>
      <permissions>
       <copyright-holder>
        John Wiley &amp; Sons, Ltd
       </copyright-holder>
      </permissions>
     </table-wrap>
     <p>
      Inclusion of RSV cases in the droplet‐transmitted pathogen category did not change the risk ratio to a large extent. If RSV cases were also included in the droplet‐transmitted pathogen category, the efficacy was 70% in the continuous N95 (RR 0.30, 95% CI 0.19‐0.46) and 51% in the targeted N95 arms (RR 0.49, 95% CI 0.30‐0.80). The rate of droplet only transmitting viral infections was also lower in the continuous N95 and targeted N95 arms. HCWs who used a continuous N95 and targeted respirator were 85% (RR 0.15, 95% CI 0.04‐0. 59) and 84% (RR 0.12, 95% CI 0.02‐0.88) less likely to acquire droplet‐transmitted viral infections.
     </p>
     <p>
      When only the continuous N95 arm was compared against control, the risk of laboratory‐confirmed influenza was significantly lower in continuous N95 arm (RR 0.23 and 95% CI 0.06‐0.93, or 77% efficacy). In the similar analysis, the risk of influenza was also lower in medical mask arm compared to control; however, the difference was not statistically significant (RR 0.81 and 95% CI 0.25‐2.68) arm. Table
      <xref ref-type="table-wrap" rid="irv12474-tbl-0005">
       5
      </xref>
      compares the results of this analysis with the individual studies.
     </p>
     <table-wrap id="irv12474-tbl-0005" orientation="portrait" position="float" xml:lang="en">
      <label>
       Table 5
      </label>
      <caption>
       <p>
        Results of individual clinical trials and pooled analysis
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <col span="1" style="border-right:solid 1px #000000"/>
       <col span="1" style="border-right:solid 1px #000000"/>
       <col span="1" style="border-right:solid 1px #000000"/>
       <col span="1" style="border-right:solid 1px #000000"/>
       <col span="1" style="border-right:solid 1px #000000"/>
       <thead valign="top">
        <tr style="border-bottom:solid 1px #000000">
         <th align="left" colspan="1" rowspan="1" valign="top">
         </th>
         <th align="left" colspan="1" rowspan="1" valign="top">
          Arms
         </th>
         <th align="center" colspan="1" rowspan="1" valign="top">
          RCT 1 (OR/ RR)
         </th>
         <th align="center" colspan="1" rowspan="1" valign="top">
          RCT 2 (HR/ RR)
         </th>
         <th align="center" colspan="1" rowspan="1" valign="top">
          Pooled analysis
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="4">
          CRI
         </td>
         <td align="left" colspan="1" rowspan="1">
          Continuous N95
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          0.46 (0.19‐1.11)
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          <bold>
           0.39 (0.21‐0.71)
          </bold>
         </td>
         <td align="left" colspan="1" rowspan="1">
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Targeted N95
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          ‐
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          0.70 (0.39‐1.24)
         </td>
         <td align="left" colspan="1" rowspan="1">
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Medical masks
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          0.74 (0.29‐1.88)
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          Ref
         </td>
         <td align="left" colspan="1" rowspan="1">
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Control
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          Ref
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          ‐
         </td>
         <td align="left" colspan="1" rowspan="1">
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="4">
          Influenza like illness
         </td>
         <td align="left" colspan="1" rowspan="1">
          Continuous N95
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          0.26 (0.06‐1.11)
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          ‐
         </td>
         <td align="left" colspan="1" rowspan="1">
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Targeted N95
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          ‐
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          ‐
         </td>
         <td align="left" colspan="1" rowspan="1">
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Medical masks
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          0.49 (0.12‐2.07)
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          ‐
         </td>
         <td align="left" colspan="1" rowspan="1">
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Control
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          Ref
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          ‐
         </td>
         <td align="left" colspan="1" rowspan="1">
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="4">
          Laboratory‐confirmed viruses
         </td>
         <td align="left" colspan="1" rowspan="1">
          Continuous N95
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          <bold>
           0.43 (0.20‐0.91)
          </bold>
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          ‐
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          <bold>
           0.46 (0.23‐0.91)
          </bold>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Targeted N95
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          ‐
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          ‐
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          0.70 (0.30‐1.67)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Medical masks
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          0.84 (0.38‐1.85)
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          ‐
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          0.78 (0.39‐1.56)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Control
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          Ref
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          ‐
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          Ref
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="4">
          Laboratory‐confirmed influenza
         </td>
         <td align="left" colspan="1" rowspan="1">
          Continuous N95
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          0.25 (0.06‐1.00)
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          ‐
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          0.34 (0.10‐1.11)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Targeted N95
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          ‐
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          ‐
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          0.46 (0.06‐3.40)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Medical masks
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          0.81 (0.25‐2.68)
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          ‐
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          0.55 (0.16‐1.91)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Control
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          Ref
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          ‐
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          Ref
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="4">
          Laboratory‐confirmed bacterial colonisation
         </td>
         <td align="left" colspan="1" rowspan="1">
          Continuous N95
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          <bold>
           0.34 (0.21‐0.56)
          </bold>
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          <bold>
           0.40 (0.21‐0.73)
          </bold>
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          <bold>
           0.33 (0.21‐0.51)
          </bold>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Targeted N95
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          ‐
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          0.70 (0.40‐1.24)
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          <bold>
           0.54 (0.33‐0.87)
          </bold>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Medical masks
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          0.67 (0.38‐1.18)
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          Ref
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          0.74 (0.48‐1.13)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Control
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          Ref
         </td>
         <td align="left" colspan="1" rowspan="1">
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          Ref
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="4">
          Droplet‐transmitted infections
         </td>
         <td align="left" colspan="1" rowspan="1">
          Continuous N95
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          ‐
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          ‐
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          <bold>
           0.26 (0.16‐0.42)
          </bold>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Targeted N95
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          ‐
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          ‐
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          <bold>
           0.43 (0.25‐0.72)
          </bold>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Medical masks
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          ‐
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          ‐
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          0.65 (0.41‐1.04)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Control
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          ‐
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          ‐
         </td>
         <td align="char" char=" " colspan="1" rowspan="1">
          Ref
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn id="irv12474-note-0001">
        <p>
         Bold value indicates statistically significant results.
        </p>
       </fn>
      </table-wrap-foot>
      <permissions>
       <copyright-holder>
        John Wiley &amp; Sons, Ltd
       </copyright-holder>
      </permissions>
     </table-wrap>
    </sec>
    <sec id="irv12474-sec-0011">
     <label>
      4
     </label>
     <title>
      DISCUSSION
     </title>
     <p>
      We demonstrated superior clinical efficacy of continuous use of N95 respirator (also known as “airborne precautions”) against infections presumed to be spread by the droplet mode, including influenza. This suggests that transmission is more complex than assumed by traditional classifications, and supports the fact that both large and small droplets are present close to the patient, and that aerosol transmission may occur for presumed “droplet” infections. Respirators are designed to provide respiratory protection through filtration and fit, and properly fitted respirators provide better protection compared to medical masks.
      <xref ref-type="ref" rid="irv12474-bib-0003">
       3
      </xref>
      ,
      <xref ref-type="ref" rid="irv12474-bib-0004">
       4
      </xref>
      We could not demonstrate efficacy of medical masks against any outcome, but the non‐significant trend appeared to be towards protection. Medical masks may well have efficacy,
      <xref ref-type="ref" rid="irv12474-bib-0005">
       5
      </xref>
      but if so, the degree of efficacy was too small to detect in this study, and larger studies are needed, given the widespread use of these devices in health care.
     </p>
     <p>
      The practical implication of this research is illustrated with influenza as a case in point. Droplet and contact are thought to be primary modes of transmission for seasonal influenza; therefore, the World Health Organisation (WHO) and the Centers for Disease Control and Prevention (CDC) guidelines recommend medical masks during routine patient care, while N95 respirators are recommended during procedures in which aerosols may be generated and during other high‐risk situations.
      <xref ref-type="ref" rid="irv12474-bib-0014">
       14
      </xref>
      ,
      <xref ref-type="ref" rid="irv12474-bib-0015">
       15
      </xref>
      However, there is increasing evidence of aerosol transmission of influenza during routine care as well (in the absence of aerosol generating procedures), which may warrant superior respiratory protection.
      <xref ref-type="ref" rid="irv12474-bib-0016">
       16
      </xref>
      ,
      <xref ref-type="ref" rid="irv12474-bib-0017">
       17
      </xref>
      Influenza research is challenging because there is high seasonal variation in activity, and the level of circulating influenza in any given year cannot be predicted when planning RCTs. In addition, a diagnosis of influenza requires the detection of virus from respiratory specimens, or a fourfold rise in serological titres, both of which are highly resource‐intensive and depend on daily subject follow‐up and on optimal timing of specimen collection. For all these reasons, the published studies to date have been unable to determine whether there is a difference in efficacy against influenza infection between medical masks and N95 respirators. This study can therefore usefully inform policies for prevention of influenza.
     </p>
     <p>
      In the first RCT, compared to medical masks, N95 respirators were found to be protective against CRI, but not against ILI or laboratory‐confirmed influenza.
      <xref ref-type="ref" rid="irv12474-bib-0003">
       3
      </xref>
      When compared with the control arm, rates of laboratory‐confirmed virus and bacterial colonisation were significantly lower in N95 arm (Table
      <xref ref-type="table-wrap" rid="irv12474-tbl-0005">
       5
      </xref>
      ). In the second RCT, continuous use of N95 respirators was associated with lower rates of CRI and laboratory‐confirmed bacterial colonisation compared to the medical mask use.
      <xref ref-type="ref" rid="irv12474-bib-0004">
       4
      </xref>
      Pooled analysis of these studies improved the power to analyse other infectious outcomes by intervention and to allow analysis by mode of transmission.
     </p>
     <p>
      An important finding of this analysis was the efficacy of N95 respirators against droplet‐transmitted infections. Generally, medical masks are considered sufficient for droplet‐transmitted infections such as influenza.
      <xref ref-type="ref" rid="irv12474-bib-0018">
       18
      </xref>
      However, this study has demonstrated a clear benefit of using N95 respirators (both continuous and targeted) to protect HCWs against droplet infections and does not show significant protection of medical masks. In the light of these findings, it may be prudent to use respirators when the transmission mode of a disease is unknown or when HCWs exposed to droplet‐transmitted infections with a high‐case fatality rate.
      <xref ref-type="ref" rid="irv12474-bib-0006">
       6
      </xref>
      Middle East respiratory syndrome coronavirus (MERS‐CoV) and Ebola virus disease (EVD) are not airborne infections, yet the CDC recommendation of using respirators to protect HCWs recognises the uncertainty around transmission.
      <xref ref-type="ref" rid="irv12474-bib-0019">
       19
      </xref>
      ,
      <xref ref-type="ref" rid="irv12474-bib-0020">
       20
      </xref>
      The CDC initially recommended medical masks for Ebola, but changed their guidelines when US HCWs became infected, amidst unrest and challenges to the prior guidelines.
      <xref ref-type="ref" rid="irv12474-bib-0006">
       6
      </xref>
      ,
      <xref ref-type="ref" rid="irv12474-bib-0021">
       21
      </xref>
      In contrast, the WHO recommends medical masks for MERS‐CoV and Ebola
      <xref ref-type="ref" rid="irv12474-bib-0022">
       22
      </xref>
      ,
      <xref ref-type="ref" rid="irv12474-bib-0023">
       23
      </xref>
      despite having older guidelines for filoviruses which recommended respirators.
      <xref ref-type="ref" rid="irv12474-bib-0024">
       24
      </xref>
      There is a need for a more evidence‐based approach to updating guidelines and ensuring consistency between different guidelines.
      <xref ref-type="ref" rid="irv12474-bib-0025">
       25
      </xref>
     </p>
     <p>
      Our study also demonstrated that, over and above the benefit of continuous use, targeted use of N95 is associated with reduced risk of infection. Many guidelines recommend targeted use,
      <xref ref-type="ref" rid="irv12474-bib-0014">
       14
      </xref>
      ,
      <xref ref-type="ref" rid="irv12474-bib-0015">
       15
      </xref>
      ,
      <xref ref-type="ref" rid="irv12474-bib-0026">
       26
      </xref>
      and our study supports this practice. However, better protection is achieved through continuous use of respirators. This may be because HCWs cannot always identify situations in which they are at risk, especially in busy clinical settings with a high level of movement of patients and staff in and out of wards.
     </p>
     <p>
      This study has some limitations. Firstly, the reporting of the results included in Figure
      <xref ref-type="fig" rid="irv12474-fig-0001">
       1
      </xref>
      is different from the IPD meta‐analysis results. This is due to the uneven distribution of randomisation arms and differing seasonal attack rates between the trials. In Figure
      <xref ref-type="fig" rid="irv12474-fig-0001">
       1
      </xref>
      , these between‐trial differences were not taken into account. The IPD meta‐analysis takes into account of these and gives an unbiased association. Secondly, the control arm in trial 1 was not randomised; however, the risk of bias is less due to similar study setting, outcome measures and participant characteristics. Moreover, whether infection was acquired in the community or the hospital cannot be determined, but the RCT design should result in community exposure being distributed equally across all arms. Finally, we categorised pathogens according to various transmission modes, while certain viruses are transmitted via multiple routes. The pooled data were suggestive of an effect of respirators against influenza, but probably did not have enough statistical power for this outcome. The major strength of this study is the use of the same endpoints, measurements and methods in the two trials, which allowed valid pooling of the data.
     </p>
    </sec>
    <sec id="irv12474-sec-0012">
     <label>
      5
     </label>
     <title>
      CONCLUSION
     </title>
     <p>
      It is a long‐held belief in hospital infection control that a mask is adequate for droplet‐transmitted infections. We showed that the use of respirators provides better protection against respiratory infections, even those presumed to be spread predominantly by the droplet mode. The targeted use of a respirator was also effective, whereas no efficacy was demonstrated for medical masks alone. However, the trends suggest some degree of protection from medical masks, and larger studies are required to measure the efficacy of these devices. The superiority of respirators should be reflected in infection control guidelines to ensure the occupational health and safety of HCWs. A growing body of clinical efficacy evidence, including this study, challenges long‐held paradigms about the transmission of infection.
     </p>
    </sec>
    <sec id="irv12474-sec-0013">
     <label>
      6
     </label>
     <title>
      SUMMARY OF KEY POINTS
     </title>
     <p>
      <list id="irv12474-list-0001" list-type="order">
       <list-item>
        <p>
         The data collected during two similar clinical trials conducted in Beijing, China, which examined the same infection outcomes, were pooled
        </p>
       </list-item>
       <list-item>
        <p>
         We showed that respirators provide superior protection against droplet‐transmitted infections, for which most guidelines recommend masks. These findings challenge the paradigm of infection transmission being simplified to droplet, airborne or contact.
        </p>
       </list-item>
       <list-item>
        <p>
         For many infections, more than one mode of transmission is possible, and our data suggest that transmission of infections is more complex than suggested by these paradigms.
        </p>
       </list-item>
       <list-item>
        <p>
         Clinical efficacy data are a higher level of evidence than theoretical paradigms of transmission, and show better protection afforded by respirators.
        </p>
       </list-item>
      </list>
     </p>
    </sec>
    <sec id="irv12474-sec-0015">
     <title>
      COMPETING INTERESTS
     </title>
     <p>
      All authors have completed the Unified Competing Interest form (available on request from the corresponding author) and declare that; (i) Professor C. Raina MacIntyre: Raina MacIntyre has held an Australian Research Council Linkage Grant with 3M as the industry partner, for investigator‐driven research. 3M have also contributed supplies of masks and respirators for investigator‐driven clinical trials. She has received research grants and laboratory testing as in‐kind support from Pfizer, GSK and Bio‐CSL for investigator‐driven research; (ii) Dr Holly Seale had a NHMRC Australian based Public Health Training Fellowship at the time of the study (1012631). She has also received funding from vaccine manufacturers GSK, bio‐CSL and Saniofi Pasteur for investigator‐driven research and presentations, and (iii) Dr. Abrar Chughtai had testing of filtration of masks by 3M for PhD. The remaining authors declare that they have no competing interests and have no non‐financial interests that may be relevant to the submitted work.
     </p>
    </sec>
    <sec id="irv12474-sec-0016">
     <title>
      AUTHORS’ CONTRIBUTIONS
     </title>
     <p>
      CRM performed the lead investigator, conception and design of the study, analysing the data and manuscript writing; AAC involved in the statistical analysis and drafting of manuscript; BR performed the contribution to the statistical analysis and revision of manuscript; YP, YZ, HS and XW performed the data management and revision of manuscript; QW performed the contribution to design, analysis and revision of study. All authors have read and approved the final version of the manuscript and ensure that this is the case.
     </p>
    </sec>
    <sec id="irv12474-sec-0017">
     <title>
      TRIAL REGISTRATION
     </title>
     <p>
      This is pooled analysis of two clinical trials.
     </p>
     <p>
      <list id="irv12474-list-0002" list-type="order">
       <list-item>
        <p>
         First clinical trial—Clinical trial registered with Australian New Zealand Clinical Trials Registry (ANZCTR) (
         <ext-link ext-link-type="uri" xlink:href="http://www.anzctr.org.au">
          http://www.anzctr.org.au
         </ext-link>
         ), registration number ACTRN 12609000257268, registered on 13/05/2009.
        </p>
       </list-item>
       <list-item>
        <p>
         Second clinical trial—Clinical trial registered with Australian New Zealand Clinical Trials Registry (ANZCTR) (
         <ext-link ext-link-type="uri" xlink:href="http://www.anzctr.org.au">
          http://www.anzctr.org.au
         </ext-link>
         ), registration number ACTRN 12609000778280, registered on 8/09/2009.
        </p>
       </list-item>
      </list>
     </p>
    </sec>
    <sec sec-type="supplementary-material">
     <title>
      Supporting information
     </title>
     <supplementary-material content-type="local-data" id="irv12474-sup-0001">
      <caption>
       <p>
       </p>
      </caption>
      <media xlink:href="IRV-11-511-s001.docx">
       <caption>
        <p>
         Click here for additional data file.
        </p>
       </caption>
      </media>
     </supplementary-material>
    </sec>
    <back>
     <ack id="irv12474-sec-0014">
      <title>
       ACKNOWLEDGEMENTS
      </title>
      <p>
       Thanks to the staff at the Beijing Centre for Disease Control and hospitals staff in both trials. Thanks to Australian National Health &amp; Medical Research Council of Australia (Grant # 630787). We acknowledge the guidance and support of 3M China for fit testing during China 1 trial and supplies of masks/respirators during China Trial 2 due to shortage during the 2009 influenza pandemic.
      </p>
     </ack>
     <ref-list content-type="cited-references" id="irv12474-bibl-0001">
      <title>
       REFERENCES
      </title>
      <ref id="irv12474-bib-0001">
       <label>
        1
       </label>
       <mixed-citation id="irv12474-cit-0001" publication-type="journal">
        <string-name>
         <surname>
          Jacobs
         </surname>
         <given-names>
          JL
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ohde
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Takahashi
         </surname>
         <given-names>
          O
         </given-names>
        </string-name>
        , et al.
        <article-title>
         Use of surgical face masks to reduce the incidence of the common cold among health care workers in Japan: a randomized controlled trial
        </article-title>
        .
        <source>
         Am J Infect Control
        </source>
        .
        <year>
         2009
        </year>
        ;
        <volume>
         37
        </volume>
        :
        <fpage>
         417
        </fpage>
        ‐
        <lpage>
         419
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19216002
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="irv12474-bib-0002">
       <label>
        2
       </label>
       <mixed-citation id="irv12474-cit-0002" publication-type="journal">
        <string-name>
         <surname>
          Loeb
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Dafoe
         </surname>
         <given-names>
          N
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Mahony
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        , et al.
        <article-title>
         Surgical mask vs N95 respirator for preventing influenza among health care workers: a randomized trial
        </article-title>
        .
        <source>
         JAMA
        </source>
        .
        <year>
         2009
        </year>
        ;
        <volume>
         302
        </volume>
        :
        <fpage>
         1865
        </fpage>
        ‐
        <lpage>
         1871
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19797474
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="irv12474-bib-0003">
       <label>
        3
       </label>
       <mixed-citation id="irv12474-cit-0003" publication-type="journal">
        <string-name>
         <surname>
          MacIntyre
         </surname>
         <given-names>
          CR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wang
         </surname>
         <given-names>
          Q
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cauchemez
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        , et al.
        <article-title>
         A cluster randomized clinical trial comparing fit‐tested and non‐fit‐tested N95 respirators to medical masks to prevent respiratory virus infection in health care workers
        </article-title>
        .
        <source>
         Influenza Other Respir Viruses
        </source>
        .
        <year>
         2011
        </year>
        ;
        <volume>
         5
        </volume>
        :
        <fpage>
         170
        </fpage>
        ‐
        <lpage>
         179
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         21477136
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="irv12474-bib-0004">
       <label>
        4
       </label>
       <mixed-citation id="irv12474-cit-0004" publication-type="journal">
        <string-name>
         <surname>
          MacIntyre
         </surname>
         <given-names>
          CR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wang
         </surname>
         <given-names>
          Q
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Seale
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        , et al.
        <article-title>
         A randomized clinical trial of three options for N95 respirators and medical masks in health workers
        </article-title>
        .
        <source>
         Am J Respir Crit Care Med
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         187
        </volume>
        :
        <fpage>
         960
        </fpage>
        ‐
        <lpage>
         966
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23413265
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="irv12474-bib-0005">
       <label>
        5
       </label>
       <mixed-citation id="irv12474-cit-0005" publication-type="journal">
        <string-name>
         <surname>
          MacIntyre
         </surname>
         <given-names>
          CR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Seale
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Dung
         </surname>
         <given-names>
          TC
         </given-names>
        </string-name>
        , et al.
        <article-title>
         A cluster randomised trial of cloth masks compared with medical masks in healthcare workers
        </article-title>
        .
        <source>
         BMJ Open
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         1
        </fpage>
        ‐
        <lpage>
         10
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="irv12474-bib-0006">
       <label>
        6
       </label>
       <mixed-citation id="irv12474-cit-0006" publication-type="journal">
        <string-name>
         <surname>
          MacIntyre
         </surname>
         <given-names>
          CR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chughtai
         </surname>
         <given-names>
          AA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Seale
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        , et al.
        <article-title>
         Respiratory protection for healthcare workers treating Ebola virus disease (EVD): are facemasks sufficient to meet occupational health and safety obligations?
        </article-title>
        <source>
         Int J Nurs Stud
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         51
        </volume>
        :
        <fpage>
         1421
        </fpage>
        ‐
        <lpage>
         1426
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25218265
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="irv12474-bib-0007">
       <label>
        7
       </label>
       <mixed-citation id="irv12474-cit-0007" publication-type="journal">
        <string-name>
         <surname>
          Wells
         </surname>
         <given-names>
          WF
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Winslow
         </surname>
         <given-names>
          CE
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Robertson
         </surname>
         <given-names>
          EC
         </given-names>
        </string-name>
        .
        <article-title>
         Bacteriologic procedures in the evaluation of methods for control of air‐borne infection
        </article-title>
        .
        <source>
         Am J Public Health Nation's Health
        </source>
        .
        <year>
         1946
        </year>
        ;
        <volume>
         36
        </volume>
        :
        <fpage>
         324
        </fpage>
        ‐
        <lpage>
         331
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="irv12474-bib-0008">
       <label>
        8
       </label>
       <mixed-citation id="irv12474-cit-0008" publication-type="journal">
        <string-name>
         <surname>
          Osterholm
         </surname>
         <given-names>
          MT
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Moore
         </surname>
         <given-names>
          KA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kelley
         </surname>
         <given-names>
          NS
         </given-names>
        </string-name>
        , et al.
        <article-title>
         Transmission of ebola viruses: what we know and what we do not know
        </article-title>
        .
        <source>
         MBio
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <fpage>
         e00137
        </fpage>
        ‐
        <lpage>
         15
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25698835
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="irv12474-bib-0009">
       <label>
        9
       </label>
       <mixed-citation id="irv12474-cit-0009" publication-type="miscellaneous">
        <string-name>
         <surname>
          Brosseau
         </surname>
         <given-names>
          LM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Jones
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        .
        <article-title>
         Health workers need optimal respiratory protection for Ebola
        </article-title>
        . The Center for Infectious Disease Research and Policy (CIDRAP) 2014.
        <ext-link ext-link-type="uri" xlink:href="http://www.cidrap.umn.edu/news-perspective/2014/09/commentary-health-workers-need-optimal-respiratory-protection-ebola">
         http://www.cidrap.umn.edu/news-perspective/2014/09/commentary-health-workers-need-optimal-respiratory-protection-ebola
        </ext-link>
        . Accessed September 29, 2014.
       </mixed-citation>
      </ref>
      <ref id="irv12474-bib-0010">
       <label>
        10
       </label>
       <mixed-citation id="irv12474-cit-0010" publication-type="miscellaneous">
        <collab collab-type="authors">
         Public Health Agency of Canada
        </collab>
        .
        <article-title>
         Pathogen Safety Data Sheets and Risk Assessment
        </article-title>
        .
        <ext-link ext-link-type="uri" xlink:href="http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/index-eng.php">
         http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/index-eng.php
        </ext-link>
        . Accessed November 10, 2014.
       </mixed-citation>
      </ref>
      <ref id="irv12474-bib-0011">
       <label>
        11
       </label>
       <mixed-citation id="irv12474-cit-0011" publication-type="miscellaneous">
        <collab collab-type="authors">
         Center for Disease Control and Prevention (CDC)
        </collab>
        .
        <article-title>
         Respiratory Syncytial Virus Infection (RSV): Transmission and Prevention
        </article-title>
        .
        <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/rsv/about/transmission.html">
         http://www.cdc.gov/rsv/about/transmission.html
        </ext-link>
        . Accessed November 10, 2014.
       </mixed-citation>
      </ref>
      <ref id="irv12474-bib-0012">
       <label>
        12
       </label>
       <mixed-citation id="irv12474-cit-0012" publication-type="miscellaneous">
        <collab collab-type="authors">
         Public Health Agency of Canada
        </collab>
        .
        <article-title>
         Respiratory syncytial virus
        </article-title>
        .
        <ext-link ext-link-type="uri" xlink:href="http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/pneumovirus-eng.php">
         http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/pneumovirus-eng.php
        </ext-link>
        . Accessed November 4, 2014.
       </mixed-citation>
      </ref>
      <ref id="irv12474-bib-0013">
       <label>
        13
       </label>
       <mixed-citation id="irv12474-cit-0013" publication-type="journal">
        <string-name>
         <surname>
          Salanti
         </surname>
         <given-names>
          G
         </given-names>
        </string-name>
        .
        <article-title>
         Indirect and mixed‐treatment comparison, network, or multiple‐treatments meta‐analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool
        </article-title>
        .
        <source>
         Res Synth Methods
        </source>
        .
        <year>
         2012
        </year>
        ;
        <volume>
         3
        </volume>
        :
        <fpage>
         80
        </fpage>
        ‐
        <lpage>
         97
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26062083
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="irv12474-bib-0014">
       <label>
        14
       </label>
       <mixed-citation id="irv12474-cit-0014" publication-type="miscellaneous">
        <collab collab-type="authors">
         Center for Disease Control and Prevention (CDC)
        </collab>
        .
        <article-title>
         Prevention Strategies for Seasonal Influenza in Healthcare Settings
        </article-title>
        .
        <year>
         2014
        </year>
        <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/flu/professionals/infectioncontrol/healthcaresettings.htm">
         http://www.cdc.gov/flu/professionals/infectioncontrol/healthcaresettings.htm
        </ext-link>
        . Accessed August 19, 2014.
       </mixed-citation>
      </ref>
      <ref id="irv12474-bib-0015">
       <label>
        15
       </label>
       <mixed-citation id="irv12474-cit-0015" publication-type="miscellaneous">
        <collab collab-type="authors">
         World Health Organization (WHO)
        </collab>
        .
        <article-title>
         Infection prevention and control of epidemic‐ and pandemic‐prone acute respiratory infections in health care
        </article-title>
        .
        <year>
         2014
        </year>
        .
       </mixed-citation>
      </ref>
      <ref id="irv12474-bib-0016">
       <label>
        16
       </label>
       <mixed-citation id="irv12474-cit-0016" publication-type="journal">
        <string-name>
         <surname>
          Bischoff
         </surname>
         <given-names>
          WE
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Swett
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Leng
         </surname>
         <given-names>
          I
         </given-names>
        </string-name>
        , et al.
        <article-title>
         Exposure to influenza virus aerosols during routine patient care
        </article-title>
        .
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         207
        </volume>
        :
        <fpage>
         1037
        </fpage>
        ‐
        <lpage>
         1046
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23372182
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="irv12474-bib-0017">
       <label>
        17
       </label>
       <mixed-citation id="irv12474-cit-0017" publication-type="journal">
        <string-name>
         <surname>
          Lindsley
         </surname>
         <given-names>
          WG
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Blachere
         </surname>
         <given-names>
          FM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Thewlis
         </surname>
         <given-names>
          RE
         </given-names>
        </string-name>
        , et al.
        <article-title>
         Measurements of airborne influenza virus in aerosol particles from human coughs
        </article-title>
        .
        <source>
         PLoS ONE
        </source>
        .
        <year>
         2010
        </year>
        ;
        <volume>
         5
        </volume>
        :
        <fpage>
         e15100
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         21152051
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="irv12474-bib-0018">
       <label>
        18
       </label>
       <mixed-citation id="irv12474-cit-0018" publication-type="journal">
        <string-name>
         <surname>
          Siegel
         </surname>
         <given-names>
          JD
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rhinehart
         </surname>
         <given-names>
          E
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Jackson
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        , et al.
        <article-title>
         2007 Guideline for Isolation Precautions: preventing Transmission of Infectious Agents in Health Care Settings
        </article-title>
        .
        <source>
         Am J Infect Control
        </source>
        .
        <year>
         2007
        </year>
        ;
        <volume>
         35
        </volume>
        (
        <issue>
         10 Suppl 2
        </issue>
        ):
        <fpage>
         S65
        </fpage>
        ‐
        <lpage>
         S164
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18068815
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="irv12474-bib-0019">
       <label>
        19
       </label>
       <mixed-citation id="irv12474-cit-0019" publication-type="miscellaneous">
        <collab collab-type="authors">
         Center for Disease Control and Prevention (CDC)
        </collab>
        .
        <article-title>
         Guidance on personal protective equipment to be used by healthcare workers during management of patients with Ebola Virus Disease in U.S. Hospitals, including procedures for putting on (Donning) and removing (Doffing) 2014
        </article-title>
        .
        <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/vhf/ebola/hcp/procedures-for-ppe.html">
         http://www.cdc.gov/vhf/ebola/hcp/procedures-for-ppe.html
        </ext-link>
        . Accessed October 23, 2014.
       </mixed-citation>
      </ref>
      <ref id="irv12474-bib-0020">
       <label>
        20
       </label>
       <mixed-citation id="irv12474-cit-0020" publication-type="miscellaneous">
        <collab collab-type="authors">
         Center for Disease Control and Prevention (CDC)
        </collab>
        .
        <article-title>
         Interim infection prevention and control recommendations for hospitalized patients with Middle East respiratory syndrome CoronaVirus (MERS‐CoV) 2014
        </article-title>
        .
        <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/coronavirus/mers/infection-prevention-control.html">
         http://www.cdc.gov/coronavirus/mers/infection-prevention-control.html
        </ext-link>
        . Accessed September 27, 2014.
       </mixed-citation>
      </ref>
      <ref id="irv12474-bib-0021">
       <label>
        21
       </label>
       <mixed-citation id="irv12474-cit-0021" publication-type="journal">
        <string-name>
         <surname>
          MacIntyre
         </surname>
         <given-names>
          CR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chughtai
         </surname>
         <given-names>
          AA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Seale
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        , et al.
        <article-title>
         Uncertainty, risk analysis and change for Ebola personal protective equipment guidelines
        </article-title>
        .
        <source>
         Int J Nurs Stud
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         52
        </volume>
        :
        <fpage>
         899
        </fpage>
        ‐
        <lpage>
         903
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25575750
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="irv12474-bib-0022">
       <label>
        22
       </label>
       <mixed-citation id="irv12474-cit-0022" publication-type="miscellaneous">
        <collab collab-type="authors">
         World Health Organization (WHO)
        </collab>
        .
        <article-title>
         Ebola and Marburg virus disease epidemics: preparedness, alert, control, and evaluation
        </article-title>
        .
        <year>
         2014
        </year>
        .
       </mixed-citation>
      </ref>
      <ref id="irv12474-bib-0023">
       <label>
        23
       </label>
       <mixed-citation id="irv12474-cit-0023" publication-type="miscellaneous">
        <collab collab-type="authors">
         World Health Organisation (WHO)
        </collab>
        .
        <article-title>
         Infection prevention and control during health care for probable or confirmed cases of novel coronavirus (nCoV) infection
        </article-title>
        .
       </mixed-citation>
      </ref>
      <ref id="irv12474-bib-0024">
       <label>
        24
       </label>
       <mixed-citation id="irv12474-cit-0024" publication-type="miscellaneous">
        <collab collab-type="authors">
         Centers for Disease Control and Prevention and World Health Organization
        </collab>
        .
        <article-title>
         Infection control for viral haemorrhagic fevers in the African health care setting
        </article-title>
        . Atlanta, Centers for Disease Control and Prevention.
        <year>
         1998
        </year>
        ;1-198.
       </mixed-citation>
      </ref>
      <ref id="irv12474-bib-0025">
       <label>
        25
       </label>
       <mixed-citation id="irv12474-cit-0025" publication-type="journal">
        <string-name>
         <surname>
          MacIntyre
         </surname>
         <given-names>
          CR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chughtai
         </surname>
         <given-names>
          AA
         </given-names>
        </string-name>
        .
        <article-title>
         Facemasks for the prevention of infection in healthcare and community settings
        </article-title>
        .
        <source>
         BMJ
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         350
        </volume>
        :
        <fpage>
         h694
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         25858901
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="irv12474-bib-0026">
       <label>
        26
       </label>
       <mixed-citation id="irv12474-cit-0026" publication-type="journal">
        <string-name>
         <surname>
          Chughtai
         </surname>
         <given-names>
          AA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Seale
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          MacIntyre
         </surname>
         <given-names>
          CR
         </given-names>
        </string-name>
        .
        <article-title>
         Availability, consistency and evidence‐base of policies and guidelines on the use of mask and respirator to protect hospital health care workers: a global analysis
        </article-title>
        .
        <source>
         BMC Res Notes
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <fpage>
         216
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         23725338
        </pub-id>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       JAMA
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       JAMA
      </journal-id>
      <journal-id journal-id-type="pmc">
       JAMA
      </journal-id>
      <journal-title-group>
       <journal-title>
        JAMA
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0098-7484
      </issn>
      <issn pub-type="epub">
       1538-3598
      </issn>
      <publisher>
       <publisher-name>
        American Medical Association
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       31479137
      </article-id>
      <article-id pub-id-type="pmc">
       6724169
      </article-id>
      <article-id pub-id-type="doi">
       10.1001/jama.2019.11645
      </article-id>
      <article-id pub-id-type="publisher-id">
       joi190087
      </article-id>
      <article-categories>
       <subj-group specific-use="electronic" subj-group-type="category">
        <subject>
         Research
        </subject>
       </subj-group>
       <subj-group specific-use="print" subj-group-type="domain">
        <subject>
         Research
        </subject>
       </subj-group>
       <subj-group subj-group-type="heading">
        <subject>
         Original Investigation
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        N95 Respirators vs Medical Masks for Preventing Influenza Among Health Care Personnel
       </article-title>
       <subtitle>
        A Randomized Clinical Trial
       </subtitle>
       <alt-title alt-title-type="headline">
        N95 Respirators vs Medical Masks for Preventing Laboratory-Confirmed Influenza in Health Care Personnel
       </alt-title>
       <alt-title alt-title-type="running-head">
        N95 Respirators vs Medical Masks for Preventing Laboratory-Confirmed Influenza in Health Care Personnel
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Radonovich
         </surname>
         <given-names>
          Lewis J.
         </given-names>
         <suffix>
          Jr
         </suffix>
        </name>
        <degrees>
         MD
        </degrees>
        <xref ref-type="aff" rid="joi190087aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Simberkoff
         </surname>
         <given-names>
          Michael S.
         </given-names>
        </name>
        <degrees>
         MD
        </degrees>
        <xref ref-type="aff" rid="joi190087aff2">
         2
        </xref>
        <xref ref-type="aff" rid="joi190087aff3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Bessesen
         </surname>
         <given-names>
          Mary T.
         </given-names>
        </name>
        <degrees>
         MD
        </degrees>
        <xref ref-type="aff" rid="joi190087aff4">
         4
        </xref>
        <xref ref-type="aff" rid="joi190087aff5">
         5
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Brown
         </surname>
         <given-names>
          Alexandria C.
         </given-names>
        </name>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="joi190087aff6">
         6
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Cummings
         </surname>
         <given-names>
          Derek A. T.
         </given-names>
        </name>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="joi190087aff7">
         7
        </xref>
        <xref ref-type="aff" rid="joi190087aff8">
         8
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Gaydos
         </surname>
         <given-names>
          Charlotte A.
         </given-names>
        </name>
        <degrees>
         MD
        </degrees>
        <xref ref-type="aff" rid="joi190087aff9">
         9
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Los
         </surname>
         <given-names>
          Jenna G.
         </given-names>
        </name>
        <degrees>
         MLA
        </degrees>
        <xref ref-type="aff" rid="joi190087aff9">
         9
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Krosche
         </surname>
         <given-names>
          Amanda E.
         </given-names>
        </name>
        <degrees>
         BS
        </degrees>
        <xref ref-type="aff" rid="joi190087aff9">
         9
        </xref>
        <xref ref-type="aff" rid="joi190087aff10">
         10
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Gibert
         </surname>
         <given-names>
          Cynthia L.
         </given-names>
        </name>
        <degrees>
         MD
        </degrees>
        <xref ref-type="aff" rid="joi190087aff11">
         11
        </xref>
        <xref ref-type="aff" rid="joi190087aff12">
         12
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Gorse
         </surname>
         <given-names>
          Geoffrey J.
         </given-names>
        </name>
        <degrees>
         MD
        </degrees>
        <xref ref-type="aff" rid="joi190087aff13">
         13
        </xref>
        <xref ref-type="aff" rid="joi190087aff14">
         14
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Nyquist
         </surname>
         <given-names>
          Ann-Christine
         </given-names>
        </name>
        <degrees>
         MD
        </degrees>
        <xref ref-type="aff" rid="joi190087aff5">
         5
        </xref>
        <xref ref-type="aff" rid="joi190087aff15">
         15
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Reich
         </surname>
         <given-names>
          Nicholas G.
         </given-names>
        </name>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="joi190087aff6">
         6
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Rodriguez-Barradas
         </surname>
         <given-names>
          Maria C.
         </given-names>
        </name>
        <degrees>
         MD
        </degrees>
        <xref ref-type="aff" rid="joi190087aff16">
         16
        </xref>
        <xref ref-type="aff" rid="joi190087aff17">
         17
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Price
         </surname>
         <given-names>
          Connie Savor
         </given-names>
        </name>
        <degrees>
         MD
        </degrees>
        <xref ref-type="aff" rid="joi190087aff5">
         5
        </xref>
        <xref ref-type="aff" rid="joi190087aff18">
         18
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Perl
         </surname>
         <given-names>
          Trish M.
         </given-names>
        </name>
        <degrees>
         MD
        </degrees>
        <xref ref-type="aff" rid="joi190087aff8">
         8
        </xref>
        <xref ref-type="aff" rid="joi190087aff19">
         19
        </xref>
       </contrib>
       <on-behalf-of>
        for the ResPECT investigators
       </on-behalf-of>
      </contrib-group>
      <aff id="joi190087aff1">
       <label>
        1
       </label>
       National Personal Protective Technology Laboratory, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Pittsburgh, Pennsylvania
      </aff>
      <aff id="joi190087aff2">
       <label>
        2
       </label>
       Veterans Affairs New York Harbor Healthcare System, New York
      </aff>
      <aff id="joi190087aff3">
       <label>
        3
       </label>
       New York University School of Medicine, New York
      </aff>
      <aff id="joi190087aff4">
       <label>
        4
       </label>
       Veterans Affairs Eastern Colorado Healthcare System, Denver
      </aff>
      <aff id="joi190087aff5">
       <label>
        5
       </label>
       University of Colorado School of Medicine, Aurora
      </aff>
      <aff id="joi190087aff6">
       <label>
        6
       </label>
       University of Massachusetts, Amherst
      </aff>
      <aff id="joi190087aff7">
       <label>
        7
       </label>
       University of Florida, Gainesville
      </aff>
      <aff id="joi190087aff8">
       <label>
        8
       </label>
       Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
      </aff>
      <aff id="joi190087aff9">
       <label>
        9
       </label>
       Johns Hopkins School of Medicine, Baltimore, Maryland
      </aff>
      <aff id="joi190087aff10">
       <label>
        10
       </label>
       Weill Cornell Medicine, New York, New York
      </aff>
      <aff id="joi190087aff11">
       <label>
        11
       </label>
       Veterans Affairs Medical Center, Washington, DC
      </aff>
      <aff id="joi190087aff12">
       <label>
        12
       </label>
       George Washington University School of Medical and Health Sciences, Washington, DC
      </aff>
      <aff id="joi190087aff13">
       <label>
        13
       </label>
       Veterans Affairs St Louis Healthcare System, St Louis, Missouri
      </aff>
      <aff id="joi190087aff14">
       <label>
        14
       </label>
       St Louis University School of Medicine, St Louis, Missouri
      </aff>
      <aff id="joi190087aff15">
       <label>
        15
       </label>
       Children’s Hospital Colorado, Aurora
      </aff>
      <aff id="joi190087aff16">
       <label>
        16
       </label>
       Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas
      </aff>
      <aff id="joi190087aff17">
       <label>
        17
       </label>
       Baylor College of Medicine, Houston, Texas
      </aff>
      <aff id="joi190087aff18">
       <label>
        18
       </label>
       Denver Health Medical Center, Denver, Colorado
      </aff>
      <aff id="joi190087aff19">
       <label>
        19
       </label>
       University of Texas Southwestern Medical Center, Dallas
      </aff>
      <author-notes>
       <title>
        Article Information
       </title>
       <corresp id="joi190087cor1">
        <bold>
         Corresponding Author:
        </bold>
        Lewis J. Radonovich Jr, MD, National Personal Protective Technology Laboratory, Centers for Disease Control and Prevention, 626 Cochrans Mill Rd, B141, R108, Pittsburgh, PA 15236 (
        <email xlink:href="mto5@cdc.gov">
         mto5@cdc.gov
        </email>
        ).
       </corresp>
       <p content-type="byline-footnote" specific-use="print">
        <bold>
         Group Information:
        </bold>
        The ResPECT investigators appear at the end of the article.
       </p>
       <p>
        <bold>
         Accepted for Publication:
        </bold>
        July 25, 2019.
       </p>
       <p content-type="author-contributions">
        <bold>
         Author Contributions:
        </bold>
        Drs Perl and Radonovich had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
       </p>
       <p>
        <italic>
         Concept and design:
        </italic>
        Radonovich, Simberkoff, Cummings, Gaydos, Gorse, Reich, Perl.
       </p>
       <p>
        <italic>
         Acquisition, analysis, or interpretation of data:
        </italic>
        All authors.
       </p>
       <p>
        <italic>
         Drafting of the manuscript:
        </italic>
        Radonovich, Simberkoff, Cummings, Gaydos, Nyquist, Reich, Perl.
       </p>
       <p>
        <italic>
         Critical revision of the manuscript for important intellectual content:
        </italic>
        Radonovich, Bessesen, Brown, Cummings, Gaydos, Los, Krosche, Gibert, Gorse, Nyquist, Reich, Rodriguez-Barradas, Price, Perl.
       </p>
       <p>
        <italic>
         Statistical analysis:
        </italic>
        Brown, Cummings, Reich.
       </p>
       <p>
        <italic>
         Obtained funding:
        </italic>
        Cummings, Perl.
       </p>
       <p>
        <italic>
         Administrative, technical, or material support:
        </italic>
        Radonovich, Simberkoff, Bessesen, Cummings, Gaydos, Los, Krosche, Gorse, Nyquist, Rodriguez-Barradas, Price, Perl.
       </p>
       <p>
        <italic>
         Supervision:
        </italic>
        Radonovich, Simberkoff, Cummings, Los, Nyquist, Reich, Price, Perl.
       </p>
       <p>
        <italic>
         Other - execution of study design; data management and monitoring:
        </italic>
        Los.
       </p>
       <p>
        <italic>
         Other - Site principal investigator for conduct of study and also contributed ongoing input on conduct and analysis of study:
        </italic>
        Gibert.
       </p>
       <p>
        <italic>
         Other - laboratory testing support:
        </italic>
        Gaydos.
       </p>
       <p>
        <italic>
         Other - recruiting patients:
        </italic>
        Price.
       </p>
       <p content-type="COI-statement">
        <bold>
         Conflict of Interest Disclosures:
        </bold>
        Dr Bessesen reported receiving grants from the Department of Veterans Affairs during the conduct of the study. Dr Brown reported receiving grants from the US Department of Veterans Affairs during the conduct of the study. Dr Cummings reported receiving grants from the Centers for Disease Control and Prevention, the National Institutes of Health, and MedImmune outside the submitted work and the Biomedical Advanced Research and Development Authority during the conduct of the study. Ms Los reported receiving grants from Centers for Disease Control and Prevention, the Veterans Health Administration, and the Biodefense Advanced Research and Development Agency during the conduct of the study. Dr Gibert reported receiving financial support for the conduct of the study, including research personnel, from the Veterans Health Administration during the conduct of the study. Dr Gorse reported receiving grants from the US Department of Veterans Affairs during the conduct of the study. Dr Nyquist reported receiving grants from the Centers for Disease Control and Prevention/Division of Healthcare Quality Promotion, the National Institute for Occupational Safety and Health, and the Veterans Health Administration during the conduct of the study; personal fees and nonfinancial support from Sequirus outside the submitted work; and serving on a policy making committee regarding infectious disease for the American Academy of Pediatrics Committee on Infectious Diseases. Dr Reich reported receiving grants from Veterans Health Administration during the conduct of the study. Dr Rodriguez-Barradas reported receiving grants from Veterans Affairs Central Office during the conduct of the study. Dr Perl reported receiving grants from the Centers for Disease Control and Prevention and Biomedical Advanced Research and Development Authority during the conduct of the study and grants from Medimmune outside the submitted work. No other disclosures were reported.
       </p>
       <p content-type="funding-statement">
        <bold>
         Funding/Support:
        </bold>
        This trial was funded by the
        <funding-source rid="sp1">
         US Centers for Disease Control and Prevention
        </funding-source>
        ,
        <funding-source rid="sp2">
         Veterans Health Administratio
        </funding-source>
        n, and the
        <funding-source rid="sp3">
         Biodefense Advanced Research and Development Agency
        </funding-source>
        .
       </p>
       <p>
        <bold>
         Role of the Funder/Sponsor:
        </bold>
        The sponsors were not involved in data collection, analysis, or interpretation; writing of the manuscript; or the decision to submit the manuscript. The sponsors reviewed and made technical comments about the study protocol prior to enrollment and the final manuscript prior to submission for publication.
       </p>
       <p content-type="study-group-members-end">
        <bold>
         Group Information:
        </bold>
        For the ResPECT Team (Contributors): The Johns Hopkins University and Health System (Baltimore, MD): Trish M. Perl, MD, MSc; Justin Getka, BA; Tina Hoang, MS; Rose Kajih, PharmD; Amanda Krosche, BS; Meghan Kubala, MS, MD: Jenna Los, MLA; Liandra Presser, MD; Kathleen Pulice, MS; Margaret Spach, DDS. VA New York Harbor Healthcare System (New York, NY): Michael S. Simberkoff, MD; Cynthia Akagbosu, BA, MA; Madeline Dansky, BA; Benedict J. Frederick, BA; Marilyn Last, RN; Scott Laverie, RN; Courtney Pike, BA; Shefali Rikhi, BS; Nicole Spector, RN; Christine A. Reel-Brander, RN. Denver Health &amp; Hospital Authority (Denver, CO): Connie Price, MD; Katie Gorman, BS; Amy Irwin, DNP, RN; Sean O’Malley; Kevin Silva, BS. UT Southwestern Medical Center (Dallas, TX) Trish M. Perl, MD, MSc; Deepa Raj, MPH; VA Eastern Colorado Healthcare System (Aurora, CO): Mary Bessesen, MD; Jill C. Adams BSN, BA; Shannon Kingery, BS; Stefanie Tuder, BS; Erron Fritchman-Palmer, MPH. Children’s Hospital Colorado (Denver, CO): Ann-Christine Nyquist, MD, MSPH; Megan Gorski, BA. VA Washington DC Medical Center (Washington, DC): Cynthia Gibert, MD, MSc; Laura Chopko, BA; Kathy Haines, MSW, MPH; Caitlin Langhorne, MPH; Dana Silver, BA; Courtney Southard, MPH. VA Michael C. DeBakey Medical Center (Houston, TX): Maria C. Rodriguez-Barradas MD; Barbara Kertz, MS; Mahwish Mushtaq, MD, MPH; Blanca Vargas, MD. Centers for Disease Control and Prevention, National Institute for Occupational Safety &amp; Health (Pittsburgh, PA): Edward Fisher, MS; Ronald Shaffer, PhD; Lewis J. Radonovich, MD. Veteran’s Health Administration Office of Public Health (Gainesville, FL): Aaron Eagan, MPH, RN; Lewis J. Radonovich, MD. HandyMetrics Corporation (Toronto, Ontario, Canada): Melanie Lipka, BS; Michael Tsang, PhD. Laboratory Core at Johns Hopkins University (Baltimore, MD): Charlotte Gaydos, DrPH, Jeffrey Holden, MA; Alexandra Valsamakis, MD, PhD. Laboratory Core at VA St Louis Healthcare System and St Louis University School of Medicine (St Louis, MO): Geoffrey J. Gorse, MD; Michelle Mitchell, BS; Gira B. Patel, MS; Yinyi Yu, BS. REDCap Core at Johns Hopkins University (Baltimore, MD): Andre Hackman, BA, Michael Sherman, BS. Statistical and Epidemiologic Core (University of Florida, Gainesville): Brooke A. Borgert MS., Derek A.T. Cummings, PhD, MPH, MSc.; Susan Rattigan (University of Massachusetts, Amherst): Alexandria C. Brown, PhD; Nicholas G. Reich, PhD (Johns Hopkins University, Baltimore, MD); Justin Lessler, PhD, MHS, MS.
       </p>
       <p>
        <bold>
         Disclaimer:
        </bold>
        The findings and conclusions in this article are the authors’ own and do not necessarily represent the views of the National Institute for Occupational Safety and Health, the Centers for Disease Control and Prevention, the Department of Veterans Affairs, or other affiliates. Mention of product names does not imply endorsement. All information and materials in this article are original.
       </p>
       <p content-type="data-sharing-statement">
        <bold>
         Data Sharing Statement:
        </bold>
        See
        <xref ref-type="supplementary-material" rid="note-JOI190087-1-s">
         Supplement 4
        </xref>
        .
       </p>
       <p>
        <bold>
         Additional Contributions:
        </bold>
        We thank the members of the data and safety monitoring board, Daniel Morgan, MD (University of Maryland, Baltimore), Elizabeth Colantuoni, PhD (Johns Hopkins Bloomberg School of Public Health, Baltimore), and Tia Powell, MD (Albert Einstein College of Medicine, Bronx). We also thank David Weissman, MD (National Institute for Occupational Safety and Health) and Michael Hodgson, MD (Occupational Safety and Health Administration). None of our consults were financially compensated for their expertise, support, and guidance throughout the study. We are immensely grateful to the study personnel and coordinators, the supporting clinical staff, and, most importantly, the participants.
       </p>
      </author-notes>
      <pub-date iso-8601-date="2019-09-03T10:00" pub-type="epub">
       <day>
        3
       </day>
       <month>
        9
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <pub-date pub-type="ppub">
       <day>
        3
       </day>
       <month>
        9
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <pub-date pub-type="pmc-release">
       <day>
        3
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 6 months and
						0 days and was based on the <pub-date
						pub-type="epub"/>. -->
      <volume>
       322
      </volume>
      <issue>
       9
      </issue>
      <fpage>
       824
      </fpage>
      <lpage>
       833
      </lpage>
      <history>
       <date date-type="received">
        <day>
         28
        </day>
        <month>
         3
        </month>
        <year>
         2019
        </year>
       </date>
       <date date-type="accepted">
        <day>
         25
        </day>
        <month>
         7
        </month>
        <year>
         2019
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright 2019 American Medical Association. All Rights Reserved.
       </copyright-statement>
      </permissions>
      <self-uri content-type="pdf-version" xlink:href="jama-322-824.pdf">
       jama-322-824.pdf
      </self-uri>
      <self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2019.11645">
      </self-uri>
      <related-article ext-link-type="doi" id="d35e449" related-article-type="commentary" xlink:href="10.1001/jama.2019.11644">
      </related-article>
      <abstract abstract-type="key-points">
       <title>
        Key Points
       </title>
       <sec id="ab-joi190087-1">
        <title>
         Question
        </title>
        <p>
         Is the use of N95 respirators or medical masks more effective in preventing influenza infection among outpatient health care personnel in close contact with patients with suspected respiratory illness?
        </p>
       </sec>
       <sec id="ab-joi190087-2">
        <title>
         Findings
        </title>
        <p>
         In this pragmatic, cluster randomized clinical trial involving 2862 health care personnel, there was no significant difference in the incidence of laboratory-confirmed influenza among health care personnel with the use of N95 respirators (8.2%) vs medical masks (7.2%).
        </p>
       </sec>
       <sec id="ab-joi190087-3">
        <title>
         Meaning
        </title>
        <p>
         As worn by health care personnel in this trial, use of N95 respirators, compared with medical masks, in the outpatient setting resulted in no significant difference in the rates of laboratory-confirmed influenza.
        </p>
       </sec>
      </abstract>
      <abstract>
       <sec id="ab-joi190087-4">
        <title>
         Importance
        </title>
        <p>
         Clinical studies have been inconclusive about the effectiveness of N95 respirators and medical masks in preventing health care personnel (HCP) from acquiring workplace viral respiratory infections.
        </p>
       </sec>
       <sec id="ab-joi190087-5">
        <title>
         Objective
        </title>
        <p>
         To compare the effect of N95 respirators vs medical masks for prevention of influenza and other viral respiratory infections among HCP.
        </p>
       </sec>
       <sec id="ab-joi190087-6">
        <title>
         Design, Setting, and Participants
        </title>
        <p>
         A cluster randomized pragmatic effectiveness study conducted at 137 outpatient study sites at 7 US medical centers between September 2011 and May 2015, with final follow-up in June 2016. Each year for 4 years, during the 12-week period of peak viral respiratory illness, pairs of outpatient sites (clusters) within each center were matched and randomly assigned to the N95 respirator or medical mask groups.
        </p>
       </sec>
       <sec id="ab-joi190087-7">
        <title>
         Interventions
        </title>
        <p>
         Overall, 1993 participants in 189 clusters were randomly assigned to wear N95 respirators (2512 HCP-seasons of observation) and 2058 in 191 clusters were randomly assigned to wear medical masks (2668 HCP-seasons) when near patients with respiratory illness.
        </p>
       </sec>
       <sec id="ab-joi190087-8">
        <title>
         Main Outcomes and Measures
        </title>
        <p>
         The primary outcome was the incidence of laboratory-confirmed influenza. Secondary outcomes included incidence of acute respiratory illness, laboratory-detected respiratory infections, laboratory-confirmed respiratory illness, and influenzalike illness. Adherence to interventions was assessed.
        </p>
       </sec>
       <sec id="ab-joi190087-9">
        <title>
         Results
        </title>
        <p>
         Among 2862 randomized participants (mean [SD] age, 43 [11.5] years; 2369 [82.8%]) women), 2371 completed the study and accounted for 5180 HCP-seasons. There were 207 laboratory-confirmed influenza infection events (8.2% of HCP-seasons) in the N95 respirator group and 193 (7.2% of HCP-seasons) in the medical mask group (difference, 1.0%, [95% CI, −0.5% to 2.5%];
         <italic>
          P
         </italic>
         = .18) (adjusted odds ratio [OR], 1.18 [95% CI, 0.95-1.45]). There were 1556 acute respiratory illness events in the respirator group vs 1711 in the mask group (difference, −21.9 per 1000 HCP-seasons [95% CI, −48.2 to 4.4];
         <italic>
          P
         </italic>
         = .10); 679 laboratory-detected respiratory infections in the respirator group vs 745 in the mask group (difference, −8.9 per 1000 HCP-seasons, [95% CI, −33.3 to 15.4];
         <italic>
          P
         </italic>
         = .47); 371 laboratory-confirmed respiratory illness events in the respirator group vs 417 in the mask group (difference, −8.6 per 1000 HCP-seasons [95% CI, −28.2 to 10.9];
         <italic>
          P
         </italic>
         = .39); and 128 influenzalike illness events in the respirator group vs 166 in the mask group (difference, −11.3 per 1000 HCP-seasons [95% CI, −23.8 to 1.3];
         <italic>
          P
         </italic>
         = .08). In the respirator group, 89.4% of participants reported “always” or “sometimes” wearing their assigned devices vs 90.2% in the mask group.
        </p>
       </sec>
       <sec id="ab-joi190087-10">
        <title>
         Conclusions and Relevance
        </title>
        <p>
         Among outpatient health care personnel, N95 respirators vs medical masks as worn by participants in this trial resulted in no significant difference in the incidence of laboratory-confirmed influenza.
        </p>
       </sec>
       <sec id="ab-joi190087-11">
        <title>
         Trial Registration
        </title>
        <p>
         ClinicalTrials.gov Identifier:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01249625">
          NCT01249625
         </ext-link>
        </p>
       </sec>
      </abstract>
      <abstract abstract-type="teaser">
       <p>
        This cluster randomized clinical trial compares the effect of N95 respirators vs medical masks worn by health care personnel for prevention of workplace-acquired influenza and other viral respiratory infections in geographically diverse, high-exposure outpatient settings.
       </p>
      </abstract>
      <funding-group>
       <award-group>
        <funding-source id="sp1">
         US Centers for Disease Control and Prevention
        </funding-source>
       </award-group>
       <award-group>
        <funding-source id="sp2">
         Veterans Health Administratio
        </funding-source>
       </award-group>
       <award-group>
        <funding-source id="sp3">
         Biodefense Advanced Research and Development Agency
        </funding-source>
       </award-group>
      </funding-group>
     </article-meta>
    </front>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Cell
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Cell
      </journal-id>
      <journal-title-group>
       <journal-title>
        Cell
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0092-8674
      </issn>
      <issn pub-type="epub">
       1097-4172
      </issn>
      <publisher>
       <publisher-name>
        Elsevier Inc.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       30712865
      </article-id>
      <article-id pub-id-type="pmc">
       6751136
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0092-8674(18)31642-8
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.cell.2018.12.028
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au1">
        <name>
         <surname>
          Walls
         </surname>
         <given-names>
          Alexandra C.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="fn" rid="fn1">
         7
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au2">
        <name>
         <surname>
          Xiong
         </surname>
         <given-names>
          Xiaoli
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="fn" rid="fn1">
         7
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au3">
        <name>
         <surname>
          Park
         </surname>
         <given-names>
          Young-Jun
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au4">
        <name>
         <surname>
          Tortorici
         </surname>
         <given-names>
          M. Alejandra
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="aff" rid="aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au5">
        <name>
         <surname>
          Snijder
         </surname>
         <given-names>
          Joost
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au6">
        <name>
         <surname>
          Quispe
         </surname>
         <given-names>
          Joel
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au7">
        <name>
         <surname>
          Cameroni
         </surname>
         <given-names>
          Elisabetta
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au8">
        <name>
         <surname>
          Gopal
         </surname>
         <given-names>
          Robin
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au9">
        <name>
         <surname>
          Dai
         </surname>
         <given-names>
          Mian
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff5">
         5
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au10">
        <name>
         <surname>
          Lanzavecchia
         </surname>
         <given-names>
          Antonio
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff6">
         6
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au11">
        <name>
         <surname>
          Zambon
         </surname>
         <given-names>
          Maria
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au12">
        <name>
         <surname>
          Rey
         </surname>
         <given-names>
          Félix A.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au13">
        <name>
         <surname>
          Corti
         </surname>
         <given-names>
          Davide
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au14">
        <name>
         <surname>
          Veesler
         </surname>
         <given-names>
          David
         </given-names>
        </name>
        <email>
         dveesler@uw.edu
        </email>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="fn" rid="fn2">
         8
        </xref>
        <xref ref-type="corresp" rid="cor1">
         ∗
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        1
       </label>
       Department of Biochemistry, University of Washington, Seattle, Washington 98195, USA
      </aff>
      <aff id="aff2">
       <label>
        2
       </label>
       Institute Pasteur &amp; CNRS UMR 3569, Unité de Virologie Structurale, 75015, Paris, France
      </aff>
      <aff id="aff3">
       <label>
        3
       </label>
       Humabs Biomed SA, Vir Biotechnology, 6500 Bellinzona, Switzerland
      </aff>
      <aff id="aff4">
       <label>
        4
       </label>
       National Infection Service, Public Health England, London NW9 5HT, UK
      </aff>
      <aff id="aff5">
       <label>
        5
       </label>
       Crick Worldwide Influenza Centre, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
      </aff>
      <aff id="aff6">
       <label>
        6
       </label>
       Institute for Research in Biomedicine, Faculty of Biomedical Sciences, Università della Svizzera italiana, 6500 Bellinzona, Switzerland
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         ∗
        </label>
        Corresponding author
        <email>
         dveesler@uw.edu
        </email>
       </corresp>
       <fn id="fn1">
        <label>
         7
        </label>
        <p id="ntpara0010">
         These authors contributed equally
        </p>
       </fn>
       <fn id="fn2">
        <label>
         8
        </label>
        <p id="ntpara0015">
         Lead Contact
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        31
       </day>
       <month>
        1
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <day>
        21
       </day>
       <month>
        2
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        31
       </day>
       <month>
        1
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <volume>
       176
      </volume>
      <issue>
       5
      </issue>
      <fpage>
       1026
      </fpage>
      <lpage>
       1039.e15
      </lpage>
      <history>
       <date date-type="received">
        <day>
         19
        </day>
        <month>
         7
        </month>
        <year>
         2018
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         29
        </day>
        <month>
         10
        </month>
        <year>
         2018
        </year>
       </date>
       <date date-type="accepted">
        <day>
         17
        </day>
        <month>
         12
        </month>
        <year>
         2018
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2018 Elsevier Inc.
       </copyright-statement>
       <copyright-year>
        2018
       </copyright-year>
       <copyright-holder>
        Elsevier Inc.
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="abs0010">
       <title>
        Summary
       </title>
       <p>
        Recent outbreaks of severe acute respiratory syndrome and Middle East respiratory syndrome, along with the threat of a future coronavirus-mediated pandemic, underscore the importance of finding ways to combat these viruses. The trimeric spike transmembrane glycoprotein S mediates entry into host cells and is the major target of neutralizing antibodies. To understand the humoral immune response elicited upon natural infections with coronaviruses, we structurally characterized the SARS-CoV and MERS-CoV S glycoproteins in complex with neutralizing antibodies isolated from human survivors. Although the two antibodies studied blocked attachment to the host cell receptor, only the anti-SARS-CoV S antibody triggered fusogenic conformational changes via receptor functional mimicry. These results provide a structural framework for understanding coronavirus neutralization by human antibodies and shed light on activation of coronavirus membrane fusion, which takes place through a receptor-driven ratcheting mechanism.
       </p>
      </abstract>
      <abstract abstract-type="graphical" id="abs0015">
       <title>
        Graphical Abstract
       </title>
       <fig id="undfig1" position="anchor">
        <graphic xlink:href="fx1_lrg">
        </graphic>
       </fig>
      </abstract>
      <abstract abstract-type="author-highlights" id="abs0020">
       <title>
        Highlights
       </title>
       <p>
        <list id="ulist0010" list-type="simple">
         <list-item id="u0010">
          <label>
           •
          </label>
          <p id="p0010">
           MERS-CoV/SARS-CoV S composite glycan shields analyzed by cryo-EM and mass spectrometry
          </p>
         </list-item>
         <list-item id="u0015">
          <label>
           •
          </label>
          <p id="p0015">
           Structures of MERS-CoV/SARS-CoV S with neutralizing antibodies from survivors
          </p>
         </list-item>
         <list-item id="u0020">
          <label>
           •
          </label>
          <p id="p0020">
           LCA60 inhibits receptor binding by interacting with MERS-CoV S protein/glycans
          </p>
         </list-item>
         <list-item id="u0025">
          <label>
           •
          </label>
          <p id="p0025">
           S230 blocks receptor binding and triggers fusogenic rearrangements via functional mimicry
          </p>
         </list-item>
        </list>
       </p>
      </abstract>
      <abstract abstract-type="teaser" id="abs0025">
       <p>
        Structural analysis of the SARS-CoV S and MERS-CoV S glycoproteins in complex with neutralizing antibodies from human survivors sheds light into the mechanisms of membrane fusion and neutralization
       </p>
      </abstract>
      <kwd-group id="kwrds0010">
       <title>
        Keywords
       </title>
       <kwd>
        coronavirus
       </kwd>
       <kwd>
        SARS-CoV
       </kwd>
       <kwd>
        MERS-CoV
       </kwd>
       <kwd>
        spike glycoprotein
       </kwd>
       <kwd>
        class I fusion protein
       </kwd>
       <kwd>
        membrane fusion
       </kwd>
       <kwd>
        neutralizing antibodies
       </kwd>
       <kwd>
        glycoproteomics
       </kwd>
       <kwd>
        N-linked glycosylation
       </kwd>
      </kwd-group>
     </article-meta>
     <notes>
      <p id="misc0010">
       Published: January 31, 2019
      </p>
     </notes>
    </front>
    <sec id="sec1">
     <title>
      Introduction
     </title>
     <p id="p0030">
      Coronaviruses are enveloped viruses responsible for up to 30% of mild respiratory tract infections and atypical pneumonia in humans. The severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002 in the Guangdong province of China and spread across the globe, resulting in 8,000 infections and nearly 800 deaths in 37 countries. The Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in the Arabian peninsula in 2012 and has caused numerous outbreaks in humans, with a fatality rate of 35%. SARS-CoV is of bat origin and crossed the species barrier using palm civets as putative intermediate hosts (
      <xref ref-type="bibr" rid="bib17">
       Ge et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib31">
       Li et al., 2005b
      </xref>
      ,
      <xref ref-type="bibr" rid="bib69">
       Wang et al., 2005
      </xref>
      ), whereas MERS-CoV is found in dromedary camels as a natural reservoir (
      <xref ref-type="bibr" rid="bib21">
       Haagmans et al., 2014
      </xref>
      ,
      <xref ref-type="bibr" rid="bib37">
       Memish et al., 2013
      </xref>
      ). Surveillance studies in bats detected numerous coronaviruses sharing high nucleotide sequence similarity with pathogenic human coronaviruses (
      <xref ref-type="bibr" rid="bib22">
       Hu et al., 2017
      </xref>
      ,
      <xref ref-type="bibr" rid="bib38">
       Menachery et al., 2015
      </xref>
      ,
      <xref ref-type="bibr" rid="bib39">
       Menachery et al., 2016
      </xref>
      ), suggesting that additional zoonotic transmission events are likely to occur in the future. Currently, no specific treatments or vaccines are available against any of the six human-infecting coronaviruses.
     </p>
     <p id="p0035">
      Coronavirus entry into host cells is mediated by the trimeric transmembrane spike (S) glycoprotein. S is composed of two functional subunits responsible for binding to the host cell receptor (S
      <sub>
       1
      </sub>
      subunit) and fusion of the viral and cellular membranes (S
      <sub>
       2
      </sub>
      subunit) (
      <xref ref-type="bibr" rid="bib20">
       Gui et al., 2017
      </xref>
      ,
      <xref ref-type="bibr" rid="bib25">
       Kirchdoerfer et al., 2016
      </xref>
      ,
      <xref ref-type="bibr" rid="bib45">
       Pallesen et al., 2017
      </xref>
      ,
      <xref ref-type="bibr" rid="bib55">
       Shang et al., 2017
      </xref>
      ,
      <xref ref-type="bibr" rid="bib56">
       Shang et al., 2018
      </xref>
      ,
      <xref ref-type="bibr" rid="bib66">
       Walls et al., 2016a
      </xref>
      ,
      <xref ref-type="bibr" rid="bib67">
       Walls et al., 2016b
      </xref>
      ,
      <xref ref-type="bibr" rid="bib68">
       Walls et al., 2017
      </xref>
      ,
      <xref ref-type="bibr" rid="bib73">
       Xiong et al., 2017
      </xref>
      ,
      <xref ref-type="bibr" rid="bib75">
       Yuan et al., 2017
      </xref>
      ). We have previously determined structures of the mouse hepatitis virus (MHV) S ectodomain in the pre-fusion and post-fusion states, which provided snapshots of the start and end points of the membrane fusion reaction (
      <xref ref-type="bibr" rid="bib66">
       Walls et al., 2016a
      </xref>
      ,
      <xref ref-type="bibr" rid="bib68">
       Walls et al., 2017
      </xref>
      ). These studies demonstrated that membrane fusion involves large conformational changes in the C-terminal (S
      <sub>
       2
      </sub>
      ) subunit, similarly to other class I fusion proteins.
     </p>
     <p id="p0040">
      Proteolytic processing and receptor-binding act in synergy to induce large-scale S conformational changes promoting coronavirus entry. Priming involves S cleavage by host proteases at the boundary between the S
      <sub>
       1
      </sub>
      and S
      <sub>
       2
      </sub>
      subunits (S
      <sub>
       1
      </sub>
      /S
      <sub>
       2
      </sub>
      ), in a subset of coronaviruses, and at a conserved site upstream of the fusion peptide (S
      <sub>
       2
      </sub>
      ’) in all known coronaviruses (
      <xref ref-type="bibr" rid="bib3">
       Belouzard et al., 2009
      </xref>
      ,
      <xref ref-type="bibr" rid="bib7">
       Burkard et al., 2014
      </xref>
      ,
      <xref ref-type="bibr" rid="bib41">
       Millet and Whittaker, 2014
      </xref>
      ,
      <xref ref-type="bibr" rid="bib46">
       Park et al., 2016
      </xref>
      ). The latter site is believed to be the most important for membrane fusion activation. The SARS-CoV and MERS-CoV S receptor-binding domain, designated domain B, exhibits multiple conformational states that modulate the accessibility of the receptor-binding motifs (RBMs) and in turn the ability to interact with host cells. Based on these findings, it was hypothesized that receptor binding may initiate membrane fusion (
      <xref ref-type="bibr" rid="bib20">
       Gui et al., 2017
      </xref>
      ,
      <xref ref-type="bibr" rid="bib45">
       Pallesen et al., 2017
      </xref>
      ,
      <xref ref-type="bibr" rid="bib75">
       Yuan et al., 2017
      </xref>
      ). However, the S glycoprotein of other coronaviruses adopt a closed domain B conformation, incompatible with receptor engagement, indicating that structural rearrangements prior to receptor binding are required for entry (
      <xref ref-type="bibr" rid="bib25">
       Kirchdoerfer et al., 2016
      </xref>
      ,
      <xref ref-type="bibr" rid="bib55">
       Shang et al., 2017
      </xref>
      ,
      <xref ref-type="bibr" rid="bib56">
       Shang et al., 2018
      </xref>
      ,
      <xref ref-type="bibr" rid="bib66">
       Walls et al., 2016a
      </xref>
      ,
      <xref ref-type="bibr" rid="bib67">
       Walls et al., 2016b
      </xref>
      ,
      <xref ref-type="bibr" rid="bib73">
       Xiong et al., 2017
      </xref>
      ). Due to this unusual mechanism of proteolytic activation and RBM conformational masking, our understanding of coronavirus membrane fusion activation remains limited.
     </p>
     <p id="p0045">
      Since the S glycoprotein densely decorates the viral surface and is a key player in pathogenesis, it is the main target of neutralizing antibodies and the focus of intense interest for vaccine design. We previously showed that coronavirus S glycoproteins are decorated with an extensive glycan shield comprising up to 100 N-linked oligosaccharides (
      <xref ref-type="bibr" rid="bib67">
       Walls et al., 2016b
      </xref>
      ,
      <xref ref-type="bibr" rid="bib73">
       Xiong et al., 2017
      </xref>
      ). Molecular-level information of the carbohydrates attached to the surface of highly pathogenic coronaviruses, however, is lacking. These glycans contribute to S stability during biogenesis, since inhibition of glycosylation by tunicamycin was reported to yield virions lacking S glycoproteins (
      <xref ref-type="bibr" rid="bib52">
       Rossen et al., 1998
      </xref>
      ) and likely participate in immune evasion via epitope masking (
      <xref ref-type="bibr" rid="bib12">
       Du et al., 2016
      </xref>
      ,
      <xref ref-type="bibr" rid="bib67">
       Walls et al., 2016b
      </xref>
      ,
      <xref ref-type="bibr" rid="bib73">
       Xiong et al., 2017
      </xref>
      ). Studies of the S glycoproteins of MERS-CoV and the bat-specific HKU4 coronavirus suggested that glycans also impact zoonosis by modulating cleavage-site accessibility to proteases for membrane-fusion activation (
      <xref ref-type="bibr" rid="bib74">
       Yang et al., 2015
      </xref>
      ). The outcome of the arms race between viral evolution mechanisms and the immune system of infected individuals can also lead to the elicitation of antibodies binding glycan-containing epitopes, such as in the case of HIV-1 (
      <xref ref-type="bibr" rid="bib53">
       Scharf et al., 2015
      </xref>
      ,
      <xref ref-type="bibr" rid="bib60">
       Stewart-Jones et al., 2016
      </xref>
      ) or Epstein-Barr virus (
      <xref ref-type="bibr" rid="bib57">
       Snijder et al., 2018
      </xref>
      ). These findings emphasize the necessity to obtain a detailed understanding of the carbohydrates covering coronavirus S glycoproteins to accelerate the development of subunit vaccines and therapeutics.
     </p>
     <p id="p0050">
      We previously reported the isolation of highly potent monoclonal neutralizing antibodies from rare memory B cells obtained from SARS-CoV and MERS-CoV survivors (
      <xref ref-type="bibr" rid="bib10">
       Corti et al., 2015
      </xref>
      ,
      <xref ref-type="bibr" rid="bib63">
       Traggiai et al., 2004
      </xref>
      ). To understand neutralization, we report here an analysis of the fine molecular structure of the SARS-CoV and MERS-CoV S glycan shields and the cryoelectron microscopy (cryo-EM) study of these glycoproteins in complex with two potent human neutralizing antibodies. Although both antibodies block receptor interaction, the anti-SARS-CoV antibody acts by functionally mimicking receptor attachment and promoting S fusogenic conformational rearrangements through a ratcheting mechanism. We found that the dynamics of the receptor-binding domain alter the apparent binding affinity of coronavirus S trimers for their cognate receptors, a phenomenon that cannot be detected using isolated B domains. The findings presented here elucidate the unique nature of the coronavirus membrane-fusion activation pathway.
     </p>
    </sec>
    <sec id="sec2">
     <title>
      Results
     </title>
     <sec id="sec2.1">
      <title>
       The MERS-CoV and SARS-CoV S Glycan Shields
      </title>
      <p id="p0055">
       We set out to obtain a blueprint of individual N-linked carbohydrates attached to the surface of the MERS-CoV and SARS-CoV S glycoproteins produced in HEK293F cells. We used the stabilized MERS-CoV S 2P and SARS-CoV S 2P ectodomains, which harbor a double proline substitution between the central helix and the heptad-repeat 1 motif to enhance the stability of the prefusion conformation (
       <xref ref-type="bibr" rid="bib45">
        Pallesen et al., 2017
       </xref>
       ). We determined that oligosaccharides account for a molecular weight of 121 kDa and 98 kDa for MERS-CoV and SARS-CoV S, respectively
       <bold>
        (
       </bold>
       <xref ref-type="fig" rid="figs1">
        Figures S1
       </xref>
       A and S1B), using multi-angle light scattering, refractometry, and UV spectrophotometry (
       <xref ref-type="bibr" rid="bib64">
        Veesler et al., 2009
       </xref>
       ). These results suggest that ∼25% of the molecular weight of a S ectodomain corresponds to oligosaccharides, whereas 50% of the HIV-1 mosaic M Env molecular weight is accounted for by glycans (
       <xref ref-type="bibr" rid="bib44">
        Nkolola et al., 2014
       </xref>
       ). We detected N-linked glycosylations at 22 and 16 unique sites for the MERS-CoV and SARS-CoV S protomers, respectively, using liquid chromatography coupled with electron transfer/high-energy collision dissociation tandem mass spectrometry (LC-MS/MS) (
       <xref ref-type="bibr" rid="bib16">
        Frese et al., 2013
       </xref>
       ). The data revealed an extraordinary heterogeneity of carbohydrates decorating the two S trimers (
       <xref ref-type="fig" rid="fig1">
        Figures 1
       </xref>
       A and 1B and
       <xref ref-type="supplementary-material" rid="mmc1">
        Tables S1
       </xref>
       and
       <xref ref-type="supplementary-material" rid="mmc2">
        S2
       </xref>
       ). Individual sequons were linked to 21 unique glycans on average and up to 64 distinct oligosaccharides for the most heterogeneous sites. The intact glycopeptides were a variety of oligomannose, hybrid, and complex glycans, with or without sialylation and (core) fucosylation. Most of the observed diversity corresponded to hybrid/complex carbohydrates (
       <xref ref-type="fig" rid="fig1">
        Figures 1
       </xref>
       A, 1B,
       <xref ref-type="fig" rid="figs1">
        S1
       </xref>
       C, and S1D and
       <xref ref-type="supplementary-material" rid="mmc1">
        Tables S1
       </xref>
       and
       <xref ref-type="supplementary-material" rid="mmc2">
        S2
       </xref>
       ). The detection of glycans with different extent of processing on coronavirus S glycoproteins is reminiscent of the composite nature of the HIV Env (
       <xref ref-type="bibr" rid="bib61">
        Struwe et al., 2018
       </xref>
       ) or Lassa virus GP (
       <xref ref-type="bibr" rid="bib72">
        Watanabe et al., 2018
       </xref>
       ) glycan shields. The large number and combinatorial diversity of N-linked glycans covering the surface of MERS-CoV and SARS-CoV S could represent a challenge to overcome for antigen recognition.
       <fig id="figs1">
        <label>
         Figure S1
        </label>
        <caption>
         <p>
          Characterization of the Fine Molecular Structure of the MERS-CoV and SARS-CoV S Glycan Shields, Related to
          <xref ref-type="fig" rid="fig1">
           Figure 1
          </xref>
         </p>
         <p>
          (A-B) Quantification of the molecular weight fraction contributed by the N-linked carbohydrates decorating the MERS-CoV (A) and SARS-CoV (B) S glycoproteins expressed using HEK293F cells. Molecular weight estimates were determined using size-exclusion chromatography coupled with multi-angle light scattering, refractometry and UV spectrophotometry(
          <xref ref-type="bibr" rid="bib64">
           Veesler et al., 2009
          </xref>
          ). (C-D) LC-MS/MS analysis of the fucosylation (C) and sialylation (D) content of the MERS-CoV S 2P and SARS-CoV S 2P ectodomain glycans (in-solution digests). Each N-linked glycosylation site is represented by a pie chart colored according to the number of fucose or sialic acid moieties detected and for which the diameter is scaled based on the number of unique glycopeptides identified. NeuAc: N-acetyl-neuraminic acid.
         </p>
        </caption>
        <graphic xlink:href="figs1_lrg">
        </graphic>
       </fig>
       <fig id="fig1">
        <label>
         Figure 1
        </label>
        <caption>
         <p>
          Characterization of the S Glycan Shield of MERS-CoV and SARS-CoV S Glycoproteins
         </p>
         <p>
          (A and B) Analysis of the glycans N-linked to MERS-CoV S 2P (A) and SARS-CoV S 2P (B) ectodomain trimers expressed using HEK293F cells. Each site is represented by a pie chart colored according to the processing state detected by LC-MS/MS and for which the diameter is scaled based on the number of unique glycopeptides identified. Glycan assignment was performed as follows: high-mannose, 2 HexNAc; hybrid, 3 HexNAc; complex, ≥4 HexNAc; GlcNAc, N-acetyl glucosamine (detected for endo-H-treated samples).
         </p>
         <p>
          (C and D) Surface representation of the fully glycosylated MERS-CoV S 2P (C) and SARS-CoV S 2P (D) ectodomain trimers (gray) with N-linked glycans rendered as spheres colored according to the processing state (i.e., corresponding to the largest number of unique N-linked glycans identified by LC-MS/MS, as in A and B).
         </p>
         <p>
          Domains A–D are labeled in (A) and (B). (C) and (D) were generated using the MERS-CoV S2P/LCA60 and SARS-CoV S2P/S230 structures for which the Fabs were removed for clarity. See also
          <xref ref-type="fig" rid="figs1">
           Figures S1
          </xref>
          and
          <xref ref-type="fig" rid="figs2">
           S2
          </xref>
          and
          <xref ref-type="supplementary-material" rid="mmc1">
           Tables S1
          </xref>
          ,
          <xref ref-type="supplementary-material" rid="mmc2">
           S2
          </xref>
          , and
          <xref ref-type="supplementary-material" rid="mmc3">
           S3
          </xref>
          .
         </p>
        </caption>
        <graphic xlink:href="gr1_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0060">
       Previous observations of SARS-CoV budding directly from the endoplasmic reticulum-Golgi intermediate compartment (ERGIC) and/or from swollen Golgi sacs led to the hypothesis that coronaviruses might only be exposed to a subset of the enzymes of the glycosylation machinery (
       <xref ref-type="bibr" rid="bib43">
        Ng et al., 2003
       </xref>
       ,
       <xref ref-type="bibr" rid="bib59">
        Stertz et al., 2007
       </xref>
       ). To address this question, we used LC-MS/MS to characterize in parallel S oligosaccharides on the MERS-CoV England1 and Erasmus Medical Center (EMC)/2012 isolates produced using African green monkey VeroE6 cells, as well as on the purified MERS-CoV S 2P ectodomain trimer recombinantly produced using HEK293F cells. We observed extensive overlap of the types of glycans detected across virion-derived and ectodomain-derived MERS-CoV samples, including the presence of hybrid and complex glycans (
       <xref ref-type="fig" rid="figs2">
        Figures S2
       </xref>
       A and S2B and
       <xref ref-type="supplementary-material" rid="mmc1">
        Tables S1
       </xref>
       ,
       <xref ref-type="supplementary-material" rid="mmc2">
        S2
       </xref>
       , and
       <xref ref-type="supplementary-material" rid="mmc3">
        S3
       </xref>
       ). Our data agree with previous work detecting hybrid/complex glycans N-linked to S present in the membrane of authentic SARS-CoV virions (
       <xref ref-type="bibr" rid="bib27">
        Krokhin et al., 2003
       </xref>
       ,
       <xref ref-type="bibr" rid="bib49">
        Ritchie et al., 2010
       </xref>
       ), which is consistent with our analysis of the SARS-CoV S 2P ectodomain trimer. Our data indicate that at least a fraction of the MERS-CoV and SARS-CoV virions produced in a cell are exposed to the glycan-processing enzymes residing in the Golgi apparatus during assembly and budding.
       <fig id="figs2">
        <label>
         Figure S2
        </label>
        <caption>
         <p>
          Comparison of Glycans N-Linked to Full-Length MERS-CoV S Incorporated in Authentic Virions and to a Purified Ectodomain. Related to
          <xref ref-type="fig" rid="fig1">
           Figure 1
          </xref>
         </p>
         <p>
          (A-B) LC-MS/MS analysis of S oligosaccharides from MERS-CoV England1 and EMC/2012 virions as well as MERS-CoV S 2P ectodomain trimer (in-gel digests). Colored dots represent individual technical replicate values and histograms represent the experimental mean signal of the relative integrated MS1 peak areas for each glycopeptide upon trypsin (A) or chymotrypsin digestion (B). NeuAc: N-acetyl-neuraminic acid, NeuGc: N-glycolyl-neuraminic acid.
         </p>
        </caption>
        <graphic xlink:href="figs2_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0065">
       The asymmetric cryoEM reconstructions of MERS-CoV S and SARS-CoV S in complex with human antibodies presented in the following sections respectively resolve glycan densities at 17 and 19 sites, virtually all of them overlapping with the MS/MS data (
       <xref ref-type="fig" rid="fig1">
        Figures 1
       </xref>
       C and 1D). At least the two core N-acetyl glucosamine moieties are resolved for the majority of glycosylation sites, which extend from the surface of both the S
       <sub>
        1
       </sub>
       and S
       <sub>
        2
       </sub>
       subunits. Although both glycoproteins are densely decorated with N-linked glycans, by comparison, the surface of the HIV Env trimer is obstructed by twice as many glycans per accessible surface area. MERS-CoV S and SARS-CoV S trimers share that the regions surrounding the S
       <sub>
        1
       </sub>
       /S
       <sub>
        2
       </sub>
       cleavage site and the fusion peptide (near the S
       <sub>
        2
       </sub>
       cleavage site) are more sparsely glycosylated than the rest of each trimer (
       <xref ref-type="fig" rid="fig1">
        Figures 1
       </xref>
       C and 1D). These glycan holes could be important for providing access to activating host proteases and for allowing membrane fusion to take place unimpeded at the onset of infection (
       <xref ref-type="bibr" rid="bib68">
        Walls et al., 2017
       </xref>
       ,
       <xref ref-type="bibr" rid="bib74">
        Yang et al., 2015
       </xref>
       ). We suggest that the identified glycan holes could be exploited for epitope-focused immunogen design or therapeutic intervention against coronaviruses. This is supported by the presence of neutralizing antibodies targeting the fusion peptide region in SARS-CoV survivor sera (
       <xref ref-type="bibr" rid="bib77">
        Zhang et al., 2004
       </xref>
       ), the high sequence conservation of this region among coronavirus S glycoproteins (
       <xref ref-type="bibr" rid="bib66">
        Walls et al., 2016a
       </xref>
       ), and the identification of a neutralization epitope within a comparable breach of the HIV-1 Env glycan shield (
       <xref ref-type="bibr" rid="bib36">
        McCoy et al., 2016
       </xref>
       ).
      </p>
     </sec>
     <sec id="sec2.2">
      <title>
       Structure of the MERS-CoV S Glycoprotein in Complex with the Human LCA60 Antibody
      </title>
      <p id="p0070">
       The LCA60 antibody was isolated from memory B cells of a MERS-CoV-infected individual and potently neutralized multiple MERS-CoV isolates (i.e., England1, EMC/2012, and Jordan-N3/2012) (
       <xref ref-type="bibr" rid="bib10">
        Corti et al., 2015
       </xref>
       ). Cryo-EM analysis of the stabilized MERS-CoV S 2P glycoprotein ectodomain in complex with the LCA60 Fab fragment showed full saturation with one Fab bound to each B domain of the homotrimeric S. 3D classification revealed that the complex adopts two distinct conformational states (
       <xref ref-type="fig" rid="fig2">
        Figures 2
       </xref>
       A–2D and
       <xref ref-type="fig" rid="figs3">
        S3
       </xref>
       A–S3E and
       <xref ref-type="supplementary-material" rid="mmc4">
        Table S4
       </xref>
       ), corresponding to two B domains closed and one B domain open (state 1, ∼50%), as well as one B domain closed and two B domains open (state 2, ∼50%). We determined asymmetric cryoEM reconstructions at 3.5 Å and 3.6 Å resolution for states 1 and 2, respectively (
       <xref ref-type="fig" rid="fig2">
        Figures 2
       </xref>
       A–2D and
       <xref ref-type="fig" rid="figs3">
        S3
       </xref>
       C–S3E and
       <xref ref-type="supplementary-material" rid="mmc4">
        Table S4
       </xref>
       ), as well as a crystal structure of the isolated LCA60 Fab at 3.0 Å resolution (
       <xref ref-type="supplementary-material" rid="mmc4">
        Table S5
       </xref>
       ). LCA60 Fabs bound to open B domains are weakly resolved in the maps, suggesting marked conformational heterogeneity, whereas the quality of the density is enhanced for closed LCA60/B domains despite radial disorder (
       <xref ref-type="fig" rid="figs3">
        Figures S3
       </xref>
       D and S3E). Analysis of the S/LCA60 contacts was done using the state 1 structure.
       <fig id="fig2">
        <label>
         Figure 2
        </label>
        <caption>
         <p>
          CryoEM Structures of the MERS-CoV S Glycoprotein in Complex with the LCA60 Neutralizing Antibody
         </p>
         <p>
          (A and B) Orthogonal views of the state 1 structure with one open and two closed B domains.
         </p>
         <p>
          (C and D) Orthogonal views of the state 2 structure with two open and one closed B domains.
         </p>
         <p>
          The structures are rendered as molecular surfaces with different colors for each S protomer (light blue, plum, and gold) and the LCA60 Fab heavy (purple) and light (pink) chains (only the variable domains are shown). The open B domains/Fabs are only included for visualization and were omitted from the final models. See also
          <xref ref-type="fig" rid="figs3">
           Figures S3
          </xref>
          and
          <xref ref-type="fig" rid="figs4">
           S4
          </xref>
          and
          <xref ref-type="supplementary-material" rid="mmc4">
           Tables S4
          </xref>
          and
          <xref ref-type="supplementary-material" rid="mmc4">
           S5
          </xref>
          .
         </p>
        </caption>
        <graphic xlink:href="gr2_lrg">
        </graphic>
       </fig>
       <fig id="figs3">
        <label>
         Figure S3
        </label>
        <caption>
         <p>
          CryoEM Characterization of the MERS-CoV S Glycoprotein in Complex with the LCA60 Fab Fragment (A-E) and the SARS-CoV S Glycoprotein in Complex with the S230 Fab Fragment (F-J), Related to
          <xref ref-type="fig" rid="fig2">
           Figures 2
          </xref>
          ,
          <xref ref-type="fig" rid="fig3">
           3
          </xref>
          , and
          <xref ref-type="fig" rid="fig4">
           4
          </xref>
         </p>
         <p>
          (A) Representative micrograph. Scale bar is 100 nm. (B) Reference-free 2D class averages. Scale bar is 100 Å. (C) Gold standard (solid lines) and map/model (dotted lines) Fourier shell correlation curves for the state 1 (blue lines) or state 2 (red lines) reconstructions. (D-E) Reconstructions for state 1 (D) and state 2 (E). (F) Representative micrograph. Scale bar is 100 nm. (G) Reference-free 2D class averages. Scale bar is 100 Å. (H) Gold standard (solid lines) and map/model (dotted lines) Fourier shell correlation curves for the state 1 (blue lines) or state 2 (red lines) reconstructions. (I-J) Reconstructions for state 1 (I) and state 2 (J).
         </p>
        </caption>
        <graphic xlink:href="figs3_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0075">
       LCA60 CDRH2, CDRH3, CDRL1, and CDRL3 interact with the MERS-CoV B domain (
       <xref ref-type="fig" rid="fig3">
        Figures 3
       </xref>
       A and 3B), which also mediates binding to human dipeptidyl-peptidase 4 (DPP4), the MERS-CoV receptor (
       <xref ref-type="bibr" rid="bib48">
        Raj et al., 2013
       </xref>
       ). The binding interface of LCA60 and MERS-CoV S involves protein/protein and protein/glycan contacts. The 17-residue long CDRH3 contacts the β8 strand and the preceding loop within the RBM. Specifically, residue W108
       <sub>
        LCA60
       </sub>
       inserts between the B domain residues P531
       <sub>
        MERS-CoV
       </sub>
       and Y541
       <sub>
        MERS-CoV
       </sub>
       on one side and the glycan N-linked to the A domain residue N166
       <sub>
        MERS-CoV
       </sub>
       from a neighboring protomer on the other side (
       <xref ref-type="fig" rid="fig3">
        Figures 3
       </xref>
       C and
       <xref ref-type="fig" rid="figs4">
        S4
       </xref>
       ). CDRH2 also contacts the loop preceding strand β8 via electrostatic interactions. CDRL3 contacts the MERS-CoV strands β6 and β9 and the loop preceding strand β8, whereas CDRL1 interacts with the loops preceding strands β6 and β8 (
       <xref ref-type="fig" rid="fig3">
        Figures 3
       </xref>
       A–3C). Domain A glycans at positions N166
       <sub>
        MERS-CoV
       </sub>
       and N236
       <sub>
        MERS-CoV
       </sub>
       appear to contact the Fab bound to the B domain of a neighboring protomer (
       <xref ref-type="fig" rid="fig3">
        Figures 3
       </xref>
       A–3D and
       <xref ref-type="fig" rid="figs4">
        S4
       </xref>
       ). The glycan N-linked to N487
       <sub>
        MERS-CoV
       </sub>
       of one protomer extends toward the Fab CDRH2 bound to the closed B domain of the neighboring protomer (
       <xref ref-type="fig" rid="fig3">
        Figure 3
       </xref>
       D) but is much less well resolved or unresolved in the other two protomers due to the absence of contact with neighboring LCA60 Fabs. The multiple contacts observed between LCA60 and oligosaccharides on the surface of the protein illustrates that the antibody accommodates MERS-CoV S glycan for binding and neutralization. Since the residues participating to the epitope and the glycosylation sequons at positions N166, N236, and N487 are conserved in &gt;99.5% of MERS-CoV isolates, LCA60 is predicted to broadly neutralize most MERS-CoV viruses sequenced to date, although the chemical composition and occupancy of each glycan could modulate binding. LCA60 therefore shares similarities with several HIV-1 broadly neutralizing antibodies, which interact to varying degree with carbohydrates N-linked to the Env glycoprotein (
       <xref ref-type="bibr" rid="bib53">
        Scharf et al., 2015
       </xref>
       ,
       <xref ref-type="bibr" rid="bib60">
        Stewart-Jones et al., 2016
       </xref>
       ).
       <fig id="fig3">
        <label>
         Figure 3
        </label>
        <caption>
         <p>
          LCA60 Interactions with the MERS-CoV S Receptor-Binding Domain
         </p>
         <p>
          (A and B) Quasi-orthogonal views of the LCA60 Fab binding to a closed B domain. The A domain from a neighboring protomer is also shown.
         </p>
         <p>
          (C) Zoomed-in view of the LCA60 CDRH3-mediated contacts. Residues involved in key interactions are shown in ball-and-stick representation colored by atom type (blue: nitrogen, red: oxygen, gray: carbon).
         </p>
         <p>
          (D) LCA60 Fabs bound to closed B domains in the state 1 structure. The glycan N-linked to N487 of one closed B domain interact with the LCA60 Fab bound to the neighboring closed B domain.
         </p>
         <p>
          (E and F) LCA60 (E) and DPP4 (F) would clash upon binding to MERS-CoV S and share partially overlapping epitopes on the B domain.
         </p>
         <p>
          In (A), (B), (D), and (F), S is rendered as molecular surfaces, the Fabs as ribbon diagrams (only the variable domains are shown), and the glycans as blue spheres. In (C), S is rendered as a ribbon diagram. The color scheme is identical to
          <xref ref-type="fig" rid="fig2">
           Figure 2
          </xref>
          . Selected glycans are labeled based on the N-linked glycosylation sequon numbering. See also
          <xref ref-type="fig" rid="figs3">
           Figures S3
          </xref>
          and
          <xref ref-type="fig" rid="figs4">
           S4
          </xref>
          and
          <xref ref-type="supplementary-material" rid="mmc4">
           Tables S4
          </xref>
          and
          <xref ref-type="supplementary-material" rid="mmc4">
           S5
          </xref>
          .
         </p>
        </caption>
        <graphic xlink:href="gr3_lrg">
        </graphic>
       </fig>
       <fig id="figs4">
        <label>
         Figure S4
        </label>
        <caption>
         <p>
          LCA60 Interactions with MERS-CoV S Involve N-Linked Glycans, Related to
          <xref ref-type="fig" rid="fig2">
           Figures 2
          </xref>
          and
          <xref ref-type="fig" rid="fig3">
           3
          </xref>
         </p>
         <p>
          (A-B) Ribbon diagrams of LCA60 binding to a closed B domain. The A domain from a neighboring protomer is also shown. LCA60 residues interacting or putatively interacting with the glycans at positions N236 and N166 are shown in ball and stick representation (blue: nitrogen, red: oxygen, gray: carbon). LCA60 atoms are colored identically except for carbon atoms that are pink/purple. The color scheme is identical to
          <xref ref-type="fig" rid="fig2">
           Figure 2
          </xref>
          . Selected glycans are labeled based on the N-linked glycosylation sequon numbering. Only the LCA60 variable domains are shown. The cryoEM density corresponding to glycans at positions N166 and N236 is shown as a transparent blue surface.
         </p>
        </caption>
        <graphic xlink:href="figs4_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0080">
       Our structure rationalizes the effect of the previously described E536A
       <sub>
        MERS-CoV
       </sub>
       escape mutant that would disrupt putative electrostatic interactions with CDRH2 residues R50
       <sub>
        LCA60
       </sub>
       and K52
       <sub>
        LCA60
       </sub>
       and/or CDRH3 residue R103
       <sub>
        LCA60
       </sub>
       (
       <xref ref-type="bibr" rid="bib10">
        Corti et al., 2015
       </xref>
       ) (
       <xref ref-type="fig" rid="fig3">
        Figure 3
       </xref>
       C). It also suggests that the K493E
       <sub>
        MERS-CoV
       </sub>
       substitution could alter the positioning of the β5-β6 loop, which might in turn prevent CDRL1 from approaching the B domain, thereby providing a potential explanation for the observed loss of binding (
       <xref ref-type="bibr" rid="bib10">
        Corti et al., 2015
       </xref>
       ). The T489A
       <sub>
        MERS-CoV
       </sub>
       substitution would remove the glycan that extends toward the Fab CDRH2 bound to the closed B domain of the neighboring protomer (
       <xref ref-type="fig" rid="fig3">
        Figure 3
       </xref>
       D). The observed abrogation of LCA60 binding for the T489A
       <sub>
        MERS-CoV
       </sub>
       mutant (
       <xref ref-type="bibr" rid="bib10">
        Corti et al., 2015
       </xref>
       ) might be explained by a loss of these protein/glycan contacts, although only one out of the three bound Fabs interact with the glycan at position N487
       <sub>
        MERS-CoV
       </sub>
       .
      </p>
      <p id="p0085">
       Comparison of the MERS-CoV S/LCA60 structure with the crystal structure of the MERS-CoV B domain in complex with DPP4 (
       <xref ref-type="bibr" rid="bib33">
        Lu et al., 2013
       </xref>
       ) shows that the two proteins would clash upon binding to MERS-CoV S and that the Fab and receptor epitopes partially overlap (
       <xref ref-type="fig" rid="fig3">
        Figures 3
       </xref>
       E and 3F). This observation supports the finding that LCA60 and DPP4 compete for binding to MERS-CoV S (
       <xref ref-type="bibr" rid="bib10">
        Corti et al., 2015
       </xref>
       ). Whereas LCA60 can bind to all possible conformations of the B domain, DPP4 binding strictly requires opening of the B domain due to burial of its binding site in the closed conformation.
      </p>
     </sec>
     <sec id="sec2.3">
      <title>
       Structure of the SARS-CoV S Glycoprotein in Complex with the Human S230 Antibody
      </title>
      <p id="p0090">
       The S230 antibody was isolated from memory B cells of a SARS-CoV-infected individual and potently neutralized a broad spectrum of SARS-CoV isolates of human and animal origin (
       <xref ref-type="bibr" rid="bib50">
        Rockx et al., 2008
       </xref>
       ,
       <xref ref-type="bibr" rid="bib63">
        Traggiai et al., 2004
       </xref>
       ). Cryo-EM characterization of the stabilized SARS-CoV S 2P glycoprotein in complex with the S230 Fab revealed that the particle images could be divided into SARS-CoV S/S230 complex with (state 1) or without (state 2) one closed B domain (
       <xref ref-type="fig" rid="fig4">
        Figures 4
       </xref>
       A–4D and
       <xref ref-type="fig" rid="figs3">
        S3
       </xref>
       F–S3J and
       <xref ref-type="supplementary-material" rid="mmc4">
        Table S4
       </xref>
       ). 3D classification of the cryo-EM data revealed that the state 1 complex features multiple orientations of each of the two S230 Fabs associated with intermediate and open conformations of the B domains. In the SARS-CoV S/S230 state 2 complex structure, the three B domains are open, albeit with conformations deviating from 3-fold symmetry, with the three bound Fabs protruding away from the S trimer apex (
       <xref ref-type="fig" rid="fig4">
        Figures 4
       </xref>
       C and 4D). We obtained asymmetric reconstructions at 4.2 Å and 4.5 Å resolution of the SARS-CoV S/S230 complex in states 1 and 2, respectively (
       <xref ref-type="fig" rid="fig4">
        Figures 4
       </xref>
       A–4D and
       <xref ref-type="fig" rid="figs3">
        S3
       </xref>
       H–S3J and
       <xref ref-type="supplementary-material" rid="mmc4">
        Table S4
       </xref>
       ). The large conformational heterogeneity of the SARS-CoV S/S230 complex contrasts with the limited number of structural states detected for the MERS-CoV S/LCA60 complex. The marked mobility of the B domain/S230 regions, which adopt a continuum of conformations in both structures, limited the resolution of this part of the map. We therefore determined a crystal structure of the isolated S230 Fab at 1.5 Å resolution to assist interpretation of the data (
       <xref ref-type="supplementary-material" rid="mmc4">
        Table S5
       </xref>
       ).
       <fig id="fig4">
        <label>
         Figure 4
        </label>
        <caption>
         <p>
          CryoEM Structure of the SARS-CoV S Glycoprotein in Complex with the S230 Neutralizing Antibody
         </p>
         <p>
          (A and B) Orthogonal views of the state 1 structure with one open, one partially open, and one closed B domain.
         </p>
         <p>
          (C and D) Orthogonal views of the state 2 structure with three open B domains that do not follow 3-fold symmetry.
         </p>
         <p>
          The structures are rendered as molecular surfaces with different colors for each S protomer (light blue, plum, and gold) and the LCA60 Fab heavy (purple) and light (pink) chains (only the variable domains are shown). See also
          <xref ref-type="fig" rid="figs3">
           Figure S3
          </xref>
          and
          <xref ref-type="supplementary-material" rid="mmc4">
           Tables S4
          </xref>
          and
          <xref ref-type="supplementary-material" rid="mmc4">
           S5
          </xref>
          .
         </p>
        </caption>
        <graphic xlink:href="gr4_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0095">
       Docking the S230 crystal structure in the cryo-EM map indicated that CDRH2, CDRH3, CDRL1, and CDRL3 contact the B domain (
       <xref ref-type="fig" rid="fig5">
        Figures 5
       </xref>
       A and 5B), which also mediates binding to human angiotensin-converting enzyme 2 (ACE2), the SARS-CoV receptor (
       <xref ref-type="bibr" rid="bib29">
        Li et al., 2003
       </xref>
       ). The S230 epitope is centered around L443
       <sub>
        SARS-CoV
       </sub>
       and places the CDRH2 residue F59
       <sub>
        S230
       </sub>
       and the CDRH3 residues Y106
       <sub>
        S230
       </sub>
       , F107
       <sub>
        S230
       </sub>
       , and Y110
       <sub>
        S230
       </sub>
       near Y408
       <sub>
        SARS-CoV
       </sub>
       , Y442
       <sub>
        SARS-CoV
       </sub>
       , F460
       <sub>
        SARS-CoV
       </sub>
       , and Y475
       <sub>
        SARS-CoV
       </sub>
       . The fitting is therefore consistent with the identification of the L443R
       <sub>
        SARS-CoV
       </sub>
       substitution as the only escape mutant isolated thus far using the SARS-CoV Urbani strain (
       <xref ref-type="bibr" rid="bib50">
        Rockx et al., 2008
       </xref>
       ), since introduction of a charged residue would affect binding to this epitope.
       <fig id="fig5">
        <label>
         Figure 5
        </label>
        <caption>
         <p>
          S230 Interactions with the SARS-CoV S Receptor-Binding Domain
         </p>
         <p>
          (A and B) Two views of the S230 Fab binding to an open B domain. The A domain of the same protomer and B domain from a neighboring protomer are also shown.
         </p>
         <p>
          (C and D) S230 (C) and ACE2 (D) would clash upon binding to SARS-CoV S and share partially overlapping epitopes on the B domain.
         </p>
         <p>
          In (A)–(D), S is rendered as molecular surfaces, the Fab as ribbon diagrams (only the variable domains are shown), and the glycans as blue spheres. The color scheme is identical to
          <xref ref-type="fig" rid="fig4">
           Figure 4
          </xref>
          . Selected glycans are labeled based on the N-linked glycosylation sequon numbering. See also
          <xref ref-type="fig" rid="figs3">
           Figure S3
          </xref>
          and
          <xref ref-type="supplementary-material" rid="mmc4">
           Tables S4
          </xref>
          and
          <xref ref-type="supplementary-material" rid="mmc4">
           S5
          </xref>
          .
         </p>
        </caption>
        <graphic xlink:href="gr5_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0100">
       Comparison of the SARS-CoV S/S230 structure with the crystal structure of the SARS-CoV B domain in complex with ACE2 (
       <xref ref-type="bibr" rid="bib30">
        Li et al., 2005a
       </xref>
       ) shows that the two proteins would clash upon binding to SARS-CoV S and that the Fab and receptor epitopes partially overlap (
       <xref ref-type="fig" rid="fig5">
        Figures 5
       </xref>
       C and 5D). This observation supports our previous results, suggesting that S230 and ACE2 compete to bind to SARS-CoV S (
       <xref ref-type="bibr" rid="bib50">
        Rockx et al., 2008
       </xref>
       ). In contrast to LCA60, which could recognize all possible arrangements of the B domain, S230 only interacts with intermediate and open states, but not with the closed conformation. Since the interaction sites of both S230 and ACE2 are only accessible in the partially or fully open B domain conformations, binding of either of these two proteins to SARS-CoV S would sterically prevent sampling of the closed state (
       <xref ref-type="fig" rid="fig4">
        Figures 4
       </xref>
       A–4D).
      </p>
     </sec>
     <sec id="sec2.4">
      <title>
       Activation Mechanism of Coronavirus Membrane Fusion
      </title>
      <p id="p0105">
       Based on the findings that (1) LCA60 and DPP4 or S230 and ACE2 compete to bind to the MERS-CoV or SARS-CoV domain B, respectively (
       <xref ref-type="fig" rid="fig3">
        Figures 3
       </xref>
       E–3F and
       <xref ref-type="fig" rid="fig5">
        5
       </xref>
       C–5D), and (2) binding of DPP4, S230, or ACE2, but not LCA60, prevents closure of the B domain, we speculated that the conformational changes we captured by cryoEM are related to membrane-fusion triggering. Incubation of the wild-type SARS-CoV S ectodomain trimer (i.e., without stabilizing mutations) with 1.6 μg/mL trypsin (w/v) to recapitulate proteolytic priming led to cleavage at the S
       <sub>
        1
       </sub>
       /S
       <sub>
        2
       </sub>
       boundary (
       <xref ref-type="bibr" rid="bib3">
        Belouzard et al., 2009
       </xref>
       ), as observed by SDS-PAGE (
       <xref ref-type="fig" rid="figs5">
        Figure S5
       </xref>
       A). Analysis of the negatively stained sample showed that the SARS-CoV S trimers largely remained in the prefusion conformation and were stable for several days on ice or at room temperature (
       <xref ref-type="fig" rid="fig6">
        Figures 6
       </xref>
       A and 6B). Complex formation between Fab S230 and wild-type SARS-CoV S led to formation of postfusion rosettes, and the frequency of this transition was enhanced with longer incubation times and/or by trypsin cleavage (
       <xref ref-type="fig" rid="fig6">
        Figures 6
       </xref>
       C–6F,
       <xref ref-type="fig" rid="figs5">
        S5
       </xref>
       B, and S5C). The S
       <sub>
        1
       </sub>
       subunit acts as a “chaperone,” contributing to stabilize S
       <sub>
        2
       </sub>
       in the prefusion state by reducing its propensity to transition to the postfusion conformation. Proteolytic cleavage at the S
       <sub>
        1
       </sub>
       /S
       <sub>
        2
       </sub>
       , S
       <sub>
        2
       </sub>
       ’ sites or shedding of the S
       <sub>
        1
       </sub>
       subunit, however, were not strictly required for refolding of the S ectodomain trimer to occur (
       <xref ref-type="fig" rid="fig6">
        Figures 6
       </xref>
       C 6E, 6G, and 6I).
       <fig id="figs5">
        <label>
         Figure S5
        </label>
        <caption>
         <p>
          SDS-PAGE Analysis of SARS-CoV S Cleavage by Trypsin, under Limited-Proteolysis Conditions, in the Presence and Absence of S230 or ACE2, Related to
          <xref ref-type="fig" rid="fig6">
           Figure 6
          </xref>
         </p>
         <p>
          (A-C) Wild-type SARS-CoV S ectodomain trimer at 7.5 μM (protomer concentration) was cleaved with 1.6 μg/mL of trypsin either directly (A), or after incubation with an equimolar concentration of Fab S230 for 30 min (B) or 30 hr (C). (D-F) Wild-type SARS-CoV S ectodomain trimer at 7.5 μM (protomer concentration) was cleaved with 1.6 μg/mL of trypsin after incubation with an equimolar concentration of the ACE2 ectodomain for 30 min (D) or 30 hr (E) or after incubation with 30 μM of the ACE2 ectodomain for 30 hr (F). Boil indicates that the sample was boiled for one minute in SDS-PAGE loading buffer prior to migration.
         </p>
        </caption>
        <graphic xlink:href="figs5_lrg">
        </graphic>
       </fig>
       <fig id="fig6">
        <label>
         Figure 6
        </label>
        <caption>
         <p>
          S230- or ACE2-Mediated Refolding of SARS-CoV S Visualized by Negative Staining EM
         </p>
         <p>
          (A–J) The effect of Fab S230 (C–F) or of the ACE2 ectodomain (G–J) on the conformational state of the wild-type SARS-CoV S ectodomain trimer was analyzed using single-particle EM of negatively stained samples. Estimates of the fraction of particles corresponding to each state are represented as pie charts based on the number of particle images clustered in each group after reference-free 2D classification. Only pre-fusion and postfusion conformations were included in the calculations, and the results are rendered using bins with a minimal width of 5%. 1.6 μg/mL trypsin was used for (B), (D), (F), (H), and (J). Time points shown at 30 min (C–D and G–H) or 30 h (E, F, I, and J). Representative 2D class averages corresponding to the different states discussed are shown at the bottom. See also
          <xref ref-type="fig" rid="figs5">
           Figure S5
          </xref>
          ,
          <xref ref-type="fig" rid="figs6">
           Figure S6
          </xref>
          ,
          <xref ref-type="fig" rid="figs7">
           Figure S7
          </xref>
          .
         </p>
        </caption>
        <graphic xlink:href="gr6_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0110">
       Incubation of the wild-type SARS-CoV S with the ACE2 ectodomain at up to 8 μM (4-fold molar excess) unexpectedly revealed that only a small percentage of the particle images corresponded to complexes, and a limited number of postfusion S trimers could be detected even in the presence of trypsin (
       <xref ref-type="fig" rid="fig6">
        Figures 6
       </xref>
       G–6H and
       <xref ref-type="fig" rid="figs5">
        S5
       </xref>
       D). Prolonged incubation, along with trypsin cleavage, acted in synergy to increase the frequency of refolding, as attested by the presence of postfusion rosettes, although a significant fraction of unbound prefusion S trimers remained (
       <xref ref-type="fig" rid="fig6">
        Figures 6
       </xref>
       I–6J, and
       <xref ref-type="fig" rid="figs5">
        S5
       </xref>
       E, and S5F). We also carried out the same set of experiments with SARS-CoV S pre-incubated with trypsin and similarly observed that S230 was more effective than ACE2 at inducing fusogenic conformational changes (
       <xref ref-type="fig" rid="figs6">
        Figures S6
       </xref>
       A–S6D).
       <fig id="figs6">
        <label>
         Figure S6
        </label>
        <caption>
         <p>
          Effect of S230 or ACE2 on Fusogenic Conformational Changes of Pre-cleaved SARS-CoV S, Related to
          <xref ref-type="fig" rid="fig6">
           Figure 6
          </xref>
         </p>
         <p>
          The effect of Fab S230 (A-B) or of the ACE2 ectodomain (C-D) on the conformational state of the wild-type SARS-CoV S ectodomain trimer was analyzed using single-particle electron microscopy of negatively stained samples. (A-D) Estimates of the fraction of particles corresponding to each state are represented as pie charts based on the number of particle images clustered in each group after reference-free 2D classification. Only prefusion and postfusion conformations were included in the calculations and the results are rendered using bins with a minimal width of 5%.
         </p>
        </caption>
        <graphic xlink:href="figs6_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0115">
       To explore whether these findings could be detected in the context of virions, we analyzed the structural rearrangements of the full-length SARS-CoV S trimer embedded in the membrane of infectious murine leukemia (pseudo)virus (MLV)(
       <xref ref-type="bibr" rid="bib42">
        Millet and Whittaker, 2016
       </xref>
       ). Refolding of coronavirus S glycoproteins to the postfusion conformation can be detected by the appearance of a proteinase-K-resistant band migrating at approximately 55 kDa when analyzed by SDS-PAGE. This molecular species comprises the postfusion 6-helix bundle, assembled from the heptad repeats 1 and 2, since its formation could be inhibited in the presence of a heptad-repeat-derived peptide that prevents completion of the conformational transition (
       <xref ref-type="bibr" rid="bib35">
        Matsuyama and Taguchi, 2009
       </xref>
       ). Addition of the S230 Fab (
       <xref ref-type="fig" rid="fig7">
        Figure 7
       </xref>
       A) or the ACE2 ectodomain (
       <xref ref-type="fig" rid="fig7">
        Figure 7
       </xref>
       B) to SARS-CoV S-pseudotyped MLV in the presence of trypsin led to the formation of a proteinase-K-resistant band migrating at approximately 55 kDa, thereby demonstrating that both the antibody and the natural receptor promoted S fusogenic conformational changes in the context of a membrane-embedded full-length S.
       <fig id="fig7">
        <label>
         Figure 7
        </label>
        <caption>
         <p>
          ACE2 or S230-Mediated Refolding of the Full-Length Membrane-Embedded SARS-CoV S Trimer Visualized by Western Blotting
         </p>
         <p>
          (A and B) The effect of 0.5 μM S230 Fab (A) or of 10 μM ACE2 ectodomain (B) on the conformational state of the full-length SARS-CoV S trimer embedded in the membrane of infectious MLV pseudovirus was probed by western blotting using an anti-SARS-CoV S
          <sub>
           2
          </sub>
          polyclonal antibody. Refolding to the postfusion conformation was detected by the appearance of a proteinase-K-resistant band migrating at approximately 55 kDa (
          <xref ref-type="bibr" rid="bib35">
           Matsuyama and Taguchi, 2009
          </xref>
          ). Trypsin was used at 5 μg/mL and proteinase K at 10μg/mL. Digestion experiments and western blots were performed in triplicates, and a representative result is shown for each of them.
         </p>
        </caption>
        <graphic xlink:href="gr7_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0120">
       Our negative-staining EM findings suggest that ACE2 bound to the SARS-CoV S trimer with a lower affinity than S230 (
       <xref ref-type="fig" rid="fig6">
        Figures 6
       </xref>
       A–6I). Since binding of ACE2 to the isolated B domain was reported to have an equilibrium dissociation constant (K
       <sub>
        D
       </sub>
       ) in the nanomolar range (
       <xref ref-type="bibr" rid="bib32">
        Li et al., 2005c
       </xref>
       ), one would expect that full saturation should occur rapidly in the conditions of our experiments (100-fold concentration excess over the K
       <sub>
        D
       </sub>
       ). Previous reports, however, suggested a lower affinity of the full-length S trimer, relative to the isolated B domain, for ACE2 (
       <xref ref-type="bibr" rid="bib26">
        Kirchdoerfer et al., 2018
       </xref>
       ,
       <xref ref-type="bibr" rid="bib35">
        Matsuyama and Taguchi, 2009
       </xref>
       ,
       <xref ref-type="bibr" rid="bib58">
        Song et al., 2018
       </xref>
       ). We propose that the conformational landscape of the B domains in the context of the SARS-CoV S trimer, sampling open and closed conformations, decreases the apparent binding affinity for ACE2 and S230 due to masking of their binding sites in the closed state. A similar effect has previously been described for ubiquitin (
       <xref ref-type="bibr" rid="bib40">
        Michielssens et al., 2014
       </xref>
       ). The higher binding affinity of S230 for SARS-CoV S, compared to ACE2 (
       <xref ref-type="fig" rid="figs7">
        Figure S7
       </xref>
       ), resulted in increased complex formation, which explains the more efficient Fab-mediated membrane fusion activation compared to the receptor (
       <xref ref-type="fig" rid="fig6">
        Figures 6
       </xref>
       C–6J and
       <xref ref-type="fig" rid="figs6">
        S6
       </xref>
       ).
       <fig id="figs7">
        <label>
         Figure S7
        </label>
        <caption>
         <p>
          Biolayer Interferometry Analysis of S230 and ACE2 Binding to the SARS-CoV S
          <sub>
           1
          </sub>
          Subunit, Related to
          <xref ref-type="fig" rid="fig6">
           Figure 6
          </xref>
         </p>
         <p>
          The SARS-CoV S
          <sub>
           1
          </sub>
          subunit was immobilized using amine coupling on ARG2 biosensors and binding of the S230 Fab (A) or the ACE2 ectodomain (B) at multiple concentrations were monitored. Equilibrium constants of dissociation and estimated errors using a global fit are indicated. The concentrations of S230 Fab or ACE2 ectodomain injected are indicated on each panel. Global fit curves are shown as black dotted lines. The vertical dashed lines indicate the transition between association and dissociation phases.
         </p>
        </caption>
        <graphic xlink:href="figs7_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0125">
       LCA60 could interact with all possible B domain states. In contrast, S230 binding was restricted to partially or fully open B domains and promoted S fusogenic conformational changes in a way reminiscent of the natural receptor, ACE2. These outcomes indicate that S triggering could work through a ratcheting mechanism involving sequential binding of a receptor molecule to each of the RBM, which in turn traps the B domains in the open conformation. Opening of the B domains releases the constraints imposed on the fusion machinery, thereby allowing the S trimer to refold and fuse the viral and host membranes.
      </p>
     </sec>
    </sec>
    <sec id="sec3">
     <title>
      Discussion
     </title>
     <p id="p0130">
      Both LCA60 and S230 bind to epitopes partially overlapping with the RBM on the B domain and in turn block attachment to DPP4 or ACE2, respectively, via a competitive mechanism. Moreover, S230 (or ACE2) binding triggered the SARS-CoV S transition to the postfusion conformation. This finding is an unprecedented example of functional mimicry, whereby an antibody activates membrane fusion by recapitulating the action of the receptor. It remains to be investigated whether binding of S230 triggers virus-cell fusion when particles are bound to the surface of cells.
     </p>
     <p id="p0135">
      Comparison of the binding modes of LCA60 and S230 with those of DPP4 and ACE2 provides a framework to understand the unique mechanism of coronavirus-membrane-fusion activation. Opening of each of the three B domains reduces the number of interactions between the S
      <sub>
       1
      </sub>
      and S
      <sub>
       2
      </sub>
      subunits and specifically releases the constraints imposed on the heptad-repeat 1-central helix hairpin, which is known to completely refold during the membrane fusion process (
      <xref ref-type="bibr" rid="bib68">
       Walls et al., 2017
      </xref>
      ). The 660-Å
      <sup>
       2
      </sup>
      decrease in buried surface area at the interface between the S
      <sub>
       1
      </sub>
      and S
      <sub>
       2
      </sub>
      subunits upon opening of the three B domains destabilizes the pre-fusion state and increases its probability of refolding, as observed upon complex formation with ACE2 or S230. Proteolytic activation is likely required to ensure that S glycoproteins will work in synergy, with proper spatial and temporal coordination, to drive fusion of the viral and host membranes. The large number of S glycoproteins decorating the surface of coronaviruses suggests that multiple trimers work in concert for formation of a fusion pore. We expect this activation mechanism to hold true for all coronaviruses using domain B for interacting with their proteinaceous receptor. We view the S
      <sub>
       1
      </sub>
      subunit as a molecular chaperone, stabilizing the prefusion state of the fusion machinery, and coordinating receptor binding with membrane fusion. In summary, coronaviruses appear to have evolved a fine-tuned balance between masking of the RBM, to limit neutralization by the humoral host immune response, and their necessary exposure, to enable receptor recognition and infection of host cells.
     </p>
    </sec>
    <sec id="sec4">
     <title>
      STAR★Methods
     </title>
     <sec id="sec4.1">
      <title>
       Key Resources Table
      </title>
      <p id="p0140">
       <table-wrap id="undtbl1" position="float">
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
            REAGENT or RESOURCE
           </th>
           <th>
            SOURCE
           </th>
           <th>
            IDENTIFIER
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td colspan="3">
            <bold>
             Antibodies
            </bold>
           </td>
          </tr>
          <tr>
           <td colspan="3">
            <hr/>
           </td>
          </tr>
          <tr>
           <td>
            SARS-CoV S polyclonal antibody
           </td>
           <td>
            ThermoFisher
           </td>
           <td>
            Cat# PA1-41385; RRID:
            <ext-link ext-link-type="uri" id="interref1900" xlink:href="nif-antibody:AB_1087215">
             AB_1087215
            </ext-link>
            <break>
            </break>
            Lot# TI2631279
           </td>
          </tr>
          <tr>
           <td>
            AlexaFluor680-conjugated AffiniPure Goat Anti Rabbit IgG
           </td>
           <td>
            JacksonImmuno (Gift from Michael Ailion lab)
           </td>
           <td>
            Cat# 111-625-144; RRID:
            <ext-link ext-link-type="uri" id="interref1905" xlink:href="nif-antibody:AB_2338085">
             AB_2338085
            </ext-link>
            <break>
            </break>
            Lot# 114199
           </td>
          </tr>
          <tr>
           <td colspan="3">
            <hr/>
           </td>
          </tr>
          <tr>
           <td colspan="3">
            <bold>
             Bacterial and Virus Strains
            </bold>
           </td>
          </tr>
          <tr>
           <td colspan="3">
            <hr/>
           </td>
          </tr>
          <tr>
           <td>
            MERS-EMC/2012
           </td>
           <td>
            Gift from Bart Haagmans and Ron Fouchier
           </td>
           <td>
            GenBank:
            <ext-link ext-link-type="uri" id="intref0010" xlink:href="ncbi-n:JX869059.2">
             JX869059.2
            </ext-link>
           </td>
          </tr>
          <tr>
           <td>
            MERS-England 1
           </td>
           <td>
            <xref ref-type="bibr" rid="bib10">
             Corti et al., 2015
            </xref>
           </td>
           <td>
            GenBank:
            <ext-link ext-link-type="uri" id="intref0015" xlink:href="ncbi-n:KC164505.2">
             KC164505.2
            </ext-link>
           </td>
          </tr>
          <tr>
           <td colspan="3">
            <hr/>
           </td>
          </tr>
          <tr>
           <td colspan="3">
            <bold>
             Chemicals, Peptides, and Recombinant Proteins
            </bold>
           </td>
          </tr>
          <tr>
           <td colspan="3">
            <hr/>
           </td>
          </tr>
          <tr>
           <td>
            Trypsin
           </td>
           <td>
            ThermoFisher
           </td>
           <td>
            Ref# 90057 Lot# TG269188
           </td>
          </tr>
          <tr>
           <td>
            Chymotrypsin
           </td>
           <td>
            Sigma-Aldrich
           </td>
           <td>
            Cat# 9004-07-3
           </td>
          </tr>
          <tr>
           <td>
            Alphalytic Protease
           </td>
           <td>
            Sigma-Aldrich
           </td>
           <td>
            Cat# A6362
           </td>
          </tr>
          <tr>
           <td>
            AspN Endoproteinase
           </td>
           <td>
            NEB
           </td>
           <td>
            Cat# P8104S
           </td>
          </tr>
          <tr>
           <td>
            EndoH
           </td>
           <td>
            NEB
           </td>
           <td>
            Cat# P0702S Lot# 0181603
           </td>
          </tr>
          <tr>
           <td>
            EndoF3
           </td>
           <td>
            CalBIOCHEM
           </td>
           <td>
            Cat# 324727 Lot# 2754801
           </td>
          </tr>
          <tr>
           <td>
            Proteinase K
           </td>
           <td>
            ThermoScientific
           </td>
           <td>
            Cat# EO0491 Lot# 00656887
           </td>
          </tr>
          <tr>
           <td>
            EDC
           </td>
           <td>
            ForteBio, Pall
           </td>
           <td>
            Cat# 18-1033
            <break>
            </break>
            Lot # SF252306
           </td>
          </tr>
          <tr>
           <td>
            Sulfo-NHS
           </td>
           <td>
            ForteBio, Pall
           </td>
           <td>
            Cat# 18-1067
            <break>
            </break>
            Lot# R124327
           </td>
          </tr>
          <tr>
           <td>
            Uranyl Formate
           </td>
           <td>
            Electron Microscopy Sciences
           </td>
           <td>
            Cat# 22451
            <break>
            </break>
            Lot# 150212
           </td>
          </tr>
          <tr>
           <td colspan="3">
            <hr/>
           </td>
          </tr>
          <tr>
           <td colspan="3">
            <bold>
             Deposited Data
            </bold>
           </td>
          </tr>
          <tr>
           <td colspan="3">
            <hr/>
           </td>
          </tr>
          <tr>
           <td>
            Raw and Analyzed Mass Spectrometry Data
           </td>
           <td>
            This Paper
           </td>
           <td>
            PRIDE: PDX010494
           </td>
          </tr>
          <tr>
           <td>
            MERS-CoV S2P/LCA60 cryoEM maps
           </td>
           <td>
            This Paper
           </td>
           <td>
            EMDB: 0401, 0402
           </td>
          </tr>
          <tr>
           <td>
            MERS-CoV S2P/LCA60 atomic models
           </td>
           <td>
            This Paper
           </td>
           <td>
            PDB:
            <ext-link ext-link-type="uri" id="intref0020" xlink:href="pdb:6NB3">
             6NB3
            </ext-link>
            ,
            <ext-link ext-link-type="uri" id="intref0025" xlink:href="pdb:6NB4">
             6NB4
            </ext-link>
           </td>
          </tr>
          <tr>
           <td>
            SARS-CoV S 2P/S230 cryoEM maps
           </td>
           <td>
            This Paper
           </td>
           <td>
            EMDB: 0403, 0404
           </td>
          </tr>
          <tr>
           <td>
            SARS-CoV S 2P/S230 atomic models
           </td>
           <td>
            This Paper
           </td>
           <td>
            PDB:
            <ext-link ext-link-type="uri" id="intref0030" xlink:href="pdb:6NB6">
             6NB6
            </ext-link>
            ,
            <ext-link ext-link-type="uri" id="intref0035" xlink:href="pdb:6NB7">
             6NB7
            </ext-link>
           </td>
          </tr>
          <tr>
           <td>
            LCA60 crystal structure
           </td>
           <td>
            This Paper
           </td>
           <td>
            PDB:
            <ext-link ext-link-type="uri" id="intref0040" xlink:href="pdb:6NB5">
             6NB5
            </ext-link>
           </td>
          </tr>
          <tr>
           <td>
            S230 crystal structure
           </td>
           <td>
            This Paper
           </td>
           <td>
            PDB:
            <ext-link ext-link-type="uri" id="intref0045" xlink:href="pdb:6NB8">
             6NB8
            </ext-link>
           </td>
          </tr>
          <tr>
           <td colspan="3">
            <hr/>
           </td>
          </tr>
          <tr>
           <td colspan="3">
            <bold>
             Experimental Models: Cell Lines
            </bold>
           </td>
          </tr>
          <tr>
           <td colspan="3">
            <hr/>
           </td>
          </tr>
          <tr>
           <td>
            Freestyle HEK293
           </td>
           <td>
            ThermoFisher
           </td>
           <td>
            Cat# R79007
           </td>
          </tr>
          <tr>
           <td>
            HEK293T/17 adherent
           </td>
           <td>
            <xref ref-type="bibr" rid="bib42">
             Millet and Whittaker, 2016
            </xref>
           </td>
           <td>
            ATCC CRL-11268
           </td>
          </tr>
          <tr>
           <td>
            Expi293F
           </td>
           <td>
            ThermoFisher
           </td>
           <td>
            Cat# A14527
           </td>
          </tr>
          <tr>
           <td>
            Vero(C1008)E6 adherent
           </td>
           <td>
            ECACC General Collection
           </td>
           <td>
            Cat# 85020206
           </td>
          </tr>
          <tr>
           <td colspan="3">
            <hr/>
           </td>
          </tr>
          <tr>
           <td colspan="3">
            <bold>
             Recombinant DNA
            </bold>
           </td>
          </tr>
          <tr>
           <td colspan="3">
            <hr/>
           </td>
          </tr>
          <tr>
           <td>
            pOPING – MERS-CoV S 2P
           </td>
           <td>
            GeneArt
           </td>
           <td>
            N/A
           </td>
          </tr>
          <tr>
           <td>
            pOPING – SARS-CoV S 2P
           </td>
           <td>
            GeneArt
           </td>
           <td>
            N/A
           </td>
          </tr>
          <tr>
           <td>
            pcD5 - ACE2
           </td>
           <td>
            <xref ref-type="bibr" rid="bib48">
             Raj et al., 2013
            </xref>
           </td>
           <td>
            N/A
           </td>
          </tr>
          <tr>
           <td>
            LCA60
           </td>
           <td>
            <xref ref-type="bibr" rid="bib10">
             Corti et al., 2015
            </xref>
           </td>
           <td>
            N/A
           </td>
          </tr>
          <tr>
           <td>
            S230
           </td>
           <td>
            <xref ref-type="bibr" rid="bib50">
             Rockx et al., 2008
            </xref>
           </td>
           <td>
            N/A
           </td>
          </tr>
          <tr>
           <td>
            pcDNA3.1(-) –Full-length wild-type SARS-CoV S
           </td>
           <td>
            <xref ref-type="bibr" rid="bib42">
             Millet and Whittaker, 2016
            </xref>
           </td>
           <td>
            N/A
           </td>
          </tr>
          <tr>
           <td>
            pCMV-murine leukemia virus gag-pol
           </td>
           <td>
            <xref ref-type="bibr" rid="bib42">
             Millet and Whittaker, 2016
            </xref>
           </td>
           <td>
            N/A
           </td>
          </tr>
          <tr>
           <td>
            pTG-Luciferase
           </td>
           <td>
            <xref ref-type="bibr" rid="bib42">
             Millet and Whittaker, 2016
            </xref>
           </td>
           <td>
            N/A
           </td>
          </tr>
          <tr>
           <td>
            pCAGGS-SARS-CoV-S
            <sub>
             1
            </sub>
            -Fc
           </td>
           <td>
            <xref ref-type="bibr" rid="bib48">
             Raj et al., 2013
            </xref>
           </td>
           <td>
            N/A
           </td>
          </tr>
          <tr>
           <td>
            pCAGGS-MERS-CoV-S
            <sub>
             1
            </sub>
            -Fc
           </td>
           <td>
            <xref ref-type="bibr" rid="bib48">
             Raj et al., 2013
            </xref>
           </td>
           <td>
            N/A
           </td>
          </tr>
          <tr>
           <td colspan="3">
            <hr/>
           </td>
          </tr>
          <tr>
           <td colspan="3">
            <bold>
             Software and Algorithms
            </bold>
           </td>
          </tr>
          <tr>
           <td colspan="3">
            <hr/>
           </td>
          </tr>
          <tr>
           <td>
            UCSF Chimera
           </td>
           <td>
            <xref ref-type="bibr" rid="bib83">
             Pettersen et al., 2004
            </xref>
           </td>
           <td>
            <ext-link ext-link-type="uri" id="intref0050" xlink:href="https://www.rbvi.ucsf.edu/chimera/">
             https://www.rbvi.ucsf.edu/chimera/
            </ext-link>
           </td>
          </tr>
          <tr>
           <td>
            UCSF ChimeraX
           </td>
           <td>
            <xref ref-type="bibr" rid="bib19">
             Goddard et al., 2018
            </xref>
           </td>
           <td>
            <ext-link ext-link-type="uri" id="intref0055" xlink:href="https://www.rbvi.ucsf.edu/chimerax/">
             https://www.rbvi.ucsf.edu/chimerax/
            </ext-link>
           </td>
          </tr>
          <tr>
           <td>
            GCTF
           </td>
           <td>
            <xref ref-type="bibr" rid="bib76">
             Zhang, 2016
            </xref>
           </td>
           <td>
            <ext-link ext-link-type="uri" id="intref0060" xlink:href="https://www.mrc-lmb.cam.ac.uk/kzhang/Gctf/">
             https://www.mrc-lmb.cam.ac.uk/kzhang/Gctf/
            </ext-link>
           </td>
          </tr>
          <tr>
           <td>
            COOT
           </td>
           <td>
            <xref ref-type="bibr" rid="bib13">
             Emsley et al., 2010
            </xref>
           </td>
           <td>
            <ext-link ext-link-type="uri" id="intref0065" xlink:href="https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/">
             https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/
            </ext-link>
           </td>
          </tr>
          <tr>
           <td>
            Relion
           </td>
           <td>
            <xref ref-type="bibr" rid="bib79">
             Zivanov et al., 2018
            </xref>
           </td>
           <td>
            <ext-link ext-link-type="uri" id="intref0070" xlink:href="https://www2.mrc-lmb.cam.ac.uk/relion/index.php?title=Main_Page">
             https://www2.mrc-lmb.cam.ac.uk/relion/index.php?title=Main_Page
            </ext-link>
           </td>
          </tr>
          <tr>
           <td>
            Protein Metrics Byonic software
           </td>
           <td>
            <xref ref-type="bibr" rid="bib4">
             Bern et al., 2012
            </xref>
           </td>
           <td>
            <ext-link ext-link-type="uri" id="intref0075" xlink:href="https://www.proteinmetrics.com/products/byonic/">
             https://www.proteinmetrics.com/products/byonic/
            </ext-link>
           </td>
          </tr>
          <tr>
           <td>
            PHENIX
           </td>
           <td>
            <xref ref-type="bibr" rid="bib1">
             Adams et al., 2010
            </xref>
           </td>
           <td>
            <ext-link ext-link-type="uri" id="intref0080" xlink:href="http://www.phenix-online.org/">
             http://www.phenix-online.org/
            </ext-link>
           </td>
          </tr>
          <tr>
           <td>
            PISA
           </td>
           <td>
            <xref ref-type="bibr" rid="bib81">
             Krissinel and Henrick, 2007
            </xref>
           </td>
           <td>
            <ext-link ext-link-type="uri" id="intref0085" xlink:href="http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html">
             http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html
            </ext-link>
           </td>
          </tr>
          <tr>
           <td>
            Rosetta
           </td>
           <td>
            <xref ref-type="bibr" rid="bib15">
             Frenz et al., 2019
            </xref>
           </td>
           <td>
            <ext-link ext-link-type="uri" id="intref0090" xlink:href="https://www.rosettacommons.org/software">
             https://www.rosettacommons.org/software
            </ext-link>
           </td>
          </tr>
          <tr>
           <td>
            Leginon
           </td>
           <td>
            <xref ref-type="bibr" rid="bib62">
             Suloway et al., 2005
            </xref>
           </td>
           <td>
            <ext-link ext-link-type="uri" id="intref0095" xlink:href="http://emg.nysbc.org/redmine/projects/leginon/wiki/Leginon_Homepage">
             http://emg.nysbc.org/redmine/projects/leginon/wiki/Leginon_Homepage
            </ext-link>
           </td>
          </tr>
          <tr>
           <td>
            DoG Picker
           </td>
           <td>
            <xref ref-type="bibr" rid="bib65">
             Voss et al., 2009
            </xref>
           </td>
           <td>
            <ext-link ext-link-type="uri" id="intref0100" xlink:href="http://emg.nysbc.org/redmine/projects/software/wiki/DoGpicker">
             http://emg.nysbc.org/redmine/projects/software/wiki/DoGpicker
            </ext-link>
           </td>
          </tr>
          <tr>
           <td>
            Privateer
           </td>
           <td>
            <xref ref-type="bibr" rid="bib2">
             Agirre et al., 2015
            </xref>
           </td>
           <td>
            <ext-link ext-link-type="uri" id="intref0105" xlink:href="http://www.ccp4.ac.uk/html/privateer.html">
             http://www.ccp4.ac.uk/html/privateer.html
            </ext-link>
           </td>
          </tr>
          <tr>
           <td>
            Buster
           </td>
           <td>
           </td>
           <td>
            <ext-link ext-link-type="uri" id="intref0110" xlink:href="https://www.globalphasing.com/buster/">
             https://www.globalphasing.com/buster/
            </ext-link>
           </td>
          </tr>
          <tr>
           <td>
            CryoSPARC
           </td>
           <td>
            <xref ref-type="bibr" rid="bib47">
             Punjani et al., 2017
            </xref>
           </td>
           <td>
            <ext-link ext-link-type="uri" id="intref0115" xlink:href="https://cryosparc.com">
             https://cryosparc.com
            </ext-link>
           </td>
          </tr>
          <tr>
           <td>
            REFMAC5
           </td>
           <td>
            <xref ref-type="bibr" rid="bib84">
             Vagin et al., 2004
            </xref>
           </td>
           <td>
            <ext-link ext-link-type="uri" id="intref0120" xlink:href="http://www.ccp4.ac.uk/html/refmac5">
             http://www.ccp4.ac.uk/html/refmac5
            </ext-link>
           </td>
          </tr>
          <tr>
           <td colspan="3">
            <hr/>
           </td>
          </tr>
          <tr>
           <td colspan="3">
            <bold>
             Other
            </bold>
           </td>
          </tr>
          <tr>
           <td colspan="3">
            <hr/>
           </td>
          </tr>
          <tr>
           <td>
            Octet Red
           </td>
           <td>
            ForteBio, Pall
           </td>
           <td>
            <ext-link ext-link-type="uri" id="intref0125" xlink:href="https://www.fortebio.com/octet-RED96.html">
             https://www.fortebio.com/octet-RED96.html
            </ext-link>
           </td>
          </tr>
          <tr>
           <td>
            Amine Reactive 2
            <sup>
             nd
            </sup>
            Generation (AR2G) Biosensors
           </td>
           <td>
            ForteBio, Pall
           </td>
           <td>
            Part# 18-5092
            <break>
            </break>
            Lot# 1805262
           </td>
          </tr>
          <tr>
           <td>
            HisTALON Superflow cartridge
           </td>
           <td>
            Takara
           </td>
           <td>
            Cat# 635683
            <break>
            </break>
            Lot# 1509573A
           </td>
          </tr>
          <tr>
           <td>
            Superose 6 Increase 10/300
           </td>
           <td>
            GE Life Sciences
           </td>
           <td>
            Cat# 29-0915-96
            <break>
            </break>
            Lot# 10226998
           </td>
          </tr>
          <tr>
           <td>
            Lacey Formvar/Carbon 400 mesh, Cu Grids
           </td>
           <td>
            Ted Pella
           </td>
           <td>
            Prod# 01885-F
            <break>
            </break>
            Lot# 020218
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
      </p>
     </sec>
     <sec id="sec4.2">
      <title>
       Contact for Reagent and Resource Sharing
      </title>
      <p id="p0145">
       Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, David Veesler (
       <ext-link ext-link-type="uri" id="intref0130" xlink:href="mailto:dveesler@uw.edu">
        dveesler@uw.edu
       </ext-link>
       ).
      </p>
     </sec>
     <sec id="sec4.3">
      <title>
       Experimental Model and Subject Details
      </title>
      <sec id="sec4.3.1">
       <title>
        Cell lines
       </title>
       <p id="p0150">
        HEK293F is a female human embryonic kidney cell line transformed and adapted to grow in suspension (Life Technologies). HEK293F cells were grown in 293FreeStyle expression medium (Life Technologies), cultured at 37°C with 5% CO
        <sub>
         2
        </sub>
        and 150 rpm. HEK293T/17 is a female human embryonic kidney cell line (ATCC). HEK293T/17 cells were cultured at 37°C with 5% CO2 in flasks with DMEM + 10% FBS + penicillin-streptomycin + 10mM HEPES. Expi293F is a female human embryonic kidney cell line transformed and adapted to grow in suspension (Life Technologies). Expi293F cells were grown in Expi293F expression medium, cultured at 37°C, 5% CO2 and 150 rpm. VeroE6 is a female kidney epithelial cell from African green monkey. VeroE6 cells were grown in serum-free medium (VP-SFM; ThermoFisher) at 37°C and 5% CO
        <sub>
         2
        </sub>
        . Cells lines were not tested for mycoplasma contamination nor authenticated except for the VeroE6 cells.
       </p>
      </sec>
     </sec>
     <sec id="sec4.4">
      <title>
       Method Details
      </title>
      <sec id="sec4.4.1">
       <title>
        Construct design
       </title>
       <p id="p0155">
        Genes encoding for the ectodomains of both MERS-CoV and SARS-CoV S were synthesized by GeneArt (ThermoFisher Scientific) and placed into a modified pOPING vector with its original N-terminal mu-phosphatase signal peptide, and an engineered C-terminal extension: SG-R
        <italic>
         ENLYFQG (TEV protease site),
        </italic>
        GGGSG-YIPEAPRDGQAYVRKDGEWVLLSTFL (foldon trimerization motif), G-HHHHHH (hexa-histidine tag), just upstream of the predicted transmembrane region (YNK for MERS-CoV S and YIK for SARS-CoV S). The MERS-CoV S
        <sub>
         1
        </sub>
        /S
        <sub>
         2
        </sub>
        furin cleavage site was mutated and both SARS-CoV and MERS-CoV S were stabilized with the 2P mutations (
        <xref ref-type="bibr" rid="bib45">
         Pallesen et al., 2017
        </xref>
        ). The SARS-CoV S
        <sub>
         1
        </sub>
        and ACE2 ectodomain constructs were fused to a sequence encoding a thrombin cleavage site and a human Fc fragment at the C-terminal end (kind gifts from Berend-Jan Bosch), as previously described (
        <xref ref-type="bibr" rid="bib48">
         Raj et al., 2013
        </xref>
        ).
       </p>
      </sec>
      <sec id="sec4.4.2">
       <title>
        Protein expression and purification
       </title>
       <p id="p0160">
        The SARS-CoV S 2P and MERS-CoV S 2P ectodomains were produced in 500mL HEK293F cells grown in suspension using FreeStyle 293 expression medium (Life technologies) at 37°C in a humidified 8% CO2 incubator rotating at 130 rpm The cultures were transfected using 293fectin (ThermoFisher Scientific) with cells grown to a density of 1 million cells per mL and cultivated for three days. The supernatants were harvested and cells resuspended for another three days, yielding two harvests. Clarified supernatants were purified using a 5mL Cobalt affinity column (Takara). Purified protein was filtered or concentrated and flash frozen in Tris-saline (50 mM Tris pH 8.0, 150 mM NaCl) prior to negative staining and cryo-EM analysis. Wild-type SARS-CoV S was expressed in 293F cells and purified the same way as the SARS-CoV S 2P. Wild-type SARS-CoV S was filtered through 0.2 μm filter and the quality of the protein was assessed by negative stain electron microscopy and SDS-PAGE. Wild-type SARS-CoV S was not frozen and was stored at 4°C and used within 7 days of purification.
       </p>
       <p id="p0165">
        Expression and purification of human angiotensin-converting enzyme ectodomain (ACE2, residues 1–614) fused to the Fc region of human IgG (hFc) was performed following the protocol previously described for CEACAM1a(
        <xref ref-type="bibr" rid="bib66">
         Walls et al., 2016a
        </xref>
        ) and cleavage of the Fc fragment was achieved using trypsin or thrombin. SARS-CoV S
        <sub>
         1
        </sub>
        -Fc was produced in 250mL HEK293F cells grown in suspension using FreeStyle 293 expression medium (Life technologies) at 37°C in a humidified 8% CO2 incubator rotating at 130 rpm The cultures were transfected using 293fectin (ThermoFisher Scientific) with cells grown to a density of 1 million cells per mL and cultivated for six days. The supernatant was harvested, clarified and incubated with 0.25mL protein A beads (0.5 mL slurry) (GenScript) overnight. Beads were washed thoroughly with phosphate buffered saline prior to elution with 0.1M glycine pH3.0 which was immediately neutralized with 1M Tris pH8.5. LCA60 and S230 Fabs were expressed using transient transfection of Expi293F cells, purified by affinity chromatography using CaptureSelect CH1-XL column (ThermoFisher), buffer exchanged to phosphate buffer saline using a HiTrap fast desalting column (GE Healthcare) and sterilized through a 0.2 μm filter.
       </p>
      </sec>
      <sec id="sec4.4.3">
       <title>
        Pseudovirus production
       </title>
       <p id="p0170">
        MLV-based SARS-CoV S-pseudotyped were prepared as previously described (
        <xref ref-type="bibr" rid="bib42">
         Millet and Whittaker, 2016
        </xref>
        ). HEK293T cells were cotransfected with a SARS-CoV S encoding-plasmid, a MLV Gag-Pol packaging construct and the MLV transfer vector encoding a luciferase reporter using the Lipofectamine 2000 transfection reagent (Life Technologies) according to the manufacturer’s instructions. Cells were incubated for 5 hours at 37°C with 5% CO
        <sub>
         2
        </sub>
        with transfection medium. Cells were then washed with DMEM 2X and DMEM containing 10% FBS was added for 12 hours. The cells were washed again 2X with DMEM and were kept in DMEM without FBS for 48 hours (
        <xref ref-type="bibr" rid="bib70">
         Wang et al., 2014
        </xref>
        ). The supernatants were then harvested and filtered through 0.45-μm membranes.
       </p>
      </sec>
      <sec id="sec4.4.4">
       <title>
        MERS-CoV production
       </title>
       <p id="p0175">
        Virions were purified from the supernatant of infected Vero E6 cells. Cells were infected at 90% confluence at multiplicity of infection of 0.01, in Serum Free Medium (VP-SFM; ThermoFisher Scientific). Cultures were maintained at 37°C, 5% (v/v) CO
        <sub>
         2
        </sub>
        until 3 days post infection when the culture supernatant was removed. Approximately 50% of cells were rounding, but most remained attached to the growth surface. For virion purification, culture supernatant was clarified by centrifugation at 1,400 g for 10 min then overlaid on a cushion of 20% (w/w) Sucrose in Hanks Buffered Saline solution (HBSS: ThermoFisher Scientific).Supernatant virions were centrifuged through the cushion at 100,000 g for 90 min at 4°C. Pelleted virions were resuspended in HBSS and disrupted by heating for 10 min at 95°C in 1% (w/v) sodium dodecyl sulfate. All live virus work was undertaken under UK ACDP Containment level 3 conditions.
       </p>
      </sec>
      <sec id="sec4.4.5">
       <title>
        MERS-CoV S/LCA60 complex formation
       </title>
       <p id="p0180">
        Flash frozen MERS-CoV 2P stabilized S at 5mg/mL was incubated in a 1:1.5 molar ratio with LCA60 at 2.3 mg/mL on ice for three hours. Trypsin at 3 μg/mL was added for twenty minutes at 37°C prior to injection over a gel filtration column (Superose 6 10/300 from GE Life Sciences) equilibrated in 20mM Tris pH8.0 and 150mM NaCl. The complex peak fractions were concentrated to 0.5 mg/mL. 3 μL was applied to a glow discharged (20 s at 20 mA) lacey carbon copper grid with a thin layer of evaporated continuous carbon prior to plunge freezing into liquid ethane with a Mark IV vitrobot (ThermoFisher Scientific) using −1 blot force and 2 s blot time at 95% humidity and 25°C.
       </p>
      </sec>
      <sec id="sec4.4.6">
       <title>
        SARS-CoV S/S230 complex formation
       </title>
       <p id="p0185">
        Lacey carbon copper grids were coated with a thin-layer of continuous carbon using a carbon evaporator and glow discharged for 20 s at 20 mA. Flash frozen SARS-CoV 2P stabilized S was diluted to 0.05 mg/mL and 2 μl was applied to the grid and incubated for 1 min. Subsequently, the grid was washed three times in Tris-saline buffer before 2 μL of S230 Fab at 0.02 mg/mL was applied to the grid and incubated for five minutes. The grid was washed again three times with Tris-saline after the Fab incubation and manually blotted prior to plunge freezing into liquid ethane at room temperature.
       </p>
      </sec>
      <sec id="sec4.4.7">
       <title>
        Cryo-EM data collection
       </title>
       <p id="p0190">
        Data were acquired using the Leginon software (
        <xref ref-type="bibr" rid="bib62">
         Suloway et al., 2005
        </xref>
        ) to control an FEI Titan Krios transmission electron microscope operated at 300 kV and equipped with a Gatan K2 Summit direct detector and Gatan Quantum GIF energy filter, operated in zero-loss mode with a slit width of 20 eV. Automated data collection was carried out using Leginon at a nominal magnification of 105,000x with a pixel size of 0.685 Å. The dose rate was adjusted to 8 counts/pixel/s, and each movie was acquired in super-resolution mode fractionated in 50 frames of 200 ms. For MERS-CoV S/LCA60, 2,400 micrographs were collected in a single session with a defocus range comprised between 0.6 and 3.0 μm. For SARS-CoV S/S230, 5,900 images were collected in a single session with a defocus range comprised between 0.8 and 3.0 μm.
       </p>
      </sec>
      <sec id="sec4.4.12">
       <title>
        CryoEM data processing of MERSCoV S/LCA60
       </title>
       <p id="p0195">
        Movie frame alignment was carried out with MotionCorr2 (
        <xref ref-type="bibr" rid="bib78">
         Zheng et al., 2017
        </xref>
        ) using a dose weighting of 40 e
        <sup>
         -
        </sup>
        /Å
        <sup>
         2
        </sup>
        . The parameters of the microscope contrast-transfer function were estimated with GCTF (
        <xref ref-type="bibr" rid="bib76">
         Zhang, 2016
        </xref>
        ). Particles were automatically picked with DoGPicker (
        <xref ref-type="bibr" rid="bib65">
         Voss et al., 2009
        </xref>
        ) through the Appion interface (
        <xref ref-type="bibr" rid="bib28">
         Lander et al., 2009
        </xref>
        ). Particle images were extracted and processed with Relion3.0 (
        <xref ref-type="bibr" rid="bib24">
         Kimanius et al., 2016
        </xref>
        ) with a box size of 768 pixels
        <sup>
         2
        </sup>
        binned to 384 pixels
        <sup>
         2
        </sup>
        yielding a pixel size of 1.37Å. Reference free 2D classification was used to parse 240,000 particles from the original 500,000 particle images using Relion3.0. An initial model was generated from PDBID
        <ext-link ext-link-type="uri" id="intref0135" xlink:href="pdb:5W9J">
         5W9J
        </ext-link>
        with all MERS-CoV S domain B closed and removing the G4 Fab (
        <xref ref-type="bibr" rid="bib45">
         Pallesen et al., 2017
        </xref>
        ). Relion3.0 3D classification with C1 symmetry was utilized to select the ∼126,000 best particles for state 1 and the ∼114,000 best particles for state 2. CTF refinement in Relion3.0 was used to refine per-particle defocus values. Particles images from each state were subjected to the Bayesian polishing procedure implemented in Relion3.0 (
        <xref ref-type="bibr" rid="bib79">
         Zivanov et al., 2018
        </xref>
        ,
        <xref ref-type="bibr" rid="bib80">
         Zivanov et al., 2019
        </xref>
        ) and 3D refinement before performing 3D classification, without refining angle and shifts, using soft masks focusing on the B domains and Fabs with a tau factor of 50. 82,000 and 78,000 particles were selected for states 1 and 2, respectively. Particle images from state 1 underwent another round of domain B/LCA60 focused classification to select 54,000 particles used for the final reconstruction. Finally, CryoSPARC non-uniform refinement (
        <xref ref-type="bibr" rid="bib47">
         Punjani et al., 2017
        </xref>
        ) was used to obtain the final reconstructions at 3.5 and 3.6 Å resolution, respectively, using soft masks excluding the open B domains and bound Fabs. Reported resolutions are based on the gold-standard FSC = 0.143 criterion (
        <xref ref-type="bibr" rid="bib51">
         Rosenthal and Henderson, 2003
        </xref>
        ,
        <xref ref-type="bibr" rid="bib54">
         Scheres and Chen, 2012
        </xref>
        ) and Fourier shell correlation curves were corrected for the effects of soft masking by high-resolution noise substitution(
        <xref ref-type="bibr" rid="bib9">
         Chen et al., 2013
        </xref>
        ). Local resolution estimation, filtering and sharpening was carried out using CryoSPARC. Analysis was carried out using the state 1 structure since the reconstruction is best resolved.
       </p>
      </sec>
      <sec id="sec4.4.13">
       <title>
        CryoEM data processing of SARS-CoV S/S230
       </title>
       <p id="p0200">
        Movie frame alignment was carried out with MotionCorr2 (
        <xref ref-type="bibr" rid="bib78">
         Zheng et al., 2017
        </xref>
        ) using a dose weighting of 40 e
        <sup>
         -
        </sup>
        /Å
        <sup>
         2
        </sup>
        . The parameters of the microscope contrast-transfer function were estimated with GCTF (
        <xref ref-type="bibr" rid="bib76">
         Zhang, 2016
        </xref>
        ). Particles were automatically picked with DoGPicker (
        <xref ref-type="bibr" rid="bib65">
         Voss et al., 2009
        </xref>
        ) through the Appion interface (
        <xref ref-type="bibr" rid="bib28">
         Lander et al., 2009
        </xref>
        ). Particle images were extracted and processed with Relion3.0 (
        <xref ref-type="bibr" rid="bib24">
         Kimanius et al., 2016
        </xref>
        ) with a box size of 768 pixels
        <sup>
         2
        </sup>
        binned to 72 pixels
        <sup>
         2
        </sup>
        (for 2D classification), 128 pixels
        <sup>
         2
        </sup>
        (for 3D classification) or 384 pixels
        <sup>
         2
        </sup>
        (for 3D refinement, yielding a pixel size of 1.37Å). Two rounds of Relion reference-free 2D classification were used to select ∼350,000 particles clustering in well-defined class averages. An initial model was generated from a SARS-CoV S structure with all B domains closed (PDB:
        <ext-link ext-link-type="uri" id="intref0140" xlink:href="pdb:5X58">
         5X58
        </ext-link>
        ) (
        <xref ref-type="bibr" rid="bib75">
         Yuan et al., 2017
        </xref>
        ). Relion 3D classification without applying symmetry was utilized to select ∼162,000 particle images for state 1 (including numerous conformations of the two bound Fabs as well as partial occupancy) and ∼126,000 particle images for state 2 (including numerous conformations of the three bound Fabs as well as partial occupancy). Particle images in each subset were then subsequently subjected to a new round of 3D classification without imposing symmetry and using the same initial model as for the previous round. A subset of ∼65,000 particle images from state 1 and ∼71,000 particle images from state 2 were selected based on reduced conformational heterogeneity of the bound Fabs (which exhibit a continuum of conformational states) and independently used to run 3D auto-refinements using Relion. Particle images from each state were subjected to the Bayesian polishing procedure implemented in Relion3.0 (
        <xref ref-type="bibr" rid="bib79">
         Zivanov et al., 2018
        </xref>
        ,
        <xref ref-type="bibr" rid="bib80">
         Zivanov et al., 2019
        </xref>
        ) and 3D refinement before performing 3D classification, without refining angle and shifts, using soft masks focusing on the B domains and Fabs with a tau factor of 30. ∼23,000 and 20,000 particles were selected for states 1 and 2, respectively, based on mobility of the bound Fabs which were less well resolved than SARS-CoV S (especially the S
        <sub>
         2
        </sub>
        subunit) in the maps. Finally, CryoSPARC non-uniform refinement (
        <xref ref-type="bibr" rid="bib47">
         Punjani et al., 2017
        </xref>
        ) was used to obtain the final reconstructions at 4.2 Å and 4.5 Å resolution for states 1 and 2, respectively. Reported resolutions are based on the gold-standard FSC = 0.143 criterion (
        <xref ref-type="bibr" rid="bib51">
         Rosenthal and Henderson, 2003
        </xref>
        ,
        <xref ref-type="bibr" rid="bib54">
         Scheres and Chen, 2012
        </xref>
        ) and Fourier shell correlation curves were corrected for the effects of soft masking by high-resolution noise substitution (
        <xref ref-type="bibr" rid="bib9">
         Chen et al., 2013
        </xref>
        ). Local resolution estimation, filtering and sharpening was carried out using CryoSPARC.
       </p>
      </sec>
      <sec id="sec4.4.8">
       <title>
        CryoEM Model building and analysis
       </title>
       <p id="p0205">
        UCSF Chimera (
        <xref ref-type="bibr" rid="bib18">
         Goddard et al., 2007
        </xref>
        ) and Coot were used to fit atomic models (PDB:
        <ext-link ext-link-type="uri" id="intref0145" xlink:href="pdb:5W9J">
         5W9J
        </ext-link>
        for MERS and PDB:
        <ext-link ext-link-type="uri" id="intref0150" xlink:href="pdb:5X58">
         5X58
        </ext-link>
        for SARS) into the cryoEM maps. The crystal structure of LCA60 or S230 were also fit into density using UCSF Chimera. The models were subsequently manually rebuilt using Coot (
        <xref ref-type="bibr" rid="bib6">
         Brown et al., 2015
        </xref>
        ,
        <xref ref-type="bibr" rid="bib13">
         Emsley et al., 2010
        </xref>
        ). N-linked glycans were hand-built into the density where visible and the models were refined and relaxed using Rosetta (
        <xref ref-type="bibr" rid="bib71">
         Wang et al., 2016
        </xref>
        ). Glycan refinement relied on a dedicated Rosetta protocol, which uses physically realistic geometries based on prior knowledge of saccharide chemical properties (
        <xref ref-type="bibr" rid="bib15">
         Frenz et al., 2019
        </xref>
        ), and was aided by using both sharpened and unsharpened maps. Models were analyzed using MolProbity (
        <xref ref-type="bibr" rid="bib8">
         Chen et al., 2010
        </xref>
        ) and privateer (
        <xref ref-type="bibr" rid="bib2">
         Agirre et al., 2015
        </xref>
        ). Figures were generated using UCSF ChimeraX (
        <xref ref-type="bibr" rid="bib19">
         Goddard et al., 2018
        </xref>
        ).
       </p>
       <sec id="sec4.4.8.1">
        <title>
         Negative stain electron microscopy
        </title>
        <p id="p0210">
         Protein was adsorbed to glow-discharged carbon-coated copper grids for 1 min prior to a 3X wash with water and 2% uranyl formate staining. Micrographs were recorded using the Leginon software (
         <xref ref-type="bibr" rid="bib62">
          Suloway et al., 2005
         </xref>
         ) on a 100kV FEI Tecnai G2 Spirit with a Gatan Ultrascan 4000 4k x 4k CCD camera at 67,000 nominal magnification. The defocus ranged from 1.0 to 2.0 μm and the pixel size was 1.6 Å. Particles were picked automatically in a reference free manner using DogPicker. Contrast transfer function (CTF) estimation was performed using GCTF (
         <xref ref-type="bibr" rid="bib76">
          Zhang, 2016
         </xref>
         ). Class averages were generated using Relion2.1 (
         <xref ref-type="bibr" rid="bib24">
          Kimanius et al., 2016
         </xref>
         ).
        </p>
       </sec>
       <sec id="sec4.4.8.2">
        <title>
         Crystallization, data collection and data processing of LCA60 and S230
        </title>
        <p id="p0215">
         Fab LCA60 crystals were grown in hanging drop set up with a mosquito at 20°C using 150 nL protein solution and 150 nL mother liquor solution containing 30% (v/v) Jeffamine ED-2001 pH 7.0 and 0.1 M HEPES pH 7.0. The LCA60 dataset was collected at the ALS beamline 5.0.1 and processed to 3.0 Å resolution in space group P2
         <sub>
          1
         </sub>
         , with cell dimensions a = 70.72 Å b = 69.57 Å and c = 93.84 Å, using XDS (
         <xref ref-type="bibr" rid="bib23">
          Kabsch, 2010
         </xref>
         ) and Aimless (
         <xref ref-type="bibr" rid="bib14">
          Evans and Murshudov, 2013
         </xref>
         ). Fab S230 crystals were grown in hanging drop set up with a mosquito at 20°C using 150 nL protein solution and 150 nL mother liquor solution containing 3.5 M sodium formate pH 7.0. Crystals were cryo-protected using the mother liquor solution supplemented with 30% glycerol. The S230 dataset was collected at the ALS beamline 5.0.1 and processed to 1.5 Å resolution in space group P2
         <sub>
          1
         </sub>
         2
         <sub>
          1
         </sub>
         2
         <sub>
          1
         </sub>
         using XDS and Aimless. The structures of Fab LCA60 and Fab S230 were solved by molecular replacement using Phaser (
         <xref ref-type="bibr" rid="bib82">
          McCoy et al., 2018
         </xref>
         ) and homology models as search models. The coordinates were subsequently improved and completed using Buccaneer (
         <xref ref-type="bibr" rid="bib11">
          Cowtan, 2006
         </xref>
         ) and COOT (
         <xref ref-type="bibr" rid="bib6">
          Brown et al., 2015
         </xref>
         ,
         <xref ref-type="bibr" rid="bib13">
          Emsley et al., 2010
         </xref>
         ) and refined with BUSTER-TNT (
         <xref ref-type="bibr" rid="bib5">
          Blanc et al., 2004
         </xref>
         ) and REFMAC5 (
         <xref ref-type="bibr" rid="bib84">
          Vagin et al., 2004
         </xref>
         ). Simulated annealing and omit map calculations were performed in Phenix (
         <xref ref-type="bibr" rid="bib1">
          Adams et al., 2010
         </xref>
         ). The quality of the crystal structures were analyzed using MolProbity (
         <xref ref-type="bibr" rid="bib8">
          Chen et al., 2010
         </xref>
         ). Crystallographic data collection and refinement statistics are shown in
         <xref ref-type="supplementary-material" rid="mmc4">
          Table S4
         </xref>
         .
        </p>
       </sec>
       <sec id="sec4.4.8.3">
        <title>
         Ligand-induced conformational change analysis using negative staining EM
        </title>
        <p id="p0220">
         The wild-type SARS-CoV S ectodomain trimer at 1 mg/mL (7.5 μM spike monomer) was incubated with equimolar amount of Fab S230 or 4-fold molar excess of ACE2 for 30 min or overnight (20-30 hours) on ice. Samples were taken at the end of the incubation and imaged by negative staining EM. The incubation mixtures were also subjected to digestion with trypsin at 1.6 μg/mL at room temperature and reactions were analyzed by SDS-PAGE at different time points. The digestion reaction was stopped by addition of 1.5 mM PMSF after 15 min for imaging by negative staining EM. To visualize the effect of ligand binding on pre-digested wild-type SARS-CoV S ectodomain trimer, the protein at 1 mg/mL was digested with 1.6 μg/mL trypsin for 15 min at room temperature before stopping the reaction using 1.5 mM PMSF. The pre-digested wild-type SARS-CoV S ectodomain trimer was incubated with S230 or ACE2 on ice for 30 min or overnight before negative staining EM imaging.
        </p>
       </sec>
       <sec id="sec4.4.8.4">
        <title>
         Ligand-induced conformational change analysis using Western-blotting
        </title>
        <p id="p0225">
         SARS-CoV S pseudovirions were thawed and incubated either with an equal volume of buffer, 10 μM of the ACE2 ectodomain or 500 nM S230 Fab for 30 min or 2 hours on ice. Trypsin (5 μg/mL) was then added to these samples for 30 min at 37°C. Subsequently, the samples were supplemented with 10 μg/mL proteinase K for 30 min at 4°C. 6X SDS-PAGE loading buffer was then added to all samples prior to boiling at 95°C for 5 min. Samples were run on a 4%–15% gradient Tris-Glycine Gel (BioRad) and transferred to PVDF membranes. An anti-S
         <sub>
          2
         </sub>
         SARS-CoV S polyclonal primary antibody (1:1,500 dilution, ThermoFisher) and an Alexa Fluor 680-conjugated goat anti-rabbit secondary antibody (1:20,000 dilution, Jackson Laboratory) were used for Western-blotting. A LI-COR processor was used to develop images.
        </p>
       </sec>
      </sec>
      <sec id="sec4.4.9">
       <title>
        Mass spectrometry
       </title>
       <p id="p0230">
        In solution: MERS-CoV S or SARS-CoV S were either unaltered or subjected to Endo-F and Endo-H deglycosylation treatment. Two microliters of the deglycosylases were allowed to incubate with 20 μg of S for 4-14 hr in 50mM sodium acetate pH 4.4 at 37°C in a 20 μL reaction. 6 μg of S were then incubated in 100mM Tris pH 8.5, 2% sodium deoxycholate, 10mM tris(2-carboxyethyl)phosphine, and 40mM iodoacetamide at 95°C for five minutes and 25°C for thirty minutes in the dark. Denaturated, reduced, and alkylated S (1.6 μg) was then diluted into fresh 50mM Ammonium bicarbonate and incubated for 14 hr at 37°C either with 0.032 μg of trypsin (Sigma Aldrich), chymotrypsin (Sigma Aldrich), trypsin then sequentially chymotrypsin, alpha lytic protease (Sigma), or AspN protease (Pierce). Formic acid was then added to a final concentration of 2% and the samples spun at 14,000 rpm for 20 min and then again for 5 min to precipitate the sodium deoxycholate and collect the peptides from the supernatants. The SARS S digests with trypsin, chymotrypsin and alpha lytic protease were processed in parallel after cotton-enrichment of glycopeptides. Approximately 0.5 mg of cotton wool was packed into 100 μL pipette tips. Glycopeptides were diluted in 80% acetonitrile with 0.1% formic acid and bound to the cotton plug, followed by washing of the cotton plug with 80% acetonitrile with 0.1% formic acid. Glycopeptides were eluted in 0.1% formic acid in water.
       </p>
       <p id="p0235">
        In gel: 120 μL of MERS-CoV England1 and EMC2012 virions and 40 μg of purified MERS2P were run on a 4%–15% gradient Tris-Glycine Gel (BioRad). One lane of each sample was loaded with 40 μL while a second lane was loaded with 40 μL, allowed to run for 2 min, and loaded with another 40 μL. The bands were excised and washed with milliQ water and acetonitrile. 1 mg/mL DTT in 50mM ammonium bicarbonate was incubated with the gel pieces at 60°C for 1 hour. Following an acetonitrile wash, 10 mg/mL iodoacetamide in 50mM ammonium bicarbonate was incubated for 30 min at room temperature in darkness. Following extensive washes, either 30 μg/mL trypsin or chymotrypsin in ammonium bicarbonate was incubated with the gel pieces for 1.5 hours on ice. The solution was replaced with ammonium bicarbonate and incubated overnight at 37°C. The supernatant was collected and dried down in a speedvac for 1 hr. The peptides were reconstituted in 40 μL 10% formic acid, 5% DMSO.
       </p>
       <p id="p0240">
        Peptide supernatant was collected and between 4 and 8 μL were run on a Orbitrap Fusion Tribrid (ThermoFisher Scientific) mass spectrometer. A 35 cm analytical column and a 3cm trap column filled with ReproSil-Pur C18AQ 5 μm (Dr. Maisch GMBH) beads was used. Nanospray LC-MS/MS was used to separate peptides over a 110-min gradient from 5% to 30% acetonitrile. A positive spray voltage of 2100 was used with an ion transfer tube temperature of 350°C. An electron-transfer/higher energy collision dissociation ion fragmentation scheme was used (
        <xref ref-type="bibr" rid="bib16">
         Frese et al., 2013
        </xref>
        ). The supplemental higher energy collision dissociation energy was 0.15 for the runs. A resolution setting of 120,000 with an AGC target of 2
        <sup>
         ∗
        </sup>
        10
        <sup>
         5
        </sup>
        was used for MS1, and a resolution setting of 30,000 with an AGC target of 1
        <sup>
         ∗
        </sup>
        10
        <sup>
         5
        </sup>
        was used for MS2. The data was then analyzed using Byonic (
        <xref ref-type="bibr" rid="bib4">
         Bern et al., 2012
        </xref>
        ) against a custom database of recombinant coronavirus spike proteins, searching for glycan modifications with 12/24 ppm search windows for MS1/MS2, respectively. The in-solution digestions of the recombinant ectodomain were searched against a custom database of recombinant coronavirus spike proteins, proteases, and common contaminants. The in-gel digestion experiments were first searched against a database comprised of the full MERS-CoV proteome and the full Chlorocebus sabaeus (virus produced in VeroE6 cells) or human proteome (ectodomain produced in HEK293F cells) retrieved from UniProt, with variable N-linked glycosylations omitted from the search to identify background contaminants. The top 16 contaminants were then assembled together with the S sequence into a focused database for the glycopeptide identifications. In all experiments, up to three missed cleavages were permitted using C-terminal cleavage at R/K for trypsin, F/Y/W/M/L for chymotrypsin, R/K/F/Y/W/M/L for trypsin-chymotrypsin, T/A/S/V for alpha lytic protease, and N-terminal cleavage at D for AspN. Carbamidomethylation of cysteine was set as fixed modification, methionine oxidation and carbamidomethylation of lysine as variable common 1, glycan modifications as variable common 2, with a variable common max. parameter of 3. The N-linked glycan databases of Byonic were merged into a single non-redundant set of glycan compositions for the searches. All reported glycopeptides in the Byonic results files were manually inspected for quality of fragment assignments. All glycopeptide identifications were merged into a single non-redundant list per sequon. Glycans were classified based on HexNAc content as high-mannose (2 HexNAc), hybrid (3 HexNAc) or complex (&gt; 3 HexNAc). Byonic search results were exported to mzIdentML format to build a spectral library in Skyline (
        <xref ref-type="bibr" rid="bib34">
         MacLean et al., 2010
        </xref>
        ) and extract peak areas for individual glycoforms from MS1 scans. The full database of variable N-linked glycan modifications from Byonic was manually added to the Skyline project file in XML format. Byonic search results from in-gel digestions of both virion samples and ectodomain were merged into a single spectral library and manually inspected for quantitation. Reported peak areas were pooled based on the number of HexNAc, Fuc or NeuAc residues to distinguish high-mannose/hybrid/complex glycosylation, fucosylation and sialylation, respectively.
       </p>
      </sec>
      <sec id="sec4.4.10">
       <title>
        SEC-MALS
       </title>
       <p id="p0245">
        30 μl of each sample at 2.5 mg/mL were loaded onto a Vanquish column (ThermoFisher Scientific) with Acquity UPLC protein BEH SEC, 450Å, 2.5 μm, 4.6 mm x 150mm (Waters) and passed through a Wyatt μDAWN coupled to a Wyatt Optilab UT-rEX differential refractive index detector. Data were analyzed using Astra 6 software (Wyatt Technology Corp) to quantify the protein and glycan weight.
       </p>
      </sec>
      <sec id="sec4.4.11">
       <title>
        Biolayer interferometry
       </title>
       <p id="p0250">
        Assays were performed on an Octet Red instrument at 30°C with shaking at 1,000 RPM. ARG2 biosensors were hydrated in water then activated for 300 s with an NHS-EDC solution (ForteBio) prior to amine coupling. 30 μg/mL SARS-S1-Fc was amine coupled to ARG2 (ForteBio) sensors in pH5.0 10mM acetate (ForteBio) respectively for 600 s (4nm shift) and then quenched with 1M ethanolamine for 600 s. A baseline in 25mM Phosphate pH8.0, 150mM NaCl, 1% BSA was collected for 120 s prior to immersing the sensors in a serial dilution of either ACE2 or S230 for 600 s prior to dissociation in buffer for 600 s. ACE2 concentrations used were 1,000 nm, 333 nM, 111 nM, 37 nM, 12.3 nM, and 4.12 nM. S230 concentrations used were 100 nM, 33.3 nM, 11.1 nM, 3.7 nM, 1.23 nM, and 0.412 nM. Curve fitting was performed using a 1:1 binding model and the ForteBio data analysis software. Mean
        <italic>
         k
        </italic>
        <sub>
         on
        </sub>
        ,
        <italic>
         k
        </italic>
        <sub>
         off
        </sub>
        values were determined with a global fit applied to all data.
       </p>
      </sec>
     </sec>
     <sec id="sec4.5">
      <title>
       Quantification and Statistical Analysis
      </title>
      <p id="p0255">
       Digestion followed by Western-blotting experiments as well as biolayer interferometry assays were performed in triplicates.
      </p>
     </sec>
     <sec id="sec4.6" sec-type="data-availability">
      <title>
       Data and Software Availability
      </title>
      <p id="p0260">
       The cryoEM maps and atomic models have been deposited at the Electron Microscopy Data Bank and the Protein Data Bank with accession codes EMDB: 0401 and PDB:
       <ext-link ext-link-type="uri" id="intref0155" xlink:href="pdb:6NB3">
        6NB3
       </ext-link>
       (MERS-CoV S/LCA60 state 1), EMDB: 0402 and PDB:
       <ext-link ext-link-type="uri" id="intref0160" xlink:href="pdb:6NB4">
        6NB4
       </ext-link>
       (MERS-CoV S/LCA60 state 2), EMDB: 0403 and PDB:
       <ext-link ext-link-type="uri" id="intref0165" xlink:href="pdb:6NB6">
        6NB6
       </ext-link>
       (SARS-CoV S/S230 state 1), EMDB: 0404 and PDB:
       <ext-link ext-link-type="uri" id="intref0170" xlink:href="pdb:6NB7">
        6NB7
       </ext-link>
       (SARS-CoV S/S230 state 2). The crystal structures have been deposited in the Protein Data Bank with accession codes PDB:
       <ext-link ext-link-type="uri" id="intref0175" xlink:href="pdb:6NB5">
        6NB5
       </ext-link>
       (LCA60) and PDB:
       <ext-link ext-link-type="uri" id="intref0180" xlink:href="pdb:6NB8">
        6NB8
       </ext-link>
       (S230). The mass spectrometry data have been deposited in the ProteomeXchange consortium (PRIDE) databank with accession codes PRIDE: PDX010494. A list of software used in this study can be found in the
       <xref ref-type="sec" rid="sec4.1">
        Key Resources Table
       </xref>
       .
      </p>
     </sec>
    </sec>
    <back>
     <ref-list id="cebib0010">
      <title>
       References
      </title>
      <ref id="bib1">
       <element-citation id="sref1" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adams
          </surname>
          <given-names>
           P.D.
          </given-names>
         </name>
         <name>
          <surname>
           Afonine
          </surname>
          <given-names>
           P.V.
          </given-names>
         </name>
         <name>
          <surname>
           Bunkóczi
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           V.B.
          </given-names>
         </name>
         <name>
          <surname>
           Davis
          </surname>
          <given-names>
           I.W.
          </given-names>
         </name>
         <name>
          <surname>
           Echols
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Headd
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
         <name>
          <surname>
           Hung
          </surname>
          <given-names>
           L.-W.
          </given-names>
         </name>
         <name>
          <surname>
           Kapral
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Gross-Kunstleve
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr
        </article-title>
        <source>
         D Biol. Crystallogr
        </source>
        <volume>
         66
        </volume>
        <year>
         2010
        </year>
        <fpage>
         213
        </fpage>
        <lpage>
         221
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib2">
       <element-citation id="sref2" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Agirre
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Iglesias-Fernández
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Rovira
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Davies
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Cowtan
          </surname>
          <given-names>
           K.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Privateer: software for the conformational validation of carbohydrate structures
        </article-title>
        <source>
         Nat. Struct. Mol. Biol.
        </source>
        <volume>
         22
        </volume>
        <year>
         2015
        </year>
        <fpage>
         833
        </fpage>
        <lpage>
         834
        </lpage>
        <pub-id pub-id-type="pmid">
         26581513
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib3">
       <element-citation id="sref3" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Belouzard
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
         <name>
          <surname>
           Whittaker
          </surname>
          <given-names>
           G.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <volume>
         106
        </volume>
        <year>
         2009
        </year>
        <fpage>
         5871
        </fpage>
        <lpage>
         5876
        </lpage>
        <pub-id pub-id-type="pmid">
         19321428
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <element-citation id="sref4" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bern
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kil
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Byonic: advanced peptide and protein identification software
        </article-title>
        <source>
         Curr. Protoc. Bioinformatics
        </source>
        <volume>
         Chapter 13
        </volume>
        <year>
         2012
        </year>
        <comment>
         Unit 13.20
        </comment>
       </element-citation>
      </ref>
      <ref id="bib5">
       <element-citation id="sref5" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Blanc
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Roversi
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Vonrhein
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Flensburg
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lea
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Bricogne
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT. Acta Crystallogr
        </article-title>
        <source>
         D Biol. Crystallogr
        </source>
        <volume>
         60
        </volume>
        <year>
         2004
        </year>
        <fpage>
         2210
        </fpage>
        <lpage>
         2221
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib6">
       <element-citation id="sref6" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Long
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Nicholls
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Toots
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Emsley
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Murshudov
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tools for macromolecular model building and refinement into electron cryo-microscopy reconstructions
        </article-title>
        <source>
         Acta Crystallogr. D Biol. Crystallogr.
        </source>
        <volume>
         71
        </volume>
        <year>
         2015
        </year>
        <fpage>
         136
        </fpage>
        <lpage>
         153
        </lpage>
        <pub-id pub-id-type="pmid">
         25615868
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib7">
       <element-citation id="sref7" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Burkard
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Verheije
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wicht
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           van Kasteren
          </surname>
          <given-names>
           S.I.
          </given-names>
         </name>
         <name>
          <surname>
           van Kuppeveld
          </surname>
          <given-names>
           F.J.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Pelkmans
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           de Haan
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <volume>
         10
        </volume>
        <year>
         2014
        </year>
        <fpage>
         e1004502
        </fpage>
        <pub-id pub-id-type="pmid">
         25375324
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib8">
       <element-citation id="sref8" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           V.B.
          </given-names>
         </name>
         <name>
          <surname>
           Arendall
          </surname>
          <given-names>
           W.B.
          </given-names>
          <suffix>
           3rd
          </suffix>
         </name>
         <name>
          <surname>
           Headd
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
         <name>
          <surname>
           Keedy
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           Immormino
          </surname>
          <given-names>
           R.M.
          </given-names>
         </name>
         <name>
          <surname>
           Kapral
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Murray
          </surname>
          <given-names>
           L.W.
          </given-names>
         </name>
         <name>
          <surname>
           Richardson
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Richardson
          </surname>
          <given-names>
           D.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MolProbity: all-atom structure validation for macromolecular crystallography
        </article-title>
        <source>
         Acta Crystallogr. D Biol. Crystallogr.
        </source>
        <volume>
         66
        </volume>
        <year>
         2010
        </year>
        <fpage>
         12
        </fpage>
        <lpage>
         21
        </lpage>
        <pub-id pub-id-type="pmid">
         20057044
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib9">
       <element-citation id="sref9" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           McMullan
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Faruqi
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
         <name>
          <surname>
           Murshudov
          </surname>
          <given-names>
           G.N.
          </given-names>
         </name>
         <name>
          <surname>
           Short
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Scheres
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Henderson
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy
        </article-title>
        <source>
         Ultramicroscopy
        </source>
        <volume>
         135
        </volume>
        <year>
         2013
        </year>
        <fpage>
         24
        </fpage>
        <lpage>
         35
        </lpage>
        <pub-id pub-id-type="pmid">
         23872039
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib10">
       <element-citation id="sref10" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corti
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Pedotti
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Simonelli
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Fett
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Fernandez-Rodriguez
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Foglierini
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Agatic
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Vanzetta
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <volume>
         112
        </volume>
        <year>
         2015
        </year>
        <fpage>
         10473
        </fpage>
        <lpage>
         10478
        </lpage>
        <pub-id pub-id-type="pmid">
         26216974
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib11">
       <element-citation id="sref11" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cowtan
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Buccaneer software for automated model building. 1. Tracing protein chains. Acta Crytallogr
        </article-title>
        <source>
         D Biol. Crystallogr
        </source>
        <volume>
         62
        </volume>
        <year>
         2006
        </year>
        <fpage>
         1002
        </fpage>
        <lpage>
         1011
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib12">
       <element-citation id="sref12" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Tai
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Tseng
          </surname>
          <given-names>
           C.K.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines
        </article-title>
        <source>
         Nat. Commun.
        </source>
        <volume>
         7
        </volume>
        <year>
         2016
        </year>
        <fpage>
         13473
        </fpage>
        <pub-id pub-id-type="pmid">
         27874853
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <element-citation id="sref13" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Emsley
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Lohkamp
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Scott
          </surname>
          <given-names>
           W.G.
          </given-names>
         </name>
         <name>
          <surname>
           Cowtan
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Features and development of Coot
        </article-title>
        <source>
         Acta Crystallogr. D Biol. Crystallogr.
        </source>
        <volume>
         66
        </volume>
        <year>
         2010
        </year>
        <fpage>
         486
        </fpage>
        <lpage>
         501
        </lpage>
        <pub-id pub-id-type="pmid">
         20383002
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib14">
       <element-citation id="sref14" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Evans
          </surname>
          <given-names>
           P.R.
          </given-names>
         </name>
         <name>
          <surname>
           Murshudov
          </surname>
          <given-names>
           G.N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         How good are my data and what is the resolution?
        </article-title>
        <source>
         Acta Crystallogr. D Biol. Crystallogr.
        </source>
        <volume>
         69
        </volume>
        <year>
         2013
        </year>
        <fpage>
         1204
        </fpage>
        <lpage>
         1214
        </lpage>
        <pub-id pub-id-type="pmid">
         23793146
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib15">
       <element-citation id="sref15" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Frenz
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Rämisch
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Borst
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Walls
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Adolf-Bryfogle
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Schief
          </surname>
          <given-names>
           W.R.
          </given-names>
         </name>
         <name>
          <surname>
           Veesler
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           DiMaio
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Automatically fixing errors in glycoprotein structures with Rosetta
        </article-title>
        <source>
         Structure
        </source>
        <volume>
         27
        </volume>
        <year>
         2019
        </year>
        <fpage>
         134
        </fpage>
        <lpage>
         139.e3
        </lpage>
        <pub-id pub-id-type="pmid">
         30344107
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib16">
       <element-citation id="sref16" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Frese
          </surname>
          <given-names>
           C.K.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Taus
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Altelaar
          </surname>
          <given-names>
           A.F.
          </given-names>
         </name>
         <name>
          <surname>
           Mechtler
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Heck
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Mohammed
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Unambiguous phosphosite localization using electron-transfer/higher-energy collision dissociation (EThcD)
        </article-title>
        <source>
         J. Proteome Res.
        </source>
        <volume>
         12
        </volume>
        <year>
         2013
        </year>
        <fpage>
         1520
        </fpage>
        <lpage>
         1525
        </lpage>
        <pub-id pub-id-type="pmid">
         23347405
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib17">
       <element-citation id="sref17" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ge
          </surname>
          <given-names>
           X.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chmura
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Epstein
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Mazet
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         503
        </volume>
        <year>
         2013
        </year>
        <fpage>
         535
        </fpage>
        <lpage>
         538
        </lpage>
        <pub-id pub-id-type="pmid">
         24172901
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib18">
       <element-citation id="sref18" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goddard
          </surname>
          <given-names>
           T.D.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Ferrin
          </surname>
          <given-names>
           T.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Visualizing density maps with UCSF Chimera
        </article-title>
        <source>
         J. Struct. Biol.
        </source>
        <volume>
         157
        </volume>
        <year>
         2007
        </year>
        <fpage>
         281
        </fpage>
        <lpage>
         287
        </lpage>
        <pub-id pub-id-type="pmid">
         16963278
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib19">
       <element-citation id="sref19" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goddard
          </surname>
          <given-names>
           T.D.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Meng
          </surname>
          <given-names>
           E.C.
          </given-names>
         </name>
         <name>
          <surname>
           Pettersen
          </surname>
          <given-names>
           E.F.
          </given-names>
         </name>
         <name>
          <surname>
           Couch
          </surname>
          <given-names>
           G.S.
          </given-names>
         </name>
         <name>
          <surname>
           Morris
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Ferrin
          </surname>
          <given-names>
           T.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         UCSF ChimeraX: Meeting modern challenges in visualization and analysis
        </article-title>
        <source>
         Protein Sci.
        </source>
        <volume>
         27
        </volume>
        <year>
         2018
        </year>
        <fpage>
         14
        </fpage>
        <lpage>
         25
        </lpage>
        <pub-id pub-id-type="pmid">
         28710774
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib20">
       <element-citation id="sref20" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gui
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Xiang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding
        </article-title>
        <source>
         Cell Res.
        </source>
        <volume>
         27
        </volume>
        <year>
         2017
        </year>
        <fpage>
         119
        </fpage>
        <lpage>
         129
        </lpage>
        <pub-id pub-id-type="pmid">
         28008928
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib21">
       <element-citation id="sref21" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Al Dhahiry
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Galiano
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Myers
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Godeke
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Jonges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Diab
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <volume>
         14
        </volume>
        <year>
         2014
        </year>
        <fpage>
         140
        </fpage>
        <lpage>
         145
        </lpage>
        <pub-id pub-id-type="pmid">
         24355866
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib22">
       <element-citation id="sref22" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           L.P.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.L.
          </given-names>
         </name>
         <name>
          <surname>
           Ge
          </surname>
          <given-names>
           X.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           J.Z.
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           X.R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.Z.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <volume>
         13
        </volume>
        <year>
         2017
        </year>
        <fpage>
         e1006698
        </fpage>
        <pub-id pub-id-type="pmid">
         29190287
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib23">
       <element-citation id="sref23" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kabsch
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Xds
        </article-title>
        <source>
         Acta Crystallogr. D Biol. Crystallogr.
        </source>
        <volume>
         66
        </volume>
        <year>
         2010
        </year>
        <fpage>
         125
        </fpage>
        <lpage>
         132
        </lpage>
        <pub-id pub-id-type="pmid">
         20124692
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib24">
       <element-citation id="sref24" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kimanius
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Forsberg
          </surname>
          <given-names>
           B.O.
          </given-names>
         </name>
         <name>
          <surname>
           Scheres
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Lindahl
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Accelerated cryo-EM structure determination with parallelisation using GPUs in RELION-2
        </article-title>
        <source>
         eLife
        </source>
        <volume>
         5
        </volume>
        <year>
         2016
        </year>
       </element-citation>
      </ref>
      <ref id="bib25">
       <element-citation id="sref25" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kirchdoerfer
          </surname>
          <given-names>
           R.N.
          </given-names>
         </name>
         <name>
          <surname>
           Cottrell
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Pallesen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yassine
          </surname>
          <given-names>
           H.M.
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           H.L.
          </given-names>
         </name>
         <name>
          <surname>
           Corbett
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           B.S.
          </given-names>
         </name>
         <name>
          <surname>
           McLellan
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Ward
          </surname>
          <given-names>
           A.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pre-fusion structure of a human coronavirus spike protein
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         531
        </volume>
        <year>
         2016
        </year>
        <fpage>
         118
        </fpage>
        <lpage>
         121
        </lpage>
        <pub-id pub-id-type="pmid">
         26935699
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib26">
       <element-citation id="sref26" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kirchdoerfer
          </surname>
          <given-names>
           R.N.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Pallesen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wrapp
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           H.L.
          </given-names>
         </name>
         <name>
          <surname>
           Cottrell
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Corbett
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           B.S.
          </given-names>
         </name>
         <name>
          <surname>
           McLellan
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Ward
          </surname>
          <given-names>
           A.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis
        </article-title>
        <source>
         Sci. Rep.
        </source>
        <volume>
         8
        </volume>
        <year>
         2018
        </year>
        <fpage>
         15701
        </fpage>
        <pub-id pub-id-type="pmid">
         30356097
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib81">
       <element-citation id="sref81" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Krissinel
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Henrick
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inference of macromolecular assemblies from crystalline state
        </article-title>
        <source>
         J. Mol. Biol.
        </source>
        <volume>
         372
        </volume>
        <year>
         2007
        </year>
        <fpage>
         774
        </fpage>
        <lpage>
         797
        </lpage>
        <pub-id pub-id-type="pmid">
         17681537
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib27">
       <element-citation id="sref27" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Krokhin
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Andonov
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Flick
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Stroeher
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Bastien
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Dasuri
          </surname>
          <given-names>
           K.V.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mass spectrometric characterization of proteins from the SARS virus: a preliminary report
        </article-title>
        <source>
         Mol. Cell. Proteomics
        </source>
        <volume>
         2
        </volume>
        <year>
         2003
        </year>
        <fpage>
         346
        </fpage>
        <lpage>
         356
        </lpage>
        <pub-id pub-id-type="pmid">
         12775768
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib28">
       <element-citation id="sref28" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lander
          </surname>
          <given-names>
           G.C.
          </given-names>
         </name>
         <name>
          <surname>
           Stagg
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Voss
          </surname>
          <given-names>
           N.R.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Fellmann
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Pulokas
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yoshioka
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Irving
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Mulder
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           P.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Appion: an integrated, database-driven pipeline to facilitate EM image processing
        </article-title>
        <source>
         J. Struct. Biol.
        </source>
        <volume>
         166
        </volume>
        <year>
         2009
        </year>
        <fpage>
         95
        </fpage>
        <lpage>
         102
        </lpage>
        <pub-id pub-id-type="pmid">
         19263523
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib29">
       <element-citation id="sref29" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Berne
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Somasundaran
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Luzuriaga
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Greenough
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         426
        </volume>
        <year>
         2003
        </year>
        <fpage>
         450
        </fpage>
        <lpage>
         454
        </lpage>
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib30">
       <element-citation id="sref30" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Harrison
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure of SARS coronavirus spike receptor-binding domain complexed with receptor
        </article-title>
        <source>
         Science
        </source>
        <volume>
         309
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1864
        </fpage>
        <lpage>
         1868
        </lpage>
        <pub-id pub-id-type="pmid">
         16166518
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib31">
       <element-citation id="sref31" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Epstein
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Crameri
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bats are natural reservoirs of SARS-like coronaviruses
        </article-title>
        <source>
         Science
        </source>
        <volume>
         310
        </volume>
        <year>
         2005
        </year>
        <fpage>
         676
        </fpage>
        <lpage>
         679
        </lpage>
        <pub-id pub-id-type="pmid">
         16195424
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib32">
       <element-citation id="sref32" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Kuhn
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           I.C.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2
        </article-title>
        <source>
         EMBO J.
        </source>
        <volume>
         24
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1634
        </fpage>
        <lpage>
         1643
        </lpage>
        <pub-id pub-id-type="pmid">
         15791205
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib33">
       <element-citation id="sref33" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         500
        </volume>
        <year>
         2013
        </year>
        <fpage>
         227
        </fpage>
        <lpage>
         231
        </lpage>
        <pub-id pub-id-type="pmid">
         23831647
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib34">
       <element-citation id="sref34" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           MacLean
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Tomazela
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Shulman
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Chambers
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Finney
          </surname>
          <given-names>
           G.L.
          </given-names>
         </name>
         <name>
          <surname>
           Frewen
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Kern
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Tabb
          </surname>
          <given-names>
           D.L.
          </given-names>
         </name>
         <name>
          <surname>
           Liebler
          </surname>
          <given-names>
           D.C.
          </given-names>
         </name>
         <name>
          <surname>
           MacCoss
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Skyline: an open source document editor for creating and analyzing targeted proteomics experiments
        </article-title>
        <source>
         Bioinformatics
        </source>
        <volume>
         26
        </volume>
        <year>
         2010
        </year>
        <fpage>
         966
        </fpage>
        <lpage>
         968
        </lpage>
        <pub-id pub-id-type="pmid">
         20147306
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib35">
       <element-citation id="sref35" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Matsuyama
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Taguchi
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Two-step conformational changes in a coronavirus envelope glycoprotein mediated by receptor binding and proteolysis
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         83
        </volume>
        <year>
         2009
        </year>
        <fpage>
         11133
        </fpage>
        <lpage>
         11141
        </lpage>
        <pub-id pub-id-type="pmid">
         19706706
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib82">
       <element-citation id="sref82" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McCoy
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Oeffner
          </surname>
          <given-names>
           R.D.
          </given-names>
         </name>
         <name>
          <surname>
           Millan
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Sammito
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Uson
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Read
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Gyre and gimble: a maximum-likelihood replacement for Patterson correlation refinement
        </article-title>
        <source>
         Acta. Crystallogr. D Struct. Biol.
        </source>
        <volume>
         74
        </volume>
        <year>
         2018
        </year>
        <fpage>
         279
        </fpage>
        <lpage>
         289
        </lpage>
        <pub-id pub-id-type="pmid">
         29652255
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib36">
       <element-citation id="sref36" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McCoy
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           van Gils
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Ozorowski
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Messmer
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Briney
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Voss
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Kulp
          </surname>
          <given-names>
           D.W.
          </given-names>
         </name>
         <name>
          <surname>
           Macauley
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Sok
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Pauthner
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies
        </article-title>
        <source>
         Cell Rep.
        </source>
        <volume>
         16
        </volume>
        <year>
         2016
        </year>
        <fpage>
         2327
        </fpage>
        <lpage>
         2338
        </lpage>
        <pub-id pub-id-type="pmid">
         27545891
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib37">
       <element-citation id="sref37" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
         <name>
          <surname>
           Mishra
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Olival
          </surname>
          <given-names>
           K.J.
          </given-names>
         </name>
         <name>
          <surname>
           Fagbo
          </surname>
          <given-names>
           S.F.
          </given-names>
         </name>
         <name>
          <surname>
           Kapoor
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Epstein
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Alhakeem
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Durosinloun
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Al Asmari
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Islam
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus in bats, Saudi Arabia
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         19
        </volume>
        <year>
         2013
        </year>
        <fpage>
         1819
        </fpage>
        <lpage>
         1823
        </lpage>
        <pub-id pub-id-type="pmid">
         24206838
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib38">
       <element-citation id="sref38" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           V.D.
          </given-names>
         </name>
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B.L.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
         <name>
          <surname>
           Debbink
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gralinski
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Plante
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Scobey
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Ge
          </surname>
          <given-names>
           X.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Donaldson
          </surname>
          <given-names>
           E.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence
        </article-title>
        <source>
         Nat. Med.
        </source>
        <volume>
         21
        </volume>
        <year>
         2015
        </year>
        <fpage>
         1508
        </fpage>
        <lpage>
         1513
        </lpage>
        <pub-id pub-id-type="pmid">
         26552008
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib39">
       <element-citation id="sref39" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           V.D.
          </given-names>
         </name>
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B.L.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
         <name>
          <surname>
           Sims
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Debbink
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Gralinski
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Scobey
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Plante
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Royal
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS-like WIV1-CoV poised for human emergence
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <volume>
         113
        </volume>
        <year>
         2016
        </year>
        <fpage>
         3048
        </fpage>
        <lpage>
         3053
        </lpage>
        <pub-id pub-id-type="pmid">
         26976607
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib40">
       <element-citation id="sref40" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Michielssens
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Peters
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Ban
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Pratihar
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Seeliger
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Sharma
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Giller
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Sabo
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A designed conformational shift to control protein binding specificity
        </article-title>
        <source>
         Angew. Chem. Int. Ed. Engl.
        </source>
        <volume>
         53
        </volume>
        <year>
         2014
        </year>
        <fpage>
         10367
        </fpage>
        <lpage>
         10371
        </lpage>
        <pub-id pub-id-type="pmid">
         25115701
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib41">
       <element-citation id="sref41" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Millet
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Whittaker
          </surname>
          <given-names>
           G.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <volume>
         111
        </volume>
        <year>
         2014
        </year>
        <fpage>
         15214
        </fpage>
        <lpage>
         15219
        </lpage>
        <pub-id pub-id-type="pmid">
         25288733
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib42">
       <element-citation id="sref42" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Millet
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Whittaker
          </surname>
          <given-names>
           G.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Murine Leukemia Virus (MLV)-based Coronavirus Spike-pseudotyped Particle Production and Infection. Biol
        </article-title>
        <source>
         Protoc.
         <italic>
          6
         </italic>
         .otherMillet and Whittaker
        </source>
        <volume>
         2016
        </volume>
        <year>
         2016
        </year>
       </element-citation>
      </ref>
      <ref id="bib43">
       <element-citation id="sref43" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           See
          </surname>
          <given-names>
           E.E.
          </given-names>
         </name>
         <name>
          <surname>
           Ooi
          </surname>
          <given-names>
           E.E.
          </given-names>
         </name>
         <name>
          <surname>
           Ling
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Proliferative growth of SARS coronavirus in Vero E6 cells
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <volume>
         84
        </volume>
        <year>
         2003
        </year>
        <fpage>
         3291
        </fpage>
        <lpage>
         3303
        </lpage>
        <pub-id pub-id-type="pmid">
         14645910
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib44">
       <element-citation id="sref44" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nkolola
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Bricault
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Shields
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Perry
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Kovacs
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Giorgi
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           van Winsen
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Apetri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Brinkman-van der Linden
          </surname>
          <given-names>
           E.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         88
        </volume>
        <year>
         2014
        </year>
        <fpage>
         9538
        </fpage>
        <lpage>
         9552
        </lpage>
        <pub-id pub-id-type="pmid">
         24965452
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib45">
       <element-citation id="sref45" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pallesen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Corbett
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Wrapp
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Kirchdoerfer
          </surname>
          <given-names>
           R.N.
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           H.L.
          </given-names>
         </name>
         <name>
          <surname>
           Cottrell
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <volume>
         114
        </volume>
        <year>
         2017
        </year>
        <fpage>
         E7348
        </fpage>
        <lpage>
         E7357
        </lpage>
        <pub-id pub-id-type="pmid">
         28807998
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib46">
       <element-citation id="sref46" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Barlan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Fehr
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           McCray
          </surname>
          <given-names>
           P.B.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <volume>
         113
        </volume>
        <year>
         2016
        </year>
        <fpage>
         12262
        </fpage>
        <lpage>
         12267
        </lpage>
        <pub-id pub-id-type="pmid">
         27791014
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib83">
       <element-citation id="sref83" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pettersen
          </surname>
          <given-names>
           E.F.
          </given-names>
         </name>
         <name>
          <surname>
           Goddard
          </surname>
          <given-names>
           T.D.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Couch
          </surname>
          <given-names>
           G.S.
          </given-names>
         </name>
         <name>
          <surname>
           Greenblatt
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Meng
          </surname>
          <given-names>
           E.C.
          </given-names>
         </name>
         <name>
          <surname>
           Ferrin
          </surname>
          <given-names>
           T.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         UCSF Chimera--a visualization system for exploratory research and analysis
        </article-title>
        <source>
         J. Comput. Chem.
        </source>
        <volume>
         25
        </volume>
        <year>
         2004
        </year>
        <fpage>
         1605
        </fpage>
        <lpage>
         1612
        </lpage>
        <pub-id pub-id-type="pmid">
         15264254
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib47">
       <element-citation id="sref47" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Punjani
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Rubinstein
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Fleet
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
         <name>
          <surname>
           Brubaker
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination
        </article-title>
        <source>
         Nat. Methods
        </source>
        <volume>
         14
        </volume>
        <year>
         2017
        </year>
        <fpage>
         290
        </fpage>
        <lpage>
         296
        </lpage>
        <pub-id pub-id-type="pmid">
         28165473
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib48">
       <element-citation id="sref48" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Mou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Dekkers
          </surname>
          <given-names>
           D.H.
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Dijkman
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Demmers
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         495
        </volume>
        <year>
         2013
        </year>
        <fpage>
         251
        </fpage>
        <lpage>
         254
        </lpage>
        <pub-id pub-id-type="pmid">
         23486063
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib49">
       <element-citation id="sref49" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ritchie
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Harvey
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Stroeher
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Royle
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Dwek
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Rudd
          </surname>
          <given-names>
           P.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of N-linked carbohydrates from severe acute respiratory syndrome (SARS) spike glycoprotein
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         399
        </volume>
        <year>
         2010
        </year>
        <fpage>
         257
        </fpage>
        <lpage>
         269
        </lpage>
        <pub-id pub-id-type="pmid">
         20129637
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib50">
       <element-citation id="sref50" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rockx
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Corti
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Donaldson
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Sheahan
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Stadler
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Lanzavecchia
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         82
        </volume>
        <year>
         2008
        </year>
        <fpage>
         3220
        </fpage>
        <lpage>
         3235
        </lpage>
        <pub-id pub-id-type="pmid">
         18199635
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib51">
       <element-citation id="sref51" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rosenthal
          </surname>
          <given-names>
           P.B.
          </given-names>
         </name>
         <name>
          <surname>
           Henderson
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Optimal determination of particle orientation, absolute hand, and contrast loss in single-particle electron cryomicroscopy
        </article-title>
        <source>
         J. Mol. Biol.
        </source>
        <volume>
         333
        </volume>
        <year>
         2003
        </year>
        <fpage>
         721
        </fpage>
        <lpage>
         745
        </lpage>
        <pub-id pub-id-type="pmid">
         14568533
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib52">
       <element-citation id="sref52" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rossen
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           de Beer
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Godeke
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Raamsman
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Horzinek
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Vennema
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The viral spike protein is not involved in the polarized sorting of coronaviruses in epithelial cells
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         72
        </volume>
        <year>
         1998
        </year>
        <fpage>
         497
        </fpage>
        <lpage>
         503
        </lpage>
        <pub-id pub-id-type="pmid">
         9420251
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib53">
       <element-citation id="sref53" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Scharf
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           McDowall
          </surname>
          <given-names>
           A.W.
          </given-names>
         </name>
         <name>
          <surname>
           Bjorkman
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env
        </article-title>
        <source>
         Cell
        </source>
        <volume>
         162
        </volume>
        <year>
         2015
        </year>
        <fpage>
         1379
        </fpage>
        <lpage>
         1390
        </lpage>
        <pub-id pub-id-type="pmid">
         26359989
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib54">
       <element-citation id="sref54" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Scheres
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention of overfitting in cryo-EM structure determination
        </article-title>
        <source>
         Nat. Methods
        </source>
        <volume>
         9
        </volume>
        <year>
         2012
        </year>
        <fpage>
         853
        </fpage>
        <lpage>
         854
        </lpage>
        <pub-id pub-id-type="pmid">
         22842542
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib55">
       <element-citation id="sref55" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Geng
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Tai
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cryo-Election Microscopy Structure of Porcine Deltacoronavirus Spike Protein in the Prefusion State
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         92
        </volume>
        <year>
         2017
        </year>
       </element-citation>
      </ref>
      <ref id="bib56">
       <element-citation id="sref56" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Geng
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cryo-EM structure of infectious bronchitis coronavirus spike protein reveals structural and functional evolution of coronavirus spike proteins
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <volume>
         14
        </volume>
        <year>
         2018
        </year>
        <fpage>
         e1007009
        </fpage>
        <pub-id pub-id-type="pmid">
         29684066
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib57">
       <element-citation id="sref57" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Ortego
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Weidle
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Stuart
          </surname>
          <given-names>
           A.B.
          </given-names>
         </name>
         <name>
          <surname>
           Gray
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
         <name>
          <surname>
           McElrath
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Pancera
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Veesler
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           McGuire
          </surname>
          <given-names>
           A.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus
        </article-title>
        <source>
         Immunity
        </source>
        <volume>
         48
        </volume>
        <year>
         2018
        </year>
        <fpage>
         799
        </fpage>
        <lpage>
         811
        </lpage>
        <pub-id pub-id-type="pmid">
         29669253
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib58">
       <element-citation id="sref58" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Gui
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Xiang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <volume>
         14
        </volume>
        <year>
         2018
        </year>
        <fpage>
         e1007236
        </fpage>
        <pub-id pub-id-type="pmid">
         30102747
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib59">
       <element-citation id="sref59" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stertz
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Reichelt
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Spiegel
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kuri
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Martínez-Sobrido
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           García-Sastre
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Kochs
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The intracellular sites of early replication and budding of SARS-coronavirus
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         361
        </volume>
        <year>
         2007
        </year>
        <fpage>
         304
        </fpage>
        <lpage>
         315
        </lpage>
        <pub-id pub-id-type="pmid">
         17210170
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib60">
       <element-citation id="sref60" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stewart-Jones
          </surname>
          <given-names>
           G.B.
          </given-names>
         </name>
         <name>
          <surname>
           Soto
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lemmin
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Chuang
          </surname>
          <given-names>
           G.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Druz
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kong
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           P.V.
          </given-names>
         </name>
         <name>
          <surname>
           Wagh
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Behrens
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G
        </article-title>
        <source>
         Cell
        </source>
        <volume>
         165
        </volume>
        <year>
         2016
        </year>
        <fpage>
         813
        </fpage>
        <lpage>
         826
        </lpage>
        <pub-id pub-id-type="pmid">
         27114034
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib61">
       <element-citation id="sref61" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Struwe
          </surname>
          <given-names>
           W.B.
          </given-names>
         </name>
         <name>
          <surname>
           Chertova
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Allen
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
         <name>
          <surname>
           Seabright
          </surname>
          <given-names>
           G.E.
          </given-names>
         </name>
         <name>
          <surname>
           Watanabe
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Harvey
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
         <name>
          <surname>
           Medina-Ramirez
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Roser
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Westcott
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen
        </article-title>
        <source>
         Cell Rep
        </source>
        <volume>
         24
        </volume>
        <year>
         2018
        </year>
        <fpage>
         1958
        </fpage>
        <lpage>
         1966
        </lpage>
        <pub-id pub-id-type="pmid">
         30134158
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib62">
       <element-citation id="sref62" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Suloway
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Pulokas
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Fellmann
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Guerra
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Quispe
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Stagg
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Potter
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Carragher
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Automated molecular microscopy: the new Leginon system
        </article-title>
        <source>
         J. Struct. Biol.
        </source>
        <volume>
         151
        </volume>
        <year>
         2005
        </year>
        <fpage>
         41
        </fpage>
        <lpage>
         60
        </lpage>
        <pub-id pub-id-type="pmid">
         15890530
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib63">
       <element-citation id="sref63" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Traggiai
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kolesnikova
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Uematsu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Gismondo
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           B.R.
          </given-names>
         </name>
         <name>
          <surname>
           Rappuoli
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Lanzavecchia
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus
        </article-title>
        <source>
         Nat. Med.
        </source>
        <volume>
         10
        </volume>
        <year>
         2004
        </year>
        <fpage>
         871
        </fpage>
        <lpage>
         875
        </lpage>
        <pub-id pub-id-type="pmid">
         15247913
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib84">
       <element-citation id="sref84" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vagin
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Steiner
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Lebedev
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Potterton
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           McNicholas
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Long
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Murshudov
          </surname>
          <given-names>
           G.N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use
        </article-title>
        <source>
         Acta. Crystallogr. D Biol. Crystallogr
        </source>
        <volume>
         60
        </volume>
        <year>
         2004
        </year>
        <fpage>
         2184
        </fpage>
        <lpage>
         2195
        </lpage>
        <pub-id pub-id-type="pmid">
         15572771
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib64">
       <element-citation id="sref64" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Veesler
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Blangy
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Siponen
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Vincentelli
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Cambillau
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Sciara
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Production and biophysical characterization of the CorA transporter from Methanosarcina mazei
        </article-title>
        <source>
         Anal. Biochem.
        </source>
        <volume>
         388
        </volume>
        <year>
         2009
        </year>
        <fpage>
         115
        </fpage>
        <lpage>
         121
        </lpage>
        <pub-id pub-id-type="pmid">
         19233118
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib65">
       <element-citation id="sref65" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Voss
          </surname>
          <given-names>
           N.R.
          </given-names>
         </name>
         <name>
          <surname>
           Yoshioka
          </surname>
          <given-names>
           C.K.
          </given-names>
         </name>
         <name>
          <surname>
           Radermacher
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Potter
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Carragher
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         DoG Picker and TiltPicker: software tools to facilitate particle selection in single particle electron microscopy
        </article-title>
        <source>
         J. Struct. Biol.
        </source>
        <volume>
         166
        </volume>
        <year>
         2009
        </year>
        <fpage>
         205
        </fpage>
        <lpage>
         213
        </lpage>
        <pub-id pub-id-type="pmid">
         19374019
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib66">
       <element-citation id="sref66" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Walls
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Tortorici
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Frenz
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           P.J.M.
          </given-names>
         </name>
         <name>
          <surname>
           DiMaio
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Rey
          </surname>
          <given-names>
           F.A.
          </given-names>
         </name>
         <name>
          <surname>
           Veesler
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         531
        </volume>
        <year>
         2016
        </year>
        <fpage>
         114
        </fpage>
        <lpage>
         117
        </lpage>
        <pub-id pub-id-type="pmid">
         26855426
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib67">
       <element-citation id="sref67" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Walls
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Tortorici
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Frenz
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Rey
          </surname>
          <given-names>
           F.A.
          </given-names>
         </name>
         <name>
          <surname>
           DiMaio
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Veesler
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy
        </article-title>
        <source>
         Nat. Struct. Mol. Biol.
        </source>
        <volume>
         23
        </volume>
        <year>
         2016
        </year>
        <fpage>
         899
        </fpage>
        <lpage>
         905
        </lpage>
        <pub-id pub-id-type="pmid">
         27617430
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib68">
       <element-citation id="sref68" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Walls
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Tortorici
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Xiong
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.-J.
          </given-names>
         </name>
         <name>
          <surname>
           Rey
          </surname>
          <given-names>
           F.A.
          </given-names>
         </name>
         <name>
          <surname>
           Veesler
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <volume>
         114
        </volume>
        <year>
         2017
        </year>
        <fpage>
         11157
        </fpage>
        <lpage>
         11162
        </lpage>
        <pub-id pub-id-type="pmid">
         29073020
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib69">
       <element-citation id="sref69" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Kan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS-CoV infection in a restaurant from palm civet
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         11
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1860
        </fpage>
        <lpage>
         1865
        </lpage>
        <pub-id pub-id-type="pmid">
         16485471
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib70">
       <element-citation id="sref70" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Xuan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Wan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ji
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26
        </article-title>
        <source>
         Cell Host Microbe
        </source>
        <volume>
         16
        </volume>
        <year>
         2014
        </year>
        <fpage>
         328
        </fpage>
        <lpage>
         337
        </lpage>
        <pub-id pub-id-type="pmid">
         25211075
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib71">
       <element-citation id="sref71" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           R.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Barad
          </surname>
          <given-names>
           B.A.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Fraser
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           DiMaio
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Automated structure refinement of macromolecular assemblies from cryo-EM maps using Rosetta
        </article-title>
        <source>
         eLife
        </source>
        <volume>
         5
        </volume>
        <year>
         2016
        </year>
       </element-citation>
      </ref>
      <ref id="bib72">
       <element-citation id="sref72" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Watanabe
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Raghwani
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Allen
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
         <name>
          <surname>
           Seabright
          </surname>
          <given-names>
           G.E.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Moser
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Huiskonen
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Strecker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Bowden
          </surname>
          <given-names>
           T.A.
          </given-names>
         </name>
         <name>
          <surname>
           Crispin
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure of the Lassa virus glycan shield provides a model for immunological resistance
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <volume>
         115
        </volume>
        <year>
         2018
        </year>
        <fpage>
         7320
        </fpage>
        <lpage>
         7325
        </lpage>
        <pub-id pub-id-type="pmid">
         29941589
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib73">
       <element-citation id="sref73" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xiong
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Tortorici
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yoshioka
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Walls
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           McGuire
          </surname>
          <given-names>
           A.T.
          </given-names>
         </name>
         <name>
          <surname>
           Rey
          </surname>
          <given-names>
           F.A.
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Veesler
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Glycan shield and fusion activation of a deltacoronavirus spike glycoprotein fine-tuned for enteric infections
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2017
        </year>
       </element-citation>
      </ref>
      <ref id="bib74">
       <element-citation id="sref74" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Two Mutations Were Critical for Bat-to-Human Transmission of Middle East Respiratory Syndrome Coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         89
        </volume>
        <year>
         2015
        </year>
        <fpage>
         9119
        </fpage>
        <lpage>
         9123
        </lpage>
        <pub-id pub-id-type="pmid">
         26063432
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib75">
       <element-citation id="sref75" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains
        </article-title>
        <source>
         Nat. Commun.
        </source>
        <volume>
         8
        </volume>
        <year>
         2017
        </year>
        <fpage>
         15092
        </fpage>
        <pub-id pub-id-type="pmid">
         28393837
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib76">
       <element-citation id="sref76" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Gctf: Real-time CTF determination and correction
        </article-title>
        <source>
         J. Struct. Biol.
        </source>
        <volume>
         193
        </volume>
        <year>
         2016
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         12
        </lpage>
        <pub-id pub-id-type="pmid">
         26592709
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib77">
       <element-citation id="sref77" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Nie
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Lian
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Yin
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         78
        </volume>
        <year>
         2004
        </year>
        <fpage>
         6938
        </fpage>
        <lpage>
         6945
        </lpage>
        <pub-id pub-id-type="pmid">
         15194770
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib78">
       <element-citation id="sref78" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           S.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Palovcak
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Armache
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Verba
          </surname>
          <given-names>
           K.A.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Agard
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy
        </article-title>
        <source>
         Nat. Methods
        </source>
        <volume>
         14
        </volume>
        <year>
         2017
        </year>
        <fpage>
         331
        </fpage>
        <lpage>
         332
        </lpage>
        <pub-id pub-id-type="pmid">
         28250466
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib79">
       <element-citation id="sref79" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zivanov
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Nakane
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Forsberg
          </surname>
          <given-names>
           B.O.
          </given-names>
         </name>
         <name>
          <surname>
           Kimanius
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Hagen
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Lindahl
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Scheres
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         New tools for automated high-resolution cryo-EM structure determination in RELION-3
        </article-title>
        <source>
         eLife
        </source>
        <volume>
         7
        </volume>
        <year>
         2018
        </year>
       </element-citation>
      </ref>
      <ref id="bib80">
       <element-citation id="sref80" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zivanov
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Nakane
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Scheres
          </surname>
          <given-names>
           S.H.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A Bayesian approach to beam-induced motion correction in cryo-EM single-particle analysis
        </article-title>
        <source>
         IUCrJ
        </source>
        <volume>
         6
        </volume>
        <year>
         2019
        </year>
        <fpage>
         5
        </fpage>
        <lpage>
         17
        </lpage>
       </element-citation>
      </ref>
     </ref-list>
     <sec id="app2" sec-type="supplementary-material">
      <title>
       Supplemental Information
      </title>
      <p id="p0285">
       <supplementary-material content-type="local-data" id="mmc1">
        <caption>
         <title>
          Table S1. Site-Specific Glycan Identifications of the MERS-CoV S 2P Ectodomain Trimer (In-Solution Digests), Related to Figure 1
         </title>
        </caption>
        <media xlink:href="mmc1.xlsx">
        </media>
       </supplementary-material>
       <supplementary-material content-type="local-data" id="mmc2">
        <caption>
         <title>
          Table S2. Site-Specific Glycan Identifications of the SARS-CoV S 2P Ectodomain Trimer (In-Solution Digests), Related to Figure 1
         </title>
        </caption>
        <media xlink:href="mmc2.xlsx">
        </media>
       </supplementary-material>
       <supplementary-material content-type="local-data" id="mmc3">
        <caption>
         <title>
          Table S3. Site-Specific Glycan Identifications of the Full-Length S Trimer from Authentic MERS-CoV England1 and EMC/2012 Virions, as well as the MERS-CoV S 2P Ectodomain Trimer (In-Gel Digests), Related to Figure 1
         </title>
        </caption>
        <media xlink:href="mmc3.xlsx">
        </media>
       </supplementary-material>
       <supplementary-material content-type="local-data" id="mmc4">
        <caption>
         <title>
          Document S1. Tables S4 and S5
         </title>
        </caption>
        <media xlink:href="mmc4.docx">
        </media>
       </supplementary-material>
      </p>
     </sec>
     <ack id="ack0010">
      <title>
       Acknowledgments
      </title>
      <p>
       We are grateful to Thomas Hinds and Ning Zheng for assistance with the crystallization robot and BLI device; to Jerome Cattin-Ortolà, Irini Topalidou, and Michael Ailion for assistance with western blotting; and to Michelle Chen (Wyatt technology) for her help with the light scattering experiments. This study was supported by the
       <funding-source id="gs1">
        National Institute of General Medical Sciences
       </funding-source>
       (R01GM120553, D.V.), the
       <funding-source id="gs2">
        National Institute of Allergy and Infectious Diseases
       </funding-source>
       (HHSN272201700059C, D.V.), a
       <funding-source id="gs3">
        Pew Biomedical Scholars Award
       </funding-source>
       (D.V.), an Investigators in the Pathogenesis of Infectious Disease Award from the
       <funding-source id="gs4">
        Burroughs Wellcome Fund
       </funding-source>
       (D.V.), the
       <funding-source id="gs5">
        Netherlands Organisation for Scientific Research
       </funding-source>
       (Rubicon 019.2015.2.310.006, J.S.), the
       <funding-source id="gs6">
        European Molecular Biology Organization
       </funding-source>
       (ALTF933-2015, J.S.), the
       <funding-source id="gs7">
        Zoonoses Anticipation and Preparedness Initiative
       </funding-source>
       (IMI115760, F.A.R.), the
       <funding-source id="gs8">
        Pasteur Institute
       </funding-source>
       (M.A.T. and F.A.R.), the
       <funding-source id="gs9">
        Centre National de la Recherche Scientifique
       </funding-source>
       (F.A.R.), the
       <funding-source id="gs10">
        LabEx Integrative Biology of Emerging Infectious Diseases
       </funding-source>
       (F.A.R.), the
       <funding-source id="gs11">
        University of Washington Arnold and Mabel Beckman CryoEM Center and Proteomics Resource
       </funding-source>
       (UWPR95794), and the beamline 5.0.1 at the
       <funding-source id="gs12">
        Advanced Light Source at Lawrence Berkley National Laboratory
       </funding-source>
       .
      </p>
      <sec id="sec5">
       <title>
        Author Contributions
       </title>
       <p id="p0270">
        A.C.W., X.X., J.S., Y.-J.P., and D.V. designed the experiments. A.C.W., X.X., M.A.T., and E.C. designed, expressed, and purified the proteins. A.C.W., X.X., J.Q., and D.V. performed cryo-EM sample preparation, data collection, processing, and built and refined the atomic models. A.C.W. and Y.-J.P. crystallized the Fabs. Y.-J.P. and D.V. processed the diffraction datasets and built and refined the atomic models. A.C.W., X.X., and J.S. performed the MS experiments. A.C.W. and X.X. performed all binding assays. R.G. produced MERS-CoV isolates. M.D., A.L., M.Z., and D.C. provided key reagents. A.C.W., X.X., Y.-J.P. M.A.T., J.S., F.A.R., D.C., and D.V. analyzed the data. A.C.W., X.X., and D.V. prepared the manuscript with input from all authors.
       </p>
      </sec>
      <sec id="sec6" sec-type="COI-statement">
       <title>
        Declaration of Interests
       </title>
       <p id="p0275">
        A.L. is the scientific founder and shareholder of Humabs BioMed. D.C. is currently Chief Scientific Officer of Humabs Biomed. The other authors declare no competing financial interests.
       </p>
      </sec>
     </ack>
     <fn-group>
      <fn fn-type="supplementary-material" id="app1">
       <p id="p0280">
        Supplemental Information includes seven figures and five tables and can be found with this article online at
        <ext-link ext-link-type="doi" id="intref0185" xlink:href="10.1016/j.cell.2018.12.028">
         https://doi.org/10.1016/j.cell.2018.12.028
        </ext-link>
        .
       </p>
      </fn>
     </fn-group>
    </back>
   </article>
   <article article-type="research-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       CMAJ
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       CMAJ
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       9711805
      </journal-id>
      <journal-title-group>
       <journal-title>
        CMAJ : Canadian Medical Association Journal
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0820-3946
      </issn>
      <issn pub-type="epub">
       1488-2329
      </issn>
      <publisher>
       <publisher-name>
        Joule Inc.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       26952529
      </article-id>
      <article-id pub-id-type="pmc">
       4868605
      </article-id>
      <article-id pub-id-type="doi">
       10.1503/cmaj.150835
      </article-id>
      <article-id pub-id-type="publisher-id">
       1880567
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Research
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Effectiveness of N95 respirators versus surgical masks in protecting health care workers from acute respiratory infection: a systematic review and meta-analysis
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Smith
         </surname>
         <given-names>
          Jeffrey D.
         </given-names>
        </name>
        <degrees>
         MSc
        </degrees>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          MacDougall
         </surname>
         <given-names>
          Colin C.
         </given-names>
        </name>
        <degrees>
         MSc
        </degrees>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Johnstone
         </surname>
         <given-names>
          Jennie
         </given-names>
        </name>
        <degrees>
         MD PhD
        </degrees>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Copes
         </surname>
         <given-names>
          Ray A.
         </given-names>
        </name>
        <degrees>
         MD
        </degrees>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Schwartz
         </surname>
         <given-names>
          Brian
         </given-names>
        </name>
        <degrees>
         MD
        </degrees>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Garber
         </surname>
         <given-names>
          Gary E.
         </given-names>
        </name>
        <degrees>
         MD
        </degrees>
        <xref ref-type="corresp" rid="c1-1880567">
        </xref>
       </contrib>
       <aff id="af1-1880567">
        Public Health Ontario (Smith, MacDougall, Johnstone, Copes, Schwartz, Garber); Department of Medicine (Johnstone), University of Toronto; Dalla Lana School of Public Health (Copes, Schwartz), University of Toronto, Toronto, Ont.; Department of Medicine (Garber), University of Ottawa, Ottawa, Ont.
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="c1-1880567">
        Correspondence to: Gary Garber,
        <email>
         gary.garber@oahpp.ca
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="ppub">
       <day>
        17
       </day>
       <month>
        5
       </month>
       <year>
        2016
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        07
       </day>
       <month>
        3
       </month>
       <year>
        2016
       </year>
      </pub-date>
      <volume>
       188
      </volume>
      <issue>
       8
      </issue>
      <fpage>
       567
      </fpage>
      <lpage>
       574
      </lpage>
      <history>
       <date date-type="accepted">
        <day>
         02
        </day>
        <month>
         12
        </month>
        <year>
         2015
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2016 Joule Inc. or its licensors
       </copyright-statement>
       <copyright-year>
        2016
       </copyright-year>
      </permissions>
      <abstract>
       <sec>
        <title>
         Background:
        </title>
        <p>
         Conflicting recommendations exist related to which facial protection should be used by health care workers to prevent transmission of acute respiratory infections, including pandemic influenza. We performed a systematic review of both clinical and surrogate exposure data comparing N95 respirators and surgical masks for the prevention of transmissible acute respiratory infections.
        </p>
       </sec>
       <sec>
        <title>
         Methods:
        </title>
        <p>
         We searched various electronic databases and the grey literature for relevant studies published from January 1990 to December 2014. Randomized controlled trials (RCTs), cohort studies and case–control studies that included data on health care workers wearing N95 respirators and surgical masks to prevent acute respiratory infections were included in the meta-analysis. Surrogate exposure studies comparing N95 respirators and surgical masks using manikins or adult volunteers under simulated conditions were summarized separately. Outcomes from clinical studies were laboratory-confirmed respiratory infection, influenza-like illness and workplace absenteeism. Outcomes from surrogate exposure studies were filter penetration, face-seal leakage and total inward leakage.
        </p>
       </sec>
       <sec>
        <title>
         Results:
        </title>
        <p>
         We identified 6 clinical studies (3 RCTs, 1 cohort study and 2 case–control studies) and 23 surrogate exposure studies. In the meta-analysis of the clinical studies, we found no significant difference between N95 respirators and surgical masks in associated risk of (a) laboratory-confirmed respiratory infection (RCTs: odds ratio [OR] 0.89, 95% confidence interval [CI] 0.64–1.24; cohort study: OR 0.43, 95% CI 0.03–6.41; case–control studies: OR 0.91, 95% CI 0.25–3.36); (b) influenza-like illness (RCTs: OR 0.51, 95% CI 0.19–1.41); or (c) reported workplace absenteeism (RCT: OR 0.92, 95% CI 0.57–1.50). In the surrogate exposure studies, N95 respirators were associated with less filter penetration, less face-seal leakage and less total inward leakage under laboratory experimental conditions, compared with surgical masks.
        </p>
       </sec>
       <sec>
        <title>
         Interpretation:
        </title>
        <p>
         Although N95 respirators appeared to have a protective advantage over surgical masks in laboratory settings, our meta-analysis showed that there were insufficient data to determine definitively whether N95 respirators are superior to surgical masks in protecting health care workers against transmissible acute respiratory infections in clinical settings.
        </p>
       </sec>
      </abstract>
     </article-meta>
    </front>
   </article>
   <article article-type="article-commentary" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Singapore Med J
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Singapore Med J
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       SMJ
      </journal-id>
      <journal-title-group>
       <journal-title>
        Singapore Medical Journal
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0037-5675
      </issn>
      <publisher>
       <publisher-name>
        Singapore Medical Association
       </publisher-name>
       <publisher-loc>
        Singapore
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       25017402
      </article-id>
      <article-id pub-id-type="pmc">
       4294054
      </article-id>
      <article-id pub-id-type="publisher-id">
       SMJ-55-294
      </article-id>
      <article-id pub-id-type="doi">
       10.11622/smedj.2014076
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Commentary
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Debate on MERS-CoV respiratory precautions: surgical mask or N95 respirators?
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chung
         </surname>
         <given-names>
          Jasmine Shimin
         </given-names>
        </name>
        <degrees>
         MBBS, MRCP
        </degrees>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="corresp" rid="cor1">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ling
         </surname>
         <given-names>
          Moi Lin
         </given-names>
        </name>
        <degrees>
         MBBS, FRCPA
        </degrees>
        <xref ref-type="aff" rid="aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Seto
         </surname>
         <given-names>
          Wing Hong
         </given-names>
        </name>
        <degrees>
         MRCP, FRCPath
        </degrees>
        <xref ref-type="aff" rid="aff3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ang
         </surname>
         <given-names>
          Brenda Sze Peng
         </given-names>
        </name>
        <degrees>
         MBBS, MPH
        </degrees>
        <xref ref-type="aff" rid="aff4">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Tambyah
         </surname>
         <given-names>
          Paul Anantharajah
         </given-names>
        </name>
        <degrees>
         MD, MBBS
        </degrees>
        <xref ref-type="aff" rid="aff5">
         5
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        1
       </label>
       Department of Infectious Diseases, Singapore General Hospital, Singapore
      </aff>
      <aff id="aff2">
       <label>
        2
       </label>
       Infection Control Unit, Singapore General Hospital, Singapore
      </aff>
      <aff id="aff3">
       <label>
        3
       </label>
       University of Hong Kong, School of Public Health, Hong Kong
      </aff>
      <aff id="aff4">
       <label>
        4
       </label>
       Communicable Disease Centre, Tan Tock Seng Hospital, Singapore
      </aff>
      <aff id="aff5">
       <label>
        5
       </label>
       Division of Infectious Diseases, National University Health System, Singapore
      </aff>
      <author-notes>
       <corresp id="cor1">
        <bold>
         Correspondence:
        </bold>
        Dr Jasmine Chung Shimin, Registrar, Department of Infectious Diseases, Singapore General Hospital, Level 3, The Academia, 20 College Road, Singapore 169856.
        <email xlink:href="jasmine.chung.s.m@sgh.com.sg">
         jasmine.chung.s.m@sgh.com.sg
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="ppub">
       <month>
        6
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <volume>
       55
      </volume>
      <issue>
       6
      </issue>
      <fpage>
       294
      </fpage>
      <lpage>
       297
      </lpage>
      <permissions>
       <copyright-statement>
        Copyright: © Singapore Medical Association
       </copyright-statement>
       <copyright-year>
        2014
       </copyright-year>
      </permissions>
      <related-article ext-link-type="pubmed" id="d35e125" issue="6" page="293" related-article-type="commentary-article" vol="55" xlink:href="25017401">
       <article-title>
        Respiratory precautions for MERS-CoV: acceptable risk-benefit determination
       </article-title>
      </related-article>
      <abstract>
       <p>
        Since the emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) in mid-2012, there has been controversy over the respiratory precaution recommendations in different guidelines from various international bodies. Our understanding of MERS-CoV is still evolving. Current recommendations on infection control practices are heavily influenced by the lessons learnt from severe acute respiratory syndrome. A debate on respiratory precautions for MERS-CoV was organised by Infection Control Association (Singapore) and the Society of Infectious Disease (Singapore). We herein discuss and present the evidence for surgical masks for the protection of healthcare workers from MERS-CoV.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        <italic>
         MERS-CoV
        </italic>
       </kwd>
       <kwd>
        <italic>
         N95 respirators
        </italic>
       </kwd>
       <kwd>
        <italic>
         surgical masks
        </italic>
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Lancet
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Lancet
      </journal-id>
      <journal-title-group>
       <journal-title>
        Lancet (London, England)
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0140-6736
      </issn>
      <issn pub-type="epub">
       1474-547X
      </issn>
      <publisher>
       <publisher-name>
        Elsevier Ltd.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32145185
      </article-id>
      <article-id pub-id-type="pmc">
       7155742
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0140-6736(19)33221-0
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/S0140-6736(19)33221-0
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Middle East respiratory syndrome
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au10">
        <name>
         <surname>
          Memish
         </surname>
         <given-names>
          Ziad A
         </given-names>
        </name>
        <degrees>
         Prof
        </degrees>
        <degrees>
         FRCP
        </degrees>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
        <xref ref-type="aff" rid="aff3">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au20">
        <name>
         <surname>
          Perlman
         </surname>
         <given-names>
          Stanley
         </given-names>
        </name>
        <degrees>
         Prof
        </degrees>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff4">
         d
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au30">
        <name>
         <surname>
          Van Kerkhove
         </surname>
         <given-names>
          Maria D
         </given-names>
        </name>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff5">
         e
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au40">
        <name>
         <surname>
          Zumla
         </surname>
         <given-names>
          Alimuddin
         </given-names>
        </name>
        <degrees>
         Prof
        </degrees>
        <degrees>
         FRCP
        </degrees>
        <email>
         a.zumla@ucl.ac.uk
        </email>
        <xref ref-type="aff" rid="aff6">
         f
        </xref>
        <xref ref-type="aff" rid="aff7">
         g
        </xref>
        <xref ref-type="corresp" rid="cor1">
         *
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        a
       </label>
       College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
      </aff>
      <aff id="aff2">
       <label>
        b
       </label>
       Research Center, King Saud Medical City Ministry of Health, Riyadh, Saudi Arabia
      </aff>
      <aff id="aff3">
       <label>
        c
       </label>
       Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA
      </aff>
      <aff id="aff4">
       <label>
        d
       </label>
       Department of Microbiology and Immunology, and Department of Pediatrics, University of Iowa, Iowa City, IA, USA
      </aff>
      <aff id="aff5">
       <label>
        e
       </label>
       Infectious Hazards Management, Health Emergencies Programme, World Health Organization, Geneva, Switzerland
      </aff>
      <aff id="aff6">
       <label>
        f
       </label>
       Department of Infection, Division of Infection and Immunity, Centre for Clinical Microbiology, University College London, London, UK
      </aff>
      <aff id="aff7">
       <label>
        g
       </label>
       National Institute for Health Research Biomedical Research Centre, University College London Hospitals, London, UK
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         *
        </label>
        Correspondence to: Prof Sir Alimuddin Zumla, Department of Infection, Division of Infection and Immunity, Centre for Clinical Microbiology, University College London, London, NW3 OPE, UK
        <email>
         a.zumla@ucl.ac.uk
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        4
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date iso-8601-date="2020-04-03" pub-type="ppub">
       <season>
        28 March-3 April
       </season>
       <year>
        2020
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        4
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <volume>
       395
      </volume>
      <issue>
       10229
      </issue>
      <fpage>
       1063
      </fpage>
      <lpage>
       1077
      </lpage>
      <permissions>
       <copyright-statement>
        © 2020 Elsevier Ltd. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
        Elsevier Ltd
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="ceab10">
       <title>
        Summary
       </title>
       <p>
        The Middle East respiratory syndrome coronavirus (MERS-CoV) is a lethal zoonotic pathogen that was first identified in humans in Saudi Arabia and Jordan in 2012. Intermittent sporadic cases, community clusters, and nosocomial outbreaks of MERS-CoV continue to occur. Between April 2012 and December 2019, 2499 laboratory-confirmed cases of MERS-CoV infection, including 858 deaths (34·3% mortality) were reported from 27 countries to WHO, the majority of which were reported by Saudi Arabia (2106 cases, 780 deaths). Large outbreaks of human-to-human transmission have occurred, the largest in Riyadh and Jeddah in 2014 and in South Korea in 2015. MERS-CoV remains a high-threat pathogen identified by WHO as a priority pathogen because it causes severe disease that has a high mortality rate, epidemic potential, and no medical countermeasures. This Seminar provides an update on the current knowledge and perspectives on MERS epidemiology, virology, mode of transmission, pathogenesis, diagnosis, clinical features, management, infection control, development of new therapeutics and vaccines, and highlights unanswered questions and priorities for research, improved management, and prevention.
       </p>
      </abstract>
     </article-meta>
    </front>
    <sec id="cesec10">
     <title>
      Introduction
     </title>
     <p id="para1370">
      During the past 17 years three lethal zoonotic diseases of humans caused by novel coronaviruses, severe acute repiratory syndrome (SARS) in November, 2002,
      <xref ref-type="bibr" rid="bib1">
       <sup>
        1
       </sup>
      </xref>
      Middle East respiratory syndrome (MERS) in April, 2012,
      <xref ref-type="bibr" rid="bib2">
       <sup>
        2
       </sup>
      </xref>
      and more recently coronavirus disease (COVID-19) in December, 2019.
      <xref ref-type="bibr" rid="bib3">
       <sup>
        3
       </sup>
      </xref>
      All three causative coronaviruses, respectively, SARS-CoV, MERS-CoV, and SARS-related coronavirus-2 (SARS-CoV-2) have focused the attention of global public health authorities and are listed in the WHO Blueprint list for priority pathogens
      <xref ref-type="bibr" rid="bib4">
       <sup>
        4
       </sup>
      </xref>
      because of their pandemic potential, threat to global health security, and the absence of any effective treatments.
     </p>
     <p id="para1380">
      SARS-CoV was first identified in humans in Guangdong, China, in November, 2002 and subsequently spread rapidly worldwide to 29 countries, resulting in 8098 human SARS cases with 774 deaths (9·6% mortality).
      <xref ref-type="bibr" rid="bib1">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="bib5">
       5
      </xref>
      The SARS epidemic ended abruptly in July, 2003,
      <xref ref-type="bibr" rid="bib1">
       <sup>
        1
       </sup>
      </xref>
      and no human cases of SARS have been detected over the past 15 years. MERS-CoV was first identified as causing human disease when it was isolated from a lung sample of an adult patient who was admitted at a hospital in Jeddah, Saudi Arabia, with severe pneumonia and died of multiorgan failure.
      <xref ref-type="bibr" rid="bib6">
       <sup>
        6
       </sup>
      </xref>
      A retrospective study then linked MERS-CoV to a hospital outbreak in April, 2012, in Jordan.
      <xref ref-type="bibr" rid="bib7">
       <sup>
        7
       </sup>
      </xref>
      MERS-CoV is considered a zoonotic pathogen, with MERS-CoV-infected dromedary camels being the animal source of infection to humans.
      <xref ref-type="bibr" rid="bib8">
       8
      </xref>
      ,
      <xref ref-type="bibr" rid="bib9">
       9
      </xref>
     </p>
     <p id="para1390">
      Unlike SARS-CoV, which was contained within a year of emerging, MERS-CoV continues to circulate and cause human disease with intermittent sporadic cases, community clusters, and nosocomial outbreaks in the Middle East with considerable risk of spreading globally.
      <xref ref-type="bibr" rid="bib2">
       2
      </xref>
      ,
      <xref ref-type="bibr" rid="bib10">
       10
      </xref>
      Several outbreaks of human-to-human MERS-CoV transmission have occurred, the largest outside the Middle East occurring in South Korea in 2015.
      <xref ref-type="bibr" rid="bib11">
       11
      </xref>
      ,
      <xref ref-type="bibr" rid="bib12">
       12
      </xref>
      This outbreak was associated with substantial morbidity and mortality, as well as having substantial economic, social, and health security effects.
      <xref ref-type="bibr" rid="bib12">
       <sup>
        12
       </sup>
      </xref>
     </p>
     <p id="para1400">
      SARS-CoV-2 (initially named 2019-nCoV) was detected in December 2019 after sequencing of clinical samples from a cluster of patients in Wuhan, China who developed pneumonia of unknown cause.
      <xref ref-type="bibr" rid="bib13">
       <sup>
        13
       </sup>
      </xref>
      This outbreak is rapidly evolving and as of March 3, 2020 there have been 88 948 laboratory confirmed cases of COVID-19, with 3043 deaths (3·4% mortality). Outside China, there have been 8774 cases reported from 64 countries with 128 deaths.
      <xref ref-type="bibr" rid="bib3">
       <sup>
        3
       </sup>
      </xref>
     </p>
     <p id="para1410">
      This Seminar reviews current knowledge and provides an update on MERS-CoV epidemiology, virology, mode of transmission, pathogenesis, diagnosis, clinical features, management, infection control, and development of new therapeutics and vaccines, and also highlights unanswered questions and priorities for research, improved management, and prevention.
     </p>
    </sec>
    <sec id="cesec20">
     <title>
      Virology
     </title>
     <p id="para1420">
      MERS-CoV, SARS-CoV, and SARS-CoV-2, are members of the
      <italic>
       Coronaviridae
      </italic>
      family of the order Nidovirales. Other human coronaviruses generally cause mild respiratory infections (eg, HCoV-229E, HCoV-NL63, HCoV-OC43, and HCoV-HKU1). MERS-CoV, like SARS-CoV and SARS-CoV-2, can cause highly lethal disease in humans. MERS-CoV is a large single-strand positive-sense RNA virus (
      <xref ref-type="fig" rid="fig1">
       figure 1
      </xref>
      ).
      <xref ref-type="bibr" rid="bib14">
       14
      </xref>
      ,
      <xref ref-type="bibr" rid="bib15">
       15
      </xref>
      ,
      <xref ref-type="bibr" rid="bib16">
       16
      </xref>
      ,
      <xref ref-type="bibr" rid="bib17">
       17
      </xref>
      ,
      <xref ref-type="bibr" rid="bib18">
       18
      </xref>
      The 30–31 kb coronavirus genome encodes a large number of proteins, which might confer versatility in adapting to new environments and enhance cross-species transmission. MERS-CoV has four structural proteins: spike (S) protein, envelope (E)protein, membrane (M) protein, and nucleocapsid (N) protein. The S protein is a type I transmembrane glycoprotein located as a trimer on the virus surface and consists of S1 and S2 subunits. It has crucial roles in binding, fusion, and entry into host cells. The S1 subunit has a receptor binding domain that binds to the host cellular receptor dipeptidyl peptidase 4 (DPP4). The S2 subunit has two regions, heptad repeats 1 and 2 (HR1 and HR2), which rearrange to form a six-helix bundle to enable membrane fusion. The E and M proteins are present in the viral membranes and are required for viral assembly, budding, and intracellular trafficking.
      <fig id="fig1">
       <label>
        Figure 1
       </label>
       <caption>
        <p>
         MERS-CoV structure, genome organisation, and replication
        </p>
        <p>
         MERS-CoV encodes a large replicase-transcriptase polyprotein (rep1A and rep1B), which is processed into 16 non-structural proteins (nsp). These proteins are required for the formation of the replicase-transcription complex, for cleavage of the polyprotein, and for immune evasion. Structural proteins (spike [S], envelope [E], membrane [M], and nucleocapsid [N]) and accessory proteins (ORFs 3, 4a, 4b, 5, 8b) are encoded in the end third of the 3' end of the genome of the genome. MERS-CoV binds to its cellular receptor DPP4 via the S protein, which is processed by host proteases to expose a fusion peptide. The viral genome is then released into the cytoplasm, where it is translated on host ribosomes into rep1A and rep1B proteins. The polyprotein is cleaved by two viral-encoded proteases, encoded by nsp3 and nsp5. Proteins involved in genome and subgenome replication and transcription include nsp12 (the RNA-dependent RNA polymerase [RdRP]) and two associated proteins, nsp7 and nsp8.
         <xref ref-type="bibr" rid="bib127">
          <sup>
           127
          </sup>
         </xref>
         Nsp13 (a helicase), nsp14 (which encodes an N7 methyltransferase and ExoN, a protein required for genome fidelity), and nsp16 (a 2'-O methyltransferase) are also necessary for optimal genomic and subgenomic RNA synthesis. MERS-CoV transcription involves the synthesis of subgenomic RNAs, which encode the structural and accessory proteins located at the 3' end of the genome. Subgenomic and genomic RNAs are co-terminal, sharing the same 5' leader and 3' sequences. Subgenomic RNAs code for structural and accessory proteins (ORF3, 4a, 4b, 5, and 8b). ORF8b is encoded within the N gene (marked with purple lines). These accessory proteins are believed to have immunoevasive properties, but are not essential for replication, and are variably deleted in human and camel virus isolates.
         <xref ref-type="bibr" rid="bib128">
          128
         </xref>
         ,
         <xref ref-type="bibr" rid="bib129">
          129
         </xref>
         ,
         <xref ref-type="bibr" rid="bib130">
          130
         </xref>
         Genomic replication occurs on membrane structures such as double membrane vesicles (DMVs), convoluted membranes (CM), and vesicle packets (VP), which are merged DMV
         <xref ref-type="bibr" rid="bib131">
          <sup>
           131
          </sup>
         </xref>
         that have been formed from the rough endoplasmic reticulum (RER) by the combined action of nsp3, nsp4, and nsp6 (lower right). After synthesis on replicase-transcription complexes, RNA is encapsidated by the N protein and transported to the ERGIC (endoplasmic reticulum–Golgi compartment), where budding into membranes containing the S, E, and M proteins occurs before release from the cell. 3CLPro=chymotrypsin-like protease. ExoN=exonuclease. MERS-CoV=Middle East respiratory syndrome coronavirus. MTase=methyltransferase. NendoU=nidoviral uridylate-specific endoribonuclease. NF-κB=nuclear factor κ-light-chain-enhancer of activated B cells. NTPase=nucleoside-triphosphatase. pp1a=polyprotein 1a. PLPro=papain-like protease.
        </p>
       </caption>
       <graphic xlink:href="gr1_lrg">
       </graphic>
      </fig>
     </p>
     <p id="para1430">
      MERS-CoV enters host cells via binding of its S protein to the host cell DPP4 receptor (
      <xref ref-type="fig" rid="fig1">
       figure 1
      </xref>
      ;
      <xref ref-type="sec" rid="sec1">
       appendix pp 2–3
      </xref>
      ).
      <xref ref-type="bibr" rid="bib15">
       15
      </xref>
      ,
      <xref ref-type="bibr" rid="bib17">
       17
      </xref>
      DPP4 is less abundant in the nasal cavity and epithelial cells of the upper airways but is highly expressed on the epithelial cells of the distal airways and type I and II pneumocytes in the lung alveoli, non-ciliated bronchial epithelial cells, endothelial cells, and some haemopoietic cells.
      <xref ref-type="bibr" rid="bib15">
       <sup>
        15
       </sup>
      </xref>
      DPP4 is also widely expressed on the epithelial cells of several other organs and tissues such as the kidneys, intestine, liver, thymus, and bone marrow—thus widespread dissemination of MERS-CoV could occur in the body. The structures of the S protein of MERS-CoV and other coronaviruses have been determined using cryo-electron microscopy
      <xref ref-type="bibr" rid="bib16">
       16
      </xref>
      ,
      <xref ref-type="bibr" rid="bib17">
       17
      </xref>
      and provide the basis for rational design of protective antibodies and other therapeutics.
     </p>
    </sec>
    <sec id="cesec30">
     <title>
      Epidemiology
     </title>
     <p id="para1440">
      A primary MERS-CoV infection is defined by WHO as a laboratory-confirmed MERS-CoV infection that has no direct epidemiological link to a human MERS-CoV infection, and was acquired outside of a health-care facility presumably from direct or indirect contact with the reservoir host—dromedary camels.
      <xref ref-type="bibr" rid="bib19">
       <sup>
        19
       </sup>
      </xref>
     </p>
     <p id="para1450">
      A secondary MERS-CoV infection is defined by WHO as a laboratory-confirmed MERS-CoV infection with a direct epidemiological link to an individual with confirmed or probable MERS-CoV infection.
      <xref ref-type="bibr" rid="bib19">
       <sup>
        19
       </sup>
      </xref>
     </p>
     <sec id="cesec40">
      <title>
       Geographical distribution
      </title>
      <p id="para1460">
       Laboratory-confirmed MERS-CoV human infections
       <xref ref-type="bibr" rid="bib19">
        <sup>
         19
        </sup>
       </xref>
       are reported to WHO as a requirement under the International Health Regulations (2005). The geographical distribution of countries reporting laboratory-confirmed human MERS cases and the numbers reported over time are shown in
       <xref ref-type="fig" rid="fig2">
        Figure 2
       </xref>
       ,
       <xref ref-type="fig" rid="fig3">
        Figure 3
       </xref>
       . Between April, 2012 and end of December, 2019, 2499 laboratory-confirmed human cases of MERS-CoV infection, including 858 deaths (34·3% mortality) were reported from 27 countries in all continents (
       <xref ref-type="fig" rid="fig2">
        figure 2
       </xref>
       ) to WHO, the majority of which were reported by Saudi Arabia (2106 cases, 780 deaths).
       <fig id="fig2">
        <label>
         Figure 2
        </label>
        <caption>
         <p>
          Geographical distribution of reported human infections of MERS-CoV
         </p>
         <p>
          Cases reported up to and including Dec 31, 2019. MERS-CoV=Middle East respiratory syndrome coronavirus. Reproduced from Dr Mamunur R Malik, WHO Regional Office for the Eastern Mediterranean.
         </p>
        </caption>
        <graphic xlink:href="gr2_lrg">
        </graphic>
       </fig>
       <fig id="fig3">
        <label>
         Figure 3
        </label>
        <caption>
         <p>
          Global MERS reported to WHO by week, 2012–19
         </p>
         <p>
          Reproduced from WHO website, by permission of Dr Mamunur R Malik, WHO Regional Office for the Eastern Mediterranean. MERS=Middle East respiratory syndrome.
         </p>
        </caption>
        <graphic xlink:href="gr3_lrg">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="cesec50">
      <title>
       Sources of infection
      </title>
      <p id="para1470">
       The origin of all primary human MERS-CoV infections remains unknown. Dromedary camels are a host reservoir species for the MERS-CoV (
       <xref ref-type="sec" rid="sec1">
        appendix pp 3–5
       </xref>
       ).
       <xref ref-type="bibr" rid="bib20">
        20
       </xref>
       ,
       <xref ref-type="bibr" rid="bib21">
        21
       </xref>
       ,
       <xref ref-type="bibr" rid="bib22">
        22
       </xref>
       ,
       <xref ref-type="bibr" rid="bib23">
        23
       </xref>
       Humans can acquire MERS-CoV through direct or indirect contact with infected dromedary camels or infected patients
       <xref ref-type="bibr" rid="bib19">
        19
       </xref>
       ,
       <xref ref-type="bibr" rid="bib20">
        20
       </xref>
       ,
       <xref ref-type="bibr" rid="bib21">
        21
       </xref>
       ,
       <xref ref-type="bibr" rid="bib22">
        22
       </xref>
       ,
       <xref ref-type="bibr" rid="bib23">
        23
       </xref>
       ,
       <xref ref-type="bibr" rid="bib24">
        24
       </xref>
       ,
       <xref ref-type="bibr" rid="bib25">
        25
       </xref>
       ,
       <xref ref-type="bibr" rid="bib26">
        26
       </xref>
       ,
       <xref ref-type="bibr" rid="bib27">
        27
       </xref>
       ,
       <xref ref-type="bibr" rid="bib28">
        28
       </xref>
       ,
       <xref ref-type="bibr" rid="bib29">
        29
       </xref>
       ,
       <xref ref-type="bibr" rid="bib30">
        30
       </xref>
       (
       <xref ref-type="fig" rid="fig4">
        figure 4A
       </xref>
       ). However not all cases infected in the community report contact with dromedary camels (
       <xref ref-type="sec" rid="sec1">
        appendix p 4–5
       </xref>
       ). The transmission of MERS-CoV from dromedary camels to humans is now well documented in the Arabian Peninsula,
       <xref ref-type="bibr" rid="bib23">
        23
       </xref>
       ,
       <xref ref-type="bibr" rid="bib24">
        24
       </xref>
       ,
       <xref ref-type="bibr" rid="bib25">
        25
       </xref>
       but the extent to which this transmission is occurring in countries outside the Arabian Peninsula requires definition. Experimental infections have shown that infected dromedaries shed MERS-CoV from their nasal secretions with minimal signs of illness, which is limited to rhinorrhoea.
       <xref ref-type="bibr" rid="bib27">
        27
       </xref>
       ,
       <xref ref-type="bibr" rid="bib28">
        28
       </xref>
       ,
       <xref ref-type="bibr" rid="bib29">
        29
       </xref>
       Full-genome phylogenetic analysis indicates that evolution of diverse MERS-CoV lineages in camels have caused human infections, perpetuating a low barrier for interspecies transmission.
       <xref ref-type="bibr" rid="bib21">
        21
       </xref>
       ,
       <xref ref-type="bibr" rid="bib29">
        29
       </xref>
       ,
       <xref ref-type="bibr" rid="bib30">
        30
       </xref>
       However, African MERS-CoV lineages in camels imported into Saudi Arabia have not established themselves in camels in Saudi Arabia,
       <xref ref-type="bibr" rid="bib9">
        9
       </xref>
       ,
       <xref ref-type="bibr" rid="bib30">
        30
       </xref>
       indicating potential differences in transmission dynamics and selection pressure. Analysis of population dynamics shows that Arabian viruses can maintain endemicity without introduction of additional lineages.
       <xref ref-type="bibr" rid="bib9">
        9
       </xref>
       ,
       <xref ref-type="bibr" rid="bib30">
        30
       </xref>
       WHO is supporting molecular and serological studies at the dromedary–human interface in several countries in Africa and south Asia.
       <xref ref-type="bibr" rid="bib31">
        <sup>
         31
        </sup>
       </xref>
       The phylogenetic relationship of complete genomes of MERS-CoV strains obtained from camels and humans has been published.
       <xref ref-type="bibr" rid="bib32">
        <sup>
         32
        </sup>
       </xref>
       <fig id="fig4">
        <label>
         Figure 4
        </label>
        <caption>
         <p>
          Epidemiological, clinical, and laboratory features of MERS
         </p>
         <p>
          ALT=alanine aminotransferase. AST=asparate aminotransferase. MERS-CoV=Middle East respiratory syndrome coronavirus.
         </p>
        </caption>
        <graphic xlink:href="gr4_lrg">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="cesec60">
      <title>
       Epidemiological patterns of human cases
      </title>
      <p id="para1480">
       The epidemiological patterns of MERS-CoV in humans have remained consistent since MERS-CoV was first identified in 2012.
       <xref ref-type="bibr" rid="bib2">
        <sup>
         2
        </sup>
       </xref>
       Primary cases often report direct or indirect contact with dromedary camels and present across a wide clinical spectrum from mild to severe fulminant disease. Individuals with severe primary MERS-CoV infections are often older than 65 years with comorbidities, and symptoms can present late. Individuals with mild primary MERS-CoV infections are often missed by current surveillance systems since they usually do not present to health-care facilities.
      </p>
      <p id="para1490">
       Secondary cases have resulted from human-to-human transmission among close contacts. To date, secondary transmission has occasionally occurred between close contacts of individuals with laboratory-confirmed MERS-CoV in household settings.
       <xref ref-type="bibr" rid="bib33">
        33
       </xref>
       ,
       <xref ref-type="bibr" rid="bib34">
        34
       </xref>
       However, secondary transmission in health-care facilities has repeatedly occurred in several countries and has, on occasion, resulted in large outbreaks (
       <xref ref-type="sec" rid="sec1">
        appendix p 5
       </xref>
       )—such as Jeddah, Saudi Arabia (2014), Seoul, South Korea (2015), and Riyadh, Saudi Arabia (2015, 2016, and 2018). In health-care settings, human-to-human transmission occurs between patients, between patients and health-care workers, and from patients to visitors.
       <xref ref-type="bibr" rid="bib21">
        21
       </xref>
       ,
       <xref ref-type="bibr" rid="bib33">
        33
       </xref>
       Approximately half of the MERS-CoV cases reported to WHO
       <xref ref-type="bibr" rid="bib2">
        <sup>
         2
        </sup>
       </xref>
       to date have resulted from human-to-human transmission in health-care facilities.
       <xref ref-type="bibr" rid="bib21">
        21
       </xref>
       ,
       <xref ref-type="bibr" rid="bib33">
        33
       </xref>
      </p>
     </sec>
     <sec id="cesec70">
      <title>
       Risk factors and transmission
      </title>
      <p id="para1500">
       Known risk factors for MERS-CoV acquisition, transmission, and outbreaks are noted (
       <xref ref-type="boxed-text" rid="box1">
        panel 1
       </xref>
       ). MERS patient data reported to WHO includes information on exposures and known risk factors during the 14 days before symptom onset, or during the 14 days before laboratory confirmation was reported (in the case of asymptomatic infection). Exposure data include travel history to MERS-CoV endemic countries, direct or indirect contact with dromedary camels or their products, contact with humans with MERS-CoV infection, and visits to health-care facilities containing patients infected with MERS-CoV are risk factors for acquiring MERS-CoV infection (
       <xref ref-type="sec" rid="sec1">
        appendix pp 4–5
       </xref>
       ).
       <xref ref-type="bibr" rid="bib2">
        2
       </xref>
       ,
       <xref ref-type="bibr" rid="bib24">
        24
       </xref>
       ,
       <xref ref-type="bibr" rid="bib25">
        25
       </xref>
       ,
       <xref ref-type="bibr" rid="bib31">
        31
       </xref>
       ,
       <xref ref-type="bibr" rid="bib32">
        32
       </xref>
       ,
       <xref ref-type="bibr" rid="bib33">
        33
       </xref>
       ,
       <xref ref-type="bibr" rid="bib34">
        34
       </xref>
       ,
       <xref ref-type="bibr" rid="bib35">
        35
       </xref>
       ,
       <xref ref-type="bibr" rid="bib36">
        36
       </xref>
       ,
       <xref ref-type="bibr" rid="bib37">
        37
       </xref>
       ,
       <xref ref-type="bibr" rid="bib38">
        38
       </xref>
       ,
       <xref ref-type="bibr" rid="bib39">
        39
       </xref>
       ,
       <xref ref-type="bibr" rid="bib40">
        40
       </xref>
       ,
       <xref ref-type="bibr" rid="bib41">
        41
       </xref>
       ,
       <xref ref-type="bibr" rid="bib42">
        42
       </xref>
       ,
       <xref ref-type="bibr" rid="bib43">
        43
       </xref>
       ,
       <xref ref-type="bibr" rid="bib44">
        44
       </xref>
       ,
       <xref ref-type="bibr" rid="bib45">
        45
       </xref>
       MERS-CoV has been detected in camel products (eg, raw milk, meat, blood, urine, or birth products); however, genomic studies to definitively show transmission from these products to humans have not yet been done. Human primary intestinal epithelial cells, small intestine explants, and the intestinal tract are highly susceptible to MERS-CoV and can sustain viral replication. After infection of mice transgenic for the expression of the host DPP4 receptor, histological examination showed MERS-CoV enteric infection in all inoculated mice with progression to infection of the lung tissues, indicating the development of sequential respiratory infection.
       <xref ref-type="bibr" rid="bib39">
        <sup>
         39
        </sup>
       </xref>
       <boxed-text id="box1">
        <label>
         Panel 1
        </label>
        <caption>
         <title>
          Risk factors for MERS-CoV infection, transmission, and outbreaks21,34,38,132–138
         </title>
        </caption>
        <p id="para10">
         <bold>
          Community risk factors
         </bold>
        </p>
        <p id="para20">
         <list id="celist10" list-type="simple">
          <list-item id="celistitem10">
           <label>
            •
           </label>
           <p id="para30">
            Indirect or direct contact with MERS-CoV-infected camels, camel nasal secretions, milk, urine, faeces, meat, or birthing products
           </p>
          </list-item>
          <list-item id="celistitem20">
           <label>
            •
           </label>
           <p id="para40">
            Travel to the Middle East and contact with camels or attendance at a health facility
           </p>
          </list-item>
          <list-item id="celistitem30">
           <label>
            •
           </label>
           <p id="para50">
            Exposure to, or contact with, patients with MERS-CoV in the community, or at healthcare facilities
           </p>
          </list-item>
          <list-item id="celistitem40">
           <label>
            •
           </label>
           <p id="para60">
            Underlying chronic medical conditions
           </p>
          </list-item>
         </list>
        </p>
        <p id="para70">
         <bold>
          Nosocomial risk factors for human-to-human transmission and outbreak amplification
         </bold>
        </p>
        <p id="para80">
         <list id="celist20" list-type="simple">
          <list-item id="celistitem50">
           <label>
            •
           </label>
           <p id="para90">
            Late diagnosis of MERS-CoV infection
           </p>
          </list-item>
          <list-item id="celistitem60">
           <label>
            •
           </label>
           <p id="para100">
            Lack of awareness in health-care workers of the possibility of MERS in patients with a fever
           </p>
          </list-item>
          <list-item id="celistitem70">
           <label>
            •
           </label>
           <p id="para110">
            Overcrowded or contaminated health-care facilities, especially emergency departments, dialysis units, and crowded inpatient wards
           </p>
          </list-item>
          <list-item id="celistitem80">
           <label>
            •
           </label>
           <p id="para120">
            Exposure of hospital staff or other patients to symptomatic patients with MERS
           </p>
          </list-item>
          <list-item id="celistitem90">
           <label>
            •
           </label>
           <p id="para130">
            Delayed implementation of infection control measures
           </p>
          </list-item>
          <list-item id="celistitem100">
           <label>
            •
           </label>
           <p id="para140">
            Poor compliance with MERS-specific infection control guidelines (hand hygiene, droplet and contact precautions, environmental cleaning)
           </p>
          </list-item>
          <list-item id="celistitem110">
           <label>
            •
           </label>
           <p id="para150">
            Poor compliance with appropriate personal protective equipment when assessing patients with febrile respiratory illness
           </p>
          </list-item>
          <list-item id="celistitem120">
           <label>
            •
           </label>
           <p id="para160">
            Aerosol-generating procedures or invasive procedures in patients with MERS (eg, nebulisers, resuscitation, intubation, and ventilation)
           </p>
          </list-item>
          <list-item id="celistitem130">
           <label>
            •
           </label>
           <p id="para170">
            Lack of proper isolation room facilities
           </p>
          </list-item>
          <list-item id="celistitem140">
           <label>
            •
           </label>
           <p id="para180">
            Distance between patient beds of less than 1 m
           </p>
          </list-item>
          <list-item id="celistitem150">
           <label>
            •
           </label>
           <p id="para190">
            Friends and family members staying as caregivers in overcrowded health-care facilities
           </p>
          </list-item>
         </list>
        </p>
        <p id="para200">
         MERS=Middle East respiratory syndrome. MERS-CoV=Middle East respiratory syndrome coronavirus.
        </p>
       </boxed-text>
      </p>
      <p id="para1510">
       Transmission via contact with contaminated hospital environments is possible during outbreaks, although genomic studies providing an evidence base are lacking. Since environmental contamination is a potential source of infection, it is prudent to take precautionary infection control measures.
      </p>
     </sec>
     <sec id="cesec80">
      <title>
       Nosocomial transmission
      </title>
      <p id="para1520">
       Health-care-associated outbreaks of MERS-CoV affecting inpatients, health-care workers, and visitors are characteristic of MERS (
       <xref ref-type="boxed-text" rid="box2">
        panel 2
       </xref>
       ) and account for approximately 50% of reported cases.
       <xref ref-type="bibr" rid="bib2">
        2
       </xref>
       ,
       <xref ref-type="bibr" rid="bib20">
        20
       </xref>
       ,
       <xref ref-type="bibr" rid="bib21">
        21
       </xref>
       ,
       <xref ref-type="bibr" rid="bib33">
        33
       </xref>
       ,
       <xref ref-type="bibr" rid="bib40">
        40
       </xref>
       ,
       <xref ref-type="bibr" rid="bib41">
        41
       </xref>
       ,
       <xref ref-type="bibr" rid="bib42">
        42
       </xref>
       ,
       <xref ref-type="bibr" rid="bib43">
        43
       </xref>
       ,
       <xref ref-type="bibr" rid="bib44">
        44
       </xref>
       ,
       <xref ref-type="bibr" rid="bib45">
        45
       </xref>
       Large nosocomial outbreaks have occurred in Abu Dhabi in United Arab Emirates, Seoul in South Korea and several cities in Saudi Arabia (
       <xref ref-type="sec" rid="sec1">
        appendix p 5
       </xref>
       ). The 2013 outbreak in Al Hasa, Saudi Arabia, involved 23 people in three different hospitals and was linked to poor infection control practices, aerosol-generating procedures, continuous positive pressure ventilation, and cardiopulmonary resuscitation.
       <xref ref-type="bibr" rid="bib42">
        <sup>
         42
        </sup>
       </xref>
       In June, 2017, an outbreak of 34 MERS-CoV cases (including 17 in health-care workers) occurred in a hospital in Riyadh, Saudi Arabia,
       <xref ref-type="bibr" rid="bib43">
        <sup>
         43
        </sup>
       </xref>
       where the primary case was a 47-year-old man admitted for emergency intubation. Before a diagnosis of MERS, this individual had contact with 220 health-care workers, patients, and visitors. Another 2017 outbreak in Riyadh involved three hospitals, with 44 MERS cases in patients, health-care workers, and family members. The outbreak arose from three severely ill people who were diagnosed with MERS late in the disease course, and involved in a superspreading event.
       <xref ref-type="bibr" rid="bib44">
        <sup>
         44
        </sup>
       </xref>
       In 2015, South Korea had the largest MERS-CoV outbreak outside the Middle East with 186 cases reported, resulting from a single imported case from an individual who had returned from travelling in the Middle East. The outbreak included 185 secondary cases who acquired infection in 16 health-care facilities and 80% of transmission events were attributed to five superspreading events.
       <xref ref-type="bibr" rid="bib45">
        <sup>
         45
        </sup>
       </xref>
       <boxed-text id="box2">
        <label>
         Panel 2
        </label>
        <caption>
         <title>
          MERS prevention and interventions21,31,33,36,67
         </title>
        </caption>
        <p id="para210">
         <bold>
          The pathogen: MERS-CoV
         </bold>
        </p>
        <p id="para220">
         <list id="celist30" list-type="simple">
          <list-item id="celistitem160">
           <label>
            •
           </label>
           <p id="para230">
            Anti-viral therapeutics including host-directed therapies or immune-based therapies are in development.
           </p>
          </list-item>
         </list>
        </p>
        <p id="para240">
         <bold>
          Intermediate host reservoir: dromedary camels
         </bold>
        </p>
        <p id="para250">
         <list id="celist40" list-type="simple">
          <list-item id="celistitem170">
           <label>
            •
           </label>
           <p id="para260">
            Vaccinating dromedary camels, the source for primary human infection, is a proposed approach to preventing human infection.
           </p>
          </list-item>
          <list-item id="celistitem180">
           <label>
            •
           </label>
           <p id="para270">
            A recombinant camelpox virus expressing the S protein has been shown to induce neutralising antibodies in camels.
           </p>
          </list-item>
          <list-item id="celistitem190">
           <label>
            •
           </label>
           <p id="para280">
            As compared to older camels, juvenile camels have higher rates of viral shedding. Past infection is not protective.
           </p>
          </list-item>
         </list>
        </p>
        <p id="para290">
         <bold>
          Humans with contact with infected camels
         </bold>
        </p>
        <p id="para300">
         <list id="celist50" list-type="simple">
          <list-item id="celistitem200">
           <label>
            •
           </label>
           <p id="para310">
            Basic hand hygiene practices.
           </p>
          </list-item>
          <list-item id="celistitem210">
           <label>
            •
           </label>
           <p id="para320">
            Gloves and face masks when handling infected camels and camel products.
           </p>
          </list-item>
          <list-item id="celistitem220">
           <label>
            •
           </label>
           <p id="para330">
            Pasteurising camel milk.
           </p>
          </list-item>
          <list-item id="celistitem230">
           <label>
            •
           </label>
           <p id="para340">
            Avoid ingesting raw camel meat, dairy products, or urine.
           </p>
          </list-item>
          <list-item id="celistitem240">
           <label>
            •
           </label>
           <p id="para350">
            Vaccine development for people with high camel exposure.
           </p>
          </list-item>
         </list>
        </p>
        <p id="para360">
         <bold>
          Human cases
         </bold>
        </p>
        <p id="para370">
         <list id="celist60" list-type="simple">
          <list-item id="celistitem250">
           <label>
            •
           </label>
           <p id="para380">
            High clinical awareness of the possibility of MERS-CoV infection and making early diagnosis.
           </p>
          </list-item>
          <list-item id="celistitem260">
           <label>
            •
           </label>
           <p id="para390">
            Isolate suspected cases early and institute infection control measures.
           </p>
          </list-item>
          <list-item id="celistitem270">
           <label>
            •
           </label>
           <p id="para400">
            Face masks and hand hygiene measures for all HCW and family contacts.
           </p>
          </list-item>
          <list-item id="celistitem280">
           <label>
            •
           </label>
           <p id="para410">
            Occupationally exposed people have a higher risk of infection compared to the general public. Human surveillance is focused on diseased people, and those with subclinical or asymptomatic infection and could serve as a source of infection of a susceptible person with comorbidities.
           </p>
          </list-item>
         </list>
        </p>
        <p id="para420">
         <bold>
          Nosocomial and community outbreaks
         </bold>
        </p>
        <p id="para430">
         <list id="celist70" list-type="simple">
          <list-item id="celistitem290">
           <label>
            •
           </label>
           <p id="para440">
            Nosocomial cases and outbreaks are diminishing due to institution of stringent infection control measures but still account for 35–50% of cases.
           </p>
          </list-item>
          <list-item id="celistitem300">
           <label>
            •
           </label>
           <p id="para450">
            More than 20 human vaccines have been developed and are being tested in animals—some are in human phase 1 or 2 trials.
           </p>
          </list-item>
         </list>
        </p>
        <p id="para460">
         MERS=Middle East respiratory syndrome. MERs-CoV=Middle East respiratory syndrome coronavirus.
        </p>
       </boxed-text>
      </p>
     </sec>
    </sec>
    <sec id="cesec90">
     <title>
      Pathogenesis and pathology
     </title>
     <p id="para1530">
      The mechanisms underlying the pathogenesis of MERS-CoV remain to be defined because autopsies are generally not done either for religious and cultural reasons or to prevent environmental contamination with subsequent infection of health-care workers. Therefore, there are few data on the histopathological changes in patients with MERS-CoV infection, even in severe disease.
      <xref ref-type="bibr" rid="bib46">
       46
      </xref>
      ,
      <xref ref-type="bibr" rid="bib47">
       47
      </xref>
      The only two autopsies available show that viral infection was confined predominantly to the respiratory tract, although viral particles were detected in the kidney in one of the reports.
      <xref ref-type="bibr" rid="bib47">
       <sup>
        47
       </sup>
      </xref>
      Further, ex vivo human kidney cultures were shown to support productive MERS-CoV infection.
      <xref ref-type="bibr" rid="bib48">
       <sup>
        48
       </sup>
      </xref>
      However, it is not known whether infection of this organ contributes to worse outcomes compared with infections confined to the respiratory tract. Viral RNA, but not infectious MERS-CoV, was detected in the blood for at least 2 weeks after diagnosis. Whether this viral RNA represented an extrapulmonary infection is not clear, since MERS-CoV neutralising antibody was detected in the serum at the same time in some patients.
      <xref ref-type="bibr" rid="bib49">
       <sup>
        49
       </sup>
      </xref>
     </p>
     <p id="para1540">
      Pathological changes in the lungs include evidence of focal haemorrhagic necrotising pneumonia with exudative diffuse alveolar damage, indistinguishable from findings detected in severe pneumonia caused by other viral agents.
     </p>
     <p id="para1550">
      Several experimentally infected animal models for MERS have been developed (
      <xref ref-type="sec" rid="sec1">
       appendix p 6
      </xref>
      ).
      <xref ref-type="bibr" rid="bib50">
       50
      </xref>
      ,
      <xref ref-type="bibr" rid="bib51">
       51
      </xref>
      Methods for gene silencing and editing are being further developed, therefore it is likely that additional viral and host factors important in MERS-CoV pathogenesis will be identified.
     </p>
    </sec>
    <sec id="cesec100">
     <title>
      Protective and deleterious immune responses
     </title>
     <p id="para1560">
      MERS-CoV pathogenesis reflects a balance between coronavirus-induced protective and pathogenic host immune responses and direct cytotoxic effects of the virus.
      <xref ref-type="bibr" rid="bib52">
       <sup>
        52
       </sup>
      </xref>
      According to studies of patients infected with SARS-CoV and of mice and other animals infected experimentally with MERS-CoV, successful resolution of MERS and long-term protection from re-infection likely requires well coordinated innate and adaptive B-cell and T-cell responses. In patients with SARS, innate immune responses characterised by an extended period of cytokine secretion (eg, IFNα and IFNβ) was correlated with delayed antibody responses and poor management outcomes; this prolonged innate response has not yet been shown in patients infected with MERS-CoV.
      <xref ref-type="bibr" rid="bib53">
       <sup>
        53
       </sup>
      </xref>
      MERS-CoV productively infects activated human T cells and induces delayed cytokine responses after infection of human myeloid cells in vitro, both of which could impair virus clearance and the development of an effective immune response.
      <xref ref-type="bibr" rid="bib54">
       54
      </xref>
      ,
      <xref ref-type="bibr" rid="bib55">
       55
      </xref>
      ,
      <xref ref-type="bibr" rid="bib56">
       56
      </xref>
     </p>
     <p id="para1570">
      During the acute phase of MERS, robust virus-specific CD8 T-cell responses were detected in most patients with severe or moderate disease, with antibody and CD4 T-cell responses appearing later in the disease course.
      <xref ref-type="bibr" rid="bib57">
       <sup>
        57
       </sup>
      </xref>
      T-cell and antibody responses were reliably detected 2–3 weeks after diagnosis, although they were detected earlier in some patients.
      <xref ref-type="bibr" rid="bib49">
       49
      </xref>
      ,
      <xref ref-type="bibr" rid="bib57">
       57
      </xref>
      Studies of MERS survivors showed that MERS-CoV-specific antibody responses tended to be lower and transient in patients with mild or subclinical disease when compared with patients with severe disease, in whom MERS-CoV-specific antibody responses were detected for at least 2 years.
      <xref ref-type="bibr" rid="bib57">
       57
      </xref>
      ,
      <xref ref-type="bibr" rid="bib58">
       58
      </xref>
      ,
      <xref ref-type="bibr" rid="bib59">
       59
      </xref>
      ,
      <xref ref-type="bibr" rid="bib60">
       60
      </xref>
      In contrast, T-cell responses were detected in all MERS survivors for at least 2 years.
      <xref ref-type="bibr" rid="bib59">
       <sup>
        59
       </sup>
      </xref>
     </p>
     <p id="para1580">
      The transitory nature of the antibody response in mild disease and greater stability of the T-cell response suggest that induction of both will be required for optimal long-term protection; the measurement of both will enhance the accuracy of prevalence studies.
     </p>
    </sec>
    <sec id="cesec110">
     <title>
      Clinical features
     </title>
     <sec id="cesec120">
      <title>
       Incubation period
      </title>
      <p id="para1590">
       The specific exposures that lead to sporadic MERS-CoV infections are unknown, therefore it is impossible to estimate the incubation period in primary cases. However, based on data from cases of human-to-human transmission, the incubation period is a median of 5–7 days, with a range of 2–14 days (median 5·2 days [95% CI 1·9–14·7]).
       <xref ref-type="bibr" rid="bib2">
        2
       </xref>
       ,
       <xref ref-type="bibr" rid="bib10">
        10
       </xref>
       ,
       <xref ref-type="bibr" rid="bib21">
        21
       </xref>
       ,
       <xref ref-type="bibr" rid="bib61">
        61
       </xref>
       ,
       <xref ref-type="bibr" rid="bib62">
        62
       </xref>
       ,
       <xref ref-type="bibr" rid="bib63">
        63
       </xref>
       Immunocompromised patients can present with longer incubation periods of up to 20 days.
       <xref ref-type="bibr" rid="bib64">
        <sup>
         64
        </sup>
       </xref>
      </p>
     </sec>
     <sec id="cesec130">
      <title>
       Presentation in adults
      </title>
      <p id="para1600">
       The clinical presentation of patients infected with MERS-CoV ranges from asymptomatic or mild upper respiratory illness to rapidly progressive pneumonitis, respiratory failure, acute respiratory distress syndrome, septic shock, and multiorgan failure with fatal outcome (
       <xref ref-type="fig" rid="fig5">
        figure 5
       </xref>
       ).
       <xref ref-type="bibr" rid="bib2">
        2
       </xref>
       ,
       <xref ref-type="bibr" rid="bib10">
        10
       </xref>
       ,
       <xref ref-type="bibr" rid="bib11">
        11
       </xref>
       ,
       <xref ref-type="bibr" rid="bib61">
        61
       </xref>
       ,
       <xref ref-type="bibr" rid="bib62">
        62
       </xref>
       ,
       <xref ref-type="bibr" rid="bib63">
        63
       </xref>
       ,
       <xref ref-type="bibr" rid="bib64">
        64
       </xref>
       ,
       <xref ref-type="bibr" rid="bib65">
        65
       </xref>
       ,
       <xref ref-type="bibr" rid="bib66">
        66
       </xref>
       ,
       <xref ref-type="bibr" rid="bib67">
        67
       </xref>
       ,
       <xref ref-type="bibr" rid="bib68">
        68
       </xref>
       ,
       <xref ref-type="bibr" rid="bib69">
        69
       </xref>
       ,
       <xref ref-type="bibr" rid="bib70">
        70
       </xref>
       It is not possible to distinguish patients with a legitimate asymptomatic MERS-CoV infection from those who develop mild disease because reports to WHO provide signs and symptoms information only at the time of reporting. Many individuals remain asymptomatic whereas some go on to develop mild disease, which is why WHO classifies these individuals as mild or asymptomatic. Asymptomatic-to-mild infection rates of 25–50% have been reported.
       <fig id="fig5">
        <label>
         Figure 5
        </label>
        <caption>
         <p>
          Chest imaging abnormalities in patients with Middle East respiratory syndrome
         </p>
         <p>
          (A) Chest x-rays showing bilateral extensive diffuse and focal opacities. (B) Chest CT scan showing bilateral extensive ground-glass reticulonodular shadowing with bronchiolar wall thickening.
         </p>
        </caption>
        <graphic xlink:href="gr5_lrg">
        </graphic>
       </fig>
      </p>
      <p id="para1610">
       The signs and symptoms associated with MERS are non-specific, with or without multisystem involvement, and thus could be mistaken for other causes of respiratory tract or gastrointestinal illnesses.
       <xref ref-type="bibr" rid="bib2">
        2
       </xref>
       ,
       <xref ref-type="bibr" rid="bib10">
        10
       </xref>
       ,
       <xref ref-type="bibr" rid="bib11">
        11
       </xref>
       ,
       <xref ref-type="bibr" rid="bib61">
        61
       </xref>
       ,
       <xref ref-type="bibr" rid="bib62">
        62
       </xref>
       ,
       <xref ref-type="bibr" rid="bib63">
        63
       </xref>
       ,
       <xref ref-type="bibr" rid="bib64">
        64
       </xref>
       ,
       <xref ref-type="bibr" rid="bib65">
        65
       </xref>
       ,
       <xref ref-type="bibr" rid="bib66">
        66
       </xref>
       ,
       <xref ref-type="bibr" rid="bib67">
        67
       </xref>
       ,
       <xref ref-type="bibr" rid="bib68">
        68
       </xref>
       ,
       <xref ref-type="bibr" rid="bib69">
        69
       </xref>
       ,
       <xref ref-type="bibr" rid="bib70">
        70
       </xref>
       Therefore, the clinical diagnosis of MERS can be easily missed. Patients with MERS can typically present with fever, chills, rigors, headache, a non-productive cough, sore throat, arthralgia, and myalgia followed by dyspnoea. Other associated symptoms include coryza, nausea, vomiting, dizziness, sputum production, diarrhoea, and abdominal pain. Some patients with MERS can present with atypical symptoms of mild respiratory illness without a fever and a gastrointestinal illness that precedes the development of pneumonia.
       <xref ref-type="bibr" rid="bib64">
        64
       </xref>
       ,
       <xref ref-type="bibr" rid="bib67">
        67
       </xref>
       ,
       <xref ref-type="bibr" rid="bib68">
        68
       </xref>
       Neuromuscular manifestations include hypersomnolence, weakness, and tingling in the extremities similar to Guillain-Barré syndrome or virus-related sensory neuropathy.
       <xref ref-type="bibr" rid="bib68">
        <sup>
         68
        </sup>
       </xref>
       Co-infection of MERS-CoV with other respiratory viruses (such as parainfluenza virus, rhinovirus, influenza A or B virus, respiratory syncytial virus, enteroviruses, and human metapneumovirus) and nosocomial bacterial infections has been reported in patients receiving intensive care.
       <xref ref-type="bibr" rid="bib61">
        61
       </xref>
       ,
       <xref ref-type="bibr" rid="bib67">
        67
       </xref>
      </p>
     </sec>
     <sec id="cesec140">
      <title>
       Immunocompromised patients or those with comorbidities
      </title>
      <p id="para1620">
       Immunocompromised patients or patients with chronic heart, liver, and kidney disease can present with atypical features, such as a longer incubation period, a longer period from initial PCR positivity to symptom onset, persistent prolonged viral shedding, and increased mortality.
       <xref ref-type="bibr" rid="bib64">
        64
       </xref>
       ,
       <xref ref-type="bibr" rid="bib65">
        65
       </xref>
       ,
       <xref ref-type="bibr" rid="bib66">
        66
       </xref>
       ,
       <xref ref-type="bibr" rid="bib67">
        67
       </xref>
       ,
       <xref ref-type="bibr" rid="bib68">
        68
       </xref>
       ,
       <xref ref-type="bibr" rid="bib69">
        69
       </xref>
       ,
       <xref ref-type="bibr" rid="bib70">
        70
       </xref>
       MERS-CoV causes more severe disease in people older than 60 years, and those with chronic comorbid diseases such as renal disease, cancer, chronic lung disease, immunosuppression, and diabetes.
      </p>
     </sec>
     <sec id="cesec150">
      <title>
       Children, pregnant women, and returning travelers
      </title>
      <p id="para1630">
       In children yonger than 5 years, MERS-CoV infection appears to be rare, and usually presents as mild disease with cough as the predominant clinical symptom. Acute and severe respiratory illness (ie, a fatal outcome after multiorgan failure) has been noted in only two of 38 reported paediatric cases and these were in boys aged 9 months and 2 years with comorbidities (infantile nephrotic syndrome and cystic fibrosis, respectively).
       <xref ref-type="bibr" rid="bib71">
        71
       </xref>
       ,
       <xref ref-type="bibr" rid="bib72">
        72
       </xref>
       ,
       <xref ref-type="bibr" rid="bib73">
        73
       </xref>
       ,
       <xref ref-type="bibr" rid="bib74">
        74
       </xref>
       Data on the prevalence of MERS-CoV in pregnant women are limited to case reports, and the clinical presentations and mortality rates are similar to non-pregnant women.
       <xref ref-type="bibr" rid="bib75">
        <sup>
         75
        </sup>
       </xref>
      </p>
      <p id="para1640">
       MERS should be kept on the differential diagnosis list for ill travellers returning home from MERS-CoV endemic areas who present with acute febrile illness (temperature ≥38°C), aches and pains, headache, cough, dyspnoea, diarrhoea, nausea, vomiting, unexplained leucopenia (white blood cell count &lt;3·5 × 110
       <sup>
        9
       </sup>
       /L), and thrombocytopenia (platelets &lt;150 × 10
       <sup>
        9
       </sup>
       /L)—either with or without prominent respiratory symptoms.
       <xref ref-type="bibr" rid="bib2">
        2
       </xref>
       ,
       <xref ref-type="bibr" rid="bib10">
        10
       </xref>
       ,
       <xref ref-type="bibr" rid="bib11">
        11
       </xref>
       ,
       <xref ref-type="bibr" rid="bib61">
        61
       </xref>
       ,
       <xref ref-type="bibr" rid="bib62">
        62
       </xref>
       ,
       <xref ref-type="bibr" rid="bib63">
        63
       </xref>
       ,
       <xref ref-type="bibr" rid="bib64">
        64
       </xref>
       ,
       <xref ref-type="bibr" rid="bib65">
        65
       </xref>
       ,
       <xref ref-type="bibr" rid="bib66">
        66
       </xref>
       ,
       <xref ref-type="bibr" rid="bib67">
        67
       </xref>
       ,
       <xref ref-type="bibr" rid="bib68">
        68
       </xref>
       ,
       <xref ref-type="bibr" rid="bib69">
        69
       </xref>
       ,
       <xref ref-type="bibr" rid="bib70">
        70
       </xref>
       It is important that clinicians are alert to the possibility that patients could have MERS in all health-care settings where the virus is circulating so that an accurate diagnosis can be made and infection control measures implemented efficiently.
       <xref ref-type="bibr" rid="bib76">
        <sup>
         76
        </sup>
       </xref>
      </p>
     </sec>
    </sec>
    <sec id="cesec160">
     <title>
      Clinical specimen types for diagnosis
     </title>
     <p id="para1650">
      The type and quality of the clinical specimen are important in the laboratory diagnosis of MERS-CoV infection. Both upper respiratory tract specimens (oropharyngeal or nasopharyngeal swabs) and lower respiratory tract specimens (sputum, endotracheal aspirate or lavage) should be analysed whenever possible.
      <xref ref-type="bibr" rid="bib77">
       77
      </xref>
      ,
      <xref ref-type="bibr" rid="bib78">
       78
      </xref>
      ,
      <xref ref-type="bibr" rid="bib79">
       79
      </xref>
      Patients with MERS might not shed the virus during the early stage of their illness; thus, initial negative results from upper respiratory samples do not rule out the possibility of MERS and patients should be retested using a lower respiratory tract sample. Several studies of MERS-CoV viral load measurements show that upper respiratory tract specimens have lower viral loads than lower respiratory specimens.
      <xref ref-type="bibr" rid="bib11">
       11
      </xref>
      ,
      <xref ref-type="bibr" rid="bib12">
       12
      </xref>
      ,
      <xref ref-type="bibr" rid="bib79">
       79
      </xref>
      ,
      <xref ref-type="bibr" rid="bib80">
       80
      </xref>
      MERS-CoV RNA has been detected in blood, urine, and stool—but at much lower viral loads than in the respiratory tract.
      <xref ref-type="bibr" rid="bib81">
       81
      </xref>
      ,
      <xref ref-type="bibr" rid="bib82">
       82
      </xref>
     </p>
     <p id="para1660">
      Clinical specimens must be collected by trained staff using appropriate personal protective equipment—eg, when taking nasopharyngeal and oropharyngeal specimens, Dacron or rayon swabs specifically designed for collecting specimens for virology must be used.
      <xref ref-type="bibr" rid="bib77">
       77
      </xref>
      ,
      <xref ref-type="bibr" rid="bib78">
       78
      </xref>
      ,
      <xref ref-type="bibr" rid="bib83">
       83
      </xref>
      These swab kits should contain virus transport medium. A single negative test result does not exclude the diagnosis and repeat sampling and testing is strongly recommended.
      <xref ref-type="bibr" rid="bib83">
       <sup>
        83
       </sup>
      </xref>
      A minimum of two samples, preferably from the lower respiratory tract, are needed to exclude MERS-CoV after initial assessment. To confirm clearance of the virus, respiratory samples should be collected sequentially (every 2 to 4 days) over ensuing days until there are two consecutive negative results at least 24 h apart in people who are clinically recovered.
      <xref ref-type="bibr" rid="bib77">
       <sup>
        77
       </sup>
      </xref>
     </p>
    </sec>
    <sec id="cesec170">
     <title>
      Laboratory testing
     </title>
     <p id="para1670">
      WHO guidelines for testing should be followed.
      <xref ref-type="bibr" rid="bib77">
       <sup>
        77
       </sup>
      </xref>
      MERS-CoV testing must be performed in appropriately equipped biosafety laboratories by staff trained in the relevant technical and safety procedures. National or WHO guidelines on the laboratory biosafety should be followed in all circumstances.
      <xref ref-type="bibr" rid="bib83">
       <sup>
        83
       </sup>
      </xref>
     </p>
     <p id="para1680">
      Three real-time RT-PCR (rRT-PCR) assays for routine detection of MERS-CoV have been developed targeting upstream of the E protein gene (upE) and open reading frame (ORF)1b and ORF1a. The assay for the upE target is considered highly sensitive and is recommended for screening, with the ORF1a assay (ORF1a assay is considered more sensitive than ORF1b assay).
      <xref ref-type="bibr" rid="bib77">
       <sup>
        77
       </sup>
      </xref>
     </p>
     <p id="para1690">
      An updated roadmap for MERS-CoV product development lists all available diagnostics and other diagnostics in the developmental phase.
      <xref ref-type="bibr" rid="bib84">
       <sup>
        84
       </sup>
      </xref>
      Several diagnostic tests are under development to accelerate turnaround times from sample analysis to result.
      <xref ref-type="bibr" rid="bib85">
       85
      </xref>
      ,
      <xref ref-type="bibr" rid="bib86">
       86
      </xref>
      ,
      <xref ref-type="bibr" rid="bib87">
       87
      </xref>
      A 2018 rapid and specific assay for the detection of MERS-CoV combines the reverse transcription loop-mediated isothermal amplification technique and a vertical flow visualisation strip (RT-LAMP-VF) to detect the nucleocapsid gene of MERS-CoV.
      <xref ref-type="bibr" rid="bib86">
       <sup>
        86
       </sup>
      </xref>
      The RT-LAMP-VF assay provides detection of MERS-CoV within 35 min and is easier to perform than the WHO-recommended rRT-PCR method.
      <xref ref-type="bibr" rid="bib86">
       <sup>
        86
       </sup>
      </xref>
     </p>
     <p id="para1700">
      Several serological assays are available for detection of MERS-CoV: ELISA, recombinant spike immunofluorescent assay, and spike pseudoparticle neutralisation and microneutralisation assay.
      <xref ref-type="bibr" rid="bib87">
       87
      </xref>
      ,
      <xref ref-type="bibr" rid="bib88">
       88
      </xref>
      ,
      <xref ref-type="bibr" rid="bib89">
       89
      </xref>
      ,
      <xref ref-type="bibr" rid="bib90">
       90
      </xref>
      A case confirmed by serology requires evidence of seroconversion in two samples, ideally taken at least 14 days apart, by a screening (eg, ELISA, immunofluorescence assay) and a neutralisation assay.
      <xref ref-type="bibr" rid="bib77">
       77
      </xref>
      ,
      <xref ref-type="bibr" rid="bib78">
       78
      </xref>
     </p>
    </sec>
    <sec id="cesec180">
     <title>
      Imaging
     </title>
     <p id="para1710">
      A range of abnormal but non-specific chest x-ray findings are seen in patients with MERS.
      <xref ref-type="bibr" rid="bib91">
       91
      </xref>
      ,
      <xref ref-type="bibr" rid="bib92">
       92
      </xref>
      These abnormalities include unilateral or bilateral bronchovascular shadowing, interstitial infiltrates, reticular opacities, reticulonodular shadowing, nodules, pleural effusions, and patchy to confluent consolidation (
      <xref ref-type="sec" rid="sec1">
       appendix pp 18–19
      </xref>
      ). Lower lobes tend to be affected more than upper lobes early in the course of MERS and rapid opacification of lungs and progression to acute respiratory distress syndrome can occur.
     </p>
     <p id="para1720">
      High-resolution CT might show ground glass opacities (
      <xref ref-type="fig" rid="fig5">
       figure 5B
      </xref>
      ) in early CT findings (with or without consolidation) followed by interlobular septal and intralobular interstitial thickening with peripheral and lower lobe involvement
      <xref ref-type="bibr" rid="bib93">
       93
      </xref>
      ,
      <xref ref-type="bibr" rid="bib94">
       94
      </xref>
      within the first week of MERS-CoV infection. During subsequent weeks, a so-called crazy-paving lung abnormality, cavitation, tree-in-bud pattern and centrilobular nodules, constrictive obliterative bronchiolitis, bronchiolitis obliterans, peribronchiolar air-trapping, thickened peripheral bronchioles, and organising pneumonia have been observed.
      <xref ref-type="bibr" rid="bib95">
       <sup>
        95
       </sup>
      </xref>
     </p>
    </sec>
    <sec id="cesec190">
     <title>
      Treatment and management
     </title>
     <p id="para1730">
      Currently, there are no specific anti-MERS-CoV therapies available for human use. The mainstay of clinical management of MERS cases is mostly symptom focused, providing supportive care
      <xref ref-type="bibr" rid="bib10">
       10
      </xref>
      ,
      <xref ref-type="bibr" rid="bib61">
       61
      </xref>
      with pain and fever management, treating concomitant or secondary bacterial infections, and supporting vital organ functions. Mild MERS cases can be managed at home.
      <xref ref-type="bibr" rid="bib96">
       <sup>
        96
       </sup>
      </xref>
      Predictive factors for development of pneumonia include older age (&gt;56 years), high fever, thrombocytopenia, lymphopenia, C-reactive protein greater than or equal to 2 mg/dL, and a high viral load in sputum (threshold cycle value of rRT-PCR &lt;28·5).
      <xref ref-type="bibr" rid="bib10">
       10
      </xref>
      ,
      <xref ref-type="bibr" rid="bib70">
       70
      </xref>
      Respiratory failure and acute kidney injury (with haematuria and proteinuria) are common among patients admitted for hospital care because of the severity of their disease and who require mechanical ventilation, extracorporeal membrane oxygenation, and dialyses.
      <xref ref-type="bibr" rid="bib10">
       10
      </xref>
      ,
      <xref ref-type="bibr" rid="bib61">
       61
      </xref>
      ,
      <xref ref-type="bibr" rid="bib70">
       70
      </xref>
     </p>
     <p id="para1740">
      Several empirical treatments have been studied in severely ill patients. Therapies used for severely ill patients with MERS have included convalescent plasma, corticosteroids, antiviral agents (eg, interferons and ribavirin), and protease inhibitors, or combination of members from these groups. A systematic review of 30 publications on therapeutic agents used for MERS treatment in various outbreaks showed a complete absence of an accurate evidence base and emphasised the need for controlled trials.
      <xref ref-type="bibr" rid="bib97">
       <sup>
        97
       </sup>
      </xref>
     </p>
     <sec id="cesec200">
      <title>
       Antiviral agents
      </title>
      <p id="para1750">
       Several agents have shown inhibitory effects against MERS-CoV in cell cultures, including interferons, ribavirin, ciclosporin, and mycophenolic acid.
       <xref ref-type="bibr" rid="bib98">
        98
       </xref>
       ,
       <xref ref-type="bibr" rid="bib99">
        99
       </xref>
       ,
       <xref ref-type="bibr" rid="bib100">
        100
       </xref>
       ,
       <xref ref-type="bibr" rid="bib101">
        101
       </xref>
       ,
       <xref ref-type="bibr" rid="bib102">
        102
       </xref>
       ,
       <xref ref-type="bibr" rid="bib103">
        103
       </xref>
       ,
       <xref ref-type="bibr" rid="bib104">
        104
       </xref>
       ,
       <xref ref-type="bibr" rid="bib105">
        105
       </xref>
       Empirical lopinavir–ritonavir, pegylated interferon alfa-2a, and ribavirin have been used for serious cases, but no efficacy data are yet available. There is an ongoing randomised clinical trial in progress in Saudi Arabia (the MIRACLE trial;
       <ext-link ext-link-type="ClinicalTrials.gov" id="interrefs10" xlink:href="NCT02845843">
        NCT02845843
       </ext-link>
       ) comparing lopinavir–ritonavir, recombinant interferon beta, and standard supportive care against placebo and standard supportive care in patients with laboratory-confirmed MERS requiring hospital admission. This recursive, multicentre, placebo-controlled, double-blind, randomised controlled trial is designed to include two components, each consisting of two stages. The first two-stage component is designed to adjust sample size and determine futility stopping, but not efficacy stopping (n=34). The second two-stage component is designed to determine efficacy stopping and possibly readjustment of sample size.
      </p>
     </sec>
     <sec id="cesec210">
      <title>
       Convalescent plasma
      </title>
      <p id="para1760">
       The use of plasma from patients with MERS who have made a full recovery (convalescent plasma) requires clinical trial evaluation. Preclinical animal data show that transfer of serum samples from MERS-CoV-immune camels to infected mice resulted in reduced weight loss and lung histopathology,
       <xref ref-type="bibr" rid="bib106">
        <sup>
         106
        </sup>
       </xref>
       thus suggesting therapeutic potential. In the 2015 Korean outbreak, three of 13 patients with MERS with respiratory failure were given four infusions of convalescent plasma.
       <xref ref-type="bibr" rid="bib107">
        <sup>
         107
        </sup>
       </xref>
       Two of three showed neutralising activity. Donor plasma with a plaque reduction neutralisation test (PRNT) titre of 1/80 had a meaningful serological response after convalescent plasma infusion, while that with a PRNT titre of 1/40 did not. The authors conclude that for effective convalescent plasma infusion in patients with MERS, donor plasma with a neutralisation activity of a PRNT titre greater than or equal to 1/80 should be used.
      </p>
     </sec>
     <sec id="cesec220">
      <title>
       Antibiotic therapy
      </title>
      <p id="para1770">
       Antibiotic therapy is commonly started empirically in seriously ill patients. A retrospective study of 136 patients with MERS found that macrolide therapy resulted in no reduction in mortality or faster MERS-CoV RNA clearance compared with those who were not treated with macrolides.
       <xref ref-type="bibr" rid="bib108">
        <sup>
         108
        </sup>
       </xref>
      </p>
     </sec>
     <sec id="cesec230">
      <title>
       Intensive care management
      </title>
      <p id="para1780">
       For serious cases, hospital inpatient care is required to reduce the risk of complications such as organ failure and secondary infections. Non-invasive ventilation is associated with a high failure rate (92%) in patients with acute hypoxaemic respiratory failure due to MERS-CoV infection.
       <xref ref-type="bibr" rid="bib109">
        <sup>
         109
        </sup>
       </xref>
       Patients with severe symptoms might need to be managed in an intensive care unit, where lung-protective ventilatory strategies for acute respiratory distress syndrome, inotropic support, antimicrobial therapy for co-infections, and renal replacement therapy for acute renal failure can be provided.
      </p>
     </sec>
     <sec id="cesec240">
      <title>
       Systemic corticosteroids
      </title>
      <p id="para1790">
       Studies show no benefit from the use of systemic corticosteroids. Systemic corticosteroids were shown to delay viral clearance in critically ill patients with MERS-CoV infection.
       <xref ref-type="bibr" rid="bib100">
        <sup>
         100
        </sup>
       </xref>
      </p>
     </sec>
     <sec id="cesec250">
      <title>
       New treatments
      </title>
      <p id="para1800">
       A range of potential treatments are under consideration, development, or evaluation (
       <xref ref-type="boxed-text" rid="box3">
        panel 3
       </xref>
       ). A phase 1, first-in-human, single site, randomised, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of single ascending doses of a co-administered monoclonal antibodies REGN3048 and REGN3051 administered intravenously in healthy adult volunteers (
       <ext-link ext-link-type="ClinicalTrials.gov" id="interrefs20" xlink:href="NCT03301090">
        NCT03301090
       </ext-link>
       ) is ongoing and study duration will be approximately 16 months. Another study is comparing patients who received extracorporeal membrane oxygenation (ECMO) support with those who did not receive ECMO support (
       <ext-link ext-link-type="ClinicalTrials.gov" id="interrefs30" xlink:href="NCT02627378">
        NCT02627378
       </ext-link>
       ). Several monoclonal and polyclonal neutralising antibody products, including novel chimeric camel or human heavy-chain antibodies, are protective in animal models,
       <xref ref-type="bibr" rid="bib110">
        110
       </xref>
       ,
       <xref ref-type="bibr" rid="bib111">
        111
       </xref>
       ,
       <xref ref-type="bibr" rid="bib112">
        112
       </xref>
       and their potential use for pre-exposure or post-exposure prophylaxis in outbreak management requires evaluations in controlled trials.
       <boxed-text id="box3">
        <label>
         Panel 3
        </label>
        <caption>
         <title>
          Potential therapies for the treatment of MERS coronavirus infection97–105, 139–143
         </title>
        </caption>
        <p id="para470">
         <bold>
          Antibody-based interventions
         </bold>
        </p>
        <p id="para480">
         <list id="celist80" list-type="simple">
          <list-item id="celistitem310">
           <label>
            •
           </label>
           <p id="para490">
            Whole blood
           </p>
          </list-item>
          <list-item id="celistitem320">
           <label>
            •
           </label>
           <p id="para500">
            Convalescent plasma
           </p>
          </list-item>
          <list-item id="celistitem330">
           <label>
            •
           </label>
           <p id="para510">
            Intravenous immunoglobulin
           </p>
          </list-item>
          <list-item id="celistitem340">
           <label>
            •
           </label>
           <p id="para520">
            Polyclonal human immunoglobulin (SAB-301) from transgenic cows
           </p>
          </list-item>
          <list-item id="celistitem350">
           <label>
            •
           </label>
           <p id="para530">
            Equine antibody fragments
           </p>
          </list-item>
          <list-item id="celistitem360">
           <label>
            •
           </label>
           <p id="para540">
            Camel antibodies
           </p>
          </list-item>
          <list-item id="celistitem370">
           <label>
            •
           </label>
           <p id="para550">
            Monoclonal antibodies (eg, MERS-4, MERS-7)
           </p>
          </list-item>
          <list-item id="celistitem380">
           <label>
            •
           </label>
           <p id="para560">
            Human monoclonal antibodies to Sprotein
           </p>
          </list-item>
          <list-item id="celistitem390">
           <label>
            •
           </label>
           <p id="para570">
            Humanised anti-S monoclonals (eg, hMS-1, m336, 4C2)
           </p>
          </list-item>
         </list>
        </p>
        <p id="para580">
         <bold>
          Interferons
         </bold>
        </p>
        <p id="para590">
         <list id="celist90" list-type="simple">
          <list-item id="celistitem400">
           <label>
            •
           </label>
           <p id="para600">
            Interferon alfa (1a, 2b)
           </p>
          </list-item>
          <list-item id="celistitem410">
           <label>
            •
           </label>
           <p id="para610">
            Interferon beta-1b
           </p>
          </list-item>
          <list-item id="celistitem420">
           <label>
            •
           </label>
           <p id="para620">
            Interferon gamma
           </p>
          </list-item>
         </list>
        </p>
        <p id="para630">
         <bold>
          Antivirals
         </bold>
        </p>
        <p id="para640">
         <list id="celist100" list-type="simple">
          <list-item id="celistitem430">
           <label>
            •
           </label>
           <p id="para650">
            Ribavirin monotherapy (with or without interferon)
           </p>
          </list-item>
          <list-item id="celistitem440">
           <label>
            •
           </label>
           <p id="para660">
            HIV protease inhibitors (eg, lopinavir, nelfinavir)
           </p>
          </list-item>
          <list-item id="celistitem450">
           <label>
            •
           </label>
           <p id="para670">
            Cyclophilin inhibitors (eg, ciclosporin, alisporivir)
           </p>
          </list-item>
          <list-item id="celistitem460">
           <label>
            •
           </label>
           <p id="para680">
            Nucleoside viral RNA polymerase inhibitors (galidesivir, remdesivir, EIDD 2801 [prodrug of EIDD 1931]
           </p>
          </list-item>
         </list>
        </p>
        <p id="para690">
         <bold>
          MERS-CoV 3C-like protease inhibitors
         </bold>
        </p>
        <p id="para700">
         <list id="celist110" list-type="simple">
          <list-item id="celistitem470">
           <label>
            •
           </label>
           <p id="para710">
            Flavinoids (eg, herbacetin, isobavachalcone, quercetin 3-β-d-glucoside, helichrysetin)
           </p>
          </list-item>
         </list>
        </p>
        <p id="para720">
         <bold>
          Combination therapies
         </bold>
        </p>
        <p id="para730">
         <list id="celist120" list-type="simple">
          <list-item id="celistitem480">
           <label>
            •
           </label>
           <p id="para740">
            Lopinavir-ritonavir and interferon beta 1b
           </p>
          </list-item>
          <list-item id="celistitem490">
           <label>
            •
           </label>
           <p id="para750">
            Cyclosporin plus interferon alpha
           </p>
          </list-item>
          <list-item id="celistitem500">
           <label>
            •
           </label>
           <p id="para760">
            Lopinavir-ritonavir
           </p>
          </list-item>
          <list-item id="celistitem510">
           <label>
            •
           </label>
           <p id="para770">
            Ribavirin and interferon alpha
           </p>
          </list-item>
         </list>
        </p>
        <p id="para780">
         <bold>
          Host-directed therapies (repurposed drugs)
         </bold>
        </p>
        <p id="para790">
         <list id="celist130" list-type="simple">
          <list-item id="celistitem520">
           <label>
            •
           </label>
           <p id="para800">
            Chlorpromazine
           </p>
          </list-item>
          <list-item id="celistitem530">
           <label>
            •
           </label>
           <p id="para810">
            Mycophenolic acid (with or without interferon beta 1b)
           </p>
          </list-item>
          <list-item id="celistitem540">
           <label>
            •
           </label>
           <p id="para820">
            Nitazoxanide
           </p>
          </list-item>
          <list-item id="celistitem550">
           <label>
            •
           </label>
           <p id="para830">
            Sitagliptin
           </p>
          </list-item>
          <list-item id="celistitem560">
           <label>
            •
           </label>
           <p id="para840">
            Omacetaxine mepesuccinate
           </p>
          </list-item>
          <list-item id="celistitem570">
           <label>
            •
           </label>
           <p id="para850">
            Aciclovir
           </p>
          </list-item>
          <list-item id="celistitem580">
           <label>
            •
           </label>
           <p id="para860">
            Imatinib mesylate (tyrosine mesylate inhibitor)
           </p>
          </list-item>
          <list-item id="celistitem590">
           <label>
            •
           </label>
           <p id="para870">
            Neurotransmitter inhibitors (eg, clomipramine, astemizole)
           </p>
          </list-item>
          <list-item id="celistitem600">
           <label>
            •
           </label>
           <p id="para880">
            Neutriceuticals (eg, zinc)
           </p>
          </list-item>
         </list>
        </p>
        <p id="para890">
         <bold>
          Host-directed therapies (cellular therapy)
         </bold>
        </p>
        <p id="para900">
         <list id="celist140" list-type="simple">
          <list-item id="celistitem610">
           <label>
            •
           </label>
           <p id="para910">
            Allogeneic mesenchymal stromal cells
           </p>
          </list-item>
         </list>
        </p>
        <p id="para920">
         <bold>
          Lectins
         </bold>
        </p>
        <p id="para930">
         <list id="celist150" list-type="simple">
          <list-item id="celistitem620">
           <label>
            •
           </label>
           <p id="para940">
            Mannose binding lectin
           </p>
          </list-item>
         </list>
        </p>
        <p id="para950">
         <bold>
          Anti-coronavirus peptides
         </bold>
        </p>
        <p id="para960">
         <list id="celist160" list-type="simple">
          <list-item id="celistitem630">
           <label>
            •
           </label>
           <p id="para970">
            Peptides derived from HR1, HR2, and RBD spike protein subunits
           </p>
          </list-item>
          <list-item id="celistitem640">
           <label>
            •
           </label>
           <p id="para980">
            Peptides inhibiting viral entry and replication
           </p>
          </list-item>
          <list-item id="celistitem650">
           <label>
            •
           </label>
           <p id="para990">
            Peptides derived from antimicrobial peptides
           </p>
          </list-item>
         </list>
        </p>
        <p id="para1000">
         <bold>
          RNA interference molecules silencing key MERS-CoV genes
         </bold>
        </p>
        <p id="para1010">
         <list id="celist170" list-type="simple">
          <list-item id="celistitem660">
           <label>
            •
           </label>
           <p id="para1020">
            miRNA molecules
           </p>
          </list-item>
          <list-item id="celistitem670">
           <label>
            •
           </label>
           <p id="para1030">
            siRNA molecules
           </p>
          </list-item>
         </list>
        </p>
        <p id="para1040">
         MERS=Middle East respiratory syndrome. MERS-CoV=Middle East respiratory syndrome coronavirus. RBD=receptor-binding domain. S=spike. RNA=ribonucleic acid. miRNA=micro RNA. siRNA=small interfering RNA.
        </p>
       </boxed-text>
      </p>
     </sec>
     <sec id="cesec260">
      <title>
       Mental health support
      </title>
      <p id="para1810">
       In a mental health study, 7·6% of 1656 patients who were quarantined showed symptoms of anxiety, and 6·4% reported feelings of anger during the 2 weeks of quarantine.
       <xref ref-type="bibr" rid="bib113">
        <sup>
         113
        </sup>
       </xref>
       Mental health support, accurate information, and appropriate supplies, including food, clothes, and accommodation, should be provided to people who feel isolated.
      </p>
     </sec>
     <sec id="cesec270">
      <title>
       Management outcomes and mortality rates
      </title>
      <p id="para1820">
       Several studies have reported disease severity and mortality risk factor data from patients in the Middle East and South Korea.
       <xref ref-type="bibr" rid="bib11">
        11
       </xref>
       ,
       <xref ref-type="bibr" rid="bib12">
        12
       </xref>
       ,
       <xref ref-type="bibr" rid="bib21">
        21
       </xref>
       ,
       <xref ref-type="bibr" rid="bib114">
        114
       </xref>
       ,
       <xref ref-type="bibr" rid="bib115">
        115
       </xref>
       ,
       <xref ref-type="bibr" rid="bib116">
        116
       </xref>
       ,
       <xref ref-type="bibr" rid="bib117">
        117
       </xref>
       Ahmed and colleagues collected the daily information on MERS-CoV cases posted online by the Saudi Arabian Ministry of Health between Dec 2, 2014, and Nov 12, 2016, and reviewed 660 laboratory-confirmed cases of MERS.
       <xref ref-type="bibr" rid="bib114">
        <sup>
         114
        </sup>
       </xref>
       They showed mortality at day 3 (13·8%), day 30 (28·3%), and overall (29·8%). Patients older than 60 years were more likely to die (45·2% mortality) from their infections than were younger patients (20%).
      </p>
      <p id="para1830">
       Several factors are associated with severe disease and high mortality rates in patients with MERS. These factors include male sex, comorbid pre-existing illnesses (such as obesity, diabetes mellitus, cancer, chronic heart, lung, and kidney disease, and immunocompromised states), low serum albumin, thrombocytopenia, lymphopenia, concomitant infections, and positive plasma MERS-CoV RNA. DPP4 receptors are upregulated in the lungs of smokers and patients with chronic obstructive pulmonary disease, which might explain why patients with comorbid lung diseases are prone to severe illness.
       <xref ref-type="bibr" rid="bib118">
        <sup>
         118
        </sup>
       </xref>
       In the 2015 Korean outbreak, the case-fatality rate was 20·4% (39 of 186 patients died), the in-hospital mortality was 19·4% (36 of 186 patients), 7-day mortality (from symptom onset) was 3·8% (seven of 186), and 28-day mortality was 17·7% (33 of 186).
       <xref ref-type="bibr" rid="bib11">
        11
       </xref>
       ,
       <xref ref-type="bibr" rid="bib12">
        12
       </xref>
       Host factors associated with mortality in this outbreak were older age (&gt;60 years), smoking history, pre-existing pneumonia, abnormal renal function, and comorbidity. Low albumin, altered mentality, and high pneumonia severity index score at admission were risk factors for mortality.
      </p>
     </sec>
     <sec id="cesec280">
      <title>
       Prognosis and long term follow-up of MERS survivors
      </title>
      <p id="para1840">
       In a study of long-term effects after recovery from MERS,
       <xref ref-type="bibr" rid="bib119">
        <sup>
         119
        </sup>
       </xref>
       patients with severe illness who were admitted to intensive care reported higher limitations in some measure of their quality of life than patients with less severe illness who were managed in medical wards. The long-term consequences of MERS illness on survivors appear to be similar to those caused by other viral causes of severe acute respiratory infections such as influenza, parainfluenza, and metapneumovirus.
       <xref ref-type="bibr" rid="bib120">
        <sup>
         120
        </sup>
       </xref>
       Follow-up imaging studies of patients who recover from MERS indicate that lung fibrosis might develop in a substantial number of patients.
       <xref ref-type="bibr" rid="bib95">
        <sup>
         95
        </sup>
       </xref>
      </p>
     </sec>
    </sec>
    <sec id="cesec290">
     <title>
      Prevention
     </title>
     <p id="para1850">
      The prevention of transmission of MERS-CoV in the community and in health-care settings is crucial to preventing outbreaks and further spread. Several substantive reviews and WHO guidelines are available on the subject.
      <xref ref-type="bibr" rid="bib21">
       21
      </xref>
      ,
      <xref ref-type="bibr" rid="bib61">
       61
      </xref>
      ,
      <xref ref-type="bibr" rid="bib76">
       76
      </xref>
      ,
      <xref ref-type="bibr" rid="bib96">
       96
      </xref>
     </p>
     <p id="para1860">
      It is important to maintain good personal and environmental hygiene, and to implement stringent contact and droplet precautions among health-care workers. To prevent community transmission, contact tracing, quarantine or isolation of close contacts, and public education are important measures.
      <xref ref-type="bibr" rid="bib20">
       20
      </xref>
      ,
      <xref ref-type="bibr" rid="bib60">
       60
      </xref>
     </p>
     <p id="para1870">
      In hospitals, early case detection followed by isolation is essential, ideally in negative pressure isolation rooms. The main infection prevention and control measures for managing patients with MERS are well documented from the SARS epidemic and from experiences from managing MERS outbreaks (
      <xref ref-type="sec" rid="sec1">
       appendix pp 7–8
      </xref>
      ).
     </p>
     <sec id="cesec300">
      <title>
       Advances in vaccine development
      </title>
      <p id="para1880">
       Advances in technology, vaccine platforms, clinical trial designs, and bioinformatics are supporting MERS-CoV vaccine development (
       <xref ref-type="sec" rid="sec1">
        appendix pp 8–9
       </xref>
       ). WHO target product profiles for MERS-CoV vaccines calls for the development of three types of MERS vaccines: a human vaccine for long-term protection of people at high exposure risk, such as health-care workers and those working with potentially infected camels; a human vaccine for reactive use in outbreak settings; and a dromedary camel vaccine to prevent zoonotic transmission.
       <xref ref-type="bibr" rid="bib121">
        <sup>
         121
        </sup>
       </xref>
       Multiple types of vaccine candidates are in development including inactivated whole virus, live attenuated virus, viral vectored vaccines, subunit vaccines, and DNA vaccines.
       <xref ref-type="bibr" rid="bib121">
        121
       </xref>
       ,
       <xref ref-type="bibr" rid="bib122">
        122
       </xref>
       Most vaccines use the S protein or the domain of the S protein required for binding to host DPP4 as an immunogen, since neutralising antibodies are mostly directed to the receptor binding domain.
      </p>
     </sec>
     <sec id="cesec310">
      <title>
       Priorities for MERS research, surveillance, management, and control
      </title>
      <p id="para1890">
       WHO, Food and Agriculture Organization of the UN, and World Organization for Animal Health, in consultation with global MERS community, identified knowledge gaps and priorities for MERS research, surveillance, management, and control (
       <xref ref-type="boxed-text" rid="box4">
        panel 4
       </xref>
       ).
       <xref ref-type="bibr" rid="bib31">
        <sup>
         31
        </sup>
       </xref>
       <boxed-text id="box4">
        <label>
         Panel 4
        </label>
        <caption>
         <title>
          Priorities for MERS research, surveillance, management, and control
         </title>
        </caption>
        <p id="para1050">
         <bold>
          Establishing a One Health global consortium:
         </bold>
        </p>
        <p id="para1060">
         <list id="celist180" list-type="simple">
          <list-item id="celistitem680">
           <label>
            •
           </label>
           <p id="para1070">
            Creation of a One Health multidisciplinary consortia in Middle Eastern and African countries to tackle zoonotic spread of MERS-CoV between animals, humans, and the environment and to monitor, respond to, and prevent major outbreaks
           </p>
          </list-item>
          <list-item id="celistitem690">
           <label>
            •
           </label>
           <p id="para1080">
            Establishing effective One Health research and surveillance collaborations between a range of expertise including public health officers, physicians, veterinarians, animal husbandry specialists, agriculturalists, ecologists, phylogeneticists, trialists, and basic scientists
           </p>
          </list-item>
         </list>
        </p>
        <p id="para1090">
         <bold>
          Priority studies in dromedary camels:
         </bold>
        </p>
        <p id="para1100">
         <list id="celist190" list-type="simple">
          <list-item id="celistitem700">
           <label>
            •
           </label>
           <p id="para1110">
            Natural history studies that evaluate evidence of re-infection
           </p>
          </list-item>
          <list-item id="celistitem710">
           <label>
            •
           </label>
           <p id="para1120">
            Value chain and production system analyses
           </p>
          </list-item>
          <list-item id="celistitem720">
           <label>
            •
           </label>
           <p id="para1130">
            Improving surveillance to evaluate any seasonal or temporal variation in viral shedding
           </p>
          </list-item>
          <list-item id="celistitem730">
           <label>
            •
           </label>
           <p id="para1140">
            Identifying important points for interventions and interruption of within-species and zoonotic transmission
           </p>
          </list-item>
          <list-item id="celistitem740">
           <label>
            •
           </label>
           <p id="para1150">
            Accelerating the development of camel vaccine candidates
           </p>
          </list-item>
         </list>
        </p>
        <p id="para1160">
         <bold>
          Priority studies at the animal–human–environmental interface:
         </bold>
        </p>
        <p id="para1170">
         <list id="celist200" list-type="simple">
          <list-item id="celistitem750">
           <label>
            •
           </label>
           <p id="para1180">
            Real-time mapping of virus circulation and geographical range of MERS-CoV infection in humans and dromedary camels
           </p>
          </list-item>
          <list-item id="celistitem760">
           <label>
            •
           </label>
           <p id="para1190">
            Development of new accurate and accessible point-of-care diagnostic tests for outbreak containment, case management, and surveillance
           </p>
          </list-item>
          <list-item id="celistitem770">
           <label>
            •
           </label>
           <p id="para1200">
            Evaluating geographical extent of spillover from animals to humans in Africa, the Middle East, and south Asia
           </p>
          </list-item>
          <list-item id="celistitem780">
           <label>
            •
           </label>
           <p id="para1210">
            Animal and human serological, virological, and genomic studies in specific locations to evaluate risk factors for human infection and exact routes of zoonotic transmission, including food and oral routes
           </p>
          </list-item>
          <list-item id="celistitem790">
           <label>
            •
           </label>
           <p id="para1220">
            Social science and anthropological studies to describe and quantify exposures to dromedary camels and identify opportunities for risk-mitigating interventions
           </p>
          </list-item>
         </list>
        </p>
        <p id="para1230">
         <bold>
          Priority studies in human populations:
         </bold>
        </p>
        <p id="para1240">
         <list id="celist210" list-type="simple">
          <list-item id="celistitem800">
           <label>
            •
           </label>
           <p id="para1250">
            Accelerating research and development, implementation, and evaluation of medical countermeasures to reduce morbidity and mortality associated with MERS (especially in high risk comorbid populations)
           </p>
          </list-item>
          <list-item id="celistitem810">
           <label>
            •
           </label>
           <p id="para1260">
            Identifying optimal interventions for reducing infection among health-care workers in hospital settings
           </p>
          </list-item>
          <list-item id="celistitem820">
           <label>
            •
           </label>
           <p id="para1270">
            Determining the role of asymptomatic cases in transmission of infections in humans and whether any specific behaviours can result in human infection from non-human sources
           </p>
          </list-item>
          <list-item id="celistitem830">
           <label>
            •
           </label>
           <p id="para1280">
            Targeted epidemiological studies in clinical settings to better understand immune response and duration of infectiousness and address the long-term medical and psychological complications in MERS survivors
           </p>
          </list-item>
          <list-item id="celistitem840">
           <label>
            •
           </label>
           <p id="para1290">
            Integrating testing for MERS-CoV into existing respiratory disease surveillance systems to identify extent and spectrum of mild infection in the community
           </p>
          </list-item>
         </list>
        </p>
        <p id="para1300">
         <bold>
          Priority studies for vaccines, therapeutics, and rapid diagnostics:
         </bold>
        </p>
        <p id="para1310">
         <list id="celist220" list-type="simple">
          <list-item id="celistitem850">
           <label>
            •
           </label>
           <p id="para1320">
            Accelerating the development of human MERS-CoV vaccine candidates
           </p>
          </list-item>
          <list-item id="celistitem860">
           <label>
            •
           </label>
           <p id="para1330">
            Accelerating development of MERS-CoV therapeutic pipeline and host-directed therapies
           </p>
          </list-item>
          <list-item id="celistitem870">
           <label>
            •
           </label>
           <p id="para1340">
            Development of new accurate and accessible diagnostic tests for outbreak containment, case management, and surveillance
           </p>
          </list-item>
          <list-item id="celistitem880">
           <label>
            •
           </label>
           <p id="para1350">
            Increased donor investment into research and development for: novel point-of-care testing options, syndromic panels for differential diagnosis, a greater understanding of viral and antibody kinetics, improved access to clinical specimens, and establishment of international reference standards
           </p>
          </list-item>
         </list>
        </p>
        <p id="para1360">
         Adapted from the FAO-OIE-WHO MERS Technical Working Group's report on MERS (2018). MERS=Middle East respiratory syndrome.
         <xref ref-type="bibr" rid="bib31">
          <sup>
           31
          </sup>
         </xref>
         MERS-CoV=Middle East respiratory syndrome coronavirus.
        </p>
       </boxed-text>
      </p>
      <p id="para1900">
       Several recent publications have highlighted the importance of a one-human-environmental-animal-health (One Health) approach to tackle and control the spread of MERS-CoV (
       <xref ref-type="sec" rid="sec1">
        appendix p 9
       </xref>
       ).
       <xref ref-type="bibr" rid="bib31">
        31
       </xref>
       ,
       <xref ref-type="bibr" rid="bib121">
        121
       </xref>
       ,
       <xref ref-type="bibr" rid="bib122">
        122
       </xref>
       ,
       <xref ref-type="bibr" rid="bib123">
        123
       </xref>
       ,
       <xref ref-type="bibr" rid="bib124">
        124
       </xref>
       ,
       <xref ref-type="bibr" rid="bib125">
        125
       </xref>
       ,
       <xref ref-type="bibr" rid="bib126">
        126
       </xref>
      </p>
     </sec>
    </sec>
    <sec id="cesec320">
     <title>
      Conclusion
     </title>
     <p id="para1910">
      MERS-CoV is a pathogen with epidemic potential that continues to cause sporadic human disease and remains on the WHO Blueprint 2020 priority list.
      <xref ref-type="bibr" rid="bib4">
       <sup>
        4
       </sup>
      </xref>
      Given that MERS-CoV appears to be highly endemic among dromedary camels from geographically widespread areas of the Middle East and Africa, zoonotic transmission with consequent risk of human epidemics will most likely continue for years to come.
      <xref ref-type="bibr" rid="bib8">
       8
      </xref>
      ,
      <xref ref-type="bibr" rid="bib9">
       9
      </xref>
      MERS-CoV endemic and at-risk countries must invest more in surveillance, in public health research, and in medical interventions—including human and camel vaccine development. The continued risk of human MERS-CoV outbreaks 7 years after its first discovery, effective human and camel MERS-CoV vaccines appear to be the ideal way to prevent continuing spread of MERS-CoV in dromedary camels in the Middle East and in humans at high risk of acquiring community and nosocomial MERS-CoV infection.
     </p>
    </sec>
    <sec id="cesec330">
     <title>
      Search strategy and selection criteria
     </title>
     <p id="para1920">
      <boxed-text id="cetextbox10">
       <p id="para1930">
        We searched publications in the English language literature on PubMed and Google Scholar (dates we used to refine our search: Sept 1, 2012, to Dec 31, 2019). We used the search terms “Middle East Respiratory Syndrome” OR “MERS-CoV” OR “MERS” in combination with the terms “Coronavirus”, OR “Middle East”, OR “Epidemiology”, “Aetiology”, “Dromedaries”, “Camels”, “Bats”, OR “Transmission”, OR “Virology” OR “Pathogenesis”, “Clinical features” OR “Infection control”, “Diagnostic tests”, OR “Diagnosis” OR “Treatment”, OR “Management”, OR “drugs”, “Therapies”, OR “Prevention” OR “Vaccines” OR “Nosocomial” OR “Hospital”. We also searched websites of global and national public health agencies such as WHO, WHO–Regional Office for the Eastern Mediterranean, UN Food and Agriculture Organization, US Centers for Disease Control and Prevention (CDC), Public Health England (UK), World Organisation for Animal Health, European Centre for Disease Prevention and Control (ECDC), and the Saudi Ministry of Health Middle East respiratory syndrome (MERS) portal. We reviewed publications on MERS from WHO, CDC, ECDC, Center for Infectious Disease Research and Policy (University of Minnesota, USA), and ProMED (Program for Monitoring Emerging Diseases) websites. We focused our review on publications published in the past 36 months to update the
        <italic>
         Lancet
        </italic>
        Seminar on MERS published in September, 2015. We also selected reference lists and substantive reviews of articles identified by this search strategy that we judged relevant to provide readers with additional details and more references than this Seminar can accommodate.
       </p>
      </boxed-text>
     </p>
    </sec>
    <back>
     <ref-list id="bibl10">
      <title>
       References
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <element-citation id="sbref10" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          WHO
         </collab>
        </person-group>
        <article-title>
         SARS (severe acute respiratory syndrome)
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs40" xlink:href="https://www.who.int/ith/diseases/sars/en/">
         https://www.who.int/ith/diseases/sars/en/
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <element-citation id="sbref20" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          WHO
         </collab>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV)
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs50" xlink:href="https://www.who.int/emergencies/mers-cov/en/">
         https://www.who.int/emergencies/mers-cov/en/
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation id="sbref30" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          WHO
         </collab>
        </person-group>
        <article-title>
         Coronavirus disease (COVID-19) outbreak
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs60" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019">
         https://www.who.int/emergencies/diseases/novel-coronavirus-2019
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <element-citation id="sbref40" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          WHO
         </collab>
        </person-group>
        <article-title>
         A research and development blueprint for action to prevent epidemics
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs70" xlink:href="https://www.who.int/blueprint/en/">
         https://www.who.int/blueprint/en/
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <element-citation id="sbref50" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           KY
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name>
          <surname>
           Stöhr
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         The severe acute respiratory syndrome
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         349
        </volume>
        <year>
         2003
        </year>
        <fpage>
         2431
        </fpage>
        <lpage>
         2441
        </lpage>
        <pub-id pub-id-type="pmid">
         14681510
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <element-citation id="sbref60" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         367
        </volume>
        <year>
         2012
        </year>
        <fpage>
         1814
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <element-citation id="sbref70" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hijawi
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Abdallat
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Sayaydeh
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation
        </article-title>
        <source>
         East Mediterr Health J
        </source>
        <volume>
         19
        </volume>
        <year>
         2013
        </year>
        <fpage>
         S12
        </fpage>
        <lpage>
         S18
        </lpage>
        <pub-id pub-id-type="pmid">
         23888790
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib8">
       <label>
        8
       </label>
       <element-citation id="sbref80" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Kellam
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence for camel-to-human transmission of MERS coronavirus
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         371
        </volume>
        <year>
         2014
        </year>
        <fpage>
         1359
        </fpage>
        <lpage>
         1360
        </lpage>
        <pub-id pub-id-type="pmid">
         25271615
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib9">
       <label>
        9
       </label>
       <element-citation id="sbref90" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           El-Kafrawy
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <name>
          <surname>
           Tolah
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Enzootic patterns of Middle East respiratory syndrome coronavirus in imported African and local Arabian dromedary camels: a prospective genomic study
        </article-title>
        <source>
         Lancet Planet Health
        </source>
        <volume>
         3
        </volume>
        <year>
         2019
        </year>
        <fpage>
         e521
        </fpage>
        <lpage>
         e528
        </lpage>
        <pub-id pub-id-type="pmid">
         31843456
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib10">
       <label>
        10
       </label>
       <element-citation id="sbref100" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         386
        </volume>
        <year>
         2015
        </year>
        <fpage>
         995
        </fpage>
        <lpage>
         1007
        </lpage>
        <pub-id pub-id-type="pmid">
         26049252
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib11">
       <label>
        11
       </label>
       <element-citation id="sbref110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Tandi
          </surname>
          <given-names>
           TE
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         <name>
          <surname>
           Moon
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in South Korea, 2015: epidemiology, characteristics and public health implications
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         95
        </volume>
        <year>
         2017
        </year>
        <fpage>
         207
        </fpage>
        <lpage>
         213
        </lpage>
        <pub-id pub-id-type="pmid">
         28153558
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib12">
       <label>
        12
       </label>
       <element-citation id="sbref120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oh
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           WB
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           SW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome: what we learned from the 2015 outbreak in the Republic of Korea
        </article-title>
        <source>
         Korean J Intern Med
        </source>
        <volume>
         33
        </volume>
        <year>
         2018
        </year>
        <fpage>
         233
        </fpage>
        <lpage>
         246
        </lpage>
        <pub-id pub-id-type="pmid">
         29506344
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <label>
        13
       </label>
       <element-citation id="sbref130" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel coronavirus from patients with pneumonia in China, 2019
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2020
        </year>
        <comment>
         published online January 24.
        </comment>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa2001017
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib14">
       <label>
        14
       </label>
       <element-citation id="sbref140" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Masters
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Coronaviridae
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Knipe
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
         <name>
          <surname>
           Howley
          </surname>
          <given-names>
           PM
          </given-names>
         </name>
        </person-group>
        <source>
         Fields virology
        </source>
        <year>
         2013
        </year>
        <publisher-name>
         Lippincott Williams &amp; Wilkins
        </publisher-name>
        <publisher-loc>
         Philadelphia, PA
        </publisher-loc>
        <fpage>
         825
        </fpage>
        <lpage>
         858
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib15">
       <label>
        15
       </label>
       <element-citation id="sbref150" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         <name>
          <surname>
           Mou
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         495
        </volume>
        <year>
         2013
        </year>
        <fpage>
         251
        </fpage>
        <lpage>
         254
        </lpage>
        <pub-id pub-id-type="pmid">
         23486063
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib16">
       <label>
        16
       </label>
       <element-citation id="sbref160" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Walls
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <name>
          <surname>
           Tortorici
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         531
        </volume>
        <year>
         2016
        </year>
        <fpage>
         114
        </fpage>
        <lpage>
         117
        </lpage>
        <pub-id pub-id-type="pmid">
         26855426
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib17">
       <label>
        17
       </label>
       <element-citation id="sbref170" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cryo-em structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains
        </article-title>
        <source>
         Nat Commun
        </source>
        <volume>
         8
        </volume>
        <year>
         2017
        </year>
        <object-id pub-id-type="publisher-id">
         15092
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib18">
       <label>
        18
       </label>
       <element-citation id="sbref180" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fehr
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses: an overview of their replication and pathogenesis
        </article-title>
        <source>
         Methods Mol Biol
        </source>
        <volume>
         1282
        </volume>
        <year>
         2015
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         23
        </lpage>
        <pub-id pub-id-type="pmid">
         25720466
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib19">
       <label>
        19
       </label>
       <element-citation id="sbref190" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          WHO
         </collab>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: case definition for reporting to WHO
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs90" xlink:href="https://www.who.int/csr/disease/coronavirus_infections/case_definition/en/">
         https://www.who.int/csr/disease/coronavirus_infections/case_definition/en/
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib20">
       <label>
        20
       </label>
       <element-citation id="sbref200" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Conzade
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Grant
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Malik
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Reported direct and indirect contact with dromedary camels among laboratory-confirmed MERS-CoV cases
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         10
        </volume>
        <year>
         2018
        </year>
        <fpage>
         425
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib21">
       <label>
        21
       </label>
       <element-citation id="sbref210" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           EI
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           YJ
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
         <name>
          <surname>
           Oh
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         18
        </volume>
        <year>
         2018
        </year>
        <fpage>
         e217
        </fpage>
        <lpage>
         e227
        </lpage>
        <pub-id pub-id-type="pmid">
         29680581
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib22">
       <label>
        22
       </label>
       <element-citation id="sbref220" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kandeil
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Gomaa
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Nageh
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels in Africa and Middle East
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         11
        </volume>
        <year>
         2019
        </year>
        <fpage>
         717
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib23">
       <label>
        23
       </label>
       <element-citation id="sbref230" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           CB
          </given-names>
         </name>
         <name>
          <surname>
           Ababneh
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013
        </article-title>
        <source>
         Euro Surveill
        </source>
        <volume>
         18
        </volume>
        <year>
         2013
        </year>
        <object-id pub-id-type="publisher-id">
         20662
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib24">
       <label>
        24
       </label>
       <element-citation id="sbref240" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           EI
          </given-names>
         </name>
         <name>
          <surname>
           El-Kafrawy
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Farraj
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence for camel-to-human transmission of MERS coronavirus
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         370
        </volume>
        <year>
         2014
        </year>
        <fpage>
         2499
        </fpage>
        <lpage>
         2505
        </lpage>
        <pub-id pub-id-type="pmid">
         24896817
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib25">
       <label>
        25
       </label>
       <element-citation id="sbref250" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         <name>
          <surname>
           Al Dhahiry
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           CB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         14
        </volume>
        <year>
         2014
        </year>
        <fpage>
         140
        </fpage>
        <lpage>
         145
        </lpage>
        <pub-id pub-id-type="pmid">
         24355866
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib26">
       <label>
        26
       </label>
       <element-citation id="sbref260" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paden
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
         <name>
          <surname>
           Yusof
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Al Hammadi
          </surname>
          <given-names>
           ZM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Zoonotic origin and transmission of Middle East respiratory syndrome coronavirus in the UAE
        </article-title>
        <source>
         Zoonoses Public Health
        </source>
        <volume>
         65
        </volume>
        <year>
         2018
        </year>
        <fpage>
         322
        </fpage>
        <lpage>
         333
        </lpage>
        <pub-id pub-id-type="pmid">
         29239118
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib27">
       <label>
        27
       </label>
       <element-citation id="sbref270" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adney
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           VR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         20
        </volume>
        <year>
         2014
        </year>
        <fpage>
         1999
        </fpage>
        <lpage>
         2005
        </lpage>
        <pub-id pub-id-type="pmid">
         25418529
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib28">
       <label>
        28
       </label>
       <element-citation id="sbref280" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Khalafalla
          </surname>
          <given-names>
           AI
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Al-Mubarak
          </surname>
          <given-names>
           AI
          </given-names>
         </name>
         <name>
          <surname>
           Dalab
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
         <name>
          <surname>
           Al-Busadah
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <name>
          <surname>
           Erdman
          </surname>
          <given-names>
           DD
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS-CoV in upper respiratory tract and lungs of dromedary camels, Saudi Arabia, 2013–2014
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         21
        </volume>
        <year>
         2015
        </year>
        <fpage>
         1153
        </fpage>
        <lpage>
         1158
        </lpage>
        <pub-id pub-id-type="pmid">
         26079346
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib29">
       <label>
        29
       </label>
       <element-citation id="sbref290" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sikkema
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Islam
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Global status of Middle East respiratory syndrome coronavirus in dromedary camels: a systematic review
        </article-title>
        <source>
         Epidemiol Infect
        </source>
        <volume>
         147
        </volume>
        <year>
         2019
        </year>
        <fpage>
         e84
        </fpage>
        <pub-id pub-id-type="pmid">
         30869000
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib30">
       <label>
        30
       </label>
       <element-citation id="sbref300" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sabir
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           TT
          </given-names>
         </name>
         <name>
          <surname>
           Ahmed
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia
        </article-title>
        <source>
         Science
        </source>
        <volume>
         351
        </volume>
        <year>
         2016
        </year>
        <fpage>
         81
        </fpage>
        <lpage>
         84
        </lpage>
        <pub-id pub-id-type="pmid">
         26678874
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib31">
       <label>
        31
       </label>
       <element-citation id="sbref310" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          FAO-OIE-WHO MERS Technical Working Group
         </collab>
        </person-group>
        <article-title>
         MERS: progress on the global response, remaining challenges and the way forward
        </article-title>
        <source>
         Antiviral Res
        </source>
        <volume>
         159
        </volume>
        <year>
         2018
        </year>
        <fpage>
         35
        </fpage>
        <lpage>
         44
        </lpage>
        <pub-id pub-id-type="pmid">
         30236531
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib32">
       <label>
        32
       </label>
       <element-citation id="sbref320" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           JI
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Bae
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evolutionary relationship analysis of Middle East respiratory syndrome coronavirus 4a and 4b protein coding sequences
        </article-title>
        <source>
         J Vet Sci
        </source>
        <volume>
         20
        </volume>
        <year>
         2019
        </year>
        <fpage>
         e1
        </fpage>
        <pub-id pub-id-type="pmid">
         30944524
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib33">
       <label>
        33
       </label>
       <element-citation id="sbref330" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Elkholy
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Grant
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Elhakim
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Malik
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <name>
          <surname>
           Van Kerkhove
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS-CoV infection among healthcare workers and risk factors for death: retrospective analysis of all laboratory-confirmed cases reported to WHO from 2012 to 2 June 2018
        </article-title>
        <source>
         J Infect Public Health
        </source>
        <year>
         2019
        </year>
        <comment>
         published online May 2.
        </comment>
        <pub-id pub-id-type="doi">
         10.1016/j.jiph.2019.04.011
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib34">
       <label>
        34
       </label>
       <element-citation id="sbref340" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al Hammadi
          </surname>
          <given-names>
           ZM
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           DK
          </given-names>
         </name>
         <name>
          <surname>
           Eltahir
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Asymptomatic MERS-CoV infection in humans possibly linked to infected dromedaries imported from Oman to United Arab Emirates, May 2015
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         21
        </volume>
        <year>
         2015
        </year>
        <fpage>
         2197
        </fpage>
        <lpage>
         2200
        </lpage>
        <pub-id pub-id-type="pmid">
         26584223
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib35">
       <label>
        35
       </label>
       <element-citation id="sbref350" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alraddadi
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
         <name>
          <surname>
           Al-Salmi
          </surname>
          <given-names>
           HS
          </given-names>
         </name>
         <name>
          <surname>
           Jacobs-Slifka
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk factors for Middle East respiratory syndrome coronavirus infection among healthcare personnel
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         22
        </volume>
        <year>
         2016
        </year>
        <fpage>
         1915
        </fpage>
        <lpage>
         1920
        </lpage>
        <pub-id pub-id-type="pmid">
         27767011
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib36">
       <label>
        36
       </label>
       <element-citation id="sbref360" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           CB
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
        </person-group>
        <article-title>
         High proportion of MERS-CoV shedding dromedaries at slaughterhouse with a potential epidemiological link to human cases, Qatar 2014
        </article-title>
        <source>
         Infect Ecol Epidemiol
        </source>
        <volume>
         5
        </volume>
        <year>
         2015
        </year>
        <object-id pub-id-type="publisher-id">
         28305
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib37">
       <label>
        37
       </label>
       <element-citation id="sbref370" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kasem
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Qasim
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Al-Hufofi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cross-sectional study of MERS-CoV-specific RNA and antibodies in animals that have had contact with MERS patients in Saudi Arabia
        </article-title>
        <source>
         J Infect Public Health
        </source>
        <volume>
         11
        </volume>
        <year>
         2018
        </year>
        <fpage>
         331
        </fpage>
        <lpage>
         338
        </lpage>
        <pub-id pub-id-type="pmid">
         28993171
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib38">
       <label>
        38
       </label>
       <element-citation id="sbref380" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muhairi
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Hosani
          </surname>
          <given-names>
           FA
          </given-names>
         </name>
         <name>
          <surname>
           Eltahir
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiological investigation of Middle East respiratory syndrome coronavirus in dromedary camel farms linked with human infection in Abu Dhabi Emirate, United Arab Emirates
        </article-title>
        <source>
         Virus Genes
        </source>
        <volume>
         52
        </volume>
        <year>
         2016
        </year>
        <fpage>
         848
        </fpage>
        <lpage>
         854
        </lpage>
        <pub-id pub-id-type="pmid">
         27357298
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib39">
       <label>
        39
       </label>
       <element-citation id="sbref390" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         Sci Adv
        </source>
        <volume>
         3
        </volume>
        <year>
         2017
        </year>
        <object-id pub-id-type="publisher-id">
         eaao4966
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib40">
       <label>
        40
       </label>
       <element-citation id="sbref400" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bernard-Stoecklin
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Nikolay
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative analysis of eleven healthcare-associated outbreaks of Middle East respiratory syndrome coronavirus (MERS-CoV) from 2015 to 2017
        </article-title>
        <source>
         Sci Rep
        </source>
        <volume>
         9
        </volume>
        <year>
         2019
        </year>
        <object-id pub-id-type="publisher-id">
         7385
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib41">
       <label>
        41
       </label>
       <element-citation id="sbref410" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           BY
          </given-names>
         </name>
         <name>
          <surname>
           Hur
          </surname>
          <given-names>
           YJ
          </given-names>
         </name>
         <name>
          <surname>
           Ki
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         High reproduction number of Middle East respiratory syndrome coronavirus in nosocomial outbreaks: mathematical modelling in Saudi Arabia and South Korea
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         99
        </volume>
        <year>
         2018
        </year>
        <fpage>
         162
        </fpage>
        <lpage>
         168
        </lpage>
        <pub-id pub-id-type="pmid">
         28958834
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib42">
       <label>
        42
       </label>
       <element-citation id="sbref420" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           McGeer
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Perl
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hospital outbreak of Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         369
        </volume>
        <year>
         2013
        </year>
        <fpage>
         407
        </fpage>
        <lpage>
         416
        </lpage>
        <pub-id pub-id-type="pmid">
         23782161
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib43">
       <label>
        43
       </label>
       <element-citation id="sbref430" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alanazi
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Killerby
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           Biggs
          </surname>
          <given-names>
           HM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Scope and extent of healthcare-associated Middle East respiratory syndrome coronavirus transmission during two contemporaneous outbreaks in Riyadh, Saudi Arabia, 2017
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         40
        </volume>
        <year>
         2019
        </year>
        <fpage>
         79
        </fpage>
        <lpage>
         88
        </lpage>
        <pub-id pub-id-type="pmid">
         30595141
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib44">
       <label>
        44
       </label>
       <element-citation id="sbref440" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Amer
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Alqahtani
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <name>
          <surname>
           Alzoman
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Aljerian
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Unusual presentation of Middle East respiratory syndrome coronavirus leading to a large outbreak in Riyadh during 2017
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         46
        </volume>
        <year>
         2018
        </year>
        <fpage>
         1022
        </fpage>
        <lpage>
         1025
        </lpage>
        <pub-id pub-id-type="pmid">
         29661625
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib45">
       <label>
        45
       </label>
       <element-citation id="sbref450" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           CK
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           PG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical and epidemiologic characteristics of spreaders of Middle East respiratory syndrome coronavirus during the 2015 outbreak in Korea
        </article-title>
        <source>
         J Korean Med Sci
        </source>
        <volume>
         32
        </volume>
        <year>
         2017
        </year>
        <fpage>
         744
        </fpage>
        <lpage>
         749
        </lpage>
        <pub-id pub-id-type="pmid">
         28378546
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib46">
       <label>
        46
       </label>
       <element-citation id="sbref460" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alsaad
          </surname>
          <given-names>
           KO
          </given-names>
         </name>
         <name>
          <surname>
           Hajeer
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
         <name>
          <surname>
           Al Balwi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Histopathology of Middle East respiratory syndrome coronovirus (MERS-CoV) infection—clinicopathological and ultrastructural study
        </article-title>
        <source>
         Histopathology
        </source>
        <volume>
         72
        </volume>
        <year>
         2018
        </year>
        <fpage>
         516
        </fpage>
        <lpage>
         524
        </lpage>
        <pub-id pub-id-type="pmid">
         28858401
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib47">
       <label>
        47
       </label>
       <element-citation id="sbref470" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Al Hosani
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Keating
          </surname>
          <given-names>
           MK
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014
        </article-title>
        <source>
         Am J Pathol
        </source>
        <volume>
         186
        </volume>
        <year>
         2016
        </year>
        <fpage>
         652
        </fpage>
        <lpage>
         658
        </lpage>
        <pub-id pub-id-type="pmid">
         26857507
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib48">
       <label>
        48
       </label>
       <element-citation id="sbref480" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Jia
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2
        </article-title>
        <source>
         Nat Microbiol
        </source>
        <volume>
         1
        </volume>
        <year>
         2016
        </year>
        <object-id pub-id-type="publisher-id">
         16004
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib49">
       <label>
        49
       </label>
       <element-citation id="sbref490" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <name>
          <surname>
           Albarrak
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Omrani
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         62
        </volume>
        <year>
         2016
        </year>
        <fpage>
         477
        </fpage>
        <lpage>
         483
        </lpage>
        <pub-id pub-id-type="pmid">
         26565003
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib50">
       <label>
        50
       </label>
       <element-citation id="sbref500" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Widagdo
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Sooksawasdi Na Ayudhya
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Hundie
          </surname>
          <given-names>
           GB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Host determinants of MERS-CoV transmission and pathogenesis
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         11
        </volume>
        <year>
         2019
        </year>
        <fpage>
         E280
        </fpage>
        <pub-id pub-id-type="pmid">
         30893947
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib51">
       <label>
        51
       </label>
       <element-citation id="sbref510" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leist
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
         <name>
          <surname>
           Cockrell
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genetically engineering a susceptible mouse model for MERS-CoV-induced acute respiratory distress syndrome
        </article-title>
        <source>
         Methods Mol Biol
        </source>
        <volume>
         2099
        </volume>
        <year>
         2020
        </year>
        <fpage>
         137
        </fpage>
        <lpage>
         159
        </lpage>
        <pub-id pub-id-type="pmid">
         31883094
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib52">
       <label>
        52
       </label>
       <element-citation id="sbref520" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Channappanavar
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology
        </article-title>
        <source>
         Semin Immunopathol
        </source>
        <volume>
         39
        </volume>
        <year>
         2017
        </year>
        <fpage>
         529
        </fpage>
        <lpage>
         539
        </lpage>
        <pub-id pub-id-type="pmid">
         28466096
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib53">
       <label>
        53
       </label>
       <element-citation id="sbref530" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cameron
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Ran
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         81
        </volume>
        <year>
         2007
        </year>
        <fpage>
         8692
        </fpage>
        <lpage>
         8706
        </lpage>
        <pub-id pub-id-type="pmid">
         17537853
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib54">
       <label>
        54
       </label>
       <element-citation id="sbref540" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           BH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         454–455
        </volume>
        <year>
         2014
        </year>
        <fpage>
         197
        </fpage>
        <lpage>
         205
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib55">
       <label>
        55
       </label>
       <element-citation id="sbref550" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment
        </article-title>
        <source>
         J Gen Virol
        </source>
        <volume>
         94
        </volume>
        <year>
         2013
        </year>
        <fpage>
         2679
        </fpage>
        <lpage>
         2690
        </lpage>
        <pub-id pub-id-type="pmid">
         24077366
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib56">
       <label>
        56
       </label>
       <element-citation id="sbref560" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         209
        </volume>
        <year>
         2014
        </year>
        <fpage>
         1331
        </fpage>
        <lpage>
         1342
        </lpage>
        <pub-id pub-id-type="pmid">
         24065148
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib57">
       <label>
        57
       </label>
       <element-citation id="sbref570" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shin
          </surname>
          <given-names>
           HS
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immune responses to Middle East respiratory syndrome coronavirus during the acute and convalescent phases of human infection
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         68
        </volume>
        <year>
         2019
        </year>
        <fpage>
         984
        </fpage>
        <lpage>
         992
        </lpage>
        <pub-id pub-id-type="pmid">
         30060038
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib58">
       <label>
        58
       </label>
       <element-citation id="sbref580" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transmission of MERS-coronavirus in household contacts
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         371
        </volume>
        <year>
         2014
        </year>
        <fpage>
         828
        </fpage>
        <lpage>
         835
        </lpage>
        <pub-id pub-id-type="pmid">
         25162889
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib59">
       <label>
        59
       </label>
       <element-citation id="sbref590" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Alshukairi
          </surname>
          <given-names>
           AN
          </given-names>
         </name>
         <name>
          <surname>
           Baharoon
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses
        </article-title>
        <source>
         Sci Immunol
        </source>
        <volume>
         2
        </volume>
        <year>
         2017
        </year>
        <object-id pub-id-type="publisher-id">
         eaan5393
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib60">
       <label>
        60
       </label>
       <element-citation id="sbref600" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alshukairi
          </surname>
          <given-names>
           AN
          </given-names>
         </name>
         <name>
          <surname>
           Khalid
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Ahmed
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antibody response and disease severity in healthcare worker MERS survivors
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         22
        </volume>
        <year>
         2016
        </year>
        <fpage>
         1113
        </fpage>
        <lpage>
         1115
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib61">
       <label>
        61
       </label>
       <element-citation id="sbref610" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arabi
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
         <name>
          <surname>
           Balkhy
          </surname>
          <given-names>
           HH
          </given-names>
         </name>
         <name>
          <surname>
           Hayden
          </surname>
          <given-names>
           FG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         376
        </volume>
        <year>
         2017
        </year>
        <fpage>
         584
        </fpage>
        <lpage>
         594
        </lpage>
        <pub-id pub-id-type="pmid">
         28177862
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib62">
       <label>
        62
       </label>
       <element-citation id="sbref620" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cauchemez
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Fraser
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Van Kerkhove
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         14
        </volume>
        <year>
         2014
        </year>
        <fpage>
         50
        </fpage>
        <lpage>
         56
        </lpage>
        <pub-id pub-id-type="pmid">
         24239323
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib63">
       <label>
        63
       </label>
       <element-citation id="sbref630" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Breban
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Riou
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Fontanet
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         382
        </volume>
        <year>
         2013
        </year>
        <fpage>
         694
        </fpage>
        <lpage>
         699
        </lpage>
        <pub-id pub-id-type="pmid">
         23831141
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib64">
       <label>
        64
       </label>
       <element-citation id="sbref640" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           GE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Atypical presentations of MERS-CoV infection in immunocompromised hosts
        </article-title>
        <source>
         J Infect Chemother
        </source>
        <volume>
         23
        </volume>
        <year>
         2017
        </year>
        <fpage>
         769
        </fpage>
        <lpage>
         773
        </lpage>
        <pub-id pub-id-type="pmid">
         28545936
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib65">
       <label>
        65
       </label>
       <element-citation id="sbref650" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Seilmaier
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         13
        </volume>
        <year>
         2013
        </year>
        <fpage>
         745
        </fpage>
        <lpage>
         751
        </lpage>
        <pub-id pub-id-type="pmid">
         23782859
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib66">
       <label>
        66
       </label>
       <element-citation id="sbref660" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Grant
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Malik
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <name>
          <surname>
           Elkholy
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Van Kerkhove
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
        </person-group>
        <article-title>
         A review of asymptomatic and sub-clinical Middle East respiratory syndrome coronavirus infections
        </article-title>
        <source>
         Epidemiol Rev
        </source>
        <year>
         2019
        </year>
        <comment>
         published online Nov 29.
        </comment>
        <pub-id pub-id-type="doi">
         10.1093/epirev/mxz009
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib67">
       <label>
        67
       </label>
       <element-citation id="sbref670" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          WHO MERS-CoV Research Group
         </collab>
        </person-group>
        <article-title>
         State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans
        </article-title>
        <source>
         PLoS Curr
        </source>
        <volume>
         5
        </volume>
        <year>
         2013
        </year>
       </element-citation>
      </ref>
      <ref id="bib68">
       <label>
        68
       </label>
       <element-citation id="sbref680" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
         <name>
          <surname>
           Heo
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           HO
          </given-names>
         </name>
        </person-group>
        <article-title>
         Neurological complications during treatment of Middle East respiratory syndrome
        </article-title>
        <source>
         J Clin Neurol
        </source>
        <volume>
         13
        </volume>
        <year>
         2017
        </year>
        <fpage>
         227
        </fpage>
        <lpage>
         233
        </lpage>
        <pub-id pub-id-type="pmid">
         28748673
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib69">
       <label>
        69
       </label>
       <element-citation id="sbref690" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alfaraj
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Altuwaijri
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         <name>
          <surname>
           Alanazi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Alzahrani
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle east respiratory syndrome coronavirus transmission among health care workers: implication for infection control
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         46
        </volume>
        <year>
         2018
        </year>
        <fpage>
         165
        </fpage>
        <lpage>
         168
        </lpage>
        <pub-id pub-id-type="pmid">
         28958446
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib70">
       <label>
        70
       </label>
       <element-citation id="sbref700" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome vs the Middle East respiratory syndrome
        </article-title>
        <source>
         Curr Opin Pulm Med
        </source>
        <volume>
         20
        </volume>
        <year>
         2014
        </year>
        <fpage>
         233
        </fpage>
        <lpage>
         241
        </lpage>
        <pub-id pub-id-type="pmid">
         24626235
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib71">
       <label>
        71
       </label>
       <element-citation id="sbref710" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Kattan
          </surname>
          <given-names>
           RF
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus disease is rare in children: an update from Saudi Arabia
        </article-title>
        <source>
         World J Clin Pediatr
        </source>
        <volume>
         5
        </volume>
        <year>
         2016
        </year>
        <fpage>
         391
        </fpage>
        <lpage>
         396
        </lpage>
        <pub-id pub-id-type="pmid">
         27872828
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib72">
       <label>
        72
       </label>
       <element-citation id="sbref720" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alfaraj
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Altuwaijri
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus in pediatrics: a report of seven cases from Saudi Arabia
        </article-title>
        <source>
         Front Med
        </source>
        <volume>
         13
        </volume>
        <year>
         2019
        </year>
        <fpage>
         126
        </fpage>
        <lpage>
         130
        </lpage>
        <pub-id pub-id-type="pmid">
         29623560
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib73">
       <label>
        73
       </label>
       <element-citation id="sbref730" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus disease in children
        </article-title>
        <source>
         Pediatr Infect Dis J
        </source>
        <volume>
         33
        </volume>
        <year>
         2014
        </year>
        <fpage>
         904
        </fpage>
        <lpage>
         906
        </lpage>
        <pub-id pub-id-type="pmid">
         24763193
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib74">
       <label>
        74
       </label>
       <element-citation id="sbref740" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mobaraki
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Ahmadzadeh
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Current epidemiological status of Middle East respiratory syndrome coronavirus in the world from 1.1.2017 to 17.1.2018: a cross-sectional study
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        <volume>
         19
        </volume>
        <year>
         2019
        </year>
        <fpage>
         351
        </fpage>
        <pub-id pub-id-type="pmid">
         31029095
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib75">
       <label>
        75
       </label>
       <element-citation id="sbref750" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alfaraj
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV) infection during pregnancy: report of two cases &amp; review of the literature
        </article-title>
        <source>
         J Microbiol Immunol Infect
        </source>
        <volume>
         52
        </volume>
        <year>
         2019
        </year>
        <fpage>
         501
        </fpage>
        <lpage>
         503
        </lpage>
        <pub-id pub-id-type="pmid">
         29907538
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib76">
       <label>
        76
       </label>
       <element-citation id="sbref760" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          WHO
         </collab>
        </person-group>
        <article-title>
         Infection prevention and control during health care for probable or confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs120" xlink:href="https://www.who.int/csr/disease/coronavirus_infections/ipc-mers-cov/en/">
         https://www.who.int/csr/disease/coronavirus_infections/ipc-mers-cov/en/
        </ext-link>
        <year>
         2015
        </year>
       </element-citation>
      </ref>
      <ref id="bib77">
       <label>
        77
       </label>
       <element-citation id="sbref770" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          WHO
         </collab>
        </person-group>
        <article-title>
         Laboratory testing for middle east respiratory syndrome coronavirus
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs130" xlink:href="https://apps.who.int/iris/bitstream/handle/10665/259952/WHO-MERS-LAB-15.1-Rev1-2018-eng.pdf?sequence=1">
         https://apps.who.int/iris/bitstream/handle/10665/259952/WHO-MERS-LAB-15.1-Rev1-2018-eng.pdf?sequence=1
        </ext-link>
        <year>
         2018
        </year>
       </element-citation>
      </ref>
      <ref id="bib78">
       <label>
        78
       </label>
       <element-citation id="sbref780" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         CDC laboratory testing for Middle East respiratory syndrome coronavirus (MERS-CoV)
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs140" xlink:href="https://www.cdc.gov/coronavirus/mers/lab/lab-testing.html">
         https://www.cdc.gov/coronavirus/mers/lab/lab-testing.html
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib79">
       <label>
        79
       </label>
       <element-citation id="sbref790" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Makhdoom
          </surname>
          <given-names>
           HQ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Respiratory tract samples, viral load, and genome fraction yield in patients with Middle East respiratory syndrome
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         210
        </volume>
        <year>
         2014
        </year>
        <fpage>
         1590
        </fpage>
        <lpage>
         1594
        </lpage>
        <pub-id pub-id-type="pmid">
         24837403
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib80">
       <label>
        80
       </label>
       <element-citation id="sbref800" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oh
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           WB
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           PG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viral load kinetics of MERS coronavirus infection
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         375
        </volume>
        <year>
         2016
        </year>
        <fpage>
         1303
        </fpage>
        <lpage>
         1305
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib81">
       <label>
        81
       </label>
       <element-citation id="sbref810" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bermingham
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Chand
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           CS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012
        </article-title>
        <source>
         Euro Surveill
        </source>
        <volume>
         17
        </volume>
        <year>
         2012
        </year>
        <object-id pub-id-type="publisher-id">
         20290
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib82">
       <label>
        82
       </label>
       <element-citation id="sbref820" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alfaraj
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle east respiratory syndrome coronavirus intermittent positive cases: implications for infection control
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         47
        </volume>
        <year>
         2019
        </year>
        <fpage>
         290
        </fpage>
        <lpage>
         293
        </lpage>
        <pub-id pub-id-type="pmid">
         30352694
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib83">
       <label>
        83
       </label>
       <element-citation id="sbref830" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          WHO
         </collab>
        </person-group>
        <article-title>
         Laboratory biorisk management for laboratories handling human specimens suspected of confirmed to contain novel coronavirus: interim recommendations
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs150" xlink:href="https://www.who.int/csr/disease/coronavirus_infections/Biosafety_InterimRecommendations_NovelCoronavirus_19Feb13.pdf?ua=1">
         https://www.who.int/csr/disease/coronavirus_infections/Biosafety_InterimRecommendations_NovelCoronavirus_19Feb13.pdf?ua=1
        </ext-link>
        <year>
         2013
        </year>
       </element-citation>
      </ref>
      <ref id="bib84">
       <label>
        84
       </label>
       <element-citation id="sbref840" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kelly-Cirino
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Mazzola
          </surname>
          <given-names>
           LT
          </given-names>
         </name>
         <name>
          <surname>
           Chua
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Oxenford
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
         <name>
          <surname>
           Van Kerkhove
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
        </person-group>
        <article-title>
         An updated roadmap for MERS-CoV research and product development: focus on diagnostics
        </article-title>
        <source>
         BMJ Glob Health
        </source>
        <volume>
         4
        </volume>
        <year>
         2019
        </year>
        <object-id pub-id-type="publisher-id">
         e001105
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib85">
       <label>
        85
       </label>
       <element-citation id="sbref850" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Frans
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Beuselinck
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Peeters
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Migrating a lab-developed MERS-CoV real-time PCR to 3 “sample to result” systems: experiences on optimization and validation
        </article-title>
        <source>
         Diagn Microbiol Infect Dis
        </source>
        <volume>
         94
        </volume>
        <year>
         2019
        </year>
        <fpage>
         349
        </fpage>
        <lpage>
         354
        </lpage>
        <pub-id pub-id-type="pmid">
         30929995
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib86">
       <label>
        86
       </label>
       <element-citation id="sbref860" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
        </person-group>
        <article-title>
         A rapid and specific assay for the detection of MERS-CoV
        </article-title>
        <source>
         Front Microbiol
        </source>
        <volume>
         9
        </volume>
        <year>
         2018
        </year>
        <object-id pub-id-type="publisher-id">
         1101
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib87">
       <label>
        87
       </label>
       <element-citation id="sbref870" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hashem
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Al-Amri
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         <name>
          <surname>
           Al-Subhi
          </surname>
          <given-names>
           TL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development and validation of different indirect ELISAS for MERS-CoV serological testing
        </article-title>
        <source>
         J Immunol Methods
        </source>
        <volume>
         466
        </volume>
        <year>
         2019
        </year>
        <fpage>
         41
        </fpage>
        <lpage>
         46
        </lpage>
        <pub-id pub-id-type="pmid">
         30659836
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib88">
       <label>
        88
       </label>
       <element-citation id="sbref880" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           SW
          </given-names>
         </name>
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           PG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparison of serological assays in human Middle East respiratory syndrome (MERS)-coronavirus infection
        </article-title>
        <source>
         Euro Surveill
        </source>
        <volume>
         20
        </volume>
        <year>
         2015
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         5
        </lpage>
        <pub-id pub-id-type="pmid">
         26132766
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib89">
       <label>
        89
       </label>
       <element-citation id="sbref890" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Gomaa
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in Dromedary camels in Egypt, June 2013
        </article-title>
        <source>
         Euro Surveill
        </source>
        <volume>
         18
        </volume>
        <year>
         2013
        </year>
        <object-id pub-id-type="publisher-id">
         20574
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib90">
       <label>
        90
       </label>
       <element-citation id="sbref900" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Okba
          </surname>
          <given-names>
           NMA
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         <name>
          <surname>
           Widjaja
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sensitive and specific detection of low-level antibody responses in mild Middle East respiratory syndrome coronavirus infections
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         25
        </volume>
        <year>
         2019
        </year>
        <fpage>
         1868
        </fpage>
        <lpage>
         1877
        </lpage>
        <pub-id pub-id-type="pmid">
         31423970
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib91">
       <label>
        91
       </label>
       <element-citation id="sbref910" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Das
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           EY
          </given-names>
         </name>
         <name>
          <surname>
           Al Jawder
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Acute Middle East respiratory syndrome coronavirus: temporal lung changes observed on the chest radiographs of 55 patients
        </article-title>
        <source>
         AJR Am J Roentgenol
        </source>
        <volume>
         205
        </volume>
        <year>
         2015
        </year>
        <fpage>
         W267
        </fpage>
        <lpage>
         W274
        </lpage>
        <pub-id pub-id-type="pmid">
         26102309
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib92">
       <label>
        92
       </label>
       <element-citation id="sbref920" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Das
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           EY
          </given-names>
         </name>
         <name>
          <surname>
           Langer
          </surname>
          <given-names>
           RD
          </given-names>
         </name>
         <name>
          <surname>
           Larsson
          </surname>
          <given-names>
           SG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: what does a radiologist need to know?
        </article-title>
        <source>
         AJR Am J Roentgenol
        </source>
        <volume>
         206
        </volume>
        <year>
         2016
        </year>
        <fpage>
         1193
        </fpage>
        <lpage>
         1201
        </lpage>
        <pub-id pub-id-type="pmid">
         26998804
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib93">
       <label>
        93
       </label>
       <element-citation id="sbref930" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ajlan
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Ahyad
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Jamjoom
          </surname>
          <given-names>
           LG
          </given-names>
         </name>
         <name>
          <surname>
           Alharthy
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Madani
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV) infection: chest CT findings
        </article-title>
        <source>
         AJR Am J Roentgenol
        </source>
        <volume>
         203
        </volume>
        <year>
         2014
        </year>
        <fpage>
         782
        </fpage>
        <lpage>
         787
        </lpage>
        <pub-id pub-id-type="pmid">
         24918624
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib94">
       <label>
        94
       </label>
       <element-citation id="sbref940" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Das
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           EY
          </given-names>
         </name>
         <name>
          <surname>
           Enani
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        <article-title>
         CT correlation with outcomes in 15 patients with acute Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         AJR Am J Roentgenol
        </source>
        <volume>
         204
        </volume>
        <year>
         2015
        </year>
        <fpage>
         736
        </fpage>
        <lpage>
         742
        </lpage>
        <pub-id pub-id-type="pmid">
         25615627
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib95">
       <label>
        95
       </label>
       <element-citation id="sbref950" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Das
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           EY
          </given-names>
         </name>
         <name>
          <surname>
           Singh
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Follow-up chest radiographic findings in patients with MERS-CoV after recovery
        </article-title>
        <source>
         Indian J Radiol Imaging
        </source>
        <volume>
         27
        </volume>
        <year>
         2017
        </year>
        <fpage>
         342
        </fpage>
        <lpage>
         349
        </lpage>
        <pub-id pub-id-type="pmid">
         29089687
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib96">
       <label>
        96
       </label>
       <element-citation id="sbref960" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          WHO
         </collab>
        </person-group>
        <article-title>
         Home care for patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection presenting with mild symptoms and management of contacts interim guidance
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs160" xlink:href="https://apps.who.int/iris/bitstream/handle/10665/272948/WHO-MERS-IPC-18.1-eng.pdf?ua=1">
         https://apps.who.int/iris/bitstream/handle/10665/272948/WHO-MERS-IPC-18.1-eng.pdf?ua=1
        </ext-link>
        <year>
         June 2018
        </year>
       </element-citation>
      </ref>
      <ref id="bib97">
       <label>
        97
       </label>
       <element-citation id="sbref970" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Momattin
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Al-Ali
          </surname>
          <given-names>
           AY
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        <article-title>
         A systematic review of therapeutic agents for the treatment of the Middle East respiratory syndrome coronavirus (MERS-CoV)
        </article-title>
        <source>
         Travel Med Infect Dis
        </source>
        <volume>
         30
        </volume>
        <year>
         2019
        </year>
        <fpage>
         9
        </fpage>
        <lpage>
         18
        </lpage>
        <pub-id pub-id-type="pmid">
         31252170
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib98">
       <label>
        98
       </label>
       <element-citation id="sbref980" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arabi
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Balkhy
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Hajeer
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol
        </article-title>
        <source>
         Springerplus
        </source>
        <volume>
         4
        </volume>
        <year>
         2015
        </year>
        <fpage>
         709
        </fpage>
        <pub-id pub-id-type="pmid">
         26618098
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib99">
       <label>
        99
       </label>
       <element-citation id="sbref990" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arabi
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
         <name>
          <surname>
           Alothman
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Balkhy
          </surname>
          <given-names>
           HH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial
        </article-title>
        <source>
         Trials
        </source>
        <volume>
         19
        </volume>
        <year>
         2018
        </year>
        <fpage>
         81
        </fpage>
        <pub-id pub-id-type="pmid">
         29382391
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib100">
       <label>
        100
       </label>
       <element-citation id="sbref1000" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arabi
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
         <name>
          <surname>
           Mandourah
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Al-Hameed
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome
        </article-title>
        <source>
         Am J Respir Crit Care Med
        </source>
        <volume>
         197
        </volume>
        <year>
         2018
        </year>
        <fpage>
         757
        </fpage>
        <lpage>
         767
        </lpage>
        <pub-id pub-id-type="pmid">
         29161116
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib101">
       <label>
        101
       </label>
       <element-citation id="sbref1010" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Behzadi
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Leyva-Grado
          </surname>
          <given-names>
           VH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Overview of current therapeutics and novel candidates against influenza, respiratory syncytial virus, and Middle East respiratory syndrome coronavirus infections
        </article-title>
        <source>
         Front Microbiol
        </source>
        <volume>
         10
        </volume>
        <year>
         2019
        </year>
        <object-id pub-id-type="publisher-id">
         1327
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib102">
       <label>
        102
       </label>
       <element-citation id="sbref1020" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Beigel
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Nam
          </surname>
          <given-names>
           HH
          </given-names>
         </name>
         <name>
          <surname>
           Adams
          </surname>
          <given-names>
           PL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Advances in respiratory virus therapeutics—a meeting report from the 6th ISIRV antiviral group conference
        </article-title>
        <source>
         Antiviral Res
        </source>
        <volume>
         167
        </volume>
        <year>
         2019
        </year>
        <fpage>
         45
        </fpage>
        <lpage>
         67
        </lpage>
        <pub-id pub-id-type="pmid">
         30974127
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib103">
       <label>
        103
       </label>
       <element-citation id="sbref1030" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rabaan
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Alahmed
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         <name>
          <surname>
           Bazzi
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Alhani
          </surname>
          <given-names>
           HM
          </given-names>
         </name>
        </person-group>
        <article-title>
         A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective
        </article-title>
        <source>
         J Med Microbiol
        </source>
        <volume>
         66
        </volume>
        <year>
         2017
        </year>
        <fpage>
         1261
        </fpage>
        <lpage>
         1274
        </lpage>
        <pub-id pub-id-type="pmid">
         28855003
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib104">
       <label>
        104
       </label>
       <element-citation id="sbref1040" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Advances in MERS-CoV vaccines and therapeutics based on the receptor-binding domain
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         11
        </volume>
        <year>
         2019
        </year>
        <fpage>
         60
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib105">
       <label>
        105
       </label>
       <element-citation id="sbref1050" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           EI
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           KY
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses—drug discovery and therapeutic options
        </article-title>
        <source>
         Nat Rev Drug Discov
        </source>
        <volume>
         15
        </volume>
        <year>
         2016
        </year>
        <fpage>
         327
        </fpage>
        <lpage>
         347
        </lpage>
        <pub-id pub-id-type="pmid">
         26868298
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib106">
       <label>
        106
       </label>
       <element-citation id="sbref1060" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Kayali
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Meyerholz
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         89
        </volume>
        <year>
         2015
        </year>
        <fpage>
         6117
        </fpage>
        <lpage>
         6120
        </lpage>
        <pub-id pub-id-type="pmid">
         25787284
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib107">
       <label>
        107
       </label>
       <element-citation id="sbref1070" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Seok
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Cho
          </surname>
          <given-names>
           SY
          </given-names>
         </name>
        </person-group>
        <article-title>
         Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience
        </article-title>
        <source>
         Antivir Ther
        </source>
        <volume>
         23
        </volume>
        <year>
         2018
        </year>
        <fpage>
         617
        </fpage>
        <lpage>
         622
        </lpage>
        <pub-id pub-id-type="pmid">
         29923831
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib108">
       <label>
        108
       </label>
       <element-citation id="sbref1080" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arabi
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
         <name>
          <surname>
           Deeb
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Al-Hameed
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Macrolides in critically ill patients with Middle East respiratory syndrome
        </article-title>
        <source>
         Int J Infect Dis
        </source>
        <volume>
         81
        </volume>
        <year>
         2019
        </year>
        <fpage>
         184
        </fpage>
        <lpage>
         190
        </lpage>
        <pub-id pub-id-type="pmid">
         30690213
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib109">
       <label>
        109
       </label>
       <element-citation id="sbref1090" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alraddadi
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
         <name>
          <surname>
           Qushmaq
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Al-Hameed
          </surname>
          <given-names>
           FM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Noninvasive ventilation in critically ill patients with the Middle East respiratory syndrome
        </article-title>
        <source>
         Influenza Other Respir Viruses
        </source>
        <volume>
         13
        </volume>
        <year>
         2019
        </year>
        <fpage>
         382
        </fpage>
        <lpage>
         390
        </lpage>
        <pub-id pub-id-type="pmid">
         30884185
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib110">
       <label>
        110
       </label>
       <element-citation id="sbref1100" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stalin Raj
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Okba
          </surname>
          <given-names>
           NMA
          </given-names>
         </name>
         <name>
          <surname>
           Gutierrez-Alvarez
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection
        </article-title>
        <source>
         Sci Adv
        </source>
        <volume>
         4
        </volume>
        <year>
         2018
        </year>
        <object-id pub-id-type="publisher-id">
         eaas9667
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib111">
       <label>
        111
       </label>
       <element-citation id="sbref1110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Chappell
          </surname>
          <given-names>
           JD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on the Middle East respiratory syndrome coronavirus spike glycoprotein to avoid neutralization escape
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         92
        </volume>
        <year>
         2018
        </year>
        <fpage>
         e02002
        </fpage>
        <lpage>
         e02017
        </lpage>
        <pub-id pub-id-type="pmid">
         29514901
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib112">
       <label>
        112
       </label>
       <element-citation id="sbref1120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Widjaja
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           van Haperen
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein
        </article-title>
        <source>
         Emerg Microbes Infect
        </source>
        <volume>
         8
        </volume>
        <year>
         2019
        </year>
        <fpage>
         516
        </fpage>
        <lpage>
         530
        </lpage>
        <pub-id pub-id-type="pmid">
         30938227
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib113">
       <label>
        113
       </label>
       <element-citation id="sbref1130" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           WS
          </given-names>
         </name>
         <name>
          <surname>
           Cho
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           JK
          </given-names>
         </name>
        </person-group>
        <article-title>
         Psychological impact of the 2015 MERS outbreak on hospital workers and quarantined hemodialysis patients
        </article-title>
        <source>
         Compr Psychiatry
        </source>
        <volume>
         87
        </volume>
        <year>
         2018
        </year>
        <fpage>
         123
        </fpage>
        <lpage>
         127
        </lpage>
        <pub-id pub-id-type="pmid">
         30343247
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib114">
       <label>
        114
       </label>
       <element-citation id="sbref1140" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ahmed
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
        </person-group>
        <article-title>
         The predictors of 3- and 30-day mortality in 660 MERS-CoV patients
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        <volume>
         17
        </volume>
        <year>
         2017
        </year>
        <fpage>
         615
        </fpage>
        <pub-id pub-id-type="pmid">
         28893197
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib115">
       <label>
        115
       </label>
       <element-citation id="sbref1150" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS transmission and risk factors: a systematic review
        </article-title>
        <source>
         BMC Public Health
        </source>
        <volume>
         18
        </volume>
        <year>
         2018
        </year>
        <fpage>
         574
        </fpage>
        <pub-id pub-id-type="pmid">
         29716568
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib116">
       <label>
        116
       </label>
       <element-citation id="sbref1160" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rahman
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Sarkar
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk factors for fatal Middle East respiratory syndrome coronavirus infections in Saudi Arabia: analysis of the WHO line list, 2013–2018
        </article-title>
        <source>
         Am J Public Health
        </source>
        <volume>
         109
        </volume>
        <year>
         2019
        </year>
        <fpage>
         1288
        </fpage>
        <lpage>
         1293
        </lpage>
        <pub-id pub-id-type="pmid">
         31318592
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib117">
       <label>
        117
       </label>
       <element-citation id="sbref1170" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sha
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           X
          </given-names>
         </name>
        </person-group>
        <article-title>
         Fatality risks for nosocomial outbreaks of Middle East respiratory syndrome coronavirus in the Middle East and South Korea
        </article-title>
        <source>
         Arch Virol
        </source>
        <volume>
         162
        </volume>
        <year>
         2017
        </year>
        <fpage>
         33
        </fpage>
        <lpage>
         44
        </lpage>
        <pub-id pub-id-type="pmid">
         27664026
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib118">
       <label>
        118
       </label>
       <element-citation id="sbref1180" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Seys
          </surname>
          <given-names>
           LJM
          </given-names>
         </name>
         <name>
          <surname>
           Widagdo
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Verhamme
          </surname>
          <given-names>
           FM
          </given-names>
         </name>
        </person-group>
        <article-title>
         DPP4, the Middle East respiratory syndrome coronavirus receptor, is upregulated in lungs of smokers and chronic obstructive pulmonary disease patients
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         66
        </volume>
        <year>
         2018
        </year>
        <fpage>
         45
        </fpage>
        <lpage>
         53
        </lpage>
        <pub-id pub-id-type="pmid">
         29020176
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib119">
       <label>
        119
       </label>
       <element-citation id="sbref1190" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Batawi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Tarazan
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Al-Raddadi
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Quality of life reported by survivors after hospitalization for Middle East respiratory syndrome (MERS)
        </article-title>
        <source>
         Health Qual Life Outcomes
        </source>
        <volume>
         17
        </volume>
        <year>
         2019
        </year>
        <fpage>
         101
        </fpage>
        <pub-id pub-id-type="pmid">
         31186042
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib120">
       <label>
        120
       </label>
       <element-citation id="sbref1200" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ngai
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           FW
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           KW
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
        </person-group>
        <article-title>
         The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status
        </article-title>
        <source>
         Respirology
        </source>
        <volume>
         15
        </volume>
        <year>
         2010
        </year>
        <fpage>
         543
        </fpage>
        <lpage>
         550
        </lpage>
        <pub-id pub-id-type="pmid">
         20337995
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib121">
       <label>
        121
       </label>
       <element-citation id="sbref1210" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          WHO
         </collab>
        </person-group>
        <article-title>
         WHO target product profiles for MERS-CoV vaccines
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs170" xlink:href="https://www.who.int/blueprint/what/research-development/MERS_CoV_TPP_15052017.pdf?ua=1&amp;ua=1">
         https://www.who.int/blueprint/what/research-development/MERS_CoV_TPP_15052017.pdf?ua=1&amp;ua=1
        </ext-link>
        <year>
         2017
        </year>
       </element-citation>
      </ref>
      <ref id="bib122">
       <label>
        122
       </label>
       <element-citation id="sbref1220" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schindewolf
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           VD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome vaccine candidates: cautious optimism
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         11
        </volume>
        <year>
         2019
        </year>
        <fpage>
         e74
        </fpage>
        <pub-id pub-id-type="pmid">
         30658390
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib123">
       <label>
        123
       </label>
       <element-citation id="sbref1230" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hemida
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus and the One Health concept
        </article-title>
        <source>
         PeerJ
        </source>
        <volume>
         7
        </volume>
        <year>
         2019
        </year>
        <object-id pub-id-type="publisher-id">
         e7556
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib124">
       <label>
        124
       </label>
       <element-citation id="sbref1240" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hemida
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <name>
          <surname>
           Alnaeem
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Some one health based control strategies for the Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         One Health
        </source>
        <volume>
         8
        </volume>
        <year>
         2019
        </year>
        <object-id pub-id-type="publisher-id">
         100102
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib125">
       <label>
        125
       </label>
       <element-citation id="sbref1250" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           How
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emerging respiratory infections threatening public health in the Asia-Pacific region: a position paper of the Asian Pacific society of respirology
        </article-title>
        <source>
         Respirology
        </source>
        <volume>
         24
        </volume>
        <year>
         2019
        </year>
        <fpage>
         590
        </fpage>
        <lpage>
         597
        </lpage>
        <pub-id pub-id-type="pmid">
         30985968
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib126">
       <label>
        126
       </label>
       <element-citation id="sbref1260" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Dar
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Kock
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Taking forward a ‘one health’ approach for turning the tide against the Middle East respiratory syndrome coronavirus and other zoonotic pathogens with epidemic potential
        </article-title>
        <source>
         Int J Infect Dis
        </source>
        <volume>
         47
        </volume>
        <year>
         2016
        </year>
        <fpage>
         5
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         27321961
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib127">
       <label>
        127
       </label>
       <element-citation id="sbref1270" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kirchdoerfer
          </surname>
          <given-names>
           RN
          </given-names>
         </name>
         <name>
          <surname>
           Ward
          </surname>
          <given-names>
           AB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors
        </article-title>
        <source>
         Nat Commun
        </source>
        <volume>
         10
        </volume>
        <year>
         2019
        </year>
        <object-id pub-id-type="publisher-id">
         2342
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib128">
       <label>
        128
       </label>
       <element-citation id="sbref1280" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           DKW
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           KPY
          </given-names>
         </name>
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS coronaviruses from camels in Africa exhibit region-dependent genetic diversity
        </article-title>
        <source>
         Proc Natl Acad Sci USA
        </source>
        <volume>
         115
        </volume>
        <year>
         2018
        </year>
        <fpage>
         3144
        </fpage>
        <lpage>
         3149
        </lpage>
        <pub-id pub-id-type="pmid">
         29507189
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib129">
       <label>
        129
       </label>
       <element-citation id="sbref1290" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lamers
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         <name>
          <surname>
           Shafei
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Deletion variants of Middle East respiratory syndrome coronavirus from humans, Jordan, 2015
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         22
        </volume>
        <year>
         2016
        </year>
        <fpage>
         716
        </fpage>
        <lpage>
         719
        </lpage>
        <pub-id pub-id-type="pmid">
         26981770
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib130">
       <label>
        130
       </label>
       <element-citation id="sbref1300" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Two deletion variants of Middle East respiratory syndrome coronavirus found in a patient with characteristic symptoms
        </article-title>
        <source>
         Arch Virol
        </source>
        <volume>
         162
        </volume>
        <year>
         2017
        </year>
        <fpage>
         2445
        </fpage>
        <lpage>
         2449
        </lpage>
        <pub-id pub-id-type="pmid">
         28421366
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib131">
       <label>
        131
       </label>
       <element-citation id="sbref1310" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Knoops
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Kikkert
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Worm
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum
        </article-title>
        <source>
         PLoS Biol
        </source>
        <volume>
         6
        </volume>
        <year>
         2008
        </year>
        <fpage>
         e226
        </fpage>
        <pub-id pub-id-type="pmid">
         18798692
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib132">
       <label>
        132
       </label>
       <element-citation id="sbref1320" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Amer
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Alqahtani
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <name>
          <surname>
           Alaklobi
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Altayeb
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Healthcare worker exposure to Middle East respiratory syndrome coronavirus (MERS-CoV): revision of screening strategies urgently needed
        </article-title>
        <source>
         Int J Infect Dis
        </source>
        <volume>
         71
        </volume>
        <year>
         2018
        </year>
        <fpage>
         113
        </fpage>
        <lpage>
         116
        </lpage>
        <pub-id pub-id-type="pmid">
         29649550
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib133">
       <label>
        133
       </label>
       <element-citation id="sbref1330" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Abdallat
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Payne
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         <name>
          <surname>
           Alqasrawi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         59
        </volume>
        <year>
         2014
        </year>
        <fpage>
         1225
        </fpage>
        <lpage>
         1233
        </lpage>
        <pub-id pub-id-type="pmid">
         24829216
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib134">
       <label>
        134
       </label>
       <element-citation id="sbref1340" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alenazi
          </surname>
          <given-names>
           TH
          </given-names>
         </name>
         <name>
          <surname>
           Al Arbash
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           El-Saed
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identified transmission dynamics of Middle East respiratory syndrome coronavirus infection during an outbreak: implications of an overcrowded emergency department
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         65
        </volume>
        <year>
         2017
        </year>
        <fpage>
         675
        </fpage>
        <lpage>
         679
        </lpage>
        <pub-id pub-id-type="pmid">
         28575307
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib135">
       <label>
        135
       </label>
       <element-citation id="sbref1350" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome
        </article-title>
        <source>
         Am J Respir Crit Care Med
        </source>
        <volume>
         192
        </volume>
        <year>
         2015
        </year>
        <fpage>
         278
        </fpage>
        <lpage>
         279
        </lpage>
        <pub-id pub-id-type="pmid">
         26120749
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib136">
       <label>
        136
       </label>
       <element-citation id="sbref1360" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nam
          </surname>
          <given-names>
           HS
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         <name>
          <surname>
           Ki
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Yeon
          </surname>
          <given-names>
           MY
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           SW
          </given-names>
         </name>
        </person-group>
        <article-title>
         High fatality rates and associated factors in two hospital outbreaks of MERS in Daejeon, the Republic of Korea
        </article-title>
        <source>
         Int J Infect Dis
        </source>
        <volume>
         58
        </volume>
        <year>
         2017
        </year>
        <fpage>
         37
        </fpage>
        <lpage>
         42
        </lpage>
        <pub-id pub-id-type="pmid">
         28223175
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib137">
       <label>
        137
       </label>
       <element-citation id="sbref1370" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oboho
          </surname>
          <given-names>
           IK
          </given-names>
         </name>
         <name>
          <surname>
           Tomczyk
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Al-Asmari
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
        </person-group>
        <article-title>
         2014 MERS-CoV outbreak in Jeddah—a link to health care facilities
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         372
        </volume>
        <year>
         2015
        </year>
        <fpage>
         846
        </fpage>
        <lpage>
         854
        </lpage>
        <pub-id pub-id-type="pmid">
         25714162
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib138">
       <label>
        138
       </label>
       <element-citation id="sbref1380" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hunter
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name>
          <surname>
           Nguyen
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Aden
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transmission of Middle East respiratory syndrome coronavirus infections in healthcare settings, Abu Dhabi
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         22
        </volume>
        <year>
         2016
        </year>
        <fpage>
         647
        </fpage>
        <lpage>
         656
        </lpage>
        <pub-id pub-id-type="pmid">
         26981708
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib139">
       <label>
        139
       </label>
       <element-citation id="sbref1390" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jo
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Shin
          </surname>
          <given-names>
           DH
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characteristics of flavonoids as potent MERS-CoV 3c-like protease inhibitors
        </article-title>
        <source>
         Chem Biol Drug Des
        </source>
        <volume>
         94
        </volume>
        <year>
         2019
        </year>
        <fpage>
         2023
        </fpage>
        <lpage>
         2030
        </lpage>
        <pub-id pub-id-type="pmid">
         31436895
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib140">
       <label>
        140
       </label>
       <element-citation id="sbref1400" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mustafa
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Balkhy
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Gabere
          </surname>
          <given-names>
           MN
          </given-names>
         </name>
        </person-group>
        <article-title>
         Current treatment options and the role of peptides as potential therapeutic components for Middle East respiratory syndrome (MERS): a review
        </article-title>
        <source>
         J Infect Public Health
        </source>
        <volume>
         11
        </volume>
        <year>
         2018
        </year>
        <fpage>
         9
        </fpage>
        <lpage>
         17
        </lpage>
        <pub-id pub-id-type="pmid">
         28864360
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib141">
       <label>
        141
       </label>
       <element-citation id="sbref1410" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Agostini
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Pruijssers
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Chappell
          </surname>
          <given-names>
           JD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Small-molecule antiviral beta-d-n
         <sup>
          4
         </sup>
         -hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         93
        </volume>
        <year>
         2019
        </year>
        <fpage>
         e01348
        </fpage>
        <lpage>
         e01419
        </lpage>
        <pub-id pub-id-type="pmid">
         31578288
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib142">
       <label>
        142
       </label>
       <element-citation id="sbref1420" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sheahan
          </surname>
          <given-names>
           TP
          </given-names>
         </name>
         <name>
          <surname>
           Sims
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
        </article-title>
        <source>
         Sci Transl Med
        </source>
        <volume>
         9
        </volume>
        <year>
         2017
        </year>
        <object-id pub-id-type="publisher-id">
         eaal3653
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib143">
       <label>
        143
       </label>
       <element-citation id="sbref1430" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Taylor
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Kotian
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Warren
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         BCX4430—a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease
        </article-title>
        <source>
         J Infect Public Health
        </source>
        <volume>
         9
        </volume>
        <year>
         2016
        </year>
        <fpage>
         220
        </fpage>
        <lpage>
         226
        </lpage>
        <pub-id pub-id-type="pmid">
         27095300
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <sec id="sec1" sec-type="supplementary-material">
      <title>
       Supplementary Material
      </title>
      <p id="para2010">
       <supplementary-material content-type="local-data" id="ecomp10">
        <caption>
         <title>
          Supplementary appendix
         </title>
        </caption>
        <media xlink:href="mmc1.pdf">
        </media>
       </supplementary-material>
      </p>
     </sec>
     <ack id="ceack10">
      <sec>
       <title>
        Acknowledgments
       </title>
       <p>
        AZ acknowledges support from the
        <funding-source id="GS1">
         PANDORA-ID-NET
        </funding-source>
        (grant RIA2016E-1609) funded by the European and Developing Countries Clinical Trials Partnership (EDCTP2) under Horizon 2020, the EU's Framework Programme for Research and Innovation. AZ is the recipient of a UK National Institutes of Health Research senior investigator award. SP is supported by grants from the US
        <funding-source id="GS2">
         National Institutes of Health
        </funding-source>
        (PO1 AI060699 RO1 AI129269). We thank Samantha Mackin (University of Iowa) for creating
        <xref ref-type="fig" rid="fig1">
         figure 1
        </xref>
        on the basis of a template provided by Benjamin W Neuman (Texas A&amp;M-Texarkana) and Michael J Buchmeier (University of California, Irvine).
       </p>
       <p>
        Editorial note: the
        <italic>
         Lancet
        </italic>
        Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations.
       </p>
      </sec>
     </ack>
     <ack>
      <title>
       Contributors
      </title>
      <p>
       This paper was conceptualised by ZAM and AZ. All authors contributed equally to the literature search, writing, and reviewing of the manuscript.
      </p>
     </ack>
     <ack>
      <title>
       Declaration of interests
      </title>
      <p>
       We declare no competing interests.
      </p>
     </ack>
    </back>
   </article>
   <article article-type="discussion" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Res Social Adm Pharm
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Res Social Adm Pharm
      </journal-id>
      <journal-title-group>
       <journal-title>
        Research in Social &amp; Administrative Pharmacy
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1551-7411
      </issn>
      <issn pub-type="epub">
       1934-8150
      </issn>
      <publisher>
       <publisher-name>
        Elsevier Inc.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32081569
      </article-id>
      <article-id pub-id-type="pmc">
       7129623
      </article-id>
      <article-id pub-id-type="publisher-id">
       S1551-7411(20)30118-2
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.sapharm.2020.02.003
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Community pharmacist in public health emergencies: Quick to action against the coronavirus 2019-nCoV outbreak
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au1">
        <name>
         <surname>
          Ung
         </surname>
         <given-names>
          Carolina Oi Lam
         </given-names>
        </name>
        <email>
         carolinaung@um.edu.mo
        </email>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, Room, 2058, N22 Building, University of Macau, Taipa, Macao
      </aff>
      <pub-date pub-type="pmc-release">
       <day>
        12
       </day>
       <month>
        2
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
       <day>
        12
       </day>
       <month>
        2
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <history>
       <date date-type="received">
        <day>
         9
        </day>
        <month>
         2
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         9
        </day>
        <month>
         2
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2020 Elsevier Inc. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
        Elsevier Inc.
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="abs0010">
       <p>
        The 2019-nCoV infection that is caused by a novel strain of coronavirus was first detected in China in the end of December 2019 and declared a public health emergency of international concern by the World Health Organization on January 30, 2020. Community pharmacists in one of the first areas that had confirmed cases of the viral infection, Macau, joined the collaborative force in supporting the local health emergency preparedness and response arrangements. This paper aimed to improve the understanding of community pharmacists’ role in case of 2019-CoV outbreak based on the practical experiences in consultation with the recommendations made by the International Pharmaceutical Federation on the Coronavirus 2019-nCoV outbreak.
       </p>
      </abstract>
      <kwd-group id="kwrds0010">
       <title>
        Keywords
       </title>
       <kwd>
        2019-nCoV
       </kwd>
       <kwd>
        Outbreak
       </kwd>
       <kwd>
        Community pharmacy
       </kwd>
       <kwd>
        Pharmacist
       </kwd>
       <kwd>
        Macau
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <p id="p0010">
     Macau confirmed its first case of the 2019-nCoV infection on 22 January 2020
     <xref ref-type="bibr" rid="bib1">
      <sup>
       1
      </sup>
     </xref>
     and as of Feb 8, 2020, there were 10 confirmed cases in the city.
     <xref ref-type="bibr" rid="bib2">
      <sup>
       2
      </sup>
     </xref>
     The 2019-nCoV is a novel strain of coronavirus that was first detected in the city of Wuhan, in the province of Hubei China. With cases confirmed earlier in its neighboring cities of Shenzhen and Zhuhai in mainland China, the small city is vulnerable to the spread of the virus and has escalated the health emergency preparedness and response arrangements soon after the reports about a cluster of pneumonia-like illnesses with unknown causes in Wuhan came into light in the end of December 2019. On January 5, 2020, the local government swiftly took the lead in coordinating and communicating actions across various sectors.
     <xref ref-type="bibr" rid="bib3">
      <sup>
       3
      </sup>
     </xref>
     To support infection prevention and control overseen by the health department, departments of economy and finance, police service and customs, information, tourism, gaming, social welfare, consumer protection, municipal affairs, education formed partnerships to step up border control and surveillance, execute isolation and quarantine measures, promote personal and environmental hygiene, ensure medical and daily supply stability and monitor the pricing, deliver public and tourist education, and disseminate accurate up-to-date information on a unified platform. This echoed the recommendations made in the
     <italic>
      2019 Novel Coronavirus (2019-nConV): Strategic Preparedness and Response Plan
     </italic>
     published by the World Health Organization on February 3, 2020.
     <xref ref-type="bibr" rid="bib4">
      <sup>
       4
      </sup>
     </xref>
     During the previous 6 weeks, the stages of “preparedness”, “high risk of imported cases”, “imported cases” and possibly “local transmission” in an infection outbreak had been experienced. The highest alert is now on to try to avoid or minimize the last stage of “community transmission”, a highly challenging task considering the possible existence of super spreaders.
     <xref ref-type="bibr" rid="bib5">
      <sup>
       5
      </sup>
     </xref>
    </p>
    <p id="p0015">
     At a professional level, while many doctors and nurses were fighting the uphill battle in the frontline, pharmacists at community settings also played an important part in the prevention of the spread of the 2019-nCoV outbreak and contributed to the overall emergency management. Apart from ensuring the stable supply of key medicines and becoming the information hub about the coronavirus infection, being the most common first point of contact, community pharmacists were also charged with the responsibility of early detection and appropriate referral. They also played a key role in implementing the government arrangement of “The Guaranteed Mask Supply for Macao Residents Scheme” which highlighted the importance of public-private partnerships and data exchange at times of emergency. On January 30, 2020, the World Health Organization (WHO) declared the emergence of 2019-nCoV a public health emergency of international concern calling on all countries to take urgent measures to contain the respiratory disease
     <xref ref-type="bibr" rid="bib6">
      <sup>
       6
      </sup>
     </xref>
     as the spread has already extended to at least 24 countries.
     <xref ref-type="bibr" rid="bib7">
      <sup>
       7
      </sup>
     </xref>
     It is speculated that pharmacists in many cities and countries are finding their ways to contribute to the collaborative forces in combating the spread of the virus. On February 5, 2020, the International Pharmaceutical Federation (FIP) issued the “
     <italic>
      Coronavirus 2019-nCoV outbreak: Information and interim guidelines for pharmacists and the pharmacy workforce
     </italic>
     ” to provide relevant information and guidelines on coronavirus outbreaks for pharmacists and the pharmacy workforce.
     <xref ref-type="bibr" rid="bib8">
      <sup>
       8
      </sup>
     </xref>
     This paper aimed to improve the understanding of community pharmacists’ role in case of 2019-CoV outbreak by sharing the experiences in Macau in consultation with the FIP guideline.
    </p>
    <sec id="sec1">
     <title>
      Knowing about the coronaviruses
     </title>
     <p id="p0020">
      To many people, the memories about severe acute respiratory syndrome (SARS) and the recent outbreak of Middle East respiratory syndrome (MERS) were still fresh and worrisome. SARS was caused by a novel betacoronavirus that emerged in Guangdong, China in November 2002.
      <xref ref-type="bibr" rid="bib9">
       <sup>
        9
       </sup>
      </xref>
      It resulted in more than 8000 human infections and 774 deaths in 37 countries during 2002–03.
      <xref ref-type="bibr" rid="bib10">
       <sup>
        10
       </sup>
      </xref>
      At that time, SARS hit hard on the neighboring city of Hong Kong which resulted in 1755 confirmed cases including 300 fatal cases
      <xref ref-type="bibr" rid="bib11">
       <sup>
        11
       </sup>
      </xref>
      but no cases were identified in Macau. On the other hand, MERS, caused by a different kind of novel coronavirus, was first detected in Saudi Arabia in 2012
      <xref ref-type="bibr" rid="bib12">
       <sup>
        12
       </sup>
      </xref>
      and was responsible for 2499 human infections and 861 fatalities since September 2012.
      <xref ref-type="bibr" rid="bib13">
       <sup>
        13
       </sup>
      </xref>
      When scientific evidence suggested that the virus responsible for the pneumonia-like disease spreading fast across China in December 2019 was closely related to SARS and MERS, any miscommunication could easily spark panic among the general public.
     </p>
     <p id="p0025">
      Out of the hundreds of coronavirues, 7 of them are known to cause human disease and only 3 of the 7 can have more serious outcomes in people including SARS, MERS and 2019-CoV.
      <xref ref-type="bibr" rid="bib13">
       <sup>
        13
       </sup>
      </xref>
      Similar to SARS and MERS, patients infected with 2019-CoV exhibited symptoms of viral pneumonia including fever, difficulty breathing, and bilateral lung infiltration.
      <xref ref-type="bibr" rid="bib14">
       <sup>
        14
       </sup>
      </xref>
      In the most severe cases, infection can cause pneumonia, severe acute respiratory syndrome, kidney failure and even death.
      <xref ref-type="bibr" rid="bib15">
       <sup>
        15
       </sup>
      </xref>
      However, the disease may occur with mild symptoms only, including: low-grade fever, cough, malaise, runny nose, sore throat but without any warning signs,
      <xref ref-type="bibr" rid="bib16">
       <sup>
        16
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib17">
       <sup>
        17
       </sup>
      </xref>
      which made early detection challenging. Epidemiological evidence shows that 2019-nCoV can be transmitted from person to person among close contacts possibly through respiratory droplets. The acute respiratory infection has an incubation period of 2–14 days before any symptoms show. Preliminary data report 11% lethality among hospitalized patients.
      <xref ref-type="bibr" rid="bib16">
       <sup>
        16
       </sup>
      </xref>
      At the time of this manuscript's authorship, there was no specific medicine or vaccine for coronavirus 2019-nCoV.
      <xref ref-type="bibr" rid="bib17">
       <sup>
        17
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib18">
       <sup>
        18
       </sup>
      </xref>
      According to the cases identified in Macau, the impact of 2019-CoV on human health appears to be mild, and the first patient with the confirmed diagnosis had full recovery and been discharged on February 6, 2020.
      <xref ref-type="bibr" rid="bib19">
       <sup>
        19
       </sup>
      </xref>
     </p>
     <p id="p0030">
      Such information is important for community pharmacist to know, convey and employ. Being able to address the public enquires with accurate up-to-date information about the local situation and the overall infection progress is the key to build trustful relationship with them at troubled times. This will in turn improve the outcomes of educating the public about the preventative measures of the 2019-CoV outbreak and the early recognition of symptoms. As FIP suggested, “
      <italic>
       community pharmacies in outbreak-affected and unaffected countries are often the first point of contact with the health system for those with health-related concerns or simply in need of information and reliable advice
      </italic>
      . “
      <xref ref-type="bibr" rid="bib8">
       <sup>
        8
       </sup>
      </xref>
     </p>
    </sec>
    <sec id="sec2">
     <title>
      Practicing and educating about personal and environment hygiene
     </title>
     <p id="p0035">
      Pharmacists, like any other health professionals, are responsible for providing safe and ethical care to the public in accordance to the professional standards at all times. Implementation of infection prevention and control practices in the community pharmacy can help both staff and customers feel safe and at ease inside the premise. More importantly, it is critical for ensuring personal safety, reducing the risks of transmitting the virus between people, and preventing the spread of infection through contacts of items in the pharmacy. For this, pharmacy managers will need to ensure the correct and regular practice of hand hygiene among all staff members, and to ensure all the necessary facilities are installed and hand hygiene products readily available for use.
      <xref ref-type="bibr" rid="bib20">
       <sup>
        20
       </sup>
      </xref>
      Additionally, regular cleaning of surfaces and items will also help to eliminate the potential sources for spread of infection.
      <xref ref-type="bibr" rid="bib21">
       <sup>
        21
       </sup>
      </xref>
      Pharmacy staff should be encouraged to educate all customers about hand hygiene, infection prevention and control strategies as instructed by the government. All these preventative measures at the community pharmacies were exceptionally important for pharmacies visited not only by local residents but also tourists from around the world. Similarly, the personal and environmental practice by the public should be reinforced whenever possible and community pharmacists are well-positioned to do so more than any other health professionals.
     </p>
     <p id="p0040">
      Routine hand hygiene is essential for preventing the spread of the virus and requires the correct use of alcohol-based formulation.
      <xref ref-type="bibr" rid="bib21">
       <sup>
        21
       </sup>
      </xref>
      However, community pharmacists encountered a major issue soon after the news about the potential spread of 2019-CoV to the city – a foreseeable short supply of hand hygiene products which were all imported products. Community pharmacy is often one of the major retail outlet of such products and is expected to play the important role of ensuring the availability of such products in the pharmacy. Ever since the first diagnosis of 2019-CoV, the supply of various disinfection products, such as alcohol, alcohol hand rub, and disinfectant, has been tight. The over-reliance on importation exposed the public health to substantial vulnerability. Community pharmacists continued to seek new product sources but without success. On February 7, 2020, the local government stepped in and commissioned two local pharmaceutical manufacturers to produce disinfectant products.
      <xref ref-type="bibr" rid="bib22">
       <sup>
        22
       </sup>
      </xref>
      On reflection, instead of being less than proactive, community pharmacists could have taken steps to try to prepare alcohol-based handrub formulations. Some of them indicated the lack of knowledge and therefore lack of confidence to do so. The underlying problem was indeed the lack of knowledge about where to locate reliable instructions of preparing such formulations. A step-by-step guide for production of handrub formulations at pharmacy bench had been provided by the WHO
      <xref ref-type="bibr" rid="bib23">
       <sup>
        23
       </sup>
      </xref>
      and re-iterated in the Annex 4 of the FIP guideline.
      <xref ref-type="bibr" rid="bib8">
       <sup>
        8
       </sup>
      </xref>
      It is important for community pharmacists to get familiarized with the procedure and to ensure all the necessary reagents and devices are available in the pharmacy.
     </p>
    </sec>
    <sec id="sec3">
     <title>
      Implementing “The Guaranteed Mask Supply for Macao Residents scheme”
     </title>
     <p id="p0045">
      One of the most unforgettable lessons learnt from the SARS outbreak was that wearing a mask could offer protection against SARS and other viral infections alike.
      <xref ref-type="bibr" rid="bib24">
       <sup>
        24
       </sup>
      </xref>
      According to the WHO, wearing a surgical mask, in combination with hand hygiene and other preventative measures, is one of the prevention measures to limit the spread of 2019- nCoV in affected areas.
      <xref ref-type="bibr" rid="bib25">
       <sup>
        25
       </sup>
      </xref>
      More importantly, stable accessibility of this protective gear was considered a key to stability in the society. This posed another vulnerability for the city as the supply of surgical mask totally relied on external sources. On this matter, community pharmacists in Macau were positioned to do three things: (1) help consumers differentiate surgical masks from other types of face masks not made for protection against virus transmission; (2) control the price of surgical masks within reasonable price range; and (3) help implement “The Guaranteed Mask Supply for Macao Residents Scheme” in response to the new government policy.
     </p>
     <p id="p0050">
      Many types of face masks are available in the local market and online. Misinformed choice of face masks that are not designed to offer protection against viral transmission would cause a false sense of security and hamper the defense mechanism at the society level. Unlike ordinary face masks, surgical masks were required to demonstrate their performance in terms of bacterial filtration efficiency, differential pressure, resistance to penetration by synthetic blood, sub-micron particulate filtration efficiency and/or flammability as stipulated in the WHO guideline and national standards.
      <xref ref-type="bibr" rid="bib26">
       26
      </xref>
      ,
      <xref ref-type="bibr" rid="bib27">
       27
      </xref>
      ,
      <xref ref-type="bibr" rid="bib28">
       28
      </xref>
      The spreading of the new coronavirus infection inevitably drove demands for protective masks and community pharmacists should play a reliable gatekeeper in advising about the right choice and stocking the appropriate surgical masks for the intended purposes. In addition, by selling the surgical masks within the reasonable price range, the community pharmacies set the reference price which could help counteract irrational pricing elsewhere. Pharmacists’ self-conscious about upholding ethical and professional responsibilities towards the safety of the community was evident across the community setting and should be continually encouraged.
     </p>
     <p id="p0055">
      One of the policies the government put in place to allay fears of surgical mask shortage and dissuade people of the need to stockpile supplies was the “The Guaranteed Mask Supply for Macao Residents Scheme” in which community pharmacy played a key role in the smooth implementation. After the first coronavirus case was confirmed in the city on January 22, 2020, the local government ordered 20 million masks and announced a controlled distribution through pharmacies.
      <xref ref-type="bibr" rid="bib29">
       <sup>
        29
       </sup>
      </xref>
      According to the scheme, each local resident and person on working visa could buy a maximum of 10 surgical masks every 10 days for only 8 patacas (US$1) at contracted pharmacies as long as they presented their valid identity card. Moreover, the government had set up a webpage with updates every 15 minutes of the number of surgical masks available at different pharmacies and their contact details for the convenience of the buyers.
      <xref ref-type="bibr" rid="bib30">
       <sup>
        30
       </sup>
      </xref>
      This scheme was feasible due to the preexisting partnership between the government and the participating pharmacies. Fifty-six of the 294 community pharmacies in Macau joined the public-private partnership and became the contracted pharmacies to share the dispensing duties and pharmaceutical care for patients from the public health institutes long before the outbreak. In order to monitor the pharmacy stock take of pharmaceutical products as required in the partnership agreement, an IT system was installed so that the data about the purchase and sales of those pharmaceutical products were collected during each transaction at the pharmacy and immediately submitted to the central data system in the government for real-time monitoring purposes. With this system already in place before the 2019-CoV outbreak, only minor adjustment was needed to include government-provided surgical masks on the monitoring list, and make such information publicly available on the official website. While the community pharmacies were the components of this “The Guaranteed Mask Supply for Macao Residents Scheme” and the IT system being the infrastructure, it was really the data that ensured the connectivity of the system for it to run smoothly and serve the purpose. Community pharmacists, therefore, played the role of custodian in data availability and accuracy.
     </p>
    </sec>
    <sec id="sec4">
     <title>
      Active surveillance of suspicious cases
     </title>
     <p id="p0060">
      All the imported cases of 2019-CoV infection in Macau were residents from Wuhan who fell ill during their stay in Macau. Considering the possibility of human-to-human transmission and the continuous growth of outbreak, the high volume of travel from Wuhan was considered a major threat to the effectiveness of infection prevention and control. Reinforcement of health inspection and isolation efforts at various cross-boundary checkpoints, mandatory requirements for all travelers from Wuhan to declare their health status, and tighter border-control took place immediately. While these measures aimed to step up the respiratory-disease-surveillance system, the potential risks of carrying and transmitting the virus by the Wuhan travelers who were still staying in Macau could not be dismissed. Early detection and referral of suspected cases were crucial to prevent large-scale community transmission. As mentioned above, the early symptoms could be mild and non-specific,
      <xref ref-type="bibr" rid="bib15">
       <sup>
        15
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib16">
       <sup>
        16
       </sup>
      </xref>
      and community pharmacy could well be the first point of contact when the affected people sought basic medical aid for symptomatic relief. Community pharmacists, therefore, must be on full alert and be able to screen patients for any necessary referral. The guide for the evaluation of patients under investigation for 2019-nCoV recommended provided by the US CDC was included in the FIP Guideline and community pharmacists should become familiar with the criteria recommended.
      <xref ref-type="bibr" rid="bib8">
       <sup>
        8
       </sup>
      </xref>
     </p>
    </sec>
    <sec id="sec5">
     <title>
      Conclusion
     </title>
     <p id="p0065">
      Community pharmacists have a key role in preventing the spread of 2019-CoV virus. They are charged with key responsibilities of informing, advising and educating the community, maintaining a stable supply of pharmaceuticals and personal hygiene products, and screening of suspected cases and making appropriate referral as required. As this or similar situations evolve, community pharmacists should remain engaged in the coordinated efforts and be readily adaptive to changes required in pharmacy practice. For pharmacists to assume a role in the health emergency preparedness and response arrangements at community level, public private partnership and the application of real-world data have been shown to be vital.
     </p>
    </sec>
    <back>
     <ref-list id="cebib0010">
      <title>
       References
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <element-citation id="sref1" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Information Bureau
          </surname>
         </name>
         <name>
          <surname>
           Macao Sar Government
          </surname>
         </name>
        </person-group>
        <chapter-title>
         Press Release “Macao Sparing No Effort to Prevent the Spread Locally of a New Coronavirus” on 22 January 2020
        </chapter-title>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intref0010" xlink:href="https://news.gov.mo/detail/en/N20AV4AiJe?2">
         https://news.gov.mo/detail/en/N20AV4AiJe?2
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <element-citation id="sref2" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Information Bureau
          </surname>
         </name>
         <name>
          <surname>
           Macao Sar Government
          </surname>
         </name>
        </person-group>
        <chapter-title>
         Press Release “Updates on the New Coronavirus” on 8 February 2020
        </chapter-title>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intref0015" xlink:href="https://news.gov.mo/detail/zh-hant/N20BHx8ATv?8">
         https://news.gov.mo/detail/zh-hant/N20BHx8ATv?8
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation id="sref3" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Information Bureau
          </surname>
         </name>
         <name>
          <surname>
           Macao Sar Government
          </surname>
         </name>
        </person-group>
        <chapter-title>
         Press Release “SAR Government Raises Warning Level for “unknown Cause of Pneumonia in Wuhan” to Level III (Heavier)” on 5 January 2020
        </chapter-title>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intref0020" xlink:href="https://news.gov.mo/detail/zh-hant/N20AEUUwwZ?9">
         https://news.gov.mo/detail/zh-hant/N20AEUUwwZ?9
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <element-citation id="sref4" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organization
          </surname>
         </name>
        </person-group>
        <chapter-title>
         Novel Coronavirus (2019-nCoV): Strategic Preparedness and Response Plan (Draft as of 3 February 2020)
        </chapter-title>
        <year>
         2019
        </year>
        <comment>
         2020
        </comment>
        <ext-link ext-link-type="uri" id="intref0025" xlink:href="https://www.who.int/docs/default-source/coronaviruse/srp-04022020.pdf">
         https://www.who.int/docs/default-source/coronaviruse/srp-04022020.pdf
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <element-citation id="sref5" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gralinski
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           V.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Return of the coronavirus: 2019-nCoV
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         12
        </volume>
        <issue>
         2
        </issue>
        <year>
         2020
        </year>
        <fpage>
         135
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <element-citation id="sref6" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organization (WHO) Emergency Committee
          </surname>
         </name>
        </person-group>
        <chapter-title>
         Statement on the Second Meeting of the International Health Regulations (2005) Emergency Committee Regarding the Outbreak of Novel Coronavirus (2019-nCoV). Geneva:WHO; 30 January 2020
        </chapter-title>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intref0030" xlink:href="https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov">
         https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <element-citation id="sref7" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organization
          </surname>
         </name>
        </person-group>
        <chapter-title>
         Novel Coronavirus(2019-nCoV) Situation Report-18
        </chapter-title>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intref0035" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200207-sitrep-18-ncov.pdf?sfvrsn=fa644293_2">
         https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200207-sitrep-18-ncov.pdf?sfvrsn=fa644293_2
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib8">
       <label>
        8
       </label>
       <element-citation id="sref8" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           International Pharmaceutical Federation
          </surname>
         </name>
        </person-group>
        <chapter-title>
         Coronavirus 2019-nCoV Outbreak: Information and Interim Guidelines for Pharmacists and the Pharmacy Workforce
        </chapter-title>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intref0040" xlink:href="https://www.fip.org/file/4413">
         https://www.fip.org/file/4413
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib9">
       <label>
        9
       </label>
       <element-citation id="sref9" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome
        </article-title>
        <source>
         Nat Med
        </source>
        <volume>
         10
        </volume>
        <issue>
         suppl 12
        </issue>
        <year>
         2004
        </year>
        <fpage>
         S88
        </fpage>
        <lpage>
         S97
        </lpage>
        <pub-id pub-id-type="pmid">
         15577937
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib10">
       <label>
        10
       </label>
       <element-citation id="sref10" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan-Yeung
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           R.H.
          </given-names>
         </name>
        </person-group>
        <source>
         SARS: Epidemiol Respirol
        </source>
        <volume>
         8
        </volume>
        <issue>
         suppl
        </issue>
        <year>
         2003
        </year>
        <fpage>
         S9
        </fpage>
        <lpage>
         S14
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib11">
       <label>
        11
       </label>
       <element-citation id="sref11" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           SARS Expert Committee
          </surname>
         </name>
        </person-group>
        <chapter-title>
         The Hong Kong SAR government
        </chapter-title>
        <source>
         SARS in Hong Kong: From Experience to Action: Summary Report
        </source>
        <year>
         2003
        </year>
        <ext-link ext-link-type="uri" id="intref0045" xlink:href="https://www.sars-expertcom.gov.hk/english/reports/summary/files/e_sumrpt_sect1.pdf">
         https://www.sars-expertcom.gov.hk/english/reports/summary/files/e_sumrpt_sect1.pdf
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib12">
       <label>
        12
       </label>
       <element-citation id="sref12" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         367
        </volume>
        <year>
         2012
        </year>
        <fpage>
         1814
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <label>
        13
       </label>
       <element-citation id="sref13" publication-type="book">
        <source>
         National Institute of Allergy and Infectious Diseases, National Institute of Health. Coronaviruses
        </source>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intref0050" xlink:href="https://www.niaid.nih.gov/diseases-conditions/coronaviruses">
         https://www.niaid.nih.gov/diseases-conditions/coronaviruses
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib14">
       <label>
        14
       </label>
       <element-citation id="sref14" publication-type="book">
        <person-group person-group-type="author">
         <collab>
          Wuhan Municipal Health Commision
         </collab>
        </person-group>
        <chapter-title>
         Wuhan Municipal Health and Health Commission's Briefing on the Current Pneumonia Epidemic Situation in Our City
        </chapter-title>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intref0055" xlink:href="http://wjw.wuhan.gov.cn/front/web/showDetail/2019123108989">
         http://wjw.wuhan.gov.cn/front/web/showDetail/2019123108989
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib15">
       <label>
        15
       </label>
       <element-citation id="sref15" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib16">
       <label>
        16
       </label>
       <element-citation id="sref16" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organization
          </surname>
         </name>
        </person-group>
        <chapter-title>
         Advice on the Use of Masks in the Community, during Home Care and in Health Care Settings in the Context of the Novel Coronavirus (2019-nCoV) Outbreak
        </chapter-title>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intref0060" xlink:href="https://www.who.int/publications-detail/advice-on-the-use-of-masks-the-community-during-home-care-and-in-health-care-settings-in-the-context-of-the-novel-coronavirus-(2019-ncov)-outbreak">
         https://www.who.int/publications-detail/advice-on-the-use-of-masks-the-community-during-home-care-and-in-health-care-settings-in-the-context-of-the-novel-coronavirus-(2019-ncov)-outbreak
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib17">
       <label>
        17
       </label>
       <element-citation id="sref17" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib18">
       <label>
        18
       </label>
       <element-citation id="sref18" publication-type="book">
        <source>
         GSAID Database. 2020 Coronavirus
        </source>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intref0065" xlink:href="https://www.gisaid.org/CoV2020/">
         https://www.gisaid.org/CoV2020/
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib19">
       <label>
        19
       </label>
       <element-citation id="sref19" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Information Bureau
          </surname>
         </name>
         <name>
          <surname>
           Macao Sar Government
          </surname>
         </name>
        </person-group>
        <chapter-title>
         Press Release “Full Recovery of the First New Coronavirus Case in Macao” on 6 February 2020
        </chapter-title>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intref0070" xlink:href="https://news.gov.mo/detail/zh-hant/N20BFr6ANe?11">
         https://news.gov.mo/detail/zh-hant/N20BFr6ANe?11
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib20">
       <label>
        20
       </label>
       <element-citation id="sref20" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organization
          </surname>
         </name>
        </person-group>
        <chapter-title>
         WHO Guidelines on Hand Hygiene in Health Care: A Summary
        </chapter-title>
        <year>
         2009
        </year>
        <ext-link ext-link-type="uri" id="intref0075" xlink:href="https://www.who.int/gpsc/5may/tools/who_guidelines-handhygiene_summary.pdf">
         https://www.who.int/gpsc/5may/tools/who_guidelines-handhygiene_summary.pdf
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib21">
       <label>
        21
       </label>
       <element-citation id="sref21" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organization
          </surname>
         </name>
        </person-group>
        <chapter-title>
         Hand Hygiene: Why, How and when?
        </chapter-title>
        <year>
         2009
        </year>
        <ext-link ext-link-type="uri" id="intref0080" xlink:href="https://www.who.int/gpsc/5may/Hand_Hygiene_Why_How_and_When_Brochure.pdf">
         https://www.who.int/gpsc/5may/Hand_Hygiene_Why_How_and_When_Brochure.pdf
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib22">
       <label>
        22
       </label>
       <element-citation id="sref22" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Information Bureau
          </surname>
         </name>
         <name>
          <surname>
           Macao Sar Government
          </surname>
         </name>
        </person-group>
        <chapter-title>
         Press Release “Updates on New Coronavirus” on 7 February 2020
        </chapter-title>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intref0085" xlink:href="https://www.gov.mo/zh-hant/news/317427/">
         https://www.gov.mo/zh-hant/news/317427/
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib23">
       <label>
        23
       </label>
       <element-citation id="sref23" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organization
          </surname>
         </name>
        </person-group>
        <chapter-title>
         Guide to Local Production: WHO-Recommended Handrubs Formulations
        </chapter-title>
        <year>
         2010
        </year>
        <ext-link ext-link-type="uri" id="intref0090" xlink:href="https://www.who.int/gpsc/5may/Guide_to_Local_Production.pdf">
         https://www.who.int/gpsc/5may/Guide_to_Local_Production.pdf
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib24">
       <label>
        24
       </label>
       <element-citation id="sref24" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           The Hong Kong Sar Government
          </surname>
         </name>
        </person-group>
        <article-title>
         Wearing mask
        </article-title>
        <ext-link ext-link-type="uri" id="intref0095" xlink:href="https://www.info.gov.hk/info/sars/en/facemask.htm">
         https://www.info.gov.hk/info/sars/en/facemask.htm
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib25">
       <label>
        25
       </label>
       <element-citation id="sref25" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organization
          </surname>
         </name>
        </person-group>
        <chapter-title>
         Advice on the Use of Masks the Community, during Home Care and in Health Care Settings in the Context of the Novel Coronavirus (2019-nCoV) Outbreak Interim Guidance
        </chapter-title>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intref0100" xlink:href="http://file:///C:/Users/carolinaung/Downloads/advice-on-the-use-of-masks-2019-ncov.pdf">
         file:///C:/Users/carolinaung/Downloads/advice-on-the-use-of-masks-2019-ncov.pdf
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib26">
       <label>
        26
       </label>
       <element-citation id="sref26" publication-type="book">
        <person-group person-group-type="author">
         <collab>
          The U.S. Food and Drug Administration
         </collab>
        </person-group>
        <chapter-title>
         Surgical Masks-Premarket Notification [51-(k0) Submissions. Guidance for Industry and FDA Staff
        </chapter-title>
        <year>
         2018
        </year>
        <ext-link ext-link-type="uri" id="intref0105" xlink:href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/surgical-masks-premarket-notification-510k-submissions">
         https://www.fda.gov/regulatory-information/search-fda-guidance-documents/surgical-masks-premarket-notification-510k-submissions
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib27">
       <label>
        27
       </label>
       <element-citation id="sref27" publication-type="book">
        <source>
         European Standards. UNE EN 14683:2019+AC:2019. Medical Face Masks - Requirements and Test Methods
        </source>
        <year>
         2019
        </year>
        <ext-link ext-link-type="uri" id="intref0110" xlink:href="https://www.en-standard.eu/une-en-14683-2019-ac-2019-medical-face-masks-requirements-and-test-methods/">
         https://www.en-standard.eu/une-en-14683-2019-ac-2019-medical-face-masks-requirements-and-test-methods/
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib28">
       <label>
        28
       </label>
       <element-citation id="sref28" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organization
          </surname>
         </name>
        </person-group>
        <article-title>
         Novel coronavirus (2019-ncov)v2 operational support &amp; logistics disease commodity packages
        </article-title>
        <ext-link ext-link-type="uri" id="intref0115" xlink:href="https://www.who.int/docs/default-source/coronaviruse/dcp--ncov.pdf?sfvrsn=f5fe6234_4&amp;download=true;2020%202019">
         https://www.who.int/docs/default-source/coronaviruse/dcp--ncov.pdf?sfvrsn=f5fe6234_4&amp;download=true;2020 2019
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib29">
       <label>
        29
       </label>
       <element-citation id="sref29" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Information Bureau
          </surname>
         </name>
         <name>
          <surname>
           Macao Sar Government
          </surname>
         </name>
        </person-group>
        <chapter-title>
         Press Release “The Guaranteed Mask Supply for Macao Residents Scheme” on 22 January 2020
        </chapter-title>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intref0120" xlink:href="https://news.gov.mo/detail/zh-hant/N20AVJspef?14">
         https://news.gov.mo/detail/zh-hant/N20AVJspef?14
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib30">
       <label>
        30
       </label>
       <element-citation id="sref30" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Macao Sar Government
          </surname>
         </name>
        </person-group>
        <chapter-title>
         Special Webpage against Epidemics
        </chapter-title>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intref0125" xlink:href="https://www.ssm.gov.mo/apps1/PreventWuhanInfection/en.aspx#clg17311">
         https://www.ssm.gov.mo/apps1/PreventWuhanInfection/en.aspx#clg17311
        </ext-link>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Front Microbiol
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Front Microbiol
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       Front. Microbiol.
      </journal-id>
      <journal-title-group>
       <journal-title>
        Frontiers in Microbiology
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       1664-302X
      </issn>
      <publisher>
       <publisher-name>
        Frontiers Media S.A.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       30984127
      </article-id>
      <article-id pub-id-type="pmc">
       6448012
      </article-id>
      <article-id pub-id-type="doi">
       10.3389/fmicb.2019.00569
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Microbiology
        </subject>
        <subj-group>
         <subject>
          Review
         </subject>
        </subj-group>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Recent Aspects on the Pathogenesis Mechanism, Animal Models and Novel Therapeutic Interventions for Middle East Respiratory Syndrome Coronavirus Infections
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Skariyachan
         </surname>
         <given-names>
          Sinosh
         </given-names>
        </name>
        <xref ref-type="corresp" rid="c001">
         <sup>
          *
         </sup>
        </xref>
        <uri xlink:href="http://loop.frontiersin.org/people/416956/overview" xlink:type="simple">
        </uri>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Challapilli
         </surname>
         <given-names>
          Sneha Basavaraj
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Packirisamy
         </surname>
         <given-names>
          Swathi
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Kumargowda
         </surname>
         <given-names>
          Supreetha Toplar
         </given-names>
        </name>
        <uri xlink:href="http://loop.frontiersin.org/people/519171/overview" xlink:type="simple">
        </uri>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Sridhar
         </surname>
         <given-names>
          Vaishnavi Sneha
         </given-names>
        </name>
       </contrib>
      </contrib-group>
      <aff>
       <institution>
        R&amp;D Centre, Department of Biotechnology, Dayananda Sagar College of Engineering
       </institution>
       ,
       <addr-line>
        Bengaluru
       </addr-line>
       ,
       <country>
        India
       </country>
      </aff>
      <author-notes>
       <fn fn-type="edited-by">
        <p>
         Edited by: Kelvin To, University of Hong Kong, Hong Kong
        </p>
       </fn>
       <fn fn-type="edited-by">
        <p>
         Reviewed by: Man Lung Yeung, University of Hong Kong, Hong Kong; Mahmoud Mohamed Shehata, National Research Centre, Egypt
        </p>
       </fn>
       <corresp id="c001">
        *Correspondence: Sinosh Skariyachan,
        <email>
         sinoshskariya@gmail.com
        </email>
        ;
        <email>
         sinosh-bt@dayanandasagar.edu
        </email>
       </corresp>
       <fn fn-type="other" id="fn002">
        <p>
         This article was submitted to Virology, a section of the journal Frontiers in Microbiology
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="epub">
       <day>
        26
       </day>
       <month>
        3
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <pub-date pub-type="collection">
       <year>
        2019
       </year>
      </pub-date>
      <volume>
       10
      </volume>
      <elocation-id>
       569
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         28
        </day>
        <month>
         10
        </month>
        <year>
         2018
        </year>
       </date>
       <date date-type="accepted">
        <day>
         05
        </day>
        <month>
         3
        </month>
        <year>
         2019
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2019 Skariyachan, Challapilli, Packirisamy, Kumargowda and Sridhar.
       </copyright-statement>
       <copyright-year>
        2019
       </copyright-year>
       <copyright-holder>
        Skariyachan, Challapilli, Packirisamy, Kumargowda and Sridhar
       </copyright-holder>
       <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
        <license-p>
         This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is an emerging zoonotic virus considered as one of the major public threat with a total number of 2 298 laboratory-confirmed cases and 811 associated deaths reported by World Health Organization as of January 2019. The transmission of the virus was expected to be from the camels found in Middle Eastern countries via the animal and human interaction. The genome structure provided information about the pathogenicity and associated virulent factors present in the virus. Recent studies suggested that there were limited insight available on the development of novel therapeutic strategies to induce immunity against the virus. The severities of MERS-CoV infection highlight the necessity of effective approaches for the development of various therapeutic remedies. Thus, the present review comprehensively and critically illustrates the recent aspects on the epidemiology of the virus, the structural and functional features of the viral genome, viral entry and transmission, major mechanisms of pathogenesis and associated virulent factors, current animal models, detection methods and novel strategies for the development of vaccines against MERS-CoV. The review further illustrates the molecular and computational virtual screening platforms which provide insights for the identification of putative drug targets and novel lead molecules toward the development of therapeutic remedies.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        MERS-CoV
       </kwd>
       <kwd>
        emerging zoonotic virus
       </kwd>
       <kwd>
        mechanisms of pathogenesis
       </kwd>
       <kwd>
        animal models
       </kwd>
       <kwd>
        probable drug targets
       </kwd>
       <kwd>
        vaccine development
       </kwd>
      </kwd-group>
      <counts>
       <fig-count count="4">
       </fig-count>
       <table-count count="4">
       </table-count>
       <equation-count count="0">
       </equation-count>
       <ref-count count="175">
       </ref-count>
       <page-count count="18">
       </page-count>
       <word-count count="0">
       </word-count>
      </counts>
     </article-meta>
    </front>
    <sec>
     <title>
      Introduction
     </title>
     <p>
      The coronaviruses such as HCoV-229E, HCoV-NL63 (α-coronavirus) and HCoV-OC43 and HKU1 (β-coronavirus) circulated in the human population and caused mild respiratory infections (
      <xref ref-type="bibr" rid="B60">
       Hamre and Procknow, 1966
      </xref>
      ;
      <xref ref-type="bibr" rid="B54">
       Fouchier et al., 2004
      </xref>
      ;
      <xref ref-type="bibr" rid="B134">
       van der Hoek et al., 2004
      </xref>
      ;
      <xref ref-type="bibr" rid="B145">
       Woo et al., 2005
      </xref>
      ). Over the last two decades, there have been two zoonotic emergence of coronaviruses into the human population, both linked with Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) (
      <xref ref-type="bibr" rid="B43">
       Drosten et al., 2003
      </xref>
      ;
      <xref ref-type="bibr" rid="B73">
       Kuiken et al., 2003
      </xref>
      ) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) (
      <xref ref-type="bibr" rid="B164">
       Zaki et al., 2012
      </xref>
      ;
      <xref ref-type="bibr" rid="B21">
       Chafekar and Fielding, 2018
      </xref>
      ).
     </p>
     <p>
      Middle East Respiratory Syndrome Coronavirus belonged to β-coronavirus, clade-c (
      <xref ref-type="bibr" rid="B132">
       van Boheemen et al., 2012
      </xref>
      ;
      <xref ref-type="bibr" rid="B36">
       de Groot et al., 2013
      </xref>
      ) and was initially known as Human Coronavirus Erasmus Medical Center/2012. or HCoV-EMC/2012 (
      <xref ref-type="bibr" rid="B24">
       Chan et al., 2012
      </xref>
      ). MERS-CoV infections resulted high mortality rate in human, and till date, very limited therapeutic intervention or vaccine are available for the treatment of infections caused by the virus (
      <xref ref-type="bibr" rid="B96">
       Mustafa et al., 2017
      </xref>
      ;
      <xref ref-type="bibr" rid="B69">
       Hui et al., 2018
      </xref>
      ).
     </p>
     <p>
      Middle East Respiratory Syndrome Coronavirus found in various natural hosts such as the dromedary calves (
      <italic>
       Camelus dromedarius
      </italic>
      ), bats (
      <italic>
       Vespertilio superans
      </italic>
      and
      <italic>
       Neoromicia capensis
      </italic>
      ), and European hedgehog (
      <italic>
       Erinaceus europaeus
      </italic>
      ) (
      <xref ref-type="bibr" rid="B166">
       Zhang et al., 2016
      </xref>
      ;
      <xref ref-type="bibr" rid="B75">
       Lau et al., 2017
      </xref>
      ). The replication of the virus has observed in various other animals such as rabbit, goat, civet, pig, camelid, and horse (
      <xref ref-type="bibr" rid="B95">
       Muller et al., 2012
      </xref>
      ;
      <xref ref-type="bibr" rid="B22">
       Chan et al., 2013a
      </xref>
      ;
      <xref ref-type="bibr" rid="B10">
       Al-Tawfiq et al., 2014
      </xref>
      ;
      <xref ref-type="bibr" rid="B49">
       Eckerle et al., 2014
      </xref>
      ;
      <xref ref-type="bibr" rid="B92">
       Meyer et al., 2015
      </xref>
      ). The prevalence MERS-CoV was recently reported in non-camelid domestic mammals such as sheep, goat, donkey, and cow that were in contact with camels (
      <xref ref-type="bibr" rid="B71">
       Kandeil et al., 2019
      </xref>
      ). The origin of human MERS-CoV is considered to be from the bats. Several coronaviruses were isolated and found that which were genetically similar to human MERS-CoV. Phylogenetic analysis of MERS-CoV showed that a close relationship to Pipistrellus bat coronavirus HKU5 and Tylonycteris bat coronavirus HKU4 (
      <xref ref-type="bibr" rid="B120">
       Selinger et al., 2014
      </xref>
      ). Studies have suggested that there were few evidences where the virus showed camel origin (
      <xref ref-type="bibr" rid="B166">
       Zhang et al., 2016
      </xref>
      ). Studies revealed that the sero-prevalence of the virus was greater among the people those who were exhibited direct and indirect contact with dromedary camels when compared to those who were exhibited with the general population (
      <xref ref-type="bibr" rid="B142">
       Watson et al., 2014
      </xref>
      ;
      <xref ref-type="bibr" rid="B171">
       Zhou et al., 2015
      </xref>
      ;
      <xref ref-type="bibr" rid="B32">
       Conzade et al., 2018
      </xref>
      ). Recent study revealed that the prevalence of MERS-CoV infection in camel workers was found to be very high in Saudi Arabia (
      <xref ref-type="bibr" rid="B9">
       Alshukairi et al., 2018
      </xref>
      ). Thus, this review provide the recent perspectives on the epidemiology and genome composition of MERS-CoV with a special emphasis on the viral entry, clinical manifestations, mechanism of pathogenesis, animal models, detection, and development of vaccines with an insight on various computational biology perspectives.
     </p>
    </sec>
    <sec>
     <title>
      Epidemiology
     </title>
     <p>
      The first case of MERS-CoV infection was reported in Saudi Arabia in 2012 (
      <xref ref-type="bibr" rid="B164">
       Zaki et al., 2012
      </xref>
      ). From the period of its emergence, the virus has infected and propagated across more than 20 countries, contributing to a wide number of laboratory-confirmed cases. In 2015, the MERS-CoV outbreak in South Korea involved 186 cases which included 38 fatalities. A total of 83% cases of transmission were due to five super spreaders, and 44% of 186 cases were in the patients those who were experienced nosocomial transmission at 16 hospitals. The epidemic lasted for 2 months and the government authorities quarantined 16,993 persons for 14 days to manage the outbreak. This outbreak provides an exclusive opportunity to seal the gap in our awareness of MERS-CoV infection (
      <xref ref-type="bibr" rid="B101">
       Oh et al., 2018
      </xref>
      ). Recent statistics suggested that as of 31 December 2018, the total of 2,279 laboratory-confirmed cases of MERS-CoV with 806 associated deaths (case fatality rate: 35.4%) were reported in 27 countries [
      <xref ref-type="bibr" rid="B61">
       Harcourt et al., 2018
      </xref>
      ;
      <xref ref-type="bibr" rid="B156">
       World Health Organization (WHO), 2018a
      </xref>
      ]. Among various cases, 1901 confirmed cases with 732 related deaths (fatality rate 38.5%) were reported from Saudi Arabia [
      <xref ref-type="bibr" rid="B61">
       Harcourt et al., 2018
      </xref>
      ;
      <xref ref-type="bibr" rid="B156">
       World Health Organization (WHO), 2018a
      </xref>
      ].
     </p>
     <p>
      In a comprehensive report by WHO, 1841 laboratory cases were confirmed between 2012 and 2016 in which 80% of them were reported from Kingdom of Saudi Arabia. The remaining cases were reported from 27 countries in Middle East, Asia, North Africa, United States of America, and Europe [
      <xref ref-type="bibr" rid="B152">
       World Health Organization (WHO), 2016a
      </xref>
      ]. A total of 13 cases were reported between October to November 2017, amongst which 12 cases were reported in male and only one case was reported in female. Most of the infected individuals were hospitalized due to the contact with camels and consumption of camel milk with the virus [
      <xref ref-type="bibr" rid="B154">
       World Health Organization (WHO), 2017a
      </xref>
      ]. Additionally, two laboratory cases were also reported in which the patients belonged to the countries such as Malaysia and United Arab Emirates [
      <xref ref-type="bibr" rid="B156">
       World Health Organization (WHO), 2018a
      </xref>
      ]. The laboratory confirmed cases and deaths reported in several countries from the year 2012 to 2018 are shown in
      <xref ref-type="table" rid="T1">
       Table 1
      </xref>
      .
     </p>
     <table-wrap id="T1" position="float">
      <label>
       Table 1
      </label>
      <caption>
       <p>
        Laboratory confirmed cases of MERS-CoV infections and deaths reported in several countries from the year 2012 to 2018.
       </p>
      </caption>
      <table cellpadding="5" cellspacing="5" frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="left" colspan="1" rowspan="1" valign="top">
          Year
         </th>
         <th align="left" colspan="1" rowspan="1" valign="top">
          Region
         </th>
         <th align="center" colspan="1" rowspan="1" valign="top">
          MERS-CoV infections
         </th>
         <th align="center" colspan="1" rowspan="1" valign="top">
          Deaths due to MERS-CoV infections
         </th>
         <th align="left" colspan="1" rowspan="1" valign="top">
          Reference
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          2012
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Saudi Arabia, Qatar, and Jordan
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          9
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          3
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          <xref ref-type="bibr" rid="B146">
           World Health Organization, 2012
          </xref>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          2013
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Saudi Arabia, United Kingdom, France, Tunisia, and Italy
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          167
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          71
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          <xref ref-type="bibr" rid="B147">
           World Health Organization (WHO), 2013a
          </xref>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          2014
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Saudi Arabia, United Arab Emirates, Jordan, Iran, and Egypt
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          765
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          273
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          <xref ref-type="bibr" rid="B149">
           World Health Organization, 2014
          </xref>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          2015
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Saudi Arabia, Republic of Korea, Jordan, Kuwait, The Philippines, Thailand, United Arab Emirates, Oman, Qatar, China, and Iran
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          680
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          237
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          <xref ref-type="bibr" rid="B150">
           World Health Organization, 2015a
          </xref>
          ,
          <xref ref-type="bibr" rid="B151">
           b
          </xref>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          2016
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Saudi Arabia, United Arab Emirates, Qatar, Lebanon, and Oman
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          243
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          75
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          <xref ref-type="bibr" rid="B153">
           World Health Organization (WHO), 2016b
          </xref>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          2017
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Saudi Arabia, United Arab Emirates, Qatar, Lebanon, and Oman
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          258
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          81
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          <xref ref-type="bibr" rid="B155">
           World Health Organization (WHO), 2017b
          </xref>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          2018
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Saudi Arabia and Malaysia, United Arab Emirates
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          96
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          41
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          <xref ref-type="bibr" rid="B156">
           World Health Organization (WHO), 2018a
          </xref>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
    </sec>
    <sec>
     <title>
      The Genome of MERS-CoV
     </title>
     <p>
      In the early years of 2000, coronaviruses were not acquired great importance in research and development. With the emergence of SARS in the year 2002 and MERS in 2012, the interest of many researchers was stimulated toward coronavirus (
      <xref ref-type="bibr" rid="B111">
       Perlman, 2015
      </xref>
      ).
     </p>
     <p>
      The morphology of coronavirus includes spherical or pleomorphic shapes with a diameter of 80–120 nm (
      <xref ref-type="bibr" rid="B81">
       Masters, 2006
      </xref>
      ). The genome of the coronavirus consists of 6 and 7 open reading frames (ORFs). The ORF 1a and 1b encompass two-third of the viral genome which encodes the non-structural poly-proteins and the other four ORFs on the downstream side encode for the structural proteins such as envelope protein (E), Spike protein (S), nucleocapsid protein (N), and membrane protein (M). In some coronaviruses, hemagglutinin-esterase (HE) gene is present in the region between ORF 1b and S (
      <xref ref-type="bibr" rid="B80">
       Marra et al., 2003
      </xref>
      ;
      <xref ref-type="bibr" rid="B119">
       Rota et al., 2003
      </xref>
      ;
      <xref ref-type="bibr" rid="B126">
       Snijder et al., 2003
      </xref>
      ). These structural proteins are folded and entered in to the endoplasmic reticulum (ER) and transported to the ER-Golgi transitional slot (
      <xref ref-type="bibr" rid="B81">
       Masters, 2006
      </xref>
      ). During the replication of coronavirus, substantial amounts of structural proteins are synthesized in order to assemble the progeny virions (
      <xref ref-type="bibr" rid="B55">
       Fung and Liu, 2014
      </xref>
      ). They occupy the RNA genome which encodes structural proteins such as S protein, M protein, and N protein (
      <xref ref-type="bibr" rid="B126">
       Snijder et al., 2003
      </xref>
      ).
     </p>
     <p>
      The genome size of the first imported MERS-CoV strain was identified to be 30,114 nucleotide (nt) long, including the 3′and 5′ UTRs. This strain showed the genome structural ornaisation of typical betacoronavirus such as a 5′-untranslated region (UTR) (nt 1 to 272), replicase complex ORF1ab (nt 273 to 21508), S gene (nt 21450 to 25511), ORF3 (nt 25526 to 25837), ORF4a (nt 25846 to 26175), ORF4b (nt 26087 to 26827), ORF5 (nt26834 to 27508), E gene (nt 27584 to 27832), M gene (nt 27847 to 28506), N gene (nt 28560 to 29801), ORF8b gene (nt 28756 to 29094), and 3′UTR (nt 29094 to 30114). The two main poly-proteins such as
      <italic>
       pp1ab
      </italic>
      and
      <italic>
       pp1a
      </italic>
      are cleaved into 15/16 non-structural proteins (nsp) by 3C-like protease (3CLpro) and papain-like protease (PLpro). These proteases are cleaved from
      <italic>
       pp1ab
      </italic>
      along with other ORFs encoding nsp which are essential for activating RNA dependent RNA polymerase, helicase, exo-ribonuclease, endo-ribonuclease, and methyltransferase. These nsp were identified to be nsp12, nsp13, nsp14, nsp15, and nsp16. The nsp14 is necessary for proofreading the ubiquitous mutation of RNA virus (
      <xref ref-type="bibr" rid="B173">
       Ziebuhr et al., 2000
      </xref>
      ;
      <xref ref-type="bibr" rid="B126">
       Snijder et al., 2003
      </xref>
      ;
      <xref ref-type="bibr" rid="B57">
       Gorbalenya et al., 2006
      </xref>
      ;
      <xref ref-type="bibr" rid="B125">
       Smith et al., 2013
      </xref>
      ;
      <xref ref-type="bibr" rid="B117">
       Raj et al., 2014
      </xref>
      ;
      <xref ref-type="bibr" rid="B48">
       Durai et al., 2015
      </xref>
      ). Studies revealed that the accessory ORF proteins play an important role in MERS-CoV infection and pathogenesis (
      <xref ref-type="bibr" rid="B89">
       Menachery et al., 2017
      </xref>
      ). This study showed that the absence of major accessory ORFs such as deletion of ORF3, -4a, -4b, and -5 (dORF3-5) played major role in the viral replication and pathogenesis. Further, the attenuation of the mutant dORF3-5 was found to be responsible for the dysregulated host responses such as augmented interferon (IFN) pathway activation, disrupted cell processes, and robust inflammation. Thus, the disruption of accessory ORFs probably provide platform to the attenuation of future emergent strains of MERS-CoV accessory ORF mutants. The accessory ORF functions can be targeted for both therapeutic and vaccine treatments in response to MERS-CoV and related group 2C corona viruses (
      <xref ref-type="bibr" rid="B89">
       Menachery et al., 2017
      </xref>
      ). The graphical representation of the genome organization of MERS-CoV is illustrated in
      <xref ref-type="fig" rid="F1">
       Figure 1
      </xref>
      . Coronaviruses have demonstrated the establishment of double membrane vesicles (DMVs) in the infected cells. Based on immune-histochemistry and electron microscopic studies, the coronavirus replicase proteins are co-localized with the DMVs and are assumed to be the site of replication/transcription complex (
      <xref ref-type="bibr" rid="B55">
       Fung and Liu, 2014
      </xref>
      ).
     </p>
     <fig id="F1" position="float">
      <label>
       FIGURE 1
      </label>
      <caption>
       <p>
        <bold>
         (A)
        </bold>
        Graphical representation of the structure of the MERS-CoV. The schematic representation shows that the structure of Middle East Respiratory Syndrome Coronavirus, which contains the RNA enclosed in the nucleocapsid within the envelope that is embedded with spike proteins, glycoproteins and membrane proteins (
        <xref ref-type="bibr" rid="B133">
         van den Brand et al., 2015
        </xref>
        ).
        <bold>
         (B)
        </bold>
        Genome organization of MERS CoV. The genomic organization of MERS-CoV displays the viral genes S, 3, 4a, 4b, 5, E, M, 8b, and N. The genome encodes for five unique accessory proteins such as 3, 4a, 4b, 5 and 8b and four major structural proteins which are illustrated in the genome scheme (
        <xref ref-type="bibr" rid="B56">
         Gao et al., 2016
        </xref>
        ).
        <bold>
         (C)
        </bold>
        Experimental structure of MERS-CoV complexes with human DPP4 (PDB ID: 4L72). DPP4 is an extracellular RBD domain, which comprises of both N- and C-terminal. The N-terminal is the β-propeller domain and C-terminal is the α/β hydrolase domain (
        <xref ref-type="bibr" rid="B139">
         Wang et al., 2013
        </xref>
        ).
        <bold>
         (D)
        </bold>
        Genome organization of receptor binding domain (RBD) that illustrates the S1 and S2 sub-domains (
        <xref ref-type="bibr" rid="B165">
         Zhang et al., 2015
        </xref>
        ).
       </p>
      </caption>
      <graphic xlink:href="fmicb-10-00569-g001">
      </graphic>
     </fig>
     <p>
      An interesting fact of coronaviruses is that they display recombination, high rates of mutation, and propensity to cross species. One such event was reported during the 2002–2003 epidemic, where the transmission of SARS-CoV has occurred from Chinese horseshoe bats to human populations (
      <xref ref-type="bibr" rid="B112">
       Perlman and Netland, 2009
      </xref>
      ). MERS-CoV has the capability to adjust new environments and acquire various virulence factors and enhance their ability to transfer these factors from human-to-human due to continues outbreak (
      <xref ref-type="bibr" rid="B175">
       Zumla et al., 2015
      </xref>
      ). The phylogenetic analysis revealed that all human and camel MERS-CoVs were identified to be homologous to each other. Additionally, the hedgehog and bat MERS-CoVs demonstrated para-phyletic group to human and camel MERS-CoV clade (
      <xref ref-type="bibr" rid="B166">
       Zhang et al., 2016
      </xref>
      ).
     </p>
     <p>
      <xref ref-type="bibr" rid="B72">
       Kim (2016)
      </xref>
      reported that the occurrence of a mutant strain of MERS-CoV toward the human CD26 receptor during the South Korean outbreak. Furthermore, they isolated 13 new viral genomes in which, 12 possessed point mutation in the receptor-binding domain (RBD) of S protein (
      <xref ref-type="bibr" rid="B72">
       Kim, 2016
      </xref>
      ). The S protein is suggested to be essential for the host tropism through its interaction with the host CD26 receptor (
      <xref ref-type="bibr" rid="B135">
       van Doremalen et al., 2014
      </xref>
      ;
      <xref ref-type="bibr" rid="B141">
       Wang et al., 2014
      </xref>
      ).
     </p>
    </sec>
    <sec>
     <title>
      Pathogenesis
     </title>
     <sec>
      <title>
       Viral Entry
      </title>
      <p>
       The entry of MERS-CoV to the host is facilitated by its type-I transmembrane glycoprotein known as S protein (
       <xref ref-type="bibr" rid="B158">
        Xia et al., 2014
       </xref>
       ). The RBD of MERS-CoV consists of S1 subunit which ranged from 367 to 606 amino acids and can be grouped into an external sub domain and core domain as shown in
       <xref ref-type="fig" rid="F1">
        Figure 1C,D
       </xref>
       . The receptor-binding motif, V484 – L567 of RBD is situated at the external sub domain and the core sub domain consists of anti-parallel β-sheet (five-stranded) and six helices in the center. The two small β-strands make a globular fold. The core domain structure is balanced by three disulfide linkages. The MERS-CoV RBD external sub domain contains a β-sheet along with one small and three large strands which are organized in anti-parallel manner. The RBD core is attached to this region by special intervening loops and it binds to the core sub-domain by a clamp at the lower and upper regions. Most of the connecting loops and two small
       <italic>
        3
        <sub>
         10
        </sub>
       </italic>
       helices are located in the inner region of the sheet. The fourth disulfide linkage is stabilized among the residues starting from C503 to C526 and β6-strand linked with η3-helix. Three helices (HR1) at the center and three chains (HR2) near to the core promote the release of the viral particle into the cytoplasm and promote the progression of the infection (
       <xref ref-type="bibr" rid="B48">
        Durai et al., 2015
       </xref>
       ).
      </p>
      <p>
       Middle East Respiratory Syndrome Coronavirus can also enter the cell through an auxiliary pathway on the cell surface via transmembrane proteases. The binding of MERS-CoV into host cell and replication of the virus is shown in
       <xref ref-type="fig" rid="F2">
        Figure 2
       </xref>
       . The host protease cleaves coronavirus S protein into two functional domains distinctive to each other at the N-terminal region (denoted as the S1 subunit) which comprised of RBD, and C-terminal portion (S2 subunit) comprised of a fusion peptide, two heptad repeats (HR2 and HR1) and the transmembrane (TM) domain (
       <xref ref-type="bibr" rid="B143">
        Weiss and Navas-Martin, 2005
       </xref>
       ). The membrane fusion is conciliated by main conformational rearrangement which exposed the fusion peptide resulting in the development of six-helix bundle (6HB). The core of 6HB consists of a triple-stranded coiled like structure constructed by HR1s of the three spike subunits forming trimers; the HR2 elements are found to be packed within the grooves of the coiled coil in an anti-parallel direction. Owing to their central role in membrane fusion, it was reported that various antiviral peptides interfere the formation 6HB (
       <xref ref-type="bibr" rid="B53">
        Forni et al., 2015
       </xref>
       ).
      </p>
      <fig id="F2" position="float">
       <label>
        FIGURE 2
       </label>
       <caption>
        <p>
         Life cycle of MERS-CoV displaying fusion with plasma membrane. The fusion of S protein to the plasma membrane of host cell, formation of a double membrane vesicle in the host cell, eventually releasing the RNA enclosed in the nucleocapsid followed by genome transcription. The viral RNA undergoes replication and transcription followed by the 4, 5, and 6 RNA synthesis and translation; the endoplasmic reticulum aids the assembly and packaging of virus particle forming a complete double membrane vesicle and lastly through exocytosis and MERS-CoV is released out of the host cell (
         <xref ref-type="bibr" rid="B46">
          Du et al., 2009
         </xref>
         ).
        </p>
       </caption>
       <graphic xlink:href="fmicb-10-00569-g002">
       </graphic>
      </fig>
     </sec>
     <sec>
      <title>
       Transmission and Clinical Presentation
      </title>
      <p>
       The clinical presentation of MERS-CoV compasses from severe respiratory diseases to subclinical infections (
       <xref ref-type="bibr" rid="B45">
        Drosten et al., 2013
       </xref>
       ;
       <xref ref-type="bibr" rid="B69">
        Hui et al., 2018
       </xref>
       ). Infected patients often indicate the presence of hemoptysis, sore throat, fever, cough, shortness of breath, and other gastrointestinal symptoms such as diarrhea and vomiting (
       <xref ref-type="bibr" rid="B6">
        Albarrak et al., 2012
       </xref>
       ;
       <xref ref-type="bibr" rid="B12">
        Assiri et al., 2013a
       </xref>
       ,
       <xref ref-type="bibr" rid="B13">
        b
       </xref>
       ;
       <xref ref-type="bibr" rid="B58">
        Guery et al., 2013
       </xref>
       ;
       <xref ref-type="bibr" rid="B63">
        Health Protection Agency, 2013
       </xref>
       ;
       <xref ref-type="bibr" rid="B104">
        Omrani et al., 2013
       </xref>
       ). A low range of lower pulmonary infiltrate associated with viral pneumonia was observed in the radiograph of patients infected with MERS-CoV (
       <xref ref-type="bibr" rid="B83">
        Memish et al., 2013a
       </xref>
       ;
       <xref ref-type="bibr" rid="B140">
        Wang, 2014
       </xref>
       ). It was observed that greater than 60% of the initially reported cases of MERS-CoV infection, the patients experienced severe disease which demanded intensive care treatments like extracorporeal membrane oxygenation and mechanical ventilation. Hematological aberrations delineated for the clinical cases of neutrophilia (8%), lymphopenia (34%), thrombocytopenia (36%), and lymphocytosis (11%). While the conditions of kidney failure necessitate renal replacement therapy for a considerable number of MERS-CoV cases, several studies detected MERS-CoV antigens and particles in the renal tissues
       <italic>
        in vivo
       </italic>
       , which is the direct indication of the virus replication in renal tissues and long term acute infection (
       <xref ref-type="bibr" rid="B161">
        Yeung et al., 2016
       </xref>
       ;
       <xref ref-type="bibr" rid="B8">
        Alsaad et al., 2018
       </xref>
       ).
      </p>
      <p>
       The first evidence of human-to-human transmission of MERS-CoV was reported in few cases in United Kingdom, when an adult male traveled to Saudi Arabia and transferred the infectious virus to two of his family members (
       <xref ref-type="bibr" rid="B112">
        Perlman and Netland, 2009
       </xref>
       ). It was suggested that MERS-CoV infections were due to the introduction of the virus in humans and the close contact with camels was one of risk factors for the transmission of MERS as reported by World Health Organization [
       <xref ref-type="bibr" rid="B153">
        World Health Organization (WHO), 2016b
       </xref>
       ].
      </p>
      <p>
       The transmission of MERS-CoV is determined as spasmodic, often healthcare associated, intra-familial, and required prolonged and close contact (
       <xref ref-type="bibr" rid="B83">
        Memish et al., 2013a
       </xref>
       ,
       <xref ref-type="bibr" rid="B84">
        b
       </xref>
       ,
       <xref ref-type="bibr" rid="B85">
        Memish et al., 2014a
       </xref>
       ,
       <xref ref-type="bibr" rid="B86">
        b
       </xref>
       ;
       <xref ref-type="bibr" rid="B113">
        Puzelli et al., 2013
       </xref>
       ;
       <xref ref-type="bibr" rid="B44">
        Drosten et al., 2014
       </xref>
       ). In a domestic study conducted with MERS-CoV infected patients, 14 out of 280 contacts of 26 positively indexed patients (antibody positive or RNA) suggested that the frequency of the transmission even during outbreaks was approximately 3% (
       <xref ref-type="bibr" rid="B44">
        Drosten et al., 2014
       </xref>
       ). Several studies suggested that the virus was not self-sustained, as during local epidemic of MERS-CoV, which has not been readily transmitted to more than one human and has been reported in majority of human related cases (
       <xref ref-type="bibr" rid="B16">
        Bauch and Oraby, 2013
       </xref>
       ;
       <xref ref-type="bibr" rid="B17">
        Breban et al., 2013
       </xref>
       ;
       <xref ref-type="bibr" rid="B20">
        Cauchemez et al., 2014
       </xref>
       ;
       <xref ref-type="bibr" rid="B26">
        Chowell and Nishiura, 2014
       </xref>
       ). The mode of transmission of the virus is illustrated in
       <xref ref-type="fig" rid="F3">
        Figure 3
       </xref>
       .
      </p>
      <fig id="F3" position="float">
       <label>
        FIGURE 3
       </label>
       <caption>
        <p>
         Transmission of MERS-CoV and symptoms possessed by infected human. The figure shows the path by which the virus is transmitted from the infected camel to the human and camel to various animals (
         <xref ref-type="bibr" rid="B71">
          Kandeil et al., 2019
         </xref>
         ); further, this virus is transmitted to other human population via human to human transmissions (
         <xref ref-type="bibr" rid="B121">
          Shehata et al., 2016
         </xref>
         ).
        </p>
       </caption>
       <graphic xlink:href="fmicb-10-00569-g003">
       </graphic>
      </fig>
      <p>
       The serological analysis and extensive investigation of those potentially exposed to the patients suggested that there were no secondary infections [
       <xref ref-type="bibr" rid="B148">
        World Health Organization (WHO), 2013b
       </xref>
       ]. As a minimum of 18 cases of asymptomatic MERS-CoV infections were reported in health care personals, the function of these subclinical cases in the transfer of infection was found to be uncertain (
       <xref ref-type="bibr" rid="B37">
        de Sousa et al., 2014
       </xref>
       ).
      </p>
     </sec>
     <sec>
      <title>
       Molecular Mechanism of the Pathogenesis
      </title>
      <p>
       While there were intensive studies on coronavirus research over the past 5 years, limited reports are available on the pathogenesis of MERS-CoV. Recent post-mortem histopathological studies revealed that the localization of viral particles in the pulmonary and extra pulmonary tissue of a 33-year-old male patient of T cell lymphoma, who acquired MERS-CoV infection (
       <xref ref-type="bibr" rid="B100">
        Ng et al., 2016
       </xref>
       ;
       <xref ref-type="bibr" rid="B8">
        Alsaad et al., 2018
       </xref>
       ). The histopathological analysis of the biopsies were collected from lung, brain, liver, heart, kidney, and skeletal muscle demonstrated that there were pulmonary diffuse alveolar damage, necrotizing pneumonia, acute kidney injury, portal and lobular hepatitis and myositis with muscle atrophic changes. Further, the viral particles were found to be localized in the pulmonary macrophages, pneumocytes, renal proximal tubular epithelial cells and macrophages infiltrating the skeletal muscles (
       <xref ref-type="bibr" rid="B8">
        Alsaad et al., 2018
       </xref>
       ).
      </p>
      <p>
       Studies suggested that the pathogenesis of MERS-CoV in human and animals are mainly due to three mechanisms such as DPP4 (dipeptidyl peptidase-4) mediated mechanism, papain like protease PLpro mediated mechanism and accessory proteins like p4a and membrane M protein mediated mechanism. Hence, these proteins are probably considered as one of the potential therapeutic targets for MERS-CoV infections (
       <xref ref-type="bibr" rid="B48">
        Durai et al., 2015
       </xref>
       ). The molecular mechanisms exhibited by various modes of pathogenesis are illustrated in
       <xref ref-type="fig" rid="F4">
        Figure 4
       </xref>
       .
      </p>
      <fig id="F4" position="float">
       <label>
        FIGURE 4
       </label>
       <caption>
        <p>
         The molecular mechanism of pathogenesis by MERS-CoV in human and animals. The pathogenesis mechanism is mainly occurred by DPP4, papian like protease PLpro, and accessory proteins such as p4a and membrane M protein (
         <xref ref-type="bibr" rid="B48">
          Durai et al., 2015
         </xref>
         ).
        </p>
       </caption>
       <graphic xlink:href="fmicb-10-00569-g004">
       </graphic>
      </fig>
     </sec>
    </sec>
    <sec>
     <title>
      DPP4 Mediated Mechanism
     </title>
     <p>
      DPP4 is a type-II transmembrane glycoprotein consists of approximately 766 amino acids and function as major receptor for MERS-CoV. The three dimensional structural analysis revealed that this receptor has α/β-hydrolase domain and a β-propeller domain with eight blades that helped in the binding of receptor binding domain in MERS-CoV (
      <xref ref-type="bibr" rid="B117">
       Raj et al., 2014
      </xref>
      ). The crystal structure of DPP4 is illustrated in
      <xref ref-type="fig" rid="F1">
       Figure 1C
      </xref>
      . A DPP4 binding protein, adenosine deaminase, is considered as one of the major inhibitors of the S protein of MERS-CoV (
      <xref ref-type="bibr" rid="B42">
       Drosten, 2013
      </xref>
      ).
     </p>
     <p>
      A number of cell lines such as human-derived HFL, Calu-3, Caco-2, Huh-7, HEK, His-1 cell lines, CD8+, and CD4+ that are susceptible to MERS-CoV were reported (
      <xref ref-type="bibr" rid="B23">
       Chan et al., 2013b
      </xref>
      ;
      <xref ref-type="bibr" rid="B123">
       Shirato et al., 2013
      </xref>
      ;
      <xref ref-type="bibr" rid="B27">
       Chu et al., 2016
      </xref>
      ). Two S protein ecto-domains can be divided into fusion-catalyzing domains (FD) and RBD. The S RBDs bind to DPP4 after which the FDs are exposed through unfolding. Further, the cellular and viral membranes were joined together by refolding (
      <xref ref-type="bibr" rid="B116">
       Raj et al., 2013
      </xref>
      ). The unfolding FD required the cleavage of S protein by host proteases. Out of various proteolytic cleavage sites between the FD and RBD, the cleavage at S1/S2 site is essential for the infection of Calu3 cells by MERS-CoV (
      <xref ref-type="bibr" rid="B106">
       Park et al., 2016
      </xref>
      ).
     </p>
     <p>
      It has been revealed that upon infection, monocyte chemo attractant protein-1 and IFN-γ-inducible protein-10 were induced and suppressed the proliferation of human myeloid progenitor cells (
      <xref ref-type="bibr" rid="B172">
       Zhou et al., 2014
      </xref>
      ). MERS-CoV can infect T-cells from human lymphoid organs and causes the peripheral blood inducing apoptosis by intrinsic and extrinsic pathways (
      <xref ref-type="bibr" rid="B27">
       Chu et al., 2016
      </xref>
      ). A study conducted by
      <xref ref-type="bibr" rid="B7">
       Al-Qahtani et al. (2017)
      </xref>
      suggested that the inhibition of DPP4 mitigated the induction of PPARγ (the transcriptional repressor) and IRAK-M (negative regulator of TLR signaling) which indicated that the immunosuppressive action of S glycoprotein regulated by DPP4.
     </p>
    </sec>
    <sec>
     <title>
      Papain Like Protease PLpro Mediated Mechanism
     </title>
     <p>
      Upon entry into the cells, two ORFs at the 5′-end of the viral genome are translated into two poly-proteins. They are processed by two viral proteases,
      <italic>
       PLpro
      </italic>
      and 3C-like proteinase (3CLpro) and form 16 nonstructural proteins which are necessary for the membrane-associated replication complex.
      <italic>
       PLpro
      </italic>
      is located in nonstructural protein 3.
      <italic>
       PLpro
      </italic>
      was found to be multifunctional enzymes with deISGylating (removal of ISG15 conjugates from host cell factors) and de-ubiquitinating (cleavage of ubiquitin from host cell factors) properties in addition to protease activity in many coronaviruses (
      <xref ref-type="bibr" rid="B28">
       Clasman et al., 2017
      </xref>
      ). This resulted in the host antiviral immune response being antagonized and promoting the viral replication.
      <italic>
       PLpro
      </italic>
      can inhibit the mitochondrial anti-viral signaling protein induced IFN-β reporter activity and reduce TNF-α induced NF-κB reporter activity. Hence, MERS-CoV
      <italic>
       PLpro
      </italic>
      is considered to be important antiviral target (
      <xref ref-type="bibr" rid="B93">
       Mielech et al., 2014
      </xref>
      ;
      <xref ref-type="bibr" rid="B62">
       Harrigan et al., 2018
      </xref>
      ).
     </p>
     <p>
      The coronavirus genome is encoded by two ubiquitin-like domains (Ubl1 and Ubl2), out of which Ubl2 is considered to be an important component which influences the
      <italic>
       PLpro
      </italic>
      activity.
      <xref ref-type="bibr" rid="B28">
       Clasman et al. (2017)
      </xref>
      reported that
      <italic>
       PLpro
      </italic>
      has not showed the deISGylating, de-ubiquitinating or protease activities in the absence of Ubl2 domain. There were no variations in the process of inhibition, substrate specificity, catalytic efficiency and thermal stability (
      <xref ref-type="bibr" rid="B28">
       Clasman et al., 2017
      </xref>
      ).
     </p>
    </sec>
    <sec>
     <title>
      Accessory Proteins Mediated Mechanism
     </title>
     <p>
      The viral genome is recognized by melanoma differentiation-associated protein-5 (MDA5), retinoic acid inducible gene-1 (RIG-1) and endosomal toll-like receptor 3 (TLR3) as pathogen-associated molecular patterns. This recognition resulted in the formation of type-1 interferon (IFN1). As an evasion mechanism, virus synthesize proteins that hinder the production IFN1 in the pathway (
      <xref ref-type="bibr" rid="B174">
       Zinzula and Tramontano, 2013
      </xref>
      ).
     </p>
     <p>
      In the absence of MDA5 and RIG-1, MERS-CoV used the protein such as 4a (p4a) which contain RNA-binding motif for binding (
      <xref ref-type="bibr" rid="B115">
       Rabouw et al., 2016
      </xref>
      ). By a direct binding, this motif masks the dsRNA of MERS-CoV. The p4a possesses αβββα fold with the β1-β2 loop and α1 helix which bind to the minor groove of dsRNA. The mutational studies revealed that p4a-dsRNA complex stabilized by the amino acids such as K27, W45, K63, and K67 (
      <xref ref-type="bibr" rid="B15">
       Batool et al., 2017
      </xref>
      ). In a study carried out by
      <xref ref-type="bibr" rid="B19">
       Canton et al. (2018)
      </xref>
      suggested that, NF-κB remained in the cytoplasm of MERS-CoV infected cells while 4b was found to be attached with the nucleus. In the absence of 4b, expression of pro-inflammatory cytokines was observed as NF-κB translocated to the nucleus. This was also observed in the case of 4b mutants that devoid of nuclear localization signal, indicating that nuclear localization signal mediated process of 4b is essential for NF-κB expression (
      <xref ref-type="bibr" rid="B19">
       Canton et al., 2018
      </xref>
      ).
     </p>
     <p>
      As a component of the viral envelope, M protein is involved in various functions such as viral assembly along with other proteins such as E, S, N. The M, E, and S proteins interact with N protein in the ER-Golgi complex. This interaction hinders the fusion of viral and cellular membranes (
      <xref ref-type="bibr" rid="B97">
       Mustafa et al., 2018
      </xref>
      ). It was observed that the expression of M protein in MERS-CoV might suppressed the type-I IFN expression in response to poly (I: C) induction or Sendai virus infection. This reaction was detected to be specific for the activation of IFN regulatory factor 3 (IRF3), however, not activated the nuclear factor-κB. The interaction of MERS-CoV M protein with TRAF3 and the association of disrupted TRAF3–TBK1 lead to reduced activation of IRF3 (
      <xref ref-type="bibr" rid="B78">
       Lui et al., 2016
      </xref>
      ).
     </p>
    </sec>
    <sec>
     <title>
      Host Immune Response
     </title>
     <p>
      Middle East Respiratory Syndrome Coronavirus can readily infect human respiratory epithelial cells, macrophages, T-cells, dendritic cells and can influence the production and induction of pro-inflammatory cytokines and chemokines (
      <xref ref-type="bibr" rid="B171">
       Zhou et al., 2015
      </xref>
      ). Studies on
      <italic>
       ex vivo
      </italic>
      human lung tissue and respiratory epithelial cell lines showed that the induction of antiviral interferons followed by MERS-CoV infection by stimulated epithelial cells was found to be limited. A study by
      <xref ref-type="bibr" rid="B88">
       Menachery et al. (2014)
      </xref>
      described that the cells infected with MERS-CoV demonstrated distinctly altered chromatin structures such as repressive histone markers, that could limit the transcription factors from binding to the promoter regions of interferon-stimulated gene. The changes in DNA methylation found to be one of the reasons for down regulation of IFN-γ–associated antigen-presenting gene after the infection (
      <xref ref-type="bibr" rid="B90">
       Menachery et al., 2018
      </xref>
      ). MERS-CoV proteins such as 4a, 4b, M, and PLpro were found to be suppressed the induction of interferons (
      <xref ref-type="bibr" rid="B159">
       Yang et al., 2013
      </xref>
      ;
      <xref ref-type="bibr" rid="B93">
       Mielech et al., 2014
      </xref>
      ;
      <xref ref-type="bibr" rid="B19">
       Canton et al., 2018
      </xref>
      ). Further, the induction of pro-inflammatory cytokine response in these cells was found to be limited. A delayed induction of pro-inflammatory cytokines/chemokines such as IL-6, IL-8, and IL-1β were observed upon the viral infection (
      <xref ref-type="bibr" rid="B74">
       Lau et al., 2013
      </xref>
      ;
      <xref ref-type="bibr" rid="B19">
       Canton et al., 2018
      </xref>
      ).
     </p>
     <p>
      Middle East Respiratory Syndrome Coronavirus could infect and replicate in human monocyte-derived macrophages and immature monocyte-derived dendritic cells, while it failed to perform similar functions in mature monocyte-derived dendritic cells. This indicate that the maturation restrict the viral replication. Immature dendritic cells were unable to stimulate T-cell even after the antigen uptake, delaying the activation of T-cells and permitting further viral replication (
      <xref ref-type="bibr" rid="B31">
       Cong et al., 2018
      </xref>
      ). The infection of human macrophages induced the expression of pro-inflammatory cytokines/chemokines such as MCP-1/CCL-2, IFN-α2, IFN-γ, MIP-1α/CCL-3, IP-10/CXCL-10, RANTES/CCL-5, IL-8, TNF-α, IL-12p40, and IL-6 (
      <xref ref-type="bibr" rid="B171">
       Zhou et al., 2015
      </xref>
      ;
      <xref ref-type="bibr" rid="B31">
       Cong et al., 2018
      </xref>
      ). The infected dendritic cells induced the expression of IL-12, RANTES/CCL-5, IP-10/CXCL-10 and IFN-γ, however, showed low expression of IFN-α and no expression of IFN-β (
      <xref ref-type="bibr" rid="B171">
       Zhou et al., 2015
      </xref>
      ).
     </p>
     <p>
      T-cells can be directed to the infection site by type-I IFN stimulated secretion of IL-10 and CXCL10. Due to their uncontrolled and strong expression, the expression of IFN-γ and IL-12 were inhibited and restricted the activation of T-helper cells. With the added effect of down-regulated antigen-presentation pathways, the activation of T cells is inhibited. Hence, the sequestered T cells failed to target the virus (
      <xref ref-type="bibr" rid="B162">
       Ying et al., 2016
      </xref>
      ). Previous studies revealed that when the serum samples and bronchoalveolar lavage were analyzed from two patients, it was observed that the patients with low level secretion of IFN-α were failed to survive and the patients displayed high level secretion of type-I IFN were survived (
      <xref ref-type="bibr" rid="B51">
       Faure et al., 2014
      </xref>
      ).
     </p>
    </sec>
    <sec>
     <title>
      Animal Models
     </title>
     <p>
      The animal models are one of the vital components for translation of the findings from drug discovery process from bench to bedside. These animal models are indispensable for the deeper understanding of any diseases and safe and protective vaccine development process (
      <xref ref-type="bibr" rid="B77">
       Lorenzen et al., 2015
      </xref>
      ). The main criteria for the validation of animal models in preclinical studies are face validity, predictive validity and target validity. The face validity means that the proper similarity between the animal model and the human disease in terms of the biology and symptoms of the disease. However, assessing face validity is a tedious task due to the lack of understanding on the core biology of the disease symptoms. Predictive validity means the display of clinical interventions which exhibited similar effect in the animal models. This is also very difficult to achieve due to the incomplete correlation between animal models, the mechanism of human diseases and the incapability of standard drugs to active in many animal models. Target validity is another essential component for the validation of animal models in which the target under study must have an analogous function in the disease model as in the clinical condition (
      <xref ref-type="bibr" rid="B40">
       Denayer et al., 2014
      </xref>
      ).
     </p>
     <p>
      An ideal animal model is the one where an immunocompetent animal, on receiving the challenge virus at a realistic dose through a suitable inoculation route, is able to replicate the characteristics of a human disease as closely as possible (
      <xref ref-type="bibr" rid="B41">
       Doremalen and Munster, 2015
      </xref>
      ). Ferrets, hamsters, mice and other small laboratory animals are not ideal animal models for MERS-CoV owing to the variations in DPP4 receptor. The rhesus macaque and the common marmoset are the first non-human primate species (NPS) to be used as the animal models for MERS-CoV. Glycosylation of mouse DPP4 (mDPP4) prevents its binding to S protein of MERS-CoV. Hence, transgenic hDPP4 (human DPP4) mice were developed as animal model (
      <xref ref-type="bibr" rid="B109">
       Peck et al., 2015
      </xref>
      ). The major advantages and limitations of MERS-CoV animal models are listed in
      <xref ref-type="table" rid="T2">
       Table 2
      </xref>
      .
     </p>
     <table-wrap id="T2" position="float">
      <label>
       Table 2
      </label>
      <caption>
       <p>
        Advantages and limitations of MERS-CoV experimental animal models.
       </p>
      </caption>
      <table cellpadding="5" cellspacing="5" frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="left" colspan="1" rowspan="1" valign="top">
          Species
         </th>
         <th align="left" colspan="1" rowspan="1" valign="top">
          Advantages
         </th>
         <th align="left" colspan="1" rowspan="1" valign="top">
          Limitations
         </th>
         <th align="left" colspan="1" rowspan="1" valign="top">
          Reference
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Rabbit
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Readily available and easy to handle
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Animal-to-animal transmission studies are not available No clinical disease, Low viral titers in tissues upon infection Develop mild pulmonary lesions
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          <xref ref-type="bibr" rid="B59">
           Haagmans et al., 2015
          </xref>
          ;
          <xref ref-type="bibr" rid="B136">
           Vergara-Alert et al., 2017
          </xref>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Rhesus macaques
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Human-specific reagents available for immunologic analysis Immune and respiratory systems similar to humans; clinical disease similar to humans Useful for confirming vaccine efficacy testing
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Limited availability and expensive Expert husbandry requirements Animal-to-animal transmission studies are not available Transient disease Ethical concerns
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          <xref ref-type="bibr" rid="B14">
           Baseler et al., 2016
          </xref>
          ;
          <xref ref-type="bibr" rid="B163">
           Yu et al., 2017
          </xref>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Common marmoset
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Model severe, potentially fatal MERS-CoV infection Some human-specific immunological reagents cross-react Respiratory and immune systems similar to humans; clinical disease similar to humans Useful for confirming antiviral and vaccine efficacy testing
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Limited availability and expensive Expert husbandry requirements Ethical concerns Animal-to-animal transmission studies are not available
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          <xref ref-type="bibr" rid="B136">
           Vergara-Alert et al., 2017
          </xref>
          ;
          <xref ref-type="bibr" rid="B163">
           Yu et al., 2017
          </xref>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          hDPP4-transgenic mice
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Model severe, potentially fatal MERS-CoV infection Easy to handle Reagents available Useful for screening antivirals and vaccines
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Global over expression of hDPP4
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          <xref ref-type="bibr" rid="B14">
           Baseler et al., 2016
          </xref>
          ;
          <xref ref-type="bibr" rid="B30">
           Coleman et al., 2017
          </xref>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
     <sec>
      <title>
       Mice
      </title>
      <p>
       Studies suggested that the glycosylation of certain amino acids prevented the binding of mouse DPP4 (mDPP4) to S protein of MERS-CoV (
       <xref ref-type="bibr" rid="B41">
        Doremalen and Munster, 2015
       </xref>
       ). The first transgenic MERS-CoV mouse model was established by
       <xref ref-type="bibr" rid="B4">
        Agrawal et al. (2015)
       </xref>
       . The mice expressed hDPP4 and developed severe respiratory MERS-CoV infections. The transgenic mice infected with an intra-nasal dose of 10
       <sup>
        6
       </sup>
       TCID50 of MERS-CoV developed pneumonia, weight loss, acute pulmonary viral infection, ruffled fur, squinting, and death within few days (
       <xref ref-type="bibr" rid="B4">
        Agrawal et al., 2015
       </xref>
       ). A transgenic mouse model developed by
       <xref ref-type="bibr" rid="B168">
        Zhao et al. (2015)
       </xref>
       showed that limited utility for pathogenic studies due to the systemic dissemination and development of severe neurological diseases. The other lung infection models were lack mortality and weight loss, however, developed lung pathology in response to 50% TCID
       <sup>
        50
       </sup>
       of MERS-CoV (
       <xref ref-type="bibr" rid="B130">
        Tao et al., 2015
       </xref>
       ).
      </p>
      <p>
       Recent studies suggested that the transgenic mice models were developed where the full-length mDPP4 gene replaced by hDPP4 (
       <xref ref-type="bibr" rid="B30">
        Coleman et al., 2017
       </xref>
       ). The infection and replication of MERS-CoV was observed in the lungs, however, disseminated slow impact to the other organs during the post injection with dose range of 102–105 PFU. The pathology of infected mice showed pneumonia-like symptoms (
       <xref ref-type="bibr" rid="B30">
        Coleman et al., 2017
       </xref>
       ).
      </p>
      <p>
       The CRISPR-Cas9 gene editing tools were used to produce mice susceptible to MERS-CoV infection by modifying their genome sequence (positions 288 and 330) homologous to the sequence of hDPP4. In certain mice model the characteristic symptoms such as pulmonary hemorrhage, low survival, decreased pulmonary function and weight loss were observed. The 288-330+/+MERS-CoV mouse model demonstrated severe respiratory infection as observed in humans (
       <xref ref-type="bibr" rid="B29">
        Cockrell et al., 2016
       </xref>
       ).
      </p>
     </sec>
     <sec>
      <title>
       Rhesus Macaques and Marmosets
      </title>
      <p>
       Upon infection with MERS-CoV, rhesus macaques and marmosets were developed moderate respiratory disease which are comparable with mild human MERS-CoV infection. As observed in human cases, they also showed complete blood count abnormalities. Rhesus macaque and marmoset models were found to be suitable for pathogenic studies of mild infections. Both the models can be used for the efficacy testing of prophylactic and therapeutic countermeasures (
       <xref ref-type="bibr" rid="B14">
        Baseler et al., 2016
       </xref>
       ).
      </p>
      <p>
       <xref ref-type="bibr" rid="B163">
        Yu et al. (2017)
       </xref>
       reported that when 2-3 old rhesus macaques and common marmosets were intra-tracheally injected with hCoV-EMC, hematoxylin and eosin stained tissues of the infected model demonstrated lesions primarily in the lungs with various degrees of inflammation, hemorrhaging, pulmonary oedema, interstitial pneumonia, eosinophil infiltration and necrosis in bronchial epithelial cells and pneumocytes. The lungs of the infected marmosets demonstrated widespread pulmonary oedema and hemorrhaging. The oedematous alveolar cavities showed fibrinous exudates and neutrophil infiltration. In both the cases, DPP4 was widely expressed in alveolar macrophages and type-I and II pneumocytes were also actively involved. The pathological changes as a result of viral infection were not observed in any other organs of the infected animal (
       <xref ref-type="bibr" rid="B163">
        Yu et al., 2017
       </xref>
       ).
      </p>
     </sec>
     <sec>
      <title>
       Rabbits
      </title>
      <p>
       In most cases, MERS-CoV causes severe infection in the lower respiratory tract in humans. Nasal swabs collected from the infected rabbits demonstrated the presence of MERS-CoV. They generally develop respiratory diseases such as asymptomatic and mild human infections as sometimes observed in immune-competent patients (
       <xref ref-type="bibr" rid="B59">
        Haagmans et al., 2015
       </xref>
       ).
      </p>
      <p>
       Recently,
       <xref ref-type="bibr" rid="B66">
        Houser et al. (2017)
       </xref>
       revealed that the infected New Zealand rabbits were developed asymptomatic pulmonary infections with high levels of viral antigens and RNA. Multiple lung lobes showed peri-vascular inflammation. The antibodies developed by the rabbits lacked neutralizing activity, and as a result the animals were susceptible to re-infection. In fact, enhanced pulmonary inflammation was observed after re-infection. However, re-infection elicited the neutralizing antibodies (Nabs). Hence, it was suggested that upon re-infection, there might be greater risk of severe lung disease in those who do not develop neutralizing antibody response, or those whose neutralizing antibody titers have decreased after the initial infection (
       <xref ref-type="bibr" rid="B66">
        Houser et al., 2017
       </xref>
       ). The clinical signs and lesions along with the occurrence of MERS-CoV RNA and antigens observed in MERS-CoV infected animal models are shown in
       <xref ref-type="table" rid="T3">
        Table 3
       </xref>
       .
      </p>
      <table-wrap id="T3" position="float">
       <label>
        Table 3
       </label>
       <caption>
        <p>
         Clinical signs and lesions along with the occurrence of MERS-CoV RNA and antigens as seen in MERS-CoV infected animal models.
        </p>
       </caption>
       <table cellpadding="5" cellspacing="5" frame="hsides" rules="groups">
        <thead>
         <tr>
          <th align="left" colspan="1" rowspan="1" valign="top">
           Animal model
          </th>
          <th align="left" colspan="1" rowspan="1" valign="top">
           Clinical signs
          </th>
          <th align="left" colspan="1" rowspan="1" valign="top">
           Lesions
          </th>
          <th align="left" colspan="1" rowspan="1" valign="top">
           Occurrence of MERS-Cov RNA
          </th>
          <th align="left" colspan="1" rowspan="1" valign="top">
           Occurrence of MERS-antigen
          </th>
          <th align="left" colspan="1" rowspan="1" valign="top">
           Reference
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Rabbit
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Asymptotic
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Rhinitis with necrosis
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Lung, upper respiratory tract, lymph nodes
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Type I and II pneumocytes
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <xref ref-type="bibr" rid="B59">
            Haagmans et al., 2015
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Rhesus Macaques
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Mild to moderate respiratory disease
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Interstitial pneumonia
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Lung, lymph nodes, upper respiratory tract
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Type I and II pneumocytes, alveolar macrophages
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <xref ref-type="bibr" rid="B38">
            de Wit et al., 2013a
           </xref>
           ,
           <xref ref-type="bibr" rid="B39">
            b
           </xref>
           ;
           <xref ref-type="bibr" rid="B160">
            Yao et al., 2014
           </xref>
           ;
           <xref ref-type="bibr" rid="B163">
            Yu et al., 2017
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Common Marmoset
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Mild to severe respiratory disease
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Broncho-interstitial pneumonia
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Lung, blood, lymph nodes, visceral organs, upper respiratory tract
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Type I pneumocytes, alveolar macrophages
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <xref ref-type="bibr" rid="B50">
            Falzarano et al., 2014
           </xref>
           ;
           <xref ref-type="bibr" rid="B163">
            Yu et al., 2017
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           hDPP4- transgenic mice
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Severe fatal respiratory disease
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Broncho-interstitial pneumonia
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Lung, brain, visceralorgans
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Type I and type II pneumocytes
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <xref ref-type="bibr" rid="B4">
            Agrawal et al., 2015
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </sec>
    </sec>
    <sec>
     <title>
      Diagnostic Approaches
     </title>
     <p>
      The primary diagnosis of MERS-CoV infection was performed by molecular techniques such as real-time reverse transcriptase PCR (RT-PCR) (
      <xref ref-type="bibr" rid="B34">
       Corman et al., 2012a
      </xref>
      ), reverses transcription–loop-mediated isothermal amplification (RT-RTPA) (
      <xref ref-type="bibr" rid="B124">
       Shirato et al., 2014
      </xref>
      ) and reverses transcription-recombinase polymerase amplification (RT-LAMP) (
      <xref ref-type="bibr" rid="B1">
       Abd et al., 2013
      </xref>
      ). Numerous serological assays were used to detect MERS-CoV or closely related viruses in seropositive camels; these tests were protein microarrays like indirect enzyme-linked immunosorbent assay (ELISA), recombinant spike immunofluorescent assay, spike pseudoparticle neutralization and microneutralization assay (
      <xref ref-type="bibr" rid="B18">
       Buchholz et al., 2013
      </xref>
      ;
      <xref ref-type="bibr" rid="B110">
       Perera et al., 2013
      </xref>
      ). However, none of the serological assays showed evidence of the precise occurrence of MERS-CoV in camels (
      <xref ref-type="bibr" rid="B127">
       Song et al., 2015
      </xref>
      ). Recent study reported that a rapid and specific assay for the detection of MERS-CoV such as nucleic acid visualization technique which combine the reverse transcription loop-mediated isothermal amplification technique and a vertical flow visualization strip (RT-LAMP-VF) to detect the N gene of MERS-CoV (
      <xref ref-type="bibr" rid="B68">
       Huang et al., 2018
      </xref>
      ). The study suggested that in comparison with the real-time RT-PCR (rRT-PCR) method recommended by the World Health Organization, the RT-LAMP-VF assay is easy to perform and the rapid detection of MERS-CoV within 35 min was achieve by this approach (
      <xref ref-type="bibr" rid="B68">
       Huang et al., 2018
      </xref>
      ).
     </p>
     <p>
      An assay was developed based on the detection of N protein of MERS-CoV (
      <xref ref-type="bibr" rid="B127">
       Song et al., 2015
      </xref>
      ). The NP protein preferred as better target than the S protein. In this type of assay, firstly, the antigen binds to gold labeled monoclonal antibodies which lead to the formation of antigen-antibody complex. The complex further passed through nitrocellulose membrane and bind to monoclonal antibody at the test region and formed band which could be conveniently analyzed (
      <xref ref-type="bibr" rid="B129">
       Tang, 2014
      </xref>
      ).
     </p>
     <p>
      Currently, multiple purified monoclonal antibodies are available in clinical and preclinical studies for the development of antimicrobials (
      <xref ref-type="bibr" rid="B118">
       Rockx et al., 2010
      </xref>
      ). Studies suggested that two human antibodies (REGN3048 and REGN3051) are known to bind with MERS-CoV RBD and prevent the interaction of cellular receptor DPP4 with S protein and effectively neutralize MERS-CoV infection (
      <xref ref-type="bibr" rid="B108">
       Pascal et al., 2015
      </xref>
      ). The antibodies such as REGN3048 and REGN3051 showed no binding with S protein, thus, employed as effective combination for inhibiting MERS-CoV (
      <xref ref-type="bibr" rid="B2">
       Aderem et al., 2011
      </xref>
      ). REGN3048 and REGN3051 co-interact with MERS-CoV RBD, which suggested that these antibodies bind to discrete epitopes as they bind to regions of MERS-CoV S protein that are conserved during the natural evolution of the virus. These two antibodies were blocked entry of the virus into susceptible cell lines and neutralize the infection (
      <xref ref-type="bibr" rid="B108">
       Pascal et al., 2015
      </xref>
      ).
     </p>
     <p>
      The diagnostically relevant variations in the neutralization activity have not been detected in several isolates of MERS-CoV. In order to detect the serological response to a specific type of single MERS-CoV serotype, specific protein based sero-assays are essential to be performed (
      <xref ref-type="bibr" rid="B98">
       Muth et al., 2015
      </xref>
      ). The development of potential serological assays demand well delineated human or animal sera and antibodies specific to MERS-CoV (
      <xref ref-type="bibr" rid="B91">
       Meyer et al., 2014
      </xref>
      ).
     </p>
    </sec>
    <sec>
     <title>
      Vaccines and Therapeutics
     </title>
     <p>
      Previous studies revealed that both cellular and humoral responses are required for the complete protection against MERS-CoV infections (
      <xref ref-type="bibr" rid="B51">
       Faure et al., 2014
      </xref>
      ;
      <xref ref-type="bibr" rid="B107">
       Park et al., 2015
      </xref>
      ;
      <xref ref-type="bibr" rid="B33">
       Corman et al., 2016
      </xref>
      ). Nabs and T-cell responses are the main agents in providing protective immunity against coronaviruses. In a study by
      <xref ref-type="bibr" rid="B169">
       Zhao et al. (2014)
      </xref>
      reported that MERS-CoV cleared by mice which lack B-cells while those deficient in T-cells failed to perform similar functions. Further, since virus-specific humoral responses were decreased over time, developing a vaccine which could induce long-lived memory T-cell response considered to be beneficial. However, any vaccine compounds which are able to induce both T and B-cell responses are required for immune protection (
      <xref ref-type="bibr" rid="B103">
       Okba et al., 2017
      </xref>
      ).
     </p>
     <sec>
      <title>
       Current Vaccine and Antiviral Candidates
      </title>
      <p>
       MERS-CoV vaccine candidates are still under development with DNA based, protein based, live attenuated and vectored-virus based vaccines (
       <xref ref-type="bibr" rid="B11">
        Arabi et al., 2017
       </xref>
       ). Out of the four structural proteins and sixteen non structural proteins encoded by the viral genome, S protein showed the highest immunogenicity which induced T-cell responses. In most of the MERS-CoV, Nabs target the RBD of the S protein. The variations in amino acid sequences of the S protein detected amongst MERS-CoV is limited, thus, designing a vaccine against one strain most likely to be protected against all the other circulating strains (
       <xref ref-type="bibr" rid="B103">
        Okba et al., 2017
       </xref>
       ). The S1 protein located outside the RBD probably considered as potential drug target to develop therapeutic strategies against MERS-CoV. RBD-specific mAbs are considered to be displayed greater neutralizing activity than those were targeted the S1 or S2 region outside RBD (
       <xref ref-type="bibr" rid="B47">
        Du et al., 2013
       </xref>
       ).
      </p>
      <p>
       DPP4-targeting therapeutic agents are capable of blocking the interaction between MERS-CoV RBD and DPP4, and therefore inhibit MERS-CoV infection. The anti-DPP4 (CD26) antibodies such as 1F7, 2F9, and YS110 prevent the entry of MERS-CoV into susceptible cells, obstructing the virus infection (
       <xref ref-type="bibr" rid="B102">
        Ohnuma et al., 2013
       </xref>
       ). Additionally, DPP4-binding protein adenosine deaminase (ADA) competes the binding with MERS-CoV RBD to DPP4, specifically at crucial residues such as Q286 and L294, defining their role as a naturally occurring antagonist (
       <xref ref-type="bibr" rid="B117">
        Raj et al., 2014
       </xref>
       ).
      </p>
      <p>
       Recent studies revealed that the DNA vaccines are the safest vaccines for immune-compromised patients. They possessed comparatively greater amounts of DNA (e.g., 0.5–2 mg) thus requires multiple inoculations to induce potent immune responses in rhesus macaques and mice (
       <xref ref-type="bibr" rid="B144">
        Wirblich et al., 2017
       </xref>
       ).
       <xref ref-type="bibr" rid="B25">
        Chi et al. (2017)
       </xref>
       developed a DNA vaccine which encoded the first 725 amino acids of S protein in MERS-CoV which induced the cell mediated and antigen-specific humoral immune responses in mice. Post three immunizations, it was observed that high titers of Nabs (up to 1: 104) were produced without any adjuvant. A prophylactic DNA-plasmid vaccine known as GLS-5300, which encodes for S protein, is the first MERS-CoV vaccine to be considered for the human trials developed by GeneOne Life Inc., which has been enlisted in the on-going list of vaccines by WHO [
       <xref ref-type="bibr" rid="B114">
        Rabaan et al., 2017
       </xref>
       ;
       <xref ref-type="bibr" rid="B157">
        World Health Organization (WHO), 2018b
       </xref>
       ].
      </p>
      <p>
       The vaccines that imitate the natural infection, such as recombinant viral vectors or live-attenuated virus present the antigens in natural ways which further stimulate the activation of humoral and cell-mediated immunity to the native protein conformation. As the live attenuated viruses have been the most immunogenic platforms available, they exhibited the capability to present numerous antigens across the viral life cycle in their native conformations (
       <xref ref-type="bibr" rid="B64">
        Henderson and Moss, 1999
       </xref>
       ).
       <xref ref-type="bibr" rid="B5">
        Agrawal et al. (2016)
       </xref>
       vaccinated the mice with an inactivated MERS-CoV vaccine and which demonstrated hypersensitivity risk factors in MERS-CoV infection. Although there were extensive research in the last few years, limited anti-MERS-CoV therapeutics have been approved for human use. Originally, conventional IFAs were employed in the human sero-surveys and these relied on the MERS-CoV infected cell cultures. These cell cultures were the primary antigen sources for detecting the presence of human anti-MERS-CoV Nabs, IgM, and IgG in human samples (
       <xref ref-type="bibr" rid="B35">
        Corman et al., 2012b
       </xref>
       ). Further, it was reported that human monoclonal antibody m336 demonstrated significant neutralizing properties against MERS-CoV
       <italic>
        in vitro
       </italic>
       conditions (
       <xref ref-type="bibr" rid="B67">
        Houser et al., 2016
       </xref>
       ).
      </p>
      <p>
       Recent studies revealed that there were few antiviral agents in the developmental stage. It was reported that the antiviral drug chlorpromazine demonstrated strong anti-MERS-CoV potential; however, the high cytotoxicity of the drug limiting the potential window for drug utilization. Similarly, another drug Toremifene showed moderate activity when tested in antigen presenting cells, however, the high cytotoxicity of this drug also narrowing its application as a therapeutic remedy against MERS-CoV (
       <xref ref-type="bibr" rid="B31">
        Cong et al., 2018
       </xref>
       ). Further, studies suggested that a nucleoside analog GS-5734 known as Remdesivir, which showed potential antiviral activity against human and zoonotic CoVs
       <italic>
        in vitro
       </italic>
       and the drug inhibited MERS-CoV at 50% effective concentration values (EC50) (
       <xref ref-type="bibr" rid="B3">
        Agostini et al., 2018
       </xref>
       ).
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      Novel Therapeutic Approaches
     </title>
     <p>
      The conserved nature of the N protein was used to develop vaccines that can induce an adaptive immune response against these proteins. In a study by
      <xref ref-type="bibr" rid="B170">
       Zhao et al. (2016)
      </xref>
      reported that a vaccine candidate induced airway memory CD4+ T cell response against N-specific epitopes of MERS-CoV. In another study suggested that vaccination with recombinant N-terminal domain (rNTD) triggered greater T-cell response than the mice vaccinated with rRBD. The neutralizing activity was also observed in the sera (
      <xref ref-type="bibr" rid="B70">
       Jiaming et al., 2017
      </xref>
      ). Recent study revealed that the combination of fusion inhibitory peptide which targets the protein HR1 domain of MERS-CoV S2 and a neutralizing antibody specific for the S1 protein RBD showed synergistic therapeutic activities against MERS-CoV (
      <xref ref-type="bibr" rid="B137">
       Wang et al., 2019
      </xref>
      ). Further, the researchers have developed novel neutralizing nanobodies (Nb) which specifically bind to the RBD of MERS-CoV S protein. The Nb was found to be interacted with the conserved domain of MERS-CoV RBD with high affinity and blocked binding of RBD to the receptor of MERS-CoV (
      <xref ref-type="bibr" rid="B167">
       Zhao et al., 2018
      </xref>
      ).
     </p>
     <p>
      Some immunodominant epitopes within the protein structure may contribute negatively to the neutralization activity of the vaccine. For example, a short region of RBD was able to induce higher titer of IgG when compared to other longer regions (
      <xref ref-type="bibr" rid="B79">
       Ma et al., 2014
      </xref>
      ). The negative effects of these epitopes can be surmounted by immunofocusing; mapping of the most neutralizing RBD fragment and eliminating unnecessary fragments. This can help in focusing the immune response to important epitopes (
      <xref ref-type="bibr" rid="B79">
       Ma et al., 2014
      </xref>
      ).
      <xref ref-type="bibr" rid="B105">
       Pallesen et al. (2017)
      </xref>
      suggested that the structure-based design of S proteins improved their immunogenicity where the high titers of Nabs were observed against MERS-CoV. The major categories of vaccines developed and tested against various animal models are shown in
      <xref ref-type="table" rid="T4">
       Table 4
      </xref>
      .
     </p>
     <table-wrap id="T4" position="float">
      <label>
       Table 4
      </label>
      <caption>
       <p>
        Categories of vaccine developed against MERS-CoV, their potential candidate, and their target long with their immunological response and efficacy.
       </p>
      </caption>
      <table cellpadding="5" cellspacing="5" frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="left" colspan="1" rowspan="1" valign="top">
          Vaccine categories
         </th>
         <th align="left" colspan="1" rowspan="1" valign="top">
          Vaccine candidate
         </th>
         <th align="left" colspan="1" rowspan="1" valign="top">
          Target antigen
         </th>
         <th align="left" colspan="1" rowspan="1" valign="top">
          Animal model
         </th>
         <th align="left" colspan="1" rowspan="1" valign="top">
          Immunological response
         </th>
         <th align="left" colspan="1" rowspan="1" valign="top">
          Efficacy
         </th>
         <th align="left" colspan="1" rowspan="1" valign="top">
          Reference
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Protein based
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          S1
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          S1
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Mice
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Nab
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Not tested
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          <xref ref-type="bibr" rid="B138">
           Wang et al., 2015
          </xref>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          rRBD-Fc
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          S377-588
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Ad/hDPP4-mice
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          T-cell, Nab
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Protective
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          <xref ref-type="bibr" rid="B79">
           Ma et al., 2014
          </xref>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          rNTD
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          S18-353
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Ad/hDPP4-mice
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          T-cell, Nab
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Protective
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          <xref ref-type="bibr" rid="B70">
           Jiaming et al., 2017
          </xref>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Recombinant viral vectors
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          BNSP333-S1
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          S1
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Ad/hDPP4-mice
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Nab
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Protective
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          <xref ref-type="bibr" rid="B144">
           Wirblich et al., 2017
          </xref>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          S377-588-Fc
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          S
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Ad/hDPP4-mice
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          T-cell, Nab
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Not tested
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          <xref ref-type="bibr" rid="B128">
           Tang et al., 2015
          </xref>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          VRP-S
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          S
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          288/330+/+mice
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Nab
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Protective
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          <xref ref-type="bibr" rid="B29">
           Cockrell et al., 2016
          </xref>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          DNA vaccine
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          pcDNA3.1-S1
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          S1
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Ad5/hDPP4-mice
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          T-cell, Nab
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Protective
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          <xref ref-type="bibr" rid="B25">
           Chi et al., 2017
          </xref>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          pVax1-S
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          S
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Non human primates
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          T-cell, Nab
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Protective
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          <xref ref-type="bibr" rid="B99">
           Muthumani et al., 2015
          </xref>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
     <sec>
      <title>
       Therapeutic Screening by Computational Biology
      </title>
      <p>
       The technological progression is reflected upon a series of genome wide molecular screening platforms and computational biology approaches that provided novel insights to prompt response against emerging viral diseases. The prototype of these approaches included the
       <italic>
        in vivo
       </italic>
       animal model, tissue culture model, human challenge model, and vaccine studies. These model systems are anxious by challenges, preferably yielding a spectra of the severity of the diseases like lethal versus sub-lethal in order to increase divergence for downstream data mining and modeling (
       <xref ref-type="bibr" rid="B82">
        McDermott et al., 2011
       </xref>
       ;
       <xref ref-type="bibr" rid="B45">
        Drosten et al., 2013
       </xref>
       ;
       <xref ref-type="bibr" rid="B76">
        Law et al., 2013
       </xref>
       ). A diversity of computational methodologies and network approach were used to detect the regulatory networks of various viral systems by
       <italic>
        de novo
       </italic>
       studies (
       <xref ref-type="bibr" rid="B65">
        Hou and Zhao, 2013
       </xref>
       ;
       <xref ref-type="bibr" rid="B94">
        Mitchell et al., 2013
       </xref>
       ).
      </p>
      <p>
       Recently, studies have shown that peptides can be utilized as highly potent signal transduction agents for various viral infections. It has been suggested that antimicrobial peptides (AMPs) can be used as potential therapeutic option against MERS-CoV infections (
       <xref ref-type="bibr" rid="B97">
        Mustafa et al., 2018
       </xref>
       ). Computational biology approach in combination with virology can be employed to design novel peptide based therapeutics against various strains of MERS-CoV with high efficacy. Recent studies have suggested that repurposing of existing and clinically approved anti-viral peptides can be used as promising lead molecules for the development of novel anti-MERS-CoV agents (
       <xref ref-type="bibr" rid="B97">
        Mustafa et al., 2018
       </xref>
       ).
      </p>
      <p>
       The RBD and S protein based vector vaccines are considered to be one of the efficient targets for designing MERS-CoV vaccine, as it comprised of multiple neutralizing epitopes which offer higher potential to prompt Nabs against the virus (
       <xref ref-type="bibr" rid="B122">
        Shi et al., 2015
       </xref>
       ). The vast developments in computational biology have led to the new line of immunoinformatics databases and tools, which are other operative ways for vaccine development (
       <xref ref-type="bibr" rid="B131">
        Terry et al., 2015
       </xref>
       ). The screening of dominant immunogens based on the availability of genome sequence data is crucial for designing novel vaccines, which is assisted by immunoinformatics (
       <xref ref-type="bibr" rid="B52">
        Firbas et al., 2006
       </xref>
       ). The epitope directed lead design was one of the critical steps involved in the lead identification by immunoinformatics approaches (
       <xref ref-type="bibr" rid="B122">
        Shi et al., 2015
       </xref>
       ). MHC-I restrained CD8+ cytotoxic T-lymphocytes (CTLs) identification provides profound insight in designing novel antiviral agents (
       <xref ref-type="bibr" rid="B131">
        Terry et al., 2015
       </xref>
       ).
      </p>
      <p>
       In conclusion, MERS-CoV infection continued to be fatal disease and has emerged as one of the epidemic concern. Irrespective of the various studies conducted to determine the distribution, the exact intermediates remain unidentified. There are various animal models available which provided profound insight in understanding the transmission and pathogenecity of the virus in human. The common pathogenesis mechanisms of the virus such as DPP4, PLpro, accessory proteins like p4a and membrane M protein provided significant insight for the screening of novel drug targets for vaccine development. The detailed understanding of the binding mechanism of various inhibitors toward the structural, non-structural, and accessory proteins of the virus probably provide profound insight for lead development. The integration of genome analysis, proteomics studies, immunoinformatics, and systems biology approaches on various animal models have made the recognition of new targets and lead molecules much easier in than the approaches available during earlier time. By considering MERS-CoV infections as one of the great public threats, there is high demand for undertaking the coronavirus research at the deeper molecular level to understand the mechanism of viral infection, development of advanced and rapid detection methods and futuristic therapeutic strategies to combat MERS-CoV infections.
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      Author Contributions
     </title>
     <p>
      SS, SC, SP, SK, and VS collected data and prepared the complete manuscript. Further, SS reviewed, revised, and edited the manuscript.
     </p>
    </sec>
    <sec>
     <title>
      Conflict of Interest Statement
     </title>
     <p>
      The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
     </p>
    </sec>
    <back>
     <ref-list>
      <title>
       References
      </title>
      <ref id="B1">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Abd
          </surname>
          <given-names>
           E. W. A.
          </given-names>
         </name>
         <name>
          <surname>
           Patel
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Heidenreich
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Hufert
          </surname>
          <given-names>
           F. T.
          </given-names>
         </name>
         <name>
          <surname>
           Weidmann
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013
        </year>
        ).
        <article-title>
         Reverse transcription recombinase polymerase amplification assay for the detection of Middle East respiratory syndrome coronavirus.
        </article-title>
        <source>
         <italic>
          PLoS Curr.
         </italic>
        </source>
        <volume>
         5
        </volume>
        :
        <issue>
         ecurrents.outbreaks.62df1c7c75ffc96cd59034531e2e8364
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1371/currents.outbreaks.62df1c7c75ffc96cd59034531e2e8364
        </pub-id>
        <pub-id pub-id-type="pmid">
         24459611
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B2">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Aderem
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Adkins
          </surname>
          <given-names>
           J. N.
          </given-names>
         </name>
         <name>
          <surname>
           Ansong
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Galagan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Kaiser
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Korth
          </surname>
          <given-names>
           M. J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2011
        </year>
        ).
        <article-title>
         A systems biology approach to infectious disease research: innovating the pathogen-host research paradigm.
        </article-title>
        <source>
         <italic>
          mBio
         </italic>
        </source>
        <volume>
         2
        </volume>
        :
        <issue>
         e00325
        </issue>
        –
        <issue>
         10
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1128/mBio.00325-10e00325-10
        </pub-id>
        <comment>
         PMID:21285433
        </comment>
        <pub-id pub-id-type="pmid">
         21285433
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B3">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Agostini
          </surname>
          <given-names>
           M. L.
          </given-names>
         </name>
         <name>
          <surname>
           Andres
          </surname>
          <given-names>
           E. L.
          </given-names>
         </name>
         <name>
          <surname>
           Sims
          </surname>
          <given-names>
           A. C.
          </given-names>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           R. L.
          </given-names>
         </name>
         <name>
          <surname>
           Sheahan
          </surname>
          <given-names>
           T. P.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2018
        </year>
        ).
        <article-title>
         Coronavirus susceptibility to the antiviral Remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease.
        </article-title>
        <source>
         <italic>
          mBio
         </italic>
        </source>
        <volume>
         9
        </volume>
        :
        <issue>
         e00221
        </issue>
        –
        <issue>
         18
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1128/mBio.00221-18e00221-18
        </pub-id>
        <pub-id pub-id-type="pmid">
         29511076
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B4">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Agrawal
          </surname>
          <given-names>
           A. S.
          </given-names>
         </name>
         <name>
          <surname>
           Garron
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           B. H.
          </given-names>
         </name>
         <name>
          <surname>
           Wakamiya
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           T. S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2015
        </year>
        ).
        <article-title>
         Generation of a transgenic mouse model of middle east respiratory syndrome coronavirus infection and disease.
        </article-title>
        <source>
         <italic>
          J. Virol.
         </italic>
        </source>
        <volume>
         89
        </volume>
        <fpage>
         3659
        </fpage>
        –
        <lpage>
         3670
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.03427-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         25589660
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B5">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Agrawal
          </surname>
          <given-names>
           A. S.
          </given-names>
         </name>
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Algaissi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Garron
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Narayanan
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           B. H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2016
        </year>
        ).
        <article-title>
         Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus.
        </article-title>
        <source>
         <italic>
          Hum. Vaccin. Immunother.
         </italic>
        </source>
        <volume>
         12
        </volume>
        <fpage>
         2351
        </fpage>
        –
        <lpage>
         2356
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1080/21645515.2016.1177688
        </pub-id>
        <pub-id pub-id-type="pmid">
         27269431
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B6">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Albarrak
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Stephens
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Hewson
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2012
        </year>
        ).
        <article-title>
         Recovery from severe novel coronavirus infection.
        </article-title>
        <source>
         <italic>
          Saudi Med. J.
         </italic>
        </source>
        <volume>
         33
        </volume>
        <fpage>
         1265
        </fpage>
        –
        <lpage>
         1269
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23232672
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B7">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Qahtani
          </surname>
          <given-names>
           A. A.
          </given-names>
         </name>
         <name>
          <surname>
           Lyroni
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Aznaourova
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Tseliou
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Anazi
          </surname>
          <given-names>
           M. R.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Ahdal
          </surname>
          <given-names>
           M. N.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2017
        </year>
        ).
        <article-title>
         Middle east respiratory syndrome corona virus spike glycoprotein suppresses macrophage responses via DPP4-mediated induction of IRAK-M and PPARγ.
        </article-title>
        <source>
         <italic>
          Oncotarget
         </italic>
        </source>
        <volume>
         8
        </volume>
        <fpage>
         9053
        </fpage>
        –
        <lpage>
         9066
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.18632/oncotarget.14754
        </pub-id>
        <pub-id pub-id-type="pmid">
         28118607
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B8">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alsaad
          </surname>
          <given-names>
           K. O.
          </given-names>
         </name>
         <name>
          <surname>
           Hajeer
          </surname>
          <given-names>
           A. H.
          </given-names>
         </name>
         <name>
          <surname>
           Al Balwi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Al Moaiqel
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Al Oudah
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Al Ajlan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2018
        </year>
        ).
        <article-title>
         Histopathology of Middle East respiratory syndrome corona virus (MERS-CoV) infection - clinicopathological and ultrastructural study.
        </article-title>
        <source>
         <italic>
          Histopathology
         </italic>
        </source>
        <volume>
         72
        </volume>
        <fpage>
         516
        </fpage>
        –
        <lpage>
         524
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1111/his.13379
        </pub-id>
        <pub-id pub-id-type="pmid">
         28858401
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B9">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alshukairi
          </surname>
          <given-names>
           A. N.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Nehdi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Baharoon
          </surname>
          <given-names>
           S. A.
          </given-names>
         </name>
         <name>
          <surname>
           Layqah
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2018
        </year>
        ).
        <article-title>
         High prevalence of MERS-CoV infection in camel workers in Saudi Arabia.
        </article-title>
        <source>
         <italic>
          mBio
         </italic>
        </source>
        <volume>
         9
        </volume>
        :
        <issue>
         e01985
        </issue>
        –
        <issue>
         18
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1128/mBio.01985-18e01985-18
        </pub-id>
        <pub-id pub-id-type="pmid">
         30377284
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B10">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J. A.
          </given-names>
         </name>
         <name>
          <surname>
           Momattin
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Dib
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z. A.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        ).
        <article-title>
         Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study.
        </article-title>
        <source>
         <italic>
          Int. J. Infect. Dis.
         </italic>
        </source>
        <volume>
         20
        </volume>
        <fpage>
         42
        </fpage>
        –
        <lpage>
         46
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.ijid.2013.12.003
        </pub-id>
        <pub-id pub-id-type="pmid">
         24406736
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B11">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arabi
          </surname>
          <given-names>
           Y. M.
          </given-names>
         </name>
         <name>
          <surname>
           Balkhy
          </surname>
          <given-names>
           H. H.
          </given-names>
         </name>
         <name>
          <surname>
           Hayden
          </surname>
          <given-names>
           F. G.
          </given-names>
         </name>
         <name>
          <surname>
           Bouchama
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Luke
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Baillie
          </surname>
          <given-names>
           J. K.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2017
        </year>
        ).
        <article-title>
         Middle East Respiratory Syndrome.
        </article-title>
        <source>
         <italic>
          N. Engl. J. Med.
         </italic>
        </source>
        <volume>
         376
        </volume>
        <fpage>
         584
        </fpage>
        –
        <lpage>
         594
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1056/NEJMsr1408795
        </pub-id>
        <pub-id pub-id-type="pmid">
         28177862
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B12">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Rabeeah
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013a
        </year>
        ).
        <article-title>
         Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome corona virus disease from Saudi Arabia: a descriptive study.
        </article-title>
        <source>
         <italic>
          Lancet Infect. Dis.
         </italic>
        </source>
        <volume>
         13
        </volume>
        <fpage>
         752
        </fpage>
        –
        <lpage>
         761
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(13)70204-4
        </pub-id>
        <pub-id pub-id-type="pmid">
         23891402
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B13">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           McGeer
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Perl
          </surname>
          <given-names>
           T. M.
          </given-names>
         </name>
         <name>
          <surname>
           Price
          </surname>
          <given-names>
           C. S.
          </given-names>
         </name>
         <name>
          <surname>
           Al Rabeeah
          </surname>
          <given-names>
           A. A.
          </given-names>
         </name>
         <name>
          <surname>
           Cummings
          </surname>
          <given-names>
           D. A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2013b
        </year>
        ).
        <article-title>
         KSA MERS-CoV investigation team. hospital outbreak of middle east respiratory syndrome coronavirus.
        </article-title>
        <source>
         <italic>
          N. Engl. J. Med.
         </italic>
        </source>
        <volume>
         369
        </volume>
        :
        <issue>
         886
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1306742
        </pub-id>
        <pub-id pub-id-type="pmid">
         23782161
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B14">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Baseler
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2016
        </year>
        ).
        <article-title>
         A comparative review of animal models of middle east respiratory syndrome coronavirus infection.
        </article-title>
        <source>
         <italic>
          Vet. Pathol.
         </italic>
        </source>
        <volume>
         53
        </volume>
        <fpage>
         521
        </fpage>
        –
        <lpage>
         531
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1177/0300985815620845
        </pub-id>
        <pub-id pub-id-type="pmid">
         26869154
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B15">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Batool
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Shah
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Patra
          </surname>
          <given-names>
           M. C.
          </given-names>
         </name>
         <name>
          <surname>
           Yesudhas
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2017
        </year>
        ).
        <article-title>
         Structural insights into the Middle East respiratory syndrome coronavirus 4a protein and its dsRNA binding mechanism.
        </article-title>
        <source>
         <italic>
          Sci. Rep.
         </italic>
        </source>
        <volume>
         7
        </volume>
        :
        <issue>
         11362
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1038/s41598-017-11736-6
        </pub-id>
        <pub-id pub-id-type="pmid">
         28900197
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B16">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bauch
          </surname>
          <given-names>
           C. T.
          </given-names>
         </name>
         <name>
          <surname>
           Oraby
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013
        </year>
        ).
        <article-title>
         Assessing the pandemic potential of MERS-CoV.
        </article-title>
        <source>
         <italic>
          Lancet
         </italic>
        </source>
        <volume>
         382
        </volume>
        <fpage>
         662
        </fpage>
        –
        <lpage>
         664
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(13)61504-4
        </pub-id>
        <pub-id pub-id-type="pmid">
         23831143
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B17">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Breban
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Riou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Fontanet
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013
        </year>
        ).
        <article-title>
         Inter-human transmissibility of Middle East respiratory syndrome corona virus: estimation of pandemic risk.
        </article-title>
        <source>
         <italic>
          Lancet
         </italic>
        </source>
        <volume>
         382
        </volume>
        <fpage>
         694
        </fpage>
        –
        <lpage>
         699
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(13)61492-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         23831141
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B18">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Buchholz
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Nitsche
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Sanewski
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Wevering
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Bauer-Balci
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2013
        </year>
        ).
        <article-title>
         Contact investigation of a case of human novel corona virus infection treated in a German hospital, October-November 2012.
        </article-title>
        <source>
         <italic>
          Euro. Surveill
         </italic>
        </source>
        <volume>
         18
        </volume>
        :
        <issue>
         20406
        </issue>
        .
       </mixed-citation>
      </ref>
      <ref id="B19">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Canton
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Fehr
          </surname>
          <given-names>
           A. R.
          </given-names>
         </name>
         <name>
          <surname>
           Fernandez-Delgado
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Gutierrez-Alvarez
          </surname>
          <given-names>
           F. J.
          </given-names>
         </name>
         <name>
          <surname>
           Sanchez-Aparicio
          </surname>
          <given-names>
           M. T.
          </given-names>
         </name>
         <name>
          <surname>
           García-Sastre
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2018
        </year>
        ).
        <article-title>
         MERS-CoV 4b protein interferes with the NF-κB-dependent innate immune response during infection.
        </article-title>
        <source>
         <italic>
          PLoS Pathog.
         </italic>
        </source>
        <volume>
         14
        </volume>
        :
        <issue>
         e1006838
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1006838
        </pub-id>
        <pub-id pub-id-type="pmid">
         29370303
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B20">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cauchemez
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Fraser
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Van
          </surname>
          <given-names>
           K. M. D.
          </given-names>
         </name>
         <name>
          <surname>
           Donnelly
          </surname>
          <given-names>
           C. A.
          </given-names>
         </name>
         <name>
          <surname>
           Riley
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rambaut
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        ).
        <article-title>
         Middle East respiratory syndrome corona virus: quantification of the extent of the epidemic, surveillance biases, and transmissibility.
        </article-title>
        <source>
         <italic>
          Lancet Infect. Dis.
         </italic>
        </source>
        <volume>
         14
        </volume>
        <fpage>
         50
        </fpage>
        –
        <lpage>
         56
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(13)70304-9
        </pub-id>
        <pub-id pub-id-type="pmid">
         24239323
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B21">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chafekar
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Fielding
          </surname>
          <given-names>
           B. C.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2018
        </year>
        ).
        <article-title>
         MERS-CoV: Understanding the latest human Corona virus threat.
        </article-title>
        <source>
         <italic>
          Viruses
         </italic>
        </source>
        <volume>
         10
        </volume>
        :
        <issue>
         E93
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.3390/v10020093
        </pub-id>
        <pub-id pub-id-type="pmid">
         29495250
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B22">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J. F.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K. H.
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           G. K.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K. K.
          </given-names>
         </name>
         <name>
          <surname>
           Tse
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           J. P.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2013a
        </year>
        ).
        <article-title>
         Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation.
        </article-title>
        <source>
         <italic>
          J. Infect. Dis.
         </italic>
        </source>
        <volume>
         207
        </volume>
        <fpage>
         1743
        </fpage>
        –
        <lpage>
         1752
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1093/infdis/jit123
        </pub-id>
        <pub-id pub-id-type="pmid">
         23532101
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B23">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J. F.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S. K.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P. C.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013b
        </year>
        ).
        <article-title>
         The emerging novel Middle East respiratory syndrome corona virus: the ‘knowns’ and ‘unknowns’.
        </article-title>
        <source>
         <italic>
          J. Formos. Med. Assoc.
         </italic>
        </source>
        <volume>
         112
        </volume>
        <fpage>
         372
        </fpage>
        –
        <lpage>
         381
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.jfma.2013.05.010
        </pub-id>
        <pub-id pub-id-type="pmid">
         23883791
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B24">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J. F.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K. S.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K. K.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V. C.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K. Y.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2012
        </year>
        ).
        <article-title>
         Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic?
        </article-title>
        <source>
         <italic>
          J. Infect.
         </italic>
        </source>
        <volume>
         65
        </volume>
        <fpage>
         477
        </fpage>
        –
        <lpage>
         489
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.jinf.2012.10.002
        </pub-id>
        <pub-id pub-id-type="pmid">
         23072791
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B25">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Gai
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2017
        </year>
        ).
        <article-title>
         DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice.
        </article-title>
        <source>
         <italic>
          Vaccine
         </italic>
        </source>
        <volume>
         35
        </volume>
        <fpage>
         2069
        </fpage>
        –
        <lpage>
         2075
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2017.02.063
        </pub-id>
        <pub-id pub-id-type="pmid">
         28314561
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B26">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chowell
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Nishiura
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        ).
        <article-title>
         Transmission dynamics and control of Ebola virus disease (EVD): a review.
        </article-title>
        <source>
         <italic>
          BMC Med.
         </italic>
        </source>
        <volume>
         12
        </volume>
        :
        <issue>
         196
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1186/s12916-014-0196-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         25300956
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B27">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B. H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J. F.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Z. S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2016
        </year>
        ).
        <article-title>
         Middle east respiratory syndrome coronavirus efficiently infects human primary T lymphocytes and activates the extrinsic and intrinsic apoptosis pathways.
        </article-title>
        <source>
         <italic>
          J. Infect. Dis.
         </italic>
        </source>
        <volume>
         213
        </volume>
        <fpage>
         904
        </fpage>
        –
        <lpage>
         914
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1093/infdis/jiv380
        </pub-id>
        <pub-id pub-id-type="pmid">
         26203058
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B28">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Clasman
          </surname>
          <given-names>
           J. R.
          </given-names>
         </name>
         <name>
          <surname>
           Báez-Santos
          </surname>
          <given-names>
           Y. M.
          </given-names>
         </name>
         <name>
          <surname>
           Mettelman
          </surname>
          <given-names>
           R. C.
          </given-names>
         </name>
         <name>
          <surname>
           O’Brien
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Baker
          </surname>
          <given-names>
           S. C.
          </given-names>
         </name>
         <name>
          <surname>
           Mesecar
          </surname>
          <given-names>
           A. D.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2017
        </year>
        ).
        <article-title>
         X-ray structure and enzymatic activity profile of a core papain-like protease of MERS coronavirus with utility for structure-based drug design.
        </article-title>
        <source>
         <italic>
          Sci. Rep.
         </italic>
        </source>
        <volume>
         7
        </volume>
        :
        <issue>
         40292
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1038/srep40292
        </pub-id>
        <pub-id pub-id-type="pmid">
         28079137
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B29">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cockrell
          </surname>
          <given-names>
           A. S.
          </given-names>
         </name>
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B. L.
          </given-names>
         </name>
         <name>
          <surname>
           Scobey
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Jensen
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Douglas
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Beall
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2016
        </year>
        ).
        <article-title>
         A mouse model for MERS coronavirus-induced acute respiratory distress syndrome.
        </article-title>
        <source>
         <italic>
          Nat. Microbiol.
         </italic>
        </source>
        <volume>
         2
        </volume>
        :
        <issue>
         16226
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1038/nmicrobiol.2016.226
        </pub-id>
        <pub-id pub-id-type="pmid">
         27892925
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B30">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Coleman
          </surname>
          <given-names>
           C. M.
          </given-names>
         </name>
         <name>
          <surname>
           Sisk
          </surname>
          <given-names>
           J. M.
          </given-names>
         </name>
         <name>
          <surname>
           Halasz
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Beck
          </surname>
          <given-names>
           S. E.
          </given-names>
         </name>
         <name>
          <surname>
           Matthews
          </surname>
          <given-names>
           K. J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2017
        </year>
        ).
        <article-title>
         CD8+ T Cells and macrophages regulate pathogenesis in a mouse model of middle east respiratory syndrome.
        </article-title>
        <source>
         <italic>
          J. Virol.
         </italic>
        </source>
        <volume>
         91
        </volume>
        :
        <issue>
         e01825
        </issue>
        –
        <issue>
         16
        </issue>
        .
        <pub-id pub-id-type="pmid">
         27795435
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B31">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cong
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hart
          </surname>
          <given-names>
           B. J.
          </given-names>
         </name>
         <name>
          <surname>
           Gross
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Bollinger
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2018
        </year>
        ).
        <article-title>
         MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells.
        </article-title>
        <source>
         <italic>
          PLoS One
         </italic>
        </source>
        <volume>
         13
        </volume>
        :
        <issue>
         e0194868
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0194868
        </pub-id>
        <pub-id pub-id-type="pmid">
         29566060
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B32">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Conzade
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Grant
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Malik
          </surname>
          <given-names>
           M. R.
          </given-names>
         </name>
         <name>
          <surname>
           Elkholy
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Elhakim
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Samhouri
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2018
        </year>
        ).
        <article-title>
         Reported direct and indirect contact with dromedary camels among laboratory-confirmed MERS-CoV cases.
        </article-title>
        <source>
         <italic>
          Viruses
         </italic>
        </source>
        <volume>
         10
        </volume>
        :
        <issue>
         E425
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.3390/v10080425
        </pub-id>
        <pub-id pub-id-type="pmid">
         30104551
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B33">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V. M.
          </given-names>
         </name>
         <name>
          <surname>
           Albarrak
          </surname>
          <given-names>
           A. M.
          </given-names>
         </name>
         <name>
          <surname>
           Omrani
          </surname>
          <given-names>
           A. S.
          </given-names>
         </name>
         <name>
          <surname>
           Albarrak
          </surname>
          <given-names>
           M. M.
          </given-names>
         </name>
         <name>
          <surname>
           Farah
          </surname>
          <given-names>
           M. E.
          </given-names>
         </name>
         <name>
          <surname>
           Almasri
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2016
        </year>
        ).
        <article-title>
         Viral shedding and antibody response in 37 patients with Middle East Respiratory Syndrome Coronavirus infection.
        </article-title>
        <source>
         <italic>
          Clin. Infect. Dis.
         </italic>
        </source>
        <volume>
         62
        </volume>
        <fpage>
         477
        </fpage>
        –
        <lpage>
         483
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1093/cid/civ951
        </pub-id>
        <pub-id pub-id-type="pmid">
         26565003
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B34">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V. M.
          </given-names>
         </name>
         <name>
          <surname>
           Eckerle
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Bleicker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Landt
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Eschbach-Bludau
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2012a
        </year>
        ).
        <article-title>
         Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction.
        </article-title>
        <source>
         <italic>
          Euro. Surveill.
         </italic>
        </source>
        <volume>
         17
        </volume>
        :
        <issue>
         20285
        </issue>
        <pub-id pub-id-type="doi">
         10.2807/ese.17.39.20285-en
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B35">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V. M.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M. A.
          </given-names>
         </name>
         <name>
          <surname>
           Costabel
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Timm
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Binger
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2012b
        </year>
        ).
        <article-title>
         Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections.
        </article-title>
        <source>
         <italic>
          Euro. Surveill.
         </italic>
        </source>
        <volume>
         17
        </volume>
        :
        <issue>
         1
        </issue>
        .
        <pub-id pub-id-type="pmid">
         23231891
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B36">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Groot
          </surname>
          <given-names>
           R. J.
          </given-names>
         </name>
         <name>
          <surname>
           Baker
          </surname>
          <given-names>
           S. C.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R. S.
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           C. S.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2013
        </year>
        ).
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group.
        </article-title>
        <source>
         <italic>
          J. Virol.
         </italic>
        </source>
        <volume>
         87
        </volume>
        <fpage>
         7790
        </fpage>
        –
        <lpage>
         7792
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.01244-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         23678167
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B37">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Sousa
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Koopmans
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        ).
        <article-title>
         MERS corona virus: Data gaps for laboratory preparedness.
        </article-title>
        <source>
         <italic>
          J. Clin. Virol.
         </italic>
        </source>
        <volume>
         59
        </volume>
        <fpage>
         4
        </fpage>
        –
        <lpage>
         11
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.jcv.2013.10.030
        </pub-id>
        <pub-id pub-id-type="pmid">
         24286807
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B38">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Prescott
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Baseler
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Lackemeyer
          </surname>
          <given-names>
           M. G.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2013a
        </year>
        ).
        <article-title>
         The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters.
        </article-title>
        <source>
         <italic>
          PLoS One
         </italic>
        </source>
        <volume>
         8
        </volume>
        :
        <issue>
         e69127
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0069127
        </pub-id>
        <pub-id pub-id-type="pmid">
         23844250
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B39">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Rasmussen
          </surname>
          <given-names>
           A. L.
          </given-names>
         </name>
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Brining
          </surname>
          <given-names>
           D. L.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013b
        </year>
        ).
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques.
        </article-title>
        <source>
         <italic>
          Proc. Natl. Acad. Sci. U.S.A.
         </italic>
        </source>
        <volume>
         110
        </volume>
        <fpage>
         16598
        </fpage>
        –
        <lpage>
         16603
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1073/pnas.1310744110
        </pub-id>
        <pub-id pub-id-type="pmid">
         24062443
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B40">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Denayer
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <person-group person-group-type="author">
         <name>
          <surname>
           Roy
          </surname>
          <given-names>
           M. V.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        ).
        <article-title>
         Animal models in translational medicine: Validation and prediction.
        </article-title>
        <source>
         <italic>
          New Horiz. Transl. Med.
         </italic>
        </source>
        <volume>
         2
        </volume>
        <fpage>
         5
        </fpage>
        –
        <lpage>
         11
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.nhtm.2014.08.001
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B41">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Doremalen
          </surname>
          <given-names>
           N. V.
          </given-names>
         </name>
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V. J.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        ).
        <article-title>
         Animal models of middle east respiratory syndrome coronavirus infection.
        </article-title>
        <source>
         <italic>
          Antiviral Res.
         </italic>
        </source>
        <volume>
         22
        </volume>
        <fpage>
         28
        </fpage>
        –
        <lpage>
         38
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2015.07.005
        </pub-id>
        <pub-id pub-id-type="pmid">
         26192750
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B42">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013
        </year>
        ).
        <article-title>
         Is MERS another SARS?
        </article-title>
        <source>
         <italic>
          Lancet Infect. Dis.
         </italic>
        </source>
        <volume>
         13
        </volume>
        <fpage>
         727
        </fpage>
        –
        <lpage>
         728
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23891403
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B43">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Günther
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Preiser
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           van der Werf
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Brodt
          </surname>
          <given-names>
           H. R.
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2003
        </year>
        ).
        <article-title>
         Identification of a novel coronavirus in patients with severe acute respiratory syndrome.
        </article-title>
        <source>
         <italic>
          N. Engl. J. Med.
         </italic>
        </source>
        <volume>
         348
        </volume>
        <fpage>
         1967
        </fpage>
        –
        <lpage>
         1976
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa030747
        </pub-id>
        <pub-id pub-id-type="pmid">
         12690091
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B44">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           M. A.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V. M.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Masri
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hossain
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2014
        </year>
        ).
        <article-title>
         Transmission of MERS-coronavirus in household contacts.
        </article-title>
        <source>
         <italic>
          N Engl J Med.
         </italic>
        </source>
        <volume>
         371
        </volume>
        <fpage>
         828
        </fpage>
        –
        <lpage>
         835
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1405858
        </pub-id>
        <pub-id pub-id-type="pmid">
         25162889
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B45">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Seilmaier
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013
        </year>
        ).
        <article-title>
         Clinical features and virological analysis of a case of Middle East respiratory syndrome corona virus infection.
        </article-title>
        <source>
         <italic>
          Lancet Infect. Dis.
         </italic>
        </source>
        <volume>
         13
        </volume>
        <fpage>
         745
        </fpage>
        –
        <lpage>
         751
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(13)70154-3
        </pub-id>
        <pub-id pub-id-type="pmid">
         23782859
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B46">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B. J.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2009
        </year>
        ).
        <article-title>
         The spike protein of SARS-CoV–a target for vaccine and therapeutic development.
        </article-title>
        <source>
         <italic>
          Nat. Rev. Microbiol.
         </italic>
        </source>
        <volume>
         7
        </volume>
        <fpage>
         226
        </fpage>
        –
        <lpage>
         236
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1038/nrmicro2090
        </pub-id>
        <pub-id pub-id-type="pmid">
         19198616
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B47">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Kou
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           V. K.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013
        </year>
        ).
        <article-title>
         Identification of a receptor-binding domain in the S protein of the novel human corona virus Middle East respiratory syndrome corona virus as an essential target for vaccine development.
        </article-title>
        <source>
         <italic>
          J. Virol.
         </italic>
        </source>
        <volume>
         87
        </volume>
        <fpage>
         9939
        </fpage>
        –
        <lpage>
         9942
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.01048-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         23824801
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B48">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Durai
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Batool
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Shah
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        ).
        <article-title>
         Middle East respiratory syndrome corona virus: transmission, virology and therapeutic targeting to aid in outbreak control.
        </article-title>
        <source>
         <italic>
          Exp. Mol. Med.
         </italic>
        </source>
        <volume>
         47
        </volume>
        :
        <issue>
         e181
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1038/emm.2015.76
        </pub-id>
        <pub-id pub-id-type="pmid">
         26315600
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B49">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eckerle
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V. M.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M. A.
          </given-names>
         </name>
         <name>
          <surname>
           Lenk
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Ulrich
          </surname>
          <given-names>
           R. G.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        ).
        <article-title>
         Replicative capacity of MERS coronavirus in livestock cell lines.
        </article-title>
        <source>
         <italic>
          Emerg. Infect. Dis.
         </italic>
        </source>
        <volume>
         20
        </volume>
        <fpage>
         276
        </fpage>
        –
        <lpage>
         279
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.3201/eid2002.131182
        </pub-id>
        <pub-id pub-id-type="pmid">
         24457147
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B50">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Rasmussen
          </surname>
          <given-names>
           A. L.
          </given-names>
         </name>
         <name>
          <surname>
           Okumura
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        ).
        <article-title>
         Infection with MERS-CoV causes lethal pneumonia in the common marmoset.
        </article-title>
        <source>
         <italic>
          PLoS Pathog.
         </italic>
        </source>
        <volume>
         10
        </volume>
        :
        <issue>
         e1004250
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1004250
        </pub-id>
        <pub-id pub-id-type="pmid">
         25144235
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B51">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Faure
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Poissy
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Goffard
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Fournier
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Kipnis
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Titecat
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2014
        </year>
        ).
        <article-title>
         Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?
        </article-title>
        <source>
         <italic>
          PLoS One
         </italic>
        </source>
        <volume>
         9
        </volume>
        :
        <issue>
         e88716
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0088716
        </pub-id>
        <pub-id pub-id-type="pmid">
         24551142
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B52">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Firbas
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Jilma
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Tauber
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Buerger
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Jelovcan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lingnau
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2006
        </year>
        ).
        <article-title>
         Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects.
        </article-title>
        <source>
         <italic>
          Vaccine
         </italic>
        </source>
        <volume>
         24
        </volume>
        <fpage>
         4343
        </fpage>
        –
        <lpage>
         4353
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2006.03.009
        </pub-id>
        <pub-id pub-id-type="pmid">
         16581161
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B53">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Forni
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Giulia
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Rachele
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Gioia
          </surname>
          <given-names>
           D. L.
          </given-names>
         </name>
         <name>
          <surname>
           Pozzoli
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Daghri
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        ).
        <article-title>
         The heptad repeat region is a major selection target in MERS-CoV and related corona viruses.
        </article-title>
        <source>
         <italic>
          Sci. Rep.
         </italic>
        </source>
        <volume>
         25
        </volume>
        :
        <issue>
         14480
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1038/srep14480
        </pub-id>
        <pub-id pub-id-type="pmid">
         26404138
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B54">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R. A.
          </given-names>
         </name>
         <name>
          <surname>
           Schneeberger
          </surname>
          <given-names>
           P. M.
          </given-names>
         </name>
         <name>
          <surname>
           Rozendaal
          </surname>
          <given-names>
           F. W.
          </given-names>
         </name>
         <name>
          <surname>
           Broekman
          </surname>
          <given-names>
           J. M.
          </given-names>
         </name>
         <name>
          <surname>
           Kemink
          </surname>
          <given-names>
           S. A.
          </given-names>
         </name>
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2004
        </year>
        ).
        <article-title>
         Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome.
        </article-title>
        <source>
         <italic>
          Proc. Natl. Acad. Sci. U.S.A.
         </italic>
        </source>
        <volume>
         101
        </volume>
        <fpage>
         1356
        </fpage>
        –
        <lpage>
         1361
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1073/pnas.0308352100
        </pub-id>
        <pub-id pub-id-type="pmid">
         14745020
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B55">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fung
          </surname>
          <given-names>
           T. S.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           D. X.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        ).
        <article-title>
         Corona virus infection, ER stresses apoptosis and innate immunity.
        </article-title>
        <source>
         <italic>
          Front. Microbiol.
         </italic>
        </source>
        <volume>
         5
        </volume>
        :
        <issue>
         296
        </issue>
        <pub-id pub-id-type="doi">
         10.3389/fmicb.2014.00296
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B56">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2016
        </year>
        ).
        <article-title>
         From SARS to MERS: evidence and speculation.
        </article-title>
        <source>
         <italic>
          Front Med.
         </italic>
        </source>
        <volume>
         10
        </volume>
        <fpage>
         377
        </fpage>
        –
        <lpage>
         382
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1007/s11684-016-0466-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         27726088
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B57">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gorbalenya
          </surname>
          <given-names>
           A. E.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Ziebuhr
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           E. J.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2006
        </year>
        ).
        <article-title>
         Nidovirales: evolving the largest RNA virus genome.
        </article-title>
        <source>
         <italic>
          Virus Res.
         </italic>
        </source>
        <volume>
         117
        </volume>
        <fpage>
         17
        </fpage>
        –
        <lpage>
         37
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2006.01.017
        </pub-id>
        <pub-id pub-id-type="pmid">
         16503362
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B58">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guery
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Poissy
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           el Mansouf
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013
        </year>
        ).
        <article-title>
         Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome corona virus: a report of nosocomial transmission.
        </article-title>
        <source>
         <italic>
          Lancet
         </italic>
        </source>
        <volume>
         381
        </volume>
        <fpage>
         2265
        </fpage>
        –
        <lpage>
         2272
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(13)60982-4
        </pub-id>
        <pub-id pub-id-type="pmid">
         23727167
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B59">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B. L.
          </given-names>
         </name>
         <name>
          <surname>
           van den Branda
          </surname>
          <given-names>
           J. M. A.
          </given-names>
         </name>
         <name>
          <surname>
           Provaciaa
          </surname>
          <given-names>
           L. B.
          </given-names>
         </name>
         <name>
          <surname>
           Raja
          </surname>
          <given-names>
           V. S.
          </given-names>
         </name>
         <name>
          <surname>
           Stittelaarb
          </surname>
          <given-names>
           K. J.
          </given-names>
         </name>
         <name>
          <surname>
           Getua
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2015
        </year>
        ).
        <article-title>
         Asymptomatic middle east respiratory syndrome coronavirus infection in rabbits.
        </article-title>
        <source>
         <italic>
          J. Virol.
         </italic>
        </source>
        <volume>
         89
        </volume>
        <fpage>
         6131
        </fpage>
        –
        <lpage>
         6135
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.00661-15
        </pub-id>
        <pub-id pub-id-type="pmid">
         25810539
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B60">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hamre
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Procknow
          </surname>
          <given-names>
           J. J.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1966
        </year>
        ).
        <article-title>
         A new virus isolated from the human respiratory tract.
        </article-title>
        <source>
         <italic>
          Proc Soc Exp Biol Med.
         </italic>
        </source>
        <volume>
         121
        </volume>
        <fpage>
         190
        </fpage>
        –
        <lpage>
         193
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.3181/00379727-121-30734
        </pub-id>
        <pub-id pub-id-type="pmid">
         4285768
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B61">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Harcourt
          </surname>
          <given-names>
           J. L.
          </given-names>
         </name>
         <name>
          <surname>
           Rudoler
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Tamin
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Leshemm
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Rasis
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Giladi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2018
        </year>
        ).
        <article-title>
         The prevalence of Middle East respiratory syndrome coronavirus (MERS-CoV) antibodies in dromedary camels in Israel.
        </article-title>
        <source>
         <italic>
          Zoonoses Public Health
         </italic>
        </source>
        <pub-id pub-id-type="doi">
         10.1111/zph.12482
        </pub-id>
        <comment>
         [Epub ahead of print]
        </comment>
        .
        <pub-id pub-id-type="pmid">
         29855166
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B62">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Harrigan
          </surname>
          <given-names>
           J. A.
          </given-names>
         </name>
         <name>
          <surname>
           Jacq
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Martin
          </surname>
          <given-names>
           N. M.
          </given-names>
         </name>
         <name>
          <surname>
           Jackson
          </surname>
          <given-names>
           S. P.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2018
        </year>
        ).
        <article-title>
         Deubiquitylating enzymes and drug discovery: emerging opportunities.
        </article-title>
        <source>
         <italic>
          Nat. Rev. Drug Discov.
         </italic>
        </source>
        <volume>
         17
        </volume>
        <fpage>
         57
        </fpage>
        –
        <lpage>
         78
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1038/nrd.2017.152
        </pub-id>
        <pub-id pub-id-type="pmid">
         28959952
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B63">
       <mixed-citation publication-type="journal">
        <collab>
         Health Protection Agency
        </collab>
        (
        <year>
         2013
        </year>
        ).
        <article-title>
         Evidence of person-to-person transmission within a family cluster of novel corona virus infections, United Kingdom, February.
        </article-title>
        <source>
         <italic>
          Euro Surveill.
         </italic>
        </source>
        <volume>
         18
        </volume>
        :
        <issue>
         20427
        </issue>
        .
       </mixed-citation>
      </ref>
      <ref id="B64">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Henderson
          </surname>
          <given-names>
           D. A.
          </given-names>
         </name>
         <name>
          <surname>
           Moss
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1999
        </year>
        ).
        <article-title>
         Recombinant Vaccinia Virus Vaccines.
        </article-title>
        <source>
         <italic>
          Vaccines
         </italic>
        </source>
        <volume>
         6
        </volume>
        <fpage>
         43
        </fpage>
        –
        <lpage>
         46
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="B65">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hou
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013
        </year>
        ).
        <article-title>
         A review of post-GWAS prioritization approaches.
        </article-title>
        <source>
         <italic>
          Front. Genet.
         </italic>
        </source>
        <volume>
         4
        </volume>
        :
        <issue>
         280
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.3389/fgene.2013.00280
        </pub-id>
        <pub-id pub-id-type="pmid">
         24367376
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B66">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Houser
          </surname>
          <given-names>
           K. V.
          </given-names>
         </name>
         <name>
          <surname>
           Broadbent
          </surname>
          <given-names>
           A. J.
          </given-names>
         </name>
         <name>
          <surname>
           Gretebeck
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Lamirande
          </surname>
          <given-names>
           E. W.
          </given-names>
         </name>
         <name>
          <surname>
           Sutton
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2017
        </year>
        ).
        <article-title>
         Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody.
        </article-title>
        <source>
         <italic>
          PLoS Pathog.
         </italic>
        </source>
        <volume>
         13
        </volume>
        :
        <issue>
         e1006565
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1006565
        </pub-id>
        <pub-id pub-id-type="pmid">
         28817732
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B67">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Houser
          </surname>
          <given-names>
           K. V.
          </given-names>
         </name>
         <name>
          <surname>
           Gretebeck
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Ying
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Lamirande
          </surname>
          <given-names>
           E. W.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2016
        </year>
        ).
        <article-title>
         Prophylaxis with a Middle East respiratory syndrome coronavirus (MERS-CoV)-specific human monoclonal antibody protects rabbits from MERS-CoV infection.
        </article-title>
        <source>
         <italic>
          J. Infect. Dis.
         </italic>
        </source>
        <volume>
         213
        </volume>
        <fpage>
         1557
        </fpage>
        –
        <lpage>
         1561
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1093/infdis/jiw080
        </pub-id>
        <pub-id pub-id-type="pmid">
         26941283
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B68">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Chi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2018
        </year>
        ).
        <article-title>
         A rapid and specific assay for the detection of MERS-CoV.
        </article-title>
        <source>
         <italic>
          Front. Microbiol.
         </italic>
        </source>
        <volume>
         9
        </volume>
        :
        <issue>
         1101
        </issue>
        <pub-id pub-id-type="doi">
         10.3389/fmicb.2018.01101
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B69">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D. S.
          </given-names>
         </name>
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           E. I.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           Y. J.
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z. A.
          </given-names>
         </name>
         <name>
          <surname>
           Oh
          </surname>
          <given-names>
           M. D.
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2018
        </year>
        ).
        <article-title>
         Middle East respiratory syndrome corona virus: risk factors and determinants of primary, household, and nosocomial transmission.
        </article-title>
        <source>
         <italic>
          Lancet Infect. Dis.
         </italic>
        </source>
        <volume>
         18
        </volume>
        <fpage>
         e217
        </fpage>
        –
        <lpage>
         e227
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(18)30127-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         29680581
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B70">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jiaming
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Yanfeng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Yawei
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Linlin
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Baoying
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2017
        </year>
        ).
        <article-title>
         The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
        </article-title>
        <source>
         <italic>
          Vaccine
         </italic>
        </source>
        <volume>
         35
        </volume>
        <fpage>
         10
        </fpage>
        –
        <lpage>
         18
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2016.11.064
        </pub-id>
        <pub-id pub-id-type="pmid">
         27899228
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B71">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kandeil
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Gomaa
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Shehata
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           El-Taweel
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kayed
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Abiadh
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2019
        </year>
        ).
        <article-title>
         Middle East respiratory syndrome coronavirus infection in non-camelid domestic mammals.
        </article-title>
        <source>
         <italic>
          Emerg. Microbes Infect.
         </italic>
        </source>
        <volume>
         8
        </volume>
        <fpage>
         103
        </fpage>
        –
        <lpage>
         108
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1080/22221751.2018.1560235
        </pub-id>
        <pub-id pub-id-type="pmid">
         30866764
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B72">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2016
        </year>
        ).
        <source>
         <italic>
          The Korean Ministry of Health &amp; Welfare. Press release: MERS statistics. Sejong: Ministry of Health &amp; Welfare.
         </italic>
        </source>
        Available at:
        <ext-link ext-link-type="uri" xlink:href="http://english.mw.go.kr/front_eng/sg/ssg0111vw.jsp?PAR_MENU_ID1001&amp;MENU_ID100111&amp;page1&amp;CONT_SEQ324470">
         http://english.mw.go.kr/front_eng/sg/ssg0111vw.jsp?PAR_MENU_ID1001&amp;MENU_ID100111&amp;page1&amp;CONT_SEQ324470
        </ext-link>
        [accessed July
        <volume>
         15
        </volume>
        <issue>
         2016
        </issue>
        ].
       </mixed-citation>
      </ref>
      <ref id="B73">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuiken
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R. A.
          </given-names>
         </name>
         <name>
          <surname>
           Schutten
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Rimmelzwaan
          </surname>
          <given-names>
           G. F.
          </given-names>
         </name>
         <name>
          <surname>
           van Amerongen
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           van Riel
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2003
        </year>
        ).
        <article-title>
         Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome.
        </article-title>
        <source>
         <italic>
          Lancet
         </italic>
        </source>
        <volume>
         362
        </volume>
        <fpage>
         263
        </fpage>
        –
        <lpage>
         270
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(03)13967-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         12892955
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B74">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S. K.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           C. C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K. H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C. P.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           D. Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2013
        </year>
        ).
        <article-title>
         Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment.
        </article-title>
        <source>
         <italic>
          J. Gen. Virol.
         </italic>
        </source>
        <volume>
         94(Pt 12)
        </volume>
        ,
        <fpage>
         2679
        </fpage>
        –
        <lpage>
         2690
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1099/vir.0.055533-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         24077366
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B75">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S. K. P.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           A. C. P.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           T. C. K.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P. C. Y.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2017
        </year>
        ).
        <article-title>
         Molecular Evolution of MERS Corona virus: dromedaries as a Recent Intermediate Host or Long-Time Animal Reservoir?
        </article-title>
        <source>
         <italic>
          Int. J. Mol. Sci.
         </italic>
        </source>
        <volume>
         18
        </volume>
        :
        <issue>
         E2138
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.3390/ijms18102138
        </pub-id>
        <pub-id pub-id-type="pmid">
         29035289
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B76">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Law
          </surname>
          <given-names>
           G. L.
          </given-names>
         </name>
         <name>
          <surname>
           Korth
          </surname>
          <given-names>
           M. J.
          </given-names>
         </name>
         <name>
          <surname>
           Benecke
          </surname>
          <given-names>
           A. G.
          </given-names>
         </name>
         <name>
          <surname>
           Katze
          </surname>
          <given-names>
           M. G.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013
        </year>
        ).
        <article-title>
         Systems virology: host-directed approaches to viral pathogenesis and drug targeting.
        </article-title>
        <source>
         <italic>
          Nat. Rev. Microbiol.
         </italic>
        </source>
        <volume>
         11
        </volume>
        <fpage>
         455
        </fpage>
        –
        <lpage>
         466
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1038/nrmicro3036
        </pub-id>
        <pub-id pub-id-type="pmid">
         23728212
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B77">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lorenzen
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Follmann
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Jungersen
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Agerholm
          </surname>
          <given-names>
           J. S.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        ).
        <article-title>
         A review of the human vs. porcine female genital tract and associated immune system in the perspective of using minipigs as a model of human genital Chlamydia infection.
        </article-title>
        <source>
         <italic>
          Vet. Res.
         </italic>
        </source>
        <volume>
         46
        </volume>
        :
        <issue>
         116
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1186/s13567-015-0241-9
        </pub-id>
        <pub-id pub-id-type="pmid">
         26411309
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B78">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lui
          </surname>
          <given-names>
           P. L.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           L. Y. R.
          </given-names>
         </name>
         <name>
          <surname>
           Fung
          </surname>
          <given-names>
           C. L.
          </given-names>
         </name>
         <name>
          <surname>
           Siu
          </surname>
          <given-names>
           K. L.
          </given-names>
         </name>
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           M. L.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K. S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2016
        </year>
        ).
        <article-title>
         Middle East respiratory syndrome coronavirus M protein suppresses type I interferon expression through the inhibition of TBK1-dependent phosphorylation of IRF3.
        </article-title>
        <source>
         <italic>
          Emerg. Microbes Infect.
         </italic>
        </source>
        <volume>
         5
        </volume>
        :
        <issue>
         e39
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1038/emi.2016.33
        </pub-id>
        <pub-id pub-id-type="pmid">
         27094905
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B79">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Tseng
          </surname>
          <given-names>
           C. K.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2014
        </year>
        ).
        <article-title>
         Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments—The importance of immunofocusing in subunit vaccine design.
        </article-title>
        <source>
         <italic>
          Vaccine
         </italic>
        </source>
        <volume>
         32
        </volume>
        <fpage>
         6170
        </fpage>
        –
        <lpage>
         6176
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2014.08.086
        </pub-id>
        <pub-id pub-id-type="pmid">
         25240756
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B80">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marra
          </surname>
          <given-names>
           M. A.
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           S. J.
          </given-names>
         </name>
         <name>
          <surname>
           Astell
          </surname>
          <given-names>
           C. R.
          </given-names>
         </name>
         <name>
          <surname>
           Holt
          </surname>
          <given-names>
           R. A.
          </given-names>
         </name>
         <name>
          <surname>
           Brooks-Wilson
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Butterfield
          </surname>
          <given-names>
           Y. S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2003
        </year>
        ).
        <article-title>
         The genome sequence of the SARS-associated coronavirus.
        </article-title>
        <source>
         <italic>
          Science
         </italic>
        </source>
        <volume>
         300
        </volume>
        <fpage>
         1399
        </fpage>
        –
        <lpage>
         1404
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1126/science.1085953
        </pub-id>
        <pub-id pub-id-type="pmid">
         12730501
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B81">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Masters
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2006
        </year>
        ).
        <article-title>
         The molecular biology of corona viruses.
        </article-title>
        <source>
         <italic>
          Adv. Virus Res.
         </italic>
        </source>
        <volume>
         66
        </volume>
        <fpage>
         193
        </fpage>
        –
        <lpage>
         292
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/S0065-3527(06)66005-3
        </pub-id>
        <pub-id pub-id-type="pmid">
         16877062
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B82">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McDermott
          </surname>
          <given-names>
           J. E.
          </given-names>
         </name>
         <name>
          <surname>
           Shankaran
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Eisfeld
          </surname>
          <given-names>
           A. J.
          </given-names>
         </name>
         <name>
          <surname>
           Belisle
          </surname>
          <given-names>
           S. E.
          </given-names>
         </name>
         <name>
          <surname>
           Neuman
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2011
        </year>
        ).
        <article-title>
         Conserved host response to highly pathogenic avian-influenza virus infection in human cell culture, mouse and macaque model systems.
        </article-title>
        <source>
         <italic>
          BMC Syst. Biol.
         </italic>
        </source>
        <volume>
         5
        </volume>
        :
        <issue>
         190
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1186/1752-0509-5-190
        </pub-id>
        <pub-id pub-id-type="pmid">
         22074594
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B83">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Mishra
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Olival
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013a
        </year>
        ).
        <article-title>
         Middle East respiratory syndrome corona virus in bats, Saudi Arabia.
        </article-title>
        <source>
         <italic>
          Emerg. Infect. Dis.
         </italic>
        </source>
        <volume>
         19
        </volume>
        <fpage>
         1819
        </fpage>
        –
        <lpage>
         1823
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.3201/eid1911.131172
        </pub-id>
        <pub-id pub-id-type="pmid">
         24206838
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B84">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013b
        </year>
        ).
        <article-title>
         Middle East respiratory syndrome corona virus infections in health care workers.
        </article-title>
        <source>
         <italic>
          N. Engl. J. Med.
         </italic>
        </source>
        <volume>
         2013
        </volume>
        <fpage>
         884
        </fpage>
        –
        <lpage>
         886
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.ajic.2017.08.010
        </pub-id>
        <pub-id pub-id-type="pmid">
         28958446
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B85">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z. A.
          </given-names>
         </name>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Alhakeem
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Yezli
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Almasri
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2014a
        </year>
        ).
        <article-title>
         Middle East Respiratory Syndrome Corona virus, MERS-CoV. Conclusions from the 2nd scientific advisory board meeting of the WHO collaborating center for mass gathering medicine, Riyadh.
        </article-title>
        <source>
         <italic>
          Int. J. Infect. Dis.
         </italic>
        </source>
        <volume>
         24
        </volume>
        <fpage>
         51
        </fpage>
        –
        <lpage>
         53
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.ijid.2014.05.001
        </pub-id>
        <pub-id pub-id-type="pmid">
         24818990
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B86">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z. A.
          </given-names>
         </name>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A. M.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J. A.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014b
        </year>
        ).
        <article-title>
         Middle East respiratory syndrome corona virus (MERS-CoV) viral shedding in the respiratory tract: an observational analysis with infection control implications.
        </article-title>
        <source>
         <italic>
          Int. J. Infect. Dis.
         </italic>
        </source>
        <volume>
         29
        </volume>
        <fpage>
         307
        </fpage>
        –
        <lpage>
         308
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.ijid.2014.10.002
        </pub-id>
        <pub-id pub-id-type="pmid">
         25448335
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B88">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           V. D.
          </given-names>
         </name>
         <name>
          <surname>
           Eisfeld
          </surname>
          <given-names>
           A. J.
          </given-names>
         </name>
         <name>
          <surname>
           Schäfer
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Josset
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Sims
          </surname>
          <given-names>
           A. C.
          </given-names>
         </name>
         <name>
          <surname>
           Proll
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2014
        </year>
        ).
        <article-title>
         Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses.
        </article-title>
        <source>
         <italic>
          mBio
         </italic>
        </source>
        <volume>
         5
        </volume>
        :
        <issue>
         e01174
        </issue>
        –
        <issue>
         14
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1128/mBio.01174-14e01174-14
        </pub-id>
        <comment>
         PMID:24846384
        </comment>
        <pub-id pub-id-type="pmid">
         24846384
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B89">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           V. D.
          </given-names>
         </name>
         <name>
          <surname>
           Mitchell
          </surname>
          <given-names>
           H. D.
          </given-names>
         </name>
         <name>
          <surname>
           Cockrell
          </surname>
          <given-names>
           A. S.
          </given-names>
         </name>
         <name>
          <surname>
           Gralinski
          </surname>
          <given-names>
           L. E.
          </given-names>
         </name>
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B. L.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           R. L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2017
        </year>
        ).
        <article-title>
         MERS-CoV Accessory ORFs play key role for infection and pathogenesis.
        </article-title>
        <source>
         <italic>
          mBio
         </italic>
        </source>
        <volume>
         8
        </volume>
        :
        <issue>
         e00665
        </issue>
        –
        <issue>
         17
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1128/mBio.00665-17e00665-17
        </pub-id>
        <pub-id pub-id-type="pmid">
         28830941
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B90">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           V. D.
          </given-names>
         </name>
         <name>
          <surname>
           Schäfer
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Burnum-Johnson
          </surname>
          <given-names>
           K. E.
          </given-names>
         </name>
         <name>
          <surname>
           Mitchell
          </surname>
          <given-names>
           H. D.
          </given-names>
         </name>
         <name>
          <surname>
           Eisfeld
          </surname>
          <given-names>
           A. J.
          </given-names>
         </name>
         <name>
          <surname>
           Walters
          </surname>
          <given-names>
           K. B.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2018
        </year>
        ).
        <article-title>
         MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape.
        </article-title>
        <source>
         <italic>
          Proc. Natl. Acad. Sci. U.S.A.
         </italic>
        </source>
        <volume>
         115
        </volume>
        <fpage>
         E1012
        </fpage>
        –
        <lpage>
         E1021
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1073/pnas.1706928115
        </pub-id>
        <pub-id pub-id-type="pmid">
         29339515
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B91">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M. A.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        ).
        <article-title>
         Serological assays for emerging corona viruses: challenges and pitfalls.
        </article-title>
        <source>
         <italic>
          Virus Res.
         </italic>
        </source>
        <volume>
         194
        </volume>
        <fpage>
         175
        </fpage>
        –
        <lpage>
         183
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2014.03.018
        </pub-id>
        <pub-id pub-id-type="pmid">
         24670324
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B92">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           García-Bocanegra
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Wernery
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Wernery
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Sieberg
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           M. A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2015
        </year>
        ).
        <article-title>
         Serologic assessment of possibility for MERS-CoV infection in equids.
        </article-title>
        <source>
         <italic>
          Emerg. Infect. Dis.
         </italic>
        </source>
        <volume>
         21
        </volume>
        <fpage>
         181
        </fpage>
        –
        <lpage>
         182
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.3201/eid2101.141342
        </pub-id>
        <pub-id pub-id-type="pmid">
         25531820
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B93">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mielech
          </surname>
          <given-names>
           A. M.
          </given-names>
         </name>
         <name>
          <surname>
           Kilianski
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Baez-Santos
          </surname>
          <given-names>
           Y. M.
          </given-names>
         </name>
         <name>
          <surname>
           Mesecar
          </surname>
          <given-names>
           A. D.
          </given-names>
         </name>
         <name>
          <surname>
           Baker
          </surname>
          <given-names>
           S. C.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        ).
        <article-title>
         MERS-CoV papain-like protease has deISGylating and deubiquitinating activities.
        </article-title>
        <source>
         <italic>
          Virology
         </italic>
        </source>
        <volume>
         45
        </volume>
        <fpage>
         64
        </fpage>
        –
        <lpage>
         70
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2013.11.040
        </pub-id>
        <pub-id pub-id-type="pmid">
         24503068
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B94">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mitchell
          </surname>
          <given-names>
           H. D.
          </given-names>
         </name>
         <name>
          <surname>
           Eisfeld
          </surname>
          <given-names>
           A. J.
          </given-names>
         </name>
         <name>
          <surname>
           Sims
          </surname>
          <given-names>
           A. C.
          </given-names>
         </name>
         <name>
          <surname>
           McDermott
          </surname>
          <given-names>
           J. E.
          </given-names>
         </name>
         <name>
          <surname>
           Matzke
          </surname>
          <given-names>
           M. M.
          </given-names>
         </name>
         <name>
          <surname>
           Webb-Robertson
          </surname>
          <given-names>
           B. J.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013
        </year>
        ).
        <article-title>
         A network integration approach to predict conserved regulators related to pathogenicity of influenza and SARS-CoV respiratory viruses.
        </article-title>
        <source>
         <italic>
          PLoS One
         </italic>
        </source>
        <volume>
         8
        </volume>
        :
        <issue>
         e69374
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0069374
        </pub-id>
        <pub-id pub-id-type="pmid">
         23935999
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B95">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M. A.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V. S.
          </given-names>
         </name>
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Kallies
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           S. L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2012
        </year>
        ).
        <article-title>
         Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines.
        </article-title>
        <source>
         <italic>
          mBio
         </italic>
        </source>
        <volume>
         3
        </volume>
        :
        <issue>
         e00515
        </issue>
        –
        <issue>
         12
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1128/mBio.00515-12
        </pub-id>
        <pub-id pub-id-type="pmid">
         23322635
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B96">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mustafa
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Balkhy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Gabere
          </surname>
          <given-names>
           M. N.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2017
        </year>
        ).
        <article-title>
         Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): a review.
        </article-title>
        <source>
         <italic>
          J. Infect. Public Health
         </italic>
        </source>
        <volume>
         11
        </volume>
        <fpage>
         9
        </fpage>
        –
        <lpage>
         17
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.jiph.2017.08.009
        </pub-id>
        <pub-id pub-id-type="pmid">
         28864360
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B97">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mustafa
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Balkhy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Gabere
          </surname>
          <given-names>
           M. N.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2018
        </year>
        ).
        <article-title>
         Current treatment options and the role of peptides as potential therapeutic components for middle east respiratory syndrome (MERS): a review.
        </article-title>
        <source>
         <italic>
          J. Infect. Public Health
         </italic>
        </source>
        <volume>
         11
        </volume>
        <fpage>
         9
        </fpage>
        –
        <lpage>
         17
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.jiph.2017.08.009
        </pub-id>
        <pub-id pub-id-type="pmid">
         28864360
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B98">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V. M.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Masri
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Farah
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        ).
        <article-title>
         Infectious Middle East respiratory Syndrome Corona virus excretion and serotype variability based on live virus isolates from patients in Saudi Arabia.
        </article-title>
        <source>
         <italic>
          J. Clin. Microbiol.
         </italic>
        </source>
        <volume>
         53
        </volume>
        <fpage>
         2951
        </fpage>
        –
        <lpage>
         2955
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JCM.01368-15
        </pub-id>
        <pub-id pub-id-type="pmid">
         26157150
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B99">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muthumani
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Reuschel
          </surname>
          <given-names>
           E. L.
          </given-names>
         </name>
         <name>
          <surname>
           Tingey
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Flingai
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Villarreal
          </surname>
          <given-names>
           D. O.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2015
        </year>
        ).
        <article-title>
         A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates.
        </article-title>
        <source>
         <italic>
          Sci. Transl. Med.
         </italic>
        </source>
        <volume>
         7
        </volume>
        :
        <issue>
         301ra132
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1126/scitranslmed.aac7462
        </pub-id>
        <pub-id pub-id-type="pmid">
         26290414
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B100">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           D. L.
          </given-names>
         </name>
         <name>
          <surname>
           Al Hosani
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Keating
          </surname>
          <given-names>
           M. K.
          </given-names>
         </name>
         <name>
          <surname>
           Gerber
          </surname>
          <given-names>
           S. I.
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           T. L.
          </given-names>
         </name>
         <name>
          <surname>
           Metcalfe
          </surname>
          <given-names>
           M. G.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2016
        </year>
        ).
        <article-title>
         Clinicopathologic, Immunohistochemical, and Ultra structural Findings of a Fatal Case of Middle East Respiratory Syndrome Corona virus Infection in the United Arab Emirates, April 2014.
        </article-title>
        <source>
         <italic>
          Am. J. Pathol.
         </italic>
        </source>
        <volume>
         186
        </volume>
        <fpage>
         652
        </fpage>
        –
        <lpage>
         658
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.ajpath.2015.10.024
        </pub-id>
        <pub-id pub-id-type="pmid">
         26857507
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B101">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oh
          </surname>
          <given-names>
           M. D.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           W. B.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           S. W.
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           P. G.
          </given-names>
         </name>
         <name>
          <surname>
           Bang
          </surname>
          <given-names>
           J. H.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           K. H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2018
        </year>
        ).
        <article-title>
         Middle East respiratory syndrome: what we learned from the 2015 outbreak in the Republic of Korea.
        </article-title>
        <source>
         <italic>
          Korean J. Intern. Med.
         </italic>
        </source>
        <volume>
         33
        </volume>
        <fpage>
         233
        </fpage>
        –
        <lpage>
         246
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.3904/kjim.2018.031
        </pub-id>
        <pub-id pub-id-type="pmid">
         29506344
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B102">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ohnuma
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B. L.
          </given-names>
         </name>
         <name>
          <surname>
           Hatano
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V. S.
          </given-names>
         </name>
         <name>
          <surname>
           Mou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Iwata
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2013
        </year>
        ).
        <article-title>
         Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody.
        </article-title>
        <source>
         <italic>
          J. Virol.
         </italic>
        </source>
        <volume>
         87
        </volume>
        <fpage>
         13892
        </fpage>
        –
        <lpage>
         13899
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.02448-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         24067970
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B103">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Okba
          </surname>
          <given-names>
           N. M.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V. S.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B. L.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2017
        </year>
        ).
        <article-title>
         Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches.
        </article-title>
        <source>
         <italic>
          Curr. Opin. Virol.
         </italic>
        </source>
        <volume>
         23
        </volume>
        <fpage>
         49
        </fpage>
        –
        <lpage>
         58
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.coviro.2017.03.007
        </pub-id>
        <pub-id pub-id-type="pmid">
         28412285
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B104">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Omrani
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Matin
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Haddad
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Nakhli
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Albarrak
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013
        </year>
        ).
        <article-title>
         A family cluster of Middle East Respiratory Syndrome Corona virus infections related to a likely unrecognized asymptomatic or mild case.
        </article-title>
        <source>
         <italic>
          Int. J. Infect. Dis.
         </italic>
        </source>
        <volume>
         17
        </volume>
        :
        <issue>
         72
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.ijid.2013.07.001
        </pub-id>
        <pub-id pub-id-type="pmid">
         23916548
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B105">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pallesen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Corbett
          </surname>
          <given-names>
           K. S.
          </given-names>
         </name>
         <name>
          <surname>
           Wrapp
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Kirchdoerfer
          </surname>
          <given-names>
           R. N.
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           H. L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2017
        </year>
        ).
        <article-title>
         Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen.
        </article-title>
        <source>
         <italic>
          Proc. Natl. Acad. Sci. U.S.A.
         </italic>
        </source>
        <volume>
         114
        </volume>
        <fpage>
         E7348
        </fpage>
        –
        <lpage>
         E7357
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1073/pnas.1707304114
        </pub-id>
        <pub-id pub-id-type="pmid">
         28807998
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B106">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           J. E.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Barlan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Fehr
          </surname>
          <given-names>
           A. R.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           McCray
          </surname>
          <given-names>
           P. B.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2016
        </year>
        ).
        <article-title>
         Proteolytic processing of middle east respiratory syndrome coronavirus spikes expands virus tropism.
        </article-title>
        <source>
         <italic>
          Proc. Natl. Acad. Sci. U.S.A.
         </italic>
        </source>
        <volume>
         113
        </volume>
        <fpage>
         12262
        </fpage>
        –
        <lpage>
         12267
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1073/pnas.1608147113
        </pub-id>
        <pub-id pub-id-type="pmid">
         27791014
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B107">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           W. B.
          </given-names>
         </name>
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           R. A.
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           P. G.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           E. H.
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           S. J.
          </given-names>
         </name>
         <name>
          <surname>
           Chun
          </surname>
          <given-names>
           J. Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2015
        </year>
        ).
        <article-title>
         Kinetics of serologic responses to MERS Coronavirus Infection in Humans. South Korea.
        </article-title>
        <source>
         <italic>
          Emerg. Infect. Dis.
         </italic>
        </source>
        <volume>
         21
        </volume>
        <fpage>
         2186
        </fpage>
        –
        <lpage>
         2189
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.3201/eid2112.151421
        </pub-id>
        <pub-id pub-id-type="pmid">
         26583829
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B108">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pascal
          </surname>
          <given-names>
           K. E.
          </given-names>
         </name>
         <name>
          <surname>
           Colemanb
          </surname>
          <given-names>
           C. M.
          </given-names>
         </name>
         <name>
          <surname>
           Mujicaa
          </surname>
          <given-names>
           A. O.
          </given-names>
         </name>
         <name>
          <surname>
           Kamata
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Badithea
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Fairhursta
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2015
        </year>
        ).
        <article-title>
         Pre- and postexposure efficacy of fully human antibodies againt Spike protein in a novel humanized mouse model of MERS-CoV infection.
        </article-title>
        <source>
         <italic>
          Proc. Natl. Acad. Sci. U.S.A.
         </italic>
        </source>
        <volume>
         112
        </volume>
        <fpage>
         8738
        </fpage>
        –
        <lpage>
         8743
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1073/pnas.1510830112
        </pub-id>
        <pub-id pub-id-type="pmid">
         26124093
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B109">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peck
          </surname>
          <given-names>
           K. M.
          </given-names>
         </name>
         <name>
          <surname>
           Cockrell
          </surname>
          <given-names>
           A. S.
          </given-names>
         </name>
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B. L.
          </given-names>
         </name>
         <name>
          <surname>
           Scobey
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R. S.
          </given-names>
         </name>
         <name>
          <surname>
           Heise
          </surname>
          <given-names>
           M. T.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        ).
        <article-title>
         Glycosylation of mouse DPP4 plays a role in inhibiting Middle East Respiratory Syndrome Coronavirus infection.
        </article-title>
        <source>
         <italic>
          J. Virol.
         </italic>
        </source>
        <volume>
         89
        </volume>
        <fpage>
         4696
        </fpage>
        –
        <lpage>
         4699
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.03445-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         25653445
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B110">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           R. A.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Gomaa
          </surname>
          <given-names>
           M. R.
          </given-names>
         </name>
         <name>
          <surname>
           El-Shesheny
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Kandeil
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Bagato
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2013
        </year>
        ).
        <article-title>
         Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt.
        </article-title>
        <source>
         <italic>
          Euro. Surveill.
         </italic>
        </source>
        <volume>
         18
        </volume>
        :
        <issue>
         20574
        </issue>
        .
        <pub-id pub-id-type="pmid">
         24079378
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B111">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        ).
        <article-title>
         Research Driven by Curiosity: the Journey from basic molecular biology and virology to studies of human pathogenic corona viruses.
        </article-title>
        <source>
         <italic>
          PLoS Pathog.
         </italic>
        </source>
        <volume>
         11
        </volume>
        :
        <issue>
         e1005023
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1005023
        </pub-id>
        <pub-id pub-id-type="pmid">
         26172373
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B112">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Netland
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2009
        </year>
        ).
        <article-title>
         Coronaviruses post-SARS: update on replication and pathogenesis.
        </article-title>
        <source>
         <italic>
          Nat. Rev. Microbiol.
         </italic>
        </source>
        <volume>
         7
        </volume>
        <fpage>
         439
        </fpage>
        –
        <lpage>
         450
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1038/nrmicro2147
        </pub-id>
        <pub-id pub-id-type="pmid">
         19430490
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B113">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Puzelli
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Azzi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Santini
          </surname>
          <given-names>
           M. G.
          </given-names>
         </name>
         <name>
          <surname>
           Di
          </surname>
          <given-names>
           M. A.
          </given-names>
         </name>
         <name>
          <surname>
           Facchini
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Castrucci
          </surname>
          <given-names>
           M. R.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013
        </year>
        ).
        <article-title>
         Investigation of an imported case of Middle East Respiratory Syndrome Corona virus (MERS-CoV) infection in Florence, Italy, May to June 2013.
        </article-title>
        <source>
         <italic>
          Euro. Surveill.
         </italic>
        </source>
        <volume>
         18
        </volume>
        :
        <issue>
         1
        </issue>
        .
       </mixed-citation>
      </ref>
      <ref id="B114">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rabaan
          </surname>
          <given-names>
           A. A.
          </given-names>
         </name>
         <name>
          <surname>
           Bazzi
          </surname>
          <given-names>
           A. M.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Ahmed
          </surname>
          <given-names>
           S. H.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J. A.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2017
        </year>
        ).
        <article-title>
         Molecular aspects of MERS-CoV.
        </article-title>
        <source>
         <italic>
          Front. Med.
         </italic>
        </source>
        <volume>
         11
        </volume>
        <fpage>
         365
        </fpage>
        –
        <lpage>
         377
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1007/s11684-017-0521-z
        </pub-id>
        <pub-id pub-id-type="pmid">
         28500431
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B115">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rabouw
          </surname>
          <given-names>
           H. H.
          </given-names>
         </name>
         <name>
          <surname>
           Langereis
          </surname>
          <given-names>
           M. A.
          </given-names>
         </name>
         <name>
          <surname>
           Knaap
          </surname>
          <given-names>
           R. C. M.
          </given-names>
         </name>
         <name>
          <surname>
           Dalebout
          </surname>
          <given-names>
           T. J.
          </given-names>
         </name>
         <name>
          <surname>
           Canton
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Sola
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2016
        </year>
        ).
        <article-title>
         Middle east respiratory coronavirus accessory protein 4a inhibits PKR-mediated antiviral stress responses.
        </article-title>
        <source>
         <italic>
          PLoS Pathog.
         </italic>
        </source>
        <volume>
         12
        </volume>
        :
        <issue>
         e1005982
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1005982
        </pub-id>
        <pub-id pub-id-type="pmid">
         27783669
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B116">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V. S.
          </given-names>
         </name>
         <name>
          <surname>
           Mou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           S. L.
          </given-names>
         </name>
         <name>
          <surname>
           Dekkers
          </surname>
          <given-names>
           D. H.
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           M. A.
          </given-names>
         </name>
         <name>
          <surname>
           Dijkman
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2013
        </year>
        ).
        <article-title>
         Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC.
        </article-title>
        <source>
         <italic>
          Nature
         </italic>
        </source>
        <volume>
         495
        </volume>
        <fpage>
         251
        </fpage>
        –
        <lpage>
         254
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1038/nature12005
        </pub-id>
        <pub-id pub-id-type="pmid">
         23486063
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B117">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V. S.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A. D.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R. A.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        ).
        <article-title>
         MERS: emergence of a novel human coronavirus.
        </article-title>
        <source>
         <italic>
          Curr. Opin. Virol.
         </italic>
        </source>
        <volume>
         5
        </volume>
        <fpage>
         58
        </fpage>
        –
        <lpage>
         62
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.coviro.2014.01.010
        </pub-id>
        <pub-id pub-id-type="pmid">
         24584035
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B118">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rockx
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Donaldson
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sheahan
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Corti
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Lanzavecchia
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2010
        </year>
        ).
        <article-title>
         Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome corona virus.
        </article-title>
        <source>
         <italic>
          J. Infect. Dis.
         </italic>
        </source>
        <volume>
         201
        </volume>
        <fpage>
         946
        </fpage>
        –
        <lpage>
         955
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1086/651022
        </pub-id>
        <pub-id pub-id-type="pmid">
         20144042
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B119">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rota
          </surname>
          <given-names>
           P. A.
          </given-names>
         </name>
         <name>
          <surname>
           Oberste
          </surname>
          <given-names>
           M. S.
          </given-names>
         </name>
         <name>
          <surname>
           Monroe
          </surname>
          <given-names>
           S. S.
          </given-names>
         </name>
         <name>
          <surname>
           Nix
          </surname>
          <given-names>
           W. A.
          </given-names>
         </name>
         <name>
          <surname>
           Campagnoli
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Icenogle
          </surname>
          <given-names>
           J. P.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2003
        </year>
        ).
        <article-title>
         Characterization of a novel coronavirus associated with severe acute respiratory syndrome.
        </article-title>
        <source>
         <italic>
          Science
         </italic>
        </source>
        <volume>
         300
        </volume>
        <fpage>
         1394
        </fpage>
        –
        <lpage>
         1399
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1126/science.1085952
        </pub-id>
        <pub-id pub-id-type="pmid">
         12730500
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B120">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Selinger
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Tisoncik-Go
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           V. D.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Law
          </surname>
          <given-names>
           G. L.
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2014
        </year>
        ).
        <article-title>
         Cytokine systems approach demonstrates differences in innate and pro-inflammatory host responses between genetically distinct MERS-CoV isolates.
        </article-title>
        <source>
         <italic>
          BMC Genomics
         </italic>
        </source>
        <volume>
         15
        </volume>
        :
        <issue>
         1161
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1186/1471-2164-15-1161
        </pub-id>
        <pub-id pub-id-type="pmid">
         25534508
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B121">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shehata
          </surname>
          <given-names>
           M. M.
          </given-names>
         </name>
         <name>
          <surname>
           Gomaa
          </surname>
          <given-names>
           M. R.
          </given-names>
         </name>
         <name>
          <surname>
           Ali
          </surname>
          <given-names>
           M. A.
          </given-names>
         </name>
         <name>
          <surname>
           Kayali
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2016
        </year>
        ).
        <article-title>
         Middle East respiratory syndrome coronavirus: a comprehensive review.
        </article-title>
        <source>
         <italic>
          Front Med.
         </italic>
        </source>
        <volume>
         10
        </volume>
        <fpage>
         120
        </fpage>
        –
        <lpage>
         136
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1007/s11684-016-0430-6
        </pub-id>
        <pub-id pub-id-type="pmid">
         26791756
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B122">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Teng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        ).
        <article-title>
         Epitope-based vaccine target screening against highly pathogenic MERS-CoV: An
         <italic>
          in silico
         </italic>
         approach applied to emerging infectious diseases.
        </article-title>
        <source>
         <italic>
          PLoS One
         </italic>
        </source>
        <volume>
         10
        </volume>
        :
        <issue>
         e0144475
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0144475
        </pub-id>
        <pub-id pub-id-type="pmid">
         26641892
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B123">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shirato
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kawase
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Matsuyama
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013
        </year>
        ).
        <article-title>
         Middle East Respiratory Syndrome Coronavirus Infection Mediated by the Transmembrane Serine Protease TMPRSS2.
        </article-title>
        <source>
         <italic>
          J. Virol.
         </italic>
        </source>
        <volume>
         87
        </volume>
        <fpage>
         12552
        </fpage>
        –
        <lpage>
         12561
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.01890-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         24027332
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B124">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shirato
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Yano
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Senba
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Akachi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kobayashi
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Nishinaka
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2014
        </year>
        ).
        <article-title>
         Detection of Middle East respiratory syndrome coronavirus using reverse transcription loop-mediated isothermal amplification (RT-LAMP).
        </article-title>
        <source>
         <italic>
          Virol J.
         </italic>
        </source>
        <volume>
         11
        </volume>
        <issue>
         139
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1186/1743-422X-11-139
        </pub-id>
        <pub-id pub-id-type="pmid">
         25103205
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B125">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           E. C.
          </given-names>
         </name>
         <name>
          <surname>
           Blanc
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Surdel
          </surname>
          <given-names>
           M. C.
          </given-names>
         </name>
         <name>
          <surname>
           Vignuzzi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Denison
          </surname>
          <given-names>
           M. R.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013
        </year>
        ).
        <article-title>
         Corona viruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics.
        </article-title>
        <source>
         <italic>
          PLoS Pathog.
         </italic>
        </source>
        <volume>
         9
        </volume>
        :
        <issue>
         e1003565
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1003565
        </pub-id>
        <pub-id pub-id-type="pmid">
         23966862
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B126">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           E. J.
          </given-names>
         </name>
         <name>
          <surname>
           Bredenbeek
          </surname>
          <given-names>
           P. J.
          </given-names>
         </name>
         <name>
          <surname>
           Dobbe
          </surname>
          <given-names>
           J. C.
          </given-names>
         </name>
         <name>
          <surname>
           Thiel
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Ziebuhr
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L. L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2003
        </year>
        ).
        <article-title>
         Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage.
        </article-title>
        <source>
         <italic>
          J. Mol. Biol.
         </italic>
        </source>
        <volume>
         331
        </volume>
        <fpage>
         991
        </fpage>
        –
        <lpage>
         1004
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/S0022-2836(03)00865-9
        </pub-id>
        <pub-id pub-id-type="pmid">
         12927536
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B127">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Ha
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Serhan
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Eltahir
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yusof
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hashem
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        ).
        <article-title>
         Development and validation of a rapid immunochromatographic assay for detection of Middle East respiratory syndrome coronavirus antigen in dromedary camels.
        </article-title>
        <source>
         <italic>
          J. Clin. Microbiol.
         </italic>
        </source>
        <volume>
         53
        </volume>
        <fpage>
         1178
        </fpage>
        –
        <lpage>
         1182
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JCM.03096-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         25631809
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B128">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Tseng
          </surname>
          <given-names>
           C. T.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2015
        </year>
        ).
        <article-title>
         Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus.
        </article-title>
        <source>
         <italic>
          Hum. Vaccin. Immunother.
         </italic>
        </source>
        <volume>
         11
        </volume>
        <fpage>
         1244
        </fpage>
        –
        <lpage>
         1250
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1080/21645515.2015.1021527
        </pub-id>
        <pub-id pub-id-type="pmid">
         25874632
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B129">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           X. C.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        ).
        <article-title>
         Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution.
        </article-title>
        <source>
         <italic>
          Proc. Natl. Acad. Sci. U.S.A.
         </italic>
        </source>
        <volume>
         2014
        </volume>
        <fpage>
         E2018
        </fpage>
        –
        <lpage>
         E2026
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1073/pnas.1402074111
        </pub-id>
        <pub-id pub-id-type="pmid">
         24778221
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B130">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Garron
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Agrawal
          </surname>
          <given-names>
           A. S.
          </given-names>
         </name>
         <name>
          <surname>
           Algaissi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           B. H.
          </given-names>
         </name>
         <name>
          <surname>
           Wakamiya
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2015
        </year>
        ).
        <article-title>
         Characterization and demonstration of the value of a lethal mouse model of middle east respiratory syndrome coronavirus infection and disease.
        </article-title>
        <source>
         <italic>
          J. Virol.
         </italic>
        </source>
        <volume>
         90
        </volume>
        <fpage>
         57
        </fpage>
        –
        <lpage>
         67
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.02009-15
        </pub-id>
        <pub-id pub-id-type="pmid">
         26446606
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B131">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Terry
          </surname>
          <given-names>
           F. E.
          </given-names>
         </name>
         <name>
          <surname>
           Moise
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Martin
          </surname>
          <given-names>
           R. F.
          </given-names>
         </name>
         <name>
          <surname>
           Torres
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Pilotte
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           S. A.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        ).
        <article-title>
         Time for T? Immunoinformatics addresses vaccine design for neglected tropical and emerging infectious diseases.
        </article-title>
        <source>
         <italic>
          Expert Rev. Vaccin.
         </italic>
        </source>
        <volume>
         14
        </volume>
        <fpage>
         21
        </fpage>
        –
        <lpage>
         35
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1586/14760584.2015.955478
        </pub-id>
        <pub-id pub-id-type="pmid">
         25193104
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B132">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           de Graaf
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Lauber
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T. M.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V. S.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A. M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2012
        </year>
        ).
        <article-title>
         Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans.
        </article-title>
        <source>
         <italic>
          mBio
         </italic>
        </source>
        <volume>
         3
        </volume>
        :
        <issue>
         e00473
        </issue>
        –
        <issue>
         12
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1128/mBio.00473-12
        </pub-id>
        <pub-id pub-id-type="pmid">
         23170002
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B133">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van den Brand
          </surname>
          <given-names>
           J. M.
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           S. L.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B. L.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        ).
        <article-title>
         Pathogenesis of Middle East respiratory syndrome coronavirus.
        </article-title>
        <source>
         <italic>
          J. Pathol.
         </italic>
        </source>
        <volume>
         235
        </volume>
        <fpage>
         175
        </fpage>
        –
        <lpage>
         184
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1002/path.4458
        </pub-id>
        <pub-id pub-id-type="pmid">
         25294366
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B134">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Pyrc
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Jebbink
          </surname>
          <given-names>
           M. F.
          </given-names>
         </name>
         <name>
          <surname>
           Vermeulen-Oost
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Berkhout
          </surname>
          <given-names>
           R. J.
          </given-names>
         </name>
         <name>
          <surname>
           Wolthers
          </surname>
          <given-names>
           K. C.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2004
        </year>
        ).
        <article-title>
         Identification of a new human coronavirus.
        </article-title>
        <source>
         <italic>
          Nat. Med.
         </italic>
        </source>
        <volume>
         10
        </volume>
        <fpage>
         368
        </fpage>
        –
        <lpage>
         373
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1038/nm1024
        </pub-id>
        <pub-id pub-id-type="pmid">
         15034574
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B135">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Miazgowicz
          </surname>
          <given-names>
           K. L.
          </given-names>
         </name>
         <name>
          <surname>
           Milne-Price
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Robertson
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Scott
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2014
        </year>
        ).
        <article-title>
         Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4.
        </article-title>
        <source>
         <italic>
          J. Virol.
         </italic>
        </source>
        <volume>
         88
        </volume>
        <fpage>
         9220
        </fpage>
        –
        <lpage>
         9232
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.00676-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         24899185
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B136">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vergara-Alert
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Vidal
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Bensaid
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Segalés
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2017
        </year>
        ).
        <article-title>
         Searching for animal models and potential target species for emerging pathogens: experience gained from Middle East respiratory syndrome (MERS) coronavirus.
        </article-title>
        <source>
         <italic>
          One Health
         </italic>
        </source>
        <volume>
         3
        </volume>
        <fpage>
         34
        </fpage>
        –
        <lpage>
         40
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.onehlt.2017.03.001
        </pub-id>
        <pub-id pub-id-type="pmid">
         28616501
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B137">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Hua
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2019
        </year>
        ).
        <article-title>
         Combining a fusion inhibitory peptide targeting the MERS-CoV S2 protein HR1 domain and a neutralizing antibody specific for the S1 protein receptor-binding domain (RBD) showed potent synergism against pseudotyped MERS-CoV with or without mutations in RBD.
        </article-title>
        <source>
         <italic>
          Viruses
         </italic>
        </source>
        <volume>
         11
        </volume>
        :
        <issue>
         E31
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.3390/v11010031
        </pub-id>
        <pub-id pub-id-type="pmid">
         30621343
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B138">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Joyce
          </surname>
          <given-names>
           M. G.
          </given-names>
         </name>
         <name>
          <surname>
           Modjarrad
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2015
        </year>
        ).
        <article-title>
         Evaluation of candidate vaccine approaches for MERS-CoV.
        </article-title>
        <source>
         <italic>
          Nat. Commun.
         </italic>
        </source>
        <volume>
         6
        </volume>
        :
        <issue>
         7712
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1038/ncomms8712
        </pub-id>
        <pub-id pub-id-type="pmid">
         26218507
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B139">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2013
        </year>
        ).
        <article-title>
         Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4.
        </article-title>
        <source>
         <italic>
          Cell Res.
         </italic>
        </source>
        <volume>
         23
        </volume>
        <fpage>
         986
        </fpage>
        –
        <lpage>
         993
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1038/cr.2013.92
        </pub-id>
        <pub-id pub-id-type="pmid">
         23835475
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B140">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        ).
        <article-title>
         Bat origins of MERS-CoV supported by bat corona virus HKU4 usage of human receptor CD26.
        </article-title>
        <source>
         <italic>
          Cell Host Microbe
         </italic>
        </source>
        <volume>
         16
        </volume>
        <fpage>
         328
        </fpage>
        –
        <lpage>
         337
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.chom.2014.08.009
        </pub-id>
        <pub-id pub-id-type="pmid">
         25211075
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B141">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Xuan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Wan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2014
        </year>
        ).
        <article-title>
         Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26.
        </article-title>
        <source>
         <italic>
          Cell Host Microbe
         </italic>
        </source>
        <volume>
         16
        </volume>
        <fpage>
         328
        </fpage>
        –
        <lpage>
         337
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.chom.2014.08.009
        </pub-id>
        <pub-id pub-id-type="pmid">
         25211075
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B142">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           J. T.
          </given-names>
         </name>
         <name>
          <surname>
           Hall
          </surname>
          <given-names>
           A. J.
          </given-names>
         </name>
         <name>
          <surname>
           Erdman
          </surname>
          <given-names>
           D. D.
          </given-names>
         </name>
         <name>
          <surname>
           Swerdlow
          </surname>
          <given-names>
           D. L.
          </given-names>
         </name>
         <name>
          <surname>
           Gerber
          </surname>
          <given-names>
           S. I.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        ).
        <article-title>
         Unraveling the mysteries of Middle East respiratory syndrome corona virus.
        </article-title>
        <source>
         <italic>
          Emerg. Infect. Dis.
         </italic>
        </source>
        <volume>
         20
        </volume>
        <fpage>
         1054
        </fpage>
        –
        <lpage>
         1056
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.3201/eid2006.140322
        </pub-id>
        <pub-id pub-id-type="pmid">
         24983095
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B143">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S. R.
          </given-names>
         </name>
         <name>
          <surname>
           Navas-Martin
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2005
        </year>
        ).
        <article-title>
         Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus.
        </article-title>
        <source>
         <italic>
          Microbiol. Mol. Biol. Rev.
         </italic>
        </source>
        <volume>
         69
        </volume>
        <fpage>
         635
        </fpage>
        –
        <lpage>
         664
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/MMBR.69.4.635-664.2005
        </pub-id>
        <pub-id pub-id-type="pmid">
         16339739
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B144">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wirblich
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Coleman
          </surname>
          <given-names>
           C. M.
          </given-names>
         </name>
         <name>
          <surname>
           Kurup
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Abraham
          </surname>
          <given-names>
           T. S.
          </given-names>
         </name>
         <name>
          <surname>
           Bernbaum
          </surname>
          <given-names>
           J. G.
          </given-names>
         </name>
         <name>
          <surname>
           Jahrling
          </surname>
          <given-names>
           P. B.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2017
        </year>
        ).
        <article-title>
         One-Health: a Safe, efficient, dual-use vaccine for humans and animals against Middle East Respiratory Syndrome Corona virus and Rabies Virus.
        </article-title>
        <source>
         <italic>
          J. Virol
         </italic>
        </source>
        <volume>
         91
        </volume>
        :
        <issue>
         e02040
        </issue>
        –
        <issue>
         16.e02040-16
        </issue>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02040-16
        </pub-id>
        <pub-id pub-id-type="pmid">
         27807241
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B145">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P. C.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S. K.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           C. M.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K. H.
          </given-names>
         </name>
         <name>
          <surname>
           Tsoi
          </surname>
          <given-names>
           H. W.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2005
        </year>
        ).
        <article-title>
         Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia.
        </article-title>
        <source>
         <italic>
          J. Virol.
         </italic>
        </source>
        <volume>
         79
        </volume>
        <fpage>
         884
        </fpage>
        –
        <lpage>
         895
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.79.2.884-895.2005
        </pub-id>
        <pub-id pub-id-type="pmid">
         15613317
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B146">
       <mixed-citation publication-type="journal">
        <collab>
         World Health Organization
        </collab>
        (
        <year>
         2012
        </year>
        ).
        <source>
         <italic>
          Novel Corona virus Infection – Update 2012.
         </italic>
        </source>
        Available at:
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/don/2012_11_30/en/">
         http://www.who.int/csr/don/2012_11_30/en/
        </ext-link>
        <comment>
         [accessed February 9, 2018]
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="B147">
       <mixed-citation publication-type="journal">
        <collab>
         World Health Organization
        </collab>
        (
        <year>
         2013a
        </year>
        ).
        <source>
         <italic>
          Middle East Respiratory Syndrome Corona Virus Joint Kingdom of Saudi Arabia/ WHO mission.
         </italic>
        </source>
        Available at:
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/disease/coronavirus_infections/MERSCov_WHO_KSA_Mission_Jun13_.pdf">
         http://www.who.int/csr/disease/coronavirus_infections/MERSCov_WHO_KSA_Mission_Jun13_.pdf
        </ext-link>
        <comment>
         [accessed January 30, 2018]
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="B148">
       <mixed-citation publication-type="journal">
        <collab>
         World Health Organization
        </collab>
        (
        <year>
         2013b
        </year>
        ).
        <source>
         <italic>
          Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – update 2013.
         </italic>
        </source>
        Available at:
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/don/2013_12_31/en/">
         http://www.who.int/csr/don/2013_12_31/en/
        </ext-link>
        <comment>
         [accessed February 9, 2018]
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="B149">
       <mixed-citation publication-type="journal">
        <collab>
         World Health Organization
        </collab>
        (
        <year>
         2014
        </year>
        ).
        <source>
         <italic>
          Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – Saudi Arabia.
         </italic>
        </source>
        Available at:
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/don/26-december-2014-mers/en/">
         http://www.who.int/csr/don/26-december-2014-mers/en/
        </ext-link>
        <comment>
         [accessed February 9, 2018]
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="B150">
       <mixed-citation publication-type="journal">
        <collab>
         World Health Organization
        </collab>
        (
        <year>
         2015a
        </year>
        ).
        <source>
         <italic>
          Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – Saudi Arabia.
         </italic>
        </source>
        Available at:
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/don/4-december-2015-mers-saudi-arabia/en/">
         http://www.who.int/csr/don/4-december-2015-mers-saudi-arabia/en/
        </ext-link>
        <comment>
         [accessed February 9, 2018]
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="B151">
       <mixed-citation publication-type="journal">
        <collab>
         World Health Organization
        </collab>
        (
        <year>
         2015b
        </year>
        ).
        <source>
         <italic>
          Summary and Risk Assessment of Current Situation in Republic of Korea and China.
         </italic>
        </source>
        Available at:
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/disease/coronavirus_infections/risk-assessment-19june2015/en/">
         http://www.who.int/csr/disease/coronavirus_infections/risk-assessment-19june2015/en/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="B152">
       <mixed-citation publication-type="journal">
        <collab>
         World Health Organization
        </collab>
        (
        <year>
         2016a
        </year>
        ).
        <source>
         <italic>
          Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – Saudi Arabia.
         </italic>
        </source>
        Available at:
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/don/19-december-2016-2-mers-saudi-arabia/en/">
         http://www.who.int/csr/don/19-december-2016-2-mers-saudi-arabia/en/
        </ext-link>
        <comment>
         [accessed February 9, 2018]
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="B153">
       <mixed-citation publication-type="journal">
        <collab>
         World Health Organization
        </collab>
        (
        <year>
         2016b
        </year>
        ).
        <source>
         <italic>
          Middle East Respiratory Syndrome Corona Virus (MERS-CoV) WHO MERS-CoV Global Summary and risk assessment 5 December 2016 WHO/MERS/RA/16.1.
         </italic>
        </source>
        Available at:
        <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/mers-cov/en/">
         https://www.who.int/emergencies/mers-cov/en/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="B154">
       <mixed-citation publication-type="journal">
        <collab>
         World Health Organization
        </collab>
        (
        <year>
         2017a
        </year>
        ).
        <source>
         <italic>
          Middle East Respiratory Syndrome Corona Virus (MERS-CoV) – Oman.
         </italic>
        </source>
        Available at:
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/don/10-november-2017-mers-oman/en/">
         http://www.who.int/csr/don/10-november-2017-mers-oman/en/
        </ext-link>
        <comment>
         [accessed December 1, 2017]
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="B155">
       <mixed-citation publication-type="journal">
        <collab>
         World Health Organization
        </collab>
        (
        <year>
         2017b
        </year>
        ).
        <source>
         <italic>
          Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – United Arab Emirates.
         </italic>
        </source>
        Available at:
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/don/22-december-2017-mers-cov-united-arab-emirates/en/">
         http://www.who.int/csr/don/22-december-2017-mers-cov-united-arab-emirates/en/
        </ext-link>
        <comment>
         [accessed February 9, 2018]
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="B156">
       <mixed-citation publication-type="journal">
        <collab>
         World Health Organization
        </collab>
        (
        <year>
         2018a
        </year>
        ).
        <source>
         <italic>
          Middle East Respiratory Syndrome Coronavirus (MERS-CoV).
         </italic>
        </source>
        Available at:
        <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/mers-cov/en/">
         https://www.who.int/emergencies/mers-cov/en/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="B157">
       <mixed-citation publication-type="journal">
        <collab>
         World Health Organization
        </collab>
        (
        <year>
         2018b
        </year>
        ).
        <source>
         <italic>
          Middle East respiratory syndrome coronavirus (MERS-CoV) – Saudi Arabia.
         </italic>
        </source>
        Available at:
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/don/31-december-2018-mers-saudi-arabia/en/">
         http://www.who.int/csr/don/31-december-2018-mers-saudi-arabia/en/
        </ext-link>
        <comment>
         [accessed December 31, 2018]
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="B158">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        ).
        <article-title>
         Middle East respiratory syndrome corona virus (MERS-CoV) entry inhibitors targeting spike protein.
        </article-title>
        <source>
         <italic>
          Virus Res.
         </italic>
        </source>
        <volume>
         194
        </volume>
        <fpage>
         200
        </fpage>
        –
        <lpage>
         210
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2014.10.007
        </pub-id>
        <pub-id pub-id-type="pmid">
         25451066
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B159">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Geng
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2013
        </year>
        ).
        <article-title>
         The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists.
        </article-title>
        <source>
         <italic>
          Protein Cell
         </italic>
        </source>
        <volume>
         4
        </volume>
        <fpage>
         951
        </fpage>
        –
        <lpage>
         961
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1007/s13238-013-3096-8
        </pub-id>
        <pub-id pub-id-type="pmid">
         24318862
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B160">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Lv
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        ).
        <article-title>
         An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus.
        </article-title>
        <source>
         <italic>
          J. Infect. Dis.
         </italic>
        </source>
        <volume>
         209
        </volume>
        <fpage>
         236
        </fpage>
        –
        <lpage>
         242
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1093/infdis/jit590
        </pub-id>
        <pub-id pub-id-type="pmid">
         24218506
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B161">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           M. L.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Jia
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J. F.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K. H.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           K. F.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2016
        </year>
        ).
        <article-title>
         MERS corona virus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2.
        </article-title>
        <source>
         <italic>
          Nat. Microbiol.
         </italic>
        </source>
        <volume>
         1
        </volume>
        :
        <issue>
         16004
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1038/nmicrobiol.2016.4
        </pub-id>
        <pub-id pub-id-type="pmid">
         27572168
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B162">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ying
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Dimitrov
          </surname>
          <given-names>
           D. S.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2016
        </year>
        ).
        <article-title>
         Discovery of T-Cell infection and apoptosis by Middle East Respiratory Syndrome Coronavirus.
        </article-title>
        <source>
         <italic>
          J. Infect. Dis.
         </italic>
        </source>
        <volume>
         213
        </volume>
        <fpage>
         877
        </fpage>
        –
        <lpage>
         879
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1093/infdis/jiv381
        </pub-id>
        <pub-id pub-id-type="pmid">
         26203059
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B163">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2017
        </year>
        ).
        <article-title>
         Comparative pathology of rhesus macaque and common marmoset animal models with middle east respiratory syndrome coronavirus.
        </article-title>
        <source>
         <italic>
          PLoS ONE.
         </italic>
        </source>
        <volume>
         12
        </volume>
        :
        <issue>
         e0172093
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0172093
        </pub-id>
        <pub-id pub-id-type="pmid">
         28234937
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B164">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A. M.
          </given-names>
         </name>
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T. M.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A. D.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R. A.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2012
        </year>
        ).
        <article-title>
         Isolation of a novel corona virus from a man with pneumonia in Saudi Arabia.
        </article-title>
        <source>
         <italic>
          N. Engl. J. Med.
         </italic>
        </source>
        <volume>
         367
        </volume>
        <fpage>
         1814
        </fpage>
        –
        <lpage>
         1820
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1211721
        </pub-id>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B165">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        ).
        <article-title>
         Receptor-binding domain-based subunit vaccines against MERS-CoV.
        </article-title>
        <source>
         <italic>
          Virus Res.
         </italic>
        </source>
        <volume>
         202
        </volume>
        <fpage>
         151
        </fpage>
        –
        <lpage>
         159
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2014.11.013
        </pub-id>
        <pub-id pub-id-type="pmid">
         25445336
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B166">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Gu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2016
        </year>
        ).
        <article-title>
         Evolutionary Dynamics of MERS-CoV: Potential Recombination, Positive Selection and Transmission.
        </article-title>
        <source>
         <italic>
          Sci. Rep.
         </italic>
        </source>
        <volume>
         6
        </volume>
        :
        <issue>
         25049
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1038/srep25049
        </pub-id>
        <pub-id pub-id-type="pmid">
         27142087
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B167">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Tai
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2018
        </year>
        ).
        <article-title>
         A novel nanobody targeting Middle East respiratory syndrome corona virus (MERS-CoV) receptor-binding domain has potent cross-neutralizing activity and protective efficacy against MERS-CoV.
        </article-title>
        <source>
         <italic>
          J. Virol.
         </italic>
        </source>
        <volume>
         92
        </volume>
        :
        <issue>
         e00837
        </issue>
        –
        <issue>
         18.e00837-18
        </issue>
        <comment>
         PMID:NOPMID
        </comment>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00837-18
        </pub-id>
        <pub-id pub-id-type="pmid">
         29950421
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B168">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2015
        </year>
        ).
        <article-title>
         Multi-organ damage in human dipeptidyl peptidase 4 transgenic mice infected with middle east respiratory syndrome-coronavirus.
        </article-title>
        <source>
         <italic>
          PLoS One
         </italic>
        </source>
        <volume>
         10
        </volume>
        :
        <issue>
         e0145561
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0145561
        </pub-id>
        <pub-id pub-id-type="pmid">
         26701103
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B169">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Wohlford-Lenane
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S. S.
          </given-names>
         </name>
         <name>
          <surname>
           Fett
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2014
        </year>
        ).
        <article-title>
         Rapid generation of a mouse model for Middle East respiratory syndrome.
        </article-title>
        <source>
         <italic>
          Proc. Natl. Acad. Sci. U.S.A.
         </italic>
        </source>
        <volume>
         111
        </volume>
        <fpage>
         4970
        </fpage>
        –
        <lpage>
         4975
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1073/pnas.1323279111
        </pub-id>
        <pub-id pub-id-type="pmid">
         24599590
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B170">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Mangalam
          </surname>
          <given-names>
           A. K.
          </given-names>
         </name>
         <name>
          <surname>
           Channappanavar
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Fett
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Meyerholz
          </surname>
          <given-names>
           D. K.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2016
        </year>
        ).
        <article-title>
         Airway memory CD4(+) T cells mediate protective immunity against emerging respiratory coronaviruses.
        </article-title>
        <source>
         <italic>
          Immunity
         </italic>
        </source>
        <volume>
         44
        </volume>
        <fpage>
         1379
        </fpage>
        –
        <lpage>
         1391
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.immuni.2016.05.006
        </pub-id>
        <pub-id pub-id-type="pmid">
         27287409
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B171">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J. F. W.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K. Y.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        ).
        <article-title>
         Middle East respiratory syndrome corona virus infection: virus-host cell interactions and implications on pathogenesis.
        </article-title>
        <source>
         <italic>
          Virol. J.
         </italic>
        </source>
        <volume>
         12
        </volume>
        :
        <issue>
         218
        </issue>
        .
        <pub-id pub-id-type="doi">
         10.1186/s12985-015-0446-6
        </pub-id>
        <pub-id pub-id-type="pmid">
         26690369
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B172">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B. H.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Z. S.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           V. K.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2014
        </year>
        ).
        <article-title>
         Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis.
        </article-title>
        <source>
         <italic>
          J. Infect. Dis.
         </italic>
        </source>
        <volume>
         209
        </volume>
        <fpage>
         1331
        </fpage>
        –
        <lpage>
         1342
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1093/infdis/jit504
        </pub-id>
        <pub-id pub-id-type="pmid">
         24065148
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B173">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ziebuhr
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           E. J.
          </given-names>
         </name>
         <name>
          <surname>
           Gorbalenya
          </surname>
          <given-names>
           A. E.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2000
        </year>
        ).
        <article-title>
         Virus-encoded proteinases and proteolytic processing in the
         <italic>
          Nidovirales
         </italic>
         .
        </article-title>
        <source>
         <italic>
          J. Gen. Virol.
         </italic>
        </source>
        <volume>
         81(Pt 4)
        </volume>
        ,
        <fpage>
         853
        </fpage>
        –
        <lpage>
         879
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1099/0022-1317-81-4-853
        </pub-id>
        <pub-id pub-id-type="pmid">
         10725411
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B174">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zinzula
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Tramontano
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013
        </year>
        ).
        <article-title>
         Strategies of highly pathogenic RNA viruses to block dsRNA detection by RIG-I-like receptors: hide, mask, hit.
        </article-title>
        <source>
         <italic>
          Antiviral Res.
         </italic>
        </source>
        <volume>
         100
        </volume>
        <fpage>
         615
        </fpage>
        –
        <lpage>
         635
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2013.10.002
        </pub-id>
        <pub-id pub-id-type="pmid">
         24129118
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B175">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D. S.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        ).
        <article-title>
         Middle East respiratory syndrome.
        </article-title>
        <source>
         <italic>
          Lancet
         </italic>
        </source>
        <volume>
         38
        </volume>
        <fpage>
         995
        </fpage>
        –
        <lpage>
         1007
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(15)60454-8
        </pub-id>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Influenza Other Respir Viruses
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Influenza Other Respir Viruses
      </journal-id>
      <journal-id journal-id-type="doi">
       10.1111/(ISSN)1750-2659
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       IRV
      </journal-id>
      <journal-title-group>
       <journal-title>
        Influenza and Other Respiratory Viruses
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1750-2640
      </issn>
      <issn pub-type="epub">
       1750-2659
      </issn>
      <publisher>
       <publisher-name>
        Blackwell Publishing Ltd
       </publisher-name>
       <publisher-loc>
        Oxford, UK
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       21477136
      </article-id>
      <article-id pub-id-type="pmc">
       4941587
      </article-id>
      <article-id pub-id-type="doi">
       10.1111/j.1750-2659.2011.00198.x
      </article-id>
      <article-id pub-id-type="publisher-id">
       IRV198
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Original Articles
        </subject>
       </subj-group>
       <subj-group subj-group-type="overline">
        <subject>
         Original Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        A cluster randomized clinical trial comparing fit‐tested and non‐fit‐tested N95 respirators to medical masks to prevent respiratory virus infection in health care workers
       </article-title>
       <alt-title alt-title-type="left-running-head">
        MacIntyre
        <italic>
         et al.
        </italic>
       </alt-title>
       <alt-title alt-title-type="right-running-head">
        RCT of face masks in health workers
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="cr1">
        <name>
         <surname>
          MacIntyre
         </surname>
         <given-names>
          Chandini Raina
         </given-names>
        </name>
        <xref ref-type="aff" rid="a1">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" id="cr2">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Quanyi
         </given-names>
        </name>
        <xref ref-type="aff" rid="a2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" id="cr3">
        <name>
         <surname>
          Cauchemez
         </surname>
         <given-names>
          Simon
         </given-names>
        </name>
        <xref ref-type="aff" rid="a3">
         <sup>
          3
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" id="cr4">
        <name>
         <surname>
          Seale
         </surname>
         <given-names>
          Holly
         </given-names>
        </name>
        <xref ref-type="aff" rid="a1">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" id="cr5">
        <name>
         <surname>
          Dwyer
         </surname>
         <given-names>
          Dominic E.
         </given-names>
        </name>
        <xref ref-type="aff" rid="a4">
         <sup>
          4
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" id="cr6">
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          Peng
         </given-names>
        </name>
        <xref ref-type="aff" rid="a2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" id="cr7">
        <name>
         <surname>
          Shi
         </surname>
         <given-names>
          Weixian
         </given-names>
        </name>
        <xref ref-type="aff" rid="a2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" id="cr8">
        <name>
         <surname>
          Gao
         </surname>
         <given-names>
          Zhanhai
         </given-names>
        </name>
        <xref ref-type="aff" rid="a1">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" id="cr9">
        <name>
         <surname>
          Pang
         </surname>
         <given-names>
          Xinghuo
         </given-names>
        </name>
        <xref ref-type="aff" rid="a2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" id="cr10">
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          Yi
         </given-names>
        </name>
        <xref ref-type="aff" rid="a2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" id="cr11">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Xiaoli
         </given-names>
        </name>
        <xref ref-type="aff" rid="a2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" id="cr12">
        <name>
         <surname>
          Duan
         </surname>
         <given-names>
          Wei
         </given-names>
        </name>
        <xref ref-type="aff" rid="a2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" id="cr13">
        <name>
         <surname>
          Rahman
         </surname>
         <given-names>
          Bayzidur
         </given-names>
        </name>
        <xref ref-type="aff" rid="a1">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" id="cr14">
        <name>
         <surname>
          Ferguson
         </surname>
         <given-names>
          Neil
         </given-names>
        </name>
        <xref ref-type="aff" rid="a3">
         <sup>
          3
         </sup>
        </xref>
       </contrib>
      </contrib-group>
      <aff id="a1">
       <label>
        <sup>
         1
        </sup>
       </label>
       School of Public Health and Community Medicine, Faculty of Medicine, University of New South Wales, Sydney, Australia
      </aff>
      <aff id="a2">
       <label>
        <sup>
         2
        </sup>
       </label>
       The Beijing Center for Disease Prevention and Control, Beijing, China
      </aff>
      <aff id="a3">
       <label>
        <sup>
         3
        </sup>
       </label>
       MRC Center for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, Imperial College London, London, UK
      </aff>
      <aff id="a4">
       <label>
        <sup>
         4
        </sup>
       </label>
       Institute for Clinical Pathology and Medical Research, Westmead Hospital, Sydney, Australia.
      </aff>
      <author-notes>
       <corresp id="correspondenceTo">
        Professor C. Raina MacIntyre, Professor of Infectious Diseases Epidemiology and Head of School, School of Public Health and Community Medicine, Faculty of Medicine, University of New South Wales, Samuels Building, Room 325, Sydney, 2052 NSW, Australia. E‐mail:
        <email>
         r.macintyre@unsw.edu.au
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="epub">
       <day>
        27
       </day>
       <month>
        1
       </month>
       <year>
        2011
       </year>
      </pub-date>
      <pub-date pub-type="ppub">
       <month>
        5
       </month>
       <year>
        2011
       </year>
      </pub-date>
      <volume>
       5
      </volume>
      <issue>
       3
      </issue>
      <issue-id pub-id-type="doi">
       10.1111/irv.2011.5.issue-3
      </issue-id>
      <fpage>
       170
      </fpage>
      <lpage>
       179
      </lpage>
      <history>
       Accepted 3 December 2010. Published Online 27 January 2011.
      </history>
      <permissions>
       <copyright-statement content-type="article-copyright">
        © 2011 Blackwell Publishing Ltd
       </copyright-statement>
      </permissions>
      <self-uri content-type="pdf" xlink:href="file:IRV-5-170.pdf" xlink:type="simple">
      </self-uri>
      <abstract>
       <p>
        <italic>
         Please cite this paper as:
        </italic>
        MacIntyre
        <italic>
         et al.
        </italic>
        (2011) A cluster randomized clinical trial comparing fit‐tested and non‐fit‐tested N95 respirators to medical masks to prevent respiratory virus infection in health care workers. Influenza and Other Respiratory Viruses DOI: 10.1111/j.1750‐2659.2010.00198.x.
       </p>
       <p>
        <bold>
         Background
        </bold>
        We compared the efficacy of medical masks, N95 respirators (fit tested and non fit tested), in health care workers (HCWs).
       </p>
       <p>
        <bold>
         Methods
        </bold>
        A cluster randomized clinical trial (RCT) of 1441 HCWs in 15 Beijing hospitals was performed during the 2008/2009 winter. Participants wore masks or respirators during the entire work shift for 4 weeks. Outcomes included clinical respiratory illness (CRI), influenza‐like illness (ILI), laboratory‐confirmed respiratory virus infection and influenza. A convenience no‐mask/respirator group of 481 health workers from nine hospitals was compared.
       </p>
       <p>
        <bold>
         Findings
        </bold>
        The rates of CRI (3·9% versus 6·7%), ILI (0·3% versus 0·6%), laboratory‐confirmed respiratory virus (1·4% versus 2·6%) and influenza (0·3% versus 1%) infection were consistently lower for the N95 group compared to medical masks. By intention‐to‐treat analysis, when
        <italic>
         P
        </italic>
        values were adjusted for clustering, non‐fit‐tested N95 respirators were significantly more protective than medical masks against CRI, but no other outcomes were significant. The rates of all outcomes were higher in the convenience no‐mask group compared to the intervention arms. There was no significant difference in outcomes between the N95 arms with and without fit testing. Rates of fit test failure were low. In a
        <italic>
         post hoc
        </italic>
        analysis adjusted for potential confounders, N95 masks and hospital level were significant, but medical masks, vaccination, handwashing and high‐risk procedures were not.
       </p>
       <p>
        <bold>
         Interpretation
        </bold>
        Rates of infection in the medical mask group were double that in the N95 group. A benefit of respirators is suggested but would need to be confirmed by a larger trial, as this study may have been underpowered. The finding on fit testing is specific to the type of respirator used in the study and cannot be generalized to other respirators.
       </p>
       <p>
        <bold>
         Trial registration
        </bold>
        Australian New Zealand Clinical Trials Registry (ANZCTR), ACTRN: ACTRN12609000257268 (
        <ext-link ext-link-type="uri" xlink:href="http://www.anzctr.org.au">
         http://www.anzctr.org.au
        </ext-link>
        ).
       </p>
      </abstract>
      <kwd-group>
       <kwd id="k1">
        Health workers
       </kwd>
       <kwd id="k2">
        influenza
       </kwd>
       <kwd id="k3">
        masks
       </kwd>
       <kwd id="k4">
        PPE
       </kwd>
      </kwd-group>
      <counts>
       <fig-count count="3">
       </fig-count>
       <table-count count="5">
       </table-count>
       <page-count count="10">
       </page-count>
      </counts>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         source-schema-version-number
        </meta-name>
        <meta-value>
         2.0
        </meta-value>
       </custom-meta>
       <custom-meta>
        <meta-name>
         cover-date
        </meta-name>
        <meta-value>
         May 2011
        </meta-value>
       </custom-meta>
       <custom-meta>
        <meta-name>
         details-of-publishers-convertor
        </meta-name>
        <meta-value>
         Converter:WILEY_ML3GV2_TO_NLMPMC version:4.6.9 mode:remove_FC converted:04.11.2015
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="ss1">
     <title>
      Introduction
     </title>
     <p>
      The current influenza A H1N1 2009 virus pandemic,
      <xref ref-type="ref" rid="b1">
       <sup>
        1
       </sup>
      </xref>
      the ongoing zoonotic transmission of influenza A H5N1 and the emergence of oseltamivir‐resistant seasonal influenza A H1N1 are threats to human health. Hospital health care workers (HCWs) are key to effective pandemic response and the capacity of health care systems. Respiratory protection is one of the key non‐pharmaceutical interventions for protection of HCWs.
     </p>
     <p>
      Nosocomial influenza and other outbreaks result in significant morbidity and costs
      <xref ref-type="ref" rid="b2">
       <sup>
        2
       </sup>
      </xref>
      ,
      <xref ref-type="ref" rid="b3">
       <sup>
        3
       </sup>
      </xref>
      and can occur in the absence of community epidemics.
      <xref ref-type="ref" rid="b4">
       <sup>
        4
       </sup>
      </xref>
      During outbreaks of infectious diseases, hospitals may amplify virus transmission, as demonstrated during severe acute respiratory syndrome (SARS).
      <xref ref-type="ref" rid="b5">
       <sup>
        5
       </sup>
      </xref>
      Furthermore, anticipated antiviral shortages and delays in vaccine development make non‐pharmaceutical interventions crucial. There are gaps in knowledge about prevention of influenza by medical masks and respirators. There are several prospective, randomized controlled trials on the use of handwashing,
      <xref ref-type="ref" rid="b6">
       <sup>
        6
       </sup>
      </xref>
      ,
      <xref ref-type="ref" rid="b7">
       <sup>
        7
       </sup>
      </xref>
      ,
      <xref ref-type="ref" rid="b8">
       <sup>
        8
       </sup>
      </xref>
      but only two trials on the use of medical masks/respirators in households.
      <xref ref-type="ref" rid="b9">
       <sup>
        9
       </sup>
      </xref>
      ,
      <xref ref-type="ref" rid="b10">
       <sup>
        10
       </sup>
      </xref>
      In one of these studies, we showed that medical masks/respirators in compliant users in the household setting were associated with reductions in the risk of influenza‐like illness (ILI)‐associated infection.
      <xref ref-type="ref" rid="b10">
       <sup>
        10
       </sup>
      </xref>
      To date, there is one small randomized controlled trial (RCT) of medical masks compared to respirators in HCWs
      <xref ref-type="ref" rid="b11">
       <sup>
        11
       </sup>
      </xref>
      which found no difference, but lacked a control arm. Medical masks are not designed to provide respiratory protection.
      <xref ref-type="ref" rid="b12">
       <sup>
        12
       </sup>
      </xref>
      They have consistently lower filtration efficiency when compared to respirators, which are designed specifically for respiratory protection.
      <xref ref-type="ref" rid="b13">
       <sup>
        13
       </sup>
      </xref>
      ,
      <xref ref-type="ref" rid="b14">
       <sup>
        14
       </sup>
      </xref>
      ,
      <xref ref-type="ref" rid="b15">
       <sup>
        15
       </sup>
      </xref>
      Medical masks were designed to prevent wound contamination when worn by the surgeon; however, three RCTs failed to show efficacy against their intended design.
      <xref ref-type="ref" rid="b16">
       <sup>
        16
       </sup>
      </xref>
      ,
      <xref ref-type="ref" rid="b17">
       <sup>
        17
       </sup>
      </xref>
      ,
      <xref ref-type="ref" rid="b18">
       <sup>
        18
       </sup>
      </xref>
     </p>
     <p>
      The aim of this study was to determine the efficacy of medical masks compared to fit‐tested and non‐fit‐tested N95 respirators in HCWs in the prevention of disease because of influenza and other respiratory viruses.
     </p>
    </sec>
    <sec id="ss2">
     <title>
      Methods
     </title>
     <p>
      A prospective, cluster randomized trial of medical mask and respirator use in frontline HCWs was conducted from December 2008 to January 2009 in Beijing, China. We initially aimed to determine the efficacy of two different kinds of respiratory protection (N95 respirators and medical masks) during the influenza season compared to each other and compared to a no‐mask group. However, although we intended to have a randomized control group, this was not acceptable to the Chinese IRB, who felt it would be unethical to assign HCWs randomly to not wear a mask, given mask use was widespread in Chinese hospitals that were included in the randomization. As such, we studied a convenience‐selected no‐mask group of HCWs who did not wear a mask. These HCWs were selected from other hospitals where mask wearing was not routine during the study period. Absence of randomization in the no‐mask group meant that we eventually had to restrict the primary analysis of the trial to the comparison of the efficacy of N95 respirators and medical masks with each other.
     </p>
     <p>
      Participants were hospital HCWs aged ≥18 years from the emergency departments and respiratory wards of 15 hospitals. These wards were selected as high‐risk settings in which repeated and multiple exposures to respiratory infections are expected. We also monitored all participating wards by active surveillance for clinically compatible illness, including in the no‐mask group, for outbreaks of respiratory infection in patients during the study period, and none was detected. All hospitals were large, tertiary hospitals in urban Beijing, and there was no variation in the start of the influenza season within this geographic area.
     </p>
     <p>
      Recruitment commenced on the 1 December 2008 and final follow‐up was completed on 15 January 2009. The study protocol was approved by the Institutional Review Board and Human Research Ethics Committee of the Beijing Ministry for Health. Verbal informed consent was provided by participants, and they were provided written information about the study.
     </p>
     <p>
      The nine hospitals in the convenience no‐arm group were not part of the randomization, but HCWs in those hospitals were selected from the same type of wards as the intervention arms (emergency departments and respiratory wards). They were followed up in the same way as the trial participants for development of infections.
     </p>
     <sec id="ss3">
      <title>
       Randomization and intervention
      </title>
      <p>
       The unit of randomization was hospitals. Hospitals were randomized to one of three intervention arms: (i) Medical masks (3M™ medical mask, catalogue number 1820, St Paul, MN, USA); (ii) N95 fit‐tested mask (3M™ flat‐fold N95 respirator, catalogue number 9132) and (iii) N95 non‐fit‐tested mask (3M™ flat‐fold N95 respirator, catalogue number 9132).
       <xref ref-type="fig" rid="f1">
        Figure 1
       </xref>
       outlines the recruitment and randomization (using a secure computerized randomization program) process. A pre‐study assessment of hospital infection control levels determined that the hospitals had sufficient diversity to warrant stratified randomization by size of hospital and level of infection control. This assessment measured ventilation, spatial dimensions, bedding configuration, handwashing facilities and personal protective equipment use. The Ministry of Health in 1989 categorizes hospitals in China into three levels (Level 3 is the highest) depending on their level of sophistication, equipment and staff/bed numbers. Fifteen hospitals were randomized – five level 2 and ten level 3.
      </p>
      <fig fig-type="Figure" id="f1" orientation="portrait" position="float" xml:lang="en">
       <label>
        Figure 1
       </label>
       <caption>
        <p>
         Consort Diagram of recruitment and follow‐up.
        </p>
       </caption>
       <graphic id="nlm-graphic-1" xlink:href="IRV-5-170-g001">
       </graphic>
      </fig>
     </sec>
     <sec id="ss4">
      <title>
       Primary endpoints
      </title>
      <p>
       (i) Clinical respiratory illness (CRI),
       <xref ref-type="ref" rid="b19">
        <sup>
         19
        </sup>
       </xref>
       defined as two or more respiratory or one respiratory symptom and a systemic symptom; (ii) ILI, defined as fever ≥38°C plus one respiratory symptom (i.e. cough, runny nose, etc.); (iii) laboratory‐confirmed viral respiratory infection (detection of adenoviruses, human metapneumovirus, coronavirus 229E/NL63, parainfluenza viruses 1, 2 and 3, influenza viruses A and B, respiratory syncytial virus A and B, rhinovirus A/B and coronavirus OC43/HKU1 by multiplex PCR); (iv) laboratory‐confirmed influenza A or B and (v) adherence with mask/respirator use.
      </p>
      <p>
       The choice of a relatively broad CRI definition was dictated by our interest in interrupting transmission of a wide range of respiratory viruses, which in adults may or may not be accompanied by fever. Also, all respiratory pathogens share a similar transmission mechanism namely aerosol, droplet and fomite spread, although the relative role of these factors may vary between different viruses and in different clinical situations. Other endpoints included adverse effects, measured using a semi‐structured questionnaire and adherence.
      </p>
     </sec>
     <sec id="ss5">
      <title>
       Eligibility
      </title>
      <p>
       Any nurse, doctor or ward clerk who worked full time in the emergency or respiratory wards at the hospital were eligible. HCWs were excluded if they: (i) were unable or refused to consent; (ii) had beards, long moustaches or long facial hair stubble; (iii) had a current respiratory illness, rhinitis and/or allergy and (iv) worked part‐time or did not work in the aforementioned wards/departments. In all participating wards, 100% of eligible health workers participated.
      </p>
     </sec>
     <sec id="ss6">
      <title>
       Intervention
      </title>
      <p>
       Participants wore the mask or respirator on every shift for 4 consecutive weeks after being shown when to wear it and how to fit it correctly. Participants were supplied daily with either three masks for the medical mask group or two N95 respirators. Participants were asked to store the mask in a paper bag every time they removed it (for toilet breaks, tea/lunch breaks and at the end of every shift) and place the bagged mask or respirator in their locker. All participants were instructed on the importance of hand hygiene prior to/after the removal of medical masks and respirators. Participants in arm two underwent a fit‐testing procedure using a 3M™ FT‐30 Bitrex Fit Test kit according to the manufacturers’ instructions (3M™, St Paul, MN, USA).
      </p>
      <p>
       Detailed demographic and clinical details of all participants were collected. This included age, sex, smoking history, comorbidities, seasonal influenza vaccination status, medications, conduct of high‐risk procedures (defined as suctioning, intubation, nebulized medications, chest physiotherapy and other aerosol generating procedures), handwashing practices, use of other personal protective equipment (gowns, gloves, eye shields and hair/foot covers) and results of laboratory tests. Use of specific interventions for influenza such as antivirals was also measured.
      </p>
     </sec>
     <sec id="ss7">
      <title>
       Follow‐up
      </title>
      <p>
       Participants were followed for 4 weeks of wearing the masks or respirators and an extra week of non‐wearing for development of respiratory symptoms.
      </p>
      <p>
       All participants received a mercury thermometer to measure their temperature at the beginning of each day and at the onset of any symptoms. Diary cards were provided for the duration to record daily the (i) number of hours worked; (ii) mask/respirator usage and (iii) recognized CRI encounters.
      </p>
      <p>
       Participants were contacted daily by phone or face‐to‐face contact to actively identify incident cases of respiratory infection. At each ward, the head nurse actively followed up all participants and identified incident illness. Staff members from the District CDC also undertook daily monitoring of the sites. If participants were symptomatic, swabs of both tonsils and the posterior pharyngeal wall were collected.
      </p>
      <p>
       We also monitored adherence with mask or respirator use over the 4‐week time course by: (i) observation: the head ward nurse observed compliance on the ward on a daily basis and recorded the information on a structured form, (ii) self‐report: a diary card with tick boxes was given to each subject, to be carried during the day. Adherence to wearing the masks or respirators was monitored by these diary cards and returned to researchers on a weekly basis. Exit interviews with participants were conducted after the 4 weeks to gain further insights into adherence and other issues around the use of masks/respirators including adverse effects.
      </p>
     </sec>
     <sec id="ss8">
      <title>
       Sample collection and laboratory testing
      </title>
      <p>
       Participants with symptoms had two pharyngeal swabs collected by a trained nurse or doctor. Double rayon‐tipped, plastic‐shafted swabs were used to scratch both tonsilar areas and the posterior pharyngeal wall. These were transported immediately after collection to the laboratory, or at 4°C within 48 hours if transport was delayed.
      </p>
      <p>
       Pharyngeal swabs were tested with at the Laboratories of the Beijing Centers for Disease Control and Prevention. Viral DNA/RNA was extracted from 300 μl of each respiratory specimen using the Viral Gene‐spin
       <sup>
        TM
       </sup>
       kit (iNtRON Biotechnology, Inc., Seoul, Korea) according to the manufacturer’s instructions. Reverse transcription was performed on 8 μl of RNA in a final reaction volume of 20 μl for 1·5 hours at 37°C, using the RevertAid
       <sup>
        TM
       </sup>
       First Strand cDNA Synthesis kit (Fermentas, Burlington, ON, Canada) to synthesize cDNA. Multiplex polymerase chain reaction (PCR) was carried out using the Seeplex
       <sup>
        ®
       </sup>
       RV12 Detection kit (Seegen, Inc., Seoul, Korea) to detect adenoviruses, human metapneumovirus, coronavirus 229E/NL63, parainfluenza viruses 1, 2 or 3, influenza viruses A or B, respiratory syncytial virus A or B, rhinovirus A/B and coronavirus OC43/HKU1. Three microlitres of synthesized first‐strand cDNA, 4 μl of multiplex primers, 10 μl master mix (hot start
       <italic>
        Taq
       </italic>
       DNA polymerase and dNTP are included in the reaction buffer) and 3 μl of 8‐methoxypsoralen (8‐MOP) were added (8‐MOP, accompanied by UV irradiation for 20 minutes, prevents amplification of contaminated DNA). A mixture of 12 viral clones was used as a positive control template, and sterile deionized water was used as a negative control. After preheating at 95°C for 15 minutes, 40 amplification cycles were carried out under the following conditions in a thermal cycler (GeneAmp PCR system 9700, Foster City, CA, USA): 94°C for 30 seconds, 60°C for 1·5 minutes and 72°C for 1·5 minutes. Amplification was completed at the final extension step at 72°C for 10 minutes. The multiplex PCR products were visualized by electrophoresis on an ethidium bromide‐stained 2% agarose gel. Viral isolation by MDCK cell culture was undertaken for some of the influenza samples which were positive by nuclei acid detection. Specimen processing, DNA/RNA extraction, PCR amplification and PCR product analyses were conducted in different rooms to avoid cross‐contamination.
      </p>
     </sec>
     <sec id="ss9">
      <title>
       Analysis
      </title>
      <p>
       The primary endpoints of interest as described above were analysed by intention‐to‐treat analysis. The two N95 arms were also combined and compared to the medical mask arm, given that there was no significant difference between them and rates of fit test failure were extremely low in the fit‐tested arm (5/461 fit test failures). Differences in proportions between the trial arms were tested by calculation of Pearson’s chi‐square using
       <sc>
        sas
       </sc>
       9.2 software (Cary, NC, USA). The distribution of key potentially confounding variables between study arms was compared. To estimate the odds ratio while adjusting for the clustering effects, we used a random effect logistic regression model. In the model, we added a hospital‐specific random intercept in the linear predictors, and maximum likelihood was estimated using adaptive quadrature.
       <xref ref-type="ref" rid="b20">
        <sup>
         20
        </sup>
       </xref>
       The model was fitted using ‘xtlogit’ command in
       <sc>
        stata
       </sc>
       (College Station, TX, USA).
       <xref ref-type="ref" rid="b21">
        <sup>
         21
        </sup>
       </xref>
      </p>
      <p>
       We also conducted multivariable analysis to adjust for the potential confounders. In the initial model, we included all the variables along with the main exposure variable those were significant (
       <italic>
        P
       </italic>
       &lt; 0·05) in the univariate analysis. We then used a backward elimination method to remove the variables that did not have any confounding effect, that is, could not make meaningful (roughly 10%) change in the effect measure with the main exposure variable.
       <xref ref-type="ref" rid="b22">
        <sup>
         22
        </sup>
       </xref>
       In case of high multi‐collinearity because of strong correlation among the potential confounders, we chose the more relevant ones having the highest confounding effect on the association of interest.
      </p>
      <p>
       We analysed compliance as wearing the mask for &gt;80% of the shift.
      </p>
     </sec>
     <sec id="ss10">
      <title>
       Sample size calculation
      </title>
      <p>
       To obtain 80% power at 2‐sided 5% significant level for detecting a significant difference of attack rate between the intervention arms, and for an assumed 5% attack rate in the N95 arm and 12% in the medical mask arm, a sample size of 488 participants or five clusters (hospitals) per arm was required for cluster size (m) 100 and intra‐cluster correlation coefficient (ICC) 0·01.
       <xref ref-type="ref" rid="b23">
        <sup>
         23
        </sup>
       </xref>
       The design effect (deff) for this cluster randomization trial was 2 (deff = 1 + (
       <italic>
        m
       </italic>
       −1) × ICC = 1 + (100−1) × 0·01 = 2). As such, we aimed to recruit a sample size of 500 per arm.
      </p>
     </sec>
    </sec>
    <sec id="ss11">
     <title>
      Results
     </title>
     <p>
      A total of 1441 nurses and doctors in 15 Beijing hospitals were recruited into the randomized arms and 481 nurses and doctors in nine hospitals were recruited into the convenience no‐mask group.
      <xref ref-type="fig" rid="f1">
       Figure 1
      </xref>
      shows the recruitment process. The distribution of demographic variables was generally similar between arms (
      <xref ref-type="table-wrap" rid="t1">
       Table 1
      </xref>
      ), but was significantly different for anyone smoking in the family, four or more people in family, four or more adults in family, influenza vaccination in 2008 and 2007, public transport, handwashing, hospital level and high‐risk procedures. In regards to hand hygiene, 83% (382/461), 87·8% (428/488) and 88·6% (435/492) of participants from the N95 fit test arm, N95 non‐fit test arm and medical mask arm stated that they washed their hands between patients, respectively.
     </p>
     <table-wrap id="t1" orientation="portrait" position="float" xml:lang="en">
      <label>
       Table 1
      </label>
      <caption>
       <p>
        Demographic and other characteristics by arm of randomization
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <thead valign="bottom">
        <tr style="border-bottom:solid 1px #000000">
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          Variable
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          Medical mask (% and 95% CI) (
          <italic>
           n
          </italic>
          = 492)
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          N95 non‐fit (% and 95% CI) (
          <italic>
           n
          </italic>
          = 488)
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          <italic>
           P
          </italic>
          value
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          N95 fit (% and 95% CI) (
          <italic>
           n
          </italic>
          = 461)
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          <italic>
           P
          </italic>
          value
         </th>
        </tr>
       </thead>
       <tbody valign="top">
        <tr>
         <td align="left" colspan="1" rowspan="2" valign="top">
          Sex (male)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          57/492
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          40/488
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·08
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          45/461
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·36
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          11·6 (8·8–14·4)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          8·2 (5·8–10·6)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          9·8 (7·1–12·5)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2" valign="top">
          Age (mean)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          32·7 (31·8–33·5)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          33 (32·2–33·8)
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·52
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          35·3 (34·4–36·2)
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          &lt;0·01
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2" valign="top">
          Education*
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          189/492
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          180/488
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·62
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          155/461
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·12
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          38·4 (34·1–42·7)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          36·9 (32·6–41·2)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          33·6 (29·3–37·9)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2" valign="top">
          Current smoker
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          18/492
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          17/488
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·88
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          13/461
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·47
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          3·7 (2·0–5·3))
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          3·5 (1·9–5·1)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          2·8 (1·3–4·3)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2" valign="top">
          Anyone smoking in family
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          187/492
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          216/488
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·05
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          213/461
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·01
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          38·0 (33·7–42·3)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          44·3 (39·9–48·7)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          46·2 (41·7–50·8)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2" valign="top">
          Four or more people of family
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          89/492
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          122/488
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·01
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          113/461
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·02
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          18·1 (14·7–21·5)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          25·0 (21·2–28·8)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          24·5 (20·6–28·4)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2" valign="top">
          Four or more adults in family
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          67/492
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          100/488
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          &lt;0·01
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          90/461
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·01
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          13·6 (10·6–16·7)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          20·5 (16·9–24·1)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          19·5 (15·9–23·1)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2" valign="top">
          One child in family**
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          201/485
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          209/464
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·26
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          197/457
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·61
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          41·4 (37·1–45·8)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          45·0 (40·5–49·6)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          43·1 (38·6–47·7)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2" valign="top">
          No children in family**
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          278/485
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          244/464
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·14
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          254/457
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·59
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          57·3 (52·9–61·7)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          52·6 (48·0–57·1)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          55·6 (51·0–60·1)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2" valign="top">
          Influenza vaccination in 2008
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          109/492
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          105/488
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·81
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          44/461
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          &lt;0·01
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          22·2 (18·5–25·8)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          21·5 (17·9–25·2)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          9·5 (6·9–12·2)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2" valign="top">
          Influenza vaccination in 2007
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          107/492
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          105/488
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·93
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          68/461
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          &lt;0·01
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          21·7 (18·1–25·4)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          21·5 (17·9–25·2)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          14·8 (11·5–18·0)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="6" rowspan="1" valign="top">
          Previous mask wearing
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2" valign="top">
          At work
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          469/492
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          475/488
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·09
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          431/461
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·22
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          95·3 (93·5–97·2)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          97·3 (95·9–98·8)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          93·5 (91·2–95·7)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2" valign="top">
          At home
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          3/492
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          4/488
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·7
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          6/461
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·27
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·6 (0–1·3)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·8 (0–1·6)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          1·3 (0·3–2·3)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2" valign="top">
          Public transport
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          7/492
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          11/488
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·33
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          19/461
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·01
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          1·4 (0·4–2·5)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          2·3 (0·9–3·6)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          4·1 (2·3–5·9)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2" valign="top">
          Staff (doctors)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          154/492
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          144/488
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·54
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          166/461
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·12
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          31·3 (27·2–35·4)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          29·5 (25·5–33·6)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          36·0 (31·6–40·4)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2" valign="top">
          Undertake handwashing after touching a patient
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          435/491
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          424/483
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·7
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          382/460
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·01
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          88·6 (85·8–91·4)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          87·8 (84·9–90·7)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          83·0 (79·6–86·5)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2" valign="top">
          Sick contact in household during trial
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          13/296
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          21/376
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·48
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          7/283
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·21
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          4·4 (2·1–6·7)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          5·6 (3·3–7·9)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          2·5 (0·7–4·3)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2" valign="top">
          Hospital level (level 2)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0/492
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          48/488
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          &lt;0·01
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          319/461
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          &lt;0·01
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          9·8 (7·2–12·5)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          69·2 (65·0–73·4)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2" valign="top">
          High‐risk procedure
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          201/492
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          171/488
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          0·06
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          108/461
         </td>
         <td align="left" colspan="1" rowspan="2" valign="top">
          &lt;0·01
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          40·9 (36·5–45·2)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          35·0 (30·8–39·3)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          23·4 (19·6–27·3)
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn id="t1_note178">
        <p>
         *Undergraduate and above.
        </p>
       </fn>
       <fn id="t1_note179">
        <p>
         **Cases without data are not included.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <p>
      For all outcomes, non‐fit‐tested N95 respirators had lower rates of infections compared to fit‐tested N95s (for all N95 versus medical masks, the rates were 3·9% versus 6·7% for CRI, 0·3% versus 0·6% for ILI, 1·4% versus 2·6% for laboratory‐confirmed virus and 0·3% versus 1% for influenza) but these differences were not significant. All infection outcomes were consistently higher (approximately double) in the medical mask group compared to the N95 group (
      <xref ref-type="fig" rid="f2">
       Figure 2
      </xref>
      ). There were no cases of influenza in the non‐fit‐tested N95 arm, three in the fit‐tested N95 arm and five in the medical mask arm. After adjustment for clustering, non‐fit‐tested N95 masks were significantly protective compared to medical masks against CRI, but other outcomes were not significant between N95 and medical masks (
      <xref ref-type="table-wrap" rid="t2">
       Table 2
      </xref>
      ). When compared to the convenience no‐mask group and adjusted for clustering, N95 non‐fit‐tested was significantly protective against CRI, and all N95 was protective against laboratory‐confirmed virus and laboratory‐confirmed influenza (
      <xref ref-type="table-wrap" rid="t3">
       Table 3
      </xref>
      ). In a
      <italic>
       post hoc
      </italic>
      analysis carried out to adjust for potential confounders which were unevenly distributed between arms, all N95 and hospital level remained significant for CRI and laboratory‐confirmed viral infection, but handwashing, vaccination and high‐risk procedures were not significant (
      <xref ref-type="table-wrap" rid="t4">
       Table 4
      </xref>
      ).
     </p>
     <fig fig-type="Figure" id="f2" orientation="portrait" position="float" xml:lang="en">
      <label>
       Figure 2
      </label>
      <caption>
       <p>
        Outcomes in trial arms.
       </p>
      </caption>
      <graphic id="nlm-graphic-3" xlink:href="IRV-5-170-g002">
      </graphic>
     </fig>
     <table-wrap id="t2" orientation="portrait" position="float" xml:lang="en">
      <label>
       Table 2
      </label>
      <caption>
       <p>
        Intention to treat analysis using random effect logistic regression analysis
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <thead valign="bottom">
        <tr style="border-bottom:solid 1px #000000">
         <th align="left" colspan="1" rowspan="2" valign="bottom">
          Arms
         </th>
         <th align="left" colspan="2" rowspan="1" style="border-bottom:solid 1px #000000" valign="bottom">
          CRI
         </th>
         <th align="left" colspan="2" rowspan="1" style="border-bottom:solid 1px #000000" valign="bottom">
          ILI*
         </th>
         <th align="left" colspan="2" rowspan="1" style="border-bottom:solid 1px #000000" valign="bottom">
          Laboratory‐confirmed virus**
         </th>
         <th align="left" colspan="2" rowspan="1" style="border-bottom:solid 1px #000000" valign="bottom">
          Influenza
         </th>
        </tr>
        <tr style="border-bottom:solid 1px #000000">
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          <italic>
           N
          </italic>
          (%)
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          OR (95% CI)***
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          <italic>
           N
          </italic>
          (%)
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          OR (95% CI)***
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          <italic>
           N
          </italic>
          (%)
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          OR (95% CI)***
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          <italic>
           N
          </italic>
          (%)
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          OR (95% CI)***
         </th>
        </tr>
       </thead>
       <tbody valign="top">
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          N95 fit‐tested
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          21/461 (4·6)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·76 (0·27–2·13)
          <italic>
           P
          </italic>
          <sub>
           m
          </sub>
          = 0·60
          <sup>
           †
          </sup>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          1/461 (0·2)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·35 (0·04–3·42)
          <italic>
           P
          </italic>
          <sub>
           m
          </sub>
          = 0·37
          <sup>
           †
          </sup>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          8/461 (1·7)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·69 (0·24–2·03)
          <italic>
           P
          </italic>
          <sub>
           m
          </sub>
          = 0·50
          <sup>
           †
          </sup>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          3/461 (0·7)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·64 (0·15–2·68)
          <italic>
           P
          </italic>
          <sub>
           m
          </sub>
          = 0·54
          <sup>
           †
          </sup>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          N95 non‐fit‐tested
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          16/488 (3·3)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·48 (0·24–0·98)
          <italic>
           P
          </italic>
          <sub>
           m
          </sub>
          = 0·045
          <sup>
           †
          </sup>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          2/488 (0·4)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·67 (0·11–4·03)
          <italic>
           P
          </italic>
          <sub>
           m
          </sub>
          = 0·66
          <sup>
           †
          </sup>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          5/488 (1)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·39 (0·12–1·22)
          <italic>
           P
          </italic>
          <sub>
           m
          </sub>
          = 0·11
          <sup>
           †
          </sup>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0/488 (0)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          All N95
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          37/949 (3·9)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·62 (0·28–1·35)
          <italic>
           P
          </italic>
          <sub>
           m
          </sub>
          = 0·23
          <sup>
           †
          </sup>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          3/949 (0·3)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·52 (0·10–2·57)
          <italic>
           P
          </italic>
          <sub>
           m
          </sub>
          = 0·42
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          13/949 (1·4)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·54 (0·21–1·36)
          <italic>
           P
          </italic>
          <sub>
           m
          </sub>
          = 0·19
          <sup>
           †
          </sup>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          3/949 (0·3)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·31 (0·07–1·32)
          <italic>
           P
          </italic>
          <sub>
           m
          </sub>
          = 0·113
          <sup>
           †
          </sup>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Medical mask
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          33/492 (6·7)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          3/492 (0·6)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          13/492 (2·6)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          5/492 (1)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn id="t2_note49">
        <p>
         *ILI definition using fever &gt;38 – note, this is less sensitive than laboratory‐confirmed infection.
        </p>
       </fn>
       <fn id="t2_note50">
        <p>
         **Any respiratory virus.
        </p>
       </fn>
       <fn id="t2_note51">
        <p>
         ***Odds Ratio – Medical group as reference. A random effect logistic model accounting for clustering was used to compute odd ratios.
        </p>
       </fn>
       <fn id="t2_note52">
        <p>
         <sup>
          †
         </sup>
         <italic>
          P
         </italic>
         <sub>
          m
         </sub>
         :
         <italic>
          P
         </italic>
         value adjusted for clustering of hospitals using random effect logistic regression model.
         <xref ref-type="ref" rid="b29">
          <sup>
           29
          </sup>
         </xref>
        </p>
       </fn>
       <fn id="t2_note53">
        <p>
         CRI, Clinical respiratory illness; ILI, influenza‐like illness.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <table-wrap id="t3" orientation="portrait" position="float" xml:lang="en">
      <label>
       Table 3
      </label>
      <caption>
       <p>
        Comparison with the convenience no‐mask group
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <thead valign="bottom">
        <tr style="border-bottom:solid 1px #000000">
         <th align="left" colspan="1" rowspan="2" valign="bottom">
          Arms
         </th>
         <th align="left" colspan="2" rowspan="1" style="border-bottom:solid 1px #000000" valign="bottom">
          CRI
         </th>
         <th align="left" colspan="2" rowspan="1" style="border-bottom:solid 1px #000000" valign="bottom">
          ILI*
         </th>
         <th align="left" colspan="2" rowspan="1" style="border-bottom:solid 1px #000000" valign="bottom">
          Laboratory‐confirmed virus**
         </th>
         <th align="left" colspan="2" rowspan="1" style="border-bottom:solid 1px #000000" valign="bottom">
          Influenza
         </th>
        </tr>
        <tr style="border-bottom:solid 1px #000000">
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          <italic>
           N
          </italic>
          (%)
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          OR (95% CI)***
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          <italic>
           N
          </italic>
          (%)
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          OR (95% CI)***
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          <italic>
           N
          </italic>
          (%)
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          OR (95% CI)***
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          <italic>
           N
          </italic>
          (%)
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          OR (95% CI)***
         </th>
        </tr>
       </thead>
       <tbody valign="top">
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          N95 fit‐tested
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          21/461 (4·6)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·58 (0·18–1·89)
          <italic>
           P
          </italic>
          = 0·37
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          1/461 (0·2)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·19 (0·02–1·78)
          <italic>
           P
          </italic>
          = 0·14
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          8/461 (1·7)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·55 (0·22–1·35)
          <italic>
           P
          </italic>
          = 0·19
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          3/461 (0·7)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·52 (0·13–2·09)
          <italic>
           P
          </italic>
          = 0·36
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          N95 non‐fit‐tested
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          16/488 (3·3)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          <bold>
           0·36
          </bold>
          (
          <bold>
           0·14–0·94
          </bold>
          )
          <bold>
           <italic>
            P
           </italic>
           = 0·038
          </bold>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          2/488 (0·4)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·33 (0·06–1·72)
          <italic>
           P
          </italic>
          = 0·19
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          5/488 (1)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          <bold>
           0·33
          </bold>
          (
          <bold>
           0·12–0·89
          </bold>
          )
          <bold>
           <italic>
            P
           </italic>
           = 0·03
          </bold>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0/488 (0)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0 –
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          All N95
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          37/949 (3·9)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·46 (0·19–1·11)
          <italic>
           P
          </italic>
          = 0·085
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          3/949 (0·3)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·26 (0·06–1·11)
          <italic>
           P
          </italic>
          = 0·068
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          13/949 (1·4)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          <bold>
           0·43
          </bold>
          (
          <bold>
           0·20–0·91
          </bold>
          )
          <bold>
           <italic>
            P
           </italic>
           = 0·02
          </bold>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          3/949 (0·3)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·25 (0·06–1·00)
          <italic>
           P
          </italic>
          = 0·051
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Medical mask
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          33/492 (6·7)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·74 (0·29–1·88)
          <italic>
           P
          </italic>
          = 0·52
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          3/492 (0·6)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·49 (0·12–2·07)
          <italic>
           P
          </italic>
          = 0·33
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          13/492 (2·6)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·84 (0·38–1·85)
          <italic>
           P
          </italic>
          = 0·67
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          5/492 (1)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·81 (0·25–2·68)
          <italic>
           P
          </italic>
          = 0·73
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn id="t3_note49">
        <p>
         *ILI definition using fever &gt;38 – note, this is less sensitive than laboratory‐confirmed infection.
        </p>
       </fn>
       <fn id="t3_note50">
        <p>
         **Any respiratory virus.
        </p>
       </fn>
       <fn id="t3_note51">
        <p>
         ***Odds Ratio – No‐mask convenience group as reference. A random effect logistic model accounting for clustering was used to compute odd ratios.
        </p>
       </fn>
       <fn id="t3_note52">
        <p>
         CRI, clinical respiratory illness; ILI, influenza‐like illness.
        </p>
       </fn>
       <fn id="t3_note53">
        <p>
         Bold text signifies statistical significance.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <table-wrap id="t4" orientation="portrait" position="float" xml:lang="en">
      <label>
       Table 4
      </label>
      <caption>
       <p>
        Multivariable random effect logistic regression model adjusting for potential confounders, for comparison of All N95 with surgical mask
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <thead valign="bottom">
        <tr style="border-bottom:solid 1px #000000">
         <th align="left" colspan="1" rowspan="2" valign="bottom">
          Variables in the model
         </th>
         <th align="left" colspan="4" rowspan="1" style="border-bottom:solid 1px #000000" valign="bottom">
          Odds ratio (95% CI)*
         </th>
        </tr>
        <tr style="border-bottom:solid 1px #000000">
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          CRI
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          ILI
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          Laboratory‐confirmed virus
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          Influenza
         </th>
        </tr>
       </thead>
       <tbody valign="top">
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          AllN95
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          <bold>
           0·38
          </bold>
          (
          <bold>
           0·17, 0·86
          </bold>
          )
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·58 (0·10, 3·47)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          <bold>
           0·19
          </bold>
          (
          <bold>
           0·05, 0·67
          </bold>
          )
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·27 (0·06, 1·17)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Hospital Level
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          <bold>
           0·40
          </bold>
          (
          <bold>
           0·17, 0·96
          </bold>
          )
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          1·10 (0·10, 12·60)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          <bold>
           0·17
          </bold>
          (
          <bold>
           0·05, 0·65
          </bold>
          )
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          *
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          High‐risk procedures
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·92 (0·53, 1·59)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·54 (0·10, 2·78)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·71 (0·30, 1·68)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          1·90 (0·37, 9·75)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Flu vaccine 2008
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          1·18 (0·59, 2·37)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          **
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          1·07 (0·35, 3·29)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          1·97 (0·23, 16·54)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Handwashing
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          1·00 (0·38, 2·58)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          **
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          **
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          **
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn id="t4_note31">
        <p>
         *Odds ratio was estimated by using random effect logistic regression model to adjust for the clustering effect.
        </p>
       </fn>
       <fn id="t4_note32">
        <p>
         **Model did not converge after including the variable because of multi‐collinearity.
        </p>
       </fn>
       <fn id="t4_note33">
        <p>
         CRI, Clinical respiratory illness; ILI, influenza‐like illness.
        </p>
       </fn>
       <fn id="t4_note34">
        <p>
         Bold text signifies statistical significance.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <p>
      Fit‐testing failure rate was very low (5/461, 1·08%). Rates of adherence in all arms of the study were high (
      <xref ref-type="fig" rid="f3">
       Figure 3
      </xref>
      ).
      <xref ref-type="table-wrap" rid="t5">
       Table 5
      </xref>
      shows adverse events associated with medical mask or N95 use, and that N95 respirators were associated with higher rates of adverse events. Adherence with mask or respirator wearing was high and not significantly different in all arms, with 74% adherence (95% CI 70–78%) in the N95 fit‐tested arm, 68% in the N95 non‐fit‐tested arm (95% CI 64–73%) and 76% in the medical mask arm (95% CI 72–79%). The duration of mask wearing in these arms, respectively, was 5·2 hours (95% CI 5·1–5·4 hours), 4·9 hours (95% CI 4·8–5·1 hours) and 5 hours (95% CI 4·9–5·2 hours;
      <xref ref-type="fig" rid="f3">
       Figure 3
      </xref>
      ).
     </p>
     <fig fig-type="Figure" id="f3" orientation="portrait" position="float" xml:lang="en">
      <label>
       Figure 3
      </label>
      <caption>
       <p>
        Rates of mask/respirator wearing (compliance defined as mask/respirator wearing ≥80% during working hours on follow‐up).
       </p>
      </caption>
      <graphic id="nlm-graphic-5" xlink:href="IRV-5-170-g003">
      </graphic>
     </fig>
     <table-wrap id="t5" orientation="portrait" position="float" xml:lang="en">
      <label>
       Table 5
      </label>
      <caption>
       <p>
        Reported problems associated with using the masks or respirators
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <thead valign="bottom">
        <tr style="border-bottom:solid 1px #000000">
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          Problems with
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          Medical mask (
          <italic>
           n
          </italic>
          = 492)
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          All N95 (
          <italic>
           n
          </italic>
          = 949)
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          <italic>
           P
          </italic>
          value
         </th>
        </tr>
       </thead>
       <tbody valign="top">
        <tr>
         <td align="left" colspan="4" rowspan="1" valign="top">
          Using the mask/respirator
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          None
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          85·5% (420/491)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          47·4% (447/943)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          &lt;0·01
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Uncomfortable
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          9·8% (48/491)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          41·9% (395/943)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          &lt;0·01
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Forgot to wear it
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0% (0/491)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          1·7% (16/943)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          &lt;0·01
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Patient felt unconformable
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·2% (1/491)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          1·8% (17/943)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·01
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Trouble communicating with the patient
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          3·0% (9/303)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          8·0% (62/775)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          &lt;0·01
         </td>
        </tr>
        <tr>
         <td align="left" colspan="4" rowspan="1" valign="top">
          Wearing the mask/respirator
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Headaches
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          3·9% (11/281)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          13·4% (94/701)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          &lt;0·01
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Skin rash
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          4·6% (13/281)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          5·0% (35/701)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·81
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Difficulty breathing
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          12·5% (35/281)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          19·4% (136/701)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·01
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Allergies
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          9·3% (26/281)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          7·1% (50/701)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·26
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Pressure on nose
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          11·0% (31/281)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          52·2% (366/701)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          &lt;0·01
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Other
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          0·7% (2/280)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          8·3% (58/701)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          &lt;0·01
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
    </sec>
    <sec id="ss12">
     <title>
      Discussion
     </title>
     <p>
      We found that rates of respiratory tract infection were approximately double in the medical mask group compared to the N95 group in health workers who wore masks throughout their shift. However, only the N95 non‐fit‐tested arm was significantly protective against CRI, and there were no other significant differences between N95 respirators and medical masks for the four primary outcomes in the adjusted analysis. However, it should be noted that under the null hypothesis where there is no difference between groups, the probability that we wrongly find at least one significant difference given the 12 tests undertaken is 46%. The trial may also be underpowered because observed attack rates were lower than expected.
     </p>
     <p>
      The rates of all outcomes were higher in the convenience no‐mask group than in the masks groups. By adjusted intention‐to‐treat analysis, N95 respirators but not medical masks had significantly lower rates of infection compared to no masks. However, the convenience no‐mask group was not a randomized control arm and hospitals in this group were actually selected on the basis that most of their staff did not wear masks (which is not the norm in hospitals in Beijing), suggesting that conditions in those hospitals were different than those in hospitals from the masks groups. As a consequence, it is not possible to make any definitive judgement on the efficacy of masks on this basis. One possible bias would be if those hospitals had differentially higher risk of infection compared to the intervention hospitals, for example because of the occurrence of outbreaks. However, we monitored all hospitals involved in the study for outbreaks which may have increased apparent attack rates, and none were documented. Other than that, possible sources of bias that could have plausibly increased the infection rate in the control arm (namely vaccination, handwashing, hospital level and high‐risk procedures) were measured. In a
      <italic>
       post hoc
      </italic>
      adjusted analysis, only hospital level and the N95 arm were significant against CRI and laboratory‐confirmed viral infection.
     </p>
     <p>
      Respiratory protection is a key strategy for pandemic control and key to sustaining the health care workforce. The fact that rates of all outcomes were consistently lower in the N95 group suggest that N95 respirators might offer better protection for HCWs; but a larger trial is needed to make a definitive judgment about the relative efficacy of respirators and medical masks. A recent, smaller trial found no difference between N95 and medical masks, but was probably underpowered to detect any differences.
      <xref ref-type="ref" rid="b11">
       <sup>
        11
       </sup>
      </xref>
      Further, the intervention in that study was use of respiratory protection only during care of identified febrile patients with ILI or high‐risk procedures. This is different from the intervention in our study, which comprised wearing the mask for the entire shift. In addition, that study measured serological evidence of influenza as an outcome, which comprised the majority of outcomes, but did not exclude influenza‐vaccinated participants, a flaw that would have resulted in false‐positive cases of ‘influenza’.
     </p>
     <p>
      The finding that fit testing did not improve the efficacy of N95 respirators is important, although it could be explained by a lack of power. The value of fit testing varies with the quality of the respirator, and our study used a high‐quality respirator. These results would not be generalizable to other respirators, where fit testing may be more important. As such, we still recommend that fit testing be part of the process of using respirators.
     </p>
     <p>
      The small number of randomization units along with the small numbers of cases means that estimation of multivariate models would not necessarily converge. In the
      <italic>
       post hoc
      </italic>
      multivariable analysis, we could not adjust for all of the factors because of high correlation among some of them.
     </p>
     <p>
      Other limitations of the study include the generalizability of our results to other types of respirators and to other HCW populations in other countries. Scoping work with Australian HCWs showed compliance of 10% with continual mask wearing during a severe influenza season.
      <xref ref-type="ref" rid="b24">
       <sup>
        24
       </sup>
      </xref>
      Beijing was selected to maximize the power of the study because of the strong culture of mask wearing among HCWs. Another limitation of the study is that cluster RCTs can be impacted by heterogeneity of behaviours, meaning that we cannot exclude such effects caused by behaviours we did not measure. The cluster design is also strength, as interventions against infectious diseases can have herd effects. In infectious diseases which can spread from person to person, the ‘herd effect’ is a real and documented phenomenon where protecting some individuals with an intervention (most commonly vaccination, but also applicable to other interventions) can also protect individuals who were not protected by the intervention. Therefore, if some individuals are randomized to masks on a ward, the individuals who do not wear masks may also be protected because of the effect the masks have on interrupting the transmission of disease from person to person. This is why it is preferable to use cluster design, where everyone in the cluster gets the same intervention.
     </p>
     <p>
      In our study, masks or respirators were worn during the entire shift. Some policies recommend mask/respirator use only when HCWs are conducting high‐risk procedures or entering an isolation room. Whether masks/respirators will be protective when used only when an identified episode of exposure occurs depends on whether HCWs accurately identify all episodes of risk, whether most transmission occurs after clearly identified exposures and whether there is transmission from asymptomatic or pre‐symptomatic infections. There is currently no evidence on how much of a HCWs’ risk is unidentified or unrecognized. In our study, HCWs who conducted high‐risk procedures had higher rates of CRI, but not of laboratory‐confirmed pathogens or influenza. Further clinical research is required to determine the efficacy of continuous versus targeted mask use.
     </p>
     <p>
      Until now, public health policy for dealing with pandemics has relied heavily on data from a modest number of often old and inadequate studies. Data from the SARS outbreak showed that masks reduced transmission of SARS and other viral respiratory infections.
      <xref ref-type="ref" rid="b25">
       <sup>
        25
       </sup>
      </xref>
      ,
      <xref ref-type="ref" rid="b26">
       <sup>
        26
       </sup>
      </xref>
      During SARS, the use of N95 respirators and medical masks was the major protective infection control measure.
      <xref ref-type="ref" rid="b27">
       <sup>
        27
       </sup>
      </xref>
      However, the relative contribution of each type or the difference between N95 respirators and medical masks cannot clearly be determined from observational data.
     </p>
     <p>
      Problems with adherence to mask/respirator use are also a potential problem. We showed that in Australia, less than half of parents who were randomized to wear a medical mask or respirator while their child was ill adhered with mask wearing.
      <xref ref-type="ref" rid="b10">
       <sup>
        10
       </sup>
      </xref>
      There may be adverse effects of wearing masks, which can reduce adherence.
      <xref ref-type="ref" rid="b28">
       <sup>
        28
       </sup>
      </xref>
      ,
      <xref ref-type="ref" rid="b29">
       <sup>
        29
       </sup>
      </xref>
      ,
      <xref ref-type="ref" rid="b30">
       <sup>
        30
       </sup>
      </xref>
      Our study showed significantly higher reported adverse effects of N95 respirators compared to medical masks, consistent with other studies.
      <xref ref-type="ref" rid="b28">
       <sup>
        28
       </sup>
      </xref>
      Interestingly, this population of Chinese HCWs reported overall similar rates of discomfort with masks as parents in our household study,
      <xref ref-type="ref" rid="b10">
       <sup>
        10
       </sup>
      </xref>
      with higher rates in the N95 group, but it did not affect their adherence with mask/respirator wearing. This suggests that discomfort is not the primary driver of adherence, and rather, cultural acceptability and other behavioural factors may be the main reason for non‐adherence. The past experience of Beijing health workers with SARS may also be a factor in the high adherence. This level of adherence may not translate to Western cultural contexts in a normal winter season, especially for N95 respirators; however, adherence can change with perception of risk. During a pandemic, we would expect HCWs to have higher adherence to infection control measures. In summary, our study adds evidence on the use of respiratory protection for HCWs, but highlights the need for larger trials and comparison of different policy options.
     </p>
    </sec>
    <sec id="ss14">
     <title>
      Author contributions
     </title>
     <p>
      Professor C. Raina MacIntyre: As the lead investigator Raina MacIntyre was responsible for conception and design of the trial, overseeing the whole study, analysing data and writing the report; Professor Quanyi Wang: Implementation, contribution to design, analysis and drafting of paper; Dr Simon Cauchemez: Statistical analysis and drafting of paper; Dr Holly Seale: Study design, form/database development, monitoring and review of paper; Professor Dominic E Dwyer: Study design, clinical and laboratory technical assistance and drafting of paper; Dr Peng Yang: Project manager; Dr Weixian Shi: Laboratory testing in China; Dr Zhanhai Gao: Statistical analysis and drafting of paper; Dr Xinghuo Pang: Recruitment and training; Dr Yi Zhang: Database management and analysis; Dr Xiaoli Wang: Database management and analysis; Dr Wei Duan: Recruitment and training; Dr Bayzidur Rahman: Statistical analysis and drafting of paper; Professor Neil Ferguson: Statistical analysis and drafting of paper.
     </p>
    </sec>
    <sec id="ss15">
     <title>
      Conflict of interests
     </title>
     <p>
      Professor Raina MacIntyre: Raina MacIntyre receives funding from influenza vaccine manufacturers GSK and CSL Biotherapies for investigator‐driven research. She has also been on advisory boards for Wyeth, GSK and Merck. Dr Simon Cauchemez received consulting fees from Sanofi‐Pasteur MSD on the modelling of varicella zoster virus. The remaining author(s) declare that they have no competing interests. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. Prior to the start of this study, NMF acted as a consultant for Roche, Novartis and GSK Biologicals (ceasing in 2007).
     </p>
    </sec>
    <back>
     <ack id="ss13">
      <title>
       Acknowledgements
      </title>
      <p>
       We acknowledge the guidance and support we received from the staff at 3M China. This comprised assistance with fit testing for the study, but not financial support. Thanks also go to the trial staff at the Beijing Centre for Disease Control and Surveillance and their affiliated public health units. Thanks to the staff from the 15 Beijing hospitals which participated. Professor Raina MacIntyre designed the study, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Dr Simon Cauchemez thanks the Research Council, UK, and Neil Ferguson thanks the Medical Research Council for Centre funding.
      </p>
     </ack>
     <ref-list id="ss16">
      <title>
       References
      </title>
      <ref id="b1">
       <label>
        1
       </label>
       <mixed-citation id="cit1" publication-type="journal">
        <string-name>
         <surname>
          Fraser
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Donnelly
         </surname>
         <given-names>
          CA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cauchemez
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Pandemic potential of a strain of influenza A (H1N1): early findings
        </article-title>
        .
        <source>
         Science
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         324
        </volume>
        (
        <issue>
         5934
        </issue>
        ):
        <fpage>
         1557
        </fpage>
        –
        <lpage>
         1561
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19433588
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b2">
       <label>
        2
       </label>
       <mixed-citation id="cit2" publication-type="journal">
        <string-name>
         <surname>
          Berg
         </surname>
         <given-names>
          HF
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Van Gendt
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rimmelzwaan
         </surname>
         <given-names>
          GF
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Peeters
         </surname>
         <given-names>
          MF
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Van Keulen
         </surname>
         <given-names>
          P
         </given-names>
        </string-name>
        .
        <article-title>
         Nosocomial influenza infection among post‐influenza‐vaccinated patients with severe pulmonary diseases
        </article-title>
        .
        <source>
         J Infect
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         46
        </volume>
        :
        <fpage>
         129
        </fpage>
        –
        <lpage>
         132
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12634075
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b3">
       <label>
        3
       </label>
       <mixed-citation id="cit3" publication-type="journal">
        <string-name>
         <surname>
          Sartor
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zandotti
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Romain
         </surname>
         <given-names>
          F
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Disruption of services in an internal medicine unit due to a nosocomial influenza outbreak
        </article-title>
        .
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <year>
         2002
        </year>
        ;
        <volume>
         23
        </volume>
        :
        <fpage>
         615
        </fpage>
        –
        <lpage>
         619
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12400893
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b4">
       <label>
        4
       </label>
       <mixed-citation id="cit4" publication-type="journal">
        <string-name>
         <surname>
          Horcajada
         </surname>
         <given-names>
          JP
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Pumarola
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Martinez
         </surname>
         <given-names>
          JA
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         A nosocomial outbreak of influenza during a period without influenza epidemic activity
        </article-title>
        .
        <source>
         Eur Respir J
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         21
        </volume>
        (
        <issue>
         2
        </issue>
        ):
        <fpage>
         303
        </fpage>
        –
        <lpage>
         307
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12608445
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b5">
       <label>
        5
       </label>
       <mixed-citation id="cit5" publication-type="journal">
        <string-name>
         <surname>
          Donnelly
         </surname>
         <given-names>
          CA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ghani
         </surname>
         <given-names>
          AC
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Leung
         </surname>
         <given-names>
          GM
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong
        </article-title>
        .
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         361
        </volume>
        (
        <issue>
         9371
        </issue>
        ):
        <fpage>
         1761
        </fpage>
        –
        <lpage>
         1766
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12781533
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b6">
       <label>
        6
       </label>
       <mixed-citation id="cit6" publication-type="journal">
        <string-name>
         <surname>
          Larson
         </surname>
         <given-names>
          E
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Aiello
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lee
         </surname>
         <given-names>
          LV
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Short‐ and long‐term effects of handwashing with antimicrobial or plain soap in the community
        </article-title>
        .
        <source>
         J Community Health
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         28
        </volume>
        (
        <issue>
         2
        </issue>
        ):
        <fpage>
         139
        </fpage>
        –
        <lpage>
         150
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12705315
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b7">
       <label>
        7
       </label>
       <mixed-citation id="cit7" publication-type="journal">
        <string-name>
         <surname>
          Larson
         </surname>
         <given-names>
          EL
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lin
         </surname>
         <given-names>
          SX
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Gomez‐Pichardo
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Effect of antibacterial home cleaning and handwashing products on infectious disease symptoms: a randomized, double‐blind trial
        </article-title>
        .
        <source>
         Ann Intern Med
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         140
        </volume>
        (
        <issue>
         5
        </issue>
        ):
        <fpage>
         321
        </fpage>
        –
        <lpage>
         329
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14996673
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b8">
       <label>
        8
       </label>
       <mixed-citation id="cit8" publication-type="journal">
        <string-name>
         <surname>
          Rabie
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Curtis
         </surname>
         <given-names>
          V
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rabie
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Curtis
         </surname>
         <given-names>
          V
         </given-names>
        </string-name>
        .
        <article-title>
         Handwashing and risk of respiratory infections: a quantitative systematic review
        </article-title>
        .
        <source>
         Trop Med Int Health
        </source>
        <year>
         2006
        </year>
        ;
        <volume>
         11
        </volume>
        (
        <issue>
         3
        </issue>
        ):
        <fpage>
         258
        </fpage>
        –
        <lpage>
         267
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16553905
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b9">
       <label>
        9
       </label>
       <mixed-citation id="cit9" publication-type="journal">
        <string-name>
         <surname>
          Cowling
         </surname>
         <given-names>
          BJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chan
         </surname>
         <given-names>
          KH
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Fang
         </surname>
         <given-names>
          VJ
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Facemasks and hand hygiene to prevent influenza transmission in households: a randomized trial
        </article-title>
        .
        <source>
         Ann Intern Med
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         151
        </volume>
        :
        <fpage>
         437
        </fpage>
        –
        <lpage>
         446
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19652172
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b10">
       <label>
        10
       </label>
       <mixed-citation id="cit10" publication-type="journal">
        <string-name>
         <surname>
          MacIntyre
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cauchemez
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Dwyer
         </surname>
         <given-names>
          DE
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Face mask use and control of respiratory virus transmission in households
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         15
        </volume>
        :
        <fpage>
         233
        </fpage>
        –
        <lpage>
         241
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19193267
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b11">
       <label>
        11
       </label>
       <mixed-citation id="cit11" publication-type="journal">
        <string-name>
         <surname>
          Loeb
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Dafoe
         </surname>
         <given-names>
          N
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Mahony
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Surgical mask vs N95 respirator for preventing influenza among health care workers: a randomized trial
        </article-title>
        .
        <source>
         JAMA
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         302
        </volume>
        (
        <issue>
         17
        </issue>
        ):
        <fpage>
         1865
        </fpage>
        –
        <lpage>
         1871
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19797474
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b12">
       <label>
        12
       </label>
       <mixed-citation id="cit12" publication-type="journal">
        <string-name>
         <surname>
          Shine
         </surname>
         <given-names>
          KI
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rogers
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Goldfrank
         </surname>
         <given-names>
          LR
         </given-names>
        </string-name>
        .
        <article-title>
         Novel H1N1 Influenza and Respiratory Protection for Health Care Workers
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         361
        </volume>
        (
        <issue>
         19
        </issue>
        ):
        <fpage>
         1823
        </fpage>
        –
        <lpage>
         1825
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19797278
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b13">
       <label>
        13
       </label>
       <mixed-citation id="cit13" publication-type="journal">
        <string-name>
         <surname>
          Balazy
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Toivola
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Adhikari
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Sivasubramani
         </surname>
         <given-names>
          SK
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Reponen
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Grinshpun
         </surname>
         <given-names>
          SA
         </given-names>
        </string-name>
        .
        <article-title>
         Do N95 respirators provide 95% protection level against airborne viruses, and how adequate are surgical masks?
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <year>
         2006
        </year>
        ;
        <volume>
         34
        </volume>
        (
        <issue>
         2
        </issue>
        ):
        <fpage>
         51
        </fpage>
        –
        <lpage>
         57
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16490606
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b14">
       <label>
        14
       </label>
       <mixed-citation id="cit14" publication-type="journal">
        <string-name>
         <surname>
          Lawrence
         </surname>
         <given-names>
          RB
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Duling
         </surname>
         <given-names>
          MG
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Calvert
         </surname>
         <given-names>
          CA
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Comparison of performance of three different types of respiratory protection devices
        </article-title>
        .
        <source>
         J Occup Environ Hyg
        </source>
        <year>
         2006
        </year>
        ;
        <volume>
         3
        </volume>
        (
        <issue>
         9
        </issue>
        ):
        <fpage>
         465
        </fpage>
        –
        <lpage>
         474
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16857645
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b15">
       <label>
        15
       </label>
       <mixed-citation id="cit15" publication-type="journal">
        <string-name>
         <surname>
          Weber
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Willeke
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Marchioni
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Aerosol penetration and leakage characteristics of masks used in the health care industry
        </article-title>
        .
        <source>
         Am J Infect Control
        </source>
        <year>
         1993
        </year>
        ;
        <volume>
         21
        </volume>
        (
        <issue>
         4
        </issue>
        ):
        <fpage>
         167
        </fpage>
        –
        <lpage>
         173
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8239046
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b16">
       <label>
        16
       </label>
       <mixed-citation id="cit16" publication-type="journal">
        <string-name>
         <surname>
          Orr
         </surname>
         <given-names>
          NW
         </given-names>
        </string-name>
        .
        <article-title>
         Is a mask necessary in the operating theatre?
        </article-title>
        <source>
         Ann R Coll Surg Engl
        </source>
        <year>
         1981
        </year>
        ;
        <volume>
         63
        </volume>
        (
        <issue>
         6
        </issue>
        ):
        <fpage>
         390
        </fpage>
        –
        <lpage>
         392
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         7294681
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b17">
       <label>
        17
       </label>
       <mixed-citation id="cit17" publication-type="journal">
        <string-name>
         <surname>
          Mitchell
         </surname>
         <given-names>
          NJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hunt
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        .
        <article-title>
         Surgical face masks in modern operating rooms‐‐a costly and unnecessary ritual?
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         1991
        </year>
        ;
        <volume>
         18
        </volume>
        (
        <issue>
         3
        </issue>
        ):
        <fpage>
         239
        </fpage>
        –
        <lpage>
         242
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         1680906
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b18">
       <label>
        18
       </label>
       <mixed-citation id="cit18" publication-type="journal">
        <string-name>
         <surname>
          Tunevall
         </surname>
         <given-names>
          TG
         </given-names>
        </string-name>
        .
        <article-title>
         Postoperative wound infections and surgical face masks: a controlled study
        </article-title>
        .
        <source>
         World J Surg
        </source>
        <year>
         1991
        </year>
        ;
        <volume>
         15
        </volume>
        (
        <issue>
         3
        </issue>
        ):
        <fpage>
         383
        </fpage>
        –
        <lpage>
         387
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         1853618
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b19">
       <label>
        19
       </label>
       <mixed-citation id="cit19" publication-type="journal">
        <string-name>
         <surname>
          Carrat
         </surname>
         <given-names>
          F
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Sahler
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rogez
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Influenza burden of illness: estimates from a national prospective survey of household contacts in France
        </article-title>
        .
        <source>
         Arch Intern Med
        </source>
        <year>
         2002
        </year>
        ;
        <volume>
         162
        </volume>
        (
        <issue>
         16
        </issue>
        ):
        <fpage>
         1842
        </fpage>
        –
        <lpage>
         1848
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12196082
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b20">
       <label>
        20
       </label>
       <mixed-citation id="cit20" publication-type="book">
        <string-name>
         <surname>
          Rabe‐Hesketh
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Skrondal
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        .
        <source>
         Multilevel and Longitudinal Modeling Using Stata
        </source>
        ,
        <edition>
         2nd edn
        </edition>
        College Station, Tex:
        <publisher-name>
         Stata Press Publication
        </publisher-name>
        ,
        <year>
         2008
        </year>
        .
       </mixed-citation>
      </ref>
      <ref id="b21">
       <label>
        21
       </label>
       <mixed-citation id="cit21" publication-type="book">
        <string-name>
         <surname>
          Vittinghoff
         </surname>
         <given-names>
          E
         </given-names>
        </string-name>
        .
        <source>
         Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models
        </source>
        . New York:
        <publisher-name>
         Springer
        </publisher-name>
        ,
        <year>
         2005
        </year>
        .
       </mixed-citation>
      </ref>
      <ref id="b22">
       <label>
        22
       </label>
       <mixed-citation id="cit22" publication-type="book">
        <string-name>
         <surname>
          Agresti
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        .
        <source>
         An Introduction to Categorical Data Analysis
        </source>
        ,
        <edition>
         2nd edn
        </edition>
        Hoboken, NJ:
        <publisher-name>
         Wiley‐Interscience
        </publisher-name>
        ,
        <year>
         2007
        </year>
        .
       </mixed-citation>
      </ref>
      <ref id="b23">
       <label>
        23
       </label>
       <mixed-citation id="cit23" publication-type="book">
        <string-name>
         <surname>
          Donner
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Klar
         </surname>
         <given-names>
          N
         </given-names>
        </string-name>
        .
        <source>
         Design and Analysis of Cluster Randomization Trials in Health Research
        </source>
        . London:
        <publisher-name>
         Arnold
        </publisher-name>
        ,
        <year>
         2000
        </year>
        .
       </mixed-citation>
      </ref>
      <ref id="b24">
       <label>
        24
       </label>
       <mixed-citation id="cit24" publication-type="journal">
        <string-name>
         <surname>
          Seale
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Corbett
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Dwyer
         </surname>
         <given-names>
          DE
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Macintyre
         </surname>
         <given-names>
          CR
         </given-names>
        </string-name>
        .
        <article-title>
         Feasibility Exercise to Evaluate the Use of Particulate Respirators by Emergency Department Staff During the 2007 Influenza Season
        </article-title>
        .
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         30
        </volume>
        :
        <fpage>
         710
        </fpage>
        –
        <lpage>
         712
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19496650
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b25">
       <label>
        25
       </label>
       <mixed-citation id="cit25" publication-type="journal">
        <string-name>
         <surname>
          Lo
         </surname>
         <given-names>
          JY
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tsang
         </surname>
         <given-names>
          TH
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Leung
         </surname>
         <given-names>
          YH
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yeung
         </surname>
         <given-names>
          EY
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wu
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lim
         </surname>
         <given-names>
          WW
         </given-names>
        </string-name>
        .
        <article-title>
         Respiratory infections during SARS outbreak, Hong Kong, 2003
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2005
        </year>
        ;
        <volume>
         11
        </volume>
        (
        <issue>
         11
        </issue>
        ):
        <fpage>
         1738
        </fpage>
        –
        <lpage>
         1741
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16318726
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b26">
       <label>
        26
       </label>
       <mixed-citation id="cit26" publication-type="journal">
        <string-name>
         <surname>
          Pang
         </surname>
         <given-names>
          X
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhu
         </surname>
         <given-names>
          Z
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Xu
         </surname>
         <given-names>
          F
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Evaluation of control measures implemented in the severe acute respiratory syndrome outbreak in Beijing, 2003
        </article-title>
        .
        <source>
         JAMA
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         290
        </volume>
        (
        <issue>
         24
        </issue>
        ):
        <fpage>
         3215
        </fpage>
        –
        <lpage>
         3221
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14693874
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b27">
       <label>
        27
       </label>
       <mixed-citation id="cit27" publication-type="journal">
        <string-name>
         <surname>
          Seto
         </surname>
         <given-names>
          WH
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tsang
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yung
         </surname>
         <given-names>
          RW
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS)
        </article-title>
        .
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         361
        </volume>
        (
        <issue>
         9368
        </issue>
        ):
        <fpage>
         1519
        </fpage>
        –
        <lpage>
         1520
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12737864
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b28">
       <label>
        28
       </label>
       <mixed-citation id="cit28" publication-type="journal">
        <string-name>
         <surname>
          Lim
         </surname>
         <given-names>
          EC
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Seet
         </surname>
         <given-names>
          RC
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lee
         </surname>
         <given-names>
          KH
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Headaches and the N95 face‐mask amongst healthcare providers
        </article-title>
        .
        <source>
         Acta Neurol Scand
        </source>
        <year>
         2006
        </year>
        ;
        <volume>
         113
        </volume>
        (
        <issue>
         3
        </issue>
        ):
        <fpage>
         199
        </fpage>
        –
        <lpage>
         202
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16441251
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b29">
       <label>
        29
       </label>
       <mixed-citation id="cit29" publication-type="journal">
        <string-name>
         <surname>
          Kao
         </surname>
         <given-names>
          TW
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Huang
         </surname>
         <given-names>
          KC
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Huang
         </surname>
         <given-names>
          YL
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         The physiological impact of wearing an N95 mask during hemodialysis as a precaution against SARS in patients with end‐stage renal disease
        </article-title>
        .
        <source>
         J Formos Med Assoc
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         103
        </volume>
        (
        <issue>
         8
        </issue>
        ):
        <fpage>
         624
        </fpage>
        –
        <lpage>
         628
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15340662
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b30">
       <label>
        30
       </label>
       <mixed-citation id="cit30" publication-type="journal">
        <string-name>
         <surname>
          Troendle
         </surname>
         <given-names>
          JF
         </given-names>
        </string-name>
        .
        <article-title>
         A Stepwise Resampling Method of Multiple Hypothesis‐Testing
        </article-title>
        .
        <source>
         J Am Stat Assoc
        </source>
        <year>
         1995
        </year>
        ;
        <volume>
         90
        </volume>
        (
        <issue>
         429
        </issue>
        ):
        <fpage>
         370
        </fpage>
        –
        <lpage>
         378
        </lpage>
        .
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Chest
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Chest
      </journal-id>
      <journal-title-group>
       <journal-title>
        Chest
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0012-3692
      </issn>
      <issn pub-type="epub">
       1931-3543
      </issn>
      <publisher>
       <publisher-name>
        The American College of Chest Physicians. Published by Elsevier Inc.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       16963681
      </article-id>
      <article-id pub-id-type="pmc">
       7094573
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0012-3692(15)52797-9
      </article-id>
      <article-id pub-id-type="doi">
       10.1378/chest.130.3.822
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Airflows Around Oxygen Masks
       </article-title>
       <subtitle>
        A Potential Source of Infection
       </subtitle>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au10">
        <name>
         <surname>
          Hui
         </surname>
         <given-names>
          David S.
         </given-names>
        </name>
        <degrees>
         MD, FCCP
        </degrees>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au20">
        <name>
         <surname>
          Ip
         </surname>
         <given-names>
          Margaret
         </given-names>
        </name>
        <degrees>
         MBChB, MD
        </degrees>
        <xref ref-type="aff" rid="aff2">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au30">
        <name>
         <surname>
          Tang
         </surname>
         <given-names>
          Julian W.
         </given-names>
        </name>
        <degrees>
         MBChB, PhD
        </degrees>
        <email>
         julian.tang@cuhk.edu.hk
        </email>
        <xref ref-type="corresp" rid="cor1">
         e
        </xref>
        <xref ref-type="aff" rid="aff2">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au40">
        <name>
         <surname>
          Wong
         </surname>
         <given-names>
          Alexandra L.N.
         </given-names>
        </name>
        <degrees>
         BSc
        </degrees>
        <xref ref-type="aff" rid="aff4">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au50">
        <name>
         <surname>
          Chan
         </surname>
         <given-names>
          Matthew T.V.
         </given-names>
        </name>
        <degrees>
         MBChB, MD
        </degrees>
        <xref ref-type="aff" rid="aff3">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au60">
        <name>
         <surname>
          Hall
         </surname>
         <given-names>
          Stephen D.
         </given-names>
        </name>
        <degrees>
         BSc, PhD
        </degrees>
        <xref ref-type="aff" rid="aff5">
         d
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au70">
        <name>
         <surname>
          Chan
         </surname>
         <given-names>
          Paul K.S.
         </given-names>
        </name>
        <degrees>
         MBBS, MD
        </degrees>
        <xref ref-type="aff" rid="aff2">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au80">
        <name>
         <surname>
          Sung
         </surname>
         <given-names>
          Joseph J.Y.
         </given-names>
        </name>
        <degrees>
         MD, PhD
        </degrees>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        *
       </label>
       From the Departments of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, Peoples Republic of China
      </aff>
      <aff id="aff2">
       <label>
        a
       </label>
       Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, Peoples Republic of China
      </aff>
      <aff id="aff3">
       <label>
        b
       </label>
       Anesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, Peoples Republic of China
      </aff>
      <aff id="aff4">
       <label>
        c
       </label>
       The Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, Peoples Republic of China
      </aff>
      <aff id="aff5">
       <label>
        d
       </label>
       The School of Mechanical Engineering, University of New South Wales, Sydney, NSW, Australia
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         e
        </label>
        Correspondence to: Julian W. Tang, MBChB, PhD, Department of Microbiology, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, Peoples Republic of China
        <email>
         julian.tang@cuhk.edu.hk
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        31
       </day>
       <month>
        12
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <month>
        9
       </month>
       <year>
        2006
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        31
       </day>
       <month>
        12
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <volume>
       130
      </volume>
      <issue>
       3
      </issue>
      <fpage>
       822
      </fpage>
      <lpage>
       826
      </lpage>
      <history>
       <date date-type="received">
        <day>
         1
        </day>
        <month>
         12
        </month>
        <year>
         2005
        </year>
       </date>
       <date date-type="accepted">
        <day>
         22
        </day>
        <month>
         2
        </month>
        <year>
         2006
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2006 The American College of Chest Physicians
       </copyright-statement>
       <copyright-year>
        2006
       </copyright-year>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="ceab10">
       <p>
        Patients with respiratory infections often require the use of supplemental oxygen via oxygen masks, which, in the hospital, may become sources of aerosolized infectious pathogens. To assess this risk, a human lung model (respiration rate, 12 breaths/min) was designed to test the potential for a simple oxygen mask at a common setting (4 L/min) to disperse potentially infectious exhaled air into the surrounding area. A laser sheet was used to illuminate the exhaled air from the mask, which contained fine tracer smoke particles. An analysis of captured digital images showed that the exhaled air at the peak of simulated exhalation reached a distance of approximately 0.40 m.
       </p>
      </abstract>
      <kwd-group id="cekeyws10">
       <title>
        Keywords
       </title>
       <kwd>
        aerosol
       </kwd>
       <kwd>
        airborne
       </kwd>
       <kwd>
        airflow
       </kwd>
       <kwd>
        hospital-acquired
       </kwd>
       <kwd>
        infection
       </kwd>
       <kwd>
        infection control
       </kwd>
       <kwd>
        nosocomial
       </kwd>
       <kwd>
        oxygen mask
       </kwd>
       <kwd>
        transmission
       </kwd>
       <kwd>
        visualization
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="cenomen10">
     <title>
      Abbreviations
     </title>
     <def-list>
      <def-item>
       <term id="defterm10">
        CoV
       </term>
       <def>
        <p id="para10">
         coronavirus
        </p>
       </def>
      </def-item>
      <def-item>
       <term id="defterm20">
        HPS
       </term>
       <def>
        <p id="para20">
         human patient simulator
        </p>
       </def>
      </def-item>
      <def-item>
       <term id="defterm30">
        SARS
       </term>
       <def>
        <p id="para30">
         severe acute respiratory syndrome
        </p>
       </def>
      </def-item>
     </def-list>
    </sec>
    <sec>
     <p id="para40">
      Patients admitted to the hospital with pneumonia often require supplemental oxygen via nasal cannula or oronasal masks. Usually, there are no additional isolation precautions taken for such patients, and they may be on an open ward with a respiratory infection, breathing with the aid of an oxygen mask that is supplying oxygen at a flow rate of up to 10 L/min. However, little is known about the airflow characteristics of such oxygen delivery devices and their ability to transmit infection by aerosol. This problem of hospital-acquired infection via infectious aerosol was highlighted in the severe acute respiratory syndrome (SARS) epidemics of 2003.
      <xref ref-type="bibr" rid="bib1">
       <sup>
        1
       </sup>
      </xref>
      Many cases of SARS occurred within hospitals with infections taking place between patients and health-care workers, in some cases apparently assisted by oxygen delivery and other respiratory support devices.
      <xref ref-type="bibr" rid="bib1">
       <sup>
        1
       </sup>
      </xref>
      Since then, it has been reported that SARS-coronavirus (CoV) RNA can be detected in air,
      <xref ref-type="bibr" rid="bib2">
       <sup>
        2
       </sup>
      </xref>
      and in some cases airborne SARS CoV can also be grown in culture, demonstrating viability.
      <xref ref-type="bibr" rid="bib3">
       <sup>
        3
       </sup>
      </xref>
      More recently, avian influenza (influenza H5N1) has led to a high mortality rate in human cases in Thailand and Vietnam.
      <xref ref-type="bibr" rid="bib4">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="bib5">
       5
      </xref>
      The strongest case implicating person-to-person transmission of influenza H5N1 also occurred in a hospital setting.
      <xref ref-type="bibr" rid="bib6">
       <sup>
        6
       </sup>
      </xref>
      The potential for long-range, airborne transmission for both influenza
      <xref ref-type="bibr" rid="bib6">
       6
      </xref>
      ,
      <xref ref-type="bibr" rid="bib7">
       7
      </xref>
      and SARS CoV
      <xref ref-type="bibr" rid="bib8">
       <sup>
        8
       </sup>
      </xref>
      has been reported. Yet, it has been difficult to demonstrate the risk of aerosol transmission of such respiratory infections in the health-care environment, and there are still many serious gaps in our knowledge.
      <xref ref-type="bibr" rid="bib7">
       <sup>
        7
       </sup>
      </xref>
     </p>
     <p id="para50">
      In one study, using aerosolized 3% hypertonic saline solution and photographic techniques, Somogyi et al
      <xref ref-type="bibr" rid="bib9">
       <sup>
        9
       </sup>
      </xref>
      demonstrated that throughout exhalation, both the nonrebreathing and Venturi-type oxygen masks channeled the exhaled gas through side vents, forming a leakage plume of exhaled gas that was directed to either side of the patient. The authors asked the volunteer to hold his breath for approximately 2 s, while the masks were fitted to his face. The volunteer then exhaled smoothly for at least 2 s, during which a series of still photographs were taken. Although the volunteer's breathing action was not physiologic in this study, the authors demonstrated that such oxygen masks could produce potentially infectious plumes from exhaled air that could be inhaled by health-care workers, visitors, and other patients.
     </p>
     <p id="para60">
      In order to further assess the potential for oxygen masks to spread infection, we designed a human lung model with a more realistic breathing cycle. In addition, we applied an engineering-based approach to visualize and analyze the airflow images recorded on digital video during simulated respiration with a simple oxygen mask.
     </p>
     <sec id="cesec10">
      <title>
       MATERIALS AND METHODS
      </title>
      <sec id="cesec20">
       <title>
        Human Lung Model
       </title>
       <p id="para70">
        A high-fidelity human patient simulator (HPS) [model 6.1; Medical Education Technologies Inc; Sarasota, FL], representing a medium-sized adult man sitting on a 45°-inclined hospital bed, was fitted with a simple oxygen mask (HS-3031; Hsiner; Taichung Hsien, Taiwan). The head, neck, and internal airways of the HPS were configured to allow realistic airflow modeling in the airways and around the face. Oxygen flow was set as 4 L/min, and the simulator was programmed for a respiratory rate of 12 breaths/min and a tidal volume of 0.5 L.
       </p>
      </sec>
      <sec id="cesec30">
       <title>
        Imaging and Video Capture System
       </title>
       <p id="para80">
        The mask airflow was visualized by smoke using an M-6000 smoke generator (model N19; DS Electronics; Tempe, AZ). The generated smoke was continuously introduced to the right main bronchus of the HPS as part of the inhaled air. This design allowed the smoke to continuously mix with the alveolar gas and then to be part of the exhaled air, to allow visualization.
       </p>
       <p id="para90">
        Initially, the smoke airflow was illuminated with a strong halogen light to reveal the full three-dimensional extent of the mask airflow and the leakage plume. Sections through the plume were then revealed by an intense laser light-sheet created by an Nd:YVO
        <sub>
         4
        </sub>
        Q-switched, frequency-doubled laser (OEM T20-BL 10–106Q; Spectra-Physics Lasers; Mountain View, CA), with custom cylindrical optics for two-dimensional laser light-sheet generation (
        <xref ref-type="fig" rid="fig1">
         Figure 1
        </xref>
        ). This was recorded with a three charge-couple device, ×48 zoom digital video system (Sony; Tokyo, Japan) at an image rate of 30 Hz.
        <fig id="fig1">
         <label>
          Figure 1
         </label>
         <caption>
          <p>
           Basic arrangement of the two-dimensional laser light-sheet and camera. The digital video camera filmed from only one side of the mask, leading to an asymmetrically illuminated image record. In the final image processing, symmetry was assumed based on the symmetrical structure of the mask.
          </p>
         </caption>
         <graphic xlink:href="gr1">
         </graphic>
        </fig>
       </p>
       <p id="para100">
        The laser light-sheet was adjusted to encompass the full leakage plume, which was previously identified from the halogen light observations and set at a thickness of approximately 1 to 2 mm. The light-sheet (green, 527-nm wavelength, transverse electromagnetic mode
        <sub>
         00
        </sub>
        , and 2-W average power) was positioned on one side of the manikin, with the plane of the light-sheet adjusted for the mask to illuminate as much of the smoke cloud as possible. The cross-sectional plane of the leakage plume and sections through it were of interest. The laser could be run in continuous wave mode (100 mW average power), or high-frequency (350 kHz) pulsed mode for pulse intensities up to an average of 2 W. Pulse frequencies of &gt; 1 kHz were found to be effectively continuous wave for both video and observation by eye.
       </p>
       <p id="para110">
        Following the positioning of the laser light-sheet, the video images captured were synchronized with the respiratory cycle by starting the video capture at the exact beginning of breath exhalation. The video recording captured many simulated breath cycles, and the images corresponding to the maximum expired volume during each respiratory cycle were analyzed. Both real-time full-motion video (30 images per second) and snapshot images of the video images were analyzed.
       </p>
      </sec>
      <sec id="cesec40">
       <title>
        Video Image Analysis
       </title>
       <p id="para120">
        Full-motion video was reviewed in real-time using a movie editor (Windows Movie Maker; Microsoft; Richmond, WA), and the best images of respiration showing airflow behavior were analyzed using software that was developed for this study (Matlab 6.5). In order to obtain the clearest boundary of dissemination, image-processing techniques were applied to these images to define the edge of the visible smoke boundary from the captured digital video images (see supplementary material at
        <ext-link ext-link-type="uri" id="interrefs20" xlink:href="http://www.chestnet.org">
         www.chestnet.org
        </ext-link>
        ). These techniques were applied to a selected video image that represented the peak of simulated exhalation during one breath cycle by the human simulator. Finally, we assumed that the smoke propagations were symmetric under the symmetric mask structure. This was observed and confirmed during the initial three-dimensional flow visualization using the halogen light. Hence, a symmetric image was constructed (
        <xref ref-type="fig" rid="fig2">
         Figure 2
        </xref>
        ).
        <fig id="fig2">
         <label>
          Figure 2
         </label>
         <caption>
          <p>
           Final processed image. The symmetry has been produced by reflection in the mid-line axis to compensate for the unilateral plane laser-sheet illumination. The white outline represents the approximate position of the mask when looking vertically down on the face of the human lung model dummy. The double-headed, white, dotted arrow shows the visible extent of the smoke plume (based on a gray scale of 0 to 255). When scaled up in real dimensions, this arrow represents a real distance of approximately 0.40 m.
          </p>
         </caption>
         <graphic xlink:href="gr2">
         </graphic>
        </fig>
       </p>
      </sec>
     </sec>
     <sec id="cesec50">
      <title>
       RESULTS
      </title>
      <p id="para130">
       The final maximum distance traveled by the exhaled smoke plume, using this simple oxygen mask (HS-3031; Hsiner) with an oxygen flow of 4 L/min, a respiratory rate of 12 breaths/min, and a tidal volume of 0.5 L, was approximately 0.40 m (
       <xref ref-type="fig" rid="fig2">
        Figure 2
       </xref>
       ). It was finally decided to choose the video image/footage of the most clearly illuminated smoke plume, demonstrating the maximum distance traveled at the peak of exhalation for image analysis. The reason for this was one of safety. Such a maximum distance will give added safety if it is used as a guide to the safe distance required for the prevention of hospital-acquired aerosol transmission infections. This distance was defined on the basis of the image analysis technique that was used to smooth and approximate the boundary of the visible smoke on video that had been recorded by the digital camera. The defined boundary of the smoke was based on the reflected light intensity of the smoke particles when illuminated by the laser sheet (see supplementary material for further details).
      </p>
     </sec>
     <sec id="cesec60">
      <title>
       DISCUSSION
      </title>
      <p id="para140">
       The HPS has been used in medical training, especially in anesthesia, emergency, and critical care medicine. It is also a realistic representation of human respiratory physiology. The HPS contains a realistic airway and a lung model that undergoes gas exchange (
       <italic>
        ie
       </italic>
       , it consumes oxygen and produces carbon dioxide). The lung compliance and airway resistance respond in a realistic manner to relevant challenges. It also produces an airflow pattern that is close to the
       <italic>
        in vivo
       </italic>
       human situation. A report on the use of an HPS to study complex respiratory physiology has been published previously.
       <xref ref-type="bibr" rid="bib10">
        10
       </xref>
       ,
       <xref ref-type="bibr" rid="bib11">
        11
       </xref>
       ,
       <xref ref-type="bibr" rid="bib12">
        12
       </xref>
       ,
       <xref ref-type="bibr" rid="bib13">
        13
       </xref>
       ,
       <xref ref-type="bibr" rid="bib14">
        14
       </xref>
      </p>
      <p id="para150">
       There have been a few studies about the production of aerosols from the use of oxygen masks. However, although their methodology was quite different, a useful comparison can still be made with the study by Somogyi et al,
       <xref ref-type="bibr" rid="bib9">
        <sup>
         9
        </sup>
       </xref>
       who produced images of exhaled airflows using three different oxygen masks on a human volunteer. Their study is not directly comparable to this one mainly because the oxygen masks they used had no oxygen flow supplied. Only the volunteer's natural exhalation after brief breath holding produced the air movement. This is not a natural breathing cycle, and, in this respect, the cyclical respiration pattern in the human lung model presented here may be more realistic. Although Somogyi et al
       <xref ref-type="bibr" rid="bib9">
        <sup>
         9
        </sup>
       </xref>
       showed images of the behavior of the exhaled air plume, they did not report quantitative data, such as the distance traveled by the visible air plumes shown in their images. However, a closer inspection of their
       <xref ref-type="fig" rid="fig1">
        Figure 1A
       </xref>
       , which illustrates a side plume of exhaled air emitted from a simple nonrebreathing oxygen mask, appears to show that it extends approximately two head diameters away from the mask. The head diameter of an adult has been reported to be approximately 13 to 16 cm.
       <xref ref-type="bibr" rid="bib15">
        <sup>
         15
        </sup>
       </xref>
       Thus, the extent of the visible plume shown in their
       <xref ref-type="fig" rid="fig1">
        Figure 1A
       </xref>
       can be estimated to be approximately 0.30 m. Furthermore, these authors stated the following: “The spread of the exhaled gas may be greater than shown, as evaporation and reduction in density of the droplets at the margin of the plume may limit their effectiveness as markers.” Although the methodology and human lung model parameters used in this study may have been somewhat different (oxygen flow, 4 L/min; respiratory rate, 12 breaths/min; tidal volume, 0.5 L), the distance traveled (0.40 m) by the exhaled smoke plume in this study seems remarkably similar.
      </p>
      <p id="para160">
       There are some limitations that are specific to this study. Most significantly, fine smoke particles rather than droplets were used in this study. This smoke consists of submicrometer m particles that will follow the path of the air flow precisely.
       <xref ref-type="bibr" rid="bib16">
        16
       </xref>
       ,
       <xref ref-type="bibr" rid="bib17">
        17
       </xref>
       Thus, the extent of spread of the smoke is representative of the airflow around the mask. This distance is derived from smoke particles that are visible enough to be analyzed from the digitally captured video images. This will almost certainly be a lower limit approximation as there will be smoke particles traveling beyond the visible boundaries seen in these images. These particles cannot be visualized effectively because there are too few at these distances to scatter sufficient light to be easily detected on the video images.
      </p>
      <p id="para170">
       Second, it has been estimated that droplets generated from the upper respiratory tract by, for instance, coughing, sneezing, talking, singing, and breathing, range from 0.5 to 12 μm in diameter.
       <xref ref-type="bibr" rid="bib18">
        <sup>
         18
        </sup>
       </xref>
       As viral and bacterial agents range from approximately 0.020 to 100 μm in size, the size of the exhaled droplet will obviously limit the number of such infectious agents that can be carried in each droplet. The majority of naturally produced aerosol droplets are much larger than the smoke particles used in this study. Therefore, most of them will not follow the exhaled airflow perfectly, but will move relatively more slowly horizontally due to their larger size and will fall more quickly under the effects of gravity
       <xref ref-type="bibr" rid="bib19">
        <sup>
         19
        </sup>
       </xref>
       and thus not travel as far as the smoke particles used in this study. However, some of the smaller droplets exhaled by a human patient may be reduced in size sufficiently by evaporation within the exhaled, oxygen-assisted airflow and remain suspended in air for considerable periods of time. These smaller particles may then more closely be represented by the smoke particles used in this study. Therefore, the boundaries of the smoke cloud indicated in
       <xref ref-type="fig" rid="fig2">
        Figure 2
       </xref>
       are likely to represent an upper boundary of the distance traveled by real infectious droplets and may therefore be taken as defining a zone of potential aerosol infection with an extra margin of safety.
      </p>
      <p id="para180">
       There is no reliable and safe marker that can be introduced into human lungs for study. The use of the human lung model here allows for only one set of parameters to be tested at one time. So, while a healthy human patient would sometimes be breathing quietly, then sometimes talking, coughing, or sneezing (when the mask may be removed), the behavior of this human lung model is unchanging. However, this study allows a baseline estimate of the distance traveled by any potentially infectious aerosols, while the patient is at rest.
      </p>
     </sec>
     <sec id="cesec70">
      <title>
       CONCLUSION
      </title>
      <p id="para190">
       This study effectively complements that of Somogyi et al
       <xref ref-type="bibr" rid="bib9">
        <sup>
         9
        </sup>
       </xref>
       and demonstrates that patients with transmissible respiratory infections such as influenza H5N1 and SARS, who are breathing with the aid of oxygen masks, may be a potential source of aerosol-transmitted infection. These patients should, ideally, be managed in a single, isolation room, under negative pressure, though with their relatively high cost, not all health-care institutions may possess such facilities. During the SARS epidemics of 2003, health-care workers managing SARS patients found that they could protect themselves by the effective and consistent use of personal protective equipment,
       <xref ref-type="bibr" rid="bib20">
        <sup>
         20
        </sup>
       </xref>
       and that the converse was also true.
       <xref ref-type="bibr" rid="bib21">
        <sup>
         21
        </sup>
       </xref>
       Influenza H5N1 is likely to be a more infectious, transmissible pathogen,
       <xref ref-type="bibr" rid="bib22">
        <sup>
         22
        </sup>
       </xref>
       so effective, well-informed infection control precautions will be even more important to prevent hospital-acquired infections in both health-care workers and patients.
      </p>
     </sec>
    </sec>
    <back>
     <ref-list id="bibl10">
      <title>
       REFERENCES
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <element-citation id="sbref10" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fowler
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Lapinsky
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
         <name>
          <surname>
           Hallett
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Critically ill patients with severe acute respiratory syndrome
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         290
        </volume>
        <year>
         2003
        </year>
        <fpage>
         367
        </fpage>
        <lpage>
         373
        </lpage>
        <pub-id pub-id-type="pmid">
         12865378
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <element-citation id="sbref20" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Booth
          </surname>
          <given-names>
           TF
          </given-names>
         </name>
         <name>
          <surname>
           Kournikakis
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Bastien
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of airborne severe acute respiratory syndrome (SARS) coronavirus and environmental contamination in SARS outbreak units
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         191
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1472
        </fpage>
        <lpage>
         1477
        </lpage>
        <pub-id pub-id-type="pmid">
         15809906
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation id="sbref30" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of SARS-CoV and RNA on aerosol samples from SARS-patients admitted to hospital
        </article-title>
        <source>
         Zhonghua Liu Xing Bing Xue Za Zhi
        </source>
        <volume>
         25
        </volume>
        <year>
         2004
        </year>
        <fpage>
         882
        </fpage>
        <lpage>
         885
        </lpage>
        <pub-id pub-id-type="pmid">
         15631748
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <element-citation id="sbref40" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tran
          </surname>
          <given-names>
           TH
          </given-names>
         </name>
         <name>
          <surname>
           Nguyen
          </surname>
          <given-names>
           TL
          </given-names>
         </name>
         <name>
          <surname>
           Nguyen
          </surname>
          <given-names>
           TD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Avian influenza A (H5N1) in 10 patients in Vietnam
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         350
        </volume>
        <year>
         2004
        </year>
        <fpage>
         1179
        </fpage>
        <lpage>
         1188
        </lpage>
        <pub-id pub-id-type="pmid">
         14985470
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <element-citation id="sbref50" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ungchusak
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Auewarakul
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Dowell
          </surname>
          <given-names>
           SF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Probable person-to-person transmission of avian influenza A (H5N1)
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         352
        </volume>
        <year>
         2005
        </year>
        <fpage>
         333
        </fpage>
        <lpage>
         340
        </lpage>
        <pub-id pub-id-type="pmid">
         15668219
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <element-citation id="sbref60" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goldmann
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transmission of viral respiratory infections in the home
        </article-title>
        <source>
         Pediatr Infect Dis J
        </source>
        <volume>
         19
        </volume>
        <year>
         2000
        </year>
        <fpage>
         S97
        </fpage>
        <lpage>
         S102
        </lpage>
        <pub-id pub-id-type="pmid">
         11052396
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <element-citation id="sbref70" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goldmann
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology and prevention of pediatric viral respiratory infections in health-care institutions
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         7
        </volume>
        <year>
         2001
        </year>
        <fpage>
         249
        </fpage>
        <lpage>
         253
        </lpage>
        <pub-id pub-id-type="pmid">
         11294717
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib8">
       <label>
        8
       </label>
       <element-citation id="sbref80" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           IT
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           TW
          </given-names>
         </name>
         <name>
          <surname>
           Chiu
          </surname>
          <given-names>
           YL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Temporal-spatial analysis of severe acute respiratory syndrome among hospital inpatients
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         40
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1237
        </fpage>
        <lpage>
         1243
        </lpage>
        <pub-id pub-id-type="pmid">
         15825024
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib9">
       <label>
        9
       </label>
       <element-citation id="sbref90" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Somogyi
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Vesely
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
         <name>
          <surname>
           Azami
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dispersal of respiratory droplets with open vs closed oxygen delivery masks: implications for the transmission of severe acute respiratory syndrome
        </article-title>
        <source>
         Chest
        </source>
        <volume>
         125
        </volume>
        <year>
         2004
        </year>
        <fpage>
         1155
        </fpage>
        <lpage>
         1157
        </lpage>
        <pub-id pub-id-type="pmid">
         15006983
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib10">
       <label>
        10
       </label>
       <element-citation id="sbref100" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Good
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
        </person-group>
        <article-title>
         Patient simulation for training basic and advanced clinical skills
        </article-title>
        <source>
         Med Educ
        </source>
        <volume>
         37
        </volume>
        <year>
         2003
        </year>
        <fpage>
         14
        </fpage>
        <lpage>
         21
        </lpage>
        <pub-id pub-id-type="pmid">
         14641634
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib11">
       <label>
        11
       </label>
       <element-citation id="sbref110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Meka
          </surname>
          <given-names>
           VV
          </given-names>
         </name>
         <name>
          <surname>
           van Oostrom
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bellows-less lung system for the human patient simulator
        </article-title>
        <source>
         Med Biol Eng Comput
        </source>
        <volume>
         42
        </volume>
        <year>
         2004
        </year>
        <fpage>
         413
        </fpage>
        <lpage>
         418
        </lpage>
        <pub-id pub-id-type="pmid">
         15191088
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib12">
       <label>
        12
       </label>
       <element-citation id="sbref120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           So
          </surname>
          <given-names>
           CY
          </given-names>
         </name>
         <name>
          <surname>
           Gomersall
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
         <name>
          <surname>
           Chui
          </surname>
          <given-names>
           PT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Performance of an oxygen delivery device for weaning potentially infectious critically ill patients
        </article-title>
        <source>
         Anaesthesia
        </source>
        <volume>
         59
        </volume>
        <year>
         2004
        </year>
        <fpage>
         710
        </fpage>
        <lpage>
         714
        </lpage>
        <pub-id pub-id-type="pmid">
         15200546
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <label>
        13
       </label>
       <element-citation id="sbref130" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goodwin
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           van Meurs
          </surname>
          <given-names>
           WL
          </given-names>
         </name>
         <name>
          <surname>
           Sa Couto
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
        </person-group>
        <article-title>
         A model for educational simulation of infant cardiovascular physiology
        </article-title>
        <source>
         Anesth Analg
        </source>
        <volume>
         99
        </volume>
        <year>
         2004
        </year>
        <fpage>
         1655
        </fpage>
        <lpage>
         1664
        </lpage>
        <pub-id pub-id-type="pmid">
         15562049
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib14">
       <label>
        14
       </label>
       <element-citation id="sbref140" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lampotang
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Lizdas
          </surname>
          <given-names>
           DE
          </given-names>
         </name>
         <name>
          <surname>
           Gravenstein
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         An audible indication of exhalation increases delivered tidal volume during bag valve mask ventilation of a patient simulator
        </article-title>
        <source>
         Anesth Analg
        </source>
        <volume>
         102
        </volume>
        <year>
         2006
        </year>
        <fpage>
         168
        </fpage>
        <lpage>
         171
        </lpage>
        <pub-id pub-id-type="pmid">
         16368824
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib15">
       <label>
        15
       </label>
       <element-citation id="sbref150" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           V
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparisons of peak SAR levels in concentric sphere head models of children and adults for irradiation by a dipole at 900 MHz
        </article-title>
        <source>
         Phys Med Biol
        </source>
        <volume>
         48
        </volume>
        <year>
         2003
        </year>
        <fpage>
         3263
        </fpage>
        <lpage>
         3275
        </lpage>
        <pub-id pub-id-type="pmid">
         14620057
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib16">
       <label>
        16
       </label>
       <element-citation id="sbref160" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hall
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
        </person-group>
        <source>
         An investigation of the turbulent backward facing step flow with the addition of a charged particle phase and electrostatic forces. PhD dissertation
        </source>
        <year>
         2001
        </year>
        <comment>
         University of New South Wales. Sydney, NSW, Australia:
        </comment>
       </element-citation>
      </ref>
      <ref id="bib17">
       <label>
        17
       </label>
       <element-citation id="sbref170" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Soo
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
        </person-group>
        <series>
         Fluid dynamics of multiphase systems
        </series>
        <year>
         1967
        </year>
        <publisher-name>
         Blaisdell Publishing Company
        </publisher-name>
        <publisher-loc>
         Toronto, ON, Canada
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib18">
       <label>
        18
       </label>
       <element-citation id="sbref180" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cole
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         <name>
          <surname>
           Cook
          </surname>
          <given-names>
           CE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of infectious aerosols in health care facilities: an aid to effective engineering controls and preventive strategies
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         26
        </volume>
        <year>
         1998
        </year>
        <fpage>
         453
        </fpage>
        <lpage>
         464
        </lpage>
        <pub-id pub-id-type="pmid">
         9721404
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib19">
       <label>
        19
       </label>
       <element-citation id="sbref190" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Crowe
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Sommerfeld
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Tsuji
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <series>
         Multiphase flows with droplets and particles
        </series>
        <year>
         1998
        </year>
        <publisher-name>
         CRC Press
        </publisher-name>
        <publisher-loc>
         Boca Raton, FL
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib20">
       <label>
        20
       </label>
       <element-citation id="sbref200" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Seto
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Yung
          </surname>
          <given-names>
           RW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS)
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         361
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1519
        </fpage>
        <lpage>
         1520
        </lpage>
        <pub-id pub-id-type="pmid">
         12737864
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib21">
       <label>
        21
       </label>
       <element-citation id="sbref210" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
         <name>
          <surname>
           Fung
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           TW
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS transmission among hospital workers in Hong Kong
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         10
        </volume>
        <year>
         2004
        </year>
        <fpage>
         280
        </fpage>
        <lpage>
         286
        </lpage>
        <pub-id pub-id-type="pmid">
         15030698
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib22">
       <label>
        22
       </label>
       <element-citation id="sbref220" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fraser
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Riley
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Factors that make an infectious disease outbreak controllable
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <volume>
         101
        </volume>
        <year>
         2004
        </year>
        <fpage>
         6146
        </fpage>
        <lpage>
         6151
        </lpage>
        <pub-id pub-id-type="pmid">
         15071187
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <fn-group>
      <fn id="d32e417">
       <p id="cenpara10">
        This project was supported by the Research Fund for the Control of Infectious Diseases from the Health, Welfare and Food Bureau of the Hong Kong Special Administrative Region Government.
       </p>
       <p id="cenpara20">
        The authors have reported to the ACCP that no significant conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
       </p>
       <p id="cenpara30">
        Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (
        <ext-link ext-link-type="uri" id="interrefs10" xlink:href="http://www.chestjournal.org/misc/reprints.shtml">
         www.chestjournal.org/misc/reprints.shtml
        </ext-link>
        ).
       </p>
      </fn>
     </fn-group>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       mBio
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       MBio
      </journal-id>
      <journal-id journal-id-type="hwp">
       mbio
      </journal-id>
      <journal-id journal-id-type="pmc">
       mbio
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       mBio
      </journal-id>
      <journal-title-group>
       <journal-title>
        mBio
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       2150-7511
      </issn>
      <publisher>
       <publisher-name>
        American Society of Microbiology
       </publisher-name>
       <publisher-loc>
        1752 N St., N.W., Washington, DC
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       26556276
      </article-id>
      <article-id pub-id-type="pmc">
       4659470
      </article-id>
      <article-id pub-id-type="publisher-id">
       mBio01697-15
      </article-id>
      <article-id pub-id-type="doi">
       10.1128/mBio.01697-15
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Research Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Human Coronavirus 229E Remains Infectious on Common Touch Surface Materials
       </article-title>
       <alt-title alt-title-type="running-head">
        Coronavirus Persistence on Common Surface Materials
       </alt-title>
       <alt-title alt-title-type="short-authors">
        Warnes et al.
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Warnes
         </surname>
         <given-names>
          Sarah L.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Little
         </surname>
         <given-names>
          Zoë R.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <contrib-id authenticated="false" contrib-id-type="orcid">
         http://orcid.org/0000-0003-1917-7706
        </contrib-id>
        <name>
         <surname>
          Keevil
         </surname>
         <given-names>
          C. William
         </given-names>
        </name>
       </contrib>
       <aff id="aff1">
        <addr-line>
         Centre for Biological Sciences, University of Southampton, Southampton, United Kingdom
        </addr-line>
       </aff>
      </contrib-group>
      <contrib-group>
       <contrib contrib-type="editor">
        <name>
         <surname>
          Colwell
         </surname>
         <given-names>
          Rita R.
         </given-names>
        </name>
        <role>
         Editor
        </role>
        <aff>
         University of Maryland
        </aff>
       </contrib>
      </contrib-group>
      <author-notes>
       <corresp id="cor1">
        Address correspondence to C. W. Keevil,
        <email>
         cwk@soton.ac.uk
        </email>
        .
       </corresp>
       <fn fn-type="other">
        <p>
         This article is a direct contribution from a Fellow of the American Academy of Microbiology.
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="epub">
       <day>
        10
       </day>
       <month>
        11
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <pub-date pub-type="collection">
       <season>
        Nov-Dec
       </season>
       <year>
        2015
       </year>
      </pub-date>
      <volume>
       6
      </volume>
      <issue>
       6
      </issue>
      <elocation-id>
       e01697-15
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         1
        </day>
        <month>
         10
        </month>
        <year>
         2015
        </year>
       </date>
       <date date-type="accepted">
        <day>
         13
        </day>
        <month>
         10
        </month>
        <year>
         2015
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2015 Warnes et al.
       </copyright-statement>
       <copyright-year>
        2015
       </copyright-year>
       <copyright-holder>
        Warnes et al.
       </copyright-holder>
       <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/">
        <license-p>
         This is an open-access article distributed under the terms of the
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/">
          Creative Commons Attribution-Noncommercial-ShareAlike 3.0 Unported license
         </ext-link>
         , which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited.
        </license-p>
       </license>
      </permissions>
      <self-uri content-type="pdf" xlink:href="mbo006152541001.pdf">
      </self-uri>
      <abstract>
       <title>
        ABSTRACT
       </title>
       <p>
        The evolution of new and reemerging historic virulent strains of respiratory viruses from animal reservoirs is a significant threat to human health. Inefficient human-to-human transmission of zoonotic strains may initially limit the spread of transmission, but an infection may be contracted by touching contaminated surfaces. Enveloped viruses are often susceptible to environmental stresses, but the human coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) have recently caused increasing concern of contact transmission during outbreaks. We report here that pathogenic human coronavirus 229E remained infectious in a human lung cell culture model following at least 5 days of persistence on a range of common nonbiocidal surface materials, including polytetrafluoroethylene (Teflon; PTFE), polyvinyl chloride (PVC), ceramic tiles, glass, silicone rubber, and stainless steel. We have shown previously that noroviruses are destroyed on copper alloy surfaces. In this new study, human coronavirus 229E was rapidly inactivated on a range of copper alloys (within a few minutes for simulated fingertip contamination) and Cu/Zn brasses were very effective at lower copper concentration. Exposure to copper destroyed the viral genomes and irreversibly affected virus morphology, including disintegration of envelope and dispersal of surface spikes. Cu(I) and Cu(II) moieties were responsible for the inactivation, which was enhanced by reactive oxygen species generation on alloy surfaces, resulting in even faster inactivation than was seen with nonenveloped viruses on copper. Consequently, copper alloy surfaces could be employed in communal areas and at any mass gatherings to help reduce transmission of respiratory viruses from contaminated surfaces and protect the public health.
       </p>
      </abstract>
      <abstract abstract-type="executive-summary">
       <title>
        IMPORTANCE
       </title>
       <p>
        Respiratory viruses are responsible for more deaths globally than any other infectious agent. Animal coronaviruses that “host jump” to humans result in severe infections with high mortality, such as severe acute respiratory syndrome (SARS) and, more recently, Middle East respiratory syndrome (MERS). We show here that a closely related human coronavirus, 229E, which causes upper respiratory tract infection in healthy individuals and serious disease in patients with comorbidities, remained infectious on surface materials common to public and domestic areas for several days. The low infectious dose means that this is a significant infection risk to anyone touching a contaminated surface. However, rapid inactivation, irreversible destruction of viral RNA, and massive structural damage were observed in coronavirus exposed to copper and copper alloy surfaces. Incorporation of copper alloy surfaces in conjunction with effective cleaning regimens and good clinical practice could help to control transmission of respiratory coronaviruses, including MERS and SARS.
       </p>
      </abstract>
      <counts>
       <count count="0" count-type="supplementary-material">
       </count>
       <fig-count count="6">
       </fig-count>
       <table-count count="1">
       </table-count>
       <equation-count count="3">
       </equation-count>
       <ref-count count="52">
       </ref-count>
       <page-count count="10">
       </page-count>
       <word-count count="8291">
       </word-count>
      </counts>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         cover-date
        </meta-name>
        <meta-value>
         November/December 2015
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="h0.0" sec-type="intro">
     <title>
      INTRODUCTION
     </title>
     <p>
      Treatment of infectious disease is currently facing a crisis. Widespread antibiotic resistance has reduced therapeutic options against bacterial pathogens. However, there is also a significant threat from reemerging, newly evolving, and zoonotic viral pathogens. In addition, new technologies are also able to identify previously unknown pathogenic viruses. The majority of these are RNA viruses transmitted through the mucosal or respiratory route and manifesting as respiratory disease (
      <xref ref-type="bibr" rid="B1">
       1
      </xref>
      ). Respiratory viruses can cause a wide range of lung disorders ranging from mild upper respiratory tract infections to more-severe life-threatening pathologies, including bronchiolitis, fever, pneumonia, and acute respiratory distress syndrome. The World Health Organization (WHO) estimated that there are 450 million cases of pneumonia per year resulting in 4 million deaths, and approximately 200 million of these are cases of viral community-acquired pneumonia (reviewed in reference
      <xref ref-type="bibr" rid="B2">
       2
      </xref>
      ). Common viruses include respiratory syncytial virus (RSV), rhinoviruses, influenza virus, parainfluenzavirus, and coronaviruses. Coinfections with two or more pathogens and comorbidities often affect disease severity and prognosis and complicate initial diagnosis (
      <xref ref-type="bibr" rid="B3">
       3
      </xref>
      ).
     </p>
     <p>
      Many coronavirus species are important animal pathogens and are often host species specific. In humans, several species, e.g., human coronavirus 229E (HuCoV-229E) and NL63 (
      <italic>
       Alphacoronavirus
      </italic>
      ) and HKU1 and OC43 (
      <italic>
       Betacoronavirus
      </italic>
      ), are a common cause of upper respiratory tract infection. There is an ever-present risk of pathogens emerging from animal reservoirs that have attained the ability to infect humans. The risk can be increased when individuals have continuous and close contact with animals; also, climate changes can change the distribution of insect vectors and hosts (
      <xref ref-type="bibr" rid="B4">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="B5">
       5
      </xref>
      ).
     </p>
     <p>
      In 2003, a highly pathogenic coronavirus believed to have originated in bats and palm civet cats transferred to humans in Guangdong Province, China, resulting in cases of severe acute respiratory syndrome (SARS). Over 8,000 people were infected in 37 different countries, but mostly in Southeast Asia, with 10% mortality. Inefficient human-to-human transmission, severe restrictions on air travel, closure of many wild-animal markets, and quarantine procedures have successfully contained the outbreak so far. However, zoonotic transmission of a coronavirus from reservoirs in bats and possibly camels gave rise to severe respiratory infection in individuals in the Arabian Peninsula in 2012. The resulting Middle East respiratory syndrome (MERS), which affects the lower respiratory tract, is clinically similar to SARS but pathologically different. A ubiquitous host cell receptor often leads to extrapulmonary disease, often in the kidneys, and viral progeny are released through apical and basolateral respiratory cell surfaces, contributing to the high (up to 40%) mortality rate (reviewed in references
      <xref ref-type="bibr" rid="B6">
       6
      </xref>
      and
      <xref ref-type="bibr" rid="B7">
       7
      </xref>
      ). Late uncontrolled inflammation leads to severe pathologies which are not dependent on viral load, and human-to-human spread does occur (reviewed in references
      <xref ref-type="bibr" rid="B3">
       3
      </xref>
      and
      <xref ref-type="bibr" rid="B4">
       4
      </xref>
      ). This, combined with a low infectious dose, suggests that transmission of very few virus particles via person-to-person or contact with contaminated surfaces may be an infection risk. Although camels and associated food products have been found to contain the virus, a recent study of individuals constantly in contact with infected herds suggested that zoonotic transmission is rare (
      <xref ref-type="bibr" rid="B8">
       8
      </xref>
      ) but that the risk may be highest from juvenile animals. The risk of transmission is increased, however, in clinical facilities (
      <xref ref-type="bibr" rid="B9">
       9
      </xref>
      ) and possibly in other crowded public areas, including care homes and areas of mass gatherings, such as the Hajj Muslim pilgrimage to Mecca. In a recent outbreak in South Korea, MERS has so far (July 2015) killed 36 people and infected 186 patients in hospital-associated cases associated with the first imported case arising from travel to the Middle East (
      <xref ref-type="bibr" rid="B10">
       10
      </xref>
      ,
      <xref ref-type="bibr" rid="B11">
       11
      </xref>
      ).
     </p>
     <p>
      Surface contamination has recently been found to be more significant than originally thought in the spread of many diseases (
      <xref ref-type="bibr" rid="B12">
       12
      </xref>
      ). Symptoms of respiratory disease often result in continuous recontamination of surfaces which are then touched, and infectious virus particles may be transferred to facial mucosa. In addition, ineffective cleaning agents may leave residual particles that can initiate infection (
      <xref ref-type="bibr" rid="B13">
       13
      </xref>
      ). The use of biocidal surfaces may help to reduce the incidence of infections spread by touching contaminated surfaces. Copper alloys have demonstrated excellent antibacterial and antifungal activity against a range of pathogens in laboratory studies (
      <xref ref-type="bibr" rid="B14">
       14
      </xref>
      <xref ref-type="bibr" rid="B15">
       –
      </xref>
      <xref ref-type="bibr" rid="B19">
       19
      </xref>
      ). Copper ion release has been found to be essential to maintaining efficacy, but the mechanism of action is variable (
      <xref ref-type="bibr" rid="B20">
       20
      </xref>
      ,
      <xref ref-type="bibr" rid="B21">
       21
      </xref>
      ). A reduction in microbial bioburden and acquisition of nosocomial infection has now been observed in clinical trials of incorporation of copper alloy surfaces in health care facilities (
      <xref ref-type="bibr" rid="B22">
       22
      </xref>
      <xref ref-type="bibr" rid="B23">
       –
      </xref>
      <xref ref-type="bibr" rid="B25">
       25
      </xref>
      ).
     </p>
     <p>
      Previous studies have shown that murine norovirus (MNV) and human norovirus, highly infectious nonenveloped viruses that are resistant to environmental stress and impervious to many cleaning agents, are destroyed on copper and copper alloy surfaces (
      <xref ref-type="bibr" rid="B26">
       26
      </xref>
      <xref ref-type="bibr" rid="B27">
       –
      </xref>
      <xref ref-type="bibr" rid="B28">
       28
      </xref>
      ). HuCoV-229E is associated with a wide range of respiratory disease from mild colds to severe pneumonia in immunocompromised people and has been implicated as an autoimmune trigger in multiple sclerosis (
      <xref ref-type="bibr" rid="B29">
       29
      </xref>
      ,
      <xref ref-type="bibr" rid="B30">
       30
      </xref>
      ). Infection with this virus occurs in a high proportion of the population in approximately 3-year cycles, incurring considerable hidden costs in lost work hours, and in this study was also used as a surrogate for the more virulent coronaviruses responsible for SARS and MERS (rather than using animal viruses or coronaviruses that primarily infect the gastrointestinal tract). In addition, a recent study also observed that HuCoV-229E shares important characteristics with MERS-coronavirus and also has an ancestral link with bats (
      <xref ref-type="bibr" rid="B31">
       31
      </xref>
      ). In this study, the ability of HuCoV-229E to retain infectivity on a range of common surface materials was investigated to understand the risk of disease dissemination. The potential use of biocidal surfaces to provide constant antiviral activity against continual surface recontamination could help to limit the spread of respiratory viruses; accordingly, the efficacy of a range of copper alloys to inactivate HuCoV-229E was also determined.
     </p>
    </sec>
    <sec id="h1" sec-type="results">
     <title>
      RESULTS
     </title>
     <sec id="s1.1">
      <title>
       Coronavirus persists in an infectious state on common surface materials for several days.
      </title>
      <p>
       An inoculum of 10
       <sup>
        3
       </sup>
       plaque forming units (PFU) persisted on polyfluorotetraethylene (Teflon; PTFE), polyvinyl chloride (PVC), ceramic tiles, glass, and stainless steel for at least 5 days (and 3 days for silicon rubber) at 21°C and a relative humidity of 30% to 40% (
       <xref ref-type="fig" rid="fig1">
        Fig. 1
       </xref>
       ).
      </p>
      <fig id="fig1" orientation="portrait" position="float">
       <label>
        FIG 1
       </label>
       <caption>
        <p>
         Persistence of infectious human coronavirus on common surface materials. Approximately 10
         <sup>
          3
         </sup>
         PFU HuCoV-229E (20 µl infected-cell lysate) was applied to 1-cm
         <sup>
          2
         </sup>
         coupons of test surface materials and incubated at ambient conditions (21°C; relative humidity, 30% to 40%). Virus was removed and assayed for infectivity at various time points as described in the text. Although the initial inoculum concentration was quite low, the virus retained infectivity for 5 days on all surfaces, except silicon rubber. Therefore, natural contamination of common surface material with very few coronavirus particles could represent a considerable risk of infection spread if touched and transferred to facial mucosa. Error bars represent ± SEM, and data are from the results of multiple experiments.
        </p>
       </caption>
       <graphic xlink:href="mbo0051525410001">
       </graphic>
      </fig>
     </sec>
     <sec id="s1.2">
      <title>
       Rapid inactivation of human coronavirus occurs on brass and copper nickel surfaces at room temperature (21°C).
      </title>
      <p>
       Brasses containing at least 70% copper were very effective at inactivating HuCoV-229E (
       <xref ref-type="fig" rid="fig2">
        Fig. 2A
       </xref>
       ), and the rate of inactivation was directly proportional to the percentage of copper. Approximately 10
       <sup>
        3
       </sup>
       PFU in a simulated wet-droplet contamination (20 µl per cm
       <sup>
        2
       </sup>
       ) was inactivated in less than 60 min. Analysis of the early contact time points revealed a lag in inactivation of approximately 10 min followed by very rapid loss of infectivity (
       <xref ref-type="fig" rid="fig2">
        Fig. 2B
       </xref>
       ). As observed previously for norovirus, zinc demonstrated a slight antiviral effect compared to that seen with stainless steel (neither metal contains copper).
      </p>
      <fig id="fig2" orientation="portrait" position="float">
       <label>
        FIG 2
       </label>
       <caption>
        <p>
         Rapid inactivation of human coronavirus occurs on brass and copper nickel surfaces. Approximately 10
         <sup>
          3
         </sup>
         PFU HuCoV-229E (20 µl infected-cell lysate) was applied to 1-cm
         <sup>
          2
         </sup>
         coupons of a range of brasses (A and B [early time points only]), copper nickels (C), and control metal surfaces that did not contain copper (stainless steel, zinc, and nickel). Virus was removed at various time points and assayed for infectivity as described in the text. Coronavirus was inactivated in ≤40 min on brasses and 120 min on copper nickels containing less than 70% copper. Analysis of the initial 30 min of contact between virus and brasses (Fig. 2B) reveals an initial lag followed by rapid inactivation. Stainless steel and nickel did not demonstrate any antiviral activity, although mild antiviral activity was observed on zinc (this was significant only at 60 min [
         <italic>
          P
         </italic>
         = 0.046]). (D) The same inoculum was applied as 1 µl/cm
         <sup>
          2
         </sup>
         , was dried immediately to simulate fingertip touch contamination, and was found to have inactivated the virus approximately 8 times faster. Error bars represent ± SEM, and data are from the results of multiple experiments.
        </p>
       </caption>
       <graphic xlink:href="mbo0051525410002">
       </graphic>
      </fig>
      <p>
       Copper nickels were also effective at inactivating HuCoV-229E but required higher (90%) copper content to produce a degree of inactivation equivalent to that seen with brasses containing 70% copper (
       <xref ref-type="fig" rid="fig2">
        Fig. 2C
       </xref>
       ). The inactivation time was reduced further in the rapidly drying fingertip contamination model by approximately 8-fold to 5 min for C26000 cartridge brass (
       <xref ref-type="fig" rid="fig2">
        Fig. 2D
       </xref>
       ).
      </p>
      <p>
       Using the same data for simulated droplet contamination, a comparison between brasses and copper nickels containing the same percentage of copper, 90% or 70%, is demonstrated in
       <xref ref-type="fig" rid="fig3">
        Fig. 3
       </xref>
       . At the higher copper content level, there was little difference in efficacy between C22000 and C70600 (
       <xref ref-type="fig" rid="fig3">
        Fig. 3A
       </xref>
       ). However, copper nickel C72500 was less effective than C70600 although it contains the same percentage of copper. The superior antiviral properties of C70600 have been observed previously for norovirus and may involve the cuprous oxide layer visible as a removable layer (
       <xref ref-type="bibr" rid="B27">
        27
       </xref>
       ). However, at a lower percentage of copper, the cartridge brass was far superior to copper nickel C71500, inactivating virus in approximately one-third the time (
       <xref ref-type="fig" rid="fig3">
        Fig. 3B
       </xref>
       ).
      </p>
      <fig id="fig3" orientation="portrait" position="float">
       <label>
        FIG 3
       </label>
       <caption>
        <p>
         Comparison between brasses and copper nickels (containing the same percentage of copper) used to inactivate human coronavirus to determine if zinc content enhances the antiviral effect. Approximately 10
         <sup>
          3
         </sup>
         PFU was inoculated onto alloys containing 90% copper for 0, 5, and 20 min (A) or 70% copper for 0, 30, and 60 min (B) and was then removed and assessed for infectivity as described in the text. Alloys containing 90% copper were very effective at inactivating human coronavirus (A), but variations in efficacy did not appear to be related only to the presence of zinc. The presence of copper nickel C70600 resulted in increased efficacy compared to that of copper nickel C72500; that result may be linked to surface oxide layer or copper ion release from this alloy. However, at a lower percentage of copper (B), synergy with zinc or Cu(I) release may be important because contact with cartridge brass resulted in virus inactivation that was at least 3 times faster than that seen with copper nickel C71500.
        </p>
       </caption>
       <graphic xlink:href="mbo0051525410003">
       </graphic>
      </fig>
     </sec>
     <sec id="s1.3">
      <title>
       Copper ion release and generation of reactive oxygen species (ROS) are involved in inactivation of HuCoV-229E on copper and copper alloy surfaces.
      </title>
      <p>
       HuCoV-229E was inoculated onto copper and cartridge brass surfaces (100% and 70% copper, respectively;
       <xref ref-type="table" rid="tab1">
        Table 1
       </xref>
       ) in the presence of ethylenediaminetetraacetic acid (EDTA) and bathocuproine disulfonate (BCS), chelators of Cu(II) and Cu(I), respectively. Both chelators initially protected the virus from inactivation for up to 2 h (although BCS was still protective after 2 h of contact with brass) (
       <xref ref-type="fig" rid="fig4">
        Fig. 4A
       </xref>
       and
       <xref ref-type="fig" rid="fig4">
        C
       </xref>
       ). This suggests that both ionic species of copper are required directly and/or indirectly for virus inactivation and that Cu(I) may be more significant in the longer term.
      </p>
      <table-wrap id="tab1" orientation="portrait" position="float">
       <label>
        TABLE 1
       </label>
       <caption>
        <p>
         Composition of metal alloys used for the study
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <colgroup span="1">
         <col span="1"/>
         <col span="1"/>
         <col span="1"/>
         <col span="1"/>
         <col span="1"/>
         <col span="1"/>
         <col span="1"/>
         <col span="1"/>
         <col span="1"/>
         <col span="1"/>
        </colgroup>
        <thead>
         <tr>
          <th colspan="1" rowspan="2">
           Metal(s)
          </th>
          <th colspan="1" rowspan="2">
           UNS ID
           <xref ref-type="table-fn" rid="ngtab1.1">
            <sup>
             a
            </sup>
           </xref>
          </th>
          <th colspan="1" rowspan="2">
           Common name
          </th>
          <th colspan="7" rowspan="1">
           Main constituent (%)
           <hr/>
          </th>
         </tr>
         <tr>
          <th colspan="1" rowspan="1">
           Copper
          </th>
          <th colspan="1" rowspan="1">
           Zinc
          </th>
          <th colspan="1" rowspan="1">
           Nickel
          </th>
          <th colspan="1" rowspan="1">
           Tin
          </th>
          <th colspan="1" rowspan="1">
           Iron
          </th>
          <th colspan="1" rowspan="1">
           Chromium
          </th>
          <th colspan="1" rowspan="1">
           Manganese
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td colspan="1" rowspan="4">
           Copper nickels
          </td>
          <td colspan="1" rowspan="1">
           C70600
          </td>
          <td colspan="1" rowspan="1">
           Copper nickel 10
          </td>
          <td colspan="1" rowspan="1">
           89–90
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           10
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           &lt;1
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           C72500
          </td>
          <td colspan="1" rowspan="1">
           Cupronickel with Sn
          </td>
          <td colspan="1" rowspan="1">
           89–90
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           9
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           &lt;2
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           C71000
          </td>
          <td colspan="1" rowspan="1">
           Cupronickel
          </td>
          <td colspan="1" rowspan="1">
           79
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           20
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           1
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           C71500
          </td>
          <td colspan="1" rowspan="1">
           Copper nickel 30
          </td>
          <td colspan="1" rowspan="1">
           70
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           30
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="5">
           Brasses
          </td>
          <td colspan="1" rowspan="1">
           C21000
          </td>
          <td colspan="1" rowspan="1">
           Gilding brass
          </td>
          <td colspan="1" rowspan="1">
           95
          </td>
          <td colspan="1" rowspan="1">
           5
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           C22000
          </td>
          <td colspan="1" rowspan="1">
           Commercial “bronze” (does not contain Sn)
          </td>
          <td colspan="1" rowspan="1">
           89–90
          </td>
          <td colspan="1" rowspan="1">
           10
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           C23000
          </td>
          <td colspan="1" rowspan="1">
           Red brass
          </td>
          <td colspan="1" rowspan="1">
           85
          </td>
          <td colspan="1" rowspan="1">
           15
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           C26000
          </td>
          <td colspan="1" rowspan="1">
           Cartridge brass
          </td>
          <td colspan="1" rowspan="1">
           70
          </td>
          <td colspan="1" rowspan="1">
           30
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           C28000
          </td>
          <td colspan="1" rowspan="1">
           Muntz metal
          </td>
          <td colspan="1" rowspan="1">
           60
          </td>
          <td colspan="1" rowspan="1">
           40
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Phosphor bronze
          </td>
          <td colspan="1" rowspan="1">
           C51000
          </td>
          <td colspan="1" rowspan="1">
           “5% A” (contains &lt;0.26% phosphorus)
          </td>
          <td colspan="1" rowspan="1">
           95
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           5
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Nickel “silver”
          </td>
          <td colspan="1" rowspan="1">
           C75200
          </td>
          <td colspan="1" rowspan="1">
           “65/18”
          </td>
          <td colspan="1" rowspan="1">
           65
          </td>
          <td colspan="1" rowspan="1">
           17
          </td>
          <td colspan="1" rowspan="1">
           18
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Copper
          </td>
          <td colspan="1" rowspan="1">
           C11000
          </td>
          <td colspan="1" rowspan="1">
           Copper
          </td>
          <td colspan="1" rowspan="1">
           100
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Nickel
          </td>
          <td colspan="1" rowspan="1">
           NO2200
          </td>
          <td colspan="1" rowspan="1">
           Nickel
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           100
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Zinc
          </td>
          <td colspan="1" rowspan="1">
           Z13000
          </td>
          <td colspan="1" rowspan="1">
           Zinc
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           100
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Stainless steel
          </td>
          <td colspan="1" rowspan="1">
           S30400
          </td>
          <td colspan="1" rowspan="1">
           “18/8”
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           8
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           74
          </td>
          <td colspan="1" rowspan="1">
           18
          </td>
          <td colspan="1" rowspan="1">
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="ngtab1.1">
         <label>
          <sup>
           a
          </sup>
         </label>
         <p>
          UNS ID, Unified Numbering System identifier.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <fig id="fig4" orientation="portrait" position="float">
       <label>
        FIG 4
       </label>
       <caption>
        <p>
         Inactivation of coronavirus on copper and cartridge brass surfaces in the presence of chelators EDTA and BCS (A and C) and quenchers
         <sc>
          d
         </sc>
         -mannitol and Tiron (B and D) to remove Cu(II) or Cu(I) ionic species and hydroxyl radical or superoxide, respectively. Both chelators protected coronavirus from inactivation on copper and brass surfaces, suggesting that release of Cu(I) and Cu(II) is required for antiviral activity. Tiron was protective for the first hour of contact on copper and brass surfaces, indicating that superoxide is directly or indirectly involved in the inactivation mechanism. However,
         <sc>
          d
         </sc>
         -mannitol gave minimum protection on copper but prolonged protection on brass surfaces. Increasing the concentration of
         <sc>
          d
         </sc>
         -mannitol did not affect the results (not shown). This suggests that copper ions are the main moieties responsible for inactivation of coronavirus on 100% copper surfaces but that generation of hydroxyl radicals becomes more significant as the concentration of copper in the alloy is reduced. EDTA, BCS,
         <sc>
          d
         </sc>
         -mannitol, and Tiron did not significantly affect the infectivity of HuCoV-229E on stainless steel controls or in suspensions (not shown). Error bars represent ± SEM, and data are from the results of multiple experiments.
        </p>
       </caption>
       <graphic xlink:href="mbo0051525410004">
       </graphic>
      </fig>
      <p>
       Inoculation of coronavirus in the presence of
       <sc>
        d
       </sc>
       -mannitol and Tiron (4,5-dihydroxy-1,3-benzene disulfonic acid) to quench hydroxyl radicals and superoxide anions, respectively, was done to determine if these moieties were involved in the coronavirus inactivation mechanism (
       <xref ref-type="fig" rid="fig4">
        Fig. 4B
       </xref>
       and
       <xref ref-type="fig" rid="fig4">
        D
       </xref>
       ). Tiron protected the virus for the first hour of contact, suggesting that superoxide generation is important. However,
       <sc>
        d
       </sc>
       -mannitol was minimally protective on copper but protected the virus for the duration of the test on brass. Increasing the concentration of
       <sc>
        d
       </sc>
       -mannitol did not prolong survival of infectivity on copper (not shown). This suggests that rapid inactivation of coronavirus on copper surfaces is primarily due to copper ion release and that the effect of reactive oxygen species is minimal. However, as the percentage of copper in the alloy decreased, ROS generation played a more significant role.
      </p>
      <p>
       EDTA, BCS,
       <sc>
        d
       </sc>
       -mannitol, and Tiron did not significantly affect the virus on stainless steel control surfaces or in suspension (not shown).
      </p>
     </sec>
     <sec id="s1.4">
      <title>
       Inactivation of coronavirus on copper and copper alloy surfaces results in fragmentation of the viral genome, ensuring that inactivation is irreversible.
      </title>
      <p>
       Coronavirus was exposed to metal surfaces and recovered, and the positive-stranded viral RNA genome was extracted and purified. A one-step reverse transcriptase real-time quantitative PCR (RTqPCR) was performed to detect a 139-bp region of ORF1 within nonstructural protein 4 (nsp4). Virus that had been exposed to copper and brass surfaces demonstrated reduced copy numbers of this fragment with increasing contact times (
       <xref ref-type="fig" rid="fig5">
        Fig. 5A
       </xref>
       ). Comparison of the entire viral genome by agarose gel electrophoresis confirmed that nonspecific fragmentation occurred on copper and brass, with fragments becoming smaller with increasing contact time (
       <xref ref-type="fig" rid="fig5">
        Fig. 5B
       </xref>
       ).
      </p>
      <fig id="fig5" orientation="portrait" position="float">
       <label>
        FIG 5
       </label>
       <caption>
        <p>
         Destruction of human coronavirus viral genome on copper and copper alloy surfaces. (A) Analysis of a small fragment (136-bp region of the nsp4 gene) of the coronavirus genome revealed a reduction in copy number from virus exposed to copper and cartridge brass surfaces in reverse transcriptase real-time PCR. There was some reduction on stainless steel but none in viral suspension (lightest gray bars), suggesting that this was due to sample drying. (B) Analysis of the entire viral genome is represented in electrophoretic separation of viral RNA extracted from virus exposed to copper (lanes 1, 4, and 7), cartridge brass (lanes 2, 5, and 8), and stainless steel (lanes 3, 6, and 9) for 0 min (lanes 1 to 3), 120 min (lanes 4 to 6), and 240 min (lanes 7 to 9). The genomic RNA from virus exposed to copper and brass degraded with increased contact time. This did not occur on stainless steel; the genomic RNA remained as fragments too large to pass through the gel. However, the total amount of intact RNA was reduced at 4 h, possibly due to drying damage as seen in panel A. Lane 10 represents untreated virus, and the unmarked lane is a Bioline marker (Hyperladder I). The same procedure was used with mock-infected cells, revealing the same pattern of RNA breakdown following application to copper surfaces (not shown).
        </p>
       </caption>
       <graphic xlink:href="mbo0051525410005">
       </graphic>
      </fig>
     </sec>
     <sec id="s1.5">
      <title>
       Exposure to copper surfaces results in morphological changes to human coronavirus particles visible in transmission electron microscopy (TEM).
      </title>
      <p>
       There was a significant difference in appearance between purified HuCoV-229E exposed to stainless steel and that exposed to copper surfaces (
       <xref ref-type="fig" rid="fig6">
        Fig. 6
       </xref>
       ). On stainless steel, uniform virions were visible following a 10-min exposure (
       <xref ref-type="fig" rid="fig6">
        Fig. 6A
       </xref>
       ), but on copper, clumps of damaged virus particles (
       <xref ref-type="fig" rid="fig6">
        Fig. 6B
       </xref>
       ) as well as a few intact particles could be seen. The extent of damage increased upon further exposure to copper (
       <xref ref-type="fig" rid="fig6">
        Fig. 6C
       </xref>
       ).
      </p>
      <fig id="fig6" orientation="portrait" position="float">
       <label>
        FIG 6
       </label>
       <caption>
        <p>
         Exposure to copper surfaces results in morphological changes to human coronavirus. Purified HUCoV-229E was applied to metal surfaces and then removed, and a negatively stained preparation was observed using transmission electron microscopy. (A) Intact virions were visible following exposure to stainless steel for 10 min. (B) However, following exposure to copper for 10 min, many virus particles appeared to be disintegrating (indicated by a star), although some intact virions were still present (arrow). (C) After a 30-min exposure to copper, further damage had occurred and virions appeared shrunken (indicated by a star), with damage to surface spikes (arrow).
        </p>
       </caption>
       <graphic xlink:href="mbo0051525410006">
       </graphic>
      </fig>
     </sec>
    </sec>
    <sec id="h2" sec-type="discussion">
     <title>
      DISCUSSION
     </title>
     <p>
      A combination of genetic reassortment in viruses with segmented genomes and point mutations, particularly evident in viruses that cause disease in the respiratory tract such as influenza virus and coronaviruses, results in constantly changing antigenicity and host immune response evasion. This can also affect the attachment to the host cell receptor and the “host jump” from animals to human that can occur if the mutation results in an increased ability of the virus to bind to human cells. If this is accompanied by a decrease in binding to the original host, then human-to-human transmission can occur, presenting a substantial threat of rapid spread of a novel virus throughout the community (reviewed in reference
      <xref ref-type="bibr" rid="B32">
       32
      </xref>
      ).
     </p>
     <p>
      Viruses causing respiratory infections are spread by droplets expelled by coughs and sneezes, which can also contaminate the environment 2 m and 6 m away, respectively (
      <xref ref-type="bibr" rid="B33">
       33
      </xref>
      ), and a single droplet may easily contain an infectious dose (
      <xref ref-type="bibr" rid="B34">
       34
      </xref>
      ). Enveloped respiratory viruses, although more susceptible to environmental stress than nonenveloped viruses, have been shown to persist on surfaces and contaminate more than 50% of surfaces in household and day care centers (
      <xref ref-type="bibr" rid="B35">
       35
      </xref>
      ). Animal coronaviruses, including transmissible gastroenteritis virus (TGEV) and mouse hepatitis virus (MHV), have been shown to retain infectivity for long periods on hard surfaces (
      <xref ref-type="bibr" rid="B36">
       36
      </xref>
      ) and for several hours on health care gowns, gloves, and masks (
      <xref ref-type="bibr" rid="B37">
       37
      </xref>
      ), but human coronavirus 229E (HuCoV-229E) did not persist for above a few hours on surfaces (
      <xref ref-type="bibr" rid="B38">
       38
      </xref>
      ). In contrast, we have observed that a relatively low titer of infectious human coronavirus 229E persisted on 5 surface materials, common to communal and domestic environments, for at least 5 days. Our virus preparation contained a high proportion of lung cell debris to mimic natural contamination in respiratory secretions, which may have protected the virus from desiccation, and a human lung cell line was used for the assay, which may have been more sensitive. The relatively low virus concentration used suggests that higher viral concentrations which can occur in sputum may persist for longer periods. During coronavirus infection, the viral load is highest later in the infection and large numbers of infectious virus which may also contaminate the surrounding environment can be shed as symptoms subside over long periods (
      <xref ref-type="bibr" rid="B4">
       4
      </xref>
      ). There is scant information on minimum infectious doses, but for many respiratory viruses, the minimum infectious dose is believed to be low, i.e., just a few virus particles. Coronavirus persistence on surfaces represents a considerable infection risk if contaminated surfaces are touched and infectious virus transferred to the mouth, nasal mucosa, or conjunctiva. Nicas and Best (
      <xref ref-type="bibr" rid="B39">
       39
      </xref>
      ) observed that individuals in office environments touched their face an average of 15 times an hour, giving ample opportunities for infection spread. The use of antiviral surfaces in health care and community facilities could help to reduce infection spread in this way. HuCoV-229E was rapidly inactivated on copper surfaces, with the inactivation rate being roughly proportional to the percentage of copper in the alloy. Alloys containing &gt;90% copper inactivated 10
      <sup>
       3
      </sup>
      PFU coronavirus in &lt;30 min, and a surface oxidation layer or increased copper ion release on C70600 increased efficacy, which has been observed for this alloy before (
      <xref ref-type="bibr" rid="B27">
       27
      </xref>
      ). Brasses were more efficacious than copper nickels at a lower percentage of copper.
     </p>
     <p>
      Previous studies by our laboratory have shown release of copper ionic species to be essential to the efficacy of copper surfaces in killing bacteria and inactivating norovirus (
      <xref ref-type="bibr" rid="B26">
       26
      </xref>
      ). Using chelators, we have determined that Cu(I) and Cu(II) are also essential for inactivation of coronaviruses. On brass (70% copper), BCS, the chelator for Cu(I), was still protective at 2 h of contact, suggesting that inactivation may have been due to Cu(II) immediately and to Cu(I) in the long term. Copper ions have been shown to directly inhibit proteases by reacting with surface cysteine and to inflict damage to the viral genome in HIV and herpes simplex virus (
      <xref ref-type="bibr" rid="B40">
       40
      </xref>
      ,
      <xref ref-type="bibr" rid="B41">
       41
      </xref>
      ).
     </p>
     <p>
      The mechanism of bacterial death on copper surfaces is complex, involving not only direct action of copper ion on multiple targets but also the generation of destructive oxygen radicals, resulting in “metabolic suicide” (
      <xref ref-type="bibr" rid="B20">
       20
      </xref>
      ). This was not observed for norovirus destruction on copper, presumably because of the lack of respiratory machinery (
      <xref ref-type="bibr" rid="B26">
       26
      </xref>
      ). However, it appears that superoxide and hydroxyl radical generation may be important in the inactivation of coronaviruses on copper alloys but that inactivation on 100% copper surfaces is primarily due to the direct effect of copper ions. Following application of a wet droplet to a copper surface, the predominant ionic species to dissolute from the metal surface is Cu(II), but reduction to Cu(I) and the Fenton reaction with oxidative intermediates from cell debris, molecular oxygen, or viral envelope could produce the highly toxic hydroxyl radical. ROS are generated in the natural course of coronavirus infection (
      <xref ref-type="bibr" rid="B42">
       42
      </xref>
      ) and contribute to pathogenesis and apoptosis. Fujimori et al. (
      <xref ref-type="bibr" rid="B43">
       43
      </xref>
      ) observed inactivation of influenza A H1N1 pandemic 2009 strain by Cu(I) iodide nanoparticles which involved hydroxyl radicals and resulted in degradation of hemagglutinin and neuraminidase viral proteins. They surmised that, although there was no exogenous hydrogen peroxide to fuel the Fenton reaction (
      <xref ref-type="disp-formula" rid="eqn3">
       equation 3
      </xref>
      ), Cu(I) reacted with molecular oxygen to generate superoxide (
      <xref ref-type="disp-formula" rid="eqn1">
       equation 1
      </xref>
      ) and, subsequently, hydrogen peroxide (
      <xref ref-type="disp-formula" rid="eqn2">
       equation 2
      </xref>
      ) (which could also produce hydroxyl radicals via the Haber Weiss reaction) as follows:
     </p>
     <disp-formula id="eqn1">
      <label>
       (1)
      </label>
      <mml:math id="M1">
       <mml:mrow>
        <mml:mn>
         2
        </mml:mn>
        <mml:msup>
         <mml:mrow>
          <mml:mtext>
           Cu
          </mml:mtext>
         </mml:mrow>
         <mml:mrow>
          <mml:mo>
           +
          </mml:mo>
         </mml:mrow>
        </mml:msup>
        <mml:mo>
         +
        </mml:mo>
        <mml:mn>
         2
        </mml:mn>
        <mml:msub>
         <mml:mrow>
          <mml:mtext>
           O
          </mml:mtext>
         </mml:mrow>
         <mml:mrow>
          <mml:mn>
           2
          </mml:mn>
         </mml:mrow>
        </mml:msub>
        <mml:mo stretchy="false">
         (
        </mml:mo>
        <mml:mtext>
         aq
        </mml:mtext>
        <mml:mo stretchy="false">
         )
        </mml:mo>
        <mml:mo>
         →
        </mml:mo>
        <mml:mn>
         2
        </mml:mn>
        <mml:msup>
         <mml:mrow>
          <mml:mtext>
           Cu
          </mml:mtext>
         </mml:mrow>
         <mml:mrow>
          <mml:mn>
           2
          </mml:mn>
          <mml:mo>
           +
          </mml:mo>
         </mml:mrow>
        </mml:msup>
        <mml:mo>
         +
        </mml:mo>
        <mml:mn>
         2
        </mml:mn>
        <mml:msup>
         <mml:mrow>
          <mml:msub>
           <mml:mrow>
            <mml:mtext>
             O
            </mml:mtext>
           </mml:mrow>
           <mml:mrow>
            <mml:mn>
             2
            </mml:mn>
           </mml:mrow>
          </mml:msub>
         </mml:mrow>
         <mml:mrow>
          <mml:mo>
           −
          </mml:mo>
         </mml:mrow>
        </mml:msup>
       </mml:mrow>
      </mml:math>
     </disp-formula>
     <disp-formula id="eqn2">
      <label>
       (2)
      </label>
      <mml:math id="M2">
       <mml:mrow>
        <mml:mn>
         2
        </mml:mn>
        <mml:msup>
         <mml:mrow>
          <mml:msub>
           <mml:mrow>
            <mml:mtext>
             O
            </mml:mtext>
           </mml:mrow>
           <mml:mrow>
            <mml:mn>
             2
            </mml:mn>
           </mml:mrow>
          </mml:msub>
         </mml:mrow>
         <mml:mrow>
          <mml:mo>
           −
          </mml:mo>
         </mml:mrow>
        </mml:msup>
        <mml:mo>
         +
        </mml:mo>
        <mml:mn>
         2
        </mml:mn>
        <mml:msup>
         <mml:mrow>
          <mml:mtext>
           H
          </mml:mtext>
         </mml:mrow>
         <mml:mrow>
          <mml:mo>
           +
          </mml:mo>
         </mml:mrow>
        </mml:msup>
        <mml:mo>
         →
        </mml:mo>
        <mml:msub>
         <mml:mrow>
          <mml:mtext>
           H
          </mml:mtext>
         </mml:mrow>
         <mml:mrow>
          <mml:mn>
           2
          </mml:mn>
         </mml:mrow>
        </mml:msub>
        <mml:msub>
         <mml:mrow>
          <mml:mtext>
           O
          </mml:mtext>
         </mml:mrow>
         <mml:mrow>
          <mml:mn>
           2
          </mml:mn>
         </mml:mrow>
        </mml:msub>
        <mml:mo>
         +
        </mml:mo>
        <mml:msub>
         <mml:mrow>
          <mml:mtext>
           O
          </mml:mtext>
         </mml:mrow>
         <mml:mrow>
          <mml:mn>
           2
          </mml:mn>
         </mml:mrow>
        </mml:msub>
       </mml:mrow>
      </mml:math>
     </disp-formula>
     <disp-formula id="eqn3">
      <label>
       (3)
      </label>
      <mml:math id="M3">
       <mml:mrow>
        <mml:msup>
         <mml:mrow>
          <mml:mtext>
           Cu
          </mml:mtext>
         </mml:mrow>
         <mml:mrow>
          <mml:mo>
           +
          </mml:mo>
         </mml:mrow>
        </mml:msup>
        <mml:mo>
         +
        </mml:mo>
        <mml:msub>
         <mml:mrow>
          <mml:mtext>
           H
          </mml:mtext>
         </mml:mrow>
         <mml:mrow>
          <mml:mn>
           2
          </mml:mn>
         </mml:mrow>
        </mml:msub>
        <mml:msub>
         <mml:mrow>
          <mml:mtext>
           O
          </mml:mtext>
         </mml:mrow>
         <mml:mrow>
          <mml:mn>
           2
          </mml:mn>
         </mml:mrow>
        </mml:msub>
        <mml:mo>
         →
        </mml:mo>
        <mml:msup>
         <mml:mrow>
          <mml:mtext>
           Cu
          </mml:mtext>
         </mml:mrow>
         <mml:mrow>
          <mml:mn>
           2
          </mml:mn>
          <mml:mo>
           +
          </mml:mo>
         </mml:mrow>
        </mml:msup>
        <mml:mo>
         +
        </mml:mo>
        <mml:msup>
         <mml:mrow>
          <mml:mtext>
           OH
          </mml:mtext>
         </mml:mrow>
         <mml:mrow>
          <mml:mo>
           −
          </mml:mo>
         </mml:mrow>
        </mml:msup>
        <mml:mo>
         +
        </mml:mo>
        <mml:msup>
         <mml:mrow>
          <mml:mtext>
           OH
          </mml:mtext>
         </mml:mrow>
         <mml:mrow>
          <mml:mo>
           ⋅
          </mml:mo>
         </mml:mrow>
        </mml:msup>
       </mml:mrow>
      </mml:math>
     </disp-formula>
     <p>
      In our results, the Cu(I) chelator BCS protected coronavirus on brass surfaces, suggesting that Cu
      <sup>
       +
      </sup>
      migrating from the metal is important in toxicity and supporting the Fenton reaction generation of hydroxyl radicals that was observed. Perhaps the reason brasses were more effective at inactivating coronavirus than copper nickels was the increased Cu(I) release and subsequent ROS generation rather than the zinc content, which had only mild antiviral activity. Presumably, as in bacteria, a multitarget attack on enveloped viruses by copper ions and ROS may result in nonenzymatic peroxidation of the envelope (
      <xref ref-type="bibr" rid="B44">
       44
      </xref>
      ) and damage to membrane proteins and the nucleoproteins.
     </p>
     <p>
      We have observed previously (
      <xref ref-type="bibr" rid="B27">
       27
      </xref>
      ) that exposure to copper surfaces resulted in significant morphological changes to nonenveloped norovirus, where possible disassociation of the capsid subunits exposed the viral genome to copper inactivation. In this study, we observed rapid damage, including clumping, breakage, membrane damage, and loss of surface spikes, to the coronavirus particles following exposure to copper, and some particles appeared smaller and seemed to have lost rigidity, folding up on themselves. These changes were not observed with virus recovered from stainless steel surfaces.
     </p>
     <p>
      Analysis of coronavirus genomic RNA from viruses exposed to copper and copper alloys revealed a nonspecific fragmentation of the entire genome that can also be observed at the gene level by the reduction in copy number of a small fragment of nsp4 proteins, and the extent of damage increased with contact time. We have observed that the reduction in the capsid integrity of norovirus allows access of copper ions to the genome inactivating the virus. For coronavirus, the envelope and nucleoprotein are likewise compromised, and the process occurs more rapidly than with nonenveloped norovirus, which has a resistant capsid, to allow copper ion and/or ROS to destroy the genome. Interestingly, there was a 10-min delay in inactivation of simulated wet-droplet contamination which may reflect the time taken to breach the envelope and disrupt the nucleoprotein which allows access of copper ions to the coronavirus genome. Further studies may determine if the use of synergistic cleaning agents to weaken the envelope could reduce this delay. Sagripanti et al. (
      <xref ref-type="bibr" rid="B45">
       45
      </xref>
      ) also reported increased sensitivity to solutions of copper ions of enveloped viruses compared to nonenveloped phages.
     </p>
     <p>
      There are concerns about the pandemic potential of MERS, especially if the efficiency of interhuman transmission increases (
      <xref ref-type="bibr" rid="B46">
       46
      </xref>
      ). The majority of cases have been in the Middle East, and concerns have been expressed because &gt;2.5 million pilgrims attend the Hajj in Mecca, Saudi Arabia, aggregating from &gt;180 countries. Analysis of data since June 2012 resulted in estimates that the risks of transmission are low (
      <xref ref-type="bibr" rid="B47">
       47
      </xref>
      ,
      <xref ref-type="bibr" rid="B48">
       48
      </xref>
      ), but members of the Health Protection Agency (HPA) UK Novel Coronavirus Investigation team (
      <xref ref-type="bibr" rid="B49">
       49
      </xref>
      ) have observed person-to-person transmission within a family cluster in the United Kingdom contracted from a family member who had visited Saudi Arabia. They also observed that the spectrum of symptoms of MERS, including mild and asymptomatic disease, is wider than initially realized and that spread of the virus may therefore already be greater than expected. MERS has so far killed 36 people and infected 186 patients in hospital-associated cases in South Korea associated with the first imported case arising from travel to the Middle East (
      <xref ref-type="bibr" rid="B10">
       10
      </xref>
      ,
      <xref ref-type="bibr" rid="B11">
       11
      </xref>
      ). The current increase in the incidence of MERS has been described as a “subcritical epidemic,” but statistics have concentrated on severe cases only. It remains to be seen if the number of cases continues to escalate, and the evolution of SARS and MERS is a timely reminder of the constant threat of other coronaviruses making the jump from a large reservoir in wild and domestic animals to the human population. Several Hajj pilgrims returning to Austria had contracted serious respiratory disease caused by influenza A and B virus and not MERS (
      <xref ref-type="bibr" rid="B50">
       50
      </xref>
      ), emphasizing that there are multiple risks of contacting infectious diseases in any highly populated areas.
     </p>
     <p>
      The results from this study have shown that a relatively low concentration of enveloped respiratory viruses may retain infectivity on common hard surfaces for longer than previously thought and may present a real risk of infection to anyone who contacts a contaminated surface. However, human coronavirus 229E, an important pathogenic virus but also a surrogate for MERS coronavirus, which is structurally very similar, was rapidly inactivated on copper alloys. Inactivation results from a combination of direct copper ion attack and reactive oxygen species generation. The latter is particularly important as the copper content decreases, ensuring that rapid inactivation still occurs in alloys with lower percentages of copper. Therefore, incorporation of copper alloys in communal areas could help to reduce infection spread from touching surfaces contaminated with coronaviruses. This is especially important in infectious disease where the infectious dose is low, surface contamination is high, and effective therapies are limited. The mechanism of action of copper is complex and may be enhanced by radical formation but is ultimately nonspecific, ensuring continuous kill and inactivation of a wide range of pathogenic microorganisms with completely different morphologies. Concerns about the biocide resistance, possible concomitant drug resistance, and horizontal gene transfer that have been observed with other biocides (
      <xref ref-type="bibr" rid="B51">
       51
      </xref>
      ) can be allayed because of the destruction of viral nucleic acid observed following exposure to copper surfaces. It is not feasible to cover every surface in copper, and many materials in the built environment, including stainless steel, will continue to be used because of resilience, anticorrosion, and other beneficial attributes. Incorporation of even a few copper surfaces may have an impact in effectively reducing transmission of infectious material from a surface to an individual, provided that stringent, regular, and effective cleaning regimens are employed for all surfaces. The use of copper does not serve as an excuse to relax cleaning regimens. However, the choice of cleaning reagents is critical for copper alloys because it is essential to maintain copper ion release for efficacy, so avoidance of chelators is necessary.
     </p>
     <p>
      There is now a large body of evidence from laboratory studies and small clinical trials to suggest that incorporation of copper surfaces could play a significant role in reducing infection transmission from contaminated surfaces. The time is nigh to investigate this further on a larger scale, but fears of the installation costs appear to be hampering the progress. Given the huge costs, human and monetary, associated with the treatment and care of patients with hospital-acquired infections, preliminary studies have suggested that the initial costs could be recouped within a few months (
      <xref ref-type="bibr" rid="B52">
       52
      </xref>
      ). New technologies in copper coatings are being developed which may allow large-scale community areas, such as transport facilities, to be rendered antimicrobial at reduced costs. A note of caution: for these to be effective, there must be actual contact between copper and the contaminating pathogenic microorganisms, because any interference from matrix components could result in false economy.
     </p>
    </sec>
    <sec id="h3" sec-type="materials|methods">
     <title>
      MATERIALS AND METHODS
     </title>
     <sec id="s3.1">
      <title>
       Viral strains and cell lines.
      </title>
      <p>
       Human coronavirus 229E (HuCoV-229E) and a fetal fibroblast cell line, MRC-5, were supplied by Public Health England (PHE), United Kingdom. Cells were maintained in minimal essential medium (MEM) supplemented with GlutaMax-1, nonessential amino acids, and 5% fetal calf serum and incubated at 37°C and 5% CO
       <sub>
        2
       </sub>
       . Cells were passaged twice a week using trypsin (0.25%)-EDTA and were not used beyond passage 30 (P30) (which occurred before the onset of senescence, but susceptibility to infection diminished greatly from P30). Viral stocks were prepared by infecting cells at multiplicity of infection of 0.01 for 4 to 7 days until a significant cytopathic effect (CPE) was observed. Infected cells were subjected to 3 freeze/thaw cycles, and infected-cell lysate was stored at −80°C.
      </p>
     </sec>
     <sec id="s3.2">
      <title>
       Preparation of sample surfaces.
      </title>
      <p>
       Metal coupons (10 by 10 by 0.5 mm) were degreased in acetone, stored in absolute ethanol, and flamed prior to use as described previously (
       <xref ref-type="bibr" rid="B19">
        19
       </xref>
       ). Metal samples were supplied by the Copper Development Association and are described in
       <xref ref-type="table" rid="tab1">
        Table 1
       </xref>
       . Coupons of nonmetal surfaces (PTFE, polyvinyl chloride [PVC], ceramic tiles, glass, and silicone rubber) of the same size were sterilized by autoclaving at 121°C and 1.06 × 10
       <sup>
        5
       </sup>
       pascals (1.06 bar) for 15 min. Stainless steel controls for comparison were also autoclaved for method consistency for these experiments.
      </p>
     </sec>
     <sec id="s3.3">
      <title>
       Infectivity assay for HuCoV-229E exposed to surfaces.
      </title>
      <p>
       Infected cell lysate preparations of HuCoV-229E were spread over coupons of the test surface and incubated at room temperature. The virus was removed from the coupons at various times and assayed for infectious virus by a plaque assay which was a modification of the murine norovirus 1 (MNV-1) assay described previously (
       <xref ref-type="bibr" rid="B26">
        26
       </xref>
       ). Briefly, coupons inoculated with virus and incubated for various times at room temperature were added to a tube containing 5 ml growth medium and 2-mm-diameter glass beads and subjected to vortex mixing for 15 s. Dilutions were prepared in growth medium, and 1-ml aliquots were plated onto confluent monolayers of MRC-5 cells that had been prepared 24 h earlier in 6-well trays. The inoculum was removed after 90 min and replaced with agarose overlays, and plates were incubated at 37°C and 5% CO
       <sub>
        2
       </sub>
       for 4 to 7 days until CPE was evident. The monolayers were stained with vital stain and neutral red, and plaques in the monolayer were enumerated. Triplicate samples were processed for each time point.
      </p>
     </sec>
     <sec id="s3.4">
      <title>
       The effect of copper chelators and reactive oxygen species quenchers on infectivity of human coronavirus exposed to copper and copper alloy surfaces.
      </title>
      <p>
       Incorporation of chelators ethylenediaminetetraacetic acid (EDTA) (20 mM) and bathocuproine disulfonic acid (BCS) (20 mM) to chelate Cu(II) and Cu(I), respectively, at the time of inoculation of virus onto the metal surfaces was investigated using a plaque assay. In addition, 20 mM
       <sc>
        d
       </sc>
       -mannitol and 20 mM Tiron (4,5-dihydroxy-1,3-benzene disulfonic acid) were used to quench hydroxyl radicals and superoxide, respectively. Stainless steel was used as a control surface and to determine if quenchers and chelators affect viral replication.
      </p>
     </sec>
     <sec id="s3.5">
      <title>
       Purification of viral RNA and analysis of integrity by agarose gel electrophoresis.
      </title>
      <p>
       The total RNA of untreated virus or virus exposed to metal surfaces (5 coupons per test, with virus removed from coupons by pipetting up and down in a small volume [100 µl]) was extracted using a Qiagen QIAamp viral RNA minikit according to the manufacturer’s instructions and the carrier RNA provided to prevent degradation.
      </p>
      <p>
       Purified RNA fragments were separated on a nondenaturing 1% agarose gel using a GelRed nucleic acid prestaining kit (Biotium, United Kingdom) according to the manufacturer’s instructions. The staining intensity is reduced because GelRed binds to single-stranded RNA (ssRNA) approximately half as much as to double-stranded nucleic acid. DNA ladders were supplied by Bioline. Gels were observed and photographed using GeneSnap software and a Syngene UV light box.
      </p>
     </sec>
     <sec id="s3.6">
      <title>
       Detection and quantification of a 139-bp region of the coronavirus nonstructural gene encoding nsp4 in virus exposed to copper and brass surfaces.
      </title>
      <p>
       To determine if exposure to copper affected the viral genome at the gene level, a 139-bp region of the gene encoding nsp4 (within polyprotein 1ab replicase) was investigated using a One-Step real-time quantitative PCR (RTqPCR) diagnostic kit (supplied by PrimerDesign, United Kingdom). The kit is based on sequences from HuCoV-229E (GenBank accession number
       <ext-link ext-link-type="NCBI:nucleotide" xlink:href="NC_002645">
        NC_002645
       </ext-link>
       ; anchor nucleotide position 8205). Amplification was performed on a BioRad iQ5 cycler, and standard curves were prepared from known copy number standards to determine copy numbers in test samples. PCR products were analyzed by gel electrophoresis as described above.
      </p>
     </sec>
     <sec id="s3.7">
      <title>
       Detection of morphological changes to HuCoV-229E using transmission electron microscopy (TEM).
      </title>
      <p>
       HuCoV-229E was purified from crude infected-cell lysate. Polyethylene glycol (PEG) precipitation (BioVision PEG virus precipitation kit) was followed by sucrose density (25% to 55%) centrifugation at 96,000 ×
       <italic>
        g
       </italic>
       for 16 h at 4°C. The virus band was resuspended in water and the virus pelleted at 77,000 ×
       <italic>
        g
       </italic>
       for 1 h at 4°C. The supernatant was discarded, the tubes were allowed to drain, and the final pellet was resuspended in ice-cold nuclease-free deionized distilled water after incubation on ice for 30 min. The preparation was applied to copper and stainless steel as described in the
       <xref ref-type="fig" rid="fig6">
        Figure 6
       </xref>
       legend and was removed by gentle pipetting. Samples were fixed, applied to TEM grids, washed with water, and stained with 5% ammonium molybdate for 10 s.
      </p>
     </sec>
     <sec id="s3.8">
      <title>
       Statistical analysis.
      </title>
      <p>
       Data are expressed as means ± standard errors of the mean (SEM) and are from the results of multiple independent experiments. Statistical analyses and representational graphic depictions were performed using GraphPad Prism 6.
      </p>
     </sec>
    </sec>
    <back>
     <fn-group>
      <fn fn-type="other">
       <p>
        <bold>
         Citation
        </bold>
        Warnes SL, Little ZR, Keevil CW. 2015. Human coronavirus 229E remains infectious on common touch surface materials. mBio 6(6):e01697-15. doi:10.1128/mBio.01697-15.
       </p>
      </fn>
     </fn-group>
     <ack>
      <title>
       ACKNOWLEDGMENTS
      </title>
      <p>
       This research was supported by the Copper Development Association, New York, and the International Copper Association, New York.
      </p>
      <p>
       We thank Anton Page, Patricia Goggin, Lizzie Angus, and everyone at the Biomedical Imaging Unit, University of Southampton, Southampton, United Kingdom, for their help with the use of the transmission electron microscope.
      </p>
     </ack>
     <ref-list>
      <title>
       REFERENCES
      </title>
      <ref id="B1">
       <label>
        1.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Zambon
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <year>
         2014
        </year>
        <article-title>
         Influenza and other emerging respiratory viruses
        </article-title>
        .
        <source>
         Medicine
        </source>
        <volume>
         42
        </volume>
        :
        <fpage>
         45
        </fpage>
        –
        <lpage>
         51
        </lpage>
        doi:
        <pub-id pub-id-type="doi">
         10.1016/j.mpmed.2013.10.017
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="B2">
       <label>
        2.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ruuskanen
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lahti
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jennings
          </surname>
          <given-names>
           LC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Murdoch
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
        </person-group>
        <year>
         2011
        </year>
        <article-title>
         Viral pneumonia
        </article-title>
        .
        <source>
         Lancet
        </source>
        <volume>
         377
        </volume>
        :
        <fpage>
         1264
        </fpage>
        –
        <lpage>
         1275
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(10)61459-6
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         21435708
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B3">
       <label>
        3.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Van den Brand
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Smits
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Haagmans
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
        </person-group>
        <year>
         2015
        </year>
        <article-title>
         Pathogenesis of Middle East respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         J Pathol
        </source>
        <volume>
         235
        </volume>
        :
        <fpage>
         175
        </fpage>
        –
        <lpage>
         184
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1002/path.4458
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         25294366
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B4">
       <label>
        4.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Gralinski
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Baric
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
        </person-group>
        <year>
         2015
        </year>
        <article-title>
         Molecular pathology of emerging coronavirus infections
        </article-title>
        .
        <source>
         J Pathol
        </source>
        <volume>
         235
        </volume>
        :
        <fpage>
         185
        </fpage>
        –
        <lpage>
         195
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1002/path.4454
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         25270030
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B5">
       <label>
        5.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Coleman
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Frieman
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
        </person-group>
        <year>
         2014
        </year>
        <article-title>
         Coronaviruses: important emerging human pathogens
        </article-title>
        .
        <source>
         J Virol
        </source>
        <volume>
         88
        </volume>
        :
        <fpage>
         5209
        </fpage>
        –
        <lpage>
         5212
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1128/JVI.03488-13
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         24600003
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B6">
       <label>
        6.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           JFW
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           SKP
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           To
          </surname>
          <given-names>
           KKW
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cheng
          </surname>
          <given-names>
           VCC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Woo
          </surname>
          <given-names>
           PCY
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yuen
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <year>
         2015
        </year>
        <article-title>
         Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease
        </article-title>
        .
        <source>
         Clin Microbiol Rev
        </source>
        <volume>
         28
        </volume>
        :
        <fpage>
         465
        </fpage>
        –
        <lpage>
         522
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1128/CMR.00102-14
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         25810418
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B7">
       <label>
        7.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Cong
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ren
          </surname>
          <given-names>
           X
          </given-names>
         </name>
        </person-group>
        <year>
         2014
        </year>
        <article-title>
         Coronavirus entry and release in polarized epithelial cells: a review
        </article-title>
        .
        <source>
         Rev Med Virol
        </source>
        <volume>
         24
        </volume>
        :
        <fpage>
         308
        </fpage>
        –
        <lpage>
         315
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1002/rmv.1792
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         24737708
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B8">
       <label>
        8.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Hemida
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Al-Naeem
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Perera
          </surname>
          <given-names>
           RAPM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chin
          </surname>
          <given-names>
           AWH
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Poon
          </surname>
          <given-names>
           LLM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Peiris
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <year>
         2015
        </year>
        <article-title>
         Lack of Middle East respiratory syndrome coronavirus transmission from infected camels
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         21
        </volume>
        :
        <fpage>
         699
        </fpage>
        –
        <lpage>
         701
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.3201/eid2104.141949
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         25811546
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B9">
       <label>
        9.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Oboho
          </surname>
          <given-names>
           IK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tomczyk
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Al-Asmari
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Banjar
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Al-Mugti
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Aloraini
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Alkhaldi
          </surname>
          <given-names>
           KZ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Almohammadi
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Alraddadi
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gerber
          </surname>
          <given-names>
           SI
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Swerdlow
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Watson
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Madani
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
        </person-group>
        <year>
         2015
        </year>
        <article-title>
         2014 MERS-CoV outbreak in Jeddah—a link to health care facilities
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <volume>
         372
        </volume>
        :
        <fpage>
         846
        </fpage>
        –
        <lpage>
         854
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1408636
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         25714162
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B10">
       <label>
        10.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Butler
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <year>
         2015
        </year>
        <article-title>
         South Korean MERS outbreak spotlights lack of research
        </article-title>
        .
        <source>
         Nature
        </source>
        <volume>
         522
        </volume>
        :
        <fpage>
         139
        </fpage>
        –
        <lpage>
         140
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1038/522139a
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         26062490
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B11">
       <label>
        11.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ki
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <year>
         2015
        </year>
        <article-title>
         2015 MERS outbreak in Korea: hospital-to-hospital transmission
        </article-title>
        .
        <source>
         Epidemiol Health
        </source>
        <volume>
         37
        </volume>
        :
        <fpage>
         e2015033
        </fpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.4178/epih/e2015033
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         26212508
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B12">
       <label>
        12.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Otter
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yezli
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Salkeld
          </surname>
          <given-names>
           JAG
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           French
          </surname>
          <given-names>
           GL
          </given-names>
         </name>
        </person-group>
        <year>
         2013
        </year>
        <article-title>
         Evidence that contaminated surfaces contribute to the transmission of hospital pathogens and an overview of strategies to address contaminated surfaces in hospital settings
        </article-title>
        .
        <source>
         Am J Infect Control
        </source>
        <volume>
         41
        </volume>
        :
        <fpage>
         S6
        </fpage>
        –
        <lpage>
         S11
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/j.ajic.2012.12.004
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         23622751
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B13">
       <label>
        13.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Bean
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Moore
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sterner
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Peterson
          </surname>
          <given-names>
           LR
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gerding
          </surname>
          <given-names>
           DN
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Balfour
          </surname>
          <given-names>
           HH
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
        </person-group>
        <year>
         1982
        </year>
        <article-title>
         Survival of influenza viruses on environmental surfaces
        </article-title>
        .
        <source>
         J Infect Dis
        </source>
        <volume>
         146
        </volume>
        :
        <fpage>
         47
        </fpage>
        –
        <lpage>
         51
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1093/infdis/146.1.47
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         6282993
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B14">
       <label>
        14.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wilks
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Michels
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Keevil
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
        </person-group>
        <year>
         2005
        </year>
        <article-title>
         The survival of
         <italic>
          Escherichia coli
         </italic>
         O157 on a range of metal surfaces
        </article-title>
        .
        <source>
         Int J Food Microbiol
        </source>
        <volume>
         105
        </volume>
        :
        <fpage>
         445
        </fpage>
        –
        <lpage>
         454
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/j.ijfoodmicro.2005.04.021
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         16253366
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B15">
       <label>
        15.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Noyce
          </surname>
          <given-names>
           JO
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Michels
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Keevil
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
        </person-group>
        <year>
         2006
        </year>
        <article-title>
         Potential use of copper surfaces to reduce survival of epidemic meticillin-resistant
         <italic>
          Staphylococcus aureus
         </italic>
         in the healthcare environment
        </article-title>
        .
        <source>
         J Hosp Infect
        </source>
        <volume>
         63
        </volume>
        :
        <fpage>
         289
        </fpage>
        –
        <lpage>
         297
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/j.jhin.2005.12.008
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         16650507
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B16">
       <label>
        16.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Noyce
          </surname>
          <given-names>
           JO
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Michels
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Keevil
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
        </person-group>
        <year>
         2006
        </year>
        <article-title>
         Use of copper cast alloys to control
         <italic>
          Escherichia coli
         </italic>
         O157 cross-contamination during food processing
        </article-title>
        .
        <source>
         Appl Environ Microbiol
        </source>
        <volume>
         72
        </volume>
        :
        <fpage>
         4239
        </fpage>
        –
        <lpage>
         4244
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1128/AEM.02532-05
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         16751537
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B17">
       <label>
        17.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Weaver
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Michels
          </surname>
          <given-names>
           HT
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Keevil
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
        </person-group>
        <year>
         2008
        </year>
        <article-title>
         Survival of
         <italic>
          Clostridium difficile
         </italic>
         on copper and steel: futuristic options for hospital hygiene
        </article-title>
        .
        <source>
         J Hosp Infect
        </source>
        <volume>
         68
        </volume>
        :
        <fpage>
         145
        </fpage>
        –
        <lpage>
         151
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/j.jhin.2007.11.011
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         18207284
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B18">
       <label>
        18.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Weaver
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Michels
          </surname>
          <given-names>
           HT
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Keevil
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
        </person-group>
        <year>
         2010
        </year>
        <article-title>
         Potential for preventing spread of fungi in air-conditioning systems constructed using copper instead of aluminium
        </article-title>
        .
        <source>
         Lett Appl Microbiol
        </source>
        <volume>
         50
        </volume>
        :
        <fpage>
         18
        </fpage>
        –
        <lpage>
         23
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1111/j.1472-765X.2009.02753.x
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         19943884
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B19">
       <label>
        19.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Warnes
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Green
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Michels
          </surname>
          <given-names>
           HT
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Keevil
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
        </person-group>
        <year>
         2010
        </year>
        <article-title>
         Biocidal efficacy of copper alloys against pathogenic enterococci involves degradation of genomic and plasmid DNAs
        </article-title>
        .
        <source>
         Appl Environ Microbiol
        </source>
        <volume>
         76
        </volume>
        :
        <fpage>
         5390
        </fpage>
        –
        <lpage>
         5401
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1128/AEM.03050-09
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         20581191
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B20">
       <label>
        20.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Warnes
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Keevil
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
        </person-group>
        <year>
         2011
        </year>
        <article-title>
         Mechanism of copper surface toxicity in vancomycin-resistant enterococci following wet or dry surface contact
        </article-title>
        .
        <source>
         Appl Environ Microbiol
        </source>
        <volume>
         77
        </volume>
        :
        <fpage>
         6049
        </fpage>
        –
        <lpage>
         6059
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1128/AEM.00597-11
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         21742916
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B21">
       <label>
        21.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Warnes
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Caves
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Keevil
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
        </person-group>
        <year>
         2012
        </year>
        <article-title>
         Mechanism of copper surface toxicity in
         <italic>
          Escherichia coli
         </italic>
         O157:H7 and
         <italic>
          Salmonella
         </italic>
         involves immediate membrane depolarization followed by slower rate of DNA destruction which differs from that observed for Gram-positive bacteria
        </article-title>
        .
        <source>
         Environ Microbiol
        </source>
        <volume>
         14
        </volume>
        :
        <fpage>
         1730
        </fpage>
        –
        <lpage>
         1743
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1111/j.1462-2920.2011.02677.x
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         22176893
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B22">
       <label>
        22.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Casey
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Adams
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Karpanen
          </surname>
          <given-names>
           TJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lambert
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cookson
          </surname>
          <given-names>
           BD
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Nightingale
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Miruszenko
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Shillam
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Christian
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Elliott
          </surname>
          <given-names>
           TSJ
          </given-names>
         </name>
        </person-group>
        <year>
         2010
        </year>
        <article-title>
         Role of copper in reducing hospital environment contamination
        </article-title>
        .
        <source>
         J Hosp Infect
        </source>
        <volume>
         74
        </volume>
        :
        <fpage>
         72
        </fpage>
        –
        <lpage>
         77
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/j.jhin.2009.08.018
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         19931938
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B23">
       <label>
        23.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Karpanen
          </surname>
          <given-names>
           TJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Casey
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lambert
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cookson
          </surname>
          <given-names>
           BD
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Nightingale
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Miruszenko
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Elliott
          </surname>
          <given-names>
           TSJ
          </given-names>
         </name>
        </person-group>
        <year>
         2012
        </year>
        <article-title>
         The antimicrobial efficacy of copper alloy furnishing in the clinical environment: a crossover study
        </article-title>
        .
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         33
        </volume>
        :
        <fpage>
         3
        </fpage>
        –
        <lpage>
         9
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1086/663644
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         22173515
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B24">
       <label>
        24.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Schmidt
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Attaway
          </surname>
          <given-names>
           HH
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sharpe
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           John
          </surname>
          <given-names>
           J
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sepkowitz
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Morgan
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Fairey
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Singh
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Steed
          </surname>
          <given-names>
           LL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cantey
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Freeman
          </surname>
          <given-names>
           KD
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Michels
          </surname>
          <given-names>
           HT
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Salgado
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
        </person-group>
        <year>
         2012
        </year>
        <article-title>
         Sustained reduction of microbial burden on common hospital surfaces through introduction of copper
        </article-title>
        .
        <source>
         J Clin Microbiol
        </source>
        <volume>
         50
        </volume>
        :
        <fpage>
         2217
        </fpage>
        –
        <lpage>
         2223
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1128/JCM.01032-12
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         22553242
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B25">
       <label>
        25.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Salgado
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sepkowitz
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           John
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cantey
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Attaway
          </surname>
          <given-names>
           HH
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Freeman
          </surname>
          <given-names>
           KD
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sharpe
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Michels
          </surname>
          <given-names>
           HT
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Schmidt
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
        </person-group>
        <year>
         2013
        </year>
        <article-title>
         Copper surfaces reduce the rate of healthcare-acquired infections in the intensive care unit
        </article-title>
        .
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         34
        </volume>
        :
        <fpage>
         479
        </fpage>
        –
        <lpage>
         486
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1086/670207
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         23571364
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B26">
       <label>
        26.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Warnes
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Keevil
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
        </person-group>
        <year>
         2013
        </year>
        <article-title>
         Inactivation of norovirus on dry copper alloy surfaces
        </article-title>
        .
        <source>
         PLoS One
        </source>
        <volume>
         8
        </volume>
        :
        <fpage>
         e75017
        </fpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0075017
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         24040380
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B27">
       <label>
        27.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Warnes
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Summersgill
          </surname>
          <given-names>
           EN
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Keevil
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
        </person-group>
        <year>
         2015
        </year>
        <article-title>
         Inactivation of murine norovirus on a range of copper alloy surfaces is accompanied by loss of capsid integrity
        </article-title>
        .
        <source>
         Appl Environ Microbiol
        </source>
        <volume>
         81
        </volume>
        :
        <fpage>
         1085
        </fpage>
        –
        <lpage>
         1091
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1128/AEM.03280-14
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         25452290
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B28">
       <label>
        28.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Manuel
          </surname>
          <given-names>
           CS
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Moore
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jaykus
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
        </person-group>
        <year>
         2015
        </year>
        <article-title>
         Destruction of the capsid and genome of GII.4 human norovirus occurs during exposure to metal alloys containing copper
        </article-title>
        .
        <source>
         Appl Environ Microbiol
        </source>
        <volume>
         81
        </volume>
        :
        <fpage>
         4940
        </fpage>
        –
        <lpage>
         4946
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1128/AEM.00388-15
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         25979897
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B29">
       <label>
        29.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Pene
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Merlat
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Vabret
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Rozenberg
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Buzyn
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Dreyfus
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cariou
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Freymuth
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lebon
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <year>
         2003
        </year>
        <article-title>
         Coronavirus 229E-related pneumonia in immunocompromised patients
        </article-title>
        .
        <source>
         Clin Infect Dis
        </source>
        <volume>
         37
        </volume>
        :
        <fpage>
         929
        </fpage>
        –
        <lpage>
         932
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1086/377612
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         13130404
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B30">
       <label>
        30.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Boucher
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Desforges
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Duquette
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Talbot
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
        </person-group>
        <year>
         2007
        </year>
        <article-title>
         Long-term human coronavirus-myelin cross-reactive T-cell clones derived from multiple sclerosis patients
        </article-title>
        .
        <source>
         Clin Immunol
        </source>
        <volume>
         123
        </volume>
        :
        <fpage>
         258
        </fpage>
        –
        <lpage>
         267
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/j.clim.2007.02.002
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         17448727
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B31">
       <label>
        31.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Baldwin
          </surname>
          <given-names>
           HJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Fumie
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Melim
          </surname>
          <given-names>
           ZR
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Annan
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Owusu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Nkrumah
          </surname>
          <given-names>
           EE
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Maganga
          </surname>
          <given-names>
           GD
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Oppong
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Adu-Sarkodie
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Vallo
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           da Silva Filho
          </surname>
          <given-names>
           LV
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Leroy
          </surname>
          <given-names>
           EM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Thiel
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Poon
          </surname>
          <given-names>
           LL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tschapka
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Drexler
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
        </person-group>
        16
        <month>
         9
        </month>
        <year>
         2015
        </year>
        <article-title>
         Evidence for an ancestral association of human coronavirus 229E with bats
        </article-title>
        .
        <source>
         J Virol
        </source>
        doi:
        <pub-id pub-id-type="doi">
         10.1128/JVI.01755-15
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="B32">
       <label>
        32.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Shi
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Qi
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gao
          </surname>
          <given-names>
           GF
          </given-names>
         </name>
        </person-group>
        <year>
         2014
        </year>
        <article-title>
         Enabling the “host jump”: structural determinants of receptor-binding specificity in influenza A viruses
        </article-title>
        .
        <source>
         Nat Rev Microbiol
        </source>
        <volume>
         12
        </volume>
        :
        <fpage>
         822
        </fpage>
        –
        <lpage>
         831
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1038/nrmicro3362
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         25383601
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B33">
       <label>
        33.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Xie
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chwang
          </surname>
          <given-names>
           ATY
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ho
          </surname>
          <given-names>
           PL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Seto
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
        </person-group>
        <year>
         2007
        </year>
        <article-title>
         How far droplets can move in indoor environments—revisiting the wells evaporation-falling curve
        </article-title>
        .
        <source>
         Indoor Air
        </source>
        <volume>
         17
        </volume>
        :
        <fpage>
         211
        </fpage>
        –
        <lpage>
         225
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1111/j.1600-0668.2007.00469.x
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         17542834
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B34">
       <label>
        34.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Yezli
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Otter
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        <year>
         2011
        </year>
        <article-title>
         Minimum infective dose of the major respiratory and enteric viruses transmitted through food and the environment
        </article-title>
        .
        <source>
         Food Environ Virol
        </source>
        <volume>
         3
        </volume>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         30
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1007/s12560-011-9056-7
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="B35">
       <label>
        35.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Boone
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gerba
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <year>
         2005
        </year>
        <article-title>
         The occurrence of influenza A virus on household and day care center fomites
        </article-title>
        .
        <source>
         J Infect
        </source>
        <volume>
         51
        </volume>
        :
        <fpage>
         103
        </fpage>
        –
        <lpage>
         109
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/j.jinf.2004.09.011
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         16038759
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B36">
       <label>
        36.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Casanova
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jeon
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Rutala
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Weber
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sobsey
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
        </person-group>
        <year>
         2010
        </year>
        <article-title>
         Effects of air temperature and relative humidity on coronavirus survival on surfaces
        </article-title>
        .
        <source>
         Appl Environ Microbiol
        </source>
        <volume>
         76
        </volume>
        :
        <fpage>
         2712
        </fpage>
        –
        <lpage>
         2717
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1128/AEM.02291-09
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         20228108
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B37">
       <label>
        37.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Casanova
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Rutala
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Weber
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sobsey
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <year>
         2010
        </year>
        <article-title>
         Coronavirus survival on healthcare personal protective equipment
        </article-title>
        .
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         31
        </volume>
        :
        <fpage>
         560
        </fpage>
        –
        <lpage>
         561
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1086/652452
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         20350196
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B38">
       <label>
        38.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sizun
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yu
          </surname>
          <given-names>
           MWN
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Talbot
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
        </person-group>
        <year>
         2000
        </year>
        <article-title>
         Survival of human coronaviruses 229E and OC43 in suspension and after drying on surfaces: a possible source of hospital-acquired infections
        </article-title>
        .
        <source>
         J Hosp Infect
        </source>
        <volume>
         46
        </volume>
        :
        <fpage>
         55
        </fpage>
        –
        <lpage>
         60
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1053/jhin.2000.0795
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         11023724
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B39">
       <label>
        39.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Nicas
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Best
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <year>
         2008
        </year>
        <article-title>
         A study quantifying the hand-to-face contact rate and its potential application to predicting respiratory tract infection
        </article-title>
        .
        <source>
         J Occup Environ Hyg
        </source>
        <volume>
         5
        </volume>
        :
        <fpage>
         347
        </fpage>
        –
        <lpage>
         352
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1080/15459620802003896
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         18357546
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B40">
       <label>
        40.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Karlstrom
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Levine
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
        </person-group>
        <year>
         1991
        </year>
        <article-title>
         Copper inhibits the protease from human immunodeficiency virus 1 by both cysteine-dependent and cysteine-independent mechanisms
        </article-title>
        .
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <volume>
         88
        </volume>
        :
        <fpage>
         5552
        </fpage>
        –
        <lpage>
         5556
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1073/pnas.88.13.5552
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         2062837
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B41">
       <label>
        41.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sagripanti
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Routson
          </surname>
          <given-names>
           LB
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Bonifacino
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lytle
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
        </person-group>
        <year>
         1997
        </year>
        <article-title>
         Mechanism of copper-mediated inactivation of herpes simplex virus
        </article-title>
        .
        <source>
         Antimicrob Agents Chemother
        </source>
        <volume>
         41
        </volume>
        :
        <fpage>
         812
        </fpage>
        –
        <lpage>
         817
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9087495
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B42">
       <label>
        42.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ding
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhao
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Huang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Du
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Dong
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Song
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tong
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <year>
         2013
        </year>
        <article-title>
         Regulation of ROS in transmissible gastroenteritis virus-activated apoptotic signaling
        </article-title>
        .
        <source>
         Biochem Biophys Res Commun
        </source>
        <volume>
         442
        </volume>
        :
        <fpage>
         33
        </fpage>
        –
        <lpage>
         37
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/j.bbrc.2013.10.164
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         24225120
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B43">
       <label>
        43.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Fujimori
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sato
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hayata
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Nagao
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Nakayama
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Nakayama
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sugamata
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Suzuki
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <year>
         2012
        </year>
        <article-title>
         Novel antiviral characteristics of nanosized copper(I) iodide particles showing inactivation activity against 2009 pandemic H1N1 influenza virus
        </article-title>
        .
        <source>
         Appl Environ Microbiol
        </source>
        <volume>
         78
        </volume>
        :
        <fpage>
         951
        </fpage>
        –
        <lpage>
         955
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1128/AEM.06284-11
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         22156433
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B44">
       <label>
        44.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Hong
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kang
          </surname>
          <given-names>
           TY
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Michels
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gadura
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <year>
         2012
        </year>
        <article-title>
         Membrane lipid peroxidation in copper alloy-mediated contact killing of
         <italic>
          Escherichia coli
         </italic>
        </article-title>
        .
        <source>
         Appl Environ Microbiol
        </source>
        <volume>
         78
        </volume>
        :
        <fpage>
         1776
        </fpage>
        –
        <lpage>
         1784
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1128/AEM.07068-11
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         22247141
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B45">
       <label>
        45.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sagripanti
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Routson
          </surname>
          <given-names>
           LB
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lytle
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
        </person-group>
        <year>
         1993
        </year>
        <article-title>
         Virus inactivation by copper or iron ions alone and in the presence of peroxide
        </article-title>
        .
        <source>
         Appl Environ Microbiol
        </source>
        <volume>
         59
        </volume>
        :
        <fpage>
         4374
        </fpage>
        –
        <lpage>
         4376
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8285724
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B46">
       <label>
        46.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Booth
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kournikakis
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Bastien
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ho
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kobasa
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Stadnyk
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Spence
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Paton
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Henry
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Mederski
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           White
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Low
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           McGeer
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Simor
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Vearncombe
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Downey
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jamieson
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tang
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Plummer
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <year>
         2005
        </year>
        <article-title>
         Detection of airborne severe acute respiratory syndrome (SARS) coronavirus and environmental contamination in SARS outbreak units
        </article-title>
        .
        <source>
         J Infect Dis
        </source>
        <volume>
         191
        </volume>
        :
        <fpage>
         1472
        </fpage>
        –
        <lpage>
         1477
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1086/429634
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         15809906
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B47">
       <label>
        47.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Breban
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Riou
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Fontanet
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <year>
         2013
        </year>
        <article-title>
         Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk
        </article-title>
        .
        <source>
         Lancet
        </source>
        <volume>
         382
        </volume>
        :
        <fpage>
         694
        </fpage>
        –
        <lpage>
         699
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(13)61492-0
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         23831141
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B48">
       <label>
        48.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Soliman
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cook
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Coker
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
        </person-group>
        <year>
         2015
        </year>
        <article-title>
         Pilgims and MERS-CoV: what’s the risk?
        </article-title>
        <source>
         Emerg Themes Epidemiol
        </source>
        <volume>
         12
        </volume>
        :
        <fpage>
         3
        </fpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1186/s12982-015-0025-8
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         25717340
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B49">
       <label>
        49.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          Health Protection Agency (HPA) UK Novel Coronavirus Investigation team
         </collab>
        </person-group>
        <year>
         2013
        </year>
        <article-title>
         Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <volume>
         18
        </volume>
        :
        <fpage>
         20427
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         23517868
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B50">
       <label>
        50.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Aberle
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Popow-Kraupp
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kreidl
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Laferl
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Heinz
          </surname>
          <given-names>
           FX
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Aberle
          </surname>
          <given-names>
           SW
          </given-names>
         </name>
        </person-group>
        <year>
         2015
        </year>
        <article-title>
         Influenza A and B viruses but not MERS-CoV in Hajj pilgrims, Austria, 2014
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         21
        </volume>
        :
        <fpage>
         726
        </fpage>
        –
        <lpage>
         727
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.3201/eid2104.141745
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         25811672
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B51">
       <label>
        51.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Webber
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Whitehead
          </surname>
          <given-names>
           RN
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Mount
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Loman
          </surname>
          <given-names>
           NJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Pallen
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Piddock
          </surname>
          <given-names>
           LJV
          </given-names>
         </name>
        </person-group>
        <year>
         2015
        </year>
        <article-title>
         Parallel evolutionary pathways to antibiotic resistance selected by biocide exposure
        </article-title>
        .
        <source>
         J Antimicrob Chemother
        </source>
        <volume>
         70
        </volume>
        :
        <fpage>
         2241
        </fpage>
        –
        <lpage>
         2248
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1093/jac/dkv109
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         25953808
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B52">
       <label>
        52.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Michels
          </surname>
          <given-names>
           HT
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Keevil
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Salgado
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Schmidt
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
        </person-group>
        <year>
         2015
        </year>
        <article-title>
         From laboratory research to a clinical trial: copper alloy surfaces kill bacteria and reduce hospital-acquired infections
        </article-title>
        .
        <source>
         HERD
        </source>
        <volume>
         9
        </volume>
        :
        <fpage>
         64
        </fpage>
        –
        <lpage>
         79
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1177/1937586715592650
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         26163568
        </pub-id>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Int J Biol Sci
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Int. J. Biol. Sci
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       ijbs
      </journal-id>
      <journal-title-group>
       <journal-title>
        International Journal of Biological Sciences
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       1449-2288
      </issn>
      <publisher>
       <publisher-name>
        Ivyspring International Publisher
       </publisher-name>
       <publisher-loc>
        Sydney
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32226295
      </article-id>
      <article-id pub-id-type="pmc">
       7098028
      </article-id>
      <article-id pub-id-type="doi">
       10.7150/ijbs.45134
      </article-id>
      <article-id pub-id-type="publisher-id">
       ijbsv16p1753
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Review
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        COVID-19: what has been learned and to be learned about the novel coronavirus disease
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yi
         </surname>
         <given-names>
          Ye
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lagniton
         </surname>
         <given-names>
          Philip N.P.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ye
         </surname>
         <given-names>
          Sen
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          Enqin
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Xu
         </surname>
         <given-names>
          Ren-He
         </given-names>
        </name>
        <xref ref-type="corresp" rid="FNA_envelop">
         ✉
        </xref>
       </contrib>
      </contrib-group>
      <aff>
       Institute of Translational Medicine, and Centre of Reproduction, Development and Aging, Faculty of Health Sciences, University of Macau, Taipa, Macau, China.
      </aff>
      <author-notes>
       <corresp id="FNA_envelop">
        ✉ Corresponding author: Ren-He Xu, Faculty of Health Sciences, University of Macau, Taipa, Macau, China. Tel: 853-8822-4993; Fax: 853-8822-8345; Email address:
        <email>
         renhexu@um.edu.mo
        </email>
        .
       </corresp>
       <fn fn-type="COI-statement">
        <p>
         Competing Interests: R.X. is a founder of ImStem Biotechnology, Inc., a stem cell company. The other authors declare no competing financial interests.
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="collection">
       <year>
        2020
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        15
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <volume>
       16
      </volume>
      <issue>
       10
      </issue>
      <fpage>
       1753
      </fpage>
      <lpage>
       1766
      </lpage>
      <history>
       <date date-type="received">
        <day>
         20
        </day>
        <month>
         2
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         29
        </day>
        <month>
         2
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © The author(s)
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <license license-type="open-access">
        <license-p>
         This is an open access article distributed under the terms of the Creative Commons Attribution License (
         <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">
          https://creativecommons.org/licenses/by/4.0/
         </ext-link>
         ). See
         <ext-link ext-link-type="uri" xlink:href="http://ivyspring.com/terms">
          http://ivyspring.com/terms
         </ext-link>
         for full terms and conditions.
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        The outbreak of Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2), has thus far killed over 3,000 people and infected over 80,000 in China and elsewhere in the world, resulting in catastrophe for humans. Similar to its homologous virus, SARS-CoV, which caused SARS in thousands of people in 2003, SARS-CoV-2 might also be transmitted from the bats and causes similar symptoms through a similar mechanism. However, COVID-19 has lower severity and mortality than SARS but is much more transmissive and affects more elderly individuals than youth and more men than women. In response to the rapidly increasing number of publications on the emerging disease, this article attempts to provide a timely and comprehensive review of the swiftly developing research subject. We will cover the basics about the epidemiology, etiology, virology, diagnosis, treatment, prognosis, and prevention of the disease. Although many questions still require answers, we hope that this review helps in the understanding and eradication of the threatening disease.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        Coronavirus
       </kwd>
       <kwd>
        pneumonia
       </kwd>
       <kwd>
        outbreak
       </kwd>
       <kwd>
        SARS-CoV-2
       </kwd>
       <kwd>
        COVID-19
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec sec-type="intro">
     <title>
      Introduction
     </title>
     <p>
      The Spring Festival on January 25, 2020 has become an unprecedented and unforgettable memory to all Chinese who were urged to stay indoors for all the holiday and for many weeks after due to the outbreak of a novel viral disease. The virus is highly homologous to the coronavirus (CoV) that caused an outbreak of severe acute respiratory syndrome (SARS) in 2003; thus, it was named SARS-CoV-2 by the World Health Organization (WHO) on February 11, 2020, and the associated disease was named CoV Disease-19 (COVID-19)
      <xref ref-type="bibr" rid="B1">
       1
      </xref>
      . The epidemic started in Wuhan, China, and quickly spread throughout the entire country and to near 50 others all over the world. As of March 2, 2020, the virus has resulted in over 80,000 confirmed cases of COVID-19, with more than 40,000 patients discharged and over 3,000 patients who died. WHO warns that COVID-19 is “public enemy number 1” and potentially more powerful than terrorism
      <xref ref-type="bibr" rid="B2">
       2
      </xref>
      .
     </p>
     <p>
      According to PubMed (
      <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/">
       https://www.ncbi.nlm.nih.gov/pubmed/
      </ext-link>
      ), in less than two months, over 200 papers have been published on COVID-19 including its virology, epidemiology, etiology, diagnosis, and treatment since the first report on January 7, 2020 that determined the sequence of the virus isolated from multiple patients
      <xref ref-type="bibr" rid="B3">
       3
      </xref>
      . This review attempts to summarize the research progress in the new and swiftly developing subject area. Whenever possible, we will try to compare COVID-19 with SARS and another CoV-caused disease, Middle East respiratory syndrome (MERS, an outbreak in 2012). We will also discuss what we have learned so far regarding the prevention and prognosis of the disease as well as some remaining yet urgent questions.
     </p>
    </sec>
    <sec>
     <title>
      The outbreak
     </title>
     <p>
      CoVs have been traditionally considered nonlethal pathogens to humans, mainly causing approximately 15% of common colds
      <xref ref-type="bibr" rid="B4">
       4
      </xref>
      . However, in this century, we have encountered highly pathogenic human CoVs twice,
      <italic>
       i.e.
      </italic>
      , SARS-CoV and MERS-CoV, which caused an outbreak originally in China in 2003 and Saudi Arabia in 2012, respectively, and soon spread to many other countries with horrible morbidity and mortality
      <xref ref-type="bibr" rid="B5">
       5
      </xref>
      . Therefore, the current COVID-19 is the third CoV outbreak in the recorded history of humans.
     </p>
     <p>
      As shown in Fig.
      <xref ref-type="fig" rid="F1">
       1
      </xref>
      , clusters of pneumonia that had unknown origins were first reported from Wuhan on December 31, 2019 to the China National Health Commission
      <xref ref-type="bibr" rid="B6">
       6
      </xref>
      . Seven days later the sequence of the CoV was released
      <xref ref-type="bibr" rid="B7">
       7
      </xref>
      . On January 15, 2020 the first fatal case from Wuhan was reported
      <xref ref-type="bibr" rid="B6">
       6
      </xref>
      . Meanwhile, the epidemic rapidly spread to the neighboring cities, provinces, and countries. On January 20, the infection of health-care providers was reported, suggesting that human-to-human transmission was possible
      <xref ref-type="bibr" rid="B8">
       8
      </xref>
      . On January 23, the city of Wuhan was locked down with all its public transportation stopped. On January 24 the first clinical study on the disease reported that, out of 41 patients with confirmed cases, only 21 had direct contact with the Wuhan seafood market that was considered the starting site of the infection from an unknown animal source
      <xref ref-type="bibr" rid="B6">
       6
      </xref>
      . On January 30, WHO declared the outbreak a global health emergency. By the time of this report, the disease has already spread throughout China and near 50 other countries all over the world (Fig.
      <xref ref-type="fig" rid="F2">
       2
      </xref>
      ). As the situation is rapidly evolving, the final scope and severity of the outbreak remain to be determined.
     </p>
     <p>
      On February 11, 2020, a multi-center study on 8,866 patients including 4,021 confirmed COVID-19 patients presented a more updated illustration of the epidemic as follows (
      <ext-link ext-link-type="uri" xlink:href="https://mp.weixin.qq.com/s/UlBi-HX_rHPXa1qHA2bhdA">
       https://mp.weixin.qq.com/s/UlBi-HX_rHPXa1qHA2bhdA
      </ext-link>
      ).
      <list list-type="bullet">
       <list-item>
        <p>
         SARS-CoV-2 infected people of all ages, but mainly at the age of 30-65. Almost half (47.7%) of the infected individuals were over 50 years old, very few were under 20, and only 14 infected individuals were under the age of 10.
        </p>
       </list-item>
       <list-item>
        <p>
         SARS-CoV-2 infected more men (0.31/100,000) than women (0.27/100,000).
        </p>
       </list-item>
       <list-item>
        <p>
         COVID-19 expanded in clusters mainly in and around Hubei.
        </p>
       </list-item>
       <list-item>
        <p>
         COVID-19 took an average of 5 (2-9) days from onset to diagnosis. The average incubation period was 4.8 (3.0-7.2) days. The average time from onset to death was 9.5 (4.8-13) days.
        </p>
       </list-item>
       <list-item>
        <p>
         The basic reproductive number (R0) was 3.77 (95% CI: 3.51-4.05), and the adjusted R0 was 2.23-4.82.
        </p>
       </list-item>
       <list-item>
        <p>
         The number of infected people increased exponentially before 23 Jan. 2020, matching the time of massive transportation before the Spring Festival in China.
        </p>
       </list-item>
       <list-item>
        <p>
         The mortality of patients with confirmed cases was 1.44% (95% CI: 1.10-1.86%), and the adjusted mortality of all the patients was 3.06% (95% CI: 2.02-4.59%).
        </p>
       </list-item>
       <list-item>
        <p>
         Three major risk factors for COVID-19 were sex (male), age (≥60), and severe pneumonia.
        </p>
       </list-item>
      </list>
     </p>
    </sec>
    <sec>
     <title>
      SARS-CoV-2
     </title>
     <sec>
      <title>
       Etiology
      </title>
      <p>
       CoVs are a subfamily of large and enveloped viruses containing a single strand of sense RNA. They can be divided into four genera,
       <italic>
        i.e
       </italic>
       ., alpha, beta, gamma, and delta, of which alpha- and beta-CoVs are known to infect humans
       <xref ref-type="bibr" rid="B11">
        11
       </xref>
       . The envelope spike (S) glycoprotein binds to its cellular receptors angiotensin-converting enzyme 2 (ACE2) and dipeptidyl peptidase 4 (DPP4) for SARS-CoV and MERS-CoV, respectively, and then membrane fusion occurs
       <xref ref-type="bibr" rid="B12">
        12
       </xref>
       . The viral RNA genome is released into the cytoplasm; after replication of the viral genome, genomic RNA accompanied by envelope glycoproteins and nucleocapsid proteins forms virion-containing vesicles, which then fuse with the plasma membrane to release the virus
       <xref ref-type="bibr" rid="B13">
        13
       </xref>
       .
      </p>
      <p>
       The first genomic sequence of SARS-CoV-2 was reported on January 10, 2020
       <xref ref-type="bibr" rid="B3">
        3
       </xref>
       . SARS-CoV-2 was found to be a new type of beta-CoV with more than 99.98% genetic identity among 10 sequenced samples collected from the original site of the outbreak, the Huanan Seafood Market in Wuhan. SARS-CoV-2 is genetically more similar to SARS-CoV than to MERS-CoV
       <xref ref-type="bibr" rid="B14">
        14
       </xref>
       -
       <xref ref-type="bibr" rid="B16">
        16
       </xref>
       . Through transmission electron microscopy, SARS-CoV-2 particles were found in ultrathin sections of human airway epithelium
       <xref ref-type="bibr" rid="B17">
        17
       </xref>
       . Human ACE2 was found to be a receptor for SARS-CoV-2 as well as SARS-CoV
       <xref ref-type="bibr" rid="B16">
        16
       </xref>
       ,
       <xref ref-type="bibr" rid="B18">
        18
       </xref>
       ,
       <xref ref-type="bibr" rid="B19">
        19
       </xref>
       . However, the S protein of SARS-CoV-2 binds to human ACE2 more weakly than that of SARS-CoV, which is coincident with the fact that SARS-CoV-2 causes less severe infection in patients than SARS-CoV
       <xref ref-type="bibr" rid="B14">
        14
       </xref>
       .
      </p>
      <p>
       SARS-CoV-2 can also form a novel short protein encoded by
       <italic>
        orf3b
       </italic>
       and a secreted protein encoded by
       <italic>
        orf8
       </italic>
       . The orf3b of SARS-CoV-2 may play a role in the viral pathogenicity and inhibit the expression of
       <italic>
        IFNβ
       </italic>
       ; however, orf8 does not contain any known functional domain or motif
       <xref ref-type="bibr" rid="B20">
        20
       </xref>
       . On February 18, 2020, Zhou,
       <italic>
        et al.
       </italic>
       , reported the cryo-EM structure of the full-length human ACE2 at 2.9 Å resolution in complex with the amino acid transporter B
       <sup>
        0
       </sup>
       AT1
       <xref ref-type="bibr" rid="B21">
        21
       </xref>
       . They found that the complex, which had open and closed conformations, was assembled as a dimer and the ACE2-B
       <sup>
        0
       </sup>
       AT1 complex can bind two S proteins, which provides evidence for CoV recognition and infection. B
       <sup>
        0
       </sup>
       AT1 may become a therapeutic target for drug screening to suppress SARS-CoV-2 infection.
      </p>
     </sec>
     <sec>
      <title>
       The origin and intermediate host
      </title>
      <p>
       It has been known that both SARS-CoV and MERS-CoV originated from bats and were transmitted to humans via civet cats and camels, respectively. Through a phylogenetic comparison of SARS-CoV-2 with other CoVs, bats were considered the native host of SARS-CoV-2 as the new virus is 96% identical to two SARS-like CoVs from bats called bat-SL-CoVZX45 and bat-SL-CoVZX21
       <xref ref-type="bibr" rid="B14">
        14
       </xref>
       -
       <xref ref-type="bibr" rid="B16">
        16
       </xref>
       ,
       <xref ref-type="bibr" rid="B19">
        19
       </xref>
       . However, what intermediate host helped the virus cross the species barrier to infect humans remains unknown, and the transmission route is yet to be elucidated. Ji,
       <italic>
        et al
       </italic>
       ., proposed snakes as a carrier of the virus from bats to humans which involved homologous recombination within the S protein
       <xref ref-type="bibr" rid="B22">
        22
       </xref>
       . According to a study, researchers in Guangzhou, China, suggested that pangolins - long-snouted, ant-eating mammals often used in traditional Chinese medicine - are the potential intermediate host of SARS-CoV-2 based on 99% genetic homology in a CoV discovered in pangolins and SARS-CoV-2
       <xref ref-type="bibr" rid="B23">
        23
       </xref>
       . However, 1% difference spread all over two genomes is still a big difference; thus, conclusive results for concrete evidence are awaited (Fig.
       <xref ref-type="fig" rid="F3">
        3
       </xref>
       ).
      </p>
     </sec>
     <sec>
      <title>
       Physicochemical properties
      </title>
      <p>
       The physicochemical properties of SARS-CoV-2 are largely not yet known. SARS-CoV and MERS-CoV can survive
       <italic>
        in vitro
       </italic>
       for 48 hours in a dry environment and up to 5 days under 20 °C and 40%-50% humidity
       <xref ref-type="bibr" rid="B24">
        24
       </xref>
       -
       <xref ref-type="bibr" rid="B26">
        26
       </xref>
       . SARS-CoV-2 may possess similar properties. It has been reported that SARS-CoV-2 is sensitive to ultraviolet rays and heat at 56 °C for 30 minutes; ether, 75% ethanol, chlorine-containing disinfectant, peracetic acid, chloroform, and other fatty solvents, but not chlorhexidine, can effectively inactivate the virus
       <xref ref-type="bibr" rid="B27">
        27
       </xref>
       .
      </p>
     </sec>
     <sec>
      <title>
       Immune responses to CoVs
      </title>
      <p>
       The entire human population generally lacks immunity to SARS-CoV-2 and hence is susceptible to the novel virus. Currently, no detailed study has been reported regarding the immunological response to SARS-CoV-2. Thus, we can only refer to previous studies on other CoVs, especially SARS-CoV and MERS-CoV (Fig.
       <xref ref-type="fig" rid="F4">
        4
       </xref>
       ). In general, after a virus invades the host, it is first recognized by the host innate immune system through pattern recognition receptors (PRRs) including C-type lectin-like receptors, Toll-like receptor (TLR), NOD-like receptor (NLR), and RIG-I-like receptor (RLR)
       <xref ref-type="bibr" rid="B28">
        28
       </xref>
       . Through different pathways, the virus induces the expression of inflammatory factors, maturation of dendritic cells, and synthesis of type I interferons (IFNs) which limit the spreading of the virus and accelerate macrophage phagocytosis of viral antigens
       <xref ref-type="bibr" rid="B28">
        28
       </xref>
       . However, the N protein of SARS-CoV can help the virus escape from the immune responses
       <xref ref-type="bibr" rid="B29">
        29
       </xref>
       .
      </p>
      <p>
       Soon, the adaptive immune response joins the fight against the virus. T lymphocytes including CD4
       <sup>
        +
       </sup>
       and CD8
       <sup>
        +
       </sup>
       T cells play an important role in the defense. CD4
       <sup>
        +
       </sup>
       T cells stimulate B cells to produce virus-specific antibodies, and CD8
       <sup>
        +
       </sup>
       T cells directly kill virus-infected cells. T helper cells produce proinflammatory cytokines to help the defending cells. However, CoV can inhibit T cell functions by inducing apoptosis of T cells. The humoral immunity including complements such as C3a and C5a and antibodies is also essential in combating the viral infection
       <xref ref-type="bibr" rid="B30">
        30
       </xref>
       ,
       <xref ref-type="bibr" rid="B31">
        31
       </xref>
       . For example, antibodies isolated from a recovered patient neutralized MERS-CoV
       <xref ref-type="bibr" rid="B32">
        32
       </xref>
       . On the other hand, an overreaction of the immune system generates a large number of free radicals locally that can cause severe damages to the lungs and other organs, and, in the worst scenario, multi-organ failure and even death
       <xref ref-type="bibr" rid="B33">
        33
       </xref>
       .
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      Clinical features
     </title>
     <sec>
      <title>
       The incubation periods
      </title>
      <p>
       The SARS-CoV-2 infection, featured by clustering onset, is more likely to affect elderly people with comorbidities and pregnant women
       <xref ref-type="bibr" rid="B8">
        8
       </xref>
       . It is common that for people who are exposed to a large number of viruses or whose immune functions are compromised, they have higher chance to be infected than others. The estimated mean incubation period of SARS-CoV-2 is 1-14 days, mostly 3-7 days based on a study of the first 425 cases in Wuhan
       <xref ref-type="bibr" rid="B36">
        36
       </xref>
       . However, a study on 1,099 cases demonstrates that the incubation period was 3 days on average and ranged from 0 to 24 days
       <xref ref-type="bibr" rid="B8">
        8
       </xref>
       . A more recent study, as described above, demonstrates that the incubation period was 4.8 (3.0-7.2) days based on the demography of 8,866 cases
       <xref ref-type="bibr" rid="B37">
        37
       </xref>
       . It is very important for health authorities to adjust the effective quarantine time based on the most accurate incubation period, thus preventing infected but symptomless people from transmitting the virus to others
       <xref ref-type="bibr" rid="B38">
        38
       </xref>
       . As a common practice, individuals exposed to, or infected by, the virus are usually required to be quarantined for 14 days. Should the quarantine time be extended to 24 days?
      </p>
     </sec>
     <sec>
      <title>
       Symptoms
      </title>
      <p>
       Fever is often the major and initial symptom of COVID-19, which can be accompanied by no symptom or other symptoms such as dry cough, shortness of breath, muscle ache, dizziness, headache, sore throat, rhinorrhea, chest pain, diarrhea, nausea, and vomiting. Some patients experienced dyspnea and/or hypoxemia one week after the onset of the disease
       <xref ref-type="bibr" rid="B8">
        8
       </xref>
       . In severe cases, patients quickly progressed to develop acute respiratory syndrome, septic shock, metabolic acidosis, and coagulopathy. Patients with fever and/or respiratory symptoms and acute fever, even without pulmonary imaging abnormalities, should be screened for the virus for early diagnosis
       <xref ref-type="bibr" rid="B39">
        39
       </xref>
       -
       <xref ref-type="bibr" rid="B41">
        41
       </xref>
       .
      </p>
      <p>
       A demographic study in late December of 2019 showed that the percentages of the symptoms were 98% for fever, 76% for dry cough, 55% for dyspnea, and 3% for diarrhea; 8% of the patients required ventilation support
       <xref ref-type="bibr" rid="B42">
        42
       </xref>
       . Similar findings were reported in two recent studies of a family cluster and a cluster caused by transmission from an asymptomatic individual
       <xref ref-type="bibr" rid="B43">
        43
       </xref>
       ,
       <xref ref-type="bibr" rid="B44">
        44
       </xref>
       . Comparably, a demographic study in 2012 showed that MERS-CoV patients also had fever (98%), dry cough (47%), and dyspnea (55%) as their main symptoms. However, 80% of them required ventilation support, much more than COVID-19 patients and consistent with the higher lethality of MERS than of COVID-19. Diarrhea (26%) and sore throat (21%) were also observed with MERS patients. In SARS patients, it has been demonstrated that fever (99%-100%), dry cough (29%-75%), dyspnea (40%-42%), diarrhea (20-25%), and sore throat (13-25%) were the major symptoms and ventilation support was required for approximately 14%-20% of the patients
       <xref ref-type="bibr" rid="B45">
        45
       </xref>
       .
      </p>
      <p>
       By February 14, the mortality of COVID-19 was 2% when the confirmed cases reached 66,576 globally. Comparably, the mortality of SARS by November 2002 was 10% of 8,096 confirmed cases
       <xref ref-type="bibr" rid="B46">
        46
       </xref>
       . For MERS, based on a demographic study in June 2012, the mortality was 37% of 2,494 confirmed cases
       <xref ref-type="bibr" rid="B47">
        47
       </xref>
       . An earlier study reported that the R0 of SARS-CoV-2 was as high as 6.47 with a 95% confidence interval (CI) of 5.71-7.23
       <xref ref-type="bibr" rid="B48">
        48
       </xref>
       , whereas the R0 of SARS-CoV only ranged from 2 to 4
       <xref ref-type="bibr" rid="B49">
        49
       </xref>
       . A comparison of SARS-CoV-2 with MERS-CoV and SARA-CoV regarding their symptoms, mortality, and R0 is presented in Table
       <xref ref-type="table" rid="T1">
        1
       </xref>
       . The above figures suggest that SARS-CoV-2 has a higher ability to spread than MERS-CoV and SARS-CoV, but it is less lethal than the latter two
       <xref ref-type="bibr" rid="B6">
        6
       </xref>
       . Thus, it is much more challenging to control the epidemic of SARS-CoV-2 than those of MERS-CoV and SARS-CoV.
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      Diagnosis
     </title>
     <sec>
      <title>
       Patient history
      </title>
      <p>
       Clustered onset often happens in the same family or from the same gathering or vehicle such as a cruise ship. Patients often have a history of travel or residence in Wuhan or other affected areas or contact with infected individuals or patients in the recent two weeks before the onset
       <xref ref-type="bibr" rid="B50">
        50
       </xref>
       . However, it has been reported that people can carry the virus without symptoms longer than two weeks and cured patients discharged from hospitals can carry the virus again
       <xref ref-type="bibr" rid="B51">
        51
       </xref>
       , which sends out an alarm to increase the time for quarantine.
      </p>
     </sec>
     <sec>
      <title>
       Laboratory results
      </title>
      <p>
       Patients have normal or reduced number of peripheral white blood cells (especially lymphocytes) at the early stage. For example, lymphopenia with white blood cell count &lt; 4×10
       <sup>
        9
       </sup>
       /L including lymphocyte count &lt; 1×10
       <sup>
        9
       </sup>
       /L, and elevated aspartate aminotransferase levels and viremia were found in 1,099 COVID-19 patients
       <xref ref-type="bibr" rid="B8">
        8
       </xref>
       . The levels of liver and muscle enzymes and myoglobin were increased in the blood of some patients, and C-reactive protein and erythrocyte sedimentation were increased in the blood of most patients
       <xref ref-type="bibr" rid="B52">
        52
       </xref>
       . In patients with severe cases, the level of D-dimer, a fibrin degradation product present in the blood, was elevated, and lymphocyte count was progressively reduced
       <xref ref-type="bibr" rid="B34">
        34
       </xref>
       .
      </p>
     </sec>
     <sec>
      <title>
       Radiography
      </title>
      <p>
       Abnormalities in chest radiography are found in most COVID-19 patients and featured by bilateral patchy shadows or ground glass opacity in the lungs. Patients often develop an atypical pneumonia, acute lung injury, and acute respiratory distress syndrome (ARDS)
       <xref ref-type="bibr" rid="B34">
        34
       </xref>
       . When ARDS happens, uncontrolled inflammation, fluid accumulation, and progressive fibrosis severely compromise the gas exchange. Dysfunction of type-I and type-II pneumocytes decreases the surfactant level and increases surface tension, thus reducing the ability of the lungs to expand and heightening the risk of lung collapse
       <xref ref-type="bibr" rid="B53">
        53
       </xref>
       ,
       <xref ref-type="bibr" rid="B54">
        54
       </xref>
       . Therefore, the worst chest radiographic findings often parallel the most severe extent of the disease
       <xref ref-type="bibr" rid="B55">
        55
       </xref>
       .
      </p>
     </sec>
     <sec>
      <title>
       Pathology
      </title>
      <p>
       On February 18, 2020, the first pathological analysis of COVID-19 demonstrated the desquamation of pneumocytes, hyaline membrane formation, and interstitial lymphocyte infiltration, and multinucleated syncytial cells in the lungs of a patient who died of the disease, consistent with the pathology of viral infection and ARDS
       <xref ref-type="bibr" rid="B56">
        56
       </xref>
       and similar to that of SARS and MERS patients
       <xref ref-type="bibr" rid="B57">
        57
       </xref>
       ,
       <xref ref-type="bibr" rid="B58">
        58
       </xref>
       .
      </p>
     </sec>
     <sec>
      <title>
       Nuclear acid assays
      </title>
      <p>
       The detection of SARS-CoV-2 RNA via reverse-transcriptase polymerase chain reaction (RT-PCR) was used as the major criteria for the diagnosis of COVID-19. However, due to the high false-negative rate, which may accelerate the epidemic, clinical manifestations started to be used for diagnosis (which no longer solely relied on RT-PCR) in China on February 13, 2020. A similar situation also occurred with the diagnosis of SARS
       <xref ref-type="bibr" rid="B59">
        59
       </xref>
       . Therefore, a combination of disease history, clinical manifestations, laboratory tests, and radiological findings is essential and imperative for making an effective diagnosis. On February 14, 2020, the Feng Zhang group described a protocol of using the CRISPR-based SHERLOCK technique to detect SARS-CoV-2, which detects synthetic SARS-CoV-2 RNA fragments at 20 × 10
       <sup>
        -18
       </sup>
       mol/L to 200 × 10
       <sup>
        -18
       </sup>
       mol/L (10-100 copies per microliter of input) using a dipstick in less than an hour without requiring elaborate instrumentation
       <xref ref-type="bibr" rid="B60">
        60
       </xref>
       . Hopefully, the new technique can dramatically enhance the sensitivity and convenience if verified in clinical samples.
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      Treatment
     </title>
     <p>
      Due to the lack of experience with the novel CoV, physicians can mainly provide supportive care to COVID-19 patients, while attempting a variety of therapies that have been used or proposed before for the treatment of other CoVs such as SARS-CoV and MERS-CoV and other viral diseases (Table
      <xref ref-type="table" rid="T2">
       2
      </xref>
      ). These therapies include current and potential treatments with antiviral drugs, immunosuppressants, steroids, plasma from recovered patients, Chinese medicine, and psychological support. Even plasma from recovered patients was proposed to be used for treatment
      <xref ref-type="bibr" rid="B61">
       61
      </xref>
      . Pharmaceutical companies are racing to develop antibodies and vaccines against the virus
      <xref ref-type="bibr" rid="B62">
       62
      </xref>
      .
     </p>
     <sec>
      <title>
       Supportive care
      </title>
      <p>
       SARS-CoV-2 mainly attacks the lungs in the beginning and probably also attacks, to a lesser degree, other organs that express ACE2, such as the gastrointestinal system and the kidneys. Nevertheless, respiratory dysfunction and failure are the major threat to the patients and the major cause of death. Thus, respiratory support is critical to relieve the symptoms and save lives and includes general oxygen therapy, high-flow oxygen, noninvasive ventilation, and invasive mechanical ventilation depending on the severity of the disease. Patients with severe respiratory symptoms have to be supported by extracorporeal membrane oxygenation (ECMO), a modified cardiopulmonary bypass technique used for the treatment of life-threatening cardiac or respiratory failure. In addition, the maintenance of electrolyte balance, the prevention and treatment of secondary infection and septic shock, and the protection of the functions of the vital organs are also essential for SARS-CoV-2 patients
       <xref ref-type="bibr" rid="B7">
        7
       </xref>
       .
      </p>
     </sec>
     <sec>
      <title>
       Tackling cytokine storms
      </title>
      <p>
       It has been known that a cytokine storm results from an overreaction of the immune system in SARS and MERS patients
       <xref ref-type="bibr" rid="B33">
        33
       </xref>
       . Cytokine storm is a form of systemic inflammatory response featured by the release of a series of cytokines including TNFα, IL-1β, IL-2, IL-6, IFNα, IFNβ, IFNγ, and MCP-1. These cytokines induce immune cells to release a vast number of free radicals which are the major cause of ARDS and multiple organ failure
       <xref ref-type="bibr" rid="B67">
        67
       </xref>
       . Immunosuppression is essential in the treatment of cytokine storms, especially in severe patients.
      </p>
      <p>
       Corticosteroids and tocilizumab, an anti-IL6 monoclonal antibody, have been used to treat cytokine storm
       <xref ref-type="bibr" rid="B68">
        68
       </xref>
       . Other immunosuppression treatments for cytokine storm include the modulation of T cell-directed immune response; the blockade of IFN-γ, IL-1, and TNF; JAK inhibition
       <xref ref-type="bibr" rid="B69">
        69
       </xref>
       ; blinatumomab
       <xref ref-type="bibr" rid="B70">
        70
       </xref>
       ; suppressor of cytokine signaling 4
       <xref ref-type="bibr" rid="B71">
        71
       </xref>
       ; and HDAC inhibitors
       <xref ref-type="bibr" rid="B72">
        72
       </xref>
       .
      </p>
      <p>
       Steroids, as immunosuppressants, were widely used in the treatment of SARS to reduce the severity of inflammatory damage
       <xref ref-type="bibr" rid="B65">
        65
       </xref>
       . However, steroids at high dosages were not beneficial to severe lung injury in SARS and COVID-19 patients
       <xref ref-type="bibr" rid="B59">
        59
       </xref>
       ,
       <xref ref-type="bibr" rid="B73">
        73
       </xref>
       . Instead, they may cause severe side effects, especially avascular osteonecrosis, dramatically affecting the prognosis
       <xref ref-type="bibr" rid="B74">
        74
       </xref>
       . Nevertheless, short courses of corticosteroids at low-to-moderate doses have been recommended to be used prudently for critically ill COVID-19 patients
       <xref ref-type="bibr" rid="B75">
        75
       </xref>
       .
      </p>
     </sec>
     <sec>
      <title>
       Antiviral therapy
      </title>
      <p>
       At the time of writing, no effective antiviral therapy has been confirmed. However, intravenous administration with remdesivir, a nucleotide analog, has been found to be efficacious in an American patient with COVID-19
       <xref ref-type="bibr" rid="B64">
        64
       </xref>
       . Remdesivir is a novel antiviral drug developed by Gilead initially for the treatment of diseases caused by Ebola and Marlburg viruses
       <xref ref-type="bibr" rid="B76">
        76
       </xref>
       . Later, remdesivir also demonstrated possible inhibition of other single stranded RNA viruses including MERS and SARS viruses
       <xref ref-type="bibr" rid="B77">
        77
       </xref>
       ,
       <xref ref-type="bibr" rid="B78">
        78
       </xref>
       . Based on these, Gilead has provided the compound to China to conduct a pair of trials on SARS-CoV-2-infected individuals
       <xref ref-type="bibr" rid="B79">
        79
       </xref>
       , and the results are highly anticipated.
      </p>
      <p>
       In addition, baricitinb, interferon-α, lopinavir/ritonavir, and ribavirin have been suggested as potential therapies for patients with acute respiratory symptoms
       <xref ref-type="bibr" rid="B80">
        80
       </xref>
       ,
       <xref ref-type="bibr" rid="B81">
        81
       </xref>
       . Diarrhea, nausea, vomiting, liver damage, and other adverse reactions can occur following combined therapy with lopinavir/ritonavir
       <xref ref-type="bibr" rid="B80">
        80
       </xref>
       . The interaction of these treatments with other drugs used in the patients should be monitored carefully.
      </p>
     </sec>
     <sec>
      <title>
       Plasma from recovered patients and antibody generation
      </title>
      <p>
       The collection of the blood from patients who recovered from a contagious disease to treat other patients suffering from the same disease or to protect healthy individuals from catching the disease has a long history
       <xref ref-type="bibr" rid="B82">
        82
       </xref>
       . Indeed, recovered patients often have a relatively high level of antibodies against the pathogen in their blood. Antibodies are an immunoglobulin (Ig) produced by B lymphocytes to fight pathogens and other foreign objects and they recognize unique molecules in the pathogens and neutralize them directly
       <xref ref-type="bibr" rid="B83">
        83
       </xref>
       . Based on this, plasma was collected from the blood of a group of patients who recovered from COVID-19 and was injected into 10 seriously ill patients. Their symptoms improved within 24 hours, accompanied by reduced inflammation and viral loads and improved oxygen saturation in the blood. However, verification and clarification are necessary to propose the method for large-scale use before specific therapies are not yet developed.
      </p>
      <p>
       In addition, given the therapeutic effects, some disadvantages associated with the plasma should be considered carefully. For example, antibodies can overstimulate the immune response and cause cytokine release syndrome, which is potentially a life-threatening toxicity
       <xref ref-type="bibr" rid="B84">
        84
       </xref>
       . The concentration of antibodies in the blood is usually low, and the demand for the plasma is large to treat critically ill patients. It is difficult to develop and produce specific antibodies rapidly enough to fight against a global epidemic
       <xref ref-type="bibr" rid="B62">
        62
       </xref>
       . Thus, it is more critical and practical to isolate B cells from recovered patients and identify the genetic codes encoding effective antibodies or screen for effective antibodies against essential proteins of the virus. This way, we can readily scale up the production of the antibodies.
      </p>
     </sec>
     <sec>
      <title>
       Traditional Chinese medicine (TCM)
      </title>
      <p>
       TCM has been used to treat a variety of diseases in China for thousands of years. However, its effects largely rely on a combination of multiple components in a formula that varies depending on the diagnosis of a disease based on the theories of TCM. Most of the effective components remain unknown or are vague as it is difficult to extract and verify such components or their optimal combinations. Currently, due to the lack of effective and specific therapy for COVID-19, TCM has become one of the major alternative treatments for patients with light to moderate symptoms or for those who have recovered from severe stages
       <xref ref-type="bibr" rid="B85">
        85
       </xref>
       . For example, Shu Feng Jie Du capsules and Lian Hua Qing Wen capsules were found to be effective for COVID-19 treatment
       <xref ref-type="bibr" rid="B86">
        86
       </xref>
       . Top cure rates in the treatment of COVID-19 patients were observed in several provinces in China that used TCM in 87% of their patients, including Gansu (63.7%), Ningxia (50%), and Hunan (50%), whereas Hubei province, which used TCM in only approximately 30% of its COVID-19 patients, had the lowest cure rate (13%)
       <xref ref-type="bibr" rid="B87">
        87
       </xref>
       . However, this is quite a rough comparison as many other impact factors such as the number and severity of the patients should be included in the evaluation.
      </p>
      <p>
       On February 18, 2020, Boli Zhang and coworkers published a study to compare western medicine (WM) treatment alone with combined treatment of WM and TCM
       <xref ref-type="bibr" rid="B88">
        88
       </xref>
       . They found that the times needed for body temperature recovery, symptom disappearance, and hospitalization were remarkably shorter in the WM+TCM group than in the WM only group. Most impressively, the rate for symptomatic worsening (from light to severe) was remarkably lower for the WM+TCM group than for the WM only group (7.4% versus 46.2%) and the mortality was lower in the WM+TCM group than WM only group (8.8% versus 39%). Nevertheless, the efficacy and safety of TCM still await more well-controlled trials at larger scales and in more centers. It would also be intriguing to characterize the mechanism of actions and clarify the effective components of TCM treatments or their combinations if possible.
      </p>
     </sec>
     <sec>
      <title>
       Mental health care
      </title>
      <p>
       Patients with suspected or confirmed COVID-19 mostly experience great fear of the highly contagious and even fatal disease, and quarantined people also experience boredom, loneliness, and anger. Furthermore, symptoms of the infection such as fever, hypoxia, and cough as well as adverse effects of the treatments such as insomnia caused by corticosteroids can lead to more anxiety and mental distress. In the early phase of the SARS outbreak, a range of psychiatric morbidities including persistent depression, anxiety, panic attacks, psychomotor excitement, psychotic symptoms, delirium, and even suicidality were reported
       <xref ref-type="bibr" rid="B89">
        89
       </xref>
       ,
       <xref ref-type="bibr" rid="B90">
        90
       </xref>
       . Mandatory contact tracing and quarantine, as a part of the public health responses to the COVID-19 outbreak, can make people more anxious and guilty about the effects of the contagion, quarantine, and stigma on their families and friends
       <xref ref-type="bibr" rid="B66">
        66
       </xref>
       .
      </p>
      <p>
       Thus, mental health care should be provided to COVID-19 patients, suspected individuals, and people in contact with them as well as the general public who are in need. The psychological support should include the establishment of multidisciplinary mental health teams, clear communications with regular and accurate updates about the SARS-CoV-2 outbreak and treatment plans and the use of professional electronic devices and applications to avoid close contact with each other
       <xref ref-type="bibr" rid="B66">
        66
       </xref>
       .
      </p>
     </sec>
     <sec>
      <title>
       Vaccination
      </title>
      <p>
       Effective vaccines are essential for interrupting the chain of transmission from animal reservoirs and infected humans to susceptible hosts and are often complementary to antiviral treatment in the control of epidemics caused by emerging viruses. Efforts have been made to develop S protein-based vaccines to generate long-term and potent neutralizing antibodies and/or protective immunity against SARS-CoV
       <xref ref-type="bibr" rid="B81">
        81
       </xref>
       ,
       <xref ref-type="bibr" rid="B91">
        91
       </xref>
       . Live-attenuated vaccines have been evaluated in animal models for SARS
       <xref ref-type="bibr" rid="B92">
        92
       </xref>
       . However, the
       <italic>
        in vivo
       </italic>
       efficacy of these vaccine candidates in elderly individuals and lethal-challenge models and their protection against zoonotic virus infection have yet to be determined before a clinical study is initiated. This is probably because SARS died down 17 years ago and no new case has been reported since.
      </p>
      <p>
       In contrast, sporadic cases and clusters of MERS continue to occur in the Middle East and spread to other regions owing to the persistence of zoonotic sources in endemic areas. Vaccination strategies have been developed for MERS by using inactivated virus, DNA plasmids, viral vectors, nanoparticles, virus-like particles and recombinant protein subunits and some have been evaluated in animal models
       <xref ref-type="bibr" rid="B93">
        93
       </xref>
       . The development of a safe and effective vaccine against SARS-CoV-2 for non-immune individuals is an urgent and critical task for controlling the ongoing epidemic. However, it is challenging to overcome the difficulty because of the long period of time (averaged 18 months) needed for vaccine development and the dynamic variations of CoVs.
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      Prognosis
     </title>
     <sec>
      <title>
       Prognosis of patients
      </title>
      <p>
       As a novel disease, COVID-19 has just started to manifest its full clinical course throughout thousands of patients. In most cases, patients can recover gradually without sequelae. However, similar to SARS and MERS, COVID-19 is also associated with high morbidity and mortality in patients with severe cases. Therefore, building a prognosis model for the disease is essential for health-care agencies to prioritize their services, especially in resource-constrained areas. Based on clinical studies reported thus far, the following factors may affect or be associated with the prognosis of COVID-19 patients (Table
       <xref ref-type="table" rid="T3">
        3
       </xref>
       ):
       <list list-type="bullet">
        <list-item>
         <p>
          <bold>
           Age:
          </bold>
          Age was the most important factor for the prognosis of SARS
          <xref ref-type="bibr" rid="B99">
           99
          </xref>
          , which is also true for COVID-19. COVID-19 mainly happened at the age of 30-65 with 47.7% of those patients being over 50 in a study of 8,866 cases as described above
          <xref ref-type="bibr" rid="B37">
           37
          </xref>
          . Patients who required intensive care were more likely to have underlying comorbidities and complications and were significantly older than those who did not (at the median age of 66 versus 51)
          <xref ref-type="bibr" rid="B34">
           34
          </xref>
          , suggesting age as a prognostic factor for the outcome of COVID-19 patients.
         </p>
        </list-item>
        <list-item>
         <p>
          <bold>
           Sex:
          </bold>
          SARS-CoV-2 has infected more men than women (0.31/100,000 versus 0.27/100,000), as described above
          <xref ref-type="bibr" rid="B37">
           37
          </xref>
          .
         </p>
        </list-item>
        <list-item>
         <p>
          <bold>
           Comorbidities and complications:
          </bold>
          Patients with COVID-19 who require intensive care are more likely to suffer from acute cardiac injury and arrhythmia
          <xref ref-type="bibr" rid="B34">
           34
          </xref>
          . Cardiac events were also the main reason for death in SARS patients
          <xref ref-type="bibr" rid="B55">
           55
          </xref>
          ,
          <xref ref-type="bibr" rid="B65">
           65
          </xref>
          ,
          <xref ref-type="bibr" rid="B99">
           99
          </xref>
          . It has been reported that SARS-CoV-2 can also bind to ACE2-positive cholangiocytes, which might lead to liver dysfunctions in COVID-19 patients
          <xref ref-type="bibr" rid="B100">
           100
          </xref>
          . It is worth noting that age and underlying disease are strongly correlated and might interfere with each other
          <xref ref-type="bibr" rid="B55">
           55
          </xref>
          .
         </p>
        </list-item>
        <list-item>
         <p>
          <bold>
           Abnormal laboratory findings
          </bold>
          : The C-reactive protein (CRP) level in blood reflects the severity of inflammation or tissue injury and has been proposed to be a potential prognostic factor for disease, response to therapy, and ultimate recovery
          <xref ref-type="bibr" rid="B101">
           101
          </xref>
          . The correlation of CRP level to the severity and prognosis of COVID-19 has also been proposed
          <xref ref-type="bibr" rid="B101">
           101
          </xref>
          . In addition, elevated lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and creatine kinase (CK) may also help predict the outcome. These enzymes are expressed extensively in multiple organs, especially in the heart and liver, and are released during tissue damage
          <xref ref-type="bibr" rid="B102">
           102
          </xref>
          ,
          <xref ref-type="bibr" rid="B103">
           103
          </xref>
          . Thus, they are traditional markers for heart or liver dysfunctions.
         </p>
        </list-item>
        <list-item>
         <p>
          <bold>
           Major clinical symptoms:
          </bold>
          Chest radiography and temporal progression of clinical symptoms should be considered together with the other issues for the prediction of outcomes and complications of COVID-19.
         </p>
        </list-item>
        <list-item>
         <p>
          <bold>
           Use of steroids:
          </bold>
          As described above, steroids are immunosuppressant commonly used as an adjunctive therapy for infectious diseases to reduce the severity of inflammatory damage
          <xref ref-type="bibr" rid="B104">
           104
          </xref>
          . Since a high dosage of corticosteroids was widely used in severe SARS patients, many survivors suffered from avascular osteonecrosis with life-long disability and poor life quality
          <xref ref-type="bibr" rid="B105">
           105
          </xref>
          . Thus, if needed, steroids should be used at low dosage and for a short time in COVID-19 patients.
         </p>
        </list-item>
        <list-item>
         <p>
          <bold>
           Mental stress:
          </bold>
          As described above, during the COVID-19 outbreak many patients have suffered from extraordinary stress as they often endured long periods of quarantine and extreme uncertainty and witnessed the death of close family members and fellow patients. It is imperative to provide psychological counseling and long-term support to help these patients recover from the stress and return to normal life
          <xref ref-type="bibr" rid="B66">
           66
          </xref>
          .
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec>
      <title>
       Prognosis of the epidemic
      </title>
      <p>
       According to demographic studies so far, COVID-19 seems to have different epidemiological features from SARS. In addition to replicating in the lower respiratory tract, SARS-CoV-2 can efficiently replicate in the upper respiratory tract and causes mild or no symptoms in the early phase of infection, similar to other CoVs that cause common colds
       <xref ref-type="bibr" rid="B106">
        106
       </xref>
       . Therefore, infected patients at the early phase or incubation period can produce a large amount of virus during daily activities, causing great difficulty for the control of the epidemic. However, the transmission of SARS-CoV was considered to occur when the patients are severely ill, while most transmission did not happen at the early phase
       <xref ref-type="bibr" rid="B107">
        107
       </xref>
       . Thus, the current outbreak of COVID-19 is much more severe and difficult to control than the outbreak of SARS.
      </p>
      <p>
       Great efforts are currently underway in China including the lockdown of Wuhan and surrounding cities and continuous quarantine of almost the entire population in hopes of interrupting the transmission of SARS-CoV-2. Although these actions have been dramatically damaging the economy and other sectors of the country, the number of new patients is declining, indicating the slowdown of the epidemic. The most optimistic estimate is that the outbreak will end by March and the downswing phase will last for 3-4 months
       <xref ref-type="bibr" rid="B108">
        108
       </xref>
       . However, some other experts are not that optimistic. Paul Hunter,
       <italic>
        et al.
       </italic>
       , estimated that COVID-19, which seems substantially more infectious than SARS, will not end in 2020
       <xref ref-type="bibr" rid="B109">
        109
       </xref>
       . Ira Longini,
       <italic>
        et al.
       </italic>
       , established a model to predict the outcome of the epidemic and suggested that SARS-CoV-2 could infect two-thirds of the global population
       <xref ref-type="bibr" rid="B110">
        110
       </xref>
       .
      </p>
      <p>
       A Canadian group reported that SARS-CoV-2 was detected in both mid-turbinate and throat swabs of patients who recovered and left the hospital 2 weeks earlier
       <xref ref-type="bibr" rid="B111">
        111
       </xref>
       , which indicates that the newly identified virus could become a cyclical episode similar to influenza. However, promising signs have occurred in China based on the declining number of new cases, indicating the current strategies might have been working. Ebola was originally predicted to cause up to a million cases with half a million deaths. However, via strict quarantine and isolation, the disease has eventually been put under control
       <xref ref-type="bibr" rid="B112">
        112
       </xref>
       ,
       <xref ref-type="bibr" rid="B113">
        113
       </xref>
       . It is possible, similar to SARS-CoV, that SARS-CoV-2 might become weaker in infectivity and eventually die down or become a less pathogenic virus co-existent with humans. A comparison of the epidemic of COVID-19 with that of SARS and MERS is provided below (Fig.
       <xref ref-type="fig" rid="F5">
        5
       </xref>
       ).
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      Prevention
     </title>
     <p>
      SARS-CoV-2 is highly transmittable through coughing or sneezing, and possibly also through direct contact with materials contaminated by the virus
      <xref ref-type="bibr" rid="B12">
       12
      </xref>
      . The virus was also found in feces, which raises a new possibility of feces-to-mouth transmission
      <xref ref-type="bibr" rid="B114">
       114
      </xref>
      . A recent study on 138 cases reported that 41% of the cases were possibly caused by nosocomial infections, including 17 patients with other prior diseases and 40 health-care providers
      <xref ref-type="bibr" rid="B115">
       115
      </xref>
      . Thus, great precaution should be used to protect humans, especially health-care providers, social workers, family members, colleagues, and even bystanders in contact with patients or infected people.
     </p>
     <sec>
      <title>
       Personal role
      </title>
      <p>
       The first line of defense that could be used to lower the risk of infection is through wearing face masks; both the use of surgical masks and N95 respirator masks (series # 1860s) helps control the spread of viruses
       <xref ref-type="bibr" rid="B116">
        116
       </xref>
       . Surgical face masks prevent liquid droplets from a potentially infected individual from traveling through the air or sticking onto surfaces of materials, where they could be passed on to others
       <xref ref-type="bibr" rid="B117">
        117
       </xref>
       . However, only N95 (series # 1860s) masks can protect against the inhalation of virions as small as 10 to 80 nm, with only 5% of the virions being able to penetrate completely; SARS-CoV-2 is similar to SARS-CoV in size and both are approximately 85 nm
       <xref ref-type="bibr" rid="B117">
        117
       </xref>
       . Since particles can penetrate even five surgical masks stacked together, health-care providers in direct contact with patients must wear N95 (series # 1860s) masks but not surgical masks
       <xref ref-type="bibr" rid="B118">
        118
       </xref>
       .
      </p>
      <p>
       In addition to masks, health-care providers should wear fitted isolation gowns in order to further reduce contact with viruses. Viruses can also infect an individual through the eyes. On January 22, 2020, a doctor was infected with SARS-CoV-2 although he wore an N95 mask; the virus might have entered his body through his inflammatory eyes
       <xref ref-type="bibr" rid="B119">
        119
       </xref>
       . Thus, health-care providers should also wear transparent face shields or goggles while working with patients.
      </p>
      <p>
       For the general public in affected or potentially affected areas, it is highly suggested that everybody wash their hands with disinfectant soaps more often than usual, try to stay indoors for self-quarantine and limit contact with potentially infected individuals. Three feet is considered an appropriate distance for people to stay away from a patient
       <xref ref-type="bibr" rid="B120">
        120
       </xref>
       . These actions are effective methods to lower the risk of infection as well as prevent the spread of the virus.
      </p>
     </sec>
     <sec>
      <title>
       Governmental role
      </title>
      <p>
       Although SARS-CoV-2 came as a new virus to the human world, its high homology to SARS-CoV as reported on 7 January 2020
       <xref ref-type="bibr" rid="B3">
        3
       </xref>
       should have caused high alert to China based on her deep memory of the SARS outbreak in 2003. However, not until 19 January 2020 did the director of the Center of Disease Control of Wuhan comfort the citizens by saying that the novel virus has low contagiousness and limited reproductivity from human to human and that it is not a problem to prevent and contain the disease. This message remarkably relaxed the alarm of the public, especially when the entire country was preparing for the Spring Festival, and the critical time was missed to contain the disease at its minimal scale in Wuhan.
      </p>
      <p>
       The disease control agencies in China may take this hard lesson and make critical improvements in the future. For example, these agencies should be (1) more careful when making public announcements as every word counts to citizens and can change their attitude and decisions; (2) more sensitive and reactive to unusual information from clinics rather than waiting for formal reports from doctors or officials; (3) more restrictive to contain a potential epidemic at its early stage rather than attempting to comfort the public; and (4) more often to issue targeted and effective drills to increase the public's awareness about epidemic diseases and to test and improve the response system of the society periodically.
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      Concluding remarks
     </title>
     <p>
      The outbreak of COVID-19 caused by the novel virus SARS-CoV-2 started in the end of December 2019. In less than two months, it has spread all over China and near 50 other countries globally at the time of this writing. Since the virus is very similar to SARS-CoV and the symptoms are also similar between COVID-19 and SARS, the outbreak of COVID-19 has created a sense of SARS recurring. However, there are some remarkable differences between COVID-19 and SARS, which are essential for containing the epidemic and treating the patients.
      <list list-type="bullet">
       <list-item>
        <p>
         COVID-19 affects more elderly individuals than youth and more men than women, and the severity and death rate are also higher in elderly individual than in youth.
        </p>
       </list-item>
       <list-item>
        <p>
         SARS has higher mortality than COVID-19 (10.91% versus 1.44%).
        </p>
       </list-item>
       <list-item>
        <p>
         COVID-19 patients transmit the virus even when they are symptomless whereas SARS patients do so usually when they are severely ill, which causes much greater difficulty to contain the spread of COVID-19 than SARS. This partially explains why SARS-CoV-2 spread much faster and broader than SARS-CoV.
        </p>
       </list-item>
       <list-item>
        <p>
         The regular RNA assay for SARS-CoV-2 can be negative in some COVID-19 patients. On the other hand, cured patients can be positive for the virus again. These findings dramatically increase the risk of virus spreading.
        </p>
       </list-item>
      </list>
     </p>
     <p>
      Given such rapid progress in research on COVID-19, several critical issues remain to be solved, as follows:
      <list list-type="bullet">
       <list-item>
        <p>
         Where did SARS-CoV-2 come from? Although 96% genetic homolog was found between SARS-CoV-2 and two bat SARS-like CoVs, we still cannot conclude that SARS-CoV-2 is from bats.
        </p>
       </list-item>
       <list-item>
        <p>
         What animal was the intermediate species to transmit the virus from the original host, say bats, to humans? Without knowing answers to #1 and 2, we cannot efficiently cut the transmission, and the outbreak can relapse at any time.
        </p>
       </list-item>
       <list-item>
        <p>
         Although molecular modeling and biochemical assays have demonstrated that SARS-CoV-2 binds to ACE2, how exactly does the virus enter the airway cells and cause subsequent pathological changes? Does the virus also bind ACE2-expressing cells in other organs
         <xref ref-type="bibr" rid="B121">
          121
         </xref>
         ? Without clear answers to these questions, we cannot achieve fast and accurate diagnosis and effective treatment.
        </p>
       </list-item>
       <list-item>
        <p>
         How long will the epidemic last? How is the virus genetically evolving during transmission among humans? Will it become a pandemic worldwide, die down like SARS or relapse periodically like the flu?
        </p>
       </list-item>
      </list>
     </p>
     <p>
      It is essential but may take some time to search for answers to the above and many other questions. However, with whatever expense it may demand, we have no other choice but to stop the epidemic as soon as possible and bring our life back to normal.
     </p>
    </sec>
    <back>
     <ack>
      <p>
       This work was supported by University of Macau Research Committee funds MYRG #2016-00070-FHS, and #2017-00124-FHS, Macau Science and Technology Development Fund (FDCT) #095/2017/A1 and 0112-2018-A3, and FDCT-National Natural Science Foundation of China joint grant #0008-2019-AFJ to R.X.
      </p>
      <sec>
       <title>
        Author contributions
       </title>
       <p>
        Y.Y. and R.X. conceived and designed the manuscript. Y.Y., P.L., S.Y., E.L. and R.X. wrote the manuscript. R.X gave the final approval of the manuscript.
       </p>
      </sec>
     </ack>
     <ref-list>
      <ref id="B1">
       <label>
        1
       </label>
       <element-citation publication-type="other">
        <name>
         <surname>
          Velavan
         </surname>
         <given-names>
          TP
         </given-names>
        </name>
        <name>
         <surname>
          Meyer
         </surname>
         <given-names>
          CG
         </given-names>
        </name>
        <article-title>
         The COVID-19 epidemic
        </article-title>
        <source>
         Trop Med Int Health
        </source>
        <year>
         2020
        </year>
        <comment>
         DOI: https://doi.org/10.1111/tmi.13383
        </comment>
       </element-citation>
      </ref>
      <ref id="B2">
       <label>
        2
       </label>
       <element-citation publication-type="webpage">
        <source>
         NEWS A: WHO warns coronavirus, now dubbed COVID-19, is 'public enemy number 1' and potentially more powerful than terrorism
        </source>
        <comment>
         <ext-link ext-link-type="uri" xlink:href="https://www.abc.net.au/news/2020-02-12/coronavirus-public-enemy-number-one-vaccine/11956446">
          https://www.abc.net.au/news/2020-02-12/coronavirus-public-enemy-number-one-vaccine/11956446
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B3">
       <label>
        3
       </label>
       <element-citation publication-type="webpage">
        <source>
         Zhang Y-Z. Novel 2019 coronavirus genome
        </source>
        <comment>
         <ext-link ext-link-type="uri" xlink:href="http://virological.org/t/novel-2019-coronavirus-genome/319">
          http://virological.org/t/novel-2019-coronavirus-genome/319
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B4">
       <label>
        4
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          de Wit
         </surname>
         <given-names>
          E
         </given-names>
        </name>
        <name>
         <surname>
          van Doremalen
         </surname>
         <given-names>
          N
         </given-names>
        </name>
        <name>
         <surname>
          Falzarano
         </surname>
         <given-names>
          D
         </given-names>
        </name>
        <name>
         <surname>
          Munster
         </surname>
         <given-names>
          VJ
         </given-names>
        </name>
        <article-title>
         SARS and MERS: recent insights into emerging coronaviruses
        </article-title>
        <source>
         Nat Rev Microbiol
        </source>
        <year>
         2016
        </year>
        <volume>
         14
        </volume>
        <fpage>
         523
        </fpage>
        <lpage>
         34
        </lpage>
        <pub-id pub-id-type="pmid">
         27344959
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B5">
       <label>
        5
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Paules
         </surname>
         <given-names>
          CI
         </given-names>
        </name>
        <name>
         <surname>
          Marston
         </surname>
         <given-names>
          HD
         </given-names>
        </name>
        <name>
         <surname>
          Fauci
         </surname>
         <given-names>
          AS
         </given-names>
        </name>
        <article-title>
         Coronavirus Infections-More Than Just the Common Cold
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2020
        </year>
        <comment>
         DOI:10.1001/jama.2020.0757
        </comment>
       </element-citation>
      </ref>
      <ref id="B6">
       <label>
        6
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          C
         </given-names>
        </name>
        <name>
         <surname>
          Horby
         </surname>
         <given-names>
          PW
         </given-names>
        </name>
        <name>
         <surname>
          Hayden
         </surname>
         <given-names>
          FG
         </given-names>
        </name>
        <name>
         <surname>
          Gao
         </surname>
         <given-names>
          GF
         </given-names>
        </name>
        <article-title>
         A novel coronavirus outbreak of global health concern
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <fpage>
         470
        </fpage>
        <lpage>
         473
        </lpage>
        <pub-id pub-id-type="pmid">
         31986257
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B7">
       <label>
        7
       </label>
       <element-citation publication-type="webpage">
        <source>
         CDC: 2019 Novel Coronavirus, Wuhan, China
        </source>
        <comment>
         <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/index.html">
          https://www.cdc.gov/coronavirus/2019-ncov/index.html
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B8">
       <label>
        8
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Guan
         </surname>
         <given-names>
          W-j
         </given-names>
        </name>
        <name>
         <surname>
          Ni
         </surname>
         <given-names>
          Z-y
         </given-names>
        </name>
        <name>
         <surname>
          Hu
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        <name>
         <surname>
          Liang
         </surname>
         <given-names>
          W-h
         </given-names>
        </name>
        <name>
         <surname>
          Ou
         </surname>
         <given-names>
          C-q
         </given-names>
        </name>
        <name>
         <surname>
          He
         </surname>
         <given-names>
          J-x
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Clinical Characteristics of Coronavirus Disease 2019 in China
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2020
        </year>
        <comment>
         DOI: 10.1056/NEJMoa2002032
        </comment>
       </element-citation>
      </ref>
      <ref id="B9">
       <label>
        9
       </label>
       <element-citation publication-type="webpage">
        <source>
         Reliefweb: Johns Hopki University. Coronavirus COVID-19 Global Cases by Johns Hopkins CSSE
        </source>
        <comment>
         <ext-link ext-link-type="uri" xlink:href="https://reliefweb.int/report/world/coronavirus-covid-19-global-cases-johns-hopkins-csse">
          https://reliefweb.int/report/world/coronavirus-covid-19-global-cases-johns-hopkins-csse
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B10">
       <label>
        10
       </label>
       <element-citation publication-type="other">
        <name>
         <surname>
          Dong
         </surname>
         <given-names>
          E
         </given-names>
        </name>
        <name>
         <surname>
          Du
         </surname>
         <given-names>
          H
         </given-names>
        </name>
        <name>
         <surname>
          Gardner
         </surname>
         <given-names>
          L
         </given-names>
        </name>
        <article-title>
         An interactive web-based dashboard to track COVID-19 in real time
        </article-title>
        <source>
         The Lancet Infect Dis
        </source>
        <year>
         2020
        </year>
        <comment>
         DOI: 10.1016/S1473-3099(20)30120-1
        </comment>
       </element-citation>
      </ref>
      <ref id="B11">
       <label>
        11
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          de Wilde
         </surname>
         <given-names>
          AH
         </given-names>
        </name>
        <name>
         <surname>
          Snijder
         </surname>
         <given-names>
          EJ
         </given-names>
        </name>
        <name>
         <surname>
          Kikkert
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        <name>
         <surname>
          van Hemert
         </surname>
         <given-names>
          MJ
         </given-names>
        </name>
        <article-title>
         Host Factors in Coronavirus Replication
        </article-title>
        <source>
         Curr Top Microbiol Immunol
        </source>
        <year>
         2018
        </year>
        <volume>
         419
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         42
        </lpage>
        <pub-id pub-id-type="pmid">
         28643204
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B12">
       <label>
        12
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Raj
         </surname>
         <given-names>
          VS
         </given-names>
        </name>
        <name>
         <surname>
          Mou
         </surname>
         <given-names>
          H
         </given-names>
        </name>
        <name>
         <surname>
          Smits
         </surname>
         <given-names>
          SL
         </given-names>
        </name>
        <name>
         <surname>
          Dekkers
         </surname>
         <given-names>
          DH
         </given-names>
        </name>
        <name>
         <surname>
          Muller
         </surname>
         <given-names>
          MA
         </given-names>
        </name>
        <name>
         <surname>
          Dijkman
         </surname>
         <given-names>
          R
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2013
        </year>
        <volume>
         495
        </volume>
        <fpage>
         251
        </fpage>
        <lpage>
         4
        </lpage>
        <pub-id pub-id-type="pmid">
         23486063
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B13">
       <label>
        13
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Sevajol
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        <name>
         <surname>
          Subissi
         </surname>
         <given-names>
          L
         </given-names>
        </name>
        <name>
         <surname>
          Decroly
         </surname>
         <given-names>
          E
         </given-names>
        </name>
        <name>
         <surname>
          Canard
         </surname>
         <given-names>
          B
         </given-names>
        </name>
        <name>
         <surname>
          Imbert
         </surname>
         <given-names>
          I
         </given-names>
        </name>
        <article-title>
         Insights into RNA synthesis, capping, and proofreading mechanisms of SARS-coronavirus
        </article-title>
        <source>
         Virus Res
        </source>
        <year>
         2014
        </year>
        <volume>
         194
        </volume>
        <fpage>
         90
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         25451065
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B14">
       <label>
        14
       </label>
       <element-citation publication-type="other">
        <name>
         <surname>
          Dong
         </surname>
         <given-names>
          N
         </given-names>
        </name>
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          X
         </given-names>
        </name>
        <name>
         <surname>
          Ye
         </surname>
         <given-names>
          L
         </given-names>
        </name>
        <name>
         <surname>
          Chen
         </surname>
         <given-names>
          K
         </given-names>
        </name>
        <name>
         <surname>
          Chan
         </surname>
         <given-names>
          EW-C
         </given-names>
        </name>
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         2020
        </article-title>
        <source>
         Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China. DOI: https://doi.org/10.1101/2020.01.20.913368
        </source>
       </element-citation>
      </ref>
      <ref id="B15">
       <label>
        15
       </label>
       <element-citation publication-type="other">
        <name>
         <surname>
          Xu
         </surname>
         <given-names>
          X
         </given-names>
        </name>
        <name>
         <surname>
          Chen
         </surname>
         <given-names>
          P
         </given-names>
        </name>
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          J
         </given-names>
        </name>
        <name>
         <surname>
          Feng
         </surname>
         <given-names>
          J
         </given-names>
        </name>
        <name>
         <surname>
          Zhou
         </surname>
         <given-names>
          H
         </given-names>
        </name>
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          X
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         2020
        </article-title>
        <source>
         Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. SCIENCE CHINA Life Sciences. Doi: https://doi.org/10.1007/s11427-020-1637-5
        </source>
       </element-citation>
      </ref>
      <ref id="B16">
       <label>
        16
       </label>
       <element-citation publication-type="other">
        <name>
         <surname>
          Lu
         </surname>
         <given-names>
          R
         </given-names>
        </name>
        <name>
         <surname>
          Zhao
         </surname>
         <given-names>
          X
         </given-names>
        </name>
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          J
         </given-names>
        </name>
        <name>
         <surname>
          Niu
         </surname>
         <given-names>
          P
         </given-names>
        </name>
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          B
         </given-names>
        </name>
        <name>
         <surname>
          Wu
         </surname>
         <given-names>
          H
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
        </article-title>
        <source>
         The Lancet
        </source>
        <year>
         2020
        </year>
        <comment>
         DOI: https://doi.org/10.1016/S0140-6736(20)30251-8
        </comment>
       </element-citation>
      </ref>
      <ref id="B17">
       <label>
        17
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Zhu
         </surname>
         <given-names>
          N
         </given-names>
        </name>
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          D
         </given-names>
        </name>
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          W
         </given-names>
        </name>
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          X
         </given-names>
        </name>
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          B
         </given-names>
        </name>
        <name>
         <surname>
          Song
         </surname>
         <given-names>
          J
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         A Novel Coronavirus from Patients with Pneumonia in China, 2019
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2020
        </year>
        <comment>
         DOI:10.1056/NEJMoa2001017
        </comment>
       </element-citation>
      </ref>
      <ref id="B18">
       <label>
        18
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Letko
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        <name>
         <surname>
          Munster
         </surname>
         <given-names>
          V
         </given-names>
        </name>
        <article-title>
         2020. Functional assessment of cell entry and receptor usage for lineage B β-coronaviruses, including 2019-nCoV
        </article-title>
        <source>
         bioRxiv
        </source>
        <comment>
         DOI: 10.1101/2020.01.22.915660
        </comment>
       </element-citation>
      </ref>
      <ref id="B19">
       <label>
        19
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Zhou
         </surname>
         <given-names>
          P
         </given-names>
        </name>
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          X-L
         </given-names>
        </name>
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          X-G
         </given-names>
        </name>
        <name>
         <surname>
          Hu
         </surname>
         <given-names>
          B
         </given-names>
        </name>
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          L
         </given-names>
        </name>
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          W
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         2020. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin
        </article-title>
        <source>
         bioRxiv
        </source>
        <comment>
         DOI: 10.1101/2020.01.22.914952
        </comment>
       </element-citation>
      </ref>
      <ref id="B20">
       <label>
        20
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Chan
         </surname>
         <given-names>
          JF
         </given-names>
        </name>
        <name>
         <surname>
          Kok
         </surname>
         <given-names>
          KH
         </given-names>
        </name>
        <name>
         <surname>
          Zhu
         </surname>
         <given-names>
          Z
         </given-names>
        </name>
        <name>
         <surname>
          Chu
         </surname>
         <given-names>
          KK
         </given-names>
        </name>
        <name>
         <surname>
          Yuan
         </surname>
         <given-names>
          TS
         </given-names>
        </name>
        <name>
         <surname>
          Yuen
         </surname>
         <given-names>
          KY
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg. Microb
        </article-title>
        <source>
         Infect
        </source>
        <year>
         2020
        </year>
        <volume>
         9
        </volume>
        <fpage>
         221
        </fpage>
        <lpage>
         36
        </lpage>
       </element-citation>
      </ref>
      <ref id="B21">
       <label>
        21
       </label>
       <element-citation publication-type="other">
        <name>
         <surname>
          Zhou
         </surname>
         <given-names>
          Q
         </given-names>
        </name>
        <name>
         <surname>
          Yan
         </surname>
         <given-names>
          R
         </given-names>
        </name>
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        <name>
         <surname>
          Xia
         </surname>
         <given-names>
          L
         </given-names>
        </name>
        <article-title>
         2020
        </article-title>
        <source>
         Structure of dimeric full-length human ACE2 in complex with B0AT1. bioRxiv. DOI: https://doi.org/10.1101/2020.02.17.951848
        </source>
       </element-citation>
      </ref>
      <ref id="B22">
       <label>
        22
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Ji
         </surname>
         <given-names>
          W
         </given-names>
        </name>
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          W
         </given-names>
        </name>
        <name>
         <surname>
          Zhao
         </surname>
         <given-names>
          X
         </given-names>
        </name>
        <name>
         <surname>
          Zai
         </surname>
         <given-names>
          J
         </given-names>
        </name>
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          X
         </given-names>
        </name>
        <article-title>
         2020. Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human
        </article-title>
        <source>
         J Med Virol
        </source>
        <comment>
         DOI:10.1002/jmv.25682
        </comment>
       </element-citation>
      </ref>
      <ref id="B23">
       <label>
        23
       </label>
       <element-citation publication-type="other">
        <name>
         <surname>
          Xiao
         </surname>
         <given-names>
          KP
         </given-names>
        </name>
        <name>
         <surname>
          Zhai
         </surname>
         <given-names>
          JQ
         </given-names>
        </name>
        <name>
         <surname>
          Feng
         </surname>
         <given-names>
          YY
         </given-names>
        </name>
        <name>
         <surname>
          Zhou
         </surname>
         <given-names>
          N
         </given-names>
        </name>
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          X
         </given-names>
        </name>
        <name>
         <surname>
          Zou
         </surname>
         <given-names>
          JJ
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         2020
        </article-title>
        <source>
         Isolation and characterization of 2019-nCoV-like coronavirus from Malayan Pangolins. bioRxiv. DOI: http://doi.org/10.1101/2020.02.17.951335
        </source>
       </element-citation>
      </ref>
      <ref id="B24">
       <label>
        24
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Duan
         </surname>
         <given-names>
          S-M
         </given-names>
        </name>
        <name>
         <surname>
          Zhao
         </surname>
         <given-names>
          X-S
         </given-names>
        </name>
        <name>
         <surname>
          Wen
         </surname>
         <given-names>
          R-F
         </given-names>
        </name>
        <name>
         <surname>
          Huang
         </surname>
         <given-names>
          J-J
         </given-names>
        </name>
        <name>
         <surname>
          Pi
         </surname>
         <given-names>
          G-H
         </given-names>
        </name>
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          S-X
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Stability of SARS coronavirus in human specimens and environment and its sensitivity to heating and UV irradiation
        </article-title>
        <source>
         Biomed Environ Sci
        </source>
        <year>
         2003
        </year>
        <volume>
         16
        </volume>
        <fpage>
         246
        </fpage>
        <lpage>
         55
        </lpage>
        <pub-id pub-id-type="pmid">
         14631830
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B25">
       <label>
        25
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Geller
         </surname>
         <given-names>
          C
         </given-names>
        </name>
        <name>
         <surname>
          Varbanov
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        <name>
         <surname>
          Duval
         </surname>
         <given-names>
          RE
         </given-names>
        </name>
        <article-title>
         Human coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategies
        </article-title>
        <source>
         Viruses
        </source>
        <year>
         2012
        </year>
        <volume>
         4
        </volume>
        <fpage>
         3044
        </fpage>
        <lpage>
         68
        </lpage>
        <pub-id pub-id-type="pmid">
         23202515
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B26">
       <label>
        26
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Rabenau
         </surname>
         <given-names>
          HF
         </given-names>
        </name>
        <name>
         <surname>
          Cinatl
         </surname>
         <given-names>
          J
         </given-names>
        </name>
        <name>
         <surname>
          Morgenstern
         </surname>
         <given-names>
          B
         </given-names>
        </name>
        <name>
         <surname>
          Bauer
         </surname>
         <given-names>
          G
         </given-names>
        </name>
        <name>
         <surname>
          Preiser
         </surname>
         <given-names>
          W
         </given-names>
        </name>
        <name>
         <surname>
          Doerr
         </surname>
         <given-names>
          HW
         </given-names>
        </name>
        <article-title>
         Stability and inactivation of SARS coronavirus
        </article-title>
        <source>
         Medical Microbiology and Immunology
        </source>
        <year>
         2004
        </year>
        <volume>
         194
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         6
        </lpage>
       </element-citation>
      </ref>
      <ref id="B27">
       <label>
        27
       </label>
       <element-citation publication-type="webpage">
        <source>
         NHC: Diagnosis and treatment of pneumonia caused by 2019 new coronavirus (trial version5)
        </source>
        <comment>
         <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/yzygj/s7652m/202002/e84bd30142ab4d8982326326e4db22ea.shtml">
          http://www.nhc.gov.cn/yzygj/s7652m/202002/e84bd30142ab4d8982326326e4db22ea.shtml
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B28">
       <label>
        28
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Ben Addi
         </surname>
         <given-names>
          A
         </given-names>
        </name>
        <name>
         <surname>
          Lefort
         </surname>
         <given-names>
          A
         </given-names>
        </name>
        <name>
         <surname>
          Hua
         </surname>
         <given-names>
          X
         </given-names>
        </name>
        <name>
         <surname>
          Libert
         </surname>
         <given-names>
          F
         </given-names>
        </name>
        <name>
         <surname>
          Communi
         </surname>
         <given-names>
          D
         </given-names>
        </name>
        <name>
         <surname>
          Ledent
         </surname>
         <given-names>
          C
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Modulation of murine dendritic cell function by adenine nucleotides and adenosine: involvement of the A(2B) receptor
        </article-title>
        <source>
         European journal of immunology
        </source>
        <year>
         2008
        </year>
        <volume>
         38
        </volume>
        <fpage>
         1610
        </fpage>
        <lpage>
         20
        </lpage>
        <pub-id pub-id-type="pmid">
         18465770
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B29">
       <label>
        29
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Lu
         </surname>
         <given-names>
          X
         </given-names>
        </name>
        <name>
         <surname>
          Pan
         </surname>
         <given-names>
          J
         </given-names>
        </name>
        <name>
         <surname>
          Tao
         </surname>
         <given-names>
          J
         </given-names>
        </name>
        <name>
         <surname>
          Guo
         </surname>
         <given-names>
          D
         </given-names>
        </name>
        <article-title>
         SARS-CoV nucleocapsid protein antagonizes IFN-beta response by targeting initial step of IFN-beta induction pathway, and its C-terminal region is critical for the antagonism
        </article-title>
        <source>
         Virus Genes
        </source>
        <year>
         2011
        </year>
        <volume>
         42
        </volume>
        <fpage>
         37
        </fpage>
        <lpage>
         45
        </lpage>
        <pub-id pub-id-type="pmid">
         20976535
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B30">
       <label>
        30
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Mathern
         </surname>
         <given-names>
          DR
         </given-names>
        </name>
        <name>
         <surname>
          Heeger
         </surname>
         <given-names>
          PS
         </given-names>
        </name>
        <article-title>
         Molecules Great and Small: The Complement System
        </article-title>
        <source>
         Clin J Am Soc Nephrol
        </source>
        <year>
         2015
        </year>
        <volume>
         10
        </volume>
        <fpage>
         1636
        </fpage>
        <lpage>
         50
        </lpage>
        <pub-id pub-id-type="pmid">
         25568220
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B31">
       <label>
        31
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Traggiai
         </surname>
         <given-names>
          E
         </given-names>
        </name>
        <name>
         <surname>
          Becker
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        <name>
         <surname>
          Subbarao
         </surname>
         <given-names>
          K
         </given-names>
        </name>
        <name>
         <surname>
          Kolesnikova
         </surname>
         <given-names>
          L
         </given-names>
        </name>
        <name>
         <surname>
          Uematsu
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        <name>
         <surname>
          Gismondo
         </surname>
         <given-names>
          MR
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus
        </article-title>
        <source>
         Nat Med
        </source>
        <year>
         2004
        </year>
        <volume>
         10
        </volume>
        <fpage>
         871
        </fpage>
        <lpage>
         5
        </lpage>
        <pub-id pub-id-type="pmid">
         15247913
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B32">
       <label>
        32
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Niu
         </surname>
         <given-names>
          P
         </given-names>
        </name>
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        <name>
         <surname>
          Zhou
         </surname>
         <given-names>
          P
         </given-names>
        </name>
        <name>
         <surname>
          Huang
         </surname>
         <given-names>
          B
         </given-names>
        </name>
        <name>
         <surname>
          Deng
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        <name>
         <surname>
          Qin
         </surname>
         <given-names>
          K
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient
        </article-title>
        <source>
         J Infect Dis
        </source>
        <year>
         2018
        </year>
        <volume>
         218
        </volume>
        <fpage>
         1249
        </fpage>
        <lpage>
         60
        </lpage>
        <pub-id pub-id-type="pmid">
         29846635
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B33">
       <label>
        33
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Channappanavar
         </surname>
         <given-names>
          R
         </given-names>
        </name>
        <name>
         <surname>
          Perlman
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        <article-title>
         Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology
        </article-title>
        <source>
         Seminars in Immunopathology
        </source>
        <year>
         2017
        </year>
        <volume>
         39
        </volume>
        <fpage>
         529
        </fpage>
        <lpage>
         39
        </lpage>
        <pub-id pub-id-type="pmid">
         28466096
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B34">
       <label>
        34
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          D
         </given-names>
        </name>
        <name>
         <surname>
          Hu
         </surname>
         <given-names>
          B
         </given-names>
        </name>
        <name>
         <surname>
          Hu
         </surname>
         <given-names>
          C
         </given-names>
        </name>
        <name>
         <surname>
          Zhu
         </surname>
         <given-names>
          F
         </given-names>
        </name>
        <name>
         <surname>
          Liu
         </surname>
         <given-names>
          X
         </given-names>
        </name>
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          J
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2020
        </year>
        <comment>
         DOI:10.1001/jama.2020.1585
        </comment>
       </element-citation>
      </ref>
      <ref id="B35">
       <label>
        35
       </label>
       <element-citation publication-type="other">
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          G
         </given-names>
        </name>
        <name>
         <surname>
          Fan
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        <name>
         <surname>
          Lai
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        <name>
         <surname>
          Han
         </surname>
         <given-names>
          T
         </given-names>
        </name>
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          Z
         </given-names>
        </name>
        <name>
         <surname>
          Zhou
         </surname>
         <given-names>
          P
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Coronavirus infections and immune responses
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2020
        </year>
        <comment>
         DOI: https://doi.org/10.1002/jmv.25685
        </comment>
       </element-citation>
      </ref>
      <ref id="B36">
       <label>
        36
       </label>
       <element-citation publication-type="other">
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          Q
         </given-names>
        </name>
        <name>
         <surname>
          Guan
         </surname>
         <given-names>
          X
         </given-names>
        </name>
        <name>
         <surname>
          Wu
         </surname>
         <given-names>
          P
         </given-names>
        </name>
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          X
         </given-names>
        </name>
        <name>
         <surname>
          Zhou
         </surname>
         <given-names>
          L
         </given-names>
        </name>
        <name>
         <surname>
          Tong
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia
        </article-title>
        <source>
         2020. DOI:10.1056/NEJMoa2001316
        </source>
       </element-citation>
      </ref>
      <ref id="B37">
       <label>
        37
       </label>
       <element-citation publication-type="other">
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        <name>
         <surname>
          Lu
         </surname>
         <given-names>
          Q
         </given-names>
        </name>
        <name>
         <surname>
          Liu
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          A
         </given-names>
        </name>
        <name>
         <surname>
          Jalali
         </surname>
         <given-names>
          N
         </given-names>
        </name>
        <name>
         <surname>
          et
         </surname>
         <given-names>
          al.2020
         </given-names>
        </name>
        <article-title>
         Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China
        </article-title>
        <source>
         medRxiv. DOI: https://doi.org/10.1101/2020.02.10.20021675
        </source>
       </element-citation>
      </ref>
      <ref id="B38">
       <label>
        38
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Chang
         </surname>
         <given-names>
          D
         </given-names>
        </name>
        <name>
         <surname>
          Lin
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        <name>
         <surname>
          Wei
         </surname>
         <given-names>
          L
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2020
        </year>
        <comment>
         DOI:10.1001/jama.2020.1623
        </comment>
       </element-citation>
      </ref>
      <ref id="B39">
       <label>
        39
       </label>
       <element-citation publication-type="other">
        <name>
         <surname>
          Chen
         </surname>
         <given-names>
          N
         </given-names>
        </name>
        <name>
         <surname>
          Zhou
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        <name>
         <surname>
          Dong
         </surname>
         <given-names>
          X
         </given-names>
        </name>
        <name>
         <surname>
          Qu
         </surname>
         <given-names>
          J
         </given-names>
        </name>
        <name>
         <surname>
          Gong
         </surname>
         <given-names>
          F
         </given-names>
        </name>
        <name>
         <surname>
          Han
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         2020
        </article-title>
        <source>
         Epidemiological and clinical characteristics of 99 cases of
        </source>
        <year>
         2019
        </year>
        <comment>
         novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. DOI:10.1016/S0140-6736(20)30211-7
        </comment>
       </element-citation>
      </ref>
      <ref id="B40">
       <label>
        40
       </label>
       <element-citation publication-type="other">
        <name>
         <surname>
          Alexander
         </surname>
         <given-names>
          E
         </given-names>
        </name>
        <article-title>
         Gorbalenya, Susan C
        </article-title>
        <source>
         Baker, Ralph S. Baric, et al
        </source>
        <year>
         2020
        </year>
        <comment>
         Severe acute respiratory syndrome-related coronavirus: The species and its viruses - a statement of the Coronavirus Study Group. medRxiv. DOI: https://doi.org/10.1101/2020.02.07.937862
        </comment>
       </element-citation>
      </ref>
      <ref id="B41">
       <label>
        41
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Ren
         </surname>
         <given-names>
          LL
         </given-names>
        </name>
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          YM
         </given-names>
        </name>
        <name>
         <surname>
          Wu
         </surname>
         <given-names>
          ZQ
         </given-names>
        </name>
        <name>
         <surname>
          Xiang
         </surname>
         <given-names>
          ZC
         </given-names>
        </name>
        <name>
         <surname>
          Guo
         </surname>
         <given-names>
          L
         </given-names>
        </name>
        <name>
         <surname>
          Xu
         </surname>
         <given-names>
          T
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         2020. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study
        </article-title>
        <source>
         Chin Med J (Engl)
        </source>
        <comment>
         DOI:10.1097/CM9.0000000000000722
        </comment>
       </element-citation>
      </ref>
      <ref id="B42">
       <label>
        42
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Huang
         </surname>
         <given-names>
          C
         </given-names>
        </name>
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          X
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         6736
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         10
        </lpage>
       </element-citation>
      </ref>
      <ref id="B43">
       <label>
        43
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Rothe
         </surname>
         <given-names>
          C
         </given-names>
        </name>
        <name>
         <surname>
          Schunk
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        <name>
         <surname>
          Sothmann
         </surname>
         <given-names>
          P
         </given-names>
        </name>
        <name>
         <surname>
          Bretzel
         </surname>
         <given-names>
          G
         </given-names>
        </name>
        <name>
         <surname>
          Froeschl
         </surname>
         <given-names>
          G
         </given-names>
        </name>
        <name>
         <surname>
          Wallrauch
         </surname>
         <given-names>
          C
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2020
        </year>
        <comment>
         DOI:10.1056/NEJMc2001468
        </comment>
       </element-citation>
      </ref>
      <ref id="B44">
       <label>
        44
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Phan
         </surname>
         <given-names>
          LT
         </given-names>
        </name>
        <name>
         <surname>
          Nguyen
         </surname>
         <given-names>
          TV
         </given-names>
        </name>
        <name>
         <surname>
          Luong
         </surname>
         <given-names>
          QC
         </given-names>
        </name>
        <name>
         <surname>
          Nguyen
         </surname>
         <given-names>
          TV
         </given-names>
        </name>
        <name>
         <surname>
          Nguyen
         </surname>
         <given-names>
          HT
         </given-names>
        </name>
        <name>
         <surname>
          Le
         </surname>
         <given-names>
          HQ
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2020
        </year>
        <comment>
         DOI:10.1056/NEJMc2001272
        </comment>
       </element-citation>
      </ref>
      <ref id="B45">
       <label>
        45
       </label>
       <element-citation publication-type="other">
        <name>
         <surname>
          Pan
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        <name>
         <surname>
          Guan
         </surname>
         <given-names>
          H
         </given-names>
        </name>
        <article-title>
         Imaging changes in patients with 2019-nCov
        </article-title>
        <source>
         Eur Radiol
        </source>
        <year>
         2020
        </year>
        <comment>
         DOI: http://doi.org/10.1007/s00330-020-06713-z
        </comment>
       </element-citation>
      </ref>
      <ref id="B46">
       <label>
        46
       </label>
       <element-citation publication-type="webpage">
        <source>
         WHO: Geneva, Switzerland. Summary of probable SARS cases with onset of illness from 1 Nvember 2002 to 31 July 2003
        </source>
        <comment>
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/sars/country/table2003_09_23/en/">
          https://www.who.int/csr/sars/country/table2003_09_23/en/
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B47">
       <label>
        47
       </label>
       <element-citation publication-type="webpage">
        <source>
         WHO: MERS SITUATION UPDATE
        </source>
        <comment>
         <ext-link ext-link-type="uri" xlink:href="http://applications.emro.who.int/docs/EMRPUB-CSR-241-2019-EN.pdf?ua=1&amp;ua=1&amp;ua=1">
          http://applications.emro.who.int/docs/EMRPUB-CSR-241-2019-EN.pdf?ua=1&amp;ua=1&amp;ua=1
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B48">
       <label>
        48
       </label>
       <element-citation publication-type="other">
        <name>
         <surname>
          Tang
         </surname>
         <given-names>
          B
         </given-names>
        </name>
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          X
         </given-names>
        </name>
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          Q
         </given-names>
        </name>
        <name>
         <surname>
          Bragazzi
         </surname>
         <given-names>
          NL
         </given-names>
        </name>
        <name>
         <surname>
          Tang
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        <name>
         <surname>
          Xiao
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Estimation of the Transmission Risk of the 2019-nCoV and Its Implication for Public Health Interventions
        </article-title>
        <source>
         J Clin Med
        </source>
        <year>
         2020
        </year>
        <comment>
         9, 462
        </comment>
       </element-citation>
      </ref>
      <ref id="B49">
       <label>
        49
       </label>
       <element-citation publication-type="webpage">
        <source>
         WHO: Consensus Document on the Epidemiology of SARS. Wkly Epidemiol Rec. 2003; 78: 373-5
        </source>
        <comment>
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/sars/en/WHOconsensus.pdf">
          https://www.who.int/csr/sars/en/WHOconsensus.pdf
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B50">
       <label>
        50
       </label>
       <element-citation publication-type="webpage">
        <source>
         WHO: Organizaition WH. Global Surveillance for human infection with novel coronavirus (2019-nCoV)
        </source>
        <comment>
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-ncov)">
          https://www.who.int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-ncov)
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B51">
       <label>
        51
       </label>
       <element-citation publication-type="webpage">
        <source>
         CHANGDE-NHC: Epidemic Bulletin
        </source>
        <comment>
         <ext-link ext-link-type="uri" xlink:href="http://wjw.changde.gov.cn/zhdt/wjdt/content_720891">
          http://wjw.changde.gov.cn/zhdt/wjdt/content_720891
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B52">
       <label>
        52
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Chen
         </surname>
         <given-names>
          N
         </given-names>
        </name>
        <name>
         <surname>
          Zhou
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        <name>
         <surname>
          Dong
         </surname>
         <given-names>
          X
         </given-names>
        </name>
        <name>
         <surname>
          Qu
         </surname>
         <given-names>
          J
         </given-names>
        </name>
        <name>
         <surname>
          Gong
         </surname>
         <given-names>
          F
         </given-names>
        </name>
        <name>
         <surname>
          Han
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <fpage>
         507
        </fpage>
        <lpage>
         13
        </lpage>
        <pub-id pub-id-type="pmid">
         32007143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B53">
       <label>
        53
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Gunther
         </surname>
         <given-names>
          A
         </given-names>
        </name>
        <name>
         <surname>
          Ruppert
         </surname>
         <given-names>
          C
         </given-names>
        </name>
        <name>
         <surname>
          Schmidt
         </surname>
         <given-names>
          R
         </given-names>
        </name>
        <name>
         <surname>
          Markart
         </surname>
         <given-names>
          P
         </given-names>
        </name>
        <name>
         <surname>
          Grimminger
         </surname>
         <given-names>
          F
         </given-names>
        </name>
        <name>
         <surname>
          Walmrath
         </surname>
         <given-names>
          D
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Surfactant alteration and replacement in acute respiratory distress syndrome
        </article-title>
        <source>
         Respir Res
        </source>
        <year>
         2001
        </year>
        <volume>
         2
        </volume>
        <fpage>
         353
        </fpage>
        <lpage>
         64
        </lpage>
        <pub-id pub-id-type="pmid">
         11737935
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B54">
       <label>
        54
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Gralinski
         </surname>
         <given-names>
          LE
         </given-names>
        </name>
        <name>
         <surname>
          Baric
         </surname>
         <given-names>
          RS
         </given-names>
        </name>
        <article-title>
         Molecular pathology of emerging coronavirus infections
        </article-title>
        <source>
         The Journal of pathology
        </source>
        <year>
         2015
        </year>
        <volume>
         235
        </volume>
        <fpage>
         185
        </fpage>
        <lpage>
         95
        </lpage>
        <pub-id pub-id-type="pmid">
         25270030
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B55">
       <label>
        55
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          JT
         </given-names>
        </name>
        <name>
         <surname>
          Sheng
         </surname>
         <given-names>
          WH
         </given-names>
        </name>
        <name>
         <surname>
          Fang
         </surname>
         <given-names>
          CT
         </given-names>
        </name>
        <name>
         <surname>
          Chen
         </surname>
         <given-names>
          YC
         </given-names>
        </name>
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          JL
         </given-names>
        </name>
        <name>
         <surname>
          Yu
         </surname>
         <given-names>
          CJ
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2004
        </year>
        <volume>
         10
        </volume>
        <fpage>
         818
        </fpage>
        <lpage>
         24
        </lpage>
        <pub-id pub-id-type="pmid">
         15200814
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B56">
       <label>
        56
       </label>
       <element-citation publication-type="other">
        <name>
         <surname>
          Zhe
         </surname>
         <given-names>
          Xu
         </given-names>
        </name>
        <name>
         <surname>
          Lei
         </surname>
         <given-names>
          Shi
         </given-names>
        </name>
        <name>
         <surname>
          Yijin
         </surname>
         <given-names>
          Wang
         </given-names>
        </name>
        <name>
         <surname>
          Jiyuan
         </surname>
         <given-names>
          Zhang
         </given-names>
        </name>
        <name>
         <surname>
          Lei
         </surname>
         <given-names>
          Huang
         </given-names>
        </name>
        <name>
         <surname>
          Chao
         </surname>
         <given-names>
          Zhang
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Pathological findings of COVID-19 associated with acute respiratory distress syndrome Lacet Respir Med
        </article-title>
        <source>
         2020; DOI:https://doi.org/10.1016/S2213-2600(20)30076-X
        </source>
       </element-citation>
      </ref>
      <ref id="B57">
       <label>
        57
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Ding
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          H
         </given-names>
        </name>
        <name>
         <surname>
          Shen
         </surname>
         <given-names>
          H
         </given-names>
        </name>
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          Z
         </given-names>
        </name>
        <name>
         <surname>
          Geng
         </surname>
         <given-names>
          J
         </given-names>
        </name>
        <name>
         <surname>
          Han
         </surname>
         <given-names>
          H
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         The clinical pathology of severe acute respiratory syndrome (SARS): a report from China
        </article-title>
        <source>
         The Journal of pathology
        </source>
        <year>
         2003
        </year>
        <volume>
         200
        </volume>
        <fpage>
         282
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         12845623
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B58">
       <label>
        58
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Ng
         </surname>
         <given-names>
          DL
         </given-names>
        </name>
        <name>
         <surname>
          Al Hosani
         </surname>
         <given-names>
          F
         </given-names>
        </name>
        <name>
         <surname>
          Keating
         </surname>
         <given-names>
          MK
         </given-names>
        </name>
        <name>
         <surname>
          Gerber
         </surname>
         <given-names>
          SI
         </given-names>
        </name>
        <name>
         <surname>
          Jones
         </surname>
         <given-names>
          TL
         </given-names>
        </name>
        <name>
         <surname>
          Metcalfe
         </surname>
         <given-names>
          MG
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Clinicopathologic, Immunohistochemical, and Ultrastructural Findings of a Fatal Case of Middle East Respiratory Syndrome Coronavirus Infection in the United Arab Emirates, April 2014
        </article-title>
        <source>
         The American journal of pathology
        </source>
        <year>
         2016
        </year>
        <volume>
         186
        </volume>
        <fpage>
         652
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         26857507
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B59">
       <label>
        59
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Chang
         </surname>
         <given-names>
          SC
         </given-names>
        </name>
        <article-title>
         Clinical findings, treatment and prognosis in patients with severe acute respiratory syndrome (SARS)
        </article-title>
        <source>
         J Chin Med Assoc
        </source>
        <year>
         2005
        </year>
        <volume>
         68
        </volume>
        <fpage>
         106
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         15813242
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B60">
       <label>
        60
       </label>
       <element-citation publication-type="webpage">
        <source>
         Zhang F, OOA, JSG. A protocol for detection of COVID-19 using CRISPR diagnostics
        </source>
        <comment>
         <ext-link ext-link-type="uri" xlink:href="https://www.broadinstitute.org/files/publications/special/COVID-19%20detection%20(updated).pdf">
          https://www.broadinstitute.org/files/publications/special/COVID-19%20detection%20(updated).pdf
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B61">
       <label>
        61
       </label>
       <element-citation publication-type="webpage">
        <source>
         BLOOMBERG: China Seeks Plasma From Recovered Patients as Virus Treatment
        </source>
        <comment>
         <ext-link ext-link-type="uri" xlink:href="https://time.com/5784286/covid-19-china-plasma-treatment/">
          https://time.com/5784286/covid-19-china-plasma-treatment/
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B62">
       <label>
        62
       </label>
       <element-citation publication-type="webpage">
        <source>
         WIRED: NIILER E. Darpa Cranks Up Antibody Research to Stall Coronavirus
        </source>
        <comment>
         <ext-link ext-link-type="uri" xlink:href="https://www.wired.com/story/darpa-cranks-up-antibody-research-to-stall-coronavirus/">
          https://www.wired.com/story/darpa-cranks-up-antibody-research-to-stall-coronavirus/
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B63">
       <label>
        63
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Majeski
         </surname>
         <given-names>
          EI
         </given-names>
        </name>
        <name>
         <surname>
          Harley
         </surname>
         <given-names>
          RA
         </given-names>
        </name>
        <name>
         <surname>
          Bellum
         </surname>
         <given-names>
          SC
         </given-names>
        </name>
        <name>
         <surname>
          London
         </surname>
         <given-names>
          SD
         </given-names>
        </name>
        <name>
         <surname>
          London
         </surname>
         <given-names>
          L
         </given-names>
        </name>
        <article-title>
         Differential role for T cells in the development of fibrotic lesions associated with reovirus 1/L-induced bronchiolitis obliterans organizing pneumonia versus Acute Respiratory Distress Syndrome
        </article-title>
        <source>
         Am J Respir Cell Mol Biol
        </source>
        <year>
         2003
        </year>
        <volume>
         28
        </volume>
        <fpage>
         208
        </fpage>
        <lpage>
         17
        </lpage>
        <pub-id pub-id-type="pmid">
         12540488
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B64">
       <label>
        64
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Holshue
         </surname>
         <given-names>
          ML
         </given-names>
        </name>
        <name>
         <surname>
          DeBolt
         </surname>
         <given-names>
          C
         </given-names>
        </name>
        <name>
         <surname>
          Lindquist
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        <name>
         <surname>
          Lofy
         </surname>
         <given-names>
          KH
         </given-names>
        </name>
        <name>
         <surname>
          Wiesman
         </surname>
         <given-names>
          J
         </given-names>
        </name>
        <name>
         <surname>
          Bruce
         </surname>
         <given-names>
          H
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         First Case of 2019 Novel Coronavirus in the United States
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2020
        </year>
        <comment>
         DOI:10.1056/NEJMoa2001191
        </comment>
       </element-citation>
      </ref>
      <ref id="B65">
       <label>
        65
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Booth
         </surname>
         <given-names>
          CM
         </given-names>
        </name>
        <name>
         <surname>
          Matukas
         </surname>
         <given-names>
          LM
         </given-names>
        </name>
        <name>
         <surname>
          Tomlinson
         </surname>
         <given-names>
          GA
         </given-names>
        </name>
        <name>
         <surname>
          Rachlis
         </surname>
         <given-names>
          AR
         </given-names>
        </name>
        <name>
         <surname>
          Rose
         </surname>
         <given-names>
          DB
         </given-names>
        </name>
        <name>
         <surname>
          Dwosh
         </surname>
         <given-names>
          HA
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2003
        </year>
        <volume>
         289
        </volume>
        <fpage>
         2801
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         12734147
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B66">
       <label>
        66
       </label>
       <element-citation publication-type="other">
        <name>
         <surname>
          Xiang
         </surname>
         <given-names>
          YT
         </given-names>
        </name>
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          W
         </given-names>
        </name>
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          L
         </given-names>
        </name>
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          Q
         </given-names>
        </name>
        <name>
         <surname>
          Cheung
         </surname>
         <given-names>
          T
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed
        </article-title>
        <source>
         Lancet Psychiatry
        </source>
        <year>
         2020
        </year>
        <comment>
         DOI: https://doi.org/10.1016/S2215-0366(20)30046-8
        </comment>
       </element-citation>
      </ref>
      <ref id="B67">
       <label>
        67
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Tisoncik
         </surname>
         <given-names>
          JR
         </given-names>
        </name>
        <name>
         <surname>
          Korth
         </surname>
         <given-names>
          MJ
         </given-names>
        </name>
        <name>
         <surname>
          Simmons
         </surname>
         <given-names>
          CP
         </given-names>
        </name>
        <name>
         <surname>
          Farrar
         </surname>
         <given-names>
          J
         </given-names>
        </name>
        <name>
         <surname>
          Martin
         </surname>
         <given-names>
          TR
         </given-names>
        </name>
        <name>
         <surname>
          Katze
         </surname>
         <given-names>
          MG
         </given-names>
        </name>
        <article-title>
         Into the eye of the cytokine storm
        </article-title>
        <source>
         Microbiol Mol Biol Rev
        </source>
        <year>
         2012
        </year>
        <volume>
         76
        </volume>
        <fpage>
         16
        </fpage>
        <lpage>
         32
        </lpage>
        <pub-id pub-id-type="pmid">
         22390970
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B68">
       <label>
        68
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Lee
         </surname>
         <given-names>
          DW
         </given-names>
        </name>
        <name>
         <surname>
          Gardner
         </surname>
         <given-names>
          R
         </given-names>
        </name>
        <name>
         <surname>
          Porter
         </surname>
         <given-names>
          DL
         </given-names>
        </name>
        <name>
         <surname>
          Louis
         </surname>
         <given-names>
          CU
         </given-names>
        </name>
        <name>
         <surname>
          Ahmed
         </surname>
         <given-names>
          N
         </given-names>
        </name>
        <name>
         <surname>
          Jensen
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Current concepts in the diagnosis and management of cytokine release syndrome
        </article-title>
        <source>
         Blood
        </source>
        <year>
         2014
        </year>
        <volume>
         124
        </volume>
        <fpage>
         188
        </fpage>
        <lpage>
         95
        </lpage>
        <pub-id pub-id-type="pmid">
         24876563
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B69">
       <label>
        69
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Behrens
         </surname>
         <given-names>
          EM
         </given-names>
        </name>
        <name>
         <surname>
          Koretzky
         </surname>
         <given-names>
          GA
         </given-names>
        </name>
        <article-title>
         Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era
        </article-title>
        <source>
         Arthritis Rheumatol
        </source>
        <year>
         2017
        </year>
        <volume>
         69
        </volume>
        <fpage>
         1135
        </fpage>
        <lpage>
         43
        </lpage>
        <pub-id pub-id-type="pmid">
         28217930
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B70">
       <label>
        70
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Shimabukuro-Vornhagen
         </surname>
         <given-names>
          A
         </given-names>
        </name>
        <name>
         <surname>
          Godel
         </surname>
         <given-names>
          P
         </given-names>
        </name>
        <name>
         <surname>
          Subklewe
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        <name>
         <surname>
          Stemmler
         </surname>
         <given-names>
          HJ
         </given-names>
        </name>
        <name>
         <surname>
          Schlosser
         </surname>
         <given-names>
          HA
         </given-names>
        </name>
        <name>
         <surname>
          Schlaak
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Cytokine release syndrome
        </article-title>
        <source>
         J Immunother Cancer
        </source>
        <year>
         2018
        </year>
        <volume>
         6
        </volume>
        <fpage>
         56
        </fpage>
        <pub-id pub-id-type="pmid">
         29907163
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B71">
       <label>
        71
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          L
         </surname>
         <given-names>
          K
         </given-names>
        </name>
        <name>
         <surname>
          EM
         </surname>
         <given-names>
          L
         </given-names>
        </name>
        <name>
         <surname>
          TB
         </surname>
         <given-names>
          K
         </given-names>
        </name>
        <name>
         <surname>
          EB
         </surname>
         <given-names>
          D
         </given-names>
        </name>
        <name>
         <surname>
          NL
         </surname>
         <given-names>
          B
         </given-names>
        </name>
        <name>
         <surname>
          BT
         </surname>
         <given-names>
          K
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Suppressor of cytokine signaling 4 (SOCS4) protects against severe cytokine storm and enhances viral clearance during influenza infection
        </article-title>
        <source>
         PLoS pathogens
        </source>
        <year>
         2014
        </year>
        <volume>
         10
        </volume>
        <fpage>
         e1004134
        </fpage>
        <pub-id pub-id-type="pmid">
         24809749
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B72">
       <label>
        72
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          N
         </given-names>
        </name>
        <name>
         <surname>
          Zhao
         </surname>
         <given-names>
          D
         </given-names>
        </name>
        <name>
         <surname>
          Kirschbaum
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          C
         </given-names>
        </name>
        <name>
         <surname>
          Lin
         </surname>
         <given-names>
          CL
         </given-names>
        </name>
        <name>
         <surname>
          Todorov
         </surname>
         <given-names>
          I
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2008
        </year>
        <volume>
         105
        </volume>
        <fpage>
         4796
        </fpage>
        <lpage>
         801
        </lpage>
        <pub-id pub-id-type="pmid">
         18347343
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B73">
       <label>
        73
       </label>
       <element-citation publication-type="other">
        <name>
         <surname>
          Clark D Russell
         </surname>
         <given-names>
          JEM
         </given-names>
        </name>
        <name>
         <surname>
          J Kenneth
         </surname>
         <given-names>
          Baillie
         </given-names>
        </name>
        <article-title>
         Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <comment>
         DOI: https://doi.org/10.1016/S0140-6736(20)30317-2
        </comment>
       </element-citation>
      </ref>
      <ref id="B74">
       <label>
        74
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Griffith
         </surname>
         <given-names>
          JF
         </given-names>
        </name>
        <name>
         <surname>
          Antonio
         </surname>
         <given-names>
          GE
         </given-names>
        </name>
        <name>
         <surname>
          Kumta
         </surname>
         <given-names>
          SM
         </given-names>
        </name>
        <name>
         <surname>
          Hui
         </surname>
         <given-names>
          DSC
         </given-names>
        </name>
        <name>
         <surname>
          Wong
         </surname>
         <given-names>
          JKT
         </given-names>
        </name>
        <name>
         <surname>
          Joynt
         </surname>
         <given-names>
          GM
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids
        </article-title>
        <source>
         Radiology
        </source>
        <year>
         2005
        </year>
        <volume>
         235
        </volume>
        <fpage>
         168
        </fpage>
        <lpage>
         75
        </lpage>
        <pub-id pub-id-type="pmid">
         15703312
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B75">
       <label>
        75
       </label>
       <element-citation publication-type="other">
        <name>
         <surname>
          Shang
         </surname>
         <given-names>
          L
         </given-names>
        </name>
        <name>
         <surname>
          Zhao
         </surname>
         <given-names>
          J
         </given-names>
        </name>
        <name>
         <surname>
          Hu
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        <name>
         <surname>
          Du
         </surname>
         <given-names>
          R
         </given-names>
        </name>
        <name>
         <surname>
          Cao
         </surname>
         <given-names>
          B
         </given-names>
        </name>
        <article-title>
         On the use of corticosteroids for 2019-nCoV pneumonia
        </article-title>
        <source>
         The Lancet
        </source>
        <year>
         2020
        </year>
        <comment>
         DOI:https://doi.org/10.1016/S0140-6736(20)30361-5
        </comment>
       </element-citation>
      </ref>
      <ref id="B76">
       <label>
        76
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Warren
         </surname>
         <given-names>
          TK
         </given-names>
        </name>
        <name>
         <surname>
          Jordan
         </surname>
         <given-names>
          R
         </given-names>
        </name>
        <name>
         <surname>
          Lo
         </surname>
         <given-names>
          MK
         </given-names>
        </name>
        <name>
         <surname>
          Ray
         </surname>
         <given-names>
          AS
         </given-names>
        </name>
        <name>
         <surname>
          Mackman
         </surname>
         <given-names>
          RL
         </given-names>
        </name>
        <name>
         <surname>
          Soloveva
         </surname>
         <given-names>
          V
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2016
        </year>
        <volume>
         531
        </volume>
        <fpage>
         381
        </fpage>
        <lpage>
         5
        </lpage>
        <pub-id pub-id-type="pmid">
         26934220
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B77">
       <label>
        77
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Lo
         </surname>
         <given-names>
          MK
         </given-names>
        </name>
        <name>
         <surname>
          Jordan
         </surname>
         <given-names>
          R
         </given-names>
        </name>
        <name>
         <surname>
          Arvey
         </surname>
         <given-names>
          A
         </given-names>
        </name>
        <name>
         <surname>
          Sudhamsu
         </surname>
         <given-names>
          J
         </given-names>
        </name>
        <name>
         <surname>
          Shrivastava-Ranjan
         </surname>
         <given-names>
          P
         </given-names>
        </name>
        <name>
         <surname>
          Hotard
         </surname>
         <given-names>
          AL
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses
        </article-title>
        <source>
         Sci Rep
        </source>
        <year>
         2017
        </year>
        <volume>
         7
        </volume>
        <fpage>
         43395
        </fpage>
        <pub-id pub-id-type="pmid">
         28262699
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B78">
       <label>
        78
       </label>
       <element-citation publication-type="other">
        <name>
         <surname>
          Sheahan
         </surname>
         <given-names>
          TP
         </given-names>
        </name>
        <name>
         <surname>
          Sims
         </surname>
         <given-names>
          AC
         </given-names>
        </name>
        <name>
         <surname>
          Graham
         </surname>
         <given-names>
          RL
         </given-names>
        </name>
        <name>
         <surname>
          Menachery
         </surname>
         <given-names>
          VD
         </given-names>
        </name>
        <name>
         <surname>
          Gralinski
         </surname>
         <given-names>
          LE
         </given-names>
        </name>
        <name>
         <surname>
          Case
         </surname>
         <given-names>
          JB
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
        </article-title>
        <source>
         Sci Transl Med
        </source>
        <year>
         2017
        </year>
        <comment>
         9
        </comment>
       </element-citation>
      </ref>
      <ref id="B79">
       <label>
        79
       </label>
       <element-citation publication-type="webpage">
        <source>
         The New York Times: Denise Grady. China Begins Teating an Antiviral Drug in Coronavirus Patients
        </source>
        <comment>
         <ext-link ext-link-type="uri" xlink:href="https://www.nytimes.com/2020/02/06/health/coronavirus-treatments.html">
          https://www.nytimes.com/2020/02/06/health/coronavirus-treatments.html
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B80">
       <label>
        80
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Hirsch
         </surname>
         <given-names>
          HH
         </given-names>
        </name>
        <name>
         <surname>
          Martino
         </surname>
         <given-names>
          R
         </given-names>
        </name>
        <name>
         <surname>
          Ward
         </surname>
         <given-names>
          KN
         </given-names>
        </name>
        <name>
         <surname>
          Boeckh
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        <name>
         <surname>
          Einsele
         </surname>
         <given-names>
          H
         </given-names>
        </name>
        <name>
         <surname>
          Ljungman
         </surname>
         <given-names>
          P
         </given-names>
        </name>
        <article-title>
         Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2013
        </year>
        <volume>
         56
        </volume>
        <fpage>
         258
        </fpage>
        <lpage>
         66
        </lpage>
        <pub-id pub-id-type="pmid">
         23024295
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B81">
       <label>
        81
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Zumla
         </surname>
         <given-names>
          A
         </given-names>
        </name>
        <name>
         <surname>
          Chan
         </surname>
         <given-names>
          JF
         </given-names>
        </name>
        <name>
         <surname>
          Azhar
         </surname>
         <given-names>
          EI
         </given-names>
        </name>
        <name>
         <surname>
          Hui
         </surname>
         <given-names>
          DS
         </given-names>
        </name>
        <name>
         <surname>
          Yuen
         </surname>
         <given-names>
          KY
         </given-names>
        </name>
        <article-title>
         Coronaviruses - drug discovery and therapeutic options
        </article-title>
        <source>
         Nat Rev Drug Discov
        </source>
        <year>
         2016
        </year>
        <volume>
         15
        </volume>
        <fpage>
         327
        </fpage>
        <lpage>
         47
        </lpage>
        <pub-id pub-id-type="pmid">
         26868298
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B82">
       <label>
        82
       </label>
       <element-citation publication-type="other">
        <name>
         <surname>
          Etzioni
         </surname>
         <given-names>
          A
         </given-names>
        </name>
        <name>
         <surname>
          Ochs
         </surname>
         <given-names>
          HD
         </given-names>
        </name>
        <article-title>
         Primary Immunodeficiency Disorders: A Historic and Scientific Perspective: Elsevier Science
        </article-title>
        <source>
         USA: Academic Press
        </source>
        <year>
         2014
        </year>
       </element-citation>
      </ref>
      <ref id="B83">
       <label>
        83
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Kreil
         </surname>
         <given-names>
          TR
         </given-names>
        </name>
        <name>
         <surname>
          Farcet
         </surname>
         <given-names>
          MR
         </given-names>
        </name>
        <article-title>
         Immunoglobulins and virus antibody titers: of past needs, current requirements, and future options
        </article-title>
        <source>
         Transfusion
        </source>
        <year>
         2018
        </year>
        <volume>
         58
        </volume>
        <issue>
         Suppl 3
        </issue>
        <fpage>
         3090
        </fpage>
        <lpage>
         5
        </lpage>
        <pub-id pub-id-type="pmid">
         30536431
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B84">
       <label>
        84
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Lee
         </surname>
         <given-names>
          DW
         </given-names>
        </name>
        <name>
         <surname>
          Gardner
         </surname>
         <given-names>
          R
         </given-names>
        </name>
        <name>
         <surname>
          Porter
         </surname>
         <given-names>
          DL
         </given-names>
        </name>
        <name>
         <surname>
          Louis
         </surname>
         <given-names>
          CU
         </given-names>
        </name>
        <name>
         <surname>
          Ahmed
         </surname>
         <given-names>
          N
         </given-names>
        </name>
        <name>
         <surname>
          Jensen
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Current concepts in the diagnosis and management of cytokine release syndrome
        </article-title>
        <source>
         Blood
        </source>
        <year>
         2014
        </year>
        <volume>
         124
        </volume>
        <fpage>
         188
        </fpage>
        <lpage>
         95
        </lpage>
        <pub-id pub-id-type="pmid">
         24876563
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B85">
       <label>
        85
       </label>
       <element-citation publication-type="webpage">
        <source>
         Korea Biomedical Review: Song S. Traditional Chinese medicine harmed new coronavirus control
        </source>
        <comment>
         <ext-link ext-link-type="uri" xlink:href="http://www.koreabiomed.com/news/articleView.html?idxno=7370">
          http://www.koreabiomed.com/news/articleView.html?idxno=7370
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B86">
       <label>
        86
       </label>
       <element-citation publication-type="other">
        <name>
         <surname>
          Lu
         </surname>
         <given-names>
          H
         </given-names>
        </name>
        <article-title>
         Drug treatment options for the 2019-new coronavirus (2019-nCoV)
        </article-title>
        <source>
         Biosci Trends
        </source>
        <year>
         2020
        </year>
        <fpage>
         10
        </fpage>
        <lpage>
         12
        </lpage>
       </element-citation>
      </ref>
      <ref id="B87">
       <label>
        87
       </label>
       <element-citation publication-type="webpage">
        <source>
         DXY.cn: COVIND-19 Epidemic Situation in Real Time. 2020
        </source>
        <comment>
         <ext-link ext-link-type="uri" xlink:href="https://ncov.dxy.cn/ncovh5/view/pneumonia">
          https://ncov.dxy.cn/ncovh5/view/pneumonia
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B88">
       <label>
        88
       </label>
       <element-citation publication-type="other">
        <name>
         <surname>
          Xia
         </surname>
         <given-names>
          WG
         </given-names>
        </name>
        <name>
         <surname>
          An
         </surname>
         <given-names>
          CQ
         </given-names>
        </name>
        <name>
         <surname>
          Zheng
         </surname>
         <given-names>
          CJ
         </given-names>
        </name>
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          JX
         </given-names>
        </name>
        <name>
         <surname>
          Huang
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Clinical study on 34 cases of COVID-19 treated with combined traditional Chinese and western medicine (in Chinese)
        </article-title>
        <source>
         Journal of Tranditional Chinese Medicine
        </source>
        <year>
         2020
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         7
        </lpage>
       </element-citation>
      </ref>
      <ref id="B89">
       <label>
        89
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Cheung
         </surname>
         <given-names>
          YT
         </given-names>
        </name>
        <name>
         <surname>
          Chau
         </surname>
         <given-names>
          PH
         </given-names>
        </name>
        <name>
         <surname>
          Yip
         </surname>
         <given-names>
          PSF
         </given-names>
        </name>
        <article-title>
         A revisit on older adults suicides and Severe Acute Respiratory Syndrome (SARS) epidemic in Hong Kong
        </article-title>
        <source>
         Int J Geriatr Psychiatry
        </source>
        <year>
         2008
        </year>
        <volume>
         23
        </volume>
        <fpage>
         1231
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         18500689
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B90">
       <label>
        90
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Su
         </surname>
         <given-names>
          T-P
         </given-names>
        </name>
        <name>
         <surname>
          Lien
         </surname>
         <given-names>
          T-C
         </given-names>
        </name>
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          C-Y
         </given-names>
        </name>
        <name>
         <surname>
          Su
         </surname>
         <given-names>
          YL
         </given-names>
        </name>
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          J-H
         </given-names>
        </name>
        <name>
         <surname>
          Tsai
         </surname>
         <given-names>
          S-L
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Prevalence of psychiatric morbidity and psychological adaptation of the nurses in a structured SARS caring unit during outbreak: a prospective and periodic assessment study in Taiwan
        </article-title>
        <source>
         J Psychiatr Res
        </source>
        <year>
         2007
        </year>
        <volume>
         41
        </volume>
        <fpage>
         119
        </fpage>
        <lpage>
         30
        </lpage>
        <pub-id pub-id-type="pmid">
         16460760
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B91">
       <label>
        91
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Du
         </surname>
         <given-names>
          L
         </given-names>
        </name>
        <name>
         <surname>
          He
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        <name>
         <surname>
          Zhou
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        <name>
         <surname>
          Liu
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        <name>
         <surname>
          Zheng
         </surname>
         <given-names>
          BJ
         </given-names>
        </name>
        <name>
         <surname>
          Jiang
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        <article-title>
         The spike protein of SARS-CoV-a target for vaccine and therapeutic development
        </article-title>
        <source>
         Nat Rev Microbiol
        </source>
        <year>
         2009
        </year>
        <volume>
         7
        </volume>
        <fpage>
         226
        </fpage>
        <lpage>
         36
        </lpage>
        <pub-id pub-id-type="pmid">
         19198616
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B92">
       <label>
        92
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Roper
         </surname>
         <given-names>
          RL
         </given-names>
        </name>
        <name>
         <surname>
          Rehm
         </surname>
         <given-names>
          KE
         </given-names>
        </name>
        <article-title>
         SARS vaccines: where are we? Expert Rev
        </article-title>
        <source>
         Vaccines
        </source>
        <year>
         2009
        </year>
        <volume>
         8
        </volume>
        <fpage>
         887
        </fpage>
        <lpage>
         98
        </lpage>
       </element-citation>
      </ref>
      <ref id="B93">
       <label>
        93
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Xu
         </surname>
         <given-names>
          J
         </given-names>
        </name>
        <name>
         <surname>
          Jia
         </surname>
         <given-names>
          W
         </given-names>
        </name>
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          P
         </given-names>
        </name>
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        <name>
         <surname>
          Shi
         </surname>
         <given-names>
          X
         </given-names>
        </name>
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          X
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Antibodies and vaccines against Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         Emerg Microbes Infect
        </source>
        <year>
         2019
        </year>
        <volume>
         8
        </volume>
        <fpage>
         841
        </fpage>
        <lpage>
         56
        </lpage>
        <pub-id pub-id-type="pmid">
         31169078
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B94">
       <label>
        94
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Peiris
         </surname>
         <given-names>
          JS
         </given-names>
        </name>
        <name>
         <surname>
          Chu
         </surname>
         <given-names>
          CM
         </given-names>
        </name>
        <name>
         <surname>
          Cheng
         </surname>
         <given-names>
          VC
         </given-names>
        </name>
        <name>
         <surname>
          Chan
         </surname>
         <given-names>
          KS
         </given-names>
        </name>
        <name>
         <surname>
          Hung
         </surname>
         <given-names>
          IF
         </given-names>
        </name>
        <name>
         <surname>
          Poon
         </surname>
         <given-names>
          LL
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        <volume>
         361
        </volume>
        <fpage>
         1767
        </fpage>
        <lpage>
         72
        </lpage>
        <pub-id pub-id-type="pmid">
         12781535
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B95">
       <label>
        95
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Alraddadi
         </surname>
         <given-names>
          B
         </given-names>
        </name>
        <name>
         <surname>
          Bawareth
         </surname>
         <given-names>
          N
         </given-names>
        </name>
        <name>
         <surname>
          Omar
         </surname>
         <given-names>
          H
         </given-names>
        </name>
        <name>
         <surname>
          Alsalmi
         </surname>
         <given-names>
          H
         </given-names>
        </name>
        <name>
         <surname>
          Alshukairi
         </surname>
         <given-names>
          A
         </given-names>
        </name>
        <name>
         <surname>
          Qushmaq
         </surname>
         <given-names>
          I
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Patient characteristics infected with Middle East respiratory syndrome coronavirus infection in a tertiary hospital
        </article-title>
        <source>
         Ann Thorac Med
        </source>
        <year>
         2016
        </year>
        <volume>
         11
        </volume>
        <fpage>
         128
        </fpage>
        <lpage>
         31
        </lpage>
        <pub-id pub-id-type="pmid">
         27168861
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B96">
       <label>
        96
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Garbati
         </surname>
         <given-names>
          MA
         </given-names>
        </name>
        <name>
         <surname>
          Fagbo
         </surname>
         <given-names>
          SF
         </given-names>
        </name>
        <name>
         <surname>
          Fang
         </surname>
         <given-names>
          VJ
         </given-names>
        </name>
        <name>
         <surname>
          Skakni
         </surname>
         <given-names>
          L
         </given-names>
        </name>
        <name>
         <surname>
          Joseph
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        <name>
         <surname>
          Wani
         </surname>
         <given-names>
          TA
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         A Comparative Study of Clinical Presentation and Risk Factors for Adverse Outcome in Patients Hospitalised with Acute Respiratory Disease Due to MERS Coronavirus or Other Causes
        </article-title>
        <source>
         PloS one
        </source>
        <year>
         2016
        </year>
        <volume>
         11
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         12
        </lpage>
       </element-citation>
      </ref>
      <ref id="B97">
       <label>
        97
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Momattin
         </surname>
         <given-names>
          H
         </given-names>
        </name>
        <name>
         <surname>
          Mohammed
         </surname>
         <given-names>
          K
         </given-names>
        </name>
        <name>
         <surname>
          Zumla
         </surname>
         <given-names>
          A
         </given-names>
        </name>
        <name>
         <surname>
          Memish
         </surname>
         <given-names>
          ZA
         </given-names>
        </name>
        <name>
         <surname>
          Al-Tawfiq
         </surname>
         <given-names>
          JA
         </given-names>
        </name>
        <article-title>
         Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)-possible lessons from a systematic review of SARS-CoV therapy
        </article-title>
        <source>
         Int J Infect Dis
        </source>
        <year>
         2013
        </year>
        <volume>
         17
        </volume>
        <fpage>
         e792
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         23993766
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B98">
       <label>
        98
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Hwang
         </surname>
         <given-names>
          SM
         </given-names>
        </name>
        <name>
         <surname>
          Na
         </surname>
         <given-names>
          BJ
         </given-names>
        </name>
        <name>
         <surname>
          Jung
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        <name>
         <surname>
          Lim
         </surname>
         <given-names>
          HS
         </given-names>
        </name>
        <name>
         <surname>
          Seo
         </surname>
         <given-names>
          JE
         </given-names>
        </name>
        <name>
         <surname>
          Park
         </surname>
         <given-names>
          SA
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Clinical and Laboratory Findings of Middle East Respiratory Syndrome Coronavirus Infection
        </article-title>
        <source>
         Jpn J Infect Dis
        </source>
        <year>
         2019
        </year>
        <volume>
         72
        </volume>
        <fpage>
         160
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         30584196
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B99">
       <label>
        99
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Cowling
         </surname>
         <given-names>
          BJ
         </given-names>
        </name>
        <name>
         <surname>
          Muller
         </surname>
         <given-names>
          MP
         </given-names>
        </name>
        <name>
         <surname>
          Wong
         </surname>
         <given-names>
          IO
         </given-names>
        </name>
        <name>
         <surname>
          Ho
         </surname>
         <given-names>
          LM
         </given-names>
        </name>
        <name>
         <surname>
          Lo
         </surname>
         <given-names>
          SV
         </given-names>
        </name>
        <name>
         <surname>
          Tsang
         </surname>
         <given-names>
          T
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Clinical prognostic rules for severe acute respiratory syndrome in low- and high-resource settings
        </article-title>
        <source>
         Arch Intern Med
        </source>
        <year>
         2006
        </year>
        <volume>
         166
        </volume>
        <fpage>
         1505
        </fpage>
        <lpage>
         11
        </lpage>
        <pub-id pub-id-type="pmid">
         16864761
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B100">
       <label>
        100
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Chai
         </surname>
         <given-names>
          X
         </given-names>
        </name>
        <name>
         <surname>
          Hu
         </surname>
         <given-names>
          L
         </given-names>
        </name>
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        <name>
         <surname>
          Han
         </surname>
         <given-names>
          W
         </given-names>
        </name>
        <name>
         <surname>
          Lu
         </surname>
         <given-names>
          Z
         </given-names>
        </name>
        <name>
         <surname>
          Ke
         </surname>
         <given-names>
          A
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         2020. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection
        </article-title>
        <source>
         bioRxiv
        </source>
        <comment>
         DOI:10.1101/2020.02.03.931766
        </comment>
       </element-citation>
      </ref>
      <ref id="B101">
       <label>
        101
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Johnson
         </surname>
         <given-names>
          HL
         </given-names>
        </name>
        <name>
         <surname>
          Chiou
         </surname>
         <given-names>
          CC
         </given-names>
        </name>
        <name>
         <surname>
          Cho
         </surname>
         <given-names>
          CT
         </given-names>
        </name>
        <article-title>
         Applications of acute phase reactants in infectious diseases
        </article-title>
        <source>
         J Microbiol Immunol Infect
        </source>
        <year>
         1999
        </year>
        <volume>
         32
        </volume>
        <fpage>
         73
        </fpage>
        <lpage>
         82
        </lpage>
        <pub-id pub-id-type="pmid">
         11561579
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B102">
       <label>
        102
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Wrenger
         </surname>
         <given-names>
          C
         </given-names>
        </name>
        <name>
         <surname>
          Muller
         </surname>
         <given-names>
          IB
         </given-names>
        </name>
        <name>
         <surname>
          Silber
         </surname>
         <given-names>
          AM
         </given-names>
        </name>
        <name>
         <surname>
          Jordanova
         </surname>
         <given-names>
          R
         </given-names>
        </name>
        <name>
         <surname>
          Lamzin
         </surname>
         <given-names>
          VS
         </given-names>
        </name>
        <name>
         <surname>
          Groves
         </surname>
         <given-names>
          MR
         </given-names>
        </name>
        <article-title>
         Aspartate aminotransferase: bridging carbohydrate and energy metabolism in Plasmodium falciparum
        </article-title>
        <source>
         Curr Drug Metab
        </source>
        <year>
         2012
        </year>
        <volume>
         13
        </volume>
        <fpage>
         332
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="pmid">
         22455555
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B103">
       <label>
        103
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Stankovic Stojanovic
         </surname>
         <given-names>
          K
         </given-names>
        </name>
        <name>
         <surname>
          Lionnet
         </surname>
         <given-names>
          F
         </given-names>
        </name>
        <article-title>
         Lactate dehydrogenase in sickle cell disease
        </article-title>
        <source>
         Clinica chimica acta; international journal of clinical chemistry
        </source>
        <year>
         2016
        </year>
        <volume>
         458
        </volume>
        <fpage>
         99
        </fpage>
        <lpage>
         102
        </lpage>
        <pub-id pub-id-type="pmid">
         27138446
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B104">
       <label>
        104
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Cheung
         </surname>
         <given-names>
          CY
         </given-names>
        </name>
        <name>
         <surname>
          Poon
         </surname>
         <given-names>
          LL
         </given-names>
        </name>
        <name>
         <surname>
          Lau
         </surname>
         <given-names>
          AS
         </given-names>
        </name>
        <name>
         <surname>
          Luk
         </surname>
         <given-names>
          W
         </given-names>
        </name>
        <name>
         <surname>
          Lau
         </surname>
         <given-names>
          YL
         </given-names>
        </name>
        <name>
         <surname>
          Shortridge
         </surname>
         <given-names>
          KF
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease?
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2002
        </year>
        <volume>
         360
        </volume>
        <fpage>
         1831
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         12480361
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B105">
       <label>
        105
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Hong
         </surname>
         <given-names>
          N
         </given-names>
        </name>
        <name>
         <surname>
          Du
         </surname>
         <given-names>
          XK
         </given-names>
        </name>
        <article-title>
         Avascular necrosis of bone in severe acute respiratory syndrome
        </article-title>
        <source>
         Clinical radiology
        </source>
        <year>
         2004
        </year>
        <volume>
         59
        </volume>
        <fpage>
         602
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         15208066
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B106">
       <label>
        106
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Chan
         </surname>
         <given-names>
          JF
         </given-names>
        </name>
        <name>
         <surname>
          Yuan
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        <name>
         <surname>
          Kok
         </surname>
         <given-names>
          KH
         </given-names>
        </name>
        <name>
         <surname>
          To
         </surname>
         <given-names>
          KK
         </given-names>
        </name>
        <name>
         <surname>
          Chu
         </surname>
         <given-names>
          H
         </given-names>
        </name>
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          J
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <fpage>
         514
        </fpage>
        <lpage>
         523
        </lpage>
        <pub-id pub-id-type="pmid">
         31986261
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B107">
       <label>
        107
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Peiris
         </surname>
         <given-names>
          JS
         </given-names>
        </name>
        <name>
         <surname>
          Yuen
         </surname>
         <given-names>
          KY
         </given-names>
        </name>
        <name>
         <surname>
          Osterhaus
         </surname>
         <given-names>
          AD
         </given-names>
        </name>
        <name>
         <surname>
          Stohr
         </surname>
         <given-names>
          K
         </given-names>
        </name>
        <article-title>
         The severe acute respiratory syndrome
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2003
        </year>
        <volume>
         349
        </volume>
        <fpage>
         2431
        </fpage>
        <lpage>
         41
        </lpage>
        <pub-id pub-id-type="pmid">
         14681510
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B108">
       <label>
        108
       </label>
       <element-citation publication-type="webpage">
        <source>
         Terence:Rubin, Baden. Reality and Future about COVID-19
        </source>
        <comment>
         <ext-link ext-link-type="uri" xlink:href="https://mp.weixin.qq.com/s/o3Dd61yN0GtdosCtrD-CrQ">
          https://mp.weixin.qq.com/s/o3Dd61yN0GtdosCtrD-CrQ
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B109">
       <label>
        109
       </label>
       <element-citation publication-type="webpage">
        <source>
         ALJAZEERA: Casey R. How long will COVID-19 outbreak last; how can you stay protected? https://
        </source>
        <comment>
         <ext-link ext-link-type="uri" xlink:href="http://www.aljazeera.com/news/2020/02/long-covid-19-outbreak-stay-protected-200212140216674.html">
          www.aljazeera.com/news/2020/02/long-covid-19-outbreak-stay-protected-200212140216674.html
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B110">
       <label>
        110
       </label>
       <element-citation publication-type="webpage">
        <source>
         BLOOMBERG: Lauerman J. Coronavirus Could Infect Two-Thirds of Globe, Research Shows
        </source>
        <comment>
         <ext-link ext-link-type="uri" xlink:href="https://www.bloomberg.com/news/articles/2020-02-13/coronavirus-could-infect-two-thirds-of-globe-researcher-says">
          https://www.bloomberg.com/news/articles/2020-02-13/coronavirus-could-infect-two-thirds-of-globe-researcher-says
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B111">
       <label>
        111
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Silverstein
         </surname>
         <given-names>
          WK
         </given-names>
        </name>
        <name>
         <surname>
          Stroud
         </surname>
         <given-names>
          L
         </given-names>
        </name>
        <name>
         <surname>
          Cleghorn
         </surname>
         <given-names>
          GE
         </given-names>
        </name>
        <name>
         <surname>
          Leis
         </surname>
         <given-names>
          JA
         </given-names>
        </name>
        <article-title>
         First imported case of 2019 novel coronavirus in Canada, presenting as mild pneumonia
        </article-title>
        <source>
         Lancet (London, England)
        </source>
        <year>
         2020
        </year>
        <volume>
         6736
        </volume>
        <issue>
         20
        </issue>
        <fpage>
         30370
        </fpage>
       </element-citation>
      </ref>
      <ref id="B112">
       <label>
        112
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Bradol
         </surname>
         <given-names>
          JH
         </given-names>
        </name>
        <article-title>
         Ebola, the Day after
        </article-title>
        <source>
         Rev Prat
        </source>
        <year>
         2017
        </year>
        <volume>
         67
        </volume>
        <fpage>
         841
        </fpage>
        <lpage>
         4
        </lpage>
        <pub-id pub-id-type="pmid">
         30512809
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B113">
       <label>
        113
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Waheed
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        <name>
         <surname>
          Malik
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        <name>
         <surname>
          Khan
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        <name>
         <surname>
          Najmi
         </surname>
         <given-names>
          MH
         </given-names>
        </name>
        <article-title>
         The World after Ebola: An Overview of Ebola Complications, Vaccine Development, Lessons Learned, Financial Losses, and Disease Preparedness
        </article-title>
        <source>
         Crit Rev Eukaryot Gene Expr
        </source>
        <year>
         2019
        </year>
        <volume>
         29
        </volume>
        <fpage>
         77
        </fpage>
        <lpage>
         84
        </lpage>
        <pub-id pub-id-type="pmid">
         31002597
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B114">
       <label>
        114
       </label>
       <element-citation publication-type="webpage">
        <source>
         Sciencealert: Latest Study Suggests The New Coronavirus Is Also Spreading Via Feces
        </source>
        <comment>
         <ext-link ext-link-type="uri" xlink:href="https://www.sciencealert.com/latest-coronavirus-study-suggests-it-can-also-be-spread-through-poop">
          https://www.sciencealert.com/latest-coronavirus-study-suggests-it-can-also-be-spread-through-poop
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B115">
       <label>
        115
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          D
         </given-names>
        </name>
        <name>
         <surname>
          Hu
         </surname>
         <given-names>
          B
         </given-names>
        </name>
        <name>
         <surname>
          Hu
         </surname>
         <given-names>
          C
         </given-names>
        </name>
        <name>
         <surname>
          Zhu
         </surname>
         <given-names>
          F
         </given-names>
        </name>
        <name>
         <surname>
          Liu
         </surname>
         <given-names>
          X
         </given-names>
        </name>
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          J
         </given-names>
        </name>
        <etal>
        </etal>
        <article-title>
         Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2020
        </year>
        <comment>
         DOI:10.1001/jama.2020.1585
        </comment>
       </element-citation>
      </ref>
      <ref id="B116">
       <label>
        116
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Johnson
         </surname>
         <given-names>
          DF
         </given-names>
        </name>
        <name>
         <surname>
          Druce
         </surname>
         <given-names>
          JD
         </given-names>
        </name>
        <name>
         <surname>
          Birch
         </surname>
         <given-names>
          C
         </given-names>
        </name>
        <name>
         <surname>
          Grayson
         </surname>
         <given-names>
          ML
         </given-names>
        </name>
        <article-title>
         A quantitative assessment of the efficacy of surgical and N95 masks to filter influenza virus in patients with acute influenza infection
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2009
        </year>
        <volume>
         49
        </volume>
        <fpage>
         275
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         19522650
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B117">
       <label>
        117
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Balazy
         </surname>
         <given-names>
          A
         </given-names>
        </name>
        <name>
         <surname>
          Toivola
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        <name>
         <surname>
          Adhikari
         </surname>
         <given-names>
          A
         </given-names>
        </name>
        <name>
         <surname>
          Sivasubramani
         </surname>
         <given-names>
          SK
         </given-names>
        </name>
        <name>
         <surname>
          Reponen
         </surname>
         <given-names>
          T
         </given-names>
        </name>
        <name>
         <surname>
          Grinshpun
         </surname>
         <given-names>
          SA
         </given-names>
        </name>
        <article-title>
         Do N95 respirators provide 95% protection level against airborne viruses, and how adequate are surgical masks?
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <year>
         2006
        </year>
        <volume>
         34
        </volume>
        <fpage>
         51
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         16490606
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B118">
       <label>
        118
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Derrick
         </surname>
         <given-names>
          JL
         </given-names>
        </name>
        <name>
         <surname>
          Gomersall
         </surname>
         <given-names>
          CD
         </given-names>
        </name>
        <article-title>
         Protecting healthcare staff from severe acute respiratory syndrome: filtration capacity of multiple surgical masks
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2005
        </year>
        <volume>
         59
        </volume>
        <fpage>
         365
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         15749326
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B119">
       <label>
        119
       </label>
       <element-citation publication-type="other">
        <name>
         <surname>
          Lu
         </surname>
         <given-names>
          CW
         </given-names>
        </name>
        <name>
         <surname>
          Liu
         </surname>
         <given-names>
          XF
         </given-names>
        </name>
        <name>
         <surname>
          Jia
         </surname>
         <given-names>
          ZF
         </given-names>
        </name>
        <article-title>
         2019-nCoV transmission through the ocular surface must not be ignored
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <comment>
         https://doi.org/10.1016/S01406736(20)303135
        </comment>
       </element-citation>
      </ref>
      <ref id="B120">
       <label>
        120
       </label>
       <element-citation publication-type="webpage">
        <source>
         CDC: Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings (2007)
        </source>
        <comment>
         <ext-link ext-link-type="uri" xlink:href="https://stacks.cdc.gov/view/cdc/61187">
          https://stacks.cdc.gov/view/cdc/61187
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B121">
       <label>
        121
       </label>
       <element-citation publication-type="journal">
        <name>
         <surname>
          Fan
         </surname>
         <given-names>
          C
         </given-names>
        </name>
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          K
         </given-names>
        </name>
        <name>
         <surname>
          Ding
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        <name>
         <surname>
          Lu
         </surname>
         <given-names>
          WL
         </given-names>
        </name>
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          J
         </given-names>
        </name>
        <article-title>
         2020. ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Damage After 2019-nCoV Infection
        </article-title>
        <source>
         medRxiv
        </source>
        <comment>
         DOI: 10.1101/2020.02.12.20022418
        </comment>
       </element-citation>
      </ref>
     </ref-list>
    </back>
    <floats-group>
     <fig id="F1" position="float">
      <label>
       Figure 1
      </label>
      <caption>
       <p>
        Major events that occurred thus far during the outbreak of COVID-19.
       </p>
      </caption>
      <graphic xlink:href="ijbsv16p1753g001">
      </graphic>
     </fig>
     <fig id="F2" position="float">
      <label>
       Figure 2
      </label>
      <caption>
       <p>
        Worldwide distribution of COVID-19 cases on 26 Feb. 2020, according to a coronavirus monitoring system of Johns Hopkins University
        <xref ref-type="bibr" rid="B9">
         9
        </xref>
        ,
        <xref ref-type="bibr" rid="B10">
         10
        </xref>
        .
       </p>
      </caption>
      <graphic xlink:href="ijbsv16p1753g002">
      </graphic>
     </fig>
     <fig id="F3" position="float">
      <label>
       Figure 3
      </label>
      <caption>
       <p>
        The origins and intermediate hosts of SARS-CoV-2, SARS-CoV, and MERS-CoV.
       </p>
      </caption>
      <graphic xlink:href="ijbsv16p1753g003">
      </graphic>
     </fig>
     <fig id="F4" position="float">
      <label>
       Figure 4
      </label>
      <caption>
       <p>
        Immune response of the host to coronavirus infection
        <xref ref-type="bibr" rid="B4">
         4
        </xref>
        ,
        <xref ref-type="bibr" rid="B32">
         32
        </xref>
        -
        <xref ref-type="bibr" rid="B34">
         34
        </xref>
        .
       </p>
      </caption>
      <graphic xlink:href="ijbsv16p1753g004">
      </graphic>
     </fig>
     <fig id="F5" position="float">
      <label>
       Figure 5
      </label>
      <caption>
       <p>
        Comparison of epidemic of COVID-19, SARS, and MERS.
       </p>
      </caption>
      <graphic xlink:href="ijbsv16p1753g005">
      </graphic>
     </fig>
     <table-wrap id="T1" position="float">
      <label>
       Table 1
      </label>
      <caption>
       <p>
        Comparison of SARS-CoV-2 with SARS-CoV and MERS-CoV
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead valign="top">
        <tr>
         <th colspan="1" rowspan="1">
          Comparison items
         </th>
         <th colspan="1" rowspan="1">
          SARS-CoV-2
         </th>
         <th colspan="1" rowspan="1">
          MERS-CoV
         </th>
         <th colspan="1" rowspan="1">
          SARS-CoV
         </th>
         <th colspan="1" rowspan="1">
          Reference
         </th>
        </tr>
       </thead>
       <tbody valign="top">
        <tr>
         <td colspan="1" rowspan="1">
          <bold>
           Characteristics
          </bold>
         </td>
         <td colspan="1" rowspan="1">
         </td>
         <td colspan="1" rowspan="1">
         </td>
         <td colspan="1" rowspan="1">
         </td>
         <td colspan="1" rowspan="7">
          <xref ref-type="bibr" rid="B6">
           6
          </xref>
          ,
          <xref ref-type="bibr" rid="B37">
           37
          </xref>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Date extracted from
         </td>
         <td colspan="1" rowspan="1">
          Dec. 2020 - Feb. 2020
         </td>
         <td colspan="1" rowspan="1">
          Sept. 2012
         </td>
         <td colspan="1" rowspan="1">
          Dec. 2003
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Place of origin
         </td>
         <td colspan="1" rowspan="1">
          Wuhan, China
         </td>
         <td colspan="1" rowspan="1">
          Jeddah, Saudi Arabia
         </td>
         <td colspan="1" rowspan="1">
          Guangdong China
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Age range
         </td>
         <td colspan="1" rowspan="1">
          56 (22-92)
         </td>
         <td colspan="1" rowspan="1">
          56 (14-94)
         </td>
         <td colspan="1" rowspan="1">
          39.9 (1-91)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Male/Female sex ratio
         </td>
         <td colspan="1" rowspan="1">
          1:3:1
         </td>
         <td colspan="1" rowspan="1">
          3.3:1
         </td>
         <td colspan="1" rowspan="1">
          1.1.25
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Mortality rate
         </td>
         <td colspan="1" rowspan="1">
          2%
         </td>
         <td colspan="1" rowspan="1">
          34%
         </td>
         <td colspan="1" rowspan="1">
          9.6%
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Confirmed cases (Global)
         </td>
         <td colspan="1" rowspan="1">
          24554
         </td>
         <td colspan="1" rowspan="1">
          2494
         </td>
         <td colspan="1" rowspan="1">
          8096
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          R
          <sub>
           0
          </sub>
         </td>
         <td colspan="1" rowspan="1">
          4.7 - 6.6
         </td>
         <td colspan="1" rowspan="1">
          0.45 - 0.91
         </td>
         <td colspan="1" rowspan="1">
          0.86 - 1.88
         </td>
         <td colspan="1" rowspan="2">
          <xref ref-type="bibr" rid="B37">
           37
          </xref>
          ,
          <xref ref-type="bibr" rid="B42">
           42
          </xref>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Incubation period (day)
         </td>
         <td colspan="1" rowspan="1">
          7 - 14
         </td>
         <td colspan="1" rowspan="1">
          5.0 - 6.9
         </td>
         <td colspan="1" rowspan="1">
          4.4 - 6.9
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          <bold>
           Symptoms
          </bold>
         </td>
         <td colspan="1" rowspan="1">
         </td>
         <td colspan="1" rowspan="1">
         </td>
         <td colspan="1" rowspan="1">
         </td>
         <td colspan="1" rowspan="6">
          <xref ref-type="bibr" rid="B6">
           6
          </xref>
          ,
          <xref ref-type="bibr" rid="B34">
           34
          </xref>
          ,
          <xref ref-type="bibr" rid="B37">
           37
          </xref>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Fever
         </td>
         <td colspan="1" rowspan="1">
          258 (93%)
         </td>
         <td colspan="1" rowspan="1">
          98%
         </td>
         <td colspan="1" rowspan="1">
          99-100%
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Dry cough
         </td>
         <td colspan="1" rowspan="1">
          194 (70%)
         </td>
         <td colspan="1" rowspan="1">
          47%
         </td>
         <td colspan="1" rowspan="1">
          29-75%
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Dyspnea
         </td>
         <td colspan="1" rowspan="1">
          96 (35%)
         </td>
         <td colspan="1" rowspan="1">
          72%
         </td>
         <td colspan="1" rowspan="1">
          40-42%
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Diarrhea
         </td>
         <td colspan="1" rowspan="1">
          17 (6%)
         </td>
         <td colspan="1" rowspan="1">
          26%
         </td>
         <td colspan="1" rowspan="1">
          20-25%
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Sore throat
         </td>
         <td colspan="1" rowspan="1">
          10 (4%)
         </td>
         <td colspan="1" rowspan="1">
          21%
         </td>
         <td colspan="1" rowspan="1">
          13-25%
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
     <table-wrap id="T2" position="float">
      <label>
       Table 2
      </label>
      <caption>
       <p>
        Treatments of COVID-19
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead valign="top">
        <tr>
         <th colspan="1" rowspan="1">
          Treatment
         </th>
         <th colspan="1" rowspan="1">
          Efficacy
         </th>
         <th colspan="1" rowspan="1">
          References
         </th>
        </tr>
       </thead>
       <tbody valign="top">
        <tr>
         <td colspan="1" rowspan="1">
          General oxygen therapy, high-flow oxygen/noninvasive ventilation, and invasive mechanical ventilation, conservation fluid management, management of septic shock, infection control
         </td>
         <td colspan="1" rowspan="1">
          Respiratory supports
         </td>
         <td colspan="1" rowspan="1">
          <xref ref-type="bibr" rid="B7">
           7
          </xref>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Antiviral therapy
         </td>
         <td colspan="1" rowspan="1">
          Reduce the viral load
         </td>
         <td colspan="1" rowspan="1">
          <xref ref-type="bibr" rid="B63">
           63
          </xref>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Remdesivir
         </td>
         <td colspan="1" rowspan="1">
          -
         </td>
         <td colspan="1" rowspan="1">
          <xref ref-type="bibr" rid="B64">
           64
          </xref>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Steroids
         </td>
         <td colspan="1" rowspan="1">
          Reduce the severity of inflammatory damage
         </td>
         <td colspan="1" rowspan="1">
          <xref ref-type="bibr" rid="B65">
           65
          </xref>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Psychological supports
         </td>
         <td colspan="1" rowspan="1">
          Relieve stress and improve mental health
         </td>
         <td colspan="1" rowspan="1">
          <xref ref-type="bibr" rid="B66">
           66
          </xref>
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
     <table-wrap id="T3" position="float">
      <label>
       Table 3
      </label>
      <caption>
       <p>
        Prognostic factors for COVID-19 in comparison with SARS and MERS
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead valign="top">
        <tr>
         <th align="center" colspan="1" rowspan="1">
          Disease
         </th>
         <th align="center" colspan="1" rowspan="1">
          Laboratory results
         </th>
         <th align="center" colspan="1" rowspan="1">
          Chest radiography
         </th>
         <th align="center" colspan="1" rowspan="1">
          Others
         </th>
         <th align="center" colspan="1" rowspan="1">
          Reference
         </th>
        </tr>
       </thead>
       <tbody valign="top">
        <tr>
         <td align="center" colspan="1" rowspan="1">
          COVID-19
         </td>
         <td align="center" colspan="1" rowspan="1">
          CRP
          <break>
          </break>
          AST
          <break>
          </break>
          ALT
          <break>
          </break>
          CK
          <break>
          </break>
          LDH
          <break>
          </break>
          D-dimer
          <break>
          </break>
          Lymphopenia
         </td>
         <td align="center" colspan="1" rowspan="1">
          Chest radiography
         </td>
         <td align="center" colspan="1" rowspan="1">
          Age
          <break>
          </break>
          Gender
          <break>
          </break>
          Pregnancy
          <break>
          </break>
          Viral load
          <break>
          </break>
          Underlying disease
         </td>
         <td align="center" colspan="1" rowspan="1">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          SARS
         </td>
         <td align="center" colspan="1" rowspan="1">
          CRP
          <break>
          </break>
          AST
          <break>
          </break>
          ALT
          <break>
          </break>
          CK
          <break>
          </break>
          LDH
          <break>
          </break>
          D-dimer
          <break>
          </break>
          Low platelet
          <break>
          </break>
          Plasma electrolyte
         </td>
         <td align="center" colspan="1" rowspan="1">
          Chest radiography
         </td>
         <td align="center" colspan="1" rowspan="1">
          Age
          <break>
          </break>
          Gender
          <break>
          </break>
          Pregnancy
          <break>
          </break>
          Underlying diseases
         </td>
         <td align="center" colspan="1" rowspan="1">
          <xref ref-type="bibr" rid="B55">
           55
          </xref>
          ,
          <xref ref-type="bibr" rid="B59">
           59
          </xref>
          ,
          <xref ref-type="bibr" rid="B65">
           65
          </xref>
          ,
          <xref ref-type="bibr" rid="B94">
           94
          </xref>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          MERS
         </td>
         <td align="center" colspan="1" rowspan="1">
          Neutrophilia
          <break>
          </break>
          Lymphopenia
          <break>
          </break>
          Serum creatinine
          <break>
          </break>
          LDH
         </td>
         <td align="center" colspan="1" rowspan="1">
          The diffuse or brochopneumonia
         </td>
         <td align="center" colspan="1" rowspan="1">
          Age,
          <break>
          </break>
          Chronic kidney disease,
          <break>
          </break>
          Hypertension,
          <break>
          </break>
          Viral load
         </td>
         <td align="center" colspan="1" rowspan="1">
          <xref ref-type="bibr" rid="B95">
           95
          </xref>
          -
          <xref ref-type="bibr" rid="B98">
           98
          </xref>
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
    </floats-group>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Int J Environ Res Public Health
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Int J Environ Res Public Health
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       ijerph
      </journal-id>
      <journal-title-group>
       <journal-title>
        International Journal of Environmental Research and Public Health
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1661-7827
      </issn>
      <issn pub-type="epub">
       1660-4601
      </issn>
      <publisher>
       <publisher-name>
        MDPI
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32155789
      </article-id>
      <article-id pub-id-type="pmc">
       7084952
      </article-id>
      <article-id pub-id-type="doi">
       10.3390/ijerph17051729
      </article-id>
      <article-id pub-id-type="publisher-id">
       ijerph-17-01729
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         https://orcid.org/0000-0001-8612-5194
        </contrib-id>
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Cuiyan
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-ijerph-17-01729">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Pan
         </surname>
         <given-names>
          Riyu
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-ijerph-17-01729">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wan
         </surname>
         <given-names>
          Xiaoyang
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-ijerph-17-01729">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Tan
         </surname>
         <given-names>
          Yilin
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-ijerph-17-01729">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Xu
         </surname>
         <given-names>
          Linkang
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-ijerph-17-01729">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         https://orcid.org/0000-0002-7092-9566
        </contrib-id>
        <name>
         <surname>
          Ho
         </surname>
         <given-names>
          Cyrus S.
         </given-names>
        </name>
        <xref ref-type="aff" rid="af2-ijerph-17-01729">
         2
        </xref>
        <xref ref-type="aff" rid="af3-ijerph-17-01729">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         https://orcid.org/0000-0001-9629-4493
        </contrib-id>
        <name>
         <surname>
          Ho
         </surname>
         <given-names>
          Roger C.
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-ijerph-17-01729">
         1
        </xref>
        <xref ref-type="aff" rid="af3-ijerph-17-01729">
         3
        </xref>
        <xref ref-type="aff" rid="af4-ijerph-17-01729">
         4
        </xref>
        <xref ref-type="corresp" rid="c1-ijerph-17-01729">
         *
        </xref>
       </contrib>
      </contrib-group>
      <aff id="af1-ijerph-17-01729">
       <label>
        1
       </label>
       Institute of Cognitive Neuroscience, Faculty of Education, Huaibei Normal University, Huaibei 235000, China;
       <email>
        wcy@chnu.edu.cn
       </email>
       (C.W.);
       <email>
        riyu0402@chnu.edu.cn
       </email>
       (R.P.);
       <email>
        wming624@sina.com
       </email>
       (X.W.);
       <email>
        977367tan@sina.com
       </email>
       (Y.T.);
       <email>
        lgb@chnu.edu.cn
       </email>
       (L.X.)
      </aff>
      <aff id="af2-ijerph-17-01729">
       <label>
        2
       </label>
       Department of Psychological Medicine, National University Health System, Kent Ridge 119228, Singapore;
       <email>
        su_hui_ho@nuhs.edu.sg
       </email>
      </aff>
      <aff id="af3-ijerph-17-01729">
       <label>
        3
       </label>
       Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Kent Ridge 119228, Singapore
      </aff>
      <aff id="af4-ijerph-17-01729">
       <label>
        4
       </label>
       Institute of Health Innovation and Technology (iHealthtech), National University of Singapore, Kent Ridge 119077, Singapore
      </aff>
      <author-notes>
       <corresp id="c1-ijerph-17-01729">
        <label>
         *
        </label>
        Correspondence:
        <email>
         pcmrhcm@nus.edu.sg
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="epub">
       <day>
        06
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <pub-date pub-type="ppub">
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <volume>
       17
      </volume>
      <issue>
       5
      </issue>
      <elocation-id>
       1729
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         14
        </day>
        <month>
         2
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         03
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2020 by the authors.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <license license-type="open-access">
        <license-p>
         Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          http://creativecommons.org/licenses/by/4.0/
         </ext-link>
         ).
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        <italic>
         Background:
        </italic>
        The 2019 coronavirus disease (COVID-19) epidemic is a public health emergency of international concern and poses a challenge to psychological resilience. Research data are needed to develop evidence-driven strategies to reduce adverse psychological impacts and psychiatric symptoms during the epidemic. The aim of this study was to survey the general public in China to better understand their levels of psychological impact, anxiety, depression, and stress during the initial stage of the COVID-19 outbreak. The data will be used for future reference.
        <italic>
         Methods:
        </italic>
        From 31 January to 2 February 2020, we conducted an online survey using snowball sampling techniques. The online survey collected information on demographic data, physical symptoms in the past 14 days, contact history with COVID-19, knowledge and concerns about COVID-19, precautionary measures against COVID-19, and additional information required with respect to COVID-19. Psychological impact was assessed by the Impact of Event Scale-Revised (IES-R), and mental health status was assessed by the Depression, Anxiety and Stress Scale (DASS-21).
        <italic>
         Results:
        </italic>
        This study included 1210 respondents from 194 cities in China. In total, 53.8% of respondents rated the psychological impact of the outbreak as moderate or severe; 16.5% reported moderate to severe depressive symptoms; 28.8% reported moderate to severe anxiety symptoms; and 8.1% reported moderate to severe stress levels. Most respondents spent 20–24 h per day at home (84.7%); were worried about their family members contracting COVID-19 (75.2%); and were satisfied with the amount of health information available (75.1%). Female gender, student status, specific physical symptoms (e.g., myalgia, dizziness, coryza), and poor self-rated health status were significantly associated with a greater psychological impact of the outbreak and higher levels of stress, anxiety, and depression (
        <italic>
         p
        </italic>
        &lt; 0.05). Specific up-to-date and accurate health information (e.g., treatment, local outbreak situation) and particular precautionary measures (e.g., hand hygiene, wearing a mask) were associated with a lower psychological impact of the outbreak and lower levels of stress, anxiety, and depression (
        <italic>
         p
        </italic>
        &lt; 0.05).
        <italic>
         Conclusions:
        </italic>
        During the initial phase of the COVID-19 outbreak in China, more than half of the respondents rated the psychological impact as moderate-to-severe, and about one-third reported moderate-to-severe anxiety. Our findings identify factors associated with a lower level of psychological impact and better mental health status that can be used to formulate psychological interventions to improve the mental health of vulnerable groups during the COVID-19 epidemic.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        anxiety
       </kwd>
       <kwd>
        coronavirus
       </kwd>
       <kwd>
        depression
       </kwd>
       <kwd>
        epidemic
       </kwd>
       <kwd>
        knowledge
       </kwd>
       <kwd>
        precaution
       </kwd>
       <kwd>
        psychological impact
       </kwd>
       <kwd>
        respiratory symptoms
       </kwd>
       <kwd>
        stress
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec1-ijerph-17-01729" sec-type="intro">
     <title>
      1. Introduction
     </title>
     <p>
      The 2019 coronavirus disease (COVID-19) epidemic in China is a global health threat [
      <xref ref-type="bibr" rid="B1-ijerph-17-01729">
       1
      </xref>
      ], and is by far the largest outbreak of atypical pneumonia since the severe acute respiratory syndrome (SARS) outbreak in 2003. Within weeks of the initial outbreak the total number of cases and deaths exceeded those of SARS [
      <xref ref-type="bibr" rid="B2-ijerph-17-01729">
       2
      </xref>
      ]. The outbreak was first revealed in late December 2019 when clusters of pneumonia cases of unknown etiology were found to be associated with epidemiologically linked exposure to a seafood market and untraced exposures in the city of Wuhan of Hubei Province [
      <xref ref-type="bibr" rid="B3-ijerph-17-01729">
       3
      </xref>
      ]. Since then, the number of cases has continued to escalate exponentially within and beyond Wuhan, spreading to all 34 regions of China by 30 January 2020. On the same day, the World Health Organization (WHO) declared the COVID-19 outbreak a public health emergency of international concern [
      <xref ref-type="bibr" rid="B4-ijerph-17-01729">
       4
      </xref>
      ].
     </p>
     <p>
      COVID-19, similarly to SARS, is a beta-coronavirus that can be spread to humans through intermediate hosts such as bats [
      <xref ref-type="bibr" rid="B5-ijerph-17-01729">
       5
      </xref>
      ], though the actual route of transmission is still debatable. Human-to-human transmission has been observed via virus-laden respiratory droplets, as a growing number of patients reportedly did not have animal market exposure, and cases have also occurred in healthcare workers [
      <xref ref-type="bibr" rid="B6-ijerph-17-01729">
       6
      </xref>
      ]. Transmissibility of COVID-19 as indicated by its reproductive number has been estimated at 4.08 [
      <xref ref-type="bibr" rid="B7-ijerph-17-01729">
       7
      </xref>
      ], suggesting that on average, every case of COVID-19 will create up to 4 new cases. The reporting rate after 17 January 2020 has been considered to have increased 21-fold in comparison to the situation in the first half of January 2020 [
      <xref ref-type="bibr" rid="B8-ijerph-17-01729">
       8
      </xref>
      ]. The average incubation period is estimated to be 5.2 days, with significant variation among patients [
      <xref ref-type="bibr" rid="B9-ijerph-17-01729">
       9
      </xref>
      ], and it may be capable of asymptomatic spread [
      <xref ref-type="bibr" rid="B10-ijerph-17-01729">
       10
      </xref>
      ,
      <xref ref-type="bibr" rid="B11-ijerph-17-01729">
       11
      </xref>
      ]. Symptoms of infection include fever, chills, cough, coryza, sore throat, breathing difficulty, myalgia, nausea, vomiting, and diarrhea [
      <xref ref-type="bibr" rid="B12-ijerph-17-01729">
       12
      </xref>
      ]. Older men with medical comorbidities are more likely to get infected, with worse outcomes [
      <xref ref-type="bibr" rid="B12-ijerph-17-01729">
       12
      </xref>
      ]. Severe cases can lead to cardiac injury, respiratory failure, acute respiratory distress syndrome, and death [
      <xref ref-type="bibr" rid="B13-ijerph-17-01729">
       13
      </xref>
      ]. The provisional case fatality rate by WHO is around 2%, but some researchers estimate the rate to range from 0.3% to 0.6% [
      <xref ref-type="bibr" rid="B14-ijerph-17-01729">
       14
      </xref>
      ].
     </p>
     <p>
      Since the outbreak, response efforts by the China government have been swift, and three weeks into the epidemic, in an unprecedented move to retard the spread of the virus, a lockdown was imposed on Wuhan on 23 January, with travel restrictions. Within days, the quarantine was extended to additional provinces and cities, affecting more than 50 million people in total. Many stayed at home and socially isolated themselves to prevent being infected, leading to a “desperate plea” [
      <xref ref-type="bibr" rid="B15-ijerph-17-01729">
       15
      </xref>
      ]. There have also been accounts of shortages of masks and health equipment. The ongoing COVID-19 epidemic is inducing fear, and a timely understanding of mental health status is urgently needed for society [
      <xref ref-type="bibr" rid="B16-ijerph-17-01729">
       16
      </xref>
      ]. Previous research has revealed a profound and wide range of psychosocial impacts on people at the individual, community, and international levels during outbreaks of infection. On an individual level, people are likely to experience fear of falling sick or dying themselves, feelings of helplessness, and stigma [
      <xref ref-type="bibr" rid="B17-ijerph-17-01729">
       17
      </xref>
      ]. During one influenza outbreak, around 10% to 30% of general public were very or fairly worried about the possibility of contracting the virus [
      <xref ref-type="bibr" rid="B18-ijerph-17-01729">
       18
      </xref>
      ]. With the closure of schools and business, negative emotions experienced by individuals are compounded [
      <xref ref-type="bibr" rid="B19-ijerph-17-01729">
       19
      </xref>
      ]. During the SARS outbreak, many studies investigated the psychological impact on the non-infected community, revealing significant psychiatric morbidities which were found to be associated with younger age and increased self-blame [
      <xref ref-type="bibr" rid="B20-ijerph-17-01729">
       20
      </xref>
      ]. Those who were older, of female gender, more highly educated, with higher risk perceptions of SARS, a moderate anxiety level, a positive contact history, and those with SARS-like symptoms were more likely to take precautionary measures against the infection [
      <xref ref-type="bibr" rid="B21-ijerph-17-01729">
       21
      </xref>
      ].
     </p>
     <p>
      Currently, there is no known information on the psychological impact and mental health of the general public during the peak of the COVID-19 epidemic. This is especially pertinent with the uncertainty surrounding an outbreak of such unparalleled magnitude. Based on our understanding, most of the research related to this outbreak focuses on identifying the epidemiology and clinical characteristics of infected patients [
      <xref ref-type="bibr" rid="B6-ijerph-17-01729">
       6
      </xref>
      ,
      <xref ref-type="bibr" rid="B12-ijerph-17-01729">
       12
      </xref>
      ], the genomic characterization of the virus [
      <xref ref-type="bibr" rid="B22-ijerph-17-01729">
       22
      </xref>
      ], and challenges for global health governance [
      <xref ref-type="bibr" rid="B23-ijerph-17-01729">
       23
      </xref>
      ]. However, there are no research articles examining the psychological impact on COVID-19 on the general population in China.
     </p>
     <p>
      Therefore, this present study represents the first psychological impact and mental health survey conducted in the general population in China within the first two weeks of the COVID-19 outbreak. This study aims to establish the prevalence of psychiatric symptoms and identify risk and protective factors contributing to psychological stress. This may assist government agencies and healthcare professionals in safeguarding the psychological wellbeing of the community in the face of COVID-19 outbreak expansion in China and different parts of the world.
     </p>
    </sec>
    <sec id="sec2-ijerph-17-01729" sec-type="methods">
     <title>
      2. Methods
     </title>
     <sec id="sec2dot1-ijerph-17-01729" sec-type="subjects">
      <title>
       2.1. Setting and Participants
      </title>
      <p>
       We adopted a cross-sectional survey design to assess the public’s immediate psychological response during the epidemic of COVID-19 by using an anonymous online questionnaire. A snowball sampling strategy, focused on recruiting the general public living in mainland China during the epidemic of COVID-19, was utilized. The online survey was first disseminated to university students and they were encouraged to pass it on to others.
      </p>
     </sec>
     <sec id="sec2dot2-ijerph-17-01729">
      <title>
       2.2. Procedure
      </title>
      <p>
       As the Chinese Government recommended the public to minimize face-to-face interaction and isolate themselves at home, potential respondents were electronically invited by existing study respondents. They completed the questionnaires in Chinese through an online survey platform (‘SurveyStar’, Changsha Ranxing Science and Technology, Shanghai, China). Expedited ethics approval was obtained from the Institutional Review Board of the Huaibei Normal University (HBU-IRB-2020-001), which conformed to the principles embodied in the Declaration of Helsinki. Information about this study was posted on a dedicated university website. All respondents provided informed consent. Data collection took place over three days (31 January–2 February 2020) after the WHO declared the COVID-19 outbreak as a public health emergency of international concern.
      </p>
     </sec>
     <sec id="sec2dot3-ijerph-17-01729">
      <title>
       2.3. Survey Development
      </title>
      <p>
       Previous surveys on the psychological impacts of SARS and influenza outbreaks were reviewed [
       <xref ref-type="bibr" rid="B18-ijerph-17-01729">
        18
       </xref>
       ,
       <xref ref-type="bibr" rid="B21-ijerph-17-01729">
        21
       </xref>
       ,
       <xref ref-type="bibr" rid="B24-ijerph-17-01729">
        24
       </xref>
       ]. Authors included additional questions related to the COVID-19 outbreak. The structured questionnaire consisted of questions that covered several areas: (1) demographic data; (2) physical symptoms in the past 14 days; (3) contact history with COVID-19 in the past 14 days; (4) knowledge and concerns about COVID-19; (5) precautionary measures against COVID-19 in the past 14 days; (6) additional information required with respect to COVID-19; (7) the psychological impact of the COVID-19 outbreak; and (8) mental health status.
      </p>
      <p>
       Sociodemographic data were collected on gender, age, education, residential location in the past 14 days, marital status, employment status, monthly income, parental status, and household size. Physical symptom variables in the past 14 days included fever, chills, headache, myalgia, cough, difficulty in breathing, dizziness, coryza, sore throat, and persistent fever, as well as persistent fever and cough or difficulty breathing. Respondents were asked to rate their physical health status and state any history of chronic medical illness. Health service utilization variables in the past 14 days included consultation with a doctor in the clinic, admission to the hospital, being quarantined by a health authority, and being tested for COVID-19. Contact history variables included close contact with an individual with confirmed COVID-19, indirect contact with an individual with confirmed COVID-19, and contact with an individual with suspected COVID-19 or infected materials.
      </p>
      <p>
       Knowledge about COVID-19 variables included knowledge about the routes of transmission, level of confidence in diagnosis, level of satisfaction of health information about COVID-19, the trend of new cases and death, and potential treatment for COVID-19 infection. Respondents were asked to indicate their source of information. The actual number of confirmed cases of COVID-19 and deaths in the city on the day of the survey were collected. Concern about COVID-19 variables included self and other family members contracting COVID-19 and the chance of surviving if infected.
      </p>
      <p>
       Precautionary measures against COVID-19 variables included avoidance of sharing of utensils (e.g., chopsticks) during meals, covering mouth when coughing and sneezing, washing hands with soap, washing hands immediately after coughing, sneezing, or rubbing the nose, washing hands after touching contaminated objects, and wearing a mask regardless of the presence or absence of symptoms. The respondents were asked the average number of hours staying at home per day to avoid COVID-19. Respondents were also asked whether they felt too much -unnecessary worry had been made about the COVID-19 epidemic. Additional health information about COVID-19 needed by respondents included more information about symptoms after contraction of COVID-19, routes of transmission, treatment, prevention of the spread of COVID-19, local outbreaks, travel advice, and other measures imposed by other countries.
      </p>
      <p>
       The psychological impact of COVID-19 was measured using the Impact of Event Scale-Revised (IES-R). The IES-R is a self-administered questionnaire that has been well-validated in the Chinese population for determining the extent of psychological impact after exposure to a public health crisis within one week of exposure [
       <xref ref-type="bibr" rid="B25-ijerph-17-01729">
        25
       </xref>
       ]. This 22-item questionnaire is composed of three subscales and aims to measure the mean avoidance, intrusion, and hyperarousal [
       <xref ref-type="bibr" rid="B26-ijerph-17-01729">
        26
       </xref>
       ]. The total IES-R score was divided into 0–23 (normal), 24–32 (mild psychological impact), 33–36 (moderate psychological impact), and &gt;37 (severe psychological impact) [
       <xref ref-type="bibr" rid="B27-ijerph-17-01729">
        27
       </xref>
       ].
      </p>
      <p>
       Mental health status was measured using the Depression, Anxiety and Stress Scale (DASS-21) and calculations of scores were based on the previous study [
       <xref ref-type="bibr" rid="B28-ijerph-17-01729">
        28
       </xref>
       ]. Questions 3, 5, 10, 13, 16, 17 and 21formed the depression subscale. The total depression subscale score was divided into normal (0–9), mild depression (10–12), moderate depression (13–20), severe depression (21–27), and extremely severe depression (28–42). Questions 2, 4, 7, 9, 15, 19, and 20 formed the anxiety subscale. The total anxiety subscale score was divided into normal (0–6), mild anxiety (7–9), moderate anxiety (10–14), severe anxiety (15–19), and extremely severe anxiety (20–42). Questions 1, 6, 8, 11, 12, 14, and 18 formed the stress subscale. The total stress subscale score was divided into normal (0–10), mild stress (11–18), moderate stress (19–26), severe stress (27–34), and extremely severe stress (35–42). The DASS has been demonstrated to be a reliable and valid measure in assessing mental health in the Chinese population [
       <xref ref-type="bibr" rid="B29-ijerph-17-01729">
        29
       </xref>
       ,
       <xref ref-type="bibr" rid="B30-ijerph-17-01729">
        30
       </xref>
       ]. The DASS was previously used in research related to SARS [
       <xref ref-type="bibr" rid="B31-ijerph-17-01729">
        31
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec2dot4-ijerph-17-01729">
      <title>
       2.4. Statistical Analysis
      </title>
      <p>
       Descriptive statistics were calculated for sociodemographic characteristics, physical symptoms and health service utilization variables, contact history variables, knowledge and concern-related variables, precautionary measure variables, and additional health information variables. Percentages of response were calculated according to the number of respondents per response with respect to the number of total responses of a question. The scores of the IES-R and DASS subscales were expressed as mean and standard deviation. We used linear regressions to calculate the univariate associations between sociodemographic characteristics, physical symptom and health service utilization variables, contact history variables, knowledge and concern variables, precautionary measure variables, additional health information variables, and the IES-S score as well as the subscales of the DASS. All tests were two-tailed, with a significance level of
       <italic>
        p
       </italic>
       &lt; 0.05. Statistical analysis was performed using SPSS Statistic 21.0 (IBM SPSS Statistics, New York, United States).
      </p>
     </sec>
    </sec>
    <sec id="sec3-ijerph-17-01729" sec-type="results">
     <title>
      3. Results
     </title>
     <sec id="sec3dot1-ijerph-17-01729">
      <title>
       3.1. Development of the COVID-19 Epidemic from January 7 to February 2 2020
      </title>
      <p>
       <xref ref-type="fig" rid="ijerph-17-01729-f001">
        Figure 1
       </xref>
       shows the development trend of the COVID-19 epidemic in China in January and February 2020. Since China first announced the national epidemic data on 20 January 2020, the number of confirmed cases, suspected cases, recovered individuals, and deaths related to COVID-19 infection have continued to escalate, with a sharp increase in the number of suspected cases after 26 January 2020. Both children and the elderly have been particularly vulnerable to the virus, with the youngest confirmed case being that of a 9-month-old infant.
      </p>
     </sec>
     <sec id="sec3dot2-ijerph-17-01729">
      <title>
       3.2. Survey Respondents
      </title>
      <p>
       We received responses from 1304 respondents, and 102 respondents did not complete the questionnaires. Eventually, we included 1210 respondents from 194 cities in China who had completed the questionnaires (completion rate: 92.79%). Overall, 1120 respondents submitted the questionnaires on the first day (31 January), 86 respondents submitted the questionnaires on the second day (1 February), and only 4 respondents submitted the questionnaires on the third day (2 February).
      </p>
      <p>
       The psychological impact of COVID-19 outbreak, measured using the IES-R scale, revealed a sample mean score of 32.98 (SD = 15.42). Of all respondents, 296 (24.5%) reported minimal psychological impact (score
       <underline>
        &lt;
       </underline>
       23); 263 (21.7%) rated mild psychological impact (scores 24–32); and 651 (53.8%) reported a moderate or severe psychological impact (score &gt; 33). Respondents’ depression, anxiety and stress levels, measured using the DASS 21-item scale, revealed a sample mean score of 20.16 (SD = 20.42). For the depression subscale, 843 (69.7%) were considered to have a normal score (score: 0–9); 167 (13.8%) were considered to suffer from mild depression (score: 10–12); 148 (12.2%) were considered to suffer from moderate depression (score: 13–20); and 52 (4.3%) were considered to suffer from severe and extremely severe depression (score: 21–42). For the anxiety subscale, 770 (63.6%) were considered to have a normal score (score: 0–6); 91 (7.5%) were considered to suffer from mild anxiety (score: 7–9); 247 (20.4%) were considered to suffer from moderate anxiety (score: 10–14); and 102 (8.4%) were considered to suffer from severe and extremely severe anxiety (score: 15–42). For the stress subscale, 821 (67.9%) were considered to have a normal score (score: 0–10); 292 (24.1%) were considered to suffer from mild stress (score: 11–18); 66 (5.5%) were considered to suffer from moderate stress (score: 19–26); and 31 (2.6%) were considered to suffer from severe and extremely severe stress (score: 27–42).
      </p>
     </sec>
     <sec id="sec3dot3-ijerph-17-01729">
      <title>
       3.3. Sociodemographic Variables and Psychological Impact
      </title>
      <p>
       Sociodemographic characteristics are presented in
       <xref ref-type="table" rid="ijerph-17-01729-t001">
        Table 1
       </xref>
       . The majority of respondents were women (67.3%), aged 21.4 to 30.8 years (53.1%), married (76.4%), with a household size of 3–5 people (80.7%), with children (67.4%), students (52.8%), and well educated (87.9% ≥ bachelor’s degree). Male gender was significantly associated with lower scores in the IES-R (B = −0.20, 95% Confidence Interval (95% CI) −0.35 to −0.05) but higher scores in the DASS stress subscale (B = 0.10, 95% CI: 0.02 to 0.19), DASS anxiety subscale (B = 0.19 95% CI: 0.05 to 0.33), and DASS depression subscale (B = 0.12, 95% CI: 0.01 to 0.23). Student status was significantly associated with higher IES-R (B = 0.20, 95% CI: 0.05 to 0.35), DASS stress subscale (B = 0.11, 95% CI: 0.02 to 0.19), and DASS anxiety subscale (B = 0.16, 95% CI: 0.02 to 0.30) scores as compared to those who were employed. Uneducated status was significantly associated with higher DASS depression subscale scores (B = 1.81, 95% CI: 0.46 to 3.16). Other sociodemographic variables including age, parental status, marital status, and household size were not associated with IES-R and DASS subscale scores.
      </p>
     </sec>
     <sec id="sec3dot4-ijerph-17-01729">
      <title>
       3.4. Symptoms and Psychological Impact
      </title>
      <p>
       For physical symptoms,
       <xref ref-type="table" rid="ijerph-17-01729-t002">
        Table 2
       </xref>
       shows that 0.5% of the sample reported a fever of 38 °C for at least one day within the previous two weeks. Some respondents reported a range of physical symptoms, most frequently coryza (16.9%), cough (13.9%), sore throat (11.5%), headache (9.7%), myalgia (7.9%), dizziness (7.3%), chills (3.5%), fever (0.5%), and breathing difficulty (0.4%). Around 0.3% of respondents reported a dyad of symptoms such as fever with cough or fever with breathing difficulty. Overall, 793 respondents reported no symptoms (60.81%); 182 respondents reported one symptom (15.04%); 114 respondents reported two symptoms (9.42%); and 68 respondents reported three symptoms (5.62%). Linear regression showed that chills, myalgia, cough, dizziness, coryza, and sore throat were significantly associated with higher IES-R, DASS stress subscale, DASS anxiety subscale, and DASS depression subscale scores, while breathing difficulty was associated with only DASS anxiety and depression subscale scores. In contrast, the presence of a dyad of symptoms such as fever with cough or breathing difficulty was not associated with IES-R, DASS stress subscale, DASS anxiety subscale, and DASS depression subscale scores.
      </p>
     </sec>
     <sec id="sec3dot5-ijerph-17-01729">
      <title>
       3.5. Health Status and Psychological Impact
      </title>
      <p>
       In the prior two weeks, 3.5% of respondents had consulted a doctor in the clinic; 0.3% had been admitted to the hospital; 0.9% had been tested for COVID-19; 2.1% had been under quarantine by a health authority; and 68.3% reported good or very good health status. Around 93.6% of respondents did not suffer from any chronic illness, and 92.4% were covered by medical insurance. Clinic consultations (B = 0.38, 95% CI: 0.02 to 0.73) and hospitalizations (B = 1.23, 95 % CI: 0.09 to 2.36) were significantly associated with higher DASS anxiety subscale score. Poor or very poor self-rated health status was significantly associated with a greater psychological impact of the outbreak (B = 0.76, 95% CI: 0.02 to 1.49), and higher DASS stress subscale (B = 0.45, 95% CI: 0.02 to 0.88), DASS anxiety subscale (B = 0.90, 95% CI: 0.22 to 1.58), and DASS depression subscale (B = 0.65, 95% CI: 0.10 to 1.20) scores as compared to those with very good or good self-rated health status. History of chronic illness was significantly associated with higher IES-R, DASS stress subscale, DASS anxiety subscale, and DASS depression subscale scores.
      </p>
     </sec>
     <sec id="sec3dot6-ijerph-17-01729">
      <title>
       3.6. Contact History and Psychological Impact
      </title>
      <p>
       <xref ref-type="table" rid="ijerph-17-01729-t003">
        Table 3
       </xref>
       shows the contact history of confirmed and suspected cases of COVID-19. Overall, 1% of respondents had been in contact with an individual with suspected COVID-19 or infected materials; 0.5% reported indirect contact with an individual with confirmed COVID-19; and 0.3% reported close contact with an individual with confirmed COVID-19. Variables in the contact history were not associated with IES-R and DASS scores, with the exception of contact with an individual with suspected COVID-19 or infected materials, which were significantly associated with anxiety (B = 0.98, 95% CI: 0.32 to 1.64).
      </p>
     </sec>
     <sec id="sec3dot7-ijerph-17-01729">
      <title>
       3.7. Knowledge about COVID-19 and Psychological Impact
      </title>
      <p>
       Regarding knowledge about COVID-19,
       <xref ref-type="table" rid="ijerph-17-01729-t004">
        Table 4
       </xref>
       also shows that the most common perceived route of transmission was through droplets (92.1%), followed by contaminated objects (73.7%), and airborne transmission (60.5%). Nearly all respondents had heard that the number of infected individuals had increased (98.8%), the number of deaths had increased (97.8%), and the number of recovered individuals had increased (93.3%). The most common source of health information about COVID-19 was from the Internet (93.5%). The majority of respondents (75.1%) were very satisfied or fairly satisfied with the amount of health information available. Dissatisfaction with the amount of health information available about COVID-19 was significantly associated with higher IES-R score (B = 0.63, 95% CI: 0.11 to 1.14) and DASS stress subscale score (B = 0.32, 95% CI: 0.02 to 0.62). The information on the increase in the number of recovered individuals was significantly associated with a low DASS stress subscale score (B =−0.24, 95% CI: −0.40 to −0.07).
      </p>
     </sec>
     <sec id="sec3dot8-ijerph-17-01729">
      <title>
       3.8. Concerns about COVID -19 and Psychological Impact
      </title>
      <p>
       Regarding concerns about COVID-19, about 75.2% of respondents were very worried or somewhat worried about other family members getting COVID-19. In contrast, 50.9% of respondents were very worried or somewhat worried about a child younger than 16 years getting COVID-19. About 46.5% of the respondents expressed a high level of confidence in their doctor’s ability to diagnose or recognize COVID-19; and 46.1% believed the risk of contracting COVID-19 during the current outbreak was unlikely or not likely at all. The majority of respondents (69.2%) believed that they would be very likely or somewhat likely to survive COVID-19 if infected.
      </p>
      <p>
       Those who had no confidence in their own doctor’s ability to diagnose or recognize COVID-19 were significantly more likely to have higher scores in the DASS stress subscale (B = 1.18, 95% CI: 0.61–1.75), DASS anxiety subscale (B = 1.86, 95% CI: 0.96 to 2.76), and DASS depression subscale (B = 1.66, 95% CI:0.94 to 2.38). A higher perceived likelihood of contracting COVID-19 during the current outbreak was significantly associated with lower IES-R score (B = −0.33, 95% CI: −0.61 to −0.05). In contrast, low perceived likelihood of contracting COVID-19 during the current outbreak was significantly associated with low DASS stress subscale (B = −0.18, 95% CI: −0.35 to −0.01) and low DASS anxiety subscale (B = −0.36, 95% CI: −0.63 to −0.09) scores. A low perceived likelihood of surviving COVID-19 if infected was significantly associated with high DASS stress subscale score (B = 0.34, 95% CI: 0.01 to 0.68).
      </p>
      <p>
       High levels of concern about other family members getting COVID-19 were significantly associated with higher DASS stress subscale scores (B = 0.50, 95% CI: 0.04 to 0.96). Similarly, high levels of concern about a child younger than 16 years getting COVID-19 were significantly associated with higher IES-R scores (B = 0.25, 95% CI: 0.05 to 0.44) and DASS anxiety subscale scores (B = 0.24, 95% CI: 0.07 to 0.42).
      </p>
     </sec>
     <sec id="sec3dot9-ijerph-17-01729">
      <title>
       3.9. Precautionary Measures and Psychological Impact
      </title>
      <p>
       <xref ref-type="table" rid="ijerph-17-01729-t005">
        Table 5
       </xref>
       shows the precautionary measures adopted by the respondents in the past 14 days, which were most frequently always washing hands after touching contaminated objects (66.6%), always wearing a mask regardless of the presence or absence of symptoms (59.8%), always covering mouth when coughing and sneezing (57.4%), always washing hands with soap (56.5%), always washing hands immediately after coughing, sneezing, or rubbing nose (41%), and always avoiding sharing utensils (e.g., chopsticks) during meals (40.5%). Linear regression analysis showed that avoiding the sharing of utensils (e.g., chopsticks) during meals was significantly associated with lower scores in the IES-R (B= −0.29, 95% CI: −0.50 to −0.09) and the DASS stress (B = −0.18, 95% CI: −0.31 to −0.06), anxiety (B = −0.36, 95% CI: −0.55 to −0.17), and depression subscales (B = −0.31, 95% CI: −0.46 to −0.15). Similarly, washing hands immediately after coughing, sneezing, or rubbing the nose was significantly associated with lower scores in the IES-R (B = −0.47, 95% CI: −0.77 to −0.17) and the DASS stress (B = −0.31, 95% CI: −0.49 to −0.13), anxiety (B = −0.63, 95 CI: −0.91 to −0.35), and depression subscales (B = −0.38, 95% CI: −0.6 to −0.16). Washing hands with soap was significantly associated with lower scores in the DASS stress (B =−0.34, 95% CI: −0.60 to −0.09), anxiety (B = −0.54, 95% CI: −0.94 to −0.14), and depression subscales (B = −0.39, 95% CI: −0.71 to −0.07). Infrequency of wearing masks regardless of the presence or absence of symptoms was significantly associated with higher IES-R scores (B = 0.52, 95% CI: 0.04 to 1.01). High frequency of wearing masks regardless of the presence or absence of symptoms was significantly associated with lower scores in the DASS anxiety (B = −0.43, 95% CI: −0.81 to −0.06) and depression subscales (B = −0.37, 95% CI: −0.67 to −0.07). Washing hands after touching contaminated objects was significantly associated with lower DASS depression scores (B = −0.53, 95% CI: −0.96 to −0.10). The majority of respondents stayed at home for 20–24 h per day (84.7%) to avoid COVID-19.
      </p>
     </sec>
     <sec id="sec3dot10-ijerph-17-01729">
      <title>
       3.10. Additional Health Information Required and Psychological Impact
      </title>
      <p>
       <xref ref-type="table" rid="ijerph-17-01729-t006">
        Table 6
       </xref>
       shows additional health information required by respondents. Nearly all respondents desired additional information about COVID-19, most frequently with respect to the route of transmission (96.9%), the availability and effectiveness of medicines/vaccines (96.8%), travel advice (95.9%), overseas experience in handling COVID-19 (94.5%), the number of infected cases and locations (94.1%), advice on prevention of the COVID-19(93.7%), more tailored information (e.g., for people with chronic illnesses) (93.6%), outbreaks in the local area (92.7%), and details on symptoms of COVID-19 infection (91.6%). About 96.9% of respondents preferred regular updates for the latest information and these were found to be significantly associated with lower DASS anxiety subscale scores (B = −0.62, 95% CI: −1.00 to −0.24). Additional information on the availability and effectiveness of medicines/vaccines (B = −0.63, 95% CI: −0.99 to −0.26), the number of infections and locations (B = −0.30, 95% CI: −0.57 to −0.02), and the routes of transmission (B = −0.39, 95% CI: −0.77 to −0.02) were significantly associated with lower scores in DASS anxiety subscale. Additional information on availability and effectiveness of medicines/vaccines was significantly associated with lower scores in the DASS depression subscale (B = −0.35, 95% CI: −0.65 to −0.06).
      </p>
     </sec>
    </sec>
    <sec id="sec4-ijerph-17-01729" sec-type="discussion">
     <title>
      4. Discussion
     </title>
     <p>
      Our findings suggest that with respect to the initial psychological responses of the general public from 31 January to 2 February 2020, just two weeks into the country’s outbreak of COVID-19 and one day after WHO declared public health emergency of international concern, 53.8% of respondents rated the psychological impact of outbreak as moderate or severe; 16.5% of respondents reported moderate to severe depressive symptoms; 28.8% of respondents reported moderate to severe anxiety symptoms; and 8.1% reported moderate to severe stress levels. The prevalence of moderate or severe psychological impact as measured by IES-R was higher than the prevalence of depression, anxiety, and stress as measured by the DASS-21. The difference between IES-R and DASS-21 is due to the fact that the IES-R assesses the psychological impact after an event. In this study, respondents might refer the COVID-19 outbreak as the event while the DASS-21 did not specify any such event.
     </p>
     <p>
      In this study, the majority of respondents spent 20–24 h per day at home (84.7%), did not report any physical symptoms (60.81%), and presented with good self-rated health status (68.3%). In this study, very few respondents had a direct or indirect contact history with individuals with confirmed or suspected COVID-19, or had undergone medical consultations related to COVID-19 (≤1%). The majority of respondents (&gt;70%) were worried about their family members contracting COVID-19, but they believed that they would survive if infected.
     </p>
     <p>
      Overall, the Internet (93.5%) was the primary health information channel for the general public during the initial stage of COVID-19 epidemic in China. Nearly all respondents (&gt;90%) requested regular updates on the latest information on the route of transmission, availability and effectiveness of medicines/vaccines, travel advice, overseas experience in handling COVID-19, number of cases and location, advice on prevention, more tailored information (e.g., for people with chronic illnesses), information on outbreaks in the local area, and details on symptoms. The majority of respondents (&gt;70%) were satisfied with the amount of health information available. More than half of the respondents washed their hands with soaps after touching contaminated objects, covered their mouth when coughing or sneezing, and wore masks regardless of the presence or absence of symptoms as precaution strategies.
     </p>
     <p>
      As the COVID-19 epidemic continues to spread, our findings will provide vital guidance for the development of a psychological support strategy and areas to prioritize in China and other places which are affected by the epidemic. As the epidemic is ongoing, it is important to prepare health care systems and the general public to be medically and psychologically ready if widespread transmission occurs outside China [
      <xref ref-type="bibr" rid="B32-ijerph-17-01729">
       32
      </xref>
      ]. Our findings have clinical and policy implications. First, health authorities need to identify high-risk groups based on sociodemographic information for early psychological interventions. Our sociodemographic data suggest that females suffered a greater psychological impact of the outbreak as well as higher levels of stress, anxiety, and depression. This finding corresponds to previously extensive epidemiological studies which found that women were at higher risk of depression [
      <xref ref-type="bibr" rid="B33-ijerph-17-01729">
       33
      </xref>
      ]. Students were also found to experience a psychological impact of the outbreak and higher levels of stress, anxiety, and depression. As the total number of people infected by COVID-19 currently surpasses those stricken by the 2003 SARS-CoV epidemic, major cities in China have shut down schools at all levels indefinitely. The uncertainty and potential negative impact on academic progression could have an adverse effect on the mental health of students. During the epidemic, education authorities need to develop online portals and web-based applications to deliver lectures or other teaching activities [
      <xref ref-type="bibr" rid="B34-ijerph-17-01729">
       34
      </xref>
      ]. As young people are more receptive towards smartphone applications [
      <xref ref-type="bibr" rid="B35-ijerph-17-01729">
       35
      </xref>
      ], health authorities could consider providing online or smartphone-based psychoeducation and psychological interventions (e.g., cognitive behavior therapy, CBT) to reduce risk of virus transmission by face-to-face therapy. Online platforms could also provide a support network for those people spending most of their time at home during the epidemic. We found that the general public with no formal education had a greater likelihood of depression during the epidemic. Local agencies need to provide information in a diagrammatic or audio format in simple languages to support those with no educational background during the epidemic.
     </p>
     <p>
      Second, health authorities need to identify the immediate psychological needs of the general population presenting with physical symptoms during the epidemic. Our results revealed that the general population presenting with specific symptoms including chills, coryza, cough, dizziness, myalgia, and sore throat, as well as those with poor self-rated health status and history of chronic illnesses, experienced a psychological impact of the outbreak and higher levels of stress, anxiety, and depression. After presentation to the clinic or hospital with the above physical symptoms, patients may be sent home, quarantined, or admitted for further investigation. Health professionals should take the opportunity to provide resources for psychological support and interventions for those who present with the above symptoms, especially during hospitalization. Taking a family history is essential, and health professionals should enquire about the level of concern for other family members, especially children, of contracting COVID-19, as these concerns are associated with stress and anxiety, respectively.
     </p>
     <p>
      Third, government and health authorities need to provide accurate health information during the epidemic to reduce the impact of rumors [
      <xref ref-type="bibr" rid="B23-ijerph-17-01729">
       23
      </xref>
      ]. Higher satisfaction with the health information received was associated with a lower psychological impact of the outbreak and lower levels of stress, anxiety, and depression. The content of health information provided during the epidemic needs to be based on evidence to avoid adverse psychological reactions. Our results showed that up-to-date and accurate health information, especially on the number of recovered individuals, was associated with lower stress levels. Additional information on medicines or vaccines, routes of transmission, and updates on the number of infected cases and location (e.g., real-time, online tracking map) were associated with lower levels of anxiety.
     </p>
     <p>
      Fourth, the content of psychological interventions (for example CBT) needs to be modified to suit the needs of the general population during the epidemic. CBT should preferably be delivered online or via telephone to avoid the spread of infection. As online CBT does not require the presence of mental health professionals (e.g., psychologists), this will be helpful to the general public in China as there is a shortage of psychologists. Based on our findings, cognitive therapy can provide information or evidence to enhance confidence in the doctor’s ability to diagnose COVID-19. Cognitive therapy can challenge cognitive bias when recipients overestimate the risk of contracting and dying from COVID-19. As the majority of the general population in this study was homebound for 20–24 h per day during the epidemic, behavior therapy could focus on relaxation exercises to counteract anxiety and activity scheduling (e.g., home-based exercise and entertainment) to counteract depression in the home environment. Self-administered acupressure and emotional freedom techniques derived from key principles within traditional Chinese medicine are potential interventions which may benefit the mental health of general public during the COVID-19 outbreak. Further research Is required to evaluate the effectiveness of these interventions.
     </p>
     <p>
      Fifth, our findings suggest that the precautionary measures adopted to prevent the spread of COVID-19 could have had protective psychological effects during the early stage of the epidemic. During the 2003 SARS-CoV epidemic, researchers found that moderate levels of anxiety were associated with higher uptake of preventive measures by respondents [
      <xref ref-type="bibr" rid="B21-ijerph-17-01729">
       21
      </xref>
      ]. Our findings showed the opposite trend. Specific precautionary measures including avoidance of sharing utensils (e.g., chopsticks), hand hygiene, and wearing masks regardless of the presence or absence of symptoms were associated with lower levels of psychological impact, depression, anxiety, and stress. The experiences of the 2003 SARS-CoV epidemic could have changed the perception of the general public towards precautionary measures and have led to a positive effect on the initial psychological responses to the COVID-19 epidemic by giving respondents confidence and sense of control in prevention. As the Chinese prefer to use chopsticks to pick up food commonly shared on a plate during mealtime as part of their culture, it is not unexpected that avoidance of sharing utensils (e.g., chopsticks) during meals is significantly associated with less psychological impact and lower levels of anxiety, depression, and stress. During the initial stage of the COVID-19 epidemic, health authorities outside China had different recommendations for mask usage due to a global shortage of masks. While some health authorities urged citizens not to wear masks if they were well (e.g., Singapore), other health authorities urged their citizens to always have masks and hand sanitizers ready (e.g., Malaysia, Vietnam) [
      <xref ref-type="bibr" rid="B36-ijerph-17-01729">
       36
      </xref>
      ]. The official guidance from the World Health Organization (WHO) advises that healthy people should only wear masks if they are taking care of a person with suspected COVID-19 infection or if people are coughing and sneezing [
      <xref ref-type="bibr" rid="B37-ijerph-17-01729">
       37
      </xref>
      ]. Our study found that wearing masks, regardless of the presence or absence of symptoms, was associated with lower levels of anxiety and depression. Although the WHO emphasizes that masks are effective only when used in combination with frequent hand-cleaning with alcohol-based hand rub or soap and water, wearing a mask regardless of the presence or absence of symptoms could offer potential psychological benefits by offering a sense of security. This finding was anticipated because wearing face masks is a common practice when people are sick or to counter urban pollution or haze in parts of Asia, including China [
      <xref ref-type="bibr" rid="B38-ijerph-17-01729">
       38
      </xref>
      ]. Governments and health authorities should ensure there are infrastructures to produce and provide an adequate supply of masks, soaps, alcohol-based hand rubs, and other personal hygiene products during the COVID-19 epidemic.
     </p>
     <p>
      This study has several limitations. Given the limited resources available and time-sensitivity of the COVID-19 outbreak, we adopted the snowball sampling strategy. The snowballing sampling strategy was not based on a random selection of the sample, and the study population did not reflect the actual pattern of the general population. Furthermore, it would be ideal to conduct a prospective study on the same group of participants after a period. Due to ethical requirements on anonymity and confidentiality, we were not allowed to collect contact details and personal information from the respondents. As a result, we could not conduct a prospective study that would provide a concrete finding to support the need for a focused public health initiative. There was an oversampling of a particular network of peers (e.g., students), leading to selection bias. As a result, the conclusion was less generalizable to the entire population, particularly less educated people. Another limitation is that self-reported levels of psychological impact, anxiety, depression and stress may not always be aligned with assessment by mental health professionals. Similarly, respondents might have provided socially desirable responses in terms of the satisfaction with the health information received and precautionary measures. Lastly, the number of respondents with contact history and who had sought medical consultations was very small. Our findings could not be generalized to confirmed or suspected cases of COVID-19. Notwithstanding the above limitations, this study provides invaluable information on the initial psychological responses 2 weeks after the outbreak of COVID-19 from respondents across 194 cities in China. Our results could be used as a historical reference. Most importantly, our findings directly inform the development of psychological interventions that can minimize psychological impact, anxiety, depression, and stress during the outbreak of COVID-19 and provide a baseline for evaluating prevention, control, and treatment efforts throughout the remainder of the COVID-19 epidemic, which is still ongoing at the time of preparing this manuscript.
     </p>
    </sec>
    <sec id="sec5-ijerph-17-01729" sec-type="conclusions">
     <title>
      5. Conclusions
     </title>
     <p>
      During the initial phase of COVID-19 outbreak in China, more than half of the respondents rated their psychological impact as moderate-to-severe, and about one-third reported moderate-to-severe anxiety. Female gender, student status, and specific physical symptoms were associated with a greater psychological impact of the outbreak and higher levels of stress, anxiety, and depression. Specific up-to-date and accurate health information and certain precautionary measures were associated with a lower psychological impact of the outbreak and lower levels of stress, anxiety, and depression. Our findings can be used to formulate psychological interventions to improve mental health and psychological resilience during the COVID-19 epidemic.
     </p>
    </sec>
    <back>
     <notes>
      <title>
       Author Contributions
      </title>
      <p>
       Conceptualization, C.W., R.P., and R.H.; methodology, C.W., R.P., and R.H.; validation, C.W., R.P., and L.X.; resources, C.W.; data curation, X.W., Y.T., and L.X.; formal analysis, C.W., R.P., X.W., Y.T., and L.X.; writing—original draft preparation, C.W., R.P., C.S.H., and R.C.H.; writing—review and editing, C.W., C.S.H., and R.C.H.; visualization, X.W., Y.T., and L.X.; supervision, C.W., R.P., and R.C.H.; project administration, C.W.; All authors have read and agreed to the published version of the manuscript.
      </p>
     </notes>
     <notes>
      <title>
       Funding
      </title>
      <p>
       There was no funding for this study.
      </p>
     </notes>
     <notes notes-type="COI-statement">
      <title>
       Conflicts of Interest
      </title>
      <p>
       The authors declare no conflict of interest.
      </p>
     </notes>
     <ref-list>
      <title>
       References
      </title>
      <ref id="B1-ijerph-17-01729">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel coronavirus outbreak of global health concern
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <fpage>
         470
        </fpage>
        <lpage>
         473
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30185-9
        </pub-id>
        <pub-id pub-id-type="pmid">
         31986257
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B2-ijerph-17-01729">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hawryluck
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS control and psychological effects of quarantine, Toronto, Canada
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2004
        </year>
        <volume>
         10
        </volume>
        <fpage>
         1206
        </fpage>
        <lpage>
         1212
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1007.030703
        </pub-id>
        <pub-id pub-id-type="pmid">
         15324539
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B3-ijerph-17-01729">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nishiura
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Extent of Transmission of Novel Coronavirus in Wuhan, China, 2020
        </article-title>
        <source>
         J. Clin. Med.
        </source>
        <year>
         2020
        </year>
        <volume>
         9
        </volume>
        <elocation-id>
         330
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.3390/jcm9020330
        </pub-id>
        <pub-id pub-id-type="pmid">
         31991628
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B4-ijerph-17-01729">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mahase
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         China coronavirus: WHO declares international emergency as death toll exceeds 200
        </article-title>
        <source>
         BMJ Clin. Res. Ed.
        </source>
        <year>
         2020
        </year>
        <volume>
         368
        </volume>
        <fpage>
         m408
        </fpage>
        <pub-id pub-id-type="doi">
         10.1136/bmj.m408
        </pub-id>
        <pub-id pub-id-type="pmid">
         32005727
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B5-ijerph-17-01729">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paules
          </surname>
          <given-names>
           C.I.
          </given-names>
         </name>
         <name>
          <surname>
           Marston
          </surname>
          <given-names>
           H.D.
          </given-names>
         </name>
         <name>
          <surname>
           Fauci
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus Infections-More Than Just the Common Cold
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1001/jama.2020.0757
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B6-ijerph-17-01729">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <fpage>
         497
        </fpage>
        <lpage>
         506
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30183-5
        </pub-id>
        <pub-id pub-id-type="pmid">
         31986264
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B7-ijerph-17-01729">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Estimating the effective reproduction number of the 2019-nCoV in China
        </article-title>
        <source>
         medRxiv
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1101/2020.01.27.20018952
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B8-ijerph-17-01729">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Estimating the Unreported Number of Novel Coronavirus (2019-nCoV) Cases in China in the First Half of January 2020: A Data-Driven Modelling Analysis of the Early Outbreak
        </article-title>
        <source>
         J. Clin. Med.
        </source>
        <year>
         2020
        </year>
        <volume>
         9
        </volume>
        <elocation-id>
         388
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.3390/jcm9020388
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B9-ijerph-17-01729">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa2001316
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B10-ijerph-17-01729">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rothe
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1056/NEJMc2001468
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B11-ijerph-17-01729">
       <label>
        11.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ryu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Chun
          </surname>
          <given-names>
           B.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Korean Society of Epidemiology-nCo, an interim review of the epidemiological characteristics of 2019 novel coronavirus
        </article-title>
        <source>
         Epidemiol. Health
        </source>
        <year>
         2020
        </year>
        <volume>
         42
        </volume>
        <fpage>
         e2020006
        </fpage>
        <pub-id pub-id-type="doi">
         10.4178/epih.e2020006
        </pub-id>
        <pub-id pub-id-type="pmid">
         32023775
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B12-ijerph-17-01729">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <fpage>
         507
        </fpage>
        <lpage>
         513
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30211-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         32007143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B13-ijerph-17-01729">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Holshue
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         First Case of 2019 Novel Coronavirus in the United States
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa2001191
        </pub-id>
        <pub-id pub-id-type="pmid">
         32004427
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B14-ijerph-17-01729">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nishiura
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Rate of Underascertainment of Novel Coronavirus (2019-nCoV) Infection: Estimation Using Japanese Passengers Data on Evacuation Flights
        </article-title>
        <source>
         J. Clin. Med.
        </source>
        <year>
         2020
        </year>
        <volume>
         9
        </volume>
        <elocation-id>
         419
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.3390/jcm9020419
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B15-ijerph-17-01729">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Horton
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Offline: 2019-nCoV—“A desperate plea”
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <fpage>
         400
        </fpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30299-3
        </pub-id>
        <pub-id pub-id-type="pmid">
         32035537
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B16-ijerph-17-01729">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xiang
          </surname>
          <given-names>
           Y.-T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed
        </article-title>
        <source>
         Lancet Psychiatry
        </source>
        <year>
         2020
        </year>
        <volume>
         7
        </volume>
        <fpage>
         228
        </fpage>
        <lpage>
         229
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S2215-0366(20)30046-8
        </pub-id>
        <pub-id pub-id-type="pmid">
         32032543
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B17-ijerph-17-01729">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hall
          </surname>
          <given-names>
           R.C.W.
          </given-names>
         </name>
         <name>
          <surname>
           Chapman
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The 1995 Kikwit Ebola outbreak: Lessons hospitals and physicians can apply to future viral epidemics
        </article-title>
        <source>
         Gen. Hosp. Psychiatry
        </source>
        <year>
         2008
        </year>
        <volume>
         30
        </volume>
        <fpage>
         446
        </fpage>
        <lpage>
         452
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.genhosppsych.2008.05.003
        </pub-id>
        <pub-id pub-id-type="pmid">
         18774428
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B18-ijerph-17-01729">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rubin
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Potts
          </surname>
          <given-names>
           H.W.W.
          </given-names>
         </name>
         <name>
          <surname>
           Michie
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The impact of communications about swine flu (influenza A H1N1v) on public responses to the outbreak: Results from 36 national telephone surveys in the UK
        </article-title>
        <source>
         Health Technol. Assess.
        </source>
        <year>
         2010
        </year>
        <volume>
         14
        </volume>
        <fpage>
         183
        </fpage>
        <lpage>
         266
        </lpage>
        <pub-id pub-id-type="doi">
         10.3310/hta14340-03
        </pub-id>
        <pub-id pub-id-type="pmid">
         20630124
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B19-ijerph-17-01729">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Van Bortel
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Psychosocial effects of an Ebola outbreak at individual, community and international levels
        </article-title>
        <source>
         Bull. World Health Organ.
        </source>
        <year>
         2016
        </year>
        <volume>
         94
        </volume>
        <fpage>
         210
        </fpage>
        <lpage>
         214
        </lpage>
        <pub-id pub-id-type="doi">
         10.2471/BLT.15.158543
        </pub-id>
        <pub-id pub-id-type="pmid">
         26966332
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B20-ijerph-17-01729">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sim
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Psychosocial and coping responses within the community health care setting towards a national outbreak of an infectious disease
        </article-title>
        <source>
         J. Psychosom. Res.
        </source>
        <year>
         2010
        </year>
        <volume>
         68
        </volume>
        <fpage>
         195
        </fpage>
        <lpage>
         202
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jpsychores.2009.04.004
        </pub-id>
        <pub-id pub-id-type="pmid">
         20105703
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B21-ijerph-17-01729">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The impact of community psychological responses on outbreak control for severe acute respiratory syndrome in Hong Kong
        </article-title>
        <source>
         J. Epidemiol. Community Health
        </source>
        <year>
         2003
        </year>
        <volume>
         57
        </volume>
        <fpage>
         857
        </fpage>
        <lpage>
         863
        </lpage>
        <pub-id pub-id-type="doi">
         10.1136/jech.57.11.857
        </pub-id>
        <pub-id pub-id-type="pmid">
         14600110
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B22-ijerph-17-01729">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30251-8
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B23-ijerph-17-01729">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rubin
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Wessely
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The psychological effects of quarantining a city
        </article-title>
        <source>
         BMJ Clin. Res. Ed.
        </source>
        <year>
         2020
        </year>
        <volume>
         368
        </volume>
        <fpage>
         m313
        </fpage>
        <pub-id pub-id-type="doi">
         10.1136/bmj.m313
        </pub-id>
        <pub-id pub-id-type="pmid">
         31992552
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B24-ijerph-17-01729">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Community psycho-behavioural surveillance and related impact on outbreak control in Hong Kong and Singapore during the SARS epidemic
        </article-title>
        <source>
         Hong Kong Med. J.
        </source>
        <year>
         2009
        </year>
        <volume>
         15
        </volume>
        <issue>
         Suppl. S9
        </issue>
        <fpage>
         30
        </fpage>
        <lpage>
         34
        </lpage>
       </element-citation>
      </ref>
      <ref id="B25-ijerph-17-01729">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           M.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Usage of social media and smartphone application in assessment of physical and psychological well-being of individuals in times of a major air pollution crisis
        </article-title>
        <source>
         JMIR mHealth uHealth
        </source>
        <year>
         2014
        </year>
        <volume>
         2
        </volume>
        <fpage>
         e16
        </fpage>
        <pub-id pub-id-type="doi">
         10.2196/mhealth.2827
        </pub-id>
        <pub-id pub-id-type="pmid">
         25098255
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B26-ijerph-17-01729">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           M.W.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Methodology of developing a smartphone application for crisis research and its clinical application
        </article-title>
        <source>
         Technol. Health Care Off. J. Eur. Soc. Eng. Med.
        </source>
        <year>
         2014
        </year>
        <volume>
         22
        </volume>
        <fpage>
         547
        </fpage>
        <lpage>
         559
        </lpage>
        <pub-id pub-id-type="doi">
         10.3233/THC-140819
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B27-ijerph-17-01729">
       <label>
        27.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Creamer
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Bell
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Failla
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Psychometric properties of the Impact of Event Scale-Revised
        </article-title>
        <source>
         Behav. Res. Ther.
        </source>
        <year>
         2003
        </year>
        <volume>
         41
        </volume>
        <fpage>
         1489
        </fpage>
        <lpage>
         1496
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.brat.2003.07.010
        </pub-id>
        <pub-id pub-id-type="pmid">
         14705607
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B28-ijerph-17-01729">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Le
          </surname>
          <given-names>
           T.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Multi-level predictors of psychological problems among methadone maintenance treatment patients in difference types of settings in Vietnam
        </article-title>
        <source>
         Subst. Abus. Treat. Prev. Policy
        </source>
        <year>
         2019
        </year>
        <volume>
         14
        </volume>
        <fpage>
         39
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/s13011-019-0223-4
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B29-ijerph-17-01729">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           C.S.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Relationship of Anxiety and Depression with Respiratory Symptoms: Comparison between Depressed and Non-Depressed Smokers in Singapore
        </article-title>
        <source>
         Int. J. Environ. Res. Public Health
        </source>
        <year>
         2019
        </year>
        <volume>
         16
        </volume>
        <elocation-id>
         163
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.3390/ijerph16010163
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B30-ijerph-17-01729">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Quek
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Misophonia in Singaporean Psychiatric Patients: A Cross-Sectional Study
        </article-title>
        <source>
         Int. J. Environ. Res. Public Health
        </source>
        <year>
         2018
        </year>
        <volume>
         15
        </volume>
        <elocation-id>
         1410
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.3390/ijerph15071410
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B31-ijerph-17-01729">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McAlonan
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immediate and sustained psychological impact of an emerging infectious disease outbreak on health care workers. Canadian journal of psychiatry
        </article-title>
        <source>
         Revue Canadienne De Psychiatrie
        </source>
        <year>
         2007
        </year>
        <volume>
         52
        </volume>
        <fpage>
         241
        </fpage>
        <lpage>
         247
        </lpage>
        <pub-id pub-id-type="pmid">
         17500305
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B32-ijerph-17-01729">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Patel
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Jernigan
          </surname>
          <given-names>
           D.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak—United States, 31 December 2019–4 February 2020
        </article-title>
        <source>
         MMWR Morb. Mortal. Wkly. Rep.
        </source>
        <year>
         2020
        </year>
        <volume>
         69
        </volume>
        <fpage>
         140
        </fpage>
        <lpage>
         146
        </lpage>
        <pub-id pub-id-type="doi">
         10.15585/mmwr.mm6905e1
        </pub-id>
        <pub-id pub-id-type="pmid">
         32027631
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B33-ijerph-17-01729">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           G.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevalence of Depression in the Community from 30 Countries between 1994 and 2014
        </article-title>
        <source>
         Sci. Rep.
        </source>
        <year>
         2018
        </year>
        <volume>
         8
        </volume>
        <fpage>
         2861
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/s41598-018-21243-x
        </pub-id>
        <pub-id pub-id-type="pmid">
         29434331
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B34-ijerph-17-01729">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           M.W.B.
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           C.S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           R.C.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Methodology of development and students’ perceptions of a psychiatry educational smartphone application
        </article-title>
        <source>
         Technol. Health Care Off. J. Eur. Soc. Eng. Med.
        </source>
        <year>
         2014
        </year>
        <volume>
         22
        </volume>
        <fpage>
         847
        </fpage>
        <lpage>
         855
        </lpage>
        <pub-id pub-id-type="doi">
         10.3233/THC-140861
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B35-ijerph-17-01729">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Do
          </surname>
          <given-names>
           T.T.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Receptiveness and preferences of health-related smartphone applications among Vietnamese youth and young adults
        </article-title>
        <source>
         BMC Public Health
        </source>
        <year>
         2018
        </year>
        <volume>
         18
        </volume>
        <fpage>
         764
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/s12889-018-5641-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         29921258
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B36-ijerph-17-01729">
       <label>
        36.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Geddie
          </surname>
          <given-names>
           J.S.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         To Mask or Not to Mask: Confusion Spreads over Coronavirus Protection. 31 January 2020
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://uk.reuters.com/article/us-china-health-masks-safety/to-mask-or-not-to-mask-confusion-spreads-over-coronavirus-protection-idUKKBN1ZU0PH">
          https://uk.reuters.com/article/us-china-health-masks-safety/to-mask-or-not-to-mask-confusion-spreads-over-coronavirus-protection-idUKKBN1ZU0PH
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-08">
         (accessed on 8 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B37-ijerph-17-01729">
       <label>
        37.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Organisation
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Novel Coronavirus (2019-nCoV) Advice for the Public: When and How to Use Masks
        </article-title>
        <year>
         2020
        </year>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/when-and-how-to-use-masks">
          https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/when-and-how-to-use-masks
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-08">
         (accessed on 8 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B38-ijerph-17-01729">
       <label>
        38.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           R.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Impact of 2013 south Asian haze crisis: Study of physical and psychological symptoms and perceived dangerousness of pollution level
        </article-title>
        <source>
         BMC Psychiatry
        </source>
        <year>
         2014
        </year>
        <volume>
         14
        </volume>
        <elocation-id>
         81
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1186/1471-244X-14-81
        </pub-id>
        <pub-id pub-id-type="pmid">
         24642046
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
    <floats-group>
     <fig id="ijerph-17-01729-f001" orientation="portrait" position="float">
      <label>
       Figure 1
      </label>
      <caption>
       <p>
        National epidemic trend of the 2019 coronavirus disease (COVID-19) outbreak in China from 7 January to 2 February 2020.
       </p>
      </caption>
      <graphic xlink:href="ijerph-17-01729-g001">
      </graphic>
     </fig>
     <table-wrap id="ijerph-17-01729-t001" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       ijerph-17-01729-t001_Table 1
      </object-id>
      <label>
       Table 1
      </label>
      <caption>
       <p>
        Association between demographic variables and the psychological impact of the 2019 coronavirus disease (COVID-19) outbreak as well as adverse mental health status during the epidemic (
        <italic>
         n
        </italic>
        = 1210).
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Variables
         </th>
         <th align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          <italic>
           N
          </italic>
          (%)
         </th>
         <th align="center" colspan="3" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Impact of event
         </th>
         <th align="center" colspan="3" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Stress
         </th>
         <th align="center" colspan="3" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Anxiety
         </th>
         <th align="center" colspan="3" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Depression
         </th>
        </tr>
        <tr>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          R-Squared (R
          <sup>
           2
          </sup>
          )
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Adjusted R-Squared (AR
          <sup>
           2
          </sup>
          )
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Beta (95% Confidence Interval) B (95% CI)
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          R
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          AR
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          B (95%CI)
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          R
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          AR
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          B (95% CI)
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          R
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          AR
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          B (95% CI)
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          <bold>
           Gender
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Male
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          396 (32.7)
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          0.005
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          0.005
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.20 * (−0.35 to −0.05)
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          0.004
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          0.004
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.10 * (0.02 to 0.19)
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          0.006
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          0.005
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.19 ** (0.05 to 0.33)
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          0.004
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.12 * (0.01 to 0.23)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Female
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          814 (67.3)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          <bold>
           Age (Years)
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          (12–21.4)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          344 (28.4)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.009
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.006
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.21 (−0.20 to 0.62)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.011
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.007
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.08 (−0.16 to 0.32)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.007
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.004
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.10 (−0.28 to 0.48)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.013
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.009
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.06 (−0.25 to 0.37)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          (21.4–30.8)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          643 (53.1)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.09 (−0.31 to 0.50)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.12 (−0.12 to 0.36)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.07 (−0.31 to 0.44)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.18 (−0.12 to 0.47)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          (30.8–40.2)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          94 (7.8)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.17 (−0.64 to 0.29)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.07 (−0.35 to 0.20)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.16 (−0.59 to 0.27)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.06 (−0.41 to 0.28)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          (40.2–49.6)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          90 (7.4)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.16 (−0.63 to 0.30)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.12 (−0.39 to 0.16)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.23 (−0.67 to 0.20)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.16 (−0.51 to 0.19)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          (49.6–59)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          39 (3.2)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          <bold>
           Status as a parent
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Has a child 16 years or under
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          234 (19.3)
         </td>
         <td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.04 (−0.16 to 0.25)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.02 (−0.14 to 0.10)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.08 (−0.11 to 0.27)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.05 (−0.10 to 0.20)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Has a child older than 16 years
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          581 (48.1)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.06 (−0.22 to 0.10)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.07 (−0.17 to 0.02)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.08 (−0.23 to 0.07)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.06 (−0.18 to 0.06)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No children
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          395 (32.6)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          <bold>
           Marital status
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Single
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          273 (22.6)
         </td>
         <td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.04 (−1.46 to 1.38)
         </td>
         <td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.02 (−0.81 to 0.86)
         </td>
         <td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.71 (−0.61 to 2.03)
         </td>
         <td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.45 (−0.60 to 1.51)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Married
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          925 (76.4)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.09 (−1.33 to 1.50)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.12 (−0.71 to 0.96)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.80 (−0.51 to 2.12)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.56 (−0.50 to 1.61)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Divorced/separated
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          9 (0.7)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.11 (−1.52 to 1.74)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          &lt;0.001 (−0.96 to 0.96)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.44 (−1.07 to 1.96)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.44 (−0.77 to 1.66)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Widowed
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          3 (0.2)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          <bold>
           Household size
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Six people or more
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          171 (14.1)
         </td>
         <td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.38 (−0.39 to 1.14)
         </td>
         <td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.23 (−0.68 to 0.22)
         </td>
         <td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">
          −0.002
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.17 (−0.87 to 0.54)
         </td>
         <td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.19 (−0.76 to 0.38)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Three to five people
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          976 (80.7)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.25 (−0.49 to 0.99)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.20 (−0.63 to 0.24)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.12 (−0.81 to 0.57)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.09 (−0.64 to 0.47)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Two people
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          52 (4.3)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.41 (−0.40 to 1.22)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.33 (−0.81 to 0.15)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.18 (−0.93 to 0.58)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.21 (−0.82 to 0.39)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          One person
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          11 (0.9)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          <bold>
           Employment status
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Unemployed
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          67 (5.5)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.009
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.006
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.13 (−0.19 to 0.45)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.007
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.004
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.12 (−0.07 to 0.31)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.007
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.21 (−0.09 to 0.51)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.005
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.16 (−0.08 to 0.40)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Farmers
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          24 (2)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.08 (−0.59 to 0.43)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.003 (−0.30 to 0.30)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.07 (−0.41 to 0.54)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.07 (−0.45 to 0.31)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Retired
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          7 (0.6)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.76 (−1.69 to 0.17)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.37 (−0.92 to 0.18)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.54 (−1.41 to 0.32)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.48 (−1.18 to 0.21)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Student
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          639 (52.8)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.20 * (0.05 to 0.35)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.11 * (0.02 to 0.19)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.16 * (0.02 to 0.30)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.08 * (−0.03 to 0.19)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Employed
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          473 (39.1)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          <bold>
           Educational attainment
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          None
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2 (0.2)
         </td>
         <td align="center" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
          0.008
         </td>
         <td align="center" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.07 (−1.88 to 1.74)
         </td>
         <td align="center" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
          0.004
         </td>
         <td align="center" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.76 (−0.30 to 1.83)
         </td>
         <td align="center" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
          0.004
         </td>
         <td align="center" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1.02 (−0.66 to 2.71)
         </td>
         <td align="center" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
          0.008
         </td>
         <td align="center" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1.81 ** (0.46 to 3.16)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Primary school
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          8 (0.7)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −1.07 *(−2.09 to −0.06)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.11 (−0.71 to 0.49)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.10 (−1.05 to 0.84)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.07 (−0.82 to 0.69)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Lower secondary school
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          55 (4.5)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.21 (−0.42 to 0.84)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.20 (−0.17 to 0.57)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.38 (−0.21 to 0.96)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.41 (−0.06 to 0.88)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Upper secondary school
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          81 (6.7)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.01 (−0.59 to 0.61)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.16 (−0.20 to 0.51)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.36 (−0.19 to 0.92)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.34 (−0.11 to 0.79)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          University—Bachelors
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          805 (66.5)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.19 (−0.35 to 0.73)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.21 (−0.11 to 0.53)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.32 (−0.18 to 0.82)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.35 (−0.05 to 0.75)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          University—Masters
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          238 (19.7)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.14 (−0.42 to 0.69)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.18 (−0.15 to 0.51)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.24 (−0.28 to 0.76)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.33 (−0.09 to 0.74)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          University—Doctorate
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          21 (1.7)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         *
         <italic>
          p
         </italic>
         &lt; 0.05; **
         <italic>
          p
         </italic>
         &lt; 0.01.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <table-wrap id="ijerph-17-01729-t002" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       ijerph-17-01729-t002_Table 2
      </object-id>
      <label>
       Table 2
      </label>
      <caption>
       <p>
        Association between physical health status in the past 14 days and the psychological impact of the 2019 coronavirus disease (COVID-19) outbreak as well as adverse mental health status during the epidemic (
        <italic>
         n
        </italic>
        = 1210).
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Variable
         </th>
         <th align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          <italic>
           n
          </italic>
          (%)
         </th>
         <th align="center" colspan="3" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Impact of Event
         </th>
         <th align="center" colspan="3" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Stress
         </th>
         <th align="center" colspan="3" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Anxiety
         </th>
         <th align="center" colspan="3" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Depression
         </th>
        </tr>
        <tr>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          R
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          AR
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          B (95% CI)
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          R
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          AR
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          B (95% CI)
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          R
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          A
          <sup>
           R2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          B (95% CI)
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          R
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          A
          <sup>
           R2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          B (95% CI)
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          <bold>
           Persistent fever (&gt;38°C for at least 1 day)
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          6 (0.5)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.23 (−1.23 to 0.78)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.40 (−0.19 to 0.99)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.006
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.005
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1.23 * (0.30 to 2.15)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.005
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.005
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.98 * (0.23 to 1.72)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1204 (99.5)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          <bold>
           Chills
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          42 (3.5)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.005
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.004
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.46 * (0.08 to 0.84)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.012
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.011
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.44 *** (0.22 to 0.67)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.009
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.008
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.60 **(0.24 to 0.96)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.007
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.006
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.41 **(0.13 to 0.70)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1168 (96.5)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          <bold>
           Headache
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          117 (9.7)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.008
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.007
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.37 ** (0.13 to 0.61)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.12 (−0.02 to 0.26)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.008
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.008
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.36 ** (0.14 to 0.58)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.005
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.004
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.23 * (0.05 to 0.40)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1093 (90.3)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          <bold>
           Myalgia
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          95 (7.9)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.019
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.018
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.63 ***(0.37 to 0.89)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.025
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.024
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.43 ***(0.28 to 0.59)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.025
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.025
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.69 *** (0.45 to 0.93)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.021
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.02
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.50 *** (0.31 to 0.69)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1115(92.1)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          <bold>
           Cough
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          168 (13.9)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.009
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.008
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.33 ** (0.13 to 0.54)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.008
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.007
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.19 ** (0.07 to 0.31)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.007
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.006
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.29 ** (0.10 to 0.47)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.006
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.005
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.21 **(0.06 to 0.36)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1042 (86.1)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          <bold>
           Breathing difficulty
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          5 (0.4)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.88 (−0.22 to 1.97)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.57 (−0.07 to 1.22)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.008
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.007
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1.63 ** (0.61 to 2.64)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.008
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.007
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1.28 ** (0.46 to 2.09)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1205 (99.6)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          <bold>
           Dizziness
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          88 (7.3)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.013
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.012
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.54 *** (0.27 to 0.81)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.014
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.013
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.33 *** (0.17 to 0.49)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.020
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.019
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.63 *** (0.38 to 0.88)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.014
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.013
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.42 *** (0.22 to 0.62)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1122 (92.7)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          <bold>
           Coryza
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          205 (16.9)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.014
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.013
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.39 *** (0.20 to 0.58)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.016
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.015
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.25 *** (0.14 to 0.36)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.022
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.021
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.46 ***(0.28 to 0.63)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.018
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.017
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.33 *** (0.19 to 0.47)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1005 (83.1)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          <bold>
           Sore throat
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          139 (11.5)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.007
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.007
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.34 ** (0.12 to 0.56)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.005
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.004
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.16 *(0.03 to 0.29)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.009
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.008
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.35 ** (0.14 to 0.55)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.004
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.17 * (0.01 to 0.34)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1071 (88.5)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          <bold>
           Persistent fever and cough or difficulty breathing
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          4 (0.3)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.23 (−1.45 to 1.00)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.32 (−0.40 to 1.04)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.98 (−0.16 to 2.11)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.22 (−0.69 to 1.13)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1206 (99.7)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          <bold>
           Consultation with doctor in the clinic in the past 14 days
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          42 (3.5)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.06 (−0.44 to 0.32)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.17 (−0.06 to 0.40)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.004
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.38 * (0.02 to 0.73)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.22 (−0.07 to 0.50)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1168 (96.5)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          <bold>
           Recent hospitalization in the past 14 days
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          4 (0.3)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.78 (−0.45 to 2.00)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.32 (−0.40 to 1.04)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.004
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1.23 * (0.09 to 2.36)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.28 (−1.19 to 0.63)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1206 (99.7)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          <bold>
           Recent testing for COVID-19 in the past 14 days
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          11 (0.9)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.18 (−0.92 to 0.56)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.07 (−0.51 to 0.37)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.22 (−0.47 to 0.91)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.02 (−0.54 to 0.57)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1199 (99.1)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          <bold>
           Recent quarantine in the past 14 days
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          26 (2.1)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.32 (−0.16 to 0.81)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.01 (−0.30 to 0.28)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.03 (−0.42 to 0.48)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.11 (−0.47 to 0.25)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1184 (97.9)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          <bold>
           Current self-rating health status
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Poor/Very poor
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          11 (1)
         </td>
         <td align="center" colspan="1" rowspan="3" valign="middle">
          0.021
         </td>
         <td align="center" colspan="1" rowspan="3" valign="middle">
          0.018
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.76 * (0.02 to 1.49)
         </td>
         <td align="center" colspan="1" rowspan="3" valign="middle">
          0.034
         </td>
         <td align="center" colspan="1" rowspan="3" valign="middle">
          0.032
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.45 * (0.02 to 0.88)
         </td>
         <td align="center" colspan="1" rowspan="3" valign="middle">
          0.034
         </td>
         <td align="center" colspan="1" rowspan="3" valign="middle">
          0.032
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.90 * (0.22 to 1.58)
         </td>
         <td align="center" colspan="1" rowspan="3" valign="middle">
          0.030
         </td>
         <td align="center" colspan="1" rowspan="3" valign="middle">
          0.027
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.65 * (0.1 to 1.20)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Average
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          372 (30.8)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.37 *** (0.21 to 0.52)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.19 *** (0.11 to 0.28)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.41 *** (0.27 to 0.55)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.26 *** (0.15 to 0.38)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Good/Very good
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          827 (68.3)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          <bold>
           Chronic illness
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          78 (6.4)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.29 * (0.01 to 0.58)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.006
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.005
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.24 ** (0.07 to 0.41)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.011
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.010
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.48 *** (0.22 to 0.75)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.010
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.009
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.38 *** (0.17 to 0.59)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1132 (93.6)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          <bold>
           Medical insurance coverage
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1118 (92.4)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.09 (−0.18 to 0.36)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.003 (−0.16 to 0.15)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.04 (−0.29 to 0.21)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.02 (−0.18 to 0.22)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          92 (7.6)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         *
         <italic>
          p
         </italic>
         &lt; 0.05; **
         <italic>
          p
         </italic>
         &lt; 0.01; ***
         <italic>
          p
         </italic>
         &lt; 0.001.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <table-wrap id="ijerph-17-01729-t003" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       ijerph-17-01729-t003_Table 3
      </object-id>
      <label>
       Table 3
      </label>
      <caption>
       <p>
        Association between contact history in the past 14 days and the psychological impact of the 2019 coronavirus disease (COVID-19) outbreak as well as adverse mental health status during the epidemic (
        <italic>
         n
        </italic>
        = 1210).
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Variables
         </th>
         <th align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          <italic>
           n
          </italic>
          (%)
         </th>
         <th align="center" colspan="3" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Impact of Event
         </th>
         <th align="center" colspan="3" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Stress
         </th>
         <th align="center" colspan="3" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Anxiety
         </th>
         <th align="center" colspan="3" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Depression
         </th>
        </tr>
        <tr>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          R
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          AR
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          B (95% CI)
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          R
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          AR
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          B (95% CI)
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          R
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          AR
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          B (95% CI)
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          R
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          AR
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          B (95% CI)
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Close contact with an individual with confirmed infection with COVID-19
          </bold>
         </td>
         <td align="center" colspan="13" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          4 (0.3)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.53 (−0.70 to 1.75)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.32 (−0.40 to 1.04)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.98 (−0.16 to 2.11)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.004
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.97 * (0.06 to 1.88)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1206 (99.7)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Indirect contact with an individual with confirmed infection with COVID-19
         </td>
         <td align="center" colspan="13" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          6 (0.5)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.06 (−1.06 to 0.94)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.27 (−0.86 to 0.32)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.28 (−1.21 to 0.65)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.37 (−1.11 to 0.38)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1204 (99.5)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Contact with an individual with suspected COVID-19 or infected materials
         </td>
         <td align="center" colspan="13" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          12 (1.0)
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.36 (−0.35 to 1.07)
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.41 (−0.01 to 0.82)
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          0.007
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          0.006
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.98 ** (0.32 to 1.64)
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          0.008
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          0.007
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.81 ** (0.29 to 1.34)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1198 (99.0)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.03 (−1.32 to 1.26)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         *
         <italic>
          p
         </italic>
         &lt; 0.05, **
         <italic>
          p
         </italic>
         &lt; 0.01.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <table-wrap id="ijerph-17-01729-t004" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       ijerph-17-01729-t004_Table 4
      </object-id>
      <label>
       Table 4
      </label>
      <caption>
       <p>
        Association between knowledge and concerns about the 2019 coronavirus disease (COVID-19) and the psychological impact of outbreak as well as adverse mental health status during the epidemic (
        <italic>
         n
        </italic>
        = 1210).
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Variables
         </th>
         <th align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          <italic>
           n
          </italic>
          (%)
         </th>
         <th align="center" colspan="3" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Impact of Event
         </th>
         <th align="center" colspan="4" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Stress
         </th>
         <th align="center" colspan="4" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Anxiety
         </th>
         <th align="center" colspan="5" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Depression
         </th>
        </tr>
        <tr>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          R
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          AR
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          B (95% CI)
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          R
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          AR
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          B (95% CI)
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          R
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          AR
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          B (95% CI)
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          R
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          AR
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="3" rowspan="1" style="border-bottom:solid thin" valign="middle">
          B (95% CI)
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          <bold>
           Knowledge of COVID-19
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Route of transmission
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Droplets
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Agree
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1115 (92.1)
         </td>
         <td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.21 (−0.07 to 0.49)
         </td>
         <td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.15 (−0.01 to 0.32)
         </td>
         <td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.17 (−0.09 to 0.43)
         </td>
         <td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">
          0.005
         </td>
         <td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">
          0.004
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          0.27 * (0.06 to 0.48)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Disagree
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          13 (1.1)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.48 (−0.25 to 1.21)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.09 (−0.34 to 0.52)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.22 (−0.45 to 0.90)
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          0.18 (−0.36 to0.72)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Do not know
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          82 (6.8)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="3" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="left" colspan="18" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Contact via contaminated objects
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Agree
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          892 (73.7)
         </td>
         <td align="center" colspan="1" rowspan="3" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="3" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.04 (−0.15 to 0.22)
         </td>
         <td align="center" colspan="1" rowspan="3" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="3" valign="middle">
          0.001
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          −0.02 (−0.13 to 0.09)
         </td>
         <td align="center" colspan="1" rowspan="3" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="3" valign="middle">
          0.001
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          −0.07 (−0.24 to 0.10)
         </td>
         <td align="center" colspan="1" rowspan="3" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="3" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          0.02 (−0.12 to 0.15)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Disagree
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          94 (7.8)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.04 (−0.34 to 0.26)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          −0.16 (−0.34 to 0.02)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          −0.23 (−0.51 to 0.05)
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          −0.10 (−0.33 to 0.12)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Do not know
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          224 (18.5)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Airborne
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Agree
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          732 (60.5)
         </td>
         <td align="center" colspan="1" rowspan="3" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="3" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.11 (−0.07 to 0.29)
         </td>
         <td align="center" colspan="1" rowspan="3" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="3" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.04 (−0.07 to 0.14)
         </td>
         <td align="center" colspan="1" rowspan="3" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="3" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.12 (−0.05 to 0.28)
         </td>
         <td align="center" colspan="1" rowspan="3" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="3" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          0.08 (−0.05 to 0.22)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Disagree
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          225 (18.6)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.17 (−0.05 to 0.40)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          −0.002 (−0.13 to 0.13)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.04 (−0.17 to 0.25)
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          0.03 (−0.14 to 0.20)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Do not know
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          253 (20.9)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="18" rowspan="1" style="border-top:solid thin" valign="middle">
          <bold>
           Have you heard that the number of infected COVID-19 individuals has increased?
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          Heard
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          1195 (98.8)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          0.40 (−0.24 to 1.03)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-top:solid thin" valign="middle">
          0.10 (−0.27 to 0.47)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-top:solid thin" valign="middle">
          −0.16 (−0.75 to 0.43)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="3" rowspan="1" style="border-top:solid thin" valign="middle">
          −0.14 (−0.61 to 0.34)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Not heard
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          15 (1.2)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="3" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="18" rowspan="1" valign="middle">
          <bold>
           Have you heard that the number of COVID-19 deaths has increased?
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          Heard
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          1183 (97.8)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          0.21 (−0.27 to 0.69)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-top:solid thin" valign="middle">
          0.18 (−0.10 to 0.46)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-top:solid thin" valign="middle">
          0.04 (−0.40 to 0.48)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="3" rowspan="1" style="border-top:solid thin" valign="middle">
          0.09 (−0.27 to 0.44)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Not heard
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          27 (2.2)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="3" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="18" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Have you heard that the number of individuals that have recovered from COVID-19 infection has increased?
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Heard
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1129 (93.3)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.19 (−0.47 to 0.09)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.007
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.006
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          −0.24 ** (−0.40 to −0.07)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          −0.25 (−0.51 to 0.01)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.004
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.003
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          −0.24 * (−0.45 to −0.03)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Not heard
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          81 (6.7)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="3" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="18" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           The main source of health information
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Internet
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1131 (93.5)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.46 (−1.46 to 0.54)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.007
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.004
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          −0.25 (−0.83 to0.34 )
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.010
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.006
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          −0.57 (−1.50 to 0.35)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.007
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.004
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          0.19 (−0.55 to 0.94)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Television
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          62 (5.1)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.22 (−1.26 to 0.83)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          −0.07 (−0.68 to 0.54)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          −0.35 (−1.32 to 0.62)
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          0.31 (−0.47 to 1.09)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Radio
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1 (0.1)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.83 (−1.81 to 3.47)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          1.33 (−0.22 to 2.89)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          2.67 * (0.22 to 5.11)
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          2.67 ** (0.70 to 4.63)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Family members
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          10 (0.8)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.47 (−1.73 to 0.80)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          −0.27 (−1.01 to 0.48)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          −0.33 (−1.50 to 0.84)
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          −0.03(−0.97 to 0.91)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Other sources
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          6 (0.5)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="3" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="18" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Satisfaction with the amount of health information available about COVID-19
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Very satisfied
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          485 (40.1)
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          0.018
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          0.014
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.02 (−0.34 to 0.37)
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          0.014
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          0.011
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          −0.09 (−0.30 to 0.13)
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          0.013
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          0.010
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          −0.20 (−0.53 to 0.14)
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          0.014
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          0.011
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          −0.12 (−0.38 to 0.15)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Somewhatsatisfied
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          423 (35.0)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.23 (−0.13 to 0.59)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.03 (−0.19 to 0.24)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          −0.02 (−0.36 to 0.31)
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          −0.001 (−0.27 to 0.27)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Not very satisfied
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          211 (17.4)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.39 * (0.01 to 0.77)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.09 (−0.14 to 0.31)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.05 (−0.31 to 0.40)
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          0.08 (−0.21 to 0.36)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Not satisfied at all
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          40 (3.3)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.63 * (0.11 to 1.14)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.32 * (0.02 to 0.62)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.41 (−0.07 to 0.88)
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          0.43 * (0.04 to 0.81)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Do not know
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          51 (4.2)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Concerns about COVID-19
          </bold>
         </td>
         <td align="center" colspan="17" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="18" rowspan="1" valign="middle">
          <bold>
           Level of confidence in own doctor’s ability to diagnose or recognize
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          Very confident
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          563 (46.5)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.025
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.022
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          −0.2 (−0.66 to 0.27)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.021
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.017
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-top:solid thin" valign="middle">
          0.05 (−0.23 to 0.32)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.024
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.021
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-top:solid thin" valign="middle">
          0.02 (−0.42 to 0.45)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.021
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.018
         </td>
         <td align="center" colspan="3" rowspan="1" style="border-top:solid thin" valign="middle">
          0.02 (−0.33 to 0.37)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Somewhat confident
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          561 (46.4)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.19 (−0.28 to 0.66)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.16 (−0.12 to 0.44)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.22 (−0.22 to 0.65)
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          0.09 (−0.26 to 0.44)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Not very confident
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          50 (4.1)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.19 (−0.39 to 0.76)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.18 (−0.16 to 0.52)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.38 (−0.15 to 0.91)
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          0.10 (−0.33 to 0.52)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Not at all confident
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          8 (0.7)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.66 (−0.31 to 1.63)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          1.18 *** (0.61 to 1.75)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          1.86 *** (0.96 to 2.76)
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          1.66 ***(0.94 to 2.38)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Do not know
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          28 (2.3)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="3" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="18" rowspan="1" valign="middle">
          <bold>
           Likelihood of contracting COVID−19 during the current outbreak
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          Very likely
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          135 (11.2)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin" valign="middle">
          0.019
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin" valign="middle">
          0.016
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          −0.33 * (−0.61 to −0.05)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin" valign="middle">
          0.008
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin" valign="middle">
          0.005
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-top:solid thin" valign="middle">
          0.05 (−0.11 to 0.22)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin" valign="middle">
          0.009
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin" valign="middle">
          0.005
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-top:solid thin" valign="middle">
          0.07 (−0.20 to 0.33)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin" valign="middle">
          0.007
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin" valign="middle">
          0.004
         </td>
         <td align="center" colspan="3" rowspan="1" style="border-top:solid thin" valign="middle">
          0.15 (−0.06 to 0.36)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Somewhat likely
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          358 (29.6)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.15 (−0.09 to 0.38)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.06 (−0.08 to 0.20)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          −0.02 (−0.23 to 0.20)
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          0.04 (−0.14 to 0.21)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Not very likely
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          437 (36.1)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.14 (−0.09 to 0.36)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          −0.002 (−0.14 to 0.13)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          −0.05 (−0.26 to 0.16)
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          0.03 (−0.14 to 0.20)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Not likely at all
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          121 (10.0)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.23(−0.52 to 0.06)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          −0.18 * (−0.35 to −0.01)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          −0.36 * (−0.63to−0.09)
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          −0.19 (−0.41 to 0.03)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Do not know
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          159 (13.1)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="18" rowspan="1" style="border-top:solid thin" valign="middle">
          <bold>
           Likelihood of surviving if infected with COVID-19
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          Very likely
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          278 (23.0)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.014
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.011
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          −0.19 (−0.41 to 0.03)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.009
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.006
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-top:solid thin" valign="middle">
          −0.02 (−0.15 to 0.11)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.006
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-top:solid thin" valign="middle">
          −0.06 (−0.27 to 0.14)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.007
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.003
         </td>
         <td align="center" colspan="3" rowspan="1" style="border-top:solid thin" valign="middle">
          0.01 (−0.15 to 0.17)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Somewhat likely
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          559 (46.2)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.12 (−0.07 to 0.31)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.01 (−0.10 to 0.13)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          −0.03 (−0.21 to 0.15)
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          −0.01 (−0.15 to 0.14)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Not very likely
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          124 (10.2)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.23 (−0.04 to 0.50)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.18 * (0.02 to 0.34)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.18 (−0.08 to 0.43)
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          0.15 (−0.06 to 0.35)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Not likely at all
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          20 (1.7)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.42 (−0.15 to 0.99)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.34 * (0.01 to 0.68)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.42 (−0.11 to 0.95)
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          0.49 * (0.07 to 0.92)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Do not know
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          229 (18.9)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="3" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="18" rowspan="1" valign="middle">
          <bold>
           Concerns about other family members getting COVID−19 infection
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          Very worried
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          417 (34.5)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin" valign="middle">
          0.017
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin" valign="middle">
          0.014
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          0.75(−0.03 to 1.53)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin" valign="middle">
          0.007
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin" valign="middle">
          0.004
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-top:solid thin" valign="middle">
          0.50
          <sup>
           *
          </sup>
          (0.04 to 0.96)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin" valign="middle">
          0.006
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin" valign="middle">
          0.003
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-top:solid thin" valign="middle">
          0.59(−0.13 to 1.32)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin" valign="middle">
          0.005
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="3" rowspan="1" style="border-top:solid thin" valign="middle">
          0.29(−0.30 to 0.87)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Somewhat worried
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          492 (40.7)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.67 (−0.10 to 1.45)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.40 (−0.05 to 0.86)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.43 (−0.30 to 1.15)
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          0.20 (−0.38 to 0.78)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Not very worried
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          221 (18.3)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.44 (−0.34 to 1.23)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.43 (−0.04 to 0.89)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.44 (−0.30 to 1.17)
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          0.26 (−0.33 to 0.85)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Not worried at all
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          70 (5.8)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.19 (−0.64 to 1.01)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.33 (−0.16 to 0.81)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.36 (−0.41 to 1.13)
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          0.04 (−0.57 to 0.66)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Do not have family members
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          10 (0.8)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="18" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          <bold>
           Concerns about a child younger than 16 years getting COVID-19 infection
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Very worried
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          309 (25.5)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.006
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.25 * (0.05 to 0.44)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          −0.003
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.05 (−0.07 to 0.16)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.007
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.004
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.24 ** (0.07 to 0.42)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          0.09 (−0.05 to 0.24)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Somewhat worried
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          307 (25.4)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.13 (−0.06 to 0.32)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.03 (−0.09 to 0.14)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.21 * (0.03 to 0.39)
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          0.08 (−0.06 to 0.23)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Not very worried
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          151 (12.5)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.10 (−0.14 to 0.34)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.04 (−0.10 to 0.18)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.21 (−0.01 to 0.43)
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          0.08 (−0.09 to 0.26)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Not worried at all
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          102 (8.4)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.02 (−0.30 to 0.26)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.004 (−0.16 to 0.17)
         </td>
         <td align="center" colspan="2" rowspan="1" valign="middle">
          0.14 (−0.12 to 0.40)
         </td>
         <td align="center" colspan="3" rowspan="1" valign="middle">
          0.03 (−0.18 to 0.23)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Do not have children
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          341 (28.2)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="3" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         *
         <italic>
          p
         </italic>
         &lt; 0.05; **
         <italic>
          p
         </italic>
         &lt; 0.01; ***
         <italic>
          p
         </italic>
         &lt; 0.001.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <table-wrap id="ijerph-17-01729-t005" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       ijerph-17-01729-t005_Table 5
      </object-id>
      <label>
       Table 5
      </label>
      <caption>
       <p>
        Association between precautionary measures in the past 14 days and the psychological impact of the 2019 coronavirus disease (COVID-19) outbreak as well as adverse mental health status during the epidemic (
        <italic>
         n
        </italic>
        = 1210).
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Variables
         </th>
         <th align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          <italic>
           n
          </italic>
          (%)
         </th>
         <th align="center" colspan="3" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Impact of Event
         </th>
         <th align="center" colspan="3" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Stress
         </th>
         <th align="center" colspan="3" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Anxiety
         </th>
         <th align="center" colspan="3" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Depression
         </th>
        </tr>
        <tr>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          R
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          AR
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          B (95% CI)
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          R
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          AR
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          B (95% CI)
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          R
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          AR
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          B (95% CI)
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          R
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          AR
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          B (95% CI)
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="center" colspan="14" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Covering mouth when coughing and sneezing
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Always
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          694 (57.4)
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          0.009
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          0.006
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.02 (−0.34 to 0.37)
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.02 (−0.19 to 0.23)
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          0.007
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          0.004
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.19 (−0.52 to 0.14)
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          −0.002
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.09 (−0.35 to 0.18)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Most of the time
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          282 (23.3)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.18 (−0.19 to 0.55)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.09 (−0.13 to 0.31)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.09 (−0.43 to 0.26)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.04 (−0.32 to 0.24)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Sometime
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          106 (8.8)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.40 (−0.02 to 0.82)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.12 (−0.13 to 0.36)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.09 (−0.30 to 0.47)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.02 (−0.30 to 0.33)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Occasionally
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          77 (6.3)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.18 (−0.26 to 0.62)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.03 (−0.29 to 0.23)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.32 (−0.73 to 0.09)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.02 (−0.35 to 0.31)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Never
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          51 (4.2)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="14" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          <bold>
           Avoiding sharing of utensils (e.g., chopsticks) during meals
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Always
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          490 (40.5)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.041
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.037
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.29 ** (−0.50 to −0.09)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.017
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.013
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.18 ** (−0.31 to −0.06)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.017
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.013
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.36 *** (−0.55 to −0.17)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.016
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.013
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.31 *** (−0.46 to −0.15)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Most of the time
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          207 (17.1)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.17 (−0.07 to 0.40)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.01 (−0.13 to 0.16)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.03 (−0.26 to 0.19)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.07 (−0.25 to 0.11)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Sometime
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          162 (13.4)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.23 (−0.02 to 0.49)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.02 (−0.17 to 0.14)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.13 (−0.37 to 0.11)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.20 * (−0.39 to −0.003)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Occasionally
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          156 (12.9)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.36 ** (0.10 to 0.62)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.03 (−0.12 to 0.18)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.14 (−0.38 to 0.11)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.12 (−0.32 to 0.07)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Never
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          195 (16.1)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="14" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Washing hands with soap and water
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Always
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          684 (56.5)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.029
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.026
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.42 (−0.85 to 0.01)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.011
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.007
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.34 ** (−0.60 to −0.09)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.015
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.012
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.54 ** (−0.94 to −0.14)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.011
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.007
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.39 * (−0.71 to −0.07)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Most of the time
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          266 (22)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.12 (−0.56 to 0.33)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.29 * (−0.56 to −0.03)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.40 (−0.81 to 0.02)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.27 (−0.60 to 0.07)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Sometime
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          127 (10.5)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.07 (−0.40 to 0.54)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.22 (−0.50 to 0.07)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.23 (−0.67 to 0.21)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.25 (−0.61 to 0.10)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Occasionally
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          100 (8.3)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.13 (−0.35 to 0.62)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.17 (−0.46 to 0.12)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.21 (−0.67 to 0.24)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.15 (−0.51 to 0.22)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Never
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          33 (2.7)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="14" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Washing hands immediately after coughing, rubbing nose, or sneezing
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Always
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          496 (41)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.042
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.039
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.47 ** (−0.77 to −0.17)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.02
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.016
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.31 ** (−0.49 to −0.13)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.22
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.019
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.63 *** (−0.91 to −0.35)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.021
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">
          0.018
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.38 ** (−0.60 to −0.16)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Most of the time
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          227 (18.8)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.003 (−0.32 to 0.32)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.17 (−0.36 to 0.02)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.44 ** (−0.74 to −0.14)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.26 * (−0.50 to −0.02)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Sometime
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          227 (18.8)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.02 (−0.30 to 0.34)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.12 (−0.32 to 0.07)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.41 ** (−0.71 to −0.11)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.18 (−0.42 to 0.06)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Occasionally
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          185 (15.2)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.14 (−0.19 to 0.47)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.08 (−0.28 to 0.12)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.29 (−0.60 to 0.02)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.04 (−0.29 to 0.20)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Never
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          75 (6.2)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="14" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Wearing mask regardless of the presence or absence of symptoms
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Always
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          723 (59.8)
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          0.026
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          0.023
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.19 (−0.59 to 0.21)
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          0.009
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          0.006
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.21 (−0.45 to 0.02)
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          0.01
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          0.006
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.43 * (−0.81 to −0.06)
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          0.015
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          0.012
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.37 * (−0.67 to −0.07)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Most of the time
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          263 (21.7)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.12 (−0.30 to 0.53)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.09 (−0.34 to 0.16)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.27 (−0.66 to 0.12)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.21 (−0.52 to 0.10)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Sometime
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          116 (9.6)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.16 (−0.29 to 0.61)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.08 (−0.35 to 0.19)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.25 (−0.67 to 0.17)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.25 (−0.59 to 0.08)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Occasionally
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          69 (5.7)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.52 * (0.04 to 1.01)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.04 (−0.33 to 0.24)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.14 (−0.60 to 0.31)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.006 (−0.36 to 0.37)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Never
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          39(3.2)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="14" rowspan="1" style="border-top:solid thin" valign="middle">
          <bold>
           Washing hands after touching contaminated objects
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          Always
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          806 (66.6)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.018
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.014
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          −0.11 (−0.69 to 0.47)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.007
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          −0.21 (−0.56 to 0.13)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.014
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.011
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          −0.52 (−1.06 to 0.02)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.012
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.008
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          −0.53 * (−0.96 to −0.10)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Most of the time
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          283 (23.4)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.19 (−0.40 to 0.78)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.15 (−0.49 to 0.21)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.37 (−0.92 to 0.18)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.41 (−0.85 to 0.03)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Sometime
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          66 (5.4)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.40 (−0.25 to 1.04)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.01 (−0.39 to 0.38)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.03 (−0.63 to 0.58)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.27 (−0.76 to 0.21)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Occasional
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          37 (3.1)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.31 (−0.39 to 1.00)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.07 (−0.48 to 0.34)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.22 (−0.87 to 0.43)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.24 (−0.76 to 0.28)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Never
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          18 (1.5)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="14" rowspan="1" valign="middle">
          <bold>
           Feeling that too much unnecessary worry has been made about the COVID-19 outbreak
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          Always
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          156 (12.9)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.019
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.016
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          −0.47 *** (−0.69 to −0.25)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          −0.08 (−0.21 to 0.05)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          0.12 (−0.09 to 0.33)
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.005
         </td>
         <td align="center" colspan="1" rowspan="5" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          0.12 (−0.04 to 0.29)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Most of the time
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          108 (8.9)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.19 (−0.44 to 0.07)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.05 (−0.20 to 0.11)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.20 (−0.04 to 0.44)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.20 * (0.003 to 0.39)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Sometime
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          242 (20)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.03 (−0.21 to 0.16)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.01 (−0.12 to 0.10)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.07 (−0.10 to 0.25)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.01 (−0.13 to 0.15)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Occasionally
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          166 (13.7)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.13 (−0.09 to 0.34)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.03 (−0.10 to 0.16)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.12 (−0.08 to 0.33)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.10 (−0.07 to 0.26)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Never
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          538 (44.5)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="14" rowspan="1" valign="middle">
          <bold>
           Average number of hours staying at home per day to avoid COVID−19
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          [0–9]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          39 (3.2)
         </td>
         <td align="center" colspan="1" rowspan="3" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="3" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          −0.15 (−0.55 to 0.25)
         </td>
         <td align="center" colspan="1" rowspan="3" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="3" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          −0.16 (−0.39 to 0.08)
         </td>
         <td align="center" colspan="1" rowspan="3" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="3" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          −0.15 (−0.52 to 0.22)
         </td>
         <td align="center" colspan="1" rowspan="3" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="3" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          −0.21 (−0.51 to 0.08)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          [10–19]
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          146 (12.1)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.11 (−0.10 to 0.33)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.03 (−0.16 to 0.10)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.06 (−0.26 to 0.14)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.08 (−0.24 to 0.08)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [20–24]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1025 (84.7)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         *
         <italic>
          p
         </italic>
         &lt; 0.05; **
         <italic>
          p
         </italic>
         &lt; 0.01; ***
         <italic>
          p
         </italic>
         &lt; 0.001.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <table-wrap id="ijerph-17-01729-t006" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       ijerph-17-01729-t006_Table 6
      </object-id>
      <label>
       Table 6
      </label>
      <caption>
       <p>
        Association between additional health information required by participants and the psychological impact of the 2019 coronavirus disease (COVID-19) outbreak as well as adverse mental health status during the epidemic (
        <italic>
         n
        </italic>
        = 1210).
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Variables
         </th>
         <th align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          <italic>
           n
          </italic>
          (%)
         </th>
         <th align="center" colspan="3" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Impact of Event
         </th>
         <th align="center" colspan="3" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Stress
         </th>
         <th align="center" colspan="3" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Anxiety
         </th>
         <th align="center" colspan="3" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Depression
         </th>
        </tr>
        <tr>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          R
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          AR
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          B (95% CI)
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          R
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          AR
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          B (95% CI)
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          R
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          AR
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          B (95% CI)
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          R
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          AR
          <sup>
           2
          </sup>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          B (95% CI)
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="center" colspan="14" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Need for further health information about the COVID-19 infection
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1048 (86.6)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.010
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.009
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.36 ** (0.15 to 0.57)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.12 * (0.00 to 0.24)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.16 (−0.03 to 0.35)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0. 1 (−0.06 to 0.25)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          162 (13.4)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="14" rowspan="1" valign="middle">
          <bold>
           Need for details on symptoms of the COVID−19 infection
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          1108 (91.6)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.006
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.005
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          0.34 ** (0.09 to 0.59)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          −0.02 (−0.17 to 0.13)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          −0.12 (−0.36 to 0.11)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          −0.11 (−0.30 to 0.08)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          102 (8.4)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="14" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Need for advice on prevention of the COVID−19 infection
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1134 (93.7)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.010
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.009
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.52 *** (0.23 to 0.81)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.11 (−0.06 to 0.28)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.13 (−0.14 to 0.40)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.05 (−0.17 to 0.26)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          76 (6.3)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="14" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Need for advice on treatment of the COVID−19 infection
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1000 (82.6)
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.19 * (0.006 to 0.38)
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.03 (−0.08 to 0.14)
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.03 (−0.14 to 0.20)
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.05 (−0.18 to 0.09)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          210 (17.4)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="14" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          <bold>
           Need for regular updates for latest information about the COVID−19 infection
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1173 (96.9)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.03 (−0.44 to 0.38)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.11 (−0.35 to 0.13)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.008
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.008
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.62 ** (−1.00 to −0.24)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.29 (−0.59 to 0.01)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          37 (3.1)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="14" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Need for the latest updates for outbreaks of the COVID−19 infection in the local area
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1122 (92.7)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.06 (−0.21 to 0.33)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.01 (−0.15 to 0.17)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.10 (−0.36 to 0.15)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.09 (−0.11 to 0.30)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          88 (7.3)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="14" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Need for advice for people who may need more tailored information, such as those with pre-existing illness
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1133 (93.6)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.19 (−0.10 to 0.48)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.004 (−0.17 to 0.17)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.14 (−0.41 to 0.13)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.02 (−0.23 to 0.20)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          77 (6.4)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="14" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Need for information on the availability and effectiveness of medicines/vaccines for the COVID−19 infection
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1171 (96.8)
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.19 (−0.21 to 0.59)
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.16 (−0.40 to 0.07)
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          0.009
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          0.008
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.63 ** (−0.99 to −0.26)
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          0.005
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          0.004
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.35 * (−0.65 to −0.06)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          39 (3.2)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="14" rowspan="1" style="border-top:solid thin" valign="middle">
          <bold>
           Need for the latest updates on the number of people infected by COVID-19 and their location
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          1139 (94.1)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          0.17 (−0.13 to 0.47)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          −0.09 (−0.27 to 0.08)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.004
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          −0.30 * (−0.57 to −0.02)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          −0.13 (−0.35 to 0.10)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          71 (5.9)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="14" rowspan="1" valign="middle">
          <bold>
           Need for travel advice for the COVID-19 epidemic
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          1160 (95.9)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          0.07 (−0.29 to 0.42)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          −0.07 (−0.28 to 0.14)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          −0.19 (−0.52 to 0.14)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          −0.07 (−0.34 to 0.19)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          50 (4.1)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="14" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Need for updates on the routes of transmission of COVID-19
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1172 (96.9)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.15 (−0.25 to 0.55)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.10 (−0.33 to 0.14)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.003
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.39 * (−0.77 to −0.02)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.21 (−0.51 to 0.09)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          38 (3.1)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
        <tr>
         <td align="center" colspan="14" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Need for updates on how other countries handle the COVID-19 outbreak
          </bold>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Yes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1144 (94.5)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.002
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.25 (−0.06 to 0.56)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          −0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.008 (−0.19 to 0.18)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.14 (−0.43 to 0.15)
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          &lt;0.001
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          −0.08 (−0.31 to 0.15)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          66 (5.5)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Reference
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         *
         <italic>
          p
         </italic>
         &lt; 0.05; **
         <italic>
          p
         </italic>
         &lt; 0.01; ***
         <italic>
          p
         </italic>
         &lt; 0.001.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
    </floats-group>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Dent Res
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       J. Dent. Res
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       JDR
      </journal-id>
      <journal-id journal-id-type="hwp">
       spjdr
      </journal-id>
      <journal-title-group>
       <journal-title>
        Journal of Dental Research
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0022-0345
      </issn>
      <issn pub-type="epub">
       1544-0591
      </issn>
      <publisher>
       <publisher-name>
        SAGE Publications
       </publisher-name>
       <publisher-loc>
        Sage CA: Los Angeles, CA
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32162995
      </article-id>
      <article-id pub-id-type="pmc">
       7140973
      </article-id>
      <article-id pub-id-type="doi">
       10.1177/0022034520914246
      </article-id>
      <article-id pub-id-type="publisher-id">
       10.1177_0022034520914246
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Discovery!
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Coronavirus Disease 2019 (COVID-19): Emerging and Future Challenges for Dental and Oral Medicine
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Meng
         </surname>
         <given-names>
          L.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1-0022034520914246">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="false" contrib-id-type="orcid">
         https://orcid.org/0000-0002-2438-5924
        </contrib-id>
        <name>
         <surname>
          Hua
         </surname>
         <given-names>
          F.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2-0022034520914246">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="false" contrib-id-type="orcid">
         https://orcid.org/0000-0002-8035-4276
        </contrib-id>
        <name>
         <surname>
          Bian
         </surname>
         <given-names>
          Z.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1-0022034520914246">
         1
        </xref>
        <xref ref-type="corresp" rid="corresp1-0022034520914246">
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1-0022034520914246">
       <label>
        1
       </label>
       The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan, China
      </aff>
      <aff id="aff2-0022034520914246">
       <label>
        2
       </label>
       Center for Evidence-Based Stomatology, School and Hospital of Stomatology, Wuhan University, Wuhan, China
      </aff>
      <author-notes>
       <corresp id="corresp1-0022034520914246">
        Z. Bian, The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Luoyu Road 237, Wuhan, Hubei 430079, China. Email:
        <email>
         bianzhuan@whu.edu.cn
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="epub">
       <day>
        12
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <elocation-id>
       0022034520914246
      </elocation-id>
      <permissions>
       <copyright-statement>
        © International &amp; American Associations for Dental Research 2020
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder content-type="society">
        International &amp; American Associations for Dental Research
       </copyright-holder>
       <license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/4.0/">
        <license-p>
         This article is distributed under the terms of the Creative Commons Attribution 4.0 License (
         <ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by/4.0/">
          http://www.creativecommons.org/licenses/by/4.0/
         </ext-link>
         ) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (
         <ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">
          https://us.sagepub.com/en-us/nam/open-access-at-sage
         </ext-link>
         ).
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        The epidemic of coronavirus disease 2019 (COVID-19), originating in Wuhan, China, has become a major public health challenge for not only China but also countries around the world. The World Health Organization announced that the outbreaks of the novel coronavirus have constituted a public health emergency of international concern. As of February 26, 2020, COVID-19 has been recognized in 34 countries, with a total of 80,239 laboratory-confirmed cases and 2,700 deaths. Infection control measures are necessary to prevent the virus from further spreading and to help control the epidemic situation. Due to the characteristics of dental settings, the risk of cross infection can be high between patients and dental practitioners. For dental practices and hospitals in areas that are (potentially) affected with COVID-19, strict and effective infection control protocols are urgently needed. This article, based on our experience and relevant guidelines and research, introduces essential knowledge about COVID-19 and nosocomial infection in dental settings and provides recommended management protocols for dental practitioners and students in (potentially) affected areas.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        virology
       </kwd>
       <kwd>
        infection control
       </kwd>
       <kwd>
        dental public health
       </kwd>
       <kwd>
        dental education
       </kwd>
       <kwd>
        transmission
       </kwd>
       <kwd>
        dental practice management
       </kwd>
      </kwd-group>
      <funding-group>
       <award-group id="award1-0022034520914246">
        <funding-source id="funding1-0022034520914246">
         <institution-wrap>
          <institution>
           National Key Research and Development Program of China
          </institution>
          <institution-id>
          </institution-id>
         </institution-wrap>
        </funding-source>
        <award-id rid="funding1-0022034520914246">
         National Key Research and Development Program of China
        </award-id>
       </award-group>
       <award-group id="award2-0022034520914246">
        <funding-source id="funding2-0022034520914246">
         <institution-wrap>
          <institution>
           Key Research Program of Provincial Department of Science and Technology
          </institution>
          <institution-id>
          </institution-id>
         </institution-wrap>
        </funding-source>
        <award-id rid="funding2-0022034520914246">
         2017ACA181
        </award-id>
       </award-group>
       <award-group id="award3-0022034520914246">
        <funding-source id="funding3-0022034520914246">
         <institution-wrap>
          <institution>
           National Natural Science Foundation of China
          </institution>
          <institution-id institution-id-type="FundRef">
           https://doi.org/10.13039/501100001809
          </institution-id>
         </institution-wrap>
        </funding-source>
        <award-id rid="funding3-0022034520914246">
         81870761
        </award-id>
       </award-group>
       <award-group id="award4-0022034520914246">
        <funding-source id="funding4-0022034520914246">
         <institution-wrap>
          <institution>
           National Natural Science Foundation of China
          </institution>
          <institution-id institution-id-type="FundRef">
           https://doi.org/10.13039/501100001809
          </institution-id>
         </institution-wrap>
        </funding-source>
        <award-id rid="funding4-0022034520914246">
         81901044
        </award-id>
       </award-group>
       <award-group id="award5-0022034520914246">
        <funding-source id="funding5-0022034520914246">
         <institution-wrap>
          <institution>
           National Natural Science Foundation of China
          </institution>
          <institution-id institution-id-type="FundRef">
           https://doi.org/10.13039/501100001809
          </institution-id>
         </institution-wrap>
        </funding-source>
        <award-id rid="funding5-0022034520914246">
         81970923
        </award-id>
       </award-group>
      </funding-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         edited-state
        </meta-name>
        <meta-value>
         corrected-proof
        </meta-value>
       </custom-meta>
       <custom-meta>
        <meta-name>
         typesetter
        </meta-name>
        <meta-value>
         ts1
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="section1-0022034520914246" sec-type="intro">
     <title>
      Introduction
     </title>
     <p>
      On January 8, 2020, a novel coronavirus was officially announced as the causative pathogen of COVID-19 by the Chinese Center for Disease Control and Prevention (
      <xref ref-type="bibr" rid="bibr15-0022034520914246">
       Li et al. 2020
      </xref>
      ). The epidemics of coronavirus disease 2019 (COVID-19) started from Wuhan, China, last December and have become a major challenging public health problem for not only China but also countries around the world (
      <xref ref-type="bibr" rid="bibr27-0022034520914246">
       Phelan et al. 2020
      </xref>
      ). On January 30, 2020, the World Health Organization (WHO) announced that this outbreak had constituted a public health emergency of international concern (
      <xref ref-type="bibr" rid="bibr19-0022034520914246">
       Mahase 2020
      </xref>
      ). The novel coronavirus was initially named 2019-nCoV and officially as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of February 26, COVID-19 has been recognized in 34 countries, with a total of 80,239 laboratory-confirmed cases and 2,700 deaths (
      <xref ref-type="bibr" rid="bibr36-0022034520914246">
       WHO 2020b
      </xref>
      ).
     </p>
     <p>
      Due to the characteristics of dental settings, the risk of cross infection may be high between dental practitioners and patients. For dental practices and hospitals in countries/regions that are (potentially) affected with COVID-19, strict and effective infection control protocols are urgently needed. This article, based on our experience and relevant guidelines and research, introduces the essential knowledge about COVID-19 and nosocomial infection in dental settings and provides recommended management protocols for dental practitioners and students in (potentially) affected areas.
     </p>
    </sec>
    <sec id="section2-0022034520914246">
     <title>
      What Is COVID-19?
     </title>
     <sec id="section3-0022034520914246">
      <title>
       Viral Etiology
      </title>
      <p>
       According to recent research, similar to SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2 is zoonotic, with Chinese horseshoe bats (
       <italic>
        Rhinolophus sinicus
       </italic>
       ) being the most probable origin (
       <xref ref-type="bibr" rid="bibr4-0022034520914246">
        Chan et al. 2020
       </xref>
       ;
       <xref ref-type="bibr" rid="bibr18-0022034520914246">
        Lu et al. 2020
       </xref>
       ) and pangolins as the most likely intermediate host (
       <xref ref-type="bibr" rid="bibr31-0022034520914246">
        The Chinese Preventive Medicine Association 2020
       </xref>
       ).
      </p>
     </sec>
     <sec id="section4-0022034520914246">
      <title>
       Epidemiologic Characteristics
      </title>
      <sec id="section5-0022034520914246">
       <title>
        Mode of Transmission
       </title>
       <p>
        Based on findings of genetic and epidemiologic research, it appears that the COVID-19 outbreak started with a single animal-to-human transmission, followed by sustained human-to-human spread (
        <xref ref-type="bibr" rid="bibr4-0022034520914246">
         Chan et al. 2020
        </xref>
        ;
        <xref ref-type="bibr" rid="bibr7-0022034520914246">
         Del Rio and Malani 2020
        </xref>
        ). It is now believed that its interpersonal transmission occurs mainly via respiratory droplets and contact transmission (
        <xref ref-type="bibr" rid="bibr31-0022034520914246">
         The Chinese Preventive Medicine Association 2020
        </xref>
        ). In addition, there may be risk of fecal-oral transmission, as researchers have identified SARS-CoV-2 in the stool of patients from China and the United States (
        <xref ref-type="bibr" rid="bibr10-0022034520914246">
         Holshue et al. 2020
        </xref>
        ). However, whether SARS-CoV-2 can be spread through aerosols or vertical transmission (from mothers to their newborns) is yet to be confirmed (
        <xref ref-type="bibr" rid="bibr5-0022034520914246">
         Chen, Guo, et al. 2020
        </xref>
        ;
        <xref ref-type="bibr" rid="bibr37-0022034520914246">
         WHO 2020c
        </xref>
        ;
        <xref ref-type="bibr" rid="bibr39-0022034520914246">
         Zhu et al. 2020
        </xref>
        ).
       </p>
      </sec>
      <sec id="section6-0022034520914246">
       <title>
        Source of Transmission
       </title>
       <p>
        Although patients with symptomatic COVID-19 have been the main source of transmission, recent observations suggest that asymptomatic patients and patients in their incubation period are also carriers of SARS-CoV-2 (
        <xref ref-type="bibr" rid="bibr4-0022034520914246">
         Chan et al. 2020
        </xref>
        ;
        <xref ref-type="bibr" rid="bibr28-0022034520914246">
         Rothe et al. 2020
        </xref>
        ). This epidemiologic feature of COVID-19 has made its control extremely challenging, as it is difficult to identify and quarantine these patients in time, which can result in an accumulation of SARS-CoV-2 in communities (
        <xref ref-type="bibr" rid="bibr31-0022034520914246">
         The Chinese Preventive Medicine Association 2020
        </xref>
        ). In addition, it remains to be proved whether patients in the recovering phase are a potential source of transmission (
        <xref ref-type="bibr" rid="bibr28-0022034520914246">
         Rothe et al. 2020
        </xref>
        ).
       </p>
      </sec>
      <sec id="section7-0022034520914246">
       <title>
        Incubation Period
       </title>
       <p>
        The incubation period of COVID-19 has been estimated at 5 to 6 d on average, but there is evidence that it could be as long as 14 d, which is now the commonly adopted duration for medical observation and quarantine of (potentially) exposed persons (
        <xref ref-type="bibr" rid="bibr2-0022034520914246">
         Backer et al. 2020
        </xref>
        ;
        <xref ref-type="bibr" rid="bibr15-0022034520914246">
         Li et al. 2020
        </xref>
        ).
       </p>
      </sec>
      <sec id="section8-0022034520914246">
       <title>
        Fatality Rate
       </title>
       <p>
        According to current data, the fatality rate (cumulative deaths divided by cumulative cases) of COVID-19 is 0.39% to 4.05%, depending on different regions of China, which is lower than that of SARS (severe acute respiratory syndrome; ≈10%) and MERS (Middle East respiratory syndrome; ≈34% (
        <xref ref-type="bibr" rid="bibr20-0022034520914246">
         Malik et al. 2020
        </xref>
        ) and higher than that of seasonal influenza (0.01% to 0.17%) according to data for 2010 to 2017 from the US
        <xref ref-type="bibr" rid="bibr3-0022034520914246">
         Centers for Disease Control and Prevention (2020)
        </xref>
        .
       </p>
      </sec>
      <sec id="section9-0022034520914246">
       <title>
        People at High Risk of Infection
       </title>
       <p>
        Current observations suggest that people of all ages are generally susceptible to this new infectious disease. However, those who are in close contact with patients with symptomatic and asymptomatic COVID-19, including health care workers and other patients in the hospital, are at higher risk of SARS-CoV-2 infection. In the early stage of the epidemic, in an analysis of 138 hospitalized patients with COVID-19 in Wuhan, 57 (41%) were presumed to have been infected in hospital, including 40 (29%) health care workers and 17 (12%) patients hospitalized for other reasons (
        <xref ref-type="bibr" rid="bibr33-0022034520914246">
         Wang et al. 2020
        </xref>
        ). As of February 14, 2020, a total of 1,716 health care workers in China were infected with SARS-CoV-2, consisting of 3.8% affected patients nationally, 6 of that group who have died.
       </p>
      </sec>
     </sec>
     <sec id="section10-0022034520914246">
      <title>
       Clinical Manifestations
      </title>
      <p>
       The majority of patients with COVID-19 represent relatively mild cases. According to recent studies (
       <xref ref-type="bibr" rid="bibr9-0022034520914246">
        Guan et al. 2020
       </xref>
       ;
       <xref ref-type="bibr" rid="bibr38-0022034520914246">
        Yang et al. 2020
       </xref>
       ) and data from the
       <xref ref-type="bibr" rid="bibr24-0022034520914246">
        National Health Commission of China (2020b)
       </xref>
       , the proportion of severe cases among all patients with COVID-19 in China was around 15% to 25%.
      </p>
      <p>
       The majority of patients experienced fever and dry cough, while some also had shortness of breath, fatigue, and other atypical symptoms, such as muscle pain, confusion, headache, sore throat, diarrhea, and vomiting (
       <xref ref-type="bibr" rid="bibr6-0022034520914246">
        Chen, Zhou, et al. 2020
       </xref>
       ;
       <xref ref-type="bibr" rid="bibr9-0022034520914246">
        Guan et al. 2020
       </xref>
       ). Among patients who underwent chest computed tomography (CT), most showed bilateral pneumonia, with ground-glass opacity and bilateral patchy shadows being the most common patterns (
       <xref ref-type="bibr" rid="bibr9-0022034520914246">
        Guan et al. 2020
       </xref>
       ;
       <xref ref-type="bibr" rid="bibr33-0022034520914246">
        Wang et al. 2020
       </xref>
       ).
      </p>
      <p>
       Among hospitalized patients in Wuhan, around one-fourth to one-third developed serious complications, such as acute respiratory distress syndrome, arrhythmia, and shock, and were therefore transferred to the intensive care unit (
       <xref ref-type="bibr" rid="bibr6-0022034520914246">
        Chen, Zhou, et al. 2020
       </xref>
       ;
       <xref ref-type="bibr" rid="bibr11-0022034520914246">
        Huang et al. 2020
       </xref>
       ;
       <xref ref-type="bibr" rid="bibr33-0022034520914246">
        Wang et al. 2020
       </xref>
       ). In general, older age and the existence of underlying comorbidities (e.g., diabetes, hypertension, and cardiovascular disease) were associated with poorer prognosis (
       <xref ref-type="bibr" rid="bibr13-0022034520914246">
        Kui et al. 2020
       </xref>
       ;
       <xref ref-type="bibr" rid="bibr33-0022034520914246">
        Wang et al. 2020
       </xref>
       ;
       <xref ref-type="bibr" rid="bibr38-0022034520914246">
        Yang et al. 2020
       </xref>
       ).
      </p>
     </sec>
     <sec id="section11-0022034520914246">
      <title>
       Diagnosis and Treatment
      </title>
      <p>
       The diagnosis of COVID-19 can be based on a combination of epidemiologic information (e.g., a history of travel to or residence in affected region 14 d prior to symptom onset), clinical symptoms, CT imaging findings, and laboratory tests (e.g., reverse transcriptase polymerase chain reaction [RT-PCR] tests on respiratory tract specimens) according to standards of either the
       <xref ref-type="bibr" rid="bibr35-0022034520914246">
        WHO (2020a)
       </xref>
       or the
       <xref ref-type="bibr" rid="bibr23-0022034520914246">
        National Health Commission of China (2020a)
       </xref>
       . It should be mentioned that a single negative RT-PCR test result from suspected patients does not exclude infection. Clinically, we should be alert of patients with an epidemiologic history, COVID-19–related symptoms, and/or positive CT imaging results.
      </p>
      <p>
       So far, there has been no evidence from randomized controlled trials to recommend any specific anti-nCoV treatment, so the management of COVID-19 has been largely supportive (
       <xref ref-type="bibr" rid="bibr35-0022034520914246">
        WHO 2020a
       </xref>
       ). Currently, the approach to COVID-19 is to control the source of infection; use infection prevention and control measures to lower the risk of transmission; and provide early diagnosis, isolation, and supportive care for affected patients (
       <xref ref-type="bibr" rid="bibr33-0022034520914246">
        Wang et al. 2020
       </xref>
       ). A series of clinical trials are being carried out to investigate interventions that are potentially more effective (e.g., lopinavir, remdesivir;
       <xref ref-type="bibr" rid="bibr7-0022034520914246">
        Del Rio and Malani 2020
       </xref>
       ).
      </p>
     </sec>
    </sec>
    <sec id="section12-0022034520914246">
     <title>
      Infection Control in Dental Settings
     </title>
     <sec id="section13-0022034520914246">
      <title>
       Risk of Nosocomial Infection in Dental Settings
      </title>
      <p>
       Dental patients who cough, sneeze, or receive dental treatment including the use of a high-speed handpiece or ultrasonic instruments make their secretions, saliva, or blood aerosolize to the surroundings. Dental apparatus could be contaminated with various pathogenic microorganisms after use or become exposed to a contaminated clinic environment. Thereafter, infections can occur through the puncture of sharp instruments or direct contact between mucous membranes and contaminated hands (
       <xref ref-type="bibr" rid="bibr12-0022034520914246">
        Kohn et al. 2003
       </xref>
       ).
      </p>
      <p>
       Due to the unique characteristics of dental procedures where a large number of droplets and aerosols could be generated, the standard protective measures in daily clinical work are not effective enough to prevent the spread of COVID-19, especially when patients are in the incubation period, are unaware they are infected, or choose to conceal their infection.
      </p>
     </sec>
     <sec id="section14-0022034520914246">
      <title>
       Effective Infection Control Protocols
      </title>
      <p>
       Hand hygiene has been considered the most critical measure for reducing the risk of transmitting microorganism to patients (
       <xref ref-type="bibr" rid="bibr14-0022034520914246">
        Larson et al. 2000
       </xref>
       ). SARS-CoV-2 can persist on surfaces for a few hours or up to several days, depending on the type of surface, the temperature, or the humidity of the environment (
       <xref ref-type="bibr" rid="bibr37-0022034520914246">
        WHO 2020c
       </xref>
       ). This reinforces the need for good hand hygiene and the importance of thorough disinfection of all surfaces within the dental clinic. The use of personal protective equipment, including masks, gloves, gowns, and goggles or face shields, is recommended to protect skin and mucosa from (potentially) infected blood or secretion. As respiratory droplets are the main route of SARS-CoV-2 transmission, particulate respirators (e.g., N-95 masks authenticated by the National Institute for Occupational Safety and Health or FFP2-standard masks set by the European Union) are recommended for routine dental practice.
      </p>
     </sec>
    </sec>
    <sec id="section15-0022034520914246">
     <title>
      Recommended Measures during the COVID-19 Outbreak
     </title>
     <sec id="section16-0022034520914246">
      <title>
       Recommendations for Management
      </title>
      <p>
       In January 2020, the National Health Commission of China added COVID-19 to the category of group B infectious diseases, which includes SARS and highly pathogenic avian influenza. However, it also suggested that all health care workers use protection measures similar to those indicated for group A infections—a category reserved for extremely infectious pathogens, such as cholera and plague.
      </p>
      <p>
       Since then, in most cities of the mainland of China, only dental emergency cases have been treated when strict implementation of infection prevention and control measures are recommended. Routine dental practices have been suspended until further notification according to the situation of epidemics.
      </p>
      <p>
       Additionally, dentistry-related quality control centers and professional societies in many provinces and cities have put forward their recommendations for dental services during the COVID-19 outbreak, which, as supplementary measures, should be helpful in ensuring the quality of infection control (
       <xref ref-type="bibr" rid="bibr17-0022034520914246">
        Li and Meng 2020
       </xref>
       ).
      </p>
     </sec>
     <sec id="section17-0022034520914246">
      <title>
       Current Status of Our School and Hospital
      </title>
      <p>
       The School and Hospital of Stomatology, Wuhan University provided dental care (including oral and maxillofacial surgery) to around 890,000 patients last year and is home to 1,098 staff and 828 students. Our hospital does not have a fever clinic or belong to a designated one for patients with COVID-19. Any staff member who has fever, cough, sneezing, or COVID-19–related symptoms or has a close family member who is confirmed with the infection is advised to undergo a medical examination in a designated hospital and cease working. Since this epidemic, 9 of our colleagues have been confirmed to have COVID-19, including 3 doctors, 3 nurses, 2 administrative staff, and 1 postgraduate student (
       <xref ref-type="fig" rid="fig1-0022034520914246">
        Fig. 1
       </xref>
       ,
       <xref ref-type="table" rid="table1-0022034520914246">
        Table
       </xref>
       ). So far, there have been no further cases among colleagues or patients who had close contact with them. According to analyses of epidemiologic investigation and medical history, all these cases are without obvious aggregation, except 2 nurses from the same department (patients 2 and 3), and are unlikely to result from cross infection. The infection was possibly limited because medical masks and gloves worn during routine clinic work of dental practitioners prevented further transmission.
      </p>
      <fig id="fig1-0022034520914246" orientation="portrait" position="float">
       <label>
        Figure 1.
       </label>
       <caption>
        <p>
         Location of staff and student confirmed with coronavirus disease 2019 (COVID-19) in the main buildings in the School and Hospital of Stomatology, Wuhan University. There are 3 main buildings in our hospital. Building 1 mainly contains outpatients, classrooms, and a library. Its air renewal system depends on air conditioners. Building 2 contains outpatients, wards, and administrative regions. This building was equipped with central air conditioners and a fresh air system. Building 3 is a research laboratory, and it also depends on air conditioners. See
         <xref ref-type="table" rid="table1-0022034520914246">
          Table
         </xref>
         for details.
        </p>
       </caption>
       <graphic xlink:href="10.1177_0022034520914246-fig1">
       </graphic>
      </fig>
      <table-wrap id="table1-0022034520914246" orientation="portrait" position="float">
       <label>
        Table.
       </label>
       <caption>
        <p>
         A Brief Introduction to the Staff and Student Confirmed with COVID-19 in School and Hospital of Stomatology, Wuhan University.
        </p>
       </caption>
       <alternatives>
        <graphic xlink:href="10.1177_0022034520914246-table1">
        </graphic>
        <table frame="hsides" rules="groups">
         <colgroup span="1">
          <col align="left" span="1"/>
          <col align="char" char="." span="1"/>
          <col align="char" char="." span="1"/>
          <col align="char" char="." span="1"/>
          <col align="char" char="." span="1"/>
          <col align="char" char="." span="1"/>
          <col align="char" char="." span="1"/>
         </colgroup>
         <thead>
          <tr>
           <th align="center" colspan="1" rowspan="1">
            Patient No.
            <sup>
             <xref ref-type="table-fn" rid="table-fn2-0022034520914246">
              a
             </xref>
            </sup>
           </th>
           <th align="center" colspan="1" rowspan="1">
            Occupation
           </th>
           <th align="center" colspan="1" rowspan="1">
            Department
           </th>
           <th align="center" colspan="1" rowspan="1">
            Workplace
           </th>
           <th align="center" colspan="1" rowspan="1">
            No. of Persons on Same Floor or Dept
           </th>
           <th align="center" colspan="1" rowspan="1">
            Are There Any Close Contacts Infected?
           </th>
           <th align="center" colspan="1" rowspan="1">
            Date of Initial Symptom
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td colspan="1" rowspan="1">
            1
           </td>
           <td colspan="1" rowspan="1">
            Doctor
           </td>
           <td colspan="1" rowspan="1">
            Preventive dentistry
           </td>
           <td colspan="1" rowspan="1">
            Bldg 1
           </td>
           <td colspan="1" rowspan="1">
            10
           </td>
           <td colspan="1" rowspan="1">
            No
           </td>
           <td colspan="1" rowspan="1">
            Jan 23
           </td>
          </tr>
          <tr>
           <td colspan="1" rowspan="1">
            2
           </td>
           <td colspan="1" rowspan="1">
            Nurse
           </td>
           <td colspan="1" rowspan="1">
            Prosthodontics
           </td>
           <td colspan="1" rowspan="1">
            Bldg 1
           </td>
           <td colspan="1" rowspan="1">
            51
           </td>
           <td colspan="1" rowspan="1">
            No
           </td>
           <td colspan="1" rowspan="1">
            Jan 28
           </td>
          </tr>
          <tr>
           <td colspan="1" rowspan="1">
            3
           </td>
           <td colspan="1" rowspan="1">
            Nurse
           </td>
           <td colspan="1" rowspan="1">
            Prosthodontics
           </td>
           <td colspan="1" rowspan="1">
            Bldg 1
           </td>
           <td colspan="1" rowspan="1">
            51
           </td>
           <td colspan="1" rowspan="1">
            Family members
            <sup>
             <xref ref-type="table-fn" rid="table-fn3-0022034520914246">
              b
             </xref>
            </sup>
           </td>
           <td colspan="1" rowspan="1">
            Feb 4
           </td>
          </tr>
          <tr>
           <td colspan="1" rowspan="1">
            4
           </td>
           <td colspan="1" rowspan="1">
            Administrator
           </td>
           <td colspan="1" rowspan="1">
            Library
           </td>
           <td colspan="1" rowspan="1">
            Bldg 1
           </td>
           <td colspan="1" rowspan="1">
            2
           </td>
           <td colspan="1" rowspan="1">
            1 family member
           </td>
           <td colspan="1" rowspan="1">
            Jan 27
           </td>
          </tr>
          <tr>
           <td colspan="1" rowspan="1">
            5
           </td>
           <td colspan="1" rowspan="1">
            Nurse
           </td>
           <td colspan="1" rowspan="1">
            Oncology surgery
           </td>
           <td colspan="1" rowspan="1">
            Bldg 2
           </td>
           <td colspan="1" rowspan="1">
            37
           </td>
           <td colspan="1" rowspan="1">
            Family members
           </td>
           <td colspan="1" rowspan="1">
            Jan 31
           </td>
          </tr>
          <tr>
           <td colspan="1" rowspan="1">
            6
           </td>
           <td colspan="1" rowspan="1">
            Administrator
           </td>
           <td colspan="1" rowspan="1">
            Teaching office
           </td>
           <td colspan="1" rowspan="1">
            Bldg 2
           </td>
           <td colspan="1" rowspan="1">
            18
           </td>
           <td colspan="1" rowspan="1">
            Family members
            <sup>
             <xref ref-type="table-fn" rid="table-fn3-0022034520914246">
              b
             </xref>
            </sup>
           </td>
           <td colspan="1" rowspan="1">
            Jan 29
           </td>
          </tr>
          <tr>
           <td colspan="1" rowspan="1">
            7
           </td>
           <td colspan="1" rowspan="1">
            MD student
           </td>
           <td colspan="1" rowspan="1">
            Research group
            <sup>
             <xref ref-type="table-fn" rid="table-fn4-0022034520914246">
              c
             </xref>
            </sup>
           </td>
           <td colspan="1" rowspan="1">
            Bldg 3
           </td>
           <td colspan="1" rowspan="1">
            19
           </td>
           <td colspan="1" rowspan="1">
            1 family member
           </td>
           <td colspan="1" rowspan="1">
            Jan 28
           </td>
          </tr>
          <tr>
           <td colspan="1" rowspan="1">
            8
           </td>
           <td colspan="1" rowspan="1">
            Doctor
           </td>
           <td colspan="1" rowspan="1">
            Zhongshang clinic
            <sup>
             <xref ref-type="table-fn" rid="table-fn5-0022034520914246">
              d
             </xref>
            </sup>
           </td>
           <td colspan="1" rowspan="1">
            Satellite clinic
           </td>
           <td colspan="1" rowspan="1">
            18
           </td>
           <td colspan="1" rowspan="1">
            1 family member
           </td>
           <td colspan="1" rowspan="1">
            Jan 29
           </td>
          </tr>
          <tr>
           <td colspan="1" rowspan="1">
            9
           </td>
           <td colspan="1" rowspan="1">
            Doctor
           </td>
           <td colspan="1" rowspan="1">
            Yichang clinic
            <sup>
             <xref ref-type="table-fn" rid="table-fn5-0022034520914246">
              d
             </xref>
            </sup>
           </td>
           <td colspan="1" rowspan="1">
            Satellite clinic
           </td>
           <td colspan="1" rowspan="1">
            15
           </td>
           <td colspan="1" rowspan="1">
            1 family member
           </td>
           <td colspan="1" rowspan="1">
            Jan 29
           </td>
          </tr>
         </tbody>
        </table>
       </alternatives>
       <table-wrap-foot>
        <fn id="table-fn1-0022034520914246">
         <p>
          COVID-19, coronavirus disease 2019.
         </p>
        </fn>
        <fn id="table-fn2-0022034520914246">
         <label>
          a
         </label>
         <p>
          The staff and the student confirmed with COVID-19 did not contact one another closely, and most of them had been away since January 22 or 23, 2020, because of the Chinese Spring Festival.
         </p>
        </fn>
        <fn id="table-fn3-0022034520914246">
         <label>
          b
         </label>
         <p>
          Family member with COVID-19–related symptom at least 1 d earlier.
         </p>
        </fn>
        <fn id="table-fn4-0022034520914246">
         <label>
          c
         </label>
         <p>
          Patient 7 is a research group member supervised by a professor. No classmates or roommates of his were reported to be infected.
         </p>
        </fn>
        <fn id="table-fn5-0022034520914246">
         <label>
          d
         </label>
         <p>
          Zhongshang clinic and Yichang clinic are 2 of 16 satellite clinics of our hospital. The former, located within Wuhan city, is 4 km away from the hospital, and the latter is 300 km away and located in Yichang city. They both solely depend on air conditioners. Patients 8 and 9 are a couple. They were reunited, took a high-speed train back home on January 21, and had respiratory symptoms after 8 d.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <p>
       Despite the increasing number of confirmed cases during this period in Wuhan, we (169 staff involved in duty of dental emergency) have treated &gt;700 patients with emergent dental treatment need since January 24 (
       <xref ref-type="fig" rid="fig2-0022034520914246">
        Fig. 2
       </xref>
       ), under the premise of adequate protection measures. All the dental procedures were recorded daily, and patients and their accompanying persons were requested to provide their phone number and home address in the case that either our staff or patients are suspected or confirmed with COVID-19 in the future. We have also provided consultations to &gt;1,600 patients on our online platform since February 3. No further COVID-19 infection has been reported among our staff, which confirmed the effectiveness of our infection control measures in COVID-19 prevention within dental settings (
       <xref ref-type="fig" rid="fig3-0022034520914246">
        Fig. 3
       </xref>
       ).
      </p>
      <fig id="fig2-0022034520914246" orientation="portrait" position="float">
       <label>
        Figure 2.
       </label>
       <caption>
        <p>
         Number of outpatients treated at the School and Hospital of Stomatology, Wuhan University (WHUSS), and cumulative number of confirmed cases with coronavirus disease 2019 (COVID-19) in Wuhan city from December 30, 2019, to February 25, 2020. *Weekends and national holidays (including the extended spring festival holiday).
         <sup>
          #
         </sup>
         Huanan Seafood Market was closed in Wuhan city after the majority of the earliest COVID-19 cases were linked to the Huanan Seafood Wholesale Market.
         <sup>
          &amp;
         </sup>
         Lockdown of Wuhan city started. According to the epidemic situation, the notification of city lockdown was made to stop any transportation, including airplane, train, and bus, from Wuhan city to prevent COVID-19 transmission, especially because of population movement during Chinese Spring Festival. Before January 21, WHUSS staff had only medical masks and gloves. On January 22, we started to use disposable surgical masks, N95 masks, and gowns. Goggles and protective suits were not available until January 28.
        </p>
       </caption>
       <graphic xlink:href="10.1177_0022034520914246-fig2">
       </graphic>
      </fig>
      <fig id="fig3-0022034520914246" orientation="portrait" position="float">
       <label>
        Figure 3.
       </label>
       <caption>
        <p>
         The personal protective equipment (PPE) diagram for divisions in the emergency care area at the School and Hospital of Stomatology, Wuhan University, during the coronavirus disease 2019 (COVID-19) outbreak. Yellow: triage and waiting area. Orange: dental clinic. Red: isolation clinic. Green: resting area for staff only. As shown in the diagram, our triage staff in the yellow area wear disposable surgical mask, cap, and work clothes. In the orange area, dental staff is provided with PPE, including disposable N95 masks, gloves, gowns, cap, shoe cover, and goggles or face shield. The area is disinfected once every half day. Before February 21, all the patients were treated in this area. The isolation clinic in the red area was set up on February 21. It is designed for patients who are suspected with COVID-19, who are recovering from COVID-19 (but &lt;1 mo after they are discharged from hospital), or who need dental procedures producing droplets and/or aerosols. Separate entrances for patients (red arrow) and staff (blue arrow) are provided in the area. Dental staff should wear protective clothing besides the aforementioned PPE. In addition, the entire isolation area is disinfected immediately after the treatment is over and the patient has left. The grid area behind the red line is for staff only. Staff can have a rest in the room (green area). They are recommended to enter the room by turn and to keep wearing medical masks unless they are eating or drinking.
        </p>
       </caption>
       <graphic xlink:href="10.1177_0022034520914246-fig3">
       </graphic>
      </fig>
      <p>
       According to the instructions from the Ministry of Education of China, all students, including those in our school, have been required to not return to school until further notification. Students are recommended to learn online after the Chinese Spring Festival on the mainland of China.
      </p>
     </sec>
     <sec id="section18-0022034520914246">
      <title>
       Recommendations for Dental Practice
      </title>
      <p>
       Interim guidance on infection prevention and control during health care is recommended when COVID-19 infection is suspected (
       <xref ref-type="bibr" rid="bibr35-0022034520914246">
        WHO 2020a
       </xref>
       ). Up to now, there has been no consensus on the provision of dental services during the epidemic of COVID-19. On the basis of our experience and relevant guidelines and research, dentists should take strict personal protection measures and avoid or minimize operations that can produce droplets or aerosols. The 4-handed technique is beneficial for controlling infection. The use of saliva ejectors with low or high volume can reduce the production of droplets and aerosols (
       <xref ref-type="bibr" rid="bibr12-0022034520914246">
        Kohn et al. 2003
       </xref>
       ;
       <xref ref-type="bibr" rid="bibr16-0022034520914246">
        Li et al. 2004
       </xref>
       ;
       <xref ref-type="bibr" rid="bibr30-0022034520914246">
        Samaranayake and Peiris 2004
       </xref>
       ).
      </p>
      <sec id="section19-0022034520914246">
       <title>
        Evaluation of Patients
       </title>
       <p>
        During the outbreak of COVID-19, dental clinics are recommended to establish precheck triages to measure and record the temperature of every staff and patient as a routine procedure. Precheck staff should ask patients questions about the health status and history of contact or travel (
        <xref ref-type="bibr" rid="bibr35-0022034520914246">
         WHO 2020a
        </xref>
        ). Patients and their accompanying persons are provided with medical masks and temperature measurement once they enter our hospital. Patients with fever should be registered and referred to designated hospitals. If a patient has been to epidemic regions within the past 14 d, quarantine for at least 14 d is suggested. In areas where COVID-19 spreads, nonemergency dental practices should be postponed (
        <xref ref-type="bibr" rid="bibr12-0022034520914246">
         Kohn et al. 2003
        </xref>
        ;
        <xref ref-type="bibr" rid="bibr16-0022034520914246">
         Li et al. 2004
        </xref>
        ;
        <xref ref-type="bibr" rid="bibr30-0022034520914246">
         Samaranayake and Peiris 2004
        </xref>
        ).
       </p>
       <p>
        It was reported that dental practice should be postponed at least 1 mo for convalescing patients with SARS (
        <xref ref-type="bibr" rid="bibr30-0022034520914246">
         Samaranayake and Peiris 2004
        </xref>
        ). It is unknown yet whether the same suggestion should be recommended for patients with COVID-19.
       </p>
      </sec>
      <sec id="section20-0022034520914246">
       <title>
        Oral Examination
       </title>
       <p>
        Preoperative antimicrobial mouth rinse could reduce the number of microbes in the oral cavity (
        <xref ref-type="bibr" rid="bibr12-0022034520914246">
         Kohn et al. 2003
        </xref>
        ;
        <xref ref-type="bibr" rid="bibr22-0022034520914246">
         Marui et al. 2019
        </xref>
        ). Procedures that are likely to induce coughing should be avoided (if possible) or performed cautiously (
        <xref ref-type="bibr" rid="bibr35-0022034520914246">
         WHO 2020a
        </xref>
        ). Aerosol-generating procedures, such as the use of a 3-way syringe, should be minimized as much as possible. Intraoral x-ray examination is the most common radiographic technique in dental imaging; however, it can stimulate saliva secretion and coughing (
        <xref ref-type="bibr" rid="bibr32-0022034520914246">
         Vandenberghe et al. 2010
        </xref>
        ). Therefore, extraoral dental radiographies, such as panoramic radiography and cone beam CT, are appropriate alternatives during the outbreak of COVID-19.
       </p>
      </sec>
      <sec id="section21-0022034520914246">
       <title>
        Treatment of Emergency Cases
       </title>
       <p>
        Dental emergencies can occur and exacerbate in a short period and therefore need immediate treatment. Rubber dams and high-volume saliva ejectors can help minimize aerosol or spatter in dental procedures. Furthermore, face shields and goggles are essential with use of high- or low-speed drilling with water spray (
        <xref ref-type="bibr" rid="bibr29-0022034520914246">
         Samaranayake et al. 1989
        </xref>
        ). According to our clinic experience during the outbreak, if a carious tooth is diagnosed with symptomatic irreversible pulpitis, pulp exposure could be made with chemomechanical caries removal under rubber dam isolation and a high-volume saliva ejector after local anesthesia; then, pulp devitalization can be performed to reduce the pain. The filling material can be replaced gently without a devitalizing agent later according to the manufacturer’s recommendation. We also met a patient who had a spontaneous toothache because of a cracked tooth without dental decay, and a high-speed handpiece had to be used to access cavity preparation. Given that the patient wanted to retain the tooth, she was scheduled as the last patient in the day to decrease the risk of nosocomial infection. After treatment, environmental cleaning and disinfection procedures were followed. Alternatively, patients could be treated in an isolated and well-ventilated room (
        <xref ref-type="fig" rid="fig3-0022034520914246">
         Fig. 3
        </xref>
        ) or negatively pressured rooms if available for suspected cases with COVID-19.
       </p>
       <p>
        The treatment planning of tooth fracture, luxation, or avulsion is dependent on the age, the traumatic severity of dental tissue, the development of the apex, and the duration of tooth avulsion (
        <xref ref-type="bibr" rid="bibr1-0022034520914246">
         Andersson et al. 2012
        </xref>
        ;
        <xref ref-type="bibr" rid="bibr8-0022034520914246">
         DiAngelis et al. 2012
        </xref>
        ;
        <xref ref-type="bibr" rid="bibr21-0022034520914246">
         Malmgren et al. 2012
        </xref>
        ). If the tooth needs to be extracted, absorbable suture is preferred. For patients with facial soft tissue contusion, debridement and suturing should be performed. It is recommended to rinse the wound slowly and use the saliva ejector to avoid spraying. Life-threatening cases with oral and maxillofacial compound injuries should be admitted to the hospital immediately, and chest CT should be prescribed if available to exclude suspected infection because the RT-PCR test, besides time-consuming, needs a laboratory with pan-coronavirus or specific SARS-CoV-2 detection capacity.
       </p>
      </sec>
     </sec>
     <sec id="section22-0022034520914246">
      <title>
       Recommendations for Dental Education
      </title>
      <p>
       Education-related challenges for medical and dental schools, as well as their affiliated hospitals, are significant. It was reported that open communication among students, clinical teachers, and administrative staff would enhance mutual trust and facilitate adequate cooperation (
       <xref ref-type="bibr" rid="bibr25-0022034520914246">
        Park et al. 2016
       </xref>
       ).
      </p>
      <p>
       On the basis of our experience with SARS and relevant highly pathogenic infectious disease, we provide a few basic recommendations for dental education during an outbreak: First, during the outbreak period, online lectures, case studies, and problem-based learning tutorials should be adopted to avoid unnecessary aggregation of people and associated risk of infection (
       <xref ref-type="bibr" rid="bibr26-0022034520914246">
        Patil et al. 2003
       </xref>
       ). Existing smart devices and applications have already made it possible for students to listen to and review lectures whenever and wherever possible. In fact, our students started online learning from February 17. Second, it is worth advocating to encourage students to engage in self-learning, make full use of online resources, and learn about the latest academic developments. Third, during this period, it is easy for students to be affected by disease-associated fear and pressure, and dental schools should be prepared to provide psychological services to those who need them (
       <xref ref-type="bibr" rid="bibr34-0022034520914246">
        Wong et al. 2004
       </xref>
       ).
      </p>
      <p>
       With the increased knowledge of viral features, epidemiologic characteristics, clinical spectrum, and treatment, efficient strategies have been taken to prevent, control, and stop the spread of COVID-19. The infection prevention and control strategies that we have adopted are determined by the fact that we are in the center of COVID-19. Other regions should follow the recommendations from the disease control centers for infection prevention and control according to the local epidemic situation.
      </p>
      <p>
       What should we do to improve the current infection prevention and control strategies after the epidemic? How should we respond to similar contagious diseases in the future? These are open questions in need of further discussion and research.
      </p>
      <p>
       We must be constantly aware of infectious threats that may challenge the current infection control regimen, especially in dental practices and schools of dental medicine.
      </p>
     </sec>
    </sec>
    <sec id="section23-0022034520914246">
     <title>
      Author Contributions
     </title>
     <p>
      L. Meng, contributed to conception, design, data acquisition, and analysis, drafted and critically revised the manuscript; F. Hua, contributed to design and data acquisition, drafted and critically revised the manuscript; Z. Bian, contributed to conception, design, data acquisition, analysis, and interpretation, drafted and critically revised the manuscript. All authors gave final approval and agree to be accountable for all aspects of the work.
     </p>
    </sec>
    <back>
     <ack>
      <p>
       The authors acknowledge technical assistance from Chujian Jiang and clinical advice from Prof. Yong Cheng and Tianjuan Xia and all the other staff and students from the School and Hospital of Stomatology, Wuhan University, China, who contributed directly or indirectly to the article. Fortunately, 5 staff confirmed to have COVID-19 have been convalescing and discharged from hospital.
      </p>
     </ack>
     <fn-group>
      <fn fn-type="supported-by">
       <p>
        The article was supported by grants from the National Natural Science Foundation of China (Nos. 81870761, 81970923, 81901044), The National Key Research and Development Program of China (2016YFC1000505), and the Key Research Program of the Provincial Department of Science and Technology (No. 2017ACA181).
       </p>
      </fn>
      <fn fn-type="COI-statement">
       <p>
        The authors declare no potential conflicts of interest with respect to the authorship and/or publication of this article.
       </p>
      </fn>
      <fn fn-type="other">
       <p>
        <bold>
         ORCID iDs:
        </bold>
        F. Hua
        <inline-graphic xlink:href="10.1177_0022034520914246-img1.jpg">
        </inline-graphic>
        <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-2438-5924">
         https://orcid.org/0000-0002-2438-5924
        </ext-link>
       </p>
       <p>
        Z. Bian
        <inline-graphic xlink:href="10.1177_0022034520914246-img1.jpg">
        </inline-graphic>
        <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-8035-4276">
         https://orcid.org/0000-0002-8035-4276
        </ext-link>
       </p>
      </fn>
     </fn-group>
     <ref-list>
      <title>
       References
      </title>
      <ref id="bibr1-0022034520914246">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Andersson
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Andreasen
          </surname>
          <given-names>
           JO
          </given-names>
         </name>
         <name>
          <surname>
           Day
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Heithersay
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Trope
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           DiAngelis
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Kenny
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Sigurdsson
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Bourguignon
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Flores
          </surname>
          <given-names>
           MT
          </given-names>
         </name>
        </person-group>
        <year>
         2012
        </year>
        <article-title>
         International Association of Dental Traumatology guidelines for the management of traumatic dental injuries: 2. Avulsion of permanent teeth
        </article-title>
        .
        <source>
         Dent Traumatol
        </source>
        .
        <volume>
         28
        </volume>
        (
        <issue>
         2
        </issue>
        ):
        <fpage>
         88
        </fpage>
        –
        <lpage>
         96
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22409417
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr2-0022034520914246">
       <mixed-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Backer
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Klinkenberg
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Wallinga
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <year>
         2020
        </year>
        <article-title>
         Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan
        </article-title>
        ,
        <publisher-loc>
         China
        </publisher-loc>
        ,
        <day>
         20–28
        </day>
        <month>
         1
        </month>
        <year>
         2020
        </year>
        <source>
         Euro Surveill
        </source>
        .
        <volume>
         25
        </volume>
        (
        <issue>
         5
        </issue>
        ). doi:
        <pub-id pub-id-type="doi">
         10.2807/1560-7917.ES.2020.2825.2805.2000062.
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr3-0022034520914246">
       <mixed-citation publication-type="gov">
        <collab>
         Centers for Disease Control and Prevention
        </collab>
        .
        <year>
         2020
        </year>
        <article-title>
         Disease burden of influenza
        </article-title>
        ; [
        <comment>
         accessed 2020 Feb 25
        </comment>
        ].
        <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/flu/about/burden/index.html">
         https://www.cdc.gov/flu/about/burden/index.html
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bibr4-0022034520914246">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kok
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           KK
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Xing
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Yip
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           RW
          </given-names>
         </name>
        </person-group>
        ,
        <etal>
         et al
        </etal>
        <year>
         2020
        </year>
        <article-title>
         A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
        </article-title>
        .
        <source>
         Lancet
        </source>
        .
        <volume>
         395
        </volume>
        (
        <issue>
         10223
        </issue>
        ):
        <fpage>
         514
        </fpage>
        –
        <lpage>
         523
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         31986261
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr5-0022034520914246">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Gong
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
        </person-group>
        ,
        <etal>
         et al
        </etal>
        <year>
         2020
        </year>
        <article-title>
         Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records
        </article-title>
        .
        <source>
         Lancet
        </source>
        [epub ahead of print 12 Feb 2020] in press. doi:
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30360-3.
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr6-0022034520914246">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Gong
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        ,
        <etal>
         et al
        </etal>
        <year>
         2020
        </year>
        <article-title>
         Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
        </article-title>
        .
        <source>
         Lancet
        </source>
        .
        <volume>
         395
        </volume>
        (
        <issue>
         10223
        </issue>
        ):
        <fpage>
         507
        </fpage>
        –
        <lpage>
         513
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         32007143
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr7-0022034520914246">
       <mixed-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Del Rio
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Malani
          </surname>
          <given-names>
           PN
          </given-names>
         </name>
        </person-group>
        <year>
         2020
        </year>
        <article-title>
         2019 novel coronavirus-important information for clinicians
        </article-title>
        .
        <source>
         JAMA
        </source>
        [epub ahead of print 5 Feb 2020] in press. doi:
        <pub-id pub-id-type="doi">
         10.1001/jama.2020.1490.
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr8-0022034520914246">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           DiAngelis
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Andreasen
          </surname>
          <given-names>
           JO
          </given-names>
         </name>
         <name>
          <surname>
           Ebeleseder
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <name>
          <surname>
           Kenny
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Trope
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Sigurdsson
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Andersson
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Bourguignon
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Flores
          </surname>
          <given-names>
           MT
          </given-names>
         </name>
         <name>
          <surname>
           Hicks
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
        </person-group>
        <year>
         2012
        </year>
        <article-title>
         International Association of Dental Traumatology guidelines for the management of traumatic dental injuries: 1
        </article-title>
        .
        <source>
         Fractures and luxations of permanent teeth. Dent Traumatol
        </source>
        .
        <volume>
         28
        </volume>
        (
        <issue>
         1
        </issue>
        ):
        <fpage>
         2
        </fpage>
        –
        <lpage>
         12
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22230724
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr9-0022034520914246">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           W-J
          </given-names>
         </name>
         <name>
          <surname>
           Ni
          </surname>
          <given-names>
           Z-Y
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           W-H
          </given-names>
         </name>
         <name>
          <surname>
           Ou
          </surname>
          <given-names>
           C-Q
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           J-X
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Shan
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Lei
          </surname>
          <given-names>
           C-L
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
        </person-group>
        ,
        <etal>
         et al
        </etal>
        <year>
         2020
        </year>
        <article-title>
         Clinical characteristics of 2019 novel coronavirus infection in China
        </article-title>
        .
        <source>
         medRxiv
        </source>
        . doi:
        <pub-id pub-id-type="doi">
         10.1101/2020.1102.1106.20020974.
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr10-0022034520914246">
       <mixed-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Holshue
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           DeBolt
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Lindquist
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Lofy
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Wiesman
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Bruce
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Spitters
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Ericson
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Wilkerson
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Tural
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        ,
        <etal>
         et al
        </etal>
        <year>
         2020
        </year>
        <article-title>
         First case of 2019 novel coronavirus in the United States
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        [epub ahead of print 31 Jan 2020] in press. doi:
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa2001191.
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr11-0022034520914246">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Fan
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Gu
          </surname>
          <given-names>
           X
          </given-names>
         </name>
        </person-group>
        ,
        <etal>
         et al
        </etal>
        <year>
         2020
        </year>
        <article-title>
         Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
        </article-title>
        .
        <source>
         Lancet
        </source>
        .
        <volume>
         395
        </volume>
        (
        <issue>
         10223
        </issue>
        ):
        <fpage>
         497
        </fpage>
        –
        <lpage>
         506
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         31986264
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr12-0022034520914246">
       <mixed-citation publication-type="gov">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kohn
          </surname>
          <given-names>
           WG
          </given-names>
         </name>
         <name>
          <surname>
           Collins
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <name>
          <surname>
           Cleveland
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Harte
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Eklund
          </surname>
          <given-names>
           KJ
          </given-names>
         </name>
         <name>
          <surname>
           Malvitz
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
        </person-group>
        ;
        <collab>
         Centers for Disease Control and Prevention
        </collab>
        .
        <year>
         2003
        </year>
        <article-title>
         Guidelines for infection control in dental health-care settings—2003
        </article-title>
        .
        <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5217a1.htm">
         https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5217a1.htm
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bibr13-0022034520914246">
       <mixed-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kui
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           YY
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           YN
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           CH
          </given-names>
         </name>
        </person-group>
        ,
        <etal>
         et al
        </etal>
        <year>
         2020
        </year>
        <article-title>
         Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei province
        </article-title>
        .
        <source>
         Chin Med J (Engl) [epub ahead of print 7 Feb 2020] in press
        </source>
        . doi:
        <pub-id pub-id-type="doi">
         10.1097/CM1099.0000000000000744.
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr14-0022034520914246">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Larson
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
         <name>
          <surname>
           Early
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Cloonan
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Sugrue
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Parides
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <year>
         2000
        </year>
        <article-title>
         An organizational climate intervention associated with increased handwashing and decreased nosocomial infections
        </article-title>
        .
        <source>
         Behav Med
        </source>
        .
        <volume>
         26
        </volume>
        (
        <issue>
         1
        </issue>
        ):
        <fpage>
         14
        </fpage>
        –
        <lpage>
         22
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         10971880
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr15-0022034520914246">
       <mixed-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           KSM
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           EHY
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
        </person-group>
        ,
        <etal>
         et al
        </etal>
        <year>
         2020
        </year>
        <article-title>
         Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
        </article-title>
        .
        <source>
         N Engl J Med [epub ahead of print 29 Jan 2020] in press
        </source>
        . doi:
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa2001316.
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr16-0022034520914246">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Samaranayake
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <year>
         2004
        </year>
        <article-title>
         Severe acute respiratory syndrome (SARS) and the GDP. Part II: implications for GDPs
        </article-title>
        .
        <source>
         Br Dent J
        </source>
        .
        <volume>
         197
        </volume>
        (
        <issue>
         3
        </issue>
        ):
        <fpage>
         130
        </fpage>
        –
        <lpage>
         134
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15311240
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr17-0022034520914246">
       <mixed-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           ZY
          </given-names>
         </name>
         <name>
          <surname>
           Meng
          </surname>
          <given-names>
           LY
          </given-names>
         </name>
        </person-group>
        <year>
         2020
        </year>
        <article-title>
         Prevention and control of new coronavirus infection in department of stomatology
        </article-title>
        .
        <source>
         Chin J Stomatol [epub ahead of print 14 Feb 2020] in press
        </source>
        . doi:
        <pub-id pub-id-type="doi">
         10.3760/cma.j.issn.1002-0098.2020.0001.
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr18-0022034520914246">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        ,
        <etal>
         et al
        </etal>
        <year>
         2020
        </year>
        <article-title>
         Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
        </article-title>
        .
        <source>
         Lancet
        </source>
        .
        <volume>
         395
        </volume>
        (
        <issue>
         10224
        </issue>
        ):
        <fpage>
         565
        </fpage>
        –
        <lpage>
         574
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         32007145
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr19-0022034520914246">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mahase
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <year>
         2020
        </year>
        <article-title>
         China coronavirus: WHO declares international emergency as death toll exceeds 200
        </article-title>
        .
        <source>
         BMJ
        </source>
        .
        <volume>
         368
        </volume>
        :m408.
       </mixed-citation>
      </ref>
      <ref id="bibr20-0022034520914246">
       <mixed-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Malik
          </surname>
          <given-names>
           YS
          </given-names>
         </name>
         <name>
          <surname>
           Sircar
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Bhat
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Sharun
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Dhama
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Dadar
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Tiwari
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Chaicumpa
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        <year>
         2020
        </year>
        <article-title>
         Emerging novel coronavirus (2019-nCoV)— current scenario, evolutionary perspective based on genome analysis and recent developments
        </article-title>
        .
        <source>
         Vet Q [epub ahead of print 8 Feb 2020] in press
        </source>
        . doi:10.1080 /01652176.2020.1727993.
       </mixed-citation>
      </ref>
      <ref id="bibr21-0022034520914246">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Malmgren
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Andreasen
          </surname>
          <given-names>
           JO
          </given-names>
         </name>
         <name>
          <surname>
           Flores
          </surname>
          <given-names>
           MT
          </given-names>
         </name>
         <name>
          <surname>
           Robertson
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           DiAngelis
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Andersson
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Cavalleri
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Cohenca
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Day
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Hicks
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
        </person-group>
        ,
        <etal>
         et al
        </etal>
        <year>
         2012
        </year>
        <article-title>
         International Association of Dental Traumatology guidelines for the management of traumatic dental injuries: 3. Injuries in the primary dentition
        </article-title>
        .
        <source>
         Dent Traumatol
        </source>
        .
        <volume>
         28
        </volume>
        (
        <issue>
         3
        </issue>
        ):
        <fpage>
         174
        </fpage>
        –
        <lpage>
         182
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22583659
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr22-0022034520914246">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marui
          </surname>
          <given-names>
           VC
          </given-names>
         </name>
         <name>
          <surname>
           Souto
          </surname>
          <given-names>
           MLS
          </given-names>
         </name>
         <name>
          <surname>
           Rovai
          </surname>
          <given-names>
           ES
          </given-names>
         </name>
         <name>
          <surname>
           Romito
          </surname>
          <given-names>
           GA
          </given-names>
         </name>
         <name>
          <surname>
           Chambrone
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Pannuti
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
        </person-group>
        <year>
         2019
        </year>
        <article-title>
         Efficacy of preprocedural mouthrinses in the reduction of microorganisms in aerosol: a systematic review
        </article-title>
        .
        <source>
         J Am Dent Assoc
        </source>
        .
        <volume>
         150
        </volume>
        (
        <issue>
         12
        </issue>
        ):
        <fpage>
         1015
        </fpage>
        –
        <lpage>
         1026
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         31761015
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr23-0022034520914246">
       <mixed-citation publication-type="gov">
        <collab>
         National Health Commission of China
        </collab>
        .
        <year>
         2020
        </year>
        a.
        <article-title>
         The diagnosis and treatment protocol for novel coronavirus pneumonia (interim sixth edition)
        </article-title>
        [
        <comment>
         accessed 2020 Feb 19
        </comment>
        ].
        <ext-link ext-link-type="uri" xlink:href="http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm">
         http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bibr24-0022034520914246">
       <mixed-citation publication-type="gov">
        <collab>
         National Health Commission of China
        </collab>
        .
        <year>
         2020
        </year>
        b.
        <article-title>
         An update of novel coronavirus pneumonia outbreak as of 24:00 on February 25
        </article-title>
        [
        <comment>
         accessed 2020 Feb 26
        </comment>
        ].
        <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/xcs/yqtb/list_gzbd.shtml">
         http://www.nhc.gov.cn/xcs/yqtb/list_gzbd.shtml
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bibr25-0022034520914246">
       <mixed-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           SW
          </given-names>
         </name>
         <name>
          <surname>
           Jang
          </surname>
          <given-names>
           HW
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           YH
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         <name>
          <surname>
           Ahn
          </surname>
          <given-names>
           YC
          </given-names>
         </name>
         <name>
          <surname>
           Chung
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           K-S
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <year>
         2016
        </year>
        <article-title>
         Avoiding student infection during a Middle East respiratory syndrome (MERS)
        </article-title>
        <publisher-loc>
         outbreak
        </publisher-loc>
        :
        <publisher-name>
         a single medical school experience
        </publisher-name>
        <source>
         Korean J Med Educ
        </source>
        .
        <volume>
         28
        </volume>
        (
        <issue>
         2
        </issue>
        ):
        <fpage>
         209
        </fpage>
        –
        <lpage>
         217
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27240893
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr26-0022034520914246">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Patil
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <year>
         2003
        </year>
        <article-title>
         SARS and its effect on medical education in Hong Kong
        </article-title>
        .
        <source>
         Med Educ
        </source>
        .
        <volume>
         37
        </volume>
        (
        <issue>
         12
        </issue>
        ):
        <fpage>
         1127
        </fpage>
        –
        <lpage>
         1128
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14984121
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr27-0022034520914246">
       <mixed-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Phelan
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
         <name>
          <surname>
           Katz
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Gostin
          </surname>
          <given-names>
           LO
          </given-names>
         </name>
        </person-group>
        <year>
         2020
        </year>
        <article-title>
         The novel coronavirus originating in Wuhan, China: challenges for global health governance [epub ahead of print 30 Jan 2020] in press
        </article-title>
        .
        <source>
         JAMA
        </source>
        . doi:
        <pub-id pub-id-type="doi">
         10.1001/jama.2020.1097.
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr28-0022034520914246">
       <mixed-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rothe
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Schunk
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Sothmann
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Bretzel
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Froeschl
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Wallrauch
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Zimmer
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Thiel
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Janke
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Guggemos
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        ,
        <etal>
         et al
        </etal>
        <year>
         2020
        </year>
        <article-title>
         Transmission of 2019-nCoV infection from an asymptomatic contact in Germany [epub ahead of print 30 Jan 2020] in press
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        . doi:
        <pub-id pub-id-type="doi">
         10.1056/NEJMc2001468.
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr29-0022034520914246">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Samaranayake
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Reid
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Evans
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <year>
         1989
        </year>
        <article-title>
         The efficacy of rubber dam isolation in reducing atmospheric bacterial contamination
        </article-title>
        .
        <source>
         ASDC J Dent Child
        </source>
        .
        <volume>
         56
        </volume>
        (
        <issue>
         6
        </issue>
        ):
        <fpage>
         442
        </fpage>
        –
        <lpage>
         444
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         2681303
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr30-0022034520914246">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Samaranayake
          </surname>
          <given-names>
           LP
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <year>
         2004
        </year>
        <article-title>
         Severe acute respiratory syndrome and dentistry: a retrospective view
        </article-title>
        .
        <source>
         J Am Dent Assoc
        </source>
        .
        <volume>
         135
        </volume>
        (
        <issue>
         9
        </issue>
        ):
        <fpage>
         1292
        </fpage>
        –
        <lpage>
         1302
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15493394
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr31-0022034520914246">
       <mixed-citation publication-type="journal">
        <collab>
         The Chinese Preventive Medicine Association
        </collab>
        .
        <year>
         2020
        </year>
        <article-title>
         An update on the epidemiological characteristics of novel coronavirus pneumonia (COVID-19)
        </article-title>
        .
        <source>
         Chin J Epidemiol
        </source>
        .
        <volume>
         41
        </volume>
        (
        <issue>
         2
        </issue>
        ):
        <fpage>
         139
        </fpage>
        –
        <lpage>
         144
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="bibr32-0022034520914246">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vandenberghe
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Jacobs
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Bosmans
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <year>
         2010
        </year>
        <article-title>
         Modern dental imaging: a review of the current technology and clinical applications in dental practice
        </article-title>
        .
        <source>
         Eur Radiol
        </source>
        .
        <volume>
         20
        </volume>
        (
        <issue>
         11
        </issue>
        ):
        <fpage>
         2637
        </fpage>
        –
        <lpage>
         2655
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         20544352
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr33-0022034520914246">
       <mixed-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Xiang
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Xiong
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        ,
        <etal>
         et al
        </etal>
        <year>
         2020
        </year>
        <article-title>
         Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China
        </article-title>
        .
        <source>
         JAMA
        </source>
        [epub ahead of print 7 Feb 2020] in press. doi:
        <pub-id pub-id-type="doi">
         10.1001/jama.2020.1585.
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr34-0022034520914246">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           JG
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           EP
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           MT
          </given-names>
         </name>
         <name>
          <surname>
           Chua
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
         <name>
          <surname>
           McAlonan
          </surname>
          <given-names>
           GM
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           KW
          </given-names>
         </name>
         <name>
          <surname>
           Ip
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
        </person-group>
        <year>
         2004
        </year>
        <article-title>
         Psychological responses to the SARS outbreak in healthcare students in Hong Kong
        </article-title>
        .
        <source>
         Med Teach
        </source>
        .
        <volume>
         26
        </volume>
        (
        <issue>
         7
        </issue>
        ):
        <fpage>
         657
        </fpage>
        –
        <lpage>
         659
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15763860
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr35-0022034520914246">
       <mixed-citation publication-type="web">
        <collab>
         World Health Organization
        </collab>
        .
        <year>
         2020
        </year>
        a.
        <article-title>
         Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance
        </article-title>
        [
        <comment>
         accessed 2020 Feb 17
        </comment>
        ].
        <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected">
         https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bibr36-0022034520914246">
       <mixed-citation publication-type="web">
        <collab>
         World Health Organization
        </collab>
        .
        <year>
         2020
        </year>
        b.
        <article-title>
         Coronavirus disease 2019 (COVID-19): situation report-36
        </article-title>
        [
        <comment>
         accessed 2020 Feb 26
        </comment>
        ].
        <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200225-sitrep-36-covid-19.pdf?sfvrsn=2791b4e0_2">
         https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200225-sitrep-36-covid-19.pdf?sfvrsn=2791b4e0_2
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bibr37-0022034520914246">
       <mixed-citation publication-type="web">
        <collab>
         World Health Organization
        </collab>
        .
        <year>
         2020
        </year>
        c.
        <article-title>
         Questions and answers on coronaviruses
        </article-title>
        [
        <comment>
         accessed 2020 Feb 26
        </comment>
        ].
        <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/q-a-detail/q-a-coronaviruses">
         https://www.who.int/news-room/q-a-detail/q-a-coronaviruses
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bibr38-0022034520914246">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Jalali
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Dean
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Longini
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Halloran
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        ,
        <etal>
         et al
        </etal>
        <year>
         2020
        </year>
        <article-title>
         Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China
        </article-title>
        .
        <source>
         medRxiv
        </source>
        . doi:
        <pub-id pub-id-type="doi">
         10.1101/2020.1102.1110.20021675.
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bibr39-0022034520914246">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <year>
         2020
        </year>
        <article-title>
         Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia
        </article-title>
        .
        <source>
         Transl Pediatr
        </source>
        .
        <volume>
         9
        </volume>
        (
        <issue>
         1
        </issue>
        ):
        <fpage>
         51
        </fpage>
        –
        <lpage>
         60
        </lpage>
        . doi:10.21037/tp.2020.02.06.
        <pub-id pub-id-type="pmid">
         32154135
        </pub-id>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Infect Dis Poverty
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Infect Dis Poverty
      </journal-id>
      <journal-title-group>
       <journal-title>
        Infectious Diseases of Poverty
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       2095-5162
      </issn>
      <issn pub-type="epub">
       2049-9957
      </issn>
      <publisher>
       <publisher-name>
        BioMed Central
       </publisher-name>
       <publisher-loc>
        London
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32183901
      </article-id>
      <article-id pub-id-type="pmc">
       7079521
      </article-id>
      <article-id pub-id-type="publisher-id">
       646
      </article-id>
      <article-id pub-id-type="doi">
       10.1186/s40249-020-00646-x
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Scoping Review
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Adhikari
         </surname>
         <given-names>
          Sasmita Poudel
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Meng
         </surname>
         <given-names>
          Sha
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wu
         </surname>
         <given-names>
          Yu-Ju
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Mao
         </surname>
         <given-names>
          Yu-Ping
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ye
         </surname>
         <given-names>
          Rui-Xue
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Qing-Zhi
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Sun
         </surname>
         <given-names>
          Chang
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Sylvia
         </surname>
         <given-names>
          Sean
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Rozelle
         </surname>
         <given-names>
          Scott
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Raat
         </surname>
         <given-names>
          Hein
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff5">
         5
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Zhou
         </surname>
         <given-names>
          Huan
         </given-names>
        </name>
        <address>
         <email>
          zhouhuan@scu.edu.cn
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <aff id="Aff1">
        <label>
         1
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.13291.38
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000 0001 0807 1581
         </institution-id>
         <institution>
          West China School of Public Health and West China Fourth Hospital,
         </institution>
         <institution>
          Sichuan University,
         </institution>
        </institution-wrap>
        Chengdu, China
       </aff>
       <aff id="Aff2">
        <label>
         2
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.213902.b
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000 0000 9093 6830
         </institution-id>
         <institution>
          Department of Communication Studies,
         </institution>
         <institution>
          California State University,
         </institution>
        </institution-wrap>
        Long Beach, CA 90802 USA
       </aff>
       <aff id="Aff3">
        <label>
         3
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.10698.36
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000000122483208
         </institution-id>
         <institution>
          Health Policy and Management,
         </institution>
         <institution>
          University of North Carolina at Chapel Hill,
         </institution>
        </institution-wrap>
        Chapel Hill, NC USA
       </aff>
       <aff id="Aff4">
        <label>
         4
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.168010.e
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000000419368956
         </institution-id>
         <institution>
          Freeman Spogli Institute for International Studies,
         </institution>
         <institution>
          Stanford University,
         </institution>
        </institution-wrap>
        Stanford, CA USA
       </aff>
       <aff id="Aff5">
        <label>
         5
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.5645.2
         </institution-id>
         <institution-id institution-id-type="ISNI">
          000000040459992X
         </institution-id>
         <institution>
          Department of Public Health,
         </institution>
         <institution>
          Erasmus MC—University Medical Center Rotterdam,
         </institution>
        </institution-wrap>
        3000 CA Rotterdam, The Netherlands
       </aff>
      </contrib-group>
      <pub-date pub-type="epub">
       <day>
        17
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <pub-date pub-type="pmc-release">
       <day>
        17
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <pub-date pub-type="collection">
       <year>
        2020
       </year>
      </pub-date>
      <volume>
       9
      </volume>
      <elocation-id>
       29
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         11
        </day>
        <month>
         2
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         5
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © The Author(s) 2020
       </copyright-statement>
       <license license-type="OpenAccess">
        <license-p>
         <bold>
          Open Access
         </bold>
         This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          http://creativecommons.org/licenses/by/4.0/
         </ext-link>
         . The Creative Commons Public Domain Dedication waiver (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">
          http://creativecommons.org/publicdomain/zero/1.0/
         </ext-link>
         ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
        </license-p>
       </license>
      </permissions>
      <abstract id="Abs1">
       <sec>
        <title>
         Background
        </title>
        <p id="Par1">
         The coronavirus disease (COVID-19) has been identified as the cause of an outbreak of respiratory illness in Wuhan, Hubei Province, China beginning in December 2019. As of 31 January 2020, this epidemic had spread to 19 countries with 11 791 confirmed cases, including 213 deaths. The World Health Organization has declared it a Public Health Emergency of International Concern.
        </p>
       </sec>
       <sec>
        <title>
         Methods
        </title>
        <p id="Par2">
         A scoping review was conducted following the methodological framework suggested by Arksey and O’Malley. In this scoping review, 65 research articles published before 31 January 2020 were analyzed and discussed to better understand the epidemiology, causes, clinical diagnosis, prevention and control of this virus. The research domains, dates of publication, journal language, authors’ affiliations, and methodological characteristics were included in the analysis. All the findings and statements in this review regarding the outbreak are based on published information as listed in the references.
        </p>
       </sec>
       <sec>
        <title>
         Results
        </title>
        <p id="Par3">
         Most of the publications were written using the English language (89.2%). The largest proportion of published articles were related to causes (38.5%) and a majority (67.7%) were published by Chinese scholars. Research articles initially focused on causes, but over time there was an increase of the articles related to prevention and control. Studies thus far have shown that the virus’ origination is in connection to a seafood market in Wuhan, but specific animal associations have not been confirmed. Reported symptoms include fever, cough, fatigue, pneumonia, headache, diarrhea, hemoptysis, and dyspnea. Preventive measures such as masks, hand hygiene practices, avoidance of public contact, case detection, contact tracing, and quarantines have been discussed as ways to reduce transmission. To date, no specific antiviral treatment has proven effective; hence, infected people primarily rely on symptomatic treatment and supportive care.
        </p>
       </sec>
       <sec>
        <title>
         Conclusions
        </title>
        <p id="Par4">
         There has been a rapid surge in research in response to the outbreak of COVID-19. During this early period, published research primarily explored the epidemiology, causes, clinical manifestation and diagnosis, as well as prevention and control of the novel coronavirus. Although these studies are relevant to control the current public emergency, more high-quality research is needed to provide valid and reliable ways to manage this kind of public health emergency in both the short- and long-term.
        </p>
       </sec>
      </abstract>
      <kwd-group xml:lang="en">
       <title>
        Keywords
       </title>
       <kwd>
        COVID-19
       </kwd>
       <kwd>
        Epidemiology
       </kwd>
       <kwd>
        Causes
       </kwd>
       <kwd>
        Prevention and control
       </kwd>
       <kwd>
        Review
       </kwd>
      </kwd-group>
      <funding-group>
       <award-group>
        <funding-source>
         <institution-wrap>
          <institution-id institution-id-type="FundRef">
           http://dx.doi.org/10.13039/100001547
          </institution-id>
          <institution>
           China Medical Board
          </institution>
         </institution-wrap>
        </funding-source>
        <award-id>
         CMB-18-297
        </award-id>
        <principal-award-recipient>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Huan
          </given-names>
         </name>
        </principal-award-recipient>
       </award-group>
      </funding-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         issue-copyright-statement
        </meta-name>
        <meta-value>
         © The Author(s) 2020
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="Sec1">
     <title>
      Background
     </title>
     <p id="Par12">
      The coronavirus belongs to a family of viruses that may cause various symptoms such as pneumonia, fever, breathing difficulty, and lung infection [
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      ]. These viruses are common in animals worldwide, but very few cases have been known to affect humans. The World Health Organization (WHO) used the term 2019 novel coronavirus to refer to a coronavirus that affected the lower respiratory tract of patients with pneumonia in Wuhan, China on 29 December 2019 [
      <xref ref-type="bibr" rid="CR2">
       2
      </xref>
      –
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ]. The WHO announced that the official name of the 2019 novel coronavirus is coronavirus disease (COVID-19) [
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ]. And the current reference name for the virus is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was reported that a cluster of patients with pneumonia of unknown cause was linked to a local Huanan South China Seafood Market in Wuhan, Hubei Province, China in December 2019 [
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
      ].
     </p>
     <p id="Par13">
      In response to the outbreak, the Chinese Center for Disease Control and Prevention (China CDC) dispatched a rapid response team to accompany health authorities of Hubei province and Wuhan city to conduct epidemiological and etiological investigations. The WHO confirmed that the outbreak of the coronavirus epidemic was associated with the Huanan South China Seafood Marketplace, but no specific animal association was identified [
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ]. Scientists immediately started to research the source of the new coronavirus, and the first genome of COVID-19 was published by the research team led by Prof. Yong-Zhen Zhang, on 10 January 2020 [
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
      ]. Within 1 month, this virus spread quickly throughout China during the Chinese New Year – a period when there is a high level of human mobility among Chinese people. Although it is still too early to predict susceptible populations, early patterns have shown a trend similar to Severe Acute Respiratory Syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses. Susceptibility seems to be associated with age, biological sex, and other health conditions [
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
      ]. COVID-19 has now been declared as a Public Health Emergency of International Concern by the WHO [
      <xref ref-type="bibr" rid="CR9">
       9
      </xref>
      ].
     </p>
     <p id="Par14">
      Given the spread of the new coronavirus and its impacts on human health, the research community has responded rapidly to the new virus and many preliminary research articles have already been published about this epidemic (Additional file
      <xref ref-type="media" rid="MOESM1">
       1
      </xref>
      ). We conducted a scoping review to summarize and critically analyze all the published scientific articles regarding the new coronavirus in January 2020. This review aims to provide the evidence of early findings on the epidemiology, causes, clinical diagnosis, as well as prevention and control of COVID-19 in relation to time, location, and source of publication. This review can provide meaningful information for future research related to this topic and may support government decision-making on strategies to handle this public health emergency at the community, national, and international levels.
     </p>
    </sec>
    <sec id="Sec2">
     <title>
      Methods
     </title>
     <sec id="Sec3">
      <title>
       Study design
      </title>
      <p id="Par15">
       A scoping review was conducted following the methodological framework suggested by Arksey and O’Malley [
       <xref ref-type="bibr" rid="CR10">
        10
       </xref>
       ]. The following five steps were followed to conduct this scoping review: a) identifying a clear research objective and search strategies, b) identifying relevant research articles, c) selection of research articles, d) extraction and charting of data, and e) summarizing, discussing, analyzing, and reporting the results.
      </p>
     </sec>
     <sec id="Sec4">
      <title>
       Literature search strategies
      </title>
      <p id="Par16">
       Literature for this review was identified by searching the following online databases: bioRxiv, medRxiv, ChemRxiv, Google scholar, PubMed, as well as CNKI and WanFang Data (the two primary databases for biomedical research in mainland China). These online databases contain archives of most English and Chinese biomedical journals. In addition, some white papers published online by the National Health Commission of the People’s Republic of China, Chinese Center for Disease Prevention and Control, and the WHO were included in the analysis. We searched scientific publications from 1 January to 31 January 2020. The search terms were ‘nCoV’, ‘2019 novel coronavirus’, ‘2019-nCoV’, ‘novel coronavirus’, ‘Pneumonia’, ‘新型冠状病毒’ (Chinese), ‘新型肺炎’ (Chinese), and ‘新冠病毒’ (Chinese). We included all the relevant scientific publications written in English or Chinese in the review. Non-scientific commentary, reports, and news articles were excluded from the analysis.
      </p>
     </sec>
     <sec id="Sec5">
      <title>
       Identification and selection of relevant studies
      </title>
      <p id="Par17">
       Two researchers (YW and SPA) independently searched through the literature. The two sets of literature were then compared. Disagreements on the inclusion or exclusion of literature were resolved through discussion or, if necessary, by including a third researcher (HZ) to make the final decision. Duplicate articles were eliminated. Eventually, 65 unique academic publications were included in this analysis (Additional file
       <xref ref-type="media" rid="MOESM1">
        1
       </xref>
       ). Figure
       <xref ref-type="fig" rid="Fig1">
        1
       </xref>
       presents a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram showing the process of searching and selecting the research articles [
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
       ].
       <fig id="Fig1">
        <label>
         Fig. 1
        </label>
        <caption>
         <p>
          PRISMA flow diagram for the scoping review process
         </p>
        </caption>
        <graphic id="MO1" xlink:href="40249_2020_646_Fig1_HTML">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="Sec6">
      <title>
       Data extraction from the included studies
      </title>
      <p id="Par18">
       After the articles were selected, data were extracted and recorded in an excel spreadsheet. The extracted data were date of publication, language of publication, title of article, name of journal, author’s country and affiliation, study design, targets of study, sample size, study setting, data collection instrument, research domain, and key findings.
      </p>
     </sec>
     <sec id="Sec7">
      <title>
       Summarizing the findings
      </title>
      <p id="Par19">
       Based on the main research objectives, articles were classified into one of the following four research domains: epidemiology, causes, clinical manifestation and diagnosis, or prevention and control. ‘Epidemiology’ includes studies on the epidemic distribution (when, where, who); ‘causes’ includes studies on virology, pathogenesis, and transmission patterns; ‘clinical manifestation and diagnosis’ includes studies on the clinical features (signs and symptoms) and diagnosis; and ‘prevention and control’ includes studies on prevention, control, and treatment measures.
      </p>
      <p id="Par20">
       Authors’ affiliations were used to categorize the type of research collaboration. A publication was considered as deriving from ‘inside China’ when all affiliations of the authors were from China; a publication was considered as deriving from ‘outside China’ when all affiliations were outside China; a publication was considered as deriving from ‘international collaboration’ when at least one affiliation was from China and at least one was from outside China. The research domains, publishing dates, journal language, authors’ affiliations, as well as methodological characteristics were analyzed respectively. All findings and statements regarding the outbreak in this review are based on published information as listed in the references.
      </p>
     </sec>
    </sec>
    <sec id="Sec8">
     <title>
      Results and discussion
     </title>
     <sec id="Sec9">
      <title>
       Characteristics of published studies
      </title>
      <p id="Par21">
       Among the 65 research articles included in the analysis, more than 31 are on preprint servers, and 34 are published in peer-reviewed journals, including
       <italic>
        The Lancet
       </italic>
       and
       <italic>
        The New England Journal of Medicine
       </italic>
       . Most of the publications (
       <italic>
        n
       </italic>
       = 58, 89.2%) are in English and few (
       <italic>
        n
       </italic>
       = 7, 10.8%) are in Chinese. Around 75.9% of English language publications focus on epidemiology and causes, while 85.7% of Chinese papers focus on prevention and control (Table
       <xref ref-type="table" rid="Tab1">
        1
       </xref>
       ).
       <table-wrap id="Tab1">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          Breakdown of research domains by language in January 2020
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th rowspan="2">
            Research domains
           </th>
           <th colspan="2">
            English literature
           </th>
           <th colspan="2">
            Chinese literature
           </th>
           <th colspan="2">
            Total
           </th>
          </tr>
          <tr>
           <th>
            <italic>
             n
            </italic>
           </th>
           <th>
            %
           </th>
           <th>
            <italic>
             n
            </italic>
           </th>
           <th>
            %
           </th>
           <th>
            <italic>
             n
            </italic>
           </th>
           <th>
            %
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            Epidemiology
           </td>
           <td>
            19
           </td>
           <td>
            32.8
           </td>
           <td>
            0
           </td>
           <td>
            0.0
           </td>
           <td>
            19
           </td>
           <td>
            29.2
           </td>
          </tr>
          <tr>
           <td>
            Causes
           </td>
           <td>
            25
           </td>
           <td>
            43.1
           </td>
           <td>
            0
           </td>
           <td>
            0.0
           </td>
           <td>
            25
           </td>
           <td>
            38.5
           </td>
          </tr>
          <tr>
           <td>
            Clinical manifestation and diagnosis
           </td>
           <td>
            8
           </td>
           <td>
            13.8
           </td>
           <td>
            1
           </td>
           <td>
            14.3
           </td>
           <td>
            9
           </td>
           <td>
            13.8
           </td>
          </tr>
          <tr>
           <td>
            Prevention and control
           </td>
           <td>
            6
           </td>
           <td>
            10.3
           </td>
           <td>
            6
           </td>
           <td>
            85.7
           </td>
           <td>
            12
           </td>
           <td>
            18.5
           </td>
          </tr>
          <tr>
           <td>
            Total
           </td>
           <td>
            58
           </td>
           <td>
            89.2
           </td>
           <td>
            7
           </td>
           <td>
            10.8
           </td>
           <td>
            65
           </td>
           <td>
            100
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
      </p>
      <p id="Par22">
       As shown in Fig.
       <xref ref-type="fig" rid="Fig2">
        2
       </xref>
       , academic publications are distributed across the following research domains: epidemiology, causes, clinical manifestation and diagnosis, and prevention and control. The largest portion of the papers (
       <italic>
        n
       </italic>
       = 25, 38.5%) are related to causes, followed by papers on epidemiology (
       <italic>
        n
       </italic>
       = 19, 29.2%), while 18.5% examined prevention and control and 13.8% reported clinical manifestations and diagnosis. Initially, there were more research articles focused on causes of the outbreak, yet studies on prevention and control gradually increased over time (Fig.
       <xref ref-type="fig" rid="Fig3">
        3
       </xref>
       ). The majority of the articles (
       <italic>
        n
       </italic>
       = 44, 67.7%) were published by Chinese scholars whereas 29.2% (
       <italic>
        n
       </italic>
       = 19) articles were from scholars outside of China. A small number (
       <italic>
        n
       </italic>
       = 2, 3.1%) were based on international collaborative research by scholars from different countries (Table
       <xref ref-type="table" rid="Tab2">
        2
       </xref>
       ).
       <fig id="Fig2">
        <label>
         Fig. 2
        </label>
        <caption>
         <p>
          Research domains of published research articles
         </p>
        </caption>
        <graphic id="MO2" xlink:href="40249_2020_646_Fig2_HTML">
        </graphic>
       </fig>
       <fig id="Fig3">
        <label>
         Fig. 3
        </label>
        <caption>
         <p>
          Publication dates of research articles
         </p>
        </caption>
        <graphic id="MO3" xlink:href="40249_2020_646_Fig3_HTML">
        </graphic>
       </fig>
       <table-wrap id="Tab2">
        <label>
         Table 2
        </label>
        <caption>
         <p>
          Breakdown of research domains by collaboration type in January 2020
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th rowspan="2">
            Research domains
           </th>
           <th colspan="2">
            Inside China
           </th>
           <th colspan="2">
            Outside China
           </th>
           <th colspan="2">
            International collaboration
           </th>
           <th colspan="2">
            Total
           </th>
          </tr>
          <tr>
           <th>
            <italic>
             n
            </italic>
           </th>
           <th>
            %
           </th>
           <th>
            <italic>
             n
            </italic>
           </th>
           <th>
            %
           </th>
           <th>
            <italic>
             n
            </italic>
           </th>
           <th>
            %
           </th>
           <th>
            <italic>
             n
            </italic>
           </th>
           <th>
            %
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            Epidemiology
           </td>
           <td>
            8
           </td>
           <td>
            18.2
           </td>
           <td>
            9
           </td>
           <td>
            47.4
           </td>
           <td>
            2
           </td>
           <td>
            100
           </td>
           <td>
            19
           </td>
           <td>
            29.2
           </td>
          </tr>
          <tr>
           <td>
            Causes
           </td>
           <td>
            17
           </td>
           <td>
            38.6
           </td>
           <td>
            8
           </td>
           <td>
            42.1
           </td>
           <td>
            0
           </td>
           <td>
            0.0
           </td>
           <td>
            25
           </td>
           <td>
            38.5
           </td>
          </tr>
          <tr>
           <td>
            Clinical manifestation and diagnosis
           </td>
           <td>
            8
           </td>
           <td>
            18.2
           </td>
           <td>
            1
           </td>
           <td>
            5.3
           </td>
           <td>
            0
           </td>
           <td>
            0.0
           </td>
           <td>
            9
           </td>
           <td>
            13.8
           </td>
          </tr>
          <tr>
           <td>
            Prevention and control
           </td>
           <td>
            11
           </td>
           <td>
            25.0
           </td>
           <td>
            1
           </td>
           <td>
            5.3
           </td>
           <td>
            0
           </td>
           <td>
            0.0
           </td>
           <td>
            12
           </td>
           <td>
            18.5
           </td>
          </tr>
          <tr>
           <td>
            Total
           </td>
           <td>
            44
           </td>
           <td>
            67.7
           </td>
           <td>
            19
           </td>
           <td>
            29.2
           </td>
           <td>
            2
           </td>
           <td>
            3.1
           </td>
           <td>
            65
           </td>
           <td>
            100
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
      </p>
      <p id="Par23">
       We also analyzed the methodological characteristics of the publications in the final sample. The majority of the articles are based on mathematical modeling (44.6%) and cross-sectional study designs (18.5%). Around half of the studies include targeted populations (patients, general populations, and healthcare workers) (49.2%) in their analysis, followed by studies that attempt to identify the species of the virus (virus structure, gene sequence) (36.9%). Among the 32 articles with population as the target of study, 34.4% had a sample size of less than 10, 31.3% were conducted in a hospital setting, and 50% used secondary data. Quality control activities for data collection were mentioned in 56.3% of the population studies (Table
       <xref ref-type="table" rid="Tab3">
        3
       </xref>
       ).
       <table-wrap id="Tab3">
        <label>
         Table 3
        </label>
        <caption>
         <p>
          Methodological characteristics of COVID-19 research articles in January 2020
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
            Characteristics
           </th>
           <th>
            Categories
           </th>
           <th>
            <italic>
             n
            </italic>
           </th>
           <th>
            %
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td rowspan="6">
            <p>
             Study design
            </p>
            <p>
             (
             <italic>
              n
             </italic>
             = 65)
            </p>
           </td>
           <td>
            Cross-sectional studies
           </td>
           <td>
            12
           </td>
           <td>
            18.5
           </td>
          </tr>
          <tr>
           <td>
            Mathematical modeling
           </td>
           <td>
            29
           </td>
           <td>
            44.6
           </td>
          </tr>
          <tr>
           <td>
            Molecular studies
           </td>
           <td>
            10
           </td>
           <td>
            15.4
           </td>
          </tr>
          <tr>
           <td>
            Diagnostic studies
           </td>
           <td>
            2
           </td>
           <td>
            3.1
           </td>
          </tr>
          <tr>
           <td>
            Review
           </td>
           <td>
            3
           </td>
           <td>
            4.6
           </td>
          </tr>
          <tr>
           <td>
            Theoretical study
           </td>
           <td>
            9
           </td>
           <td>
            13.9
           </td>
          </tr>
          <tr>
           <td rowspan="6">
            <p>
             Targets of study
            </p>
            <p>
             (
             <italic>
              n
             </italic>
             = 65)
            </p>
           </td>
           <td>
            Population
           </td>
           <td>
            32
           </td>
           <td>
            49.2
           </td>
          </tr>
          <tr>
           <td>
            Patients
           </td>
           <td>
            22
           </td>
           <td>
            33.9
           </td>
          </tr>
          <tr>
           <td>
            General population
           </td>
           <td>
            6
           </td>
           <td>
            9.2
           </td>
          </tr>
          <tr>
           <td>
            Healthcare workers
           </td>
           <td>
            4
           </td>
           <td>
            6.2
           </td>
          </tr>
          <tr>
           <td>
            Species (virus structure, gene sequence)
           </td>
           <td>
            24
           </td>
           <td>
            36.9
           </td>
          </tr>
          <tr>
           <td>
            Other
           </td>
           <td>
            9
           </td>
           <td>
            13.9
           </td>
          </tr>
          <tr>
           <td colspan="4">
            Study related to population (
            <italic>
             n
            </italic>
            = 32)
           </td>
          </tr>
          <tr>
           <td rowspan="5">
            Sample size
           </td>
           <td>
            1–10
           </td>
           <td>
            11
           </td>
           <td>
            34.4
           </td>
          </tr>
          <tr>
           <td>
            11–50
           </td>
           <td>
            5
           </td>
           <td>
            15.6
           </td>
          </tr>
          <tr>
           <td>
            51–100
           </td>
           <td>
            3
           </td>
           <td>
            9.4
           </td>
          </tr>
          <tr>
           <td>
            &gt; 100
           </td>
           <td>
            3
           </td>
           <td>
            9.4
           </td>
          </tr>
          <tr>
           <td>
            Not specified
           </td>
           <td>
            10
           </td>
           <td>
            31.3
           </td>
          </tr>
          <tr>
           <td rowspan="6">
            Study setting
           </td>
           <td>
            Laboratory
           </td>
           <td>
            2
           </td>
           <td>
            6.3
           </td>
          </tr>
          <tr>
           <td>
            Hospital
           </td>
           <td>
            10
           </td>
           <td>
            31.3
           </td>
          </tr>
          <tr>
           <td>
            Community
           </td>
           <td>
            0
           </td>
           <td>
            0.0
           </td>
          </tr>
          <tr>
           <td>
            Hospital and community
           </td>
           <td>
            0
           </td>
           <td>
            0.0
           </td>
          </tr>
          <tr>
           <td>
            Not specified
           </td>
           <td>
            20
           </td>
           <td>
            62.5
           </td>
          </tr>
          <tr>
           <td>
            Questionnaire
           </td>
           <td>
            7
           </td>
           <td>
            10.8
           </td>
          </tr>
          <tr>
           <td rowspan="5">
            Data-collection instrument
            <sup>
             a
            </sup>
           </td>
           <td>
            Biological specimen collection
           </td>
           <td>
            1
           </td>
           <td>
            3.1
           </td>
          </tr>
          <tr>
           <td>
            Physical examinations
           </td>
           <td>
            0
           </td>
           <td>
            0.0
           </td>
          </tr>
          <tr>
           <td>
            Environmental sample
           </td>
           <td>
            0
           </td>
           <td>
            0.0
           </td>
          </tr>
          <tr>
           <td>
            Hospital, medical, or exposure records
           </td>
           <td>
            14
           </td>
           <td>
            43.7
           </td>
          </tr>
          <tr>
           <td>
            Secondary data
           </td>
           <td>
            16
           </td>
           <td>
            50.0
           </td>
          </tr>
          <tr>
           <td rowspan="2">
            Quality-control activities for data collection
           </td>
           <td>
            Indicated in the article
           </td>
           <td>
            14
           </td>
           <td>
            56.3
           </td>
          </tr>
          <tr>
           <td>
            Not specified
           </td>
           <td>
            18
           </td>
           <td>
            43.8
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <p>
          <sup>
           a
          </sup>
          Percentages in this section do not add up to 100% because multiple answers were possible
         </p>
        </table-wrap-foot>
       </table-wrap>
      </p>
     </sec>
     <sec id="Sec10">
      <title>
       Research domains
      </title>
      <sec id="Sec11">
       <title>
        Epidemiology
       </title>
       <p id="Par24">
        On 29 December 2019, the first four cases of an acute respiratory syndrome of unknown etiology were reported in Wuhan City, Hubei Province, China among people linked to a local seafood market (“wet market”) [
        <xref ref-type="bibr" rid="CR2">
         2
        </xref>
        ]. Research is underway to understand more about transmissibility, severity, and other features associated with COVID-19 [
        <xref ref-type="bibr" rid="CR3">
         3
        </xref>
        ]. It appears that most of the early cases had some sort of contact history with the original seafood market [
        <xref ref-type="bibr" rid="CR2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="CR12">
         12
        </xref>
        –
        <xref ref-type="bibr" rid="CR14">
         14
        </xref>
        ]. Soon, a secondary source of infection was found to be human-to-human transmission via close contact. There was an increase of infected people with no history of exposure to wildlife or visiting Wuhan, and multiple cases of infection were detected among medical professionals [
        <xref ref-type="bibr" rid="CR2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="CR14">
         14
        </xref>
        –
        <xref ref-type="bibr" rid="CR17">
         17
        </xref>
        ]. It became clear that the COVID-19 infection occurs through exposure to the virus, and both the immunosuppressed and normal population appear susceptible. Some studies have reported an age distribution of adult patients between 25 and 89 years old. Most adult patients were between 35 and 55 years old [
        <xref ref-type="bibr" rid="CR14">
         14
        </xref>
        ], and there were fewer identified cases among children and infants [
        <xref ref-type="bibr" rid="CR14">
         14
        </xref>
        ,
        <xref ref-type="bibr" rid="CR18">
         18
        </xref>
        ]. A study on early transmission dynamics of the virus reported the median age of patients to be 59 years, ranging from 15 to 89 years, with the majority (59%) being male [
        <xref ref-type="bibr" rid="CR2">
         2
        </xref>
        ]. It was suggested that the population most at risk may be people with poor immune function such as older people and those with renal and hepatic dysfunction [
        <xref ref-type="bibr" rid="CR2">
         2
        </xref>
        ].
       </p>
       <p id="Par25">
        The COVID-19 has been found to have higher levels of transmissibility and pandemic risk than the SARS-CoV, as the effective reproductive number (R) of COVID-19 (2.9) is estimated to be higher than the reported effective reproduction number (R) of SARS (1.77) at this early stage [
        <xref ref-type="bibr" rid="CR15">
         15
        </xref>
        ]. Different studies of COVID-19 have estimated the basic reproduction (R
        <sub>
         0
        </sub>
        ) range to be from 2.6 to 4.71 (Table
        <xref ref-type="table" rid="Tab4">
         4
        </xref>
        ). The average incubation duration of COVID-19 was estimated to be 4.8 ± 2.6, ranging from 2 to 11 days [
        <xref ref-type="bibr" rid="CR15">
         15
        </xref>
        ] and 5.2 days (95% confidence interval, 4.1 to 7) [
        <xref ref-type="bibr" rid="CR2">
         2
        </xref>
        ]. The latest guidelines from Chinese health authorities stated an average incubation duration of 7 days, ranging from 2 to 14 days [
        <xref ref-type="bibr" rid="CR23">
         23
        </xref>
        ]. Table
        <xref ref-type="table" rid="Tab4">
         4
        </xref>
        summarizes the findings on important indicators from these epidemiological studies.
        <table-wrap id="Tab4">
         <label>
          Table 4
         </label>
         <caption>
          <p>
           Main epidemiological indicators of COVID-19 research articles in January 2020
          </p>
         </caption>
         <table frame="hsides" rules="groups">
          <thead>
           <tr>
            <th>
             Indicators
            </th>
            <th>
             Description
            </th>
           </tr>
          </thead>
          <tbody>
           <tr>
            <td rowspan="4">
             Age of patients
            </td>
            <td>
             • Cases range between 25 and 89 years, with most patients aged between 35 and 55 years and fewer cases among children and infants [
             <xref ref-type="bibr" rid="CR14">
              14
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • Median age of patients is 59 years, ranging from 51 to 89 [
             <xref ref-type="bibr" rid="CR2">
              2
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • Average age of patients was 55.5 years; age distribution: ≤ 39: 10%; 40–49: 22%, 50–59: 30%; 60–69: 22%, ≥ 70: 15% [
             <xref ref-type="bibr" rid="CR19">
              19
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • Cases range from 2 to 72 years [
             <xref ref-type="bibr" rid="CR20">
              20
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td rowspan="3">
             Sex of patients
            </td>
            <td>
             • More cases were males [
             <xref ref-type="bibr" rid="CR20">
              20
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • 59% males [
             <xref ref-type="bibr" rid="CR2">
              2
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • 68% males [
             <xref ref-type="bibr" rid="CR19">
              19
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             Age of the deaths
            </td>
            <td>
             • Median age of death was 75 (with a range between 48 and 89 years) [
             <xref ref-type="bibr" rid="CR21">
              21
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td rowspan="2">
             Exposure history
            </td>
            <td>
             • Huanan Seafood Market in Wuhan [
             <xref ref-type="bibr" rid="CR19">
              19
             </xref>
             ,
             <xref ref-type="bibr" rid="CR22">
              22
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • Wuhan residents or people who visited Wuhan [
             <xref ref-type="bibr" rid="CR20">
              20
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td rowspan="6">
             Incubation time
            </td>
            <td>
             • 4.8 ± 2.6 days (2–11 days) [
             <xref ref-type="bibr" rid="CR15">
              15
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • 5.2 days (4.1–7 days) [
             <xref ref-type="bibr" rid="CR2">
              2
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • Average of 7 days (2–14 days) [
             <xref ref-type="bibr" rid="CR23">
              23
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • Average of 10 days [
             <xref ref-type="bibr" rid="CR22">
              22
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • 5–6 days [
             <xref ref-type="bibr" rid="CR24">
              24
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • Average of 6.4 days (5.6–7.7 days) [
             <xref ref-type="bibr" rid="CR20">
              20
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td rowspan="5">
             Basic Reproduction (R
             <sub>
              0
             </sub>
             )
            </td>
            <td>
             • 2.6 (uncertainty range: 1.5–3.5) [
             <xref ref-type="bibr" rid="CR25">
              25
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • 3.8 (95%
             <italic>
              CI
             </italic>
             : 3.6–4.0) [
             <xref ref-type="bibr" rid="CR26">
              26
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • 2.2 (1.4–3.8) [
             <xref ref-type="bibr" rid="CR27">
              27
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • 4.71 (4.50–4.92) [
             <xref ref-type="bibr" rid="CR24">
              24
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • 2.68 (95%
             <italic>
              CI
             </italic>
             : 2.47–2.86) [
             <xref ref-type="bibr" rid="CR28">
              28
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td rowspan="5">
             Susceptible populations
            </td>
            <td>
             • Elderly people [
             <xref ref-type="bibr" rid="CR21">
              21
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • People with poor immune function [
             <xref ref-type="bibr" rid="CR2">
              2
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • People with chronic co-morbidities [
             <xref ref-type="bibr" rid="CR2">
              2
             </xref>
             ,
             <xref ref-type="bibr" rid="CR15">
              15
             </xref>
             ,
             <xref ref-type="bibr" rid="CR19">
              19
             </xref>
             ,
             <xref ref-type="bibr" rid="CR21">
              21
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • People with long-term use of immunosuppressive agents [
             <xref ref-type="bibr" rid="CR19">
              19
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • Surgery history before admission [
             <xref ref-type="bibr" rid="CR21">
              21
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td rowspan="6">
             Mortality rate
            </td>
            <td>
             • 3% (between 29 December 2019 to 23 January, 2020) [
             <xref ref-type="bibr" rid="CR15">
              15
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • 2.3% (as of 28 January 2020) [
             <xref ref-type="bibr" rid="CR29">
              29
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • 2.8% (as of 25 January, 2020) [
             <xref ref-type="bibr" rid="CR21">
              21
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • 2.9% (as of 25 January, 2020) [
             <xref ref-type="bibr" rid="CR30">
              30
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • 11% (as of 25 January, 2020) [
             <xref ref-type="bibr" rid="CR19">
              19
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • 3.1% (as of 24 January 2020) [
             <xref ref-type="bibr" rid="CR31">
              31
             </xref>
             ]
            </td>
           </tr>
          </tbody>
         </table>
        </table-wrap>
       </p>
       <p id="Par26">
        In China, 11 791 cases were confirmed and 17 988 cases were suspected in 34 provinces as of 24:00, 31 January 2020 (Fig.
        <xref ref-type="fig" rid="Fig4">
         4
        </xref>
        ) [
        <xref ref-type="bibr" rid="CR32">
         32
        </xref>
        ]. Studies indicated that the spread of COVID-19 was relatively quick and reported that it had spread to several other countries after its outbreak in China. On 31 January 2020, there were 213 deaths reported globally [
        <xref ref-type="bibr" rid="CR33">
         33
        </xref>
        ]. Confirmed cases were reported in the following 19 countries outside of China: Australia (9), Canada (3), Cambodia (1), France (6), Finland (1), Germany (5), India (1), Italy (2), Japan (14), Nepal (1), Malaysia (8), the Philippines (1), the Republic of Korea (11), Singapore (13), Sri Lanka (1), Thailand (14), the United States of America (6), United Arab Emirates (4) and Vietnam (5) (Fig.
        <xref ref-type="fig" rid="Fig5">
         5
        </xref>
        ) [
        <xref ref-type="bibr" rid="CR33">
         33
        </xref>
        ].
        <fig id="Fig4">
         <label>
          Fig. 4
         </label>
         <caption>
          <p>
           Distribution of COVID-19 cases in China
          </p>
         </caption>
         <graphic id="MO4" xlink:href="40249_2020_646_Fig4_HTML">
         </graphic>
        </fig>
        <fig id="Fig5">
         <label>
          Fig. 5
         </label>
         <caption>
          <p>
           Global distribution of COVID-19 cases
          </p>
         </caption>
         <graphic id="MO5" xlink:href="40249_2020_646_Fig5_HTML">
         </graphic>
        </fig>
       </p>
      </sec>
      <sec id="Sec12">
       <title>
        Causes
       </title>
       <sec id="FPar1">
        <title>
         Virology and pathogenesis
        </title>
        <p id="Par27">
         Coronaviruses are enveloped single-stranded RNA viruses that are zoonotic in nature and cause symptoms ranging from those similar to the common cold to more severe respiratory, enteric, hepatic, and neurological symptoms [
         <xref ref-type="bibr" rid="CR5">
          5
         </xref>
         ,
         <xref ref-type="bibr" rid="CR34">
          34
         </xref>
         ]. Other than SARS-CoV-2, there are six known coronaviruses in humans: HCoV-229E, HCoV-OC43, SARS-CoV, HCoV-NL63, HCoV-HKU1, and MERS-CoV [
         <xref ref-type="bibr" rid="CR2">
          2
         </xref>
         ,
         <xref ref-type="bibr" rid="CR23">
          23
         </xref>
         ,
         <xref ref-type="bibr" rid="CR35">
          35
         </xref>
         ,
         <xref ref-type="bibr" rid="CR36">
          36
         </xref>
         ]. Coronavirus has caused two large-scale pandemics in the last two decades: SARS [
         <xref ref-type="bibr" rid="CR37">
          37
         </xref>
         ] and MERS [
         <xref ref-type="bibr" rid="CR12">
          12
         </xref>
         ,
         <xref ref-type="bibr" rid="CR38">
          38
         </xref>
         ].
        </p>
        <p id="Par28">
         To detect the infection source of COVID-19, China CDC researchers collected 585 environmental samples from the Huanan Seafood Market in Wuhan, Hubei Province, China on 1 January and 12 January 2020. They detected 33 samples containing SARS-CoV-2 and indicated that it originated from wild animals sold in the market [
         <xref ref-type="bibr" rid="CR39">
          39
         </xref>
         ]. Then, researchers used the lung fluid, blood, and throat swab samples of 15 patients to conduct laboratory tests. These laboratory tests found that the virus-specific nucleic acid sequences in the sample are different from those of known human coronavirus species. Laboratory results also indicated that SARS-CoV-2 is similar to some of the beta (β) coronaviruses genera identified in bats [
         <xref ref-type="bibr" rid="CR12">
          12
         </xref>
         ,
         <xref ref-type="bibr" rid="CR18">
          18
         </xref>
         ,
         <xref ref-type="bibr" rid="CR40">
          40
         </xref>
         ], which is situated in a group of SARS/SARS-like CoV [
         <xref ref-type="bibr" rid="CR12">
          12
         </xref>
         ].
        </p>
        <p id="Par29">
         To conduct next-generation sequencing from bronchoalveolar lavage fluid and cultured isolates, researchers enrolled nine inpatients in Wuhan with viral pneumonia and negative in common respiratory pathogens. The results of this next-generation sequencing indicated that SARS-CoV-2 was more distant from SARS-CoV (with about 79% sequence identity) and MERS-CoV (with about 50% sequence identity) than from two bat-derived SARS-like coronaviruses – bat-SL-CoVZC45 (with 87.9% sequence identity) and bat-SL-CoVZXC21 (with 87.2% sequence identity) [
         <xref ref-type="bibr" rid="CR41">
          41
         </xref>
         ]. Studies also reported that COVID-19 S-protein supported strong interaction with human ACE2 molecules despite the dissimilarity of its sequence with that of SARS-CoV [
         <xref ref-type="bibr" rid="CR12">
          12
         </xref>
         ,
         <xref ref-type="bibr" rid="CR42">
          42
         </xref>
         ].
        </p>
       </sec>
       <sec id="FPar2">
        <title>
         Transmission pattern
        </title>
        <p id="Par30">
         Many domestic and wild animals, including camels, cattle, cats, and bats, may serve as hosts for coronaviruses [
         <xref ref-type="bibr" rid="CR23">
          23
         </xref>
         ]. It is considered that, generally, animal coronaviruses do not spread among humans [
         <xref ref-type="bibr" rid="CR3">
          3
         </xref>
         ]. However, there are exceptions, such as SARS and MERS, which are mainly spread though close contact with infected people via respiratory droplets from cough or sneezing. With regard to COVID-19, early patients were reported to have some link to the Huanan Seafood Market in Wuhan, China, suggesting that these early infections were due to animal-to-person transmission. However, later cases were reported among medical staff and others with no history of exposure to that market or visiting Wuhan, which was taken as an indication of human-to-human transmission [
         <xref ref-type="bibr" rid="CR2">
          2
         </xref>
         ,
         <xref ref-type="bibr" rid="CR4">
          4
         </xref>
         ,
         <xref ref-type="bibr" rid="CR15">
          15
         </xref>
         –
         <xref ref-type="bibr" rid="CR17">
          17
         </xref>
         ].
        </p>
        <p id="Par31">
         The latest guidelines from Chinese health authorities [
         <xref ref-type="bibr" rid="CR23">
          23
         </xref>
         ,
         <xref ref-type="bibr" rid="CR43">
          43
         </xref>
         ] described three main transmission routes for the COVID-19: 1) droplets transmission, 2) contact transmission, and 3) aerosol transmission. Droplets transmission was reported to occur when respiratory droplets (as produced when an infected person coughs or sneezes) are ingested or inhaled by individuals nearby in close proximity; contact transmission may occur when a subject touches a surface or object contaminated with the virus and subsequently touch their mouth, nose, or eyes; and aerosol transmission may occur when respiratory droplets mix into the air, forming aerosols and may cause infection when inhaled high dose of aerosols into the lungs in a relatively closed environment [
         <xref ref-type="bibr" rid="CR23">
          23
         </xref>
         ,
         <xref ref-type="bibr" rid="CR43">
          43
         </xref>
         ]. In addition to these three routes, one study also indicated the digestive system as a potential transmission route for COVID-19 infection. Since patients had abdominal discomfort and diarrhea symptoms, researchers analyzed four datasets with single-cell transcriptomes of digestive systems and found that ACE2 was highly expressed in absorptive enterocytes from ileum and colon [
         <xref ref-type="bibr" rid="CR44">
          44
         </xref>
         ].
        </p>
       </sec>
      </sec>
      <sec id="Sec1111">
       <title>
        Clinical manifestation and diagnosis
       </title>
       <p id="Par32">
        The complete clinical manifestation is not clear yet, as the reported symptoms range from mild to severe, with some cases even resulting in death [
        <xref ref-type="bibr" rid="CR3">
         3
        </xref>
        ]. The most commonly reported symptoms are fever, cough, myalgia or fatigue, pneumonia, and complicated dyspnea, whereas less common reported symptoms include headache, diarrhea, hemoptysis, runny nose, and phlegm-producing cough [
        <xref ref-type="bibr" rid="CR3">
         3
        </xref>
        ,
        <xref ref-type="bibr" rid="CR16">
         16
        </xref>
        ]. Patients with mild symptoms were reported to recover after 1 week while severe cases were reported to experience progressive respiratory failure due to alveolar damage from the virus, which may lead to death [
        <xref ref-type="bibr" rid="CR13">
         13
        </xref>
        ]. Cases resulting in death were primarily middle-aged and elderly patients with pre-existing diseases (tumor surgery, cirrhosis, hypertension, coronary heart disease, diabetes, and Parkinson’s disease) [
        <xref ref-type="bibr" rid="CR13">
         13
        </xref>
        ]. Case definition guidelines mention the following symptoms: fever, decrease in lymphocytes and white blood cells, new pulmonary infiltrates on chest radiography, and no improvement in symptoms after 3 days of antibiotics treatment [
        <xref ref-type="bibr" rid="CR2">
         2
        </xref>
        ].
       </p>
       <p id="Par33">
        For patients with suspected infection, the following procedures have been suggested for diagnosis: performing real-time fluorescence (RT-PCR) to detect the positive nucleic acid of SARS-CoV-2 in sputum, throat swabs, and secretions of the lower respiratory tract samples [
        <xref ref-type="bibr" rid="CR13">
         13
        </xref>
        ,
        <xref ref-type="bibr" rid="CR14">
         14
        </xref>
        ,
        <xref ref-type="bibr" rid="CR43">
         43
        </xref>
        ].
       </p>
      </sec>
      <sec id="Sec121">
       <title>
        Prevention and control
       </title>
       <p id="Par34">
        Prevention and control strategies and methods are reported at three levels: national level, case-related population level, and general population level. At the national level, the National Health Commission of the People’s Republic of China issued the “No.1 announcement” on 20 January 2020, which officially included the COVID-19 into the management of class B legal infectious diseases, and allowed for class A infectious disease preventive and control measures to be implemented [
        <xref ref-type="bibr" rid="CR45">
         45
        </xref>
        ]. Under this policy, medical institutes can adopt isolation treatment and observation protocols to prevent and control the spread of the COVID-19. On 22 January 2020, the National Health Commission published national guidelines for the prevention and control of COVID-19 for medical institutes to prevent nosocomial infection [
        <xref ref-type="bibr" rid="CR46">
         46
        </xref>
        ]. On 28 January 2020, the National Health Commission issued protocols for rapid prevention and control measures in order to effectively contain the spread of the epidemic through a “big isolation and big disinfection” policy during the Chinese Spring Festival [
        <xref ref-type="bibr" rid="CR47">
         47
        </xref>
        ]. National-level strategies have also been issued with targeted measures for rural areas (issued on 28 January 2020) and the elderly population (issued on 31 January 2020) [
        <xref ref-type="bibr" rid="CR48">
         48
        </xref>
        ,
        <xref ref-type="bibr" rid="CR49">
         49
        </xref>
        ]. Several public health measures that may prevent or slow down the transmission of the COVID-19 were introduced; these include case isolation, identification and follow-up of contacts, environmental disinfection, and use of personal protective equipment [
        <xref ref-type="bibr" rid="CR50">
         50
        </xref>
        ].
       </p>
       <p id="Par35">
        To date, no specific antiviral treatment has been confirmed to be effective against COVID-19. Regarding patients infected with COVID-19, it has been recommended to apply appropriate symptomatic treatment and supportive care [
        <xref ref-type="bibr" rid="CR3">
         3
        </xref>
        ,
        <xref ref-type="bibr" rid="CR16">
         16
        </xref>
        ]. There are six clinical trials registered in both the International Clinical Trials Registry platform and the Chinese Clinical Trial Registry to evaluate the efficacy or safety of targeted medicine in the treatment or prognosis of COVID-19 (Additional file
        <xref ref-type="media" rid="MOESM2">
         2
        </xref>
        ) [
        <xref ref-type="bibr" rid="CR51">
         51
        </xref>
        ,
        <xref ref-type="bibr" rid="CR52">
         52
        </xref>
        ]. Regarding infected patients with COVID-19, it has been recommended to apply appropriate symptomatic treatment and supportive care [
        <xref ref-type="bibr" rid="CR3">
         3
        </xref>
        ,
        <xref ref-type="bibr" rid="CR16">
         16
        </xref>
        ]. Studies have also explored the prevention of nosocomial infection and psychological health issues associated with COVID-19. A series of measures have been suggested to reduce nosocomial infection, including knowledge training for prevention and control, isolation, disinfection, classified protections at different degrees in infection areas, and protection of confirmed cases [
        <xref ref-type="bibr" rid="CR18">
         18
        </xref>
        ,
        <xref ref-type="bibr" rid="CR50">
         50
        </xref>
        ,
        <xref ref-type="bibr" rid="CR53">
         53
        </xref>
        ]. Concerning psychological health, some suggested psychological intervention for confirmed cases, suspected cases, and medical staff [
        <xref ref-type="bibr" rid="CR18">
         18
        </xref>
        ,
        <xref ref-type="bibr" rid="CR54">
         54
        </xref>
        ].
       </p>
       <p id="Par36">
        For the general population, at this moment there is no vaccine preventing COVID-19. The best prevention is to avoid being exposed to the virus [
        <xref ref-type="bibr" rid="CR55">
         55
        </xref>
        ]. Airborne precautions and other protective measures have been discussed and proposed for prevention. Infection preventive and control (IPC) measures that may reduce the risk of exposure include the following: use of face masks; covering coughs and sneezes with tissues that are then safely disposed of (or, if no tissues are available, use a flexed elbow to cover the cough or sneeze); regular hand washing with soap or disinfection with hand sanitizer containing at least 60% alcohol (if soap and water are not available); avoidance of contact with infected people and maintaining an appropriate distance as much as possible; and refraining from touching eyes, nose, and mouth with unwashed hands [
        <xref ref-type="bibr" rid="CR3">
         3
        </xref>
        ].
       </p>
       <p id="Par37">
        The WHO also issued detailed guidelines on the use of face masks in the community, during care at home, and in the health care settings of COVID-19 [
        <xref ref-type="bibr" rid="CR56">
         56
        </xref>
        ]. In this document, health care workers are recommended to use particulate respirators such as those certified N95 or FFP2 when performing aerosol-generating procedures and to use medical masks while providing any care to suspected or confirmed cases. According to this guideline, individuals with respiratory symptoms are advised to use medical masks both in health care and home care settings properly following the infection prevention guidelines. According to this guideline, an individual without respiratory symptoms is not required to wear a medical mask when in public. Proper use and disposal of masks is important to avoid any increase in risk of transmission [
        <xref ref-type="bibr" rid="CR56">
         56
        </xref>
        ].
       </p>
       <p id="Par38">
        In addition to articles published in research journals, the China CDC published a guideline to raise awareness of the prevention and control of COVID-19 among the general population. The key messages of the guideline include causes, how to choose and wear face masks, proper hand washing habits, preventive measures at different locations (e.g., at home, on public transportation, and in public space), disinfection methods, and medical observation at home [
        <xref ref-type="bibr" rid="CR57">
         57
        </xref>
        ]. In addition to scientific knowledge on ways to handle the COVID-19 outbreak, the guideline also suggests ways to eliminate panic among the general population [
        <xref ref-type="bibr" rid="CR57">
         57
        </xref>
        ].
       </p>
      </sec>
     </sec>
     <sec id="Sec13">
      <title>
       Strengths and limitations of the study
      </title>
      <p id="Par39">
       The review applied a systematic and rigorous search strategy to retrieve relevant articles according to the research objectives. This research summarizes scientific foundations, identifies literature gaps, and suggests some evidence for future research directions on COVID-19 which will provide information for research community, policymakers, and health professionals to adjust and/or come up with new research, policies, and practices. Our study only focuses on the articles published either in English or in Chinese during the early outbreak period. Although, it cannot reflect the entire body of research on COVID-19 worldwide, it will provide some evidences for future study and control.
      </p>
     </sec>
    </sec>
    <sec id="Sec14">
     <title>
      Conclusions
     </title>
     <p id="Par40">
      This study shows a holistic picture of the current research in response to the outbreak of COVID-19. During this early period, many studies have been published exploring the epidemiology, causes, clinical manifestation and diagnosis, and prevention and control of the novel coronavirus. Thus far, most studies have focused on the epidemiology and potential causes. However, studies exploring prevention and control measures have begun to gradually increase. Studies in this domain are urgently needed to minimize the impact of the outbreak. Government agencies have quickly incorporated recent scientific findings into public policies at the community, regional, and national levels to slow down and/or prevent the further spread of the COVID-19. We recommend that the scholarly community conduct further research to provide valid and reliable ways to manage this kind of public health emergency in both the short-term and long-term.
     </p>
    </sec>
    <sec sec-type="supplementary-material">
     <title>
      Supplementary information
     </title>
     <sec id="Sec15">
      <p>
       <supplementary-material content-type="local-data" id="MOESM1">
        <media xlink:href="40249_2020_646_MOESM1_ESM.docx">
         <caption>
          <p>
           <bold>
            Additional file 1.
           </bold>
           Published research articles on COVID-19 in January 2020.
          </p>
         </caption>
        </media>
       </supplementary-material>
       <supplementary-material content-type="local-data" id="MOESM2">
        <media xlink:href="40249_2020_646_MOESM2_ESM.docx">
         <caption>
          <p>
           <bold>
            Additional file 2.
           </bold>
           Clinical trials registered as of 31 January 2020.
          </p>
         </caption>
        </media>
       </supplementary-material>
      </p>
     </sec>
    </sec>
    <back>
     <glossary>
      <title>
       Abbreviations
      </title>
      <def-list>
       <def-item>
        <term>
         ACE2
        </term>
        <def>
         <p id="Par5">
          Angiotensin converting enzyme 2
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         CDC
        </term>
        <def>
         <p id="Par6">
          Center for Disease Control
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         IPC
        </term>
        <def>
         <p id="Par7">
          Infection prevention and control
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         MERS
        </term>
        <def>
         <p id="Par8">
          Middle East Respiratory Syndrome
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         PRISMA
        </term>
        <def>
         <p id="Par9">
          Preferred Reporting Items for Systematic Reviews and Meta-Analyses
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         SARS
        </term>
        <def>
         <p id="Par10">
          Severe Acute Respiratory Syndrome
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         WHO
        </term>
        <def>
         <p id="Par11">
          World Health Organization
         </p>
        </def>
       </def-item>
      </def-list>
     </glossary>
     <sec>
      <title>
       Supplementary information
      </title>
      <p>
       <bold>
        Supplementary information
       </bold>
       accompanies this paper at 10.1186/s40249-020-00646-x.
      </p>
     </sec>
     <ack>
      <p>
       Our sincere thanks go to all the experts who have given insights for the writing of this paper.
      </p>
     </ack>
     <notes notes-type="author-contribution">
      <title>
       Authors’ contributions
      </title>
      <p>
       SPA and HZ designed the study, guided the methodology, and wrote the first draft; SM, WY, QW, SC, RY were responsible for searching the articles; WY, SPA, HZ were responsible for database selection, search strategy, article screening against inclusion criteria, and charting the data; QW, SM, SPA, and HZ were responsible for analysis; SPA, HZ, SS, YM, SR and HR critically reviewed, discussed, and modified the manuscript. All authors read and approved the final manuscript for publication.
      </p>
     </notes>
     <notes notes-type="funding-information">
      <title>
       Funding
      </title>
      <p>
       This study was funded by China Medical Board (CMB-18-297).
      </p>
     </notes>
     <notes notes-type="data-availability">
      <title>
       Availability of data and materials
      </title>
      <p>
       The dataset supporting the conclusions of this article is included as an Additional file table.
      </p>
     </notes>
     <notes>
      <title>
       Ethics approval and consent to participate
      </title>
      <p id="Par41">
       Not applicable.
      </p>
     </notes>
     <notes>
      <title>
       Consent for publication
      </title>
      <p id="Par42">
       Not applicable.
      </p>
     </notes>
     <notes notes-type="COI-statement">
      <title>
       Competing interests
      </title>
      <p id="Par43">
       The authors declare that they have no competing interests.
      </p>
     </notes>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1.
       </label>
       <mixed-citation publication-type="other">
        WMHC. Wuhan Municipal Health and Health Commission’s Briefing on the Current Pneumonia Epidemic Situation in Our City. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://wjw.wuhan.gov.cn/front/web/showDetail/2019123108989">
         http://wjw.wuhan.gov.cn/front/web/showDetail/2019123108989
        </ext-link>
        . Accessed 1 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR2">
       <label>
        2.
       </label>
       <mixed-citation publication-type="other">
        Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020. 10.1056/NEJMoa2001316.
       </mixed-citation>
      </ref>
      <ref id="CR3">
       <label>
        3.
       </label>
       <mixed-citation publication-type="other">
        CDC. 2019 Novel coronavirus, Wuhan, China. 2020.
        <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-nCoV/summary.html">
         https://www.cdc.gov/coronavirus/2019-nCoV/summary.html
        </ext-link>
        . Accessed 1 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR4">
       <label>
        4.
       </label>
       <mixed-citation publication-type="other">
        WHO. Novel Coronavirus–China. 2020.
        <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/">
         https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/
        </ext-link>
        . Accessed 1 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR5">
       <label>
        5.
       </label>
       <mixed-citation publication-type="other">
        Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020. 10.1056/NEJMoa2001017.
       </mixed-citation>
      </ref>
      <ref id="CR6">
       <label>
        6.
       </label>
       <mixed-citation publication-type="other">
        WHO. Novel Coronavirus-Japan (ex-China). 2020.
        <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/don/17-january-2020-novel-coronavirus-japan-ex-china/en/">
         https://www.who.int/csr/don/17-january-2020-novel-coronavirus-japan-ex-china/en/
        </ext-link>
        . Accessed 1 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR7">
       <label>
        7.
       </label>
       <mixed-citation publication-type="other">
        Virological.org. Novel 2019 Coronavirus Genome 2020.
        <ext-link ext-link-type="uri" xlink:href="http://virological.org/t/novel-2019-coronavirus-genome/319">
         http://virological.org/t/novel-2019-coronavirus-genome/319
        </ext-link>
        . Accessed 1 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR8">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fehr
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         <name>
          <surname>
           Channappanavar
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome: emergence of a pathogenic human coronavirus
        </article-title>
        <source>
         Annu Rev Med
        </source>
        <year>
         2017
        </year>
        <volume>
         68
        </volume>
        <fpage>
         387
        </fpage>
        <lpage>
         399
        </lpage>
        <pub-id pub-id-type="doi">
         10.1146/annurev-med-051215-031152
        </pub-id>
        <pub-id pub-id-type="pmid">
         27576010
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR9">
       <label>
        9.
       </label>
       <mixed-citation publication-type="other">
        WHO. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). 2020.
        <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)">
         https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov
        </ext-link>
        ). Accessed 1 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR10">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arksey
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           O’Malley
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Scoping studies: towards a methodological framework
        </article-title>
        <source>
         Int J Soc Res Methodol
        </source>
        <year>
         2005
        </year>
        <volume>
         8
        </volume>
        <fpage>
         19
        </fpage>
        <lpage>
         32
        </lpage>
        <pub-id pub-id-type="doi">
         10.1080/1364557032000119616
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR11">
       <label>
        11.
       </label>
       <mixed-citation publication-type="other">
        Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6 (e100097). 10.1371/journal.pmed.1000097.
       </mixed-citation>
      </ref>
      <ref id="CR12">
       <label>
        12.
       </label>
       <mixed-citation publication-type="other">
        Zhou P, Yang XL, Wang, XG, Hu B, Zhang L, Zhang W, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv. 2020; doi: 10.1101/2020.01.22.914952.
       </mixed-citation>
      </ref>
      <ref id="CR13">
       <label>
        13.
       </label>
       <mixed-citation publication-type="other">
        Li T, Wei C, Li W, Hongwei F, Shi J. Beijing Union Medical College Hospital on "pneumonia of novel coronavirus infection" diagnosis and treatment proposal (V2.0). Med J Peking Union Med Coll Hosp. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://kns.cnki.net/kcms/detail/11.5882.r.20200130.1430.002.html">
         http://kns.cnki.net/kcms/detail/11.5882.r.20200130.1430.002.html
        </ext-link>
        . Accessed 2 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR14">
       <label>
        14.
       </label>
       <mixed-citation publication-type="other">
        Medical expert group of Tongji hospital. Quick guide to the diagnosis and treatment of pneumonia for novel coronavirus infections (third edition). Herald Med. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://kns.cnki.net/kcms/detail/42.1293.r.20200130.1803.002.html">
         http://kns.cnki.net/kcms/detail/42.1293.r.20200130.1803.002.html
        </ext-link>
        . Accessed 2 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR15">
       <label>
        15.
       </label>
       <mixed-citation publication-type="other">
        Liu T, Hu J, Kang M, Lin L, Zhong H, Xiao J, et al. Transmission dynamics of 2019 novel coronavirus (2019-nCoV). 2020; doi: 10.1101/2020.01.25.919787.
       </mixed-citation>
      </ref>
      <ref id="CR16">
       <label>
        16.
       </label>
       <mixed-citation publication-type="other">
        Huang C, Wang Y, Li X, Ren L, Zhao Jianping, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395:497–506. 10.1016/S0140-6736(20)30183-5.
       </mixed-citation>
      </ref>
      <ref id="CR17">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gralinski
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           VD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Return of the coronavirus: 2019-nCoV
        </article-title>
        <source>
         Viruses.
        </source>
        <year>
         2020
        </year>
        <volume>
         12
        </volume>
        <fpage>
         135
        </fpage>
        <pub-id pub-id-type="doi">
         10.3390/v12020135
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR18">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevalence, nosocomial infection and psychological prevention of novel coronavirus infection
        </article-title>
        <source>
         Chin General Pract Nurs
        </source>
        <year>
         2020
        </year>
        <volume>
         18
        </volume>
        <fpage>
         2
        </fpage>
        <lpage>
         3
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR19">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Gong
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
        </article-title>
        <source>
         Lancet.
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <fpage>
         507
        </fpage>
        <lpage>
         513
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30211-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         32007143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR20">
       <label>
        20.
       </label>
       <mixed-citation publication-type="other">
        Backer JA, Klinkenberg D, Wallinga J. The incubation period of 2019-nCoV infections among travellers from Wuhan. China Euro Surveill. 2020; 10.2807/1560-7917.ES.2020.25.5.2000062.
       </mixed-citation>
      </ref>
      <ref id="CR21">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2020
        </year>
        <volume>
         92
        </volume>
        <fpage>
         441
        </fpage>
        <lpage>
         447
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/jmv.25689
        </pub-id>
        <pub-id pub-id-type="pmid">
         31994742
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR22">
       <label>
        22.
       </label>
       <mixed-citation publication-type="other">
        Imai N, Dorigatti I, Cori A, Riley S, Ferguson, NM. Estimating the potential total number of novel Coronavirus cases in Wuhan City, China. 2020.
        <ext-link ext-link-type="uri" xlink:href="https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/2019-nCoV-outbreak-report-17-01-2020.pdf">
         https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/2019-nCoV-outbreak-report-17-01-2020.pdf
        </ext-link>
        . Accessed 31 Jan, 2020.
       </mixed-citation>
      </ref>
      <ref id="CR23">
       <label>
        23.
       </label>
       <mixed-citation publication-type="other">
        National Health Commission of People’s Republic of China. Prevent guideline of 2019-nCoV. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/xcs/yqfkdt/202001/bc661e49b5bc487dba182f5c49ac445b.shtml">
         http://www.nhc.gov.cn/xcs/yqfkdt/202001/bc661e49b5bc487dba182f5c49ac445b.shtml
        </ext-link>
        . Accessed 1 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR24">
       <label>
        24.
       </label>
       <mixed-citation publication-type="other">
        Shen M, Peng Z, Xiao Y, Zhang L. Modelling the epidemic trend of the 2019 novel coronavirus outbreak in China. bioRxiv. 2020; 10.1101/2020.01.23.916726.
       </mixed-citation>
      </ref>
      <ref id="CR25">
       <label>
        25.
       </label>
       <mixed-citation publication-type="other">
        Imai N, Cori A, Dorigatti I, Baguelin M, Donnelly CA, Riley S, et al. Report 3: Transmissibility of 2019-nCoV. 2020.
        <ext-link ext-link-type="uri" xlink:href="https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-2019-nCoV-transmissibility.pdf">
         https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-2019-nCoV-transmissibility.pdf
        </ext-link>
        . Accessed 31 Jan, 2020.
       </mixed-citation>
      </ref>
      <ref id="CR26">
       <label>
        26.
       </label>
       <mixed-citation publication-type="other">
        Read JM, Bridgen JRE, Cummings DAT, Ho A, Jewell CP. Novel coronavirus 2019-nCoV: early estimation of epidemiological parameters and epidemic predictions. medRxiv
        <italic>
         .
        </italic>
        2020; doi: 10.1101/2020.01.23.20018549.
       </mixed-citation>
      </ref>
      <ref id="CR27">
       <label>
        27.
       </label>
       <mixed-citation publication-type="other">
        Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Euro Surveill. 2020;25(4). 10.2807/1560-7917.ES.2020.25.4.2000058.
       </mixed-citation>
      </ref>
      <ref id="CR28">
       <label>
        28.
       </label>
       <mixed-citation publication-type="other">
        Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020; 10.1016/S0140-6736(20)30260-9.
       </mixed-citation>
      </ref>
      <ref id="CR29">
       <label>
        29.
       </label>
       <mixed-citation publication-type="other">
        Ming WK, Huang J, Zhang CJ. Breaking down of healthcare system: mathematical modelling for controlling the novel coronavirus (2019-nCoV) outbreak in Wuhan. China bioRxiv. 2020. 10.1101/2020.01.27.922443.
       </mixed-citation>
      </ref>
      <ref id="CR30">
       <label>
        30.
       </label>
       <mixed-citation publication-type="other">
        Lai S, Bogoch II, Watts A, Khan K, Li Z, Tatem A. Preliminary risk analysis of 2019 novel coronavirus spread within and beyond China. 2020.
        <ext-link ext-link-type="uri" xlink:href="https://www.worldpop.org/resources/docs/china/WorldPop-coronavirus-spread-risk-analysis-v1-25Jan.pdf">
         https://www.worldpop.org/resources/docs/china/WorldPop-coronavirus-spread-risk-analysis-v1-25Jan.pdf
        </ext-link>
        . Accessed 31 Jan 2020.
       </mixed-citation>
      </ref>
      <ref id="CR31">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nishiura
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Linton
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
         <name>
          <surname>
           Kinoshita
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Hayashi
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The extent of transmission of novel coronavirus in Wuhan, China, 2020
        </article-title>
        <source>
         J Clin Med
        </source>
        <year>
         2020
        </year>
        <volume>
         9
        </volume>
        <fpage>
         330
        </fpage>
        <pub-id pub-id-type="doi">
         10.3390/jcm9020330
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR32">
       <label>
        32.
       </label>
       <mixed-citation publication-type="other">
        National Health Commission of People’s Republic of China. An update on the incidence of pneumonia with novel coronavirus infection as at 24:00 on 31 January 2020.
        <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/xcs/yqfkdt/202002/84faf71e096446fdb1ae44939ba5c528.shtml">
         http://www.nhc.gov.cn/xcs/yqfkdt/202002/84faf71e096446fdb1ae44939ba5c528.shtml
        </ext-link>
        . Accessed 1 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR33">
       <label>
        33.
       </label>
       <mixed-citation publication-type="other">
        WHO. Novel Coronavirus (2019-nCoV) Situation Report–11. 2020.
        <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200131-sitrep-11-ncov.pdf?sfvrsn=de7c0f7_4">
         https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200131-sitrep-11-ncov.pdf?sfvrsn=de7c0f7_4
        </ext-link>
        . Accessed 1 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR34">
       <label>
        34.
       </label>
       <mixed-citation publication-type="other">
        WHO. Coronavirus. 2020.
        <ext-link ext-link-type="uri" xlink:href="https://www.who.int/health-topics/coronavirus">
         https://www.who.int/health-topics/coronavirus
        </ext-link>
        . Accessed 1 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR35">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           ACK
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiology, genetic recombination, and pathogenesis of coronaviruses
        </article-title>
        <source>
         Trend Microbiol
        </source>
        <year>
         2016
        </year>
        <volume>
         24
        </volume>
        <fpage>
         490
        </fpage>
        <lpage>
         502
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.tim.2016.03.003
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR36">
       <label>
        36.
       </label>
       <mixed-citation publication-type="other">
        Chen Y, Liu Q, Guo D. Coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020. 10.1002/jmv.25681.
       </mixed-citation>
      </ref>
      <ref id="CR37">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome
        </article-title>
        <source>
         Nature Med
        </source>
        <year>
         2004
        </year>
        <volume>
         10
        </volume>
        <fpage>
         S88
        </fpage>
        <lpage>
         S97
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nm1143
        </pub-id>
        <pub-id pub-id-type="pmid">
         15577937
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR38">
       <label>
        38.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Boheemen
          </surname>
          <given-names>
           SV
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           ADME
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           RAM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2012
        </year>
        <volume>
         367
        </volume>
        <fpage>
         1814
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1211721
        </pub-id>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR39">
       <label>
        39.
       </label>
       <mixed-citation publication-type="other">
        Chinese Center for Disease Control and Prevention. 585 environmental samples from the South China Seafood Market in Wuhan, Hubei Province, China. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://www.chinacdc.cn/yw_9324/202001/t20200127_211469.html">
         http://www.chinacdc.cn/yw_9324/202001/t20200127_211469.html
        </ext-link>
        . Accessed 1 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR40">
       <label>
        40.
       </label>
       <mixed-citation publication-type="other">
        Lu H, Tang CW, Tang Y. Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle. J Medl Virol. 2020; doi: 10.1002/jmv/25678.
       </mixed-citation>
      </ref>
      <ref id="CR41">
       <label>
        41.
       </label>
       <mixed-citation publication-type="other">
        Roujian L, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 10.1016/S0140-6736(20)30251-8.
       </mixed-citation>
      </ref>
      <ref id="CR42">
       <label>
        42.
       </label>
       <mixed-citation publication-type="other">
        Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci Chin Life Sci. 2020; 10.1007/s11427-020-1637-5.
       </mixed-citation>
      </ref>
      <ref id="CR43">
       <label>
        43.
       </label>
       <mixed-citation publication-type="other">
        National Health Commission of People’s Republic of China. Pneumonia diagnosis and treatment of 2019-nCoV infection from Chinese NHC and CDC 2020. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/xcs/zhengcwj/202001/4294563ed35b43209b31739bd0785e67/files/7a9309111267475a99d4306962c8bf78.pdf">
         http://www.nhc.gov.cn/xcs/zhengcwj/202001/4294563ed35b43209b31739bd0785e67/files/7a9309111267475a99d4306962c8bf78.pdf
        </ext-link>
        . Accessed 1 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR44">
       <label>
        44.
       </label>
       <mixed-citation publication-type="other">
        Zhang H, Kang Z, Gong H, Xu D, Wang J, Li Z, et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. bioRxiv. 2020; doi: 10.1101/2020.01.30.927806.
       </mixed-citation>
      </ref>
      <ref id="CR45">
       <label>
        45.
       </label>
       <mixed-citation publication-type="other">
        National Health Commission of People’s Republic of China. Pneumonia infected with novel coronavirus is included in the management of legal infectious diseases. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/jkj/s7915/202001/e4e2d5e6f01147e0a8df3f6701d49f33.shtml">
         http://www.nhc.gov.cn/jkj/s7915/202001/e4e2d5e6f01147e0a8df3f6701d49f33.shtml
        </ext-link>
        . Accessed 31 Jan 2020.
       </mixed-citation>
      </ref>
      <ref id="CR46">
       <label>
        46.
       </label>
       <mixed-citation publication-type="other">
        National Health Commission of People’s Republic of China. Notice on printing and distributing the technical guide for prevention and control of novel coronavirus infection in medical institutions (First Edition). 2020.
        <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/yzygj/s7659/202001/b91fdab7c304431eb082d67847d27e14.shtml">
         http://www.nhc.gov.cn/yzygj/s7659/202001/b91fdab7c304431eb082d67847d27e14.shtml
        </ext-link>
        . Accessed 31 Jan 2020.
       </mixed-citation>
      </ref>
      <ref id="CR47">
       <label>
        47.
       </label>
       <mixed-citation publication-type="other">
        National Health Commission of People’s Republic of China. Notice on printing and distributing the work plan for prevention and control of pneumonia caused by novel coronavirus infection in the near future. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/tigs/s7848/202001/808bbf75e5ce415aa19f74c78ddc653f.shtml">
         http://www.nhc.gov.cn/tigs/s7848/202001/808bbf75e5ce415aa19f74c78ddc653f.shtml
        </ext-link>
        . Accessed 31 Jan 2020.
       </mixed-citation>
      </ref>
      <ref id="CR48">
       <label>
        48.
       </label>
       <mixed-citation publication-type="other">
        National Health Commission of People’s Republic of China. Notice on further prevention and control of pneumonia caused by novel coronavirus infection in rural areas. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/jkj/s3578/202001/f8d45f6af1d24ef18151c1d91cf8a028.shtml">
         http://www.nhc.gov.cn/jkj/s3578/202001/f8d45f6af1d24ef18151c1d91cf8a028.shtml
        </ext-link>
        . Accessed 31 Jan 2020.
       </mixed-citation>
      </ref>
      <ref id="CR49">
       <label>
        49.
       </label>
       <mixed-citation publication-type="other">
        National Health Commission of People’s Republic of China. Notice on prevention and control of novel coronavirus infection pneumonia in the elderly people. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/lljks/tggg/202001/96e82ba8a14d41b283da990d39771493.shtml">
         http://www.nhc.gov.cn/lljks/tggg/202001/96e82ba8a14d41b283da990d39771493.shtml
        </ext-link>
        . Accessed 31 Jan 2020.
       </mixed-citation>
      </ref>
      <ref id="CR50">
       <label>
        50.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
        </person-group>
        <article-title>
         Disinfection measures for pneumonia foci infected by novel coronavirus in 2019
        </article-title>
        <source>
         Chin J Disinfect
        </source>
        <year>
         2020
        </year>
        <volume>
         37
        </volume>
        <fpage>
         59
        </fpage>
        <lpage>
         62
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR51">
       <label>
        51.
       </label>
       <mixed-citation publication-type="other">
        World Health Organization. International clinical trials registry platform. 2020.
        <ext-link ext-link-type="uri" xlink:href="https://apps.who.int/trialsearch/default.aspx">
         https://apps.who.int/trialsearch/default.aspx
        </ext-link>
        . Accessed 23 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR52">
       <label>
        52.
       </label>
       <mixed-citation publication-type="other">
        Chinese Clinical Trial Registry. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn">
         http://www.chictr.org.cn
        </ext-link>
        . Accessed 23 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR53">
       <label>
        53.
       </label>
       <mixed-citation publication-type="other">
        Bin C, Fang X, Chen H. Application effect of disaster vulnerability analysis in coping with the transmission of new coronavirus in non-closed hematology ward. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://kns.cnki.net/kcms/detail/14.1272.R.20200131.1909.002.html">
         http://kns.cnki.net/kcms/detail/14.1272.R.20200131.1909.002.html
        </ext-link>
        . Accessed 2 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR54">
       <label>
        54.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Investigation on the psychological status of the first batch of clinical first-line support nurses to fight against pneumonia caused by novel coronavirus
        </article-title>
        <source>
         Chin Nurs Res
        </source>
        <year>
         2020
        </year>
        <volume>
         34
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         3
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR55">
       <label>
        55.
       </label>
       <mixed-citation publication-type="other">
        Ou F, Wu H, Yang Y, Tan W, Zhang J, Gu J. Countermeasures for rapid spread of new coronavirus pneumonia in Wuhan. Chin General Pract Nurs. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://kns.cnki.net/kcms/detail/14.1349.R.20200131.1319.002.html">
         http://kns.cnki.net/kcms/detail/14.1349.R.20200131.1319.002.html
        </ext-link>
        . Accessed 2 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR56">
       <label>
        56.
       </label>
       <mixed-citation publication-type="other">
        WHO. Advice on the use of masks in the community, during home care and in health care settings in the context of the novel coronavirus 2019-nCoV outbreak (Interim guidance). 2020. WHO/nCov/IPC_Masks/2020. Accessed 3 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR57">
       <label>
        57.
       </label>
       <mixed-citation publication-type="other">
        National Health Commission of People’s Republic of China. Guidelines for public protection against novel coronavirus infection. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/jkj/s7915/202001/bc661e49b5bc487dba182f5c49ac445b.shtml">
         http://www.nhc.gov.cn/jkj/s7915/202001/bc661e49b5bc487dba182f5c49ac445b.shtml
        </ext-link>
        . Accessed 31 Jan 2020.
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Influenza Other Respir Viruses
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Influenza Other Respir Viruses
      </journal-id>
      <journal-id journal-id-type="doi">
       10.1111/(ISSN)1750-2659
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       IRV
      </journal-id>
      <journal-title-group>
       <journal-title>
        Influenza and Other Respiratory Viruses
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1750-2640
      </issn>
      <issn pub-type="epub">
       1750-2659
      </issn>
      <publisher>
       <publisher-name>
        Blackwell Publishing Ltd
       </publisher-name>
       <publisher-loc>
        Oxford, UK
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       22188875
      </article-id>
      <article-id pub-id-type="pmc">
       5779801
      </article-id>
      <article-id pub-id-type="doi">
       10.1111/j.1750-2659.2011.00307.x
      </article-id>
      <article-id pub-id-type="publisher-id">
       IRV307
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Review Articles
        </subject>
       </subj-group>
       <subj-group subj-group-type="overline">
        <subject>
         Review Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        The use of masks and respirators to prevent transmission of influenza: a systematic review of the scientific evidence
       </article-title>
       <alt-title alt-title-type="left-running-head">
        bin‐Reza
        <italic>
         et al.
        </italic>
       </alt-title>
       <alt-title alt-title-type="right-running-head">
        Masks and respirators to prevent influenza
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="cr1">
        <name>
         <surname>
          bin‐Reza
         </surname>
         <given-names>
          Faisal
         </given-names>
        </name>
        <xref ref-type="aff" rid="a1">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" id="cr2">
        <name>
         <surname>
          Lopez Chavarrias
         </surname>
         <given-names>
          Vicente
         </given-names>
        </name>
        <xref ref-type="aff" rid="a2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" id="cr3">
        <name>
         <surname>
          Nicoll
         </surname>
         <given-names>
          Angus
         </given-names>
        </name>
        <xref ref-type="aff" rid="a1">
         <sup>
          1
         </sup>
        </xref>
        <xref ref-type="aff" rid="a2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" id="cr4">
        <name>
         <surname>
          Chamberland
         </surname>
         <given-names>
          Mary E.
         </given-names>
        </name>
        <xref ref-type="aff" rid="a1">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
      </contrib-group>
      <aff id="a1">
       <label>
        <sup>
         1
        </sup>
       </label>
       Health Protection Agency, London, England.
      </aff>
      <aff id="a2">
       <label>
        <sup>
         2
        </sup>
       </label>
       European Centre for Disease Prevention and Control, Stockholm, Sweden.
      </aff>
      <author-notes>
       <corresp id="correspondenceTo">
        Mary E. Chamberland, MD, MPH, Private public health consultant, 78 Lindbergh Drive Unit 70, Atlanta, GA 30305, USA.  E‐mail:
        <email>
         mechamberland@googlemail.com
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="epub">
       <day>
        21
       </day>
       <month>
        12
       </month>
       <year>
        2011
       </year>
      </pub-date>
      <pub-date pub-type="ppub">
       <month>
        7
       </month>
       <year>
        2012
       </year>
      </pub-date>
      <volume>
       6
      </volume>
      <issue>
       4
      </issue>
      <issue-id pub-id-type="doi">
       10.1111/irv.2012.6.issue-4
      </issue-id>
      <fpage>
       257
      </fpage>
      <lpage>
       267
      </lpage>
      <history>
       Accepted 10 October 2011. Published Online 21 December 2011.
      </history>
      <permissions>
       <copyright-statement content-type="article-copyright">
        © 2011 Blackwell Publishing Ltd
       </copyright-statement>
      </permissions>
      <self-uri content-type="pdf" xlink:href="file:IRV-6-257.pdf" xlink:type="simple">
      </self-uri>
      <abstract>
       <p>
        <italic>
         Please cite this paper as:
        </italic>
        bin‐Reza
        <italic>
         et al.
        </italic>
        (2012) The use of masks and respirators to prevent transmission of influenza: a systematic review of the scientific evidence. Influenza and Other Respiratory Viruses 6(4), 257–267.
       </p>
       <p>
        There are limited data on the use of masks and respirators to reduce transmission of influenza. A systematic review was undertaken to help inform pandemic influenza guidance in the United Kingdom. The initial review was performed in November 2009 and updated in June 2010 and January 2011. Inclusion criteria included randomised controlled trials and quasi‐experimental and observational studies of humans published in English with an outcome of laboratory‐confirmed or clinically‐diagnosed influenza and other viral respiratory infections. There were 17 eligible studies. Six of eight randomised controlled trials found no significant differences between control and intervention groups (masks with or without hand hygiene; N95/P2 respirators). One household trial found that mask wearing coupled with hand sanitiser use reduced secondary transmission of upper respiratory infection/influenza‐like illness/laboratory‐confirmed influenza compared with education; hand sanitiser alone resulted in no reduction. One hospital‐based trial found a lower rate of clinical respiratory illness associated with non‐fit‐tested N95 respirator use compared with medical masks. Eight of nine retrospective observational studies found that mask and/or respirator use was independently associated with a reduced risk of severe acute respiratory syndrome (SARS). Findings, however, may not be applicable to influenza and many studies were suboptimal. None of the studies established a conclusive relationship between mask/respirator use and protection against influenza infection. Some evidence suggests that mask use is best undertaken as part of a package of personal protection especially hand hygiene. The effectiveness of masks and respirators is likely linked to early, consistent and correct usage.
       </p>
      </abstract>
      <kwd-group>
       <kwd id="k1">
        Influenza
       </kwd>
       <kwd id="k2">
        mask
       </kwd>
       <kwd id="k3">
        pandemic
       </kwd>
       <kwd id="k4">
        respirator
       </kwd>
      </kwd-group>
      <counts>
       <fig-count count="1">
       </fig-count>
       <table-count count="4">
       </table-count>
      </counts>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         source-schema-version-number
        </meta-name>
        <meta-value>
         2.0
        </meta-value>
       </custom-meta>
       <custom-meta>
        <meta-name>
         cover-date
        </meta-name>
        <meta-value>
         July 2012
        </meta-value>
       </custom-meta>
       <custom-meta>
        <meta-name>
         details-of-publishers-convertor
        </meta-name>
        <meta-value>
         Converter:WILEY_ML3GV2_TO_NLMPMC version:4.6.9 mode:remove_FC converted:04.11.2015
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
     <notes>
      <fn-group>
       <fn id="fn1">
        <p>
         Faisal bin‐Reza, Angus Nicoll and Mary E Chamberland undertook this work whilst at the Health Protection Agency but no longer work at the HPA.
        </p>
       </fn>
       <fn id="fn2">
        <p>
         An earlier version of this review was published on‐line by the Department of Health at:
         <ext-link ext-link-type="uri" xlink:href="http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_125425.pdf">
          http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_125425.pdf
         </ext-link>
         . This version has been updated and revised.
        </p>
       </fn>
      </fn-group>
     </notes>
    </front>
    <sec id="ss1">
     <title>
      Introduction
     </title>
     <p>
      Personal protective equipment to help reduce transmission of influenza is generally advised according to the risk of exposure to the influenza virus and the degree of infectivity and human pathogenicity of the virus. The paucity of scientific evidence upon which to base guidance for the use of masks and respirators in healthcare and community settings has been a particularly vexing issue for policymakers.
     </p>
     <p>
      The Health Protection Agency (HPA) undertook a scientific evidence‐based review of the use of masks and respirators in an influenza pandemic to inform relevant guidance following the emergence of pandemic A (H1N1) 2009 influenza. The Department of Health commissioned the HPA to update the review in support of the revision of the United Kingdom (UK) influenza pandemic preparedness strategy.
      <xref ref-type="ref" rid="b1">
       <sup>
        1
       </sup>
      </xref>
      The review was published on‐line at:
      <ext-link ext-link-type="uri" xlink:href="http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_125425.pdf">
       http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_125425.pdf
      </ext-link>
      . A further update of the evidence base subsequently was performed in January 2011 and described herein.
     </p>
    </sec>
    <sec id="ss2">
     <title>
      Methods
     </title>
     <sec id="ss3">
      <title>
       Search strategy
      </title>
      <p>
       We generally followed the approach detailed in the University of York’s
       <italic>
        Systematic Reviews: CRD’s Guidance for Undertaking Reviews in Health
       </italic>
       Care.
       <xref ref-type="ref" rid="b2">
        <sup>
         2
        </sup>
       </xref>
      </p>
      <p>
       The original search of the PubMed database was conducted on 7 November 2009; subsequent updates of the PubMed database search were undertaken on 23 June 2010 and 12 January 2011.
       <xref ref-type="fn" rid="fn3">
        <sup>
         1
        </sup>
       </xref>
       The November 2009 search also included the following scientific databases: Bandolier, the Cochrane Library Database of Systematic Reviews, the Database of Abstracts of Reviews of Effects, the Health Technology Assessment database, the National Health Service (NHS) Economic Evaluation database, the UK Database of Uncertainties about the Effects of Treatments, the NHS Centre for Reviews and Dissemination and the Cumulative Index to Nursing and Allied Health Literature.
       <xref ref-type="fn" rid="fn4">
        <sup>
         2
        </sup>
       </xref>
       No additional publications resulted from these databases. The initial search in November 2009 had no time period restrictions.
      </p>
      <p>
       A limited effort was made to identify additional studies: reference lists of review articles were examined; the European Centre for Disease Prevention and Control’s (ECDC) Antimicrobial Resistance and Health Care Associated Infection Programme was consulted; and MEC’s and AN’s hardcopy literature files were hand‐searched.
      </p>
     </sec>
     <sec id="ss4">
      <title>
       Study selection
      </title>
      <p>
       We included the following types of studies listed in the hierarchical order of study design quality: randomised controlled trials (i.e. randomised cross‐over trial and cluster randomised trial); quasi‐experimental studies (i.e. non‐randomised controlled study, before‐and‐after study and interrupted time series); and observational studies (cohort study and case–control study). Only human studies published in English which had an abstract were included (
       <xref ref-type="table-wrap" rid="t1">
        Table 1
       </xref>
       ).
      </p>
      <table-wrap id="t1" orientation="portrait" position="float" xml:lang="en">
       <label>
        Table 1
       </label>
       <caption>
        <p>
         Summary of criteria for the review
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <col align="left" span="1"/>
        <tbody valign="top">
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Inclusion criteria
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Type of study: Randomised controlled trial, quasi‐experimental and observational studies
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Participants: Humans
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Setting: Healthcare or community
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Language: English only
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Abstract: Available
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Outcome: Laboratory‐confirmed or clinically‐diagnosed influenza and other viral respiratory infections
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Exclusion criteria
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Type of study: Case series, case report, mathematical modelling and human/non‐human experimental laboratory studies, reviews
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Participants: Animals
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Setting: Laboratory
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Language: non‐English
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Abstract: not available
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
      <p>
       Infection with pandemic strains, seasonal influenza A or B viruses and zoonotic viruses such as swine or avian influenza were included because mask/respirator guidance is needed for all types of influenza. Studies that evaluated the effect of masks/respirators on transmission of other respiratory viruses were included as a proxy for influenza.
      </p>
     </sec>
     <sec id="ss5">
      <title>
       Study selection and validity assessment
      </title>
      <p>
       A two‐stage selection process was used to identify studies that appeared to meet the inclusion criteria. Firstly, Fb‐R or VLC scanned and excluded papers on the basis of the ‘title’ for relevance; in the second and third searches, some relevant titles were excluded because they had been selected for review during a prior search. Secondly, to enhance the reliability of the selection process, Fb‐R, VLC, MEC and AN independently reviewed the abstracts for the remaining papers.
      </p>
      <p>
       Fb‐R or VLC used a pre‐designed form to perform an initial data extraction of the full article and make an initial determination regarding its eligibility. MEC or AN subsequently reviewed all of the papers, supplemented Fb‐R’s and VLC’s initial abstraction as necessary and re‐assessed each paper for inclusion in the review. Any differences were resolved by mutual agreement. MEC and AN assessed the quality of the eligible studies using the Critical Appraisal Skills Programme tools
       <xref ref-type="ref" rid="b3">
        <sup>
         3
        </sup>
       </xref>
       for randomised controlled trials, case–control studies and cohort studies.
      </p>
     </sec>
    </sec>
    <sec id="ss6">
     <title>
      Results
     </title>
     <p>
      The three separate database searches yielded a total of 6015 titles; five articles were identified by scanning the reference lists of review articles and three articles were from MEC’s hard copy collection (
      <xref ref-type="fig" rid="f1">
       Figure 1
      </xref>
      ). Full papers were obtained for 76 articles; of these, 17 studies were eligible for inclusion. Descriptions, findings and comments for these studies are detailed in
      <xref ref-type="table-wrap" rid="t2">
       2
      </xref>
      ,
      <xref ref-type="table-wrap" rid="t3">
       3
      </xref>
      ,
      <xref ref-type="table-wrap" rid="t4">
       4
      </xref>
      .
     </p>
     <fig fig-type="Figure" id="f1" orientation="portrait" position="float" xml:lang="en">
      <label>
       Figure 1
      </label>
      <caption>
       <p>
        Diagram of search strategy results and article selection for three searches.
        <sup>
         1
        </sup>
        Includes 3 papers that were sought for review and abstraction in the first search.
        <sup>
         2
        </sup>
        Includes 6 papers that were sought for review and abstraction in the second search.
        <sup>
         3
        </sup>
        One of these papers (reference no. 6) became available on‐line on 27 January 2011.
        <sup>
         4
        </sup>
        Reasons for exclusion included an inability to distinguish the effect of mask use from other personal protective equipment or lack of quantitative data.
       </p>
      </caption>
      <graphic id="nlm-graphic-1" xlink:href="IRV-6-257-g001">
      </graphic>
     </fig>
     <table-wrap id="t2" orientation="portrait" position="float" xml:lang="en">
      <label>
       Table 2
      </label>
      <caption>
       <p>
        Synopsis of randomised controlled trials evaluating mask and respirator use for influenza
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <thead valign="bottom">
        <tr style="border-bottom:solid 1px #000000">
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          Author/country/year of exposure/(reference)
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          Study design and participants
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          Reported results
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          Limitations
         </th>
        </tr>
       </thead>
       <tbody valign="top">
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Jacobs/Japan 2008 (
          <xref ref-type="ref" rid="b4">
           4
          </xref>
          )
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Block randomisation to 2 arms and analysed as mask group (17 HCWs wore surgical mask on duty) and no mask group (15 HCWs only wore mask if job‐required e.g. surgical nurse).  Outcome measure: Self‐reported cold symptoms scaled to severity.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          No difference between two groups; HCWs living with children reported higher severity scores.  84·3% of participants reported full compliance with mask use and non‐use.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Underpowered study; no exposure data; compliance self‐reported; no confirmatory laboratory testing.
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Loeb/Canada 2008/09 (
          <xref ref-type="ref" rid="b5">
           5
          </xref>
          )
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Non‐inferiority randomisation of 446 nurses in emergency departments and medical and paediatric units in 8 hospitals to 2 arms and analysed as surgical mask group (212 nurses) and fit‐tested N95 respirator group (210 nurses); mask/respirator worn when caring for patients with febrile respiratory illness during influenza season; assigned respiratory device worn for aerosol‐generating procedures.  Outcome measure: Laboratory confirmed influenza by PCR; serology only if no receipt of 2008/09 vaccine.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          No difference in influenza infection: 50 (23·6%) of 212 in mask group versus 48 (22·9%) of 210 in N95 group (absolute risk difference, −0·73%; 95% CI −8·8% to 7·3%;
          <italic>
           P
          </italic>
          = 0·86).  Limited audit found high compliance.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Hard to generalise findings given lack of control arm.  Incomplete assessment of compliance and lack of detailed descriptions of exposures.
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Cowling/China ‐ Hong Kong 2007 (
          <xref ref-type="ref" rid="b7">
           7
          </xref>
          )
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Cluster randomisation of 198 HHs (index case and HH contacts) to 3 arms and analysed as control (71 HHs and 205 contacts), surgical masks (21 HHs and 61 contacts) or hand hygiene (30 HHs and 84 HH contacts); index cases and contacts asked to wear masks as often as possible at home during the 7‐day follow‐up period (including when with index patient outside of the household).  Outcome measure: Culture‐confirmed influenza; self‐reported influenza symptoms.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          No difference in laboratory‐confirmed secondary attack ratios in controls 0·06 (95% CI 0·03–0·10), mask 0·07(95% CI 0·02–0·16) and hand hygiene groups 0·06 (95% CI 0·02–0·13),
          <italic>
           P
          </italic>
          = 0·99.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Underpowered pilot study; some index cases wore masks in control and hand hygiene arms; difficulty in starting the intervention quickly may have underestimated its true effect.  Compliance low: 45% (21%) of index cases (HH contacts) wore mask often/always.
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Cowling/China ‐ Hong Kong 2008 (
          <xref ref-type="ref" rid="b8">
           8
          </xref>
          )
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Cluster randomisation of 407 HHs (index case and HH contacts) to 3 arms and analysed as control (91 HHs and 279 contacts), surgical masks and hand hygiene by both index case and contacts (83 HHs and 258 contacts) or hand hygiene (85 HHs and 257 contacts); index cases and contacts asked to wear masks as often as possible at home during the 7‐day follow‐up period (including when with index patient outside of the household).  Outcome measure: RT‐PCR positive confirmed influenza; self‐reported influenza symptoms.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          No difference in laboratory‐confirmed secondary attack ratios in controls 10% (95% CI 6–14), hand hygiene 5% (95% CI 3–9) and mask plus hand hygiene groups 7% (95% CI 4–11);
          <italic>
           P
          </italic>
          = 0·22.  Significant reduction in secondary attack ratio if either intervention applied within 36 hours of index case’s onset.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Control and hand hygiene arms ‘contaminated’ as some index cases wore masks; delay in starting intervention quickly may have underestimated its true effect  Adherence low: 49% (26%) of index cases (HH contacts) wore mask often/always.  Cannot distinguish relative contributions of hand hygiene and mask as they were combined.
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          MacIntyre/Australia 2006/07 (
          <xref ref-type="ref" rid="b9">
           9
          </xref>
          )
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Cluster randomisation of 145 HHs (index case and HH contacts &gt;16 years) to 3 arms and analysed as control (50 HHs and 100 contacts) or surgical mask (47 HHs and 94 contacts) or P2 respirator (46 HHs and 92 contacts); mask/respirator to be worn at all times when in room with index case.  Outcome measure: ILI or laboratory‐ confirmed respiratory virus infection.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          No significant differences between ILI rates in controls 16 (16·0%) of 100, in surgical mask group 21 (22·3%) of 94 (RR 1·29, 95%.CI 0·69–2·31,
          <italic>
           P
          </italic>
          = 0·46) and in P2 respirator group 14 (15·2%) of 92 (RR 0·95, 95%.CI = 0·49–1·84,
          <italic>
           P
          </italic>
          = 1); no difference in respiratory virus isolation rates in controls 3 (3·0%) of 100; in surgical mask group 6 (6·4%) of 94 (RR 2·13, 95% CI 0·55–8·26,
          <italic>
           P
          </italic>
          = 0·32); and in P2 respirator group 8 (8·7%) of 92 (RR 2·90, 95% CI 0·79–10·6,
          <italic>
           P
          </italic>
          = 0·12).  Reduced risk for ILI with adherent mask or respirator use (hazard ratio 0·26, CI 0·09–0·77,
          <italic>
           P
          </italic>
          = 0·015).
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Underpowered to detect differences between 2 interventions; low level of self‐reported adherence (21% of contacts in the surgical mask and respirator arms wore mask often/always).  Interval between index case’s symptom onset and start of intervention not stated; if delayed may have underestimated true effect of intervention.
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Aiello/USA, 2006/07 (
          <xref ref-type="ref" rid="b10">
           10
          </xref>
          )
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Cluster parallel randomisation of 1437 students living in university residence halls to 3 arms and analysed as control group (552 students); mask plus hand sanitiser group (367 students); and mask‐only group (378 students); instructed to wear mask as much as possible in residence hall during 6 week intervention period; encouraged to wear outside residence hall also.  Outcome measure: self‐reported ILI.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Adjusted analyses found ILI significantly reduced in mask plus hand sanitiser hygiene group compared with controls (during weeks 4–6), ranging from 35% (95% CI 9–53%) to 51% (95% CI 13–73%); reductions in the mask group not significant at
          <italic>
           P
          </italic>
          &lt; 0·025.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Hard to generalise given limited age group and specialised setting.  Study underpowered to detect small reductions in ILI across arms and the relative contributions of hand hygiene and masks.
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Larson/USA 2006/08 (
          <xref ref-type="ref" rid="b11">
           11
          </xref>
          )
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Block randomisation of 617 urban HHs allocated into education (control) group (174 HHs); hand sanitiser group (169 HHs); and hand sanitiser and mask group (166 HHs); household caretaker to wear mask when within 3 feet of person with ILI for 7 days or until symptoms disappeared and to change mask between interactions; ill person encouraged to wear mask when within 3 feet of other HH members.  Outcome measure: Self‐reported ILI/URI symptoms and viral culture.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Hand sanitiser group more likely to report no symptomatic HH members (545/946 [57·6%] compared with education (447/904 [49·4%] and hand sanitiser/mask (363/938 [38·7%] groups,
          <italic>
           P
          </italic>
          &lt; 0·01; no significant differences in rates of URI, ILI or influenza infection by intervention group in multivariate analyses.  Hand sanitiser/mask group had significant reduction in secondary attack rates for URI/ILI/influenza infection (OR 0·82, 95% CI 0·70–0·97) compared with education. No reduction with hand sanitiser alone (OR 1·01, 95% CI 0·85–1·21).
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Poor self‐reported compliance with mask use: 22 (50%) of 44 HHs reporting ILI used masks within 48 hours of episode onset; average of 2 (range 0–9) masks/day/ILI episode used.  Limited power to detect differences amongst 3 groups; some use of hand sanitiser in control group in response to media reports about methicillin‐resistant
          <italic>
           Staphylococcus aureus.
          </italic>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          MacIntyre/China –Beijing/2008/09 (
          <xref ref-type="ref" rid="b6">
           6
          </xref>
          )
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Cluster, stratified (by size of hospital and level of infection control) randomisation of 1441 HCWs in 15 Beijing hospitals into mask group (492 HCWs/5 hospitals); N95 fit‐tested group (461 HCWs/5 hospitals; and N95 non‐fit‐tested group (488 HCWs/5 hospitals); supplemented with convenience sample of non‐mask‐wearing HCWs from 9 hospitals; participants wore the mask/respirator on every shift for 4 consecutive weeks after being shown when/how to wear it.  Outcome measure: Self‐reported CRI, ILI and laboratory‐confirmed viral infection by PCR.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          For all outcomes N95 respirators had lower, but not significant, rates compared with masks. Intention‐to‐treat analysis adjusted for clustering of hospitals found only non‐fit‐tested N95s protective against CRI (16/488 [3·3%], OR 0·48, 95% CI 0·24–0·98,
          <italic>
           P
          </italic>
          = 0·045) compared with mask group (33/492 [6·7%]) as ref.  Multivariate analysis found wearing N95s and hospital level each reduced odds of CRI and laboratory‐confirmed infection.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Monitored and self‐reported compliance good (68–76%) in the 3 arms; however, monitoring by HCWs’ supervisors not optimal method.  Limited power to detect differences amongst 3 groups as observed attack rates low. Authors note 46% probability of incorrectly finding one significant difference. Despite stratified randomisation, mask group comprised of only level 3 (most sophisticated) hospitals. Hard to generalise beyond unique study population. Detailed data on potential exposures and information on community levels of influenza not provided.
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn id="t2_note36">
        <p>
         HCW, healthcare worker; PPE, personal protective equipment; RT‐PCR, reverse transcription‐polymerase chain reaction; ILI, influenza‐like illness; HH, household; URI, upper respiratory infection; CRI, clinical respiratory illness; ref, reference group.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <table-wrap id="t3" orientation="portrait" position="float" xml:lang="en">
      <label>
       Table 3
      </label>
      <caption>
       <p>
        Synopsis of observational case–control studies evaluating mask and respirator use for SARS
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <thead valign="bottom">
        <tr style="border-bottom:solid 1px #000000">
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          Author/country (reference)
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          Study design and participants
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          Reported results
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          Comments
         </th>
        </tr>
       </thead>
       <tbody valign="top">
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Chen/China (
          <xref ref-type="ref" rid="b12">
           12
          </xref>
          )
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          91 SARS IgG positive HCWs compared with 657 SARS IgG negative HCWs who cared for SARS patients in two hospitals.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Double‐layer cotton mask (versus a single‐layer cotton mask) protective against SARS infection in univariate analysis (OR 2·53, 95% CI 1·57–4·07); not significant in multivariate analysis.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Possible recall bias as questionnaire survey conducted 4 months after outbreak; limited data on frequency and type of exposures to SARS patients.
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Lau/China‐Hong Kong (
          <xref ref-type="ref" rid="b13">
           13
          </xref>
          )
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          72 HCWS with SARS from 5 hospitals compared with 144 matched controls; PPE use examined during (i) direct contact with SARS patient; (ii) general contact with SARS and non‐SARS patients; and (iii) no patient contact.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Almost all HCWs wore N95 respirator or surgical mask in all patient settings.  Unadjusted univariate analysis found inconsistent use of masks or respirators not associated with higher risk of SARS in any of the 3 contact settings; multivariate analysis found inconsistent use of &gt;1 type of PPE during direct contact independent risk for SARS.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          No serological testing of controls; reporting bias possible.
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Nishiura/Viet Nam (
          <xref ref-type="ref" rid="b14">
           14
          </xref>
          )
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Period 1: Time from admission of index case to occurrence of secondary cases in one hospital: 25 laboratory‐confirmed SARS cases compared with 90 controls (HCWs and relatives of patients).  Period 2: During a nosocomial outbreak in the hospital with strict isolation procedures, quarantine of HCWs and increased use of PPE: 4 laboratory‐confirmed SARS cases compared with 26 controls with only physicians and nurses in both groups.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Period 1: univariate analysis found masks (OR 0·3, 95%CI 0·1–0·7) and gowns (OR 0·2, 95%CI 0·0–0·8) protective; in logistic regression analyses, only masks protective (OR = 0·29, 95% CI 0·11–0·73)  Period 2: use of masks (OR &lt; 0·1, 95% CI 0·0–0·3) and gowns (
          <italic>
           P
          </italic>
          = 0·010, OR and CI not calculable) associated with non‐infection for doctors and nurses.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Possible recall bias; exposures imprecisely quantified; no serological testing of controls.
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Nishiyama/Viet Nam (
          <xref ref-type="ref" rid="b15">
           15
          </xref>
          )
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Risk factors for serologically‐ confirmed SARS infection assessed for 85 case and control HCWs who had direct contact with SARS patients.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Multivariate logistic regression analysis found significant risk for SARS amongst HCWs who never wore mask compared with those who always wore a mask (OR 12·6, 95% CI 2·0–80·0,
          <italic>
           P
          </italic>
          &lt; 0·01)
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Possible reporting bias as interview conducted 7 months after outbreak; nature of exposures to SARS not specified; community exposures not assessed.
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Seto/China ‐ Hong Kong (
          <xref ref-type="ref" rid="b16">
           16
          </xref>
          )
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          13 SARS‐infected HCWs with no community exposures compared with 241 HCWs without clinical SARS; all reported direct contact with 11 SARS patients in 5 hospitals.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Univariate analysis found HCWs who used surgical masks or N95 respirators, gowns or hand washing less likely to develop SARS; logistic regression analysis found use of any mask significant (OR 13, 95% CI 3–60).
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          No serological testing of controls; reporting bias possible as interviews conducted a month after cases identified; community exposures not assessed.
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Teleman/Singapore (
          <xref ref-type="ref" rid="b17">
           17
          </xref>
          )
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Evaluated risk factors for serologically‐confirmed SARS amongst 36 ill case‐HCWs exposed to 3 highly infectious source patients and 50 well control‐HCWs that came within 1 m of serologically‐confirmed SARS patients.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Adjusted logistic regression analyses found that wearing N95 respirator during each patient contact (adj OR 0·1, 95% CI 0·02–0·86,
          <italic>
           P
          </italic>
          = 0·04) and hand washing after patient contact (adj OR 0·07, 95% CI 0·008–0·66,
          <italic>
           P
          </italic>
          = 0·02) protective.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Small sample size; no serological testing of the controls; limited recall of precise exposure data; no assessment of community/household exposures.
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Lau/China ‐ Hong Kong (
          <xref ref-type="ref" rid="b19">
           19
          </xref>
          )
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          330 probable SARS cases with ‘undefined’ source of infection compared with 660 controls recruited by random telephone survey matched for age, sex and reference time for behaviours in question.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Matched multivariate analyses found using mask frequently in public places 27·9% of 330 cases versus 58·7% of 660 controls (OR = 0·36, 95% CI 0·25–0·52); washing one’s hands &gt;10 times a day (OR = 0·58, 95% CI 0·38–0·87) and disinfecting living quarters (OR = 0·41, 95% CI 0·29–0·58) protective.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Likely misclassification because no laboratory testing for most cases and no testing of controls; non‐specific questions about exposures and potential protective measures.
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Wu/China (
          <xref ref-type="ref" rid="b20">
           20
          </xref>
          )
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          94 unlinked, probable clinical SARS cases without reported contact with other SARS cases and 281 community‐based age‐ and sex‐matched controls in Beijing recruited by sequential digit dialling.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Multivariate analysis found ‘sometimes’ and ‘always’ wearing mask when outside home protective (matched OR 0·4, 95% CI 0·2–0·9,
          <italic>
           P
          </italic>
          = 0·03 and OR 0·3, 95% CI 0·1–0·6,
          <italic>
           P
          </italic>
          = 0·002, respectively).
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Likely misclassification because no laboratory testing for most cases and no testing of controls; lack of information about community exposures; recall and self‐selection bias possible.
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn id="t3_note36">
        <p>
         SARS, severe acute respiratory syndrome; HCW, healthcare worker.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <table-wrap id="t4" orientation="portrait" position="float" xml:lang="en">
      <label>
       Table 4
      </label>
      <caption>
       <p>
        Synopsis of an observational cohort study evaluating mask and respirator use for SARS
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <col align="left" span="1"/>
       <thead valign="bottom">
        <tr style="border-bottom:solid 1px #000000">
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          Author/country (reference)
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          Study design and participants
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          Reported results
         </th>
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          Comments
         </th>
        </tr>
       </thead>
       <tbody valign="top">
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Loeb/Canada (
          <xref ref-type="ref" rid="b18">
           18
          </xref>
          )
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Retrospective cohort of 43 nurses who worked in ICU or CCU when laboratory‐confirmed SARS patient in unit; analysis limited to 32 nurses who entered patient’s room at least once.
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          3 (13%) of 23 nurses who consistently wore mask (either surgical or N95 respirator) developed SARS compared with 5 (56%) of 9 nurses who did not consistently wear either (RR 0·23,
          <italic>
           P
          </italic>
          = 0·02).  2 (13%) of 16 nurses who consistently wore N95 respirator developed SARS compared with 1 (25%) of 4 nurses who consistently wore a surgical mask (RR = 0·50,
          <italic>
           P
          </italic>
          = 0·51).
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Underpowered study; recall bias possible; community exposure not explored; no serological testing of controls.
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn id="t4_note8">
        <p>
         SARS, severe acute respiratory syndrome; PPE, personal protective equipment; ILI, influenza‐like illness; ICU, intensive care unit; CCU, coronary care unit.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <sec id="ss7">
      <title>
       Randomised controlled trials
      </title>
      <p>
       Three of the randomised trials were hospital‐based studies,
       <xref ref-type="ref" rid="b4">
        <sup>
         4
        </sup>
       </xref>
       ,
       <xref ref-type="ref" rid="b5">
        <sup>
         5
        </sup>
       </xref>
       ,
       <xref ref-type="ref" rid="b6">
        <sup>
         6
        </sup>
       </xref>
       and five were conducted in community settings.
       <xref ref-type="ref" rid="b7">
        <sup>
         7
        </sup>
       </xref>
       ,
       <xref ref-type="ref" rid="b8">
        <sup>
         8
        </sup>
       </xref>
       ,
       <xref ref-type="ref" rid="b9">
        <sup>
         9
        </sup>
       </xref>
       ,
       <xref ref-type="ref" rid="b10">
        <sup>
         10
        </sup>
       </xref>
       ,
       <xref ref-type="ref" rid="b11">
        <sup>
         11
        </sup>
       </xref>
       Two of these studies compared N95 respirators (designed to seal tightly to the wearer’s face and filter out very small particles or aerosols that may contain viruses) and surgical masks (used to block large droplets from coming into contact with the wearer’s mouth or nose) amongst healthcare workers; one trial found a lower rate of clinical respiratory illness associated with the use of non‐fit‐tested N95 respirators compared with medical masks,
       <xref ref-type="ref" rid="b6">
        <sup>
         6
        </sup>
       </xref>
       whilst a non‐inferiority trial found that masks and respirators offered similar protection to nurses against laboratory‐confirmed influenza infection.
       <xref ref-type="ref" rid="b5">
        <sup>
         5
        </sup>
       </xref>
       A trial conducted amongst crowded, urban households found that, despite poor compliance, mask wearing coupled with hand sanitiser use, reduced secondary transmission of upper respiratory infection/influenza‐like illness/laboratory‐confirmed influenza compared with education; hand sanitiser alone resulted in no reduction in this aggregated outcome.
       <xref ref-type="ref" rid="b11">
        <sup>
         11
        </sup>
       </xref>
      </p>
      <p>
       Although the remaining five trials found no significant differences between control and intervention groups, there were some notable findings. Household contacts who wore a P2 respirator (considered to have an equivalent rating to an N95 respirator) ‘all’ or ‘most’ of the time for the first 5 days were less likely to develop an influenza‐like illness compared with less frequent users in one study.
       <xref ref-type="ref" rid="b9">
        <sup>
         9
        </sup>
       </xref>
       Another study found a significant reduction in laboratory‐confirmed influenza amongst household contacts that began hand hygiene or hand hygiene plus a mask within 36 hours of the index case’s illness.
       <xref ref-type="ref" rid="b8">
        <sup>
         8
        </sup>
       </xref>
       A trial conducted amongst resident university students detected significant reductions in influenza‐like illness during weeks 4–6 in the mask and hand hygiene group after adjusting for vaccine receipt and other potential confounders.
       <xref ref-type="ref" rid="b10">
        <sup>
         10
        </sup>
       </xref>
      </p>
      <p>
       The requirements for mask/respirator wearing and subsequent compliance varied by study (
       <xref ref-type="table-wrap" rid="t2">
        Table 2
       </xref>
       ); for example, in MacIntyre’s study of healthcare workers in China in December 2008 through January 2009
       <xref ref-type="ref" rid="b6">
        <sup>
         6
        </sup>
       </xref>
       ‘participants wore the mask or respirator on every shift for 4 consecutive weeks after being shown when to wear it’, whilst nurses in Canada wore a mask or respirator during the 2008/09 influenza season when caring for patients with febrile respiratory illness and during aerosol‐generating procedures.
       <xref ref-type="ref" rid="b5">
        <sup>
         5
        </sup>
       </xref>
      </p>
     </sec>
     <sec id="ss8">
      <title>
       Observational studies
      </title>
      <p>
       All of the observational studies evaluated mask and respirator use following the outbreaks of severe acute respiratory syndrome (SARS) in 2003;
       <xref ref-type="ref" rid="b12">
        <sup>
         12
        </sup>
       </xref>
       ,
       <xref ref-type="ref" rid="b13">
        <sup>
         13
        </sup>
       </xref>
       ,
       <xref ref-type="ref" rid="b14">
        <sup>
         14
        </sup>
       </xref>
       ,
       <xref ref-type="ref" rid="b15">
        <sup>
         15
        </sup>
       </xref>
       ,
       <xref ref-type="ref" rid="b16">
        <sup>
         16
        </sup>
       </xref>
       ,
       <xref ref-type="ref" rid="b17">
        <sup>
         17
        </sup>
       </xref>
       ,
       <xref ref-type="ref" rid="b18">
        <sup>
         18
        </sup>
       </xref>
       ,
       <xref ref-type="ref" rid="b19">
        <sup>
         19
        </sup>
       </xref>
       ,
       <xref ref-type="ref" rid="b20">
        <sup>
         20
        </sup>
       </xref>
       seven studies were conducted amongst healthcare workers and two were community‐based. All but two
       <xref ref-type="ref" rid="b12">
        <sup>
         12
        </sup>
       </xref>
       ,
       <xref ref-type="ref" rid="b13">
        <sup>
         13
        </sup>
       </xref>
       of the case–control studies in healthcare workers reported that wearing masks and/or respirators appeared to protect workers from acquiring SARS.
       <xref ref-type="ref" rid="b14">
        <sup>
         14
        </sup>
       </xref>
       ,
       <xref ref-type="ref" rid="b15">
        <sup>
         15
        </sup>
       </xref>
       ,
       <xref ref-type="ref" rid="b16">
        <sup>
         16
        </sup>
       </xref>
       ,
       <xref ref-type="ref" rid="b17">
        <sup>
         17
        </sup>
       </xref>
       A retrospective cohort study of nurses who worked in two Toronto hospital intensive care units found that the relative risk of SARS for nurses who consistently wore a N95 respirator was half that for nurses who consistently wore a surgical mask; however, the difference was not significant because of a small sample size.
       <xref ref-type="ref" rid="b18">
        <sup>
         18
        </sup>
       </xref>
      </p>
     </sec>
    </sec>
    <sec id="ss9">
     <title>
      Discussion
     </title>
     <p>
      None of the studies we reviewed established a conclusive relationship between mask/respirator use and protection against influenza infection. Some useful clues, however, could be gleaned. Subanalyses performed for one of the larger randomised controlled studies in a household setting found evidence of reduced rates of influenza‐like illness if household contacts consistently wore the mask or respirator.
      <xref ref-type="ref" rid="b9">
       <sup>
        9
       </sup>
      </xref>
      The authors of a randomised trial of mask plus alcohol‐based sanitiser and mask‐only group amongst U.S. university students living in residence halls noted that their study may have been better positioned to identify a protective effect because participants initiated the interventions at the beginning of the influenza season.
      <xref ref-type="ref" rid="b10">
       <sup>
        10
       </sup>
      </xref>
      Cowling’s
      <xref ref-type="ref" rid="b8">
       <sup>
        8
       </sup>
      </xref>
      finding that there was a significant reduction in the secondary attack ratio if the hand hygiene and mask plus hand hygiene interventions were begun within 36 hours of the index case lends support to this hypothesis.
     </p>
     <p>
      Anticipating the paucity of studies that focused solely on influenza, we included the effect of masks/respirators on respiratory viruses other than influenza. Such studies have often been used to support infection control guidance for influenza. However, the difficulties in interpreting the observational studies of SARS suggest that they are of limited use for guiding policy on influenza. Firstly, SARS is an unusual acute viral respiratory infection with a very different epidemiology to almost all other respiratory viral infections. It is fundamentally different from human influenza: it rarely infects children, has a long incubation period, transmits little early on, mostly transmits in healthcare settings, is not prone to extensive global spread and has only appeared once. Secondly, the studies were poorly designed, had many weaknesses and so were very difficult to interpret. Issues of concern include the use of a non‐specific definition for exposure to a SARS patient (e.g. coming within one metre of a patient), inconsistency in providing information about the comparability of cases and controls and collection of data after a lengthy period following the outbreak. Several lacked microbiological confirmation of cases or controls and it would seem likely that a number of the SARS cases were not cases at all. Because all the cases knew they were cases, recall bias was highly likely. The single case–control study that tried to address some of these limitations did not find that inconsistent use of masks or respirators was associated with SARS infection.
      <xref ref-type="ref" rid="b13">
       <sup>
        13
       </sup>
      </xref>
     </p>
     <p>
      It is important to note three considerations when assessing the practical implications of the review’s findings. Firstly, development of evidence‐based guidance about mask/respirator use is inextricably linked to what is known about how influenza is spread and specific risk factors that can affect transmissibility (e.g. host factors, pathogen factors, environmental factors and particle size). However, this is an area equally fraught with uncertainty; there are limited and conflicting evidence regarding the relative importance and frequency of direct contact, indirect contact, droplet and aerosol modes of transmission.
      <xref ref-type="ref" rid="b21">
       <sup>
        21
       </sup>
      </xref>
      ,
      <xref ref-type="ref" rid="b22">
       <sup>
        22
       </sup>
      </xref>
      Historically, transmission has been thought to occur principally through respiratory droplets and masks have been used as a barrier against droplets emitted by coughing and sneezing. In the last decade, there has been increasing interest in a possible role for aerosol transmission of influenza and the advisability of filtering respirators to block such transmission. For example, studies have found that infected patients can produce aerosol particles containing influenza virus
      <xref ref-type="ref" rid="b23">
       <sup>
        23
       </sup>
      </xref>
      and that hospital airflow patterns can influence influenza transmission via aerosols.
      <xref ref-type="ref" rid="b24">
       <sup>
        24
       </sup>
      </xref>
     </p>
     <p>
      Secondly, although the focus of this review has been on masks and respirators, limiting transmission of influenza in both healthcare and community settings requires a multifaceted approach, of which masks and respirators are but one component. In the healthcare setting, this ‘hierarchy of controls’ includes administrative controls help to reduce the introduction and spread of infection (e.g. policies to restrict entrance of ill visitors and workers, vaccination of healthcare workers); environmental/ engineering controls (e.g. adequate ventilation); and lastly, use of personal protective equipment and hand hygiene.
      <xref ref-type="ref" rid="b25">
       <sup>
        25
       </sup>
      </xref>
      In the community setting, a similarly structured approach is advised. However, during both the planning for an eventual pandemic and the subsequent public health response to the H1N1 pandemic, concern over policy and guidance related to mask/respirator use has at times seemed to overshadow other important controls.
      <xref ref-type="ref" rid="b26">
       <sup>
        26
       </sup>
      </xref>
      It is somewhat paradoxical that whilst continued effort and resources are needed to assess the independent effect of masks and respirators on influenza transmission, their use would always be recommended in combination with other control measures.
     </p>
     <p>
      Thirdly the practical implications of policy, guidance and recommendations on mask/respirator use and other infection control measures must be considered. The only two studies that compared mask and respirators to protect healthcare workers from influenza infection essentially reached different conclusions
      <xref ref-type="ref" rid="b5">
       <sup>
        5
       </sup>
      </xref>
      ,
      <xref ref-type="ref" rid="b6">
       <sup>
        6
       </sup>
      </xref>
      illustrating the difficulties facing policymakers.
      <xref ref-type="ref" rid="b27">
       <sup>
        27
       </sup>
      </xref>
      Further, a simulation study found that strict adherence to guidance about personal protective equipment (which included masks and respirators) compromised normal ward functioning in a UK hospital setting.
      <xref ref-type="ref" rid="b28">
       <sup>
        28
       </sup>
      </xref>
     </p>
     <p>
      This review had a prescribed narrow focus that permitted us to examine a relatively small number of studies. We considered employing quantitative techniques, but on analysis found the studies comprised a range of study designs, pathogens, participants, interventions and opportunities for bias and confounding would render any meta‐analysis findings open to criticism. A review that included interventions other than mask/respirator use, experimental laboratory and/animal–human studies on mask/respirator efficacy, cost‐effectiveness studies and the occurrence of adverse events would present a more comprehensive picture.
     </p>
     <p>
      Several systematic reviews of interventions to limit the transmission of respiratory viral infections and/or specifically influenza have been undertaken. Most have considered a range of interventions;
      <xref ref-type="ref" rid="b29">
       <sup>
        29
       </sup>
      </xref>
      ,
      <xref ref-type="ref" rid="b30">
       <sup>
        30
       </sup>
      </xref>
      ,
      <xref ref-type="ref" rid="b31">
       <sup>
        31
       </sup>
      </xref>
      ,
      <xref ref-type="ref" rid="b32">
       <sup>
        32
       </sup>
      </xref>
      ,
      <xref ref-type="ref" rid="b33">
       <sup>
        33
       </sup>
      </xref>
      one focused specifically on respiratory protection.
      <xref ref-type="ref" rid="b34">
       <sup>
        34
       </sup>
      </xref>
      Within the boundaries established by our inclusion criteria, our search strategy captured essentially the same studies on masks and respirators that others have identified. Jefferson
      <italic>
       et al
      </italic>
      derived pooled estimates of the effectiveness of wearing an N95 respirator (91%) and wearing a mask (68%) for any respiratory viral infection;
      <xref ref-type="ref" rid="b29">
       <sup>
        29
       </sup>
      </xref>
      however, these estimates were derived from the analyses of six SARS studies whose methodology was problematic. We carefully noted how well exposures in various studies were detailed and if cases and controls were laboratory‐confirmed to avoid misclassification bias. We did not feel that such a heterogeneous group of studies could be combined even for SARS.
     </p>
     <p>
      In conclusion, there is a limited evidence base to support the use of masks and/or respirators in healthcare or community settings. Mask use is best undertaken as part of a package of personal protection, especially including hand hygiene in both home and healthcare settings. Early initiation and correct and consistent wearing of masks/respirators may improve their effectiveness. However, this remains a major challenge – both in the context of a formal study and in everyday practice.
     </p>
     <p>
      Continued research on the effectiveness masks/respirators use and other closely associated considerations remains an urgent priority with emphasis being on carefully designed observational studies and trials best conducted outside a crisis situation.
      <xref ref-type="ref" rid="b35">
       <sup>
        35
       </sup>
      </xref>
      However, examination of the literature has highlighted that well‐designed studies in this field are challenging.
      <xref ref-type="ref" rid="b27">
       <sup>
        27
       </sup>
      </xref>
      Studies need to be adequately powered to assess potentially small differences between interventions and the independent effect of mask/respirator wearing when a second intervention (e.g. hand hygiene) is employed; an appropriate control group must be identified (e.g. no use of masks/respirators). Most of the studies we examined were too small to reliably detect what would be anticipated to be moderate effects. Perhaps, one solution is to fund large multi‐centre trials with similar protocols in different sites for multiple years to achieve sufficient power. Protocols should include the collection of detailed exposure data, objective monitoring of compliance and assessment of potential confounders. It may be difficult to design studies employing a control group that does not use any protective equipment (including masks/respirators), particularly in healthcare settings, as such precautions are routinely recommended. Finally, there is a striking paucity of published studies with microbiologically proven influenza infection as an outcome; inclusion of laboratory outcomes is essential in any future study of masks/respirators on transmission of influenza.
     </p>
    </sec>
    <sec id="ss12">
     <title>
      Funding
     </title>
     <p>
      Supported by funding from the Health Protection Agency and the European Centre for Disease Prevention and Control.
     </p>
    </sec>
    <sec id="ss13">
     <title>
      Declarations of interest
     </title>
     <p>
      Mary E Chamberland provided assistance to the Health Protection Agency, U.S. Centers for Disease Control and Prevention and the World Health Organization in the development of infection control recommendations for pandemic influenza. Angus Nicoll helped develop the ECDC infection control guidance for pandemic, seasonal and avian influenza.
     </p>
    </sec>
    <sec id="ss14">
     <title>
      Authors’ contributions
     </title>
     <p>
      Fb‐R, VLC, AN and MEC analysed the data. Fb‐R and MEC were the principal writers of the manuscript with contributions from AN and VLC.
     </p>
    </sec>
    <back>
     <fn-group>
      <title>
       Footnotes
      </title>
      <fn id="fn3">
       <label>
        1
       </label>
       <p>
        Search terms for PubMed database search: [1] Respiratory viruses: influenza OR influenza[tw] OR flu OR flu[tw] OR common cold OR common cold[tw] OR rhinovirus OR rhinovirus*[tw] OR adenoviridae OR adenovirus*[tw] OR coronavirus OR coronavirus infections OR coronavirus*[tw] OR respiratory syncytial viruses OR respiratory syncytial virus infections OR respiratory syncytial virus*[tw] OR respiratory syncitial virus[tw] OR parainfluenza virus 1 OR parainfluenza virus 2 OR parainfluenza virus 3 OR parainfluenza virus 4 OR parainfluenza[tw] OR parainfluenza[tw] OR parainfluenza[tw] OR severe acute respiratory syndrome OR severe acute respiratory syndrome[tw] OR SARS[tw] OR acute respiratory infection*[tw] OR acute respiratory tract infection*[tw] OR influenza‐like illness OR influenza‐like illness[tw] OR ILI OR Severe acute respiratory infection OR Severe acute respiratory infection[tw] OR pandemic influenza OR pandemic flu  [2] Interventions and population groups: masks OR mask*[tw] OR patient isolators OR personal protective equipment OR face protection OR N95 OR FFP2 OR FFP3 OR respirator OR home OR household* OR community OR nursing home OR nosocomial OR HCAI OR healthcare associated infection OR healthcare associated infections OR airborne precautions OR droplet precautions OR non‐pharmaceutical intervention OR nonpharmaceutical intervention OR aerosol‐generating procedures OR healthcare workers OR healthcare workers OR HCW OR healthcare personnel OR healthcare personnel.
       </p>
      </fn>
      <fn id="fn4">
       <label>
        2
       </label>
       <p>
        Search terms for the additional databases were respiratory viruses, mask, respirator, N95, FFP, FFP2, FFP3, influenza.
       </p>
      </fn>
     </fn-group>
     <ack id="ss11">
      <title>
       Acknowledgements
      </title>
      <p>
       We gratefully acknowledge the librarians at the Health Protection Agency (Sheila O’Malley) and ECDC (Ana‐Belen Escriva and Indu Kadlac) for assistance with the literature reviews; and Anthony Kessel, Jeremy Hawker, Anna Cichowska, John Watson and Nick Phin of the HPA, Marc Struelens (ECDC) and others for helpful suggestions.
      </p>
     </ack>
     <ref-list id="ss15">
      <title>
       References
      </title>
      <ref id="b1">
       <label>
        1
       </label>
       <mixed-citation id="cit1" publication-type="miscellaneous">
        <collab collab-type="authors">
         Department of Health
        </collab>
        .
        <article-title>
         UK influenza pandemic preparedness strategy 2011: strategy for consultation
        </article-title>
        . 22 March 2011. Available at
        <ext-link ext-link-type="uri" xlink:href="http://www.dh.gov.uk/en/Consultations/Liveconsultations/DH_125316">
         http://www.dh.gov.uk/en/Consultations/Liveconsultations/DH_125316
        </ext-link>
        (Accessed 25 March 2011).
       </mixed-citation>
      </ref>
      <ref id="b2">
       <label>
        2
       </label>
       <mixed-citation id="cit2" publication-type="miscellaneous">
        <collab collab-type="authors">
         Centre for Reviews and Dissemination, University of York
        </collab>
        .
        <article-title>
         CRD’s guidance for undertaking reviews in health care
        </article-title>
        .
        <year>
         2009
        </year>
        Available at
        <ext-link ext-link-type="uri" xlink:href="http://www.york.ac.uk/inst/crd/systematic_reviews_book.htm">
         http://www.york.ac.uk/inst/crd/systematic_reviews_book.htm
        </ext-link>
        (Accessed 22 December 2009).
       </mixed-citation>
      </ref>
      <ref id="b3">
       <label>
        3
       </label>
       <mixed-citation id="cit3" publication-type="miscellaneous">
        <collab collab-type="authors">
         National Health Service Critical Appraisal Skills Programme
        </collab>
        . Available at
        <ext-link ext-link-type="uri" xlink:href="http://www.phru.nhs.uk/casp/CASP.htm">
         http://www.phru.nhs.uk/casp/CASP.htm
        </ext-link>
        (Accessed 16 November 2009).
       </mixed-citation>
      </ref>
      <ref id="b4">
       <label>
        4
       </label>
       <mixed-citation id="cit4" publication-type="journal">
        <string-name>
         <surname>
          Jacobs
         </surname>
         <given-names>
          JL
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ohde
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Takahashi
         </surname>
         <given-names>
          O
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tokuda
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Omata
         </surname>
         <given-names>
          F
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Fukui
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        .
        <article-title>
         Use of surgical face masks to reduce the incidence of the common cold among health care workers in Japan: a randomized controlled trial
        </article-title>
        .
        <source>
         Am J Infect Control
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         37
        </volume>
        :
        <fpage>
         417
        </fpage>
        –
        <lpage>
         419
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19216002
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b5">
       <label>
        5
       </label>
       <mixed-citation id="cit5" publication-type="journal">
        <string-name>
         <surname>
          Loeb
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Dafoe
         </surname>
         <given-names>
          N
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Mahony
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Surgical mask vs N95 respirator for preventing influenza among health care workers: a randomized trial
        </article-title>
        .
        <source>
         JAMA
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         302
        </volume>
        :
        <fpage>
         1865
        </fpage>
        –
        <lpage>
         1871
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19797474
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b6">
       <label>
        6
       </label>
       <mixed-citation id="cit6" publication-type="journal">
        <string-name>
         <surname>
          MacIntyre
         </surname>
         <given-names>
          CR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wang
         </surname>
         <given-names>
          Q
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cauchemez
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         A cluster randomized clinical trial comparing fit‐tested and non‐fit‐tested N95 respirators to medical masks to prevent respiratory virus infection in health care workers
        </article-title>
        .
        <source>
         Influenza Other Respi Viruses
        </source>
        <year>
         2011
        </year>
        ;
        <volume>
         5
        </volume>
        :
        <fpage>
         170
        </fpage>
        –
        <lpage>
         179
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="b7">
       <label>
        7
       </label>
       <mixed-citation id="cit7" publication-type="journal">
        <string-name>
         <surname>
          Cowling
         </surname>
         <given-names>
          BJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Fung
         </surname>
         <given-names>
          ROP
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cheng
         </surname>
         <given-names>
          CKY
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Preliminary findings of a randomized trial of non‐pharmaceutical interventions to prevent influenza transmission in households
        </article-title>
        .
        <source>
         PLoS ONE
        </source>
        <year>
         2008
        </year>
        ;
        <volume>
         3
        </volume>
        :
        <fpage>
         e2101
        </fpage>
        . doi:
        <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0002101">
         10.1371/journal.pone.0002101
        </ext-link>
        .
        <pub-id pub-id-type="pmid">
         18461182
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b8">
       <label>
        8
       </label>
       <mixed-citation id="cit8" publication-type="journal">
        <string-name>
         <surname>
          Cowling
         </surname>
         <given-names>
          BJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chan
         </surname>
         <given-names>
          K‐H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Fang
         </surname>
         <given-names>
          VJ
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Facemasks and hand hygiene to prevent influenza transmission in households: a cluster randomized trial
        </article-title>
        .
        <source>
         Ann Intern Med
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         151
        </volume>
        :
        <fpage>
         437
        </fpage>
        –
        <lpage>
         446
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19652172
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b9">
       <label>
        9
       </label>
       <mixed-citation id="cit9" publication-type="journal">
        <string-name>
         <surname>
          MacIntyre
         </surname>
         <given-names>
          CR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cauchemez
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Dwyer
         </surname>
         <given-names>
          DE
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Face mask use and control of respiratory virus transmission in households
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         15
        </volume>
        :
        <fpage>
         233
        </fpage>
        –
        <lpage>
         241
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19193267
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b10">
       <label>
        10
       </label>
       <mixed-citation id="cit10" publication-type="journal">
        <string-name>
         <surname>
          Aiello
         </surname>
         <given-names>
          AE
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Murray
         </surname>
         <given-names>
          GF
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Perez
         </surname>
         <given-names>
          V
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Mask use, hand hygiene, and seasonal influenza‐like illness among young adults: a randomized intervention trial
        </article-title>
        .
        <source>
         J Infect Dis
        </source>
        <year>
         2010
        </year>
        ;
        <volume>
         201
        </volume>
        :
        <fpage>
         491
        </fpage>
        –
        <lpage>
         498
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         20088690
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b11">
       <label>
        11
       </label>
       <mixed-citation id="cit11" publication-type="journal">
        <string-name>
         <surname>
          Larson
         </surname>
         <given-names>
          EL
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ferng
         </surname>
         <given-names>
          Y‐H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wong‐McLoughlin
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wang
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Haber
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Morse
         </surname>
         <given-names>
          SS
         </given-names>
        </string-name>
        .
        <article-title>
         Impact of non‐pharmaceutical interventions on URIs and influenza in crowded, urban households
        </article-title>
        .
        <source>
         Public Health Rep
        </source>
        <year>
         2010
        </year>
        ;
        <volume>
         125
        </volume>
        :
        <fpage>
         178
        </fpage>
        –
        <lpage>
         191
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         20297744
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b12">
       <label>
        12
       </label>
       <mixed-citation id="cit12" publication-type="journal">
        <string-name>
         <surname>
          Chen
         </surname>
         <given-names>
          W‐Q
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ling
         </surname>
         <given-names>
          W‐H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lu
         </surname>
         <given-names>
          C‐Y
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Which preventive measures might protect health care workers from SARS?
        </article-title>
        <source>
         BMC Public Health
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         9
        </volume>
        :
        <fpage>
         81
        </fpage>
        . doi:
        <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2458-9-81">
         10.1186/1471‐2458‐9‐81
        </ext-link>
        .
        <pub-id pub-id-type="pmid">
         19284644
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b13">
       <label>
        13
       </label>
       <mixed-citation id="cit13" publication-type="journal">
        <string-name>
         <surname>
          Lau
         </surname>
         <given-names>
          JTF
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Fung
         </surname>
         <given-names>
          KS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wong
         </surname>
         <given-names>
          TW
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         SARS transmission among hospital workers in Hong Kong
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         280
        </fpage>
        –
        <lpage>
         286
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15030698
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b14">
       <label>
        14
       </label>
       <mixed-citation id="cit14" publication-type="journal">
        <string-name>
         <surname>
          Nishiura
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kuratsuji
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Quy
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Rapid awareness and transmission of severe acute respiratory syndrome in Hanoi French Hospital, Vietnam
        </article-title>
        .
        <source>
         Am J Trop Med Hyg
        </source>
        <year>
         2005
        </year>
        ;
        <volume>
         73
        </volume>
        :
        <fpage>
         17
        </fpage>
        –
        <lpage>
         25
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16014825
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b15">
       <label>
        15
       </label>
       <mixed-citation id="cit15" publication-type="journal">
        <string-name>
         <surname>
          Nishiyama
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wakasugi
         </surname>
         <given-names>
          N
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kirikae
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Risk factors for SARS infection within hospitals in Hanoi, Vietnam
        </article-title>
        .
        <source>
         Jpn J Infect Dis
        </source>
        <year>
         2008
        </year>
        ;
        <volume>
         61
        </volume>
        :
        <fpage>
         388
        </fpage>
        –
        <lpage>
         390
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18806349
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b16">
       <label>
        16
       </label>
       <mixed-citation id="cit16" publication-type="journal">
        <string-name>
         <surname>
          Seto
         </surname>
         <given-names>
          WH
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tsang
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yung
         </surname>
         <given-names>
          RWH
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS)
        </article-title>
        .
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         361
        </volume>
        :
        <fpage>
         1519
        </fpage>
        –
        <lpage>
         1520
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12737864
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b17">
       <label>
        17
       </label>
       <mixed-citation id="cit17" publication-type="journal">
        <string-name>
         <surname>
          Teleman
         </surname>
         <given-names>
          MD
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Boudville
         </surname>
         <given-names>
          IC
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Heng
         </surname>
         <given-names>
          BH
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhu
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Leo
         </surname>
         <given-names>
          YS
         </given-names>
        </string-name>
        .
        <article-title>
         Factors associated with transmission of severe acute respiratory syndrome among health‐care workers in Singapore
        </article-title>
        .
        <source>
         Epidemiol Infect
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         132
        </volume>
        :
        <fpage>
         797
        </fpage>
        –
        <lpage>
         803
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15473141
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b18">
       <label>
        18
       </label>
       <mixed-citation id="cit18" publication-type="journal">
        <string-name>
         <surname>
          Loeb
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          McGeer
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Henry
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         SARS among critical care nurses, Toronto
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         251
        </fpage>
        –
        <lpage>
         255
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15030692
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b19">
       <label>
        19
       </label>
       <mixed-citation id="cit19" publication-type="journal">
        <string-name>
         <surname>
          Lau
         </surname>
         <given-names>
          JTF
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tsui
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lau
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yang
         </surname>
         <given-names>
          X
         </given-names>
        </string-name>
        .
        <article-title>
         SARS transmission, risk factors, and prevention in Hong Kong
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         587
        </fpage>
        –
        <lpage>
         592
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15200846
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b20">
       <label>
        20
       </label>
       <mixed-citation id="cit20" publication-type="journal">
        <string-name>
         <surname>
          Wu
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Xu
         </surname>
         <given-names>
          F
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhou
         </surname>
         <given-names>
          W
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Risk factors for SARS among persons without known contact with SARS patients, Beijing, China
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         210
        </fpage>
        –
        <lpage>
         216
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15030685
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b21">
       <label>
        21
       </label>
       <mixed-citation id="cit21" publication-type="journal">
        <string-name>
         <surname>
          Brankston
         </surname>
         <given-names>
          G
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Gitterman
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hirji
         </surname>
         <given-names>
          Z
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lemieux
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Gardam
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        .
        <article-title>
         Transmission of influenza A in human beings
        </article-title>
        .
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2007
        </year>
        ;
        <volume>
         7
        </volume>
        :
        <fpage>
         257
        </fpage>
        –
        <lpage>
         265
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17376383
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b22">
       <label>
        22
       </label>
       <mixed-citation id="cit22" publication-type="journal">
        <string-name>
         <surname>
          Tellier
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        .
        <article-title>
         Aerosol transmission of influenza A virus: a review of new studies
        </article-title>
        .
        <source>
         J R Soc Interface
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         6
        </volume>
        (
        <issue>
         Suppl 6
        </issue>
        ):
        <fpage>
         S783
        </fpage>
        –
        <lpage>
         S790
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19773292
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b23">
       <label>
        23
       </label>
       <mixed-citation id="cit23" publication-type="journal">
        <string-name>
         <surname>
          Lindsley
         </surname>
         <given-names>
          WG
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Blachere
         </surname>
         <given-names>
          FM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Thewlis
         </surname>
         <given-names>
          RE
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Measurements of airborne influenza virus in aerosol particles from human coughs
        </article-title>
        .
        <source>
         PLoS ONE
        </source>
        <year>
         2010
        </year>
        ;
        <volume>
         5
        </volume>
        :
        <fpage>
         e15100
        </fpage>
        . doi:
        <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0015100">
         10.1371/journal.pone.0015100
        </ext-link>
        .
        <pub-id pub-id-type="pmid">
         21152051
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b24">
       <label>
        24
       </label>
       <mixed-citation id="cit24" publication-type="journal">
        <string-name>
         <surname>
          Wong
         </surname>
         <given-names>
          BCK
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lee
         </surname>
         <given-names>
          N
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Li
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Possible role of aerosol transmission in a hospital outbreak of influenza
        </article-title>
        .
        <source>
         Clin Infect Dis
        </source>
        <year>
         2010
        </year>
        ;
        <volume>
         51
        </volume>
        :
        <fpage>
         1176
        </fpage>
        –
        <lpage>
         1183
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         20942655
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b25">
       <label>
        25
       </label>
       <mixed-citation id="cit25" publication-type="miscellaneous">
        <collab collab-type="authors">
         Department of Health and Health Protection Agency
        </collab>
        .
        <article-title>
         Pandemic (H1N1) 2009 influenza – a summary of guidance for infection control in healthcare settings
        </article-title>
        . 8 Jan 2010. Available at
        <ext-link ext-link-type="uri" xlink:href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_110902">
         http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_110902
        </ext-link>
        (Accessed 12 February 2010).
       </mixed-citation>
      </ref>
      <ref id="b26">
       <label>
        26
       </label>
       <mixed-citation id="cit26" publication-type="journal">
        <string-name>
         <surname>
          Srinivasan
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Perl
         </surname>
         <given-names>
          TM
         </given-names>
        </string-name>
        .
        <article-title>
         Respiratory protection against influenza (editorial)
        </article-title>
        .
        <source>
         JAMA
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         302
        </volume>
        :
        <fpage>
         1903
        </fpage>
        –
        <lpage>
         1904
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19797473
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b27">
       <label>
        27
       </label>
       <mixed-citation id="cit27" publication-type="journal">
        <string-name>
         <surname>
          Killingley
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        .
        <article-title>
         Respirators versus medical masks: evidence accumulates but the jury remains out (editorial)
        </article-title>
        .
        <source>
         Influenza Other Respi Viruses
        </source>
        <year>
         2011
        </year>
        ;
        <volume>
         5
        </volume>
        :
        <fpage>
         143
        </fpage>
        –
        <lpage>
         145
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="b28">
       <label>
        28
       </label>
       <mixed-citation id="cit28" publication-type="journal">
        <string-name>
         <surname>
          Phin
         </surname>
         <given-names>
          NF
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rylands
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Allan
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Edwards
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Enstone
         </surname>
         <given-names>
          JE
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Nguyen‐Van‐Tam
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        .
        <article-title>
         Personal protective equipment in an influenza pandemic: a UK simulation exercise
        </article-title>
        .
        <source>
         J Hosp Infect
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         71
        </volume>
        :
        <fpage>
         15
        </fpage>
        –
        <lpage>
         21
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19013670
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b29">
       <label>
        29
       </label>
       <mixed-citation id="cit29" publication-type="journal">
        <string-name>
         <surname>
          Jefferson
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Del Mar
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Dooley
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review [published online 21September 2009]
        </article-title>
        .
        <source>
         BMJ
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         339
        </volume>
        :
        <fpage>
         b3675
        </fpage>
        . doi:
        <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/bmj.b3675">
         10.1136/bmj.b3675
        </ext-link>
        .
        <pub-id pub-id-type="pmid">
         19773323
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b30">
       <label>
        30
       </label>
       <mixed-citation id="cit30" publication-type="journal">
        <string-name>
         <surname>
          Jefferson
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Foxlee
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Del Mar
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review [published online 27 November 2007]
        </article-title>
        .
        <source>
         BMJ
        </source>
        <year>
         2008
        </year>
        ;
        <volume>
         336
        </volume>
        :
        <fpage>
         77
        </fpage>
        –
        <lpage>
         80
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18042961
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b31">
       <label>
        31
       </label>
       <mixed-citation id="cit31" publication-type="journal">
        <string-name>
         <surname>
          Jefferson
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Del Mar
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Dooley
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Physical interventions to interrupt or reduce the spread of respiratory viruses
        </article-title>
        .
        <source>
         Cochrane Database Syst Rev
        </source>
        <year>
         2010
        </year>
        :
        <fpage>
         CD006207
        </fpage>
        . doi:
        <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/14651858.CD006207.pub3">
         10.1002/14651858.CD006207.pub3
        </ext-link>
        .
        <pub-id pub-id-type="pmid">
         20091588
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b32">
       <label>
        32
       </label>
       <mixed-citation id="cit32" publication-type="journal">
        <string-name>
         <surname>
          Aledort
         </surname>
         <given-names>
          JE
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lurie
         </surname>
         <given-names>
          N
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wasserman
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bozzette
         </surname>
         <given-names>
          SA
         </given-names>
        </string-name>
        .
        <article-title>
         Non‐pharmaceutical public health interventions for pandemic influenza: an evaluation of the evidence base
        </article-title>
        .
        <source>
         BMC Public Health
        </source>
        <year>
         2007
        </year>
        ;
        <volume>
         7
        </volume>
        :
        <fpage>
         208
        </fpage>
        . doi:
        <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2458-7-208">
         10.1186/1471‐2458‐7‐208
        </ext-link>
        .
        <pub-id pub-id-type="pmid">
         17697389
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b33">
       <label>
        33
       </label>
       <mixed-citation id="cit33" publication-type="journal">
        <string-name>
         <surname>
          Gamage
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Moore
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Copes
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Protecting health care workers from SARS and other respiratory pathogens: a review of the infection control literature
        </article-title>
        .
        <source>
         Am J Infect Control
        </source>
        <year>
         2005
        </year>
        ;
        <volume>
         33
        </volume>
        :
        <fpage>
         114
        </fpage>
        –
        <lpage>
         121
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15761412
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b34">
       <label>
        34
       </label>
       <mixed-citation id="cit34" publication-type="journal">
        <string-name>
         <surname>
          Cowling
         </surname>
         <given-names>
          BJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhou
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ip
         </surname>
         <given-names>
          DKM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Leung
         </surname>
         <given-names>
          GM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Aiello
         </surname>
         <given-names>
          AE
         </given-names>
        </string-name>
        .
        <article-title>
         Face masks to prevent transmission of influenza virus: a systematic review [published online January 22, 2010]
        </article-title>
        .
        <source>
         Epidemiol Infect
        </source>
        <year>
         2010
        </year>
        ;
        <volume>
         138
        </volume>
        :
        <fpage>
         449
        </fpage>
        –
        <lpage>
         456
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         20092668
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="b35">
       <label>
        35
       </label>
       <mixed-citation id="cit35" publication-type="journal">
        <string-name>
         <surname>
          Aiello
         </surname>
         <given-names>
          AE
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Coulborn
         </surname>
         <given-names>
          RM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Aragon
         </surname>
         <given-names>
          TJ
         </given-names>
        </string-name>
        <italic>
         et al.
        </italic>
        <article-title>
         Research findings from nonpharmaceutical intervention studies for pandemic influenza and current gaps in the research
        </article-title>
        .
        <source>
         Am J Infect Control
        </source>
        <year>
         2010
        </year>
        ;
        <volume>
         38
        </volume>
        :
        <fpage>
         251
        </fpage>
        –
        <lpage>
         258
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         20226569
        </pub-id>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
  </pmc-articleset>
 </body>
</html>